



No. 2000-4

CURRENT BIBLIOGRAPHIES IN MEDICINE



Phenylketonuria (PKU): Screening and Management



**January 1980
through
July 2000**

3394 Citations

CBM 2000-4

Phenylketonuria (PKU): Screening and Management

January 1980 through July 2000, plus selected earlier citations

3394 Citations

Prepared by

Karen Patrias, M.L.S., National Library of Medicine

Felix F. de la Cruz, M.D., M.P.H., National Institute of Child Health and Human Development

2000 September

**U.S. DEPARTMENT OF HEALTH
AND HUMAN SERVICES**

Public Health Service

National Institutes of Health

National Library of Medicine

Reference Section

8600 Rockville Pike

Bethesda, Maryland 20894

SERIES NOTE

Each bibliography in the *Current Bibliographies in Medicine* (CBM) series covers a distinct subject area of biomedicine and is intended to fulfill a current awareness function. Citations are usually derived from searching a variety of online databases. NLM databases utilized include MEDLINE®, BIOETHICSLINE®, HEALTHSTAR™, LOCATORplus® , POPLINE™, PubMed®, and TOXLINE®. The only criterion for the inclusion of a particular published work is its relevance to the topic being presented; the format, ownership, or location of the material is not considered.

Publications in the *Current Bibliographies in Medicine* series are available at no cost to anyone with Internet access through the Library's World Wide Web site at <http://www.nlm.nih.gov/pubs/resources.html>.

Comments and suggestions on this series may be addressed to:

Karen Patrias, Editor
Current Bibliographies in Medicine
Reference Section
National Library of Medicine
Bethesda, MD 20894
Phone: 301-496-6097
Fax: 301-402-1384
Internet: ref@nlm.nih.gov

PubMed® and Internet Grateful Med®

To make online searching easier and more efficient, the Library offers two user-friendly interfaces to its databases. Both PubMed and Internet Grateful Med are available from the World Wide Web. The user with Internet access need only point a compatible Web browser to the NLM Web site <http://www.nlm.nih.gov>. No other software at the user end is required. Searching through either PubMed or Internet Grateful Med is free-of-charge. Further information on both PubMed and Internet Grateful Med may be found at the NLM Web site given above.

For those users without access to the World Wide Web, please contact the Library's Customer Service Desk at 1-888-FINDNLM (301-594-5983 international) or e-mail custserv@nlm.nih.gov for information on alternative ways to search.

*Use of funds for printing this periodical has been approved by the Director
of the Office of Management and Budget through September 30, 2000.*

TABLE OF CONTENTS

	<i>page</i>
Introduction	v
Sample Citations	vi
History and Classic Material	1
Overviews and Reviews	3
Ethics, Laws, and Policies	14
Economics and Socioeconomics	18
Classification	22
Incidence, Prevalence, and Demographics	23
Screening and Diagnosis	34
Isolation and Analysis	70
Genetics	83
Pathology and Physiopathology	126
Metabolism, Enzymology, and Biochemistry	147
Psychology, Neuropsychology, Sociology, and Behavior	203
Nutrition, Diet, and Diet Therapy	225
Drug Therapy	274
Other Therapies and Therapy in General	278
Maternal PKU	283
Animal, Plant, and Other Non-Human Studies	299

INTRODUCTION

Phenylketonuria or PKU is a rare, inherited metabolic disorder that, if untreated, causes mental retardation. Approximately one of every 10,000 infants in the United States is born with PKU, which usually results from a deficiency of a liver enzyme known as phenylalanine hydroxylase (PAH). This enzyme deficiency leads to elevated levels of the amino acid phenylalanine in the bloodstream.

All infants in this country undergo blood testing for PKU. The current treatment for this disorder involves dietary modification. When a very strict diet is begun early and maintained, children with PKU can expect normal development and a normal lifespan. The diet generally excludes all high protein foods, such as meat, milk, eggs, and nuts, since all protein contains phenylalanine. Dietary noncompliance can result in a decline in mental and behavioral performance. Women with PKU must also maintain a strictly controlled diet before and during pregnancy to prevent fetal damage. Scientists are actively exploring nondietary treatments for PKU.

This bibliography was prepared in support of the National Institutes of Health (NIH) Consensus Development Conference titled Phenylketonuria (PKU): Screening and Management held in Bethesda, MD on October 16–18, 2000. It includes citations to journal articles, books and book chapters, conference proceedings and conference papers, and dissertations in all languages published primarily from January 1980 through July 2000. Works of historical significance and other selected references from earlier years have also been included. Citations have been arranged by subject and then alphabetically by author within each subject. A citation may appear under more than one subject. For example, a citation discussing the economic aspects of screening for PKU would be found under both “Economics and Socioeconomics” and “Screening and Diagnosis.”

The compilers wish to thank Ms. Twann Dailey of the National Library of Medicine for her assistance in the production of this bibliography.

This publication is not copyrighted and may be freely reproduced. However any reproductions of this bibliography, in whole or in part, should include all credits. If you wish to cite this bibliography, the correct format is:

Patrias, Karen; de la Cruz, Felix F., compilers. Phenylketonuria (PKU): screening and management [bibliography]. Bethesda (MD): National Library of Medicine (US); 2000 Sep. (Current bibliographies in medicine; no. 2000-4). 3394 citations from January 1980 through July 2000, plus selected earlier citations.

SAMPLE CITATIONS

Citations in this bibliographic series are formatted according to the rules established for *Index Medicus*®*. Sample journal and monograph citations appear below. For journal articles written in a foreign language, the English translation of the title is placed in brackets; for monographs, the title is given in the original language. In both cases the language of publication is shown by a three letter abbreviation appearing at the end of the citation.

Journal Article:

Authors *Article Title*

DiLella AG, Woo SL. Molecular basis of phenylketonuria and its clinical applications.
Mol Biol Med 1987 Aug;4(4):183-92.

Abbreviated Journal Title *Date* *Volume* *Issue* *Pages*

Monograph:

Authors/Editors *Title*

Demirkol M, Shin YS, editors. Diagnosis and treatment of inborn errors of metabolism.
Istanbul (Turkey): Turkish Society for PKU, Istanbul Branch; 1996. 233 p.

Place of Publication *Publisher* *Date* *Total No. of Pages*

*For details of the formats used for references, see the following publication:

Patrias, Karen. *National Library of Medicine recommended formats for bibliographic citation*.
Bethesda (MD): The Library; 1991 Apr. Available from: NTIS, Springfield, VA; PB91-182030.

History and Classic Material

Acuff KL, Faden RR. A history of prenatal and newborn screening programs: lessons for the future. In: Faden R, Geller G, Powers M, editors. *AIDS, women and the next generation*. New York: Oxford University Press; 1991. p. 59-93.

Ambrus CM, Ambrus JL, Horvath C, Pedersen H, Sharma S, Kant C, Mirand E, Guthrie R, Paul T. Phenylalanine depletion for the management of phenylketonuria: use of enzyme reactors with immobilized enzymes. *Science* 1978 Sep 1;201(4358):837-9.

Bartholome K, Lutz P. [Determination of phenylalanine hydroxylase in patients with phenylketonuria and hyperphenylalaninemia]. *Monatsschr Kinderheilkd* 1976 May;124(5):421-2. (Ger).

Bessman SP. Historical perspective: tyrosine and maternal phenylketonuria, welcome news [editorial]. *Am J Clin Nutr* 1998 Mar;67(3):357-8. Comment on: *Am J Clin Nutr* 1998 Mar;67(3):473-6. Comment in: *Am J Clin Nutr* 1998 Mar;67(3):488; *Am J Clin Nutr* 1998 Dec;68(6):1304-6.

Bickel H. Dietary restriction in inborn errors of amino acid metabolism. *Curr Concepts Nutr* 1979;8:35-53.

Bickel H. [Early diagnosis of phenylketonuria]. *Monatsschr Kinderheilkd* 1966 Jan;114(1):23-5. (Ger).

Bickel H. The first treatment of phenylketonuria. *Eur J Pediatr* 1996 Jul;155 Suppl 1:S2-3.

Bickel H. Phenylalaninaemia or classical phenylketonuria (PKU)? *Neuropadiatrie* 1970 Apr;1(4):379-82.

Bickel H. [Phenylketonuria. Yesterday, today and tomorrow]. *Arch Fr Pediatr* 1983;40 Suppl 1:207-13. (Fre).

Bickel H. Recent advances in the early detection and treatment of inborn errors with brain damage. *Neuropadiatrie* 1969 Jun-Jul;1(1):1-11.

Bickel H, Bremer HJ. [On phenylketonuria. Carrying out of phenylalanine-low diet]. *Dtsch Med Wochenschr* 1967 Apr 14;92(15):700-10. (Ger).

Bickel H, Gerrard J, Hickmans EM. Influence of phenylalanine intake on phenylketonuria. *Lancet* 1953 Oct 17;2:812-3.

Bickel H, Ruter E, Nutzenadel W. [Early detection of hereditary enzyme defects of amino acid metabolism by means of microbiological inhibitor tests and thin

layer chromatography]. *Z Klin Chem Klin Biochem* 1969 Mar;7(2):203-4. (Ger).

Bush JW, Chen MM, Patrick DL. Health status index in cost effectiveness: analysis of PKU program. In: Berg RL, editor. *Health status indexes. Proceedings of the Conference on a Health Status Index*; 1972 Oct 1-4; Tucson, AZ. Chicago: Hospital Research and Educational Trust; 1973. p. 172-209.

Centerwall SA, Centerwall WR. The discovery of phenylketonuria: the story of a young couple, two retarded children, and a scientist. *Pediatrics* 2000 Jan;105(1 Pt 1):89-103.

Eggers C, Bickel H. [Pre-, peri- and postnatal causes of mental retardation]. *Ergeb Inn Med Kinderheilkd* 1974;34(0):155-205. (Ger).

Eisensmith RC, Goltsov AA, O'Neill C, Tyfield LA, Schwartz EI, Kuzmin AI, Baranovskaya SS, Tsukerman GL, Treacy E, Scriver CR, et al. Recurrence of the R408W mutation in the phenylalanine hydroxylase locus in Europeans. *Am J Hum Genet* 1995 Jan;56(1):278-86.

Elgjo RF. Asbjorn Folling, his life and work. *Prog Clin Biol Res* 1985;177:79-92.

Folling A. [Phenylketonuria]. *Tidsskr Nor Laegeforen* 1967 Mar 1;87(5 Suppl):451-4. (Nor).

Folling A. Uber Ausscheidung von Phenylbrenztraubensaure in den Harn als Stoffwechselanomalie in Verbindung mit Imbezillitat. *Hoppe Seylers Z Physiol Chem* 1934;277:169-79. (Ger).

Folling I. The discovery of phenylketonuria. *Acta Paediatr Suppl* 1994 Dec;407:4-10.

Gerrard JW. Phenylketonuria revisited. *Clin Invest Med* 1994 Oct;17(5):510-3.

Guthrie R. Blood screening for phenylketonuria [letter]. *JAMA* 1961 Nov 25;178(8):863.

Guthrie R. The introduction of newborn screening for phenylketonuria. A personal history. *Eur J Pediatr* 1996 Jul;155 Suppl 1:S4-5.

Guthrie R, Susi A. A simple phenylalanine method for detecting phenylketonuria in large populations of newborn infants. *Pediatrics* 1963 Sep;32(3):338-43.

Guttler F. [Folling's disease: 50 years and still a catalyst of new discoveries in clinical medicine]. *Nord Med* 1984;99(3):78-81. (Dan).

Guttler F. Phenylketonuria: 50 years since Folling's discovery and still expanding our clinical and

- biochemical knowledge. *Acta Paediatr Scand* 1984 Nov;73(6):705-16.
- Jervis GA. Studies on phenylpyruvic oligophrenia: the position of the metabolic error. *J Biol Chem* 1947 Aug;169(3):651-6.
- Kaufman S. Experiencing classical enzymology in its prime. *Protein Sci* 1996 Aug;5(8):1742-6.
- Kaufman S. The phenylalanine hydroxylating system from mammalian liver. *Adv Enzymol* 1971;35:245-319.
- Koch J. Robert Guthrie--the PKU story: a crusade against mental retardation. Pasadena (CA): Hope Pub. House; c1997. 190 p.
- Koch R, de la Cruz F. Historical aspects and overview of research on phenylketonuria. *Ment Retard Dev Disabil Res Rev* 1999;5(2):101-3.
- Koch R, Williamson ML, Donnell GN, Guthrie R, Straus R, Coffelt W, Fish CH. A cooperative study of two methods for phenylalanine determination: McCaman-Robins fluorimetric and microbiologic inhibition methods. *J Pediatr* 1966 Jun;68(6):905-11.
- Ledley FD. Somatic gene therapy for human disease: a problem of eugenics? *Trends Genet* 1987 Apr;3(4):112-5.
- Lie SO. [Asbjorn Folling's disease. Reflections on a 50-year anniversary]. *Tidsskr Nor Laegeforen* 1984 Dec 10;104(34):2381-5. (Nor).
- McDonald JD. The PKU mouse project: its history, potential and implications. *Acta Paediatr Suppl* 1994 Dec;407:122-3.
- Murphey WH, Patchen L, Guthrie R. Screening tests for argininosuccinic aciduria, orotic aciduria, and other inherited enzyme deficiencies using dried blood specimens. *Biochem Genet* 1972 Feb;6(1):51-9.
- Nutrition classics, the *Journal of Clinical Investigation*, volume 34, 1955. Studies on phenylketonuria. I. Restricted phenylalanine intake in phenylketonuria. By Marvin D. Armstrong and Frank H. Tyler. *Nutr Rev* 1983 Jan;41(1):15-8.
- Paul D. A double-edged sword. *Nature* 2000 Jun 1;405(6786):515.
- Phenylketonuria in adolescence. International Symposium on the Advances in the Management of PKU. Brussels, Belgium, October 1986. Dedicated to Horst Bickel. *Eur J Pediatr* 1987;146 Suppl 1:A1-43.
- Schmidt H, Bickel H. [Phenylketonuria]. *Internist (Berl)* 1976 Jul;17(7):354-61. (Ger).
- Schroeder SR. The PKU story - Guthrie, R. *Am J Ment Retard* 1999;104:392-3.
- Scriver CC. A simple phenylalanine method for detecting phenylketonuria in large populations of newborn infants, by Robert Guthrie and Ada Susi, *Pediatrics*, 1963;32:318-343. *Pediatrics* 1998 Jul;102(1 Pt 2):236-7.
- Scriver CR. Whatever happened to PKU? *Clin Biochem* 1995 Apr;28(2):137-44.
- Smith I, Lobascher ME, Stevenson JE, Wolff OH, Schmidt H, Grubel-Kaiser S, Bickel H. Effect of stopping low-phenylalanine diet on intellectual progress of children with phenylketonuria. *Br Med J* 1978 Sep 9;2(6139):723-6.
- Udenfriend S, Cooper JR. The enzymatic conversion of phenylalanine to tyrosine. *J Biol Chem* 1952 Feb;194(2):503-11.
- Zschocke J, Mallory JP, Eiken HG, Nevin NC. Phenylketonuria and the peoples of Northern Ireland. *Hum Genet* 1997 Aug;100(2):189-94.

Overviews and Reviews

Abadie V, Depondt E, Farriaux JP, Lepercq J, Lyonnet S, Maurin N, Ogier de Baulny H, Vidailhet M. [Pregnancy and the child of a mother with phenylketonuria]. *Arch Pediatr* 1996 May;3(5):489-6. (Fre).

Acosta PB, Yannicelli S. Nutrition support of inherited disorders of amino acid metabolism: part 2. *Top Clin Nutr* 1995 Mar;10(2):48-72.

Addison GM, et al., editors. Practical developments in inherited metabolic disease: DNA analysis, phenylketonuria, and screening for congenital adrenal hyperplasia. Proceedings of the 23rd Annual Symposium of the Society for the Study of Inborn Errors of Metabolism; 1985 Sep; Liverpool, England. Boston: MTP Press; c1986. 335 p.

Allen RJ, Brunberg J, Schwartz E, Schaefer AM, Jackson G. MRI characterization of cerebral dysgenesis in maternal PKU. *Acta Paediatr Suppl* 1994 Dec;407:83-5.

Alvarez Dominguez L, Campistol Plana J, Ribes Rubio A, Riverola de Vecina AT. [Phenylalanine metabolites in hyperphenylalaninemic children]. *An Esp Pediatr* 1992 May;36(5):371-4. (Spa).

Ambulatory nutrition care: infants. *J Am Diet Assoc* 1989 Apr;89(4):S15-6.

Ambulatory Nutrition Care: pregnant women. *J Am Diet Assoc* 1989 Apr;89(4 Suppl):S10-4.

Annenkov GA. [Genetical heterogeneity of phenylketonuria]. *Vopr Med Khim* 1982 May-Jun;28(3):62-70. (Rus).

Antel JP, Arnason BG. Genetic predisposition to environmental factors. *Res Publ Assoc Res Nerv Ment Dis* 1983;60:255-71.

Aoki K. [Disorders of amino acids]. *Nippon Rinsho* 1993 Jan;51 Suppl:332-9. (Jpn).

Armarego WL, Randles D, Waring P. Dihydropteridine reductase (DHPR), its cofactors, and its mode of action. *Med Res Rev* 1984 Jul-Sep;4(3):267-321.

Bailey SW, Boerth SR, Dillard SB, Ayling JE. The mechanism of cofactor regeneration during phenylalanine hydroxylation. *Adv Exp Med Biol* 1993;338:47-54.

Ball SP, Kenwrick SJ, Davies KE. The molecular genetics of human monogenic diseases. *Biotechnol Genet Eng Rev* 1985;3:275-309.

Bamforth FJ. Laboratory screening for genetic disorders and birth defects. *Clin Biochem* 1994 Oct;27(5):333-42.

Baranov VS. [Successes and prospects of molecular diagnosis of the most widespread inherited diseases]. *Tsitol Genet* 1992 Jul-Aug;26(4):64-72. (Rus).

Barker HA. Amino acid degradation by anaerobic bacteria. *Annu Rev Biochem* 1981;50:23-40.

Batshaw ML. PKU and other inborn errors of metabolism. In: Batshaw ML, et al., editors. *Children with disabilities*. 4th ed. Baltimore (MD): Paul H. Brookes Publishing Co.; 1997. p. 389-404.

Baumeister AA, Baumeister AA. Dietary treatment of destructive behavior associated with hyperphenylalaninemia. *Clin Neuropharmacol* 1998 Jan-Feb;21(1):18-27.

Bequette BJ, Backwell FR, Crompton LA. Current concepts of amino acid and protein metabolism in the mammary gland of the lactating ruminant. *J Dairy Sci* 1998 Sep;81(9):2540-59.

Bessman SP. The justification theory: the essential nature of the non-essential amino acids. *Nutr Rev* 1979 Jul;37(7):209-20.

Bessman SP. Phenylketonuria--a genetic intrauterine nutritional deficiency. *Nutr MD* 1992 Jan;18(1):5.

Bick U, Ullrich K, Stober U, Moller H, Schuierer G, Ludolph AC, Oberwittler C, Weglage J, Wendel U. White matter abnormalities in patients with treated hyperphenylalaninaemia: magnetic resonance relaxometry and proton spectroscopy findings. *Eur J Pediatr* 1993 Dec;152(12):1012-20.

Bickel H. Phenylalaninaemia or classical phenylketonuria (PKU)? *Neuropadiatrie* 1970 Apr;1(4):379-82.

Bickel H. Recent advances in the early detection and treatment of inborn errors with brain damage. *Neuropadiatrie* 1969 Jun-Jul;1(1):1-11.

Bickel H, Wachtel U, editors. *Inherited diseases of amino acid metabolism: recent progress in the understanding, recognition, and management*. New York: Thieme; 1985. 399 p. Based on the international symposium in Heidelberg in 1984.

Blau N, Niederwieser A. GTP-cyclohydrolases: a review. *J Clin Chem Clin Biochem* 1985 Apr;23(4):169-76.

Blau N, Thony B, Spada M, Ponzzone A. Tetrahydrobiopterin and inherited hyperphenylalaninemia. *Turk J Pediatr* 1996 Jan-Mar;38(1):19-35.

- Bodamer OA, Leonard JV, Tasker RC, Hoffmann GF, Halliday D. Protein turnover in critically ill children. *Eur J Pediatr* 1997 Aug;156 Suppl 1:S59-61.
- Boyce RA. The dietetic implications of maternal phenylketonuria. *Aust J Nutr Diet* 1991 Sep;48(3):82-8.
- Brenton DP. Cardiac defects in the children of mothers with high concentrations of plasma phenylalanine. *Br Heart J* 1990 Mar;63(3):143-4.
- Campistol Plana J, Alvarez Dominguez L, Riverola de Veciana AT, Castillo Rivera P, Giner Soria P. [Hyperphenylalaninemia and phenylketonuria. The importance of early diagnosis and follow up at a health center]. *An Esp Pediatr* 1991 Jan;34(1):51-6. (Spa).
- Chestkov VV, Shishkin SS. [Genetic heterogeneity and approaches to the prenatal diagnosis of phenylketonuria (review)]. *Vopr Med Khim* 1986 Jul-Aug;32(4):7-12. (Rus).
- Childs B. Genetic screening. *Annu Rev Genet* 1975;9:67-89.
- Christensen HN. Hypothesis: where the depleted plasma amino acids go in phenylketonuria, and why. *Perspect Biol Med* 1987 Winter;30(2):186-96.
- Ciske JB, Hoffman G, Hanson K, Annable KM, Wolff J, Litsheim T, Laessig R, Aronson R. Newborn screening in Wisconsin: program overview and test addition. *WMJ* 2000;99(2):38-42.
- Collins JE, Leonard JV. The dietary management of inborn errors of metabolism. *Hum Nutr Appl Nutr* 1985 Aug;39(4):255-72.
- Copel JA, Pilu G, Kleinman CS. Congenital heart disease and extracardiac anomalies: associations and indications for fetal echocardiography. *Am J Obstet Gynecol* 1986 May;154(5):1121-32.
- Cotton RG. Heterogeneity of phenylketonuria at the clinical, protein and DNA levels. *J Inherit Metab Dis* 1990;13(5):739-50.
- Cowie V. Injury and insult--considerations of the neuropathological aetiology of mental subnormality. *Br J Psychiatry* 1980 Oct;137:305-12.
- Crawford MD. Severe mental handicap: pathogenesis, treatment, and prevention. *Br Med J (Clin Res Ed)* 1982 Sep 18;285(6344):762-6.
- Cynober L. Amino acid metabolism in thermal burns. *JPEN J Parenter Enteral Nutr* 1989 Mar-Apr;13(2):196-205.
- Dalery J, Maillet J, de Villard R. [Behavior problems in phenylketonuria. Attempt at a biochemical interpretation based on a personal case and a review of the literature]. *Encephale* 1983;9(3):279-90. (Fre).
- Dashman T, Sansaricq C. Nutrition in the management of inborn errors of metabolism. *Clin Lab Med* 1993 Jun;13(2):407-32. Published erratum appears in *Clin Lab Med* 1993 Dec;13(4):following table of contents.
- de Freitas O, Izumi C, Lara MG, Greene LJ. New approaches to the treatment of phenylketonuria. *Nutr Rev* 1999 Mar;57(3):65-70.
- de Valk HW, de Sonnevill LM, Duran M, Poll-The BT, Erkelens DW. [Phenylketonuria: a children's disease in adulthood]. *Ned Tijdschr Geneesk* 2000 Jan 1;144(1):11-5. (Dut).
- Dement'eva NF, Ermolina LA, Ezhkova VA, Mozhaeva EG. [Therapy and social adaptation of patients with mental retardation (a review of the literature)]. *Zh Nevropatol Psikhiatr* 1981;81(3):439-50. (Rus).
- Demirkol M, Shin YS, editors. Diagnosis and treatment of inborn errors of metabolism: contribution to an equal opportunity for children in Asia and Europe. Istanbul (Turkey): Turkish Society for PKU, Istanbul Branch; 1996. 233 p.
- Dhondt JL. Tetrahydrobiopterin deficiencies: preliminary analysis from an international survey. *J Pediatr* 1984 Apr;104(4):501-8.
- Dhondt JL. [Tetrahydrobiopterin deficiency. Lessons from the analysis of 90 patients collected in the international register]. *Arch Fr Pediatr* 1987;44 Suppl 1:655-9. (Fre).
- Dhondt JL, Farriaux JP. Atypical cases of phenylketonuria. *Eur J Pediatr* 1987;146 Suppl 1:A38-43.
- Dhondt JL, Farriaux JP. [Tetrahydrobiopterin. Metabolism and metabolic role of unconjugated pteridines (author's transl)]. *Pathol Biol (Paris)* 1980 Jun;28(6):397-405. (Fre).
- Diament AJ. [Recent advances in inborn errors of metabolism]. *Arq Neuropsiquiatr* 1987 Jun;45(2):177-87. (Por).
- Diamond A. Evidence for the importance of dopamine for prefrontal cortex functions early in life. *Philos Trans R Soc Lond B Biol Sci* 1996 Oct 29;351(1346):1483-93; discussion 1494.
- Diamond A. Phenylalanine levels of 6-10 mg/dl may not be as benign as once thought. *Acta Paediatr Suppl* 1994 Dec;407:89-91.

- Dietary D-tyrosine as an antimetabolite in mice. *Nutr Rev* 1985 May;43(5):156-8.
- DiLella AG, Woo SL. Molecular basis of phenylketonuria and its clinical applications. *Mol Biol Med* 1987 Aug;4(4):183-92.
- Druml W, Roth E, Lenz K, Lochs H, Kopsa H. Phenylalanine and tyrosine metabolism in renal failure: dipeptides as tyrosine source. *Kidney Int Suppl* 1989 Nov;27:S282-6.
- Duch DS, Smith GK. Biosynthesis and function of tetrahydrobiopterin. *J Nutr Biochem* 1991 Aug;2(8):411-23.
- Edmond J, Korsak RA, Auestad N, Morrow JW, Greenough WT, Black JE, Chang F-LF, Sirevaag AM, Smith A, et al. Biomedical aspects. In: Fraser WI, et al., editors. Key issues in mental retardation research: Proceedings of the 8th Congress of the International Association for the Scientific Study of Mental Deficiency (IASSMD). London: Routledge; 1990. p. 37-105.
- Education of students with phenylketonuria (PKU). Information for teachers, administrators and other school personnel. Bethesda (MD): National Inst. of Child Health and Human Development (US); 1991 Nov. Report No.: NIH-92-3318. Available from: ERIC, Springfield, VA; ED402717.
- Eggers C, Bickel H. [Pre-, peri- and postnatal causes of mental retardation]. *Ergeb Inn Med Kinderheilkd* 1974;34(0):155-205. (Ger).
- Eisensmith RC, Woo SL. Gene therapy for phenylketonuria. *Acta Paediatr Suppl* 1994 Dec;407:124-9.
- Eisensmith RC, Woo SL. Gene therapy for phenylketonuria. *Eur J Pediatr* 1996 Jul;155 Suppl 1:S16-9.
- Eisensmith RC, Woo SL. Molecular basis of phenylketonuria and related hyperphenylalaninemia: mutations and polymorphisms in the human phenylalanine hydroxylase gene. *Hum Mutat* 1992;1(1):13-23.
- Eisensmith RC, Woo SL. Molecular genetics of phenylketonuria: from molecular anthropology to gene therapy. *Adv Genet* 1995;32:199-271.
- Eisensmith RC, Woo SL. Phenylketonuria and the phenylalanine hydroxylase gene. *Mol Biol Med* 1991 Feb;8(1):3-18.
- Eisensmith RC, Woo SL. Population genetics of phenylketonuria. *Acta Paediatr Suppl* 1994 Dec;407:19-26.
- Eisensmith RC, Woo SL. Somatic gene therapy for phenylketonuria and other hepatic deficiencies. *J Inher Metab Dis* 1996;19(4):412-23.
- Elliman D, Garner J. Review of neonatal screening programme for phenylketonuria [letter]. *BMJ* 1991 Aug 24;303(6800):471. Comment on: *BMJ* 1991 Aug 10;303(6798):333-5; *BMJ* 1991 Sep 21;303(6804):716.
- Endo F. [Inborn errors of tyrosine metabolism: abnormalities in catabolic pathway of phenylalanine and tyrosine]. *Seikagaku* 1999 Nov;71(11):1327-31. (Jpn).
- Endres W. Diet in phenylketonuria: how long? Policies under discussion. *Ann Nutr Metab* 1998;42(2):63-7.
- Endres W. [Differential diagnosis and therapy of various forms of hyperphenylalaninemia: facts and fiction]. *Wien Klin Wochenschr* 1992;104(16):503-9. (Ger).
- Endres W. [Phenylketonuria and its treatment in and beyond adolescence]. *Internist (Berl)* 1994 Mar;35(3):250-4. (Ger).
- Erlandsen H, Fusetti F, Martinez A, Hough E, Flatmark T, Stevens RC. Crystal structure of the catalytic domain of human phenylalanine hydroxylase reveals the structural basis for phenylketonuria [letter]. *Nat Struct Biol* 1997 Dec;4(12):995-1000.
- Erlandsen H, Stevens RC. The structural basis of phenylketonuria. *Mol Genet Metab* 1999 Oct;68(2):103-25.
- Estrov Y, Scaglia F, Bodamer OA. Psychiatric symptoms of inherited metabolic disease. *J Inher Metab Dis* 2000 Feb;23(1):2-6.
- Ferencz C, Boughman JA. Congenital heart disease in adolescents and adults. *Teratology, genetics, and recurrence risks. Cardiol Clin* 1993 Nov;11(4):557-67.
- Fernstrom JD. Role of precursor availability in control of monoamine biosynthesis in brain. *Physiol Rev* 1983 Apr;63(2):484-546.
- Finley WH. Genetic screening: an overview. *Ala J Med Sci* 1982 Apr;19(2):147-50.
- Fisch RO, Burke B, Bass J, Ferrara TB, Matri A. Maternal phenylketonuria-chronology of the detrimental effects on embryogenesis and fetal development: pathological report, survey, clinical application. *Pediatr Pathol* 1986;5(3-4):449-61.
- Fisch RO, Tagatz G, Stassart JP. Gestational carrier--a reproductive haven for offspring of mothers with phenylketonuria (PKU): an alternative therapy for

- maternal PKU. *J Inherit Metab Dis* 1993;16(6):957-61.
- Fitzpatrick PF. The aromatic amino acid hydroxylases. *Adv Enzymol Relat Areas Mol Biol* 2000;74:235-94.
- Fletcher JC. Ethical issues in genetic screening and antenatal diagnosis. *Clin Obstet Gynecol* 1981 Dec;24(4):1151-68.
- Franz M. Is it safe to consume aspartame during pregnancy? A review. *Nutrition update. Diabetes Educ* 1986 Spring;12(2):145-7.
- Freitas TN. Fenilcetonuria e hipotireoidismo congenito: diagnostico precoce e prevencao da deficiencia mental. Brazil: Universidade Federal Fluminense; 1990. 118 p. (Por).
- Frezal J, Farriaux JP. [Phenylketonuria yesterday and today. Evaluation of the work of systematic neonatal screening]. *Rev Prat* 1992 Nov 15;42(18):2316-26. (Fre).
- Fujii K. [Inherited metabolic disorders of children, with special reference to phenylketonuria]. Tokyo: Ishiyaku Shuppan Kabushiki Kaisha; [1980]. 163 p. (Jpn).
- Gardiner RM. Transport of amino acids across the blood-brain barrier: implications for treatment of maternal phenylketonuria. *J Inherit Metab Dis* 1990;13(4):627-33.
- Garriga MM, Metcalfe DD. Aspartame intolerance. *Ann Allergy* 1988 Dec;61(6 Pt 2):63-9.
- Giltay JC, van Hoef AM, de Weger R, Duran M, Berger R, Beemer FA. [Molecular genetic aspects of phenylketonuria (PKU)]. *Tijdschr Kindergeneeskd* 1991 Jun;59(3):77-80. (Dut).
- Giovannini M, Biasucci G, Agostoni C, Luotti D, Riva E. Lipid status and fatty acid metabolism in phenylketonuria. *J Inherit Metab Dis* 1995;18(3):265-72.
- Giovannini M, Biasucci G, Luotti D, Fiori L, Riva E. Nutrition in children affected by inherited metabolic diseases. *Ann Ist Super Sanita* 1995;31(4):489-502.
- Gjedde A, Crone C. Biochemical modulation of blood-brain barrier permeability. *Acta Neuropathol Suppl (Berl)* 1983;8:59-74.
- Goldman JM, Laws SC, Balchak SK, Cooper RL, Kavlock RJ. Endocrine-disrupting chemicals: Prepubertal exposures and effects on sexual maturation and thyroid activity in the female rat. A focus on the EDSTAC recommendations. *Crit Rev Toxicol* 2000;30(2):135-96.
- Grasso AW, Wu GY. Therapeutic implications of delivery and expression of foreign genes in hepatocytes. *Adv Pharmacol* 1994;28:169-92.
- Green A. Neonatal screening: current trends and quality control in the United Kingdom. *Rinsho Byori* 1998 Mar;46(3):211-6.
- Guldberg P, Guttler F. Mutations in the phenylalanine hydroxylase gene: methods for their characterization. *Acta Paediatr Suppl* 1994 Dec;407:27-33.
- Guttler F. Hyperphenylalaninemia: diagnosis and classification of the various types of phenylalanine hydroxylase deficiency in childhood. *Acta Paediatr Scand Suppl* 1980;280:1-80.
- Guttler F. Phenylketonuria: 50 years since Folling's discovery and still expanding our clinical and biochemical knowledge. *Acta Paediatr Scand* 1984 Nov;73(6):705-16.
- Guttler F, Guldberg P. The influence of mutations of enzyme activity and phenylalanine tolerance in phenylalanine hydroxylase deficiency. *Eur J Pediatr* 1996 Jul;155 Suppl 1:S6-10.
- Guttler F, Guldberg P. Mutations in the phenylalanine hydroxylase gene: genetic determinants for the phenotypic variability of hyperphenylalaninemia. *Acta Paediatr Suppl* 1994 Dec;407:49-56.
- Hall DM, Stewart-Brown S. Screening in child health. *Br Med Bull* 1998;54(4):929-43.
- Hanley WB, Clarke JT, Schoonheydt W. Maternal phenylketonuria (PKU)--a review. *Clin Biochem* 1987 Jun;20(3):149-56.
- Hanley WB, Clarke JT, Schoonheydt WE. Undiagnosed phenylketonuria in adult women: a hidden public health problem. *CMAJ* 1990 Sep 15;143(6):513-6.
- Hanley WB, Platt LD, Bachman RP, Buist N, Geraghty MT, Isaacs J, O'Flynn ME, Rhead WJ, Seidlitz G, Tishler B. Undiagnosed maternal phenylketonuria: the need for prenatal selective screening or case finding. *Am J Obstet Gynecol* 1999 Apr;180(4):986-94.
- Harper AE. Some recent developments in the study of amino acid metabolism. *Proc Nutr Soc* 1983 Sep;42(3):437-49.
- Hayden MR, Nichols JL. Molecular genetic approaches to the study of the nervous system. *Dev Neurosci* 1983-84;6(4-5):189-214.
- Holt KS. Diets and development. *Child Care Health Dev* 1982 Jul-Aug;8(4):183-201.

- Holtzman NA. The diffusion of new genetic tests for predicting disease. *FASEB J* 1992 Jul;6(10):2806-12.
- Hommes FA. On the mechanism of permanent brain dysfunction in hyperphenylalaninemia. *Biochem Med Metab Biol* 1991 Dec;46(3):277-87.
- Hommes FA. The role of the blood-brain barrier in the aetiology of permanent brain dysfunction in hyperphenylalaninaemia. *J Inherit Metab Dis* 1989;12(1):41-6.
- Horwitz DL, Bauer-Nehrling JK. Can aspartame meet our expectations? *J Am Diet Assoc* 1983 Aug;83(2):142-6.
- Howell RR, Stevenson RE. The offspring of phenylketonuric women. *Soc Biol* 1971 Sep;18:S19-29.
- Hufton SE, Jennings IG, Cotton RG. Structure and function of the aromatic amino acid hydroxylases. *Biochem J* 1995 Oct 15;311 (Pt 2):353-66.
- Hyanek J, Kubik M, Simkova M, Zeman J, Houst'kova H. [Phenylketonuria undiagnosed, unrecognizable and neglected. Review of failures in diagnosis, therapy, and prevention of hereditary disorders of phenylalanine]. *Cesk Pediatr* 1987 Mar;42(3):134-8. (Cze).
- Hyland K. Presentation, diagnosis, and treatment of the disorders of monoamine neurotransmitter metabolism. *Semin Perinatol* 1999 Apr;23(2):194-203.
- Imura K, Okada A. Amino acid metabolism in pediatric patients. *Nutrition* 1998 Jan;14(1):143-8.
- Ionescu S. [Psychophysiology of mental deficiency: evaluation of studies involving the recording of autonomic indices]. *Psychiatr Infant* 1985;28(1):39-134. (Fre).
- Irons M. Screening for metabolic disorders. How are we doing? *Pediatr Clin North Am* 1993 Oct;40(5):1073-85.
- Irons M, Levy HL. Metabolic syndromes with dermatologic manifestations. *Clin Rev Allergy* 1986 Feb;4(1):101-24.
- Janssen PJ, van der Heijden CA. Aspartame: review of recent experimental and observational data. *Toxicology* 1988 Jun;50(1):1-26.
- Jaruzelska J, Slomski R. [Molecular basis of phenylketonuria]. *Postepy Biochem* 1990;36(3-4):24-31. (Pol).
- Jimenez Soto Z. [Methodology of care for children with phenylketonuria and maple-syrup urine disease]. *Arch Latinoam Nutr* 1993 Sep;43(3):204-10. (Spa).
- Johnston MV, Singer HS. Brain neurotransmitters and neuromodulators in pediatrics. *Pediatrics* 1982 Jul;70(1):57-68.
- Kalter H, Warkany J. Medical progress. Congenital malformations: etiologic factors and their role in prevention (first of two parts). *N Engl J Med* 1983 Feb 24;308(8):424-31.
- Kaufman S. Biopterin-responsive hyperphenylalaninemia. *J Nutr Sci Vitaminol (Tokyo)* 1992;Spec No:601-6.
- Kaufman S. Classical phenylketonuria and its variants caused by defects in biopterin metabolism. *UCLA Symp Mol Cell Biol* 1987;55:517-38.
- Kaufman S. Enzymology of the phenylalanine-hydroxylating system. *Enzyme* 1987;38(1-4):286-95.
- Kaufman S. An evaluation of the possible neurotoxicity of metabolites of phenylalanine. *J Pediatr* 1989 May;114(5):895-900. Comment in: *J Pediatr* 1990 Apr;116(4):665-6.
- Kaufman S. New tetrahydrobiopterin-dependent systems. *Annu Rev Nutr* 1993;13:261-86.
- Kaufman S. Novel aspects of metabolism and function of tetrahydrobiopterin. *J Nutr Sci Vitaminol (Tokyo)* 1992;Spec No:492-6.
- Kaufman S. The phenylalanine hydroxylating system. *Adv Enzymol Relat Areas Mol Biol* 1993;67:77-264.
- Kaufman S. Phenylketonuria and its variants. *Adv Hum Genet* 1983;13:217-97.
- Kaufman S. Regulation of the activity of hepatic phenylalanine hydroxylase. *Adv Enzyme Regul* 1986;25:37-64.
- Kaufman S. Tetrahydrobiopterin: basic biochemistry and role in human disease. Baltimore (MD): Johns Hopkins University Press; 1997. Phenylketonuria and its variants; p. 262-322.
- Kaufman S, editor. Amino acids in health and disease: new perspectives. Proceedings of a Searle-UCLA symposium; 1986 May 30-Jun 4; Keystone, Colorado. New York: Liss; 1987. 619 p. (UCLA symposium on molecular and cellular biology; new series vol. 55).
- Kidd VJ, Woo SL. Recombinant DNA probes used to detect genetic disorders of the liver. *Hepatology* 1984 Jul-Aug;4(4):731-6.
- Kirby ML, Miyagawa ST. The effects of high phenylalanine concentration on chick embryonic development. *J Inherit Metab Dis* 1990;13(4):634-40.

- Kirby RB. Maternal phenylketonuria: a new cause for concern. *J Obstet Gynecol Neonatal Nurs* 1999 May-Jun;28(3):227-34.
- Klein D, Marcoz JP, Mounoud RL, Bettschart W. [Final result of a clinical, genetic and cytogenetic investigation of 182 mentally retarded patients of a medico-educative institution]. *Schweiz Rundsch Med Prax* 1982 Jul 27;71(30):1209-21. (Fre).
- Koch R, Acosta PB, Williams JC. Nutritional therapy for pregnant women with a metabolic disorder. *Clin Perinatol* 1995 Mar;22(1):1-14.
- Koch R, de la Cruz F. Historical aspects and overview of research on phenylketonuria. *Ment Retard Dev Disabil Res Rev* 1999;5(2):101-3.
- Koch R, Wenz E. Phenylketonuria. *Annu Rev Nutr* 1987;7:117-35.
- Kolodny EH, Cable WJ. Inborn errors of metabolism. *Ann Neurol* 1982 Mar;11(3):221-32.
- Konecki DS, Lichter-Konecki U. The phenylketonuria locus: current knowledge about alleles and mutations of the phenylalanine hydroxylase gene in various populations. *Hum Genet* 1991 Aug;87(4):377-88.
- Korson MS. Advances in newborn screening for metabolic disorders: What the pediatrician needs to know. *Pediatr Ann* 2000;29(5):294-301.
- Kostiuk PG, Martyniuk AE. [Possible molecular mechanisms of brain dysfunction in phenylketonuria]. *Patol Fiziol Eksp Ter* 1992 Jul-Aug;(4):34-6. (Rus).
- Krywawych S, Haseler M, Brenton DP. Theoretical and practical aspects of preventing fetal damage in women with phenylketonuria. *Nestle Nutr Workshop Ser* 1991;24:125-35.
- Kudo Y, Boyd CA. Transport of amino acids by the human placenta: predicted effects thereon of maternal hyperphenylalaninaemia. *J Inherit Metab Dis* 1990;13(4):617-26.
- Kurth E. Research in mental retardation in the German Democratic Republic (GDR). *Appl Res Ment Retard* 1984;5(3):361-73.
- Laberge C, Ferreira P, Grenier A, Laframboise R, Morissette J. [Hyperphenylalaninemia. The Canadian and Quebec experience]. *Arch Fr Pediatr* 1987;44 Suppl 1:643-7. (Fre).
- Labrune P, Lyonnet S. [Correlations between genotype and phenotype in children with phenylketonuria?]. *Arch Fr Pediatr* 1991 May;48(5):369-70. (Fre).
- Laing S. Special feeds for special infants: 1. The baby with a metabolic or allergic disorder. *Prof Care Mother Child* 1995;5(5):123, 126-7.
- Lajtha A, Reilly MA, Dunlop DS. Aspartame consumption: lack of effects on neural function. *J Nutr Biochem* 1994 Jun;5(6):266-83.
- Lappe M. The limits of genetic inquiry. *Hastings Cent Rep* 1987 Aug;17(4):5-10.
- Larsson BA, Norstmo A, Guthenberg C, Olsson GL, Danielsson P, Hagenfeldt L, Elander G, Larsson A. [The routine sampling procedure for PKU should be changed. Venous puncture is less painful than heel lancing]. *Lakartidningen* 1997 Dec 3;94(49):4625-8. (Swe).
- Ledley FD. Clinical application of genotypic diagnosis for phenylketonuria: theoretical considerations. *Eur J Pediatr* 1991 Sep;150(11):752-6.
- Lee EB. Metabolic diseases and the skin. *Pediatr Clin North Am* 1983 Aug;30(4):597-608.
- Lee KS, Perlman M. The impact of early obstetric discharge on newborn health care. *Curr Opin Pediatr* 1996 Apr;8(2):96-101.
- Leeming RJ. The role of tetrahydrobiopterin in neurological disease: a review. *J Ment Defic Res* 1981 Dec;25 Pt 4:231-41.
- Legrays VA. A practicum in clinical laboratory of selected genetic and diseases [dissertation]. Washington: The Catholic University of America; 1982. 225 p.
- Lehmann WD. Progress in the identification of the heterozygote in phenylketonuria. *J Pediatr* 1989 Jun;114(6):915-24.
- Levine RA. Tetrahydrobiopterin and biogenic amine metabolism in neuropsychiatry, immunology, and aging. *Ann N Y Acad Sci* 1988;521:129-39.
- Levy HL. Genetic screening. *Adv Hum Genet* 1973;4:1-104.
- Levy HL. Maternal phenylketonuria. *Prog Clin Biol Res* 1988;281:227-42.
- Levy HL. Maternal phenylketonuria. Review with emphasis on pathogenesis. *Enzyme* 1987;38(1-4):312-20.
- Levy HL. Molecular genetics of phenylketonuria and its implications. *Am J Hum Genet* 1989 Nov;45(5):667-70.

- Levy HL. Neonatal screening for inborn errors of amino acid metabolism. *Clin Endocrinol Metab* 1974 Mar;3(1):153-66.
- Levy HL. Nutritional therapy for selected inborn errors of metabolism. *J Am Coll Nutr* 1989;8 Suppl:54S-60S.
- Levy HL. Phenylketonuria--1986. *Pediatr Rev* 1986 Mar;7(9):269-75.
- Levy HL. Phenylketonuria: old disease, new approach to treatment. *Proc Natl Acad Sci U S A* 1999 Mar 2;96(5):1811-3. Comment on: *Proc Natl Acad Sci U S A* 1999 Mar 2;96(5):2339-44.
- Levy HL. Reproductive effects of maternal metabolic disorders: implications for pediatrics and obstetrics. *Turk J Pediatr* 1996 Jul-Sep;38(3):335-44.
- Levy HL, Ghavami M. Maternal phenylketonuria: a metabolic teratogen. *Teratology* 1996 Mar;53(3):176-84.
- Levy HL, Waisbren SE. PKU in adolescents: rationale and psychosocial factors in diet continuation. *Acta Paediatr Suppl* 1994 Dec;407:92-7.
- Liebl B, Fingerhut R, Roschinger W, Muntau A, Knerr I, Olgemoller B, Zapf A, Roscher AA. [Model project for updating neonatal screening in Bavaria: concept and initial results]. *Gesundheitswesen* 2000 Apr;62(4):189-95. (Ger).
- Lord J, Thomason MJ, Littlejohns P, Chalmers RA, Bain MD, Addison GM, Wilcox AH, Seymour CA. Secondary analysis of economic data: a review of cost-benefit studies of neonatal screening for phenylketonuria. *J Epidemiol Community Health* 1999 Mar;53(3):179-86.
- Lou HC. Dopamine precursors and brain function in phenylalanine hydroxylase deficiency. *Acta Paediatr Suppl* 1994 Dec;407:86-8.
- Lowe JB. Clinical applications of gene probes in human genetic disease, malignancy, and infectious disease. *Clin Chim Acta* 1986 May 30;157(1):1-32.
- Lowitzer AC. Maternal phenylketonuria: cause for concern among women with PKU. *Res Dev Disabil* 1987;8(1):1-14.
- Luke B. Maternal-fetal nutrition. *Clin Obstet Gynecol* 1994 Mar;37(1):93-109.
- Luke B, Keith LG. The challenge of maternal phenylketonuria screening and treatment. *J Reprod Med* 1990 Jul;35(7):667-73.
- Mabry CC. Phenylketonuria: contemporary screening and diagnosis. *Ann Clin Lab Sci* 1990 Nov-Dec;20(6):393-7.
- Mahowald MB. A feminist standpoint for genetics. *J Clin Ethics* 1996 Winter;7(4):333-40.
- Mamunes P. Neonatal screening tests. *Pediatr Clin North Am* 1980 Nov;27(4):733-51.
- Matalon R, Michals K. Phenylketonuria: screening, treatment and maternal PKU. *Clin Biochem* 1991 Aug;24(4):337-42.
- Matalon R, Michals K, Blau N, Rouse B. Hyperphenylalaninemia due to inherited deficiencies of tetrahydrobiopterin. *Adv Pediatr* 1989;36:67-89.
- Matsuda I. [Inborn error of amino acids metabolism--general aspect]. *Ryoikibetsu Shokogun Shirizu* 1998;(18 Pt 1):109-13. (Jpn).
- Matsuo N. Hyperphenylalaninemia syndromes: current status of diagnosis and management. *Keio J Med* 1988 Mar;37(1):1-9.
- Matsuoka A. [The course of the past twenty years of mass-screening for congenital metabolic disorders: racial difference in PKU genotypes]. *Rinsho Byori* 1998 Mar;46(3):199-202. (Jpn).
- Meaney FJ. Computerized tracking for newborn screening and follow-up: a review. *J Med Syst* 1988 Apr;12(2):69-75.
- Medical Research Council Working Party on Phenylketonuria. Phenylketonuria due to phenylalanine hydroxylase deficiency: an unfolding story. *BMJ* 1993 Jan 9;306(6870):115-9.
- Mellgren SI, Gotestam KG. Research on mental retardation in Norway 1970-1980: a review. *Appl Res Ment Retard* 1983;4(2):103-12.
- Michels VV. Phenylketonuria and hyperphenylalaninemia. In: Gomez MR, editor. *Neurocutaneous diseases: a practical approach*. Stoneham (UK): Butterworths; 1987. p. 155-70.
- Muntau AC, Beblo S, Koletzko B. [Phenylketonuria and hyperphenylalaninemia]. *Monatsschr Kinderheilkd* 2000;148(2):179-93. (Ger).
- Nagao M. [Molecular pathology and DNA diagnosis of phenylketonuria and hypermethioninemia]. *Tanpakushitsu Kakusan Koso* 1998 May;43(6):762-9. (Jpn).
- Nagatsu T, Ichinose H. Regulation of pteridine-requiring enzymes by the cofactor tetrahydrobiopterin. *Mol Neurobiol* 1999 Feb;19(1):79-96.

- Nagatsu T, Matsuura S, Sugimoto T. Physiological and clinical chemistry of biopterin. *Med Res Rev* 1989 Jan-Mar;9(1):25-44.
- Naidu S, Moser HW. Value of neuroimaging in metabolic diseases affecting the CNS. *AJNR Am J Neuroradiol* 1991 May-Jun;12(3):413-6. Comment on: *AJNR Am J Neuroradiol* 1991 May-Jun;12(3):403-6; *AJNR Am J Neuroradiol* 1991 May-Jun;12(3):407-9; *AJNR Am J Neuroradiol* 1991 May-Jun;12(3):410-2.
- Nakazato M, Ohi T, Matsukura S. [Trend in molecular biochemical studies on neurological disorders]. *Nippon Rinsho* 1989 Jan;47(1):227-38. (Jpn).
- National Center for Education in Maternal and Child Health (US). Proceedings of the Tri-Regional Conference on Completed Maternal and Child Health Research, Translating MCH Research Findings into Health Care Applications: A Challenge; 1988. Rockville (MD): The Center; 1989 Sep. 268 p. Report No.: NCEMCH-C071. Available from: NTIS, Springfield, VA; PB90-114356.
- Nichol CA, Smith GK, Duch DS. Biosynthesis and metabolism of tetrahydrobiopterin and molybdopterin. *Annu Rev Biochem* 1985;54:729-64.
- Niederwieser A, Curtius HC. [Detection, differential diagnosis, and prenatal diagnosis of tetrahydrobiopterin deficiency]. *Arch Fr Pediatr* 1987;44 Suppl 1:661-4. (Fre).
- Niederwieser A, Curtius HC. Tetrahydrobiopterin biosynthetic pathway and deficiency. *Enzyme* 1987;38(1-4):302-11.
- Nielsen KB. [Dietary treatment of women with Folling's disease. A review of current experiences and future perspectives]. *Ugeskr Laeger* 1985 Jan 21;147(4):246-9. (Dan).
- Nyhan WL. Understanding inherited metabolic disease. *Clin Symp* 1980;32(5):1-36.
- O'Tuama LA, Treves ST. Brain single-photon emission computed tomography for behavior disorders in children. *Semin Nucl Med* 1993 Jul;23(3):255-64.
- Owada M. [Maternal phenylketonuria]. *Ryoikibetsu Shokogun Shirizu* 1998;(18 Pt 1):119-23. (Jpn).
- Owada M. [Phenylketonuria (phenylalanine hydroxylase deficiency)]. *Ryoikibetsu Shokogun Shirizu* 1998;(18 Pt 1):114-8. (Jpn).
- Pardridge WM. Potential effects of the dipeptide sweetener aspartame on the brain. *Nutr Brain* 1986;7:199-241.
- Pardridge WM, Choi TB. Neutral amino acid transport at the human blood-brain barrier. *Fed Proc* 1986 Jun;45(7):2073-8.
- Patterson RE, Eaton DL, Potter JD. The genetic revolution: change and challenge for the dietetics profession. *J Am Diet Assoc* 1999 Nov;99(11):1412-20.
- Pennington BF. Genetics of learning disabilities. *J Child Neurol* 1995 Jan;10 Suppl 1:S69-77.
- Pennington BF, Smith SD. Genetic influences on learning disabilities and speech and language disorders. *Child Dev* 1983 Apr;54(2):369-87.
- Penrose LS. Phenylketonuria--a problem in eugenics. *Ann Hum Genet* 1998 May;62 (Pt 3):193-202.
- Phenylketonuria--Past, Present, Future. Proceedings of a symposium. Elsinore, Denmark, May 23-25, 1994. *Acta Paediatr Suppl* 1994 Dec;407:1-129.
- Phenylketonuria (PKU). Arlington (TX): Arc; 1997. Contract No.: DE-FG03-96ER62162. Sponsored by US Department of Energy, Washington, DC. (ARC Q&A; no. 101-53).
- Pietz J. Neurological aspects of adult phenylketonuria. *Curr Opin Neurol* 1998 Dec;11(6):679-88.
- Pitt DB, O'Day J. Phenylketonuria does not cause cataracts. *Eur J Pediatr* 1991 Jul;150(9):661-4.
- Pittard J. The various strategies within the TyrR regulation of *Escherichia coli* to modulate gene expression. *Genes Cells* 1996 Aug;1(8):717-25.
- Pogson CI, Knowles RG, Salter M. The control of aromatic amino acid catabolism and its relationship to neurotransmitter amine synthesis. *Crit Rev Neurobiol* 1989;5(1):29-64.
- Porter IH. Control of hereditary disorders. *Annu Rev Public Health* 1982;3:277-319.
- Potocnik U, Widhalm K. Long-term follow-up of children with classical phenylketonuria after diet discontinuation: a review. *J Am Coll Nutr* 1994 Jun;13(3):232-6.
- Poustie VJ, Rutherford P. Dietary interventions for phenylketonuria. *Cochrane Database Syst Rev* 2000;(2):CD001304.
- Poustie VJ, Rutherford P. Tyrosine supplementation for phenylketonuria. *Cochrane Database Syst Rev* 2000;(2):CD001507.
- Pueschel SM. Central nervous system effects in individuals with phenylketonuria. *Dev Brain Dysfunc* 1996 Jul-Aug;9(4):165-79.

- Raper SE, Wilson JM. Cell transplantation in liver-directed gene therapy. *Cell Transplant* 1993 Sep-Oct;2(5):381-400; discussion 407-10. Comment in: *Cell Transplant* 1993 Sep-Oct;2(5):401-3; *Cell Transplant* 1993 Sep-Oct;2(5):405-6.
- Ratzmann GW, Grimm U, Jahrig K, Knapp A. [Plasma-cerebrospinal fluid distribution of phenylalanine and tyrosine in children]. *Padiatr Grenzgeb* 1988;27(3):211-20. (Ger).
- Regulation of aromatic amino acid catabolism. *Nutr Rev* 1986 Nov;44(11):377-9.
- Reiss MJ. The ethics of genetic research on intelligence. *Bioethics* 2000;14(1):1-15.
- Rey F, Munnich A, Lyonnet S, Rey J. [Classification and heterogeneity of hyperphenylalaninemias linked to a phenylalanine hydroxylase deficiency]. *Arch Fr Padiatr* 1987;44 Suppl 1:639-42. (Fre).
- Rey F, Rey J. [Catalog of mutations of the phenylalanine hydroxylase gene]. *Arch Fr Padiatr* 1992 Jan;49(1):63-5. (Fre).
- Rey J, Rey F. [What can we expect from identification of mutations of the phenylalanine hydroxylase gene? (editorial)]. *Arch Fr Padiatr* 1992 Jan;49(1):1-3. (Fre).
- Rogowiecka E, Sendek E, Chazan B, Cabalska B, Bankowska E. [Maternal PKU syndrome as an obstetric problem: literature review and own clinical experience]. *Ginekol Pol* 1998 Dec;69(12):1007-15. (Pol).
- Rossiter JP, Johnson TR. Management of genetic disorders during pregnancy. *Obstet Gynecol Clin North Am* 1992 Dec;19(4):801-13.
- Rozenfel'd EL. [Models of enzymopathies and their role in elaborating methods of enzyme therapy (review)]. *Vopr Med Khim* 1981 Jan-Feb;27(1):7-18. (Rus).
- Runge DM, Runge D. [Somatic gene therapy. Initial clinical applications and current research approach]. *Fortschr Med* 1995 Aug 30;113(24):337-40. Comment in: *Fortschr Med* 1995 Aug 30;113(24):341. (Ger).
- Sadler TW, Denno KM, Hunter ES 3d. Effects of altered maternal metabolism during gastrulation and neurulation stages of embryogenesis. *Ann N Y Acad Sci* 1993 Mar 15;678:48-61.
- Sanjurjo Crespo P. [Diet therapy of phenylketonuria. Current aspects]. *An Esp Padiatr* 1991 Oct;35(4):259-61. (Spa).
- Schallreuter KU. A review of recent advances on the regulation of pigmentation in the human epidermis. *Cell Mol Biol (Noisy-le-grand)* 1999 Nov;45(7):943-9.
- Scheffler RM, Paringer L. A review of the economic evidence on prevention. *Med Care* 1980 May;18(5):473-84.
- Schmidt H, Bickel H. [Phenylketonuria]. *Internist (Berl)* 1976 Jul;17(7):354-61. (Ger).
- Schuett VE, Yandow JL, Pringle DJ. Screening & treatment of PKU [slide]. Carrboro (NC): Health Sciences Consortium; 1986. 131 slides: color; 1 audiocassette: 38 min., 1 7/8 ips. Accompanied by: 1 guide.
- Schulman JD. Treatment of the embryo and the fetus in the first trimester: current status and future prospects. *Am J Med Genet* 1990 Feb;35(2):197-200.
- Schweitzer LB, Desnick RJ. Inherited metabolic diseases: advances in delineation, diagnosis, and treatment. *Birth Defects Orig Artic Ser* 1983;19(5):39-71.
- Scriver CR. Mutants: consumers with special needs. *Nutr Rev* 1971 Jul;29(7):155-8.
- Scriver CR. Science, medicine and phenylketonuria. *Acta Paediatr Suppl* 1994 Dec;407:11-8.
- Scriver CR, Byck S, Prevost L, Hoang L. The phenylalanine hydroxylase locus: a marker for the history of phenylketonuria and human genetic diversity. *PAH Mutation Analysis Consortium. Ciba Found Symp* 1996;197:73-90; discussion 90-6.
- Scriver CR, Clow CL. Avoiding phenylketonuria: why parents seek prenatal diagnosis. *J Padiatr* 1988 Sep;113(3):495-7.
- Scriver CR, Clow CL. Phenylketonuria and other phenylalanine hydroxylation mutants in man. *Annu Rev Genet* 1980;14:179-202.
- Scriver CR, Clow CL. Phenylketonuria: epitome of human biochemical genetics (first of two parts). *N Engl J Med* 1980 Dec 4;303(23):1336-42.
- Scriver CR, Eisensmith RC, Woo SL, Kaufman S. The hyperphenylalaninemias of man and mouse. *Annu Rev Genet* 1994;28:141-65.
- Scriver CR, Kaufman S, Eisensmith RC, Woo SL. The hyperphenylalaninemias. In: Scriver CR, Beaudet AL, Sly WS, Valle D, editors. *The metabolic and molecular bases of inherited disease*. 7th ed. Vol. 1. New York: McGraw-Hill, Inc.; c1995. p. 1015-75.
- Scriver CR, Kaufman S, Woo SL. Mendelian hyperphenylalaninemia. *Annu Rev Genet* 1988;22:301-21.

- Scriver CR, Waters PJ. Monogenic traits are not simple: lessons from phenylketonuria. *Trends Genet* 1999 Jul;15(7):267-72.
- Seashore MR. Neonatal screening for inborn errors of metabolism: update. *Semin Perinatol* 1990 Dec;14(6):431-8.
- Seim AR, Reichelt KL. An enzyme/brain-barrier theory of psychiatric pathogenesis: unifying observations on phenylketonuria, autism, schizophrenia and postpartum psychosis. *Med Hypotheses* 1995 Nov;45(5):498-502.
- Seymour CA, Thomason MJ, Chalmers RA, Addison GM, Bain MD, Cockburn F, Littlejohns P, Lord J, Wilcox AH. Newborn screening for inborn errors of metabolism: a systematic review. *Health Technol Assess* 1997;1(11):i-iv, 1-95.
- Shiman R. Phenylalanine hydroxylase and dihydropterin reductase. In: Blakley RL, Benkovic SJ, editors. *Folates and pterins*. Vol 2. New York: Wiley; c1984. p. 179-249.
- Shintaku H, Asada M, Isshiki G, Sawada Y. [Disorders of tetrahydrobiopterin homeostasis]. *Ryokibetsu Shokogun Shirizu* 1998;(18 Pt 1):125-9. (Jpn).
- Simonsen H, Brandt NJ, Norgaard-Pedersen B. [Neonatal screening in Denmark. Status and future perspectives]. *Ugeskr Laeger* 1998 Sep 28;160(40):5777-82. (Dan).
- Smith I. Treatment of phenylalanine hydroxylase deficiency. *Acta Paediatr Suppl* 1994 Dec;407:60-5.
- Smith I, Cook B, Beasley M. Review of neonatal screening programme for phenylketonuria. *BMJ* 1991 Aug 10;303(6798):333-5. Published erratum appears in *BMJ* 1991 Oct 5;303(6806):824. Comment in: *BMJ* 1991 Aug 24;303(6800):471; *BMJ* 1991 Sep 21;303(6804):716.
- Smith I, Howells DW, Hyland K. Pteridines and mono-amines: relevance to neurological damage. *Postgrad Med J* 1986 Feb;62(724):113-23.
- Sommer SS, Cassady JD, Sobell JL, Bottema CD. A novel method for detecting point mutations or polymorphisms and its application to population screening for carriers of phenylketonuria. *Mayo Clin Proc* 1989 Nov;64(11):1361-72.
- Start K. Treating phenylketonuria by a phenylalanine-free diet. *Prof Care Mother Child* 1998;8(4):109-10.
- Stegink LD. Aspartame: review of the safety issues. *Food Technol* 1987 Jan;41(1):119-21.
- Stein Z, Susser M. Effects of early nutrition on neurological and mental competence in human beings. *Psychol Med* 1985 Nov;15(4):717-26.
- Stern J. The biochemical approach to mental handicap: 30 years of achievements and disappointments. *J Ment Defic Res* 1987 Dec;31 (Pt 4):357-64.
- Sturtevant FM. Use of aspartame in pregnancy. *Int J Fertil* 1985;30(1):85-7.
- Sullivan JE, Chang P. Review: emotional and behavioral functioning in phenylketonuria. *J Pediatr Psychol* 1999 Jun;24(3):281-99.
- Tabolin VI, Deshchekina MF, Demin VF, Vnukova AI, Volodin NN. [Selenium metabolism in normal and pathologic states; its significance in pediatrics]. *Pediatriia* 1983 Nov;(11):76-8. (Rus).
- Tada K, Narisawa K. [Biogenic amines and hyperphenylalaninemia (author's transl)]. *Tanpakushitsu Kakusan Koso* 1981 Aug;26(11):1765-71. (Jpn).
- Takada G. [Brain function in inborn error of amino acid metabolism]. *Tanpakushitsu Kakusan Koso* 1984 Dec;29(14):1783-93. (Jpn).
- Tam SY, Roth RH. Mesoprefrontal dopaminergic neurons: can tyrosine availability influence their functions? *Biochem Pharmacol* 1997 Feb 21;53(4):441-53.
- Terdal LG. Children at risk: Two contrasting examples. In: Craig KD, Weiss SM, et al., editors. *Health enhancement, disease prevention, and early intervention: Biobehavioral perspectives*. New York: Springer; 1990. p. 94-113.
- Thalhammer O. [21 years Austrian Program for Early Detection of Congenital Metabolic Abnormalities. Did the screening programs also contribute scientific knowledge?]. *Wien Klin Wochenschr* 1988 Oct 7;100(19):641-5. (Ger).
- Theile H, Wasser S, Buhrdel P, Graustein I. [Results, problems and consequences of early treatment of phenylketonuria]. *Z Gesamte Inn Med* 1989 Jun 1;44(11):317-20. (Ger).
- Thomason MJ, Lord J, Bain MD, Chalmers RA, Littlejohns P, Addison GM, Wilcox AH, Seymour CA. A systematic review of evidence for the appropriateness of neonatal screening programmes for inborn errors of metabolism. *J Public Health Med* 1998 Sep;20(3):331-43.
- Thompson AJ. Phenylketonuria: An unfolding story. In: Robertson MM, Eapen V, et al., editors. *Movement and allied disorders in childhood*.

- Chichester (UK): John Wiley & Sons; 1995. p. 83-103.
- Thony B, Auerbach G, Blau N. Tetrahydrobiopterin biosynthesis, regeneration and functions. *Biochem J* 2000 Apr 1;347 Pt 1:1-16.
- Thony B, Blau N. Mutations in the GTP cyclohydrolase I and 6-pyruvoyl-tetrahydropterin synthase genes. *Hum Mutat* 1997;10(1):11-20.
- Touraine RL, Guibaud P. [Genetics and hyperphenylalaninemia in 1992]. *Pediatrie (Bucur)* 1992;47(1):9-21. Published erratum appears in *Pediatrie* 1992;47(4):331. (Fre).
- Tourian A. Phenylketonuria and hyperphenylalaninemia. In: Sidbury JB, editor. *The metabolic basis of inherited disease*. 5th ed. New York; McGraw-Hill. p. 270-86.
- Trefz FK, Lichter-Konecki U, Krawczak M, Schmidtke J, Dueck M, Nutzenadel W, Konecki DS. [DNA diagnosis of monogene hereditary diseases exemplified by phenylketonuria and mucoviscidosis]. *Monatsschr Kinderheilkd* 1989 Apr;137(4):201-7. (Ger).
- Tsukada Y, Takamatsu K. [Correlation between monoamine content in the brain and discriminative learning ability (author's transl)]. *Tanpakushitsu Kakusan Koso* 1981 Aug;26(11):1725-34. (Jpn).
- Tu JB. Theory and practice of psychopharmacogenetics. *Am J Med Genet* 1994 Dec 15;54(4):391-7.
- Tyfield LA. Phenylketonuria in Britain: genetic analysis gives a historical perspective of the disorder but will it predict the future for affected individuals? *Mol Pathol* 1997 Aug;50(4):169-74.
- Ullrich K, Moller H, Weglage J, Schuierer G, Bick U, Ludolph A, Hahn-Ullrich H, Funders B, Koch HG. White matter abnormalities in phenylketonuria: results of magnetic resonance measurements. *Acta Paediatr Suppl* 1994 Dec;407:78-82.
- United States Congress, Office of Technology Assessment. *Healthy children: investing in the future*. Washington: The Office; 1988 Feb. Available from: US Government Printing Office, Washington, DC; OTA-H-345.
- University of Colorado Health Sciences Center, Inherited Metabolic Diseases Clinic. *Living with PKU*. Denver (CO): The Clinic; c1984. 23 p.
- Vis HL, Elmer C, Goyens P, Roumat G. [Phenylketonuria: current status of the problem]. *Bull Mem Acad R Med Belg* 1988;143(3-4):231-47. (Fre).
- Vogel F. Clinical consequences of heterozygosity for autosomal-recessive diseases. *Clin Genet* 1984 May;25(5):381-415.
- Vorhees CV, Butcher RE, Berry HK. Progress in experimental phenylketonuria: a critical review. *Neurosci Biobehav Rev* 1981 Spring;5(1):177-90.
- Wachtel U. Review of current practices in management of inherited disorders of amino acid metabolism in Western Europe. *Hum Nutr Appl Nutr* 1986;40 Suppl 1:61-9.
- Waggoner WF. Aspartame--a review. *Pediatr Dent* 1984 Sep;6(3):153-8.
- Waisbren SE. Developmental and neuropsychological outcome in children born to mothers with phenylketonuria. *Ment Retard Dev Disabil Res Rev* 1999;5(2):125-31.
- Waisbren SE. Phenylketonuria. In: Goldstein S, Reynolds CR, et al., editors. *Handbook of neurodevelopmental and genetic disorders in children*. New York: The Guilford Press; 1999. p. 433-58.
- Waisbren SE, Brown MJ, de Sonneville LM, Levy HL. Review of neuropsychological functioning in treated phenylketonuria: an information processing approach. *Acta Paediatr Suppl* 1994 Dec;407:98-103.
- Waisbren SE, Schnell RR, Levy HL. Diet termination in children with phenylketonuria: a review of psychological assessments used to determine outcome. *J Inher Metab Dis* 1980;3(4):149-53.
- Walker JD, Crall JJ, McDonnell JE. Phenylketonuria and dentistry: review of the literature. *ASDC J Dent Child* 1982 Jul-Aug;49(4):280-4.
- Walter JH. Late effects of phenylketonuria. *Arch Dis Child* 1995 Dec;73(6):485-6.
- Wappner R, Cho S, Kronmal RA, Schuett V, Seashore MR. Management of phenylketonuria for optimal outcome: a review of guidelines for phenylketonuria management and a report of surveys of parents, patients, and clinic directors. *Pediatrics* 1999 Dec;104(6):e68.
- Waters PJ, Parniak MA, Nowacki P, Scriver CR. In vitro expression analysis of mutations in phenylalanine hydroxylase: linking genotype to phenotype and structure to function. *Hum Mutat* 1998;11(1):4-17.
- Wellner D, Meister A. A survey of inborn errors of amino acid metabolism and transport in man. *Annu Rev Biochem* 1981;50:911-68.
- Welsh M, Pennington B. Phenylketonuria. In: Yeates KO, Ris MS, Taylor HG, editors. *Pediatric*

neuropsychology: research, theory and practice. New York: Guilford Press; 2000. p. 275-99.

Welsh MC. A prefrontal dysfunction model of early-treated phenylketonuria. *Eur J Pediatr* 1996 Jul;155 Suppl 1:S87-9.

West R, Hale C. Overview of newborn screening in Arkansas. *J Ark Med Soc* 1995 Dec;92(7):329-33.

Whitehead RG. Nutritional requirements of healthy adolescents and their significance during the management of PKU. *Eur J Pediatr* 1987;146 Suppl 1:A25-31.

Why does phenylalanine do harm in PKU? *Nutr Rev* 1986 Oct;44(10):331-3.

Wolf ME, Mosnaim AD. Phenylethylamine in neuropsychiatric disorders. *Gen Pharmacol* 1983;14(4):385-90.

Woo SL. Molecular basis and population genetics of phenylketonuria. *Biochemistry* 1989 Jan 10;28(1):1-7.

Woo SL. Molecular genetic analysis of phenylketonuria and mental retardation. *Res Publ Assoc Res Nerv Ment Dis* 1991;69:193-203.

Wraith JE, Coutts J. Inborn errors of metabolism in children. In: Dickerson JW, Lee HA, editors. *Nutrition in the clinical management of disease*. 2nd ed. London: Edward Arnold; 1988. p. 69-87.

Wu JT. Screening for inborn errors of amino acid metabolism. *Ann Clin Lab Sci* 1991 Mar-Apr;21(2):123-42.

Yadav GC, Reavey PC. Aminoacidopathies: a review of 3 years experience of investigations in a Kuwait hospital. *J Inher Metab Dis* 1988;11(3):277-84.

Young SN, Palmour RM. Research on genes: promises and limitations. *J Psychiatry Neurosci* 1999 Sep;24(4):300-3.

Zachara B. [Selenium and glutathione peroxidase in the blood of children]. *Pol Tyg Lek* 1983 Jul 11-18;38(28-29):909-13. (Pol).

Ethics, Laws, and Policies

Adelman CS. The constitutionality of mandatory genetic screening statutes. *Case West Reserv Law Rev* 1981 Summer;31(4):897-948.

Andrews LB, editor. *Legal liability and quality assurance in newborn screening*. Chicago: American Bar Foundation; 1985. 242 p.

Annas GJ. Mandatory PKU screening: the other side of the looking glass. *Am J Public Health* 1982 Dec;72(12):1401-3.

Bamforth FJ. Laboratory screening for genetic disorders and birth defects. *Clin Biochem* 1994 Oct;27(5):333-42.

Beardsley T. Genetic diseases: problems of prenatal testing [news]. *Nature* 1985 Mar 21;314(6008):211.

Billings PR, Kohn MA, de Cuevas M, Beckwith J, Alper JS, Natowicz MR. Discrimination as a consequence of genetic testing. *Am J Hum Genet* 1992 Mar;50(3):476-82.

Blank RH. Public policy implications of human genetic technology: genetic screening. *J Med Philos* 1982 Nov;7(4):355-74.

Boyle PJ. Shaping priorities in genetic medicine. *Hastings Cent Rep* 1995 May-Jun;25(3 Suppl):S2-8.

Burt RA. Legal and ethical aspects of interventions. In: *Genetic variation and nutrition. Proceedings of the 1st International Conference on Genetic Variation and Nutrition*; 1989 Jun 22-23; Washington, DC. New York: Karger; c1990. p. 266-76.

Cloud HH. Feeding the special needs child: a new dimension for school food service. *Sch Food Serv Res Rev* 1992 Spring;16(1):47-51.

Culliton BJ. Genetic screening: NAS recommends proceeding with caution. *Science* 1975 Jul 11;189(4197):119-20.

Czartoryska B. [Prenatal diagnosis: a chance? risk? dilemma?]. *Postepy Biochem* 1990;36(3-4):31-3. (POL).

Dumars KW, Gawron TW, Pearce CL, Foster CA. Prevention of developmental disabilities: a model for organizing clinical activities. *Res Dev Disabil* 1987;8(4):507-20.

Dworkin RB. Common sense and common decency: some thoughts about maternal-fetal conflict. In: Humber JM, Almeder RF, editors. *Biomedical Ethics Reviews*, 1991. Bioethics and the fetus: medical,

- moral and legal issues. Totowa (NJ): Humana Press; 1991. p. 9-38.
- Ebomoyi E. Family planning needs in Nigeria [letter]. *World Health Forum* 1984;5(1):40-1.
- Eisenberg L. Child mental health in the Americas: a public health approach. *Bull Pan Am Health Organ* 1992;26(3):230-41.
- Eisenberg L. Prevention: rhetoric and reality. *J R Soc Med* 1984 Apr;77(4):268-80.
- Endres W. Diet in phenylketonuria: how long? Policies under discussion. *Ann Nutr Metab* 1998;42(2):63-7.
- Erbe RW. Issues in newborn genetic screening. *Birth Defects Orig Artic Ser* 1981;17(1):167-79.
- Faden R, Holtzman NA, Chwalow AJ, Horn S, Capron A. (School of Hygiene and Public Health, Johns Hopkins University, Baltimore, MD). Feasibility and effectiveness of obtaining consent for neonatal screening. Final report. 1977 Oct 1-1980 Jun 30. Rockville (MD): Bureau of Community Health Services (US); 1980 Sep. 250 p. Report No.: MCH/CCS-80/02. Available from: NTIS, Springfield, VA; PB81-162901.
- Faden RR, Chwalow AJ, Holtzman NA, Horn SD. A survey to evaluate parental consent as public policy for neonatal screening. *Am J Public Health* 1982 Dec;72(12):1347-52.
- Faden RR, Holtzman NA, Chwalow AJ. Parental rights, child welfare, and public health: the case of PKU screening. *Am J Public Health* 1982 Dec;72(12):1396-400.
- Farriaux JP. [Prenatal diagnosis of genetic diseases. Indications, methods, legal and ethic aspects. Neonatal screening of phenylketonuria and hypothyroidism]. *Rev Prat* 1997 Dec 1;47(19):2159-68. (Fre).
- Fletcher JC. Ethical issues in genetic screening and antenatal diagnosis. *Clin Obstet Gynecol* 1981 Dec;24(4):1151-68.
- Fletcher JC. Ethical issues in genetic screening, prenatal diagnosis, and counseling. In: Weil WB, Benjamin M, editors. *Ethical issues at the outset of life*. Boston: Blackwell Scientific Publications; 1987. p. 63-99.
- Fost N. Ethical implications of screening asymptomatic individuals. *FASEB J* 1992 Jul;6(10):2813-7.
- Fost N. Genetic diagnosis and treatment: ethical considerations. *Am J Dis Child* 1993 Nov;147(11):1190-5.
- Fost N. Introduction: ethics, ethics everywhere. *Curr Probl Pediatr* 1992 Nov-Dec;22(10):422-3. Comment on: *Curr Probl Pediatr* 1992 Nov-Dec;22(10):424-31; *Curr Probl Pediatr* 1992 Nov-Dec;22(10):432-51.
- Fost N. Maternal-fetal conflicts: Ethical and legal considerations. In: Hutchings DE, et al., editors. *Prenatal abuse of licit and illicit drugs*. New York: New York Academy of Sciences; 1989. p. 248-54. (*Annals of the New York Academy of Sciences*; vol. 562).
- Frezal J, Ogier H. [The administrative management of children with phenylketonuria]. *Arch Fr Pediatr* 1983;40 Suppl 1:269-71. (Fre).
- Friedman JM, Smith JP, Lerner BN, Helgeson JS, Howard-Peebles PN, Mize CE, Mize SG, Singleton WL, Smith ME. ReCAP: the Registry of Cytogenetic Abnormalities and Phenylketonuria. *Am J Med Genet* 1987 Jun;27(2):325-36.
- Goldman JM, Laws SC, Balchak SK, Cooper RL, Kavlock RJ. Endocrine-disrupting chemicals: Prepubertal exposures and effects on sexual maturation and thyroid activity in the female rat. A focus on the EDSTAC recommendations. *Crit Rev Toxicol* 2000;30(2):135-96.
- Hanley WB, Demshar H, Preston MA, Borczyk A, Schoonheydt WE, Clarke JT, Feigenbaum A. Newborn phenylketonuria (PKU) Guthrie (BIA) screening and early hospital discharge. *Early Hum Dev* 1997 Jan 3;47(1):87-96.
- Hard choices: genetic screening. Kent (OH): PTV Publications; 1981. 21 p. From a six-part television series on bioethics produced by KCTS/9, Seattle.
- Hepburn ER. Genetic testing and early diagnosis and intervention: boon or burden? *J Med Ethics* 1996 Apr;22(22):105-10.
- Hiller EH, Landenburger G, Natowicz MR. Public participation in medical policy-making and the status of consumer autonomy: the example of newborn-screening programs in the United States. *Am J Public Health* 1997 Aug;87(8):1280-8.
- Holtzman C, Slazyk WE, Cordero JF, Hannon WH. Descriptive epidemiology of missed cases of phenylketonuria and congenital hypothyroidism. *Pediatrics* 1986 Oct;78(4):553-8.
- Holtzman NA. Ethical issues in the prenatal diagnosis of phenylketonuria. *Pediatrics* 1984 Sep;74(3):424-7.
- Holtzman NA. What drives neonatal screening programs? [editorial]. *New Engl J Med* 1991 Sep 12;325(11):802-4.

- Hook EB. Muddling genetic discrimination [letter]. *Am J Hum Genet* 1992 Oct;51(4):899-901.
- Juengst ET. "Prevention" and the goals of genetic medicine. *Hum Gene Ther* 1995 Dec;6(12):1595-605.
- Kalaydjieva L, Kremensky I. Screening for phenylketonuria in a totalitarian state. *J Med Genet* 1992 Sep;29(9):656-8.
- Kelly TE. *Clinical genetics and genetic counseling*. Chicago: Year Book Medical Publishers; 1980. Genetic screening--eugenics--ethics; p. 262-77.
- Kesby G. Repeated adverse fetal outcome in pregnancy complicated by uncontrolled maternal phenylketonuria. *J Paediatr Child Health* 1999 Oct;35(5):499-502.
- Kirkman HN, Carroll CL, Moore EG, Matheson MS. Fifteen-year experience with screening for phenylketonuria with an automated fluorometric method. *Am J Hum Genet* 1982 Sep;34(5):743-52.
- Koch RK. Issues in newborn screening for phenylketonuria. *Am Fam Physician* 1999 Oct 1;60(5):1462-6.
- Lappe M. The limits of genetic inquiry. *Hastings Cent Rep* 1987 Aug;17(4):5-10.
- Laurence M, Harper PS, Harris R, Nevin NC, Roberts DF. Report of the delegation of clinical geneticists to China, Spring 1986. *Biol Soc* 1987 Jun;4(2):61-77.
- Ledley FD. Somatic gene therapy for human disease: a problem of eugenics? *Trends Genet* 1987 Apr;3(4):112-5.
- Levy HL. Problems in genetic screening which confront the law. In: Milunsky A, Annas GJ, editors. *Genetics and the law*. New York: Plenum Press; 1976. p. 133-8.
- Levy HL, Waisbren SE. PKU in adolescents: rationale and psychosocial factors in diet continuation. *Acta Paediatr Suppl* 1994 Dec;407:92-7.
- Lewis V, Krause S, Myers C. Public and private academic medical partnerships in improving nutritional management in phenylketonuria [letter]. *Am J Public Health* 1997 Aug;87(8):1379.
- Lowitzer AC. Maternal phenylketonuria: cause for concern among women with PKU. *Res Dev Disabil* 1987;8(1):1-14.
- Mahowald MB. A feminist standpoint for genetics. *J Clin Ethics* 1996 Winter;7(4):333-40.
- Manghi E, Belloni L, Cambie F, Cerisola N, Dagnino G, Felisi G, Manghi D, Oppici W, Carella L. [Neurologic diseases, mental retardation and reduction in work capacity]. *Riv Neurol* 1985 Jul-Aug;55(4):256-300. (Ita).
- McCabe LL, McCabe ERB. Population studies of allele frequencies in single gene disorders: methodological and policy considerations. *Epidemiol Rev* 1997;19(1):52-60.
- Medical Research Council Steering Committee for the MRC/DHSS Phenylketonuria Register. Routine neonatal screening for phenylketonuria in the United Kingdom 1964-78. *Br Med J (Clin Res Ed)* 1981 May 23;282(6277):1680-4.
- Miller SA, Chopra JG. Problems with human milk and infant formulas. *Pediatrics* 1984 Oct;74(4 Pt 2):639-47.
- Millner BN. Insurance coverage of special foods needed in the treatment of phenylketonuria. *Public Health Rep* 1993 Jan-Feb;108(1):60-5.
- Motulsky AG. Screening for genetic diseases [editorial]. *New Engl J Med* 1997 May 1;336(18):1314-6. Comment on: *N Engl J Med* 1997 May 1;336(18):1298-301. Comment in: *N Engl J Med* 1997 Aug 28;337(9):639-40.
- Mugarra Bidea I, Cabases Hita JM. [Cost-benefit analysis of the early detection program for metabolic diseases in the Autonomous Basque Community]. *Gac Sanit* 1990 Jul-Aug;4(19):140-4. (Spa).
- National Clearinghouse for Human Genetic Diseases. State laws and regulations on genetic disorders. Rockville (MD): Bureau of Community Health Services (US); 1980 Jul. 80 p. (DHHS Publication; no. (HSA) 81-5243.).
- Natowicz MR, Alper JS. Genetic screening: triumphs, problems, and controversies. *J Public Health Policy* 1991 Winter;12(4):475-91.
- Newborn screening. U.S. Public Health Service. *Am Fam Physician* 1994 Aug;50(2):354-8.
- Norgaard-Pedersen B. [The PKU registry and biobank at the National Serum Institute. Rules and applications]. *Ugeskr Laeger* 1998 Apr 6;160(15):2266-7. (Dan).
- Order of 14 September 1989 laying down instructions on the carrying out of tests for the early detection of hypothyroidism and phenylketonuria in neonates. *Int Dig Health Legis* 1991;42(3):479.
- Paul D. Contesting consent: the challenge to compulsory neonatal screening for PKU. *Perspect Biol Med* 1999 Winter;42(2):207-19.

- Paul DB. The politics of heredity: essays on eugenics, biomedicine, and the nature-nurture debate. Albany (NY): State University of New York Press; 1998. 219 p.
- Paul DB. What is a genetic test, and why does it matter? *Endeavour* 1999;23(4):159-61.
- Pettersen RD, Saugstad OD, Lie SO. [Neonatal screening for metabolic diseases--a task without priority in the Norwegian health policy?]. *Tidsskr Nor Laegeforen* 1995 Feb 20;115(5):607-8. (Nor).
- Phenylketonuria. Ill. Ann. Stat. ch. 111 1/2, Sect. 4901-4905 (Smith-Hurd 1982):2 p. Illinois law effective 1 Jan 1982.
- Pickering N, Billings P. Not my problem [letter]. *Hastings Cent Rep* 1993 Jan-Feb;23(1):45-6.
- Powledge TM. Commerce and the future of gene transfer. In: Milunsky A, Annas GJ, editors. *Genetics and the law III*. New York: Plenum Press; 1985. p. 75-9.
- Preventive Services Task Force (US). Guide to clinical preventive services. Baltimore: Williams & Wilkins; c1996. Chapter 44, Screening for phenylketonuria; p. 495-502.
- Rabin DL. Presidential address: preventive medical practice. *J Community Health* 1981 Summer;6(4):237-45.
- Recommended guidelines for PKU programs for the newborn. [Rev. ed.]. Rockville (MD): Maternal and Child Health Service (US), Children's Bureau; 1971. 12 p. (Public Health Service publication, no. 2160/G).
- Reilly PR. Laws to regulate the use of genetic information. In: Rothstein MA, editor. *Genetic secrets: protecting privacy and confidentiality in the genetic era*. New Haven (CT): Yale University Press; 1997. p. 369-91.
- Reiss MJ. The ethics of genetic research on intelligence. *Bioethics* 2000;14(1):1-15.
- Robertson JA, Schulman JD. Pregnancy and prenatal harm to offspring: the case of mothers with PKU. *Hastings Cent Rep* 1987 Aug-Sep;17(4):23-33.
- Ross LJ. Developmental disabilities: genetic implications. *J Obstet Gynecol Neonatal Nurs* 1994 Jul-Aug;23(6):502-5.
- Rowley PT. Genetic screening: marvel or menace? *Science* 1984 Jul 13;225(4658):138-44.
- Saboe BJ, Alexander RC. Noncompliance with PKU treatment recommendations may be medical neglect in some states [letter]. *Pediatr Nurs* 1987 May-Jun;13(3):202-3, 215.
- Salzano FM, Pena SD. Ethics and medical genetics in Brazil. Wertz DC, Fletcher JC, editors. *Ethics and human genetics: a cross-cultural perspective*. New York: Springer-Verlag; 1989. p. 100-18.
- Sardharwalla IB, Wraith JE. A clinician's view of the mass screening of the newborn for inherited diseases: current practice and future considerations. *J Inherit Metab Dis* 1989;12 Suppl 1:55-63.
- Schuett VE, Brown ES. Diet policies of PKU clinics in the United States. *Am J Public Health* 1984 May;74(5):501-3.
- Schuett VE, Gurda RF, Brown ES. Diet discontinuation policies and practices of PKU clinics in the United States. *Am J Public Health* 1980 May;70(5):498-503.
- Seashore MR. Genetic screening and the pediatrician. *Pediatr Ann* 2000;29(5):272-6.
- Sepe SJ, Marks JS, Oakley GP, Manley AF. Genetic services in the United States. *JAMA* 1982 Oct 8;248(14):1733-5.
- Seymour CA, Thomason MJ, Chalmers RA, Addison GM, Bain MD, Cockburn F, Littlejohns P, Lord J, Wilcox AH. Newborn screening for inborn errors of metabolism: a systematic review. *Health Technol Assess* 1997;1(11):i-iv, 1-95.
- Simpson N, Randall R, Lenton S, Walker S. Audit of neonatal screening programme for phenylketonuria and congenital hypothyroidism. *Arch Dis Child Fetal Neonatal Ed* 1997 Nov;77(3):F228-34.
- Sinai LN, Kim SC, Casey R, Pinto-Martin JA. Phenylketonuria screening: effect of early newborn discharge. *Pediatrics* 1995 Oct;96(4 Pt 1):605-8.
- Slazyk WE, Hannon WH, Powell MK, Jensen RJ, Myrick JE, Spierto FW. National laboratory performance surveillance program for congenital hypothyroidism, phenylketonuria, and galactosemia. In: Schmidt BJ, Diament AJ, Loghini-Grosso NS, editors. *Current trends in infant screening. Proceedings of the 7th International Screening Symposium*; 1988 Nov 6-9; Sao Paulo, Brazil. New York: Excerpta Medica; 1989. p. 27-30. (International congress series; no. 848).
- Smijers JJ. [15 years of national screening for phenylketonuria in The Netherlands; 4th report of the National Advisory Commission Phenylketonuria (letter)]. *Ned Tijdschr Geneesk* 1991 Apr 27;135(17):776-7. (Dut).

Starfield B. Motherhood and apple pie: the effectiveness of medical care for children. *Milbank Mem Fund Q Health Soc* 1985 Summer;63(3):523-46.

Tiwary CM. Proposed guidelines for screening of metabolic and endocrine diseases of dependent neonates of the U.S. Armed Forces. Derived from a survey of state guidelines for neonatal screening of metabolic diseases. *Clin Pediatr (Phila)* 1987 Jul;26(7):349-54.

Wada Y, Nakajima H, Irie M, Hirayama M, Suwa S. Newborn mass screening in Japan--1984. *Jinrui Idengaku Zasshi* 1984 Sep;29(3):277-86.

Wadlington W, Waltz JR, Dworkin RB. Cases and materials on law and medicine. Mineola (NY): Foundation Press; 1980. Technology and values in transition: the role of law; p. 688-1032.

Witkowski RC, Koerner H, Metzke H. Ethics and medical genetics in the German Democratic Republic (GDR). In: Wertz DC, Fletcher JC, editors. *Ethics and human genetics: a cross-cultural perspective*. New York: Springer-Verlag; 1989. p. 194-208.

Wuu KD, Chiu PC, Li SY, Chen JY, Chao MC, Ko FJ, Wang TR, Hsiao KJ. Chromosomal and biochemical screening on mentally retarded school children in Taiwan. *Jinrui Idengaku Zasshi* 1991 Sep;36(3):267-74.

Yellowlees H. Aspartame [letter]. *Br Med J (Clin Res Ed)* 1983 Sep 24;287(6396):912-3.

Economics and Socioeconomics

Ahrens D, Guntert B, Brand A. [Comparative presentation of current economic evaluation studies for phenylketonuria screening]. *Gesundheitswesen* 1999 Apr;61(4):190-6. (Ger).

Alm J, Larsson A, Rosenqvist U. Health economic analysis of the Swedish neonatal metabolic screening programme. A method of optimizing routines. *Med Decis Making* 1982;2(1):33-45.

Ambulatory nutrition care: infants. *J Am Diet Assoc* 1989 Apr;89(4):S15-6.

Ambulatory Nutrition Care: pregnant women. *J Am Diet Assoc* 1989 Apr;89(4 Suppl):S10-4.

Antonozzi I, Dominici R, Andreoli M, Monaco F. Neonatal screening in Italy for congenital hypothyroidism and metabolic disorders: hyperphenylalaninemia, maple syrup urine disease and homocystinuria. *J Endocrinol Invest* 1980 Oct-Dec;3(4):357-63.

Azen CG, Koch R, Friedman EG, Berlow S, Coldwell J, Krause W, Matalon R, McCabe E, O'Flynn M, Peterson R, et al. Intellectual development in 12-year-old children treated for phenylketonuria. *Am J Dis Child* 1991 Jan;145(1):35-9. Comment in: *Am J Dis Child* 1991 Jan;145(1):33.

Bamforth FJ. Laboratory screening for genetic disorders and birth defects. *Clin Biochem* 1994 Oct;27(5):333-42.

Barden HS, Kessel R, Schuett VE. The costs and benefits of screening for PKU in Wisconsin. *Soc Biol* 1984 Spring-Summer;31(1-2):1-17.

Blank RH. Public policy implications of human genetic technology: genetic screening. *J Med Philos* 1982 Nov;7(4):355-74.

Boyle PJ. Shaping priorities in genetic medicine. *Hastings Cent Rep* 1995 May-Jun;25(3 Suppl):S2-8.

Brown MC, Guest JF. Economic impact of feeding a phenylalanine-restricted diet to adults with previously untreated phenylketonuria. *J Intellect Disabil Res* 1999 Feb;43 (Pt 1):30-7.

Bush JW, Chen MM, Patrick DL. Health status index in cost effectiveness: analysis of PKU program. In: Berg RL, editor. *Health status indexes. Proceedings of the Conference on a Health Status Index*; 1972 Oct 1-4; Tucson, AZ. Chicago: Hospital Research and Educational Trust; 1973. p. 172-209.

California Department of Health Services, Genetic Disease Branch. Cost and availability of dietary

- treatment of phenylketonuria (PKU): report of a national survey. Berkeley (CA): The Branch; 1997. [76] leaves.
- Clark BJ. After a positive Guthrie--what next? Dietary management for the child with phenylketonuria. *Eur J Clin Nutr* 1992 Jun;46 Suppl 1:S33-9.
- Clow CL, Reade TM, Scriver CR. Management of hereditary metabolic disease. The role of allied health personnel. *N Engl J Med* 1971 Jun 10;284(23):1292-8.
- Coleman EA. Commentary on Trends in Health Care: the Price of Prevention. *ONS Nurs Scan Oncol* 1995 Jul-Aug;4(4):7. Original article by Leutwyler K appears in *Sci Am* 1995;272(4):124-9.
- Dagenais DL, Courville L, Dagenais MG. A cost-benefit analysis of the Quebec Network of Genetic Medicine. *Soc Sci Med* 1985;20(6):601-7.
- Dhondt JL, Farriaux JP, Lebrun T, Saily JC. [Cost/benefit study of the neonatal detection of phenylketonuria and hypothyroidism]. *Pediatrie* 1988;43(4):345-8. (Fre).
- Dhondt JL, Farriaux JP, Saily JC, Lebrun T. Economic evaluation of cost-benefit ratio of neonatal screening procedure for phenylketonuria and hypothyroidism. *J Inher Metab Dis* 1991;14(4):633-9.
- Dworkin RB. Common sense and common decency: some thoughts about maternal-fetal conflict. In: Humber JM, Almeder RF, editors. *Biomedical Ethics Reviews*, 1991. Bioethics and the fetus: medical, moral and legal issues. Totowa (NJ): Humana Press; 1991. p. 9-38.
- Ebomoyi E. Family planning needs in Nigeria [letter]. *World Health Forum* 1984;5(1):40-1.
- Eisenberg L. Prevention: rhetoric and reality. *J R Soc Med* 1984 Apr;77(4):268-80.
- Faden RR, Chwalow AJ, Holtzman NA, Horn SD. A survey to evaluate parental consent as public policy for neonatal screening. *Am J Public Health* 1982 Dec;72(12):1347-52.
- Farriaux JP. [Neonatal detection of phenylketonuria and hypothyroidism. Realities and perspectives]. *An Esp Pediatr* 1988 Sep;29 Suppl 32:272-9. (Spa).
- Farriaux JP, Dhondt JL. [Neonatal screening for phenylketonuria]. *J Genet Hum* 1981 Mar;29(1):3-11. (Fre).
- Fingerhut R, Stehn M, Kohlschutter A. Comparison of four different phenylalanine determination methods. *Clin Chim Acta* 1997 Aug 8;264(1):65-73.
- Fletcher JC. Ethical issues in genetic screening and antenatal diagnosis. *Clin Obstet Gynecol* 1981 Dec;24(4):1151-68.
- Forsberg SA. Infant metabolic screening: a total quality management approach. *Obst Gynecol Neonat Nurs* 1997 May-Jun;26(3):257-61.
- Fost N. Genetic diagnosis and treatment: ethical considerations. *Am J Dis Child* 1993 Nov;147(11):1190-5.
- Frezal J, Ogier H. [The administrative management of children with phenylketonuria]. *Arch Fr Pediatr* 1983;40 Suppl 1:269-71. (Fre).
- Friedman EG, Koch R, Azen C, Levy H, Hanley W, Matalon R, Rouse B, Trefz F, de la Cruz F. The International Collaborative Study on maternal phenylketonuria: organization, study design and description of the sample. *Eur J Pediatr* 1996 Jul;155 Suppl 1:S158-61.
- Gerasimova NS, Steklova IV, Tuuminen T. Fluorometric method for phenylalanine microplate assay adapted for phenylketonuria screening. *Clin Chem* 1989 Oct;35(10):2112-5.
- Graziado-Marques B, Kennedy B, Anderson K. Cost justifying computerization of diet analysis. *J Am Diet Assoc* 1991 Apr;91(4):469-70.
- Griffiths PV, Demellweek C, Fay N, Robinson PH, Davidson DC. Wechsler subscale IQ and subtest profile in early treated phenylketonuria. *Arch Dis Child* 2000 Mar;82(3):209-15.
- Hepburn ER. Genetic testing and early diagnosis and intervention: boon or burden? *J Med Ethics* 1996 Apr;22(22):105-10.
- Hisashige A. Health economic analysis of the neonatal screening program in Japan. *Int J Technol Assess Health Care* 1994 Summer;10(3):382-91.
- Hitzeroth HW, Niehaus CE, Brill DC. Phenylketonuria in South Africa. A report on the status quo. *S Afr Med J* 1995 Jan;85(1):33-6.
- Hoffman GL, Laessig RH, Hassemer DJ, Makowski ER. Dual-channel continuous-flow system for determination of phenylalanine and galactose: application to newborn screening. *Clin Chem* 1984 Feb;30(2):287-90.
- Holton JB. Neonatal screening for biochemical disorders. *Br J Hosp Med* 1988 Apr;39(4):317-9, 322-4.
- Holtzman NA. The diffusion of new genetic tests for predicting disease. *FASEB J* 1992 Jul;6(10):2806-12.

- Holtzman NA. Pitfalls of newborn screening (with special attention to hypothyroidism): when will we ever learn? *Birth Defects Orig Artic Ser* 1983;19(5):111-20.
- Holtzman NA. What drives neonatal screening programs? [editorial]. *New Engl J Med* 1991 Sep 12;325(11):802-4.
- Holtzman NA, Faden R, Chwalow AJ, Horn SD. Effect of informed parental consent on mothers' knowledge of newborn screening. *Pediatrics* 1983 Dec;72(6):807-12.
- Hook EB. Muddling genetic discrimination [letter]. *Am J Hum Genet* 1992 Oct;51(4):899-901.
- Keffler S, Denmeade R, Green A. Neonatal screening for phenylketonuria: evaluation of an automated enzymatic method. *Ann Clin Biochem* 1994 Mar;31 (Pt 2):134-9.
- Koch R, Yusin M, Fishler K. Successful adjustment to society by adults with phenylketonuria. *J Inherit Metab Dis* 1985;8(4):209-11.
- Koch RK. Issues in newborn screening for phenylketonuria. *Am Fam Physician* 1999 Oct 1;60(5):1462-6.
- Lee KS, Perlman M. The impact of early obstetric discharge on newborn health care. *Curr Opin Pediatr* 1996 Apr;8(2):96-101.
- Levy HL, Waisbren SE. PKU in adolescents: rationale and psychosocial factors in diet continuation. *Acta Paediatr Suppl* 1994 Dec;407:92-7.
- Liebl B, Fingerhut R, Roschinger W, Muntau A, Knerr I, Olgemoller B, Zapf A, Roscher AA. [Model project for updating neonatal screening in Bavaria: concept and initial results]. *Gesundheitswesen* 2000 Apr;62(4):189-95. (Ger).
- Liu SR, Zuo QH. Newborn screening for phenylketonuria in eleven districts. *Chin Med J (Engl)* 1986 Feb;99(2):113-8.
- Lord J, Thomason MJ, Littlejohns P, Chalmers RA, Bain MD, Addison GM, Wilcox AH, Seymour CA. Secondary analysis of economic data: a review of cost-benefit studies of neonatal screening for phenylketonuria. *J Epidemiol Community Health* 1999 Mar;53(3):179-86.
- Luder AS, Greene CL. Maternal phenylketonuria and hyperphenylalaninemia: implications for medical practice in the United States. *Am J Obstet Gynecol* 1989 Nov;161(5):1102-5.
- Mamunes P. Neonatal screening tests. *Pediatr Clin North Am* 1980 Nov;27(4):733-51.
- Manghi E, Belloni L, Cambie F, Cerisola N, Dagnino G, Felisi G, Manghi D, Oppici W, Carella L. [Neurologic diseases, mental retardation and reduction in work capacity]. *Riv Neurol* 1985 Jul-Aug;55(4):256-300. (Ita).
- Millner BN. Insurance coverage of special foods needed in the treatment of phenylketonuria. *Public Health Rep* 1993 Jan-Feb;108(1):60-5.
- Moats RA, Koch R, Moseley K, Guldberg P, Guttler F, Boles RG, Nelson MD Jr. Brain phenylalanine concentration in the management of adults with phenylketonuria. *J Inherit Metab Dis* 2000 Feb;23(1):7-14.
- Modell B. Biochemical neonatal screening: preconceptional and antenatal screening may be preferable in some cases [editorial]. *BMJ* 1990 Jun 30;300(6741):1667-8.
- Mugarra Bidea I, Cabases Hita JM. [Cost-benefit analysis of the early detection program for metabolic diseases in the Autonomous Basque Community]. *Gac Sanit* 1990 Jul-Aug;4(19):140-4. (Spa).
- Natowicz MR, Alper JS. Genetic screening: triumphs, problems, and controversies. *J Public Health Policy* 1991 Winter;12(4):475-91.
- Novello AC. Inherited metabolic diseases: collaborating for the health of all children. *Biochem Med Metab Biol* 1993 Jun;49(3):277-84.
- Osorio RV, Vilarinho L, Soares JP. [National screening for phenylketonuria, congenital hypothyroidism and congenital adrenal hyperplasia]. *Acta Med Port* 1992 Mar;5(3):131-4. (Por).
- Paul D. Contesting consent: the challenge to compulsory neonatal screening for PKU. *Perspect Biol Med* 1999 Winter;42(2):207-19.
- Pettersen RD, Saugstad OD, Heyerdahl S, Motzfeldt K, Lie SO. [Screening of newborn infants in Norway for severe metabolic disease]. *Tidsskr Nor Laegeforen* 1995 Feb 20;115(5):584-7. (Nor).
- Pettersen RD, Saugstad OD, Lie SO. [Neonatal screening for metabolic diseases--a task without priority in the Norwegian health policy?]. *Tidsskr Nor Laegeforen* 1995 Feb 20;115(5):607-8. (Nor).
- Pollitt RJ, Green A, McCabe CJ, Booth A, Cooper NJ, Leonard JV, Nicholl J, Nicholson P, Tunaley JR, Virdi NK. Neonatal screening for inborn errors of metabolism: cost, yield and outcome. *Health Technol Assess* 1997;1(7):1-202.
- Rabin DL. Presidential address: preventive medical practice. *J Community Health* 1981 Summer;6(4):237-45.

- Reber M, Kazak AE, Himmelberg P. Phenylalanine control and family functioning in early-treated phenylketonuria. *J Dev Behav Pediatr* 1987 Dec;8(6):311-7.
- Rey F, Abadie V, Plainguet F, Rey J. Long-term follow up of patients with classical phenylketonuria after diet relaxation at 5 years of age. The Paris Study. *Eur J Pediatr* 1996 Jul;155 Suppl 1:S39-44.
- Roesel RA, Blankenship PR, Hommes FA. HPLC assay of phenylalanine and tyrosine in blood spots on filter paper. *Clin Chim Acta* 1986 Apr 15;156(1):91-6.
- Rottoli A, Gianni ML, Verduci E, Biondi ML, Fiori L, Giovannini M, Riva E. Should genetic analysis in newborn screening and a heterozygote test for hyperphenylalaninaemia be recommended? An Italian study. *J Med Screen* 1999;6(4):193-4.
- Rowley PT. Genetic screening: marvel or menace? *Science* 1984 Jul 13;225(4658):138-44.
- Saudubray JM, Rey F, Ogier H, Abadie V, Farriaux JP, Ghisolfi J, Guibaud P, Rey J, Vidailhet M. Intellectual and school performances in early-treated classical PKU patients. The French collaborative study. *Eur J Pediatr* 1987;146 Suppl 1:A20-2.
- Scheffler RM, Paringer L. A review of the economic evidence on prevention. *Med Care* 1980 May;18(5):473-84.
- Scheibenreiter S, Tiefenthaler M, Hinteregger V, Strobl W, Muhl A, Ewald A, Schadler M. Austrian report on longitudinal outcome in phenylketonuria. *Eur J Pediatr* 1996 Jul;155 Suppl 1:S45-9.
- Schmidt BJ, Diament AJ, Krynski S, Kamei ME, Rodrigues MM, Takata S. [Detection of inborn errors of metabolism in San Pablo, Brazil]. *Bol Med Hosp Infant Mex* 1981 Mar-Apr;38(2):217-29. (Spa).
- Schoos R, Verloes A, Bourguignon JP, Koulischer L. [Programs of systematic screening in neonatology. Pharmaco-economic aspects]. *Rev Med Liege* 1998 May;53(5):311-5. (Fre).
- Scriver CR. PKU and beyond: when do costs exceed benefits? *Pediatrics* 1974 Nov;54(5):616-9.
- Scriver CR, Clow CL. Phenylketonuria: epitome of human biochemical genetics (second of two parts). *N Engl J Med* 1980 Dec 11;303(24):1394-400.
- Seashore MR. Genetic screening and the pediatrician. *Pediatr Ann* 2000;29(5):272-6.
- Sepe SJ, Levy HL, Mount FW. An evaluation of routine follow-up blood screening of infants for phenylketonuria. *N Engl J Med* 1979 Mar 15;300(11):606-9.
- Sepe SJ, Marks JS, Oakley GP, Manley AF. Genetic services in the United States. *JAMA* 1982 Oct 8;248(14):1733-5.
- Seymour CA, Thomason MJ, Chalmers RA, Addison GM, Bain MD, Cockburn F, Littlejohns P, Lord J, Wilcox AH. Newborn screening for inborn errors of metabolism: a systematic review. *Health Technol Assess* 1997;1(11):i-iv, 1-95.
- Simonsen H, Brandt NJ, Norgaard-Pedersen B. [Neonatal screening in Denmark. Status and future perspectives]. *Ugeskr Laeger* 1998 Sep 28;160(40):5777-82. (Dan).
- Smijers JJ. [15 years of national screening for phenylketonuria in The Netherlands; 4th report of the National Advisory Commission Phenylketonuria (letter)]. *Ned Tijdschr Geneesk* 1991 Apr 27;135(17):776-7. (Dut).
- Sobra J. [Nutrition and metabolic diseases with a mass incidence]. *Cas Lek Cesk* 1990 Jul 20;129(29):897-901. (Cze).
- St James PJ, Younger MD, Hamilton BD, Waibren SE. Unplanned pregnancies in young women with diabetes. An analysis of psychosocial factors. *Diabetes Care* 1993 Dec;16(12):1572-8.
- Steiner KC, Smith HA. Application of cost-benefit analysis to a PKU screening program. *Inquiry* 1973 Dec;10(4):34-40.
- Thalhammer O, Scheibenreiter S, Knoll E, Wehle E, Schon R. [12 years Austrian newborn screening for inborn errors of metabolism. Results with special reference to phenylketonuria, hyperphenylalaninemia and histidinemia (author's transl)]. *Klin Padiatr* 1980 Nov;192(6):589-98. (Ger).
- Thomason MJ, Lord J, Bain MD, Chalmers RA, Littlejohns P, Addison GM, Wilcox AH, Seymour CA. A systematic review of evidence for the appropriateness of neonatal screening programmes for inborn errors of metabolism. *J Public Health Med* 1998 Sep;20(3):331-43.
- Tiway CM. Neonatal screening for metabolic and endocrine diseases. *Nurse Pract* 1987 Sep;12(9):28-35, 38, 41.
- Tiway CM. Proposed guidelines for screening of metabolic and endocrine diseases of dependent neonates of the U.S. Armed Forces. Derived from a survey of state guidelines for neonatal screening of metabolic diseases. *Clin Pediatr (Phila)* 1987 Jul;26(7):349-54.
- Wallman CM. Lab values and diagnostics. Newborn genetic screening. *Neonat Netw* 1998 Apr;17(3):55-60, 22-4.

Wappner R, Cho S, Kronmal RA, Schuett V, Seashore MR. Management of phenylketonuria for optimal outcome: a review of guidelines for phenylketonuria management and a report of surveys of parents, patients, and clinic directors. *Pediatrics* 1999 Dec;104(6):e68.

Wasser S, Theile H. [The interaction of biological and social factors on the effect of treatment in cases of phenylketonuria (author's transl)]. *Padiatr Padol* 1981;16(4):417-26. (Ger).

Weglage J, Funders B, von Teeffelen-Heithoff A, Ullrich K. [Phenylketonuria: illness experience and coping mechanisms]. *Z Kinder Jugendpsychiatr* 1993 Sep;21(3):156-62. (Ger).

Weglage J, Funders B, Wilken B, Schubert D, Schmidt E, Burgard P, Ullrich K. Psychological and social findings in adolescents with phenylketonuria. *Eur J Pediatr* 1992 Jul;151(7):522-5.

Weglage J, Funders B, Wilken B, Schubert D, Ullrich K. School performance and intellectual outcome in adolescents with phenylketonuria. *Acta Paediatr* 1993 Jun-Jul;82(6-7):582-6.

Weglage J, Grenzebach M, Pietsch M, Feldmann R, Linnenbank R, Denecke J, Koch HG. Behavioural and emotional problems in early-treated adolescents with phenylketonuria in comparison with diabetic patients and healthy controls. *J Inher Metab Dis* 2000;23:487-96.

Weglage J, Ullrich K, Pietsch M, Funders B, Guttler F, Harms E. Intellectual, neurologic, and neuropsychologic outcome in untreated subjects with nonphenylketonuria hyperphenylalaninemia. German Collaborative Study on Phenylketonuria. *Pediatr Res* 1997 Sep;42(3):378-84.

White JE, Kronmal RA, Acosta PB. Excess weight among children with phenylketonuria. *J Am Coll Nutr* 1982;1(3):293-303.

Widaman KF. Process of analyses of data: Benefits and costs associated with collaborative studies. *Ment Retard Dev Disabil Res Rev* 1999;5(2):155-61.

Zelinskaia DI, Ladodo KS, Rybakova EP, Baikov AD. [Organization of dietetic assistance to children with phenylketonuria]. *Vopr Pitan* 1998;(2):12-4. (Rus).

Classification

Annenkov GA. [Phenylketonuria and hyperphenylalaninemia: clinico-genetic classification of 14 forms]. *Zh Nevropatol Psikhiatr* 1984;84(3):351-6. (Rus).

Bickel H. Phenylalaninaemia or classical phenylketonuria (PKU)? *Neuropadiatrie* 1970 Apr;1(4):379-82.

Clemens PC, Schunemann MH, Plettner C, Gruttner R. [The phenylalanine stress test in the classification of patients with phenylketonuria]. *Klin Padiatr* 1989 May-Jun;201(3):163-6. (Ger).

Dhondt JL, Largilliere C, Farriaux JP. [An attempt at classification of the hyperphenylalaninemias. Apropos of 62 patients]. *Arch Fr Pediatr* 1983;40 Suppl 1:243-5. (Fre).

Donlon J. Variant forms of phenylketonuria. *Ir Med J* 1981 Jun;74(6):174, 176.

Farriaux JP, Dhont JL. [Hyperphenylalaninemia in 1983]. *Rev Med Brux* 1983 Apr;4(4):305-10. (Fre).

Guldberg P, Rey F, Zschocke J, Romano V, Francois B, Michiels L, Ullrich K, Hoffmann GF, Burgard P, Schmidt H, Meli C, Riva E, Dianzani I, Ponzzone A, Rey J, Guttler F. A European multicenter study of phenylalanine hydroxylase deficiency: classification of 105 mutations and a general system for genotype-based prediction of metabolic phenotype. *Am J Hum Genet* 1998 Jul;63(1):71-9. Published erratum appears in *Am J Hum Genet* 1998 Oct;63(4):1252-3.

Guttler F. Hyperphenylalaninemia: diagnosis and classification of the various types of phenylalanine hydroxylase deficiency in childhood. *Acta Paediatr Scand Suppl* 1980;280:1-80.

Guttler F, Hansen G. Different phenotypes for phenylalanine hydroxylase deficiency. *Ann Clin Biochem* 1977 May;14(3):124-34.

Korson MS. Advances in newborn screening for metabolic disorders: What the pediatrician needs to know. *Pediatr Ann* 2000;29(5):294-301.

Netley C, Hanley WB, Rudner HL. Phenylketonuria and its variants: observations on intellectual functioning. *Can Med Assoc J* 1984 Oct 1;131(7):751-5.

Perez B, Desviat LR, Ugarte M. Expression analysis of mutation P244L, which causes mild hyperphenylalaninemia. *Hum Mutat* 1995;5(2):188-90.

Rey F, Munnich A, Lyonnet S, Rey J. [Classification and heterogeneity of hyperphenylalaninemias linked to a phenylalanine hydroxylase deficiency]. *Arch Fr Pediatr* 1987;44 Suppl 1:639-42. (Fre).

Wachtel U. Review of current practices in management of inherited disorders of amino acid metabolism in Western Europe. *Hum Nutr Appl Nutr* 1986;40 Suppl 1:61-9.

Wiens M, Koziol C, Batel R, Muller WE. Phenylalanine hydroxylase from the sponge *Geodia cydonium*: implication for allorecognition and evolution of aromatic amino acid hydroxylases. *Dev Comp Immunol* 1998 Sep-Dec;22(5-6):469-78.

Wood N, Tyfield L, Bidwell J. Rapid classification of phenylketonuria genotypes by analysis of heteroduplexes generated by PCR-amplifiable synthetic DNA. *Hum Mutat* 1993;2(2):131-7.

Incidence, Prevalence, and Demographics

Ahrens D, Guntert B, Brand A. [Comparative presentation of current economic evaluation studies for phenylketonuria screening]. *Gesundheitswesen* 1999 Apr;61(4):190-6. (Ger).

Alm J, Bodegard G, Larsson A, Nyberg G, Zetterstrom R. Children with inborn errors of phenylalanine metabolism: prognosis and phenylalanine tolerance. *Acta Paediatr Scand* 1986 Jul;75(4):619-25.

Alm J, Larsson A. Evaluation of a nation-wide neonatal metabolic screening programme in Sweden 1965-1979. *Acta Paediatr Scand* 1981 Sep;70(5):601-7.

Antisdell JE, Chrisler JC. Comparison of eating attitudes and behaviors among adolescent and young women with type 1 diabetes mellitus and phenylketonuria. *J Dev Behav Pediatr* 2000 Apr;21(2):81-6.

Aoki K. [Disorders of amino acids]. *Nippon Rinsho* 1993 Jan;51 Suppl:332-9. (Jpn).

Apold J, Eiken HG, Odland E, Fredriksen A, Bakken A, Lorens JB, Boman H. A termination mutant prevalent in Norwegian haplotype 7 phenylketonuria genes. *Am J Hum Genet* 1990 Dec;47(6):1002-7.

Apold J, Eiken HG, Svensson E, Kunert E, Kozak L, Cechak P, Guttler F, Giltay J, Lichter-Konecki U, Melle D, et al. The phenylketonuria G272X haplotype 7 mutation in European populations. *Hum Genet* 1993 Sep;92(2):107-9.

Applegarth DA, Toone JR, Lowry RB. Incidence of inborn errors of metabolism in British Columbia, 1969-1996. *Pediatrics* 2000 Jan;105(1):e10.

Araki K, Matsuo N, Kodoh J, Shimizu N. RFLPs at the PAH (phenylalanine hydroxylase) gene in the Japanese population. *Nucleic Acids Res* 1991 Apr 25;19(8):1960.

Avigad S, Cohen BE, Bauer S, Schwartz G, Frydman M, Woo SL, Niny Y, Shiloh Y. A single origin of phenylketonuria in Yemenite Jews. *Nature* 1990 Mar 8;344(6262):168-70.

Bachmann C, Colombo JP. Incidence of disorders tested by systematic screening: confidence limits and comparison of programmes. *J Inherit Metab Dis* 1982;5(1):3-5.

Baranovskaia SS, Shevtsov SP, Maksimova SP, Kuz'min AI, Shvarts EI. [The spectrum of mutational

- damage to the phenylalanine hydroxylase gene in patients with phenylketonuria in St. Petersburg]. *Dokl Akad Nauk* 1995 Feb;340(5):709-11. (Rus).
- Beaudette T. Metabolic disorders of childhood: nutritional management. *Semin Nutr* 1994 Mar-Apr;13(4):1-18.
- Bender C, Buchler A, Schmidt-Mader B, Schlotter M, Teebi AS, Konecki DS, Trefz FK. Haplotype analysis and a new MspI-polymorphism at the phenylalanine hydroxylase gene in the Arabian population [letter]. *Eur J Pediatr* 1994 May;153(5):392.
- Berardi R, Baracchi MR, Borgogni P, Margollicci MA, Mattei R, Fois A. [Results of a screening project for congenital hypothyroidism in 4 years of experience]. *Pediatr Med Chir* 1982 Nov-Dec;4(6):657-60. (Ita).
- Bessman SP. The justification theory: the essential nature of the non-essential amino acids. *Nutr Rev* 1979 Jul;37(7):209-20.
- Bickel H. Phenylketonuria: past, present, future. F. P. Hudson Memorial Lecture, Leeds, 1979. *J Inherit Metab Dis* 1980;3(4):123-32.
- Bickel H. [Screening for congenital metabolic disorders. Indication and results]. *Monatsschr Kinderheilkd* 1983 Jun;131(6):323-7. (Ger).
- Blau N, Barnes I, Dhondt JL. International database of tetrahydrobiopterin deficiencies. *J Inherit Metab Dis* 1996;19(1):8-14.
- Blomquist HK, Gustavson KH, Holmgren G. Severe mental retardation in five siblings due to maternal phenylketonuria. *Neuropediatrics* 1980 Aug;11(3):256-61.
- Bodley JL, Austin VJ, Hanley WB, Clarke JT, Zlotkin S. Low iron stores in infants and children with treated phenylketonuria: a population at risk for iron-deficiency anaemia and associated cognitive deficits. *Eur J Pediatr* 1993 Feb;152(2):140-3.
- Briard ML. [Neonatal screening for phenylketonuria and hypothyroidism in France. A 12-year experience]. *Ann Biol Clin (Paris)* 1988;46(6):387-92. (Fre).
- Briard ML. [Neonatal screening of phenylketonuria in France. Statistical data]. *Arch Fr Pediatr* 1983;40 Suppl 1:215-7. (Fre).
- Brookfield JF, Pollitt RJ, Young ID. Family size limitation: a method for demonstrating recessive inheritance. *J Med Genet* 1988 Mar;25(3):181-5.
- Byck S, Morgan K, Tyfield L, Dworniczak B, Scriver CR. Evidence for origin, by recurrent mutation, of the phenylalanine hydroxylase R408W mutation on two haplotypes in European and Quebec populations. *Hum Mol Genet* 1994 Sep;3(9):1675-7.
- Byck S, Tyfield L, Carter K, Scriver CR. Prediction of multiple hypermutable codons in the human PAH gene: codon 280 contains recurrent mutations in Quebec and other populations. *Hum Mutat* 1997;9(4):316-21.
- Cabalska B, Duczynska N, Nowaczewska I, Bozkowa K. Hyperphenylalaninemia in Polish children's population. *Acta Anthropogenet* 1985;9(1-3):91-102.
- Campistol Plana J, Alvarez Dominguez L, Riverola de Veciana AT, Castillo Rivera P, Giner Soria P. [Hyperphenylalaninemia and phenylketonuria. The importance of early diagnosis and follow up at a health center]. *An Esp Pediatr* 1991 Jan;34(1):51-6. (Spa).
- Carson NA. Diagnosis and management of hyperphenylalaninaemia. *Arch Dis Child* 1971 Dec;46(250):878-9.
- Carter KC, Byck S, Waters PJ, Richards B, Nowacki PM, Laframboise R, Lambert M, Treacy E, Scriver CR. Mutation at the phenylalanine hydroxylase gene (PAH) and its use to document population genetic variation: the Quebec experience. *Eur J Hum Genet* 1998 Jan;6(1):61-70.
- Cerone R, Cohen A, Romano C. Prevention and screening. *J Perinat Med* 1994;22 Suppl 1:5-8.
- Chen RG, Pan XS, Qian DL, Guo H. Twenty-one cases of phenylketonuria out of 358,767 newborns in Shanghai, China. *J Inherit Metab Dis* 1989;12(4):485.
- Chen RG, Sun M, Ni YY, Pan XS, Chen JZ, Zhang YF, Liu H, Zhang MH, Xu HZ, Wu YL, et al. Neonatal hypothyroidism, phenylketonuria and galactosemia screening in metropolitan Shanghai. *Chin Med J (Engl)* 1984 Jan;97(1):61-5.
- Ciske JB, Hoffman G, Hanson K, Annable KM, Wolff J, Litsheim T, Laessig R, Aronson R. Newborn screening in Wisconsin: program overview and test addition. *WMJ* 2000;99(2):38-42.
- Clemens P, Plettner C, Gruttner R. [Screening for phenylketonuria without false readings from antibacterial agents]. *Offentl Gesundheitswes* 1982 Jun;44(6):435. (Ger).
- Clemens PC, Neumann SJ, Wulke AP, Burmester JG. Newborn screening for hyperphenylalaninemia on day 5: is 240 $\mu\text{mol/liter}$ the most appropriate cut-off level? *Prev Med* 1990 Jan;19(1):54-60.
- Crocker AC. Current strategies in prevention of mental retardation. *Pediatr Ann* 1982 May;11(5):450-4, 457.

- Cruz-Coke R, Moreno RS. Genetic epidemiology of single gene defects in Chile. *J Med Genet* 1994 Sep;31(9):702-6.
- Darling PB, Bross R, Wykes LJ, Ball RO, Pencharz PB. Isotopic enrichment of amino acids in urine following oral infusions of L-[1-(13)C]phenylalanine and L-[1-(13)C]lysine in humans: confounding effect of D-[13C]amino acids. *Metabolism* 1999 Jun;48(6):732-7.
- Dasovich M, Konecki D, Lichter-Konecki U, Eisensmith RC, Guttler F, Naughton E, Mullins C, Giovannini M, Riva E, Woo SL. Molecular characterization of PKU allele prevalent in southern Europe and Ireland. *Somat Cell Mol Genet* 1991 May;17(3):303-9.
- de Almeida IT, Leandro PP, Portela R, Cabral A, Eusebio F, Tasso T, Matasovic A, Blau N. Tetrahydrobiopterin deficiency in Portugal: results of the screening for hyperphenylalaninemia. *Adv Exp Med Biol* 1993;338:263-6.
- de Valk HW, de Sonnevile LM, Duran M, Poll-The BT, Erkelens DW. [Phenylketonuria: a children's disease in adulthood]. *Ned Tijdschr Geneesk* 2000 Jan 1;144(1):11-5. (Dut).
- Desviat LR, Perez B, Garcia MJ, Martinez-Pardo M, Baldellou A, Arena J, Sanjurjo P, Campistol J, Couce ML, Fernandez A, Cardesa J, Ugarte M. Relationship between mutation genotype and biochemical phenotype in a heterogeneous Spanish phenylketonuria population. *Eur J Hum Genet* 1997 Jul-Aug;5(4):196-202.
- Desviat LR, Perez B, Ugarte M. Molecular basis of non-PKU hyperphenylalaninaemia in Spain: prevalence of A403V, a mutation with high residual activity. *J Inherit Metab Dis* 1996;19(2):227-30.
- Desviat LR, Perez B, Ugarte M. Phenylketonuria in Spain: RFLP haplotypes and linked mutations. *Hum Genet* 1993 Oct 1;92(3):254-8.
- Desviat LR, Perez B, Ugarte M. Phenylketonuria in Spanish Gypsies: prevalence of the IVS10nt546 mutation on haplotype 34. *Hum Mutat* 1997;9(1):66-8.
- Dhondt JL, Farriaux JP, Blehova B, Pazoutova N. Incidence of cofactor deficiency in the hyperphenylalaninemic population of Czechoslovakia. In: Schmidt BJ, Diamant AJ, Loghini-Grosso NS, editors. *Current trends in infant screening. Proceedings of the 7th International Screening Symposium*; 1988 Nov 6-9; Sao Paulo, Brazil. New York: Excerpta Medica; 1989. p. 105-6. (International congress series; no. 848).
- Dianzani I. Molecular basis of hyperphenylalaninemia in Italy [dissertation]. Uxbridge (Middlesex, UK): Brunel University; 1991. 249 p.
- Dianzani I, Farinasso L, Fortina P, Camaschella C, Ponzzone R, Dahl HH, Cotton RG, Ponzzone A. RFLPs of the phenylalanine hydroxylase gene in the Italian population. *J Inherit Metab Dis* 1989;12(2):162-5.
- Dianzani I, Giannattasio S, de Sanctis L, Alliaudi C, Lattanzio P, Vici CD, Burlina A, Burrioni M, Sebastio G, Carnevale F, et al. Characterization of phenylketonuria alleles in the Italian population. *Eur J Hum Genet* 1995;3(5):294-302.
- Dobson JC, Williamson M, Koch R. Sex ratio in hyperphenylalaninemia. *N Engl J Med* 1970 Aug 27;283(9):491.
- Dodinval P. [Does medical progress entail deterioration of our genetic heritage?]. *Rev Med Liege* 1980 Jan 1;35(1):11-9. (Fre).
- Donnai D. Pre-conceptual genetic advice. *Br J Family Planning* 1983 Oct;9(3):75-9.
- Eiken HG, Knappskog PM, Boman H, Thune KS, Kaada G, Motzfeldt K, Apold J. Relative frequency, heterogeneity and geographic clustering of PKU mutations in Norway. *Eur J Hum Genet* 1996;4(4):205-13.
- Eisenberg L. Child mental health in the Americas: a public health approach. *Bull Pan Am Health Organ* 1992;26(3):230-41.
- Eisensmith RC, Goltsov AA, O'Neill C, Tyfield LA, Schwartz EI, Kuzmin AI, Baranovskaya SS, Tsukerman GL, Treacy E, Scriver CR, et al. Recurrence of the R408W mutation in the phenylalanine hydroxylase locus in Europeans. *Am J Hum Genet* 1995 Jan;56(1):278-86.
- Eisensmith RC, Martinez DR, Kuzmin AI, Goltsov AA, Brown A, Singh R, Elsas LJ II, Woo SL. Molecular basis of phenylketonuria and a correlation between genotype and phenotype in a heterogeneous southeastern US population. *Pediatrics* 1996 Apr;97(4):512-6.
- Eisensmith RC, Woo SL. Molecular genetics of phenylketonuria: from molecular anthropology to gene therapy. *Adv Genet* 1995;32:199-271.
- Eisensmith RC, Woo SL. Phenylketonuria and the phenylalanine hydroxylase gene. *Mol Biol Med* 1991 Feb;8(1):3-18.
- Eisensmith RC, Woo SL. Population genetics of phenylketonuria. *Acta Paediatr Suppl* 1994 Dec;407:19-26.

- Enns GM, Martinez DR, Kuzmin AI, Koch R, Wakeem CK, Woo SL, Eisensmith RC, Packman S. Molecular correlations in phenylketonuria: mutation patterns and corresponding biochemical and clinical phenotypes in a heterogeneous California population. *Pediatr Res* 1999 Nov;46(5):594-602.
- Farhud DD, Kabiri M. Incidence of phenylketonuria (PKU) in Iran. *Indian J Pediatr* 1982 Sep-Oct;49(400):685-8.
- Farriaux JP. [Results of screening for phenylketonuria in France]. *Presse Med* 1987 Jun 13;16(22):1072-4. (Fre).
- Ferencz C, Boughman JA. Congenital heart disease in adolescents and adults. *Teratology, genetics, and recurrence risks. Cardiol Clin* 1993 Nov;11(4):557-67.
- Fernhoff PM, Fitzmaurice N, Milner J, McEwen CT, Dembure PP, Brown AL, Wright L, Acosta PB, Elsas LJ 2d. Coordinated system for comprehensive newborn metabolic screening. *South Med J* 1982 May;75(5):529-32.
- Fisch RO, Matalon R, Weisberg S, Michals K. Children of fathers with phenylketonuria: an international survey. *J Pediatr* 1991 May;118(5):739-41.
- Flatz G, Oelbe M, Herrmann H. Ethnic distribution of phenylketonuria in the north German population. *Hum Genet* 1984;65(4):396-9.
- Frezal J, Farriaux JP. [Phenylketonuria yesterday and today. Evaluation of the work of systematic neonatal screening]. *Rev Prat* 1992 Nov 15;42(18):2316-26. (Fre).
- Friedman JM, Smith JP, Lerner BN, Helgeson JS, Howard-Peebles PN, Mize CE, Mize SG, Singleton WL, Smith ME. ReCAP: the Registry of Cytogenetic Abnormalities and Phenylketonuria. *Am J Med Genet* 1987 Jun;27(2):325-36.
- Frontera-Izquierdo P. Phenylketonuria and neonatal hypothyroidism in Spain. Priority of screening for neonatal hypothyroidism. *Eur J Pediatr* 1980 May;133(3):297.
- Garcia de Juan JF. Valores de referencia de las magnitudes bioquímicas l-fenilalanina y l-tirosina en la población de Navarra: estudio de tirosinemia transitoria del recién nacido [Reference values of the biochemical magnitudes l-phenylalanine l-tyrosine in the Navarra population: study of transient neonatal tyrosinaemia] [dissertation]. Ciudad Universitaria (Spain): University of Navarra; 1991. 331 p. (Spa).
- Giannattasio S, Bisceglia L, Lattanzio P, Grifa A, Dianzani I, Gasparini P, Marra E. Molecular screening of genetic defects with RNA-SSCP analysis: the PKU and cystinuria model. *Mol Cell Probes* 1995 Jun;9(3):201-5.
- Giannattasio S, Jurgelevicius V, Lattanzio P, Cimbalistiene L, Marra E, Kucinskas V. Phenylketonuria mutations and linked haplotypes in the Lithuanian population: origin of the most common R408W mutation. *Hum Hered* 1997 May-Jun;47(3):155-60.
- Giannattasio S, Lattanzio P, Bobba A, Marra E. Detection of microsatellites by ethidium bromide staining. The analysis of an STR system in the human phenylalanine hydroxylase gene. *Mol Cell Probes* 1997 Feb;11(1):81-3.
- Ginter EK, Mamedova RA, Kozlova SI, Galkina VA, Moshkina IS, Rudenskaia GE, Khlebnikova OV, Nurbaev SD, Balanovskaia EV, Rassanov VP. [Diversity of hereditary pathology in the population of Marii El Republic and its differentiation with respect to gene frequencies for hereditary diseases]. *Genetika* 1998 Jul;34(7):963-72. (Rus).
- Grobe H. [Screening studies in newborn infants]. *Monatsschr Kinderheilkd* 1983 Nov;131(11):806-9. (Ger).
- Gu XF, Chen RG. Current status of neonatal screening in China. *J Med Screen* 1999;6(4):186-7.
- Guldberg P, Henriksen KF, Guttler F. Molecular analysis of phenylketonuria in Denmark: 99% of the mutations detected by denaturing gradient gel electrophoresis. *Genomics* 1993 Jul;17(1):141-6.
- Guldberg P, Henriksen KF, Sipila I, Guttler F, de la Chapelle A. Phenylketonuria in a low incidence population: molecular characterisation of mutations in Finland. *J Med Genet* 1995 Dec;32(12):976-8.
- Guldberg P, Levy HL, Henriksen KF, Guttler F. Three prevalent mutations in a patient with phenylalanine hydroxylase deficiency: implications for diagnosis and genetic counselling. *J Med Genet* 1996 Feb;33(2):161-4.
- Guldberg P, Mallmann R, Henriksen KF, Guttler F. Phenylalanine hydroxylase deficiency in a population in Germany: mutational profile and nine novel mutations. *Hum Mutat* 1996;8(3):276-9.
- Guldberg P, Rey F, Zschocke J, Romano V, Francois B, Michiels L, Ullrich K, Hoffmann GF, Burgard P, Schmidt H, Meli C, Riva E, Dianzani I, Ponzzone A, Rey J, Guttler F. A European multicenter study of phenylalanine hydroxylase deficiency: classification of 105 mutations and a general system for genotype-based prediction of metabolic phenotype. *Am J Hum Genet* 1998 Jul;63(1):71-9. Published erratum appears in *Am J Hum Genet* 1998 Oct;63(4):1252-3.

- Guldberg P, Romano V, Ceratto N, Bosco P, Ciuna M, Indelicato A, Mollica F, Meli C, Giovannini M, Riva E, et al. Mutational spectrum of phenylalanine hydroxylase deficiency in Sicily: implications for diagnosis of hyperphenylalaninemia in southern Europe. *Hum Mol Genet* 1993 Oct;2(10):1703-7.
- Guldberg P, Zschocke J, Dagbjartsson A, Henriksen KF, Guttler F. A molecular survey of phenylketonuria in Iceland: identification of a founding mutation and evidence of predominant Norse settlement. *Eur J Hum Genet* 1997 Nov-Dec;5(6):376-81.
- Guneral F, Ozalp I, Tatlidil H. Heterozygous carriers of classical phenylketonuria in a sample of the Turkish population: detection by a spectrofluorimetric method. *J Inher Metab Dis* 1991;14(5):741-8. Comment in: *J Inher Metab Dis* 1992;15(2):293-4.
- Guttler F. Hyperphenylalaninemia: diagnosis and classification of the various types of phenylalanine hydroxylase deficiency in childhood. *Acta Paediatr Scand Suppl* 1980;280:1-80.
- Guttler F, Guldberg P. Mutations in the phenylalanine hydroxylase gene: genetic determinants for the phenotypic variability of hyperphenylalaninemia. *Acta Paediatr Suppl* 1994 Dec;407:49-56.
- Guttler F, Woo SL. Molecular genetics of PKU. *J Inher Metab Dis* 1986;9 Suppl 1:58-68.
- Hagenfeldt L, Lundberg K, Larsson A, Thuresson M. [Information from the PKU-section - report of activities 1981]. *Jordmodern* 1982 Sep;95(9):287-90. (Swe).
- Haibach H, Woodruff CW. Neonatal screening for metabolic diseases in Missouri. *Mo Med* 1982 Sep;79(9):615-20.
- Hashem N, Bosco P, Chiavetta V, Cali F, Ceratto N, Romano V. Preliminary studies on the molecular basis of hyperphenylalaninemia in Egypt. *Hum Genet* 1996 Jul;98(1):3-6.
- Henderson HE, Goodman R, Schram J, Diamond E, Daneel A. Biochemical screening for inherited metabolic disorders in the mentally retarded. *S Afr Med J* 1981 Nov 7;60(19):731-3.
- Hertzberg M, Jahromi K, Ferguson V, Dahl HH, Mercer J, Mickleson KN, Trent RJ. Phenylalanine hydroxylase gene haplotypes in Polynesians: evolutionary origins and absence of alleles associated with severe phenylketonuria. *Am J Hum Genet* 1989 Mar;44(3):382-7.
- Hitzeroth HW. Phenylketonuria in South Africa [letter]. *S Afr Med J* 1983 May 14;63(20):756.
- Hitzeroth HW, Niehaus CE, Brill DC. Phenylketonuria in South Africa. A report on the status quo. *S Afr Med J* 1995 Jan;85(1):33-6.
- Hofman KJ, Antonarakis SE, Missiou-Tsangaraki S, Boehm CD, Valle D. Phenylketonuria in the Greek population. Haplotype analysis of the phenylalanine hydroxylase gene and identification of a PKU mutation. *Mol Biol Med* 1989 Jun;6(3):245-50.
- Holtzman C, Slazyk WE, Cordero JF, Hannon WH. Descriptive epidemiology of missed cases of phenylketonuria and congenital hypothyroidism. *Pediatrics* 1986 Oct;78(4):553-8.
- Holtzman NA, Faden R, Chwalow AJ, Horn SD. Effect of informed parental consent on mothers' knowledge of newborn screening. *Pediatrics* 1983 Dec;72(6):807-12.
- Holtzman NA, Leonard CO, Farfel MR. Issues in antenatal and neonatal screening and surveillance for hereditary and congenital disorders. *Annu Rev Public Health* 1981;2:219-51.
- Howell RR. Phenylketonuria in the general population. *N Engl J Med* 1970 Jun 25;282(26):1486-8.
- Hsia DY, Dobson J, Koch R, Woolf LI. Sex ratio in phenylketonuria. *Lancet* 1970 Jul 11;1(7663):96.
- Hsiao KJ, Chen CH, Liu TT, Wu SJ, Plettner C, Clemens P. Screening of congenital hypothyroidism, phenylketonuria, galactosemia, homocystinuria, and maple syrup urine disease in moderate to severe mentally retarded Chinese children. *Taiwan I Hsueh Hui Tsa Chih* 1989 Jan;88(1):18-22.
- Hutchesson AC, Hall SK, Preece MA, Green A. Screening for tyrosinaemia type I. *Arch Dis Child Fetal Neonatal Ed* 1996 May;74(3):F191-4.
- Hyanek J, Bendl J, Zeman J, Soukup K, Dolezal A, Kozich V, St'astna S, Kubik M, Viletova H. [Maternal hyperphenylalaninemia in a population of healthy Czech women. 18 years' experience with mass screening, diet therapy and metabolic monitoring]. *Cas Lek Cesk* 1996 Jan 17;135(2):50-3. (Cze).
- Jancar J. Increased life expectancy in people with untreated phenylketonuria. *J Intellect Disabil Res* 1998 Feb;42 (Pt 1):97-9.
- Jardim LB, Giugliani R, Coelho JC, Dutra-Filho CS, Blau N. Possible high frequency of tetrahydrobiopterin deficiency in south Brazil. *J Inher Metab Dis* 1994;17(2):223-9.
- Jaruzelska J, Henriksen KF, Guttler F, Riess O, Borski K, Blin N, Slomski R. The codon 408 mutation associated with haplotype 2 is predominant in Polish

- families with phenylketonuria. *Hum Genet* 1991 Jan;86(3):247-50.
- Jaruzelska J, Matuszak R, Lyonnet S, Rey F, Rey J, Filipowicz J, Borski K, Munnich A. Genetic background of clinical homogeneity of phenylketonuria in Poland. *J Med Genet* 1993 Mar;30(3):232-4.
- Jenkins MB. Newborn metabolic screening in Minnesota. II. PKU and galactosemia. *Minn Med* 1981 Jul;64(7):429-32, 398.
- Kalaydjieva L, Dworniczak B, Aulehla-Schol C, Kremensky I, Bronzova J, Eigel A, Horst J. Classical phenylketonuria in Bulgaria: RFLP haplotypes and frequency of the major mutations. *J Med Genet* 1990 Dec;27(12):742-5.
- Kalaydjieva L, Dworniczak B, Kucinskas V, Yurgeliavicius V, Kunert E, Horst J. Geographical distribution gradients of the major PKU mutations and the linked haplotypes. *Hum Genet* 1991 Feb;86(4):411-3.
- Kalaydjieva L, Kremensky I. Screening for phenylketonuria in a totalitarian state. *J Med Genet* 1992 Sep;29(9):656-8.
- Kalter H, Warkany J. Medical progress. Congenital malformations: etiologic factors and their role in prevention (first of two parts). *N Engl J Med* 1983 Feb 24;308(8):424-31.
- Kaufman S. Genetic disorders involving recycling and formation of tetrahydrobiopterin. *Adv Pharmacol* 1998;42:41-3.
- Kawamura M. [Laboratory examinations for inborn errors of metabolism]. *Rinsho Byori* 1986 Feb;34(2):133-5. (Jpn).
- Khusnutdinova EK, Khidiatova IM, Viktoronva TV, Fatkhislavoma RI, Galeeva AR, Limborskaia SA. [Genetic distances and taxonomic analysis of human populations of the Volga-Ural region based on data on DNA polymorphism]. *Genetika* 1999 Jul;35(7):982-7. (Rus).
- Kidd KK. Phenylketonuria. Population genetics of a disease [news]. *Nature* 1987 May 28-Jun 3;327(6120):282-3.
- Kietduriyakul V, Komkris V, Tongkittikul K, Leangphibul P. The incidence of phenylketonuria in Thailand. *J Med Assoc Thai* 1989 Sep;72(9):516-9.
- Kietduriyakul V, Leangphibul P, Tongkittikul K. Study of phenylketonuria incidence in Thai children. *J Med Assoc Thai* 1988 May;71(5):258-61.
- Kilpatrick NM, Awang H, Wilcken B, Christodoulou J. The implication of phenylketonuria on oral health. *Pediatr Dent* 1999 Nov-Dec;21(7):433-7.
- Kitagawa T. [Inborn errors of metabolism among the Japanese]. *Nippon Rinsho* 1980 Oct;38(10):4209-18. (Jpn).
- Kleiman S, Avigad S, Vanagaite L, Shmuelevitz A, David M, Eisensmith RC, Brand N, Schwartz G, Rey F, Munnich A. Origins of hyperphenylalaninemia in Israel. *Eur J Hum Genet* 1994;2(1):24-34.
- Koch R, Dobson J, Hsia DY, Woolf LI. Conference on sex ratio in phenylketonuria. *J Pediatr* 1971 Jan;78(1):157-9.
- Koch R, Hanley W, Levy H, Matalon R, Rouse B, Dela Cruz F, Azen C, Gross Friedman E. A preliminary report of the collaborative study of maternal phenylketonuria in the United States and Canada. *J Inherit Metab Dis* 1990;13(4):641-50.
- Koch R, Levy HL, Matalon R, Rouse B, Hanley W, Azen C. The North American Collaborative Study of Maternal Phenylketonuria. Status report 1993. *Am J Dis Child* 1993 Nov;147(11):1224-30.
- Koch R, Williams J. Prevalence of congenital heart disease in patients with phenylketonuria [letter]. *J Pediatr* 1992 Jul;121(1):163-5. Comment on: *J Pediatr* 1991 Aug;119(2):282-3.
- Konecki DS, Lichter-Konecki U. The phenylketonuria locus: current knowledge about alleles and mutations of the phenylalanine hydroxylase gene in various populations. *Hum Genet* 1991 Aug;87(4):377-88.
- Korson MS. Advances in newborn screening for metabolic disorders: What the pediatrician needs to know. *Pediatr Ann* 2000;29(5):294-301.
- Kotzer AM, Jackson GG, McCabe ER. A tool for quick and easy data collection. *MCN Am J Matern Child Nurs* 1985 Jul-Aug;10(4):238.
- Kutter D. [Frequency of phenylketonuria heterozygotes]. *Kinderarztl Prax* 1980 Mar;48(3):121-4. (Ger).
- Kutter D, Thoma J. Frequency of phenylketonuria carriers. *Biochem Med* 1982 Dec;28(3):285-9.
- Kwon C, Farrell PM. The magnitude and challenge of false-positive newborn screening test results. *Arch Pediatr Adolesc Med* 2000;154(7):714-8.
- Kyu H, Thu A, Cook PJ. Human genetics in Burma. *Hum Hered* 1981;31(5):291-5.
- Laberge C, Ferreira P, Grenier A, Laframboise R, Morissette J. [Hyperphenylalaninemia]. *The Canadian*

- and Quebec experience]. *Arch Fr Pediatr* 1987;44 Suppl 1:643-7. (Fre).
- Lambotte C. [Current status of neonatal screening on the national and regional level]. *Rev Med Liege* 1984 May 15;39(10):413-5. (Fre).
- Laurence M, Harper PS, Harris R, Nevin NC, Roberts DF. Report of the delegation of clinical geneticists to China, Spring 1986. *Biol Soc* 1987 Jun;4(2):61-77.
- Le Coutour X, Brouard J, Bordenave-Tilliard C. [Phenylketonuria: new questions for another generation]. *J Gynecol Obstet Biol Reprod (Paris)* 1992;21(1):85-8. (Fre).
- Leandro P, Rivera I, Ribeiro V, de Almeida IT, da Silveira C, Lechner MC. Mutation analysis of phenylketonuria in south and central Portugal: prevalence of V388M mutation. *Hum Mutat* 1995;6(2):192-4.
- Lebedev BV, Bliumina MG, Ladodo KS. [Pressing problems of phenylketonuria]. *Pediatrics* 1980 Jun;66(6):65-7. (Rus).
- Leonard HM, Fletcher JM. Inherited metabolic diseases: beyond newborn screening [editorial]. *Med J Aust* 1999 Jun 21;170(12):573-4. Comment on: *Med J Aust* 1999 Jun 21;170(12):592-5.
- Levy HL. Genetic screening. *Adv Hum Genet* 1973;4:1-104.
- Levy HL. Genetic screening: notes added in proof. *Adv Hum Genet* 1973;4:389-94.
- Levy HL, Karolkewicz V, Houghton SA, MacCready RA. Screening the "normal" population in Massachusetts for phenylketonuria. *N Engl J Med* 1970 Jun 25;282(26):1455-8.
- Levy HL, Lobbregt D, Koch R, de la Cruz F. Paternal phenylketonuria. *J Pediatr* 1991 May;118(5):741-3.
- Lichter-Konecki U, Schlotter M, Konecki DS, Labeit S, Woo SL, Trefz FK. Linkage disequilibrium between mutation and RFLP haplotype at the phenylalanine hydroxylase locus in the German population. *Hum Genet* 1988 Apr;78(4):347-52.
- Lichter-Konecki U, Schlotter M, Trefz FK, Konecki DS. Direct detection of a major mutation responsible for phenylketonuria in the population of the Federal Republic of Germany. *Eur J Pediatr* 1989 Nov;149(2):120-3.
- Lichter-Konecki U, Schlotter M, Yaylak C, Ozguc M, Coskun T, Ozalp I, Wendel U, Batzler U, Trefz FK, Konecki D. DNA haplotype analysis at the phenylalanine hydroxylase locus in the Turkish population. *Hum Genet* 1989 Mar;81(4):373-6.
- Lie SO. [Asbjorn Folling's disease. Reflections on a 50-year anniversary]. *Tidsskr Nor Laegeforen* 1984 Dec 10;104(34):2381-5. (Nor).
- Liu SR, Zuo QH. Newborn screening for phenylketonuria in eleven districts. *Chin Med J (Engl)* 1986 Feb;99(2):113-8.
- Lord J, Thomason MJ, Littlejohns P, Chalmers RA, Bain MD, Addison GM, Wilcox AH, Seymour CA. Secondary analysis of economic data: a review of cost-benefit studies of neonatal screening for phenylketonuria. *J Epidemiol Community Health* 1999 Mar;53(3):179-86.
- MacDonald A, Rylance GW, Asplin DA, Hall K, Harris G, Booth IW. Feeding problems in young PKU children. *Acta Paediatr Suppl* 1994 Dec;407:73-4.
- Machill G, Gedschold J, Kropf S. Birth distribution in cystic fibrosis and phenylketonuria. *Eur J Pediatr* 1990 Mar;149(6):406-7.
- Mallolas J, Vilaseca MA, Campistol J, Lambruschini N, Cambra FJ, Estivill X, Mila M. Mutational spectrum of phenylalanine hydroxylase deficiency in the population resident in Catalonia: genotype-phenotype correlation. *Hum Genet* 1999 Nov;105(5):468-73.
- Malone JL. Infant screening for phenylketonuria in Florida. *J Fla Med Assoc* 1983 Sep;70(9):782-3.
- Manghi E, Belloni L, Cambie F, Cerisola N, Dagnino G, Felisi G, Manghi D, Oppici W, Carella L. [Neurologic diseases, mental retardation and reduction in work capacity]. *Riv Neurol* 1985 Jul-Aug;55(4):256-300. (Ita).
- Martinez-Pardo M, Colmenares AR, Garcia MJ, Perez B, Desviat LR, Ugarte M. Phenotype distribution in the Spanish phenylketonuria population and related genotypes. *J Inher Metab Dis* 1994;17(3):366-8.
- Mathias D, Bickel H. Follow-up study of 16 years neonatal screening for inborn errors of metabolism in West Germany. *Eur J Pediatr* 1986 Sep;145(4):310-2.
- McCabe LL, McCabe ERB. Population studies of allele frequencies in single gene disorders: methodological and policy considerations. *Epidemiol Rev* 1997;19(1):52-60.
- Medical Research Council Steering Committee for the MRC/DHSS Phenylketonuria Register. Routine neonatal screening for phenylketonuria in the United Kingdom 1964-78. *Br Med J (Clin Res Ed)* 1981 May 23;282(6277):1680-4.
- Meijer WJ. [10 years' national screening study of the incidence of phenylketonuria in the Netherlands; 3d report of the National Advisory Phenylketonuria

- Commission]. *Ned Tijdschr Geneesk* 1985 Jan 12;129(2):74-6. (Dut).
- Michiels L, Francois B, Raus J, Vandevyver C. Identification of seven new mutations in the phenylalanine hydroxylase gene, associated with hyperphenylalaninemia in the Belgian population. *Hum Mutat* 1998;Suppl 1:S123-4.
- Morisi G, Patriarca M, Marano G, Giampaoli S, Taggi F. Age and sex specific reference serum selenium levels estimated for the Italian population. *Ann Ist Super Sanita* 1989;25(3):393-403.
- Mowat DR, Hayden MC, Thompson SM, Wilcken B. Maternal phenylketonuria: a continuing problem. *Med J Aust* 1999 Jun 21;170(12):592-5. Comment in: *Med J Aust* 1999 Jun 21;170(12):573-4.
- Mugarra Bidea I, Cabases Hita JM. [Cost-benefit analysis of the early detection program for metabolic diseases in the Autonomous Basque Community]. *Gac Sanit* 1990 Jul-Aug;4(19):140-4. (Spa).
- Nagao M. A simple and rapid polymerase chain reaction-based method for detecting a prevalent mutation (R413P) in Japanese phenylketonuria patients. *Acta Paediatr Jpn* 1997 Feb;39(1):6-9.
- Naylor EW. Newborn screening for urea cycle disorders. *Adv Exp Med Biol* 1982;153:9-18.
- [Neonatal screening of phenylketonuria and hypothyroidism in France. 1985 statistics. French Association for the Screening and Prevention of Metabolic Diseases and Handicaps in Children]. *Arch Fr Pediatr* 1987;44 Suppl 1:749-54. (Fre).
- Newborn screening. U.S. Public Health Service. *Am Fam Physician* 1994 Aug;50(2):354-8.
- Norgaard-Pedersen B. [The PKU registry and biobank at the National Serum Institute. Rules and applications]. *Ugeskr Laeger* 1998 Apr 6;160(15):2266-7. (Dan).
- Norum KR. Studies on inborn errors of metabolism in Norway. *Arteriosclerosis* 1989 Jan-Feb;9(1 Suppl):1164-8.
- Novello AC. Inherited metabolic diseases: collaborating for the health of all children. *Biochem Med Metab Biol* 1993 Jun;49(3):277-84.
- O'Neill CA, Eisensmith RC, Croke DT, Naughten ER, Cahalane SF, Woo SL. Molecular analysis of PKU in Ireland. *Acta Paediatr Suppl* 1994 Dec;407:43-4.
- Okano Y, Eisensmith RC, Dasovich M, Wang T, Guttler F, Woo SL. A prevalent missense mutation in Northern Europe associated with hyperphenylalaninaemia. *Eur J Pediatr* 1991 Mar;150(5):347-52.
- Okano Y, Eisensmith RC, Guttler F, Lichter-Konecki U, Konecki DS, Trefz FK, Dasovich M, Wang T, Henriksen K, Lou H, et al. Molecular basis of phenotypic heterogeneity in phenylketonuria. *N Engl J Med* 1991 May 2;324(18):1232-8. Comment in: *N Engl J Med* 1991 May 2;324(18):1280-1.
- Okano Y, Hase Y, Lee DH, Takada G, Shigematsu Y, Oura T, Isshiki G. Molecular and population genetics of phenylketonuria in Orientals: correlation between phenotype and genotype. *J Inher Metab Dis* 1994;17(1):156-9.
- Okano Y, Isshiki G. Newborn mass screening and molecular genetics of phenylketonuria in east Asia. *Southeast Asian J Trop Med Public Health* 1995;26 Suppl 1:123-9.
- Okano Y, Wang T, Eisensmith RC, Longhi R, Riva E, Giovannini M, Cerone R, Romano C, Woo SL. Phenylketonuria missense mutations in the Mediterranean. *Genomics* 1991 Jan;9(1):96-103.
- Oorthuys JW, Gons MH, Kwakman JV, Schutgens RB, Tegelaers WH. [Screening for raised serum phenylalanine levels in women of reproductive age in Volendam]. *Ned Tijdschr Geneesk* 1985 Jan 12;129(2):62-5. (Dut).
- Op't Hof J, Hitzeroth HW. Phenylketonuria (PKU) in the RSA [letter]. *S Afr Med J* 1987 Apr 18;71(8):538-9.
- Op't Hof J, Hitzeroth HW. Phenylketonuria, pyruvate kinase deficiency and Kouska's fallacy [letter]. *S Afr Med J* 1987 Nov 7;72(9):648.
- Osorio RV, Vilarinho L, Soares JP. [National screening for phenylketonuria, congenital hypothyroidism and congenital adrenal hyperplasia]. *Acta Med Port* 1992 Mar;5(3):131-4. (Por).
- Ounap K, Lillevali H, Klaassen T, Metspalu A, Sitska M. The incidence and characterization of phenylketonuric patients in Estonia. *J Inher Metab Dis* 1996;19(3):381-2.
- Ounap K, Lillevali H, Metspalu A, Lipping-Sitska M. Development of the phenylketonuria screening programme in Estonia. *J Med Screen* 1998;5(1):22-3.
- Ozalp I, Coskun T, Tokol S, Demircin G, Monch E. Inherited metabolic disorders in Turkey. *J Inher Metab Dis* 1990;13(5):732-8.
- Ozand PT, Devol EB, Gascon GG. Neurometabolic diseases at a national referral center: five years experience at the King Faisal Specialist Hospital and

- Research Centre. *J Child Neurol* 1992 Apr;7 Suppl:S4-11.
- Perez B, Desviat LR, De Lucca M, Schmidt B, Loghin-Grosso N, Giugliani R, Pires RF, Ugarte M. Mutation analysis of phenylketonuria in south Brazil. *Hum Mutat* 1996;8(3):262-4.
- Perez B, Desviat LR, De Lucca M, Ugarte M. Spectrum and origin of phenylketonuria mutations in Spain. *Acta Paediatr Suppl* 1994 Dec;407:34-6.
- Perez B, Desviat LR, Die M, Ugarte M. Mutation analysis of phenylketonuria in Spain: prevalence of two Mediterranean mutations. *Hum Genet* 1992 May;89(3):341-2.
- Perez B, Desviat LR, Ugarte M. Analysis of the phenylalanine hydroxylase gene in the Spanish population: mutation profile and association with intragenic polymorphic markers. *Am J Hum Genet* 1997 Jan;60(1):95-102.
- Persha AJ. Early identification and prevention of mental retardation. *ICCW News B* 1992 Jan-Mar;40(1):9-12.
- Pitt DB, O'Day J. Phenylketonuria does not cause cataracts. *Eur J Pediatr* 1991 Jul;150(9):661-4.
- Priscu AR, Manolescu E, Sichitiu S, Iordachescu F, Tomescu E, Stamate M, Ciurea A, Poboran V, Iacob C, Bugariu E, Milcu M, Caniola I, Gasparovici L, Bucur I, Stefanache O, Georgescu BG, Zaharescu J, Opris CC, Paltineau V, Horincaru N, Wirtz A, Tertan I, Szabo I, Tamas N. [Pilot experiment concerning the concomitant detection of congenital hypothyroidism and phenylketonuria in newborn infants in a high-risk geographical zone. (Results for the year 1979)]. *Rev Pediatr Obstet Ginecol Pediatr* 1980 Apr-Jun;29(2):131-8. (Rum).
- Rall JE. Where are the genes specifying mental illness? *J Nerv Ment Dis* 1998 Nov;186(11):722-3.
- Ramus SJ, Treacy EP, Cotton RG. Characterization of phenylalanine hydroxylase alleles in untreated phenylketonuria patients from Victoria, Australia: origin of alleles and haplotypes. *Am J Hum Genet* 1995 May;56(5):1034-41.
- Reiss MJ. The ethics of genetic research on intelligence. *Bioethics* 2000;14(1):1-15.
- Rivera I, Leandro P, Lichter-Konecki U, de Almeida IT, Lechner MC. Relative frequency of IVS10nt546 mutation in a Portuguese phenylketonuric population. *Hum Mutat* 1997;9(3):272-3.
- Rivera I, Leandro P, Lichter-Konecki U, Tavares de Almeida I, Lechner MC. Population genetics of hyperphenylalaninaemia resulting from phenylalanine hydroxylase deficiency in Portugal. *J Med Genet* 1998 Apr;35(4):301-4.
- Romano V, Cali F, Guldborg P, Guttler F, Indelicato A, Bosco P, Ceratto N. Association between haplotypes, hind III-VNTR alleles and mutations at the PAH locus in Sicily. *Acta Paediatr Suppl* 1994 Dec;407:39-40.
- Romano V, Guldborg P, Guttler F, Meli C, Mollica F, Pavone L, Giovannini M, Riva E, Biasucci G, Luotti D, Palillo L, Cali F, Ceratto N, Anello G, Bosco P. PAH deficiency in Italy: correlation of genotype with phenotype in the Sicilian population. *J Inher Metab Dis* 1996;19(1):15-24.
- Romeo G, Menozzi P, Ferlini A, Prosperi L, Cerone R, Scalisi S, Romano C, Antonozzi I, Riva E, Piceni Sereni L, et al. Incidence of classic PKU in Italy estimated from consanguineous marriages and from neonatal screening. *Clin Genet* 1983 Nov;24(5):339-45.
- Roth KS. Newborn metabolic screening: a search for nature's experiments. *South Med J* 1986 Jan;79(1):47-54.
- Rozen R, Mascisch A, Lambert M, Laframboise R, Sriver CR. Mutation profiles of phenylketonuria in Quebec populations: evidence of stratification and novel mutations. *Am J Hum Genet* 1994 Aug;55(2):321-6.
- Ruzickova S, Kozak L, Blazkova M, Kapras J, St'astna S. [Mutation of the phenylalanine hydroxylase gene in the population of central Bohemia. Relation to the clinical picture of phenylketonuria]. *Cas Lek Cesk* 1997 May 7;136(9):282-5. (Cze).
- Saito T. An expected decrease in the incidence of autosomal recessive disease due to decreasing consanguineous marriages. *Genet Epidemiol* 1988;5(6):421-32.
- Sayle AE, Cooper GS, Savitz DA. Menstrual and reproductive history of mothers of galactosemic children. *Fertil Steril* 1996 Mar;65(3):534-8.
- Sriver CC. A simple phenylalanine method for detecting phenylketonuria in large populations of newborn infants, by Robert Guthrie and Ada Susi, *Pediatrics*, 1963;32:318-343. *Pediatrics* 1998 Jul;102(1 Pt 2):236-7.
- Sriver CR. Science, medicine and phenylketonuria. *Acta Paediatr Suppl* 1994 Dec;407:11-8.
- Sriver CR, Waters PJ, Sarkissian C, Ryan S, Prevost L, Cote D, Novak J, Teebi S, Nowacki PM. PAHdb: a locus-specific knowledgebase. *Hum Mutat* 2000;15(1):99-104.

- Seashore MR. Genetic screening and the pediatrician. *Pediatr Ann* 2000;29(5):272-6.
- Sengers RC. [Early detection of phenylketonuria in the Netherlands, 1977-1979. 2d report of the National Care Commission on Phenylketonuria]. *Ned Tijdschr Geneesk* 1981 Dec 26;125(52):2135-40. (Dut).
- Seymour CA, Thomason MJ, Chalmers RA, Addison GM, Bain MD, Cockburn F, Littlejohns P, Lord J, Wilcox AH. Newborn screening for inborn errors of metabolism: a systematic review. *Health Technol Assess* 1997;1(11):i-iv, 1-95.
- Shintaku H. [The metabolic basis of the hyperphenylalaninemia and tyrosinemia]. *Nippon Rinsho* 1992 Jul;50(7):1542-7. (Jpn).
- Simonsen H, Brandt NJ, Norgaard-Pedersen B. [Neonatal screening in Denmark. Status and future perspectives]. *Ugeskr Laeger* 1998 Sep 28;160(40):5777-82. (Dan).
- Skorkowska-Zieleniewska J, Cabalska B, Golabek B, Symonowicz H, Nowakowska M. [Biochemical analysis of lead level in the hair of a mixed population. II. Comparison of the lead level in the hair of healthy children and in those with various diseases]. *Rocz Panstw Zakl Hig* 1984;35(4):337-40. (Pol).
- Smith I, Cook B, Beasley M. Review of neonatal screening programme for phenylketonuria. *BMJ* 1991 Aug 10;303(6798):333-5. Published erratum appears in *BMJ* 1991 Oct 5;303(6806):824. Comment in: *BMJ* 1991 Aug 24;303(6800):471; *BMJ* 1991 Sep 21;303(6804):716.
- Sobra J. [Nutrition and metabolic diseases with a mass incidence]. *Cas Lek Cesk* 1990 Jul 20;129(29):897-901. (Cze).
- Somers DG, Favreau L. Newborn screening for phenylketonuria: incidence and screening procedures in North America. *Can J Public Health* 1982 May-Jun;73(3):206-7.
- Sommer SS, Cassady JD, Sobell JL, Bottema CD. A novel method for detecting point mutations or polymorphisms and its application to population screening for carriers of phenylketonuria. *Mayo Clin Proc* 1989 Nov;64(11):1361-72.
- St James PJ, Younger MD, Hamilton BD, Waisbren SE. Unplanned pregnancies in young women with diabetes. An analysis of psychosocial factors. *Diabetes Care* 1993 Dec;16(12):1572-8.
- Starfield B. Motherhood and apple pie: the effectiveness of medical care for children. *Milbank Mem Fund Q Health Soc* 1985 Summer;63(3):523-46.
- Steiner KC, Smith HA. Application of cost-benefit analysis to a PKU screening program. *Inquiry* 1973 Dec;10(4):34-40.
- Stevens MB, Rigilano JC, Wilson CC. State screening for metabolic disorders in newborns. *Am Fam Physician* 1988 Apr;37(4):223-8.
- Subramanyam SB. Saudi aminoacidemias: a six-year study. *Indian J Pediatr* 1996 Sep-Oct;63(5):641-4.
- Szabo L, Somogyi C, Mate M. Experience based on 800,000 newborn screening tests of the Budapest Phenylketonuria Centre. *Acta Paediatr Hung* 1985;26(2):113-25.
- Tada K, Tateda H, Arashima S, Sakai K, Kitagawa T, Aoki K, Suwa S, Kawamura M, Oura T, Takesada M, et al. Follow-up study of a nation-wide neonatal metabolic screening program in Japan. A collaborative study group of neonatal screening for inborn errors of metabolism in Japan. *Eur J Pediatr* 1984 Aug;142(3):204-7.
- Takarada Y, Kalanin J, Yamashita K, Ohtsuka N, Kagawa S, Matsuoka A. Phenylketonuria mutant alleles in different populations: missense mutation in exon 7 of phenylalanine hydroxylase gene [letter]. *Clin Chem* 1993 Nov;39(11 Pt 1):2354-5.
- Takarada Y, Yamashita K, Kalanin J, Kagawa S, Matsuoka A. [Genetic diagnosis of phenylketonuria. IV. Mutations of phenylalanine hydroxylase gene in Caucasian and Gypsy populations in Czech and Slovakia Republics]. *Rinsho Byori* 1994 Nov;42(11):1165-71. (Jpn).
- Teebi AS, Al-Awadi SA, Farag TI, Naguib KK, el-Khalifa MY. Phenylketonuria in Kuwait and Arab countries. *Eur J Pediatr* 1987 Jan;146(1):59-60.
- Thalhammer O, Scheibenreiter S, Knoll E, Wehle E, Schon R. [12 years Austrian newborn screening for inborn errors of metabolism. Results with special reference to phenylketonuria, hyperphenylalaninemia and histidinemia (author's transl)]. *Klin Padiatr* 1980 Nov;192(6):589-98. (Ger).
- Therrell BL Jr, Brown LO, Dziuk PE, Peter WP Jr. The Texas Newborn Screening Program. *Tex Med* 1983 Feb;79(2):44-6.
- Tillotson SL, Costello PM, Smith I. No reduction in birth weight in phenylketonuria. *Eur J Pediatr* 1995 Oct;154(10):847-9. Comment in: *Eur J Pediatr* 1997 Feb;156(2):157.
- Treacy E, Byck S, Clow C, Scriver CR. 'Celtic' phenylketonuria chromosomes found? Evidence in two regions of Quebec Province. *Eur J Hum Genet* 1993;1(3):220-8.

- Tyfield LA, Meredith AL, Osborn MJ, Harper PS. Identification of the haplotype pattern associated with the mutant PKU allele in the Gypsy population of Wales. *J Med Genet* 1989 Aug;26(8):499-503.
- Tyfield LA, Osborn MJ, Holton JB. Molecular heterogeneity at the phenylalanine hydroxylase locus in the population of the south-west of England. *J Med Genet* 1991 Apr;28(4):244-7.
- Tyfield LA, Stephenson A, Bidwell JL, Wood NA, Cockburn F, Harvie A, Smith I. Mutation analysis of the phenylalanine hydroxylase gene using heteroduplex analysis with synthetic DNA constructs. *Acta Paediatr Suppl* 1994 Dec;407:47-8.
- Uma SM, Jyothy A, Reddy PP, Reddi OS. Aminoacidopathies in Andhra Pradesh; report of a screening programme. *J Inherit Metab Dis* 1982;5(4):211-4.
- Velazquez A, Bilbao G, Gonzalez-Trujillo JL, Hernandez D, Perez-Andrade ME, Vela M, Ciceron I, Loera-Luna A, Cederbaum S, Phoenix B. Apparent higher frequency of phenylketonuria in the Mexican state of Jalisco. *Hum Genet* 1996 Jan;97(1):99-102.
- Velazquez A, Loera-Luna A, Aguirre BE, Gamboa S, Vargas H, Robles C. [Neonatal screening for congenital hypothyroidism and phenylketonuria]. *Salud Publica Mex* 1994 May-Jun;36(3):249-56. (Spa).
- Velazquez A, Vela-Amieva M, Ciceron-Arellano I, Ibarra-Gonzalez I, Perez-Andrade ME, Olivares-Sandoval Z, Jimenez-Sanchez G. Diagnosis of inborn errors of metabolism. *Arch Med Res* 2000 Mar 4;31(2):145-50.
- Verkerk PH. [20-year national screening for phenylketonuria in The Netherlands. National Guidance Commission PKU]. *Ned Tijdschr Geneesk* 1995 Nov 11;139(45):2302-5. (Dut).
- Verkerk PH, Vaandrager GJ, Sengers RC. [15 years of national screening for phenylketonuria in The Netherlands; 4th Report of the National Commission for Management of Phenylketonuria]. *Ned Tijdschr Geneesk* 1990 Dec 29;134(52):2533-6. (Dut).
- Verkerk PH, van Spronsen FJ, Smit GP, Cornel MC, Kuipers JR, Verloove-Vanhorick SP. Prevalence of congenital heart disease in patients with phenylketonuria. *J Pediatr* 1991 Aug;119(2):282-3. Comment in: *J Pediatr* 1992 Jul;121(1):163-5.
- Viktorova TV, Murzabaeva SSh, Karunas AU, Magzhanov RV, Khusnutdinova EK. [Molecular genetic analysis of phenylketonuria in Bashkiria]. *Genetika* 1997 Jul;33(7):992-5. (Rus).
- Wachtel U. Review of current practices in management of inherited disorders of amino acid metabolism in Western Europe. *Hum Nutr Appl Nutr* 1986;40 Suppl 1:61-9.
- Waisbren SE, Doherty LB, Bailey IV, Rohr FJ, Levy HL. The New England Maternal PKU Project: identification of at-risk women. *Am J Public Health* 1988 Jul;78(7):789-92.
- Walker V, Clayton BE, Ersler RS, Francis DE, Lilly P, Seakins JW, Smith I, Whiteman PD. Hyperphenylalaninaemia of various types among three-quarters of a million neonates tested in a screening programme. *Arch Dis Child* 1981 Oct;56(10):759-64.
- Wang T, Okano Y, Eisensmith RC, Harvey ML, Lo WH, Huang SZ, Zeng YT, Yuan LF, Furuyama JI, Oura T, et al. Founder effect of a prevalent phenylketonuria mutation in the Oriental population. *Proc Natl Acad Sci U S A* 1991 Mar 15;88(6):2146-50.
- Wang T, Okano Y, Eisensmith RC, Lo WH, Huang SZ, Zeng YT, Yuan LF, Liu SR, Woo SL. Missense mutations prevalent in Orientals with phenylketonuria: molecular characterization and clinical implications. *Genomics* 1991 Jun;10(2):449-56.
- West R, Hale C. Overview of newborn screening in Arkansas. *J Ark Med Soc* 1995 Dec;92(7):329-33.
- Woo SL. Molecular basis and population genetics of phenylketonuria. *Biochemistry* 1989 Jan 10;28(1):1-7.
- Woolf LI. Phenylketonuria in Turkey, Ireland and west Scotland. *J Inherit Metab Dis* 1994;17(2):246-7.
- Wuu KD, Hsiao KJ, Chen CH, Hsiao TS, Chang CY, Chu YK. Screening for inherited metabolic diseases and congenital hypothyroidism in 4,744 mentally retarded school children in Taiwan. *Jinrui Idengaku Zasshi* 1988 Mar;33(1):33-40.
- Yadav G, Farag TI, al Awadi SA, Sam T, Marafie MJ, Bastaki L, el Khalifa MY, Kasrawi B, Wahba RA. Aminoacidopathies among institutionalised mentally retarded in Kuwait [letter]. *Clin Genet* 1992 Oct;42(4):212.
- Yasuda N. Geographical variations in inborn errors of metabolism in Japan. *Hum Hered* 1984;34(1):1-8.
- Zekanowski C, Nowacka M, Zgulska M, Horst J, Cabalska B, Mazurczak T. Frequencies of the most common mutations responsible for phenylketonuria in Poland. *Mol Cell Probes* 1994 Aug;8(4):323-4.
- Zschocke J, Graham CA. A fluorescent multiplex ARMS method for rapid mutation analysis. *Mol Cell Probes* 1995 Dec;9(6):447-51.

Zschocke J, Graham CA, McKnight JJ, Nevin NC. The STR system in the human phenylalanine hydroxylase gene: true fragment length obtained with fluorescent labelled PCR primers. *Acta Paediatr Suppl* 1994 Dec;407:41-2.

Zschocke J, Graham CA, Stewart FJ, Carson DJ, Nevin NC. Automated sequencing detects all mutations in Northern Irish patients with phenylketonuria and mild hyperphenylalaninaemia. *Acta Paediatr Suppl* 1994 Dec;407:37-8.

Zschocke J, Graham CA, Stewart FJ, Carson DJ, Nevin NC. Non-phenylketonuria hyperphenylalaninaemia in Northern Ireland: frequent mutation allows screening and early diagnosis. *Hum Mutat* 1994;4(2):114-8.

Zschocke J, Mallory JP, Eiken HG, Nevin NC. Phenylketonuria and the peoples of Northern Ireland. *Hum Genet* 1997 Aug;100(2):189-94.

Zygulska M, Eigel A, Aulehla-Scholz C, Pietrzyk JJ, Horst J. Molecular analysis of PKU haplotypes in the population of southern Poland. *Hum Genet* 1991 Jan;86(3):292-4.

Zygulska M, Eigel A, Pietrzyk JJ, Miny P, Horst J. A novel mutation in exon 8 of the phenylalanine hydroxylase gene in the Polish population. *Hum Mutat* 1993;2(1):74-6.

Screening and Diagnosis

Acuff KL, Faden RR. A history of prenatal and newborn screening programs: lessons for the future. In: Faden R, Geller G, Powers M, editors. *AIDS, women and the next generation*. New York: Oxford University Press; 1991. p. 59-93.

Adelman CS. The constitutionality of mandatory genetic screening statutes. *Case West Reserv Law Rev* 1981 Summer;31(4):897-948.

Ades AE, Walker J, Jones R, Thompson S, Leonard JV, Smith I. Obstacles to timely neonatal screening in North Thames. *J Med Screen* 1998;5(4):183-6.

Afanas'eva NA, Bychkova AM, Livshits LA, Bariliak IR. [The clinical and molecular genetic characteristics of phenylketonuria patients in the Republic of Crimea]. *Tsitol Genet* 1998 Jan-Feb;32(1):8-14. (Rus).

Ahrens D, Guntert B, Brand A. [Comparative presentation of current economic evaluation studies for phenylketonuria screening]. *Gesundheitswesen* 1999 Apr;61(4):190-6. (Ger).

Aldis B, Hoffman G, Therrell BL Jr. Laboratory methods for phenylalanine analysis on newborn screening specimens. In: Therrell BL Jr, editor. *Laboratory methods for neonatal screening*. Washington: American Public Health Association; c1993. p. 47-75.

Allanson J, McInnes R, Bradley L, Tarby T, Naylor E, Nardella M. Combined transient and peripheral defects in tetrahydrobiopterin synthesis. *J Pediatr* 1991 Feb;118(2):261-3.

Allen KR, Degg TJ, Rushworth PA, Smith M, Henderson MJ. Measurement of phenylalanine and tyrosine in plasma by high-performance liquid chromatography using the inherent fluorescence of aromatic amino acids. *Ann Clin Biochem* 1999 Mar;36(Pt 2):207-11.

Alm J, Larsson A. Evaluation of a nation-wide neonatal metabolic screening programme in Sweden 1965-1979. *Acta Paediatr Scand* 1981 Sep;70(5):601-7.

Alm J, Larsson A, Rosenqvist U. Health economic analysis of the Swedish neonatal metabolic screening programme. A method of optimizing routines. *Med Decis Making* 1982;2(1):33-45.

Alos T, Bel Y, Cabello ML, Catala JL, Dalmau J, Ferre J, Garcia AM, Ruiz-Vazquez P. Improved identification of heterozygotes for phenylketonuria using blood neopterin and biopterin. *J Inherit Metab Dis* 1993;16(2):457-64.

- Altland K, Kaempfer M, Forssbohm M, Werner W. Monitoring for changing mutation rates using blood samples submitted for PKU screening. *Prog Clin Biol Res* 1982;103 Pt A:277-87.
- American Academy of Pediatrics, Committee on Genetics. New issues in newborn screening for phenylketonuria and congenital hypothyroidism. *Pediatrics* 1982 Jan;69(1):104-6.
- American Academy of Pediatrics, Committee on Genetics. Newborn screening fact sheets. *Pediatrics* 1996 Sep;98(3):473-501. Phenylketonuria; p. 489-91.
- American Academy of Pediatrics, Committee on Genetics. Issues in newborn screening. *Pediatrics* 1992 Feb;89(2):345-9.
- American Academy of Pediatrics, Committee on Genetics. Screening for congenital metabolic disorders in the newborn infant. Evanston (IL): American Academy of Pediatrics; 1977. Congenital deficiency of thyroid hormone and hyperphenylalaninemia; p. 389-404. (*Pediatrics*; vol. 60, no. 3, pt. 2).
- Andrews LB, editor. Legal liability and quality assurance in newborn screening. Chicago: American Bar Foundation; 1985. 242 p.
- Annas GJ. Mandatory PKU screening: the other side of the looking glass. *Am J Public Health* 1982 Dec;72(12):1401-3.
- Annenkov GA. [Phenylketonuria and hyperphenylalaninemia: clinico-genetic classification of 14 forms]. *Zh Nevropatol Psikhiatr* 1984;84(3):351-6. (Rus).
- Annenkov GA, Safronova EE, Gubernieva LM, Volkova NM. [Detection of phenylalanine hydroxylase activity in human leukocytes and fibroblasts]. *Vopr Med Khim* 1980 Nov-Dec;26(6):723-6. (Rus).
- Annenkov GA, Safronova EE, Rozovskii IS, Bakharev VA. [Possibility of the prenatal diagnosis of phenylketonuria]. *Akush Ginekol (Mosk)* 1981 Nov;(11):25-7. (Rus).
- Antonozzi I, Carducci C, Vestri L, Pontecorvi A, Moretti F. Rapid and sensitive method for high-performance liquid chromatographic analysis of pterins in biological fluids. *J Chromatogr* 1988 Dec 28;459:319-24.
- Antonozzi I, Dominici R, Andreoli M, Monaco F. Neonatal screening in Italy for congenital hypothyroidism and metabolic disorders: hyperphenylalaninemia, maple syrup urine disease and homocystinuria. *J Endocrinol Invest* 1980 Oct-Dec;3(4):357-63.
- Aoki K. [Disorders of amino acids]. *Nippon Rinsho* 1993 Jan;51 Suppl:332-9. (Jpn).
- Aoki K, Wada Y. Outcome of the patients detected by newborn screening in Japan. *Acta Paediatr Jpn* 1988 Aug;30(4):429-34.
- Appleton RE, Baumer JH, Holton JB. A loophole in the phenylketonuria screening programme [letter]. *Lancet* 1984 Sep 29;2(8405):752.
- Arai N, Narisawa K, Hayakawa H, Tada K. Hyperphenylalaninemia due to dihydropteridine reductase deficiency: diagnosis by enzyme assays on dried blood spots. *Pediatrics* 1982 Sep;70(3):426-30.
- Aulehla-Scholz C, Vorgerd M, Sautter E, Leupold D, Mahlmann R, Ullrich K, Olek K, Horst J. Phenylketonuria: distribution of DNA diagnostic patterns in German families. *Hum Genet* 1988 Apr;78(4):353-5.
- Bachmann C, Colombo JP. Incidence of disorders tested by systematic screening: confidence limits and comparison of programmes. *J Inher Metab Dis* 1982;5(1):3-5.
- Bailey MK, Blackledge L, Day CM, Garcia LS, Parks D, Street T. PKU testing and early newborn release. *MLO Med Lab Observ* 1994 Sep;26(9):63-4.
- Ball SP, Kenwrick SJ, Davies KE. The molecular genetics of human monogenic diseases. *Biotechnol Genet Eng Rev* 1985;3:275-309.
- Bamforth FJ. Laboratory screening for genetic disorders and birth defects. *Clin Biochem* 1994 Oct;27(5):333-42.
- Bankier A. Syndrome quiz. Maternal phenylketonuria. *Aust Fam Physician* 1990 Oct;19(10):1595-6.
- Baranov VS. [Successes and prospects of molecular diagnosis of the most widespread inherited diseases]. *Tsitol Genet* 1992 Jul-Aug;26(4):64-72. (Rus).
- Barasnev J. [Enzyme activity and the character of metabolic changes in brain tissue in children with phenylketonuria and histidinemia]. *Cesk Pediatr* 1980;35(2):49-52. (Cze).
- Barden HS, Kessel R, Schuett VE. The costs and benefits of screening for PKU in Wisconsin. *Soc Biol* 1984 Spring-Summer;31(1-2):1-17.
- Barwell BE, Pollitt RJ. [Attitude of parents toward the prenatal diagnosis of phenylketonuria]. *Arch Fr Pediatr* 1987;44 Suppl 1:665-6. (Fre).
- Beardsley T. Genetic diseases: problems of prenatal testing [news]. *Nature* 1985 Mar 21;314(6008):211.

- Beck B, Brandt NJ, Christensen E, Niederwieser A, Pedersen PS. Diagnostic and therapeutic aspects of dihydrobiopterin deficiency. *Acta Paediatr Scand* 1983 May;72(3):449-54.
- Becker K, Harenz J, Kalle N, Hommel G, Behbehani AW. Comparative column chromatographic estimations of phenylalanine in plasma, whole blood, native and paper-dried capillary blood of healthy children and adults, and patients with hyperphenylalaninaemia. *J Inherit Metab Dis* 1985;8(3):119-22.
- Behbehani AW, Krtisch H, Schulte FJ. Cranial computerized tomography in phenylketonuria. *Neuropediatrics* 1981 Nov;12(4):295-302.
- Berardi R, Baracchi MR, Borgogni P, Margollicci MA, Mattei R, Fois A. [Results of a screening project for congenital hypothyroidism in 4 years of experience]. *Pediatr Med Chir* 1982 Nov-Dec;4(6):657-60. (Ita).
- Berenbaum SA. Neuropsychological follow-up in neonatal screening: issues, methods and findings. *Acta Paediatr Suppl* 1999 Dec;88(432):83-7.
- Berman JL. PKU-hypothesis concerning failures of screening [letter]. *J Pediatr* 1980 May;96(5):953-4.
- Bernat K. [The early diagnosis of phenylketonuria]. *Pieleg Polozna* 1989;(6):4, 23. (Pol).
- Bernat K. [Evaluation of the phenylalanine tolerance test in detection of heterozygote carriers of phenylketonuria gene]. *Pol Tyg Lek* 1992 Mar 2-9;47(9-10):219-21. (Pol).
- Berry HK. Screening newborns for genetic disease: the PKU model. *Diagn Med* 1984 Jan;7(1):50-4, 56, 58-9.
- Berry HK, Hsieh MH, Bofinger MK, Schubert WK. Diagnosis of phenylalanine hydroxylase deficiency (phenylketonuria). *Am J Dis Child* 1982 Feb;136(2):111-4.
- Berry HK, Porter LJ. Newborn screening for phenylketonuria [letter]. *Pediatrics* 1982 Sep;70(3):505-6.
- Bickel H. [Early diagnosis of phenylketonuria]. *Monatsschr Kinderheilkd* 1966 Jan;114(1):23-5. (Ger).
- Bickel H. Phenylalaninaemia or classical phenylketonuria (PKU)? *Neuropadiatrie* 1970 Apr;1(4):379-82.
- Bickel H. Phenylketonuria. In: Schmidt BJ, Diamant AJ, Loghin-Grosso NS, editors. *Current trends in infant screening. Proceedings of the 7th International Screening Symposium; 1988 Nov 6-9; Sao Paulo, Brazil.* New York: Excerpta Medica; 1989. p. 45-53. (International congress series; no. 848).
- Bickel H. Phenylketonuria: past, present, future. F. P. Hudson Memorial Lecture, Leeds, 1979. *J Inherit Metab Dis* 1980;3(4):123-32.
- Bickel H. [Phenylketonuria. Yesterday, today and tomorrow]. *Arch Fr Pediatr* 1983;40 Suppl 1:207-13. (Fre).
- Bickel H. Recent advances in the early detection and treatment of inborn errors with brain damage. *Neuropadiatrie* 1969 Jun-Jul;1(1):1-11.
- Bickel H. [Screening for congenital metabolic disorders. Indication and results]. *Monatsschr Kinderheilkd* 1983 Jun;131(6):323-7. (Ger).
- Bickel H, Ruter E, Nutzenadel W. [Early detection of hereditary enzyme defects of amino acid metabolism by means of microbiological inhibitor tests and thin layer chromatography]. *Z Klin Chem Klin Biochem* 1969 Mar;7(2):203-4. (Ger).
- Bickel H, Wachtel U, editors. *Screening auf maternale Störungen des Phenylalaninstoffwechsels : neuere Entwicklungen beim Screening von Neugeborenen auf hereditäre und endokrine Störungen. 3. Tagung der Arbeitsgemeinschaft Neugeborenen-Screening.* New York: Thieme; 1987. 183 p. (Ger).
- Billings PR, Kohn MA, de Cuevas M, Beckwith J, Alper JS, Natowicz MR. Discrimination as a consequence of genetic testing. *Am J Hum Genet* 1992 Mar;50(3):476-82.
- Birnbacher R, Scheibenreiter S, Blau N, Bieglmayer C, Frisch H, Waldhauser F. Hyperprolactinemia, a tool in treatment control of tetrahydrobiopterin deficiency: endocrine studies in an affected girl. *Pediatr Res* 1998 Apr;43(4 Pt 1):472-7.
- Blank RH. Public policy implications of human genetic technology: genetic screening. *J Med Philos* 1982 Nov;7(4):355-74.
- Blaskovics ME. Diagnosis in relationship to treatment of hyperphenylalaninaemia. *J Inherit Metab Dis* 1986;9 Suppl 2:178-82.
- Blau N, Barnes I, Dhondt JL. International database of tetrahydrobiopterin deficiencies. *J Inherit Metab Dis* 1996;19(1):8-14.
- Blau N, Curtius HC. Cofactor defects in atypical phenylketonuria. In: Schmidt BJ, Diamant AJ, Loghin-Grosso NS, editors. *Current trends in infant screening. Proceedings of the 7th International Screening Symposium; 1988 Nov 6-9; Sao Paulo,*

- Brazil. New York: Excerpta Medica; 1989. p. 95-104. (International congress series; no. 848).
- Blau N, Curtius HC, Kuster T, Matasovic A, Schoedon G, Dhondt JL, Guibaud P, Giudici T, Blaskovics M. Primapterinuria: a new variant of atypical phenylketonuria. *J Inher Metab Dis* 1989;12 Suppl 2:335-8.
- Blau N, Dhondt JL. Tetrahydrobiopterin deficiency and an international database of patients. *Adv Exp Med Biol* 1993;338:255-61.
- Blau N, Heizmann CW, Sperl W, Korenke C, Hoffmann GF, Smooker PM, Cotton RG. Mild forms of PKU due to dihydropteridine reductase deficiency. In: Wilcken B, Webster D, editors. Neonatal screening in the nineties. Proceedings of the 8th International Neonatal Screening Symposium; 1991 Nov 12-15; Leura, New South Wales, Australia and the Arthur Veale Memorial Meeting; 1991 Nov 5-9; Auckland, New Zealand. Australia: The Symposium; 1991. p. 63.
- Blau N, Heizmann CW, Sperl W, Korenke GC, Hoffmann GF, Smooker PM, Cotton RG. Atypical (mild) forms of dihydropteridine reductase deficiency: neurochemical evaluation and mutation detection. *Pediatr Res* 1992 Dec;32(6):726-30.
- Blau N, Ichinose H, Nagatsu T, Heizmann CW, Zacchello F, Burlina AB. A missense mutation in a patient with guanosine triphosphate cyclohydrolase I deficiency missed in the newborn screening program. *J Pediatr* 1995 Mar;126(3):401-5.
- Blau N, Kierat L, Curtius HC, Blaskovics M, Giudici T. Hyperphenylalaninaemia presumably due to carbinolamine dehydratase deficiency: loading tests with pterin derivatives. *J Inher Metab Dis* 1992;15(3):409-12.
- Blau N, Kierat L, Heizmann CW, Endres W, Giudici T, Wang M. Screening for tetrahydrobiopterin deficiency in newborns using dried urine on filter paper. *J Inher Metab Dis* 1992;15(3):402-4.
- Blau N, Niederwieser A, Curtius HC, Kierat L, Leimbacher W, Matasovic A, Binkert F, Lehmann H, Leupold D, Guardamagna O, et al. Prenatal diagnosis of atypical phenylketonuria. *J Inher Metab Dis* 1989;12 Suppl 2:295-8.
- Blau N, Thony B, Spada M, Ponzzone A. Tetrahydrobiopterin and inherited hyperphenylalaninemias. *Turk J Pediatr* 1996 Jan-Mar;38(1):19-35.
- Blitzer MG, Bailey-Wilson JE, Shapira E. Discrimination of phenylketonurics from persistent hyperphenylalaninemia patients using a simple phenylalanine loading test. *Clin Chim Acta* 1985 Dec 13;153(2):137-42.
- Bliumina MG. [Malignant forms of phenylketonuria]. *Zh Nevropatol Psikhiatr* 1984;84(10):1462-5. (Rus).
- Bodsch W, Coenen HH, Stocklin G, Takahashi K, Hossmann KA. Biochemical and autoradiographic study of cerebral protein synthesis with [¹⁸F]- and [¹⁴C]fluorophenylalanine. *J Neurochem* 1988 Mar;50(3):979-83.
- Bogatyeva EG, Berezhaia MI, Krasnopol'skaia KD. [Use of Soviet makes of chromatographic paper and paper backing for rapid tests in programs of screening for hereditary metabolic defects]. *Lab Delo* 1990;(8):79-80. (Rus).
- Bohles H, Stehr K. [Early diagnosis of congenital metabolic diseases]. *Fortschr Med* 1980 Jul 3;98(25):955-7. (Ger).
- Borresen AL, Hovig E, Smith-Sorensen B, Vrieling H, Apold J, Brogger A. Screening for base mutations in the PAH and HPRT loci using the polymerase chain reaction (PCR) in combination with denaturing gradient gel electrophoresis (DGGE). *Prog Clin Biol Res* 1990;340A:389-98.
- Boyle PJ. Shaping priorities in genetic medicine. *Hastings Cent Rep* 1995 May-Jun;25(3 Suppl):S2-8.
- Bracco G, Pagliardini S. Guthrie test recalls due to antibiotic inhibition [letter]. *Lancet* 1983 Jun 11;1(8337):1331-2.
- Bracco G, Pagliardini S. [Method of eliminating inhibition by antibiotics in the Guthrie test for phenylketonuria]. *Pathologica* 1983;75 Suppl:72-4. (Ita).
- Brearley GM, Price CP, Atkinson T, Hammond PM. Isolation, identification and characterisation of a soil bacterium producing an enzyme with L-phenylalanine oxidase activity. *Arch Microbiol* 1994 May;161(5):409-13.
- Briard ML. [Neonatal screening for phenylketonuria and hypothyroidism in France. A 12-year experience]. *Ann Biol Clin (Paris)* 1988;46(6):387-92. (Fre).
- Briard ML. [Neonatal screening of phenylketonuria in France. Statistical data]. *Arch Fr Pediatr* 1983;40 Suppl 1:215-7. (Fre).
- Briard ML, Farriaux JP. [Neonatal screening in France]. *Soins Gynecol Obstet Pueric Pediatr* 1990 Mar;(106):37-41. (Fre).
- Buhrdel P, Grimm U, Wasser S, Knapp A, Wulff K. [Tryptophan metabolism in infants with

- phenylketonuria]. *Pediatr Grenzgeb* 1982;21(4):309-17. (Ger).
- Burgard P, Bremer HJ, Buhrdel P, Clemens PC, Monch E, Przyrembel H, Trefz FK, Ullrich K. Rationale for the German recommendations for phenylalanine level control in phenylketonuria 1997. *Eur J Pediatr* 1999 Jan;158(1):46-54.
- Burgard P, Rupp A, Konecki DS, Trefz FK, Schmidt H, Lichter-Konecki U. Phenylalanine hydroxylase genotypes, predicted residual enzyme activity and phenotypic parameters of diagnosis and treatment of phenylketonuria. *Eur J Pediatr* 1996 Jul;155 Suppl 1:S11-5.
- Burke DG, Halpern B, Malegan D, McCairns E, Danks D, Schlesinger P, Wilken B. Profiles of urinary volatiles from metabolic disorders characterized by unusual odors. *Clin Chem* 1983 Oct;29(10):1834-8.
- Butler IJ, O'Flynn ME, Seifert WE Jr, Howell RR. Neurotransmitter defects and treatment of disorders of hyperphenylalaninemia. *J Pediatr* 1981 May;98(5):729-33.
- Cabalska B. [Advances in the diagnosis and treatment of phenylketonuria]. *Pediatr Pol* 1984 Nov;59(11):905-15. (Pol).
- Cabalska B, Duczynska N, Nowaczewska I, Bozkowa K. Hyperphenylalaninemia in Polish children's population. *Acta Anthropogenet* 1985;9(1-3):91-102.
- Cabalska MB, Nowaczewska I, Sendek E, Zorska K. Longitudinal study on early diagnosis and treatment of phenylketonuria in Poland. *Eur J Pediatr* 1996 Jul;155 Suppl 1:S53-5.
- Campistol Plana J, Alvarez Dominguez L, Riverola de Veciana AT, Castillo Rivera P, Giner Soria P. [Hyperphenylalaninemia and phenylketonuria. The importance of early diagnosis and follow up at a health center]. *An Esp Pediatr* 1991 Jan;34(1):51-6. (Spa).
- Campistol Plana J, Arellano Pedrola M, Poo Arguelles P, Escofet Sotera C, Perez Olarte P, Vilaseca Busca MA. [Embryonic pathology caused by maternal phenylketonuria. A cause of underdiagnosed mental retardation. A report of 8 cases]. *An Esp Pediatr* 1999 Aug;51(2):139-42. (Spa).
- Carducci C, Birarelli M, Leuzzi V, Santagata G, Serafini P, Antonozzi I. Automated method for the measurement of amino acids in urine by high-performance liquid chromatography. *J Chromatogr A* 1996 Apr 5;729(1-2):173-80.
- Carducci C, Ellul L, Leuzzi V, Antonozzi I, Pontecorvi A. Genetic analysis at the phenylalanine hydroxylase locus in phenylketonuric families from central and southern Italy. In: Wilcken B, Webster D, editors. Neonatal screening in the nineties. Proceedings of the 8th International Neonatal Screening Symposium; 1991 Nov 12-15; Leura, New South Wales, Australia and the Arthur Veale Memorial Meeting; 1991 Nov 5-9; Auckland, New Zealand. Australia: The Symposium; 1991. p. 53-8.
- Carson NA. Diagnosis and management of hyperphenylalaninaemia. *Arch Dis Child* 1971 Dec;46(250):878-9.
- Cartier L, Clow CL, Lippman-Hand A, Morissette J, Sriver CR. Prediction and prevention of maternal phenylketonuria (PKU) with a registry. In: Schmidt BJ, Diament AJ, Loughin-Grosso NS, editors. Current trends in infant screening. Proceedings of the 7th International Screening Symposium; 1988 Nov 6-9; Sao Paulo, Brazil. New York: Excerpta Medica; 1989. p. 63. (International congress series; no. 848).
- Cederbaum S, Vilain E. Newborn screening for inborn errors of metabolism is going to expand: are we ready? [editorial]. *J Pediatr* 1999 Jun;134(6):666-7. Comment on: *J Pediatr* 1999 Jun;134(6):675-80; *J Pediatr* 1999 Jun;134(6):761-3.
- Cerone R, Cohen A, Romano C. Prevention and screening. *J Perinat Med* 1994;22 Suppl 1:5-8.
- Chace DH, Millington DS, Terada N, Kahler SG, Roe CR, Hofman LF. Rapid diagnosis of phenylketonuria by quantitative analysis for phenylalanine and tyrosine in neonatal blood spots by tandem mass spectrometry. *Clin Chem* 1993 Jan;39(1):66-71.
- Chace DH, Naylor EW. Expansion of newborn screening programs using automated tandem mass spectrometry. *Ment Retard Dev Disabil Res Rev* 1999;5(2):150-4.
- Chace DH, Sherwin JE, Hillman SL, Lorey F, Cunningham GC. Use of phenylalanine-to-tyrosine ratio determined by tandem mass spectrometry to improve newborn screening for phenylketonuria of early discharge specimens collected in the first 24 hours. *Clin Chem* 1998 Dec;44(12):2405-9. Comment in: *Clin Chem* 1998 Dec;44(12):2401-2.
- Chen RG, Sun M, Ni YY, Pan XS, Chen JZ, Zhang YF, Liu H, Zhang MH, Xu HZ, Wu YL, et al. Neonatal hypothyroidism, phenylketonuria and galactosemia screening in metropolitan Shanghai. *Chin Med J (Engl)* 1984 Jan;97(1):61-5.
- Chen SH, Hsiao KJ, Lin LH, Liu TT, Tang RB, Su TS. Study of restriction fragment length polymorphisms at the human phenylalanine hydroxylase locus and evaluation of its potential application in prenatal diagnosis of phenylketonuria in Chinese. *Hum Genet* 1989 Feb;81(3):226-30.

- Chestkov VV, Shepkina IuV, Jennings IG, Cotton RG, Shishkin SS. [Phenylalanine hydroxylase-like antibody in human chorionic villi]. *Biull Eksp Biol Med* 1992 Sep;114(9):308-10. (Rus).
- Chestkov VV, Shishkin SS. [Genetic heterogeneity and approaches to the prenatal diagnosis of phenylketonuria (review)]. *Vopr Med Khim* 1986 Jul-Aug;32(4):7-12. (Rus).
- Childs B. Genetic screening. *Annu Rev Genet* 1975;9:67-89.
- Ciske JB, Hoffman G, Hanson K, Annable KM, Wolff J, Litsheim T, Laessig R, Aronson R. Newborn creening in Wisconsin: program overview and test addition. *WMJ* 2000;99(2):38-42.
- Clemens P, Plettner C, Gruttner R. [Phenylketonuria screening: false-positive and false-negative results]. *Dtsch Med Wochenschr* 1983 Apr 22;108(16):627-8. (Ger).
- Clemens P, Plettner C, Gruttner R. [Screening for phenylketonuria without false readings from antibacterial agents]. *Offentl Gesundheitswes* 1982 Jun;44(6):435. (Ger).
- Clemens P, Voltmer C, Plettner C. Effect of antimicrobial agents on Guthrie test and its reversal by autoclaving [letter]. *Lancet* 1985 Oct 5;2(8458):778-9.
- Clemens PC, Neumann SJ, Wulke AP, Burmester JG. Newborn screening for hyperphenylalaninemia on day 5: is 240 mumol/liter the most appropriate cut-off level? *Prev Med* 1990 Jan;19(1):54-60.
- Clemens PC, Plettner C. Phenylketonuria screening: avoiding a source of error by simplifying the procedure [letter]. *Am J Clin Pathol* 1989 Jun;91(6):747.
- Clow CL. Genetic services in Canada: the view from Medicare. *Prog Clin Biol Res* 1982;103 Pt B:389-98.
- Clow CL, Reade TM, Sriver CR. Management of hereditary metabolic disease. The role of allied health personnel. *N Engl J Med* 1971 Jun 10;284(23):1292-8.
- Cohen BE, Szeinberg A, Quint J, Normand M, Blonder J, Peled I. Malignant phenylketonuria due to defective synthesis of dihydrobiopterin. *Isr J Med Sci* 1985 Jun;21(6):520-5.
- Colombo M, Troncoso L, Raimann E, Perales CG, Barros TL, Cornejo V. [Diagnosis of phenylketonuria in Chile]. *Rev Chil Pediatr* 1988 Jul-Aug;59(4):235-9. (Spa).
- Copel JA, Pilu G, Kleinman CS. Congenital heart disease and extracardiac anomalies: associations and indications for fetal echocardiography. *Am J Obstet Gynecol* 1986 May;154(5):1121-32.
- Corbett V. Clinical update. Heel prick screening of neonates: the role of the health visitor. *Health Visit* 1997 Nov;70(11):428-30.
- Corbett V, Bedford H, Grant J, Addison M, Streetly A. Clinical. Heelprick testing of neonates: the role of the midwife. *Br J Midwifery* 1998 Jun;6(6):390-4.
- Cornejo V, Raimann E, Moraga M, Colombo M. [Program of neonatal screening for phenylketonuria]. *Rev Chil Pediatr* 1990 Nov-Dec;61(6):309-12. (Spa).
- Corsello G, Bosco P, Cali F, Greco D, Cammarata M, Ciaccio M, Piccione M, Romano V. Maternal phenylketonuria in two Sicilian families identified by maternal blood phenylalanine level screening and identification of a new phenylalanine hydroxylase gene mutation (P407L) [letter]. *Eur J Pediatr* 1999 Jan;158(1):83-4.
- Cortes Castell E, Campello Oltra MJ, Moya Benavent M, Ballester Galindo I, Herrero Galiana A, Clemente Yago F. [Reference levels for phenylalanine and tyrosine in discs impregnated with blood during analysis by HPLC]. *An Esp Pediatr* 1988 May;28(5):405-8. (Spa).
- Coskun T, Karagoz T, Kalkanoglu S, Tokatli A, Ozalp I, Thony B, Blau N. Guanosine triphosphate cyclohydrolase I deficiency: a rare cause of hyperphenylalaninemia. *Turk J Pediatr* 1999 Apr-Jun;41(2):231-7.
- Coskun T, Topcu M, Ustundag I, Ozalp I, Renda Y, Ciger A, Nurlu G. Neurophysiological studies of patients with classical phenylketonuria: evaluation of results of IQ scores, EEG and evoked potentials. *Turk J Pediatr* 1993 Jan-Mar;35(1):1-10.
- Costello PM, Beasley MG, Tillotson SL, Smith I. Intelligence in relation to phenylalanine concentrations in mild phenylketonuria (PKU). In: Farriaux JP, Dhondt JL, editors. *New horizons in neonatal screening. Proceedings of the 9th International Neonatal Screening Symposium and the 2nd Meeting of the International Society for Neonatal Screening*; 1993 Sep 13-17; Lille, France. New York: Elsevier Science; 1994. p. 107-8. (International congress series; no. 1041).
- Cotton RG. Heterogeneity of phenylketonuria at the clinical, protein and DNA levels. *J Inherit Metab Dis* 1990;13(5):739-50.
- Cotton RG, Jennings I, Bracco G, Ponzzone A, Guardamagna O. Tetrahydrobiopterin non-responsiveness in dihydropteridine reductase deficiency is associated with the presence of mutant protein. *J Inherit Metab Dis* 1986;9(3):239-43.

- Coutelle C, Speer A. Genomics in the German Democratic Republic. *Genomics* 1990 Sep;8(1):182-6.
- Creel D, Buehler BA. Pattern evoked potentials in phenylketonuria. *Electroencephalogr Clin Neurophysiol* 1982 Feb;53(2):220-3.
- Crocker AC. Current strategies in prevention of mental retardation. *Pediatr Ann* 1982 May;11(5):450-4, 457.
- Culliton BJ. Genetic screening: NAS recommends proceeding with caution. *Science* 1975 Jul 11;189(4197):119-20.
- Curtius HC, Niederwieser A. [Development of the biosynthesis and excretion of pterins in phenylketonuria and its variants]. *Arch Fr Pediatr* 1983;40 Suppl 1:227-30. (Fre).
- Curtius HC, Wang M, Niederwieser A. Screening of newborns with hyperphenylalaninemia for tetrahydrobiopterin deficiency. In: Naruse H, Irie M, editors. *Neonatal screening. Proceedings of the 2nd International Conference on Neonatal Thyroid Screening; 1982 Aug 16-19; Tokyo and the International Symposium on Neonatal Screening for Inborn Errors of Metabolism; 1982 Aug 19-21; Tokyo.* Princeton (NJ): Excerpta Medica; 1983. p. 191-200. (International congress series; no. 606).
- Czartoryska B. [Prenatal diagnosis: a chance? risk? dilemma?]. *Postepy Biochem* 1990;36(3-4):31-3. (POL).
- Dagenais DL, Courville L, Dagenais MG. A cost-benefit analysis of the Quebec Network of Genetic Medicine. *Soc Sci Med* 1985;20(6):601-7.
- Dahl HH, Osborn AH, Hutchison WM, Thorburn DR, Sheffield LJ. Late diagnosis of maternal PKU in a family segregating an arylsulfatase [corrected] E mutation causing symmetrical chondrodysplasia punctata. *Mol Genet Metab* 1999 Dec;68(4):503-6.
- Daiger SP, Lidsky AS, Chakraborty R, Koch R, Guttler F, Woo SL. Polymorphic DNA haplotypes at the phenylalanine hydroxylase locus in prenatal diagnosis of phenylketonuria. *Lancet* 1986 Feb 1;1(8475):229-32.
- Dasovich M, Konecki D, Lichter-Konecki U, Eisensmith RC, Guttler F, Naughton E, Mullins C, Giovannini M, Riva E, Woo SL. Molecular characterization of PKU allele prevalent in southern Europe and Ireland. *Somat Cell Mol Genet* 1991 May;17(3):303-9.
- Davidson A. Screening for PKU [letter]. *MCN Am J Matern Child Nurs* 1988 Mar-Apr;13(2):84.
- Davidson DC. Maternal PKU pre-conception treatment--the need for free prescriptions. *Midwives Chron* 1989 Feb;102(1213):43.
- Davis TA, Karl IE, Tegtmeyer ED, Osborne DF, Klahr S, Harter HR. Muscle protein turnover: effects of exercise training and renal insufficiency. *Am J Physiol* 1985 Mar;248(3 Pt 1):E337-45.
- de Almeida IT, Leandro PP, Portela R, Cabral A, Eusebio F, Tasso T, Matasovic A, Blau N. Tetrahydrobiopterin deficiency in Portugal: results of the screening for hyperphenylalaninemia. *Adv Exp Med Biol* 1993;338:263-6.
- de Freitas O, Izumi C, Lara MG, Greene LJ. New approaches to the treatment of phenylketonuria. *Nutr Rev* 1999 Mar;57(3):65-70.
- de Pediatria SC, de Neonatologia R. [Early diagnosis of phenylketonuria and congenital hypothyroidism. Prevention of mental retardation]. *Rev Chil Pediatr* 1988 May-Jun;59(3):200-3. (Spa).
- Desviat LR, Perez B, Gamez A, Sanchez A, Garcia MJ, Martinez-Pardo M, Marchante C, Boveda D, Baldellou A, Arena J, Sanjurjo P, Fernandez A, Cabello ML, Ugarte M. Genetic and phenotypic aspects of phenylalanine hydroxylase deficiency in Spain: molecular survey by regions. *Eur J Hum Genet* 1999 Apr;7(3):386-92.
- Dezortova M, Hejcmanova L, Hajek M. Decreasing choline signal--a marker of phenylketonuria? *MAGMA* 1996 Sep-Dec;4(3-4):181-6.
- Dhondt JL. Clinical presentation of tetrahydrobiopterin deficiency. In: Schmidt BJ, Diament AJ, Loghini-Grosso NS, editors. *Current trends in infant screening. Proceedings of the 7th International Screening Symposium; 1988 Nov 6-9; Sao Paulo, Brazil.* New York: Excerpta Medica; 1989. p. 73-6. (International congress series; no. 848).
- Dhondt JL. Screening of tetrahydrobiopterin deficiency among hyperphenylalaninemic patients. In: Farriaux JP, Dhondt JL, editors. *New horizons in neonatal screening. Proceedings of the 9th International Neonatal Screening Symposium and the 2nd Meeting of the International Society for Neonatal Screening; 1993 Sep 13-17; Lille, France.* New York: Elsevier Science; 1994. p. 111-4. (International congress series; no. 1041).
- Dhondt JL. Strategy for the screening of tetrahydrobiopterin deficiency among hyperphenylalaninaemic patients: 15-years experience. *J Inher Metab Dis* 1991;14(2):117-27.
- Dhondt JL, Farriaux JP. [Hyperphenylalaninemia in 1981. A diagnostic approach (author's transl)]. *Arch Fr Pediatr* 1981 Oct;38(8):573-8. (Fre).

- Dhondt JL, Farriaux JP. Neonatal screening and follow-up procedures for hyperphenylalaninemia. In: Naruse H, Irie M, editors. Neonatal screening. Proceedings of the 2nd International Conference on Neonatal Thyroid Screening; 1982 Aug 16-19; Tokyo and the International Symposium on Neonatal Screening for Inborn Errors of Metabolism; 1982 Aug 19-21; Tokyo. Princeton (NJ): Excerpta Medica; 1983. p. 207-8. (International congress series; no. 606).
- Dhondt JL, Farriaux JP, Blehova B, Pazoutova N. Incidence of cofactor deficiency in the hyperphenylalaninemic population of Czechoslovakia. In: Schmidt BJ, Diament AJ, Loghin-Grosso NS, editors. Current trends in infant screening. Proceedings of the 7th International Screening Symposium; 1988 Nov 6-9; Sao Paulo, Brazil. New York: Excerpta Medica; 1989. p. 105-6. (International congress series; no. 848).
- Dhondt JL, Farriaux JP, Boudha A, Largilliere C, Ringel J, Roger MM, Leeming RJ. Neonatal hyperphenylalaninemia presumably caused by guanosine triphosphate-cyclohydrolase deficiency. *J Pediatr* 1985 Jun;106(6):954-6.
- Dhondt JL, Farriaux JP, Hayte JM. [Evaluation of 6-years' experience of screening for hyperphenylalaninemia caused by cofactor deficiency]. *Arch Fr Pediatr* 1986 Dec;43(10):785-9. (Fre).
- Dhondt JL, Farriaux JP, Largilliere C, Dautrevaux M, Ardouin P. Pterin metabolism in normal subjects and hyperphenylalaninaemic patients. *J Inherit Metab Dis* 1981;4(2):47-8.
- Dhondt JL, Farriaux JP, Raux M, Paux E, Bouchery AM, Debersee J. [Evaluation of the detection of phenylketonuria and hypothyroidism at the Lille Regional Center]. *Arch Fr Pediatr* 1987 Nov;44(9):787-90. (Fre).
- Dhondt JL, Farriaux JP, Saily JC, Lebrun T. Economic evaluation of cost-benefit ratio of neonatal screening procedure for phenylketonuria and hypothyroidism. *J Inherit Metab Dis* 1991;14(4):633-9.
- Dhondt JL, Largilliere C, Ardouin P, Farriaux JP, Dautrevaux M. Diagnosis of variants of hyperphenylalaninemia by determination of pterins in urine. *Clin Chim Acta* 1981 Mar 5;110(2-3):205-14.
- Dhondt JL, Leroux B, Farriaux JP, Largilliere C, Leeming RJ. Dihydrobiopterin biosynthesis deficiency. *Eur J Pediatr* 1983 Dec;141(2):92-5.
- Dhondt JL, Loeber J, Elvers LH, Paux E. Preparation of the first European working standard for phenylalanine determination in dried blood spots. *J Med Screen* 1998;5(2):63-6.
- Dhondt JL, Paux E, Farriaux JP. Need for a standardized procedure in the preparation of phenylalanine calibrators. *Early Hum Dev* 1996 Jul 19;45(3):277-85.
- Dhondt JL, Tilmont P, Ringel J, Farriaux JP. Pterins analysis in amniotic fluid for the prenatal diagnosis of GTP cyclohydrolase deficiency. *J Inherit Metab Dis* 1990;13(6):879-82.
- Diament AJ. [Recent advances in inborn errors of metabolism]. *Arq Neuropsiquiatr* 1987 Jun;45(2):177-87. (Por).
- Dianzani I, Farinasso L, Fortina P, Camaschella C, Ponzzone R, Dahl HH, Cotton RG, Ponzzone A. RFLPs of the phenylalanine hydroxylase gene in the Italian population. *J Inherit Metab Dis* 1989;12(2):162-5.
- Dianzani I, Forrest SM, Camaschella C, Saglio G, Ponzzone A, Cotton RG. Screening for mutations in the phenylalanine hydroxylase gene from Italian patients with phenylketonuria by using the chemical cleavage method: a new splice mutation. *Am J Hum Genet* 1991 Mar;48(3):631-5.
- DiLella AG, Huang WM, Woo SL. Screening for phenylketonuria mutations by DNA amplification with the polymerase chain reaction. *Lancet* 1988 Mar 5;1(8584):497-9.
- DiLella AG, Woo SL. Molecular basis of phenylketonuria and its clinical applications. *Mol Biol Med* 1987 Aug;4(4):183-92.
- Dobson JC, Kushida E, Williamson M, Friedman EG. Intellectual performance of 36 phenylketonuria patients and their nonaffected siblings. *Pediatrics* 1976 Jul;58(1):53-8.
- Dockhorn-Dworniczak B, Dworniczak B, Brommelkamp L, Bulles J, Horst J, Bocker WW. Non-isotopic detection of single strand conformation polymorphism (PCR-SSCP): a rapid and sensitive technique in diagnosis of phenylketonuria. *Nucleic Acids Res* 1991 May 11;19(9):2500.
- Doherty LB, Rohr FJ, Levy HL. Detection of phenylketonuria in the very early newborn blood specimen. *Pediatrics* 1991 Feb;87(2):240-4.
- Dong GZ. [Clinical analysis of 74 cases of phenylketonuria and hyperphenylalanemia]. *Chung Hua Shen Ching Ching Shen Ko Tsa Chih* 1986 Feb;19(1):49-51. (Chi).
- Donlon J. Variant forms of phenylketonuria. *Ir Med J* 1981 Jun;74(6):174, 176.
- Dooley KC. Enzymatic method for phenylketonuria screening using phenylalanine dehydrogenase. *Clin Biochem* 1992 Aug;25(4):271-5.

- Dorner WG. [Campaign against hereditary diseases. A curse for future generations]. *Minerva Med* 1981 Dec 22;72(51):3555-6. (Ita).
- Dougherty FE, Levy HL. Present newborn screening for phenylketonuria. *Ment Retard Dev Disabil Res Rev* 1999;5(2):144-9.
- Eggertsen SC, Schneeweiss R, Bergman JJ. An updated protocol for pediatric health screening. *J Fam Pract* 1980 Jan;10(1):25-37.
- Eiken HG, Odland E, Boman H, Skjelkvale L, Engebretsen LF, Apold J. Application of natural and amplification created restriction sites for the diagnosis of PKU mutations. *Nucleic Acids Res* 1991 Apr 11;19(7):1427-30.
- Eiken HG, Odland E, Hordnes K, Boman H, Apold J. Rapid diagnosis of the phenylketonuria haplotype 2 mutation by DNA amplification and MnlI digestion. *Clin Chem* 1990 May;36(5):809-10.
- Eisenberg L. Child mental health in the Americas: a public health approach. *Bull Pan Am Health Organ* 1992;26(3):230-41.
- Eisensmith RC, Goltsov AA, Woo SL. A simple, rapid, and highly informative PCR-based procedure for prenatal diagnosis and carrier screening of phenylketonuria. *Prenat Diagn* 1994 Dec;14(12):1113-8.
- Elliman D, Garner J. Review of neonatal screening programme for phenylketonuria [letter]. *BMJ* 1991 Aug 24;303(6800):471. Comment on: *BMJ* 1991 Aug 10;303(6798):333-5; *BMJ* 1991 Sep 21;303(6804):716.
- Elvers LH, Diependaal GA, Blonk HJ, Loeber JG. Evaluatie van de Quantase Phenylalanine Bepaling en het Millipore Multiscreen Assay System als Methode voor de Screening van Pasgeborenen op PKU [Evaluation of Quantase Phenylalanine Assay and the Millipore Multiscreen Assay System as a screening method of newborns on PKU]. Bilthoven (Netherlands): Rijksinstituut voor de Volksgezondheid en Milieuhygiene; 1994 Jan. Report No.: RIVM-199003029. 50 p. Available from: NTIS, Springfield, VA; PB95132791. (Dut).
- Endres W. [Differential diagnosis and therapy of various forms of hyperphenylalaninemia: facts and fiction]. *Wien Klin Wochenschr* 1992;104(16):503-9. (Ger).
- Endres W. Hyperphenylalaninämien: Mangel an Dihydropteridinreduktase-Aktivität und Störungen der Biopterinsynthese - Klinik und Behandlung. In: Bickel H, Wachtel U, editors. *Neugeborenen-Screening auf hereditäre Stoffwechselstörungen : gegenwärtiger Stand und künftige Entwicklung*. 1 Tagung der Arbeitsgemeinschaft Neugeborenen-Screening. New York: Thieme; 1983. p. 54. (Ger).
- Endres W, Blau N, Curtius HC. Newborn screening and treatment of hyperphenylalaninemia due to tetrahydrobiopterin deficiency. In: Schmidt BJ, Diament AJ, Loghin-Grosso NS, editors. *Current trends in infant screening. Proceedings of the 7th International Screening Symposium*; 1988 Nov 6-9; Sao Paulo, Brazil. New York: Excerpta Medica; 1989. p. 77-82. (International congress series; no. 848).
- Endres W, Niederwieser A, Curtius HC, Wang M, Ohrt B, Schaub J. Atypical phenylketonuria due to biopterin deficiency. Early treatment with tetrahydrobiopterin and neurotransmitter precursors, trials of monotherapy. *Helv Paediatr Acta* 1982;37(5):489-98.
- Enns GM, Martinez DR, Kuzmin AI, Koch R, Wakeem CK, Woo SL, Eisensmith RC, Packman S. Molecular correlations in phenylketonuria: mutation patterns and corresponding biochemical and clinical phenotypes in a heterogeneous California population. *Pediatr Res* 1999 Nov;46(5):594-602.
- Erbe RW. Issues in newborn genetic screening. *Birth Defects Orig Artic Ser* 1981;17(1):167-79.
- Eyskens FJ. Screening for inborn errors of metabolism: the experience in the province of Antwerp [dissertation]. Antwerp (Belgium): University of Antwerp Instelling; 1997. 161 p.
- Faden R, Holtzman NA, Chwalow AJ, Horn S, Capron A. (School of Hygiene and Public Health, Johns Hopkins University, Baltimore, MD). Feasibility and effectiveness of obtaining consent for neonatal screening. Final report. 1977 Oct 1-1980 Jun 30. Rockville (MD): Bureau of Community Health Services (US); 1980 Sep. 250 p. Report No.: MCH/CCS-80/02. Available from: NTIS, Springfield, VA; PB81-162901.
- Faden RR, Chwalow AJ, Holtzman NA, Horn SD. A survey to evaluate parental consent as public policy for neonatal screening. *Am J Public Health* 1982 Dec;72(12):1347-52.
- Faden RR, Holtzman NA, Chwalow AJ. Parental rights, child welfare, and public health: the case of PKU screening. *Am J Public Health* 1982 Dec;72(12):1396-400.
- Fallstrom SP, Lindblad B, Steen G. On the renal tubular damage in hereditary tyrosinemia and on the formation of succinylacetoacetate and succinylacetone. *Acta Paediatr Scand* 1981;70(3):315-20.
- False-negative PKU results. *Lab Med* 1998 Oct;29(10):588.

- Fang B, Yuan L, Wang M, Huang S, Wang T, Miao S, Ye J, Sun N, Lo H, Savio LC. Detection of point mutations of the phenylalanine hydroxylase gene and prenatal diagnosis of phenylketonuria. *Chin Med Sci J* 1992 Dec;7(4):205-8.
- Farriaux JP. [Mass neonatal screening. A reality which is sometimes poorly understood]. *Arch Fr Pediatr* 1980 Jun;37(6):367-70. (Fre).
- Farriaux JP. [Neonatal detection of phenylketonuria and hypothyroidism. Realities and perspectives]. *An Esp Pediatr* 1988 Sep;29 Suppl 32:272-9. (Spa).
- Farriaux JP. [Prenatal diagnosis of genetic diseases. Indications, methods, legal and ethic aspects. Neonatal screening of phenylketonuria and hypothyroidism]. *Rev Prat* 1997 Dec 1;47(19):2159-68. (Fre).
- Farriaux JP. [Results of screening for phenylketonuria in France]. *Presse Med* 1987 Jun 13;16(22):1072-4. (Fre).
- Farriaux JP. [Systematic neonatal screening. Status and organization. Apropos of the French experience]. *LARC Med* 1982 Dec;2(11):963-7. (Fre).
- Farriaux JP, Dhondt JL. [Neonatal screening for phenylketonuria]. *J Genet Hum* 1981 Mar;29(1):3-11. (Fre).
- Farriaux JP, Dhondt JL, Leger J. False negative cases of neonatal screening for phenylketonuria and congenital hypothyroidism. In: Schmidt BJ, Diament AJ, Loghini-Grosso NS, editors. *Current trends in infant screening. Proceedings of the 7th International Screening Symposium*; 1988 Nov 6-9; Sao Paulo, Brazil. New York: Excerpta Medica; 1989. p. 11-4. (International congress series; no. 848).
- Faust D, Libon D, Puschel S. Neuropsychological functioning in treated phenylketonuria. *Int J Psychiatry Med* 1986-87;16(2):169-77.
- Fernhoff PM, Fitzmaurice N, Milner J, McEwen CT, Dembure PP, Brown AL, Wright L, Acosta PB, Elsas LJ 2d. Coordinated system for comprehensive newborn metabolic screening. *South Med J* 1982 May;75(5):529-32.
- Fibison WJ. The nursing perspective: genetic screening and testing. *J Sch Nurs* 1993 Dec;9(4):16-24.
- Fingerhut R, Stehn M, Kohlschutter A. Comparison of four different phenylalanine determination methods. *Clin Chim Acta* 1997 Aug 8;264(1):65-73.
- Fink RM, Elstner EF. Comparison of different methods for the determination of phenylalanine hydroxylase activity in rat liver and *Euglena gracilis*. *Z Naturforsch [C]* 1984 Jul-Aug;39(7-8):728-33.
- Finley WH. Genetic screening: an overview. *Ala J Med Sci* 1982 Apr;19(2):147-50.
- Firgaira FA, Cotton RG, Danks DM, Fowler K, Lipson A, Yu JS. Prenatal determination of dihydropteridine reductase in a normal fetus at risk for malignant hyperphenylalaninemia. *Prenat Diagn* 1983 Jan;3(1):7-11.
- Fisch RO, Thomas A. Phenylketonuria screening tests for American children born outside the United States [letter]. *Am J Dis Child* 1990 Jun;144(6):618-9.
- Flatz G, Oelbe M, Herrmann H. Ethnic distribution of phenylketonuria in the north German population. *Hum Genet* 1984;65(4):396-9.
- Fletcher JC. Ethical issues in genetic screening and antenatal diagnosis. *Clin Obstet Gynecol* 1981 Dec;24(4):1151-68.
- Fletcher JC. Ethical issues in genetic screening, prenatal diagnosis, and counseling. In: Weil WB, Benjamin M, editors. *Ethical issues at the outset of life*. Boston: Blackwell Scientific Publications; 1987. p. 63-99.
- "For the nurse in the know": use your nose! Sniff out disease. *Tex Nurs* 1991 Oct;65(9):13.
- Forrest SM, Dahl HH, Howells DW, Dianzani I, Cotton RG. Mutation detection in phenylketonuria by using chemical cleavage of mismatch: importance of using probes from both normal and patient samples. *Am J Hum Genet* 1991 Jul;49(1):175-83. Published erratum appears in *Am J Hum Genet* 1992 Mar;50(3):659.
- Forsberg SA. Infant metabolic screening: a total quality management approach. *Obst Gynecol Neonat Nurs* 1997 May-Jun;26(3):257-61.
- Fost N. Ethical implications of screening asymptomatic individuals. *FASEB J* 1992 Jul;6(10):2813-7.
- Fost N. Genetic diagnosis and treatment: ethical considerations. *Am J Dis Child* 1993 Nov;147(11):1190-5.
- Francis I. Newborn screening in Australia and New Zealand 1984-1990. Human Genetics Society of Australasia/Australian College of Paediatrics Committee on Newborn Metabolic Screening. *Med J Aust* 1991 Dec 2-16;155(11-12):821-3.
- Freehauf CL, Lezotte D, Goodman SI, McCabe ER. Carrier screening for phenylketonuria: comparison of two discriminant analysis procedures. *Am J Hum Genet* 1984 Nov;36(6):1180-9.

- Frezal J. [Detection of phenylketonuria. 10,000,000 tests]. *Presse Med* 1983 Oct 22;12(37):2301-2. (Fre).
- Frezal J, Briard ML, Saudubray JM. [After PKU and hypothyroidism, what other screening?]. *J Genet Hum* 1981 Mar;29(1):47-57. (Fre).
- Frontera-Izquierdo P. Phenylketonuria and neonatal hypothyroidism in Spain. Priority of screening for neonatal hypothyroidism. *Eur J Pediatr* 1980 May;133(3):297.
- Galloway A, Stevenson J. Audit improves neonatal (Guthrie) screening programme [letter]. *BMJ* 1994 Oct 1;309(6958):878. Comment on: *BMJ* 1994 Aug 6;309(6951):372-4.
- Galloway A, Stevenson J. An audit of the organisation of neonatal screening for phenylketonuria and congenital hypothyroidism in the Northern Region. *Public Health* 1996 Mar;110(2):119-21.
- Galloway A, Stevenson J. Performance of neonatal screening programme must be monitored [letter]. *BMJ* 1996 May 4;312(7039):1158. Comment on: *BMJ* 1996 Jan 20;312(7024):182.
- Garcia de Juan JF. Valores de referencia de las magnitudes bioquímicas l-fenilalanina y l-tirosina en la población de Navarra: estudio de tirosinemia transitoria del recién nacido [Reference values of the biochemical magnitudes l-phenylalanine l-tyrosine in the Navarra population: study of transient neonatal tyrosinaemia] [dissertation]. Ciudad Universitaria (Spain): University of Navarra; 1991. 331 p. (Spa).
- Gashkoff P, Matalon R, Papa V, Sebasta D. Analysis of the pentafluorobenzoyl derivative of phenylethylamine utilizing negative ion chemical ionization and gas chromatography/mass spectrometry. *Biomed Environ Mass Spectrom* 1988 Oct;16(1-12):327-9.
- Gazmararian JA, Solomon FM. Receipt of home health care after early discharge: results from a national managed care organization. *Matern Child Health J* 1997 Sep;1(3):151-6.
- Gerasimova NS, Samutin AA, Steklova IV, Tuuminen T. Sixteen months experience using fluorometric microplate assay for phenylketonuria in Moscow. In: Wilcken B, Webster D, editors. Neonatal screening in the nineties. Proceedings of the 8th International Neonatal Screening Symposium; 1991 Nov 12-15; Leura, New South Wales, Australia and the Arthur Veale Memorial Meeting; 1991 Nov 5-9; Auckland, New Zealand. Australia: The Symposium; 1991. p. 61-2.
- Gerasimova NS, Steklova IV, Tuuminen T. Fluorometric method for phenylalanine microplate assay adapted for phenylketonuria screening. *Clin Chem* 1989 Oct;35(10):2112-5.
- Gfrorer S, Junghanns U. [Screening of newborn infants for phenylketonuria and galactosemia--comments on the procedure]. *Offentl Gesundheitswes* 1987 Jan;49(1):34-5. (Ger).
- Giannattasio S, Bisceglia L, Lattanzio P, Grifa A, Dianzani I, Gasparini P, Marra E. Molecular screening of genetic defects with RNA-SSCP analysis: the PKU and cystinuria model. *Mol Cell Probes* 1995 Jun;9(3):201-5.
- Giannattasio S, Lattanzio P, Bobba A, Marra E. Detection of microsatellites by ethidium bromide staining. The analysis of an STR system in the human phenylalanine hydroxylase gene. *Mol Cell Probes* 1997 Feb;11(1):81-3.
- Gibbings B. Phenylketonuria--a personal view. *Mod Midwife* 1994 Oct;4(10):27.
- Giovannini M, Valsasina R, Biasucci G, Longhi R, Riva E. Tetrahydrobiopterin deficiency screening in hyperphenylalaninemic children. In: Schmidt BJ, Diamant AJ, Lohin-Grosso NS, editors. Current trends in infant screening. Proceedings of the 7th International Screening Symposium; 1988 Nov 6-9; Sao Paulo, Brazil. New York: Excerpta Medica; 1989. p. 83-7. (International congress series; no. 848).
- Goebel-Schreiner B, Schreiner R. Identification of a new missense mutation in Japanese phenylketonuric patients. *J Inher Metab Dis* 1993;16(6):950-6. Published erratum appears in *J Inher Metab Dis* 1994;17(1):66.
- Gold RJ, Maag UR, Neal JL, Scriver CR. The use of biochemical data in screening for mutant alleles and in genetic counselling. *Ann Hum Genet* 1974 Jan;37(3):315-26.
- Goldman JM, Laws SC, Balchak SK, Cooper RL, Kavlock RJ. Endocrine-disrupting chemicals: Prepubertal exposures and effects on sexual maturation and thyroid activity in the female rat. A focus on the EDSTAC recommendations. *Crit Rev Toxicol* 2000;30(2):135-96.
- Goltsov AA, Eisensmith RC, Naughton ER, Jin L, Chakraborty R, Woo SL. A single polymorphic STR system in the human phenylalanine hydroxylase gene permits rapid prenatal diagnosis and carrier screening for phenylketonuria. *Hum Mol Genet* 1993 May;2(5):577-81.
- Green A. Neonatal screening: current trends and quality control in the United Kingdom. *Rinsho Byori* 1998 Mar;46(3):211-6.

- Green AK, Cotton RG, Jennings I, Fisher MJ. Experimental determination of the phosphorylation state of phenylalanine hydroxylase. *Biochem J* 1990 Jan 15;265(2):563-8.
- Greene PE, Bressman SB, Ford B, Hyland K. Parkinsonism, dystonia, and hemiatrophy. *Mov Disord* 2000;15(3):537-41.
- Greeves LG, McCarthy HL, Redmond A, Carson DJ. Coexistence of cystic fibrosis and phenylketonuria. *Ulster Med J* 1997 May;66(1):59-61.
- Grenier A, Morissette J, Dussault JH, Laberge C, Gagne R. [Hereditary metabolic diseases in Quebec: blood screening]. *Union Med Can* 1980 Apr;109(4):591-5. (Fre).
- Griffiths P, Paterson L, Harvie A. Neuropsychological effects of subsequent exposure to phenylalanine in adolescents and young adults with early-treated phenylketonuria. *J Intellect Disabil Res* 1995 Oct;39 (Pt 5):365-72.
- Grobe H. Andere Aminosäurenstoffwechselstörungen, die im Guthrie-Test erfasst werden können: Schwefelhaltige Aminosäuren. In: Bickel H, Wachtel U, editors. Neugeborenen-Screening auf hereditäre Stoffwechselstörungen : gegenwärtiger Stand und künftige Entwicklung. 1. Tagung der Arbeitsgemeinschaft Neugeborenen-Screening. New York: Thieme; 1983. p. 62. (Ger).
- Grobe H. Hyperphenylalaninämien: neue Erkenntnisse zur Einteilung und Definition. In: Bickel H, Wachtel U, editors. Neugeborenen-Screening auf hereditäre Stoffwechselstörungen : gegenwärtiger Stand und künftige Entwicklung. 1. Tagung der Arbeitsgemeinschaft Neugeborenen-Screening. New York: Thieme; 1983. p. 52-3. (Ger).
- Grobe H. [Screening studies in newborn infants]. *Monatsschr Kinderheilkd* 1983 Nov;131(11):806-9. (Ger).
- Gromov PS, Bakharev VA, Annenkov GA. [Active form of dihydropteridine reductase in human chorion cells. Possibility of prenatal diagnosis]. *Vopr Med Khim* 1985 Jul-Aug;31(4):73-5. (Rus).
- Gross PT, Berlow S, Schuett VE, Fariello RG. EEG in phenylketonuria. Attempt to establish clinical importance of EEG changes. *Arch Neurol* 1981 Feb;38(2):122-6.
- Gu XF, Chen RG. Current status of neonatal screening in China. *J Med Screen* 1999;6(4):186-7.
- Gudat JC, Maclaren NK. Neonatal screening for congenital disorders. *J Fla Med Assoc* 1980 Feb;67(2):137-22.
- Gudinchet F, Maeder P, Meuli RA, Deonna T, Mathieu JM. Cranial CT and MRI in malignant phenylketonuria. *Pediatr Radiol* 1992;22(3):223-4.
- Guillet GY, Dore N, Hehunstre JP, Maleville J, Battin J. Pseudoscleroderma and phenylketonuria. *Int J Dermatol* 1983 Sep;22(7):422-6.
- Guldberg P, Guttler F. Mutation screening versus gene scanning for genotyping phenylketonuria patients. *J Inher Metab Dis* 1994;17(3):359-61.
- Guldberg P, Guttler F. Mutations in the phenylalanine hydroxylase gene: methods for their characterization. *Acta Paediatr Suppl* 1994 Dec;407:27-33.
- Guldberg P, Guttler F. PCR in the diagnosis of phenylketonuria. *Ann Med* 1992 Jun;24(3):187-90.
- Guldberg P, Henriksen KF, Guttler F. Molecular analysis of phenylketonuria in Denmark: 99% of the mutations detected by denaturing gradient gel electrophoresis. *Genomics* 1993 Jul;17(1):141-6.
- Guldberg P, Henriksen KF, Thony B, Blau N, Guttler F. Molecular heterogeneity of nonphenylketonuria hyperphenylalaninemia in 25 Danish patients. *Genomics* 1994 May 15;21(2):453-5.
- Guldberg P, Levy HL, Hanley WB, Koch R, Matalon R, Rouse BM, Trefz F, de la Cruz F, Henriksen KF, Guttler F. Phenylalanine hydroxylase gene mutations in the United States: report from the Maternal PKU Collaborative Study. *Am J Hum Genet* 1996 Jul;59(1):84-94.
- Guldberg P, Levy HL, Henriksen KF, Guttler F. Three prevalent mutations in a patient with phenylalanine hydroxylase deficiency: implications for diagnosis and genetic counselling. *J Med Genet* 1996 Feb;33(2):161-4.
- Guldberg P, Romano V, Ceratto N, Bosco P, Ciuna M, Indelicato A, Mollica F, Meli C, Giovannini M, Riva E, et al. Mutational spectrum of phenylalanine hydroxylase deficiency in Sicily: implications for diagnosis of hyperphenylalaninemia in southern Europe. *Hum Mol Genet* 1993 Oct;2(10):1703-7.
- Guneral F, Ozalp I, Tatlidil H. Heterozygous carriers of classical phenylketonuria in a sample of the Turkish population: detection by a spectrofluorimetric method. *J Inher Metab Dis* 1991;14(5):741-8. Comment in: *J Inher Metab Dis* 1992;15(2):293-4.
- Gungor N, Tokath A, Coskun T, Ozcuc M, Ozalp I. Microcephaly in a hyperphenylalaninemic infant leading to the diagnosis of maternal hyperphenylalaninemia [letter]. *Eur J Pediatr* 1996 Mar;155(3):257-8. Comment in: *Eur J Pediatr* 1996 Nov;155(11):992.

- Guthrie R. Blood screening for phenylketonuria [letter]. *JAMA* 1961 Nov 25;178(8):863.
- Guthrie R. The introduction of newborn screening for phenylketonuria. A personal history. *Eur J Pediatr* 1996 Jul;155 Suppl 1:S4-5.
- Guthrie R. Maternal PKU--a continuing problem [editorial]. *Am J Public Health* 1988 Jul;78(7):771.
- Guthrie R, Susi A. Laboratory confirmation of phenylketonuria. Combined paper chromatography and inhibition assay. *Pediatr Padol* 1982;17(2):165-9.
- Guthrie R, Susi A. A simple phenylalanine method for detecting phenylketonuria in large populations of newborn infants. *Pediatrics* 1963 Sep;32(3):338-43.
- Gutierrez E, Barrios B, Heredero L, Machado C, Solis RL, Casanave J, Robaina R, Fernandez-Yero JL. Use of ultramicroanalytical system (SUMA) in determination of hyperphenylalaninemia in neonatal blood spots in Cuba. In: Wilcken B, Webster D, editors. Neonatal screening in the nineties. Proceedings of the 8th International Neonatal Screening Symposium; 1991 Nov 12-15; Leura, New South Wales, Australia and the Arthur Veale Memorial Meeting; 1991 Nov 5-9; Auckland, New Zealand. Australia: The Symposium; 1991. p. 66.
- Guttler F. [Does phenylalanine load disclose genetic variants?]. *Lakartidningen* 1974 Mar 20;71(12):1170-1. (Nor).
- Guttler F. [Folling's disease: 50 years and still a catalyst of new discoveries in clinical medicine]. *Nord Med* 1984;99(3):78-81. (Dan).
- Guttler F. [Folling's disease: 50-years and still a catalyst of new discoveries in medicine]. *Ugeskr Laeger* 1984 Jan 9;146(2):83-7. (Dan).
- Guttler F. Hyperphenylalaninemia: diagnosis and classification of the various types of phenylalanine hydroxylase deficiency in childhood. *Acta Paediatr Scand Suppl* 1980;280:1-80.
- Guttler F. Modern techniques of differentiating the various phenotypes of phenylketonuria. *Postgrad Med J* 1989;65 Suppl 2:S2-6.
- Guttler F. [Prolonged phenylalanine load]. *Lakartidningen* 1974 Mar 20;71(12):1168-9. (Dan).
- Guttler F, DiLella AG, Ledley FD, Lidsky AS, Kvak SC, Marvit J, Woo SL. Molecular biology of phenylketonuria. *Eur J Pediatr* 1987;146 Suppl 1:A5-11.
- Guttler F, Guldberg P. Mutations in the phenylalanine hydroxylase gene: genetic determinants for the phenotypic variability of hyperphenylalaninemia. *Acta Paediatr Suppl* 1994 Dec;407:49-56.
- Guttler F, Guldberg P, Henriksen KF. Screening for common phenylketonuria mutations using filter paper blood spots. In: Wilcken B, Webster D, editors. Neonatal screening in the nineties. Proceedings of the 8th International Neonatal Screening Symposium; 1991 Nov 12-15; Leura, New South Wales, Australia and the Arthur Veale Memorial Meeting; 1991 Nov 5-9; Auckland, New Zealand. Australia: The Symposium; 1991. p. 47-52.
- Guttler F, Guldberg P, Henriksen KF, Holck B, Lou H, Mikkelsen I, Rasmussen V, Toft T. Follow-up testing and diagnosis of the newborn with hyperphenylalaninemia. In: Wilcken B, Webster D, editors. Neonatal screening in the nineties. Proceedings of the 8th International Neonatal Screening Symposium; 1991 Nov 12-15; Leura, New South Wales, Australia and the Arthur Veale Memorial Meeting; 1991 Nov 5-9; Auckland, New Zealand. Australia: The Symposium; 1991. p. 286-91.
- Guttler F, Hansen G. Heterozygote detection in phenylketonuria. *Clin Genet* 1977 Feb;11(2):137-46.
- Guttler F, Lou H, Lykkelund C, Niederwieser A. Combined tetrahydrobiopterin-phenylalanine loading test in the detection of partially defective biopterin synthesis. *Eur J Pediatr* 1984 Jun;142(2):126-9.
- Guttler F, Wamberg E. On indications for treatment of the hyperphenylalaninemic neonate. *Acta Paediatr Scand* 1977 May;66(3):339-44.
- Guttler F, Wamberg E. Persistent hyperphenylalaninemia. *Acta Paediatr Scand* 1972 May;61(3):321-8.
- Hagenfeldt L, Lundberg K, Larsson A, Thuresson M. [Information from the PKU-section - report of activities 1981]. *Jordemodern* 1982 Sep;95(9):287-90. (Swe).
- Haibach H, Woodruff CW. Neonatal screening for metabolic diseases in Missouri. *Mo Med* 1982 Sep;79(9):615-20.
- Hajek M, Hejzmanova L, Pradny J. Proton in vivo spectroscopy of patients with hyperphenylalaninaemia. *Neuropediatrics* 1993 Apr;24(2):111-2.
- Hall DM, Stewart-Brown S. Screening in child health. *Br Med Bull* 1998;54(4):929-43.
- Hanley WB, Bell L. Maternal phenylketonuria: finding and treating women before conception. *Can Med Assoc J* 1982 Jun 1;126(11):1259-60.

- Hanley WB, Clarke JT, Schoonheydt WE. Undiagnosed phenylketonuria in adult women: a hidden public health problem. *CMAJ* 1990 Sep 15;143(6):513-6.
- Hanley WB, Demshar H, Preston MA, Borczyk A, Schoonheydt WE, Clarke JT, Feigenbaum A. Newborn phenylketonuria (PKU) Guthrie (BIA) screening and early hospital discharge. *Early Hum Dev* 1997 Jan 3;47(1):87-96.
- Hanley WB, Lee AW, Hanley AJ, Lehotay DC, Austin VJ, Schoonheydt WE, Platt BA, Clarke JT. 'Hypotyrosinemia' in phenylketonuria. *Mol Genet Metabol* 2000;69(4):286-94.
- Hanley WB, Platt LD, Bachman RP, Buist N, Geraghty MT, Isaacs J, O'Flynn ME, Rhead WJ, Seidlitz G, Tishler B. Undiagnosed maternal phenylketonuria: the need for prenatal selective screening or case finding. *Am J Obstet Gynecol* 1999 Apr;180(4):986-94.
- Hard choices: genetic screening. Kent (OH): PTV Publications; 1981. 21 p. From a six-part television series on bioethics produced by KCTS/9, Seattle.
- Harpey JP. [Biopterin synthesis defects: complete deficiencies (reductase and synthetase)]. *Arch Fr Pediatr* 1983;40 Suppl 1:231-5. (Fre).
- Harte FB, Molloy O, Cahalane SF. Maternal screening trial for inborn errors of metabolism. *Ir Med J* 1982 Aug;75(8):274-5.
- Hashem N, Bosco P, Chiavetta V, Cali F, Ceratto N, Romano V. Preliminary studies on the molecular basis of hyperphenylalaninemia in Egypt. *Hum Genet* 1996 Jul;98(1):3-6.
- Hayakawa H, Narisawa K, Arai N, Tada K, Matsuo N, Tanaka T, Naritomi K. Differential diagnosis of variant forms of hyperphenylalaninaemia by urinary pterins. *J Inherit Metab Dis* 1983;6(3):123-4.
- Hayden MR, Nichols JL. Molecular genetic approaches to the study of the nervous system. *Dev Neurosci* 1983-84;6(4-5):189-214.
- Henderson HE, Goodman R, Schram J, Diamond E, Daneel A. Biochemical screening for inherited metabolic disorders in the mentally retarded. *S Afr Med J* 1981 Nov 7;60(19):731-3.
- Hepburn ER. Genetic testing and early diagnosis and intervention: boon or burden? *J Med Ethics* 1996 Apr;22(22):105-10.
- Hiller EH, Landenburger G, Natowicz MR. Public participation in medical policy-making and the status of consumer autonomy: the example of newborn-screening programs in the United States. *Am J Public Health* 1997 Aug;87(8):1280-8.
- Hilton MA, Sharpe JN, Hicks LG, Andrews BF. A simple method for detection of heterozygous carriers of the gene for classic phenylketonuria. *J Pediatr* 1986 Oct;109(4):601-4.
- Hisashige A. Health economic analysis of the neonatal screening program in Japan. *Int J Technol Assess Health Care* 1994 Summer;10(3):382-91.
- Hitzeroth HW, Niehaus CE, Brill DC. Phenylketonuria in South Africa. A report on the status quo. *S Afr Med J* 1995 Jan;85(1):33-6.
- Hoffman GL, Laessig RH, Hassemer DJ, Makowski ER. Dual-channel continuous-flow system for determination of phenylalanine and galactose: application to newborn screening. *Clin Chem* 1984 Feb;30(2):287-90.
- Hoganson G, Berlow S, Kaufman S, Milstien S, Schuett V, Matalon R, Naylor E, Seifert W. Biopterin synthesis defects: problems in diagnosis. *Pediatrics* 1984 Dec;74(6):1004-11.
- Holmstrom S, Abens J, Boman J, Grankvist O, Johansson B, Landegren U, Levi R, Marke LA, Olerup O. Gendiagnostik med PCR [Genetic diagnosis by PCR]. Stockholm: Swedish Council on Technology Assessment in Health Care; 1993 Jan. 54 p. (Swe).
- Holton JB. Neonatal screening for biochemical disorders. *Br J Hosp Med* 1988 Apr;39(4):317-9, 322-4.
- Holtzman C, Slazyk WE, Cordero JF, Hannon WH. Descriptive epidemiology of missed cases of phenylketonuria and congenital hypothyroidism. *Pediatrics* 1986 Oct;78(4):553-8.
- Holtzman NA. The diffusion of new genetic tests for predicting disease. *FASEB J* 1992 Jul;6(10):2806-12.
- Holtzman NA. Ethical issues in the prenatal diagnosis of phenylketonuria. *Pediatrics* 1984 Sep;74(3):424-7.
- Holtzman NA. Pitfalls of newborn screening (with special attention to hypothyroidism): when will we ever learn? *Birth Defects Orig Artic Ser* 1983;19(5):111-20.
- Holtzman NA. What drives neonatal screening programs? [editorial]. *New Engl J Med* 1991 Sep 12;325(11):802-4.
- Holtzman NA, Faden R, Chwalow AJ, Horn SD. Effect of informed parental consent on mothers' knowledge of newborn screening. *Pediatrics* 1983 Dec;72(6):807-12.
- Holtzman NA, Leonard CO, Farfel MR. Issues in antenatal and neonatal screening and surveillance for

- hereditary and congenital disorders. *Annu Rev Public Health* 1981;2:219-51.
- Holtzman NA, McCabe ER, Cunningham GC, Berry HK. Screening for phenylketonuria [letter]. *N Engl J Med* 1981 May 21;304(21):1300-1.
- Hook EB. Muddling genetic discrimination [letter]. *Am J Hum Genet* 1992 Oct;51(4):899-901.
- Hornchen H. Hyperphenylalaninämien: Maternal Phenylketonurie - Behandlung und genetische Beratung. In: Bickel H, Wachtel U, editors. *Neugeborenen-Screening auf hereditäre Stoffwechselstörungen : gegenwärtiger Stand und künftige Entwicklung. 1. Tagung der Arbeitsgemeinschaft Neugeborenen-Screening*. New York: Thieme; 1983. p. 59-60. (Ger).
- Horst J. Entwicklung und Adaptierung genanalytischer Methoden an die Erfordernisse der pränatalen Diagnostik. Abschlussbericht [Development and adaptation of gene analysis methods to the requirements of prenatal diagnosis. Final report]. Munster (Germany): Munster University, Institute for Human Genetics; 1993. Contract No.: BMFT 0706523. 64 p. Available from: NTIS, Springfield, VA; TIB/A96-00555. (Ger).
- Horst J. Impact of systematic screening for PKU. In: Farriax JP, Dhondt JL, editors. *New horizons in neonatal screening. Proceedings of the 9th International Neonatal Screening Symposium and the 2nd Meeting of the International Society for Neonatal Screening*; 1993 Sep 13-17; Lille, France. New York: Elsevier Science; 1994. p. 101-5. (International congress series; no. 1041).
- Hoskins JA, Greenway AM. The metabolism of L-tyrosine: the use of a putative precursor to investigate the increased production of m-hydroxymandelic acid in phenylketonuria. *Clin Chim Acta* 1983 Jun 15;130(3):329-38.
- Howell RR. Phenylketonuria in the general population. *N Engl J Med* 1970 Jun 25;282(26):1486-8.
- Hsiao KJ, Chen CH, Chiu PC, Huang SC, Wu KD. A Chinese family with phenylketonuria and maternal phenylketonuria detected by family screening. *Eur J Pediatr* 1986 Oct;145(5):409-12.
- Hsiao KJ, Chen CH, Liu TT, Wu SJ, Plettner C, Clemens P. Screening of congenital hypothyroidism, phenylketonuria, galactosemia, homocystinuria, and maple syrup urine disease in moderate to severely mentally retarded Chinese children. *Taiwan I Hsueh Hui Tsai Chih* 1989 Jan;88(1):18-22.
- Hsieh MC, Berry HK, Bofinger MK, Phillips PJ, Guilfoile MB, Hunt MM. Comparative diagnostic value of phenylalanine challenge and phenylalanine hydroxylase activity in phenylketonuria. *Clin Genet* 1983 Jun;23(6):415-21.
- Huang S, Fang B, Chu H. [Analysis of short tandem repeats polymorphism in the phenylalanine hydroxylase gene and its application to prenatal gene diagnosis of phenylketonuria]. *Chung Hua I Hsueh Tsai Chih* 1995 Jan;75(1):22-4, 61. (Chi).
- Huang S, Li Hui, Miao S, Xu L, Fang B, Liu G, Luo H. [Analysis of the A/C polymorphic site within the phenylalanine hydroxylase gene]. *I Chuan Hsueh Pao* 1996;23(3):169-73. (Chi).
- Huang SZ, Ren ZR, Zeng YT. Application of a new DNA sequence polymorphism as a genetic marker in prenatal diagnosis of phenylketonuria. *J Med Genet* 1990 Jan;27(1):65-6.
- Huang SZ, Zhou XD, Ren ZR, Zeng YT, Woo SL. A new silent mutation found in the Chinese PAH locus and its role in the prenatal diagnosis of phenylketonuria. *SCI CHINA B* 1991 May;34(5):606-10.
- Huang SZ, Zhou XD, Ren ZR, Zeng YT, Woo SL. Prenatal detection of an Arg----Ter mutation at codon 111 of the PAH gene using DNA amplification. *Prenat Diagn* 1990 May;10(5):289-93.
- Huisman J, van der Schot LW, Hendrikx MM, Kalverboer AF, Slijper FM. [Intellectual development of patients with phenylketonuria; 15-year national screening in The Netherlands]. *Ned Tijdschr Geneesk* 1992 Nov 14;136(46):2277-81. (Dut).
- Hummel W. Screening and characterization of new enzymes for biosensing and analytics. *EXS* 1997;80:49-61.
- Hunt S, Grimes A, Kirby D, Cotton RG, Danks DM, Connelly JF. Seven years' experience in investigation of babies with a positive Guthrie test for pterin deficient variants. In: Naruse H, Irie M, editors. *Neonatal screening. Proceedings of the 2nd International Conference on Neonatal Thyroid Screening*; 1982 Aug 16-19; Tokyo and the *International Symposium on Neonatal Screening for Inborn Errors of Metabolism*; 1982 Aug 19-21; Tokyo. Princeton (NJ): Excerpta Medica; 1983. p. 209-10. (International congress series; no. 606).
- Hurwitz A, Castells S. Misdiagnosed child abuse and metabolic diseases. *Pediatr Nurs* 1987 Jan-Feb;13(1):33-6.
- Hutchesson AC, Hall SK, Preece MA, Green A. Screening for tyrosinaemia type I. *Arch Dis Child Fetal Neonatal Ed* 1996 May;74(3):F191-4.

- Hyanek J. [Maternal hyperphenylalaninemia]. *Cesk Gynkol* 1993 Jun;58(3):149-51. (Cze).
- Hyanek J, Bendl J, Zeman J, Soukup K, Dolezal A, Kozich V, St'astna S, Kubik M, Viletova H. [Maternal hyperphenylalaninemia in a population of healthy Czech women. 18 years' experience with mass screening, diet therapy and metabolic monitoring]. *Cas Lek Cesk* 1996 Jan 17;135(2):50-3. (Cze).
- Hyanek J, Homolka J, Trnka J, Seemanova E, Cervenka J, Tresohlava Z, Kapras J, Dolezal A, Sracek J, Vacha V, Hoza J, Losan F, Nevsimalova S, Mala M, Viletova H. Results of screening for phenylalanine and other amino acid disturbances among pregnant women. *J Inherit Metab Dis* 1980;2(3):59-63.
- Hyanek J, Kubik M, Simkova M, Zeman J, Houst'kova H. [Phenylketonuria undiagnosed, unrecognizable and neglected. Review of failures in diagnosis, therapy, and prevention of hereditary disorders of phenylalanine]. *Cesk Pediatr* 1987 Mar;42(3):134-8. (Cze).
- Hyanek J, Viletova H, Kunova V, Kubik M. Phenylalanine loading tests in genetic counselling: 5 years experience with its premarital use. *J Inherit Metab Dis* 1981;4(2):51-2.
- Hyland K. Presentation, diagnosis, and treatment of the disorders of monoamine neurotransmitter metabolism. *Semin Perinatol* 1999 Apr;23(2):194-203.
- Hyland K, Fryburg JS, Wilson WG, Bebin EM, Arnold LA, Gunasekera RS, Jacobson RD, Rost-Ruffner E, Trugman JM. Oral phenylalanine loading in dopa-responsive dystonia: a possible diagnostic test. *Neurology* 1997 May;48(5):1290-7.
- Irons M. Screening for metabolic disorders. How are we doing? *Pediatr Clin North Am* 1993 Oct;40(5):1073-85.
- Ivaschenko T, Baranov VS. Rapid and efficient PCR/StyI test for identification of common mutation R408W in phenylketonuria patients. *J Med Genet* 1993 Feb;30(2):153-4.
- Ivashchenko TE, Belova EG, Baranov VS. [A simple and reliable method for detection of the R408W mutation in exon 12 of the phenylalanine hydroxylase gene in the molecular diagnosis of phenylketonuria]. *Genetika* 1993 May;29(5):862-5. (Rus).
- Jaruzelska J, Matuszak R, Lyonnet S, Rey F, Rey J, Filipowicz J, Borski K, Munnich A. Genetic background of clinical homogeneity of phenylketonuria in Poland. *J Med Genet* 1993 Mar;30(3):232-4.
- Jellum E. Chromatography for diagnosis of metabolic diseases. *J Chromatogr* 1988 Oct 28;452:435-41.
- Jenkins MB. Newborn metabolic screening in Minnesota. II. PKU and galactosemia. *Minn Med* 1981 Jul;64(7):429-32, 398.
- Jimenez Soto Z. [Methodology of care for children with phenylketonuria and maple-syrup urine disease]. *Arch Latinoam Nutr* 1993 Sep;43(3):204-10. (Spa).
- Jinks DC, Guthrie R, Naylor EW. Simplified procedure for producing *Bacillus subtilis* spores for the Guthrie phenylketonuria and other microbiological screening tests. *J Clin Microbiol* 1985 May;21(5):826-9.
- Jochum F, Terwolbeck K, Meinhold H, Behne D, Menzel H, Lombeck I. Effects of a low selenium state in patients with phenylketonuria. *Acta Paediatr* 1997 Jul;86(7):775-7.
- Juttman RE, de Koning HJ, Meulmeester JF, van der Maas PJ. [Published effects of screening in parental and child health care]. *Ned Tijdschr Geneesk* 1996 Jun 22;140(25):1303-7. (Ger).
- Kadasi L, Polakova H, Ferakova E, Hudecova S, Bohusova T, Szomolayova I, Strnova J, Hruskovic I, Moschonas NK, Ferak V. PKU in Slovakia: mutation screening and haplotype analysis. *Hum Genet* 1995 Jan;95(1):112-4.
- Kadasi L, Polakova H, Ferakova E, Krivusova T, Hudecova S, Szomolayova I, Strnova J, Hruskovic I, Ferak V. [DNA analysis in classic phenylketonuria--screening for mutations and haplotype analysis in Slovak families]. *Bratisl Lek Listy* 1994 Apr;95(4):147-50. (Slo).
- Kajita M, Niwa T, Watanabe K. Analysis of urinary organic acids by liquid chromatography-atmospheric pressure chemical ionization mass spectrometry. *J Chromatogr* 1993 Dec 22;622(2):263-8.
- Kalaydjieva L, Dworniczak B, Aulehla-Scholz C, Devoto M, Romeo G, Sturhmann M, Kucinkas V, Yurgelyavicius V, Horst J. Silent mutations in the phenylalanine hydroxylase gene as an aid to the diagnosis of phenylketonuria. *J Med Genet* 1991 Oct;28(10):686-90.
- Kalaydjieva L, Kremensky I. Screening for phenylketonuria in a totalitarian state. *J Med Genet* 1992 Sep;29(9):656-8.
- Kamerling JP, Aarsen GJ, Duran M, de Bree PK, van Sprang FJ, Wadman SK. Chromatographic determination and mass spectrometric identification of gamma-glutamylphenylalanine, a urinary constituent in phenylketonuria. *Clin Chim Acta* 1980 Mar 28;102(2-3):137-45.

- Kaufman S. Differential diagnosis of variant forms of hyperphenylalaninemia. *Pediatrics* 1980 Apr;65(4):840-2.
- Kaufman S. Phenylketonuria and its variants. *Adv Hum Genet* 1983;13:217-97.
- Kaufman S. Unsolved problems in diagnosis and therapy of hyperphenylalaninemia caused by defects in tetrahydrobiopterin metabolism. *J Pediatr* 1986 Oct;109(4):572-8.
- Kawamura M. [Laboratory examinations for inborn errors of metabolism]. *Rinsho Byori* 1986 Feb;34(2):133-5. (Jpn).
- Keffler S, Denmeade R, Green A. Neonatal screening for phenylketonuria: evaluation of an automated enzymatic method. *Ann Clin Biochem* 1994 Mar;31 (Pt 2):134-9.
- Kelly TE. *Clinical genetics and genetic counseling*. Chicago: Year Book Medical Publishers; 1980. Genetic screening--eugenics--ethics; p. 262-77.
- Kesby G. Repeated adverse fetal outcome in pregnancy complicated by uncontrolled maternal phenylketonuria. *J Paediatr Child Health* 1999 Oct;35(5):499-502.
- Kidd VJ, Woo SL. Recombinant DNA probes used to detect genetic disorders of the liver. *Hepatology* 1984 Jul-Aug;4(4):731-6.
- Kietduriyakul V, Komkris V, Tongkittikul K, Leangphibul P. The incidence of phenylketonuria in Thailand. *J Med Assoc Thai* 1989 Sep;72(9):516-9.
- Kirby LT, Applegarth DA, Norman MG, Hardwick DF. False positive phenylketonuria tests [letter]. *Lancet* 1980 Sep 13;2(8194):585.
- Kirby RB. Maternal phenylketonuria: a new cause for concern. *J Obstet Gynecol Neonatal Nurs* 1999 May-Jun;28(3):227-34.
- Kirkman HN. Projections of a rebound in frequency of mental retardation from phenylketonuria. *Appl Res Ment Retard* 1982;3(3):319-28.
- Kirkman HN, Carroll CL, Moore EG, Matheson MS. Fifteen-year experience with screening for phenylketonuria with an automated fluorometric method. *Am J Hum Genet* 1982 Sep;34(5):743-52.
- Kitamura M. [Clinical laboratory--II]. *Rinsho Byori* 1986 Apr;34(4):423-6. (Jpn).
- Koch R, Dobson J, Hsia DY, Woolf LI. Conference on sex ratio in phenylketonuria. *J Pediatr* 1971 Jan;78(1):157-9.
- Koch R, Friedman EG. Accuracy of newborn screening programs for phenylketonuria. *J Pediatr* 1981 Feb;98(2):267-9.
- Koch R, Levy HL, Matalon R, Rouse B, Hanley W, Azen C. The North American Collaborative Study of Maternal Phenylketonuria. Status report 1993. *Am J Dis Child* 1993 Nov;147(11):1224-30.
- Koch R, Moseley K, Ning J, Romstad A, Guldberg P, Guttler F. Long-term beneficial effects of the phenylalanine-restricted diet in late-diagnosed individuals with phenylketonuria. *Mol Genet Metab* 1999 Jun;67(2):148-55.
- Koch R, Shaw KN, Acosta PB, Fishler K, Schaeffler G, Wenz E, Wohlers A. An approach to management of phenylketonuria. *J Pediatr* 1970 Jun;76(6):815-28.
- Koch R, Wenz E. Phenylketonuria. *Annu Rev Nutr* 1987;7:117-35.
- Koch R, Williamson ML, Donnell GN, Guthrie R, Straus R, Coffelt W, Fish CH. A cooperative study of two methods for phenylalanine determination: McCaman-Robins fluorimetric and microbiologic inhibition methods. *J Pediatr* 1966 Jun;68(6):905-11.
- Koch RK. Issues in newborn screening for phenylketonuria. *Am Fam Physician* 1999 Oct 1;60(5):1462-6.
- Koepp P, Hinze G, Held KR. [Growth and nutrition: long term follow-up in early treated phenylketonuric and hyperphenylalaninemic children (author's transl)]. *Monatsschr Kinderheilkd* 1981 Mar;129(3):154-9. (Ger).
- Kolodny EH, Cable WJ. Inborn errors of metabolism. *Ann Neurol* 1982 Mar;11(3):221-32.
- Kolodny EH, Yatziv S. Laboratory approaches for inherited neurometabolic diseases. *Dev Med Child Neurol* 1985 Apr;27(2):252-7.
- Korson MS. Advances in newborn screening for metabolic disorders: What the pediatrician needs to know. *Pediatr Ann* 2000;29(5):294-301.
- Kotzer AM, McCabe ER. Newborn screening for inherited metabolic disease: principles and practice. *Neonatal Netw* 1988 Feb;6(4):15-9.
- Kowalska B. [Effect of maternal phenylketonuria on the development of 2 children with phenylketonuria]. *Pol Tyg Lek* 1986 Apr 7;41(14):448-50. (Pol).
- Kozak L, Kuhrova V, Blazkova M, Fajkusova L, Dvorakova D, Pijackova A. [Advances in the diagnosis of phenylketonuria with the introduction of

- direct detection of PAH gene mutation]. *Cas Lek Cesk* 1995 Jun 14;134(12):385-7. (Cze).
- Kreimberg CE, et al. [Study on prevention of phenylketonuria and neonatal hypothyroidism in newborn children]. *Neuropsiquiatr Salud Ment* 1982 Sep-Dec;13(3):21-3. (Spa).
- Kukla L, Mrskos A, Pijackova A, Podhradská O. [Determination of phenylalanine-4-hydroxylase as a parameter in the differential diagnosis of hyperphenylalaninemia]. *Cesk Pediatr* 1987 Sep;42(9):542-5. (Cze).
- Kure S, Hou DC, Ohura T, Iwamoto H, Suzuki S, Sugiyama N, Sakamoto O, Fujii K, Matsubara Y, Narisawa K. Tetrahydrobiopterin-responsive phenylalanine hydroxylase deficiency. *J Pediatr* 1999 Sep;135(3):375-8.
- Kwon C, Farrell PM. The magnitude and challenge of false-positive newborn screening test results. *Arch Pediatr Adolesc Med* 2000;154(7):714-8.
- Labadie P. [Phenylalanine hydroxylase]. *Rev Prat* 1982 May 11;32(27):1884-90. (Fre).
- Laguna Serrano C. [Congenital errors of metabolism: phenylketonuria and hyperphenylalanemias]. *An R Acad Nac Med (Madr)* 1982;99(4):783-814. (Spa).
- Lahdesmaki P. Inhibition of protein and aminoacyl-tRNA synthesis, and binding and transport sites for aromatic amino acids in the brain in vitro with aromatic acids. *Int J Neurosci* 1984 Mar;23(1):1-13.
- Lambotte C. [Current status of neonatal screening on the national and regional level]. *Rev Med Liege* 1984 May 15;39(10):413-5. (Fre).
- Langerova E, Sindelarova M, Machackova V, Balastikova B, Nahunek K, Podhradská O, Mrkos A, Kasparkova Z. [Maternal phenylketonuria. Psychopathological study of families]. *Cesk Psychiatr* 1982 Oct;78(5):289-97. (Cze).
- Lappe M. The limits of genetic inquiry. *Hastings Cent Rep* 1987 Aug;17(4):5-10.
- Laptev AV, Chestkov VV. [The dynamics of the properties of liver phenylalanine hydroxylase in human embryogenesis]. *Ontogenez* 1990 Mar-Apr;21(2):138-44. (Rus).
- Larsson A. Neonatal screening for metabolic and endocrine disorders. *Ups J Med Sci Suppl* 1987;44:231-6.
- Larsson BA, Jylli L, Lagercrantz H, Olsson GL. Does a local anaesthetic cream (EMLA) alleviate pain from heel-lancing in neonates? *Acta Anaesthesiol Scand* 1995 Nov;39(8):1028-31.
- Larsson BA, Norstmo A, Guthenberg C, Olsson GL, Danielsson P, Hagenfeldt L, Elander G, Larsson A. [The routine sampling procedure for PKU should be changed. Venous puncture is less painful than heel lancing]. *Lakartidningen* 1997 Dec 3;94(49):4625-8. (Swe).
- Larsson BA, Tannfeldt G, Lagercrantz H, Olsson GL. Alleviation of the pain of venepuncture in neonates. *Acta Paediatr* 1998 Jul;87(7):774-9. Comment in: *Acta Paediatr* 1998 Jul;87(7):723-5.
- Larsson BA, Tannfeldt G, Lagercrantz H, Olsson GL. Venipuncture is more effective and less painful than heel lancing for blood tests in neonates. *Pediatrics* 1998 May;101(5):882-6.
- Ledley FD. Clinical application of genotypic diagnosis for phenylketonuria: theoretical considerations. *Eur J Pediatr* 1991 Sep;150(11):752-6.
- Ledley FD. Somatic gene therapy for human disease: a problem of eugenics? *Trends Genet* 1987 Apr;3(4):112-5.
- Ledley FD, Grenett HE, DiLella AG, Kwok SC, Woo SL. Gene transfer and expression of human phenylalanine hydroxylase. *Science* 1985 Apr 5;228(4695):77-9.
- Ledley FD, Koch R, Jew K, Beaudet A, O'Brien WE, Bartos DP, Woo SL. Phenylalanine hydroxylase expression in liver of a fetus with phenylketonuria. *J Pediatr* 1988 Sep;113(3):463-8.
- Leeming RJ, Barford PA, Blair JA, Smith I. Blood spots on Guthrie cards can be used for inherited tetrahydrobiopterin deficiency screening in hyperphenylalaninaemic infants. *Arch Dis Child* 1984 Jan;59(1):58-61.
- Leeming RJ, Hall SK, Friday H, Hurley P, Green A. A microtitre plate method for measuring biopterin with cryopreserved *Crithidia fasciculata*. *Adv Exp Med Biol* 1993;338:267-70.
- Lehmann WD. Progress in the identification of the heterozygote in phenylketonuria. *J Pediatr* 1989 Jun;114(6):915-24.
- Lehmann WD, Fischer R, Heinrich HC, Clemens P, Gruttner R. Metabolic conversion of L-[U-14C]phenylalanine to respiratory $^{14}\text{CO}_2$ in healthy subjects, phenylketonuria heterozygotes and classic phenylketonurics. *Clin Chim Acta* 1986 Jun 30;157(3):253-66.
- Lehmann WD, Heinrich HC. Impaired phenylalanine-tyrosine conversion in patients with iron-deficiency anemia studied by a L-(2H5)phenylalanine-loading test. *Am J Clin Nutr* 1986 Oct;44(4):468-74.

- Lehmann WD, Heinrich HC. The NIH-shift in the in vivo hydroxylation of ring-deuterated L-phenylalanine in man. *Arch Biochem Biophys* 1986 Oct;250(1):180-5.
- Lehmann WD, Theobald N, Heinrich HC, Clemens P, Gruttner R. Detection of heterozygous carriers for phenylketonuria by a L-[2H5]phenylalanine stable isotope loading test. *Clin Chim Acta* 1984 Mar 27;138(1):59-71.
- Lei XD, Kaufman S. Human white blood cells and hair follicles are good sources of mRNA for the pterin carbinolamine dehydratase/dimerization cofactor of HNF1 for mutation detection. *Biochem Biophys Res Commun* 1998 Jul 20;248(2):432-5.
- Lenke RR, Platt LD, Koch R. Ultrasonographic failure of early detection of fetal microcephaly in maternal phenylketonuria. *J Ultrasound Med* 1983 Apr;2(4):177-9.
- Leonard HM, Fletcher JM. Inherited metabolic diseases: beyond newborn screening [editorial]. *Med J Aust* 1999 Jun 21;170(12):573-4. Comment on: *Med J Aust* 1999 Jun 21;170(12):592-5.
- Lequien P. [Examination of newborn infants in the first week. Techniques and objectives including early and systematic screening of congenital hypothyroidism and phenylketonuria]. *Rev Prat* 1991 Feb 1;41(4):357-60. (Fre).
- Leupold D. Andere Aminosäurenstoffwechselstörungen, die im Guthrie-Test erfasst werden können: Verzweigt-kettige Aminosäuren. In: Bickel H, Wachtel U, editors. *Neugeborenen-Screening auf hereditäre Stoffwechselstörungen : gegenwärtiger Stand und künftige Entwicklung*. 1. Tagung der Arbeitsgemeinschaft Neugeborenen-Screening. New York: Thieme; 1983. p. 61. (Ger).
- Levy HL. Editorial: Newborn metabolic screening: past and prospect. *N Engl J Med* 1975 Oct 16;293(16):824-5.
- Levy HL. Genetic screening. *Adv Hum Genet* 1973;4:1-104.
- Levy HL. Genetic screening: notes added in proof. *Adv Hum Genet* 1973;4:389-94.
- Levy HL. Maternal phenylketonuria and hyperphenylalaninemia. In: Naruse H, Irie M, editors. *Neonatal screening. Proceedings of the 2nd International Conference on Neonatal Thyroid Screening; 1982 Aug 16-19; Tokyo and the International Symposium on Neonatal Screening for Inborn Errors of Metabolism; 1982 Aug 19-21; Tokyo. Princeton (NJ): Excerpta Medica; 1983. p. 231-4. (International congress series; no. 606).*
- Levy HL. Maternal PKU: control of an emerging problem. *Am J Public Health* 1982 Dec;72(12):1320-1.
- Levy HL. Neonatal screening for inborn errors of amino acid metabolism. *Clin Endocrinol Metab* 1974 Mar;3(1):153-66.
- Levy HL. Newborn screening by tandem mass spectrometry: a new era [editorial]. *Clin Chem* 1998 Dec;44(12):2401-2. Comment on: *Clin Chem* 1998 Dec;44(12):2405-9.
- Levy HL. Phenylketonuria--1986. *Pediatr Rev* 1986 Mar;7(9):269-75.
- Levy HL. Problems in genetic screening which confront the law. In: Milunsky A, Annas GJ, editors. *Genetics and the law*. New York: Plenum Press; 1976. p. 133-8.
- Levy HL. Screening: perinatal aspects. In: Kelly S, et al., editors. *Birth defects: risks and consequences*. New York: Academic Press; 1976. p. 289-96.
- Levy HL, Baullinger PC, Madigan PM. A rapid procedure for the determination of phenylalanine and tyrosine from blood filter paper specimens. *Clin Chim Acta* 1971 Feb;31(2):447-52.
- Levy HL, Ghavami M. Maternal phenylketonuria: a metabolic teratogen. *Teratology* 1996 Mar;53(3):176-84.
- Levy HL, Karolkewicz V, Houghton SA, MacCready RA. Screening the "normal" population in Massachusetts for phenylketonuria. *N Engl J Med* 1970 Jun 25;282(26):1455-8.
- Levy HL, Lobbregt D, Barnes PD, Poussaint TY. Maternal phenylketonuria: magnetic resonance imaging of the brain in offspring. *J Pediatr* 1996 Jun;128(6):770-5.
- Levy HL, Mitchell ML. The current status of newborn screening. *Hosp Pract (Off Ed)* 1982 Jul;17(7):89-97.
- Levy HL, Mitchell ML, Ridley SE. Newborn screening [letter]. *Pediatrics* 1984 Mar;73(3):417.
- Levy HL, Shih VE, Karolkewicz V, MacCready RA. Screening for phenylketonuria. *Lancet* 1970 Sep 5;2(7671):522-3.
- Levy HL, Simmons JR, MacCready RA. Stability of amino acids and galactose in the newborn screening filter paper blood specimen. *J Pediatr* 1985 Nov;107(5):757-60.
- Levy PA, Miller JB, Shapira E. The advantage of phenylalanine to tyrosine ratio for the early detection

- of phenylketonuria. *Clin Chim Acta* 1998 Feb 23;270(2):177-81.
- Liappis N, Schlebusch H, Mallmann R. [Comparison of free amino acids in capillary and venous blood serum of children and adolescents with phenylketonuria and leucinosi]. *Klin Padiatr* 1992 Mar-Apr;204(2):107-10. (Ger).
- Lichter-Konecki U, Rupp A, Konecki DS, Trefz FK, Schmidt H, Burgard P. Relation between phenylalanine hydroxylase genotypes and phenotypic parameters of diagnosis and treatment of hyperphenylalaninaemic disorders. German Collaborative Study of PKU. *J Inherit Metab Dis* 1994;17(3):362-5.
- Lidsky AS, Guttler F, Woo SL. Prenatal diagnosis of classic phenylketonuria by DNA analysis. *Lancet* 1985 Mar 9;1(8428):549-51.
- Lidsky AS, Ledley FD, DiLella AG, Kwok SC, Daiger SP, Robson KJ, Woo SL. Extensive restriction site polymorphism at the human phenylalanine hydroxylase locus and application in prenatal diagnosis of phenylketonuria. *Am J Hum Genet* 1985 Jul;37(4):619-34.
- Lie SO. [Asbjorn Folling's disease. Reflections on a 50-year anniversary]. *Tidsskr Nor Laegeforen* 1984 Dec 10;104(34):2381-5. (Nor).
- Liebl B, Fingerhut R, Roschinger W, Muntau A, Knerr I, Olgemoller B, Zapf A, Roscher AA. [Model project for updating neonatal screening in Bavaria: concept and initial results]. *Gesundheitswesen* 2000 Apr;62(4):189-95. (Ger).
- Lillevali H, Ounap K, Metspalu A. Phenylalanine hydroxylase gene mutation R408W is present on 84% of Estonian phenylketonuria chromosomes. *Eur J Hum Genet* 1996;4(5):296-300.
- Lin JK, Wang CH. Determination of urinary amino acids by liquid chromatography with dabsyl chloride. *Clin Chem* 1980 Apr;26(5):579-83.
- Lipson A, Yu J, O'Halloran M, Potter M, Wilken B. Dihydropteridine reductase deficiency: non-response to oral tetrahydrobiopterin load test. *J Inherit Metab Dis* 1984;7(2):69-71.
- Lipson AH, Yu JS, O'Halloran MT, Williams R. Alcohol and phenylketonuria [letter]. *Lancet* 1981 Mar 28;1(8222):717-8.
- Liu SR, Zuo QH. Newborn screening for phenylketonuria in eleven districts. *Chin Med J (Engl)* 1986 Feb;99(2):113-8.
- Liu TT, Hsiao KJ, Lu SF, Wu SJ, Wu KF, Chiang SH, Liu XQ, Chen RG, Yu WM. Mutation analysis of the 6-pyruvoyl-tetrahydropterin synthase gene in Chinese hyperphenylalaninemia caused by tetrahydrobiopterin synthesis deficiency. *Hum Mutat* 1998;11(1):76-83.
- Lluch Fernandez MD, Ramos Sanchez I, Marchante Cobos C, Perez Perez G, Martinez Martinez JJ, Estefania Gallardo C. [Phenylketonuria. Treatment and developmental control]. *An Esp Padiatr* 1988 Apr;28(4):327-30. (Spa).
- Lo WH, Wang T, Eisensmith R, Woo SL. Molecular basis of PKU in China. *Chin Med Sci J* 1993 Sep;8(3):180-5.
- Longhi R, Riva E, Valsasina R, Paccanelli S, Giovannini M. Phenylketonuria due to dihydropteridine reductase deficiency: presentation of two cases. *J Inherit Metab Dis* 1985;8 Suppl 2:97-8.
- Lord J, Thomason MJ, Littlejohns P, Chalmers RA, Bain MD, Addison GM, Wilcox AH, Seymour CA. Secondary analysis of economic data: a review of cost-benefit studies of neonatal screening for phenylketonuria. *J Epidemiol Community Health* 1999 Mar;53(3):179-86.
- Lou HC, Toft PB, Andresen J, Mikkelsen I, Olsen B, Guldberg P, Guttler F. Unchanged MRI of myelin in adolescents with PKU supplied with non-phe essential amino acids after dietary relaxation. *Acta Paediatr* 1994 Dec;83(12):1312-4.
- Lowe JB. Clinical applications of gene probes in human genetic disease, malignancy, and infectious disease. *Clin Chim Acta* 1986 May 30;157(1):1-32.
- Lubenow N, Diepenbrock F, Schickling H, Bock D, Heckler R, Sander J. Phenylketonuria screening with a fluorometric microplate assay. *Eur J Clin Chem Clin Biochem* 1994 Jul;32(7):525-8.
- Luke B, Keith LG. The challenge of maternal phenylketonuria screening and treatment. *J Reprod Med* 1990 Jul;35(7):667-73.
- Lutz P. Schwierigkeiten bei der Durchführung des mikrobiologischen Hemmtests nach Guthrie. In: Bickel H, Wachtel U, editors. *Neugeborenen-Screening auf hereditäre Stoffwechselstörungen : gegenwärtiger Stand und künftige Entwicklung. 1. Tagung der Arbeitsgemeinschaft Neugeborenen-Screening*. New York: Thieme; 1983. p. 5-10. (Ger).
- Lutz P, Schmidt H, Batzler U. Study design and description of patients. *Eur J Pediatr* 1990;149 Suppl 1:S5-12.
- Lutz P, Schmidt H, Frey G, Bickel H. Standardized loading test with protein for the differentiation of phenylketonuria from hyperphenylalaninaemia. *J Inherit Metab Dis* 1982;5(1):29-35.

- Ma J, Huang S, Wang M, Li H, Lu X, Luo H. [Detection of the mutant phenylalanine hydroxylase gene by dideoxy fingerprinting]. *Chung Hua I Hsueh I Chuan Hsueh Tsa Chih* 1998 Aug;15(4):235-7. (Chi).
- Mabry CC. Phenylketonuria: contemporary screening and diagnosis. *Ann Clin Lab Sci* 1990 Nov-Dec;20(6):393-7.
- Mabry CC, Reid MC, Kuhn RJ. A source of error in phenylketonuria screening. *Am J Clin Pathol* 1988 Sep;90(3):279-83. Comment in: *Am J Clin Pathol* 1989 Sep;92(3):396; *Am J Clin Pathol* 1989 Sep;92(3):396-7.
- MacCready RA. Admissions of phenylketonuric patients to residential institutions before and after screening programs of the newborn infant. *J Pediatr* 1974 Sep;85(3):383-5.
- MacCready RA, Levy HL. The problem of maternal phenylketonuria. *Am J Obstet Gynecol* 1972 May 1;113(1):121-8.
- Machill G, Knapp A. [Sensitivity of phenylketonuria screening]. *Kinderarztl Prax* 1984 Jul;52(7):347-50. (Ger).
- Machill G, Seidlitz G, Ebener U, Knapp A, Herrmann FH. Evaluation of the screening of pregnant women for phenylketonuria during 1972-1992. In: Farriaux JP, Dhondt JL, editors. *New horizons in neonatal screening. Proceedings of the 9th International Neonatal Screening Symposium and the 2nd Meeting of the International Society for Neonatal Screening*; 1993 Sep 13-17; Lille, France. New York: Elsevier Science; 1994. p. 119-22. (International congress series; no. 1041).
- Maddox MA. Is there a link between dementia and phenylketonuria? *J Gerontol Nurs* 1990 May;16(5):18-23.
- Madira WM, Xavier F, Stern J, Wilcox AH, Barron JL. Determination and assessment of the stability of phenylalanine and tyrosine in blood spots by HPLC [letter]. *Clin Chem* 1992 Oct;38(10):2162-3.
- Mallolas J, Campistol J, Lambruschini N, Vilaseca MA, Cambra FJ, Estivill X, Mila M. Two novel mutations in exon 11 of the PAH gene (V1163del TG and P362T) associated with classic phenylketonuria and mild phenylketonuria. *Mutations in brief* no. 143. Online. *Hum Mutat* 1998;11(6):482.
- Malone JL. Infant screening for phenylketonuria in Florida. *J Fla Med Assoc* 1983 Sep;70(9):782-3.
- Mamunes P. Neonatal screening tests. *Pediatr Clin North Am* 1980 Nov;27(4):733-51.
- Manghi E, Belloni L, Cambie F, Cerisola N, Dagnino G, Felisi G, Manghi D, Oppici W, Carella L. [Neurologic diseases, mental retardation and reduction in work capacity]. *Riv Neurol* 1985 Jul-Aug;55(4):256-300. (Ita).
- Matalon R. Current status of biopterin screening [editorial]. *J Pediatr* 1984 Apr;104(4):579-81.
- Matalon R, Justice P, Deanching MN. Phenylalanine hydroxylase in human placenta: novel system for study of phenylketonuria [letter]. *Lancet* 1977 Apr 16;1(8016):853-4.
- Matalon R, Matthews DE, Michals K, Bier D. The use of deuterated phenylalanine for the in vivo assay of phenylalanine hydroxylase activity in children. *J Inher Metab Dis* 1982;5(1):17-9.
- Matalon R, Michals K. Phenylketonuria: screening, treatment and maternal PKU. *Clin Biochem* 1991 Aug;24(4):337-42.
- Matalon R, Michals K, Blau N, Rouse B. Hyperphenylalaninemia due to inherited deficiencies of tetrahydrobiopterin. *Adv Pediatr* 1989;36:67-89.
- Matalon R, Michals K, Lee CL, Nixon JC. Screening for biopterin defects in newborns with phenylketonuria and other hyperphenylalaninemias. *Ann Clin Lab Sci* 1982 Sep-Oct;12(5):411-4.
- Mathias D. Guthrie-Test und quantitative Methoden. In: Bickel H, Wachtel U, editors. *Neugeborenen-Screening auf hereditäre Stoffwechselstörungen : gegenwärtiger Stand und künftige Entwicklung*. 1. Tagung der Arbeitsgemeinschaft Neugeborenen-Screening. New York: Thieme; 1983. p. 4. (Ger).
- Mathias D, Bickel H. Follow-up study of 16 years neonatal screening for inborn errors of metabolism in West Germany. *Eur J Pediatr* 1986 Sep;145(4):310-2.
- Mathias D, Bickel H. Inter-laboratory quality control in neonatal screening for inborn errors of metabolism. *Eur J Pediatr* 1985 Jul;144(2):171-3.
- Matsubara Y, Heining JA, Lin YY. Improved diagnosis of classical vs atypical phenylketonuria by liquid chromatography. *Clin Chem* 1984 Feb;30(2):278-80.
- Matsuo N. Hyperphenylalaninemia syndromes: current status of diagnosis and management. *Keio J Med* 1988 Mar;37(1):1-9.
- Matsuoka A. [The course of the past twenty years of mass-screening for congenital metabolic disorders: racial difference in PKU genotypes]. *Rinsho Byori* 1998 Mar;46(3):199-202. (Jpn).

- McCabe ER, McCabe L. Screening for PKU in sick or premature neonates [letter]. *J Pediatr* 1983 Sep;103(3):502-3.
- McCabe ER, McCabe L, Mosher GA, Allen RJ, Berman JL. Newborn screening for phenylketonuria: predictive validity as a function of age. *Pediatrics* 1983 Sep;72(3):390-8.
- McCabe LL, McCabe ERB. Population studies of allele frequencies in single gene disorders: methodological and policy considerations. *Epidemiol Rev* 1997;19(1):52-60.
- McCormack MK. Screening for genetic traits and diseases. *Am Fam Physician* 1981 Oct;24(4):153-66.
- McDonnell GV, Esmonde TF, Hadden DR, Morrow JI. A neurological evaluation of adult phenylketonuria in Northern Ireland. *Eur Neurol* 1998;39(1):38-43.
- Meaney FJ. Computerized tracking for newborn screening and follow-up: a review. *J Med Syst* 1988 Apr;12(2):69-75.
- Medical Research Council Steering Committee for the MRC/DHSS Phenylketonuria Register. Routine neonatal screening for phenylketonuria in the United Kingdom 1964-78. *Br Med J (Clin Res Ed)* 1981 May 23;282(6277):1680-4.
- Meijer H, Hekking M, van den Enden AT, Jongbloed RJ, Schrandt-Stumpel CT, Geraedts JP. [Phenylketonuria as a model system for DNA diagnosis of hereditary disorders]. *Ned Tijdschr Geneesk* 1990 Oct 6;134(40):1954-8. Published erratum appears in *Ned Tijdschr Geneesk* 1990 Nov 3;134(44):2168. (Dut).
- Meijer WJ. [10 years' national screening study of the incidence of phenylketonuria in the Netherlands; 3d report of the National Advisory Phenylketonuria Commission]. *Ned Tijdschr Geneesk* 1985 Jan 12;129(2):74-6. (Dut).
- Meryash DL, Levy HL, Guthrie R, Warner R, Bloom S, Carr JR. Prospective study of early neonatal screening for phenylketonuria. *N Engl J Med* 1981 Jan 29;304(5):294-6.
- Meyer M, Malpuech G, Geneste J, Palcoux JB, Francannet C, Vanlieferinghen P. [Diagnosis of deficiency in cofactor of phenylalanine hydroxylase: a metabolic emergency]. *J Genet Hum* 1989 Dec;37(4-5):315-9. (Fre).
- Mikaeloff Y, Pinton F, Sevin C, Dhondt JL, Ponsot G. [Progressive convulsive encephalopathy: considering a abnormality of bipterin metabolism]. *Arch Pediatr* 1999 Jul;6(7):759-61. (Fre).
- Miller ME, Plumeau P, Blakely E. Elevated phenylalanine concentrations in benign hyperphenylalaninemia from evaporated milk feedings. *Clin Pediatr (Phila)* 1993 Feb;32(2):124-5.
- Milstien S, Holtzman NA, O'Flynn ME, Thomas GH, Butler IJ, Kaufman S. Hyperphenylalaninemia due to dihydropteridine reductase deficiency. Assay of the enzyme in fibroblasts from affected infants, heterozygotes, and in normal amniotic fluid cells. *J Pediatr* 1976 Nov;89(5):763-6.
- Milstien S, Kaufman S, Summer GK. Hyperphenylalaninemia due to dihydropteridine reductase deficiency: diagnosis by measurement of oxidized and reduced pterins in urine. *Pediatrics* 1980 Apr;65(4):806-10.
- Minato S. Purification of human liver phenylalanine hydroxylase with a monoclonal antibody to it and characterization of the enzyme. *Acta Paediatr Jpn* 1987 Aug;29(4):569-70.
- Mizuno T, Abe N, Teshima H, Yamauchi E, Itagaki Y, Matsumoto I, Kuhara T, Shinka T. Application of a gas chromatography mass spectrometry computer system for clinical diagnosis. *Biomed Mass Spectrom* 1981 Dec;8(12):593-7.
- Modell B. Biochemical neonatal screening: preconceptional and antenatal screening may be preferable in some cases [editorial]. *BMJ* 1990 Jun 30;300(6741):1667-8.
- Moller HE, Vermathen P, Ullrich K, Weglage J, Koch HG, Peters PE. In-vivo NMR spectroscopy in patients with phenylketonuria: changes of cerebral phenylalanine levels under dietary treatment. *Neuropediatrics* 1995 Aug;26(4):199-202.
- Moller HE, Weglage J, Wiedermann D, Ullrich K. Blood-brain barrier phenylalanine transport and individual vulnerability in phenylketonuria. *J Cereb Blood Flow Metab* 1998 Nov;18(11):1184-91.
- Mordaunt VL, Cunningham GC, Kan K. Computer assisted management of a regionalized newborn screening program. *J Med Syst* 1988 Apr;12(2):77-88.
- More on newborn screening for phenylketonuria: recommendations of the Committee on Genetics [letter]. *Pediatrics* 1983 Jul;72(1):139-42.
- Morris AF, Holton JB, Burman D, Colley JR. Phenylalanine and tyrosine levels in newborn screening blood samples. *Arch Dis Child* 1983 Apr;58(4):271-5.
- Motulsky AG. Screening for genetic diseases [editorial]. *New Engl J Med* 1997 May 1;336(18):1314-6. Comment on: *N Engl J Med* 1997

- May 1;336(18):1298-301. Comment in: *N Engl J Med* 1997 Aug 28;337(9):639-40.
- Motzfeldt K, Lilje R, Nylander G. Breastfeeding in phenylketonuria. *Acta Paediatr Suppl* 1999 Dec;88(432):25-7.
- Mugarra Bidea I, Cabases Hita JM. [Cost-benefit analysis of the early detection program for metabolic diseases in the Autonomous Basque Community]. *Gay Sanit* 1990 Jul-Aug;4(19):140-4. (Spa).
- Murphey WH, Patchen L, Guthrie R. Screening tests for argininosuccinic aciduria, orotic aciduria, and other inherited enzyme deficiencies using dried blood specimens. *Biochem Genet* 1972 Feb;6(1):51-9.
- Nagao M. [Molecular pathology and DNA diagnosis of phenylketonuria and hypermethioninemia]. *Tanpakushitsu Kakusan Koso* 1998 May;43(6):762-9. (Jpn).
- Naidu S, Moser HW. Value of neuroimaging in metabolic diseases affecting the CNS. *AJNR Am J Neuroradiol* 1991 May-Jun;12(3):413-6. Comment on: *AJNR Am J Neuroradiol* 1991 May-Jun;12(3):403-6; *AJNR Am J Neuroradiol* 1991 May-Jun;12(3):407-9; *AJNR Am J Neuroradiol* 1991 May-Jun;12(3):410-2.
- Nakabayashi H, Owada M, Kitagawa T. A mild case of dihydropteridine reductase deficiency with residual activity in erythrocytes. *J Inherit Metab Dis* 1984;7(3):135-6.
- Nakazato M, Ohi T, Matsukura S. [Trend in molecular biochemical studies on neurological disorders]. *Nippon Rinsho* 1989 Jan;47(1):227-38. (Jpn).
- Narisawa K, Arai N, Hayakawa H, Tada K. Diagnosis of variant forms of hyperphenylalaninemia using filter paper spots of blood and urine. In: Naruse H, Irie M, editors. Neonatal screening. Proceedings of the 2nd International Conference on Neonatal Thyroid Screening; 1982 Aug 16-19; Tokyo and the International Symposium on Neonatal Screening for Inborn Errors of Metabolism; 1982 Aug 19-21; Tokyo. Princeton (NJ): Excerpta Medica; 1983. p. 201-6. (International congress series; no. 606).
- Narisawa K, Arai N, Ishizawa S, Ogasawara Y, Onuma A, Iinuma K, Tada K. Dihydropteridine reductase deficiency: diagnosis by leukocyte enzyme assay. *Clin Chim Acta* 1980 Aug 19;105(3):335-42.
- Narisawa K, Hayakawa H, Arai N, Matsuo N, Tanaka T, Naritomi K, Tada K. Diagnosis of variant forms of hyperphenylalaninemia using filter paper spots of urine. *J Pediatr* 1983 Oct;103(4):577-9.
- Naruse H, Ohashi YY, Watanabe N, Tsuji A, Maeda M, Nakamura K, Fujii T, Yamaguchi A, Matsumoto M, Shibata M. New screening methods using colorimetric microplate system for PKU, maple syrup urine disease, and galactosemia. In: Wilcken B, Webster D, editors. Neonatal screening in the nineties. Proceedings of the 8th International Neonatal Screening Symposium; 1991 Nov 12-15; Leura, New South Wales, Australia and the Arthur Veale Memorial Meeting; 1991 Nov 5-9; Auckland, New Zealand. Australia: The Symposium; 1991. p. 59-60.
- Natowicz MR, Alper JS. Genetic screening: triumphs, problems, and controversies. *J Public Health Policy* 1991 Winter;12(4):475-91.
- Naylor EW. Newborn screening for urea cycle disorders. *Adv Exp Med Biol* 1982;153:9-18.
- Naylor EW. Recent developments in neonatal screening. *Semin Perinatol* 1985 Apr;9(3):232-49.
- Naylor EW, Chace DH. Automated tandem mass spectrometry for mass newborn screening for disorders in fatty acid, organic acid, and amino acid metabolism. *J Child Neurol* 1999 Nov;14 Suppl 1:S4-8.
- Naylor EW, Ennis DC, Guethhoff M. Eight years of screening for cofactor variant forms of phenylketonuria in North America. In: Schmidt BJ, Diament AJ, Loghin-Grosso NS, editors. Current trends in infant screening. Proceedings of the 7th International Screening Symposium; 1988 Nov 6-9; Sao Paulo, Brazil. New York: Excerpta Medica; 1989. p. 89-93. (International congress series; no. 848).
- Neonatal screening for phenylketonuria [letter]. *Pediatrics* 1984 May;73(5):737-40.
- [Neonatal screening of phenylketonuria and hypothyroidism in France. 1985 statistics. French Association for the Screening and Prevention of Metabolic Diseases and Handicaps in Children]. *Arch Fr Pediatr* 1987;44 Suppl 1:749-54. (Fre).
- Neonatal screening programme for phenylketonuria [letter]. *BMJ* 1991 Sep 21;303(6804):716. Comment on: *BMJ* 1991 Aug 10;303(6798):333-5. Comment on: *BMJ* 1991 Aug 24;303(6800):471.
- Netzloff ML. Neonatal screening for phenylketonuria. *Ann Clin Lab Sci* 1982 Sep-Oct;12(5):368-71.
- Newborn screening for metabolic disorders in Australia and New Zealand. results for 1983. Human Genetics Society of Australasia Newborn Screening Committee. *Med J Aust* 1985 Aug 19;143(4):159-60.
- Newborn screening tests and your baby. [Seattle (WA)] : Washington State Department of Social & Health Services, Health Services Division, Genetics Program; [198-?]. 4 vols. (Eng, Cam, Chi, Lao, Vie).

- Newborn screening. U.S. Public Health Service. *Am Fam Physician* 1994 Aug;50(2):354-8.
- NICHHD-supported scientists design test for prenatal diagnosis of PKU. Washington: Department of Health and Human Services (US); 1984 Feb. 1 p. Available from: NTIS, Springfield, VA; TN84-0090.
- Nichols MJ. PKU testing... phenylketonuria (PKU). *MLO Med Lab Observ* 1994 Jun;26(6):11-2.
- Niederwieser A. Diagnosis and treatment of tetrahydrobiopterin deficiency (malignant hyperphenylalaninemia). In: Benson PF, editor. *Screening and management of potentially treatable genetic metabolic disorders. Proceedings of the workshop*; 1983 Mar 17-18; London. Boston: MTP Press for the Commission; c1984. p. 115-25. (EUR; 9020).
- Niederwieser A, Curtius HC. [Detection, differential diagnosis, and prenatal diagnosis of tetrahydrobiopterin deficiency]. *Arch Fr Pediatr* 1987;44 Suppl 1:661-4. (Fre).
- Niederwieser A, Curtius HC. Tetrahydrobiopterin biosynthetic pathway and deficiency. *Enzyme* 1987;38(1-4):302-11.
- Niederwieser A, Curtius HC, Wang M, Leupold D. Atypical phenylketonuria with defective biopterin metabolism. Monotherapy with tetrahydrobiopterin or sepiapterin, screening and study of biosynthesis in man. *Eur J Pediatr* 1982 Mar;138(2):110-2.
- Niederwieser A, Ponzone A, Curtius HC. Differential diagnosis of tetrahydrobiopterin deficiency. *J Inherit Metab Dis* 1985;8 Suppl 1:34-8.
- Niederwieser A, Shintaku H, Hasler T, Curtius HC, Lehmann H, Guardamagna O, Schmidt H. Prenatal diagnosis of dihydrobiopterin synthetase deficiency, a variant form of phenylketonuria. *Eur J Pediatr* 1986 Aug;145(3):176-8.
- Ning C, Liu SR, Wei H, Wang S, Shu D, Blau N, Wang MT. The screening diagnosis of tetrahydrobiopterin deficient phenylketonuria. *J Tongji Med Univ* 1992;12(4):216-8.
- Norgaard-Pedersen B. [The PKU registry and biobank at the National Serum Institute. Rules and applications]. *Ugeskr Laeger* 1998 Apr 6;160(15):2266-7. (Dan).
- Norgaard-Pederson B. Use of stored samples from the Danish PKU register. In: Knoppers BM, editor. *Human DNA: law and policy: international and comparative perspectives. Proceedings of the 1st International Conference on DNA Sampling and Human Genetic Research: Ethical, Legal, and Policy Aspects*; 1996 Sep 6-8; Montreal, Canada. Boston (MA): Kluwer Law International; 1997. 303-11.
- Novello AC. Inherited metabolic diseases: collaborating for the health of all children. *Biochem Med Metab Biol* 1993 Jun;49(3):277-84.
- Nyhan WL. Neonatal screening for inherited disease [editorial]. *N Engl J Med* 1985 Jul 4;313(1):43-4.
- Nyhan WL. Understanding inherited metabolic disease. *Clin Symp* 1980;32(5):1-36.
- Nyhan WL, Sakati NA. Diagnostic recognition of genetic disease. Philadelphia: Lea & Febiger; 1987. *Phenylketonuria (PKU)*; p. 100-6.
- Nyhan WL, Sakati NA. Diagnostic recognition of genetic disease. Philadelphia: Lea & Febiger; 1987. *Hyperphenylalaninemia and defective metabolism of tetrahydrobiopterin*; p. 107-11.
- O'Brien D. Screening for biopterin disorders in PKU [letter]. *Pediatrics* 1980 Nov;66(5):813.
- O'Flynn ME. Newborn screening for phenylketonuria: thirty years of progress. *Curr Probl Pediatr* 1992 Apr;22(4):159-65.
- O'Flynn ME, Holtzman NA, Blaskovics M, Azen C, Williamson ML. The diagnosis of phenylketonuria: a report from the Collaborative Study of Children Treated for Phenylketonuria. *Am J Dis Child* 1980 Aug;134(8):769-74.
- O'Grady DJ, Berry HK, Sutherland BS. Cognitive development in early treated phenylketonuria. *Am J Dis Child* 1971 Jan;121(1):20-3.
- Okano Y, Isshiki G. Newborn mass screening and molecular genetics of phenylketonuria in east Asia. *Southeast Asian J Trop Med Public Health* 1995;26 Suppl 1:123-9.
- Okano Y, Oura T. [DNA diagnosis for inherited metabolic disorders]. *Nippon Rinsho* 1992 Jul;50(7):1536-41. (Jpn).
- Oorthuys JW, Gons MH, Kwakman JV, Schutgens RB, Tegelaers WH. [Screening for raised serum phenylalanine levels in women of reproductive age in Volendam]. *Ned Tijdschr Geneesk* 1985 Jan 12;129(2):62-5. (Dut).
- Orgad S, Yaar L, Barkai G, Avigad S, Lieberman A, Goldmann B, Gazit E. [Carrier detection and prenatal diagnosis in phenylketonuria, cystic fibrosis and adrenal hyperplasia use of molecular biology techniques]. *Harefuah* 1989 Mar 15;116(6):297-300. (Heb).

- Osorio RV, Vilarinho L, Soares JP. [National screening for phenylketonuria, congenital hypothyroidism and congenital adrenal hyperplasia]. *Acta Med Port* 1992 Mar;5(3):131-4. (Por).
- Ounap K, Lillevali H, Metspalu A, Lipping-Sitska M. Development of the phenylketonuria screening programme in Estonia. *J Med Screen* 1998;5(1):22-3.
- Overgaard C, Knudsen A. Pain-relieving effect of sucrose in newborns during heel prick. *Biol Neonate* 1999 May;75(5):279-84.
- Owada M. [Phenylketonuria (phenylalanine hydroxylase deficiency)]. *Ryoikibetsu Shokogun Shirizu* 1998;(18 Pt 1):114-8. (Jpn).
- Owada M, Kitagawa T. [Biochemical diagnosis and mass screening for hereditary amino acid disorders]. *Nippon Rinsho* 1992 Jul;50(7):1522-9. (Jpn).
- Ozand PT, Devol EB, Gascon GG. Neurometabolic diseases at a national referral center: five years experience at the King Faisal Specialist Hospital and Research Centre. *J Child Neurol* 1992 Apr;7 Suppl:S4-11.
- Paans AM, Pruim J, Smit GP, Visser G, Willemsen AT, Ullrich K. Neurotransmitter positron emission tomographic-studies in adults with phenylketonuria, a pilot study. *Eur J Pediatr* 1996 Jul;155 Suppl 1:S78-81.
- Paez X, Rada P, Hernandez L. Neutral amino acids monitoring in phenylketonuric plasma microdialysates using micellar electrokinetic chromatography and laser-induced fluorescence detection. *J Chromatogr B Biomed Sci Appl* 2000 Mar 10;739(2):247-54.
- Palmer CG, Miles JH, Howard-Peebles PN, Magenis RE, Patil S, Friedman JM. Fetal karyotype following ascertainment of fetal anomalies by ultrasound. *Prenat Diagn* 1987 Oct;7(8):551-5.
- Pasali D, Deseta E, Pjanovic Z. [Hearing disorders and audiometry findings in children with phenylketonuria]. *Srp Arh Celok Lek* 1981 Mar;109(3):415-20. (Scc).
- Pasquo A, Britton KL, Baker PJ, Brearley G, Hinton RJ, Moir AJ, Stillman TJ, Rice DW. Crystallization of NAD⁺-dependent phenylalanine dehydrogenase from *Nocardia sp239*. *Acta Crystallogr D Biol Crystallogr* 1998 Mar 1;54 (Pt 2):269-72.
- Paul D. Contesting consent: the challenge to compulsory neonatal screening for PKU. *Perspect Biol Med* 1999 Winter;42(2):207-19.
- Paul DB. What is a genetic test, and why does it matter? *Endeavour* 1999;23(4):159-61.
- Paunier L. [Detections tests for newborn infants]. *Rev Med Suisse Romande* 1981 May;101(5):359-62. (Fre).
- [The pediatrician and early detection of hyperphenylalaninemia. Study Group on Hyperphenylalaninemia]. *An Esp Pediatr* 1993 May;38(5):477. (Spa).
- Perez B, Desviat LR, De Lucca M, Schmidt B, Loghin-Grosso N, Giugliani R, Pires RF, Ugarte M. Mutation analysis of phenylketonuria in south Brazil. *Hum Mutat* 1996;8(3):262-4.
- Perez B, Desviat LR, De Lucca M, Ugarte M. Spectrum and origin of phenylketonuria mutations in Spain. *Acta Paediatr Suppl* 1994 Dec;407:34-6.
- Perry TL, Hansen S. Cystinylglycine in plasma: diagnostic relevance for pyroglutamic acidemia, homocystinuria, and phenylketonuria. *Clin Chim Acta* 1981 Nov 25;117(1):7-12.
- Persha AJ. Early identification and prevention of mental retardation. *ICCW News B* 1992 Jan-Mar;40(1):9-12.
- Pettersen RD, Saugstad OD, Heyerdahl S, Motzfeldt K, Lie SO. [Screening of newborn infants in Norway for severe metabolic disease]. *Tidsskr Nor Laegeforen* 1995 Feb 20;115(5):584-7. (Nor).
- Pettersen RD, Saugstad OD, Lie SO. [Neonatal screening for metabolic diseases--a task without priority in the Norwegian health policy?]. *Tidsskr Nor Laegeforen* 1995 Feb 20;115(5):607-8. (Nor).
- Phenylketonuria. Ill. Ann. Stat. ch. 111 1/2, Sect. 4901-4905 (Smith-Hurd 1982):2 p. Illinois law effective 1 Jan 1982.
- Phenylketonuria: diagnosis and management. Proceedings of a symposium. London, 17 June 1987. *Postgrad Med J* 1989;65 Suppl 2:S1-26.
- Pierzchala K, Rosciszewska D, Kwiecinski J. [Adult age phenylketonuria with extrapyramidal syndrome: therapeutic management]. *Neurol Neurochir Pol* 1993 Nov-Dec;27(6):899-904. (Pol).
- Pietz J. Neurological aspects of adult phenylketonuria. *Curr Opin Neurol* 1998 Dec;11(6):679-88.
- Pietz J, Kreis R, Schmidt H, Meyding-Lamade UK, Rupp A, Boesch C. Phenylketonuria: findings at MR imaging and localized in vivo H-1 MR spectroscopy of the brain in patients with early treatment. *Radiology* 1996 Nov;201(2):413-20.
- Pietz J, Landwehr R, Kutscha A, Schmidt H, de Sonneville L, Trefz FK. Effect of high-dose tyrosine

supplementation on brain function in adults with phenylketonuria. *J Pediatr* 1995 Dec;127(6):936-43.

Pietz J, Meyding-Lamade UK, Schmidt H. Magnetic resonance imaging of the brain in adolescents with phenylketonuria and in one case of 6-pyruvoyl tetrahydropteridine synthase deficiency. *Eur J Pediatr* 1996 Jul;155 Suppl 1:S69-73.

Pietz J, Schmidt E, Matthis P, Kobialka B, Kutscha A, de Sonneville L. EEGs in phenylketonuria. I: Follow-up to adulthood; II: Short-term diet-related changes in EEGs and cognitive function. *Dev Med Child Neurol* 1993 Jan;35(1):54-64.

Pitt D, Connelly J, Francis I, Wilcken B, Brown DA, Robertson E, Hill G, Masters P, Raby J, McFarlane J, Bowling F, Hancock J. Genetic screening of newborn in Australia. Results for 1981. *Med J Aust* 1983 Apr 2;1(7):333-5.

Pitt D, Connelly J, Francis I, Wilcken B, Brown DA, Robertson E, Hill G, Masters P, Tucker RG, Raby J, McFarlane J, Hancock J. Genetic screening of newborn in Australia: results for 1980. *Med J Aust* 1982 Feb 6;1(3):119-20.

Pitt D, Connelly J, Francis I, Wilcken B, Brown DA, Robertson E, Hill G, Masters P, Tucker RG, Raby J, McFarlane J, Hancock J. Genetic screening of newborn in Australia: results for 1979. *Med J Aust* 1981 Jan 10;1(1):39-40.

Pogson D. Issues for consideration in dihydropteridine reductase (DHPR) deficiency: a variant form of hyperphenylalaninaemia. *J Intellect Disabil Res* 1997 Jun;41 (Pt 3):208-14.

Polichroniadis M. Parental understanding and attitudes towards neonatal biochemical screening. *Midwives Chron* 1989 Feb;102(1213):42-3.

Pollitt RJ. Neonatal screening. *J Clin Pathol* 1993 Jun;46(6):497-9.

Pollitt RJ. Neonatal screening in France. *J Inherit Metab Dis* 1983;6(2):49-50.

Pollitt RJ, Green A, McCabe CJ, Booth A, Cooper NJ, Leonard JV, Nicholl J, Nicholson P, Tunaley JR, Virdi NK. Neonatal screening for inborn errors of metabolism: cost, yield and outcome. *Health Technol Assess* 1997;1(7):1-202.

Ponzzone A, Blau N, Guardamagna O, Ferrero GB, Dianzani I, Endres W. Progression of 6-pyruvoyl-tetrahydropteridine synthase deficiency from a peripheral into a central phenotype. *J Inherit Metab Dis* 1990;13(3):298-300.

Ponzzone A, Ferraris S, Spada M, Blau N, Piovan S, Burlina AB. Combined phenylalanine-

tetrahydrobiopterin loading test in GTP cyclohydrolase 1 deficiency [letter]. *Eur J Pediatr* 1994 Aug;153(8):616.

Ponzzone A, Guardamagna O, Ferraris S, Bracco G, Cotton RG. Screening for malignant phenylketonuria [letter]. *Lancet* 1987 Feb 28;1(8531):512-3.

Ponzzone A, Guardamagna O, Ferraris S, Ferrero GB, Dianzani I, Cotton RG. Tetrahydrobiopterin loading test in hyperphenylalaninemia. *Pediatr Res* 1991 Nov;30(5):435-8.

Ponzzone A, Guardamagna O, Spada M, Ferraris S, Ponzzone R, Kierat L, Blau N. Differential diagnosis of hyperphenylalaninaemia by a combined phenylalanine-tetrahydrobiopterin loading test. *Eur J Pediatr* 1993 Aug;152(8):655-61.

Ponzzone A, Spada M, de Sanctis L, Dianzani I. Phenotyping of phenylketonuric patients by oral phenylalanine loading [letter]. *Eur J Pediatr* 1996 Jun;155(6):523-5. Comment on: *Eur J Pediatr* 1995 Jul;154(7):551-6.

Ponzzone A, Spada M, Ferrero GB, Ferraris S, Guardamagna O, Burlina A, Blau N. Experience with the combined phenylalanine-tetrahydrobiopterin loading test in hyperphenylalaninemia. In: Farriaux JP, Dhondt JL, editors. *New horizons in neonatal screening. Proceedings of the 9th International Neonatal Screening Symposium and the 2nd Meeting of the International Society for Neonatal Screening*; 1993 Sep 13-17; Lille, France. New York: Elsevier Science; 1994. p. 115-8. (International congress series; no. 1041).

Ponzzone A, Spada M, Ferrero GB, Ponzzone R, Ferraris S. Newborn feeding and screening for phenylketonuria [letter]. *Acta Paediatr* 1999 Mar;88(3):347-8.

Popescu A, Andrian T, Guttler F, Guldberg P. Genotype-phenotype correlation in 11 Romanian PKU families. *J Inherit Metab Dis* 1994;17(3):374-5.

Popescu A, Butnariu J, Toma C, Farcas A, Gelmareanu K. [Data on phenylketonuria screening]. *Rev Pediatr Obstet Ginecol Pediatr* 1983 Jan-Mar;32(1):67-9. (Rum).

Popescu A, Butnariu J, Toma C, Scurtu C, Milcu M, Bojan O, Muschievici D. [Preliminary data on the detection of phenylketonuria in the Cluj district]. *Rev Pediatr Obstet Ginecol Pediatr* 1980 Apr-Jun;29(2):139-45. (Rum).

Popescu V, Dragomir D, Osanu D, Arion C, Leu E, Esanu M, Mogos I. [Alkaptonuria. Considerations on 3 clinical cases]. *Rev Pediatr Obstet Ginecol Pediatr* 1983 Jul-Sep;32(3):247-60. (Rum).

- Porter IH. Control of hereditary disorders. *Annu Rev Public Health* 1982;3:277-319.
- Preston MA, Borczyk A. Destructive effect of prolonged autoclaving of blood specimens in Guthrie test [letter]. *Lancet* 1992 Jul 18;340(8812):187.
- Preventive Services Task Force (US). Guide to clinical preventive services : an assessment of the effectiveness of 169 interventions. Baltimore: Williams and Wilkins; c1989. Screening for phenylketonuria; p. 115-9.
- Preventive Services Task Force (US), Office of Disease Prevention and Health Promotion. Guide to clinical preventive services. Washington: Department of Health and Human Services (US), Office Public Health Sciences; 1989 Apr. Screening for phenylketonuria; p. 495-502.
- Priscu AR, Manolescu E, Sichițiu S, Iordachescu F, Tomescu E, Stamate M, Ciurea A, Poboran V, Iacob C, Bugariu E, Milcu M, Caniola I, Gasparovici L, Bucur I, Stefanache O, Georgescu BG, Zaharescu J, Opris CC, Paltineau V, Horincar N, Wirtz A, Tertan I, Szabo I, Tamas N. [Pilot experiment concerning the concomitant detection of congenital hypothyroidism and phenylketonuria in newborn infants in a high-risk geographical zone. (Results for the year 1979)]. *Rev Pediatr Obstet Ginecol Pediatr* 1980 Apr-Jun;29(2):131-8. (Rum).
- Pueschel SM, Herman R, Groden G. Brief report: screening children with autism for fragile-X syndrome and phenylketonuria. *J Autism Dev Disord* 1985 Sep;15(3):335-8.
- Pullon DH. Maternal phenylketonuria. In: Wilcken B, Webster D, editors. Neonatal screening in the nineties. Proceedings of the 8th International Neonatal Screening Symposium; 1991 Nov 12-15; Leura, New South Wales, Australia and the Arthur Veale Memorial Meeting; 1991 Nov 5-9; Auckland, New Zealand. Australia: The Symposium; 1991. p. 327-8.
- Put prevention into practice: newborn screening. *J Am Acad Nurse Pract* 1995 Oct;7(10):513-7. Adapted from the Clinician's Handbook of Preventive Services, published by the US Department of Health and Human Services, Public Health Service.
- Qu Y, Miller JB, Slocum RH, Shapira E. Rapid automated quantitation of isoleucine, leucine, tyrosine and phenylalanine from dried blood filter paper specimens. *Clin Chim Acta* 1991 Dec 16;203(2-3):191-7.
- Rabinoff M. Possible uses of urinary neopterin and biopterin measurement. *Med Hypotheses* 1989 Aug;29(4):241-3.
- Ramus SJ, Forrest SM, Cotton RG. Illegitimate transcription of phenylalanine hydroxylase for detection of mutations in patients with phenylketonuria. *Hum Mutat* 1992;1(2):154-8.
- Rapoport D, Saudubray JM, Ogier H, Hatt A, Berges J, Depondt E, Charpentier C, Frezal J. [Psychological prospects and scholastic performance of 33 children with early diagnosis of hyperphenylalaninemia]. *Arch Fr Pediatr* 1983;40 Suppl 1:273-9. (Fre).
- Ratzmann GW, Grimm U, Jahrig K. Increased concentrations of tyrosine and phenylalanine in the cerebrospinal fluid as a possible reflection of related changes of the brain tissue in newborns with intra-uterine growth retardation. *Biomed Biochim Acta* 1988;47(12):1037-41.
- Realmuto GM, Garfinkel BD, Tuchman M, Tsai MY, Chang PN, Fisch RO, Shapiro S. Psychiatric diagnosis and behavioral characteristics of phenylketonuric children. *J Nerv Ment Dis* 1986 Sep;174(9):536-40.
- Recommended guidelines for PKU programs for the newborn. [Rev. ed.]. Rockville (MD): Maternal and Child Health Service (US), Children's Bureau; 1971. 12 p. (Public Health Service publication, no. 2160/G).
- Redford-Ellis M, Gibbs AC, Haider SA, Holzel A. Aminoaciduria in handicapped children: a study using ion-exchange chromatography as a screening test. *Lancet* 1981 Jul 4;2(8236):10-5.
- Reilly AA, Bellisario R, Pass KA. Multivariate discrimination for phenylketonuria (PKU) and non-PKU hyperphenylalaninemia after analysis of newborns' dried blood-spot specimens for six amino acids by ion-exchange chromatography. *Clin Chem* 1998 Feb;44(2):317-26.
- Reilly PR. Laws to regulate the use of genetic information. In: Rothstein MA, editor. Genetic secrets: protecting privacy and confidentiality in the genetic era. New Haven (CT): Yale University Press; 1997. p. 369-91.
- Reinecke CJ, Mienie LJ, Hitzeroth HW, Op't Hof J. Screening for inborn errors of metabolism among mentally retarded patients. Outcome of a surgery at the Witrand Care and Rehabilitation Centre. *S Afr Med J* 1983 Jan 1;63(1):14-6.
- Reveley AM, Reveley MA. Screening for adult phenylketonuria in psychiatric inpatients. *Biol Psychiatry* 1982 Nov;17(11):1343-5.
- Reviron D, Auquier P, Giusiano B, Maurin N, Sambuc R, Giraud F. [Neonatal screening for phenylketonuria and hypothyroidism. An optimizing system]. *Arch Fr Pediatr* 1990 Apr;47(4):255-6. (Fre).

- Rey F, Berthelon M, Munnich A, Frezal J, Rey J. [Prenatal screening for phenylketonuria in 2 families by trophoblast biopsy]. *Arch Fr Pediatr* 1987 Oct;44(8):565-8. (Fre).
- Rey F, Leeming RJ, Blair JA, Rey J. Biopterin defect in a normal-appearing child affected by a transient phenylketonuria. *Arch Dis Child* 1980 Aug;55(8):637-9.
- Rey F, Saudubray JM, Leeming RJ, Niederwieser A, Curtius HC, Rey J. [Partial deficiency of tetrahydrobiopterin]. *Arch Fr Pediatr* 1983;40 Suppl 1:237-41. (Fre).
- Richardson SC, Green AK, Fisher MJ. Phosphorylation-dephosphorylation of renal phenylalanine hydroxylase. *Biochem Soc Trans* 1991 Apr;19(2):229S.
- Riess O, Michel A, Speer A, Cobet G, Coutelle C. Introduction of genomic diagnosis of classical phenylketonuria to the health care system of the German Democratic Republic. *Clin Genet* 1987 Oct;32(4):209-15.
- Robertson M. Towards a medical eugenics? [editorial]. *BMJ* 1984 Feb 11;288(6415):429-30.
- Robinson M, White FJ, Cleary MA, Wraith E, Lam WK, Walter JH. Increased risk of vitamin B12 deficiency in patients with phenylketonuria on an unrestricted or relaxed diet. *J Pediatr* 2000 Apr;136(4):545-7.
- Roesel RA, Blankenship PR, Hommes FA. HPLC assay of phenylalanine and tyrosine in blood spots on filter paper. *Clin Chim Acta* 1986 Apr 15;156(1):91-6.
- Rogowiecka E, Sendek E, Chazan B, Cabalska B, Bankowska E. [Maternal PKU syndrome as an obstetric problem: literature review and own clinical experience]. *Ginekol Pol* 1998 Dec;69(12):1007-15. (Pol).
- Romano V, Dianzani I, Ponzone A, Zammarchi E, Eisensmith R, Ceratto N, Bosco P, Indelicato A. Prenatal diagnosis by minisatellite analysis in Italian families with phenylketonuria. *Prenat Diagn* 1994 Oct;14(10):959-62.
- Romano V, Guldborg P, Guttler F, Meli C, Mollica F, Pavone L, Giovannini M, Riva E, Biasucci G, Luotti D, Palillo L, Cali F, Ceratto N, Anello G, Bosco P. PAH deficiency in Italy: correlation of genotype with phenotype in the Sicilian population. *J Inher Metab Dis* 1996;19(1):15-24.
- Romeo G, Menozzi P, Ferlini A, Prosperi L, Cerone R, Scalisi S, Romano C, Antonozzi I, Riva E, Piceni Sereni L, et al. Incidence of classic PKU in Italy estimated from consanguineous marriages and from neonatal screening. *Clin Genet* 1983 Nov;24(5):339-45.
- Romstad A, Guldborg P, Blau N, Guttler F. Single-step mutation scanning of the 6-pyruvoyltetrahydropterin synthase gene in patients with hyperphenylalaninemia. *Clin Chem* 1999 Dec;45(12):2102-8.
- Ross LJ. Developmental disabilities: genetic implications. *J Obstet Gynecol Neonatal Nurs* 1994 Jul-Aug;23(6):502-5.
- Roth KS. Newborn metabolic screening: a search for nature's experiments. *South Med J* 1986 Jan;79(1):47-54.
- Rottoli A, Gianni ML, Verduci E, Biondi ML, Fiori L, Giovannini M, Riva E. Should genetic analysis in newborn screening and a heterozygote test for hyperphenylalaninaemia be recommended? An Italian study. *J Med Screen* 1999;6(4):193-4.
- [Round table: neonatal screening programs in Europe]. *J Genet Hum* 1981 Mar;29(1):23-38. (Fre).
- Rowley PT. Genetic screening: marvel or menace? *Science* 1984 Jul 13;225(4658):138-44.
- Ruban VF. Rapid determination of phenylalanine in plasma by capillary high-performance liquid chromatography with electrochemical detection. *J Chromatogr* 1991 Jan 18;563(1):134-41.
- Rylance G. Outcome of early detected and early treated phenylketonuria patients. *Postgrad Med J* 1989;65 Suppl 2:S7-9.
- Safronova EE, Rybakova NA, Annenkov GA. [Use of modified Ayling's method for detection of homozygotes and heterozygotes for phenylketonuria gene]. *Vopr Med Khim* 1982 May-Jun;28(3):70-3. (Rus).
- Salize HJ, Funders-Bucker B, Knorrek U, Kolbe S, Pietsch V, Seidlitz G, Ullrich K, Trefz FK. [Maternal phenylketonuria. Problems in detecting and risk educating identified females]. *Monatsschr Kinderheilkd* 1992 Jan;140(1):42-6. (Ger).
- Salzano FM, Pena SD. Ethics and medical genetics in Brazil. Wertz DC, Fletcher JC, editors. *Ethics and human genetics: a cross-cultural perspective*. New York: Springer-Verlag; 1989. p. 100-18.
- Sander J. [Impairment of phenylketonuria tests by antibiotics]. *Offentl Gesundheitswes* 1981 May;43(5):246. (Ger).
- Sansom C. Tandem mass spectrometry: the tool of choice for diagnosing inborn errors of metabolism [news]. *Mol Med Today* 1999 Mar;5(3):95.

- Sardharwalla IB, Wraith JE. A clinician's view of the mass screening of the newborn for inherited diseases: current practice and future considerations. *J Inherit Metab Dis* 1989;12 Suppl 1:55-63.
- Sartorio R, Greco L, Carozzo R, Budillon C, Andria G. A simplified test to detect PKU heterozygotes by discriminant analysis in mentally retarded children and their mothers. *Clin Genet* 1988 Apr;33(4):241-5.
- Scaglioni S, Virdis R, Zuccotti G, Vedovello M, Marcianesi M, Longhi R, Riva E, Giovannini M, Giovannelli G. Pubertal maturation and classical phenylketonuria. *J Inherit Metab Dis* 1986;9(3):285-6.
- Scheffler RM, Paringer L. A review of the economic evidence on prevention. *Med Care* 1980 May;18(5):473-84.
- Schettini F. [Neonatal screenings]. *Minerva Pediatr* 1987 Nov 15;39(21):993-5. (Ita).
- Schier E. [The risk concept and optimality concept in the identification of children at risk--procedural methods and application in practice]. *Pediatr Grenzgeb* 1982;21(5):373-83. (Ger).
- Schmidt BJ, Diament AJ, Krynski S, Kamei ME, Rodrigues MM, Takata S. [Detection of inborn errors of metabolism in San Pablo, Brazil]. *Bol Med Hosp Infant Mex* 1981 Mar-Apr;38(2):217-29. (Spa).
- Schmidt BJ, Martins AM, Fisberg R, Adell AC, Soares D, Muller R, Bechara J, Loughlin-Grosso N, Diament AJ. Phenylketonuria (PKU): the Brazilian experience. In: Schmidt BJ, Diament AJ, Loughlin-Grosso NS, editors. *Current trends in infant screening. Proceedings of the 7th International Screening Symposium*; 1988 Nov 6-9; Sao Paulo, Brazil. New York: Excerpta Medica; 1989. p. 65-70. (International congress series; no. 848).
- Schmidt BJ, Martins AM, Grosso NL, Maion CM, Carvalho BT, Fisberg RM, Jurkiewicz B, Takeda MF, Carvalho TM, Costa MM, Beghini AP, Tanabe E, Costa FG, Taniguchi H, Freitas JC, Yamasaki M, Pacheco NR, Ogs S, Yanagawa VN. PKU screening in Sao Paulo - Brazil. In: Wilcken B, Webster D, editors. *Neonatal screening in the nineties. Proceedings of the 8th International Neonatal Screening Symposium*; 1991 Nov 12-15; Leura, New South Wales, Australia and the Arthur Veale Memorial Meeting; 1991 Nov 5-9; Auckland, New Zealand. Australia: The Symposium; 1991. p. 64-5.
- Schmidt BJ, Vargas PR, Martins AM, Jurkiewicz B, Muoio M, Pinhal I, Carvalho TM, Costa MM, Loguin-Grosso NS. PKU screening in Brazil. In: Farriaux JP, Dhondt JL, editors. *New horizons in neonatal screening. Proceedings of the 9th International Neonatal Screening Symposium and the 2nd Meeting of the International Society for Neonatal Screening*; 1993 Sep 13-17; Lille, France. New York: Elsevier Science; 1994. p. 329-32. (International congress series; no. 1041).
- Schmidt E. [The German phenylketonuria study. Description of a longitudinal study and its results]. *Dtsch Krankenpflegez* 1993 Feb;46(2):84-6. (Ger).
- Schmidt H. Hyperphenylalaninämien: Praktisches Vorgehen zur Differentialdiagnose von Hyperphenylalaninämien. In: Bickel H, Wachtel U, editors. *Neugeborenen-Screening auf hereditäre Stoffwechselstörungen : gegenwärtiger Stand und künftige Entwicklung. 1. Tagung der Arbeitsgemeinschaft Neugeborenen-Screening*. New York: Thieme; 1983. p. 55-8. (Ger).
- Schmidt H, Bickel H. [Phenylketonuria]. *Internist (Berl)* 1976 Jul;17(7):354-61. (Ger).
- Schneider AJ. Newborn phenylalanine/tyrosine metabolism. Implications for screening for phenylketonuria. *Am J Dis Child* 1983 May;137(5):427-32.
- Schoos R, Verloes A, Bourguignon JP, Koulischer L. [Programs of systematic screening in neonatology. Pharmacoeconomic aspects]. *Rev Med Liege* 1998 May;53(5):311-5. (Fre).
- Schreier K. [Modern possibilities in the early diagnosis of congenital metabolic diseases]. *Med Welt* 1982 Apr 2;33(13):462-5. (Ger).
- Schuett VE, Yandow JL, Pringle DJ. Screening & treatment of PKU [slide]. Carrboro (NC): Health Sciences Consortium; 1986. 131 slides: color; 1 audiocassette: 38 min., 1 7/8 ips. Accompanied by: 1 guide.
- Schulze A, Kohlmüller D, Mayatepek E. Sensitivity of electrospray-tandem mass spectrometry using the phenylalanine/tyrosine-ratio for differential diagnosis of hyperphenylalaninemia in neonates. *Clin Chim Acta* 1999 May;283(1-2):15-20.
- Schwahn B, Mokov E, Scheidhauer K, Lettgen B, Schonau E. Decreased trabecular bone mineral density in patients with phenylketonuria measured by peripheral quantitative computed tomography. *Acta Paediatr* 1998 Jan;87(1):61-3.
- Schweitzer LB, Desnick RJ. Inherited metabolic diseases: advances in delineation, diagnosis, and treatment. *Birth Defects Orig Artic Ser* 1983;19(5):39-71.
- Scriber CC. A simple phenylalanine method for detecting phenylketonuria in large populations of newborn infants, by Robert Guthrie and Ada Susi, *Pediatrics*, 1963;32:318-343. *Pediatrics* 1998 Jul;102(1 Pt 2):236-7.

- Scriver CR. PKU and beyond: when do costs exceed benefits? *Pediatrics* 1974 Nov;54(5):616-9.
- Scriver CR. Screening for medical intervention: the PKU experience. *Prog Clin Biol Res* 1982;103 Pt B:437-45.
- Scriver CR, Byck S, Prevost L, Hoang L. The phenylalanine hydroxylase locus: a marker for the history of phenylketonuria and human genetic diversity. PAH Mutation Analysis Consortium. *Ciba Found Symp* 1996;197:73-90; discussion 90-6.
- Scriver CR, Clow CL. Avoiding phenylketonuria: why parents seek prenatal diagnosis. *J Pediatr* 1988 Sep;113(3):495-7.
- Scriver CR, Clow CL. Phenylketonuria and other phenylalanine hydroxylation mutants in man. *Annu Rev Genet* 1980;14:179-202.
- Scriver CR, Clow CL. Phenylketonuria: epitome of human biochemical genetics (second of two parts). *N Engl J Med* 1980 Dec 11;303(24):1394-400.
- Seakins JW, Hjelm M, Wang KJ. Statistical properties of the Michaelis-Menten equation and their implication for inborn errors of metabolism. *J Inher Metab Dis* 1992;15(3):431-4.
- Seashore MR. Genetic screening and the pediatrician. *Pediatr Ann* 2000;29(5):272-6.
- Seashore MR. Neonatal screening for inborn errors of metabolism: update. *Semin Perinatol* 1990 Dec;14(6):431-8.
- Sepe SJ, Levy HL, Mount FW. An evaluation of routine follow-up blood screening of infants for phenylketonuria. *N Engl J Med* 1979 Mar 15;300(11):606-9.
- Sepe SJ, Marks JS, Oakley GP, Manley AF. Genetic services in the United States. *JAMA* 1982 Oct 8;248(14):1733-5.
- Seymour CA, Thomason MJ, Chalmers RA, Addison GM, Bain MD, Cockburn F, Littlejohns P, Lord J, Wilcox AH. Newborn screening for inborn errors of metabolism: a systematic review. *Health Technol Assess* 1997;1(11):i-iv, 1-95.
- Shaw DW, Maravilla KR, Weinberger E, Garretson J, Trahms CM, Scott CR. MR imaging of phenylketonuria. *AJNR Am J Neuroradiol* 1991 May-Jun;12(3):403-6. Comment in: *AJNR Am J Neuroradiol* 1991 May-Jun;12(3):413-6.
- Shen RS, Richardson CJ, Rouse BM, Abell CW. An enzymatic assay of plasma phenylalanine and tyrosine for the detection and management of phenylketonuria. *Biochem Med* 1981 Oct;26(2):211-21.
- Shen Y, Xu Q, Han F, Ding K, Song F, Fan Y, Zhu N, Wu G, Lin B. Application of capillary nongel sieving electrophoresis for gene analysis. *Electrophoresis* 1999 Jul;20(9):1822-8.
- Shintaku H. [Malignant hyperphenylalaninemia--tetrahydrobiopterin (BH4) deficiency]. *Tanpakushitsu Kakusan Koso* 1988 Apr;33(5):493-6. (Jpn).
- Shintaku H. [The metabolic basis of the hyperphenylalaninemias and tyrosinemia]. *Nippon Rinsho* 1992 Jul;50(7):1542-7. (Jpn).
- Shintaku H, Asada M, Isshiki G, Sawada Y. [Disorders of tetrahydrobiopterin homeostasis]. *Ryoikibetsu Shokogun Shirizu* 1998;(18 Pt 1):125-9. (Jpn).
- Shintaku H, Isshiki G, Hase Y, Tsuruhara T, Oura T. Early diagnosis of tetrahydrobiopterin (BH4) deficiency. In: Naruse H, Irie M, editors. *Neonatal screening. Proceedings of the 2nd International Conference on Neonatal Thyroid Screening; 1982 Aug 16-19; Tokyo and the International Symposium on Neonatal Screening for Inborn Errors of Metabolism; 1982 Aug 19-21; Tokyo.* Princeton (NJ): Excerpta Medica; 1983. p. 211-2. (International congress series; no. 606).
- Simonsen H, Brandt NJ, Norgaard-Pedersen B. [Neonatal screening in Denmark. Status and future perspectives]. *Ugeskr Laeger* 1998 Sep 28;160(40):5777-82. (Dan).
- Simpson D. Phenylketonuria. *Midwives Chron* 1989 Feb;102(1213):37-41.
- Simpson N, Randall R, Lenton S, Walker S. Audit of neonatal screening programme for phenylketonuria and congenital hypothyroidism. *Arch Dis Child Fetal Neonatal Ed* 1997 Nov;77(3):F228-34.
- Sinai LN, Kim SC, Casey R, Pinto-Martin JA. Phenylketonuria screening: effect of early newborn discharge. *Pediatrics* 1995 Oct;96(4 Pt 1):605-8.
- Skovby F. [Neonatal screening for hereditary diseases (editorial)]. *Ugeskr Laeger* 1998 Sep 28;160(40):5765. (Dan).
- Slazyk WE, Hannon WH, Powell MK, Jensen RJ, Myrick JE, Spierto FW. National laboratory performance surveillance program for congenital hypothyroidism, phenylketonuria, and galactosemia. In: Schmidt BJ, Diament AJ, Loghini-Grosso NS, editors. *Current trends in infant screening. Proceedings of the 7th International Screening Symposium; 1988 Nov 6-9; Sao Paulo, Brazil.* New York: Excerpta Medica; 1989. p. 27-30. (International congress series; no. 848).

- Slazyk WE, Phillips DL, Therrell BL Jr, Hannon WH. Effect of lot-to-lot variability in filter paper on the quantification of thyroxin, thyrotropin, and phenylalanine in dried-blood specimens. *Clin Chem* 1988 Jan;34(1):53-8.
- Slazyk WE, Spierto FW. Liquid-chromatographic measurement of biopterin and neopterin in serum and urine. *Clin Chem* 1990 Jul;36(7):1364-8.
- Smith I. Long term outcome of early treated PKU due to phenylalanine hydroxylase deficiency. In: Farriau JP, Dhondt JL, editors. *New horizons in neonatal screening. Proceedings of the 9th International Neonatal Screening Symposium and the 2nd Meeting of the International Society for Neonatal Screening*; 1993 Sep 13-17; Lille, France. New York: Elsevier Science; 1994. p. 73-7. (International congress series; no. 1041).
- Smith I. The natural history of phenylketonuria. *Arch Dis Child* 1971 Dec;46(250):879.
- Smith I. Treatment of phenylalanine hydroxylase deficiency. *Acta Paediatr Suppl* 1994 Dec;407:60-5.
- Smith I, Cook B, Beasley M. Review of neonatal screening programme for phenylketonuria. *BMJ* 1991 Aug 10;303(6798):333-5. Published erratum appears in *BMJ* 1991 Oct 5;303(6806):824. Comment in: *BMJ* 1991 Aug 24;303(6800):471; *BMJ* 1991 Sep 21;303(6804):716.
- Smith I, Wolff OH. Natural history of phenylketonuria and influence of early treatment. *Lancet* 1974 Sep 7;2(7880):540-4.
- Snyderman SE, Sansaricq C, Norton PM, Castro JV. Plasma and cerebrospinal fluid amino acid concentrations in phenylketonuria during the newborn period. *J Pediatr* 1981 Jul;99(1):63-7.
- Somers DG, Favreau L. Newborn screening for phenylketonuria: incidence and screening procedures in North America. *Can J Public Health* 1982 May-Jun;73(3):206-7.
- Sommer SS, Cassady JD, Sobell JL, Bottema CD. A novel method for detecting point mutations or polymorphisms and its application to population screening for carriers of phenylketonuria. *Mayo Clin Proc* 1989 Nov;64(11):1361-72.
- Spaapen LJ, Ketting D, Wadman SK, Bruinvis L, Duran M. Urinary D-4-hydroxyphenyllactate, D-phenyllactate and D-2-hydroxyisocaproate, abnormalities of bacterial origin. *J Inher Metab Dis* 1987;10(4):383-90.
- Spady DW. Who gets missed: coverage in the 1992 Alberta newborn screening [masters thesis]. Alberta (Canada): University of Alberta; 1997. 99 p.
- Speer A, Bollman R, Michel A, Neumann R, Bommer C, Hanke R, Riess O, Cobet G, Coutelle C. Prenatal diagnosis of classical phenylketonuria by linked restriction fragment length polymorphism analysis. *Prenat Diagn* 1986 Nov-Dec;6(6):447-50.
- Speer A, Dahl HH, Riess O, Cobet G, Hanke R, Cotton RG, Coutelle C. Typing of families with classical phenylketonuria using three alleles of the HindIII linked restriction fragment polymorphism, detectable with a phenylalanine hydroxylase cDNA probe. Family typing for PKU by linked HindIII RFLP. *Clin Genet* 1986 Jun;29(6):491-5.
- Stanage WF, Gregg JB. Hyperphenylalaninemia (PKU) and hypothyroid testing. *S D J Med* 1982 Jul;35(7):8.
- Standing SJ, Taylor RP. Phenylalanine: application of a simple HPLC technique to its measurement in dried blood spots. *Ann Clin Biochem* 1992 Nov;29 (Pt 6):668-70.
- Starfield B. Motherhood and apple pie: the effectiveness of medical care for children. *Milbank Mem Fund Q Health Soc* 1985 Summer;63(3):523-46.
- Start K. Treating phenylketonuria by a phenylalanine-free diet. *Prof Care Mother Child* 1998;8(4):109-10.
- Statham H, Green J, Snowdon C. Mothers' consent to screening newborn babies for disease [letter]. *BMJ* 1993 Mar 27;306(6881):858-9.
- Steele S. Phenylketonuria: counseling and teaching functions of the nurse on an interdisciplinary team. *Issues Compr Pediatr Nurs* 1989;12(5):395-409.
- Steiner KC, Smith HA. Application of cost-benefit analysis to a PKU screening program. *Inquiry* 1973 Dec;10(4):34-40.
- Steuer W. [Early detection of hereditary metabolic diseases (author's transl)]. *Offentl Gesundheitswes* 1980 Dec;42(12):949-54. (Ger).
- Steuer W. Qualitätskontrollen der Screening-Zentren. In: Bickel H, Wachtel U, editors. *Neugeborenen-Screening auf hereditäre Stoffwechselstörungen : gegenwärtiger Stand und künftige Entwicklung. 1. Tagung der Arbeitsgemeinschaft Neugeborenen-Screening*. New York: Thieme; 1983. p. 11. (Ger).
- Stevens MB, Rigilano JC, Wilson CC. State screening for metabolic disorders in newborns. *Am Fam Physician* 1988 Apr;37(4):223-8.
- Streetly A, Grant C, Pollitt RJ, Addison GM. Survey of scope of neonatal screening in the United Kingdom. *BMJ* 1995 Sep 16;311(7007):726. Comment in: *BMJ* 1996 Jan 20;312(7024):182; *BMJ* 1996 Jan 20;312(7024):182-3; *BMJ* 1996 Feb 3;312(7026):312.

- Strupp BJ, Levitsky DA, Blumstein L. PKU, learning, and models of mental retardation. *Dev Psychobiol* 1984 Mar;17(2):109-20.
- Subramanyam SB. Saudi aminoacidemias: a six-year study. *Indian J Pediatr* 1996 Sep-Oct;63(5):641-4.
- Sueoka H, Moshinetsky A, Nagao M, Chiba S. Mutation screening of phenylketonuria in the Far East of Russia. *J Hum Genet* 1999;44(6):368-71.
- Superti-Furga A, Steinmann B, Duc G, Gitzelmann R. Microcephaly and maternal phenylketonuria [letter]. *Eur J Pediatr* 1996 Nov;155(11):992. Comment on: *Eur J Pediatr* 1996 Mar;155(3):257-8.
- Surplice IM, Griffiths PD, Green A, Leeming RJ. Dihydropteridine reductase activity in eluates from dried blood spots: automation of an assay for a national screening service. *J Inher Metab Dis* 1990;13(2):169-77.
- Suyama I, Oura T, Kawamura T, Isshiki G, Ozaki H, Nishimura K. Experimental approaches to maternal phenylketonuria. In: Wilcken B, Webster D, editors. Neonatal screening in the nineties. Proceedings of the 8th International Neonatal Screening Symposium; 1991 Nov 12-15; Leura, New South Wales, Australia and the Arthur Veale Memorial Meeting; 1991 Nov 5-9; Auckland, New Zealand. Australia: The Symposium; 1991. p. 333-5.
- Svensson E, Andersson B, Hagenfeldt L. Two mutations within the coding sequence of the phenylalanine hydroxylase gene. *Hum Genet* 1990 Aug;85(3):300-4.
- Svensson E, Eisensmith RC, Dworniczak B, von Döbeln U, Hagenfeldt L, Horst J, Woo SL. Two missense mutations causing mild hyperphenylalaninemia associated with DNA haplotype 12. *Hum Mutat* 1992;1(2):129-37.
- Svensson E, von Döbeln U, Hagenfeldt L. Polymorphic DNA haplotypes at the phenylalanine hydroxylase locus and their relation to phenotype in Swedish phenylketonuria families. *Hum Genet* 1991 May;87(1):11-7.
- Svensson E, Wang Y, Eisensmith RC, Hagenfeldt L, Woo SL. Three polymorphisms but no disease-causing mutations in the proximal part of the promoter of the phenylalanine hydroxylase gene. *Eur J Hum Genet* 1993;1(4):306-13.
- Sweetman L. Newborn screening by tandem mass spectrometry (MS-MS) [editorial]. *Clin Chem* 1996 Mar;42(3):345-6. Comment on: *Clin Chem* 1996 Mar;42(3):349-55.
- Szeinberg A, Cohen BE. Early blood sampling in neonatal programs for the detection of phenylketonuria. *Pediatr Padol* 1982;17(2):287-92.
- Szymanski HV, Friedman S, Guthrie R. Screening for phenylketonuria in chronic psychiatric inpatients. *Hosp Community Psychiatry* 1984 Sep;35(9):936-8.
- Tada K, Narisawa K. [Biogenic amines and hyperphenylalaninemia (author's transl)]. *Tanpakushitsu Kakusan Koso* 1981 Aug;26(11):1765-71. (Jpn).
- Tagliaro F, Moretto S, Valentini R, Gambaro G, Antonioli C, Moffa M, Tato L. Capillary zone electrophoresis determination of phenylalanine in serum: a rapid, inexpensive and simple method for the diagnosis of phenylketonuria. *Electrophoresis* 1994 Jan;15(1):94-7.
- Takarada Y, Yamashita K, Kagawa S, Zhang QZ, Matsuoka A. [Genetic diagnosis of phenylketonuria. III. Mutations of phenylalanine hydroxylase gene in Orientals]. *Rinsho Byori* 1994 Nov;42(11):1158-64. (Jpn).
- Takarada Y, Yamashita K, Kalanin J, Kagawa S, Matsuoka A. [Genetic diagnosis of phenylketonuria. IV. Mutations of phenylalanine hydroxylase gene in Caucasian and Gypsy populations in Czech and Slovakia Republics]. *Rinsho Byori* 1994 Nov;42(11):1165-71. (Jpn).
- Tanase-Mogos I, Ciortoloman H, Grigorescu G, Popescu M, Ankar V. [Combined and isolated forms of metabolic errors detected in children]. *Physiologie* 1980 Jan-Mar;17(1):57-66. (Fre).
- Tenenholz B, Wenger SL, Breck J, Steele MW. A simplified PKU gene carrier detection test using fasting blood. *Clin Genet* 1983 Feb;23(2):115-9.
- Tessari P, Deferrari G, Robaudo C, Vettore M, Pastorino N, De Biasi L, Garibotto G. Phenylalanine hydroxylation across the kidney in humans rapid communication. *Kidney Int* 1999 Dec;56(6):2168-72.
- Thalhammer D. Andere Aminosäurenstoffwechselstörungen, die im Guthrie-Test erfasst werden können: Histidin. In: Bickel H, Wachtel U, editors. Neugeborenen-Screening auf hereditäre Stoffwechselstörungen : gegenwärtiger Stand und künftige Entwicklung. 1. Tagung der Arbeitsgemeinschaft Neugeborenen-Screening. New York: Thieme; 1983. p. 63. (Ger).
- Thalhammer O, Scheibenreiter S, Knoll E, Wehle E, Schon R. [12 years Austrian newborn screening for inborn errors of metabolism. Results with special reference to phenylketonuria, hyperphenylalaninemia and histidinemia (author's transl)]. *Klin Padiatr* 1980 Nov;192(6):589-98. (Ger).

- Theile H, Machill G. [Follow-up in mild hyperphenylalaninemia]. *Kinderarztl Prax* 1980 Mar;48(3):124-9. (Ger).
- Therrell BL. Blood from all newborns [letter]. *Pediatrics* 1982 Jul;70(1):156-7.
- Therrell BL Jr, Brown LO, Dziuk PE, Peter WP Jr. The Texas Newborn Screening Program. *Tex Med* 1983 Feb;79(2):44-6.
- Thibaud D, Ploussard JP, Vaquant PO, Chemouny S, Kleitz T. [Diagnosis of phenylketonuria in a 35-year-old mother in relation to prenatal diagnosis of intrauterine growth retardation with microcephaly]. *Arch Pediatr* 1998 Nov;5(11):1229-31. (Fre).
- Thomas GH, Parmley TH, Stevenson RE, Howell RR. Developmental changes in amino acid concentrations in human amniotic fluid: abnormal findings in maternal phenylketonuria. *Am J Obstet Gynecol* 1971 Sep;111(1):38-42.
- Thomason MJ, Lord J, Bain MD, Chalmers RA, Littlejohns P, Addison GM, Wilcox AH, Seymour CA. A systematic review of evidence for the appropriateness of neonatal screening programmes for inborn errors of metabolism. *J Public Health Med* 1998 Sep;20(3):331-43.
- Thompson S, Gruca M, Holliday K, Yu J, Lipson A. Maternal PKU - the Sydney experience. In: Wilcken B, Webster D, editors. *Neonatal screening in the nineties. Proceedings of the 8th International Neonatal Screening Symposium*; 1991 Nov 12-15; Leura, New South Wales, Australia and the Arthur Veale Memorial Meeting; 1991 Nov 5-9; Auckland, New Zealand. Australia: The Symposium; 1991. p. 329-31.
- Tillotson SL, Costello PM, Smith I. No reduction in birth weight in phenylketonuria. *Eur J Pediatr* 1995 Oct;154(10):847-9. Comment in: *Eur J Pediatr* 1997 Feb;156(2):157.
- Tiwary CM. Neonatal screening for metabolic and endocrine diseases. *Nurse Pract* 1987 Sep;12(9):28-35, 38, 41.
- Tiwary CM. Proposed guidelines for screening of metabolic and endocrine diseases of dependent neonates of the U.S. Armed Forces. Derived from a survey of state guidelines for neonatal screening of metabolic diseases. *Clin Pediatr (Phila)* 1987 Jul;26(7):349-54.
- Tolmie JL, Harvie A, Cockburn F. The teratogenic effects of undiagnosed maternal hyperphenylalaninaemia: a case for prevention? *Br J Obstet Gynaecol* 1992 Apr;99(4):347-8.
- Trefz FK, Bartholome K, Bickel H, Lutz P, Schmidt H. In vivo determination of phenylalanine hydroxylase activity using heptadeutero-phenylalanine and comparison to the in vitro assay values. *Monogr Hum Genet* 1978;9:108-13.
- Trefz FK, Bartholome K, Bickel H, Lutz P, Schmidt H, Seyberth HW. In vivo residual activities of the phenylalanine hydroxylating system in phenylketonuria and variants. *J Inher Metab Dis* 1981;4(2):101-2.
- Trefz FK, Batzler U, Konig T, Michel U, Schmidt E, Schmidt H, Bickel H. Significance of the in vivo deuterated phenylalanine load for long-term phenylalanine tolerance and psycho-intellectual outcome in patients with PKU. *Eur J Pediatr* 1990;149 Suppl 1:S25-7.
- Trefz FK, Erlenmaier T, Hunneman DH, Bartholome K, Lutz P. Sensitive in vivo assay of the phenylalanine hydroxylating system with a small intravenous dose of heptadeutero L-phenylalanine using high pressure liquid chromatography and capillary gas chromatography/mass fragmentography. *Clin Chim Acta* 1979 Dec 17;99(3):211-30.
- Trefz FK, Lichter-Konecki U, Konecki DS, Schlotter M, Bickel H. PKU and NON-PKU hyperphenylalaninemia: differentiation, indication for therapy and therapeutic results. *Acta Paediatr Jpn* 1988 Aug;30(4):397-404.
- Trefz FK, Lichter-Konecki U, Krawczak M, Schmidtke J, Dueck M, Nutzenadel W, Konecki DS. [DNA diagnosis of monogene hereditary diseases exemplified by phenylketonuria and mucoviscidosis]. *Monatsschr Kinderheilkd* 1989 Apr;137(4):201-7. (Ger).
- Tsukerman GL. [Simple method of mass screening for phenylketonuria]. *Lab Delo* 1985;(6):326-7. (Rus).
- Tu JB. Theory and practice of psychopharmacogenetics. *Am J Med Genet* 1994 Dec 15;54(4):391-7.
- Tuchman M, Fisch RO, Ramnaraine ML, Krivit W. Acidic metabolites of phenylalanine in plasma of phenylketonurics. *Biochem Med* 1985 Oct;34(2):203-6.
- Tuuhinen T. Development of a combined diagnostic system for neonatal phenylketonuria and congenital hypothyroidism [dissertation]. Helsinki (Finland): University of Helsinki; 1993. 106 p.
- Tuuminen T. Changing of critical variables in the fluorometric microplate-based method for phenylketonuria screening [letter]. *Clin Chem* 1992 May;38(5):784-5.

- Tyfield LA, Stephenson A, Bidwell JL, Wood NA, Cockburn F, Harvie A, Smith I. Mutation analysis of the phenylalanine hydroxylase gene using heteroduplex analysis with synthetic DNA constructs. *Acta Paediatr Suppl* 1994 Dec;407:47-8.
- Ullrich K, Weglage J, Schuierer G, Funders B, Pietsch M, Koch HG, Hahn-Ullrich H. Cranial MRI in PKU: evaluation of a critical threshold for blood phenylalanine [letter]. *Neuropediatrics* 1994 Oct;25(5):278-9.
- Vaca G, Hernandez A, Ibarra B, Velazquez A, Olivares N, Sanchez-Corona J, Medina C, Cantu JM. [Detection of inborn errors of metabolism in 1,117 patients studied because of suspected inherited disease]. *Arch Invest Med (Mex)* 1981;12(3):341-8. (Spa).
- Valman HB. The first year of life: routine examination of the newborn. *Br Med J* 1980 Jan 12;280(6207):91-4.
- van der Schot LW, Doesburg WH, Sengers RC. The phenylalanine response curve in relation to growth and mental development in the first year of life. *Acta Paediatr Suppl* 1994 Dec;407:68-9.
- Veale AM. Screening for phenylketonuria. In: Bickel H, Guthrie R, Hammersen G, editors. *Neonatal screening for inborn errors of metabolism*. New York: Springer-Verlag; 1980. p. 7-18.
- Velazquez A, Bilbao G, Gonzalez-Trujillo JL, Hernandez D, Perez-Andrade ME, Vela M, Ciceron I, Loera-Luna A, Cederbaum S, Phoenix B. Apparent higher frequency of phenylketonuria in the Mexican state of Jalisco. *Hum Genet* 1996 Jan;97(1):99-102.
- Velazquez A, Loera-Luna A, Aguirre BE, Gamboa S, Vargas H, Robles C. [Neonatal screening for congenital hypothyroidism and phenylketonuria]. *Salud Publica Mex* 1994 May-Jun;36(3):249-56. (Spa).
- Verkerk PH. [20-year national screening for phenylketonuria in The Netherlands. National Guidance Commission PKU]. *Ned Tijdschr Geneesk* 1995 Nov 11;139(45):2302-5. (Dut).
- Verkerk PH, Loeber JG, Verloove-Vanhorick SP. [Age in neonatal screening and birth weight]. *Ned Tijdschr Geneesk* 1992 Oct 10;136(41):2013-4. (Dut).
- Verkerk PH, Vaandrager GJ, Sengers RC. [15 years of national screening for phenylketonuria in The Netherlands; 4th Report of the National Commission for Management of Phenylketonuria]. *Ned Tijdschr Geneesk* 1990 Dec 29;134(52):2533-6. (Dut).
- Verkerk PH, van der Meer SB. Failure to detect phenylketonuria [letter]. *Eur J Pediatr* 1995 Feb;154(2):163.
- Verlinsky Y, Rechitsky S, Verlinsky O, Ivachenko V, Lifchez A, Kaplan B, Moise J, Valle J, Borkowski A, Nefedova J, Goltzman E, Strom C, Kuliev A. Prepregnancy testing for single-gene disorders by polar body analysis. *Genet Test* 1999;3(2):185-90.
- Veropotvelian PN, Krupoder GI, Avksent'ev ON. [Phenylketonuria]. *Feldsher Akush* 1982;47(5):33-5. (Rus).
- Vetrone P, Leuzzi V, Zazzara V, Antonozzi I. Psychological effects on parents of children with early detected phenylketonuria. *J Inher Metab Dis* 1989;12(3):345-6.
- Vidailhet M. [Prenatal and postnatal diagnosis (trisomy 21, phenylketonuria, hypothyroidism). Methods, indications, legal and ethical aspects]. *Rev Prat* 1994 May 1;44(9):1241-8. (Fre).
- Vollmer DW, Jinks DC, Guthrie R. Isocratic reverse-phase liquid chromatography assay for amino acid metabolic disorders using eluates of dried blood spots. *Anal Biochem* 1990 Aug 15;189(1):115-21.
- Volpe EP. *Patient in the womb*. Macon (GA): Mercer University Press; 1984. 157 p.
- Voogd CE. [Phenylketonuria inspite of screening (letter)]. *Ned Tijdschr Geneesk* 1993 Oct 30;137(44):2279. Comment on: *Ned Tijdschr Geneesk* 1993 Aug 21;137(34):1727-9. (Dut).
- Vorstenbosch EL, Potapov AP, De Graaf JM, Kraal B. The effect of mutations in EF-Tu on its affinity for tRNA as measured by two novel and independent methods of general applicability. *J Biochem Biophys Methods* 2000;42(1-2):1-14.
- Vyborova L, Nahunek K, Drtilkova I, Balastikova B, Sindelarova M, Machackova V, Podhradská O, Mrskos A. Psychic changes in phenylketonuric children at phenylalanine load. *Act Nerv Super (Praha)* 1981 Dec;23(4):298-300.
- Wachtel U. Review of current practices in management of inherited disorders of amino acid metabolism in Western Europe. *Hum Nutr Appl Nutr* 1986;40 Suppl 1:61-9.
- Wada Y, Nakajima H, Irie M, Hirayama M, Suwa S. Newborn mass screening in Japan--1984. *Jinrui Idengaku Zasshi* 1984 Sep;29(3):277-86.
- Waisbren SE, Brown MJ, de Sonnevile LM, Levy HL. Review of neuropsychological functioning in treated phenylketonuria: an information processing approach. *Acta Paediatr Suppl* 1994 Dec;407:98-103.

- Waisbren SE, Hanley W, Levy HL, Shifrin H, Allred E, Azen C, Chang PN, Cipic-Schmidt S, de la Cruz F, Hall R, Matalon R, Nanson J, Rouse B, Trefz F, Koch R. Outcome at age 4 years in offspring of women with maternal phenylketonuria: the Maternal PKU Collaborative Study. *JAMA* 2000 Feb 9;283(6):756-62.
- Waisbren SE, Levy HL. Effects of untreated maternal hyperphenylalaninemia on the fetus: further study of families identified by routine cord blood screening. *J Pediatr* 1990 Jun;116(6):926-9.
- Walker JD, Crall JJ, McDonnell JE. Phenylketonuria and dentistry: review of the literature. *ASDC J Dent Child* 1982 Jul-Aug;49(4):280-4.
- Walker V, Clayton BE, Ersler RS, Francis DE, Lilly P, Seakins JW, Smith I, Whiteman PD. Hyperphenylalaninaemia of various types among three-quarters of a million neonates tested in a screening programme. *Arch Dis Child* 1981 Oct;56(10):759-64.
- Walker V, Smythe PJ, Cook NJ, Ball NA, Veall RM, Whiteman P. Urinary screening for abnormalities of amino acid or mucopolysaccharide metabolism in patients in a hospital for the mentally handicapped in Wessex. *J Ment Defic Res* 1983 Jun;27 (Pt 2):105-14.
- Wallman CM. Lab values and diagnostics. Newborn genetic screening. *Neonat Netw* 1998 Apr;17(3):55-60, 22-4.
- Wallman CM, Witt CL. Newborn genetic screening. *Neonatal Netw* 1998 Apr;17(3):55-60.
- Wang M. [Frequencies of 6 known mutations in phenylalanine hydroxylase gene and their application in prenatal gene diagnosis]. *Chung Hua I Hsueh Tsa Chih (Taipei)* 1992 Nov;72(11):670-3, 702-3. (Chi).
- Wang N, Zhu Y, Xu K, Qiu Z, Song W, Huang S. [Identification of mutations in the phenylalanine hydroxylase gene and exon 5 novel mutation Y166X(C->G) in Yunnan]. *Chung Hua I Hsueh Tsa Chih* 1999 Feb 10;16(1):9-11. (Chi).
- Wang ST, Pizzolato S, Demshar HP. Receiver operating characteristic plots to evaluate Guthrie, Wallac, and Isolab phenylalanine kit performance for newborn phenylketonuria screening. *Clin Chem* 1997 Oct;43(10):1838-42.
- Wang T, Okano Y, Eisensmith RC, Lo WH, Huang SZ, Zeng YT, Yuan LF, Liu SR, Woo SL. Missense mutations prevalent in Orientals with phenylketonuria: molecular characterization and clinical implications. *Genomics* 1991 Jun;10(2):449-56.
- Weglage J, Pietsch M, Funders B, Koch HG, Ullrich K. Deficits in selective and sustained attention processes in early treated children with phenylketonuria--result of impaired frontal lobe functions? *Eur J Pediatr* 1996 Mar;155(3):200-4.
- Wendel U, Koppelkamm M, Hummel W. Enzymatic phenylalanine estimation for the management of patients with phenylketonuria. *Clin Chim Acta* 1991 Sep 14;201(1-2):95-8.
- Wendel U, Koppelkamm M, Hummel W, Sander J, Langenbeck U. A new approach to the newborn screening for hyperphenylalaninemias: use of L-phenylalanine dehydrogenase and microtiter plates. *Clin Chim Acta* 1990 Dec 3;192(3):165-70.
- West R, Hale C. Overview of newborn screening in Arkansas. *J Ark Med Soc* 1995 Dec;92(7):329-33.
- White JE, Kronmal RA, Acosta PB. Excess weight among children with phenylketonuria. *J Am Coll Nutr* 1982;1(3):293-303.
- Wilcken B, Brown AR, Liu A, Jones K. Eliminating some possible errors in phenylketonuria screening [letter]. *Am J Clin Pathol* 1989 Sep;92(3):396. Comment on: *Am J Clin Pathol* 1988 Sep;90(3):279-83.
- Wiley V, Carpenter K, Wilcken B. Newborn screening with tandem mass spectrometry: 12 months' experience in NSW Australia. *Acta Paediatr Suppl* 1999 Dec;88(432):48-51.
- Willett AB, Nelson JE, Foss DK. Screening for adult phenylketonuria in state psychiatric hospitals. *Am J Psychiatry* 1980 Dec;137(12):1607-8.
- Witt M, Jaruzelska J, Kuczora I, Matuszak R, Cichy W, Borski K. A simplified method for detection of the mutations predominantly causing cystic fibrosis and phenylketonuria in Polish families. *Clin Genet* 1993 Jul;44(1):44-5.
- Woo SL. Molecular genetic analysis of phenylketonuria and mental retardation. *Res Publ Assoc Res Nerv Ment Dis* 1991;69:193-203.
- Woo SL. Prenatal diagnosis and carrier detection of classic phenylketonuria by gene analysis. *Pediatrics* 1984 Sep;74(3):412-23.
- Woo SL, Guttler F, Ledley FD, Lidsky AS, Kwok SC, DiLella AG, Robson KJ. The human phenylalanine hydroxylase gene. *Prog Clin Biol Res* 1985;177:123-35.
- Woo SL, Lidsky AS, Guttler F, Chandra T, Robson KJ. Cloned human phenylalanine hydroxylase gene allows prenatal diagnosis and carrier detection of

- classical phenylketonuria. *Nature* 1983 Nov 10-16;306(5939):151-5.
- Woo SL, Lidsky AS, Guttler F, Thirumalachary C, Robson KJ. Prenatal diagnosis of classical phenylketonuria by gene mapping. *JAMA* 1984 Apr 20;251(15):1998-2002.
- Woo SL, Robson JH, Guttler F. The possibility for prenatal diagnosis of PKU by linkage analyses based on phenylalanine hydroxylase locus specific DNA-polymorphisms. *J Inherit Metab Dis* 1984;7 Suppl 2:139-40.
- Wood N, Bidwell J. Genetic screening and testing by induced heteroduplex formation. *Electrophoresis* 1996 Jan;17(1):247-54.
- Woody RC, Brewster MA, Glasier C. Progressive intracranial calcification in dihydropteridine reductase deficiency prior to folinic acid therapy. *Neurology* 1989 May;39(5):673-5.
- Woolf LI. Late onset phenylalanine intoxication [letter]. *J Inherit Metab Dis* 1980;2(1):19-20.
- Wright L, Brown A, Davidson Mundt A. Newborn screening: the miracle and the challenge. *J Pediatr Nurs* 1992 Feb;7(1):26-42.
- Wu JT. Screening for inborn errors of amino acid metabolism. *Ann Clin Lab Sci* 1991 Mar-Apr;21(2):123-42.
- Wulff K, Herrmann FH, Wehnert M, Seidlitz G, Schutz M. [Genetic diagnosis in classical phenylketonuria]. *Z Arztl Fortbild (Jena)* 1988;82(22):1127-31. (Ger).
- Wulff K, Wehnert M, Schutz M, Seidlitz G, Herrmann FH. Prenatal diagnosis of phenylketonuria by haplotype analysis. *Prenat Diagn* 1989 Jun;9(6):421-5.
- Wuu KD, Chiu PC, Li SY, Chen JY, Chao MC, Ko FJ, Wang TR, Hsiao KJ. Chromosomal and biochemical screening on mentally retarded school children in Taiwan. *Jinrui Idengaku Zasshi* 1991 Sep;36(3):267-74.
- Wuu KD, Hsiao KJ, Chen CH, Hsiao TS, Chang CY, Chu YK. Screening for inherited metabolic diseases and congenital hypothyroidism in 4,744 mentally retarded school children in Taiwan. *Jinrui Idengaku Zasshi* 1988 Mar;33(1):33-40.
- Xu L, Miao S, Liu G. [Screening for mutations in the PAH gene in Chinese: a new splice and a novel polymorphic mutation]. *Chung Hua I Hsueh Tsa Chih* 1996 Jun;76(6):451-4. (Chi).
- Yamaguchi S, Koda N, Eto Y, Aoki K. Rapid screening of metabolic disease by proton NMR urinalysis [letter]. *Lancet* 1984 Aug 4;2(8397):284.
- Yamashita K, Takarada Y, Otsuka N, Kagawa S, Matsuoka A, Kalanin J. [Genetic diagnosis of phenylketonuria: identification of the mutations of phenylalanine hydroxylase gene by PCR direct sequencing]. *Rinsho Byori* 1992 Oct;40(10):1060-6. (Jpn).
- Yamashita M, Minato S, Arai M, Kishida Y, Nagatsu T, Umezawa H. Purification of phenylalanine hydroxylase from human adult and foetal livers with a monoclonal antibody. *Biochem Biophys Res Commun* 1985 Nov 27;133(1):202-7.
- Yanai K, Iinuma K, Matsuzawa T, Ito M, Miyabayashi S, Narisawa K, Ido T, Yamada K, Tada K. Cerebral glucose utilization in pediatric neurological disorders determined by positron emission tomography. *Eur J Nucl Med* 1987;13(6):292-6.
- Yang T, Yuan L, Huang S. [Detection of the mutational gene in phenylketonuria and prenatal diagnoses by using single strand conformation polymorphism methods]. *Chung Hua Fu Chan Ko Tsa Chih* 1996 Jul;31(7):401-3. (Chi).
- Yang T, Yuan L, Huang S, Zhao S. [Screening mutations in phenylketonuria by means of nonradioactive reverse dot blot hybridization]. *Chung Hua I Hsueh I Chuan Hsueh Tsa Chih* 1998 Oct 10;15(5):307-9. (Chi).
- Yannicelli S, Ryan A. Improvements in behaviour and physical manifestations in previously untreated adults with phenylketonuria using a phenylalanine-restricted diet: a national survey. *J Inherit Metab Dis* 1995;18(2):131-4.
- Yao Y, Matsubara Y, Narisawa K. Rapid detection of phenylketonuria mutations by non-radioactive single-strand conformation polymorphism analysis. *Acta Paediatr Jpn* 1994 Jun;36(3):231-5.
- Yokoyama Y, Tsuchiya M, Sato H, Kakinuma H. Determination of creatinine and ultraviolet-absorbing amino acids and organic acids in urine by reversed-phase high-performance liquid chromatography. *J Chromatogr* 1992 Nov 27;583(1):1-10.
- Zammarchi E, Donati MA, Pasquini E, Ciani F, Lori S, Fonda C. Electromyographic alterations in hyperphenylalaninemia due to dihydropteridine reductase deficiency. *J Child Neurol* 1997 Feb;12(2):137-9.
- Zamotrinskii AV, Jennings IG, Cotton RG, Chestkov VV. [Detection of phenylalanine hydroxylase protein in human platelets. Immunochemical detection]. *Biokhimiia* 1990 Apr;55(4):760-5. (Rus).

Zekanowski C, Nowacka M, Zgulska M, Horst J, Cabalska B, Mazurczak T. Frequencies of the most common mutations responsible for phenylketonuria in Poland. *Mol Cell Probes* 1994 Aug;8(4):323-4.

Zeng YT. [Antenatal gene diagnosis of phenylketonuria]. *Chung Hua I Hsueh Tsa Chih* 1986 Aug;66(8):493-4. (Chi).

Zeng YT. [Prenatal diagnosis of phenylketonuria (with a report of 10 cases)]. *Chung Hua I Hsueh Tsa Chih* 1988 Feb;68(2):61-4. (Chi).

Zetterstrom R. Editorial comment on phenylketonuria [editorial]. *Acta Paediatr* 1995 Jul;84(7):716-8.

Zhou AQ. [Clinical and laboratory study on 36 cases of phenylketonuria]. *Chung Hua I Hsueh Tsa Chih* 1983 Mar;63(3):150-3. (Chi).

Ziyai F, Wong PW, Justice P, Michals K. Protein-induced hypoglycemia in a phenylketonuric patient. *J Pediatr* 1978 Apr;92(4):681-2.

Zschocke J, Graham CA. A fluorescent multiplex ARMS method for rapid mutation analysis. *Mol Cell Probes* 1995 Dec;9(6):447-51.

Zschocke J, Graham CA, Carson DJ, Nevin NC. Phenylketonuria mutation analysis in Northern Ireland: a rapid stepwise approach. *Am J Hum Genet* 1995 Dec;57(6):1311-7.

Zschocke J, Graham CA, McKnight JJ, Nevin NC. The STR system in the human phenylalanine hydroxylase gene: true fragment length obtained with fluorescent labelled PCR primers. *Acta Paediatr Suppl* 1994 Dec;407:41-2.

Zschocke J, Graham CA, Stewart FJ, Carson DJ, Nevin NC. Non-phenylketonuria hyperphenylalaninaemia in Northern Ireland: frequent mutation allows screening and early diagnosis. *Hum Mutat* 1994;4(2):114-8.

Zschocke J, Quak E, Knauer A, Fritz B, Aslan M, Hoffmann GF. Large heterozygous deletion masquerading as homozygous missense mutation: a pitfall in diagnostic mutation analysis. *J Inherit Metab Dis* 1999 Aug;22(6):687-92.

Zwaan J. Eye findings in patients with phenylketonuria. *Arch Ophthalmol* 1983 Aug;101(8):1236-7.

Isolation and Analysis

Adak S, Wang Q, Stuehr DJ. Molecular basis for hyperactivity in tryptophan 409 mutants of neuronal NO synthase. *J Biol Chem* 2000 Jun 9;275(23):17434-9.

Adam BW, Alexander JR, Smith SJ, Chace DH, Loeber JG, Elvers LH, Hannon WH. Recoveries of phenylalanine from two sets of dried-blood-spot reference materials: prediction from hematocrit, spot volume, and paper matrix. *Clin Chem* 2000 Jan;46(1):126-8.

Addison GM, et al., editors. Practical developments in inherited metabolic disease: DNA analysis, phenylketonuria, and screening for congenital adrenal hyperplasia. Proceedings of the 23rd Annual Symposium of the Society for the Study of Inborn Errors of Metabolism; 1985 Sep; Liverpool, England. Boston: MTP Press; c1986. 335 p.

Ambrus CM, Horvath C, Kalghatgi K, Clowsley M, Huzella C, Warner R, Ambrus JL, Cooley CM, Mirand EA. Depletion of phenylalanine in the blood of phenylketonuric patients using a PAL-enzyme reactor. An in vitro study. *Res Commun Chem Pathol Pharmacol* 1982 Jul;37(1):105-11.

Ambrus CM, Sharma SD, Horvath C, Kalghatgi K, Anthone S, Ambrus JL, Cooley C, Mirand EA. In vivo safety of hollow fiber enzyme-reactors with immobilized phenylalanine ammonia-lyase in a large animal model for phenylketonuria. *J Pharmacol Exp Ther* 1983 Mar;224(3):598-602.

Antonozzi I, Carducci C, Vestri L, Manzari V, Dominici R. Plasma amino acid values and pancreatic beta-cell function in phenylketonuria. *J Inherit Metab Dis* 1987;10(1):66-72.

Antoshechkin AG, Tatur VYu, Maximova LA. Discovery of methoxyacetylcarbamide in the urine of normal adults and phenylketonuric children. *Clin Chim Acta* 1988 Oct 31;177(3):239-44.

Arakawa H, Nakashiro S, Tsuji A, Maeda M. Analysis of polymerase chain reaction products by high-performance liquid chromatography with fluorimetric detection and its application to DNA diagnosis. *J Chromatogr B Biomed Sci Appl* 1998 Sep 25;716(1-2):119-28.

Atherton ND. HPLC measurement of phenylalanine by direct injection of plasma onto an internal-surface reversed-phase silica support. *Clin Chem* 1989 Jun;35(6):975-8.

Atherton ND, Green A. HPLC measurement of phenylalanine in plasma. *Clin Chem* 1988 Nov;34(11):2241-4.

- Bach FW, Nielsen JB, Buchholt J, Lou H, Guttler F. Correlation between cerebrospinal fluid phenylalanine and beta-endorphin in patients with phenylketonuria. *Neurosci Lett* 1991 Aug 5;129(1):131-3.
- Barclay A, Walton O. Phenylketonuria: implications of initial serum phenylalanine levels on cognitive development. *Psychol Rep* 1988 Aug;63(1):135-42.
- Bartholome K, Lutz P. [Determination of phenylalanine hydroxylase in patients with phenylketonuria and hyperphenylalaninemia]. *Monatsschr Kinderheilkd* 1976 May;124(5):421-2. (Ger).
- Bartholome K, Olek K, Trefz F. Compound heterozygotes in hyperphenylalaninaemia. *Hum Genet* 1984;65(4):405-6.
- Bechara-Andere J, Mota de Avelar-Alchorne M, Schmidt BJ, Schwery-Michalany N. [Classic phenylketonuria: dermatological and histopathological aspects in 35 patients]. *Bol Med Hosp Infant Mex* 1988 Feb;45(2):73-8. (Spa).
- Berio A. [Monodimensional electrophoretic picture of the most frequent hyperaminoacidurias caused by disorders of the intermediate metabolism of aminoacids (pre-renal)]. *Minerva Pediatr* 1984 Sep 15;36(17):791-6. (Ita).
- Berry HK, Bofinger MK, Hunt MM, Phillips PJ, Guilfoile MB. Reduction of cerebrospinal fluid phenylalanine after oral administration of valine, isoleucine, and leucine. *Pediatr Res* 1982 Sep;16(9):751-5.
- Berry HK, Brunner RL, Hunt MM, White PP. Valine, isoleucine, and leucine. A new treatment for phenylketonuria. *Am J Dis Child* 1990 May;144(5):539-43.
- Bick U, Ullrich K, Stober U, Moller H, Schuierer G, Ludolph AC, Oberwittler C, Weglage J, Wendel U. White matter abnormalities in patients with treated hyperphenylalaninaemia: magnetic resonance relaxometry and proton spectroscopy findings. *Eur J Pediatr* 1993 Dec;152(12):1012-20.
- Bickel H. Phenylalaninaemia or classical phenylketonuria (PKU)? *Neuropadiatrie* 1970 Apr;1(4):379-82.
- Blaskovics M, Giudici TA. A new variant of bipterin deficiency [letter]. *N Engl J Med* 1988 Dec 15;319(24):1611-2.
- Blau K. Determination of phenylalanine in filter paper blood spots by a simplified automated fluorimetric method without dialysis. *Clin Chim Acta* 1983 Apr;129(2):197-200.
- Blau N, Curtius AC, Kierat L, Leupold D, Kohne E. Hyperphenylalaninemia caused by dihydropteridine reductase deficiency in children receiving chemotherapy for acute lymphoblastic leukemia [letter]. *J Pediatr* 1989 Oct;115(4):661-3.
- Blitzer MG, Bailey-Wilson JE, Shapira E. Discrimination of heterozygotes for phenylketonuria, persistent hyperphenylalaninemia and controls by phenylalanine loading. *Clin Chim Acta* 1986 Dec 30;161(3):347-52.
- Bliumina MG, Lebedev BV, Kopylova NV, Sitnichenko EI, Gerasimova NS. [Relationship between the severity of brain damage in phenylketonuria and the degree of hyperphenylalaninemia]. *Zh Nevropatol Psikiatr* 1980;80(12):1778-81. (Rus).
- Bosco P, Cali F, Meli C, Mollica F, Zammarchi E, Cerone R, Vanni C, Palillo L, Greco D, Romano V. Eight new mutations of the phenylalanine hydroxylase gene in Italian patients with hyperphenylalaninemia. *Hum Mutat* 1998;11(3):240-3.
- Bourget L, Chang TM. Phenylalanine ammonia-lyase immobilized in microcapsules for the depletion of phenylalanine in plasma in phenylketonuric rat model. *Biochim Biophys Acta* 1986 Oct 1;883(3):432-8.
- Brenton DP. Cardiac defects in the children of mothers with high concentrations of plasma phenylalanine. *Br Heart J* 1990 Mar;63(3):143-4.
- Briard ML, Frezel J. [Coordinated case finding of phenylketonuria and hypothyroidism in France]. *Soins* 1980 Dec 5-20;25(23-24):25-7. (Fre).
- Brismar J, Aqeel A, Gascon G, Ozand P. Malignant hyperphenylalaninemia: CT and MR of the brain. *AJNR Am J Neuroradiol* 1990 Jan-Feb;11(1):135-8.
- Brown ES. Paternal hyperphenylalaninemia. *Pediatrics* 1986 Aug;78(2):201-5.
- Brown KJ, Vesey BV, Tannock GW, Bell EB, Lines DR, Elliott RB. The assay on a defined medium of the effects of beta-2-thienylalanine on the growth of anaerobic bacterial isolates from phenylketonuric patients. *Med Microbiol Immunol (Berl)* 1980 Feb;168(1):11-24.
- Brusov OS, Lideman RR. [Nerve growth factor and the state of serotonergic system in endogenous depression and mental retardation]. *Vestn Ross Akad Med Nauk* 1992;(8):16-21. (Rus).
- Buist NR, Tuerck J, Lis E, Penn R. Effects of untreated maternal phenylketonuria and hyperphenylalaninemia on the fetus [letter]. *N Engl J Med* 1984 Jul 5;311(1):52-3.

- Cabalska B, Nowaczewska I, Duczynska N. Plasma amino acid pattern in phenylketonuric heterozygotes during pregnancy. *Biochem Med* 1982 Jun;27(3):269-77.
- Calomme MR, Vanderpas JB, Francois B, Van Caillie-Bertrand M, Herchuelz A, Vanovervelt N, Van Hoorebeke C, Vanden Berghe DA. Thyroid function parameters during a selenium repletion/depletion study in phenylketonuric subjects. *Experientia* 1995 Dec 18;51(12):1208-15.
- Carducci C, Moretti F, Birarelli M, Antonozzi I. Rapid and sensitive high-performance liquid chromatographic method for the analysis of tryptophan, tyrosine and phenylalanine in biological samples. *J Chromatogr* 1991 Aug 16;553(1-2):149-54.
- Carlson HE, Hyman DB, Bauman C, Koch R. Prolactin responses to phenylalanine and tyrosine in phenylketonuria. *Metabolism* 1992 May;41(5):518-21. Comment in: *Metabolism* 1993 Apr;42(4):531-2.
- Chang TM. Medical applications of artificial cells in transfusion, phenylketonuria, essential amino acid production, and liver support. *Ann N Y Acad Sci* 1988;542:507-14.
- Charikova EV, Khalchitskii SE, Antoshechkin AG, Schwartz EI. Distribution of some point mutations in the phenylalanine hydroxylase gene of phenylketonuria patients from the Moscow region. *Hum Hered* 1993 Jul-Aug;43(4):244-9.
- Chestkov VV, Laptsev AV, Shchepkina IuV. [Immunochemical detection of phenylalanine hydroxylase in extracts of various human organs]. *Vopr Med Khim* 1988 May-Jun;34(3):113-6. (Rus).
- Christensen HN. Where do the depleted plasma amino acids go in phenylketonuria? [letter]. *Biochem J* 1986 Jun 15;236(3):929-30.
- Cockburn F, Farquhar JW, Forfar JO, Giles M, Robins SP. Maternal hyperphenylalaninaemia in the normal and phenylketonuric mother and its influence on maternal plasma and fetal fluid amino acid concentrations. *J Obstet Gynaecol Br Commonw* 1972 Aug;79(8):698-707.
- Coleman EA. Commentary on Trends in Health Care: the Price of Prevention. *ONS Nurs Scan Oncol* 1995 Jul-Aug;4(4):7. Original article by Leutwyler K appears in *Sci Am* 1995;272(4):124-9.
- Cowie V. The effect of the environment... can put fetuses at risk of mental subnormality. *Nurs Mirror* 1982 Sep 15;155(11):34-6.
- Crowley JR, Midgley JM, Couch MW, Garnica A, Williams CM. Increased excretion of o-hydroxymandelic acid in phenylketonuria. *Biomed Mass Spectrom* 1980 Aug;7(8):349-53.
- Curtius HC, Adler C, Heizmann C, Blau N, Rebrin I, Ghisla S. 7-substituted pterins: formation and occurrence. *J Nutr Sci Vitaminol (Tokyo)* 1992;Spec No:501-4.
- Curtius HC, Kuster T, Matasovic A, Blau N, Dhondt JL. Primapterin, anapterin, and 6-oxo-primapterin, three new 7-substituted pterins identified in a patient with hyperphenylalaninemia. *Biochem Biophys Res Commun* 1988 Jun 16;153(2):715-21.
- Cynober L, Saizy R, Nguyen Dinh F, Dreyse C, Lioret N, Mousset L. [Blood cortisol level variations in burn patients and their relation to variations in plasma amino acids. Biochemical study of 19 subjects]. *Ann Fr Anesth Reanim* 1982;1(3):307-12. (Fre).
- Darling PB, Bross R, Wykes LJ, Ball RO, Pencharz PB. Isotopic enrichment of amino acids in urine following oral infusions of L-[1-(13C)]phenylalanine and L-[1-(13C)]lysine in humans: confounding effect of D-[13C]amino acids. *Metabolism* 1999 Jun;48(6):732-7.
- de Cespedes C, Santisteban I, Ortiz D, Rojas E, Rodriguez J, Nanne C, Orlich J. [Patterns of urinary aminoacid excretion in exceptional children and patients with mental disorders in Costa Rica]. *Rev Biol Trop* 1983 Jun;31(1):1-9. (Spa).
- De Giorgis GF, Nonnis E, Crocioni F, Gregori P, Rosini MP, Leuzzi V, Loizzo A. Evolution of daytime quiet sleep components in early treated phenylketonuric infants. *Brain Dev* 1996 May-Jun;18(3):201-6.
- De Groot CJ, Hommes FA. Plasma phenylalanine and tyrosine levels during the day in normal female controls and female obligate phenylketonuria heterozygotes. *Enzyme* 1982;28(4):404-7.
- Degioanni A, Darlu P. Analysis of the molecular variance at the phenylalanine hydroxylase (PAH) locus. *Eur J Hum Genet* 1994;2(3):166-76.
- Desviat LR, Perez B, De Lucca M, Cornejo V, Schmidt B, Ugarte M. Evidence in Latin America of recurrence of V388M, a phenylketonuria mutation with high in vitro residual activity. *Am J Hum Genet* 1995 Aug;57(2):337-42.
- Desviat LR, Perez B, Ugarte M. Molecular basis of non-PKU hyperphenylalaninaemia in Spain: prevalence of A403V, a mutation with high residual activity. *J Inher Metab Dis* 1996;19(2):227-30.

- Desviat LR, Perez B, Ugarte M. Phenylketonuria in Spain: RFLP haplotypes and linked mutations. *Hum Genet* 1993 Oct 1;92(3):254-8.
- Devi KS, Devi AR, Kondaiah P. Amplification of phenylalanine hydroxylase and cystathionine beta-synthase transcripts in human peripheral lymphocytes by RT-PCR. *Biochem Mol Biol Int* 1998 Jul;45(4):643-50.
- Dhondt JL, Bellhasene Z, Largilliere C, Bonnetterre J, Farriaux JP. [Normal and pathologic metabolism of pteridines in man]. *LARC Med* 1982 May;2(5):431-3. (Fre).
- Dhondt JL, Farriaux JP, Lebrun T, Saily JC. [Cost/benefit study of the neonatal detection of phenylketonuria and hypothyroidism]. *Pediatric* 1988;43(4):345-8. (Fre).
- Di Silvestre D, Pandya A, Koch R, Groffen J. DNA haplotype analyses of patients with hyperphenylalaninemia. *Am J Hum Genet* 1990 Oct;47(4):706-11.
- Diamond A, Herzberg C. Impaired sensitivity to visual contrast in children treated early and continuously for phenylketonuria. *Brain* 1996 Apr;119 (Pt 2):523-38.
- Diamond A, Prevor MB, Callender G, Druin DP. Prefrontal cortex cognitive deficits in children treated early and continuously for PKU. *Monogr Soc Res Child Dev* 1997;62(4):i-v, 1-208.
- Dianzani I, Giannattasio S, de Sanctis L, Alliaudi C, Lattanzio P, Vici CD, Burlina A, Burroni M, Sebastio G, Carnevale F, et al. Characterization of phenylketonuria alleles in the Italian population. *Eur J Hum Genet* 1995;3(5):294-302.
- DiLella AG, Marvit J, Lidsky AS, Guttler F, Woo SL. Tight linkage between a splicing mutation and a specific DNA haplotype in phenylketonuria. *Nature* 1986 Aug 28-Sep 3;322(6082):799-803.
- DiSilvestre D, Koch R, Groffen J. Different clinical manifestations of hyperphenylalaninemia in three siblings with identical phenylalanine hydroxylase genes [letter]. *Am J Hum Genet* 1991 May;48(5):1014-6.
- Dobson JC, Williamson M, Koch R. Sex ratio in hyperphenylalaninemia. *N Engl J Med* 1970 Aug 27;283(9):491.
- Dworniczak B, Aulehla-Scholz C, Horst J. Phenylalanine hydroxylase gene: silent mutation uncovers evolutionary origin of different alleles. *Clin Genet* 1990 Oct;38(4):270-3.
- Dworniczak B, Aulehla-Scholz C, Kalaydjieva L, Bartholome K, Grudka K, Horst J. Aberrant splicing of phenylalanine hydroxylase mRNA: the major cause for phenylketonuria in parts of southern Europe. *Genomics* 1991 Oct;11(2):242-6.
- Economou-Petersen E, Henriksen KF, Guldberg P, Guttler F. Molecular basis for nonphenylketonuria hyperphenylalaninemia. *Genomics* 1992 Sep;14(1):1-5.
- Edmond J, Korsak RA, Auestad N, Morrow JW, Greenough WT, Black JE, Chang F-LF, Sirevaag AM, Smith A, et al. Biomedical aspects. In: Fraser WI, et al., editors. Key issues in mental retardation research: Proceedings of the 8th Congress of the International Association for the Scientific Study of Mental Deficiency (IASSMD). London: Routledge; 1990. p. 37-105.
- Eiken HG, Knappskog PM, Boman H, Thune KS, Kaada G, Motzfeldt K, Apold J. Relative frequency, heterogeneity and geographic clustering of PKU mutations in Norway. *Eur J Hum Genet* 1996;4(4):205-13.
- Eiken HG, Stangeland K, Skjelkvale L, Knappskog PM, Boman H, Apold J. PKU mutations R408Q and F299C in Norway: haplotype associations, geographic distributions and phenotype characteristics. *Hum Genet* 1992 Mar;88(6):608-12.
- Eisensmith RC, Martinez DR, Kuzmin AI, Goltsov AA, Brown A, Singh R, Elsas LJ II, Woo SL. Molecular basis of phenylketonuria and a correlation between genotype and phenotype in a heterogeneous southeastern US population. *Pediatrics* 1996 Apr;97(4):512-6.
- Endres W, Ibel H, Kierat L, Blau N, Curtius HC. Tetrahydrobiopterin and non-responsive dihydropteridine reductase deficiency [letter]. *Lancet* 1987 Jul 25;2(8552):223.
- Epstein CM, Trotter JF, Averbook A, Freeman S, Kutner MH, Elsas LJ. EEG mean frequencies are sensitive indices of phenylalanine effects on normal brain. *Electroencephalogr Clin Neurophysiol* 1989 Feb;72(2):133-9.
- Farhud DD, Kabiri M. Incidence of phenylketonuria (PKU) in Iran. *Indian J Pediatr* 1982 Sep-Oct;49(400):685-8.
- Farriaux JP. [20 years' neonatal detection. Results and prospects]. *Pediatric* 1988;43(4):293-5. (Fre).
- Fekkes D, Voskuilen-Kooyman A, Jankie R, Huijman J. Precise analysis of primary amino acids in urine by an automated high-performance liquid chromatography method: Comparison with ion-exchange chromatography. *J Chromatog B Biomed Sci Appl* 2000 Jul 7;744(1):183-8.

- Fisch RO, Feinberg SB, Weisberg S, Day D. Bony changes of PKU neonates unrelated to phenylalanine levels. *J Inher Metab Dis* 1991;14(6):890-5.
- Fischer GM, Nemeti B, Farkas V, Debreceni B, Laszlo A, Schaffer Z, Somogyi C, Sandor A. Metabolism of carnitine in phenylacetic acid-treated rats and in patients with phenylketonuria. *Biochim Biophys Acta* 2000 Jun 15;1501(2-3):200-10.
- Folling I. The discovery of phenylketonuria. *Acta Paediatr Suppl* 1994 Dec;407:4-10.
- Furukawa Y, Kish SJ, Bebin EM, Jacobson RD, Fryburg JS, Wilson WG, Shimadzu M, Hyland K, Trugman JM. Dystonia with motor delay in compound heterozygotes for GTP-cyclohydrolase I gene mutations. *Ann Neurol* 1998 Jul;44(1):10-6.
- Galluzzo CR, Ortisi MT, Castelli L, Agostoni C, Longhi R. Plasma lipid concentrations in 42 treated phenylketonuric children. *J Inher Metab Dis* 1985;8 Suppl 2:129.
- Gatlin CL, Turecek F. Quantitative electrospray ionization mass spectrometric studies of ternary complexes of amino acids with Cusup 2sup + and phenanthroline. *J Mass Spectrom* 2000;35(2):172-7.
- Giovannini M, Biasucci G, Agostoni C, Bellu R, Riva E. Fatty acid supplementation in a case of maternal phenylketonuria. *J Inher Metab Dis* 1994;17(5):630-1.
- Gjedde A, Crone C. Biochemical modulation of blood-brain barrier permeability. *Acta Neuropathol Suppl (Berl)* 1983;8:59-74.
- Gleason LA, Michals K, Matalon R, Langenberg P, Kamath S. A treatment program for adolescents with phenylketonuria. *Clin Pediatr (Phila)* 1992 Jun;31(6):331-5.
- Glick SD, Greengard O. Exaggerated cerebral lateralization in rats after early postnatal hyperphenylalaninemia. *Brain Res* 1980 Nov 24;202(1):243-8.
- Goldin KR. Maternal and infant serum phenylalanine levels and pregnancy outcome in infants of nonphenylketonuric mothers. *J Natl Med Assoc* 1993 Aug;85(8):617-20.
- Greeves LG, Carson DJ, McMaster D, Craig BG. Cardiac status of patients with phenylketonuria. *Acta Paediatr* 1994 Oct;83(10):1100-1.
- Griffiths P, Tarrini M, Robinson P. Executive function and psychosocial adjustment in children with early treated phenylketonuria: correlation with historical and concurrent phenylalanine levels. *J Intellect Disabil Res* 1997 Aug;41 (Pt 4):317-23.
- Guddat LW, Cowan SW, Machin KJ, Isaacs NW, Cotton RG. Crystallization and preliminary crystallographic data of the Fab fragment of an anti-phenylalanine hydroxylase monoclonal antibody. *J Mol Biol* 1985 Nov 20;186(2):479-80.
- Guldberg P, Guttler F. 'Broad-range' DGGE for single-step mutation scanning of entire genes: application to human phenylalanine hydroxylase gene. *Nucleic Acids Res* 1994 Mar 11;22(5):880-1.
- Guldberg P, Levy HL, Koch R, Berlin CM Jr, Francois B, Henriksen KF, Guttler F. Mutation analysis in families with discordant phenotypes of phenylalanine hydroxylase deficiency. Inheritance and expression of the hyperphenylalaninaemias. *J Inher Metab Dis* 1994;17(6):645-51.
- Guldberg P, Mikkelsen I, Henriksen KF, Lou HC, Guttler F. In vivo assessment of mutations in the phenylalanine hydroxylase gene by phenylalanine loading: characterization of seven common mutations. *Eur J Pediatr* 1995 Jul;154(7):551-6. Comment in: *Eur J Pediatr* 1996 Jun;155(6):523-5.
- Guldberg P, Rey F, Zschocke J, Romano V, Francois B, Michiels L, Ullrich K, Hoffmann GF, Burgard P, Schmidt H, Meli C, Riva E, Dianzani I, Ponzzone A, Rey J, Guttler F. A European multicenter study of phenylalanine hydroxylase deficiency: classification of 105 mutations and a general system for genotype-based prediction of metabolic phenotype. *Am J Hum Genet* 1998 Jul;63(1):71-9. Published erratum appears in *Am J Hum Genet* 1998 Oct;63(4):1252-3.
- Guldberg P, Zschocke J, Dagbjartsson A, Henriksen KF, Guttler F. A molecular survey of phenylketonuria in Iceland: identification of a founding mutation and evidence of predominant Norse settlement. *Eur J Hum Genet* 1997 Nov-Dec;5(6):376-81.
- Guttler F, Rosleff F. Urinary phenylalanine excretion in hyperphenylalaninemic children. *Acta Paediatr Scand* 1973 Jul;62(4):333-6.
- Hagenfeldt L, Larsson A, von Döbeln U, Lundberg K, Eriksson G. [Information from the PKU-sections--account of activities 1984]. *Jordmodern* 1985 Jun;98(6):184-6. (Swe).
- Haktan M, Aydin A, Bahat H, Tuysuz B, Yazici H, Altay S. Progressive systemic scleroderma in an infant with partial phenylketonuria. *J Inher Metab Dis* 1989;12(4):486-7.
- Hanaoka S, Lin J-M, Yamada M. Chemiluminescence behavior of the decomposition of hydrogen peroxide catalyzed by copper(II)-amino acid complexes and its application to the determination of tryptophan and phenylalanine. *Anal Chim Acta* 2000;409(1-2):65-73.

- Hase Y, Shintaku H, Turuhara T, Oura T, Kobashi M, Iwai K. A case of tetrahydrobiopterin deficiency due to a defective synthesis of dihydrobiopterin. *J Inher Metab Dis* 1982;5(2):81-2.
- Haynes PA, Sheumack D, Greig LG, Kibby J, Redmond JW. Applications of automated amino acid analysis using 9-fluorenylmethyl chloroformate. *J Chromatogr* 1991 Dec 27;588(1-2):107-14.
- Held KR, Koepf P, Plettner C, Gruttner R. Plasma amino acid pattern at noon in early treated hyperphenylalaninemic, phenylketonuric, and normal children. *Ann Nutr Metab* 1983;27(4):278-85.
- Henderson RM, McCulloch DL, Herbert AM, Robinson PH, Taylor MJ. Visual event-related potentials in children with phenylketonuria. *Acta Paediatr* 2000 Jan;89(1):52-7.
- Henglein D, Niederhoff H, Bode H. Origin of the left coronary artery from the right pulmonary artery and ventricular septal defect in a child of a mother with raised plasma phenylalanine concentrations throughout pregnancy. *Br Heart J* 1990 Mar;63(3):180-2.
- Hennermann JB, Vetter B, Wolf C, Windt E, Buhrdel P, Seidel J, Monch E, Kulozik AE. Phenylketonuria and hyperphenylalaninemia in eastern Germany: a characteristic molecular profile and 15 novel mutations. *Hum Mutat* 2000;15(3):254-60.
- Hilliges C, Awiszus D, Wendel U. Intellectual performance of children with maple syrup urine disease. *Eur J Pediatr* 1993 Feb;152(2):144-7.
- Hilton MA. Liquid-chromatographic direct determination of phenylalanine and tyrosine in serum or plasma, with application to patients with phenylketonuria. *Clin Chem* 1982 May;28(5):1215-8.
- Hnikova O, Hejzmanova L, Marek J, Schreiberova O. [Blood somatomedin levels in neonates with congenital hypothyroidism and phenylketonuria]. *Cesk Pediatr* 1991 Dec;46(12):537-40. (Cze).
- Hoang L, Byck S, Prevost L, Scriver CR. PAH Mutation Analysis Consortium Database: a database for disease-producing and other allelic variation at the human PAH locus. *Nucleic Acids Res* 1996 Jan 1;24(1):127-31.
- Hogan RN, Coleman PD. Experimental hyperphenylalaninemia: dendritic alterations in cerebellum of rat. *Exp Neurol* 1981 Oct;74(1):234-44.
- Hogan RN, Coleman PD. Experimental hyperphenylalaninemia: dendritic alterations in motor cortex of rat. *Exp Neurol* 1981 Oct;74(1):218-33.
- Howells D, Smith I, Leonard J, Hyland K. Tetrahydrobiopterin in dihydropteridine reductase deficiency [letter]. *N Engl J Med* 1986 Feb 20;314(8):520-1.
- Howells DW, Smith I, Hyland K. Estimation of tetrahydrobiopterin and other pterins in cerebrospinal fluid using reversed-phase high-performance liquid chromatography with electrochemical and fluorescence detection. *J Chromatogr* 1986 Sep 5;381(2):285-94.
- Hsiao KJ, Hung SH, Wu SJ, Yeh SF. Gas chromatographic analysis of abnormal urinary organic acids in phenylketonuria. *Taiwan I Hsueh Hui Tsa Chih* 1985 Nov;84(11):1240-50.
- Huether G, Kaus R, Neuhoef V. Brain development in experimental hyperphenylalaninaemia: myelination. *Neuropediatrics* 1982 Nov;13(4):177-82.
- Hyanek J, Zeman J, Niederwieser A, Leeming R, Grimm U, Sahota A, Komarek V, Houstkova H, Bohm J, Verner P, et al. [Malignant hyperphenylalaninemia with dihydropteridine reductase deficiency]. *Cesk Pediatr* 1986 Nov;41(11):664-8. (Cze).
- Ikeda H, Matsubara Y, Mikami H, Kure S, Owada M, Gough T, Smooker PM, Dobbs M, Dahl HH, Cotton RG, Narisawa K. Molecular analysis of dihydropteridine reductase deficiency: identification of two novel mutations in Japanese patients. *Hum Genet* 1997 Oct;100(5-6):637-42.
- Imamura T, Okano Y, Shintaku H, Hase Y, Isshiki G. Molecular characterization of 6-pyruvoyl-tetrahydropterin synthase deficiency in Japanese patients. *J Hum Genet* 1999;44(3):163-8.
- Imashuka S, Kodo N, Esumi N, Morioka Y, Todo S, Furukawa N, Kinugasa A. Hyperphenylalaninemia in malignant histiocytosis and virus-associated hemophagocytic syndrome. *Acta Paediatr Scand* 1988 May;77(3):444-5.
- Imashuku S, Morioka Y, Kodo N, Esumi N, Hibi S, Todo S. Abnormal serum phenylalanine-tyrosine ratio and hyperferritinemia in malignant histiocytosis. *Pediatr Hematol Oncol* 1988;5(4):299-307.
- Ionescu S. [Psychophysiology of mental deficiency: evaluation of studies involving the recording of autonomic indices]. *Psychiatr Infant* 1985;28(1):39-134. (Fre).
- Jardim LB, Palma-Dias R, Silva LC, Ashton-Prolla P, Giugliani R. Maternal hyperphenylalaninaemia as a cause of microcephaly and mental retardation. *Acta Paediatr* 1996 Aug;85(8):943-6.

- Jellum E, Horn L, Thoresen O, Kvittingen EA, Stokke O. Urinary excretion of N-acetyl amino acids in patients with some inborn errors of amino acid metabolism. *Scand J Clin Lab Invest Suppl* 1986;184:21-6.
- Johnson CF, Koch R, Peterson RM, Friedman EG. Congenital and neurological abnormalities in infants with phenylketonuria. *Am J Ment Defic* 1978 Jan;82(4):375-9.
- Kalanin J, Takarada Y, Kagawa S, Yamashita K, Ohtsuka N, Matsuoka A. Gypsy phenylketonuria: a point mutation of the phenylalanine hydroxylase gene in Gypsy families from Slovakia. *Am J Med Genet* 1994 Jan 15;49(2):235-9.
- Kalaydjieva L, Dworniczak B, Aulehla-Scholz C, Kremensky I, Bronzova J, Eigel A, Horst J. Classical phenylketonuria in Bulgaria: RFLP haplotypes and frequency of the major mutations. *J Med Genet* 1990 Dec;27(12):742-5.
- Kalaydjieva L, Dworniczak B, Kremensky I, Koprivarova K, Radeva B, Milusheva R, Aulehla-Scholz C, Horst J. Heterogeneity of mutations in Bulgarian phenylketonuria haplotype 1 and 4 alleles. *Clin Genet* 1992 Mar;41(3):123-8.
- Kalghatgi K, Ambrus CM, Horvath C, Karakousis CP, Sharma SD, Barren E. Determination of aromatic amino acids by ion-pair reversed-phase liquid chromatography in human sera from healthy and phenylketonuric individuals. *Res Commun Chem Pathol Pharmacol* 1984 Aug;45(2):253-9.
- Kaul R, Matalon R, Allen R, Fisch RO, Michals K, Petrosky A, Sullivan D. Frequency of 12 mutations in 114 children with phenylketonuria in the Midwest region of the USA. *J Inher Metab Dis* 1994;17(3):356-8.
- Kaur H, Halliwell B. Aromatic hydroxylation of phenylalanine as an assay for hydroxyl radicals. Measurement of hydroxyl radical formation from ozone and in blood from premature babies using improved HPLC methodology. *Anal Biochem* 1994 Jul;220(1):11-5.
- Kietduriyakul V, Leangphibul P, Tongkittikul K. Study of phenylketonuria incidence in Thai children. *J Med Assoc Thai* 1988 May;71(5):258-61.
- Kirkman HN Jr, Hicks RE. More on untreated maternal hyperphenylalaninemia [letter]. *N Engl J Med* 1984 Oct 25;311(17):1125-6.
- Kishida M, Makita Y, Suzuki T, Yamada M, Hobo T. Cobalt(II)-catalyzed chemiluminescence in a dioctadecyldimethylammonium chloride bilayer membranous medium for the flow injection determination of phenylpyruvic acid. *Anal Chem* 1991 Oct 15;63(20):2301-5.
- Kleiman S, Avigad S, Vanagaite L, Shmuelevitz A, David M, Eisensmith RC, Brand N, Schwartz G, Rey F, Munnich A. Origins of hyperphenylalaninemia in Israel. *Eur J Hum Genet* 1994;2(1):24-34.
- Kluge C, Brecevic L, Heizmann CW, Blau N, Thony B. Chromosomal localization, genomic structure and characterization of the human gene and a retropseudogene for 6-pyruvoyltetrahydropterin synthase. *Eur J Biochem* 1996 Sep 1;240(2):477-84. Published erratum appears in *Eur J Biochem* 1996 Oct 15;241(2):697.
- Knapp A. About changes of the phenylalanine-tyrosine metabolism in psoriasis vulgaris. *Acta Univ Carol [Med] (Praha)* 1986;32(3-4):203-6.
- Knapp A, Tintschewa R, Scheibe E, Scheibe E, Jager B, Biebler KE. The genetic linkage between the PKU locus and the loci for amylase 1, amylase 2, Fy, PGM 1, and Rh and the question of assignment of the PKU locus to chromosome no. 1. *Hum Genet* 1982;60(2):122-5.
- Koch R, Guttler F, Guldberg P, Rouse B. Mild hyperphenylalaninemia and heterozygosity of the phenylalanine hydroxylase gene. *Mol Genet Metab* 1998 Feb;63(2):148-50.
- Koizumi S, Nagatsu T, Iinuma H, Ohno M, Takeuchi T, Umezawa H. Inhibition of phenylalanine hydroxylase, a pterin-requiring monooxygenase, by ouidenone and its derivatives. *J Antibiot (Tokyo)* 1982 Apr;35(4):458-62.
- Konecki DS, Schlotter M, Trefz FK, Lichter-Konecki U. The identification of two mis-sense mutations at the PAH gene locus in a Turkish patient with phenylketonuria. *Hum Genet* 1991 Aug;87(4):389-93.
- Konecki DS, Schweitzer-Krantz S, Byrd D, Trefz FK, Lichter-Konecki U. Facilitation of hyperphenylalaninaemia phenotype assessment by genotype analysis [letter]. *Eur J Pediatr* 1993 Dec;152(12):1048-9.
- Kozak L, Kuhrova V, Blazkova M, Romano V, Fajkusova L, Dvorakova D, Pijackova A. Phenylketonuria mutations and their relation to RFLP haplotypes at the PAH locus in Czech PKU families. *Hum Genet* 1995 Oct;96(4):472-6.
- Krause W, Epstein C, Averbook A, Dembure P, Elsas L. Phenylalanine alters the mean power frequency of electroencephalograms and plasma L-dopa in treated patients with phenylketonuria. *Pediatr Res* 1986 Nov;20(11):1112-6.

- Langenbeck U, Behbehani A, MENCH-Hoinowski A, Petersen M. Absence of a significant renal threshold for two aromatic acids in phenylketonuric children over two years of age. *Eur J Pediatr* 1980 Aug;134(2):115-8.
- Larue C, Munnich A, Charpentier C, Saudubray JM, Frezal J, Remy MH, Rivat C. An extracorporeal hollow-fiber reactor for phenylketonuria using immobilized phenylalanine ammonia lyase. *Dev Pharmacol Ther* 1986;9(2):73-81.
- Latorre RM, Saurina J, Hernandez-Cassou S. Determination of amino acids in overlapped capillary electrophoresis peaks by means of partial least-squares regression. *J Chromatogr A* 2000;871(1-2):331-40.
- Leandro P, Rivera I, Ribeiro V, de Almeida IT, da Silveira C, Lechner MC. Mutation analysis of phenylketonuria in south and central Portugal: prevalence of V388M mutation. *Hum Mutat* 1995;6(2):192-4.
- Ledley FD. Somatic gene therapy for human disease: background and prospects. Part II. *J Pediatr* 1987 Feb;110(2):167-74.
- Ledley FD, Levy HL, Woo SL. Molecular analysis of the inheritance of phenylketonuria and mild hyperphenylalaninemia in families with both disorders. *N Engl J Med* 1986 May 15;314(20):1276-80.
- Lee EB. Metabolic diseases and the skin. *Pediatr Clin North Am* 1983 Aug;30(4):597-608.
- Leeming RJ, Karim AR, Sahota AS, Blair JA, Green A. [Measurement in samples of dry blood of dihydropteridine reductase and ratio of total biopterin in hyperphenylalaninemia and other neurological diseases]. *Arch Fr Pediatr* 1987;44 Suppl 1:649-54. (Fre).
- Lenke RR. Maternal phenylketonuria and hyperphenylalaninemia: a problem born of success. *J Pediatr Perinat Nutr* 1987 Spring-Summer;1(1):67-74.
- Leuzzi V, Fois D, Carducci C, Antonozzi I, Trasimeni G. Neuropsychological and neuroradiological (MRI) variations during phenylalanine load: protective effect of valine, leucine, and isoleucine supplementation. *J Child Neurol* 1997 Aug;12(5):338-40.
- Levy HL, Barkin E. Comparison of amino acid concentrations between plasma and erythrocytes. Studies in normal human subjects and those with metabolic disorders. *J Lab Clin Med* 1971 Oct;78(4):517-23.
- Levy HL, Waisbren SE. Effects of untreated maternal phenylketonuria and hyperphenylalaninemia on the fetus. *N Engl J Med* 1983 Nov 24;309(21):1269-74.
- Levy HL, Waisbren SE, Lobbregt D, Allred E, Leviton A, Koch R, Hanley WB, Rouse B, Matalon R, de la Cruz F. Maternal non-phenylketonuric mild hyperphenylalaninemia. *Eur J Pediatr* 1996 Jul;155 Suppl 1:S20-5.
- Levy HL, Waisbren SE, Lobbregt D, Allred E, Schuler A, Trefz FK, Schweitzer SM, Sardharwalla IB, Walter JH, Barwell BE, et al. Maternal mild hyperphenylalaninemia: an international survey of offspring outcome. *Lancet* 1994 Dec 10;344(8937):1589-94. Comment in: *Lancet* 1995 Feb 11;345(8946):385-6.
- Lewis SA, Lyon IC, Elliott RB. Outcome of pregnancy in the rat with mild hyperphenylalaninemia and hypertyrosinemia: implications for the management of human maternal PKU. *J Inher Metab Dis* 1985;8(3):113-7.
- Lichter-Konecki U, Schlotter M, Konecki DS. DNA sequence polymorphisms in exonic and intronic regions of the human phenylalanine hydroxylase gene aid in the identification of alleles. *Hum Genet* 1994 Sep;94(3):307-10.
- Lichter-Konecki U, Schlotter M, Trefz FK, Konecki DS. Direct detection of a major mutation responsible for phenylketonuria in the population of the Federal Republic of Germany. *Eur J Pediatr* 1989 Nov;149(2):120-3.
- Lidksy AS, Robson KJ, Thirumalachary C, Barker PE, Ruddle FH, Woo SL. The PKU locus in man is on chromosome 12. *Am J Hum Genet* 1984 May;36(3):527-33.
- Link RM, Wachtel U. [Clinical experiences with an amino acid preparation in children with phenylketonuria]. *Rev Med Liege* 1984 May 15;39(10):422-8. (Fre).
- Lipson A, Beuhler B, Bartley J, Walsh D, Yu J, O'Halloran M, Webster W. Maternal hyperphenylalaninemia fetal effects. *J Pediatr* 1984 Feb;104(2):216-20.
- Lombeck I, Menzel H, Steiner G, Kasperek K. Selenium supplementation: plasma glutathione peroxidase an indicator of selenium intake. *Klin Padiatr* 1982 Sep-Oct;194(5):303-5.
- Lopez-Grio S, Torres-Lapasio JR, Baeza-Baeza JJ, Garcia-Alvarez-Coque MC. Micellar liquid chromatographic separation of amino acids using pre- and post-column o-phthalaldehyde/N-acetylcysteine derivatization. *Anal Chim Acta* 2000;418(2):153-65.
- Lou HC, Toft PB, Andresen J, Mikkelsen I, Olsen B, Guttler F, Wieslander S, Henriksen O. An occipito-temporal syndrome in adolescents with optimally

- controlled hyperphenylalaninaemia. *J Inherit Metab Dis* 1992;15(5):687-95.
- Lowe TL, Tanaka K, Seashore MR, Young JG, Cohen DJ. Detection of phenylketonuria in autistic and psychotic children. *JAMA* 1980 Jan 11;243(2):126-8.
- Lu F-M, Xue J, Li M-X, Lin S-Y. [Effect and mechanism of erythropoietin on amino acid in hemodialysis patients]. *J Shanghai Med Univ* 2000;27(2):127-8, 137. (Chi).
- Luder AS, Greene CL. Maternal phenylketonuria and hyperphenylalaninemia: implications for medical practice in the United States. *Am J Obstet Gynecol* 1989 Nov;161(5):1102-5.
- Lykkelund C, Lou HC, Rasmussen V, Guttler F, Niederwieser A. Biopterin, neopterin and tyrosine responses to combined oral phenylalanine and tetrahydrobiopterin loading tests in two normal children and in a girl with partial biopterin deficiency. *J Inherit Metab Dis* 1985;8 Suppl 2:95-6.
- Lyon IC. Maternal phenylketonuria [letter]. *N Z Med J* 1984 Mar 14;97(751):165-6.
- Lyonnet S, Caillaud C, Rey F, Berthelon M, Frezal J, Rey J, Munnich A. Guthrie cards for detection of point mutations in phenylketonuria [letter]. *Lancet* 1988 Aug 27;2(8609):507.
- Marques JM. Phenylketonuria with familial hyperglycinuria. *J Inherit Metab Dis* 1994;17(5):641.
- Maternal phenylketonuria. Committee on Genetics. *Pediatrics* 1985 Aug;76(2):313-4.
- Matsuishi T, Yamashita Y. [Neurochemical and neurotransmitter studies in patients with learning disabilities]. *No To Hattatsu* 1999 May;31(3):245-8. (Jpn).
- Matthieu JM. [Maternal phenylketonuria: a misdiagnosed cause of embryopathy or fetal disease]. *Rev Med Suisse Romande* 1994 Oct;114(10):841-3. (Fre).
- McDonald JD, Bode VC. Hyperphenylalaninemia in the hph-1 mouse mutant. *Pediatr Res* 1988 Jan;23(1):63-7.
- McDonald JD, Bode VC, Dove WF, Shedlovsky A. The use of N-ethyl-N-nitrosourea to produce mouse models for human phenylketonuria and hyperphenylalaninemia. *Prog Clin Biol Res* 1990;340C:407-13.
- McDowall IL, Fisher MJ. The immediate 5'-flanking region of the rat phenylalanine hydroxylase-encoding gene. *Gene* 1995 Feb 14;153(2):289-90.
- McKnight RP, Willis JE, Shen RS, Abell CW. Evaluation of the PaT Stat Kinetic UV Test set for the determination of phenylalanine and tyrosine in serum or plasma. *Clin Biochem* 1983 Jun;16(3):157-62.
- Meijer H, Perizonius WR, Geraedts JP. Recovery and identification of DNA sequences harboured in preserved ancient human bones. *Biochem Biophys Res Commun* 1992 Mar 16;183(2):367-74.
- Mercer JF, Hunt SM, Cotton RG. The two molecular weight forms of rat phenylalanine hydroxylase are encoded by different messenger RNAs. *J Biol Chem* 1983 May 10;258(9):5854-7.
- Milovanovic DD, Milovanovic L, Vranjesevic D. Serum tryptophan to large neutral amino acid ratio and urinary tryptophan in three patients with phenylketonuria in a family. A clinical and biochemical study. *Adv Exp Med Biol* 1999;467:289-95.
- Moats RA, Scadeng M, Nelson MD Jr. MR imaging and spectroscopy in PKU. *Ment Retard Dev Disabil Res Rev* 1999; 5(2):132-5.
- Morisi G, Patriarca M, Marano G, Giampaoli S, Taggi F. Age and sex specific reference serum selenium levels estimated for the Italian population. *Ann Ist Super Sanita* 1989;25(3):393-403.
- Mowat DR, Hayden MC, Thompson SM, Wilcken B. Maternal phenylketonuria: a continuing problem. *Med J Aust* 1999 Jun 21;170(12):592-5. Comment in: *Med J Aust* 1999 Jun 21;170(12):573-4.
- [Neonatal screening for congenital errors of metabolism. *Evian*, April 1986]. *Arch Fr Pediatr* 1987;44 Suppl 1:635-754. (Fre).
- Niederwieser A, Curtius HC, Gitzelmann R, Otten A, Baerlocher K, Blehova B, Berlow S, Grobe H, Rey F, Schaub J, Scheibenreiter S, Schmidt H, Viscontini M. Excretion of pterins in phenylketonuria and phenylketonuria variants. *Helv Paediatr Acta* 1980 Sep;35(4):335-42.
- Novotny EJ Jr, Avison MJ, Herschkowitz N, Petroff OA, Prichard JW, Seashore MR, Rothman DL. In vivo measurement of phenylalanine in human brain by proton nuclear magnetic resonance spectroscopy. *Pediatr Res* 1995 Feb;37(2):244-9.
- Okano Y, Asada M, Kang Y, Nishi Y, Hase Y, Oura T, Isshiki G. Molecular characterization of phenylketonuria in Japanese patients. *Hum Genet* 1998 Nov;103(5):613-8.
- Okano Y, Hase Y, Lee DH, Furuyama J, Shintaku H, Oura T, Isshiki G. Frequency and distribution of phenylketonuric mutations in Orientals. *Hum Mutat* 1992;1(3):216-20.

- Osadchaia LM, Putilina FE. [Effect of hyperphenylalaninemia on the metabolism of free amino acids in the brain]. *Nerv Sist* 1982;23:112-6. (Rus).
- Ozguç M, Ozalp I, Coskun T, Yilmaz E, Erdem H, Ayter S. Mutation analysis in Turkish phenylketonuria patients. *J Med Genet* 1993 Feb;30(2):129-30.
- Partington MW. Long term studies of untreated phenylketonuria II: the plasma phenylalanine level. *Neuropadiatrie* 1978 Aug;9(3):255-67.
- Perez B, Desviat LR, De Lucca M, Cornejo V, Raimann E, Ugarte M. Molecular characterization of phenylalanine hydroxylase deficiency in Chile. Mutations in brief no. 243. Online. *Hum Mutat* 1999;13(6):503.
- Perez B, Desviat LR, Garcia MJ, Ugarte M. Different phenotypic manifestations associated with identical phenylketonuria genotypes in two Spanish families. *J Inherit Metab Dis* 1994;17(3):377-8.
- Peterson K, Slover R, Gass S, Seltzer WK, McCabe LL, McCabe ER. Blood phenylalanine estimation for the patient with phenylketonuria using a portable device. *Biochem Med Metab Biol* 1988 Feb;39(1):98-104.
- Pitt DB, Danks DM. The natural history of untreated phenylketonuria over 20 years. *J Paediatr Child Health* 1991 Jun;27(3):189-90.
- Popescu T, Blazkova M, Kozak L, Jebeleanu G, Popescu A. Mutation spectrum and phenylalanine hydroxylase RFLP/VNTR background in 44 Romanian phenylketonuric alleles. *Hum Mutat* 1998;12(5):314-9.
- Potkin SG, Cannon-Spoor HE, DeLisi LE, Neckers LM, Wyatt RJ. Plasma phenylalanine, tyrosine, and tryptophan in schizophrenia. *Arch Gen Psychiatry* 1983 Jul;40(7):749-52.
- Pueschel SM. Maternal phenylketonuria. *Soc Biol* 1985 Spring-Summer;32(1-2):31-44.
- Pullon DH, Macfarlane SD, Lyon IC. Maternal phenylketonuria. *N Z Med J* 1990 Aug 22;103(896):397-8.
- Radeva B. Relation between phenotype and genotype in phenylketonuric patients from Bulgaria. *J Inherit Metab Dis* 1993;16(1):158-9.
- Ramus SJ, Forrest SM, Pitt DB, Saleeba JA, Cotton RG. Comparison of genotype and intellectual phenotype in untreated PKU patients. *J Med Genet* 1993 May;30(5):401-5.
- Ramus SJ, Forrest SM, Pitt DD, Cotton RG. Genotype and intellectual phenotype in untreated phenylketonuria patients. *Pediatr Res* 1999 Apr;45(4 Pt 1):474-81.
- Rey F, Abadie V, Lyonnet S, Berthelon M, Caillaud C, Melle D, Labrune P, Saudubray JM, Munnich A, Rey J. [Phenotypic expression of 12 mutations of the phenylalanine hydroxylase gene]. *Arch Fr Pediatr* 1992 Oct;49(8):705-10. (Fre).
- Riess O, Michel A, Speer A, Meiske W, Cobet G, Coutelle C. Linkage disequilibrium between RFLP haplotype 2 and the affected PAH allele in PKU families from the Berlin area of the German Democratic Republic. *Hum Genet* 1988 Apr;78(4):343-6.
- Rittinger O, Plochl E, Jarosch E. [Maternal phenylketonuria]. *Padiatr Padol* 1984;19(1):87-92. (Ger).
- Rivera I, Leandro P, Lichter-Konecki U, de Almeida IT, Lechner MC. Relative frequency of IVS10nt546 mutation in a Portuguese phenylketonuric population. *Hum Mutat* 1997;9(3):272-3.
- Robson KJ, Chandra T, MacGillivray RT, Woo SL. Polysome immunoprecipitation of phenylalanine hydroxylase mRNA from rat liver and cloning of its cDNA. *Proc Natl Acad Sci U S A* 1982 Aug;79(15):4701-5.
- Rohr FJ, Lobbregt D, Levy HL. Tyrosine supplementation in the treatment of maternal phenylketonuria. *Am J Clin Nutr* 1998 Mar;67(3):473-6. Comment in: *Am J Clin Nutr* 1998 Mar;67(3):357-8; *Am J Clin Nutr* 1998 Dec;68(6):1306-7.
- Roskamp R, Mallmann R, Liappis N, Soetadjii S. Circulating serum phenylalanine concentrations and the effect of arginine infusion on plasma levels of growth hormone and insulin in treated phenylketonuric children. *Acta Endocrinol (Copenh)* 1987 Apr;114(4):483-7.
- Rottoli A, Lista G, Zecchini G, Butte C, Longhi R. Plasma selenium levels in treated phenylketonuric patients. *J Inherit Metab Dis* 1985;8 Suppl 2:127-8.
- Rouse B, Azen C, Koch R, Matalon R, Hanley W, de la Cruz F, Trefz F, Friedman E, Shifrin H. Maternal Phenylketonuria Collaborative Study (MPKUCS) offspring: facial anomalies, malformations, and early neurological sequelae. *Am J Med Genet* 1997 Mar 3;69(1):89-95.
- Rozen R, Mascisch A, Lambert M, Laframboise R, Scriver CR. Mutation profiles of phenylketonuria in Quebec populations: evidence of stratification and novel mutations. *Am J Hum Genet* 1994 Aug;55(2):321-6.

- Sadava D, Sutcliffe D. The effects of maternal hyperphenylalaninemia on learning in mature rats. *Life Sci* 1988;43(14):1119-23.
- Saliba Z, Bah G, Martin D, Abadie V, Azar Z, Fraisse A, Sidi D, Kachaner J, Bonnet D. [Pseudo-inherited form of left heart obstructive defects revealing maternal phenylketonuria]. *Arch Mal Coeur Vaiss* 2000 May;93(5):649-52. (Fre).
- Sanjurjo P, Perteagudo L, Rodriguez Soriano J, Vilaseca A, Campistol J. Polyunsaturated fatty acid status in patients with phenylketonuria. *J Inherit Metab Dis* 1994;17(6):704-9.
- Saraiva JM, Seakins JW, Smith I. Plasma phenylalanine and tyrosine levels revisited in heterozygotes for hyperphenylalaninaemia. *J Inherit Metab Dis* 1993;16(1):105-9.
- Sarles J, Maurin N, Giraud F. [A rare cause of neonatal hyperphenylalaninemia: tyrosinemia type I]. *Pediatric (Bucur)* 1992;47(12):809-11. (Fre).
- Scaglioni S, Zuccotti G, Vedovello M, Rottoli A, Paccanelli S, Longhi R, Riva E, Giovannini M. Study of serum ferritin in 58 children with classic phenylketonuria and persistent hyperphenylalaninaemia. *J Inherit Metab Dis* 1985;8(3):160.
- Scherer-Opplinger T, Matasovic A, Laufs S, Levy HL, Quackenbush EJ, Blau N, Thony B. Dominant negative allele (N47D) in a compound heterozygote for a variant of 6-pyruvoyltetrahydropterin synthase deficiency causing transient hyperphenylalaninemia. *Hum Mutat* 1999;13(4):286-9.
- Schmidt H, Ullrich K, Korinthenberg R, Peters PE. Basal ganglion calcification in hyperphenylalaninemia due to deficiency of dihydropteridine reductase. *Pediatr Radiol* 1988;19(1):54-6.
- Schmidt K, Werner-felmayer G, Mayer B, Werner ER. Preferential inhibition of inducible nitric oxide synthase in intact cells by the 4-amino analogue of tetrahydrobiopterin. *Eur J Biochem* 1999 Jan;259(1-2):25-31.
- Schoonheydt WE, Clarke JT, Hanley WB, Johnson JM, Lehotay DC. Feto-maternal plasma phenylalanine concentration gradient from 19 weeks gestation to term. *Clin Chim Acta* 1994 Mar;225(2):165-9.
- Schrynemackers-Pitance P, Schoos-Barbette S. Determination of aromatic and neutral aminoacids by HPLC in blood specimens collected on filter paper. *Clin Chim Acta* 1987 Jun 30;166(1):91-7.
- Seashore MR, Wappner R, Cho S, de La Cruz F. Development of guidelines for treatment of children with phenylketonuria: report of a meeting at the National Institute of Child Health and Human Development held August 15, 1995, National Institutes of Health, Bethesda, Maryland. *Pediatrics* 1999 Dec;104(6):e67.
- Smith I, Leeming RJ, Cavanagh NP, Hyland K. Neurological aspects of biopterin metabolism. *Arch Dis Child* 1986 Feb;61(2):130-7.
- Smith I, Tillotson S. Outcome in offspring of women with mild hyperphenylalaninaemia [letter]. *Lancet* 1995 Feb 11;345(8946):385-6. Comment on: *Lancet* 1994 Dec 10;344(8937):1589-94.
- Smith ML, Saltzman J, Klim P, Hanley WB, Feigenbaum A, Clarke JT. Neuropsychological function in mild hyperphenylalaninemia. *Am J Ment Retard* 2000 Mar;105(2):69-80.
- Soto-Urzuza L, Xochinua-Corona YG, Flores-Encarnacion M, Baca BE. Purification and properties of aromatic amino acid aminotransferases from *Azospirillum brasilense* UAP 14 strain. *Can J Microbiol* 1996 Mar;42(3):294-8.
- St James PJ, Younger MD, Hamilton BD, Waisbren SE. Unplanned pregnancies in young women with diabetes. An analysis of psychosocial factors. *Diabetes Care* 1993 Dec;16(12):1572-8.
- Stemerdink BA, van der Meere JJ, van der Molen MW, Kalverboer AF, Hendriks MM, Huisman J, van der Schot LW, Slijper FM, van Spronsen FJ, Verkerk PH. Information processing in patients with early and continuously-treated phenylketonuria. *Eur J Pediatr* 1995 Sep;154(9):739-46.
- Stokes AH, Xu Y, Daunais JA, Tamir H, Gershon MD, Butkerait P, Kayser B, Altman J, Beck W, Vrana KE. p-ethynylphenylalanine: A potent inhibitor of tryptophan hydroxylase. *J Neurochem* 2000;74(5):2067-73.
- Strupp BJ, Bunsey M, Levitsky DA, Hamberger K. Deficient cumulative learning: an animal model of retarded cognitive development. *Neurotoxicol Teratol* 1994 Jan-Feb;16(1):71-9.
- Strupp BJ, Himmelstein S, Bunsey M, Levitsky DA, Kesler M. Cognitive profile of rats exposed to lactational hyperphenylalaninemia: correspondence with human mental retardation. *Dev Psychobiol* 1990 Apr;23(3):195-214.
- Sugita R, Takahashi S, Ishii K, Matsumoto K, Ishibashi T, Sakamoto K, Narisawa K. Brain CT and MR findings in hyperphenylalaninemia due to dihydropteridine reductase deficiency (variant of phenylketonuria). *J Comput Assist Tomogr* 1990 Sep-Oct;14(5):699-703.

- Svensson E, von Döbeln U, Eisensmith RC, Hagenfeldt L, Woo SL. Relation between genotype and phenotype in Swedish phenylketonuria and hyperphenylalaninemia patients. *Eur J Pediatr* 1993 Feb;152(2):132-9.
- Szabo L, Somogyi C, Mate M. [Maternal phenylketonuria syndrome: teratogenic effect of hyperphenylalaninemia]. *Orv Hetil* 1982 Nov 21;123(47):2895-901. (Hun).
- Takahashi K, Masamune A, Kure S, Matsubara Y, Narisawa K. Ectopic transcription: an application to the analysis of splicing errors in phenylalanine hydroxylase mRNA. *Acta Paediatr Suppl* 1994 Dec;407:45-6.
- Tarbit IF, Richardson JP, Dale G. Rapid automated ion-exchange analysis of plasma tyrosine and phenylalanine with data print-out. *J Chromatogr* 1980 Mar 14;181(3-4):337-46.
- Taylor RP, Smith IC, Standing SJ. Rapid automated enzymatic measurement of phenylalanine in plasma and blood spots. *Clin Chim Acta* 1993 Sep 30;218(2):207-14.
- Teebi AS, Al-Awadi SA, Farag TI, Naguib KK, el-Khalifa MY. Phenylketonuria in Kuwait and Arab countries. *Eur J Pediatr* 1987 Jan;146(1):59-60.
- Thalhammer O, Pollak A, Lubec G, Königshofer H. [Intracellular concentration of phenylalanine, tyrosine and alpha-amino butyric acid in 13 homozygotes and 19 heterozygotes for phenylketonuria (PKU) compared with 26 normals (author's transl)]. *Klin Padiatr* 1980 Nov;192(6):608-12. (Ger).
- Thalhammer O, Pollak A, Lubec G, Königshofer H. Intracellular concentrations of phenylalanine, tyrosine and alpha-aminobutyric acid in 13 homozygotes and 19 heterozygotes for phenylketonuria (PKU) compared with 26 normals. *Hum Genet* 1980;54(2):213-6.
- Todoriki H, Hayashi T, Naruse H, Ikeda S. Prepurification and derivatization of alpha-keto acids using hydrazide gel. Application in gas chromatography and gas chromatography--mass spectrometry. *J Chromatogr* 1982 Nov 12;232(2):394-9.
- Toft PB, Lou HC, Krageloh-Mann I, Andresen J, Guttler F, Guldborg P, Henriksen O. Brain magnetic resonance imaging in children with optimally controlled hyperphenylalaninaemia. *J Inherit Metab Dis* 1994;17(5):575-83.
- Treacy E, Byck S, Clow C, Scriver CR. 'Celtic' phenylketonuria chromosomes found? Evidence in two regions of Quebec Province. *Eur J Hum Genet* 1993;1(3):220-8.
- Trefz FK, Byrd DJ, Kochen W. [Point of micropreparative high pressure liquid chromatography and thin-layer chromatography for the identification of indole compounds in human plasma (author's transl)]. *J Clin Chem Clin Biochem* 1976 Feb;14(2):65-72. (Ger).
- Tsai MY, Marshall JG, Josephson MW. Free amino acid analysis of untimed and 24-h urine samples compared. *Clin Chem* 1980 Dec;26(13):1804-8.
- Tuchman M, Bowers LD, Fregien KD, Crippin PJ, Krivit W. Capillary gas chromatographic separation of urinary organic acids. Retention indices of 101 urinary acids on a 5% phenylmethyl silicone capillary column. *J Chromatogr Sci* 1984 May;22(5):198-202.
- Tyfield LA, Meredith AL, Osborn MJ, Primavesi R, Chambers TL, Holton JB, Harper PS. Genetic analysis of treated and untreated phenylketonuria in one family. *J Med Genet* 1990 Sep;27(9):564-8.
- Ugarte M, Maties M, Ugarte JL. The offspring of a phenylketonuric couple. *J Ment Defic Res* 1980 Jun;24(2):119-27.
- Ullrich K, Weglage J, Oberwittler C, Pietsch M, Funders B, van Eckhardstein H, Colombo JP. Effect of L-dopa on pattern visual evoked potentials (P-100) and neuropsychological tests in untreated adult patients with phenylketonuria. *J Inherit Metab Dis* 1994;17(3):349-52.
- Ullrich K, Weglage J, Oberwittler C, Pietsch M, Funders B, von Eckardstein H, Colombo JP. Effect of L-dopa on visual evoked potentials and neuropsychological tests in adult phenylketonuria patients. *Eur J Pediatr* 1996 Jul;155 Suppl 1:S74-7.
- Usenko VS, Kornilovskaya IN, Lizogubov VV, Apostolov EO, Gubkina EA, Ushakova GA, Lepekhin EA. Some morphological changes in the rat thyroid gland during experimental hyperphenylalaninemia. *Anat Rec* 1997 Jun;248(2):251-8.
- Vavich JM, Howell RR. Rapid identification and quantitation of urinary metabolites of phenylalanine in phenylketonuria by gas chromatography. *J Lab Clin Med* 1971 Jan;77(1):159-67.
- Vorhees CV, Acuff-Smith KD, Weisenburger WP, Minck DR, Berry HK. Branched chain amino acids improve radial-arm maze acquisition and water maze forced-choice learning in rat offspring exposed in utero to hyperphenylalaninemia. *Neurotoxicol Teratol* 1992 Jan-Feb;14(1):35-41.
- Vorhees CV, Berry HK. Branched chain amino acids improve complex maze learning in rat offspring prenatally exposed to hyperphenylalaninemia: implications for maternal phenylketonuria. *Pediatr Res* 1989 Jun;25(6):568-72.

- Waisbren SE, Doherty LB, Bailey IV, Rohr FJ, Levy HL. The New England Maternal PKU Project: identification of at-risk women. *Am J Public Health* 1988 Jul;78(7):789-92.
- Waisbren SE, Schnell R, Levy HL. Intelligence and personality characteristics in adults with untreated atypical phenylketonuria and mild hyperphenylalaninemia. *J Pediatr* 1984 Dec;105(6):955-8.
- Wang YL, Yu B. Effect of peroxovanadate compound on phenylalanine hydroxylase gene expression. *Biol Trace Elem Res* 2000;74(3):237-44.
- Wasser S, Ettrich KU, Schmidt KD, Selle D, Theile H. [Case studies of the effect of tyrosine administration in children with phenylketonuria on cognitive processes]. *Klin Padiatr* 1992 Nov-Dec;204(6):417-21. (Ger).
- Waters PJ, Parniak MA, Nowacki P, Scriver CR. In vitro expression analysis of mutations in phenylalanine hydroxylase: linking genotype to phenotype and structure to function. *Hum Mutat* 1998;11(1):4-17.
- Watts RW, Baraitser M, Chalmers RA, Purkiss P. Organic acidurias and amino acidurias in the aetiology of long-term mental handicap. *J Ment Defic Res* 1980 Dec;24 Pt 4:257-70.
- Weglage J, Bick U, Schuierer G, Pietsch M, Sprinz A, Zass R, Ullrich K. Progression of cerebral white matter abnormalities in early treated patients with phenylketonuria during adolescence [letter]. *Neuropediatrics* 1997 Aug;28(4):239-40.
- Weglage J, Pietsch M, Funders B, Koch HG, Ullrich K. Neurological findings in early treated phenylketonuria. *Acta Paediatr* 1995 Apr;84(4):411-5.
- Weglage J, Ullrich K, Pietsch M, Funders B, Zass R, Koch HG. No fine motor deficits in patients with untreated non-phenylketonuria hyperphenylalaninaemia. *Acta Paediatr* 1996 Mar;85(3):320-3.
- Weglage J, Ullrich K, Schuierer G, Pietsch M, Funders B. No white matter abnormalities in untreated patients with persistent hyperphenylalaninaemia: findings in magnetic resonance imaging. German PKU Collaborative Study [letter]. *Eur J Pediatr* 1994 Dec;153(12):918-9.
- Weinstein M, Eisensmith RC, Abadie V, Avigad S, Lyonnet S, Schwartz G, Munnich A, Woo SL, Shiloh Y. A missense mutation, S349P, completely inactivates phenylalanine hydroxylase in north African Jews with phenylketonuria. *Hum Genet* 1993 Feb;90(6):645-9.
- Wendel U, Ozalp I, Langenbeck U, Hummel W. Phenylketonuria in Turkey: experience with an enzymatic colorimetric test for measurement of serum phenylalanine. *J Inher Metab Dis* 1990;13(3):295-7.
- Wenger SL, Vieira PW, Breck JM, Steele MW. Relative reliability of three different discriminant analysis methods for detecting PKU gene carriers. *Clin Genet* 1986 Jul;30(1):38-40.
- Widaman KF. Process of analyses of data: Benefits and costs associated with collaborative studies. *Ment Retard Dev Disabil Res Rev* 1999;5(2):155-61.
- Wilke BC, Vidailhet M, Favier A, Guillemin C, Ducros V, Arnaud J, Richard MJ. Selenium, glutathione peroxidase (GSH-Px) and lipid peroxidation products before and after selenium supplementation. *Clin Chim Acta* 1992 Apr 30;207(1-2):137-42.
- Wilke BC, Vidailhet M, Richard MJ, Ducros V, Arnaud J, Favier A. [Trace elements balance in treated phenylketonuria children. Consequences of selenium deficiency on lipid peroxidation]. *Arch Latinoam Nutr* 1993 Jun;43(2):119-22. (Fre).
- Witkowski RC, Koerner H, Metzke H. Ethics and medical genetics in the German Democratic Republic (GDR). In: Wertz DC, Fletcher JC, editors. *Ethics and human gGenetics: a cross-cultural perspective*. New York: Springer-Verlag; 1989. p. 194-208.
- Yasuda N. Geographical variations in inborn errors of metabolism in Japan. *Hum Hered* 1984;34(1):1-8.
- Yokoyama Y, Sato H, Tsuchiya M, Kakinuma H. Simultaneous determination of urinary creatinine and aromatic amino acids by cation-exchange chromatography with ultraviolet detection. *J Chromatogr* 1991 May 3;566(1):19-28.
- Zarfin Y, Szeinberg A, Cohen B. [Malignant hyperphenylalaninemia (editorial)]. *Harefuah* 1981 Jun 1;100(11):539-40. (Heb).
- Zekanowski C, Cabalska B, Borsuk P, Bal J. Mutations of the phenylalanine hydroxylase gene in mild hyperphenylalaninemia: a novel mutation in exon 3. *Hum Mutat* 1997;10(3):258-9.
- Zekanowski C, Nowacka M, Gi-zewska M, Filipowicz J, Cabalska B, Bal J. Mutations in exon 3 of the PAH gene causing mild hyperphenylalaninemia. *Genet Test* 1999;3(3):297-9.
- Zeman J, Houst'kova H, Hyaneek J, Rubin A, Niederwieser A, Simkova M, Leeming RJ. [Transitory hyperphenylalaninemia with a tetrahydrobiopterin synthesis deficiency]. *Cesk Pediatr* 1987 Jul;42(7):426-8. (Cze).

Zhang LF, Yu YL, Yang RY. Direct determination of phenylalanine in serum extracts of phenylketonuria patients by reversed-phase high-performance liquid chromatography. *J Chromatogr* 1983 Dec 30;282:333-9.

Zhao G, Xia T, Song J, Jensen RA. *Pseudomonas aeruginosa* possesses homologues of mammalian phenylalanine hydroxylase and 4 alpha-carbinolamine dehydratase/DCoH as part of a three-component gene cluster. *Proc Natl Acad Sci U S A* 1994 Feb 15;91(4):1366-70.

Zschocke J, Graham CA, Stewart FJ, Carson DJ, Nevin NC. Automated sequencing detects all mutations in Northern Irish patients with phenylketonuria and mild hyperphenylalaninaemia. *Acta Paediatr Suppl* 1994 Dec;407:37-8.

Zygulska M, Eigel A, Aulehla-Scholz C, Pietrzyk JJ, Horst J. Molecular analysis of PKU haplotypes in the population of southern Poland. *Hum Genet* 1991 Jan;86(3):292-4.

Zygulska M, Eigel A, Pietrzyk JJ, Horst J. Phenylketonuria in southern Poland: a new splice mutation in intron 9 at the PAH locus. *Hum Mutat* 1994;4(4):297-9.

Genetics

Abadie V, Jaruzelska J, Lyonnet S, Millasseau P, Berthelot M, Rey F, Munnich A, Rey J. Illegitimate transcription of the phenylalanine hydroxylase gene in lymphocytes for identification of mutations in phenylketonuria. *Hum Mol Genet* 1993 Jan;2(1):31-4.

Abadie V, Lyonnet S, Maurin N, Berthelot M, Caillaud C, Giraud F, Mattei JF, Rey J, Rey F, Munnich A. CpG dinucleotides are mutation hot spots in phenylketonuria. *Genomics* 1989 Nov;5(4):936-9.

Afanas'eva NA, Bychkova AM, Livshits LA, Bariliak IR. [The clinical and molecular genetic characteristics of phenylketonuria patients in the Republic of Crimea]. *Tsitol Genet* 1998 Jan-Feb;32(1):8-14. (Rus).

al Aqeel A, Ozand PT, Gascon G, Nester M, al Nasser M, Brismar J, Blau N, Hughes H, Subramanyan SB, Reynolds CT. Biopterin-dependent hyperphenylalaninemia due to deficiency of 6-pyruvoyl tetrahydropterin synthase. *Neurology* 1991 May;41(5):730-7. Comment in: *Neurology* 1992 Mar;42(3 Pt 1):704-5.

Alos T, Bel Y, Cabello ML, Catala JL, Dalmau J, Ferre J, Garcia AM, Ruiz-Vazquez P. Improved identification of heterozygotes for phenylketonuria using blood neopterin and biopterin. *J Inher Metab Dis* 1993;16(2):457-64.

Altland K, Kaempfer M, Forssbohm M, Werner W. Monitoring for changing mutation rates using blood samples submitted for PKU screening. *Prog Clin Biol Res* 1982;103 Pt A:277-87.

Ananth J, Brown RD, Kravitz E. Familial manic depression, phenylketonuria and acromegaly [letter]. *Can J Psychiatry* 1982 Apr;27(3):258-60.

Ando A, Momomura K, Tobe K, Yamamoto-Honda R, Sakura H, Tamori Y, Kaburagi Y, Koshio O, Akanuma Y, Yazaki Y, et al. Enhanced insulin-induced mitogenesis and mitogen-activated protein kinase activities in mutant insulin receptors with substitution of two COOH-terminal tyrosine autophosphorylation sites by phenylalanine. *J Biol Chem* 1992 Jun 25;267(18):12788-96.

Annenkov GA. [Genetical heterogeneity of phenylketonuria]. *Vopr Med Khim* 1982 May-Jun;28(3):62-70. (Rus).

Annenkov GA. [Phenylketonuria and hyperphenylalaninemia: clinico-genetic classification of 14 forms]. *Zh Nevropatol Psikhiatr* 1984;84(3):351-6. (Rus).

- Annenkov GA, Safronova EE. [Presence of active phenylalanine hydroxylase in human leukocytes]. *Vopr Med Khim* 1981 Mar-Apr;27(2):266-71. (Rus).
- Annenkov GA, Safronova EE, Gubernieva LM, Volkova NM. [Detection of phenylalanine hydroxylase activity in human leukocytes and fibroblasts]. *Vopr Med Khim* 1980 Nov-Dec;26(6):723-6. (Rus).
- Antel JP, Arnason BG. Genetic predisposition to environmental factors. *Res Publ Assoc Res Nerv Ment Dis* 1983;60:255-71.
- Apold J, Eiken HG, Odland E, Fredriksen A, Bakken A, Lorens JB, Boman H. A termination mutant prevalent in Norwegian haplotype 7 phenylketonuria genes. *Am J Hum Genet* 1990 Dec;47(6):1002-7.
- Apold J, Eiken HG, Svensson E, Kunert E, Kozak L, Cechak P, Guttler F, Giltay J, Lichter-Konecki U, Melle D, et al. The phenylketonuria G272X haplotype 7 mutation in European populations. *Hum Genet* 1993 Sep;92(2):107-9.
- Arakawa H, Nakashiro S, Tsuji A, Maeda M. Analysis of polymerase chain reaction products by high-performance liquid chromatography with fluorimetric detection and its application to DNA diagnosis. *J Chromatogr B Biomed Sci Appl* 1998 Sep 25;716(1-2):119-28.
- Araki K, Matsuo N, Kodoh J, Shimizu N. RFLPs at the PAH (phenylalanine hydroxylase) gene in the Japanese population. *Nucleic Acids Res* 1991 Apr 25;19(8):1960.
- Argaet VP, Wilson TJ, Davidson BE. Purification of the *Escherichia coli* regulatory protein TyrR and analysis of its interactions with ATP, tyrosine, phenylalanine, and tryptophan. *J Biol Chem* 1994 Feb 18;269(7):5171-8.
- Argiolas A, Bosco P, Cali F, Ceratto N, Anello G, Riva E, Biasucci G, Carducci C, Romano V. Two novel PAH gene mutations detected in Italian phenylketonuric patients. *Hum Genet* 1997 Feb;99(2):275-8.
- Ashida A, Owada M, Hatakeyama K. A missense mutation (A to G) of 6-pyruvoyltetrahydropterin synthase in tetrahydrobiopterin-deficient form of hyperphenylalaninemia. *Genomics* 1994 Nov 15;24(2):408-10.
- Atypical phenylketonuria due to dihydrobiopterin synthetase deficiency. *Nutr Rev* 1980 Feb;38(2):81-3.
- Aulehla-Scholz C, Vorgerd M, Sautter E, Leupold D, Mahlmann R, Ullrich K, Olek K, Horst J. Phenylketonuria: distribution of DNA diagnostic patterns in German families. *Hum Genet* 1988 Apr;78(4):353-5.
- Avigad S, Cohen BE, Bauer S, Schwartz G, Frydman M, Woo SL, Niny Y, Shiloh Y. A single origin of phenylketonuria in Yemenite Jews. *Nature* 1990 Mar 8;344(6262):168-70.
- Avigad S, Kleiman S, Weinstein M, Cohen BE, Schwartz G, Woo SL, Shiloh Y. Compound heterozygosity in nonphenylketonuria hyperphenylalanemia: the contribution of mutations for classical phenylketonuria. *Am J Hum Genet* 1991 Aug;49(2):393-9.
- Balasubramanian S, Carr RT, Bender CJ, Peisach J, Benkovic SJ. Identification of metal ligands in Cu(II)-inhibited *Chromobacterium violaceum* phenylalanine hydroxylase by electron spin echo envelope modulation analysis of histidine to serine mutations. *Biochemistry* 1994 Jul 19;33(28):8532-7.
- Balci S, Tanzer F, Atasu M, Ozalp I. Dermatoglyphic study in children with phenylketonuria. *J Inher Metab Dis* 1989;12(3):323-6.
- Ball SP, Kenwick SJ, Davies KE. The molecular genetics of human monogenic diseases. *Biotechnol Genet Eng Rev* 1985;3:275-309.
- Bamforth FJ. Laboratory screening for genetic disorders and birth defects. *Clin Biochem* 1994 Oct;27(5):333-42.
- Baranov VS. [Successes and prospects of molecular diagnosis of the most widespread inherited diseases]. *Tsitol Genet* 1992 Jul-Aug;26(4):64-72. (Rus).
- Baranovskaia SS, Shevtsov SP, Maksimova SP, Kuz'min AI, Shvarts EI. [The spectrum of mutational damage to the phenylalanine hydroxylase gene in patients with phenylketonuria in St. Petersburg]. *Dokl Akad Nauk* 1995 Feb;340(5):709-11. (Rus).
- Baranovskaya S, Shevtsov S, Maksimova S, Kuzmin A, Schwartz E. The mutations and VNTRs in the phenylalanine hydroxylase gene of phenylketonuria in St Petersburg. *J Inher Metab Dis* 1996;19(5):705.
- Barendse W, Armitage SM, Womack JE, Hetzel J. Linkage relations between A2M, HOX3, INT1, KRAS2, and PAH on bovine chromosome 5. *Genomics* 1992 Sep;14(1):38-42.
- Baric I, Mardesic D, Gjuric G, Sarnavka V, Gobel-Schreiner B, Lichter-Konecki U, Konecki DS, Trefz FK. Haplotype distribution and mutations at the PAH locus in Croatia. *Hum Genet* 1992 Sep-Oct;90(1-2):155-7.
- Baric I, Mardesic D, Sarnavka V, Lichter-Konecki U, Konecki DS, Trefz FK. Geographical distribution of

- the P281L mutation at the phenylalanine hydroxylase locus: possible origin in southeastern Europe. *J Inher Metab Dis* 1994;17(3):376-7.
- Bartholome K, Olek K, Trefz F. Compound heterozygotes in hyperphenylalaninaemia. *Hum Genet* 1984;65(4):405-6.
- Bel Y, Ferre J. Regulation of pteridine biosynthesis and aromatic amino acid hydroxylation in *Drosophila melanogaster*. *Biochem Genet* 1989 Feb;27(1-2):59-76.
- Bender C, Buchler A, Schmidt-Mader B, Schlotter M, Teebi AS, Konecki DS, Trefz FK. Haplotype analysis and a new MspI-polymorphism at the phenylalanine hydroxylase gene in the Arabian population [letter]. *Eur J Pediatr* 1994 May;153(5):392.
- Benit P, Rey F, Blandin-Savoja F, Munnich A, Abadie V, Rey J. The mutant genotype is the main determinant of the metabolic phenotype in phenylalanine hydroxylase deficiency. *Mol Genet Metab* 1999 Sep;68(1):43-7.
- Benit P, Rey F, Melle D, Munnich A, Rey J. Five novel missense mutations of the phenylalanine hydroxylase gene in phenylketonuria. *Hum Mutat* 1994;4(3):229-31.
- Benit P, Rey F, Melle D, Munnich A, Rey J. Novel frame shift deletions of the phenylalanine hydroxylase gene in phenylketonuria. *Hum Mol Genet* 1994 Apr;3(4):675-6.
- Bernat K. [Evaluation of the phenylalanine tolerance test in detection of heterozygote carriers of phenylketonuria gene]. *Pol Tyg Lek* 1992 Mar 2-9;47(9-10):219-21. (Pol).
- Berry A, Johnson JL, Jensen RA. Phenylalanine hydroxylase and isozymes of 3-deoxy-D-arabino-heptulosonate 7-phosphate synthase in relationship to the phylogenetic position of *Pseudomonas acidovorans* (Ps. sp. ATCC 11299a). *Arch Microbiol* 1985 Feb;141(1):32-9.
- Berthelon M, Caillaud C, Rey F, Labrune P, Melle D, Feingold J, Frezal J, Briard ML, Farriaux JP, Guibaud P, et al. Spectrum of phenylketonuria mutations in western Europe and north Africa, and their relation to polymorphic DNA haplotypes at the phenylalanine hydroxylase locus. *Hum Genet* 1991 Feb;86(4):355-8.
- Bessman SP. Historical perspective: tyrosine and maternal phenylketonuria, welcome news [editorial]. *Am J Clin Nutr* 1998 Mar;67(3):357-8. Comment on: *Am J Clin Nutr* 1998 Mar;67(3):473-6. Comment in: *Am J Clin Nutr* 1998 Mar;67(3):488; *Am J Clin Nutr* 1998 Dec;68(6):1304-6.
- Bessman SP. The justification theory: the essential nature of the non-essential amino acids. *Nutr Rev* 1979 Jul;37(7):209-20.
- Bessman SP. Phenylketonuria--a genetic intrauterine nutritional deficiency. *Nutr MD* 1992 Jan;18(1):5.
- Bessman SP, Choi H, Tomaszewski L. The justification theory: the effect of tyrosine deficiency on tubulin synthesis in the brain. *Prog Clin Biol Res* 1982;79:187-92.
- Bessman SP, Williamson ML, Koch R. Diet, genetics, and mental retardation interaction between phenylketonuric heterozygous mother and fetus to produce nonspecific diminution of IQ: evidence in support of the justification hypothesis. *Proc Natl Acad Sci U S A* 1978 Mar;75(3):1562-6.
- Bickel H. Differential diagnosis and treatment of hyperphenylalaninaemia. *Prog Clin Biol Res* 1985;177:93-107.
- Bickel H, Trefz FK. [Aspartame: a sweetening agent with a high phenylalanine content]. *Monatsschr Kinderheilkd* 1986 Jul;134(7):478-80. (Ger).
- Bjorgo E, Knappskog PM, Martinez A, Stevens RC, Flatmark T. Partial characterization and three-dimensional-structural localization of eight mutations in exon 7 of the human phenylalanine hydroxylase gene associated with phenylketonuria. *Eur J Biochem* 1998 Oct 1;257(1):1-10.
- Blau K, Levitt GA, Harvey DR. Hyperphenylalaninemia with defective transamination. *Clin Chim Acta* 1983 Jul 31;132(1):43-51.
- Blau N, Barnes I, Dhondt JL. International database of tetrahydrobiopterin deficiencies. *J Inher Metab Dis* 1996;19(1):8-14.
- Blau N, Heizmann CW, Sperl W, Korenke GC, Hoffmann GF, Smooker PM, Cotton RG. Atypical (mild) forms of dihydropteridine reductase deficiency: neurochemical evaluation and mutation detection. *Pediatr Res* 1992 Dec;32(6):726-30.
- Blau N, Ichinose H, Nagatsu T, Heizmann CW, Zacchello F, Burlina AB. A missense mutation in a patient with guanosine triphosphate cyclohydrolase I deficiency missed in the newborn screening program. *J Pediatr* 1995 Mar;126(3):401-5.
- Blau N, Niederwieser A, Curtius HC, Kierat L, Leimbacher W, Matasovic A, Binkert F, Lehmann H, Leupold D, Guardamagna O, et al. Prenatal diagnosis of atypical phenylketonuria. *J Inher Metab Dis* 1989;12 Suppl 2:295-8.
- Blau N, Scherer-Oppliger T, Baumer A, Riegel M, Matasovic A, Schinzel A, Jaeken J, Thony B. Isolated

- central form of tetrahydrobiopterin deficiency associated with hemizygoty on chromosome 11q and a mutant allele of PTPS. *Hum Mutat* 2000;16(1):54-60.
- Blau N, Thony B, Spada M, Ponzzone A. Tetrahydrobiopterin and inherited hyperphenylalaninemias. *Turk J Pediatr* 1996 Jan-Mar;38(1):19-35.
- Blitzer MG, Bailey-Wilson JE, Shapira E. Discrimination of heterozygotes for phenylketonuria, persistent hyperphenylalaninemia and controls by phenylalanine loading. *Clin Chim Acta* 1986 Dec 30;161(3):347-52.
- Blumina MG. [Malignant forms of phenylketonuria]. *Zh Nevropatol Psikhiatr* 1984;84(10):1462-5. (Rus).
- Blumina MG. [Phenylalanine level in the serum of heterozygotes for phenylketonuria under intensified protein catabolism]. *Genetika* 1981;17(5):910-4. (Rus).
- Blomquist HK, Gustavson KH, Holmgren G. Severe mental retardation in five siblings due to maternal phenylketonuria. *Neuropediatrics* 1980 Aug;11(3):256-61.
- Bode VC, McDonald JD, Guenet JL, Simon D. hph-1: a mouse mutant with hereditary hyperphenylalaninemia induced by ethylnitrosourea mutagenesis. *Genetics* 1988 Feb;118(2):299-305.
- Borresen AL, Hovig E, Smith-Sorensen B, Vrieling H, Apold J, Brogger A. Screening for base mutations in the PAH and HPRT loci using the polymerase chain reaction (PCR) in combination with denaturing gradient gel electrophoresis (DGGE). *Prog Clin Biol Res* 1990;340A:389-98.
- Bosco P, Cali F, Meli C, Mollica F, Zammarchi E, Cerone R, Vanni C, Palillo L, Greco D, Romano V. Eight new mutations of the phenylalanine hydroxylase gene in Italian patients with hyperphenylalaninemia. *Hum Mutat* 1998;11(3):240-3.
- Bosco P, Ceratto N, Cali F, Goltsov AA, Eisensmith RC, Novelli G, Dalla Piccola B, Romano V. RFLP discordance in a PKU family due to a deletion in the PAH gene. *Turk J Pediatr* 1996 Oct-Dec;38(4):497-504.
- Boyaval P, Moreira E, Desmazeaud MJ. [Transport of phenylalanine and tyrosine in *Brevibacterium linens*: specificity and incorporation into proteins]. *Can J Microbiol* 1984 Apr;30(4):430-8. (Fre).
- Boyce MW. The child with phenylketonuria (PKU). *Aust J Early Child* 1980 Jun;5(2):4-6.
- Boyle PJ. Shaping priorities in genetic medicine. *Hastings Cent Rep* 1995 May-Jun;25(3 Suppl):S2-8.
- Brand MP, Heales SJ, Land JM, Clark JB. Tetrahydrobiopterin deficiency and brain nitric oxide synthase in the hph1 mouse. *J Inher Metab Dis* 1995;18(1):33-9.
- Brantley D. A genetics primer for social workers. *Health Soc Work* 1980 Feb;5(1):5-13.
- Brdicka R, Hrachovinova I. [The human genome--chromosome 12]. *Cas Lek Cesk* 1995 Jun 14;134(12):382-4. (Cze).
- Brookfield JF, Pollitt RJ, Young ID. Family size limitation: a method for demonstrating recessive inheritance. *J Med Genet* 1988 Mar;25(3):181-5.
- Brown ER, Coker GT 3d, O'Malley KL. Organization and evolution of the rat tyrosine hydroxylase gene. *Biochemistry* 1987 Aug 11;26(16):5208-12.
- Brown ES. Paternal hyperphenylalaninemia. *Pediatrics* 1986 Aug;78(2):201-5.
- Brown KJ. Physiological phenylketonuria: a biochemical defect caused by delayed maturation of the phenylalanine hydroxylation pathway and by competition with the phenylalanine biosynthetic pathway. *Med Hypotheses* 1980 Feb;6(2):215-24.
- Brown RM, James R, Cotton RG. Amplification and expression of phenylalanine hydroxylase in mouse erythroleukemia cells. *Somat Cell Mol Genet* 1985 May;11(3):203-9.
- Brunner RL, Brown EH, Berry HK. Phenylketonuria revisited: treatment of adults with behavioural manifestations. *J Inher Metab Dis* 1987;10(2):171-3.
- Buck M, Griffiths E. Regulation of aromatic amino acid transport by tRNA: role of 2-methylthio-N6-(delta2-isopentenyl)-adenosine. *Nucleic Acids Res* 1981 Jan 24;9(2):401-14.
- Burgard P, Rey F, Rupp A, Abadie V, Rey J. Neuropsychologic functions of early treated patients with phenylketonuria, on and off diet: results of a cross-national and cross-sectional study. *Pediatr Res* 1997 Mar;41(3):368-74.
- Burgard P, Rupp A, Konecki DS, Trefz FK, Schmidt H, Lichter-Konecki U. Phenylalanine hydroxylase genotypes, predicted residual enzyme activity and phenotypic parameters of diagnosis and treatment of phenylketonuria. *Eur J Pediatr* 1996 Jul;155 Suppl 1:S11-5.
- Burns JK, Azen CG, Rouse B, Vespa H. Impact of PKU on the reproductive patterns in collaborative

- study families. *Am J Med Genet* 1984 Nov;19(3):515-24.
- Burt RA. Legal and ethical aspects of interventions. In: Genetic variation and nutrition. Proceedings of the 1st International Conference on Genetic Variation and Nutrition; 1989 Jun 22-23; Washington, DC. New York: Karger; c1990. p. 266-76.
- Bush RT, Dukes PC. Women with phenylketonuria: successful management of pregnancy and implications. *N Z Med J* 1985 Mar 27;98(775):181-3.
- Byck S, Morgan K, Tyfield L, Dworniczak B, Scriver CR. Evidence for origin, by recurrent mutation, of the phenylalanine hydroxylase R408W mutation on two haplotypes in European and Quebec populations. *Hum Mol Genet* 1994 Sep;3(9):1675-7.
- Byck S, Tyfield L, Carter K, Scriver CR. Prediction of multiple hypermutable codons in the human PAH gene: codon 280 contains recurrent mutations in Quebec and other populations. *Hum Mutat* 1997;9(4):316-21.
- Caballero B. Dietary management of inborn errors of amino acid metabolism. *Clin Nutr* 1985 May-Jun;4(3):85-94.
- Caballero B, Mahon BE, Rohr FJ, Levy HL, Wurtman RJ. Plasma amino acid levels after single-dose aspartame consumption in phenylketonuria, mild hyperphenylalaninemia, and heterozygous state for phenylketonuria. *J Pediatr* 1986 Oct;109(4):668-71.
- Cabalska B, Miesowicz I, Zorska K, Nowaczewska I, Duczynska N. Influence of the phenylketonuric heterozygote on the developing fetus. *J Inherit Metab Dis* 1982;5(3):129-31.
- Cabalska B, Nowaczewska I, Duczynska N. Plasma amino acid pattern in phenylketonuric heterozygotes during pregnancy. *Biochem Med* 1982 Jun;27(3):269-77.
- Cai ZN, Yu YN, Chen XX, Yuan LF. [High-level expression of phenylalanine ammonia lyase with enzyme activity in *E. coli* by BL21DE3(pET28C-rPAL-1-cDNA)]. *Chin J Pharmacol Toxicol* 2000;14(3):211-5. (Kor).
- Caillaud C, Lyonnet S, Rey F, Melle D, Frebourg T, Berthelon M, Vilarinho L, Vaz Osorio R, Rey J, Munnich A. A 3-base pair in-frame deletion of the phenylalanine hydroxylase gene results in a kinetic variant of phenylketonuria. *J Biol Chem* 1991 May 25;266(15):9351-4.
- Caillaud C, Vilarinho L, Vilarinho A, Rey F, Berthelon M, Santos R, Lyonnet S, Briard ML, Osorio RV, Rey J, et al. Linkage disequilibrium between phenylketonuria and RFLP haplotype 1 at the phenylalanine hydroxylase locus in Portugal. *Hum Genet* 1992 Apr;89(1):69-72.
- Cali F, Dianzani I, Desviat LR, Perez B, Ugarte M, Ozguc M, Seyrantepe V, Shiloh Y, Giannattasio S, Carducci C, Bosco P, De Leo G, Piazza A, Romano V. The STR252-IVS10nt546-VNTR7 phenylalanine hydroxylase minihaplotype in five Mediterranean samples. *Hum Genet* 1997 Sep;100(3-4):350-5.
- Callus BA, Mathey-Prevot B. Hydrophobic residues Phe751 and Leu753 are essential for STAT5 transcriptional activity. *J Biol Chem* 2000 Jun 2;275(22):16954-62.
- Carducci C, Ellul L, Leuzzi V, Antonozzi I, Pontecorvi A. Genetic analysis at the phenylalanine hydroxylase locus in phenylketonuric families from central and southern Italy. In: Wilcken B, Webster D, editors. Neonatal screening in the nineties. Proceedings of the 8th International Neonatal Screening Symposium; 1991 Nov 12-15; Leura, New South Wales, Australia and the Arthur Veale Memorial Meeting; 1991 Nov 5-9; Auckland, New Zealand. Australia: The Symposium; 1991. p. 53-8.
- Carter KC. Population genetic variation at the human phenylalanine locus [masters thesis]. Montreal (Canada): McGill University; 1996. 109 p.
- Carter KC, Byck S, Waters PJ, Richards B, Nowacki PM, Laframboise R, Lambert M, Treacy E, Scriver CR. Mutation at the phenylalanine hydroxylase gene (PAH) and its use to document population genetic variation: the Quebec experience. *Eur J Hum Genet* 1998 Jan;6(1):61-70.
- Cartier L, Clow CL, Lippman-Hand A, Morissette J, Scriver CR. Prevention of mental retardation in offspring of hyperphenylalaninemic mothers. *Am J Public Health* 1982 Dec;72(12):1386-90.
- Castoria G, Migliaccio A, Green S, Di Domenico M, Chambon P, Auricchio F. Properties of a purified estradiol-dependent calf uterus tyrosine kinase. *Biochemistry* 1993 Feb 23;32(7):1740-50.
- Cederbaum SD. Phenylketonuria. In: Velaquez A, Orlando HB, editors. Genetic factors in nutrition. Orlando (FL): Academic Press; c1984. p. 79-91.
- Cederbaum SD, Koch R, Donnell GN. Symposium on genetic engineering and phenylketonuria. *Pediatrics* 1984 Sep;74(3):406-7.
- Chakraborty R, Lidsky AS, Daiger SP, Guttler F, Sullivan S, Dilella AG, Woo SL. Polymorphic DNA haplotypes at the human phenylalanine hydroxylase locus and their relationship with phenylketonuria. *Hum Genet* 1987 May;76(1):40-6.

- Charikova EV. Novel mutation identified in the PAH gene. *Hum Hered* 1996 Jan-Feb;46(1):36-40.
- Charikova EV, Khalchitskii SE, Antoshechkin AG, Schwartz EI. Distribution of some point mutations in the phenylalanine hydroxylase gene of phenylketonuria patients from the Moscow region. *Hum Hered* 1993 Jul-Aug;43(4):244-9.
- Chen D, Frey PA. Phenylalanine hydroxylase from *Chromobacterium violaceum*. Uncoupled oxidation of tetrahydropterin and the role of iron in hydroxylation. *J Biol Chem* 1998 Oct 2;273(40):25594-601.
- Chen HY, Demidkina TV, Phillips RS. Site-directed mutagenesis of tyrosine-71 to phenylalanine in *Citrobacter freundii* tyrosine phenol-lyase: evidence for dual roles of tyrosine-71 as a general acid catalyst in the reaction mechanism and in cofactor binding. *Biochemistry* 1995 Sep 26;34(38):12276-83.
- Chen SH, Hsiao KJ, Lin LH, Liu TT, Tang RB, Su TS. Study of restriction fragment length polymorphisms at the human phenylalanine hydroxylase locus and evaluation of its potential application in prenatal diagnosis of phenylketonuria in Chinese. *Hum Genet* 1989 Feb;81(3):226-30.
- Chestkov VV, Shishkin SS. [Genetic heterogeneity and approaches to the prenatal diagnosis of phenylketonuria (review)]. *Vopr Med Khim* 1986 Jul-Aug;32(4):7-12. (Rus).
- Chiappelli F, Haggerty DF, Lynch M, Popjak G. Translation of phenylalanine hydroxylase-specific mRNA in vitro: evidence for pretranslational control by glucocorticoids. *Proc Natl Acad Sci U S A* 1981 Apr;78(4):2105-9.
- Childs B. Genetic screening. *Annu Rev Genet* 1975;9:67-89.
- Choo KH, Cotton RG, Jennings IG, Danks DM. Observations indicating the nature of the mutation in phenylketonuria. *J Inherit Metab Dis* 1980;2(4):79-84.
- Choo KH, Cotton RG, Jennings IG, Fowler K, Danks DM. Genetics of mammalian phenylalanine hydroxylase system. IV. Evidence of phenylalanine hydroxylase in a cultured human hepatoma cell line. *Biochem Genet* 1980 Oct;18(9-10):955-68.
- Choo KH, Filby RG, Jennings IG, Peterson G, Fowler K. Vectors for expression and amplification of cDNA in mammalian cells: expression of rat phenylalanine hydroxylase. *DNA* 1986 Dec;5(6):529-37.
- Citron BA, Davis MD, Kaufman S. Purification and biochemical characterization of recombinant rat liver phenylalanine hydroxylase produced in *Escherichia coli*. *Protein Expr Purif* 1992 Apr;3(2):93-100.
- Citron BA, Davis MD, Milstien S, Gutierrez J, Mendel DB, Crabtree GR, Kaufman S. Identity of 4a-carbinolamine dehydratase, a component of the phenylalanine hydroxylation system, and DCoH, a transregulator of homeodomain proteins. *Proc Natl Acad Sci U S A* 1992 Dec 15;89(24):11891-4.
- Citron BA, Kaufman S, Milstien S, Naylor EW, Greene CL, Davis MD. Mutation in the 4a-carbinolamine dehydratase gene leads to mild hyperphenylalaninemia with defective cofactor metabolism. *Am J Hum Genet* 1993 Sep;53(3):768-74.
- Clark AG. Mutation-selection balance with multiple alleles. *Genetica* 1998;102-103(1-6):41-7.
- Clow CL. Genetic services in Canada: the view from Medicare. *Prog Clin Biol Res* 1982;103 Pt B:389-98.
- Cohen BE, Szeinberg A, Quint J, Normand M, Blonder J, Peled I. Malignant phenylketonuria due to defective synthesis of dihydrobiopterin. *Isr J Med Sci* 1985 Jun;21(6):520-5.
- Coleman M. Nutritional treatments currently under investigation in autism. *Clin Nutr* 1989 Sep-Oct;8(5):210-2.
- Copel JA, Pilu G, Kleinman CS. Congenital heart disease and extracardiac anomalies: associations and indications for fetal echocardiography. *Am J Obstet Gynecol* 1986 May;154(5):1121-32.
- Corsello G, Bosco P, Cali F, Greco D, Cammarata M, Ciaccio M, Piccione M, Romano V. Maternal phenylketonuria in two Sicilian families identified by maternal blood phenylalanine level screening and identification of a new phenylalanine hydroxylase gene mutation (P407L) [letter]. *Eur J Pediatr* 1999 Jan;158(1):83-4.
- Coskun T, Ozalp I, Tokatli A, Blau N, Niederwieser A. Hyperphenylalaninaemia due to tetrahydrobiopterin deficiency: a report of 16 cases. *J Inherit Metab Dis* 1993;16(3):605-7.
- Cotton RG. Heterogeneity of phenylketonuria at the clinical, protein and DNA levels. *J Inherit Metab Dis* 1990;13(5):739-50.
- Cotton RG, Horaitis O. Quality control in the discovery, reporting, and recording of genomic variation. *Hum Mutat* 2000;15(1):16-21.
- Cotton RG, Jennings I, Bracco G, Ponzzone A, Guardamagna O. Tetrahydrobiopterin non-responsiveness in dihydropteridine reductase deficiency is associated with the presence of mutant protein. *J Inherit Metab Dis* 1986;9(3):239-43.
- Coutelle C, Speer A. Genomics in the German Democratic Republic. *Genomics* 1990 Sep;8(1):182-6.

- Cowie V. Genetic causes of retardation. *Nurs Mirror* 1982 Sep 15;155(11):29-34.
- Cowie V. Injury and insult--considerations of the neuropathological aetiology of mental subnormality. *Br J Psychiatry* 1980 Oct;137:305-12.
- Crawford MD. Severe mental handicap: pathogenesis, treatment, and prevention. *Br Med J (Clin Res Ed)* 1982 Sep 18;285(6344):762-6.
- Cristiano RJ, Smith LC, Woo SL. Hepatic gene therapy: adenovirus enhancement of receptor-mediated gene delivery and expression in primary hepatocytes. *Proc Natl Acad Sci U S A* 1993 Mar 15;90(6):2122-6.
- Crocker AC. Current strategies in prevention of mental retardation. *Pediatr Ann* 1982 May;11(5):450-4, 457.
- Crockett DJ, Woolf LI, McBean MS, Woolf FM, Cahalane SF. Birth weight and pathogenesis in phenylketonuria. *Int J Neurosci* 1990 Oct;54(3-4):259-66.
- Crosley CJ, Schneider AJ. Phenylketonuria and neonatal myotonic dystrophy. *Clin Pediatr (Phila)* 1982 Jan;21(1):56-7.
- Cruz-Coke R, Moreno RS. Genetic epidemiology of single gene defects in Chile. *J Med Genet* 1994 Sep;31(9):702-6.
- Curtius HC, Endres W, Blau N. Effect of high-protein meal plus aspartame ingestion on plasma phenylalanine concentrations in obligate heterozygotes for phenylketonuria. *Metabolism* 1994 Apr;43(4):413-6.
- Czartoryska B. [Prenatal diagnosis: a chance? risk? dilemma?]. *Postepy Biochem* 1990;36(3-4):31-3. (POL).
- D'Amato TA. Gene-enzyme relationships in *Nicotiana glauca*: subcellular localization of genes and enzymes for aromatic amino acid (chloroplasts, tryptophan, phenylalanine, metabolism, tyrosine) [dissertation]. Binghamton (NY): State University of New York at Binghamton; 1987. 163 p.
- D'Sa CM, Arthur RE Jr, States JC, Kuhn DM. Tryptophan hydroxylase: cloning and expression of the rat brain enzyme in mammalian cells. *J Neurochem* 1996 Sep;67(3):900-6.
- Dagenais DL, Courville L, Dagenais MG. A cost-benefit analysis of the Quebec Network of Genetic Medicine. *Soc Sci Med* 1985;20(6):601-7.
- Dahl HH, Hutchison W, McAdam W, Wake S, Morgan FJ, Cotton RG. Human dihydropteridine reductase: characterisation of a cDNA clone and its use in analysis of patients with dihydropteridine reductase deficiency. *Nucleic Acids Res* 1987 Mar 11;15(5):1921-32.
- Dahl HH, Mercer JF. Isolation and sequence of a cDNA clone which contains the complete coding region of rat phenylalanine hydroxylase. Structural homology with tyrosine hydroxylase, glucocorticoid regulation, and use of alternate polyadenylation sites. *J Biol Chem* 1986 Mar 25;261(9):4148-53.
- Dahl HH, Osborn AH, Hutchison WM, Thorburn DR, Sheffield LJ. Late diagnosis of maternal PKU in a family segregating an arylsulfatase [corrected] E mutation causing symmetrical chondrodysplasia punctata. *Mol Genet Metab* 1999 Dec;68(4):503-6.
- Daiger SP, Chakraborty R, Reed L, Fekete G, Schuler D, Berenssi G, Nasz I, Brdicka R, Kamaryt J, Pijackova A, et al. Polymorphic DNA haplotypes at the phenylalanine hydroxylase (PAH) locus in European families with phenylketonuria (PKU). *Am J Hum Genet* 1989 Aug;45(2):310-8.
- Daiger SP, Lidsky AS, Chakraborty R, Koch R, Guttler F, Woo SL. Polymorphic DNA haplotypes at the phenylalanine hydroxylase locus in prenatal diagnosis of phenylketonuria. *Lancet* 1986 Feb 1;1(8475):229-32.
- Daiger SP, Reed L, Huang SS, Zeng YT, Wang T, Lo WH, Okano Y, Hase Y, Fukuda Y, Oura T, et al. Polymorphic DNA haplotypes at the phenylalanine hydroxylase (PAH) locus in Asian families with phenylketonuria (PKU). *Am J Hum Genet* 1989 Aug;45(2):319-24.
- Danks DM, Cotton RG. Future developments in phenylketonuria. *Enzyme* 1987;38(1-4):296-301.
- Darmon MC, Grima B, Cash CD, Maitre M, Mallet J. Isolation of a rat pineal gland cDNA clone homologous to tyrosine and phenylalanine hydroxylases. *FEBS Lett* 1986 Sep 29;206(1):43-6.
- Dasovich M, Konecki D, Lichter-Konecki U, Eisensmith RC, Guttler F, Naughton E, Mullins C, Giovannini M, Riva E, Woo SL. Molecular characterization of PKU allele prevalent in southern Europe and Ireland. *Somat Cell Mol Genet* 1991 May;17(3):303-9.
- Daubner SC, Hillas PJ, Fitzpatrick PF. Characterization of chimeric pterin-dependent hydroxylases: contributions of the regulatory domains of tyrosine and phenylalanine hydroxylase to substrate specificity. *Biochemistry* 1997 Sep 30;36(39):11574-82.
- Daubner SC, Hillas PJ, Fitzpatrick PF. Expression and characterization of the catalytic domain of human

- phenylalanine hydroxylase. *Arch Biochem Biophys* 1997 Dec 15;348(2):295-302.
- Davidson A. Management and counseling of children with inherited metabolic disorders. *J Pediatr Health Care* 1992 May-Jun;6(3):146-52.
- Davidson DC. Maternal phenylketonuria. *Postgrad Med J* 1989;65 Suppl 2:S10-20.
- Davidson DC. Maternal PKU pre-conception treatment--the need for free prescriptions. *Midwives Chron* 1989 Feb;102(1213):43.
- De Groot CJ, Hommes FA. Plasma phenylalanine and tyrosine levels during the day in normal female controls and female obligate phenylketonuria heterozygotes. *Enzyme* 1982;28(4):404-7.
- De Klerk JB, Wadman SK, Dijkhuis HJ, Meuleman EE. Maternal PKU syndrome in an exceptional family with unexpected PKU. *J Inherit Metab Dis* 1987;10(2):162-70.
- De Lucca M, Perez B, Desviat LR, Ugarte M. Molecular basis of phenylketonuria in Venezuela: presence of two novel null mutations. *Hum Mutat* 1998;11(5):354-9.
- de Sanctis L, Alliaudi C, Spada M, Farrugia R, Cerone R, Biasucci G, Meli C, Zammarchi E, Coskun T, Blau N, Ponzzone A, Dianzani I. Genotype-phenotype correlation in dihydropteridine reductase deficiency. *J Inherit Metab Dis* 2000;23(4):333-7.
- DeClue TJ, Davis J, Schocken DM, Kangas R, Benford SA. Serum lipid concentrations in subjects with phenylketonuria and their families. *Am J Dis Child* 1991 Nov;145(11):1266-8.
- DeGioanni A, Darlu P. Analysis of the molecular variance at the phenylalanine hydroxylase (PAH) locus. *Eur J Hum Genet* 1994;2(3):166-76.
- Denno KM, Sadler TW. Phenylalanine and its metabolites induce embryopathies in mouse embryos in culture. *Teratology* 1990 Nov;42(5):565-70.
- Desviat LR, Perez B, De Lucca M, Cornejo V, Schmidt B, Ugarte M. Evidence in Latin America of recurrence of V388M, a phenylketonuria mutation with high in vitro residual activity. *Am J Hum Genet* 1995 Aug;57(2):337-42.
- Desviat LR, Perez B, Gamez A, Sanchez A, Garcia MJ, Martinez-Pardo M, Marchante C, Boveda D, Baldellou A, Arena J, Sanjurjo P, Fernandez A, Cabello ML, Ugarte M. Genetic and phenotypic aspects of phenylalanine hydroxylase deficiency in Spain: molecular survey by regions. *Eur J Hum Genet* 1999 Apr;7(3):386-92.
- Desviat LR, Perez B, Garcia MJ, Martinez-Pardo M, Baldellou A, Arena J, Sanjurjo P, Campistol J, Couce ML, Fernandez A, Cardesa J, Ugarte M. Relationship between mutation genotype and biochemical phenotype in a heterogeneous Spanish phenylketonuria population. *Eur J Hum Genet* 1997 Jul-Aug;5(4):196-202.
- Desviat LR, Perez B, Ugarte M. Molecular basis of non-PKU hyperphenylalaninaemia in Spain: prevalence of A403V, a mutation with high residual activity. *J Inherit Metab Dis* 1996;19(2):227-30.
- Desviat LR, Perez B, Ugarte M. A new PKU mutation associated with haplotype 12. *Hum Mol Genet* 1992 Dec;1(9):765-6.
- Desviat LR, Perez B, Ugarte M. Phenylketonuria in Spain: RFLP haplotypes and linked mutations. *Hum Genet* 1993 Oct 1;92(3):254-8.
- Desviat LR, Perez B, Ugarte M. Phenylketonuria in Spanish Gypsies: prevalence of the IVS10nt546 mutation on haplotype 34. *Hum Mutat* 1997;9(1):66-8.
- Devi KS, Devi AR, Kondaiah P. Amplification of phenylalanine hydroxylase and cystathionine beta-synthase transcripts in human peripheral lymphocytes by RT-PCR. *Biochem Mol Biol Int* 1998 Jul;45(4):643-50.
- Dhondt JL. Tetrahydrobiopterin deficiencies: preliminary analysis from an international survey. *J Pediatr* 1984 Apr;104(4):501-8.
- Dhondt JL. [Tetrahydrobiopterin deficiency. Lessons from the analysis of 90 patients collected in the international register]. *Arch Fr Pediatr* 1987;44 Suppl 1:655-9. (Fre).
- Dhondt JL, Farriaux JP. Atypical cases of phenylketonuria. *Eur J Pediatr* 1987;146 Suppl 1:A38-43.
- Di Silvestre D, Pandya A, Koch R, Groffen J. DNA haplotype analyses of patients with hyperphenylalaninemia. *Am J Hum Genet* 1990 Oct;47(4):706-11.
- Dianzani I. Molecular basis of hyperphenylalaninemia in Italy [dissertation]. Uxbridge (Middlesex, UK): Brunel University; 1991. 249 p.
- Dianzani I, Camaschella C, Saglio G, Ferrero GB, Ramus S, Ponzzone A, Cotton RG. Molecular analysis of contiguous exons of the phenylalanine hydroxylase gene: identification of a new PKU mutation. *J Med Genet* 1993 Mar;30(3):228-31.
- Dianzani I, Camaschella C, Saglio G, Ferrero GB, Romeo G, Devoto M, Romano C, Cerone R, Giovannini M, Riva E, et al. Haplotype distribution

- and molecular defects of PKU in Italy. *J Inherit Metab Dis* 1990;13(3):292-4.
- Dianzani I, de Sanctis L, Smooker PM, Gough TJ, Alliaudi C, Brusco A, Spada M, Blau N, Dobos M, Zhang HP, Yang N, Ponzzone A, Armarego WL, Cotton RG. Dihydropteridine reductase deficiency: physical structure of the QDPR gene, identification of two new mutations and genotype-phenotype correlations. *Hum Mutat* 1998;12(4):267-73.
- Dianzani I, Devoto M, Camaschella C, Saglio G, Ferrero GB, Cerone R, Romano C, Romeo G, Giovannini M, Riva E, et al. Haplotype distribution and molecular defects at the phenylalanine hydroxylase locus in Italy. *Hum Genet* 1990 Nov;86(1):69-72.
- Dianzani I, Farinasso L, Fortina P, Camaschella C, Ponzzone R, Dahl HH, Cotton RG, Ponzzone A. RFLPs of the phenylalanine hydroxylase gene in the Italian population. *J Inherit Metab Dis* 1989;12(2):162-5.
- Dianzani I, Forrest SM, Camaschella C, Saglio G, Ponzzone A, Cotton RG. Screening for mutations in the phenylalanine hydroxylase gene from Italian patients with phenylketonuria by using the chemical cleavage method: a new splice mutation. *Am J Hum Genet* 1991 Mar;48(3):631-5.
- Dianzani I, Giannattasio S, de Sanctis L, Alliaudi C, Lattanzio P, Vici CD, Burlina A, Burroni M, Sebastio G, Carnevale F, et al. Characterization of phenylketonuria alleles in the Italian population. *Eur J Hum Genet* 1995;3(5):294-302.
- Dianzani I, Knappskog PM, de Sanctis L, Giannattasio S, Riva E, Ponzzone A, Apold J, Camaschella C. Novel missense mutation in the phenylalanine hydroxylase gene leading to complete loss of enzymatic activity. *Hum Mutat* 1995;6(3):247-9.
- Dickson PW, Jennings IG, Cotton RG. Delineation of the catalytic core of phenylalanine hydroxylase and identification of glutamate 286 as a critical residue for pterin function. *J Biol Chem* 1994 Aug 12;269(32):20369-75.
- DiLella AG, Huang WM, Woo SL. Screening for phenylketonuria mutations by DNA amplification with the polymerase chain reaction. *Lancet* 1988 Mar 5;1(8584):497-9.
- DiLella AG, Kwok SC, Ledley FD, Marvit J, Woo SL. Molecular structure and polymorphic map of the human phenylalanine hydroxylase gene. *Biochemistry* 1986 Feb 25;25(4):743-9.
- DiLella AG, Ledley FD, Rey F, Munnich A, Woo SL. Detection of phenylalanine hydroxylase messenger RNA in liver biopsy samples from patients with phenylketonuria [letter]. *Lancet* 1985 Jan 19;1(8421):160-1.
- DiLella AG, Marvit J, Brayton K, Woo SL. An amino-acid substitution involved in phenylketonuria is in linkage disequilibrium with DNA haplotype 2. *Nature* 1987 May 28-Jun 3;327(6120):333-6.
- DiLella AG, Marvit J, Lidsky AS, Guttler F, Woo SL. Tight linkage between a splicing mutation and a specific DNA haplotype in phenylketonuria. *Nature* 1986 Aug 28-Sep 3;322(6082):799-803.
- DiLella AG, Marvit J, Woo SLC. The molecular genetics of phenylketonuria. *UCLA Symp Mol Cell Biol* 1987;55:553-64.
- DiLella AG, Woo SL. Molecular basis of phenylketonuria and its clinical applications. *Mol Biol Med* 1987 Aug;4(4):183-92.
- DiSilvestre D, Koch R, Groffen J. Different clinical manifestations of hyperphenylalaninemia in three siblings with identical phenylalanine hydroxylase genes [letter]. *Am J Hum Genet* 1991 May;48(5):1014-6.
- Dobson JC, Kushida E, Williamson M, Friedman EG. Intellectual performance of 36 phenylketonuria patients and their nonaffected siblings. *Pediatrics* 1976 Jul;58(1):53-8.
- Dockhorn-Dworniczak B, Dworniczak B, Brommelkamp L, Bulles J, Horst J, Bocker WW. Non-isotopic detection of single strand conformation polymorphism (PCR-SSCP): a rapid and sensitive technique in diagnosis of phenylketonuria. *Nucleic Acids Res* 1991 May 11;19(9):2500.
- Dodinval P. [Does medical progress entail deterioration of our genetic heritage?]. *Rev Med Liege* 1980 Jan 1;35(1):11-9. (Fre).
- Donnai D. Pre-conceptual genetic advice. *Br J Family Planning* 1983 Oct;9(3):75-9.
- Dorland L, Poll-The BT, Duran M, Smeitink JA, Berger R. Phenylpyruvate, fetal damage, and maternal phenylketonuria syndrome [letter]. *Lancet* 1993 May 22;341(8856):1351-2.
- Duran GP, Rohr FJ, Slonim A, Guttler F, Levy HL. Necessity of complete intake of phenylalanine-free amino acid mixture for metabolic control of phenylketonuria. *J Am Diet Assoc* 1999 Dec;99(12):1559-63.
- Dvorakova D, Fajkusova L. Direct analysis of R408W mutation in phenylalanine hydroxylase gene by allele-specific PCR amplification. *Hum Mol Genet* 1993 Mar;2(3):323.

- Dworniczak B, Aulehla-Scholz C, Horst J. Phenylalanine hydroxylase gene: silent mutation uncovers evolutionary origin of different alleles. *Clin Genet* 1990 Oct;38(4):270-3.
- Dworniczak B, Aulehla-Scholz C, Horst J. Phenylketonuria: detection of a frequent haplotype 4 allele mutation. *Hum Genet* 1989 Dec;84(1):95-6.
- Dworniczak B, Aulehla-Scholz C, Kalaydjieva L, Bartholome K, Grudda K, Horst J. Aberrant splicing of phenylalanine hydroxylase mRNA: the major cause for phenylketonuria in parts of southern Europe. *Genomics* 1991 Oct;11(2):242-6.
- Dworniczak B, Grudda K, Stumper J, Bartholome K, Aulehla-Scholz C, Horst J. Phenylalanine hydroxylase gene: novel missense mutation in exon 7 causing severe phenylketonuria. *Genomics* 1991 Jan;9(1):193-9.
- Dworniczak B, Kalaydjieva L, Aulehla-Scholz C, Ullrich K, Kremensky I, Radeva B, Horst J. Recurrent nonsense mutation in exon 7 of the phenylalanine hydroxylase gene. *Hum Genet* 1991 Oct;87(6):731-3.
- Dworniczak B, Kalaydjieva L, Pankoke S, Aulehla-Scholz C, Allen G, Horst J. Analysis of exon 7 of the human phenylalanine hydroxylase gene: a mutation hot spot? *Hum Mutat* 1992;1(2):138-46.
- Dworniczak B, Wedemeyer N, Eigel A, Horst J. PCR detection of the PvuII (Ea) RFLP at the human phenylalanine hydroxylase (PAH) locus. *Nucleic Acids Res* 1991 Apr 25;19(8):1958.
- Dworniczak B, Wedemeyer N, Horst J. PCR detection of the BglIII RFLP at the human phenylalanine hydroxylase (PAH) locus. *Nucleic Acids Res* 1991 Apr 25;19(8):1958.
- Dyer CA, Kendler A, Jean-Guillaume D, Awatramani R, Lee A, Mason LM, Kamholz J. GFAP-positive and myelin marker-positive glia in normal and pathologic environments. *J Neurosci Res* 2000 May 1;60(3):412-26.
- Dyer CA, Kendler A, Philibotte T, Gardiner P, Cruz J, Levy HL. Evidence for central nervous system glial cell plasticity in phenylketonuria. *J Neuropathol Exp Neurol* 1996 Jul;55(7):795-814.
- Dzhura I, Naidenov V, Zhuravleva S, Kostyuk P, Shuba Y. Expression of Ca²⁺ channels from rat brain with model phenylketonuria in *Xenopus* oocytes. *Brain Res* 1998 Feb 9;783(2):280-5.
- Ebomoyi E. Family planning needs in Nigeria [letter]. *World Health Forum* 1984;5(1):40-1.
- Economou-Petersen E, Henriksen KF, Guldberg P, Guttler F. Molecular basis for nonphenylketonuria hyperphenylalaninemia. *Genomics* 1992 Sep;14(1):1-5.
- Edara S, Goodtzova K, Pegg AE. The role of tyrosine-158 in O⁶-alkylguanine-DNA alkyltransferase activity. *Carcinogenesis* 1995 Jul;16(7):1637-42.
- Effat L, Kuzmin A, Kasem N, Meguid NA, Kotb S, Eisensmith RC, Temtamy SA, Rushdi S, Woo S, el-Awady M. Haplotypes and mutations of the PAH locus in Egyptian families with PKU. *Eur J Hum Genet* 1999 Feb-Mar;7(2):259-62.
- Eigel A, Dworniczak B, Kalaydjieva L, Horst J. A frameshift mutation in exon 2 of the phenylalanine hydroxylase gene linked to RFLP haplotype 1. *Hum Genet* 1991 Oct;87(6):739-41.
- Eiken HG, Knappskog PM, Apold J, Flatmark T. PKU mutation G46S is associated with increased aggregation and degradation of the phenylalanine hydroxylase enzyme. *Hum Mutat* 1996;7(3):228-38.
- Eiken HG, Knappskog PM, Apold J, Skjelkvale L, Boman H. A de novo phenylketonuria mutation: ATG (Met) to ATA (Ile) in the start codon of the phenylalanine hydroxylase gene. *Hum Mutat* 1992;1(5):388-91.
- Eiken HG, Knappskog PM, Boman H, Thune KS, Kaada G, Motzfeldt K, Apold J. Relative frequency, heterogeneity and geographic clustering of PKU mutations in Norway. *Eur J Hum Genet* 1996;4(4):205-13.
- Eiken HG, Knappskog PM, Guldberg P, Apold J. DGGE analysis as supplement to SSCP analysis of the phenylalanine hydroxylase gene: detection of eight (one de novo, seven inherited) of nine remaining Norwegian PKU mutations. *Hum Mutat* 1996;8(1):19-22.
- Eiken HG, Knappskog PM, Motzfeldt K, Boman H, Apold J. Phenylketonuria genotypes correlated to metabolic phenotype groups in Norway. *Eur J Pediatr* 1996 Jul;155(7):554-60.
- Eiken HG, Odland E, Boman H, Skjelkvale L, Engebretsen LF, Apold J. Application of natural and amplification created restriction sites for the diagnosis of PKU mutations. *Nucleic Acids Res* 1991 Apr 11;19(7):1427-30.
- Eiken HG, Odland E, Hordnes K, Boman H, Apold J. Rapid diagnosis of the phenylketonuria haplotype 2 mutation by DNA amplification and MnlI digestion. *Clin Chem* 1990 May;36(5):809-10.
- Eiken HG, Stangeland K, Skjelkvale L, Knappskog PM, Boman H, Apold J. PKU mutations R408Q and F299C in Norway: haplotype associations, geographic

- distributions and phenotype characteristics. *Hum Genet* 1992 Mar;88(6):608-12.
- Eisensmith RC, Goltsov AA, O'Neill C, Tyfield LA, Schwartz EI, Kuzmin AI, Baranovskaya SS, Tsukerman GL, Treacy E, Scriver CR, et al. Recurrence of the R408W mutation in the phenylalanine hydroxylase locus in Europeans. *Am J Hum Genet* 1995 Jan;56(1):278-86.
- Eisensmith RC, Goltsov AA, Woo SL. A simple, rapid, and highly informative PCR-based procedure for prenatal diagnosis and carrier screening of phenylketonuria. *Prenat Diagn* 1994 Dec;14(12):1113-8.
- Eisensmith RC, Martinez DR, Kuzmin AI, Goltsov AA, Brown A, Singh R, Elsas LJ II, Woo SL. Molecular basis of phenylketonuria and a correlation between genotype and phenotype in a heterogeneous southeastern US population. *Pediatrics* 1996 Apr;97(4):512-6.
- Eisensmith RC, Okano Y, Dasovich M, Wang T, Guttler F, Lou H, Guldborg P, Lichter-Konecki U, Konecki DS, Svensson E, et al. Multiple origins for phenylketonuria in Europe. *Am J Hum Genet* 1992 Dec;51(6):1355-65.
- Eisensmith RC, Woo SL. Gene therapy for phenylketonuria. *Acta Paediatr Suppl* 1994 Dec;407:124-9.
- Eisensmith RC, Woo SL. Gene therapy for phenylketonuria. *Eur J Pediatr* 1996 Jul;155 Suppl 1:S16-9.
- Eisensmith RC, Woo SL. Molecular basis of phenylketonuria and related hyperphenylalaninemias: mutations and polymorphisms in the human phenylalanine hydroxylase gene. *Hum Mutat* 1992;1(1):13-23.
- Eisensmith RC, Woo SL. Molecular genetics of phenylketonuria: from molecular anthropology to gene therapy. *Adv Genet* 1995;32:199-271.
- Eisensmith RC, Woo SL. Molecular-genetics of phenylketonuria: from molecular anthropology to gene therapy. In: Hall JC, Dunlap JC, editors. *Incorporating molecular genetic medicine*. San Diego: Academic Press; 1995. p. 199-272. (*Advances in genetics*; vol. 32).
- Eisensmith RC, Woo SL. Phenylketonuria and the phenylalanine hydroxylase gene. *Mol Biol Med* 1991 Feb;8(1):3-18.
- Eisensmith RC, Woo SL. Population genetics of phenylketonuria. *Acta Paediatr Suppl* 1994 Dec;407:19-26.
- Eisensmith RC, Woo SL. The potential application of somatic gene therapy to the treatment of phenylketonuria and other monogenic diseases. In: Platt LD, Koch R, de la Cruz F, editors. *Genetic disorders and pregnancy outcomes*. Lancaster (UK): Parthenon; 1997. p. 113-20.
- Eisensmith RC, Woo SL. Somatic gene therapy for phenylketonuria and other hepatic deficiencies. *J Inher Metab Dis* 1996;19(4):412-23.
- Eisensmith RC, Woo SL. Updated listing of haplotypes at the human phenylalanine hydroxylase (PAH) locus [letter]. *Am J Hum Genet* 1992 Dec;51(6):1445-8.
- El-Batal AI, Abo-State MA, Shihab A. Phenylalanine ammonia lyase production by gamma irradiated and analog-resistant mutants of *Rhodotorula glutinis*. *Acta Microbiol Pol* 2000;49(1):51-61.
- Elgjo RF. Asbjorn Folling, his life and work. *Prog Clin Biol Res* 1985;177:79-92.
- Ellingsen S, Knappskog PM, Apold J, Eiken HG. Diverse PAH transcripts in lymphocytes of PKU patients with putative nonsense (G272X, Y356X) and missense (P281L, R408Q) mutations. *FEBS Lett* 1999 Sep 3;457(3):505-8.
- Ellingsen S, Knappskog PM, Eiken HG. Phenylketonuria splice mutation (EXON6nt-96A-->g) masquerading as missense mutation (Y204C). *Hum Mutat* 1997;9(1):88-90.
- Ellis HR, Daubner SC, Fitzpatrick PF. Mutation of serine 395 of tyrosine hydroxylase decouples oxygen-oxygen bond cleavage and tyrosine hydroxylation. *Biochemistry* 2000 Apr 11;39(14):4174-81.
- Elsiger MA, Theriault GR, Gauthier D. In vitro localization of the protein synthesis defect associated with experimental phenylketonuria. *Neurochem Res* 1989 Jan;14(1):81-4.
- Ems-McClung SC. Molecular engineering and characterization of recombinant for the dietary treatment of phenylketonuria (PKU) [dissertation]. Bloomington (IN): Indiana University; 1998. 158 p.
- Endo F. [Inborn errors of tyrosine metabolism: abnormalities in catabolic pathway of phenylalanine and tyrosine]. *Seikagaku* 1999 Nov;71(11):1327-31. (Jpn).
- Endres W. [Phenylketonuria and its treatment in and beyond adolescence]. *Internist (Berl)* 1994 Mar;35(3):250-4. (Ger).
- Enns GM, Martinez DR, Kuzmin AI, Koch R, Wakeem CK, Woo SL, Eisensmith RC, Packman S. Molecular correlations in phenylketonuria: mutation

patterns and corresponding biochemical and clinical phenotypes in a heterogeneous California population. *Pediatr Res* 1999 Nov;46(5):594-602.

Epstein CM, Trotter JF, Averbook A, Freeman S, Kutner MH, Elsas LJ. EEG mean frequencies are sensitive indices of phenylalanine effects on normal brain. *Electroencephalogr Clin Neurophysiol* 1989 Feb;72(2):133-9.

Erlandsen H, Bjorgo E, Flatmark T, Stevens RC. Crystal structure and site-specific mutagenesis of pterin-bound human phenylalanine hydroxylase. *Biochemistry* 2000 Mar 7;39(9):2208-17.

Erlandsen H, Fusetti F, Martinez A, Hough E, Flatmark T, Stevens RC. Crystal structure of the catalytic domain of human phenylalanine hydroxylase reveals the structural basis for phenylketonuria [letter]. *Nat Struct Biol* 1997 Dec;4(12):995-1000.

Erlandsen H, Stevens RC. The structural basis of phenylketonuria. *Mol Genet Metab* 1999 Oct;68(2):103-25.

Eschrich K, van der Bolt FJ, de Kok A, van Berkel WJ. Role of Tyr201 and Tyr385 in substrate activation by p-hydroxybenzoate hydroxylase from *Pseudomonas fluorescens*. *Eur J Biochem* 1993 Aug 15;216(1):137-46.

Fahsold R, Rott HD, Lorenz P. A third gene locus for tuberous sclerosis is closely linked to the phenylalanine hydroxylase gene locus. *Hum Genet* 1991 Nov;88(1):85-90.

Fang B. [Analysis of RFLP haplotypes and point mutations at the phenylalanine hydroxylase (PAH) locus in PKU families from north China]. *Chung Kuo I Hsueh Ko Hsueh Yuan Hsueh Pao* 1992 Feb;14(1):46-50. (Chi).

Fang B, Eisensmith RC, Li XH, Finegold MJ, Shedlovsky A, Dove W, Woo SL. Gene therapy for phenylketonuria: phenotypic correction in a genetically deficient mouse model by adenovirus-mediated hepatic gene transfer. *Gene Ther* 1994 Jul;1(4):247-54.

Fang B, Yuan L, Wang M, Huang S, Wang T, Miao S, Ye J, Sun N, Lo H, Savio LC. Detection of point mutations of the phenylalanine hydroxylase gene and prenatal diagnosis of phenylketonuria. *Chin Med Sci J* 1992 Dec;7(4):205-8.

Farmer AA, Goss SJ. BWTG3 hepatoma cells can acquire phenylalanine hydroxylase, cystathionine synthase and CPS-I without genetic manipulation, but activation of the silent OTC gene requires cell fusion with hepatocytes. *J Cell Sci* 1991 Apr;98 (Pt 4):533-8.

Farriaux JP. [Prenatal diagnosis of genetic diseases. Indications, methods, legal and ethic aspects. Neonatal screening of phenylketonuria and hypothyroidism]. *Rev Prat* 1997 Dec 1;47(19):2159-68. (Fre).

Faust DM, Catherin AM, Barbaux S, Belkadi L, Imaizumi-Scherrer T, Weiss MC. The activity of the highly inducible mouse phenylalanine hydroxylase gene promoter is dependent upon a tissue-specific, hormone-inducible enhancer. *Mol Cell Biol* 1996 Jun;16(6):3125-37.

Faust DM, Imaizumi-Scherrer T, Fulchignoni-Lataud MC, Catherin AM, Iost I, Weiss MC. Activation of phenylalanine hydroxylase expression following genomic DNA transfection of hepatoma cells. *Differentiation* 1990 Jul;44(1):74-9.

Ferakova E, Ferak V, Kadasi L, Polakova H, Hejzmanova L, Pijackova A. A unique RFLP haplotype at the phenylalanine hydroxylase locus in Czechoslovak Gypsies with phenylketonuria. *Funct Dev Morphol* 1992;2(2):139-40.

Ferencz C, Boughman JA. Congenital heart disease in adolescents and adults. *Teratology, genetics, and recurrence risks*. *Cardiol Clin* 1993 Nov;11(4):557-67.

Ficner R, Sauer UH, Ceska TA, Stier G, Suck D. Crystallization and preliminary crystallographic studies of recombinant dimerization cofactor of transcription factor HNF1/pterin-4 alpha-carbinolamine dehydratase from liver. *FEBS Lett* 1995 Jan 2;357(1):62-4.

Ficner R, Sauer UH, Stier G, Suck D. Three-dimensional structure of the bifunctional protein PCD/DCoH, a cytoplasmic enzyme interacting with transcription factor HNF1. *EMBO J* 1995 May 1;14(9):2034-42.

Filer LJ Jr, Stegink LD. Aspartame metabolism in normal adults, phenylketonuric heterozygotes, and diabetic subjects. *Diabetes Care* 1989 Jan;12(1):67-74.

Fisch RO, Chang PN, Sines L, Weisberg S, Bessman SP. Relationship between phenylalanine tolerance and psychological characteristics of phenylketonuric families. *Biochem Med* 1985 Apr;33(2):236-45.

Fisch RO, Goosens KA, Tsai MY, Seelig S, Schwichtenberg K. The occurrence of phenylketonuria and galactosemia within the same family. *Clin Pediatr (Phila)* 1985 Aug;24(8):456-8.

Fisch RO, Matalon R, Weisberg S, Michals K. Children of fathers with phenylketonuria: an international survey. *J Pediatr* 1991 May;118(5):739-41.

Fisch RO, Sines LK, Chang P. Personality characteristics of nonretarded phenylketonurics and

- their family members. *J Clin Psychiatry* 1981 Mar;42(3):106-13.
- Fisch RO, Tagatz G, Stassart JP. Gestational carrier--a reproductive haven for offspring of mothers with phenylketonuria (PKU): an alternative therapy for maternal PKU. *J Inher Metab Dis* 1993;16(6):957-61.
- Fischer GM, Nemeti B, Farkas V, Debreceni B, Laszlo A, Schaffer Z, Somogyi C, Sandor A. Metabolism of carnitine in phenylacetic acid-treated rats and in patients with phenylketonuria. *Biochim Biophys Acta* 2000 Jun 15;1501(2-3):200-10.
- Fitzpatrick PF. The aromatic amino acid hydroxylases. *Adv Enzymol Relat Areas Mol Biol* 2000;74:235-94.
- Flatz G, Oelbe M, Herrmann H. Ethnic distribution of phenylketonuria in the north German population. *Hum Genet* 1984;65(4):396-9.
- Fletcher JC. Ethical issues in genetic screening and antenatal diagnosis. *Clin Obstet Gynecol* 1981 Dec;24(4):1151-68.
- Folling A. [Phenylketonuria]. *Tidsskr Nor Laegeforen* 1967 Mar 1;87(5 Suppl):451-4. (Nor).
- Folling I. The discovery of phenylketonuria. *Acta Paediatr Suppl* 1994 Dec;407:4-10.
- Fost N. Genetic diagnosis and treatment: ethical considerations. *Am J Dis Child* 1993 Nov;147(11):1190-5.
- Foster MS, Carroll JN, Niederhoffer EC. Phenylalanine- and tyrosine-dependent production of enterobactin in *Escherichia coli*. *FEMS Microbiol Lett* 1994 Mar 15;117(1):79-83.
- Francois B, Vandevyver C, Verelst P, Phillipaert L, Raus J. Heterogeneity of phenylketonuria in Belgium at the genotype-phenotype level. *J Inher Metab Dis* 1994;17(3):369-70.
- Freedman M. Consumption of aspartame by heterozygotes for phenylketonuria [letter]. *J Pediatr* 1987 Apr;110(4):662-3.
- Freehauf CL, Lezotte D, Goodman SI, McCabe ER. Carrier screening for phenylketonuria: comparison of two discriminant analysis procedures. *Am J Hum Genet* 1984 Nov;36(6):1180-9.
- Friedman JM, Smith JP, Lerner BN, Helgeson JS, Howard-Peebles PN, Mize CE, Mize SG, Singleton WL, Smith ME. ReCAP: the Registry of Cytogenetic Abnormalities and Phenylketonuria. *Am J Med Genet* 1987 Jun;27(2):325-36.
- Friedrich CA. Cytoplasmic malate dehydrogenase is the aromatic alpha-keto reductase in man (phenylketonuria, PKU, tyrosine) [dissertation]. Houston: University of Texas Health Science Center at Houston, Graduate School of Biomedical Science; 1986. 137 p.
- Friedrich CA, Ferrell RE, Siciliano MJ, Kitto GB. Biochemical and genetic identity of alpha-keto acid reductase and cytoplasmic malate dehydrogenase from human erythrocytes. *Ann Hum Genet* 1988 Jan;52 (Pt 1):25-37.
- Fulchignoni-Lataud MC, Weiss MC, Szpirer C, Levan G. Assignment of the rat genes coding for phenylalanine hydroxylase (PAH), tyrosine aminotransferase (TAT), and pyruvate kinase (PKL) to chromosomes 7, 19, 2, respectively. *Cytogenet Cell Genet* 1990;53(2-3):172-4.
- Furukawa Y, Kish SJ, Bebin EM, Jacobson RD, Fryburg JS, Wilson WG, Shimadzu M, Hyland K, Trugman JM. Dystonia with motor delay in compound heterozygotes for GTP-cyclohydrolase I gene mutations. *Ann Neurol* 1998 Jul;44(1):10-6.
- Geltosky JE, Mitchell HK. Developmental regulation of phenylalanine hydroxylase activity in *Drosophila melanogaster*. *Biochem Genet* 1980 Aug;18(7-8):781-91.
- Giannattasio S, Bisceglia L, Lattanzio P, Grifa A, Dianzani I, Gasparini P, Marra E. Molecular screening of genetic defects with RNA-SSCP analysis: the PKU and cystinuria model. *Mol Cell Probes* 1995 Jun;9(3):201-5.
- Giannattasio S, Jurgelevicius V, Lattanzio P, Cimbaliene L, Marra E, Kucinskas V. Phenylketonuria mutations and linked haplotypes in the Lithuanian population: origin of the most common R408W mutation. *Hum Hered* 1997 May-Jun;47(3):155-60.
- Giannattasio S, Lattanzio P, Bobba A, Marra E. Detection of microsatellites by ethidium bromide staining. The analysis of an STR system in the human phenylalanine hydroxylase gene. *Mol Cell Probes* 1997 Feb;11(1):81-3.
- Gibbins B. Keeping phenylketonuria under control. *Mod Midwife* 1994 Oct;4(10):23-6.
- Gibbs BS, Wojchowski D, Benkovic SJ. Expression of rat liver phenylalanine hydroxylase in insect cells and site-directed mutagenesis of putative non-heme iron-binding sites. *J Biol Chem* 1993 Apr 15;268(11):8046-52.
- Gibson SB. Role of the TEC family tyrosine kinase EMT in T cell activation (phenylalanine)

- [dissertation]. Toronto (Canada): University of Toronto; 1997. 170 p.
- Giltay JC, van Hoef AM, de Weger R, Duran M, Berger R, Beemer FA. [Molecular genetic aspects of phenylketonuria (PKU)]. *Tijdschr Kindergeneeskd* 1991 Jun;59(3):77-80. (Dut).
- Ginter EK, Mamedova RA, Kozlova SI, Galkina VA, Moshkina IS, Rudenskaia GE, Khlebnikova OV, Nurbaev SD, Balanovskaia EV, Rassanov VP. [Diversity of hereditary pathology in the population of Marii El Republic and its differentiation with respect to gene frequencies for hereditary diseases]. *Genetika* 1998 Jul;34(7):963-72. (Rus).
- Giovannini M, Biasucci G, Luotti D, Fiori L, Riva E. Nutrition in children affected by inherited metabolic diseases. *Ann Ist Super Sanita* 1995;31(4):489-502.
- Goebel-Schreiner B, Schreiner R. Identification of a new missense mutation in Japanese phenylketonuric patients. *J Inherit Metab Dis* 1993;16(6):950-6. Published erratum appears in *J Inherit Metab Dis* 1994;17(1):66.
- Gold RJ, Maag UR, Neal JL, Scriver CR. The use of biochemical data in screening for mutant alleles and in genetic counselling. *Ann Hum Genet* 1974 Jan;37(3):315-26.
- Goltsov AA, Eisensmith RC, Konecki DS, Lichter-Konecki U, Woo SL. Associations between mutations and a VNTR in the human phenylalanine hydroxylase gene. *Am J Hum Genet* 1992 Sep;51(3):627-36.
- Goltsov AA, Eisensmith RC, Naughton ER, Jin L, Chakraborty R, Woo SL. A single polymorphic STR system in the human phenylalanine hydroxylase gene permits rapid prenatal diagnosis and carrier screening for phenylketonuria. *Hum Mol Genet* 1993 May;2(5):577-81.
- Goltsov AA, Eisensmith RC, Woo SL. Detection of the XmnI RFLP at the human PAH locus by PCR. *Nucleic Acids Res* 1992 Feb 25;20(4):927.
- Goodwill KE, Sabatier C, Marks C, Raag R, Fitzpatrick PF, Stevens RC. Crystal structure of tyrosine hydroxylase at 2.3 Å and its implications for inherited neurodegenerative diseases. *Nat Struct Biol* 1997 Jul;4(7):578-85.
- Gopalakrishnan TV. DNA-mediated restoration of phenylalanine hydroxylase gene expression in enzyme-deficient derivatives of enzyme-constitutive mouse cell hybrids. *Somat Cell Mol Genet* 1984 Jan;10(1):3-16.
- Gopalakrishnan TV, Littlefield JW. RNA from rat hepatoma cells can activate phenylalanine hydroxylase gene of mouse erythroleukemia cells. *Somatic Cell Genet* 1983 Jan;9(1):121-31.
- Grasso AW, Wu GY. Therapeutic implications of delivery and expression of foreign genes in hepatocytes. *Adv Pharmacol* 1994;28:169-92.
- Green AK, McDowall IL, Richardson SC, Fisher MJ. The effect of vanadate upon the expression of phenylalanine hydroxylase in streptozotocin-diabetic rat liver. *Biochim Biophys Acta* 1992 Oct 13;1180(1):21-7.
- Greeves LG, Patterson CC, Carson DJ, Thom R, Wolfenden MC, Zschocke J, Graham CA, Nevin NC, Trimble ER. Effect of genotype on changes in intelligence quotient after dietary relaxation in phenylketonuria and hyperphenylalaninaemia. *Arch Dis Child* 2000 Mar;82(3):216-21.
- Griffin HG, Gasson MJ. Genetic aspects of aromatic amino acid biosynthesis in *Lactococcus lactis*. *Mol Gen Genet* 1995 Jan 6;246(1):119-27.
- Gu W, Song J, Bonner CA, Xie G, Jensen RA. PhhC is an essential aminotransferase for aromatic amino acid catabolism in *Pseudomonas aeruginosa*. *Microbiology* 1998 Nov;144 (Pt 11):3127-34.
- Gu XF, Zhang M, Chen RG. Phenylketonuria mutations in southern Chinese detected by denaturing gradient gel electrophoresis in exon 7 of PAH gene. *J Inherit Metab Dis* 1995;18(6):753-4.
- Guettler F, Guldberg P, Henriksen KF. Mutation genotype of mentally retarded patients with phenylketonuria. *Dev Brain Dysfunct* 1993 Jan-Jun;6(1-3):92-6.
- Guldberg P, Guttler F. 'Broad-range' DGGE for single-step mutation scanning of entire genes: application to human phenylalanine hydroxylase gene. *Nucleic Acids Res* 1994 Mar 11;22(5):880-1.
- Guldberg P, Guttler F. Mutation screening versus gene scanning for genotyping phenylketonuria patients. *J Inherit Metab Dis* 1994;17(3):359-61.
- Guldberg P, Guttler F. Mutations in the phenylalanine hydroxylase gene: methods for their characterization. *Acta Paediatr Suppl* 1994 Dec;407:27-33.
- Guldberg P, Guttler F. PCR in the diagnosis of phenylketonuria. *Ann Med* 1992 Jun;24(3):187-90.
- Guldberg P, Henriksen KF, Guttler F. Molecular analysis of phenylketonuria in Denmark: 99% of the mutations detected by denaturing gradient gel electrophoresis. *Genomics* 1993 Jul;17(1):141-6.
- Guldberg P, Henriksen KF, Lou HC, Guttler F. Aberrant phenylalanine metabolism in

- phenylketonuria heterozygotes. *J Inherit Metab Dis* 1998 Jun;21(4):365-72.
- Guldberg P, Henriksen KF, Mammen KC, Levy HL, Guttler F. Large deletions in the phenylalanine hydroxylase gene as a cause of phenylketonuria in India. *J Inherit Metab Dis* 1997 Nov;20(6):845-6.
- Guldberg P, Henriksen KF, Sipila I, Guttler F, de la Chapelle A. Phenylketonuria in a low incidence population: molecular characterisation of mutations in Finland. *J Med Genet* 1995 Dec;32(12):976-8.
- Guldberg P, Henriksen KF, Thony B, Blau N, Guttler F. Molecular heterogeneity of nonphenylketonuria hyperphenylalaninemia in 25 Danish patients. *Genomics* 1994 May 15;21(2):453-5.
- Guldberg P, Levy HL, Hanley WB, Koch R, Matalon R, Rouse BM, Trefz F, de la Cruz F, Henriksen KF, Guttler F. Phenylalanine hydroxylase gene mutations in the United States: report from the Maternal PKU Collaborative Study. *Am J Hum Genet* 1996 Jul;59(1):84-94.
- Guldberg P, Levy HL, Henriksen KF, Guttler F. Three prevalent mutations in a patient with phenylalanine hydroxylase deficiency: implications for diagnosis and genetic counselling. *J Med Genet* 1996 Feb;33(2):161-4.
- Guldberg P, Levy HL, Koch R, Berlin CM Jr, Francois B, Henriksen KF, Guttler F. Mutation analysis in families with discordant phenotypes of phenylalanine hydroxylase deficiency. Inheritance and expression of the hyperphenylalaninaemias. *J Inherit Metab Dis* 1994;17(6):645-51.
- Guldberg P, Lou HC, Henriksen KF, Mikkelsen I, Olsen B, Holck B, Guttler F. A novel missense mutation in the phenylalanine hydroxylase gene of a homozygous Pakistani patient with non-PKU hyperphenylalaninemia. *Hum Mol Genet* 1993 Jul;2(7):1061-2.
- Guldberg P, Mallmann R, Henriksen KF, Guttler F. Phenylalanine hydroxylase deficiency in a population in Germany: mutational profile and nine novel mutations. *Hum Mutat* 1996;8(3):276-9.
- Guldberg P, Mikkelsen I, Henriksen KF, Lou HC, Guttler F. In vivo assessment of mutations in the phenylalanine hydroxylase gene by phenylalanine loading: characterization of seven common mutations. *Eur J Pediatr* 1995 Jul;154(7):551-6. Comment in: *Eur J Pediatr* 1996 Jun;155(6):523-5.
- Guldberg P, Rey F, Zschocke J, Romano V, Francois B, Michiels L, Ullrich K, Hoffmann GF, Burgard P, Schmidt H, Meli C, Riva E, Dianzani I, Ponzzone A, Rey J, Guttler F. A European multicenter study of phenylalanine hydroxylase deficiency: classification of 105 mutations and a general system for genotype-based prediction of metabolic phenotype. *Am J Hum Genet* 1998 Jul;63(1):71-9. Published erratum appears in *Am J Hum Genet* 1998 Oct;63(4):1252-3.
- Guldberg P, Romano V, Ceratto N, Bosco P, Ciuna M, Indelicato A, Mollica F, Meli C, Giovannini M, Riva E, et al. Mutational spectrum of phenylalanine hydroxylase deficiency in Sicily: implications for diagnosis of hyperphenylalaninemia in southern Europe. *Hum Mol Genet* 1993 Oct;2(10):1703-7.
- Guldberg P, Zschocke J, Dagbjartsson A, Henriksen KF, Guttler F. A molecular survey of phenylketonuria in Iceland: identification of a founding mutation and evidence of predominant Norse settlement. *Eur J Hum Genet* 1997 Nov-Dec;5(6):376-81.
- Guneral F, Ozalp I, Tatlidil H. Heterozygous carriers of classical phenylketonuria in a sample of the Turkish population: detection by a spectrofluorimetric method. *J Inherit Metab Dis* 1991;14(5):741-8. Comment in: *J Inherit Metab Dis* 1992;15(2):293-4.
- Gungor N, Tokath A, Coskun T, Ozguc M, Ozalp I. Microcephaly in a hyperphenylalaninemic infant leading to the diagnosis of maternal hyperphenylalaninemia [letter]. *Eur J Pediatr* 1996 Mar;155(3):257-8. Comment in: *Eur J Pediatr* 1996 Nov;155(11):992.
- Guttler F. [Does phenylalanine load disclose genetic variants?]. *Lakartidningen* 1974 Mar 20;71(12):1170-1. (Nor).
- Guttler F. Hyperphenylalaninemia: diagnosis and classification of the various types of phenylalanine hydroxylase deficiency in childhood. *Acta Paediatr Scand Suppl* 1980;280:1-80.
- Guttler F. Impact of medical genetics concerning phenylketonuria: accomplishments, status and practical future possibilities. *Clin Genet* 1989 Nov;36(5):333-4.
- Guttler F. Modern techniques of differentiating the various phenotypes of phenylketonuria. *Postgrad Med J* 1989;65 Suppl 2:S2-6.
- Guttler F. Phenylketonuria: 50 years since Folling's discovery and still expanding our clinical and biochemical knowledge. *Acta Paediatr Scand* 1984 Nov;73(6):705-16.
- Guttler F. The significance of allelic variation for the phenotypic diversity of phenylketonuria examined by application of a new and fast mutation detection assay and by the development of a European database. In: Hallen M, editor. *Human genome analysis*. Amsterdam: I S O Press; 1998. p. 400-7. (Biomedical and health research; vol. 23).

- Guttler F, Azen C, Guldberg P, Romstad A, Hanley WB, Levy HL, Matalon R, Rouse BM, Trefz F, de la Cruz F, Koch R. Relationship among genotype, biochemical phenotype, and cognitive performance in females with phenylalanine hydroxylase deficiency: report from the Maternal Phenylketonuria Collaborative Study. *Pediatrics* 1999 Aug;104(2 Pt 1):258-62.
- Guttler F, DiLella AG, Ledley FD, Lidsky AS, Kvak SC, Marvit J, Woo SL. Molecular biology of phenylketonuria. *Eur J Pediatr* 1987;146 Suppl 1:A5-11.
- Guttler F, Guldberg P. The influence of mutations of enzyme activity and phenylalanine tolerance in phenylalanine hydroxylase deficiency. *Eur J Pediatr* 1996 Jul;155 Suppl 1:S6-10.
- Guttler F, Guldberg P. Mutations in the phenylalanine hydroxylase gene: genetic determinants for the phenotypic variability of hyperphenylalaninemia. *Acta Paediatr Suppl* 1994 Dec;407:49-56.
- Guttler F, Guldberg P, Eisensmith RC, Woo SL. Molecular genetics and outcome in PKU. *Ment Retard Dev Disabil Res Rev* 1999;5(2):113-6.
- Guttler F, Guldberg P, Henriksen KF, Mikkelsen I, Olsen B, Lou H. Molecular basis for the phenotypical diversity of phenylketonuria and related hyperphenylalaninaemias. *J Inher Metab Dis* 1993;16(3):602-4.
- Guttler F, Hansen G. Different phenotypes for phenylalanine hydroxylase deficiency. *Ann Clin Biochem* 1977 May;14(3):124-34.
- Guttler F, Hansen G. Heterozygote detection in phenylketonuria. *Clin Genet* 1977 Feb;11(2):137-46.
- Guttler F, Hansen G. Serum tyrosine within the first hour after an oral load of phenylalanine. *Scand J Clin Lab Invest* 1977 Dec;37(8):717-21.
- Guttler F, Ledley FD, Lidsky AS, DiLella AG, Sullivan SE, Woo SL. Correlation between polymorphic DNA haplotypes at phenylalanine hydroxylase locus and clinical phenotypes of phenylketonuria. *J Pediatr* 1987 Jan;110(1):68-71.
- Guttler F, Lou H, Andresen J, Kok K, Mikkelsen I, Nielsen KB, Nielsen JB. Cognitive development in offspring of untreated and preconceptionally treated maternal phenylketonuria. *J Inher Metab Dis* 1990;13(4):665-71.
- Guttler F, Woo SL. Molecular genetics of PKU. *J Inher Metab Dis* 1986;9 Suppl 1:58-68.
- Guzzetta V, Bonapace G, Dianzani I, Parenti G, Lecora M, Giannattasio S, Concolino D, Strisciuglio P, Sebastio G, Andria G. Phenylketonuria in Italy: distinct distribution pattern of three mutations of the phenylalanine hydroxylase gene. *J Inher Metab Dis* 1997 Sep;20(5):619-24.
- Haggerty DF, Chiappelli F, Kern R, Scully S, Lynch M. Regulation by glucocorticoids of rat-liver phenylalanine hydroxylase in vivo. *Biochem Biophys Res Commun* 1983 Sep 30;115(3):965-70.
- Hall GC, Jensen RA. Enzymological basis for growth inhibition by L-phenylalanine in the cyanobacterium *Synechocystis* sp. 29108. *J Bacteriol* 1980 Dec;144(3):1034-42.
- Hanley WB, Clarke JT, Schoonheydt WE. Undiagnosed phenylketonuria in adult women: a hidden public health problem. *CMAJ* 1990 Sep 15;143(6):513-6.
- Harding CO, Wild K, Chang D, Messing A, Wolff JA. Metabolic engineering as therapy for inborn errors of metabolism--development of mice with phenylalanine hydroxylase expression in muscle. *Gene Ther* 1998 May;5(5):677-83.
- Harper P, Roberts DF. Mating patterns and genetic disease. In: Mascie-Taylor CG, Boyce AJ, et al., editors. *Human mating patterns*. Cambridge (UK): Cambridge University Press; 1988. p. 169-81. (Society for the Study of Human Biology symposium series; no. 28).
- Harper PS. Genetic registers and the prevention of inherited disorders. *Proc Annu Symp Eugen Soc* 1983;19:117-37.
- Harsanyi Z, Hutton R. Genetic prophecy: beyond the double helix. New York: Rawson, Wade; 1981. The perils of prophecy; p. 243-76, 308.
- Harte FB, Molloy O, Cahalane SF. Maternal screening trial for inborn errors of metabolism. *Ir Med J* 1982 Aug;75(8):274-5.
- Hashem N, Bosco P, Chiavetta V, Cali F, Ceratto N, Romano V. Preliminary studies on the molecular basis of hyperphenylalaninemia in Egypt. *Hum Genet* 1996 Jul;98(1):3-6.
- Hashishe MM. Genetic study of phenylketonuria. *J Egypt Public Health Assoc* 1992;67(3-4):443-63.
- Hayakawa H, Narisawa K, Arai N, Tada K, Matsuo N, Tanaka T, Naritomi K. Differential diagnosis of variant forms of hyperphenylalaninaemia by urinary pterins. *J Inher Metab Dis* 1983;6(3):123-4.
- Hayden MR, Nichols JL. Molecular genetic approaches to the study of the nervous system. *Dev Neurosci* 1983-84;6(4-5):189-214.

- Hennermann JB, Vetter B, Wolf C, Windt E, Buhrdel P, Seidel J, Monch E, Kulozik AE. Phenylketonuria and hyperphenylalaninemia in eastern Germany: a characteristic molecular profile and 15 novel mutations. *Hum Mutat* 2000;15(3):254-60.
- Henry RA. Molecular analysis of human tRNA genes (phenylalanine tRNA tyrosine tRNA gene) [dissertation]. Edmonton (Alberta, Canada): University of Alberta; 1992. 225 p.
- Herrmann FH, Wulff K, Wehnert M, Seidlitz G, Guttler F. Haplotype analysis of classical and mild phenotype of phenylketonuria in the German Democratic Republic. *Clin Genet* 1988 Sep;34(3):176-80.
- Hertzberg M, Jahromi K, Ferguson V, Dahl HH, Mercer J, Mickleson KN, Trent RJ. Phenylalanine hydroxylase gene haplotypes in Polynesians: evolutionary origins and absence of alleles associated with severe phenylketonuria. *Am J Hum Genet* 1989 Mar;44(3):382-7.
- Hilton MA, Sharpe JN, Hicks LG, Andrews BF. A simple method for detection of heterozygous carriers of the gene for classic phenylketonuria. *J Pediatr* 1986 Oct;109(4):601-4.
- Hirano M, Ueno S. Mutant GTP cyclohydrolase I in autosomal dominant dystonia and recessive hyperphenylalaninemia. *Neurology* 1999 Jan 1;52(1):182-4.
- Hoang L, Byck S, Prevost L, Scriver CR. PAH Mutation Analysis Consortium Database: a database for disease-producing and other allelic variation at the human PAH locus. *Nucleic Acids Res* 1996 Jan 1;24(1):127-31.
- Hoff RH, Hengge AC, Wu L, Keng Y-F, Zhang Z-Y. Effects on general acid catalysis from mutations of the invariant tryptophan and arginine residues in the protein tyrosine phosphatase from *Yersinia*. *Biochemistry* 2000 Jan 11;39(1):46-54.
- Hoffman GR, Walkowicz MJ, Mason JM, Atkins JF. Genetic instability associated with the aroC321 allele in *Salmonella typhimurium* involves genetic duplication. *Mol Gen Genet* 1983;190(2):183-8.
- Hofman KJ, Antonarakis SE, Missiou-Tsangaraki S, Boehm CD, Valle D. Phenylketonuria in the Greek population. Haplotype analysis of the phenylalanine hydroxylase gene and identification of a PKU mutation. *Mol Biol Med* 1989 Jun;6(3):245-50.
- Hofman KJ, Steel G, Kazazian HH, Valle D. Phenylketonuria in U.S. blacks: molecular analysis of the phenylalanine hydroxylase gene. *Am J Hum Genet* 1991 Apr;48(4):791-8.
- Holder MD. Effects of perinatal exposure to aspartame on rat pups. *Neurotoxicol Teratol* 1989 Jan-Feb;11(1):1-6.
- Holmstrom S, Abens J, Boman J, Grankvist O, Johansson B, Landegren U, Levi R, Marke LA, Olerup O. Gendiagnostik med PCR [Genetic diagnosis by PCR]. Stockholm: Swedish Council on Technology Assessment in Health Care; 1993 Jan. 54 p. (Swe).
- Hommes FA. The effect of hyperphenylalaninaemia on the muscarinic acetylcholine receptor in the HPH-5 mouse brain. *J Inher Metab Dis* 1993;16(6):962-74.
- Hommes FA. On the mechanism of permanent brain dysfunction in hyperphenylalaninemia. *Biochem Med Metab Biol* 1991 Dec;46(3):277-87.
- Horst J. Entwicklung und Adaptierung genanalytischer Methoden an die Erfordernisse der prae-natalen Diagnostik. Abschlussbericht [Development and adaptation of gene analysis methods to the requirements of prenatal diagnosis. Final report]. Munster (Germany): Munster University, Institute for Human Genetics; 1993. Contract No.: BMFT 0706523. 64 p. Available from: NTIS, Springfield, VA; TIB/A96-00555. (Ger).
- Howell RR, Stevenson RE. The offspring of phenylketonuric women. *Soc Biol* 1971 Sep;18:S19-29.
- Hsiao KJ, Chen CH, Chiu PC, Huang SC, Wu KD. A Chinese family with phenylketonuria and maternal phenylketonuria detected by family screening. *Eur J Pediatr* 1986 Oct;145(5):409-12.
- Huang S, Fang B, Chu H. [Analysis of short tandem repeats polymorphism in the phenylalanine hydroxylase gene and its application to prenatal gene diagnosis of phenylketonuria]. *Chung Hua I Hsueh Tsa Chih* 1995 Jan;75(1):22-4, 61. (Chi).
- Huang S, Li Hui, Miao S, Xu L, Fang B, Liu G, Luo H. [Analysis of the A/C polymorphic site within the phenylalanine hydroxylase gene]. *I Chuan Hsueh Pao* 1996;23(3):169-73. (Chi).
- Huang SZ, Ren ZR, Zeng YT. Application of a new DNA sequence polymorphism as a genetic marker in prenatal diagnosis of phenylketonuria. *J Med Genet* 1990 Jan;27(1):65-6.
- Huang SZ, Ren ZR, Zeng YT, Woo SL. PAH 399 GTA (Val)---GTT(Val), a new silent mutation found in the Chinese. *Hum Genet* 1991 Jan;86(3):305-6.
- Huang SZ, Zhou XD, Ren ZR, Zeng YT, Woo SL. A new silent mutation found in the Chinese PAH locus and its role in the prenatal diagnosis of phenylketonuria. *SCI CHINA B* 1991 May;34(5):606-10.

- Huang SZ, Zhou XD, Ren ZR, Zeng YT, Woo SL. Prenatal detection of an Arg----Ter mutation at codon 111 of the PAH gene using DNA amplification. *Prenat Diagn* 1990 May;10(5):289-93.
- Hufton SE, Jennings IG, Cotton RG. Structure and function of the aromatic amino acid hydroxylases. *Biochem J* 1995 Oct 15;311 (Pt 2):353-66.
- Hufton SE, Jennings IG, Cotton RG. Structure/function analysis of the domains required for the multimerisation of phenylalanine hydroxylase. *Biochim Biophys Acta* 1998 Feb 17;1382(2):295-304.
- Hyanek J, Homolka J, Trnka J, Seemanova E, Cervenka J, Tresohlava Z, Kapras J, Dolezal A, Sracek J, Vacha V, Hoza J, Losan F, Nevsimalova S, Mala M, Viletova H. Results of screening for phenylalanine and other amino acid disturbances among pregnant women. *J Inherit Metab Dis* 1980;2(3):59-63.
- Hyanek J, Viletova H, Kunova V, Kubik M. Phenylalanine loading tests in genetic counselling: 5 years experience with its premarital use. *J Inherit Metab Dis* 1981;4(2):51-2.
- Hyanek J, Viletova H, Zeman J, Vyhalkova H, Soukup J. [Offspring of mothers with hyperphenylalaninemia treated with a low phenylalanine diet before conception and during pregnancy]. *Cas Lek Cesk* 1988 Jun 3;127(23):715-9. (Cze).
- Ikeda H, Matsubara Y, Mikami H, Kure S, Owada M, Gough T, Smooker PM, Dobbs M, Dahl HH, Cotton RG, Narisawa K. Molecular analysis of dihydropteridine reductase deficiency: identification of two novel mutations in Japanese patients. *Hum Genet* 1997 Oct;100(5-6):637-42.
- Imamura T, Okano Y, Shintaku H, Hase Y, Isshiki G. Molecular characterization of 6-pyruvoyl-tetrahydropterin synthase deficiency in Japanese patients. *J Hum Genet* 1999;44(3):163-8.
- Inoue M, Muto Y, Sakamoto H, Kigawa T, Takio K, Shimura Y, Yokoyama S. A characteristic arrangement of aromatic amino acid residues in the solution structure of the amino-terminal RNA-binding domain of *Drosophila* sex-lethal. *J Mol Biol* 1997 Sep 12;272(1):82-94.
- Iraqi I, Vissers S, Andre B, Urrestarazu A. Transcriptional induction by aromatic amino acids in *Saccharomyces cerevisiae*. *Mol Cell Biol* 1999 May;19(5):3360-71.
- Irons M, Levy HL. Metabolic syndromes with dermatologic manifestations. *Clin Rev Allergy* 1986 Feb;4(1):101-24.
- Ivaschenko T, Baranov VS. Rapid and efficient PCR/StyI test for identification of common mutation R408W in phenylketonuria patients. *J Med Genet* 1993 Feb;30(2):153-4.
- Ivashchenko TE, Belova EG, Baranov VS. [A simple and reliable method for detection of the R408W mutation in exon 12 of the phenylalanine hydroxylase gene in the molecular diagnosis of phenylketonuria]. *Genetika* 1993 May;29(5):862-5. (Rus).
- Jaruzelska J, Abadie V, d'Aubenton-Carafa Y, Brody E, Munnich A, Marie J. In vitro splicing deficiency induced by a C to T mutation at position -3 in the intron 10 acceptor site of the phenylalanine hydroxylase gene in a patient with phenylketonuria. *J Biol Chem* 1995 Sep 1;270(35):20370-5.
- Jaruzelska J, Borski K, Riess O, Blin N, Slomski R. Haplotype analysis of phenylalanine hydroxylase alleles in Polish families with phenylketonuria. *Acta Biochim Pol* 1989;36(3-4):323-32.
- Jaruzelska J, Henriksen KF, Guttler F, Riess O, Borski K, Blin N, Slomski R. The codon 408 mutation associated with haplotype 2 is predominant in Polish families with phenylketonuria. *Hum Genet* 1991 Jan;86(3):247-50.
- Jaruzelska J, Matuszak R, Lyonnet S, Rey F, Rey J, Filipowicz J, Borski K, Munnich A. Genetic background of clinical homogeneity of phenylketonuria in Poland. *J Med Genet* 1993 Mar;30(3):232-4.
- Jaruzelska J, Melle D, Matuszak R, Borski K, Munnich A. A new 15 bp deletion in exon 11 of the phenylalanine hydroxylase gene in phenylketonuria. *Hum Mol Genet* 1992 Dec;1(9):763-4.
- Jaruzelska J, Slomski R. [Molecular basis of phenylketonuria]. *Postepy Biochem* 1990;36(3-4):24-31. (Pol).
- Jimenez N, Gonzalez-Candelas F, Silva FJ. Prephenate dehydratase from the aphid endosymbiont (*Buchnera*) displays changes in the regulatory domain that suggest its desensitization to inhibition by phenylalanine. *J Bacteriol* 2000 May;182(10):2967-9.
- Jingzhong L, Hua X, Wei H, Zhangling Z, Jin Z, Qingyuan L. Cloning and expression of phenylalanine ammonia lyase cDNA in *Escherichia coli*. *Chin J Biotechnol* 1998;14(4):227-32.
- John SW, Rozen R, Laframboise R, Laberge C, Scriver CR. Five mutations at the PAH locus account for almost 90% of PKU mutations in French-Canadians from eastern Quebec. *Hum Mutat* 1992;1(1):72-4.

- John SW, Rozen R, Laframboise R, Laberge C, Scriver CR. Novel PKU mutation on haplotype 2 in French-Canadians. *Am J Hum Genet* 1989 Dec;45(6):905-9.
- John SW, Rozen R, Scriver CR, Laframboise R, Laberge C. Recurrent mutation, gene conversion, or recombination at the human phenylalanine hydroxylase locus: evidence in French-Canadians and a catalog of mutations. *Am J Hum Genet* 1990 May;46(5):970-4.
- John SW, Scriver CR, Laframboise R, Rozen R. In vitro and in vivo correlations for I65T and M1V mutations at the phenylalanine hydroxylase locus. *Hum Mutat* 1992;1(2):147-53.
- Johnen G, Kowlessur D, Citron BA, Kaufman S. Characterization of the wild-type form of 4a-carbinolamine dehydratase and two naturally occurring mutants associated with hyperphenylalaninemia. *Proc Natl Acad Sci U S A* 1995 Dec 19;92(26):12384-8. Published erratum appears in *Proc Natl Acad Sci U S A* 1996 Apr 30;93(9):4519.
- Johnson WG. DNA polymorphism-diet-cofactor-development hypothesis and the gene-teratogen model for schizophrenia and other developmental disorders. *Am J Med Genet* 1999 Aug 20;88(4):311-23.
- Juengst ET. "Prevention" and the goals of genetic medicine. *Hum Gene Ther* 1995 Dec;6(12):1595-605.
- Juminaga D, Wedemeyer WJ, Garduno-Juarez R, McDonald MA, Scheraga HA. Tyrosyl interactions in the folding and unfolding of bovine pancreatic ribonuclease A: a study of tyrosine-to-phenylalanine mutants. *Biochemistry* 1997 Aug 19;36(33):10131-45.
- Kadasi L, Polakova H, Ferakova E, Hudecova S, Bohusova T, Szomolayova I, Strnova J, Hruskovic I, Moschonas NK, Ferak V. PKU in Slovakia: mutation screening and haplotype analysis. *Hum Genet* 1995 Jan;95(1):112-4.
- Kadasi L, Polakova H, Ferakova E, Krivusova T, Hudecova S, Szomolayova I, Strnova J, Hruskovic I, Ferak V. [DNA analysis in classic phenylketonuria--screening for mutations and haplotype analysis in Slovak families]. *Bratisl Lek Listy* 1994 Apr;95(4):147-50. (Slo).
- Kalanin J, Takarada Y, Kagawa S, Yamashita K, Ohtsuka N, Matsuoka A. Gypsy phenylketonuria: a point mutation of the phenylalanine hydroxylase gene in Gypsy families from Slovakia. *Am J Med Genet* 1994 Jan 15;49(2):235-9.
- Kalaydjieva L, Dworniczak B, Aulehla-Scholz C, Devoto M, Romeo G, Sturhmann M, Horst J. Phenylketonuria mutation in southern Europeans [letter]. *Lancet* 1991 Apr 6;337(8745):865.
- Kalaydjieva L, Dworniczak B, Aulehla-Scholz C, Devoto M, Romeo G, Sturhmann M, Kucinskas V, Yurgelyavicius V, Horst J. Silent mutations in the phenylalanine hydroxylase gene as an aid to the diagnosis of phenylketonuria. *J Med Genet* 1991 Oct;28(10):686-90.
- Kalaydjieva L, Dworniczak B, Kremensky I, Bronzova J, Eigel A, Horst J. Classical phenylketonuria in Bulgaria: RFLP haplotypes and frequency of the major mutations. *J Med Genet* 1990 Dec;27(12):742-5.
- Kalaydjieva L, Dworniczak B, Kremensky I, Koprivarova K, Radeva B, Milusheva R, Aulehla-Scholz C, Horst J. Heterogeneity of mutations in Bulgarian phenylketonuria haplotype 1 and 4 alleles. *Clin Genet* 1992 Mar;41(3):123-8.
- Kalaydjieva L, Dworniczak B, Kucinskas V, Yurgeliavicius V, Kunert E, Horst J. Geographical distribution gradients of the major PKU mutations and the linked haplotypes. *Hum Genet* 1991 Feb;86(4):411-3.
- Kalinin VN, Olek K, Schmidt W, Cotton RG. [Allele-specific sequencing]. *Dokl Akad Nauk* 1995 Aug;343(5):692-4. (Rus).
- Kalkanoglu HS, Anadol D, Yilmaz E, Coskun T. Phenylketonuria and cystic fibrosis in the same patient. *Pediatr Int* 2000 Feb;42(1):92-3.
- Kalter H, Warkany J. Medical progress. Congenital malformations: etiologic factors and their role in prevention (first of two parts). *N Engl J Med* 1983 Feb 24;308(8):424-31.
- Kang Y, Okano Y, Hase Y, Oura T, Isshiki G. Short tandem repeat polymorphisms in Japanese families with phenylketonuria. *J Inher Metab Dis* 1996;19(3):375-6.
- Kappock TJ, Harkins PC, Friedenber S, Caradonna JP. Spectroscopic and kinetic properties of unphosphorylated rat hepatic phenylalanine hydroxylase expressed in *Escherichia coli*. Comparison of resting and activated states. *J Biol Chem* 1995 Dec 22;270(51):30532-44.
- Kasahara T, Kasahara M. Interaction between the critical aromatic amino acid residues Tyr(352) and Phe(504) in the yeast Gal2 transporter. *FEBS Lett* 2000 Apr 7;471(1):103-7.
- Kaufman S. Genetic disorders involving recycling and formation of tetrahydrobiopterin. *Adv Pharmacol* 1998;42:41-3.

- Kaufman S. Phenylketonuria and its variants. *Adv Hum Genet* 1983;13:217-97.
- Kaufman S, Milstien S. Phenylketonuria and its variants. *Ann Clin Lab Sci* 1977 Mar-Apr;7(2):178-85.
- Kaul R, Matalon R, Allen R, Fisch RO, Michals K, Petrosky A, Sullivan D. Frequency of 12 mutations in 114 children with phenylketonuria in the Midwest region of the USA. *J Inher Metab Dis* 1994;17(3):356-8.
- Kayaalp E, Treacy E, Waters PJ, Byck S, Nowacki P, Scriver CR. Human phenylalanine hydroxylase mutations and hyperphenylalaninemia phenotypes: a metanalysis of genotype-phenotype correlations. *Am J Hum Genet* 1997 Dec;61(6):1309-17.
- Kelly TE. *Clinical genetics and genetic counseling*. Chicago: Year Book Medical Publishers; 1980. Genetic screening--eugenics--ethics; p. 262-77.
- Kennedy B, Anderson K, Acosta PB. Nutrition support of inborn errors of amino acid metabolism. *Int J Biomed Comput* 1985 Jul;17(1):69-76.
- Khusnutdinova EK, Khidiatova IM, Viktoronva TV, Fatkhislavoma RI, Galeeva AR, Limborskaia SA. [Genetic distances and taxonomic analysis of human populations of the Volga-Ural region based on data on DNA polymorphism]. *Genetika* 1999 Jul;35(7):982-7. (Rus).
- Khusnutdinova EK, Khidiatova IM, Viktorova TV, Galeeva AR, Mustafina OE. [Analysis of the genetic differentiation of Bashkirs and peoples from the Volgo-Ural region from data on polymorphic markers of the nuclear genome]. *Genetika* 1999 Jun;35(6):831-7. (Rus).
- Kidd KK. Phenylketonuria. Population genetics of a disease [news]. *Nature* 1987 May 28-Jun 3;327(6120):282-3.
- Kidd VJ, Woo SL. Recombinant DNA probes used to detect genetic disorders of the liver. *Hepatology* 1984 Jul-Aug;4(4):731-6.
- Kim DH, Nam GH, Jang DS, Choi G, Joo S, Kim JS, Oh BH, Choi KY. Roles of active site aromatic residues in catalysis by ketosteroid isomerase from *Pseudomonas putida* biotype B. *Biochemistry* 1999 Oct 19;38(42):13810-9.
- Kirkman HN. Projections of a rebound in frequency of mental retardation from phenylketonuria. *Appl Res Ment Retard* 1982;3(3):319-28.
- Kleiman S, Avigad S, Vanagaite L, Shmuelevitz A, David M, Eisensmith RC, Brand N, Schwartz G, Rey F, Munnich A. Origins of hyperphenylalaninemia in Israel. *Eur J Hum Genet* 1994;2(1):24-34.
- Kleiman S, Bernstein J, Schwartz G, Eisensmith RC, Woo SL, Shiloh Y. A defective splice site at the phenylalanine hydroxylase gene in phenylketonuria and benign hyperphenylalaninemia among Palestinian Arabs. *Hum Mutat* 1992;1(4):340-3.
- Kleiman S, Li J, Schwartz G, Eisensmith RC, Woo SL, Shiloh Y. Inactivation of phenylalanine hydroxylase by a missense mutation, R270S, in a Palestinian kinship with phenylketonuria. *Hum Mol Genet* 1993 May;2(5):605-6.
- Kleiman S, Schwartz G, Woo SL, Shiloh Y. A 22-bp deletion in the phenylalanine hydroxylase gene causing phenylketonuria in an Arab family. *Hum Mutat* 1992;1(4):344-6.
- Kleiman S, Vanagaite L, Bernstein J, Schwartz G, Brand N, Elitzur A, Woo SL, Shiloh Y. Phenylketonuria: variable phenotypic outcomes of the R261Q mutation and maternal PKU in the offspring of a healthy homozygote. *J Med Genet* 1993 Apr;30(4):284-8.
- Klein D, Marcoz JP, Mounoud RL, Bettschart W. [Final result of a clinical, genetic and cytogenetic investigation of 182 mentally retarded patients of a medico-educative institution]. *Schweiz Rundsch Med Prax* 1982 Jul 27;71(30):1209-21. (Fre).
- Klein LE, Nordlund JJ. Genetic basis of pigmentation and its disorders. *Int J Dermatol* 1981 Dec;20(10):621-31.
- Kluge C, Brecevic L, Heizmann CW, Blau N, Thony B. Chromosomal localization, genomic structure and characterization of the human gene and a retropseudogene for 6-pyruvoyltetrahydropterin synthase. *Eur J Biochem* 1996 Sep 1;240(2):477-84. Published erratum appears in *Eur J Biochem* 1996 Oct 15;241(2):697.
- Knapp A. About changes of the phenylalanine-tyrosine metabolism in psoriasis vulgaris. *Acta Univ Carol [Med] (Praha)* 1986;32(3-4):203-6.
- Knapp A, Grimm U, Postrach E. [Phenylalanine-tyrosine metabolism in psoriasis vulgaris. Search on a genetic basic defect (author's transl)]. *Dermatol Monatsschr* 1980 Jul;166(7):470-7. (Ger).
- Knapp A, Tintschewa R, Scheibe E, Scheibe E, Jager B, Biebler KE. The genetic linkage between the PKU locus and the loci for amylase 1, amylase 2, Fy, PGM 1, and Rh and the question of assignment of the PKU locus to chromosome no. 1. *Hum Genet* 1982;60(2):122-5.

- Knappskog M, Eiken HG, Martinez A, Olafsdotti S, Haavik J, Flatmark T, Apold J. Expression of wild type and mutant forms of human phenylalanine hydroxylase in *E. coli*. *Adv Exp Med Biol* 1993;338:59-62.
- Knappskog PM, Eiken HG, Martinez A, Bruland O, Apold J, Flatmark T. PKU mutation (D143G) associated with an apparent high residual enzyme activity: expression of a kinetic variant form of phenylalanine hydroxylase in three different systems. *Hum Mutat* 1996;8(3):236-46.
- Knappskog PM, Eiken HG, Martinez A, Flatmark T, Apold J. The PKU mutation S349P causes complete loss of catalytic activity in the recombinant phenylalanine hydroxylase enzyme. *Hum Genet* 1995 Feb;95(2):171-3.
- Knappskog PM, Haavik J. Tryptophan fluorescence of human phenylalanine hydroxylase produced in *Escherichia coli*. *Biochemistry* 1995 Sep 19;34(37):11790-9.
- Knappskog PM, Martinez A. Effect of mutations at Cys237 on the activation state and activity of human phenylalanine hydroxylase. *FEBS Lett* 1997 Jun 2;409(1):7-11.
- Kobayashi H, Kato J, Morioka H, Stewart JD, Ohtsuka E. Tryptophan H33 plays an important role in pyrimidine (6-4) pyrimidone photoproduct binding by a high-affinity antibody. *Protein Eng* 1999 Oct;12(10):879-84.
- Kobe B, Jennings IG, House CM, Feil SC, Michell BJ, Tiganis T, Parker MW, Cotton RG, Kemp BE. Regulation and crystallization of phosphorylated and dephosphorylated forms of truncated dimeric phenylalanine hydroxylase. *Protein Sci* 1997 Jun;6(6):1352-7.
- Kobe B, Jennings IG, House CM, Michell BJ, Goodwill KE, Santarsiero BD, Stevens RC, Cotton RG, Kemp BE. Structural basis of autoregulation of phenylalanine hydroxylase. *Nat Struct Biol* 1999 May;6(5):442-8. Comment in: *Nat Struct Biol* 1999 May;6(5):401-2.
- Koch R, Azen C, Friedman EG, Williamson ML. Paired comparisons between early treated PKU children and their matched sibling controls on intelligence and school achievement test results at eight years of age. *J Inher Metab Dis* 1984;7(2):86-90.
- Koch R, Fishler K, Azen C, Guldberg P, Guttler F. The relationship of genotype to phenotype in phenylalanine hydroxylase deficiency. *Biochem Mol Med* 1997 Apr;60(2):92-101.
- Koch R, Guttler F, Guldberg P, Rouse B. Mild hyperphenylalaninemia and heterozygosity of the phenylalanine hydroxylase gene. *Mol Genet Metab* 1998 Feb;63(2):148-50.
- Koch R, Moseley K, Ning J, Romstad A, Guldberg P, Guttler F. Long-term beneficial effects of the phenylalanine-restricted diet in late-diagnosed individuals with phenylketonuria. *Mol Genet Metab* 1999 Jun;67(2):148-55.
- Koch R, Shaw KN, Williamson M, Haber M. Use of aspartame in phenylketonuric heterozygous adults. *J Toxicol Environ Health* 1976 Nov;2(2):453-7.
- Koch R, Wenz E. Phenylketonuria. *Annu Rev Nutr* 1987;7:117-35.
- Kolodny EH, Cable WJ. Inborn errors of metabolism. *Ann Neurol* 1982 Mar;11(3):221-32.
- Konecki DS, Lichter-Konecki U. The phenylketonuria locus: current knowledge about alleles and mutations of the phenylalanine hydroxylase gene in various populations. *Hum Genet* 1991 Aug;87(4):377-88.
- Konecki DS, Schlotter M, Trefz FK, Lichter-Konecki U. The identification of two mis-sense mutations at the PAH gene locus in a Turkish patient with phenylketonuria. *Hum Genet* 1991 Aug;87(4):389-93.
- Konecki DS, Schweitzer-Krantz S, Byrd D, Trefz FK, Lichter-Konecki U. Facilitation of hyperphenylalaninaemia phenotype assessment by genotype analysis [letter]. *Eur J Pediatr* 1993 Dec;152(12):1048-9.
- Konecki DS, Wang Y, Trefz FK, Lichter-Konecki U, Woo SL. Structural characterization of the 5' regions of the human phenylalanine hydroxylase gene. *Biochemistry* 1992 Sep 8;31(35):8363-8.
- Kotzer AM, McCabe ER. Newborn screening for inherited metabolic disease: principles and practice. *Neonatal Netw* 1988 Feb;6(4):15-9.
- Kowalska B. [Effect of maternal phenylketonuria on the development of 2 children with phenylketonuria]. *Pol Tyg Lek* 1986 Apr 7;41(14):448-50. (Pol).
- Kowlessur D, Citron BA, Kaufman S. Recombinant human phenylalanine hydroxylase: novel regulatory and structural properties. *Arch Biochem Biophys* 1996 Sep 1;333(1):85-95.
- Kozak L, Blazkova M, Kuhrova V, Pijackova A, Ruzickova S, St'astna S. Mutation and haplotype analysis of phenylalanine hydroxylase alleles in classical PKU patients from the Czech Republic: identification of four novel mutations. *J Med Genet* 1997 Nov;34(11):893-8.

- Kozak L, Dvorakova D, Pijackova A, Kamaryt J. Haplotype distribution at the phenylalanine hydroxylase locus in PKU families from the Moravian area of Czechoslovakia. *J Inherit Metab Dis* 1993;16(2):451-6.
- Kozak L, Kuhrova V, Blazkova M, Fajkusova L, Dvorakova D, Pijackova A. [Advances in the diagnosis of phenylketonuria with the introduction of direct detection of PAH gene mutation]. *Cas Lek Cesk* 1995 Jun 14;134(12):385-7. (Cze).
- Kozak L, Kuhrova V, Blazkova M, Romano V, Fajkusova L, Dvorakova D, Pijackova A. Phenylketonuria mutations and their relation to RFLP haplotypes at the PAH locus in Czech PKU families. *Hum Genet* 1995 Oct;96(4):472-6.
- Kronick JB, Whelan DT, McCallion DJ. Experimental hyperphenylalaninemia in the pregnant guinea pig: possible phenylalanine teratogenesis and p-chlorophenylalanine embryotoxicity. *Teratology* 1987 Oct;36(2):245-58.
- Kucinkas V, Jurgelevicius V, Cimbalistiene L, Holmgren G. Distributions of phenylalanine hydroxylase mutations and haplotypes in Lithuanian phenylketonuria patients. *Hum Hered* 1994 Mar-Apr;44(2):110-3.
- Kure S, Hou DC, Ohura T, Iwamoto H, Suzuki S, Sugiyama N, Sakamoto O, Fujii K, Matsubara Y, Narisawa K. Tetrahydrobiopterin-responsive phenylalanine hydroxylase deficiency. *J Pediatr* 1999 Sep;135(3):375-8.
- Kutter D. [Frequency of phenylketonuria heterozygotes]. *Kinderarztl Prax* 1980 Mar;48(3):121-4. (Ger).
- Kutter D, Thoma J. Frequency of phenylketonuria carriers. *Biochem Med* 1982 Dec;28(3):285-9.
- Kuzmin AI, Eisensmith RC, Goltsov AA, Sergeeva NA, Schwartz EI, Woo SL. Complete spectrum of PAH mutations in Tataria: presence of Slavic, Turkic and Scandinavian mutations. *Eur J Hum Genet* 1995;3(4):246-55.
- Kwok SC, Ledley FD, DiLella AG, Robson KJ, Woo SL. Nucleotide sequence of a full-length complementary DNA clone and amino acid sequence of human phenylalanine hydroxylase. *Biochemistry* 1985 Jan 29;24(3):556-61.
- Kyu H, Thu A, Cook PJ. Human genetics in Burma. *Hum Hered* 1981;31(5):291-5.
- Labrune P, Lyonnet S. [Correlations between genotype and phenotype in children with phenylketonuria?]. *Arch Fr Pediatr* 1991 May;48(5):369-70. (Fre).
- Labrune P, Melle D, Rey F, Berthelon M, Caillaud C, Rey J, Munnich A, Lyonnet S. Single-strand conformation polymorphism for detection of mutations and base substitutions in phenylketonuria. *Am J Hum Genet* 1991 Jun;48(6):1115-20.
- Lacey DJ, Terplan K. Abnormal cerebral cortical neurons in a child with maternal PKU syndrome. *J Child Neurol* 1987 Jul;2(3):201-4.
- Laguna Serrano C. [Congenital errors of metabolism: phenylketonuria and hyperphenylalanemias]. *An R Acad Nac Med (Madr)* 1982;99(4):783-814. (Spa).
- Lambert DM. The genetic epidemiology of hyperphenylalaninemia in Quebec [masters thesis]. Montreal (Canada): McGill University; 1994. 187 p.
- Langenbeck U. Exact calculation of gene frequency ($q^2 - q + pq = 0$) [letter]. *J Inherit Metab Dis* 1992;15(2):293-4. Comment on: *J Inherit Metab Dis* 1991;14(5):741-8.
- Langerova E, Sindelarova M, Machackova V, Balastikova B, Nahunek K, Podhradská O, Mrkos A, Kasparkova Z. [Maternal phenylketonuria. Psychopathological study of families]. *Cesk Psychiatr* 1982 Oct;78(5):289-97. (Cze).
- Lappe M. The limits of genetic inquiry. *Hastings Cent Rep* 1987 Aug;17(4):5-10.
- Latorra D, Stern CM, Schanfield MS. Characterization of human AFLP systems apolipoprotein B, phenylalanine hydroxylase, and D1S80. *PCR Methods Appl* 1994 Jun;3(6):351-8.
- Laufs S, Blau N, Thony B. Retrovirus-mediated double transduction of the GTPCH and PTPS genes allows 6-pyruvoyltetrahydropterin synthase-deficient human fibroblasts to synthesize and release tetrahydrobiopterin. *J Neurochem* 1998 Jul;71(1):33-40.
- Laurence M, Harper PS, Harris R, Nevin NC, Roberts DF. Report of the delegation of clinical geneticists to China, Spring 1986. *Biol Soc* 1987 Jun;4(2):61-77.
- Leandro P, Rivera I, Lechner MC, de Almeida IT, Konecki D. The V388M mutation results in a kinetic variant form of phenylalanine hydroxylase. *Mol Genet Metab* 2000 Mar;69(3):204-12.
- Leandro P, Rivera I, Ribeiro V, de Almeida IT, da Silveira C, Lechner MC. Mutation analysis of phenylketonuria in south and central Portugal: prevalence of V388M mutation. *Hum Mutat* 1995;6(2):192-4.
- Ledley FD. Clinical application of genotypic diagnosis for phenylketonuria: theoretical considerations. *Eur J Pediatr* 1991 Sep;150(11):752-6.

- Ledley FD. Somatic gene therapy for human disease: a problem of eugenics? *Trends Genet* 1987 Apr;3(4):112-5.
- Ledley FD. Somatic gene therapy for human disease: background and prospects. Part II. *J Pediatr* 1987 Feb;110(2):167-74.
- Ledley FD, DiLella AG, Kwok SC, Woo SL. Homology between phenylalanine and tyrosine hydroxylases reveals common structural and functional domains. *Biochemistry* 1985 Jul 2;24(14):3389-94.
- Ledley FD, Grenett HE, DiLella AG, Kwok SC, Woo SL. Gene transfer and expression of human phenylalanine hydroxylase. *Science* 1985 Apr 5;228(4695):77-9.
- Ledley FD, Grenett HE, Dunbar BS, Woo SL. Mouse phenylalanine hydroxylase. Homology and divergence from human phenylalanine hydroxylase. *Biochem J* 1990 Apr 15;267(2):399-405.
- Ledley FD, Grenett HE, McGinnis-Shelnett M, Woo SL. Retroviral-mediated gene transfer of human phenylalanine hydroxylase into NIH 3T3 and hepatoma cells. *Proc Natl Acad Sci U S A* 1986 Jan;83(2):409-13.
- Ledley FD, Grenett HE, Woo SL. Biochemical characterization of recombinant human phenylalanine hydroxylase produced in *Escherichia coli*. *J Biol Chem* 1987 Feb 15;262(5):2228-33.
- Ledley FD, Hahn T, Woo SL. Selection for phenylalanine hydroxylase activity in cells transformed with recombinant retroviruses. *Somat Cell Mol Genet* 1987 Mar;13(2):145-54.
- Ledley FD, Koch R, Jew K, Beaudet A, O'Brien WE, Bartos DP, Woo SL. Phenylalanine hydroxylase expression in liver of a fetus with phenylketonuria. *J Pediatr* 1988 Sep;113(3):463-8.
- Ledley FD, Ledbetter SA, Ledbetter DH, Woo SL. Localization of mouse phenylalanine hydroxylase locus on chromosome 10. *Cytogenet Cell Genet* 1988;47(3):125-6.
- Ledley FD, Levy HL, Woo SL. Molecular analysis of the inheritance of phenylketonuria and mild hyperphenylalaninemia in families with both disorders. *N Engl J Med* 1986 May 15;314(20):1276-80.
- Ledley FD, Woo SLC. Prospects for somatic gene therapy of phenylketonuria. *UCLA Symp Mol Cell Biol* 1987;55:565-79.
- Lehmann WD. Progress in the identification of the heterozygote in phenylketonuria. *J Pediatr* 1989 Jun;114(6):915-24.
- Lehmann WD, Fischer R, Heinrich HC, Clemens P, Gruttner R. Metabolic conversion of L-[U-¹⁴C]phenylalanine to respiratory ¹⁴CO₂ in healthy subjects, phenylketonuria heterozygotes and classic phenylketonurics. *Clin Chim Acta* 1986 Jun 30;157(3):253-66.
- Lehmann WD, Heinrich HC. Impaired phenylalanine-tyrosine conversion in patients with iron-deficiency anemia studied by a L-(²H⁵)phenylalanine-loading test. *Am J Clin Nutr* 1986 Oct;44(4):468-74.
- Lehmann WD, Heinrich HC. The NIH-shift in the in vivo hydroxylation of ring-deuterated L-phenylalanine in man. *Arch Biochem Biophys* 1986 Oct;250(1):180-5.
- Lehmann WD, Theobald N, Heinrich HC, Clemens P, Gruttner R. Detection of heterozygous carriers for phenylketonuria by a L-[²H⁵]phenylalanine stable isotope loading test. *Clin Chim Acta* 1984 Mar 27;138(1):59-71.
- Lei XD, Kaufman S. Human white blood cells and hair follicles are good sources of mRNA for the pterin carbinolamine dehydratase/dimerization cofactor of HNF1 for mutation detection. *Biochem Biophys Res Commun* 1998 Jul 20;248(2):432-5.
- Lei XD, Kaufman S. Identification of hepatic nuclear factor 1 binding sites in the 5' flanking region of the human phenylalanine hydroxylase gene: implication of a dual function of phenylalanine hydroxylase stimulator in the phenylalanine hydroxylation system. *Proc Natl Acad Sci U S A* 1998 Feb 17;95(4):1500-4.
- Leititis JU, Stahl M, Tackmann W, Wick H, Wildberg A. Homozygous hypobetalipoproteinaemia and phenylketonuria. *Eur J Pediatr* 1985 Jul;144(2):174-6.
- Lenke RR. Maternal phenylketonuria and hyperphenylalanemia: a problem born of success. *J Pediatr Perinat Nutr* 1987 Spring-Summer;1(1):67-74.
- Leonard HM, Fletcher JM. Inherited metabolic diseases: beyond newborn screening [editorial]. *Med J Aust* 1999 Jun 21;170(12):573-4. Comment on: *Med J Aust* 1999 Jun 21;170(12):592-5.
- Levy HL. Genetic screening. *Adv Hum Genet* 1973;4:1-104.
- Levy HL. Genetic screening: notes added in proof. *Adv Hum Genet* 1973;4:389-94.
- Levy HL. Maternal PKU. *Prog Clin Biol Res* 1985;177:109-22.

- Levy HL. Molecular genetics of phenylketonuria and its implications. *Am J Hum Genet* 1989 Nov;45(5):667-70.
- Levy HL. Phenylketonuria: old disease, new approach to treatment. *Proc Natl Acad Sci U S A* 1999 Mar 2;96(5):1811-3. Comment on: *Proc Natl Acad Sci U S A* 1999 Mar 2;96(5):2339-44.
- Levy HL. Treatment of phenylketonuria. *Prog Clin Biol Res* 1979;34:171-82.
- Levy HL, Ghavami M. Maternal phenylketonuria: a metabolic teratogen. *Teratology* 1996 Mar;53(3):176-84.
- Levy HL, Goss BS, Sullivan DK, Michals-Matalon K, Dobbs JM, Guldberg P, Guttler F. Maternal mild hyperphenylalaninemia: results of treated and untreated pregnancies in two sisters. *J Pediatr* 1994 Sep;125(3):467-9.
- Levy HL, Kaplan GN, Erickson AM. Comparison of treated and untreated pregnancies in a mother with phenylketonuria. *J Pediatr* 1982 Jun;100(6):876-80.
- Levy HL, Lobbregt D, Barnes PD, Poussaint TY. Maternal phenylketonuria: magnetic resonance imaging of the brain in offspring. *J Pediatr* 1996 Jun;128(6):770-5.
- Levy HL, Lobbregt D, Koch R, de la Cruz F. Paternal phenylketonuria. *J Pediatr* 1991 May;118(5):741-3.
- Levy HL, Lobbregt D, Sansaricq C, Snyderman SE. Comparison of phenylketonuric and nonphenylketonuric sibs from untreated pregnancies in a mother with phenylketonuria. *Am J Med Genet* 1992 Nov 1;44(4):439-42.
- Levy HL, Shih VE, Karolkewicz V, French WA, Carr JR, Cass V, Kennedy JL Jr, MacCready RA. Persistent mild hyperphenylalaninemia in the untreated state. A prospective study. *N Engl J Med* 1971 Aug 19;285(8):424-9.
- Levy HL, Waisbren SE. Effects of untreated maternal phenylketonuria and hyperphenylalaninemia on the fetus. *N Engl J Med* 1983 Nov 24;309(21):1269-74.
- Li J, Eisensmith RC, Wang T, Lo WH, Huang SZ, Zeng YT, Yuan LF, Liu SR, Woo SL. Identification of three novel missense PKU mutations among Chinese. *Genomics* 1992 Jul;13(3):894-5.
- Li J, Eisensmith RC, Wang T, Lo WH, Huang SZ, Zeng YT, Yuan LF, Liu SR, Woo SL. Phenylketonuria in China: identification and characterization of three novel nucleotide substitutions in the human phenylalanine hydroxylase gene. *Hum Mutat* 1994;3(3):312-4.
- Lichter-Konecki U, Hipke CM, Konecki DS. Human phenylalanine hydroxylase gene expression in kidney and other nonhepatic tissues. *Mol Genet Metab* 1999 Aug;67(4):308-16.
- Lichter-Konecki U, Konecki DS, DiLella AG, Brayton K, Marvit J, Hahn TM, Trefz FK, Woo SL. Phenylalanine hydroxylase deficiency caused by a single base substitution in an exon of the human phenylalanine hydroxylase gene. *Biochemistry* 1988 Apr 19;27(8):2881-5.
- Lichter-Konecki U, Rupp A, Konecki DS, Trefz FK, Schmidt H, Burgard P. Relation between phenylalanine hydroxylase genotypes and phenotypic parameters of diagnosis and treatment of hyperphenylalaninaemic disorders. German Collaborative Study of PKU. *J Inher Metab Dis* 1994;17(3):362-5.
- Lichter-Konecki U, Schlotter M, Konecki DS. DNA sequence polymorphisms in exonic and intronic regions of the human phenylalanine hydroxylase gene aid in the identification of alleles. *Hum Genet* 1994 Sep;94(3):307-10.
- Lichter-Konecki U, Schlotter M, Konecki DS, Labeit S, Woo SL, Trefz FK. Linkage disequilibrium between mutation and RFLP haplotype at the phenylalanine hydroxylase locus in the German population. *Hum Genet* 1988 Apr;78(4):347-52.
- Lichter-Konecki U, Schlotter M, Trefz FK, Konecki DS. Direct detection of a major mutation responsible for phenylketonuria in the population of the Federal Republic of Germany. *Eur J Pediatr* 1989 Nov;149(2):120-3.
- Lichter-Konecki U, Schlotter M, Yaylak C, Ozguc M, Coskun T, Ozalp I, Wendel U, Batzler U, Trefz FK, Konecki D. DNA haplotype analysis at the phenylalanine hydroxylase locus in the Turkish population. *Hum Genet* 1989 Mar;81(4):373-6.
- Lidsky AS, Robson KJ, Thirumalachary C, Barker PE, Ruddle FH, Woo SL. The PKU locus in man is on chromosome 12. *Am J Hum Genet* 1984 May;36(3):527-33.
- Lidsky AS, Guttler F, Woo SL. Prenatal diagnosis of classic phenylketonuria by DNA analysis. *Lancet* 1985 Mar 9;1(8428):549-51.
- Lidsky AS, Law ML, Morse HG, Kao FT, Rabin M, Ruddle FH, Woo SL. Regional mapping of the phenylalanine hydroxylase gene and the phenylketonuria locus in the human genome. *Proc Natl Acad Sci U S A* 1985 Sep;82(18):6221-5.
- Lidsky AS, Ledley FD, DiLella AG, Kwok SC, Daiger SP, Robson KJ, Woo SL. Extensive restriction site polymorphism at the human phenylalanine

- hydroxylase locus and application in prenatal diagnosis of phenylketonuria. *Am J Hum Genet* 1985 Jul;37(4):619-34.
- Lillevali H, Ounap K, Metspalu A. Phenylalanine hydroxylase gene mutation R408W is present on 84% of Estonian phenylketonuria chromosomes. *Eur J Hum Genet* 1996;4(5):296-300.
- Lin CH, Hsiao KJ, Tsai TF, Chao HK, Su TS. Identification of a missense phenylketonuria mutation at codon 408 in Chinese. *Hum Genet* 1992 Aug;89(6):593-6.
- Lin CM, Tan Y, Lee YM, Chang CC, Hsiao KJ. Expression of human phenylalanine hydroxylase activity in T lymphocytes of classical phenylketonuria children by retroviral-mediated gene transfer. *J Inherit Metab Dis* 1997 Nov;20(6):742-54.
- Liu TJ, Kay MA, Darlington GJ, Woo SL. Reconstitution of enzymatic activity in hepatocytes of phenylalanine hydroxylase-deficient mice. *Somat Cell Mol Genet* 1992 Jan;18(1):89-96.
- Liu TT, Hsiao KJ. Identification of a common 6-pyruvoyl-tetrahydropterin synthase mutation at codon 87 in Chinese phenylketonuria caused by tetrahydrobiopterin synthesis deficiency. *Hum Genet* 1996 Sep;98(3):313-6.
- Liu TT, Hsiao KJ, Lu SF, Wu SJ, Wu KF, Chiang SH, Liu XQ, Chen RG, Yu WM. Mutation analysis of the 6-pyruvoyl-tetrahydropterin synthase gene in Chinese hyperphenylalaninemia caused by tetrahydrobiopterin synthesis deficiency. *Hum Mutat* 1998;11(1):76-83.
- Livshits LA. [The molecular genetic nature of the mutations responsible for the development in Ukraine of more widely spread forms of neuromuscular pathology and mental retardation with a monogenic nature of the heredity]. *Tsitol Genet* 1998 Jan-Feb;32(1):3-8. (Rus).
- Lo WH, Wang T, Eisensmith R, Woo SL. Molecular basis of PKU in China. *Chin Med Sci J* 1993 Sep;8(3):180-5.
- Lott JW. PKU: a nursing update. *J Pediatr Nurs* 1988 Feb;3(1):29-34.
- Lou HC, Toft PB, Andresen J, Mikkelsen I, Olsen B, Guttler F, Wieslander S, Henriksen O. An occipito-temporal syndrome in adolescents with optimally controlled hyperphenylalaninaemia. *J Inherit Metab Dis* 1992;15(5):687-95.
- Lowe JB. Clinical applications of gene probes in human genetic disease, malignancy, and infectious disease. *Clin Chim Acta* 1986 May 30;157(1):1-32.
- Luder AS, Greene CL. Maternal phenylketonuria and hyperphenylalaninemia: implications for medical practice in the United States. *Am J Obstet Gynecol* 1989 Nov;161(5):1102-5.
- Luke B, Keith LG. The challenge of maternal phenylketonuria screening and treatment. *J Reprod Med* 1990 Jul;35(7):667-73.
- Lyon IC. Maternal phenylketonuria [letter]. *N Z Med J* 1984 Mar 14;97(751):165-6.
- Lyonnet S, Caillaud C, Rey F, Berthelon M, Frezal J, Rey J, Munnich A. Guthrie cards for detection of point mutations in phenylketonuria [letter]. *Lancet* 1988 Aug 27;2(8609):507.
- Lyonnet S, Caillaud C, Rey F, Berthelon M, Frezal J, Rey J, Munnich A. Molecular genetics of phenylketonuria in Mediterranean countries: a mutation associated with partial phenylalanine hydroxylase deficiency. *Am J Hum Genet* 1989 Apr;44(4):511-7.
- Lyonnet S, Melle D, de Braekeleer M, Laframboise R, Rey F, John SW, Berthelon M, Berthelot J, Journel H, Le Marec B, et al. Time and space clusters of the French-Canadian M1V phenylketonuria mutation in France. *Am J Hum Genet* 1992 Jul;51(1):191-6.
- Ma J, Huang S, Wang M, Li H, Lu X, Luo H. [Detection of the mutant phenylalanine hydroxylase gene by dideoxy fingerprinting]. *Chung Hua I Hsueh I Chuan Hsueh Tsa Chih* 1998 Aug;15(4):235-7. (Chi).
- Maas JA, France J, McBride BW. Model of milk protein synthesis. A mechanistic model of milk protein synthesis in the lactating bovine mammary gland. *J Theor Biol* 1997 Aug 7;187(3):363-78.
- MacCready RA, Levy HL. The problem of maternal phenylketonuria. *Am J Obstet Gynecol* 1972 May 1;113(1):121-8.
- Mackey SA, Berlin CM Jr. Effect of dietary aspartame on plasma concentrations of phenylalanine and tyrosine in normal and homozygous phenylketonuric patients. *Clin Pediatr (Phila)* 1992 Jul;31(7):394-9.
- Mahowald MB. A feminist standpoint for genetics. *J Clin Ethics* 1996 Winter;7(4):333-40.
- Mallolas J, Campistol J, Lambruschini N, Vilaseca MA, Cambra FJ, Estivill X, Mila M. Two novel mutations in exon 11 of the PAH gene (V1163del TG and P362T) associated with classic phenylketonuria and mild phenylketonuria. Mutations in brief no. 143. Online. *Hum Mutat* 1998;11(6):482.
- Mallolas J, Mila M, Lambruschini N, Cambra FJ, Campistol J, Vilaseca MA. Biochemical phenotype and its relationship with genotype in

- hyperphenylalaninemia heterozygotes. *Mol Genet Metab* 1999 Jun;67(2):156-61.
- Mallolas J, Vilaseca MA, Campistol J, Lambruschini N, Cambra FJ, Estivill X, Mila M. Mutational spectrum of phenylalanine hydroxylase deficiency in the population resident in Catalonia: genotype-phenotype correlation. *Hum Genet* 1999 Nov;105(5):468-73.
- Marques JM. Phenylketonuria with familial hyperglycinuria. *J Inherit Metab Dis* 1994;17(5):641.
- Martinez A, Knappskog PM, Olafsdottir S, Dorskeland AP, Eiken HG, Svebak RM, Bozzini M, Apold J, Flatmark T. Expression of recombinant human phenylalanine hydroxylase as fusion protein in *Escherichia coli* circumvents proteolytic degradation by host cell proteases. Isolation and characterization of the wild-type enzyme. *Biochem J* 1995 Mar 1;306 (Pt 2):589-97.
- Martinez-Pardo M, Colmenares AR, Garcia MJ, Perez B, Desviat LR, Ugarte M. Phenotype distribution in the Spanish phenylketonuria population and related genotypes. *J Inherit Metab Dis* 1994;17(3):366-8.
- Marvit J. Identification and characterization of a mutation causing phenylketonuria [dissertation]. Waco (TX): Baylor College of Medicine; 1987.
- Marvit J, DiLella AG, Brayton K, Ledley FD, Robson KJ, Woo SL. GT to AT transition at a splice donor site causes skipping of the preceding exon in phenylketonuria. *Nucleic Acids Res* 1987 Jul 24;15(14):5613-28.
- Matalon R, Michals K. Phenylketonuria: screening, treatment and maternal PKU. *Clin Biochem* 1991 Aug;24(4):337-42.
- Matalon R, Michals K, Blau N, Rouse B. Hyperphenylalaninemia due to inherited deficiencies of tetrahydrobiopterin. *Adv Pediatr* 1989;36:67-89.
- Maternal Phenylketonuria Collaborative Study: a status report. *Nutr Rev* 1994 Nov;52(11):390-3.
- Maternal phenylketonuria. Committee on Genetics. *Pediatrics* 1985 Aug;76(2):313-4.
- Matsubara Y, Narisawa K, Tada K. Simple and rapid detection of phenylketonuria mutation tightly linked to haplotype 2 by modified polymerase chain reaction. *J Inherit Metab Dis* 1990;13(5):775-9.
- Matsuda I. [Inborn error of amino acids metabolism--general aspect]. *Ryoikibetsu Shokogun Shirizu* 1998;(18 Pt 1):109-13. (Jpn).
- Matsuoka A. [The course of the past twenty years of mass-screening for congenital metabolic disorders: racial difference in PKU genotypes]. *Rinsho Byori* 1998 Mar;46(3):199-202. (Jpn).
- Matthieu JM. [Maternal phenylketonuria: a misdiagnosed cause of embryopathy or fetal disease]. *Rev Med Suisse Romande* 1994 Oct;114(10):841-3. (Fre).
- McCabe LL, McCabe ERB. Population studies of allele frequencies in single gene disorders: methodological and policy considerations. *Epidemiol Rev* 1997;19(1):52-60.
- McCombe PA, McLaughlin DB, Chalk JB, Brown NN, McGill JJ, Pender MP. Spasticity and white matter abnormalities in adult phenylketonuria. *J Neurol Neurosurg Psychiatry* 1992 May;55(5):359-61.
- McCormack MK. Screening for genetic traits and diseases. *Am Fam Physician* 1981 Oct;24(4):153-66.
- McDonald JD. Biochemical and genetic characterization of HPH-1: an mutation resulting in heritable hyperphenylalaninemia [dissertation]. Manhattan (KS): Kansas State University; 1987. 123 p.
- McDonald JD. The PKU mouse project: its history, potential and implications. *Acta Paediatr Suppl* 1994 Dec;407:122-3.
- McDonald JD, Bode VC. Hyperphenylalaninemia in the hph-1 mouse mutant. *Pediatr Res* 1988 Jan;23(1):63-7.
- McDonald JD, Bode VC, Dove WF, Shedlovsky A. Pahhph-5: a mouse mutant deficient in phenylalanine hydroxylase. *Proc Natl Acad Sci U S A* 1990 Mar;87(5):1965-7.
- McDonald JD, Bode VC, Dove WF, Shedlovsky A. The use of N-ethyl-N-nitrosourea to produce mouse models for human phenylketonuria and hyperphenylalaninemia. *Prog Clin Biol Res* 1990;340C:407-13.
- McDonald JD, Charlton CK. Characterization of mutations at the mouse phenylalanine hydroxylase locus. *Genomics* 1997 Feb 1;39(3):402-5.
- McDonald JD, Cotton RG, Jennings I, Ledley FD, Woo SL, Bode VC. Biochemical defect of the hph-1 mouse mutant is a deficiency in GTP-cyclohydrolase activity. *J Neurochem* 1988 Feb;50(2):655-7.
- McDonald JD, Dyer CA, Gailis L, Kirby ML. Cardiovascular defects among the progeny of mouse phenylketonuria females. *Pediatr Res* 1997 Jul;42(1):103-7.

- McDowall IL, Fisher MJ. Analysis of the 5'-flanking region of the rat phenylalanine hydroxylase gene. *Biochem Soc Trans* 1996 Aug;24(3):424S.
- McDowall IL, Fisher MJ. The immediate 5'-flanking region of the rat phenylalanine hydroxylase-encoding gene. *Gene* 1995 Feb 14;153(2):289-90.
- McDowall IL, Palwala Y, Fisher MJ. Differential effects of streptozotocin-induced diabetes on phenylalanine hydroxylase protein and mRNA abundance in isolated rat liver cells. *Int J Biochem Cell Biol* 1996 Jul;28(7):761-70.
- McHugh PR, McKusick VA, editors. *Genes, brain, and behavior*. New York: Raven Press; 1991. 237 p. (Association for Research in Nervous and Mental Disease Research publications; vol. 69).
- Medical Research Council Working Party on Phenylketonuria. Phenylketonuria due to phenylalanine hydroxylase deficiency: an unfolding story. *BMJ* 1993 Jan 9;306(6870):115-9.
- Meijer H, Hekking M, van den Enden AT, Jongbloed RJ, Schrander-Stumpel CT, Geraedts JP. [Phenylketonuria as a model system for DNA diagnosis of hereditary disorders]. *Ned Tijdschr Geneesk* 1990 Oct 6;134(40):1954-8. Published erratum appears in *Ned Tijdschr Geneesk* 1990 Nov 3;134(44):2168. (Dut).
- Meijer H, Jongbloed RJ, Hekking M, Spaapen LJ, Geraedts JP. RFLP haplotyping and mutation analysis of the phenylalanine hydroxylase gene in Dutch phenylketonuria families. *Hum Genet* 1993 Dec;92(6):588-92.
- Meijer H, Perizonius WR, Geraedts JP. Recovery and identification of DNA sequences harboured in preserved ancient human bones. *Biochem Biophys Res Commun* 1992 Mar 16;183(2):367-74.
- Melle D, Verelst P, Rey F, Berthelon M, Francois B, Munnich A, Lyonnet S. Two distinct mutations at a single BamHI site in phenylketonuria. *J Med Genet* 1991 Jan;28(1):38-40.
- Mercer JF, Grimes A, Jennings I, Cotton RG. Identification of two molecular-mass forms of phenylalanine hydroxylase that segregate independently in rats. Specific association of each form with certain rat strains. *Biochem J* 1984 May 1;219(3):891-8.
- Mercer JF, Hunt SM, Cotton RG. The two molecular weight forms of rat phenylalanine hydroxylase are encoded by different messenger RNAs. *J Biol Chem* 1983 May 10;258(9):5854-7.
- Mercer JF, McAdam W, Chambers GW, Walker ID. The W and L allelic forms of phenylalanine hydroxylase in the rat differ by a threonine to isoleucine substitution. *Biochem J* 1986 Jun 15;236(3):679-83.
- Michels VV, Justice CL. Treatment of phenylketonuria during pregnancy. *Clin Genet* 1982 Feb;21(2):141-4.
- Michiels L, Francois B, Raus J, Vandevyver C. Identification of seven new mutations in the phenylalanine hydroxylase gene, associated with hyperphenylalaninemia in the Belgian population. *Hum Mutat* 1998;Suppl 1:S123-4.
- Michiels L, Francois B, Raus J, Vandevyver C. Rapid identification of PKU-associated mutations by multiplex DGGE analysis of the PAH gene. *J Inher Metab Dis* 1996;19(6):735-8.
- Mihalick SM, Langlois JC, Krienke JD, Dube WV. An olfactory discrimination procedure for mice. *J Exp Anal Behav* 2000; 73(3):305-18.
- Milovanovic DD, Milovanovic L, Vranjesevic D. Serum tryptophan to large neutral amino acid ratio and urinary tryptophan in three patients with phenylketonuria in a family. A clinical and biochemical study. *Adv Exp Med Biol* 1999;467:289-95.
- Milstien S, Holtzman NA, O'Flynn ME, Thomas GH, Butler IJ, Kaufman S. Hyperphenylalaninemia due to dihydropteridine reductase deficiency. Assay of the enzyme in fibroblasts from affected infants, heterozygotes, and in normal amniotic fluid cells. *J Pediatr* 1976 Nov;89(5):763-6.
- Milstien S, Jaffe H, Kowlessur D, Bonner TI. Purification and cloning of the GTP cyclohydrolase I feedback regulatory protein, GFRP. *J Biol Chem* 1996 Aug 16;271(33):19743-51.
- Missiou-Tsagaraki S, Soulpi K, Loumakou M. Phenylketonuria in Greece: 12 years' experience. *J Ment Defic Res* 1988 Aug;32 (Pt 4):271-87.
- Moller HE, Weglage J, Wiedermann D, Ullrich K. Blood-brain barrier phenylalanine transport and individual vulnerability in phenylketonuria. *J Cereb Blood Flow Metab* 1998 Nov;18(11):1184-91.
- Morales G, Requena JM, Jimenez-Ruiz A, Lopez MC, Ugarte M, Alonso C. Sequence and expression of the *Drosophila* phenylalanine hydroxylase mRNA. *Gene* 1990 Sep 14;93(2):213-9.
- Mowat DR, Hayden MC, Thompson SM, Wilcken B. Maternal phenylketonuria: a continuing problem. *Med J Aust* 1999 Jun 21;170(12):592-5. Comment in: *Med J Aust* 1999 Jun 21;170(12):573-4.

- Muntau AC, Beblo S, Koletzko B. [Phenylketonuria and hyperphenylalaninemia]. *Monatsschr Kinderheilkd* 2000;148(2):179-93. (Ger).
- Murphey RM. Phenylketonuria (PKU) and the single gene: an old story retold. *Behav Genet* 1983 Mar;13(2):141-57.
- Nagao M. [Molecular pathology and DNA diagnosis of phenylketonuria and hypermethioninemia]. *Tanpakushitsu Kakusan Koso* 1998 May;43(6):762-9. (Jpn).
- Nagao M. A simple and rapid polymerase chain reaction-based method for detecting a prevalent mutation (R413P) in Japanese phenylketonuria patients. *Acta Paediatr Jpn* 1997 Feb;39(1):6-9.
- Nagasaki Y, Matsubara Y, Takano H, Fujii K, Senoo M, Akanuma J, Takahashi K, Kure S, Hara M, Kanegae Y, Saito I, Narisawa K. Reversal of hypopigmentation in phenylketonuria mice by adenovirus-mediated gene transfer. *Pediatr Res* 1999 Apr;45(4 Pt 1):465-73.
- Nagata S, Maru I, Ishihara F, Misono H, Nagasaki S. Cloning and expression of endo-beta-1,3-glucanase gene from *Flavobacterium dormitator* in *Escherichia coli* and characterization of the gene product. *Agric Biol Chem* 1990 Oct;54(10):2675-80.
- Nagatsu T, Ichinose H. Regulation of pteridine-requiring enzymes by the cofactor tetrahydrobiopterin. *Mol Neurobiol* 1999 Feb;19(1):79-96.
- Nakazato M, Ohi T, Matsukura S. [Trend in molecular biochemical studies on neurological disorders]. *Nippon Rinsho* 1989 Jan;47(1):227-38. (Jpn).
- Neckameyer WS, White K. A single locus encodes both phenylalanine hydroxylase and tryptophan hydroxylase activities in *Drosophila*. *J Biol Chem* 1992 Feb 25;267(6):4199-206.
- Nehls U, Ecke M, Hampp R. Sugar- and nitrogen-dependent regulation of an *Amanita muscaria* phenylalanine ammonium lyase gene. *J Bacteriol* 1999 Mar;181(6):1931-3.
- Nevin NC, Carson NA. Severe mental retardation due to maternal phenylketonuria. *Ulster Med J* 1982;51(2):133-5.
- Nicolini H, Cruz C, Camarena B, Fernanda Merino M, Bilbao G, Vela M, Velazquez A, Perez B, Desviat L, Ugarte M. Molecular analysis of the phenylalanine hydroxylase gene in Mexican phenylketonuric patients. *Arch Med Res* 1995 Spring;26(1):53-7.
- Niederwieser A, Curtius HC, Gitzelmann R, Otten A, Baerlocher K, Blehova B, Berlow S, Grobe H, Rey F, Schaub J, Scheibenreiter S, Schmidt H, Visconti M. Excretion of pterins in phenylketonuria and phenylketonuria variants. *Helv Paediatr Acta* 1980 Sep;35(4):335-42.
- Niederwieser A, Shintaku H, Leimbacher W, Curtius HC, Hyaneck J, Zeman J, Endres W. Peripheral tetrahydrobiopterin deficiency with hyperphenylalaninaemia due to incomplete 6-pyruvoyl tetrahydropterin synthase deficiency or heterozygosity. *Eur J Pediatr* 1987 May;146(3):228-32.
- Nielsen KB. [Dietary treatment of women with Folling's disease. A review of current experiences and future perspectives]. *Ugeskr Laeger* 1985 Jan 21;147(4):246-9. (Dan).
- Nishimiya Y, Tsumoto K, Shiroishi M, Yutani K, Kumagai I. Thermodynamic consequences of grafting enhanced affinity toward the mutated antigen onto an antibody. The case of anti-lysozyme antibody HyHEL-10. *J Biol Chem* 2000 Apr 28;275(17):12813-20.
- Nowacki P, Byck S, Prevost L, Scriver CR. The PAH mutation analysis consortium database: update 1996. *Nucleic Acids Res* 1997 Jan 1;25(1):139-42.
- Nowacki PM, Byck S, Prevost L, Scriver CR. PAH Mutation Analysis Consortium Database: 1997. Prototype for relational locus-specific mutation databases. *Nucleic Acids Res* 1998 Jan 1;26(1):220-5.
- Nyhan WL. Understanding inherited metabolic disease. *Clin Symp* 1980;32(5):1-36.
- O'Neill CA, Eisensmith RC, Croke DT, Naughten ER, Cahalane SF, Woo SL. Molecular analysis of PKU in Ireland. *Acta Paediatr Suppl* 1994 Dec;407:43-4.
- Okano Y, Asada M, Kang Y, Nishi Y, Hase Y, Oura T, Isshiki G. Molecular characterization of phenylketonuria in Japanese patients. *Hum Genet* 1998 Nov;103(5):613-8.
- Okano Y, Eisensmith RC, Dasovich M, Wang T, Guttler F, Woo SL. A prevalent missense mutation in Northern Europe associated with hyperphenylalaninaemia. *Eur J Pediatr* 1991 Mar;150(5):347-52.
- Okano Y, Eisensmith RC, Guttler F, Lichter-Konecki U, Konecki DS, Trefz FK, Dasovich M, Wang T, Henriksen K, Lou H, et al. Molecular basis of phenotypic heterogeneity in phenylketonuria. *N Engl J Med* 1991 May 2;324(18):1232-8. Comment in: *N Engl J Med* 1991 May 2;324(18):1280-1.
- Okano Y, Hase Y, Lee DH, Furuyama J, Shintaku H, Oura T, Isshiki G. Frequency and distribution of phenylketonuric mutations in Orientals. *Hum Mutat* 1992;1(3):216-20.

- Okano Y, Hase Y, Lee DH, Takada G, Shigematsu Y, Oura T, Isshiki G. Molecular and population genetics of phenylketonuria in Orientals: correlation between phenotype and genotype. *J Inherit Metab Dis* 1994;17(1):156-9.
- Okano Y, Hase Y, Shintaku H, Araki K, Furuyama J, Oura T, Isshiki G. Molecular characterization of phenylketonuric mutations in Japanese by analysis of phenylalanine hydroxylase mRNA from lymphoblasts. *Hum Mol Genet* 1994 Apr;3(4):659.
- Okano Y, Isshiki G. Newborn mass screening and molecular genetics of phenylketonuria in east Asia. *Southeast Asian J Trop Med Public Health* 1995;26 Suppl 1:123-9.
- Okano Y, Oura T. [DNA diagnosis for inherited metabolic disorders]. *Nippon Rinsho* 1992 Jul;50(7):1536-41. (Jpn).
- Okano Y, Wang T, Eisensmith RC, Guttler F, Woo SL. Recurrent mutation in the human phenylalanine hydroxylase gene. *Am J Hum Genet* 1990 May;46(5):919-24.
- Okano Y, Wang T, Eisensmith RC, Longhi R, Riva E, Giovannini M, Cerone R, Romano C, Woo SL. Phenylketonuria missense mutations in the Mediterranean. *Genomics* 1991 Jan;9(1):96-103.
- Okano Y, Wang T, Eisensmith RC, Steinmann B, Gitzelmann R, Woo SL. Missense mutations associated with RFLP haplotypes 1 and 4 of the human phenylalanine hydroxylase gene. *Am J Hum Genet* 1990 Jan;46(1):18-25.
- Onishi A, Liotta LJ, Benkovic SJ. Cloning and expression of *Chromobacterium violaceum* phenylalanine hydroxylase in *Escherichia coli* and comparison of amino acid sequence with mammalian aromatic amino acid hydroxylases. *J Biol Chem* 1991 Oct 5;266(28):18454-9.
- Oppliger T, Thony B, Kluge C, Matasovic A, Heizmann CW, Ponzzone A, Spada M, Blau N. Identification of mutations causing 6-pyruvoyl-tetrahydropterin synthase deficiency in four Italian families. *Hum Mutat* 1997;10(1):25-35.
- Oppliger T, Thony B, Nar H, Burgisser D, Huber R, Heizmann CW, Blau N. Structural and functional consequences of mutations in 6-pyruvoyltetrahydropterin synthase causing hyperphenylalaninemia in humans. Phosphorylation is a requirement for in vivo activity. *J Biol Chem* 1995 Dec 8;270(49):29498-506.
- Orgad S, Yaar L, Barkai G, Avigad S, Lieberman A, Goldmann B, Gazit E. [Carrier detection and prenatal diagnosis in phenylketonuria, cystic fibrosis and adrenal hyperplasia use of molecular biology techniques]. *Harefuah* 1989 Mar 15;116(6):297-300. (Heb).
- Ounap K, Lillevali H, Klaassen T, Metspalu A, Sitska M. The incidence and characterization of phenylketonuric patients in Estonia. *J Inherit Metab Dis* 1996;19(3):381-2.
- Owada M. [Phenylketonuria (phenylalanine hydroxylase deficiency)]. *Ryoikibetsu Shokogun Shirizu* 1998;(18 Pt 1):114-8. (Jpn).
- Ozalp I, Coskun T, Ozguc M, Tokatli A, Yalaz K, Vanli L, Yilmaz E, Erbay A. Genetic and neurological evaluation of untreated and late-treated patients with phenylketonuria. *J Inherit Metab Dis* 1994;17(3):371.
- Ozand PT, Devol EB, Gascon GG. Neurometabolic diseases at a national referral center: five years experience at the King Faisal Specialist Hospital and Research Centre. *J Child Neurol* 1992 Apr;7 Suppl:S4-11.
- Ozguc M, Ozalp I, Coskun T, Yilmaz E, Erdem H, Ayter S. Frequency of the IVS-10nt546 mutation in 44 Turkish phenylketonuria patients. *Turk J Pediatr* 1993 Jan-Mar;35(1):11-4.
- Ozguc M, Ozalp I, Coskun T, Yilmaz E, Erdem H, Ayter S. Mutation analysis in Turkish phenylketonuria patients. *J Med Genet* 1993 Feb;30(2):129-30.
- Ozguc M, Yilmaz E, Erdem H, Coskun T, Tokatli A, Ozalp I. Association between mutations and the variable number tandem repeat alleles in a sample of Turkish phenylketonuria patients. *J Inherit Metab Dis* 1994;17(3):373-4.
- Palmer CG, Miles JH, Howard-Peebles PN, Magenis RE, Patil S, Friedman JM. Fetal karyotype following ascertainment of fetal anomalies by ultrasound. *Prenat Diagn* 1987 Oct;7(8):551-5.
- Park YS, Seoung CS, Lee SW, Oh KH, Lee DH, Yim J. Identification of three novel mutations in Korean phenylketonuria patients: R53H, N207D, and Y325X. *Hum Mutat* 1998;Suppl 1:S121-2.
- Pasquo A, Britton KL, Baker PJ, Brearley G, Hinton RJ, Moir AJ, Stillman TJ, Rice DW. Crystallization of NAD⁺-dependent phenylalanine dehydrogenase from *Nocardia sp239*. *Acta Crystallogr D Biol Crystallogr* 1998 Mar 1;54 (Pt 2):269-72.
- Patterson RE, Eaton DL, Potter JD. The genetic revolution: change and challenge for the dietetics profession. *J Am Diet Assoc* 1999 Nov;99(11):1412-20.
- Paul DB. What is a genetic test, and why does it matter? *Endeavour* 1999;23(4):159-61.

- Peng H, Armentano D, MacKenzie-Graham L, Shen RF, Darlington G, Ledley FD, Woo SL. Retroviral-mediated gene transfer and expression of human phenylalanine hydroxylase in primary mouse hepatocytes. *Proc Natl Acad Sci U S A* 1988 Nov;85(21):8146-50.
- Pennington BF. Genetics of learning disabilities. *J Child Neurol* 1995 Jan;10 Suppl 1:S69-77.
- Pennington BF, Smith SD. Genetic influences on learning disabilities and speech and language disorders. *Child Dev* 1983 Apr;54(2):369-87.
- Penrose LS. Phenylketonuria--a problem in eugenics. *Ann Hum Genet* 1998 May;62 (Pt 3):193-202.
- Perez B, Desviat LR, De Lucca M, Cornejo V, Raimann E, Ugarte M. Molecular characterization of phenylalanine hydroxylase deficiency in Chile. Mutations in brief no. 243. Online. *Hum Mutat* 1999;13(6):503.
- Perez B, Desviat LR, De Lucca M, Schmidt B, Loghin-Grosso N, Giugliani R, Pires RF, Ugarte M. Mutation analysis of phenylketonuria in south Brazil. *Hum Mutat* 1996;8(3):262-4.
- Perez B, Desviat LR, De Lucca M, Ugarte M. Spectrum and origin of phenylketonuria mutations in Spain. *Acta Paediatr Suppl* 1994 Dec;407:34-6.
- Perez B, Desviat LR, Die M, Cornejo V, Chamoles NA, Nicolini H, Ugarte M. Presence of the Mediterranean PKU mutation IVS10 in Latin America. *Hum Mol Genet* 1993 Aug;2(8):1289-90.
- Perez B, Desviat LR, Die M, Ugarte M. Mutation analysis of phenylketonuria in Spain: prevalence of two Mediterranean mutations. *Hum Genet* 1992 May;89(3):341-2.
- Perez B, Desviat LR, Garcia MJ, Ugarte M. Different phenotypic manifestations associated with identical phenylketonuria genotypes in two Spanish families. *J Inherit Metab Dis* 1994;17(3):377-8.
- Perez B, Desviat LR, Ugarte M. Analysis of the phenylalanine hydroxylase gene in the Spanish population: mutation profile and association with intragenic polymorphic markers. *Am J Hum Genet* 1997 Jan;60(1):95-102.
- Perez B, Desviat LR, Ugarte M. Expression analysis of mutation P244L, which causes mild hyperphenylalaninemia. *Hum Mutat* 1995;5(2):188-90.
- Persha AJ. Early identification and prevention of mental retardation. *ICCW News B* 1992 Jan-Mar;40(1):9-12.
- Peterson AG, Platt LJ, Berry HK, Schafer IA, Quilty JF. Maternal PKU--a problem born of success. *Ohio State Med J* 1984 May;80(5):397-8.
- Phua SH, Wood NJ. A high-frequency TaqI polymorphism at the ovine phenylalanine hydroxylase (PAH) locus. *Anim Genet* 1996 Apr;27(2):124.
- Pickering N, Billings P. Not my problem [letter]. *Hastings Cent Rep* 1993 Jan-Feb;23(1):45-6.
- Piedrafita AC, Martinez-Ramirez AC, Silva FJ. A genetic analysis of aromatic amino acid hydroxylases involvement in DOPA synthesis during *Drosophila* adult development. *Insect Biochem Mol Biol* 1994 Jun;24(6):581-8. Published erratum appears in *Insect Biochem Mol Biol* 1995 Jan;25(1):151.
- Pietz J. Neurological aspects of adult phenylketonuria. *Curr Opin Neurol* 1998 Dec;11(6):679-88.
- Pinarbasi E, Kan MS, Duran C, Ford GC, Hornby DP. Substitution of the conserved phenylalanine in the S-adenosyl-L-methionine binding site of M.MspI with tyrosine modifies the kinetic properties of the enzyme. *Biol Chem* 1998 Apr-May;379(4-5):591-4.
- Pitt D. The natural history of untreated phenylketonuria. *Med J Aust* 1971 Feb 13;1(7):378-83.
- Pittard J. The various strategies within the TyrR regulation of *Escherichia coli* to modulate gene expression. *Genes Cells* 1996 Aug;1(8):717-25.
- Pogge v Strandmann E, Senkel S, Ryffel GU. Ectopic pigmentation in *Xenopus* in response to DCoH/PCD, the cofactor of HNF1 transcription factor/pterin-4alpha-carbinolamine dehydratase. *Mech Dev* 2000;91(1-2):53-60.
- Pogson D. Issues for consideration in dihydropteridine reductase (DHPR) deficiency: a variant form of hyperphenylalaninaemia. *J Intellect Disabil Res* 1997 Jun;41 (Pt 3):208-14.
- Pollak S, Vardy PA, Barzilai A. [Maternal phenylketonuria syndrome]. *Harefuah* 1981 Jan 15;100(2):78-80. (Heb).
- Pontoglio M, Barra J, Hadchouel M, Doyen A, Kress C, Bach JP, Babinet C, Yaniv M. Hepatocyte nuclear factor 1 inactivation results in hepatic dysfunction, phenylketonuria, and renal Fanconi syndrome. *Cell* 1996 Feb 23;84(4):575-85.
- Pontoglio M, Faust DM, Doyen A, Yaniv M, Weiss MC. Hepatocyte nuclear factor 1alpha gene inactivation impairs chromatin remodeling and demethylation of the phenylalanine hydroxylase gene. *Mol Cell Biol* 1997 Sep;17(9):4948-56.

- Ponzone A, Guardamagna O, Ferraris S, Bracco G, Niederwieser A, Cotton RG. Two mutations of dihydropteridine reductase deficiency. *Arch Dis Child* 1988 Feb;63(2):154-7.
- Ponzone A, Spada M, de Sanctis L, Dianzani I. Phenotyping of phenylketonuric patients by oral phenylalanine loading [letter]. *Eur J Pediatr* 1996 Jun;155(6):523-5. Comment on: *Eur J Pediatr* 1995 Jul;154(7):551-6.
- Popescu A, Andrian T, Guttler F, Guldborg P. Genotype-phenotype correlation in 11 Romanian PKU families. *J Inher Metab Dis* 1994;17(3):374-5.
- Popescu T, Blazkova M, Kozak L, Jebeleanu G, Popescu A. Mutation spectrum and phenylalanine hydroxylase RFLP/VNTR background in 44 Romanian phenylketonuric alleles. *Hum Mutat* 1998;12(5):314-9.
- Popescu T, Popescu A, Kozak L, Blazkova M, Jebeleanu G. R252W/E178G phenylalanine hydroxylase genotype in a Romanian non-PKU hyperphenylalaninaemic patient [letter]. *Acta Paediatr* 1998 Oct;87(10):1103-4.
- Porter IH. Control of hereditary disorders. *Annu Rev Public Health* 1982;3:277-319.
- Potkin SG, Cannon-Spoor HE, DeLisi LE, Neckers LM, Wyatt RJ. Plasma phenylalanine, tyrosine, and tryptophan in schizophrenia. *Arch Gen Psychiatry* 1983 Jul;40(7):749-52.
- Prasad C, Dalton L, Levy H. Role of diet therapy in management of hereditary metabolic diseases. *Nutr Res* 1998 Feb;18(2):391-402.
- Primrose DA. Phenylketonuria with normal intelligence. *J Ment Defic Res* 1983 Dec;27 (Pt 4):239-46.
- Pueschel SM. Maternal phenylketonuria. *Soc Biol* 1985 Spring-Summer;32(1-2):31-44.
- Pueschel SM, Herman R, Groden G. Brief report: screening children with autism for fragile-X syndrome and phenylketonuria. *J Autism Dev Disord* 1985 Sep;15(3):335-8.
- Puglisi-Allegra S, Cabib S, Pascucci T, Ventura R, Cali F, Romano V. Dramatic brain aminergic deficit in a genetic mouse model of phenylketonuria. *Neuroreport* 2000 Apr 27;11(6):1361-4.
- Radeva B. Relation between phenotype and genotype in phenylketonuric patients from Bulgaria. *J Inher Metab Dis* 1993;16(1):158-9.
- Rall JE. Where are the genes specifying mental illness? *J Nerv Ment Dis* 1998 Nov;186(11):722-3.
- Ramus SJ, Cotton RG. Mutations Ivs4nt1, 47delCT, and G148S identified in the phenylalanine hydroxylase gene by RT-PCR of illegitimate transcripts and chemical cleavage of mismatch. *Hum Mutat* 1995;6(3):250-1.
- Ramus SJ, Cotton RG. Polymorphism in the 3' untranslated region of the phenylalanine hydroxylase gene detected by enzyme mismatch cleavage: evolution of haplotypes. *Hum Genet* 1995 Dec;96(6):741-3.
- Ramus SJ, Forrest SM, Cotton RG. Illegitimate transcription of phenylalanine hydroxylase for detection of mutations in patients with phenylketonuria. *Hum Mutat* 1992;1(2):154-8.
- Ramus SJ, Forrest SM, Pitt DB, Saleeba JA, Cotton RG. Comparison of genotype and intellectual phenotype in untreated PKU patients. *J Med Genet* 1993 May;30(5):401-5.
- Ramus SJ, Forrest SM, Pitt DD, Cotton RG. Genotype and intellectual phenotype in untreated phenylketonuria patients. *Pediatr Res* 1999 Apr;45(4 Pt 1):474-81.
- Ramus SJ, Forrest SM, Saleeba JA, Cotton RG. CpG hotspot causes second mutation in codon 408 of the phenylalanine hydroxylase gene. *Hum Genet* 1992 Sep-Oct;90(1-2):147-8.
- Ramus SJ, Treacy EP, Cotton RG. Characterization of phenylalanine hydroxylase alleles in untreated phenylketonuria patients from Victoria, Australia: origin of alleles and haplotypes. *Am J Hum Genet* 1995 May;56(5):1034-41.
- Raper SE, Wilson JM. Cell transplantation in liver-directed gene therapy. *Cell Transplant* 1993 Sep-Oct;2(5):381-400; discussion 407-10. Comment in: *Cell Transplant* 1993 Sep-Oct;2(5):401-3; *Cell Transplant* 1993 Sep-Oct;2(5):405-6.
- Reiss MJ. The ethics of genetic research on intelligence. *Bioethics* 2000;14(1):1-15.
- Rey F, Abadie V, Lyonnet S, Berthelon M, Caillaud C, Melle D, Labrune P, Saudubray JM, Munnich A, Rey J. [Phenotypic expression of 12 mutations of the phenylalanine hydroxylase gene]. *Arch Fr Pediatr* 1992 Oct;49(8):705-10. (Fre).
- Rey F, Berthelon M, Caillaud C, Lyonnet S, Abadie V, Blandin-Savoja F, Feingold J, Saudubray JM, Frezal J, Munnich A, et al. Clinical and molecular heterogeneity of phenylalanine hydroxylase deficiencies in France. *Am J Hum Genet* 1988 Dec;43(6):914-21.
- Rey F, Berthelon M, Munnich A, Frezal J, Rey J. [Prenatal screening for phenylketonuria in 2 families

- by trophoblast biopsy]. *Arch Fr Pediatr* 1987 Oct;44(8):565-8. (Fre).
- Rey F, Munnich A, Lyonnet S, Rey J. [Classification and heterogeneity of hyperphenylalaninemias linked to a phenylalanine hydroxylase deficiency]. *Arch Fr Pediatr* 1987;44 Suppl 1:639-42. (Fre).
- Rey F, Rey J. [Catalog of mutations of the phenylalanine hydroxylase gene]. *Arch Fr Pediatr* 1992 Jan;49(1):63-5. (Fre).
- Rey F, Saudubray JM, Leeming RJ, Niederwieser A, Curtius HC, Rey J. [Partial deficiency of tetrahydrobiopterin]. *Arch Fr Pediatr* 1983;40 Suppl 1:237-41. (Fre).
- Rey J, Rey F. [What can we expect from identification of mutations of the phenylalanine hydroxylase gene? (editorial)]. *Arch Fr Pediatr* 1992 Jan;49(1):1-3. (Fre).
- Richardson MA, Guttler F, Guldborg P, Reilly M, Suckow R, Read L, Chao H, Clelland J. Phenylalanine hydroxylase gene mutation associated with schizophrenia and African-American ethnic status. *Schizophr Res* 1999;36:95.
- Riess O, Michel A, Berger W, Nurnberg P, Epplen JT, Speer A, Coutelle C. RFLP-discordance within the human phenylalanine hydroxylase locus. *Hum Genet* 1989 Sep;83(2):199-201.
- Riess O, Michel A, Speer A, Cobet G, Coutelle C. Introduction of genomic diagnosis of classical phenylketonuria to the health care system of the German Democratic Republic. *Clin Genet* 1987 Oct;32(4):209-15.
- Riess O, Michel A, Speer A, Meiske W, Cobet G, Coutelle C. Linkage disequilibrium between RFLP haplotype 2 and the affected PAH allele in PKU families from the Berlin area of the German Democratic Republic. *Hum Genet* 1988 Apr;78(4):343-6.
- Rittinger O, Plochl E, Jarosch E. [Maternal phenylketonuria]. *Padiatr Padol* 1984;19(1):87-92. (Ger).
- Rivera I, Cabral A, Almeida M, Leandro P, Carmona C, Eusebio F, Tasso T, Vilarinho L, Martins E, Lechner MC, de Almeida IT, Konecki DS, Lichter-Konecki U. The correlation of genotype and phenotype in Portuguese hyperphenylalaninemic patients. *Mol Genet Metab* 2000 Mar;69(3):195-203.
- Rivera I, Leandro P, Lichter-Konecki U, de Almeida IT, Lechner MC. Relative frequency of IVS10nt546 mutation in a Portuguese phenylketonuric population. *Hum Mutat* 1997;9(3):272-3.
- Rivera I, Leandro P, Lichter-Konecki U, Tavares de Almeida I, Lechner MC. Population genetics of hyperphenylalaninaemia resulting from phenylalanine hydroxylase deficiency in Portugal. *J Med Genet* 1998 Apr;35(4):301-4.
- Robertson M. Towards a medical eugenics? [editorial]. *BMJ* 1984 Feb 11;288(6415):429-30.
- Robson KJ, Beattie W, James RJ, Cotton RC, Morgan FJ, Woo SL. Sequence comparison of rat liver phenylalanine hydroxylase and its cDNA clones. *Biochemistry* 1984 Nov 20;23(24):5671-5.
- Robson KJ, Chandra T, MacGillivray RT, Woo SL. Polysome immunoprecipitation of phenylalanine hydroxylase mRNA from rat liver and cloning of its cDNA. *Proc Natl Acad Sci U S A* 1982 Aug;79(15):4701-5.
- Rodriguez B, Torres N, Rincon AR, Bourges H, Panduro A, Tovar AR. Hepatic phenylalanine-hydroxylase and tyrosine-aminotransferase mRNA levels in rats adapted to diets with different concentrations of protein. *Rev Invest Clin* 1996 Nov-Dec;48(6):413-9.
- Romano V, Cali F, Guldborg P, Guttler F, Indelicato A, Bosco P, Ceratto N. Association between haplotypes, hind III-VNTR alleles and mutations at the PAH locus in Sicily. *Acta Paediatr Suppl* 1994 Dec;407:39-40.
- Romano V, Ceratto N, Chiavetta V, Bosco P. Identification of two new phenylalanine hydroxylase alleles in Sicilian phenylketonuric families. *J Inherit Metab Dis* 1993;16(3):599-601.
- Romano V, Dianzani I, Ponzone A, Zammarchi E, Eisensmith R, Ceratto N, Bosco P, Indelicato A. Prenatal diagnosis by minisatellite analysis in Italian families with phenylketonuria. *Prenat Diagn* 1994 Oct;14(10):959-62.
- Romano V, Guldborg P, Guttler F, Meli C, Mollica F, Pavone L, Giovannini M, Riva E, Biasucci G, Luotti D, Palillo L, Cali F, Ceratto N, Anello G, Bosco P. PAH deficiency in Italy: correlation of genotype with phenotype in the Sicilian population. *J Inherit Metab Dis* 1996;19(1):15-24.
- Romeo G, Menozzi P, Ferlini A, Prosperi L, Cerone R, Scalisi S, Romano C, Antonozzi I, Riva E, Piceni Sereni L, et al. Incidence of classic PKU in Italy estimated from consanguineous marriages and from neonatal screening. *Clin Genet* 1983 Nov;24(5):339-45.
- Romstad A, Guldborg P, Blau N, Guttler F. Single-step mutation scanning of the 6-pyruvoyltetrahydropterin synthase gene in patients

- with hyperphenylalaninemia. *Clin Chem* 1999 Dec;45(12):2102-8.
- Rose S. DNA in medicine. Human perfectibility. *Lancet* 1984 Dec 15;2(8416):1380-3.
- Ross LJ. Developmental disabilities: genetic implications. *J Obstet Gynecol Neonatal Nurs* 1994 Jul-Aug;23(6):502-5.
- Rossiter JP, Johnson TR. Management of genetic disorders during pregnancy. *Obstet Gynecol Clin North Am* 1992 Dec;19(4):801-13.
- Rottoli A, Gianni ML, Verduci E, Biondi ML, Fiori L, Giovannini M, Riva E. Should genetic analysis in newborn screening and a heterozygote test for hyperphenylalaninaemia be recommended? An Italian study. *J Med Screen* 1999;6(4):193-4.
- Rouse B, Matalon R, Koch R, Azen C, Levy H, Hanley W, Trefz F, de la Cruz F. Maternal phenylketonuria syndrome: congenital heart defects, microcephaly, and developmental outcomes. *J Pediatr* 2000 Jan;136(1):57-61. Comment in: *J Pediatr* 2000 Jan;136(1):12-3.
- Rowley PT. Genetic screening: marvel or menace? *Science* 1984 Jul 13;225(4658):138-44.
- Rozen R, Mascisch A, Lambert M, Laframboise R, Sriver CR. Mutation profiles of phenylketonuria in Quebec populations: evidence of stratification and novel mutations. *Am J Hum Genet* 1994 Aug;55(2):321-6.
- Ruiz-Vazquez P, Moulard M, Silva FJ. Structure of the phenylalanine hydroxylase gene in *Drosophila melanogaster* and evidence of alternative promoter usage. *Biochem Biophys Res Commun* 1996 Aug 5;225(1):238-42.
- Ruiz-Vazquez P, Silva FJ. Aberrant splicing of the *Drosophila melanogaster* phenylalanine hydroxylase pre-mRNA caused by the insertion of a B104/roo transposable element in the Henna locus. *Insect Biochem Mol Biol* 1999 Apr;29(4):311-8.
- Runge DM, Runge D. [Somatic gene therapy. Initial clinical applications and current research approach]. *Fortschr Med* 1995 Aug 30;113(24):337-40. Comment in: *Fortschr Med* 1995 Aug 30;113(24):341. (Ger).
- Ruzickova S, Kozak L, Blazkova M, Kapras J, St'astna S. [Mutation of the phenylalanine hydroxylase gene in the population of central Bohemia. Relation to the clinical picture of phenylketonuria]. *Cas Lek Cesk* 1997 May 7;136(9):282-5. (Cze).
- Ryan AA, Acosta PB, Yannicelli S. Mutations in the phenylalanine hydroxylase gene: implications for teaching physical anthropology. *Am J Hum Biol* 1999;11:167.
- Saborio M. Experience in providing genetic services in Costa Rica. *Birth Defects Orig Artic Ser* 1992;28(3):96-102.
- Safos S, Chang TM. Enzyme replacement therapy in ENU2 phenylketonuric mice using oral microencapsulated phenylalanine ammonia-lyase: a preliminary report. *Artif Cells Blood Substit Immobil Biotechnol* 1995;23(6):681-92.
- Safronova EE, Annenkov GA. [Modification of Ayling's method for determining phenylalanine hydroxylase activity]. *Lab Delo* 1982;(5):296-9. (Rus).
- Safronova EE, Rybakova NA, Annenkov GA. [Use of modified Ayling's method for detection of homozygotes and heterozygotes for phenylketonuria gene]. *Vopr Med Khim* 1982 May-Jun;28(3):70-3. (Rus).
- Saito T. An expected decrease in the incidence of autosomal recessive disease due to decreasing consanguineous marriages. *Genet Epidemiol* 1988;5(6):421-32.
- Saliba Z, Bah G, Martin D, Abadie V, Azar Z, Fraisse A, Sidi D, Kachaner J, Bonnet D. [Pseudo-inherited form of left heart obstructive defects revealing maternal phenylketonuria]. *Arch Mal Coeur Vaiss* 2000 May;93(5):649-52. (Fre).
- Salize HJ, Funders-Bucker B, Knorrek U, Kolbe S, Pietsch V, Seidlitz G, Ullrich K, Trefz FK. [Maternal phenylketonuria. Problems in detecting and risk educating identified females]. *Monatsschr Kinderheilkd* 1992 Jan;140(1):42-6. (Ger).
- Salomon F, Fagioli I, Rey F, Salzarulo P. [EEG sleep activity in a phenylketonuric child of the 'new variant' type, before and after treatment with 5-HTP and L-DOPA (author's transl)]. *Rev Electroencephalogr Neurophysiol Clin* 1981 Nov;11(2):212-7. (Fre).
- Sanford YM, Orias E. Phenylketonuric Tetrahymena: phenylalanine hydroxylase mutants and other tyrosine auxotrophs. *Proc Natl Acad Sci U S A* 1981 Dec;78(12):7614-8.
- Santos M, Kuzmin AI, Eisensmith RC, Goltsov AA, Woo SL, Barrantes R, de Cespedes C. Phenylketonuria in Costa Rica: preliminary spectrum of PAH mutations and their associations with highly polymorphic haplotypes. *Hum Hered* 1996 May-Jun;46(3):128-31.
- Saraiva JM, Seakins JW, Smith I. Plasma phenylalanine and tyrosine levels revisited in

- heterozygotes for hyperphenylalaninaemia. *J Inherit Metab Dis* 1993;16(1):105-9.
- Sardharwalla IB, Wraith JE. A clinician's view of the mass screening of the newborn for inherited diseases: current practice and future considerations. *J Inherit Metab Dis* 1989;12 Suppl 1:55-63.
- Sarkissian CN, Boulais DM, McDonald JD, Scriver CR. A heteroallelic mutant mouse model: A new orthologue for human hyperphenylalaninemia. *Mol Genet Metab* 2000 Mar;69(3):188-94.
- Sarkissian CN, Scriver CR, Mamer OA. Measurement of phenyllactate, phenylacetate, and phenylpyruvate by negative ion chemical ionization-gas chromatography/mass spectrometry in brain of mouse genetic models of phenylketonuria and non-phenylketonuria hyperphenylalaninemia. *Anal Biochem* 2000 May 1;280(2):242-9.
- Sarkissian CN, Shao Z, Blain F, Peevers R, Su H, Heft R, Chang TM, Scriver CR. A different approach to treatment of phenylketonuria: phenylalanine degradation with recombinant phenylalanine ammonia lyase. *Proc Natl Acad Sci U S A* 1999 Mar 2;96(5):2339-44. Comment in: *Proc Natl Acad Sci U S A* 1999 Mar 2;96(5):1811-3.
- Sartorio R, Greco L, Carrozzo R, Budillon C, Andria G. A simplified test to detect PKU heterozygotes by discriminant analysis in mentally retarded children and their mothers. *Clin Genet* 1988 Apr;33(4):241-5.
- Sato T, Imura E, Murata A, Minami S, Okabe T, Ohno I. Effects of maternal phenylalanine or tyrosine hydroxylase inhibition on postnatal maturation of catecholamine and amino acid metabolism in rats. *Acta Paediatr Jpn* 1988 Feb;30(1):56-62.
- Sayle AE, Cooper GS, Savitz DA. Menstrual and reproductive history of mothers of galactosemic children. *Fertil Steril* 1996 Mar;65(3):534-8.
- Schallreuter KU, Wood JM, Ziegler I, Lemke KR, Pittelkow MR, Lindsey NJ, Gutlich M. Defective tetrahydrobiopterin and catecholamine biosynthesis in the depigmentation disorder vitiligo. *Biochim Biophys Acta* 1994 May 25;1226(2):181-92.
- Schallreuter KU, Zschiesche M, Moore J, Panske A, Hibberts NA, Herrmann FH, Metelmann HR, Sawatzki J. In vivo evidence for compromised phenylalanine metabolism in vitiligo. *Biochem Biophys Res Commun* 1998 Feb 13;243(2):395-9.
- Scherer-Opplinger T, Matasovic A, Laufs S, Levy HL, Quackenbush EJ, Blau N, Thony B. Dominant negative allele (N47D) in a compound heterozygote for a variant of 6-pyruvoyltetrahydropterin synthase deficiency causing transient hyperphenylalaninemia. *Hum Mutat* 1999;13(4):286-9.
- Schuler A, Somogyi C, Mate M, Pataki L, Toros I, Woo SL, Eisensmith RC, Fekete G. Cognitive development related to metabolic phenotype and mutation genotype in 25 Hungarian patients with phenylketonuria. *J Inherit Metab Dis* 1994;17(3):372. Published erratum appears in *J Inherit Metab Dis* 1994;17(6):651.
- Schuster B, Retey J. The mechanism of action of phenylalanine ammonia-lyase: the role of prosthetic dehydroalanine. *Proc Natl Acad Sci U S A* 1995 Aug 29;92(18):8433-7.
- Schweitzer LB, Desnick RJ. Inherited metabolic diseases: advances in delineation, diagnosis, and treatment. *Birth Defects Orig Artic Ser* 1983;19(5):39-71.
- Scriver CR. Child health, the genome project and phenylketonuria. *Turk J Pediatr* 1993 Jul-Sep;35(3):227-37.
- Scriver CR. Human biochemical genetics: a view on individuality. In: Armendares S, Lisker R, editors. *Human genetics*. Amsterdam: Excerpta Medica; 1977. p. 142-54.
- Scriver CR. Mutants: consumers with special needs. *Nutr Rev* 1971 Jul;29(7):155-8.
- Scriver CR. An ongoing debate over phenylalanine hydroxylase deficiency in phenylketonuria [editorial]. *J Clin Invest* 1998 Jun 15;101(12):2613-4.
- Scriver CR. Phenylketonuria--genotypes and phenotypes [editorial]. *N Engl J Med* 1991 May 2;324(18):1280-1. Comment on: *N Engl J Med* 1991 May 2;324(18):1232-8.
- Scriver CR. PKU and beyond: when do costs exceed benefits? *Pediatrics* 1974 Nov;54(5):616-9.
- Scriver CR. Realized and potential neutralization of mutant genes in man by nutritional selection. *Fed Proc* 1976 Sep;35(11):2286-90.
- Scriver CR. Science, medicine and phenylketonuria. *Acta Paediatr Suppl* 1994 Dec;407:11-8.
- Scriver CR. Whatever happened to PKU? *Clin Biochem* 1995 Apr;28(2):137-44.
- Scriver CR, Byck S, Prevost L, Hoang L. The phenylalanine hydroxylase locus: a marker for the history of phenylketonuria and human genetic diversity. *PAH Mutation Analysis Consortium*. *Ciba Found Symp* 1996;197:73-90; discussion 90-6.
- Scriver CR, Clow CL. Avoiding phenylketonuria: why parents seek prenatal diagnosis. *J Pediatr* 1988 Sep;113(3):495-7.

- Scriver CR, Clow CL. Phenylketonuria and other phenylalanine hydroxylation mutants in man. *Annu Rev Genet* 1980;14:179-202.
- Scriver CR, Clow CL. Phenylketonuria: epitome of human biochemical genetics (first of two parts). *N Engl J Med* 1980 Dec 4;303(23):1336-42.
- Scriver CR, Clow CL. Phenylketonuria: epitome of human biochemical genetics (second of two parts). *N Engl J Med* 1980 Dec 11;303(24):1394-400.
- Scriver CR, Clow CL, Kaplan P, Niederwieser A. Hyperphenylalaninemia due to deficiency of 6-pyruvoyl tetrahydropterin synthase. Unusual gene dosage effect in heterozygotes. *Hum Genet* 1987 Oct;77(2):168-71.
- Scriver CR, Eisensmith RC, Woo SL, Kaufman S. The hyperphenylalaninemias of man and mouse. *Annu Rev Genet* 1994;28:141-65.
- Scriver CR, Kaufman S, Woo SL. Mendelian hyperphenylalaninemia. *Annu Rev Genet* 1988;22:301-21.
- Scriver CR, Waters PJ. Monogenic traits are not simple: lessons from phenylketonuria. *Trends Genet* 1999 Jul;15(7):267-72.
- Scriver CR, Waters PJ, Sarkissian C, Ryan S, Prevost L, Cote D, Novak J, Teebi S, Nowacki PM. PAHdb: a locus-specific knowledgebase. *Hum Mutat* 2000;15(1):99-104.
- Seashore MR. Genetic screening and the pediatrician. *Pediatr Ann* 2000;29(5):272-6.
- Sepe SJ, Marks JS, Oakley GP, Manley AF. Genetic services in the United States. *JAMA* 1982 Oct 8;248(14):1733-5.
- Shedlovsky A, McDonald JD, Symula D, Dove WF. Mouse models of human phenylketonuria. *Genetics* 1993 Aug;134(4):1205-10.
- Shen Y, Xu Q, Han F, Ding K, Song F, Fan Y, Zhu N, Wu G, Lin B. Application of capillary nongel sieving electrophoresis for gene analysis. *Electrophoresis* 1999 Jul;20(9):1822-8.
- Shintaku H. [The metabolic basis of the hyperphenylalaninemias and tyrosinemia]. *Nippon Rinsho* 1992 Jul;50(7):1542-7. (Jpn).
- Shirahase W, Oya N, Shimada M. A new single base substitution in a Japanese phenylketonuria (PKU) patient. *Brain Dev* 1991 Jul;13(4):283-4.
- Silva LC, Pires RF, Coelho JC, Jardim LB, Giugliani R. Evaluation of an aspartame loading test for the detection of heterozygotes for classical phenylketonuria. *Clin Genet* 1997 Apr;51(4):231-5.
- Skriabin BV, Koval'chuk LA, Khal'chitskii SE, Gol'tsov AA, Kaboev OK, Plutalov OV, Berlin IuA, Shvarts EI. [Identification of a nature of mutation in the 12th exon of phenylalanine hydroxylase gene in patients with phenylketonuria]. *Bioorg Khim* 1989 Dec;15(12):1690-2. (Rus).
- Smith I, Wolff OH. Natural history of phenylketonuria and influence of early treatment. *Lancet* 1974 Sep 7;2(7880):540-4.
- Smith JE, Sheng ZF, Kallen RG. Effects of tyrosine-->phenylalanine mutations on auto- and trans-phosphorylation reactions catalyzed by the insulin receptor beta-subunit cytoplasmic domain. *DNA Cell Biol* 1994 Jun;13(6):593-604.
- Smith SC, McAdam W, Cotton RG, Mercer JF. A novel two-dimensional polyacrylamide-gel pattern, which may be due to allelic genes, of phenylalanine hydroxylase in monkeys. *Biochem J* 1985 Oct 1;231(1):197-9.
- Smooker PM, Gough TJ, Cotton RG, Alliaudi C, de Sanctis L, Dianzani I. A series of mutations in the dihydropteridine reductase gene resulting in either abnormal RNA splicing or DHPR protein defects. Mutations in brief no. 244. Online. *Hum Mutat* 1999;13(6):503-4.
- Snyderman SE. Dietary and genetic therapy of inborn errors of metabolism: a summary. *Ann N Y Acad Sci* 1986;477:231-6.
- Sobell JL. Schizophrenia and heterozygosity for phenylketonuria [dissertation]. Minneapolis (MN): University of Minnesota; 1991. 224 p.
- Sommer SS, Cassady JD, Sobell JL, Bottema CD. A novel method for detecting point mutations or polymorphisms and its application to population screening for carriers of phenylketonuria. *Mayo Clin Proc* 1989 Nov;64(11):1361-72.
- Song J. Multi-level regulation of phenylalanine hydroxylase in *aeruginosa* [dissertation]. Gainesville (FL): University of Florida; 1997. 100 p.
- Song J, Jensen RA. PhhR, a divergently transcribed activator of the phenylalanine hydroxylase gene cluster of *Pseudomonas aeruginosa*. *Mol Microbiol* 1996 Nov;22(3):497-507.
- Song J, Xia T, Jensen RA. PhhB, a *Pseudomonas aeruginosa* homolog of mammalian pterin 4a-carbinolamine dehydratase/DCoH, does not regulate expression of phenylalanine hydroxylase at the transcriptional level. *J Bacteriol* 1999 May;181(9):2789-96.

- Spada M, Dianzani I, Bonetti G, Biondi A, Leone L, Giannattasio S, Ponzone A. Phenylalanine and tyrosine metabolism in phenylketonuria heterozygotes: influence of different phenylalanine hydroxylase mutations. *J Inher Metab Dis* 1998 Jun;21(3):236-9.
- Speer A, Bollman R, Michel A, Neumann R, Bommer C, Hanke R, Riess O, Cobet G, Coutelle C. Prenatal diagnosis of classical phenylketonuria by linked restriction fragment length polymorphism analysis. *Prenat Diagn* 1986 Nov-Dec;6(6):447-50.
- Speer A, Dahl HH, Riess O, Cobet G, Hanke R, Cotton RG, Coutelle C. Typing of families with classical phenylketonuria using three alleles of the HindIII linked restriction fragment polymorphism, detectable with a phenylalanine hydroxylase cDNA probe. Family typing for PKU by linked HindIII RFLP. *Clin Genet* 1986 Jun;29(6):491-5.
- Steffens C. No difference in dermatoglyphics of fingers and palms between phenylketonuria patients and controls [letter]. *Hum Genet* 1985;69(2):195.
- Stegenga SL. Regulation of GTP Cyclohydrolase I: isolation and the rat GTP Cyclohydrolase I promoter (tetrahydrobiopterin, transcription) [dissertation]. Detroit (MI): Wayne State University; 1997. 255 p.
- Stegink LD, Filer LJ Jr, Baker GL, Bell EF, Ziegler EE, Brummel MC, Krause WL. Repeated ingestion of aspartame-sweetened beverage: effect on plasma amino acid concentrations in individuals heterozygous for phenylketonuria. *Metabolism* 1989 Jan;38(1):78-84.
- Stegink LD, Filer LJ Jr, Baker GL, McDonnell JE. Effect of an abuse dose of aspartame upon plasma and erythrocyte levels of amino acids in phenylketonuric heterozygous and normal adults. *J Nutr* 1980 Nov;110(11):2216-24.
- Stegink LD, Filer LJ Jr, Bell EF, Ziegler EE, Tephly TR, Krause WL. Repeated ingestion of aspartame-sweetened beverages: further observations in individuals heterozygous for phenylketonuria. *Metabolism* 1990 Oct;39(10):1076-81.
- Stegink LD, Filer LJ Jr, Brummel MC, Baker GL, Krause WL, Bell EF, Ziegler EE. Plasma amino acid concentrations and amino acid ratios in normal adults and adults heterozygous for phenylketonuria ingesting a hamburger and milk shake meal. *Am J Clin Nutr* 1991 Mar;53(3):670-5.
- Stegink LD, Koch R, Blaskovics ME, Filer LJ Jr, Baker GL, McDonnell JE. Plasma phenylalanine levels in phenylketonuric heterozygous and normal adults administered aspartame at 34 mg/kg body weight. *Toxicology* 1981;20(1):81-90.
- Stegink LD, Wolf-Novak LC, Filer LJ Jr, Bell EF, Ziegler EE, Krause WL, Brummel MC. Aspartame-sweetened beverage: effect on plasma amino acid concentrations in normal adults and adults heterozygous for phenylketonuria. *J Nutr* 1987 Nov;117(11):1989-95.
- Stern J. The biochemical approach to mental handicap: 30 years of achievements and disappointments. *J Ment Defic Res* 1987 Dec;31 (Pt 4):357-64.
- Strupp BJ, Bunsey M, Levitsky DA, Hamberger K. Deficient cumulative learning: an animal model of retarded cognitive development. *Neurotoxicol Teratol* 1994 Jan-Feb;16(1):71-9.
- Stuhrmann M, Riess O, Monch E, Kurdoglu G. Haplotype analysis of the phenylalanine hydroxylase gene in Turkish phenylketonuria families. *Clin Genet* 1989 Aug;36(2):117-21.
- Subramanyam SB. Saudi aminoacidemias: a six-year study. *Indian J Pediatr* 1996 Sep-Oct;63(5):641-4.
- Sueoka H, Moshinetsky A, Nagao M, Chiba S. Mutation screening of phenylketonuria in the Far East of Russia. *J Hum Genet* 1999;44(6):368-71.
- Sugita R, Takahashi S, Ishii K, Matsumoto K, Ishibashi T, Sakamoto K, Narisawa K. Brain CT and MR findings in hyperphenylalaninemia due to dihydropteridine reductase deficiency (variant of phenylketonuria). *J Comput Assist Tomogr* 1990 Sep-Oct;14(5):699-703.
- Sullivan SE, Moore SD, Connor JM, King M, Cockburn F, Steinmann B, Gitzelmann R, Daiger SP, Woo SL. Haplotype distribution of the human phenylalanine hydroxylase locus in Scotland and Switzerland. *Am J Hum Genet* 1989 May;44(5):652-9.
- Sun G, Jiang L, Zhang X, Tong B, Dong G, Sun K. [Novel mutations identified in exon 7 of phenylalanine hydroxylase gene in Chinese]. *I Chuan Hsueh Pao* 1997;24(6):492-5. (Chi).
- Superti-Furga A, Steinmann B, Duc G, Gitzelmann R. Maternal phenylketonuria syndrome in cousins caused by mild, unrecognized phenylketonuria in their mothers homozygous for the phenylalanine hydroxylase Arg-261-Gln mutation. *Eur J Pediatr* 1991 May;150(7):493-7.
- Svensson E, Andersson B, Hagenfeldt L. Two mutations within the coding sequence of the phenylalanine hydroxylase gene. *Hum Genet* 1990 Aug;85(3):300-4.
- Svensson E, Eisensmith RC, Dworniczak B, von Döbeln U, Hagenfeldt L, Horst J, Woo SL. Two missense mutations causing mild

- hyperphenylalaninemia associated with DNA haplotype 12. *Hum Mutat* 1992;1(2):129-37.
- Svensson E, Iselius L, Hagenfeldt L. Severity of mutation in the phenylalanine hydroxylase gene influences phenylalanine metabolism in phenylketonuria and hyperphenylalaninaemia heterozygotes. *J Inher Metab Dis* 1994;17(2):215-22.
- Svensson E, von Döbeln U, Eisensmith RC, Hagenfeldt L, Woo SL. Relation between genotype and phenotype in Swedish phenylketonuria and hyperphenylalaninemia patients. *Eur J Pediatr* 1993 Feb;152(2):132-9.
- Svensson E, von Döbeln U, Hagenfeldt L. Polymorphic DNA haplotypes at the phenylalanine hydroxylase locus and their relation to phenotype in Swedish phenylketonuria families. *Hum Genet* 1991 May;87(1):11-7.
- Svensson E, Wang Y, Eisensmith RC, Hagenfeldt L, Woo SL. Three polymorphisms but no disease-causing mutations in the proximal part of the promoter of the phenylalanine hydroxylase gene. *Eur J Hum Genet* 1993;1(4):306-13.
- Svensson EI. Relationship between genotype and biochemical phenotype in children with phenylketonuria [dissertation]. Stockholm (Sweden): Karolinska Institute; 1993. 150 p.
- Szabo L, Somogyi C, Mate M. [Maternal phenylketonuria syndrome: teratogenic effect of hyperphenylalaninemia]. *Orv Hetil* 1982 Nov 21;123(47):2895-901. (Hun).
- Szeinberg A, Cohen BE. Early blood sampling in neonatal programs for the detection of phenylketonuria. *Pediatr Padol* 1982;17(2):287-92.
- Tada K, Narisawa K, Arai N, Ogasawara Y, Ishizawa S. A sibling case of hyperphenylalaninemia due to a deficiency of dihydropteridine reductase: biochemical and pathological findings. *Tohoku J Exp Med* 1980 Oct;132(2):123-31.
- Takahashi K, Masamune A, Kure S, Matsubara Y, Narisawa K. Ectopic transcription: an application to the analysis of splicing errors in phenylalanine hydroxylase mRNA. *Acta Paediatr Suppl* 1994 Dec;407:45-6.
- Takarada Y, Kalanin J, Yamashita K, Ohtsuka N, Kagawa S, Matsuoka A. Phenylketonuria mutant alleles in different populations: missense mutation in exon 7 of phenylalanine hydroxylase gene [letter]. *Clin Chem* 1993 Nov;39(11 Pt 1):2354-5.
- Takarada Y, Yamashita K, Kagawa S, Zhang QZ, Matsuoka A. [Genetic diagnosis of phenylketonuria. III. Mutations of phenylalanine hydroxylase gene in Orientals]. *Rinsho Byori* 1994 Nov;42(11):1158-64. (Jpn).
- Takarada Y, Yamashita K, Kalanin J, Kagawa S, Matsuoka A. [Genetic diagnosis of phenylketonuria. IV. Mutations of phenylalanine hydroxylase gene in Caucasian and Gypsy populations in Czech and Slovakia Republics]. *Rinsho Byori* 1994 Nov;42(11):1165-71. (Jpn).
- Takarada Y, Yamashita K, Ohtsuka N, Kagawa S, Matsuoka A. Novel homozygous mutation of phenylalanine hydroxylase gene in a Chinese patient with phenylketonuria [letter]. *Clin Chem* 1993 Jun;39(6):1350.
- Takarada Y, Yamashita K, Ohtsuka N, Kagawa S, Matsuoka A. Novel mutation in exon 7 of phenylalanine hydroxylase gene in a Chinese patient with phenylketonuria [letter]. *Clin Chem* 1993 Nov;39(11 Pt 1):2357.
- Takashima S, Chan F, Becker LE. Cortical dysgenesis in a variant of phenylketonuria (dihydropteridine reductase deficiency). *Pediatr Pathol* 1991 Sep-Oct;11(5):771-9.
- Taylor DS, Dahl HH, Mercer JF, Green AK, Fisher MJ. The effect of streptozotocin-induced diabetes on phenylalanine hydroxylase expression in rat liver. *Biochem J* 1989 Nov 15;264(1):185-90.
- Teebi AS, Al-Awadi SA, Farag TI, Naguib KK, el-Khalifa MY. Phenylketonuria in Kuwait and Arab countries. *Eur J Pediatr* 1987 Jan;146(1):59-60.
- Tenenholz B, Wenger SL, Breck J, Steele MW. A simplified PKU gene carrier detection test using fasting blood. *Clin Genet* 1983 Feb;23(2):115-9.
- Thalhammer O. [21 years Austrian Program for Early Detection of Congenital Metabolic Abnormalities. Did the screening programs also contribute scientific knowledge?]. *Wien Klin Wochenschr* 1988 Oct 7;100(19):641-5. (Ger).
- Thalhammer O, Lubec G, Königshofer H, Scheibenreiter S, Coradello H. Intracellular phenylalanine and tyrosine concentration in homozygotes and heterozygotes for phenylketonuria (PKU) and hyperphenylalaninemia compared with normals. *Hum Genet* 1982;60(4):320-1.
- Thalhammer O, Pollak A, Lubec G, Königshofer H. [Intracellular concentration of phenylalanine, tyrosine and alpha-amino butyric acid in 13 homozygotes and 19 heterozygotes for phenylketonuria (PKU) compared with 26 normals (author's transl)]. *Klin Padiatr* 1980 Nov;192(6):608-12. (Ger).
- Thalhammer O, Pollak A, Lubec G, Königshofer H. Intracellular concentrations of phenylalanine, tyrosine

and alpha-aminobutyric acid in 13 homozygotes and 19 heterozygotes for phenylketonuria compared with 26 normals. *J Inher Metab Dis* 1981;4(2):73-4.

Thalhammer O, Pollak A, Lubec G, Konigshofer H. Intracellular concentrations of phenylalanine, tyrosine and alpha-aminobutyric acid in 13 homozygotes and 19 heterozygotes for phenylketonuria (PKU) compared with 26 normals. *Hum Genet* 1980;54(2):213-6.

Thibaud D, Ploussard JP, Vaquant PO, Chemouny S, Kleitz T. [Diagnosis of phenylketonuria in a 35-year-old mother in relation to prenatal diagnosis of intrauterine growth retardation with microcephaly]. *Arch Pediatr* 1998 Nov;5(11):1229-31. (Fre).

Thony B, Blau N. Mutations in the GTP cyclohydrolase I and 6-pyruvoyl-tetrahydropterin synthase genes. *Hum Mutat* 1997;10(1):11-20.

Thony B, Heizmann CW, Mattei MG. Chromosomal location of two human genes encoding tetrahydrobiopterin-metabolizing enzymes: 6-pyruvoyl-tetrahydropterin synthase maps to 11q22.3-q23.3, and pterin-4 alpha-carbinolamine dehydratase maps to 10q22. *Genomics* 1994 Jan 15;19(2):365-8.

Thony B, Leimbacher W, Blau N, Harvie A, Heizmann CW. Hyperphenylalaninemia due to defects in tetrahydrobiopterin metabolism: molecular characterization of mutations in 6-pyruvoyl-tetrahydropterin synthase. *Am J Hum Genet* 1994 May;54(5):782-92.

Thony B, Leimbacher W, Burgisser D, Heizmann CW. Human 6-pyruvoyltetrahydropterin synthase: cDNA cloning and heterologous expression of the recombinant enzyme. *Biochem Biophys Res Commun* 1992 Dec 30;189(3):1437-43.

Thony B, Leimbacher W, Stuhlmann H, Heizmann CW, Blau N. Retrovirus-mediated gene transfer of 6-pyruvoyl-tetrahydropterin synthase corrects tetrahydrobiopterin deficiency in fibroblasts from hyperphenylalaninemic patients. *Hum Gene Ther* 1996 Aug 20;7(13):1587-93.

Thony B, Neuheiser F, Kierat L, Blaskovics M, Arn PH, Ferreira P, Rebrin I, Ayling J, Blau N. Hyperphenylalaninemia with high levels of 7-biopterin is associated with mutations in the PCBD gene encoding the bifunctional protein pterin-4 α -carbinolamine dehydratase and transcriptional coactivator (DCoH). *Am J Hum Genet* 1998 Jun;62(6):1302-11.

Thony B, Neuheiser F, Kierat L, Rolland MO, Guibaud P, Schluter T, Germann R, Heidenreich RA, Duran M, de Klerk JB, Ayling JE, Blau N. Mutations in the pterin-4 α -carbinolamine dehydratase (PCBD) gene cause a benign form of

hyperphenylalaninemia. *Hum Genet* 1998 Aug;103(2):162-7.

Tice KS, Wenz E, Jew K, Koch R. Reproductive counselling for adolescent females with phenylketonuria. *J Inher Metab Dis* 1980;3(3):105-7.

Tillotson SL, Costello PM, Smith I. No reduction in birth weight in phenylketonuria. *Eur J Pediatr* 1995 Oct;154(10):847-9. Comment in: *Eur J Pediatr* 1997 Feb;156(2):157.

Tolmie JL, Harvie A, Cockburn F. The teratogenic effects of undiagnosed maternal hyperphenylalaninaemia: a case for prevention? *Br J Obstet Gynaecol* 1992 Apr;99(4):347-8.

Touraine RL, Guibaud P. [Genetics and hyperphenylalaninemias in 1992]. *Pediatric (Bucur)* 1992;47(1):9-21. Published erratum appears in *Pediatric* 1992;47(4):331. (Fre).

Traeger-Synodinos J, Kanavakis E, Kalogerakou M, Soulpi K, Missiou-Tsangaraki S, Kattamis C. Preliminary mutation analysis in the phenylalanine hydroxylase gene in Greek PKU and HPA patients. *Hum Genet* 1994 Nov;94(5):573-5.

Treacy E, Byck S, Clow C, Scriver CR. 'Celtic' phenylketonuria chromosomes found? Evidence in two regions of Quebec Province. *Eur J Hum Genet* 1993;1(3):220-8.

Treacy E, Pitt JJ, Seller K, Thompson GN, Ramus S, Cotton RG. In vivo disposal of phenylalanine in phenylketonuria: a study of two siblings. *J Inher Metab Dis* 1996;19(5):595-602.

Treacy EP, Delente JJ, Elkas G, Carter K, Lambert M, Waters PJ, Scriver CR. Analysis of phenylalanine hydroxylase genotypes and hyperphenylalaninemia phenotypes using L-[1-13C]phenylalanine oxidation rates in vivo: a pilot study. *Pediatr Res* 1997 Oct;42(4):430-5.

Trefz F, de Sonneville L, Matthis P, Benninger C, Lanz-Englert B, Bickel H. Neuropsychological and biochemical investigations in heterozygotes for phenylketonuria during ingestion of high dose aspartame (a sweetener containing phenylalanine). *Hum Genet* 1994 Apr;93(4):369-74.

Trefz FK, Burgard P, Konig T, Goebel-Schreiner B, Lichter-Konecki U, Konecki D, Schmidt E, Schmidt H, Bickel H. Genotype-phenotype correlations in phenylketonuria. *Clin Chim Acta* 1993 Jul 30;217(1):15-21.

Trefz FK, Lichter-Konecki U, Konecki DS, Schlotter M, Bickel H. PKU and NON-PKU hyperphenylalaninemia: differentiation, indication for

- therapy and therapeutic results. *Acta Paediatr Jpn* 1988 Aug;30(4):397-404.
- Trefz FK, Lichter-Konecki U, Krawczak M, Schmidtke J, Dueck M, Nutzenadel W, Konecki DS. [DNA diagnosis of monogene hereditary diseases exemplified by phenylketonuria and mucoviscidosis]. *Monatsschr Kinderheilkd* 1989 Apr;137(4):201-7. (Ger).
- Trefz FK, Yoshino M, Nishiyori A, Aengeneyndt F, Schmidt-Mader B, Lichter-Konecki U, Konecki DS. RFLP-patterns in Japanese PKU families: new polymorphisms for the mutant phenylalanine hydroxylase gene. *Hum Genet* 1990 Jun;85(1):121-2.
- Tsai TF, Hsiao KJ, Su TS. Phenylketonuria mutation in Chinese haplotype 44 identical with haplotype 2 mutation in northern-European Caucasians. *Hum Genet* 1990 Apr;84(5):409-11.
- Tu JB. Theory and practice of psychopharmacogenetics. *Am J Med Genet* 1994 Dec 15;54(4):391-7.
- Turri MO, Ilg EC, Thony B, Blau N. Structure, genomic localization and recombinant expression of the mouse 6-pyruvoyl-tetrahydropterin synthase gene. *Biol Chem* 1998 Dec;379(12):1441-7.
- Tyfield LA. Phenylketonuria in Britain: genetic analysis gives a historical perspective of the disorder but will it predict the future for affected individuals? *Mol Pathol* 1997 Aug;50(4):169-74.
- Tyfield LA, Meredith AL, Osborn MJ, Harper PS. Identification of the haplotype pattern associated with the mutant PKU allele in the Gypsy population of Wales. *J Med Genet* 1989 Aug;26(8):499-503.
- Tyfield LA, Meredith AL, Osborn MJ, Primavesi R, Chambers TL, Holton JB, Harper PS. Genetic analysis of treated and untreated phenylketonuria in one family. *J Med Genet* 1990 Sep;27(9):564-8.
- Tyfield LA, Osborn MJ, Holton JB. Molecular heterogeneity at the phenylalanine hydroxylase locus in the population of the south-west of England. *J Med Genet* 1991 Apr;28(4):244-7.
- Tyfield LA, Stephenson A, Bidwell JL, Wood NA, Cockburn F, Harvie A, Smith I. Mutation analysis of the phenylalanine hydroxylase gene using heteroduplex analysis with synthetic DNA constructs. *Acta Paediatr Suppl* 1994 Dec;407:47-8.
- Tyfield LA, Stephenson A, Cockburn F, Harvie A, Bidwell JL, Wood NA, Pilz DT, Harper P, Smith I. Sequence variation at the phenylalanine hydroxylase gene in the British Isles. *Am J Hum Genet* 1997 Feb;60(2):388-96.
- Tyfield LA, Zschocke J, Stephenson A, Cockburn F, Harvie A, Bidwell JL, Wood NA, Hunt LP. Discordant phenylketonuria phenotypes in one family: the relationship between genotype and clinical outcome is a function of multiple effects. *J Med Genet* 1995 Nov;32(11):867-70.
- Uebelhack R, Franke L, Kutter D, Thoma J, Seidel K. [In vitro synthesis of tyrosine from phenylalanine in human platelets]. *Biomed Biochim Acta* 1984;43(7):1037-9. (Ger).
- Ugarte M, Maties M, Ugarte JL. The offspring of a phenylketonuric couple. *J Ment Defic Res* 1980 Jun;24(2):119-27.
- van der Sijs-Bos CJ, Diepstraten CM, Juyn JA, Plaisier M, Giltay JC, van Spronsen FJ, Smit GP, Berger R, Smeitink JA, Poll-The BT, Ploos van Amstel JK. Phenylketonuria in The Netherlands: 93% of the mutations are detected by single-strand conformation analysis. *Hum Hered* 1996 Jul-Aug;46(4):185-90.
- Van Dyke DC, Lin Dyken DC. The new genetics, developmental disabilities, and early intervention. *Infants Young Child* 1993 Apr;5(4):8-19.
- Varughese KI, Xuong NH, Whiteley JM. Structural and mechanistic implications of incorporating naturally occurring aberrant mutations of human dihydropteridine reductase into a rat model. *Int J Pept Protein Res* 1994 Sep;44(3):278-87.
- Velazquez A. Gene-nutrient interactions in single-gene defects and polygenic diseases: methodologic considerations. In: Simopoulos AP, Nestel PJ, editors. *Genetic variation and dietary response*. New York: Karger; 1997. p. 145-64.
- Velazquez A, Bilbao G, Gonzalez-Trujillo JL, Hernandez D, Perez-Andrade ME, Vela M, Ciceron I, Loera-Luna A, Cederbaum S, Phoenix B. Apparent higher frequency of phenylketonuria in the Mexican state of Jalisco. *Hum Genet* 1996 Jan;97(1):99-102.
- Verlinsky Y, Rechitsky S, Verlinsky O, Ivachnenko V, Lifchez A, Kaplan B, Moise J, Valle J, Borkowski A, Nefedova J, Goltsman E, Strom C, Kuliev A. Prepregnancy testing for single-gene disorders by polar body analysis. *Genet Test* 1999;3(2):185-90.
- Viktorova TV, Murzabaeva SSh, Karunas AU, Magzhanov RV, Khusnutdinova EK. [Molecular genetic analysis of phenylketonuria in Bashkiria]. *Genetika* 1997 Jul;33(7):992-5. (Rus).
- Vogel F. Clinical consequences of heterozygosity for autosomal-recessive diseases. *Clin Genet* 1984 May;25(5):381-415.

- Vogel F. Phenotypic deviations in heterozygotes of phenylketonuria (PKU). *Prog Clin Biol Res* 1985;177:337-49.
- Vorhees CV. Concepts in teratology and developmental toxicology derived from animal research. *Ann N Y Acad Sci* 1989;562:31-41.
- Vorhees CV, Acuff-Smith KD, Weisenburger WP, Minck DR, Berry HK. Branched chain amino acids improve radial-arm maze acquisition and water maze forced-choice learning in rat offspring exposed in utero to hyperphenylalaninemia. *Neurotoxicol Teratol* 1992 Jan-Feb;14(1):35-41.
- Vorhees CV, Butcher RE, Berry HK. Progress in experimental phenylketonuria: a critical review. *Neurosci Biobehav Rev* 1981 Spring;5(1):177-90.
- Vorstenbosch EL, Potapov AP, De Graaf JM, Kraal B. The effect of mutations in EF-Tu on its affinity for tRNA as measured by two novel and independent methods of general applicability. *J Biochem Biophys Methods* 2000;42(1-2):1-14.
- Wachtel U. Review of current practices in management of inherited disorders of amino acid metabolism in Western Europe. *Hum Nutr Appl Nutr* 1986;40 Suppl 1:61-9.
- Wallen MA, Packman S. Nutrition and inborn errors of metabolism. *Nutr Update* 1985;2:71-89.
- Walsh DA, Christian ZH. The effects of phenylalanine on cultured rat embryos. *Teratog Carcinog Mutagen* 1984;4(6):505-13.
- Walter JH. Inborn errors of metabolism and pregnancy. *J Inherit Metab Dis* 2000;23(3):229-36.
- Walter JH, Tyfield LA, Holton JB, Johnson C. Biochemical control, genetic analysis and magnetic resonance imaging in patients with phenylketonuria. *Eur J Pediatr* 1993 Oct;152(10):822-7.
- Wang M. [Frequencies of 6 known mutations in phenylalanine hydroxylase gene and their application in prenatal gene diagnosis]. *Chung Hua I Hsueh Tsa Chih (Taipei)* 1992 Nov;72(11):670-3, 702-3. (Chi).
- Wang N, Zhu Y, Xu K, Qiu Z, Song W, Huang S. [Identification of mutations in the phenylalanine hydroxylase gene and exon 5 novel mutation Y166X(C->G) in Yunnan]. *Chung Hua I Hsueh Tsa Chih* 1999 Feb 10;16(1):9-11. (Chi).
- Wang T. [Molecular genetics of phenylketonuria in Orientals--linkage disequilibrium between a termination mutation and haplotype 4 of the phenylalanine hydroxylase gene]. *Chung Kuo I Hsueh Ko Hsueh Yuan Hsueh Pao* 1991 Feb;13(1):1-6. (Chi).
- Wang T, Okano Y, Eisensmith R, Huang SZ, Zeng YT, Lo WH, Woo SL. Molecular genetics of phenylketonuria in Orientals: linkage disequilibrium between a termination mutation and haplotype 4 of the phenylalanine hydroxylase gene. *Am J Hum Genet* 1989 Nov;45(5):675-80.
- Wang T, Okano Y, Eisensmith RC, Fekete G, Schuler D, Berencsi G, Nasz I, Woo SL. Molecular genetics of PKU in eastern Europe: a nonsense mutation associated with haplotype 4 of the phenylalanine hydroxylase gene. *Somat Cell Mol Genet* 1990 Jan;16(1):85-90.
- Wang T, Okano Y, Eisensmith RC, Harvey ML, Lo WH, Huang SZ, Zeng YT, Yuan LF, Furuyama JI, Oura T, et al. Founder effect of a prevalent phenylketonuria mutation in the Oriental population. *Proc Natl Acad Sci U S A* 1991 Mar 15;88(6):2146-50.
- Wang T, Okano Y, Eisensmith RC, Lo WH, Huang SZ, Zeng YT, Woo SL. Identification of a novel phenylketonuria (PKU) mutation in the Chinese: further evidence for multiple origins of PKU in Asia. *Am J Hum Genet* 1991 Mar;48(3):628-30.
- Wang T, Okano Y, Eisensmith RC, Lo WH, Huang SZ, Zeng YT, Yuan LF, Liu SR, Woo SL. Identification of three novel PKU mutations among Chinese: evidence for recombination or recurrent mutation at the PAH locus. *Genomics* 1992 May;13(1):230-1.
- Wang T, Okano Y, Eisensmith RC, Lo WH, Huang SZ, Zeng YT, Yuan LF, Liu SR, Woo SL. Missense mutations prevalent in Orientals with phenylketonuria: molecular characterization and clinical implications. *Genomics* 1991 Jun;10(2):449-56.
- Wang Y, DeMayo JL, Hahn TM, Finegold MJ, Konecki DS, Lichter-Konecki U, Woo SL. Tissue- and development-specific expression of the human phenylalanine hydroxylase/chloramphenicol acetyltransferase fusion gene in transgenic mice. *J Biol Chem* 1992 Jul 25;267(21):15105-10.
- Wang Y, Hahn TM, Tsai SY, Woo SL. Functional characterization of a unique liver gene promoter. *J Biol Chem* 1994 Mar 25;269(12):9137-46.
- Wang YL, Yu B. Effect of peroxovanadate compound on phenylalanine hydroxylase gene expression. *Biol Trace Elem Res* 2000;74(3):237-44.
- Ward J. New developments in common genetic diseases. *J Tenn Med Assoc* 1986 Aug;79(8):500-1.

- Waters PI, Hewson AS, Scriver CR, Treacy EP, Martinez A, Knappskog PM, Parniak MA. Comparative analysis of phenylalanine hydroxylase A104D mutant, associated with variant phenylketonuria, and wild-type enzyme. *Biochem Soc Trans* 1997 May;25(2):362S.
- Waters PJ, Parniak MA, Akerman BR, Jones AO, Scriver CR. Missense mutations in the phenylalanine hydroxylase gene (PAH) can cause accelerated proteolytic turnover of PAH enzyme: a mechanism underlying phenylketonuria. *J Inherit Metab Dis* 1999 May;22(3):208-12.
- Waters PJ, Parniak MA, Akerman BR, Scriver CR. Characterization of phenylketonuria missense substitutions, distant from the phenylalanine hydroxylase active site, illustrates a paradigm for mechanism and potential modulation of phenotype. *Mol Genet Metab* 2000 Feb;69(2):101-10.
- Waters PJ, Parniak MA, Hewson AS, Scriver CR. Alterations in protein aggregation and degradation due to mild and severe missense mutations (A104D, R157N) in the human phenylalanine hydroxylase gene (PAH). *Hum Mutat* 1998;12(5):344-54.
- Waters PJ, Parniak MA, Nowacki P, Scriver CR. In vitro expression analysis of mutations in phenylalanine hydroxylase: linking genotype to phenotype and structure to function. *Hum Mutat* 1998;11(1):4-17.
- Waters PJ, Scriver CR, Parniak MA. Degradation rates differ between mutant and wild-type forms of phenylalanine hydroxylase expressed in vitro. *Biochem Soc Trans* 1998 Aug;26(3):S276.
- Watts RW, Baraitser M, Chalmers RA, Purkiss P. Organic acidurias and amino acidurias in the aetiology of long-term mental handicap. *J Ment Defic Res* 1980 Dec;24 Pt 4:257-70.
- Wedemeyer N, Dworniczak B, Horst J. PCR detection of the MspI (Aa) RFLP at the human phenylalanine hydroxylase (PAH) locus. *Nucleic Acids Res* 1991 Apr 25;19(8):1959.
- Weglage J, Funders B, von Teeffelen-Heithoff A, Ullrich K. [Phenylketonuria--change in therapeutic strategies. Study of intellectual development and dietary compliance of young phenylketonuria patients]. *Fortschr Med* 1993 Nov 10;111(31):485-8. (Ger).
- Weglage J, Ullrich K, Pietsch M, Funders B, Guttler F, Harms E. Intellectual, neurologic, and neuropsychologic outcome in untreated subjects with nonphenylketonuria hyperphenylalaninemia. German Collaborative Study on Phenylketonuria. *Pediatr Res* 1997 Sep;42(3):378-84.
- Weglage J, Wiedermann D, Moller H, Ullrich K. Pathogenesis of different clinical outcomes in spite of identical genotypes and comparable blood phenylalanine concentrations in phenylketonurics. *J Inherit Metab Dis* 1998 Apr;21(2):181-2.
- Weinstein M, Eisensmith RC, Abadie V, Avigad S, Lyonnet S, Schwartz G, Munnich A, Woo SL, Shiloh Y. A missense mutation, S349P, completely inactivates phenylalanine hydroxylase in north African Jews with phenylketonuria. *Hum Genet* 1993 Feb;90(6):645-9.
- Wenger SL, Vieira PW, Breck JM, Steele MW. Relative reliability of three different discriminant analysis methods for detecting PKU gene carriers. *Clin Genet* 1986 Jul;30(1):38-40.
- Whipp MJ, Halsall DM, Pittard AJ. Isolation and characterization of an Escherichia coli K-12 mutant defective in tyrosine- and phenylalanine-specific transport systems. *J Bacteriol* 1980 Jul;143(1):1-7.
- Wiens M, Koziol C, Batel R, Muller WE. Phenylalanine hydroxylase from the sponge Geodia cydonium: implication for allorecognition and evolution of aromatic amino acid hydroxylases. *Dev Comp Immunol* 1998 Sep-Dec;22(5-6):469-78.
- Witkowski RC, Koerner H, Metzke H. Ethics and medical genetics in the German Democratic Republic (GDR). In: Wertz DC, Fletcher JC, editors. *Ethics and human gGenetics: a cross-cultural perspective*. New York: Springer-Verlag; 1989. p. 194-208.
- Witt M, Jaruzelska J, Kuczora I, Matuszak R, Cichy W, Borski K. A simplified method for detection of the mutations predominantly causing cystic fibrosis and phenylketonuria in Polish families. *Clin Genet* 1993 Jul;44(1):44-5.
- Wittstock U, Halkier BA. Cytochrome P450 CYP79A2 from Arabidopsis thaliana L. catalyzes the conversion of L-phenylalanine to phenylacetaldoxime in the biosynthesis of benzylglucosinolate. *J Biol Chem* 2000 May 12;275(19):14659-66.
- Wong DL, Ciaranello RD. Molecular biological approaches to mental retardation. *Clin Neuropharmacol* 1986;9 Suppl 4:519-21.
- Woo SL. Collation of RFLP haplotypes at the human phenylalanine hydroxylase (PAH) locus [letter]. *Am J Hum Genet* 1988 Nov;43(5):781-3.
- Woo SL. Molecular basis and population genetics of phenylketonuria. *Biochemistry* 1989 Jan 10;28(1):1-7.
- Woo SL. Molecular genetic analysis of phenylketonuria and mental retardation. *Res Publ Assoc Res Nerv Ment Dis* 1991;69:193-203.

- Woo SL. Molecular genetic-analysis of phenylketonuria and mental retardation. In: McHugh PR, McKusick VA, editors. *Genes, brain, and behavior*. New York: Raven; 1991. p. 193-204.
- Woo SL. Prenatal diagnosis and carrier detection of classic phenylketonuria by gene analysis. *Pediatrics* 1984 Sep;74(3):412-23.
- Woo SL, DiLella AG, Marvit J, Ledley FD. Molecular basis of phenylketonuria and potential somatic gene therapy. *Cold Spring Harb Symp Quant Biol* 1986;51 Pt 1:395-401.
- Woo SL, DiLella AG, Marvit J, Ledley FD. Molecular basis of phenylketonuria and recombinant DNA strategies for its therapy. *Enzyme* 1987;38(1-4):207-13.
- Woo SL, Guttler F, Ledley FD, Lidsky AS, Kwok SC, DiLella AG, Robson KJ. The human phenylalanine hydroxylase gene. *Prog Clin Biol Res* 1985;177:123-35.
- Woo SL, Lidsky AS, Guttler F, Chandra T, Robson KJ. Cloned human phenylalanine hydroxylase gene allows prenatal diagnosis and carrier detection of classical phenylketonuria. *Nature* 1983 Nov 10-16;306(5939):151-5.
- Woo SL, Lidsky AS, Guttler F, Thirumalachary C, Robson KJ. Prenatal diagnosis of classical phenylketonuria by gene mapping. *JAMA* 1984 Apr 20;251(15):1998-2002.
- Woo SL, Robson JH, Guttler F. The possibility for prenatal diagnosis of PKU by linkage analyses based on phenylalanine hydroxylase locus specific DNA-polymorphisms. *J Inherit Metab Dis* 1984;7 Suppl 2:139-40.
- Wood N, Bidwell J. Genetic screening and testing by induced heteroduplex formation. *Electrophoresis* 1996 Jan;17(1):247-54.
- Wood N, Tyfield L, Bidwell J. Rapid classification of phenylketonuria genotypes by analysis of heteroduplexes generated by PCR-amplifiable synthetic DNA. *Hum Mutat* 1993;2(2):131-7.
- Woolf LI. The heterozygote advantage in phenylketonuria [letter]. *Am J Hum Genet* 1986 May;38(5):773-5.
- Woolf LI. Phenylketonuria in Turkey, Ireland and west Scotland. *J Inherit Metab Dis* 1994;17(2):246-7.
- Wulff K, Herrmann FH, Wehnert M, Seidlitz G, Schutz M. [Genetic diagnosis in classical phenylketonuria]. *Z Arztl Fortbild (Jena)* 1988;82(22):1127-31. (Ger).
- Wulff K, Wehnert M, Schutz M, Seidlitz G, Herrmann FH. Prenatal diagnosis of phenylketonuria by haplotype analysis. *Prenat Diagn* 1989 Jun;9(6):421-5.
- Wuu KD, Chiu PC, Li SY, Chen JY, Chao MC, Ko FJ, Wang TR, Hsiao KJ. Chromosomal and biochemical screening on mentally retarded school children in Taiwan. *Jinrui Idengaku Zasshi* 1991 Sep;36(3):267-74.
- Xu L, Miao S, Liu G. [Screening for mutations in the PAH gene in Chinese: a new splice and a novel polymorphic mutation]. *Chung Hua I Hsueh Tsa Chih* 1996 Jun;76(6):451-4. (Chi).
- Yamakawa A, Kameoka Y, Hashimoto K, Yoshitake Y, Nishikawa K, Tanihara K, Date T. cDNA cloning and chromosomal mapping of genes encoding novel protein kinases termed PKU-alpha and PKU-beta, which have nuclear localization signal. *Gene* 1997 Nov 20;202(1-2):193-201.
- Yamashita K, Takarada Y, Otsuka N, Kagawa S, Matsuoka A, Kalanin J. [Genetic diagnosis of phenylketonuria: identification of the mutations of phenylalanine hydroxylase gene by PCR direct sequencing]. *Rinsho Byori* 1992 Oct;40(10):1060-6. (Jpn).
- Yang J, Wang P, Pittard AJ. Mechanism of repression of the *aroP* P2 promoter by the TyrR protein of *Escherichia coli*. *J Bacteriol* 1999 Oct;181(20):6411-8.
- Yang R. Regulation of the rat tryptophan hydroxylase gene (serotonin, gland) [dissertation]. Newark (NJ): Rutgers - The State University; 1993. 138 p.
- Yang T, Yuan L, Huang S. [Detection of the mutational gene in phenylketonuria and prenatal diagnoses by using single strand conformation polymorphism methods]. *Chung Hua Fu Chan Ko Tsa Chih* 1996 Jul;31(7):401-3. (Chi).
- Yang T, Yuan L, Huang S, Zhao S. [Screening mutations in phenylketonuria by means of nonradioactive reverse dot blot hybridization]. *Chung Hua I Hsueh I Chuan Hsueh Tsa Chih* 1998 Oct 10;15(5):307-9. (Chi).
- Yao Y, Matsubara Y, Narisawa K. Rapid detection of phenylketonuria mutations by non-radioactive single-strand conformation polymorphism analysis. *Acta Paediatr Jpn* 1994 Jun;36(3):231-5.
- Yeoh GC, Edkins E, Mackenzie K, Fuller S, Mercer JF, Dahl HH. The development of phenylalanine hydroxylase in rat liver; in vivo, and in vitro studies utilizing fetal hepatocyte cultures. *Differentiation* 1988 Jun;38(1):42-8.

- Young SN, Palmour RM. Research on genes: promises and limitations. *J Psychiatry Neurosci* 1999 Sep;24(4):300-3.
- Yuan L, Fang B, Wang M, Wang T, Huang S, Yang T, Zhao S. [Comparison of genotype and intellectual phenotype in untreated phenylketonuric children]. *Chung Hua I Hsueh I Chuan Hsueh Tsa Chih* 1998 Oct 10;15(5):297-9. (Chi).
- Zagreda L, Goodman J, Druin DP, McDonald D, Diamond A. Cognitive deficits in a genetic mouse model of the most common biochemical cause of human mental retardation. *J Neurosci* 1999 Jul 15;19(14):6175-82.
- Zekanowski C, Cabalska B, Borsuk P, Bal J. Mutations of the phenylalanine hydroxylase gene in mild hyperphenylalaninemia: a novel mutation in exon 3. *Hum Mutat* 1997;10(3):258-9.
- Zekanowski C, Nowacka M, Cabalska B, Bal J. Molecular basis of mild hyperphenylalaninaemia in Poland. *J Med Genet* 1997 Dec;34(12):1035-6.
- Zekanowski C, Nowacka M, Giżewska M, Filipowicz J, Cabalska B, Bal J. Mutations in exon 3 of the PAH gene causing mild hyperphenylalaninemia. *Genet Test* 1999;3(3):297-9.
- Zekanowski C, Nowacka M, Zgulska M, Horst J, Cabalska B, Mazurczak T. Frequencies of the most common mutations responsible for phenylketonuria in Poland. *Mol Cell Probes* 1994 Aug;8(4):323-4.
- Zeng YT. [Antenatal gene diagnosis of phenylketonuria]. *Chung Hua I Hsueh Tsa Chih* 1986 Aug;66(8):493-4. (Chi).
- Zeng YT. [Prenatal diagnosis of phenylketonuria (with a report of 10 cases)]. *Chung Hua I Hsueh Tsa Chih* 1988 Feb;68(2):61-4. (Chi).
- Zeng YT, Huang SZ, Chen MJ, Zhang ML, Ren ZR, Xu YH, Peng SF, Woo SL. A study on Chinese phenylalanine hydroxylase gene restriction site polymorphism. *Sci Sin [B]* 1988 Dec;31(12):1447-53.
- Zetterstrom R. Editorial comment on phenylketonuria [editorial]. *Acta Paediatr* 1995 Jul;84(7):716-8.
- Zhao G. [Inherited metabolic aberration of phenylalanine in the family members of patients with essential hypertension and stroke]. *Chung Hua I Hsueh Tsa Chih (Taipei)* 1991 Jul;71(7):388-90, 28. (Chi).
- Zhao G, Xia T, Song J, Jensen RA. *Pseudomonas aeruginosa* possesses homologues of mammalian phenylalanine hydroxylase and 4 alpha-carbinolamine dehydratase/DCoH as part of a three-component gene cluster. *Proc Natl Acad Sci U S A* 1994 Feb 15;91(4):1366-70.
- Zschocke J. The molecular genetics of phenylketonuria in Northern Ireland (hyperphenylalaninaemia) [dissertation]. Belfast (Northern Ireland): Queen's University of Belfast; 1996.
- Zschocke J, Carson DJ. Transient neonatal hyperphenylalaninaemia is not related to mutations at the phenylalanine hydroxylase gene. *J Inherit Metab Dis* 1995;18(3):369-70.
- Zschocke J, Graham CA. A fluorescent multiplex ARMS method for rapid mutation analysis. *Mol Cell Probes* 1995 Dec;9(6):447-51.
- Zschocke J, Graham CA, Carson DJ, Nevin NC. Phenylketonuria mutation analysis in Northern Ireland: a rapid stepwise approach. *Am J Hum Genet* 1995 Dec;57(6):1311-7.
- Zschocke J, Graham CA, McKnight JJ, Nevin NC. The STR system in the human phenylalanine hydroxylase gene: true fragment length obtained with fluorescent labelled PCR primers. *Acta Paediatr Suppl* 1994 Dec;407:41-2.
- Zschocke J, Graham CA, Stewart FJ, Carson DJ, Nevin NC. Automated sequencing detects all mutations in Northern Irish patients with phenylketonuria and mild hyperphenylalaninaemia. *Acta Paediatr Suppl* 1994 Dec;407:37-8.
- Zschocke J, Graham CA, Stewart FJ, Carson DJ, Nevin NC. Non-phenylketonuria hyperphenylalaninaemia in Northern Ireland: frequent mutation allows screening and early diagnosis. *Hum Mutat* 1994;4(2):114-8.
- Zschocke J, Hoffmann GF. Phenylketonuria mutations in Germany. *Hum Genet* 1999 May;104(5):390-8.
- Zschocke J, Mallory JP, Eiken HG, Nevin NC. Phenylketonuria and the peoples of Northern Ireland. *Hum Genet* 1997 Aug;100(2):189-94.
- Zschocke J, Quak E, Knauer A, Fritz B, Aslan M, Hoffmann GF. Large heterozygous deletion masquerading as homozygous missense mutation: a pitfall in diagnostic mutation analysis. *J Inherit Metab Dis* 1999 Aug;22(6):687-92.
- Zygulska M, Eigel A, Aulehla-Scholz C, Pietrzyk JJ, Horst J. Molecular analysis of PKU haplotypes in the population of southern Poland. *Hum Genet* 1991 Jan;86(3):292-4.
- Zygulska M, Eigel A, Dworniczak B, Sutkowska A, Pietrzyk JJ, Horst J. Phenylketonuria in Poland: 66%

of PKU alleles are caused by three mutations. *Hum Genet* 1991 Nov;88(1):91-4.

Zygulska M, Eigel A, Pietrzyk JJ, Horst J. Phenylalanine hydroxylase gene: a novel splice mutation in intron 2 in two German and Polish families with severe phenylketonuria. *Hum Mutat* 1993;2(3):238-9.

Zygulska M, Eigel A, Pietrzyk JJ, Horst J. Phenylketonuria in southern Poland: a new splice mutation in intron 9 at the PAH locus. *Hum Mutat* 1994;4(4):297-9.

Zygulska M, Eigel A, Pietrzyk JJ, Miny P, Horst J. A novel mutation in exon 8 of the phenylalanine hydroxylase gene in the Polish population. *Hum Mutat* 1993;2(1):74-6.

Pathology and Physiopathology

Abadie V, Rey F, Plainguet F, Rey J. [Intellectual development after relaxing the diet at the age of 5 years in typical phenylketonuria]. *Arch Fr Pediatr* 1992 Nov;49(9):773-8. (Fre).

Aboul-Ezz EH, Hilal ED, Girgis AS, Temtamy SA, Nassar NM, Ismail SR. Orodonatal and ultrastructural studies of pulp and gingiva in phenylketonuria. *J Egypt Public Health Assoc* 1988;63(3-4):227-39.

Acosta PB, Fernhoff PM, Warshaw HS, Elsas LJ, Hambidge KM, Ernest A, McCabe ER. Zinc status and growth of children undergoing treatment for phenylketonuria. *J Inher Metab Dis* 1982;5(2):107-10.

Acosta PB, Yannicelli S. Protein intake affects phenylalanine requirements and growth of infants with phenylketonuria. *Acta Paediatr Suppl* 1994 Dec;407:66-7.

Acosta PB, Yannicelli S, Marriage B, Mantia C, Gaffield B, Porterfield M, Hunt M, McMaster N, Bernstein L, Parton P, Kuehn M, Lewis V. Nutrient intake and growth of infants with phenylketonuria undergoing therapy. *J Pediatr Gastroenterol Nutr* 1998 Sep;27(3):287-91.

Agostoni C, Riva E, Galli C, Marangoni F, Luotti D, Giovannini M. Plasma arachidonic acid and serum thromboxane B2 concentrations in phenylketonuric children are correlated with dietary compliance. *Z Ernährungswiss* 1998;37 Suppl 1:122-4.

Al-Qadreh A, Schulpis KH, Athanasopoulou H, Mengreli C, Skarpalezou A, Voskaki I. Bone mineral status in children with phenylketonuria under treatment. *Acta Paediatr* 1998 Nov;87(11):1162-6.

Alejandre MJ, Marco C, Ramirez H, Segovia JL, Garcia-Peregrin E. Lipid composition of brain myelin from normal and hyperphenylalaninemic chick embryos. *Comp Biochem Physiol B* 1984;77(2):329-32.

Allanson J, McInnes R, Bradley L, Tarby T, Naylor E, Nardella M. Combined transient and peripheral defects in tetrahydrobiopterin synthesis. *J Pediatr* 1991 Feb;118(2):261-3.

Allen JR, Baur LA, Waters DL, Humphries IR, Allen BJ, Roberts DC, Gaskin KJ. Body protein in prepubertal children with phenylketonuria. *Eur J Clin Nutr* 1996 Mar;50(3):178-86.

Allen JR, Humphries IR, Waters DL, Roberts DC, Lipson AH, Howman-Giles RG, Gaskin KJ. Decreased bone mineral density in children with

- phenylketonuria. *Am J Clin Nutr* 1994 Feb;59(2):419-22.
- Allen RJ. Neurological deterioration in young adults with phenylketonuria [letter]. *Lancet* 1990 Oct 13;336(8720):949.
- Anderson DN, Wilkinson AM, Abou-Saleh MT, Blair JA. Recovery from depression after electroconvulsive therapy is accompanied by evidence of increased tetrahydrobiopterin-dependent hydroxylation. *Acta Psychiatr Scand* 1994 Jul;90(1):10-3.
- Anderson GH, Leiter LA. Effects of aspartame and phenylalanine on meal-time food intake of humans. *Appetite* 1988;11Suppl 1:48-53.
- Anderson PA, Baker DH, Sherry PA, Corbin JE. Histidine, phenylalanine-tyrosine and tryptophan requirements for growth of the young kitten. *J Anim Sci* 1980 Mar;50(3):479-83.
- Antisdel JE, Chrisler JC. Comparison of eating attitudes and behaviors among adolescent and young women with type 1 diabetes mellitus and phenylketonuria. *J Dev Behav Pediatr* 2000 Apr;21(2):81-6.
- Antonozzi I, Carducci C, Vestri L, Manzari V, Dominici R. Plasma amino acid values and pancreatic beta-cell function in phenylketonuria. *J Inherit Metab Dis* 1987;10(1):66-72.
- Arakawa T, Saito TG, Minagawa A, Shioji R, Kobayashi M, Chikaoka H, Katsushima N. Higher excretion of urinary bound amino acids in infants: probably related to protein-anabolic effect of growth hormone. *Tohoku J Exp Med* 1982 May;137(1):1-10.
- Arnold GL, Kramer BM, Kirby RS, Plumeau PB, Blakely EM, Sanger Cregan LS, Davidson PW. Factors affecting cognitive, motor, behavioral and executive functioning in children with phenylketonuria. *Acta Paediatr* 1998 May;87(5):565-70.
- Atwell RA, Berlin SJ. Lower extremity manifestations of phenylketonuria. *J Foot Surg* 1983 Spring;22(1):3-8.
- Baba H, Sato S, Inuzuka T, Miyatake T. Developmental changes of myelin-associated glycoprotein in rat brain: study on experimental hyperphenylalaninemia. *Neurochem Res* 1987 May;12(5):459-63.
- Backwell FR, Bequette BJ, Wilson D, Calder AG, Metcalf JA, Wray-Cahen D, MacRae JC, Beever DE, Lobley GE. Utilization of dipeptides by the caprine mammary gland for milk protein synthesis. *Am J Physiol* 1994 Jul;267(1 Pt 2):R1-6.
- Balci S, Tanzer F, Atasu M, Ozalp I. Dermatoglyphic study in children with phenylketonuria. *J Inherit Metab Dis* 1989;12(3):323-6.
- Ball RO, Atkinson JL, Bayley HS. Proline as an essential amino acid for the young pig. *Br J Nutr* 1986 May;55(3):659-68.
- Ball RO, Bayley HS. Time course of the total and radioactive carbon dioxide production by piglets receiving dietary [¹⁴C]phenylalanine. *Can J Physiol Pharmacol* 1985 Sep;63(9):1170-4.
- Ballinger AB, Clark ML. L-phenylalanine releases cholecystokinin (CCK) and is associated with reduced food intake in humans: evidence for a physiological role of CCK in control of eating. *Metab Clin Exp* 1994 Jun;43(6):735-8.
- Barashnev YI, Korneichuk VV, Klembovsky AI, Klyushina LA. Role of the liver in the pathogenesis of cerebral disorders in phenylketonuria. *J Inherit Metab Dis* 1982;5(4):204-10.
- Barden HS, Kessel R, Schuett VE. The costs and benefits of screening for PKU in Wisconsin. *Soc Biol* 1984 Spring-Summer;31(1-2):1-17.
- Battistini S, De Stefano N, Parlanti S, Federico A. Unexpected white matter changes in an early treated PKU case and improvement after dietary treatment. *Funct Neurol* 1991 Apr-Jun;6(2):177-80.
- Bauman ML, Kemper TL. Morphologic and histoanatomic observations of the brain in untreated human phenylketonuria. *Acta Neuropathol (Berl)* 1982;58(1):55-63.
- Beaudette T. Metabolic disorders of childhood: nutritional management. *Semin Nutr* 1994 Mar-Apr;13(4):1-18.
- Bechara-Andere J, Mota de Avelar-Alchorne M, Schmidt BJ, Schwery-Michalany N. [Classic phenylketonuria: dermatological and histopathological aspects in 35 patients]. *Bol Med Hosp Infant Mex* 1988 Feb;45(2):73-8. (Spa).
- Behbehani AW. Termination of strict diet therapy in phenylketonuria. A study on EEG sleep patterns and computer spectral analysis. *Neuropediatrics* 1985 May;16(2):92-7.
- Behbehani AW, Krtisch H, Schulte FJ. Cranial computerized tomography in phenylketonuria. *Neuropediatrics* 1981 Nov;12(4):295-302.
- Bel Y, Jacobson KB, Ferre J. A comparative study of *Drosophila* phenylalanine hydroxylase with a natural and a synthetic tetrahydropterin as cofactor. *Comp Biochem Physiol [B]* 1992 Nov;103(3):557-62.

- Bel Y, Jacobson KB, Silva FJ, Ferre J. Developmental and biochemical studies on the phenylalanine hydroxylation system in *Drosophila melanogaster*. *Insect Biochem Mol Biol* 1992 Oct;22(7):633-8.
- Bell JM, John AM. Amino acid requirements of growing mice: arginine, lysine, tryptophan and phenylalanine. *J Nutr* 1981 Mar;111(3):525-30.
- Bell L, Acosta PB, Chan L. Amino acid content of low-protein recipes. *J Am Diet Assoc* 1982 Jun;80(6):579-80.
- Bequette BJ, Backwell FR, Crompton LA. Current concepts of amino acid and protein metabolism in the mammary gland of the lactating ruminant. *J Dairy Sci* 1998 Sep;81(9):2540-59.
- Beschle HG, Sussmuth R, Lingens F. Conversion of chloramphenicol degradation products by tyrosine aminotransferase from *Flavobacteria*. *Hoppe Seylers Z Physiol Chem* 1982 Apr;363(4):439-44.
- Bick U, Fahrendorf G, Ludolph AC, Vassallo P, Weglage J, Ullrich K. Disturbed myelination in patients with treated hyperphenylalaninaemia: evaluation with magnetic resonance imaging. *Eur J Pediatr* 1991 Jan;150(3):185-9.
- Bick U, Ullrich K, Stober U, Moller H, Schuierer G, Ludolph AC, Oberwittler C, Weglage J, Wendel U. White matter abnormalities in patients with treated hyperphenylalaninaemia: magnetic resonance relaxometry and proton spectroscopy findings. *Eur J Pediatr* 1993 Dec;152(12):1012-20.
- Bickel H. Dietary restriction in inborn errors of amino acid metabolism. *Curr Concepts Nutr* 1979;8:35-53.
- Bickel H. [Screening for congenital metabolic disorders. Indication and results]. *Monatsschr Kinderheilkd* 1983 Jun;131(6):323-7. (Ger).
- Biolo G, Maggi SP, Williams BD, Tipton KD, Wolfe RR. Increased rates of muscle protein turnover and amino acid transport after resistance exercise in humans. *Am J Physiol* 1995 Mar;268(3 Pt 1):E514-20.
- Biolo G, Tessari P, Inchiostro S, Bruttomesso D, Sabadin L, Fongher C, Panebianco G, Fratton MG, Tiengo A. Fasting and postmeal phenylalanine metabolism in mild type 2 diabetes. *Am J Physiol* 1992 Nov;263(5 Pt 1):E877-83.
- Birnbacher R, Scheibenreiter S, Blau N, Bieglmayer C, Frisch H, Waldhauser F. Hyperprolactinemia, a tool in treatment control of tetrahydrobiopterin deficiency: endocrine studies in an affected girl. *Pediatr Res* 1998 Apr;43(4 Pt 1):472-7.
- Blaauw Ide, Deutz NEP, Meyenfeldt MF von. In vivo amino acid metabolism of gut and liver during short and prolonged starvation. *Am J Physiol* 1996 Feb;270(2 Pt 1):G298-306.
- Blaskovics M, Engel R, Podosin RL, Azen CG, Friedman EG. EEG pattern in phenylketonuria under early initiated dietary treatment. *Am J Dis Child* 1981 Sep;135(9):802-8.
- Bliudzin YuA, Zuber VL. [Composition of fatty acids of glycerophospholipids in the brain of growing rats during demyelination]. *Nervn Sist* 1982;1982(23):125-9. (Rus).
- Bliumina MG. [Phenylketonuria with congenital megaloblastic anemia]. *Pediatriia* 1981 Dec;(12):56-7. (Rus).
- Blomstrand E, Newsholme EA. Effect of branched-chain amino acid supplementation on the exercise-induced change in aromatic amino acid concentration in human muscle. *Acta Physiol Scand* 1992 Nov;146(3):293-8.
- Blomstrand E, Perrett D, Parry-Billings M, Newsholme EA. Effect of sustained exercise on plasma amino acid concentrations and on 5-hydroxytryptamine metabolism in six different brain regions in the rat. *Acta Physiol Scand* 1989 Jul;136(3):473-81.
- Bodley JL, Austin VJ, Hanley WB, Clarke JT, Zlotkin S. Low iron stores in infants and children with treated phenylketonuria: a population at risk for iron-deficiency anaemia and associated cognitive deficits. *Eur J Pediatr* 1993 Feb;152(2):140-3.
- Bouteloup-Demange C, Boirie Y, Dechelotte P, Gachon P, Beaufriere B. Gut mucosal protein synthesis in fed and fasted humans. *Am J Physiol* 1998 Mar;274(3 Pt 1):E541-6.
- Bowe K. Phenylketonuria: an update for pediatric community health nurses. *Pediatr Nurs* 1995 Mar-Apr;21(2):191-4.
- Bradburn NC, Wappner RS, Lemons JA, Meyer BA, Roberts RS. Lactation and phenylketonuria. *Am J Perinatol* 1985 Apr;2(2):138-41.
- Brismar J, Aqeel A, Gascon G, Ozand P. Malignant hyperphenylalaninemia: CT and MR of the brain. *AJNR Am J Neuroradiol* 1990 Jan-Feb;11(1):135-8.
- Bross R, Ball RO, Clarke JT, Pencharz PB. Tyrosine requirements in children with classical PKU determined by indicator amino acid oxidation. *Am J Physiol Endocrinol Metab* 2000 Feb;278(2):E195-201.
- Brown EH, Berry HK, Olson J, Levinson J. Phenylketonuria and scleroderma. *J Inher Metab Dis* 1986;9(4):405-6.

- Brown KJ. Physiological phenylketonuria: a biochemical defect caused by delayed maturation of the phenylalanine hydroxylation pathway and by competition with the phenylalanine biosynthetic pathway. *Med Hypotheses* 1980 Feb;6(2):215-24.
- Brunner RL, Berch DB, Berry H. Phenylketonuria and complex spatial visualization: an analysis of information processing. *Dev Med Child Neurol* 1987 Aug;29(4):460-8.
- Buhrdel P, Dabritz S, Theile H. [Effect of dietary measures on body weight and height of children with phenylketonuria in East Germany]. *Klin Padiatr* 1997 Jan-Feb;209(1):26-9. (Ger).
- Burgard P, Armbruster M, Schmidt E, Rupp A. Psychopathology of patients treated early for phenylketonuria: results of the German collaborative study of phenylketonuria. *Acta Paediatr Suppl* 1994 Dec;407:108-10.
- Burgard P, Rey F, Rupp A, Abadie V, Rey J. Neuropsychological functions of early treated patients with phenylketonuria, on and off diet: results of a cross-national and cross-sectional study. *Pediatr Res* 1997 Mar;41(3):368-74.
- Burgert SL, Andersen DW, Stegink LD, Takeuchi H, Schedl HP. Metabolism of aspartame and its L-phenylalanine methyl ester decomposition product by the porcine gut. *Metab Clin Exp* 1991 Jun;40(6):612-8.
- Burns TS, Stargel WW, Hurwitz A. Bioavailability of phenylalanine and aspartate from aspartame (20 mg/kg) in capsules and solution. *Metab Clin Exp* 1990 Nov;39(11):1200-3.
- Burri R, Matthieu JM, Vandeveld M, Lazeyras F, Posse S, Herschkowitz N. Brain damage and recovery in hyperphenylalaninemic rats. *Dev Neurosci* 1990;12(2):116-25.
- Burri R, Steffen C, Stieger S, Brodbeck U, Colombo JP, Herschkowitz N. Reduced myelinogenesis and recovery in hyperphenylalaninemic rats. Correlation between brain phenylalanine levels, characteristic brain enzymes for myelination, and brain development. *Mol Chem Neuropathol* 1990 Aug-Oct;13(1-2):57-69.
- Burrin DG, Davis TA, Ebner S, Schoknecht PA, Fiorotto ML, Reeds PJ. Colostrum enhances the nutritional stimulation of vital organ protein synthesis in neonatal pigs. *J Nutr* 1997 Jul;127(7):1284-9.
- Burton EG, Dal Monte P, Spears C, Frank P, Oppermann JA. Absorption by the rhesus monkey of phenylalanine methyl ester and species differences in its metabolism by blood, plasma and intestinal mucosa. *J Nutr* 1984 Oct;114(10):1940-5.
- Burton EG, Schoenhard GL, Hill JA, Schmidt RE, Hribar JD, Kotsolis FN, Oppermann JA. Identification of N-beta-L-aspartyl-L-phenylalanine as a normal constituent of human plasma and urine. *J Nutr* 1989 May;119(5):713-21.
- Buyukgebiz B, Eroglu Y, Buy ukgebiz A. True precocious puberty associated with phenylketonuria. *J Pediatr Endocrinol* 1994 Oct-Dec;7(4):361-3.
- Calomme M, Vanderpas J, Francois B, Van Caillie-Bertrand M, Vanovervelt N, Van Hoorebeke C, Vanden Berghe D. Effects of selenium supplementation on thyroid hormone metabolism in phenylketonuria subjects on a phenylalanine restricted diet. *Biol Trace Elem Res* 1995 Jan-Mar;47(1-3):349-53.
- Calomme MR, Vanderpas JB, Francois B, Van Caillie-Bertrand M, Herchuelz A, Vanovervelt N, Van Hoorebeke C, Vanden Berghe DA. Thyroid function parameters during a selenium repletion/depletion study in phenylketonuric subjects. *Experientia* 1995 Dec 18;51(12):1208-15.
- Cardona F, Leuzzi V, Antonozzi I, Benedetti P, Loizzo A. The development of auditory and visual evoked potentials in early treated phenylketonuric children. *Electroencephalogr Clin Neurophysiol* 1991 Jan-Feb;80(1):8-15.
- Carson DJ, Greeves LG, Sweeney LE, Crone MD. Osteopenia and phenylketonuria. *Pediatr Radiol* 1990;20(8):598-9.
- Casamassimo PS, et al. Dental health in children with Phenylketonuria, PKU: and other inborn errors of metabolism managed by diet. Rockville (MD): Department of Health and Human Services (US), Public Health Service, Health Resources and Services Administration, Bureau of Health Care Delivery and Assistance, Division of Maternal and Child Health; 1984. 28 p. (DHHS publication; HRS-D-MC 84-1).
- Celiker V, Dural O, Erdem K. Anesthetic management of a patient with hereditary fructose intolerance and phenylketonuria. *Turk J Pediatr* 1993 Apr-Jun;35(2):127-30.
- Cerone R, Schiaffino MC, Di Stefano S, Veneselli E. Phenylketonuria: diet for life or not? *Acta Paediatr* 1999 Jun;88(6):664-6.
- Choi YH, Furuse M, Okumura J, Shimoyama Y, Sugahara K, Denbow DM. Intracerebroventricularly administered phenylalanine and tyrosine: effects on feeding behavior and norepinephrine concentrations of specific brain sites in the chicken. *Asian Australas J Anim Sci* 1996 Jun;9(3):255-9.
- Citron BA, Davis MD, Milstien S, Gutierrez J, Mendel DB, Crabtree GR, Kaufman S. Identity of 4a-

carbinolamine dehydratase, a component of the phenylalanine hydroxylation system, and DCoH, a transregulator of homeodomain proteins. *Proc Natl Acad Sci U S A* 1992 Dec 15;89(24):11891-4.

Cleary MA, Walter JH, Wraith JE, Jenkins JP, Alani SM, Tyler K, Whittle D. Magnetic resonance imaging of the brain in phenylketonuria. *Lancet* 1994 Jul 9;344(8915):87-90.

Cleary MA, Walter JH, Wraith JE, White F, Tyler K, Jenkins JP. Magnetic resonance imaging in phenylketonuria: reversal of cerebral white matter change. *J Pediatr* 1995 Aug;127(2):251-5.

Cordero ME, Trejo M, Colombo M, Aranda V. Histological maturation of the neocortex in phenylketonuric rats. *Early Hum Dev* 1983 Jul;8(2):157-73.

Coskun T, Karagoz T, Kalkanoglu S, Tokatli A, Ozalp I, Thony B, Blau N. Guanosine triphosphate cyclohydrolase I deficiency: a rare cause of hyperphenylalaninemia. *Turk J Pediatr* 1999 Apr-Jun;41(2):231-7.

Coskun T, Ozalp I, Kale G, Gogus S. Scleroderma-like skin lesions in two patients with phenylketonuria. *Eur J Pediatr* 1990 Dec;150(2):109-10.

Coskun T, Topcu M, Ustundag I, Ozalp I, Renda Y, Ciger A, Nurlu G. Neurophysiological studies of patients with classical phenylketonuria: evaluation of results of IQ scores, EEG and evoked potentials. *Turk J Pediatr* 1993 Jan-Mar;35(1):1-10.

Cotticelli L, Costagliola C, Rinaldi E, DiMeo A, Sartorio R, Vajro P, Andria G. Ophthalmological findings of phenylketonuria: a survey of 14 cases. *J Pediatr Ophthalmol Strabismus* 1985 Mar-Apr;22(2):78-9.

Craft S, Gourovitch ML, Downton SB, Swanson JM, Bonforte S. Lateralized deficits in visual attention in males with developmental dopamine depletion. *Neuropsychologia* 1992 Apr;30(4):341-51.

Creel D, Buehler BA. Pattern evoked potentials in phenylketonuria. *Electroencephalogr Clin Neurophysiol* 1982 Feb;53(2):220-3.

Cristiano RJ, Smith LC, Woo SL. Hepatic gene therapy: adenovirus enhancement of receptor-mediated gene delivery and expression in primary hepatocytes. *Proc Natl Acad Sci U S A* 1993 Mar 15;90(6):2122-6.

Crockett DJ, Woolf LI, McBean MS, Woolf FM, Cahalane SF. Birth weight and pathogenesis in phenylketonuria. *Int J Neurosci* 1990 Oct;54(3-4):259-66.

Crosley CJ, Schneider AJ. Phenylketonuria and neonatal myotonic dystrophy. *Clin Pediatr (Phila)* 1982 Jan;21(1):56-7.

Curtius HC, Adler C, Heizmann C, Blau N, Rebrin I, Ghisla S. 7-substituted pterins: formation and occurrence. *J Nutr Sci Vitaminol (Tokyo)* 1992;Spec No:501-4.

Czartoryska B. [Prenatal diagnosis: a chance? risk? dilemma?]. *Postepy Biochem* 1990;36(3-4):31-3. (POL).

Dahl HH, Osborn AH, Hutchison WM, Thorburn DR, Sheffield LJ. Late diagnosis of maternal PKU in a family segregating an arylsulfatase [corrected] E mutation causing symmetrical chondrodysplasia punctata. *Mol Genet Metab* 1999 Dec;68(4):503-6.

Dalery J, Maillet J, de Villard R. [Behavior problems in phenylketonuria. Attempt at a biochemical interpretation based on a personal case and a review of the literature]. *Encephale* 1983;9(3):279-90. (Fre).

Danks DM, Bartholome K, Clayton BE, Curtius H, Grobe H, Kaufman S, Leeming R, Pfeleiderer W, Rembold H, Rey F. Malignant hyperphenylalaninaemia--current status (June 1977). *J Inherit Metab Dis* 1978;1(2):49-53.

Davis TA, Fiorotto ML, Nguyen HV, Burrin DG. Aminoacyl-tRNA and tissue free amino acid pools are equilibrated after a flooding dose of phenylalanine. *Am J Physiol* 1999 Jul;277(1 Pt. 1):E103-9.

Davis TA, Karl IE, Tegtmeyer ED, Osborne DF, Klahr S, Harter HR. Muscle protein turnover: effects of exercise training and renal insufficiency. *Am J Physiol* 1985 Mar;248(3 Pt 1):E337-45.

De Giorgis GF, Antonozzi I, Del Castello PG, Rosano M, Loizzo A. EEG as a possible prognostic tool in phenylketonuria. *Electroencephalogr Clin Neurophysiol* 1983 Jan;55(1):60-8.

De Giorgis GF, Nonnis E, Crocioni F, Gregori P, Rosini MP, Leuzzi V, Loizzo A. Evolution of daytime quiet sleep components in early treated phenylketonuric infants. *Brain Dev* 1996 May-Jun;18(3):201-6.

de la Fuente Aguado J, Jimenez-Beatty Navarro MD, Rego Iraeta A, Prieto Lopez MI, Paramo C. [Peptic ulcer disease associated with phenylketonuria (letter)]. *An Med Interna* 1994 Nov;11(11):567. (Spa).

de Sanctis L, Alliaudi C, Spada M, Farrugia R, Cerone R, Biasucci G, Meli C, Zammarchi E, Coskun T, Blau N, Ponzzone A, Dianzani I. Genotype-phenotype correlation in dihydropteridine reductase deficiency. *J Inherit Metab Dis* 2000;23(4):333-7.

- Dhondt JL. Clinical presentation of tetrahydrobiopterin deficiency. In: Schmidt BJ, Diamant AJ, Loghin-Grosso NS, editors. *Current trends in infant screening. Proceedings of the 7th International Screening Symposium*; 1988 Nov 6-9; Sao Paulo, Brazil. New York: Excerpta Medica; 1989. p. 73-6. (International congress series; no. 848).
- Dhondt JL. [Measurement of dihydropteridine reductase activity in dried blood eluates: physiological and pathological implications]. *Ann Biol Clin (Paris)* 1992;50(9):653-8. (Fre).
- Dhondt JL, Largilliere C, Moreno L, Farriaux JP. Physical growth in patients with phenylketonuria. *J Inher Metab Dis* 1995;18(2):135-7.
- Diamond A. Evidence for the importance of dopamine for prefrontal cortex functions early in life. *Philos Trans R Soc Lond B Biol Sci* 1996 Oct 29;351(1346):1483-93; discussion 1494.
- Diamond A. Phenylalanine levels of 6-10 mg/dl may not be as benign as once thought. *Acta Paediatr Suppl* 1994 Dec;407:89-91.
- Diamond A, Herzberg C. Impaired sensitivity to visual contrast in children treated early and continuously for phenylketonuria. *Brain* 1996 Apr;119 (Pt 2):523-38.
- Diamond A, Prevor MB, Callender G, Druin DP. Prefrontal cortex cognitive deficits in children treated early and continuously for PKU. *Monogr Soc Res Child Dev* 1997;62(4):i-v, 1-208.
- DiLella AG, Woo SL. Molecular basis of phenylketonuria and its clinical applications. *Mol Biol Med* 1987 Aug;4(4):183-92.
- Dillehay L, Bass R, Englesberg E. Inhibition of growth of cells in culture by L-phenylalanine as a model system for the analysis of phenylketonuria. I. amino acid antagonism and the inhibition of protein synthesis. *J Cell Physiol* 1980 Mar;102(3):395-405.
- Duch DS, Smith GK. Biosynthesis and function of tetrahydrobiopterin. *J Nutr Biochem* 1991 Aug;2(8):411-23.
- Dyer CA. Pathophysiology of phenylketonuria. *Ment Retard Dev Disabil Res Rev* 1999;5(2):104-12.
- Dyer CA, Kendler A, Philibotte T, Gardiner P, Cruz J, Levy HL. Evidence for central nervous system glial cell plasticity in phenylketonuria. *J Neuropathol Exp Neurol* 1996 Jul;55(7):795-814.
- Dzhura I, Naidenov V, Zhuravleva S, Kostyuk P, Shuba Y. Expression of Ca²⁺ channels from rat brain with model phenylketonuria in *Xenopus* oocytes. *Brain Res* 1998 Feb 9;783(2):280-5.
- Economou-Petersen E, Henriksen KF, Guldborg P, Guttler F. Molecular basis for nonphenylketonuria hyperphenylalaninemia. *Genomics* 1992 Sep;14(1):1-5.
- Eggers C, Bickel H. [Pre-, peri- and postnatal causes of mental retardation]. *Ergeb Inn Med Kinderheilkd* 1974;34(0):155-205. (Ger).
- Eiken HG, Knappskog PM, Motzfeldt K, Boman H, Apold J. Phenylketonuria genotypes correlated to metabolic phenotype groups in Norway. *Eur J Pediatr* 1996 Jul;155(7):554-60.
- Eisenberg L. Child mental health in the Americas: a public health approach. *Bull Pan Am Health Organ* 1992;26(3):230-41.
- Elkin RG, Chrisman CL, Rogler JC, Featherston WR. Influence of (dietary) phenylalanine and lysine deficiencies on thyroid morphology in the chick. *Poultry Sci* 1981 Apr;60(4):878-81.
- Elkin RG, Rogler JC. Partial alleviation of phenylalanine toxicity in the chick by supplemental dietary tryptophan. *Poult Sci* 1983 Apr;62(4):647-58.
- Elstad CA, Meadows GG. Modulation of B16-BL6 murine melanoma metastatic phenotype by tyrosine and phenylalanine restriction in the absence of host selection pressures. *Anticancer Res* 1993 Mar-Apr;13(2):523-8.
- Elstad CA, Meadows GG, Aslakson CJ, Starkey JR. Evidence for nutrient modulation of tumor phenotype: impact of tyrosine and phenylalanine restriction. *Adv Exp Med Biol* 1994;354:171-83.
- Elstad CA, Thrall BD, Raha G, Meadows GG. Tyrosine and phenylalanine restriction sensitizes adriamycin-resistant P388 leukemia cells to adriamycin. *Nutr Cancer* 1996;25(1):47-60.
- Epstein CM, Trotter JF, Averbok A, Freeman S, Kutner MH, Elsas LJ. EEG mean frequencies are sensitive indices of phenylalanine effects on normal brain. *Electroencephalogr Clin Neurophysiol* 1989 Feb;72(2):133-9.
- Eriksson T, Carlsson A. Beta-adrenergic control of brain uptake of large neutral amino acids. *Life Sci* 1988;42(17):1583-9.
- Fallstrom SP, Lindblad B, Steen G. On the renal tubular damage in hereditary tyrosinemia and on the formation of succinylacetoacetate and succinylacetone. *Acta Paediatr Scand* 1981;70(3):315-20.
- Fang CH, Li BG, James JH, Fischer JE, Hasselgren PO. The anabolic effects of IGF-1 in skeletal muscle after burn injury are not caused by increased cell

- volume. JPEN J Parenter Enteral Nutr 1998 May-Jun;22(3):115-9.
- Fehrenbach AM, Peterson L. Parental problem-solving skills, stress, and dietary compliance in phenylketonuria. J Consult Clin Psychol 1989 Apr;57(2):237-41.
- Fernstrom JD. Role of precursor availability in control of monoamine biosynthesis in brain. Physiol Rev 1983 Apr;63(2):484-546.
- Fisch RO, Burke B, Bass J, Ferrara TB, Mastri A. Maternal phenylketonuria-chronology of the detrimental effects on embryogenesis and fetal development: pathological report, survey, clinical application. Pediatr Pathol 1986;5(3-4):449-61.
- Fisch RO, Chang PN, Weisberg S, Guldborg P, Guttler F, Tsai MY. Phenylketonuric patients decades after diet. J Inherit Metab Dis 1995;18(3):347-53.
- Fisch RO, Feinberg SB, Weisberg S, Day D. Bony changes of PKU neonates unrelated to phenylalanine levels. J Inherit Metab Dis 1991;14(6):890-5.
- Fisch RO, Tsai MY, Gentry WC Jr. Studies of phenylketonurics with dermatitis. J Am Acad Dermatol 1981 Mar;4(3):284-90.
- Fisher MJ, Dickson AJ, Pogson CI. The polyamine-dependent modulation of phenylalanine hydroxylase phosphorylation state and enzymic activity in isolated liver cells. Biochem J 1986 Jul 1;237(1):277-9.
- Fitzgerald B, Morgan J, Keene N, Rollinson R, Hodgson A, Dalrymple-Smith J. An investigation into diet treatment for adults with previously untreated phenylketonuria and severe intellectual disability. J Intellect Disabil Res 2000 Feb;44(Pt 1):53-9.
- Forlani G, Lejczak B, Kafarski P. The herbicidally active compound N-2-(6-methyl-pyridyl)-aminomethylane bisphosphonic acid inhibits in vivo aromatic biosynthesis. J Plant Growth Regul 1999 Spring ;18(2):73-9.
- Franke W, Dyrna G, Wegner H. [Oral findings in phenylketonuria with early and late dietetic therapy (author's transl)]. Zahn Mund Kieferheilkd Zentralbl 1982;70(3):211-6. (Ger).
- Fulton TR, Triano T, Rabe A, Loo YH. Phenylacetate and the enduring behavioral deficit in experimental phenylketonuria. Life Sci 1980 Oct 6;27(14):1271-81.
- Garcia C, Baldellou A, Gimenez-Mas JA, Gracia J, Sanz-Moncasi MP, Enriquez JA, Muino-Blanco MT, Lopez-Perez MJ, Perez-Gonzalez J. Synaptosomal development in rats from phenylketonuric mothers. J Inherit Metab Dis 1996;19(3):385-6.
- Garcia Vera C, Baldellou Vazquez A, Gracia Romero J, Ventura Faci P, Perez-Gonzalez J. [An experimental study on the effects of maternal hyperphenylalaninemia on the central nervous system and behavior of offspring rats]. An Esp Pediatr 1998 Jan;48(1):11-6. (Spa).
- Giffin FD, Clarke JT, d'Entremont DM. Effect of dietary phenylalanine restriction on visual attention span in mentally retarded subjects with phenylketonuria. Can J Neurol Sci 1980 May;7(2):127-31.
- Giovannini M, Valsasina R, Villani R, Ducati A, Riva E, Landi A, Longhi R. Pattern reversal visual evoked potentials in phenylketonuria. J Inherit Metab Dis 1988;11(4):416-21.
- Gjedde A, Crone C. Biochemical modulation of blood-brain barrier permeability. Acta Neuropathol Suppl (Berl) 1983;8:59-74.
- Glasgow JF, Moore R. Plasma amino acid ratio as an index of hepatocellular maturity in the neonate. Biol Neonate 1983;44(3):146-52.
- Gonczewicz M, Socha J, Ignys I, Zachman E, Wolnik-Brzozowska D. [Morphological state and the activity of dipeptidyl peptidases and disaccharidases of the intestinal mucosa in children with untreated phenylketonuria (PKU)]. Pediatr Pol 1980 Apr;55(4):427-32. (Pol).
- Gordon SJ, Latham SC, Spink JD, Galbraith AJ. Assessment of cardiac function by M-mode echocardiography in selenium-deficient phenylketonuric children. J Paediatr Child Health 1991 Feb;27(1):47-50.
- Gourovitch ML, Craft S, Dowton SB, Ambrose P, Sparta S. Interhemispheric transfer in children with early-treated phenylketonuria. J Clin Exp Neuropsychol 1994 Jun;16(3):393-404.
- Greeves LG, Carson DJ, Craig BG, McMaster D. Potentially life-threatening cardiac dysrhythmia in a child with selenium deficiency and phenylketonuria. Acta Paediatr Scand 1990 Dec;79(12):1259-62.
- Greeves LG, Carson DJ, Dodge JA. Peptic ulceration and phenylketonuria: a possible link? Gut 1988 May;29(5):691-2.
- Greeves LG, Carson DJ, Magee A, Patterson CC. Fractures and phenylketonuria. Acta Paediatr 1997 Mar;86(3):242-4.
- Greeves LG, Carson DJ, McMaster D, Craig BG. Cardiac status of patients with phenylketonuria. Acta Paediatr 1994 Oct;83(10):1100-1.

- Greeves LG, Leeming RJ, Hyland K, Dempsey SI, Carson DJ. Neuroblastoma in a patient with dihydropteridine reductase deficiency. *Eur J Pediatr* 1990 Jul;149(10):713-5.
- Greeves LG, McCarthy HL, Redmond A, Carson DJ. Coexistence of cystic fibrosis and phenylketonuria. *Ulster Med J* 1997 May;66(1):59-61.
- Greeves LG, Thomas PS, Carson DJ. Radiological assessment of the hand and wrist in phenylketonuria and hyperphenylalaninaemia. *Pediatr Radiol* 1995;25(5):353-5.
- Griffiths P, Smith C, Harvie A. Transitory hyperphenylalaninaemia in children with continuously treated phenylketonuria. *Am J Ment Retard* 1997 Jul;102(1):27-36.
- Griffiths P, Tarrini M, Robinson P. Executive function and psychosocial adjustment in children with early treated phenylketonuria: correlation with historical and concurrent phenylalanine levels. *J Intellect Disabil Res* 1997 Aug;41 (Pt 4):317-23.
- Grinde B. Effect of amino acid metabolites on lysosomal protein degradation. A regulatory role for kynurenine? *Eur J Biochem* 1984 Dec 17;145(3):623-7.
- Gudinchet F, Maeder P, Meuli RA, Deonna T, Mathieu JM. Cranial CT and MRI in malignant phenylketonuria. *Pediatr Radiol* 1992;22(3):223-4.
- Guldberg P, Mikkelsen I, Henriksen KF, Lou HC, Guttler F. In vivo assessment of mutations in the phenylalanine hydroxylase gene by phenylalanine loading: characterization of seven common mutations. *Eur J Pediatr* 1995 Jul;154(7):551-6. Comment in: *Eur J Pediatr* 1996 Jun;155(6):523-5.
- Gunasekera RS. Pathophysiological mechanisms in dopa-responsive dystonia and regulation of the aromatic amino acid hydroxylases (tyrosine hydroxylase, tetrahydrobiopterin, phenylalanine) [dissertation]. Waco (TX): Baylor University; 1997. 211 p.
- Guttler F, Guldberg P, Henriksen KF, Mikkelsen I, Olsen B, Lou H. Molecular basis for the phenotypical diversity of phenylketonuria and related hyperphenylalaninaemias. *J Inherit Metab Dis* 1993;16(3):602-4.
- Guttler F, Kaufman S, Milstien S. Phenylalanine has no effect on dihydropteridine reductase activity in phenylketonuria fibroblasts [letter]. *Lancet* 1977 Nov 26;2(8048):1139-40.
- Guttler F, Lou H. Dietary problems of phenylketonuria: effect on CNS transmitters and their possible role in behaviour and neuropsychological function. *J Inherit Metab Dis* 1986;9 Suppl 2:169-77.
- Hajek M, Hejcmanova L, Pradny J. Proton in vivo spectroscopy of patients with hyperphenylalaninaemia. *Neuropediatrics* 1993 Apr;24(2):111-2.
- Haktan M, Aydin A, Bahat H, Tuysuz B, Yazici H, Altay S. Progressive systemic scleroderma in an infant with partial phenylketonuria. *J Inherit Metab Dis* 1989;12(4):486-7.
- Haley CJ, Harper AE. Glucagon stimulation of phenylalanine metabolism. The effects of acute and chronic glucagon treatment (Phenylalanine hydroxylase). *Metab Clin Exp* 1982 Jun;31(6):524-32.
- Hanley WB, Feigenbaum A, Clarke JT, Schoonheydt W, Austin V. Vitamin B12 deficiency in adolescents and young adults with phenylketonuria [letter]. *Lancet* 1993 Oct 16;342(8877):997.
- Hanley WB, Feigenbaum AS, Clarke JT, Schoonheydt WE, Austin VJ. Vitamin B12 deficiency in adolescents and young adults with phenylketonuria. *Eur J Pediatr* 1996 Jul;155 Suppl 1:S145-7.
- Hanley WB, Linsao L, Davidson W, Moes CA. Malnutrition with early treatment of phenylketonuria. *Pediatr Res* 1970 Jul;4(4):318-27.
- Harada T, Kagamiyama H, Hatakeyama K. Feedback regulation mechanisms for the control of GTP cyclohydrolase I activity. *Science* 1993 Jun 4;260(5113):1507-10.
- Harper AE. Some recent developments in the study of amino acid metabolism. *Proc Nutr Soc* 1983 Sep;42(3):437-49.
- Hasselbalch S, Knudsen GM, Toft PB, Hogh P, Tedeschi E, Holm S, Videbaek C, Henriksen O, Lou HC, Paulson OB. Cerebral glucose metabolism is decreased in white matter changes in patients with phenylketonuria. *Pediatr Res* 1996 Jul;40(1):21-4.
- Hauw JJ, Escourolle R. Abnormal delayed myelination (hypomyelination) in humans. *Bull Soc Belge Ophtalmol* 1983 Nov;208 Pt 1:89-95.
- Hayden MR, Nichols JL. Molecular genetic approaches to the study of the nervous system. *Dev Neurosci* 1983-84;6(4-5):189-214.
- Henderson HE, Goodman R, Schram J, Diamond E, Daneel A. Biochemical screening for inherited metabolic disorders in the mentally retarded. *S Afr Med J* 1981 Nov 7;60(19):731-3.
- Henderson RM, McCulloch DL, Herbert AM, Robinson PH, Taylor MJ. Visual event-related

- potentials in children with phenylketonuria. *Acta Paediatr* 2000 Jan;89(1):52-7.
- Hertz MM, Bolwig TG, Grandjean P, Westergaard E. Lead poisoning and the blood-brain barrier. *Acta Neurol Scand* 1981 May;63(5):286-96.
- Hidalgo IJ, Borchardt RT. Carrier-mediated transport of bile acids and amino acids in Caco-2 cells. *NATO ASI Ser Ser A Life Sci* 1991;218:77-91.
- Hilliges C, Awiszus D, Wendel U. Intellectual performance of children with maple syrup urine disease. *Eur J Pediatr* 1993 Feb;152(2):144-7.
- Hillman L, Schlotzhauer C, Lee D, Grasela J, Witter S, Allen S, Hillman R. Decreased bone mineralization in children with phenylketonuria under treatment. *Eur J Pediatr* 1996 Jul;155 Suppl 1:S148-52.
- Hoffmann GF. [Phenylketonuria and hyperphenylalaninemia]. *Dtsch Krankenpflegez* 1993 Feb;46(2):80-3. (Ger).
- Hommes FA. Loss of neurotransmitter receptors by hyperphenylalaninemia in the HPH-5 mouse brain. *Acta Paediatr Suppl* 1994 Dec;407:120-1.
- Hommes FA. On the mechanism of permanent brain dysfunction in hyperphenylalaninemia. *Biochem Med Metab Biol* 1991 Dec;46(3):277-87.
- Hommes FA. The role of the blood-brain barrier in the aetiology of permanent brain dysfunction in hyperphenylalaninaemia. *J Inherit Metab Dis* 1989;12(1):41-6.
- Hommes FA, Lee JS. The control of 5-hydroxytryptamine and dopamine synthesis in the brain: a theoretical approach. *J Inherit Metab Dis* 1990;13(1):37-57.
- House JD, Pencharz PB, Ball RO. Phenylalanine requirements determined by using L-[1-¹⁴C]phenylalanine in neonatal piglets receiving total parenteral nutrition supplemented with tyrosine. *Am J Clin Nutr* 1997 Apr;65(4):984-93.
- Howell RR. Phenylketonuria in the general population. *N Engl J Med* 1970 Jun 25;282(26):1486-8.
- Hsiao KJ, Chen CH, Chiu PC, Huang SC, Wu KD. A Chinese family with phenylketonuria and maternal phenylketonuria detected by family screening. *Eur J Pediatr* 1986 Oct;145(5):409-12.
- Huether G, Kaus R, Neuhoff V. Brain development in experimental hyperphenylalaninaemia: myelination. *Neuropediatrics* 1982 Nov;13(4):177-82.
- Huether G, Neuhoff V. Use of alpha-methylphenylalanine for studies of brain development in experimental phenylketonuria. *J Inherit Metab Dis* 1981;4(2):67-8.
- Huether G, Neuhoff V, Kaus R. Brain development in experimental hyperphenylalaninaemia: disturbed proliferation and reduced cell numbers in the cerebellum. *Neuropediatrics* 1983 Feb;14(1):12-9.
- Hufton SE, Jennings IG, Cotton RG. Structure and function of the aromatic amino acid hydroxylases. *Biochem J* 1995 Oct 15;311 (Pt 2):353-66.
- Iinuma K, Narisawa K, Tateda H, Suzuki K, Tada K, Onuma A. [Diet therapy and EEG in phenylketonuria]. *No To Hattatsu* 1983 Nov;15(6):497-502. (Jpn).
- Ionescu S. [Psychophysiology of mental deficiency: evaluation of studies involving the recording of autonomic indices]. *Psychiatr Infant* 1985;28(1):39-134. (Fre).
- Irons M, Levy HL. Metabolic syndromes with dermatologic manifestations. *Clin Rev Allergy* 1986 Feb;4(1):101-24.
- Ishihara A, Ohtsu Y, Iwamura H. Induction of biosynthetic enzymes for avenanthramides in elicitor-treated oat leaves. *Planta* 1999 Jun;208(4):512-8.
- Ishii H, Sasaki Y, Goshima Y, Kanai Y, Endou H, Ayusawa D, Ono H, Miyamae T, Mitsu Y. Involvement of rBAT in Nasup +-dependent and -independent transport of the neurotransmitter candidate L-DOPA in *Xenopus laevis* oocytes injected with rabbit small intestinal epithelium poly Asup + RNA. *Biochim Biophys Acta* 2000 Jun 1;1466(1-2):61-70.
- Jacobson KB, Manos RE. Effects of sepiapterin and 6-acetyldihydrohomopterin on the guanosine triphosphate cyclohydrolase I of mouse, rat and the fruit-fly *Drosophila*. *Biochem J* 1989 May 15;260(1):135-41.
- Jinks DC, Guthrie R, Naylor EW. Simplified procedure for producing *Bacillus subtilis* spores for the Guthrie phenylketonuria and other microbiological screening tests. *J Clin Microbiol* 1985 May;21(5):826-9.
- Johnson CF, Koch R, Peterson RM, Friedman EG. Congenital and neurological abnormalities in infants with phenylketonuria. *Am J Ment Defic* 1978 Jan;82(4):375-9.
- Johnston MV, Singer HS. Brain neurotransmitters and neuromodulators in pediatrics. *Pediatrics* 1982 Jul;70(1):57-68.

- Jones SJ, Turano G, Kriss A, Shawkat F, Kendall B, Thompson AJ. Visual evoked potentials in phenylketonuria: association with brain MRI, dietary state, and IQ. *J Neurol Neurosurg Psychiatry* 1995 Sep;59(3):260-5.
- Kalkanoglu HS, Anadol D, Yilmaz E, Coskun T. Phenylketonuria and cystic fibrosis in the same patient. *Pediatr Int* 2000 Feb;42(1):92-3.
- Kalverboer AF, van der Schot LW, Hendriks MM, Huisman J, Slijper FM, Stemerink BA. Social behaviour and task orientation in early-treated PKU. *Acta Paediatr Suppl* 1994 Dec;407:104-5.
- Kaplan H, Triano T, Donadio M. Behavioral deficit in phenylketonuric rats: role of aromatic acid metabolites of phenylalanine. *Dev Psychobiol* 1981 May;14(3):201-7.
- Kaufman S. New tetrahydrobiopterin-dependent systems. *Annu Rev Nutr* 1993;13:261-86.
- Kaufman S. Novel aspects of metabolism and function of tetrahydrobiopterin. *J Nutr Sci Vitaminol (Tokyo)* 1992;Spec No:492-6.
- Kaur H, Halliwell B. Aromatic hydroxylation of phenylalanine as an assay for hydroxyl radicals. Measurement of hydroxyl radical formation from ozone and in blood from premature babies using improved HPLC methodology. *Anal Biochem* 1994 Jul;220(1):11-5.
- Kawashima H, Kawano M, Masaki A, Sato T. Three cases of untreated classical PKU: a report on cataracts and brain calcification. *Am J Med Genet* 1988 Jan;29(1):89-93.
- Kee AJ, Smith RC. Organ clearance of tyrosyl-arginine and its effect on amino acid metabolism in young sheep. *Metabolism* 1993 Aug;42(8):958-66.
- Kietduriyakul V, Komkris V, Tongkittikul K, Leangphibul P. The incidence of phenylketonuria in Thailand. *J Med Assoc Thai* 1989 Sep;72(9):516-9.
- Kilpatrick NM, Awang H, Wilcken B, Christodoulou J. The implication of phenylketonuria on oral health. *Pediatr Dent* 1999 Nov-Dec;21(7):433-7.
- Kindt E, Halvorsen S, Lie SO. Does a marginal protein intake result in osteoporosis? *J Inherit Metab Dis* 1987;10(2):195.
- Kirby ML, Miyagawa ST. The effects of high phenylalanine concentration on chick embryonic development. *J Inherit Metab Dis* 1990;13(4):634-40.
- Klein D, Marcoz JP, Mounoud RL, Bettschart W. [Final result of a clinical, genetic and cytogenetic investigation of 182 mentally retarded patients of a medico-educative institution]. *Schweiz Rundsch Med Prax* 1982 Jul 27;71(30):1209-21. (Fre).
- Klein LE, Nordlund JJ. Genetic basis of pigmentation and its disorders. *Int J Dermatol* 1981 Dec;20(10):621-31.
- Kobayashi H, Kato J, Morioka H, Stewart JD, Ohtsuka E. Tryptophan H33 plays an important role in pyrimidine (6-4) pyrimidone photoproduct binding by a high-affinity antibody. *Protein Eng* 1999 Oct;12(10):879-84.
- Koch R, Azen C, Friedman EG, Williamson ML. Paired comparisons between early treated PKU children and their matched sibling controls on intelligence and school achievement test results at eight years of age. *J Inherit Metab Dis* 1984;7(2):86-90.
- Koch R, Blaskovics M. Four cases of hyperphenylalaninaemia: studies during pregnancy and of the offspring produced. *J Inherit Metab Dis* 1982;5(1):11-5.
- Korinthenberg R, Ullrich K, Fullenkemper F. Evoked potentials and electroencephalography in adolescents with phenylketonuria. *Neuropediatrics* 1988 Nov;19(4):175-8.
- Kornguth S, Anderson M, Markley JL, Shedlovsky A. Near-microscopic magnetic resonance imaging of the brains of phenylalanine hydroxylase-deficient mice, normal littermates, and of normal BALB/c mice at 9.4 Tesla. *Neuroimage* 1994 Jun;1(3):220-9.
- Kornguth S, Gilbert-Barnes E, Langer E, Hegstrand L. Golgi-Kopsch silver study of the brain of a patient with untreated phenylketonuria, seizures, and cortical blindness. *Am J Med Genet* 1992 Nov 1;44(4):443-8.
- Korpi ER. Aromatic amino acid incorporation into proteins in rat brain slices: influences of other amino acids affecting transport. *Acta Physiol Scand* 1981 Aug;112(4):353-8.
- Koslacz-Folga A, Pakszys M, Cabalska B, Zdanowska W. [Evaluation of the maturity of the bioelectrical activity of the brain of infants with phenylketonuria during sleep]. *Probl Med Wiekow Rozwoj* 1982;11:27-37. (Pol).
- Kostiuk PG, Martyniuk AE. [Possible molecular mechanisms of brain dysfunction in phenylketonuria]. *Patol Fiziol Eksp Ter* 1992 Jul-Aug;4(4):34-6. (Rus).
- Krause W, Epstein C, Averbook A, Dembure P, Elsas L. Phenylalanine alters the mean power frequency of electroencephalograms and plasma L-dopa in treated patients with phenylketonuria. *Pediatr Res* 1986 Nov;20(11):1112-6.

- Krause W, Halminski M, McDonald L, Dembure P, Salvo R, Freides D, Elsas L. Biochemical and neuropsychological effects of elevated plasma phenylalanine in patients with treated phenylketonuria. A model for the study of phenylalanine and brain function in man. *J Clin Invest* 1985 Jan;75(1):40-8.
- Kurth E. Research in mental retardation in the German Democratic Republic (GDR). *Appl Res Ment Retard* 1984;5(3):361-73.
- Lacey DJ. Hippocampal dendritic abnormalities in a rat model of phenylketonuria. *Ann Neurol* 1984 Nov;16(5):577-80.
- Lacey DJ. Normalization of dendritic spine numbers in rat hippocampus after termination of phenylacetate injections (PKU model). *Brain Res* 1985 Mar 11;329(1-2):354-5.
- Lacey DJ, Terplan K. Abnormal cerebral cortical neurons in a child with maternal PKU syndrome. *J Child Neurol* 1987 Jul;2(3):201-4.
- Laguna Serrano C. [Congenital errors of metabolism: phenylketonuria and hyperphenylalanemias]. *An R Acad Nac Med (Madr)* 1982;99(4):783-814. (Spa).
- Landi A, Ducati A, Villani R, Longhi R, Riva E, Rodocanachi C, Giovannini M. Pattern-reversal visual evoked potentials in phenylketonuric children. *Childs Nerv Syst* 1987;3(5):278-81.
- Lane JD, Neuhoff V. Phenylketonuria: clinical and experimental considerations revealed by the use of animal models. *Naturwissenschaften* 1980 May;67(5):227-33.
- Larsson A. Neonatal screening for metabolic and endocrine disorders. *Ups J Med Sci Suppl* 1987;44:231-6.
- Lastochkina NA. [Characteristics of the EEG and systemic activity in classical phenylketonuria]. *Zh Nevropatol Psikhiatr* 1981;81(11):1684-90. (Rus).
- Lastochkina NA. [Features of the convulsive activity in the EEG of patients with classic phenylketonuria]. *Zh Nevropatol Psikhiatr* 1983;83(3):79-86. (Rus).
- Laufs S, Blau N, Thony B. Retrovirus-mediated double transduction of the GTPCH and PTPS genes allows 6-pyruvoyltetrahydropterin synthase-deficient human fibroblasts to synthesize and release tetrahydrobiopterin. *J Neurochem* 1998 Jul;71(1):33-40.
- Lee EB. Metabolic diseases and the skin. *Pediatr Clin North Am* 1983 Aug;30(4):597-608.
- Lei XD, Kaufman S. Identification of hepatic nuclear factor 1 binding sites in the 5' flanking region of the human phenylalanine hydroxylase gene: implication of a dual function of phenylalanine hydroxylase stimulator in the phenylalanine hydroxylation system. *Proc Natl Acad Sci U S A* 1998 Feb 17;95(4):1500-4.
- Leititis JU, Stahl M, Tackmann W, Wick H, Wildberg A. Homozygous hypobetalipoproteinaemia and phenylketonuria. *Eur J Pediatr* 1985 Jul;144(2):174-6.
- Lenke RR, Platt LD, Koch R. Ultrasonographic failure of early detection of fetal microcephaly in maternal phenylketonuria. *J Ultrasound Med* 1983 Apr;2(4):177-9.
- Leuzzi V, Cardona F, Antonozzi I, Loizzo A. Visual, auditory, and somatosensory evoked potentials in early and late treated adolescents with phenylketonuria. *J Clin Neurophysiol* 1994 Nov;11(6):602-6.
- Leuzzi V, Fois D, Carducci C, Antonozzi I, Trasimeni G. Neuropsychological and neuroradiological (MRI) variations during phenylalanine load: protective effect of valine, leucine, and isoleucine supplementation. *J Child Neurol* 1997 Aug;12(5):338-40.
- Leuzzi V, Rinalduzzi S, Chiarotti F, Garzia P, Trasimeni G, Accornero N. Subclinical visual impairment in phenylketonuria. A neurophysiological study (VEP-P) with clinical, biochemical, and neuroradiological (MRI) correlations. *J Inherit Metab Dis* 1998 Jun;21(4):351-64.
- Leuzzi V, Seri S, Cerquiglini A, Carducci C, Carducci C, Antonozzi I. Derangement of the dopaminergic system in phenylketonuria: Study of the event-related potential (P300). *J Inherit Metab Dis* 2000;23(4):317-20.
- Leuzzi V, Trasimeni G, Gualdi GF, Antonozzi I. Biochemical, clinical and neuroradiological (MRI) correlations in late-detected PKU patients. *J Inherit Metab Dis* 1995;18(5):624-34.
- Levine RA. Tetrahydrobiopterin and biogenic amine metabolism in neuropsychiatry, immunology, and aging. *Ann N Y Acad Sci* 1988;521:129-39.
- Levy HL. Molecular genetics of phenylketonuria and its implications. *Am J Hum Genet* 1989 Nov;45(5):667-70.
- Levy HL, Karolkewicz V, Houghton SA, MacCready RA. Screening the "normal" population in Massachusetts for phenylketonuria. *N Engl J Med* 1970 Jun 25;282(26):1455-8.
- Levy HL, Waisbren SE. PKU in adolescents: rationale and psychosocial factors in diet continuation. *Acta Paediatr Suppl* 1994 Dec;407:92-7.

- Leyton M, Young SN, Pihl RO, Etezadi S, Lauze C, Blier P, Baker GB, Benkelfat C. Effects on mood of acute phenylalanine/tyrosine depletion in healthy women. *Neuropsychopharmacology* 2000 Jan;22(1):52-63.
- Lierse W. The vulnerability of retina neuroblast after metabolic errors. *Folia Morphol (Praha)* 1980;28(1):70-1.
- Liu TJ, Kay MA, Darlington GJ, Woo SL. Reconstitution of enzymatic activity in hepatocytes of phenylalanine hydroxylase-deficient mice. *Somat Cell Mol Genet* 1992 Jan;18(1):89-96.
- Lluch Fernandez MD, Ramos Sanchez I, Marchante Cobos C, Perez Perez G, Martinez Martinez JJ, Estefania Gallardo C. [Phenylketonuria. Treatment and developmental control]. *An Esp Pediatr* 1988 Apr;28(4):327-30. (Spa).
- Lo GS, Liang SC, Raha SR, Hunter JB, Longenecker JB. Biochemical and neurological effects of an experimental phenylketonuria-like condition in infant rats during the first 2 weeks after birth. *Am J Clin Nutr* 1981 Apr;34(4):498-506.
- Lombeck I, Kasperek K, Bachmann D, Feinendegen LE, Bremer HJ. Selenium requirements in patients with inborn errors of amino acid metabolism and selenium deficiency. *Eur J Pediatr* 1980 Jun;134(1):65-8.
- Loo YH, Fulton T, Miller K, Wisniewski HM. Phenylacetate and brain dysfunction in experimental phenylketonuria: synaptic development. *Life Sci* 1980 Oct 6;27(14):1283-90.
- Lou HC, Toft PB, Andresen J, Mikkelsen I, Olsen B, Guttler F, Wieslander S, Henriksen O. An occipito-temporal syndrome in adolescents with optimally controlled hyperphenylalaninaemia. *J Inherit Metab Dis* 1992;15(5):687-95.
- Lovenberg WM. Biochemical regulation of brain function. *Nutr Rev* 1986 May;44 Suppl:6-11.
- Ludolph AC, Ullrich K, Nedjat S, Masur H, Bick U. Neurological outcome in 22 treated adolescents with hyperphenylalaninemia. A clinical and electrophysiological study. *Acta Neurol Scand* 1992 Apr;85(4):243-8.
- Ludolph AC, Vetter U, Ullrich K. Studies of multimodal evoked potentials in treated phenylketonuria: the pattern of vulnerability. *Eur J Pediatr* 1996 Jul;155 Suppl 1:S64-8.
- Luke B, Keith LG. The challenge of maternal phenylketonuria screening and treatment. *J Reprod Med* 1990 Jul;35(7):667-73.
- Maas JA, France J, Dijkstra J, Bannink A, McBride BW. Application of a mechanistic model to study competitive inhibition of amino acid uptake by the lactating bovine mammary gland. *J Dairy Sci* 1998 Jun;81(6):1724-34.
- MacDonald A, Rylance G, Hall SK, Asplin D, Booth IW. Factors affecting the variation in plasma phenylalanine in patients with phenylketonuria on diet. *Arch Dis Child* 1996 May;74(5):412-7.
- Macfarlane RG, Midgley JM, Watson DG. Identification and quantitation of phenylalanine, tyrosine and dihydroxyphenylalanine in the thoracic nervous system of the locust, *Schistocerca gregaria*, by gas chromatography-negative-ion chemical ionisation mass spectrometry. *J Chromatogr* 1990 Oct 26;532(1):1-11.
- MacLeod MD, Munro JF, Ledingham JG, Farquhar JW. Management of the extrapyramidal manifestations of phenylketonuria with L-dopa. *Arch Dis Child* 1983 Jun;58(6):457-8.
- Maddox MA. Is there a link between dementia and phenylketonuria? *J Gerontol Nurs* 1990 May;16(5):18-23.
- Maenz DD, Chenu C, Berteloot A. Heterotropic effects of dipolar amino acids on the activity of the anionic amino acid transport system X-(AG) in rabbit jejunal brush-border membrane vesicles. *J Biol Chem* 1993 Jul 25;268(21):15361-7.
- Maher TJ, Glaeser BS, Wurtman RJ. Diurnal variations in plasma concentrations of basic and neutral amino acids and in red cell concentrations of aspartate and glutamate: Effects of dietary protein intake. *Am J Clin Nutr* 1984 May;39(5):722-9.
- Matalon R, Michals K, Azen C, Friedman E, Koch R, Rouse B, Hanley WB, de la Cruz F. Maternal PKU Collaborative Study: pregnancy outcome and postnatal head growth. *J Inherit Metab Dis* 1994;17(3):353-5.
- Mathur R, Manchanda SK. Ontogeny of phenylalanine (endogenous cholecystokinin) induced modulation of food intake in normal and undernourished rats. *Prog Neuropsychopharmacol Biol Psychiatry* 1991;15(3):405-13.
- Matsuo K, Hommes FA. The development of the muscarinic acetylcholine receptor in normal and hyperphenylalaninemic rat cerebrum. *Neurochem Res* 1988 Sep;13(9):867-70.
- McArthur KE, Isenberg JI, Hogan DL, Dreier SJ. Intravenous infusion of L-isomers of phenylalanine and tryptophan stimulate gastric acid secretion at physiologic plasma concentrations in normal subjects and after parietal cell vagotomy. *J Clin Invest* 1983 May;71(5):1254-62.

- McBurnie MA, Kronmal RA, Schuett VE, Koch R, Azeng CG. Physical growth of children treated for phenylketonuria. *Ann Hum Biol* 1991 Jul-Aug;18(4):357-68.
- McCombe PA, McLaughlin DB, Chalk JB, Brown NN, McGill JJ, Pender MP. Spasticity and white matter abnormalities in adult phenylketonuria. *J Neurol Neurosurg Psychiatry* 1992 May;55(5):359-61.
- McDonnell GV, Esmonde TF, Hadden DR, Morrow JI. A neurological evaluation of adult phenylketonuria in Northern Ireland. *Eur Neurol* 1998;39(1):38-43.
- McDowall IL, Fisher MJ. The immediate 5'-flanking region of the rat phenylalanine hydroxylase-encoding gene. *Gene* 1995 Feb 14;153(2):289-90.
- Meijer WJ. [10 years' national screening study of the incidence of phenylketonuria in the Netherlands; 3d report of the National Advisory Phenylketonuria Commission]. *Ned Tijdschr Geneesk* 1985 Jan 12;129(2):74-6. (Dut).
- Mellgren SI, Gotestam KG. Research on mental retardation in Norway 1970-1980: a review. *Appl Res Ment Retard* 1983;4(2):103-12.
- Michals K, Lopus M, Matalon R. Phenylalanine metabolites as indicators of dietary compliance in children with phenylketonuria. *Biochem Med Metab Biol* 1988 Feb;39(1):18-23.
- Michel U, Schmidt E, Batzler U. Results of psychological testing of patients aged 3-6 years. *Eur J Pediatr* 1990;149 Suppl 1:S34-8.
- Milner RD, Wirdnam PK. The pancreatic beta cell fraction in children with errors of amino acid metabolism. *Pediatr Res* 1982 Mar;16(3):213-6.
- Moller HE, Vermathen P, Ullrich K, Weglage J, Koch HG, Peters PE. In-vivo NMR spectroscopy in patients with phenylketonuria: changes of cerebral phenylalanine levels under dietary treatment. *Neuropediatrics* 1995 Aug;26(4):199-202.
- Moller HE, Weglage J, Wiedermann D, Ullrich K. Blood-brain barrier phenylalanine transport and individual vulnerability in phenylketonuria. *J Cereb Blood Flow Metab* 1998 Nov;18(11):1184-91.
- Moller HE, Weglage J, Wiedermann D, Vermathen P, Bick U, Ullrich K. Kinetics of phenylalanine transport at the human blood-brain barrier investigated in vivo. *Brain Res* 1997 Dec 19;778(2):329-37.
- Motzfeldt K, Lilje R, Nylander G. Breastfeeding in phenylketonuria. *Acta Paediatr Suppl* 1999 Dec;88(432):25-7.
- Muntau AC, Beblo S, Koletzko B. [Phenylketonuria and hyperphenylalaninemia]. *Monatsschr Kinderheilkd* 2000;148(2):179-93. (Ger).
- Nagasaki Y, Matsubara Y, Takano H, Fujii K, Senoo M, Akanuma J, Takahashi K, Kure S, Hara M, Kanegae Y, Saito I, Narisawa K. Reversal of hypopigmentation in phenylketonuria mice by adenovirus-mediated gene transfer. *Pediatr Res* 1999 Apr;45(4 Pt 1):465-73.
- Nagatsu T, Ichinose H. Regulation of pteridine-requiring enzymes by the cofactor tetrahydrobiopterin. *Mol Neurobiol* 1999 Feb;19(1):79-96.
- Nagatsu T, Matsuura S, Sugimoto T. Physiological and clinical chemistry of biopterin. *Med Res Rev* 1989 Jan-Mar;9(1):25-44.
- Naughten ER. Continuation vs discontinuation of diet in phenylketonuria. *Eur J Clin Nutr* 1989;43 Suppl 1:7-12.
- Navab F, Winter CG. Effect of aging on intestinal absorption of aromatic amino acids in vitro in the rat. *Am J Physiol* 1988 Apr;254(4 Pt 1):G631-6.
- Netley C, Hanley WB, Rudner HL. Phenylketonuria and its variants: observations on intellectual functioning. *Can Med Assoc J* 1984 Oct 1;131(7):751-5.
- Netzloff ML. Neonatal screening for phenylketonuria. *Ann Clin Lab Sci* 1982 Sep-Oct;12(5):368-71.
- Niederwieser A, Blau N, Wang M, Joller P, Atares M, Cardesa-Garcia J. GTP cyclohydrolase I deficiency, a new enzyme defect causing hyperphenylalaninemia with neopterin, biopterin, dopamine, and serotonin deficiencies and muscular hypotonia. *Eur J Pediatr* 1984 Feb;141(4):208-14.
- Noziglia C, Contreras J, Arevalo QF. [Phenylketonuria associated with craniostenosis and cleft palate]. *Rev Chil Pediatr* 1981 Jan-Feb;52(1):69-71. (Spa).
- O'Grady DJ, Berry HK, Sutherland BS. Cognitive development in early treated phenylketonuria. *Am J Dis Child* 1971 Jan;121(1):20-3.
- Okajima K, Inoue M, Morino Y. Studies on the mechanism for renal elimination of N-acetylphenylalanine: its pathophysiologic significance in phenylketonuria. *J Lab Clin Med* 1985 Jan;105(1):132-8.
- Oorschot DE, Jones DG. A quantitative ultrastructural study of the effects of phenylacetate on synaptic organization in the developing rat cerebral cortex. *Dev Neurosci* 1983-84;6(1):45-57.

- Opplinger T, Thony B, Nar H, Burgisser D, Huber R, Heizmann CW, Blau N. Structural and functional consequences of mutations in 6-pyruvoyltetrahydropterin synthase causing hyperphenylalaninemia in humans. Phosphorylation is a requirement for in vivo activity. *J Biol Chem* 1995 Dec 8;270(49):29498-506.
- Oulis C, Kostopoulou M. [Phenylketonuria in children: problems of special interest to the dentist]. *Odontostomatol Proodos* 1984 Nov-Dec;38(6):341-50. (Gre).
- Pardridge WM. Potential effects of the dipeptide sweetener aspartame on the brain. *Nutr Brain* 1986;7:199-241.
- Pasali D, Deseta E, Pjanovic Z. [Hearing disorders and audiometry findings in children with phenylketonuria]. *Srp Arh Celok Lek* 1981 Mar;109(3):415-20. (Scc).
- Pearson KD, Gean-Marton AD, Levy HL, Davis KR. Phenylketonuria: MR imaging of the brain with clinical correlation. *Radiology* 1990 Nov;177(2):437-40.
- Pennington BF. Genetics of learning disabilities. *J Child Neurol* 1995 Jan;10 Suppl 1:S69-77.
- Penrose LS. Phenylketonuria--a problem in eugenics. *Ann Hum Genet* 1998 May;62 (Pt 3):193-202.
- Perez B, Desviat LR, Garcia MJ, Ugarte M. Different phenotypic manifestations associated with identical phenylketonuria genotypes in two Spanish families. *J Inherit Metab Dis* 1994;17(3):377-8.
- Peterson K, Slover R, Gass S, Seltzer WK, McCabe LL, McCabe ER. Blood phenylalanine estimation for the patient with phenylketonuria using a portable device. *Biochem Med Metab Biol* 1988 Feb;39(1):98-104.
- Phenylketonuria, an international survey of management over 40 years. Proceedings of a workshop. Fulda, November 16-19, 1994. *Eur J Pediatr* 1996 Jul;155 Suppl 1:S1-180.
- Piedrafita AC, Martinez-Ramirez AC, Silva FJ. A genetic analysis of aromatic amino acid hydroxylases involvement in DOPA synthesis during *Drosophila* adult development. *Insect Biochem Mol Biol* 1994 Jun;24(6):581-8. Published erratum appears in *Insect Biochem Mol Biol* 1995 Jan;25(1):151.
- Pierzchala K, Rosciszewska D, Kwiecinski J. [Adult age phenylketonuria with extrapyramidal syndrome: therapeutic management]. *Neurol Neurochir Pol* 1993 Nov-Dec;27(6):899-904. (Pol).
- Pietz J, Benninger C, Schmidt H, Scheffner D, Bickel H. Long-term development of intelligence (IQ) and EEG in 34 children with phenylketonuria treated early. *Eur J Pediatr* 1988 May;147(4):361-7.
- Pietz J, Dunkelmann R, Rupp A, Rating D, Meinck HM, Schmidt H, Bremer HJ. Neurological outcome in adult patients with early-treated phenylketonuria. *Eur J Pediatr* 1998 Oct;157(10):824-30.
- Pietz J, Fatkenheuer B, Burgard P, Armbruster M, Esser G, Schmidt H. Psychiatric disorders in adult patients with early-treated phenylketonuria. *Pediatrics* 1997 Mar;99(3):345-50.
- Pietz J, Kreis R, Rupp A, Mayatepek E, Rating D, Boesch C, Bremer HJ. Large neutral amino acids block phenylalanine transport into brain tissue in patients with phenylketonuria. *J Clin Invest* 1999 Apr;103(8):1169-78.
- Pietz J, Kreis R, Schmidt H, Meyding-Lamade UK, Rupp A, Boesch C. Phenylketonuria: findings at MR imaging and localized in vivo H-1 MR spectroscopy of the brain in patients with early treatment. *Radiology* 1996 Nov;201(2):413-20.
- Pietz J, Landwehr R, Kutscha A, Schmidt H, de Sonneville L, Trefz FK. Effect of high-dose tyrosine supplementation on brain function in adults with phenylketonuria. *J Pediatr* 1995 Dec;127(6):936-43.
- Pietz J, Lutcke A, Sontheimer D, Benninger C, Pietz B, Batzler U, Heusser A. EEG development in early treated PKU patients from birth to 6 years of age. *Eur J Pediatr* 1990;149 Suppl 1:S28-33.
- Pietz J, Meyding-Lamade UK, Schmidt H. Magnetic resonance imaging of the brain in adolescents with phenylketonuria and in one case of 6-pyruvoyl tetrahydropteridine synthase deficiency. *Eur J Pediatr* 1996 Jul;155 Suppl 1:S69-73.
- Pietz J, Schmidt E, Matthis P, Kobialka B, Kutscha A, de Sonneville L. EEGs in phenylketonuria. I: Follow-up to adulthood; II: Short-term diet-related changes in EEGs and cognitive function. *Dev Med Child Neurol* 1993 Jan;35(1):54-64.
- Piggins HD. The short- and long-term effects of neonatal exposure to and/or (d-phenylalanine(6), Psi leucine(13)-chloroparpylamid(14))BN(6-14), a Bombesin receptor antagonist [dissertation]. Ottawa (Canada): University of Ottawa; 1991. 204 p.
- Pitt D. The natural history of untreated phenylketonuria. *Med J Aust* 1971 Feb 13;1(7):378-83.
- Pitt DB, Danks DM. The natural history of untreated phenylketonuria over 20 years. *J Paediatr Child Health* 1991 Jun;27(3):189-90.

- Pitt DB, O'Day J. Phenylketonuria does not cause cataracts. *Eur J Pediatr* 1991 Jul;150(9):661-4.
- Platt LD, Koch R, Azen C, Hanley WB, Levy HL, Matalon R, Rouse B, de la Cruz F, Walla CA. Maternal phenylketonuria collaborative study, obstetric aspects and outcome: the first 6 years. *Am J Obstet Gynecol* 1992 Apr;166(4):1150-60; discussion 1160-2.
- Pogson CI, Salter M, Knowles RG. Regulation of hepatic aromatic amino acid metabolism. *Biochem Soc Trans* 1986 Dec;14(6):999-1001.
- Pogson CI, Santana MA, Fisher MJ. Phenylalanine hydroxylase: metabolic aspects. *Biochem Soc Trans* 1985 Apr;13(2):439-41.
- Poindexter BB, Karn CA, Ahlrichs JA, Wang J, Leitch CA, Liechty EA, Denne SC. Amino acids suppress proteolysis independent of insulin throughout the neonatal period. *Am J Physiol* 1997 Apr;272(4 Pt 1):E592-9.
- Pollegioni L, Fukui K, Massey V. Studies on the kinetic mechanism of pig kidney D-amino acid oxidase by site-directed mutagenesis of tyrosine 224 and tyrosine 228. *J Biol Chem* 1994 Dec 16;269(50):31666-73.
- Pontoglio M, Barra J, Hadchouel M, Doyen A, Kress C, Bach JP, Babinet C, Yaniv M. Hepatocyte nuclear factor 1 inactivation results in hepatic dysfunction, phenylketonuria, and renal Fanconi syndrome. *Cell* 1996 Feb 23;84(4):575-85.
- Potocnik U, Widhalm K. Long-term follow-up of children with classical phenylketonuria after diet discontinuation: a review. *J Am Coll Nutr* 1994 Jun;13(3):232-6.
- Prasad C, Dalton L, Levy H. Role of diet therapy in management of hereditary metabolic diseases. *Nutr Res* 1998 Feb;18(2):391-402.
- Preedy VR, Garlick PJ. The response of muscle protein synthesis to nutrient intake in postabsorptive rats: the role of insulin and amino acids. *Biosci Rep* 1986 Feb;6(2):177-83.
- Pueschel SM, Fogelson-Doyle L, Kammerer B, Matsumiya Y. Neurophysiological, psychological, and nutritional investigations during discontinuation of the phenylalanine-restricted diet in children with classic phenylketonuria. *J Ment Defic Res* 1983 Mar;27 (Pt 1):61-7.
- Pueschel SM, Herman R, Groden G. Brief report: screening children with autism for fragile-X syndrome and phenylketonuria. *J Autism Dev Disord* 1985 Sep;15(3):335-8.
- Pueschel SM, Schrier AM, Povar ML, Boylan JM. Biological and behavioural assessments of young rhesus monkeys after intrauterine exposure to high phenylalanine concentrations. *J Ment Defic Res* 1985 Sep;29 (Pt 3):247-56.
- Ramus SJ, Forrest SM, Pitt DB, Saleeba JA, Cotton RG. Comparison of genotype and intellectual phenotype in untreated PKU patients. *J Med Genet* 1993 May;30(5):401-5.
- Rasmussen BB, Tipton KD, Miller SL, Wolf SE, Wolfe RR. An oral essential amino acid-carbohydrate supplement enhances muscle protein anabolism after resistance exercise. *J Appl Physiol* 2000;88(2):386-92.
- Realmuto GM, Garfinkel BD, Tuchman M, Tsai MY, Chang PN, Fisch RO, Shapiro S. Psychiatric diagnosis and behavioral characteristics of phenylketonuric children. *J Nerv Ment Dis* 1986 Sep;174(9):536-40.
- Reber M, Kazak AE, Himmelberg P. Phenylalanine control and family functioning in early-treated phenylketonuria. *J Dev Behav Pediatr* 1987 Dec;8(6):311-7.
- Reinecke CJ, Mienie LJ, Hitzeroth HW, Op't Hof J. Screening for inborn errors of metabolism among mentally retarded patients. Outcome of a surgery at the Witrand Care and Rehabilitation Centre. *S Afr Med J* 1983 Jan 1;63(1):14-6.
- Reynolds R, Burri R, Herschkowitz N. Retarded development of neurons and oligodendroglia in rat forebrain produced by hyperphenylalaninemia results in permanent deficits in myelin despite long recovery periods. *Exp Neurol* 1993 Dec;124(2):357-67.
- Richardson SC, Aspbury RA, Fisher MJ. The role of reversible phosphorylation in the hormonal control of phenylalanine hydroxylase in isolated rat proximal kidney tubules. *Biochem J* 1993 Jun 1;292 (Pt 2):419-24.
- Richardson SC, Green AK, Fisher MJ. Phosphorylation-dephosphorylation of renal phenylalanine hydroxylase. *Biochem Soc Trans* 1991 Apr;19(2):229S.
- Robain O, Wen GY, Wisniewski HM, Shek JW, Loo YH. Purkinje cell dendritic development in experimental phenylketonuria. A quantitative analysis. *Acta Neuropathol (Berl)* 1981;53(2):107-12.
- Robain O, Wisniewski HM, Loo YH, Wen GY. Experimental phenylketonuria: effect of phenylacetate intoxication on number of synapses in the cerebellar cortex of the rat. *Acta Neuropathol (Berl)* 1983;61(3-4):313-5.
- Robinson M, White FJ, Cleary MA, Wraith E, Lam WK, Walter JH. Increased risk of vitamin B12

- deficiency in patients with phenylketonuria on an unrestricted or relaxed diet. *J Pediatr* 2000 Apr;136(4):545-7.
- Rogers PJ, Keedwell P, Blundell JE. Further analysis of the short-term inhibition of food intake in humans by the dipeptide L-aspartyl-L-phenylalanine methyl ester (aspartame). *Physiol Behav* 1991 Apr;49(4):739-43.
- Rogers PJ, Fleming HC, Blundell JE. Aspartame ingested without tasting inhibits hunger and food intake. *Physiol Behav* 1990 Jun;47(6):1239-43.
- Romano V, Ceratto N, Chiavetta V, Bosco P. Identification of two new phenylalanine hydroxylase alleles in Sicilian phenylketonuric families. *J Inherit Metab Dis* 1993;16(3):599-601.
- Roricht S, Meyer BU, Irlbacher K, Ludolph AC. Impairment of callosal and corticospinal system function in adolescents with early-treated phenylketonuria: a transcranial magnetic stimulation study. *J Neurol* 1999 Jan;246(1):21-30.
- Ryan-Harshman M, Leiter LA, Anderson GH. Phenylalanine and aspartame fail to alter feeding behavior, mood and arousal in men. *Physiol Behav* 1987;39(2):247-53.
- Rylance G. Outcome of early detected and early treated phenylketonuria patients. *Postgrad Med J* 1989;65 Suppl 2:S7-9.
- Salomon F, Fagioli I, Rey F, Salzarulo P. [EEG sleep activity in a phenylketonuric child of the 'new variant' type, before and after treatment with 5-HTP and L-DOPA (author's transl)]. *Rev Electroencephalogr Neurophysiol Clin* 1981 Nov;11(2):212-7. (Fre).
- Salomon F, Fagioli I, Rey F, Salzarulo P. Sleep patterns in the new variant phenylketonuria. *Neuropediatrics* 1981 Aug;12(3):287-91.
- Samid D, Ram Z, Hudgins WR, Shack S, Liu L, Walbridge S, Oldfield EH, Myers CE. Selective activity of phenylacetate against malignant gliomas: resemblance to fetal brain damage in phenylketonuria. *Cancer Res* 1994 Feb 15;54(4):891-5.
- Samuels SE, Baracos VE. Tissue protein turnover is altered during catch-up growth following *Escherichia coli* infection in weanling rats. *J Nutr* 1995 Mar;125(3):520-30.
- Sanchez M, El-Khoury AE, Castillo L, Chapman TE, Filho AB, Beaumier L, Young VR. Twenty-four-hour intravenous and oral tracer studies with L-[1-¹³C]phenylalanine and L-[3,3-²H₂]tyrosine at a tyrosine-free, generous phenylalanine intake in adults. *Am J Clin Nutr* 1996 Apr;63(4):532-45.
- Sanford YM, Orias E. Phenylketonuric Tetrahymena: phenylalanine hydroxylase mutants and other tyrosine auxotrophs. *Proc Natl Acad Sci U S A* 1981 Dec;78(12):7614-8.
- Sarkissian CN, Boulais DM, McDonald JD, Scriver CR. A heteroallelic mutant mouse model: A new orthologue for human hyperphenylalaninemia. *Mol Genet Metab* 2000 Mar;69(3):188-94.
- Saugstad LF. Birth weight of children with phenylketonuria [letter]. *Pediatrics* 1980 Jan;65(1):190-2.
- Schaefer F, Burgard P, Batzler U, Rupp A, Schmidt H, Gilli G, Bickel H, Bremer HJ. Growth and skeletal maturation in children with phenylketonuria. *Acta Paediatr* 1994 May;83(5):534-41.
- Schallreuter KU. A review of recent advances on the regulation of pigmentation in the human epidermis. *Cell Mol Biol (Noisy-le-grand)* 1999 Nov;45(7):943-9.
- Schallreuter KU, Wood JM. The importance of L-phenylalanine transport and its autocrine turnover to L-tyrosine for melanogenesis in human epidermal melanocytes. *Biochem Biophys Res Commun* 1999 Aug 27;262(2):423-8.
- Schmidt BJ, Diament AJ, Krynski S, Kamei ME, Rodrigues MM, Takata S. [Detection of inborn errors of metabolism in San Pablo, Brazil]. *Bol Med Hosp Infant Mex* 1981 Mar-Apr;38(2):217-29. (Spa).
- Schmidt E, Burgard P, Rupp A. Effects of concurrent phenylalanine levels on sustained attention and calculation speed in patients treated early for phenylketonuria. *Eur J Pediatr* 1996 Jul;155 Suppl 1:S82-6.
- Schmidt E, Rupp A, Burgard P, Pietz J, Weglage J, de Sonneville L. Sustained attention in adult phenylketonuria: the influence of the concurrent phenylalanine-blood-level. *J Clin Exp Neuropsychol* 1994 Oct;16(5):681-8.
- Schmitt JA, Jorissen BL, Sobczak S, Van Boxtel MP, Hogervorst E, Deutz NE, Riedel WJ. Tryptophan depletion impairs memory consolidation but improves focussed attention in healthy young volunteers. *J Psychopharmacol* 2000;14(1):21-9.
- Schuler A, Somogyi C, Mate M, Pataki L, Toros I, Woo SL, Eisensmith RC, Fekete G. Cognitive development related to metabolic phenotype and mutation genotype in 25 Hungarian patients with phenylketonuria. *J Inherit Metab Dis* 1994;17(3):372. Published erratum appears in *J Inherit Metab Dis* 1994;17(6):651.

- Schulpis KH, Nyalala JO, Papakonstantinou ED, Leondiadis L, Livaniou E, Ithakisios D, Georgala S. Biotin recycling impairment in phenylketonuric children with seborrheic dermatitis. *Int J Dermatol* 1998 Dec;37(12):918-21.
- Schwahn B, Mokov E, Scheidhauer K, Lettgen B, Schonau E. Decreased trabecular bone mineral density in patients with phenylketonuria measured by peripheral quantitative computed tomography. *Acta Paediatr* 1998 Jan;87(1):61-3.
- Schwarz HP, Pluss C, Triaca H, Schutz B, Kaufmann R, Scherz R, Bachmann C, Zuppinger K. [Disease course in 20 patients with an early diagnosis of phenylketonuria and hyperphenylalaninemia]. *Schweiz Med Wochenschr* 1988 Jan 23;118(3):94-9. (Ger).
- Scriver CR. Human biochemical genetics: a view on individuality. In: Armendares S, Lisker R, editors. *Human genetics*. Amsterdam: Excerpta Medica; 1977. p. 142-54.
- Scriver CR. Phenylketonuria: the glutamine hypothesis. *N Engl J Med* 1970 Apr 2;282(14):808-9.
- Scriver CR. Realized and potential neutralization of mutant genes in man by nutritional selection. *Fed Proc* 1976 Sep;35(11):2286-90.
- Scriver CR, Waters PJ. Monogenic traits are not simple: lessons from phenylketonuria. *Trends Genet* 1999 Jul;15(7):267-72.
- Seashore MR, Friedman E, Novelty RA, Bapat V. Loss of intellectual function in children with phenylketonuria after relaxation of dietary phenylalanine restriction. *Pediatrics* 1985 Feb;75(2):226-32.
- Sevashevich AV. [Phenylketonuria in eczema and neurodermatitis in children]. *Vestn Dermatol Venerol* 1982 Jun;(6):48-51. (Rus).
- Sharma SD, Cooley C, De La Pava E, Ambrus CM. Development of a refractory stage in a dog model for phenylketonuria. *Res Commun Chem Pathol Pharmacol* 1981 Jul;33(1):145-53.
- Shaw DW, Maravilla KR, Weinberger E, Garretson J, Trahms CM, Scott CR. MR imaging of phenylketonuria. *AJNR Am J Neuroradiol* 1991 May-Jun;12(3):403-6. Comment in: *AJNR Am J Neuroradiol* 1991 May-Jun;12(3):413-6.
- Shaw DW, Weinberger E, Maravilla KR. Cranial MR in phenylketonuria. *J Comput Assist Tomogr* 1990 May-Jun;14(3):458-60.
- Short KR, Meek SE, Moller N, Ekberg K, Nair KS. Whole body protein kinetics using Phe and Tyr tracers: an evaluation of the accuracy of approximated flux values. *Am J Physiol* 1999 Jun;276(6 Pt 1):E1194-200.
- Smith I, Beasley M. Intelligence and behaviour in children with early treated phenylketonuria. A report from the MRC/DHSS phenylketonuria register. *Eur J Clin Nutr* 1989;43 Suppl 1:1-5.
- Smith I, Beasley MG, Ades AE. Intelligence and quality of dietary treatment in phenylketonuria. *Arch Dis Child* 1990 May;65(5):472-8.
- Smith I, Beasley MG, Wolff OH, Ades AE. Behavior disturbance in 8-year-old children with early treated phenylketonuria. Report from the MRC/DHSS Phenylketonuria Register. *J Pediatr* 1988 Mar;112(3):403-8.
- Smith I, Glossop J, Beasley M. Fetal damage due to maternal phenylketonuria: effects of dietary treatment and maternal phenylalanine concentrations around the time of conception (an interim report from the UK Phenylketonuria Register). *J Inher Metab Dis* 1990;13(4):651-7.
- Smith I, Wolff OH. Natural history of phenylketonuria and influence of early treatment. *Lancet* 1974 Sep 7;2(7880):540-4.
- Song J, Jensen RA. PhhR, a divergently transcribed activator of the phenylalanine hydroxylase gene cluster of *Pseudomonas aeruginosa*. *Mol Microbiol* 1996 Nov;22(3):497-507.
- Southorn BG, Kelly JM, McBride BW. Phenylalanine flooding dose procedure is effective in measuring intestinal and liver protein synthesis in sheep. *J Nutr* 1992 Dec;122(12):2398-407.
- Spero DA. Maternal phenylketonuria: the effect on the morphological and biochemical maturation of the brain in utero [dissertation]. New Brunswick (NJ): College of Medicine and Dentistry of New Jersey, Graduate School of Biomedical Science; 1981. 191 p.
- Spero DA, Yu MC. Effects of maternal hyperphenylalaninemia on fetal brain development: a biochemical study. *Exp Neurol* 1983 Mar;79(3):641-54.
- Spero DA, Yu MC. Effects of maternal hyperphenylalaninemia on fetal brain development: a morphological study. *Exp Neurol* 1983 Mar;79(3):655-65.
- Srivastava US, Thakur ML, Van TT, Radhakrishnamurthy R. Maternal food restriction, brain polysomes and poly-U stimulated protein synthesis in the newborn and 21-day-old rat progeny. *Nutr Res* 1993 Nov;13(11):1331-41.

- Stavljenic LV, Rajic Z, Cvoriscec D, Granic P, Mardesic D, Zaninovic M, Devernay Z. Changes in the composition of salivary amino acids, proteins and enzymes in children with phenylketonuria. *Acta Stomatol Croat* 1987;21(2):87-92.
- Stegink LD, Brummel MC, Persoon TJ, Filer LJ Jr, Bell EF, Ziegler EE. Effect of sucrose on the metabolic disposition of aspartame. *Am J Clin Nutr* 1990 Aug;52(2):335-41.
- Stehle P, Weber S, Furst P. Parenteral glycyl-L-tyrosine maintains tyrosine pools and supports growth and nitrogen balance in phenylalanine-deficient rats. *J Nutr* 1996 Mar;126(3):663-7.
- Steiner KC, Smith HA. Application of cost-benefit analysis to a PKU screening program. *Inquiry* 1973 Dec;10(4):34-40.
- Stemerdink BA, van der Molen MW, Kalverboer AF, van der Meere JJ, Hendriks MM, Huisman J, van der Schot LW, Slijper FM. Information processing deficits in children with early and continuously treated phenylketonuria? *Acta Paediatr Suppl* 1994 Dec;407:106-7.
- Stoll B, Burrin DG, Henry J, Jahoor F, Reeds PJ. Phenylalanine utilization by the gut and liver measured with intravenous and intragastric tracers in pigs. *Am J Physiol* 1997 Dec;273(6 Pt 1):G1208-17.
- Stoll B, Burrin DG, Henry JF, Jahoor F, Reeds PJ. Dietary and systemic phenylalanine utilization for mucosal and hepatic constitutive protein synthesis in pigs. *Am J Physiol* 1999 Jan;276(1 Pt 1):G49-57.
- Strupp BJ, Himmelstein S, Bunsey M, Levitsky DA, Kesler M. Cognitive profile of rats exposed to lactational hyperphenylalaninemia: correspondence with human mental retardation. *Dev Psychobiol* 1990 Apr;23(3):195-214.
- Subbarao K, Jacobson HG. Other inborn errors of skeletal metabolism. *Semin Roentgenol* 1986 Oct;21(4):256-63.
- Suchozebraska-Jesionek D, Szymonik-Lesiuk S, Borkowska I. Shortlasting effect of L-phenylalanine on the level of aminoacyl-tRNA in chick embryo's brain. *Bull Acad Polonaise Sci Ser Sci Biol* 1984;32(1-2):1-8.
- Sugita R, Takahashi S, Ishii K, Matsumoto K, Ishibashi T, Sakamoto K, Narisawa K. Brain CT and MR findings in hyperphenylalaninemia due to dihydropteridine reductase deficiency (variant of phenylketonuria). *J Comput Assist Tomogr* 1990 Sep-Oct;14(5):699-703.
- Svensson E, Iselius L, Hagenfeldt L. Severity of mutation in the phenylalanine hydroxylase gene influences phenylalanine metabolism in phenylketonuria and hyperphenylalaninaemia heterozygotes. *J Inher Metab Dis* 1994;17(2):215-22.
- Szabo E, Thelen A, Petersen M. Fungal elicitor preparations and methyl jasmonate enhance rosmarinic acid accumulation in suspension cultures of *Coleus blumei*. *Plant Cell Rep* 1999 Feb;18(6):485-9.
- Takashima S, Chan F, Becker LE. Cortical dysgenesis in a variant of phenylketonuria (dihydropteridine reductase deficiency). *Pediatr Pathol* 1991 Sep-Oct;11(5):771-9.
- Tam SY, Ono N, Roth RH. Precursor control and influence of aspartame on midbrain dopamine neurons. *UCLA Symp Mol Cell Biol* 1987;55:421-35.
- Tam SY, Roth RH. Mesoprefrontal dopaminergic neurons: can tyrosine availability influence their functions? *Biochem Pharmacol* 1997 Feb 21;53(4):441-53.
- Tanaka H, Nakatomi Y, Ogura M. Metabolism of phenylalanine, tyrosine and aspartic acid in growing rats at various dietary protein levels. *Agric Biol Chem* 1987 Feb;51(2):499-505.
- Tanase-Mogos I, Ciortoloman H, Grigorescu G, Popescu M, Ankar V. [Combined and isolated forms of metabolic errors detected in children]. *Physiologie* 1980 Jan-Mar;17(1):57-66. (Fre).
- Teebi AS, Al-Awadi SA, Farag TI, Naguib KK, el-Khalifa MY. Phenylketonuria in Kuwait and Arab countries. *Eur J Pediatr* 1987 Jan;146(1):59-60.
- Tessari P, Deferrari G, Robaudo C, Vettore M, Pastorino N, De Biasi L, Garibotto G. Phenylalanine hydroxylation across the kidney in humans rapid communication. *Kidney Int* 1999 Dec;56(6):2168-72.
- Thompson AJ. Phenylketonuria: An unfolding story. In: Robertson MM, Eapen V, et al., editors. *Movement and allied disorders in childhood*. Chichester (UK): John Wiley & Sons; 1995. p. 83-103.
- Thompson AJ, Smith I, Brenton D, Youl BD, Rylance G, Davidson DC, Kendall B, Lees AJ. Neurological deterioration in young adults with phenylketonuria. *Lancet* 1990 Sep 8;336(8715):602-5.
- Thompson AJ, Smith I, Kendall BE, Youl BD, Brenton D. Magnetic resonance imaging changes in early treated patients with phenylketonuria [letter]. *Lancet* 1991 May 18;337(8751):1224.
- Thompson AJ, Tillotson S, Smith I, Kendall B, Moore SG, Brenton DP. Brain MRI changes in phenylketonuria. Associations with dietary status. *Brain* 1993 Aug;116 (Pt 4):811-21.

- Thompson GN, Pacy PJ, Watts RW, Halliday D. Protein metabolism in phenylketonuria and Lesch-Nyhan syndrome. *Pediatr Res* 1990 Sep;28(3):240-6.
- Thony B, Auerbach G, Blau N. Tetrahydrobiopterin biosynthesis, regeneration and functions. *Biochem J* 2000 Apr 1;347 Pt 1:1-16.
- Tork I, Halliday GM, Cotton RG. Application of antiphenylalanine hydroxylase antibodies to the study of the serotonergic system in the human brain. *J Chem Neuroanat* 1992 Jul-Aug;5(4):311-3.
- Torok E, Kovacs J. [Scleroderma associated with phenylketonuria]. *Orv Hetil* 1981 Sep 13;122(37):2273-5. (Hun).
- Treacy EP, Delente JJ, Elkas G, Carter K, Lambert M, Waters PJ, Scriver CR. Analysis of phenylalanine hydroxylase genotypes and hyperphenylalaninemia phenotypes using L-[1-13C]phenylalanine oxidation rates in vivo: a pilot study. *Pediatr Res* 1997 Oct;42(4):430-5.
- Trefz F, de Sonneville L, Matthis P, Benninger C, Lanz-Englert B, Bickel H. Neuropsychological and biochemical investigations in heterozygotes for phenylketonuria during ingestion of high dose aspartame (a sweetener containing phenylalanine). *Hum Genet* 1994 Apr;93(4):369-74.
- Trefz FK, Batzler U, Konig T, Michel U, Schmidt E, Schmidt H, Bickel H. Significance of the in vivo deuterated phenylalanine load for long-term phenylalanine tolerance and psycho-intellectual outcome in patients with PKU. *Eur J Pediatr* 1990;149 Suppl 1:S25-7.
- Tsukada Y, Takamatsu K. [Correlation between monoamine content in the brain and discriminative learning ability (author's transl)]. *Tanpakushitsu Kakusan Koso* 1981 Aug;26(11):1725-34. (Jpn).
- Turk E. Hyperphenylalaninemia - induced alterations of cerebral synthesis in the rat [dissertation]. Los Angeles: University of California; 1984. 173 p.
- Ullrich K, Moller H, Weglage J, Schuierer G, Bick U, Ludolph A, Hahn-Ullrich H, Funders B, Koch HG. White matter abnormalities in phenylketonuria: results of magnetic resonance measurements. *Acta Paediatr Suppl* 1994 Dec;407:78-82.
- Ullrich K, Weglage J, Oberwittler C, Pietsch M, Funders B, van Eckhardstein H, Colombo JP. Effect of L-dopa on pattern visual evoked potentials (P-100) and neuropsychological tests in untreated adult patients with phenylketonuria. *J Inher Metab Dis* 1994;17(3):349-52.
- Ullrich K, Weglage J, Oberwittler C, Pietsch M, Funders B, von Eckardstein H, Colombo JP. Effect of L-dopa on visual evoked potentials and neuropsychological tests in adult phenylketonuria patients. *Eur J Pediatr* 1996 Jul;155 Suppl 1:S74-7.
- Valdivieso F, Gimenez C, Benavides J, Aragon MC, Mayor F. [Pathogenesis of cerebral dysfunction in phenylketonuria]. *Rev Esp Fisiol* 1982;38 Suppl:189-93. (Spa).
- van der Schot LW, Doesburg WH, Sengers RC. The phenylalanine response curve in relation to growth and mental development in the first year of life. *Acta Paediatr Suppl* 1994 Dec;407:68-9.
- van Spronsen FJ, van Dijk T, Smit GP, van Rijn M, Reijngoud DJ, Berger R, Heymans HS. Large daily fluctuations in plasma tyrosine in treated patients with phenylketonuria. *Am J Clin Nutr* 1996 Dec;64(6):916-21. Comment in: *Am J Clin Nutr* 1996 Dec;64(6):974-5.
- van Spronsen FJ, Verkerk PH, van Houten M, Smit GP, van der Meer SB, Bakker HD, Sengers RC. Does impaired growth of PKU patients correlate with the strictness of dietary treatment? National Dutch PKU Steering Committee. *Acta Paediatr* 1997 Aug;86(8):816-8.
- Velkova A, Podhradská O. [Stomatologic problems in children with phenylketonuria]. *Cesk Stomatol* 1981 Jan;81(1):27-32. (Cze).
- Verkerk PH, van Spronsen FJ, Smit GP, Sengers RC. Impaired prenatal and postnatal growth in Dutch patients with phenylketonuria. The National PKU Steering Committee. *Arch Dis Child* 1994 Aug;71(2):114-8. Comment in: *Arch Dis Child* 1995 Sep;73(3):276.
- Verkerk PH, van Spronsen FJ, van Houten M, Smit GP, Sengers RC. Predictors of mean phenylalanine levels during the first five years of life in patients with phenylketonuria who were treated early. Dutch National PKU Steering Committee. *Acta Paediatr Suppl* 1994 Dec;407:70-2.
- Villasana D, Butler IJ, Williams JC, Roongta SM. Neurological deterioration in adult phenylketonuria. *J Inher Metab Dis* 1989;12(4):451-7.
- Vyborova L, Nahunek K, Drtilkova I, Balastikova B, Sindelarova M, Machackova V, Podhradská O, Mrskos A. Psychic changes in phenylketonuric children at phenylalanine load. *Act Nerv Super (Praha)* 1981 Dec;23(4):298-300.
- Waggoner WF. Aspartame--a review. *Pediatr Dent* 1984 Sep;6(3):153-8.
- Waisbren SE, Brown MJ, de Sonneville LM, Levy HL. Review of neuropsychological functioning in

- treated phenylketonuria: an information processing approach. *Acta Paediatr Suppl* 1994 Dec;407:98-103.
- Waisbren SE, Hanley W, Levy HL, Shifrin H, Allred E, Azen C, Chang PN, Cipic-Schmidt S, de la Cruz F, Hall R, Matalon R, Nanson J, Rouse B, Trefz F, Koch R. Outcome at age 4 years in offspring of women with maternal phenylketonuria: the Maternal PKU Collaborative Study. *JAMA* 2000 Feb 9;283(6):756-62.
- Waisbren SE, Levy HL. Agoraphobia in phenylketonuria. *J Inherit Metab Dis* 1991;14(5):755-64.
- Walker JD, Crall JJ, McDonnell JE. Phenylketonuria and dentistry: review of the literature. *ASDC J Dent Child* 1982 Jul-Aug;49(4):280-4.
- Walker V, Smythe PJ, Cook NJ, Ball NA, Veall RM, Whiteman P. Urinary screening for abnormalities of amino acid or mucopolysaccharide metabolism in patients in a hospital for the mentally handicapped in Wessex. *J Ment Defic Res* 1983 Jun;27 (Pt 2):105-14.
- Wallman CM. Lab values and diagnostics. Newborn genetic screening. *Neonat Netw* 1998 Apr;17(3):55-60, 22-4.
- Walsh DA, Christian ZH. The effects of phenylalanine on cultured rat embryos. *Teratog Carcinog Mutagen* 1984;4(6):505-13.
- Walter JH, Tyfield LA, Holton JB, Johnson C. Biochemical control, genetic analysis and magnetic resonance imaging in patients with phenylketonuria. *Eur J Pediatr* 1993 Oct;152(10):822-7.
- Walter JH, White F, Wraith JE, Jenkins JP, Wilson BP. Complete reversal of moderate/severe brain MRI abnormalities in a patient with classical phenylketonuria. *J Inherit Metab Dis* 1997 Jul;20(3):367-9.
- Walther F. [Cutaneous manifestations of hereditary metabolic diseases]. *Aktuel Dermatol* 2000;26(4):103-7. (Ger).
- Wasser S, Ettrich KU, Schmidt KD, Selle D, Theile H. [Case studies of the effect of tyrosine administration in children with phenylketonuria on cognitive processes]. *Klin Padiatr* 1992 Nov-Dec;204(6):417-21. (Ger).
- Wasser S, Theile H, Graustein J. [Results of the electroencephalographic examination of children after the late treatment of phenylketonuria by diet]. *Pediatrics* 1980 Oct;10(10):52-4. (Rus).
- Waters PJ, Parniak MA, Hewson AS, Scriver CR. Alterations in protein aggregation and degradation due to mild and severe missense mutations (A104D, R157N) in the human phenylalanine hydroxylase gene (PAH). *Hum Mutat* 1998;12(5):344-54.
- Waters PJ, Parniak MA, Nowacki P, Scriver CR. In vitro expression analysis of mutations in phenylalanine hydroxylase: linking genotype to phenotype and structure to function. *Hum Mutat* 1998;11(1):4-17.
- Watts RW, Baraitser M, Chalmers RA, Purkiss P. Organic acidurias and amino acidurias in the aetiology of long-term mental handicap. *J Ment Defic Res* 1980 Dec;24 Pt 4:257-70.
- Webster DR, Wallace J. PKU and diabetes: help requested [letter]. *J Inherit Metab Dis* 1995;18(5):649.
- Weglage J, Bick U, Schuierer G, Pietsch M, Sprinz A, Zass R, Ullrich K. Progression of cerebral white matter abnormalities in early treated patients with phenylketonuria during adolescence [letter]. *Neuropediatrics* 1997 Aug;28(4):239-40.
- Weglage J, Bramswig JH, Koch HG, Karassalidou S, Ullrich K. Growth in patients with phenylketonuria [letter]. *Eur J Pediatr* 1994 Jul;153(7):537-8.
- Weglage J, Funders B, Wilken B, Schubert D, Ullrich K. School performance and intellectual outcome in adolescents with phenylketonuria. *Acta Paediatr* 1993 Jun-Jul;82(6-7):582-6.
- Weglage J, Funders B, Wilken B, van Teeffelen-Heithoff A, Ullrich K. [Treatment of phenylketonuria: wish and reality]. *Monatsschr Kinderheilkd* 1993 Aug;141(8):670-4. (Ger).
- Weglage J, Oberwittler C, Marquardt T, Schellscheidt J, von Teeffelen-Heithoff A, Koch G, Gerding H. Neurological deterioration in adult phenylketonuria. *J Inherit Metab Dis* 2000 Feb;23(1):83-4.
- Weglage J, Pietsch M, Denecke J, Sprinz A, Feldmann R, Grenzbach M, Ullrich K. Regression of neuropsychological deficits in early-treated phenylketonurics during adolescence. *J Inherit Metab Dis* 1999 Aug;22(6):693-705.
- Weglage J, Pietsch M, Funders B, Koch HG, Ullrich K. Deficits in selective and sustained attention processes in early treated children with phenylketonuria--result of impaired frontal lobe functions? *Eur J Pediatr* 1996 Mar;155(3):200-4.
- Weglage J, Pietsch M, Funders B, Koch HG, Ullrich K. Neurological findings in early treated phenylketonuria. *Acta Paediatr* 1995 Apr;84(4):411-5.
- Weglage J, Schmidt E, Funders B, Pietsch M, Ullrich K. Sustained attention in untreated non-PKU-hyperphenylalaninemia. *J Clin Exp Neuropsychol* 1996 Jun;18(3):343-8.

- Weglage J, Schuierer G, Kurlemann G, Bick R, Ullrich K. Different degrees of white matter abnormalities in untreated phenylketonurics: findings in magnetic resonance imaging. *J Inherit Metab Dis* 1993;16(6):1047-8.
- Weglage J, Ullrich K, Pietsch M, Funders B, Guttler F, Harms E. Intellectual, neurologic, and neuropsychologic outcome in untreated subjects with nonphenylketonuria hyperphenylalaninemia. German Collaborative Study on Phenylketonuria. *Pediatr Res* 1997 Sep;42(3):378-84.
- Weglage J, Ullrich K, Pietsch M, Funders B, Zass R, Koch HG. Untreated non-phenylketonuric-hyperphenylalaninaemia: intellectual and neurological outcome. *Eur J Pediatr* 1996 Jul;155 Suppl 1:S26-8.
- Weglage J, Ullrich K, Schuierer G, Pietsch M, Funders B. No white matter abnormalities in untreated patients with persistent hyperphenylalaninaemia: findings in magnetic resonance imaging. German PKU Collaborative Study [letter]. *Eur J Pediatr* 1994 Dec;153(12):918-9.
- Welsh MC. A prefrontal dysfunction model of early-treated phenylketonuria. *Eur J Pediatr* 1996 Jul;155 Suppl 1:S87-9.
- Wen GY, Wisniewski HM, Shek JW, Loo YH, Fulton TR. Neuropathology of phenylacetate poisoning in rats: an experimental model of phenylketonuria. *Ann Neurol* 1980 Jun;7(6):557-66.
- Wendel U, Hummel W, Langenbeck U. Monitoring of phenylketonuria: a colorimetric method for the determination of plasma phenylalanine using L-phenylalanine dehydrogenase. *Anal Biochem* 1989 Jul;180(1):91-4.
- Wendel U, Langenbeck U. Towards self-monitoring and self-treatment in phenylketonuria—a way to better diet compliance. *Eur J Pediatr* 1996 Jul;155 Suppl 1:S105-7.
- White JE, Kronmal RA, Acosta PB. Excess weight among children with phenylketonuria. *J Am Coll Nutr* 1982;1(3):293-303.
- Wilke BC, Vidailhet M, Richard MJ, Ducros V, Arnaud J, Favier A. [Trace elements balance in treated phenylketonuria children. Consequences of selenium deficiency on lipid peroxidation]. *Arch Latinoam Nutr* 1993 Jun;43(2):119-22. (Fre).
- Williams JM, Morris JG, Rogers QR. Phenylalanine requirement of kittens and the sparing effect of tyrosine. *J Nutr* 1987 Jun;117(6):1102-7.
- Williams K. Benefits of normalizing plasma phenylalanine: impact on behaviour and health. A case report. *J Inherit Metab Dis* 1998 Dec;21(8):785-90.
- Williamson M, Dobson JC, Koch R. Collaborative study of children treated for phenylketonuria: study design. *Pediatrics* 1977 Dec;60(6):815-21.
- Wong DL, Ciaranello RD. Molecular biological approaches to mental retardation. *Clin Neuropharmacol* 1986;9 Suppl 4:519-21.
- Woo SL, Gillam SS, Woolf LI. The isolation and properties of phenylalanine hydroxylase from human liver. *Biochem J* 1974 Jun;139(3):741-9.
- Woodring JH, Rosenbaum HD. Bone changes in phenylketonuria reassessed. *AJR Am J Roentgenol* 1981 Aug;137(2):241-3.
- Woolf LI, Crockett DJ. Birth weight in phenylketonuria [letter]. *Arch Dis Child* 1995 Sep;73(3):276. Comment on: *Arch Dis Child* 1994 Aug;71(2):114-8.
- Woolf LI, Crockett DJ. Reduction in birth weight in phenylketonuria [letter]. *Eur J Pediatr* 1997 Feb;156(2):157. Comment on: *Eur J Pediatr* 1995 Oct;154(10):847-9.
- Wuu KD, Hsiao KJ, Chen CH, Hsiao TS, Chang CY, Chu YK. Screening for inherited metabolic diseases and congenital hypothyroidism in 4,744 mentally retarded school children in Taiwan. *Jinrui Idengaku Zasshi* 1988 Mar;33(1):33-40.
- Yadav G, Farag TI, al Awadi SA, Sam T, Marafie MJ, Bastaki L, el Khalifa MY, Kasrawi B, Wahba RA. Aminoacidopathies among institutionalised mentally retarded in Kuwait [letter]. *Clin Genet* 1992 Oct;42(4):212.
- Yamamoto Y, Makita K, Muramatsu K. Self-selection of phenylalanine in the rat. *J Nutr Sci Vitaminol (Tokyo)* 1984 Jun;30(3):273-83.
- Yamamoto Y, Suzuki T, Muramatsu K. Effects of high dietary phenylalanine and p-chlorophenylalanine (Para-chlorophenylalanine) treatment on phenylalanine metabolism in the rat (Amino acid balance). *Agric Biol Chem* 1982 Oct;46(10):2491-7.
- Yang SI, Furuse M, Sugishita N, Okumura J. Effect of phenylalanine on pancreatic amylase secretion in chicks (*Gallus domesticus*). *Comp Biochem Physiol A Comp Physiol* 1990;97(4):531-3.
- Yannicelli S, Ryan A. Improvements in behaviour and physical manifestations in previously untreated adults with phenylketonuria using a phenylalanine-restricted diet: a national survey. *J Inherit Metab Dis* 1995;18(2):131-4.
- Yoneyama T, Hatakeyama K. Decameric GTP cyclohydrolase I forms complexes with two pentameric GTP cyclohydrolase I feedback regulatory

proteins in the presence of phenylalanine or of a combination of tetrahydrobiopterin and GTP. *J Biol Chem* 1998 Aug 7;273(32):20102-8.

Zagreda L, Goodman J, Druin DP, McDonald D, Diamond A. Cognitive deficits in a genetic mouse model of the most common biochemical cause of human mental retardation. *J Neurosci* 1999 Jul 15;19(14):6175-82.

Zelinskaia DI, Ladodo KS, Rybakova EP, Baikov AD. [Organization of dietetic assistance to children with phenylketonuria]. *Vopr Pitan* 1998;(2):12-4. (Rus).

Zello GA, Pencharz PB, Ball RO. Phenylalanine flux, oxidation, and conversion to tyrosine in humans studied with L-[1-13C]phenylalanine. *Am J Physiol* 1990 Dec;259(6 Pt 1):E835-43.

Zeman J, Bayer M, Stepan J. Bone mineral density in patients with phenylketonuria. *Acta Paediatr* 1999 Dec;88(12):1348-51.

Ziyai F, Wong PW, Justice P, Michals K. Protein-induced hypoglycemia in a phenylketonuric patient. *J Pediatr* 1978 Apr;92(4):681-2.

Zwaan J. Eye findings in patients with phenylketonuria. *Arch Ophthalmol* 1983 Aug;101(8):1236-7.

Metabolism, Enzymology, and Biochemistry

Abadie V, Jaruzelska J, Lyonnet S, Millasseau P, Berthelon M, Rey F, Munnich A, Rey J. Illegitimate transcription of the phenylalanine hydroxylase gene in lymphocytes for identification of mutations in phenylketonuria. *Hum Mol Genet* 1993 Jan;2(1):31-4.

Abita JP, Blandin-Savoja F, Rey F. Phenylalanine 4-monooxygenase from human liver. *Methods Enzymol* 1987;142:27-35.

Abita JP, Blandin-Savoja F, Rey F. Phenylalanine hydroxylase. Evidence that the enzyme from human liver might not be a phosphoprotein. *Biochem Int* 1983 Dec;7(6):727-37.

Abita JP, Chamras H, Rosselin G, Rey F. Hormonal control of phenylalanine hydroxylase activity in isolated rat hepatocytes. *Biochem Biophys Res Commun* 1980 Feb 12;92(3):912-8.

Abita JP, Parniak M, Kaufman S. The activation of rat liver phenylalanine hydroxylase by limited proteolysis, lysolecithin, and tocopherol phosphate. Changes in conformation and catalytic properties. *J Biol Chem* 1984 Dec 10;259(23):14560-6.

Acosta PB, Alfin-Slater RB, Koch R. Serum lipids in children with phenylketonuria (PKU). *J Am Diet Assoc* 1973 Dec;63(6):631-5.

Acosta PB, Fernhoff PM, Warshaw HS, Elsas LJ, Hambidge KM, Ernest A, McCabe ER. Zinc status and growth of children undergoing treatment for phenylketonuria. *J Inher Metab Dis* 1982;5(2):107-10.

Acosta PB, Fernhoff PM, Warshaw HS, Hambidge KM, Ernest A, McCabe ER, Elsas LJ 2d. Zinc and copper status of treated children with phenylketonuria. *JPEN J Parenter Enteral Nutr* 1981 Sep-Oct;5(5):406-9.

Acosta PB, Trahms C, Wellman NS, Williamson M. Phenylalanine intakes of 1- to 6-year-old children with phenylketonuria undergoing therapy. *Am J Clin Nutr* 1983 Nov;38(5):694-700.

Acosta PB, Wenz E, Williamson M. Nutrient intake of treated infants with phenylketonuria. *Am J Clin Nutr* 1977 Feb;30(2):198-208.

Acosta PB, Yannicelli S. Plasma micronutrient concentrations in infants undergoing therapy for phenylketonuria. *Biol Trace Elem Res* 1999 Jan;67(1):75-84.

- Acosta PB, Yannicelli S. Protein intake affects phenylalanine requirements and growth of infants with phenylketonuria. *Acta Paediatr Suppl* 1994 Dec;407:66-7.
- Adler C, Ghisla S, Rebrin I, Heizmann CW, Blau N, Curtius HC. Suspected pterin-4a-carbinolamine dehydratase deficiency: hyperphenylalaninaemia due to inhibition of phenylalanine hydroxylase by tetrahydro-7-biopterin. *J Inher Metab Dis* 1992;15(3):405-8.
- Agostoni C, Marangoni F, Riva E, Giovannini M, Galli C. Plasma arachidonic acid and serum thromboxane B2 concentrations in phenylketonuric children negatively correlate with dietary compliance. *Prostaglandins Leukot Essent Fatty Acids* 1997 Mar;56(3):219-22.
- al Aqeel A, Ozand PT, Gascon G, Nester M, al Nasser M, Brismar J, Blau N, Hughes H, Subramanyan SB, Reynolds CT. Biopterin-dependent hyperphenylalaninemia due to deficiency of 6-pyruvoyl tetrahydropterin synthase. *Neurology* 1991 May;41(5):730-7. Comment in: *Neurology* 1992 Mar;42(3 Pt 1):704-5.
- al Aqeel A, Ozand PT, Gascon GG, Hughes H, Reynolds CT, Subramanyam SB. Response of 6-pyruvoyl-tetrahydropterin synthase deficiency to tetrahydrobiopterin. *J Child Neurol* 1992 Apr;7 Suppl:S26-30.
- Al-Janabi JM. Purification of rat liver phenylalanine hydroxylase by affinity chromatography. *Arch Biochem Biophys* 1980 Apr 1;200(2):603-8.
- Alejandre MJ, Marco C, Ramirez H, Segovia JL, Garcia-Peregrin E. Lipid composition of brain myelin from normal and hyperphenylalaninemic chick embryos. *Comp Biochem Physiol B* 1984;77(2):329-32.
- Allanson J, McInnes R, Bradley L, Tarby T, Naylor E, Nardella M. Combined transient and peripheral defects in tetrahydrobiopterin synthesis. *J Pediatr* 1991 Feb;118(2):261-3.
- Allen JR, Baur LA, Waters DL, Humphries IR, Allen BJ, Roberts DC, Gaskin KJ. Body protein in prepubertal children with phenylketonuria. *Eur J Clin Nutr* 1996 Mar;50(3):178-86.
- Allen JR, McCauley JC, Waters DL, O'Connor J, Roberts DC, Gaskin KJ. Resting energy expenditure in children with phenylketonuria. *Am J Clin Nutr* 1995 Oct;62(4):797-801.
- Anderson DN, Wilkinson AM, Abou-Saleh MT, Blair JA. Recovery from depression after electroconvulsive therapy is accompanied by evidence of increased tetrahydrobiopterin-dependent hydroxylation. *Acta Psychiatr Scand* 1994 Jul;90(1):10-3.
- Andersson HC, Kohn LD, Bernardini I, Blom HJ, Tietze F, Gahl WA. Characterization of lysosomal moniodotyrosine transport in rat thyroid cells. Evidence for transport by system h. *J Biol Chem* 1990 Jul 5;265(19):10950-4.
- Ando A, Momomura K, Tobe K, Yamamoto-Honda R, Sakura H, Tamori Y, Kaburagi Y, Koshio O, Akanuma Y, Yazaki Y, et al. Enhanced insulin-induced mitogenesis and mitogen-activated protein kinase activities in mutant insulin receptors with substitution of two COOH-terminal tyrosine autophosphorylation sites by phenylalanine. *J Biol Chem* 1992 Jun 25;267(18):12788-96.
- Annenkov GA. [Genetical heterogeneity of phenylketonuria]. *Vopr Med Khim* 1982 May-Jun;28(3):62-70. (Rus).
- Annenkov GA, Safronova EE. [Presence of active phenylalanine hydroxylase in human leukocytes]. *Vopr Med Khim* 1981 Mar-Apr;27(2):266-71. (Rus).
- Annenkov GA, Safronova EE, Gubernieva LM, Volkova NM. [Detection of phenylalanine hydroxylase activity in human leukocytes and fibroblasts]. *Vopr Med Khim* 1980 Nov-Dec;26(6):723-6. (Rus).
- Annual meeting of the Society for the Study of Inborn Errors of Metabolism. Liverpool, 3-6 September 1985. *J Inher Metab Dis* 1986;9 Suppl 2:157-335.
- Antener I, Verwilghen AM, van Geert C, Mauron J. Biochemical study of malnutrition. Part V. Metabolism of phenylalanine and tyrosine. *Int J Vitam Nutr Res* 1981;51(3):297-306.
- Antoshechkin AG, Chentsova TV, Tatur VYu, Naritsin DB, Railian GP. Content of phenylalanine, tyrosine and their metabolites in CSF in phenylketonuria. *J Inher Metab Dis* 1991;14(5):749-54.
- Antoshechkin AG, Zuyeva LA, Maximova LA. Excretion of phenylpyruvic, 4-hydroxyphenylpyruvic and indolyl-3-acetic acids by the skin fibroblasts from a phenylketonuric child. *J Inher Metab Dis* 1988;11(3):299-301.
- Aoki K. [Disorders of amino acids]. *Nippon Rinsho* 1993 Jan;51 Suppl:332-9. (Jpn).
- Apold J, Eiken HG, Odland E, Fredriksen A, Bakken A, Lorens JB, Boman H. A termination mutant prevalent in Norwegian haplotype 7 phenylketonuria genes. *Am J Hum Genet* 1990 Dec;47(6):1002-7.

- Aragon MC, Gimenez C, Valdivieso F. Inhibition by L-phenylalanine of tyrosine transport by synaptosomal plasma membrane vesicles: implications in the pathogenesis of phenylketonuria. *J Neurochem* 1982 Oct;39(4):1185-7.
- Arai N, Narisawa K, Hayakawa H, Tada K. Hyperphenylalaninemia due to dihydropteridine reductase deficiency: diagnosis by enzyme assays on dried blood spots. *Pediatrics* 1982 Sep;70(3):426-30.
- Arakawa T, Saito TG, Minagawa A, Shioji R, Kobayashi M, Chikaoka H, Katsushima N. Higher excretion of urinary bound amino acids in infants: probably related to protein-anabolic effect of growth hormone. *Tohoku J Exp Med* 1982 May;137(1):1-10.
- Araki K, Matsuo N, Kodoh J, Shimizu N. RFLPs at the PAH (phenylalanine hydroxylase) gene in the Japanese population. *Nucleic Acids Res* 1991 Apr 25;19(8):1960.
- Ardell MD. Activation of molecular oxygen in the reaction of hydroxylase [dissertation]. Mobile (AL): University of South Alabama; 1993. 128 p.
- Argaet VP, Wilson TJ, Davidson BE. Purification of the Escherichia coli regulatory protein TyrR and analysis of its interactions with ATP, tyrosine, phenylalanine, and tryptophan. *J Biol Chem* 1994 Feb 18;269(7):5171-8.
- Argiolas A, Bosco P, Cali F, Ceratto N, Anello G, Riva E, Biasucci G, Carducci C, Romano V. Two novel PAH gene mutations detected in Italian phenylketonuric patients. *Hum Genet* 1997 Feb;99(2):275-8.
- Armarego WL, Randles D, Waring P. Dihydropteridine reductase (DHPR), its cofactors, and its mode of action. *Med Res Rev* 1984 Jul-Sep;4(3):267-321.
- Artuch R, Vilaseca MA, Moreno J, Lambruschini N, Cambra FJ, Campistol J. Decreased serum ubiquinone-10 concentrations in phenylketonuria. *Am J Clin Nutr* 1999 Nov;70(5):892-5.
- Ashida A, Owada M, Hatakeyama K. A missense mutation (A to G) of 6-pyruvoyltetrahydropterin synthase in tetrahydrobiopterin-deficient form of hyperphenylalaninemia. *Genomics* 1994 Nov 15;24(2):408-10.
- Askin D, Green AK, Dickson AJ, Fisher MJ. Phenylalanine hydroxylation in isolated rat kidney tubules. *Int J Biochem* 1990;22(1):107-14.
- Aspartame. Review of safety issues. Council on Scientific Affairs. *JAMA* 1985 Jul 19;254(3):400-2.
- Austic RE, Su CL, Strupp BJ, Levitsky DA. Effects of dietary mixtures of amino acids on fetal growth and maternal and fetal amino acid pools in experimental maternal phenylketonuria. *Am J Clin Nutr* 1999 Apr;69(4):687-96.
- Avigad S, Kleiman S, Weinstein M, Cohen BE, Schwartz G, Woo SL, Shiloh Y. Compound heterozygosity in nonphenylketonuria hyperphenylalanemia: the contribution of mutations for classical phenylketonuria. *Am J Hum Genet* 1991 Aug;49(2):393-9.
- Avison MJ, Herschkowitz N, Novotny EJ, Petroff OA, Rothman DL, Colombo JP, Bachmann C, Shulman RG, Prichard JW. Proton NMR observation of phenylalanine and an aromatic metabolite in the rabbit brain in vivo. *Pediatr Res* 1990 Jun;27(6):566-70.
- Ayling JE. Discussion: Phenylalanine hydroxylase in human kidney; relevance to Phenylketonuria. *UCLA Forum Med Sci* 1975;(18):459-65.
- Ayling JE, Helfand GD, Pirson WD. Phenylalanine hydroxylase from human kidney. *Enzyme* 1975;20(1):6-19.
- Aziz AA, Blair JA, Leeming RJ, Sylvester PE. Tetrahydrobiopterin metabolism in Down's syndrome and in non-Down's syndrome mental retardation. *J Ment Defic Res* 1982 Jun;26 (Pt 2):67-71.
- Baba H, Sato S, Inuzuka T, Miyatake T. Developmental changes of myelin-associated glycoprotein in rat brain: study on experimental hyperphenylalaninemia. *Neurochem Res* 1987 May;12(5):459-63.
- Backwell FR, Bequette BJ, Wilson D, Calder AG, Metcalf JA, Wray-Cahen D, MacRae JC, Beever DE, Lobley GE. Utilization of dipeptides by the caprine mammary gland for milk protein synthesis. *Am J Physiol* 1994 Jul;267(1 Pt 2):R1-6.
- Bagchi SP. Cocaine and phencyclidine. Heterogenous dopaminergic interactions with tetrabenazine. *Neuropharmacology* 1985 Jan;24(1):37-41.
- Bailey SW, Ayling JE. 6,6-Dimethylpterins: stable quinoid dihydropterin substrate for dihydropteridine reductase and tetrahydropterin cofactor for phenylalanine hydroxylase. *Biochemistry* 1983 Apr 12;22(8):1790-8.
- Bailey SW, Ayling JE. An assay for picomole levels of tyrosine and related phenols and its application to the measurement of phenylalanine hydroxylase activity. *Anal Biochem* 1980 Sep 1;107(1):156-64.
- Bailey SW, Ayling JE. Cleavage of the 5-amino substituent of pyrimidine cofactors by phenylalanine

- hydroxylase. *J Biol Chem* 1980 Aug 25;255(16):7774-81.
- Bailey SW, Boerth SR, Dillard SB, Ayling JE. The mechanism of cofactor regeneration during phenylalanine hydroxylation. *Adv Exp Med Biol* 1993;338:47-54.
- Bailey SW, Dillard SB, Ayling JE. Role of C6 chirality of tetrahydropterin cofactor in catalysis and regulation of tyrosine and phenylalanine hydroxylases. *Biochemistry* 1991 Oct 22;30(42):10226-35.
- Bailey SW, Weintraub ST, Hamilton SM, Ayling JE. Incorporation of molecular oxygen into pyrimidine cofactors by phenylalanine hydroxylase. *J Biol Chem* 1982 Jul 25;257(14):8253-60.
- Baker GB, Bornstein RA, Rouget AC, Ashton SE, et al. Phenylethylaminergic mechanisms in attention-deficit disorder. *Biol Psychiatry* Jan 1991;29(1):15-22.
- Baker KG, Halliday GM, Halasz P, Hornung JP, Geffen LB, Cotton RG, Tork I. Cytoarchitecture of serotonin-synthesizing neurons in the pontine tegmentum of the human brain. *Synapse* 1991 Apr;7(4):301-20.
- Baker RE. Phenylalanine hydroxylase of cultured hepatoma cells: turnover rate and immunocytochemical identification [dissertation]. University Park (PA): The Pennsylvania State University; 1980. 115 p.
- Baker RE, Jefferson LS, Shiman R. Immunocytochemical identification of phenylalanine hydroxylase and albumin in cultured hepatoma cells and isolated rat hepatocytes. *J Cell Biol* 1981 Jul;90(1):145-52.
- Balasubramanian S, Carr RT, Bender CJ, Peisach J, Benkovic SJ. Histidines 138 and 143 are copper binding ligands in *Chromobacterium violaceum* phenylalanine hydroxylase. *Adv Exp Med Biol* 1993;338:67-70.
- Balasubramanian S, Carr RT, Bender CJ, Peisach J, Benkovic SJ. Identification of metal ligands in Cu(II)-inhibited *Chromobacterium violaceum* phenylalanine hydroxylase by electron spin echo envelope modulation analysis of histidine to serine mutations. *Biochemistry* 1994 Jul 19;33(28):8532-7.
- Ball RO, Atkinson JL, Bayley HS. Proline as an essential amino acid for the young pig. *Br J Nutr* 1986 May;55(3):659-68.
- Ball RO, Bayley HS. The effect of diarrhea on the oxidation of ¹⁴C-phenylalanine in piglets receiving diets varying in protein and proline concentration. *Can J Vet Res* 1986 Jul;50(3):393-6.
- Ball RO, Bayley HS. Influence of dietary protein concentration on the oxidation of phenylalanine by the young pig. *Br J Nutr* 1986 May;55(3):651-8.
- Ball RO, Bayley HS. Time course of the total and radioactive carbon dioxide production by piglets receiving dietary [¹⁴C]phenylalanine. *Can J Physiol Pharmacol* 1985 Sep;63(9):1170-4.
- Ball RO, Bayley HS. Tryptophan requirement of the 2.5-kg piglet determined by the oxidation of an indicator amino acid. *J Nutr* 1984 Oct;114(10):1741-6.
- Baranovskaya S, Shevtsov S, Maksimova S, Kuzmin A, Schwartz E. The mutations and VNTRs in the phenylalanine hydroxylase gene of phenylketonuria in St Petersburg. *J Inherit Metab Dis* 1996;19(5):705.
- Barashnev YI, Korneichuk VV, Klembovsky AI, Klyushina LA. Role of the liver in the pathogenesis of cerebral disorders in phenylketonuria. *J Inherit Metab Dis* 1982;5(4):204-10.
- Barasnev J. [Enzyme activity and the character of metabolic changes in brain tissue in children with phenylketonuria and histidinemia]. *Cesk Pediatr* 1980;35(2):49-52. (Cze).
- Barazzoni R, Zanetti M, Tiengo A, Tessari P. Protein metabolism in glucagonoma. *Diabetologia* 1999 Mar;42(3):326-9.
- Barker HA. Amino acid degradation by anaerobic bacteria. *Annu Rev Biochem* 1981;50:23-40.
- Bartholome K. Deficiency of tyrosine hydroxylase or tryptophan hydroxylase: a possible cause of two hypothetical metabolic diseases. *Acta Paediatr Scand* 1983 Nov;72(6):921-2.
- Bartholome K. [Molecular basis for the heterogeneity of phenylketonuria]. *Naturwissenschaften* 1980 Oct;67(10):495-8. (Ger).
- Bartholome K, Dresel A. Studies on the molecular defect in phenylketonuria and hyperphenylalaninaemia using antibodies against phenylalanine hydroxylase. *J Inherit Metab Dis* 1982;5(1):7-10.
- Bartholome K, Lutz P. [Determination of phenylalanine hydroxylase in patients with phenylketonuria and hyperphenylalaninemia]. *Monatsschr Kinderheilkd* 1976 May;124(5):421-2. (Ger).
- Basile-Filho A, el-Khoury AE, Beaumier L, Wang SY, Young VR. Continuous 24-h L-[1-¹³C]phenylalanine and L-[3,3-²H₂]tyrosine oral-tracer studies at an intermediate phenylalanine intake to estimate requirements in adults. *Am J Clin Nutr* 1997 Feb;65(2):473-88.

- Batterham ES, Bayley HS. Effect of frequency of feeding of diets containing free or protein-bound lysine on the oxidation of [¹⁴C]lysine or [¹⁴C]phenylalanine by growing pigs. *Br J Nutr* 1989 Nov;62(3):647-55.
- Baumeister AA, Baumeister AA. Dietary treatment of destructive behavior associated with hyperphenylalaninemia. *Clin Neuropharmacol* 1998 Jan-Feb;21(1):18-27.
- Beck B. [Hyperphenylalaninemia on account of bipterin deficiency. The phenylalanine hydroxylase complex and presentation of a patient with cofactor deficiency]. *Ugeskr Laeger* 1983 Nov 28;145(48):3725-7. (Dan).
- Beck B, Brandt NJ, Christensen E, Niederwieser A, Pedersen PS. Diagnostic and therapeutic aspects of dihydrobiopterin deficiency. *Acta Paediatr Scand* 1983 May;72(3):449-54.
- Beirne E, Carty MP, Donlon J. Effect of glucagon on hepatic phenylalanine hydroxylase in vivo. *Biosci Rep* 1985 Jun;5(6):463-7.
- Bel Y, Ferre J. Regulation of pteridine biosynthesis and aromatic amino acid hydroxylation in *Drosophila melanogaster*. *Biochem Genet* 1989 Feb;27(1-2):59-76.
- Bel Y, Jacobson KB, Ferre J. A comparative study of *Drosophila* phenylalanine hydroxylase with a natural and a synthetic tetrahydropterin as cofactor. *Comp Biochem Physiol [B]* 1992 Nov;103(3):557-62.
- Bel Y, Jacobson KB, Silva FJ, Ferre J. Developmental and biochemical studies on the phenylalanine hydroxylation system in *Drosophila melanogaster*. *Insect Biochem Mol Biol* 1992 Oct;22(7):633-8.
- Benit P, Rey F, Melle D, Munnich A, Rey J. Five novel missense mutations of the phenylalanine hydroxylase gene in phenylketonuria. *Hum Mutat* 1994;4(3):229-31.
- Benkovic S, Wallick D, Bloom L, Gaffney BJ, Domanico P, Dix T, Pember S. On the mechanism of action of phenylalanine hydroxylase. *Biochem Soc Trans* 1985 Apr;13(2):436-8.
- Benkovic SJ, Bloom LM, Bollag G, Dix TA, Gaffney BJ, Pember S. The mechanism of action of phenylalanine hydroxylase. *Ann N Y Acad Sci* 1986;471:226-32.
- Bentwood BJ, Henson PM. The sequential release of granule constituents from human neutrophils. *J Immunol* 1980 Feb;124(2):855-62.
- Bequette BJ, Backwell FR, Crompton LA. Current concepts of amino acid and protein metabolism in the mammary gland of the lactating ruminant. *J Dairy Sci* 1998 Sep;81(9):2540-59.
- Bequette BJ, Backwell FR, Dhanoa MS, Walker A, Calder AG, Wray-Cahen D, Metcalf JA, Sutton JD, Beever DE, Lobley GE. Kinetics of blood free and milk casein-amino acid labelling in the dairy goat at two stages of lactation. *Br J Nutr* 1994 Aug;72(2):211-20. Comment in: *Br J Nutr* 1996 Jan;75(1):139-40.
- Bequette BJ, Backwell FR, Kyle CE, Calder AG, Buchan V, Crompton LA, France J, McCrae JC. Vascular sources of phenylalanine, tyrosine, lysine, and methionine for casein synthesis in lactating goats. *J Dairy Sci* 1999 Feb;82(2):362-77.
- Berger DC, Hilton MA, Hilton FK, Duncan SD, Radmacher PG, Greene SM. Intravenous gamma-glutamyl-tyrosine elevates brain tyrosine but not catecholamine concentrations in normal rats. *Metabolism* 1996 Jan;45(1):126-32.
- Berger R, Springer J, Hommes FA. Brain protein and myelin metabolism in hyperphenylalaninemic rats. *Cell Mol Biol* 1980;26(1):31-6.
- Bergqvist PB, Vogels BA, Bosman DK, Maas MA, Hjorth S, Chamuleau RA, Bengtsson F. Neocortical dialysate monoamines of rats after acute, subacute, and chronic liver shunt. *J Neurochem* 1995 Mar;64(3):1238-44.
- Berlow S. Progress in phenylketonuria: defects in the metabolism of bipterin. *Pediatrics* 1980 Apr;65(4):837-9.
- Berry A, Ahmad S, Liss A, Jensen RA. Enzymological features of aromatic amino acid biosynthesis reflect the phylogeny of mycoplasmas. *J Gen Microbiol* 1987 Aug;133 (Pt 8):2147-54.
- Berry A, Johnson JL, Jensen RA. Phenylalanine hydroxylase and isozymes of 3-deoxy-D-arabino-heptulosonate 7-phosphate synthase in relationship to the phylogenetic position of *Pseudomonas acidovorans* (Ps. sp. ATCC 11299a). *Arch Microbiol* 1985 Feb;141(1):32-9.
- Berry HK, Hsieh MH, Bofinger MK, Schubert WK. Diagnosis of phenylalanine hydroxylase deficiency (phenylketonuria). *Am J Dis Child* 1982 Feb;136(2):111-4.
- Berthelon M, Caillaud C, Rey F, Labrune P, Melle D, Feingold J, Frezal J, Briard ML, Farriaux JP, Guibaud P, et al. Spectrum of phenylketonuria mutations in western Europe and north Africa, and their relation to polymorphic DNA haplotypes at the phenylalanine hydroxylase locus. *Hum Genet* 1991 Feb;86(4):355-8.
- Beschle HG, Sussmuth R, Lingens F. Conversion of chloramphenicol degradation products by tyrosine

- aminotransferase from Flavobacteria. Hoppe Seylers Z Physiol Chem 1982 Apr;363(4):439-44.
- Bessman SP. The justification theory: the essential nature of the non-essential amino acids. Nutr Rev 1979 Jul;37(7):209-20.
- Bessman SP, Choi H, Tomaszewski L. The justification theory: the effect of tyrosine deficiency on tubulin synthesis in the brain. Prog Clin Biol Res 1982;79:187-92.
- Bessman SP, Williamson ML, Koch R. Diet, genetics, and mental retardation interaction between phenylketonuric heterozygous mother and fetus to produce nonspecific diminution of IQ: evidence in support of the justification hypothesis. Proc Natl Acad Sci U S A 1978 Mar;75(3):1562-6.
- Bhatt DK. Acid phosphatase & 5'-nucleotidase activity in the brain of experimentally induced hyperphenylketonuric squirrels *Funambulus palmarum*. Indian J Exp Biol 1981 May;19(5):477-8.
- Bialik RJ, Li ET, Geoffroy P, Anderson GH. Route of delivery of phenylalanine influences its effect on short-term food intake in adult male rats. J Nutr 1989 Oct;119(10):1519-27.
- Bickel H. Phenylalaninaemia or classical phenylketonuria (PKU)? Neuropadiatrie 1970 Apr;1(4):379-82.
- Bickel H. [Screening for congenital metabolic disorders. Indication and results]. Monatsschr Kinderheilkd 1983 Jun;131(6):323-7. (Ger).
- Bigham EC, Smith GK, Reinhard JF Jr, Mallory WR, Nichol CA, Morrison RW Jr. Synthetic analogues of tetrahydrobiopterin with cofactor activity for aromatic amino acid hydroxylases. J Med Chem 1987 Jan;30(1):40-5.
- Binek PA, Johnson TC, Kelly CJ. Effect of alpha-methylphenylalanine and phenylalanine on brain polyribosomes and protein synthesis. J Neurochem 1981 Apr;36(4):1476-84.
- Binek-Singer P, Johnson TC. The effects of chronic hyperphenylalaninaemia on mouse brain protein synthesis can be prevented by other amino acids. Biochem J 1982 Aug 15;206(2):407-14.
- Binek-Singer PA. Prevention of the inhibition of neural protein synthesis during hyperphenylalaninemia [dissertation]. Manhattan (KS): Kansas State University; 1981. 132 p.
- Biolo G, Tessari P, Inchiostro S, Bruttomesso D, Sabadin L, Fongher C, Panebianco G, Fratton MG, Tiengo A. Fasting and postmeal phenylalanine metabolism in mild type 2 diabetes. Am J Physiol 1992 Nov;263(5 Pt 1):E877-83.
- Bjorgo E, Knappskog PM, Martinez A, Stevens RC, Flatmark T. Partial characterization and three-dimensional-structural localization of eight mutations in exon 7 of the human phenylalanine hydroxylase gene associated with phenylketonuria. Eur J Biochem 1998 Oct 1;257(1):1-10.
- Blaauw Ide, Deutz NEP, Meyenfeldt MF von. In vivo amino acid metabolism of gut and liver during short and prolonged starvation. Am J Physiol 1996 Feb;270(2 Pt 1):G298-306.
- Blackburn NJ, Strange RW, Carr RT, Benkovic SJ. X-ray absorption studies of the Cu-dependent phenylalanine hydroxylase from *Chromobacterium violaceum*. Comparison of the copper coordination in oxidized and dithionite-reduced enzymes. Biochemistry 1992 Jun 16;31(23):5298-303. Published erratum appears in Biochemistry 1993 Sep 7;32(35):9262.
- Blagoeva PM. Aminoacids--precursors of melanin synthesis in hamster melanoma. J Cancer Res Clin Oncol 1984;108(3):366-8.
- Blaskovics ME. Diagnosis in relationship to treatment of hyperphenylalaninaemia. J Inherit Metab Dis 1986;9 Suppl 2:178-82.
- Blau K, Levitt GA, Harvey DR. Hyperphenylalaninemia with defective transamination. Clin Chim Acta 1983 Jul 31;132(1):43-51.
- Blau N, Barnes I, Dhondt JL. International database of tetrahydrobiopterin deficiencies. J Inherit Metab Dis 1996;19(1):8-14.
- Blau N, Curtius HC. Cofactor defects in atypical phenylketonuria. In: Schmidt BJ, Diamant AJ, Loghin-Grosso NS, editors. Current trends in infant screening. Proceedings of the 7th International Screening Symposium; 1988 Nov 6-9; Sao Paulo, Brazil. New York: Excerpta Medica; 1989. p. 95-104. (International congress series; no. 848).
- Blau N, Dhondt JL. Tetrahydrobiopterin deficiency and an international database of patients. Adv Exp Med Biol 1993;338:255-61.
- Blau N, Dhondt JL, Guibaud P, Kuster T, Curtius HC. New variant of hyperphenylalaninaemia with excretion of 7-substituted pterins [letter]. Eur J Pediatr 1988 Nov;148(2):176.
- Blau N, Heizmann CW, Sperl W, Korenke GC, Hoffmann GF, Smooker PM, Cotton RG. Atypical (mild) forms of dihydropteridine reductase deficiency: neurochemical evaluation and mutation detection. Pediatr Res 1992 Dec;32(6):726-30.

- Blau N, Ichinose H, Nagatsu T, Heizmann CW, Zacchello F, Burlina AB. A missense mutation in a patient with guanosine triphosphate cyclohydrolase I deficiency missed in the newborn screening program. *J Pediatr* 1995 Mar;126(3):401-5.
- Blau N, Niederwieser A. GTP-cyclohydrolases: a review. *J Clin Chem Clin Biochem* 1985 Apr;23(4):169-76.
- Blau N, Thony B, Renneberg A, Penzien JM, Hyland K, Hoffmann GF. Variant of dihydropteridine reductase deficiency without hyperphenylalaninaemia: effect of oral phenylalanine loading. *J Inher Metab Dis* 1999 May;22(3):216-20.
- Blau N, Thony B, Spada M, Ponzone A. Tetrahydrobiopterin and inherited hyperphenylalaninemia. *Turk J Pediatr* 1996 Jan-Mar;38(1):19-35.
- Bliumina MG. [Malignant forms of phenylketonuria]. *Zh Nevropatol Psikhiatr* 1984;84(10):1462-5. (Rus).
- Bliumina MG. [Phenylalanine level in the serum of heterozygotes for phenylketonuria under intensified protein catabolism]. *Genetika* 1981;17(5):910-4. (Rus).
- Blomstrand E, Newsholme EA. Effect of branched-chain amino acid supplementation on the exercise-induced change in aromatic amino acid concentration in human muscle. *Acta Physiol Scand* 1992 Nov;146(3):293-8.
- Blomstrand E, Perrett D, Parry-Billings M, Newsholme EA. Effect of sustained exercise on plasma amino acid concentrations and on 5-hydroxytryptamine metabolism in six different brain regions in the rat. *Acta Physiol Scand* 1989 Jul;136(3):473-81.
- Bloom LM. Characterization of the phenylalanine hydroxylase [dissertation]. University Park (PA): The Pennsylvania State University; 1986. 56 p.
- Bloom LM, Benkovic SJ, Gaffney BJ. Characterization of phenylalanine hydroxylase. *Biochemistry* 1986 Jul 29;25(15):4204-10.
- Bodamer OA, Leonard JV, Tasker RC, Hoffmann GF, Halliday D. Protein turnover in critically ill children. *Eur J Pediatr* 1997 Aug;156 Suppl 1:S59-61.
- Bode R, Birnbaum D. Regulation of chorismate mutase activity of various yeast species by aromatic amino acids. *Antonie Van Leeuwenhoek* 1991 Jan;59(1):9-13.
- Bode VC, McDonald JD, Guenet JL, Simon D. hph-1: a mouse mutant with hereditary hyperphenylalaninemia induced by ethylnitrosourea mutagenesis. *Genetics* 1988 Feb;118(2):299-305.
- Bodsch W, Coenen HH, Stocklin G, Takahashi K, Hossmann KA. Biochemical and autoradiographic study of cerebral protein synthesis with [¹⁸F]- and [¹⁴C]fluorophenylalanine. *J Neurochem* 1988 Mar;50(3):979-83.
- Bohles H, Ullrich K, Endres W, Behbehani AW, Wendel U. Inadequate iron availability as a possible cause of low serum carnitine concentrations in patients with phenylketonuria. *Eur J Pediatr* 1991 Apr;150(6):425-8.
- Bonner CA. Molecular characterization of a bifunctional enzyme dehydratase/shikimate dehydrogenase and the post-prephenate enzymes needed for phenylalanine and tyrosine biosyntheses in SPP [dissertation]. Gainesville (FL): University of Florida; 1994. 159 p.
- Bourget L, Chang TM. Effects of oral administration of artificial cells immobilized phenylalanine ammonia-lyase on intestinal amino acids of phenylketonuric rats. *Biomater Artif Cells Artif Organs* 1989;17(2):161-81.
- Bourget LA. The effects of phenylalanine ammonia-lyase immobilized within artificial cells on the compartmental distribution of amino acids phenylketonuric rats [dissertation]. Montreal (Canada): McGill University; 1986. 300 p.
- Boyaval P, Moreira E, Desmazeaud MJ. Transport of aromatic amino acids by *Brevibacterium linens*. *J Bacteriol* 1983 Sep;155(3):1123-9.
- Boyaval P, Moreira E, Desmazeaud MJ. [Transport of phenylalanine and tyrosine in *Brevibacterium linens*: specificity and incorporation into proteins]. *Can J Microbiol* 1984 Apr;30(4):430-8. (Fre).
- Bradburn NC, Wappner RS, Lemons JA, Meyer BA, Roberts RS. Lactation and phenylketonuria. *Am J Perinatol* 1985 Apr;2(2):138-41.
- Brand MP, Heales SJ, Land JM, Clark JB. Tetrahydrobiopterin deficiency and brain nitric oxide synthase in the hph1 mouse. *J Inher Metab Dis* 1995;18(1):33-9.
- Brass CA. Hyperphenylalaninemia in the developing rat: biochemical and behavioral alterations [dissertation]. New York: City of New York; 1983. 317 p.
- Brass CA, Greengard O. Modulation of cerebral catecholamine concentrations during hyperphenylalaninaemia. *Biochem J* 1982 Dec 15;208(3):765-71.

- Brass CA, Isaacs CE, McChesney R, Greengard O. The effects of hyperphenylalaninemia on fetal development: a new animal model of maternal phenylketonuria. *Pediatr Res* 1982 May;16(5):388-94.
- Brenton DP. Maternal phenylketonuria. *Eur J Clin Nutr* 1989;43 Suppl 1:13-7.
- Bross R, Ball RO, Clarke JT, Pencharz PB. Tyrosine requirements in children with classical PKU determined by indicator amino acid oxidation. *Am J Physiol Endocrinol Metab* 2000 Feb;278(2):E195-201.
- Brown MC, Guest JF. Economic impact of feeding a phenylalanine-restricted diet to adults with previously untreated phenylketonuria. *J Intellect Disabil Res* 1999 Feb;43 (Pt 1):30-7.
- Brown RM, James R, Cotton RG. Amplification and expression of phenylalanine hydroxylase in mouse erythroleukemia cells. *Somat Cell Mol Genet* 1985 May;11(3):203-9.
- Bruch RJ. The effect of L-aspartyl-L-phenylalanine methyl ester on biosynthesis in macrophage cells [masters thesis]. Denton (TX): Texas Woman's University; 1992. 54 p.
- Buck M, Griffiths E. Regulation of aromatic amino acid transport by tRNA: role of 2-methylthio-N6-(delta2-isopentenyl)-adenosine. *Nucleic Acids Res* 1981 Jan 24;9(2):401-14.
- Buhrdel P, Grimm U, Wasser S, Knapp A, Wulff K. [Tryptophan metabolism in infants with phenylketonuria]. *Padiatr Grenzgeb* 1982;21(4):309-17. (Ger).
- Bulakhova LA, Usherenko LS. [Biogenic amine metabolism in patients with oligophrenia of different origins]. *Zh Nevropatol Psikhiatr* 1983;83(10):1563-7. (Rus).
- Burgard P, Rupp A, Konecki DS, Trefz FK, Schmidt H, Lichter-Konecki U. Phenylalanine hydroxylase genotypes, predicted residual enzyme activity and phenotypic parameters of diagnosis and treatment of phenylketonuria. *Eur J Pediatr* 1996 Jul;155 Suppl 1:S11-5.
- Burgert SL, Andersen DW, Stegink LD, Takeuchi H, Schedl HP. Metabolism of aspartame and its L-phenylalanine methyl ester decomposition product by the porcine gut. *Metab Clin Exp* 1991 Jun;40(6):612-8.
- Burke DG, Halpern B, Malegan D, McCairns E, Danks D, Schlesinger P, Wilken B. Profiles of urinary volatiles from metabolic disorders characterized by unusual odors. *Clin Chem* 1983 Oct;29(10):1834-8.
- Burri R, Matthieu JM, Vandeveld M, Lazeyras F, Posse S, Herschkowitz N. Brain damage and recovery in hyperphenylalaninemic rats. *Dev Neurosci* 1990;12(2):116-25.
- Burri R, Steffen C, Stieger S, Brodbeck U, Colombo JP, Herschkowitz N. Reduced myelinogenesis and recovery in hyperphenylalaninemic rats. Correlation between brain phenylalanine levels, characteristic brain enzymes for myelination, and brain development. *Mol Chem Neuropathol* 1990 Aug-Oct;13(1-2):57-69.
- Burrin DG, Davis TA, Ebner S, Schoknecht PA, Fiorotto ML, Reeds PJ. Colostrum enhances the nutritional stimulation of vital organ protein synthesis in neonatal pigs. *J Nutr* 1997 Jul;127(7):1284-9.
- Burton EG, Dal Monte P, Spears C, Frank P, Oppermann JA. Absorption by the rhesus monkey of phenylalanine methyl ester and species differences in its metabolism by blood, plasma and intestinal mucosa. *J Nutr* 1984 Oct;114(10):1940-5.
- Bushueva TV, Vrzhesinskaia OA, Kodentsova VM, Rybakova EP, Denisova SN, Beketova NA, Taranova AG, Pereverzeva OG, Kharitonchik LA, Kopylova NV. [Comparative study of special products Tetrapihen and Phenyl-free in diet therapy of children with phenylketonuria]. *Vopr Pitan* 1998;(2):14-8. (Rus).
- Butler IJ, O'Flynn ME, Seifert WE Jr, Howell RR. Neurotransmitter defects and treatment of disorders of hyperphenylalaninemia. *J Pediatr* 1981 May;98(5):729-33.
- Byck S, Morgan K, Tyfield L, Dworniczak B, Scriver CR. Evidence for origin, by recurrent mutation, of the phenylalanine hydroxylase R408W mutation on two haplotypes in European and Quebec populations. *Hum Mol Genet* 1994 Sep;3(9):1675-7.
- Byck S, Tyfield L, Carter K, Scriver CR. Prediction of multiple hypermutable codons in the human PAH gene: codon 280 contains recurrent mutations in Quebec and other populations. *Hum Mutat* 1997;9(4):316-21.
- Byng GS, Whitaker RJ, Shapiro CL, Jensen RA. The aromatic amino acid pathway branches at L-arogenate in *Euglena gracilis*. *Mol Cell Biol* 1981 May;1(5):426-38.
- Byrd DJ, Kochen W, Schurrle L, Trefz FK. A study of urinary tryptophan metabolites in relation to the phenylalanine content of semi-synthetic diets in a patient with phenylketonuria. *Acta Vitaminol Enzymol* 1975;29(1-6):55-61.
- Cabalska B, Skorkowska-Zieleniewska J, Nowakowska M. [Evaluation of the status of mineral nutrition of children with phenylketonuria treated by a

- low-phenylalanine diet. II. Zinc]. *Pediatr Pol* 1987 Oct;62(10):681-6. (Pol).
- Cabalska B, Skorkowska-Zieleniewska J, Nowakowska M, Banas D. [Status of mineral nutrition in children with phenylketonuria treated by low phenylalanine diet. III. Magnesium]. *Pediatr Pol* 1988 Jun;63(6):337-42. (Pol).
- Caillaud C, Vilarinho L, Vilarinho A, Rey F, Berthelon M, Santos R, Lyonnet S, Briard ML, Osorio RV, Rey J, et al. Linkage disequilibrium between phenylketonuria and RFLP haplotype 1 at the phenylalanine hydroxylase locus in Portugal. *Hum Genet* 1992 Apr;89(1):69-72.
- Callus BA, Mathey-Prevot B. Hydrophobic residues Phe751 and Leu753 are essential for STAT5 transcriptional activity. *J Biol Chem* 2000 Jun 2;275(22):16954-62.
- Carbohydrate and glycoprotein metabolism, maternal phenylketonuria. 27th annual SSIEM meeting. Munich, 1989. *J Inherit Metab Dis* 1990;13(4):393-671.
- Carr RT. Mechanistic studies of metal independent phenylalanine Chromobacterium violaceum (monooxygenase) [dissertation]. University Park (PA): The Pennsylvania State University; 1994. 140 p.
- Carr RT, Balasubramanian S, Hawkins PC, Benkovic SJ. Mechanism of metal-independent hydroxylation by Chromobacterium violaceum phenylalanine hydroxylase. *Biochemistry* 1995 Jun 6;34(22):7525-32.
- Carr RT, Benkovic SJ. An examination of the copper requirement of phenylalanine hydroxylase from Chromobacterium violaceum. *Biochemistry* 1993 Dec 28;32(51):14132-8.
- Carr RT, Benkovic SJ. A re-examination of the metal requirement of Chromobacterium violaceum phenylalanine hydroxylase. *Adv Exp Med Biol* 1993;338:63-6.
- Carter KC, Byck S, Waters PJ, Richards B, Nowacki PM, Laframboise R, Lambert M, Treacy E, Scriver CR. Mutation at the phenylalanine hydroxylase gene (PAH) and its use to document population genetic variation: the Quebec experience. *Eur J Hum Genet* 1998 Jan;6(1):61-70.
- Castillo L, Yu YM, Marchini JS, Chapman TE, Sanchez M, Young VR, Burke JF. Phenylalanine and tyrosine kinetics in critically ill children with sepsis. *Pediatr Res* 1994 May;35(5):580-8.
- Castillo M, Zafra MF, Garcia-Peregrin E. Effect of experimental hyperphenylalaninemia induced by dietary phenylalanine plus alpha-methylphenylalanine administration on amino acid concentration in neonatal chick brain, plasma, and liver. *Neurochem Res* 1988 Jun;13(6):547-50.
- Castillo M, Zafra MF, Garcia-Peregrin E. Inhibition of brain and liver 3-hydroxy-3-methylglutaryl-CoA reductase and mevalonate-5-pyrophosphate decarboxylase in experimental hyperphenylalaninemia. *Neurochem Res* 1988 Jun;13(6):551-5.
- Castoria G, Migliaccio A, Green S, Di Domenico M, Chambon P, Auricchio F. Properties of a purified estradiol-dependent calf uterus tyrosine kinase. *Biochemistry* 1993 Feb 23;32(7):1740-50.
- Castronuovo G, Elia V, Fessas D, Giordano A, Velleca F. Thermodynamics of the interaction of cyclodextrins with aromatic and alpha, omega-amino acids in aqueous solutions: a calorimetric study at 25 degrees C. *Carbohydr Res* 1995 Jul 21;272(1):31-9.
- Celikel R, Davis MD, Dai XP, Kaufman S, Xuong NH. Crystallization and preliminary X-ray analysis of phenylalanine hydroxylase from rat liver. *J Mol Biol* 1991 Apr 5;218(3):495-8.
- Cerone R, Barella C, Fantasia AR, Schiaffino MC. [Evaluation of a new amino acid mixture for the treatment of phenylketonuria]. *Minerva Pediatr* 1999 Nov-Dec;51(11-12):403-6. (Ita).
- Chaeva LS. [Effect of experimental hyperphenylalaninemia on the metabolism of gluco- and galactocerebrosides and sulfatides]. *Vopr Med Khim* 1983 Nov-Dec;29(6):51-4. (Rus).
- Chakraborty R, Lidsky AS, Daiger SP, Guttler F, Sullivan S, Dilella AG, Woo SL. Polymorphic DNA haplotypes at the human phenylalanine hydroxylase locus and their relationship with phenylketonuria. *Hum Genet* 1987 May;76(1):40-6.
- Chang TM, Bourget L, Lister C. A new theory of entero-recirculation of amino acids and its use for depleting unwanted amino acids using oral enzyme-artificial cells, as in removing phenylalanine in phenylketonuria. *Artif Cells Blood Substit Immobil Biotechnol* 1995;23(1):1-21.
- Charikova EV. Novel mutation identified in the PAH gene. *Hum Hered* 1996 Jan-Feb;46(1):36-40.
- Chehin R, Thorolfsson M, Knappskog PM, Martinez A, Flatmark T, Arrondo JL, Muga A. Domain structure and stability of human phenylalanine hydroxylase inferred from infrared spectroscopy. *FEBS Lett* 1998 Jan 30;422(2):225-30.
- Chen D, Frey PA. Phenylalanine hydroxylase from Chromobacterium violaceum. Uncoupled oxidation of

- tetrahydropterin and the role of iron in hydroxylation. *J Biol Chem* 1998 Oct 2;273(40):25594-601.
- Chen HY, Demidkina TV, Phillips RS. Site-directed mutagenesis of tyrosine-71 to phenylalanine in *Citrobacter freundii* tyrosine phenol-lyase: evidence for dual roles of tyrosine-71 as a general acid catalyst in the reaction mechanism and in cofactor binding. *Biochemistry* 1995 Sep 26;34(38):12276-83.
- Chestkov VV, Kovalev LI, Shishkin SS, Annenkov GA. [Oligomerization of phenylalanine hydroxylase during its activation with phenylalanine]. *Vopr Med Khim* 1985 Jul-Aug;31(4):60-5. (Rus).
- Chestkov VV, Kugukova IuV, Kovalev LI, Shishkin SS. [Isolation and characteristics of highly-purified phenylalanine hydroxylase from the rat liver]. *Vopr Med Khim* 1986 Jan-Feb;32(1):123-7. (Rus).
- Chestkov VV, Laptev AV. [Immunochemical detection and characteristics of the subunit composition of phenylalanine hydroxylase in the brain of man]. *Biull Eksp Biol Med* 1988 Jul;106(7):30-4. (Rus).
- Chestkov VV, Laptev AV, Danilina EM, Shishkin SS. [Isolation of inactive phenylalanine hydroxylase from autopsy specimens of human liver]. *Biokhimiia* 1986 Jul;51(7):1210-5. (Rus).
- Chestkov VV, Laptev AV, Shishkin SS. [Detection and characteristics of membrane form of phenylalanine hydroxylase (EC 1.14.16.1) from the rat liver]. *Biokhimiia* 1988 Jan;53(1):158-65. (Rus).
- Chestkov VV, Laptev AV, Shishkin SS. [Identification of the membrane form of phenylalanine hydroxylase from the human liver and characteristics of its subunit composition]. *Biokhimiia* 1988 Feb;53(2):322-7. (Rus).
- Chestkov VV, Laptev AV, Shishkin SS. Membrane-bound phenylalanine hydroxylase of human liver. *J Hepatol* 1992 Sep;16(1-2):11-5.
- Chestkov VV, Shepkina IuV, Jennings IG, Cotton RG, Shishkin SS. [Phenylalanine hydroxylase-like antibody in human chorionic villi]. *Biull Eksp Biol Med* 1992 Sep;114(9):308-10. (Rus).
- Chestkov VV, Shishkin SS. [Genetic heterogeneity and approaches to the prenatal diagnosis of phenylketonuria (review)]. *Vopr Med Khim* 1986 Jul-Aug;32(4):7-12. (Rus).
- Chiappelli F, Haggerty DF, Lynch M, Popjak G. Translation of phenylalanine hydroxylase-specific mRNA in vitro: evidence for pretranslational control by glucocorticoids. *Proc Natl Acad Sci U S A* 1981 Apr;78(4):2105-9.
- Choi TB, Pardridge WM. Phenylalanine transport at the human blood-brain barrier. Studies with isolated human brain capillaries. *J Biol Chem* 1986 May 15;261(14):6536-41.
- Choi YH, Furuse M, Okumura J, Shimoyama Y, Sugahara K, Denbow DM. Intracerebroventricularly administered phenylalanine and tyrosine: effects on feeding behavior and norepinephrine concentrations of specific brain sites in the chicken. *Asian Australas J Anim Sci* 1996 Jun;9(3):255-9.
- Choo KH, Cotton RG, Jennings IG, Danks DM. Observations indicating the nature of the mutation in phenylketonuria. *J Inher Metab Dis* 1980;2(4):79-84.
- Choo KH, Cotton RG, Jennings IG, Fowler K, Danks DM. Genetics of mammalian phenylalanine hydroxylase system. IV. Evidence of phenylalanine hydroxylase in a cultured human hepatoma cell line. *Biochem Genet* 1980 Oct;18(9-10):955-68.
- Choo KH, Jennings IG, Cotton RG. Comparative studies of four monoclonal antibodies to phenylalanine hydroxylase exhibiting different properties with respect to substrate-dependence, species-specificity and a range of effects on enzyme activity. *Biochem J* 1981 Dec 1;199(3):527-35.
- Choo KH, Myer J, Cotton RG, Camakaris J, Danks DM. Isolation of phenylalanine hydroxylase-stimulating monoclonal antibody by rat-myeloma-rat-spleen-cell fusion. *Biochem J* 1980 Nov 1;191(2):665-8.
- Christensen HN. Hypothesis: where the depleted plasma amino acids go in phenylketonuria, and why. *Perspect Biol Med* 1987 Winter;30(2):186-96.
- Christianson DW, Mangani S, Shoham G, Lipscomb WN. Binding of D-phenylalanine and D-tyrosine to carboxypeptidase A. *J Biol Chem* 1989 Aug 5;264(22):12849-53.
- Citron BA, Davis MD, Kaufman S. Electrostatic activation of rat phenylalanine hydroxylase. *Biochem Biophys Res Commun* 1994 Jan 14;198(1):174-80.
- Citron BA, Davis MD, Kaufman S. Purification and biochemical characterization of recombinant rat liver phenylalanine hydroxylase produced in *Escherichia coli*. *Protein Expr Purif* 1992 Apr;3(2):93-100.
- Citron BA, Davis MD, Milstien S, Gutierrez J, Mendel DB, Crabtree GR, Kaufman S. Identity of 4a-carbinolamine dehydratase, a component of the phenylalanine hydroxylation system, and DCoH, a transregulator of homeodomain proteins. *Proc Natl Acad Sci U S A* 1992 Dec 15;89(24):11891-4.
- Citron BA, Kaufman S, Milstien S, Naylor EW, Greene CL, Davis MD. Mutation in the 4a-

- carbinolamine dehydratase gene leads to mild hyperphenylalaninemia with defective cofactor metabolism. *Am J Hum Genet* 1993 Sep;53(3):768-74.
- Clark SE, Karn CA, Ahlrichs JA, Wang J, Leitch CA, Leichty EA, Denne SC. Acute changes in leucine and phenylalanine kinetics produced by parenteral nutrition in premature infants. *Pediatr Res* 1997 Apr;41(4 Pt 1):568-74.
- Clemens P, Gruttner R. Transient defect in the synthesis of biotin [letter]. *J Pediatr* 1985 Aug;107(2):312-3.
- Clemens PC, Burmester JG, Wiegand G, Prankel BH, Halfmann E, Erb N, Muller-Wickop J. Phenylalanine, other large neutral amino acids and RNA catabolites as markers for protein biosynthesis in phenylketonuria [letter]. *Metabolism* 1993 Apr;42(4):531-2. Comment on: *Metabolism* 1992 May;41(5):518-21.
- Clemens PC, Prankel B, Halfman E, Erb N, Muller-Wickop J. Extracellular purine nucleosides elevated in chronic recidiving central nervous injury by deranged metabolism in phenylketonuria [letter]. *Med Hypotheses* 1993 Sep;41(3):287-8. Comment on: *Med Hypotheses* 1992 Apr;37(4):232-40.
- Clemens PC, Schunemann MH, Kohlschutter A, Hoffman GF. Phenylalanine metabolites in phenylketonuria [letter]. *J Pediatr* 1990 Apr;116(4):665-6. Comment on: *J Pediatr* 1989 May;114(5):895-900.
- Cobet G, Beyreiss K. [Resorption disorders in children with phenylketonuria]. *Acta Biol Med Ger* 1982;41(7-8):659-63. (Ger).
- Cohen BE, Szeinberg A, Quint J, Normand M, Blonder J, Peled I. Malignant phenylketonuria due to defective synthesis of dihydrobiopterin. *Isr J Med Sci* 1985 Jun;21(6):520-5.
- Collins JE, Leonard JV. The dietary management of inborn errors of metabolism. *Hum Nutr Appl Nutr* 1985 Aug;39(4):255-72.
- Collins MA. Neuroamine condensations in human subjects. *Adv Exp Med Biol* 1980;126:87-102.
- Collins RJ, Boyle PJ, Clague AE, Barr AE, Latham SC. In vitro OKT3-induced mitogenesis in selenium-deficient patients on a diet for phenylketonuria. *Biol Trace Elem Res* 1991 Sep;30(3):233-44.
- Colombo M, Troncoso L, Raimann E, Perales CG, Barros TL, Cornejo V. [Diagnosis of phenylketonuria in Chile]. *Rev Chil Pediatr* 1988 Jul-Aug;59(4):235-9. (Spa).
- Comar D, Saudubray JM, Duthilleul A, Delforge J, Maziere M, Berger G, Charpentier C, Todd-Pokropek A. Brain uptake of 11C-methionine in phenylketonuria. *Eur J Pediatr* 1981 Mar;136(1):13-9.
- Connell A, Calder AG, Anderson SE, Lobley GE. Hepatic protein synthesis in the sheep: effect of intake as monitored by use of stable-isotope-labelled glycine, leucine and phenylalanine. *Br J Nutr* 1997 Feb;77(2):255-71.
- Corbeel L. [Problems posed by maternal phenylketonuria]. *Arch Fr Pediatr* 1983;40 Suppl 1:281-2. (Fre).
- Cortiella J, Marchini JS, Branch S, Chapman TE, Young VR. Phenylalanine and tyrosine kinetics in relation to altered protein and phenylalanine and tyrosine intakes in healthy young men. *Am J Clin Nutr* 1992 Sep;56(3):517-25.
- Coskun T, Karagoz T, Kalkanoglu S, Tokatli A, Ozalp I, Thony B, Blau N. Guanosine triphosphate cyclohydrolase I deficiency: a rare cause of hyperphenylalaninemia. *Turk J Pediatr* 1999 Apr-Jun;41(2):231-7.
- Cotton RG. Heterogeneity of phenylketonuria at the clinical, protein and DNA levels. *J Inherit Metab Dis* 1990;13(5):739-50.
- Cotton RG. A model for hyperphenylalaninaemia due to tetrahydrobiopterin deficiency. *J Inherit Metab Dis* 1986;9(1):4-14.
- Cotton RG, Howells DW, Saleeba JA, Dianzani I, Smooker PM, Jennings IG. Structure function studies of the phenylalanine hydroxylase active site and a summary of structural features. *Adv Exp Med Biol* 1993;338:55-7.
- Cotton RG, Jennings I, Bracco G, Ponzzone A, Guardamagna O. Tetrahydrobiopterin non-responsiveness in dihydropteridine reductase deficiency is associated with the presence of mutant protein. *J Inherit Metab Dis* 1986;9(3):239-43.
- Cotton RG, Jennings IG, Choo KH, Fowler K. Isolation and characterization of a myeloma-spleen-cell hybrid producing antibody to phenylalanine hydroxylase. *Biochem J* 1980 Dec 1;191(3):777-83.
- Cotton RG, McAdam W, Jennings I, Morgan FJ. A monoclonal antibody to aromatic amino acid hydroxylases. Identification of the epitope. *Biochem J* 1988 Oct 1;255(1):193-6.
- Cowell CT, Lu PW, Lloyd-Jones SA, Briody JN, Allen JR, Humphries IR, Reed E, Knight J, Howman-Giles R, Gaskin K. Volumetric bone mineral density--a potential role in paediatrics. *Acta Paediatr Suppl* 1995 Sep;411:12-6, discussion 17.

- Cowie V. Injury and insult--considerations of the neuropathological aetiology of mental subnormality. *Br J Psychiatry* 1980 Oct;137:305-12.
- Crandall EA, Fernstrom JD. Effect of experimental diabetes on the levels of aromatic and branched-chain amino acids in rat blood and brain. *Diabetes* 1983 Mar;32(3):222-30.
- Crawford RD. Phenylalanine hydroxylase isozymes in regenerating liver: diet and age [dissertation]. Los Angeles (CA): University of Southern California; 1981.
- Crawford RD, Layne EC, Bessman SP. Effects of phenylalanine on phenylalanine hydroxylase separation and stability. *Biochem Med* 1985 Feb;33(1):90-8.
- Crawford RD, Layne EC, Bessman SP. Phenylalanine hydroxylase isozymes in regenerating liver: effects of diet and age. *Biochem Med* 1985 Feb;33(1):77-89.
- Crawford MD, Gibbs DA, Sheppard DM. Studies on human phenylalanine Mono-oxygenase. I. Restricted expression. *J Inherit Metab Dis* 1981;4(4):191-5.
- Creppy EE, Chakor K, Fisher MJ, Dirheimer G. The mycotoxin ochratoxin A is a substrate for phenylalanine hydroxylase in isolated rat hepatocytes and in vivo. *Arch Toxicol* 1990;64(4):279-84.
- Cristiano RJ, Smith LC, Woo SL. Hepatic gene therapy: adenovirus enhancement of receptor-mediated gene delivery and expression in primary hepatocytes. *Proc Natl Acad Sci U S A* 1993 Mar 15;90(6):2122-6.
- Crow JP Jr. Multiple sites of phenylalanine hydroxylase (tetrahydrobiopterin) [dissertation]. Mobile (AL): University of South Alabama; 1991. 162 p.
- Curtius HC, Adler C, Rebrin I, Heizmann C, Ghisla S. 7-Substituted pterins: formation during phenylalanine hydroxylation in the absence of dehydratase. *Biochem Biophys Res Commun* 1990 Nov 15;172(3):1060-6.
- Curtius HC, Baerlocher K, Vollmin JA. Pathogenesis of phenylketonuria: inhibition of DOPA and catecholamine synthesis in patients with phenylketonuria. *Clin Chim Acta* 1972 Nov;42(1):235-9.
- Curtius HC, Endres W, Blau N. Effect of high-protein meal plus aspartame ingestion on plasma phenylalanine concentrations in obligate heterozygotes for phenylketonuria. *Metabolism* 1994 Apr;43(4):413-6.
- Curtius HC, Farner H, Rey F. In vivo studies of the tryptophan-5-hydroxylase system. Quantitation of serotonin and tryptamine using gas chromatography-mass fragmentography. *J Chromatogr* 1980 Oct 31;199:171-9.
- Curtius HC, Ghisla S, Hasegawa H, Blau N, Rebrin I. Progress in the study of biosynthesis and role of 7-substituted pterins: function of pterin-4a-carbinolamine dehydratase. *Adv Exp Med Biol* 1993;338:107-10.
- Curtius HC, Matasovic A, Schoedon G, Kuster T, Guibaud P, Giudici T, Blau N. 7-Substituted pterins. A new class of mammalian pteridines. *J Biol Chem* 1990 Mar 5;265(7):3923-30.
- Curtius HC, Niederwieser A. [Development of the biosynthesis and excretion of pterins in phenylketonuria and its variants]. *Arch Fr Pediatr* 1983;40 Suppl 1:227-30. (Fre).
- Curtius HC, Niederwieser A, Levine R, Muldner H. Therapeutic efficacy of tetrahydrobiopterin in Parkinson's disease. *Adv Neurol* 1984;40:463-6.
- Curtius HC, Niederwieser A, Viscontini M, Leimbacher W, Wegmann H, Blehova B, Rey F, Schaub J, Schmidt H. Serotonin and dopamine synthesis in phenylketonuria. *Adv Exp Med Biol* 1981;133:277-91.
- Cutler P. Arginase deficiency and phenylketonuria [letter]. *J Neurol Neurosurg Psychiatry* 1986 Sep;49(9):1090.
- Cynober L. Amino acid metabolism in thermal burns. *JPEN J Parenter Enteral Nutr* 1989 Mar-Apr;13(2):196-205.
- D'Amato TA. Gene-enzyme relationships in *Nicotiana glauca*: subcellular localization of genes and enzymes for aromatic amino acid (chloroplasts, tryptophan, phenylalanine, metabolism, tyrosine) [dissertation]. Binghamton (NY): State University of New York at Binghamton; 1987. 163 p.
- D'Sa CM, Arthur RE Jr, States JC, Kuhn DM. Tryptophan hydroxylase: cloning and expression of the rat brain enzyme in mammalian cells. *J Neurochem* 1996 Sep;67(3):900-6.
- Dahl HH, Hutchison W, McAdam W, Wake S, Morgan FJ, Cotton RG. Human dihydropteridine reductase: characterisation of a cDNA clone and its use in analysis of patients with dihydropteridine reductase deficiency. *Nucleic Acids Res* 1987 Mar 11;15(5):1921-32.
- Dahl HH, Mercer JF. Isolation and sequence of a cDNA clone which contains the complete coding region of rat phenylalanine hydroxylase. Structural homology with tyrosine hydroxylase, glucocorticoid

- regulation, and use of alternate polyadenylation sites. *J Biol Chem* 1986 Mar 25;261(9):4148-53.
- Daiger SP, Chakraborty R, Reed L, Fekete G, Schuler D, Berenssi G, Nasz I, Brdicka R, Kamaryt J, Pijackova A, et al. Polymorphic DNA haplotypes at the phenylalanine hydroxylase (PAH) locus in European families with phenylketonuria (PKU). *Am J Hum Genet* 1989 Aug;45(2):310-8.
- Daiger SP, Lidsky AS, Chakraborty R, Koch R, Guttler F, Woo SL. Polymorphic DNA haplotypes at the phenylalanine hydroxylase locus in prenatal diagnosis of phenylketonuria. *Lancet* 1986 Feb 1;1(8475):229-32.
- Daiger SP, Reed L, Huang SS, Zeng YT, Wang T, Lo WH, Okano Y, Hase Y, Fukuda Y, Oura T, et al. Polymorphic DNA haplotypes at the phenylalanine hydroxylase (PAH) locus in Asian families with phenylketonuria (PKU). *Am J Hum Genet* 1989 Aug;45(2):319-24.
- Dalery J, Maillet J, de Villard R. [Behavior problems in phenylketonuria. Attempt at a biochemical interpretation based on a personal case and a review of the literature]. *Encephale* 1983;9(3):279-90. (Fre).
- Danicke S, Bottcher W, Jeroch H, Thielebein J, Simon O. Replacement of soybean oil with tallow in rye-based diets without xylanase increases protein synthesis in small intestine of broilers. *J Nutr* 2000 Apr;130(4):827-34.
- Danks DM, Bartholome K, Clayton BE, Curtius H, Grobe H, Kaufman S, Leeming R, Pfliegerer W, Rembold H, Rey F. Malignant hyperphenylalaninaemia--current status (June 1977). *J Inher Metab Dis* 1978;1(2):49-53.
- Danks DM, Cotton RG. Phenylalanine hydroxylase activity [letter]. *Am J Dis Child* 1983 Apr;137(4):409-10.
- Darling PB. Threonine and phenylalanine metabolism in the human neonate protein turnover, oxidation [dissertation]. Toronto (Canada): University of Toronto; 1997. 230 p.
- Darmon MC, Grima B, Cash CD, Maitre M, Mallet J. Isolation of a rat pineal gland cDNA clone homologous to tyrosine and phenylalanine hydroxylases. *FEBS Lett* 1986 Sep 29;206(1):43-6.
- Daubner SC, Hillas PJ, Fitzpatrick PF. Characterization of chimeric pterin-dependent hydroxylases: contributions of the regulatory domains of tyrosine and phenylalanine hydroxylase to substrate specificity. *Biochemistry* 1997 Sep 30;36(39):11574-82.
- Daubner SC, Hillas PJ, Fitzpatrick PF. Expression and characterization of the catalytic domain of human phenylalanine hydroxylase. *Arch Biochem Biophys* 1997 Dec 15;348(2):295-302.
- Davis MD, Kaufman S. 7-Tetrahydrobiopterin is an uncoupled cofactor for rat hepatic phenylalanine hydroxylase. *FEBS Lett* 1991 Jul 8;285(1):17-20.
- Davis MD, Kaufman S. Evidence for the formation of the 4a-carbinolamine during the tyrosine-dependent oxidation of tetrahydrobiopterin by rat liver phenylalanine hydroxylase. *J Biol Chem* 1989 May 25;264(15):8585-96.
- Davis MD, Kaufman S. Products of the tyrosine-dependent oxidation of tetrahydrobiopterin by rat liver phenylalanine hydroxylase. *Arch Biochem Biophys* 1993 Jul;304(1):9-16.
- Davis MD, Kaufman S. Studies on the partially uncoupled oxidation of tetrahydropterins by phenylalanine hydroxylase. *Neurochem Res* 1991 Jul;16(7):813-9.
- Davis MD, Kaufman S. The tyrosine-dependent oxidation of tetrahydropterins by lysolecithin-activated rat liver phenylalanine hydroxylase. *J Biol Chem* 1988 Nov 25;263(33):17312-6.
- Davis MD, Kaufman S, Milstien S. Conversion of 6-substituted tetrahydropterins to 7-isomers via phenylalanine hydroxylase-generated intermediates. *Proc Natl Acad Sci U S A* 1991 Jan 15;88(2):385-9.
- Davis MD, Parniak MA, Kaufman S, Kempner E. The role of phenylalanine in structure-function relationships of phenylalanine hydroxylase revealed by radiation target analysis. *Proc Natl Acad Sci U S A* 1997 Jan 21;94(2):491-5.
- Davis MD, Parniak MA, Kaufman S, Kempner E. Structure-function relationships of phenylalanine hydroxylase revealed by radiation target analysis. *Arch Biochem Biophys* 1996 Jan 15;325(2):235-41.
- Davis MD, Ribeiro P, Tipper J, Kaufman S. 7-tetrahydrobiopterin, a naturally occurring analogue of tetrahydrobiopterin, is a cofactor for and a potential inhibitor of the aromatic amino acid hydroxylases. *Proc Natl Acad Sci U S A* 1992 Nov 1;89(21):10109-13.
- Davis TA, Karl IE, Tegtmeyer ED, Osborne DF, Klahr S, Harter HR. Muscle protein turnover: effects of exercise training and renal insufficiency. *Am J Physiol* 1985 Mar;248(3 Pt 1):E337-45.
- de Almeida IT, Leandro PP, Portela R, Cabral A, Eusebio F, Tasso T, Matasovic A, Blau N. Tetrahydrobiopterin deficiency in Portugal: results of

- the screening for hyperphenylalaninemia. *Adv Exp Med Biol* 1993;338:263-6.
- de Cespedes C, Thoene JG, Lowler K, Christensen HN. Evidence for inhibition of exodus of small neutral amino acids from non-brain tissues in hyperphenylalaninaemic rats. *J Inherit Metab Dis* 1989;12(2):166-80.
- de Freitas O, Izumi C, Lara MG, Greene LJ. New approaches to the treatment of phenylketonuria. *Nutr Rev* 1999 Mar;57(3):65-70.
- De Lucca M, Perez B, Desviat LR, Ugarte M. Molecular basis of phenylketonuria in Venezuela: presence of two novel null mutations. *Hum Mutat* 1998;11(5):354-9.
- Denne SC, Karn CA, Ahlrichs JA, Dorotheo AR, Wang J, Liechty EA. Proteolysis and phenylalanine hydroxylation in response to parenteral nutrition in extremely premature and normal newborns. *J Clin Invest* 1996 Feb 1;97(3):746-54.
- Depietro FR. The role of phenylalanine in catecholamine synthesis in pc12 pheochromocytoma cells (tyrosine) [dissertation]. Pittsburgh (PA): University of Pittsburgh; 1997. 195 p.
- Desviat LR, Perez B, Gamez A, Sanchez A, Garcia MJ, Martinez-Pardo M, Marchante C, Boveda D, Baldellou A, Arena J, Sanjurjo P, Fernandez A, Cabello ML, Ugarte M. Genetic and phenotypic aspects of phenylalanine hydroxylase deficiency in Spain: molecular survey by regions. *Eur J Hum Genet* 1999 Apr;7(3):386-92.
- Desviat LR, Perez B, Garcia MJ, Martinez-Pardo M, Baldellou A, Arena J, Sanjurjo P, Campistol J, Couce ML, Fernandez A, Cardesa J, Ugarte M. Relationship between mutation genotype and biochemical phenotype in a heterogeneous Spanish phenylketonuria population. *Eur J Hum Genet* 1997 Jul-Aug;5(4):196-202.
- Desviat LR, Perez B, Ugarte M. A new PKU mutation associated with haplotype 12. *Hum Mol Genet* 1992 Dec;1(9):765-6.
- Dews PB. Summary report of an International Aspartame Workshop. *Food Chem Toxicol* 1987 Jul;25(7):549-52.
- Dezortova M, Hejcmanova L, Hajek M. Decreasing choline signal--a marker of phenylketonuria? *MAGMA* 1996 Sep-Dec;4(3-4):181-6.
- Dhondt JL. [Measurement of dihydropteridine reductase activity in dried blood eluates: physiological and pathological implications]. *Ann Biol Clin (Paris)* 1992;50(9):653-8. (Fre).
- Dhondt JL. Strategy for the screening of tetrahydrobiopterin deficiency among hyperphenylalaninaemic patients: 15-years experience. *J Inherit Metab Dis* 1991;14(2):117-27.
- Dhondt JL. Tetrahydrobiopterin deficiencies: preliminary analysis from an international survey. *J Pediatr* 1984 Apr;104(4):501-8.
- Dhondt JL. [Tetrahydrobiopterin deficiency. Lessons from the analysis of 90 patients collected in the international register]. *Arch Fr Pediatr* 1987;44 Suppl 1:655-9. (Fre).
- Dhondt JL, Ardouin P, Hayte JM, Farriaux JP. Developmental aspects of pteridine metabolism and relationships with phenylalanine metabolism. *Clin Chim Acta* 1981 Oct 26;116(2):143-52.
- Dhondt JL, Cotton RG, Danks DM. Liver enzyme activities in hyperphenylalaninaemia due to a defective synthesis of tetrahydrobiopterin. *J Inherit Metab Dis* 1985;8(2):47-8.
- Dhondt JL, Delcroix M, Farriaux JP. Unconjugated pteridines in human milk. *Clin Chim Acta* 1982 May 6;121(1):33-5.
- Dhondt JL, Farriaux JP. Hepatic phenylalanine hydroxylase activity in hyperphenylalaninaemia. *J Inherit Metab Dis* 1981;4(2):59-60.
- Dhondt JL, Farriaux JP. [Hyperphenylalaninemia in 1981. A diagnostic approach (author's transl)]. *Arch Fr Pediatr* 1981 Oct;38(8):573-8. (Fre).
- Dhondt JL, Farriaux JP. [The phenylalanine hydroxylase system]. *Arch Fr Pediatr* 1983;40 Suppl 1:219-21. (Fre).
- Dhondt JL, Farriaux JP. [Tetrahydrobiopterin. Metabolism and metabolic role of unconjugated pteridines (author's transl)]. *Pathol Biol (Paris)* 1980 Jun;28(6):397-405. (Fre).
- Dhondt JL, Farriaux JP, Boudha A, Largilliere C, Ringel J, Roger MM, Leeming RJ. Neonatal hyperphenylalaninemia presumably caused by guanosine triphosphate-cyclohydrolase deficiency. *J Pediatr* 1985 Jun;106(6):954-6.
- Dhondt JL, Farriaux JP, Millot F, Taret S, Hayte JM, Mazingue F. [High-dose methotrexate and hyperphenylalaninemia]. *Arch Fr Pediatr* 1991 Apr;48(4):249-51. (Fre).
- Dhondt JL, Guibaud P, Rolland MO, Dorche C, Andre S, Forzy G, Hayte JM. Neonatal hyperphenylalaninaemia presumably caused by a new variant of biopterin synthetase deficiency. *Eur J Pediatr* 1988 Feb;147(2):153-7.

- Dhondt JL, Henichart JP, Bernier JL, Dautrevaux M. In vitro effects of L- and D-parachlorophenylalanine on rat liver phenylalanine hydroxylase. *Biochimie* 1980;62(2-3):185-6.
- Dhondt JL, Kapatos G, Parniak M, Wilgus H, Kaufman S. Biopterin metabolism and phenylalanine hydroxylase activity during early liver regeneration. *Biochem Biophys Res Commun* 1982 Jun 15;106(3):786-93.
- Dhondt JL, Leroux B, Farriaux JP, Largilliere C, Leeming RJ. Dihydrobiopterin biosynthesis deficiency. *Eur J Pediatr* 1983 Dec;141(2):92-5.
- Diamant AJ. [Recent advances in inborn errors of metabolism]. *Arq Neuropsiquiatr* 1987 Jun;45(2):177-87. (Por).
- Diamond A. Evidence for the importance of dopamine for prefrontal cortex functions early in life. *Philos Trans R Soc Lond B Biol Sci* 1996 Oct 29;351(1346):1483-93; discussion 1494.
- Diamond A, Ciaramitaro V, Donner E, Djali S, Robinson MB. An animal model of early-treated PKU. *J Neurosci* 1994 May;14(5 Pt 2):3072-82.
- Dianzani I, Camaschella C, Saglio G, Ferrero GB, Ramus S, Ponzone A, Cotton RG. Molecular analysis of contiguous exons of the phenylalanine hydroxylase gene: identification of a new PKU mutation. *J Med Genet* 1993 Mar;30(3):228-31.
- Dianzani I, Devoto M, Camaschella C, Saglio G, Ferrero GB, Cerone R, Romano C, Romeo G, Giovannini M, Riva E, et al. Haplotype distribution and molecular defects at the phenylalanine hydroxylase locus in Italy. *Hum Genet* 1990 Nov;86(1):69-72.
- Dickson PW, Jennings IG, Cotton RG. Delineation of the catalytic core of phenylalanine hydroxylase and identification of glutamate 286 as a critical residue for pterin function. *J Biol Chem* 1994 Aug 12;269(32):20369-75.
- Dienel GA. Chronic hyperphenylalaninemia produces cerebral hyperglycinemia in immature rats. *J Neurochem* 1981 Jan;36(1):34-43.
- Dietary D-tyrosine as an antimetabolite in mice. *Nutr Rev* 1985 May;43(5):156-8.
- DiLella AG, Kwok SC, Ledley FD, Marvit J, Woo SL. Molecular structure and polymorphic map of the human phenylalanine hydroxylase gene. *Biochemistry* 1986 Feb 25;25(4):743-9.
- DiLella AG, Ledley FD, Rey F, Munnich A, Woo SL. Detection of phenylalanine hydroxylase messenger RNA in liver biopsy samples from patients with phenylketonuria [letter]. *Lancet* 1985 Jan 19;1(8421):160-1.
- Dillehay L, Bass R, Englesberg E. Inhibition of growth of cells in culture by L-phenylalanine as a model system for the analysis of phenylketonuria. I. amino acid antagonism and the inhibition of protein synthesis. *J Cell Physiol* 1980 Mar;102(3):395-405.
- Diomedede L, Romano M, Guiso G, Caccia S, Nava S, Salmons M. Interspecies and interstrain studies on the increased susceptibility to metrazol-induced convulsions in animals given aspartame. *Food Chem Toxicol* 1991 Feb;29(2):101-6.
- Dix TA, Benkovic SJ. Mechanism of uncoupled tetrahydropterin oxidation by phenylalanine hydroxylase. *Biochemistry* 1985 Oct 8;24(21):5839-46.
- Dix TA, Bollag GE, Domanico PL, Benkovic SJ. Phenylalanine hydroxylase: absolute configuration and source of oxygen of the 4a-hydroxytetrahydropterin species. *Biochemistry* 1985 Jun 4;24(12):2955-8.
- Doherty LB, Rohr FJ, Levy HL. Detection of phenylketonuria in the very early newborn blood specimen. *Pediatrics* 1991 Feb;87(2):240-4.
- Donlon J, Beirne E. Modulations of rat hepatic phenylalanine hydroxylase due to induced diabetes or high-protein diet. *Biochem Biophys Res Commun* 1982 Sep 30;108(2):746-51.
- Donlon J, Kaufman S. Relationship between the multiple forms of rat hepatic phenylalanine hydroxylase and degree of phosphorylation. *J Biol Chem* 1980 Mar 10;255(5):2146-52.
- Dorland L, Poll-The BT, Duran M, Smeitink JA, Berger R. Phenylpyruvate, fetal damage, and maternal phenylketonuria syndrome [letter]. *Lancet* 1993 May 22;341(8856):1351-2.
- Dorner WG. [Campaign against hereditary diseases. A curse for future generations]. *Minerva Med* 1981 Dec 22;72(51):3555-6. (Ita).
- Doskeland A, Ljones T, Skotland T, Flatmark T. Phenylalanine 4-monooxygenase from bovine and rat liver: some physical and chemical properties. *Neurochem Res* 1982 Apr;7(4):407-21.
- Doskeland AP. Regulatory properties of phenylalanine 4-monooxygenase hydroxylase [dissertation]. Bergen (Norway): University of Bergen; 1991. 125 p.
- Doskeland AP, Doskeland SO, Flatmark T. Phenylalanine 4-monooxygenase from bovine liver. *Methods Enzymol* 1987;142:35-44.

- Doskeland AP, Doskeland SO, Ogreid D, Flatmark T. The effect of ligands of phenylalanine 4-monoxygenase on the cAMP-dependent phosphorylation of the enzyme. *J Biol Chem* 1984 Sep 25;259(18):11242-8.
- Doskeland AP, Flatmark T. Recombinant human phenylalanine hydroxylase is a substrate for the ubiquitin-conjugating enzyme system. *Biochem J* 1996 Nov 1;319 (Pt 3):941-5.
- Doskeland AP, Haavik J, Flatmark T, Doskeland SO. Modulation by pterins of the phosphorylation and phenylalanine activation of phenylalanine 4-monoxygenase. *Biochem J* 1987 Mar 15;242(3):867-74.
- Doskeland AP, Martinez A, Knappskog PM, Flatmark T. Phosphorylation of recombinant human phenylalanine hydroxylase: effect on catalytic activity, substrate activation and protection against non-specific cleavage of the fusion protein by restriction protease. *Biochem J* 1996 Jan 15;313 (Pt 2):409-14.
- Doskeland AP, Schworer CM, Doskeland SO, Chrisman TD, Soderling TR, Corbin JD, Flatmark T. Some aspects of the phosphorylation of phenylalanine 4-monoxygenase by a calcium-dependent and calmodulin-dependent protein kinase. *Eur J Biochem* 1984 Nov 15;145(1):31-7.
- Doskeland AP, Vintermyr OK, Flatmark T, Cotton RG, Doskeland SO. Phenylalanine positively modulates the cAMP-dependent phosphorylation and negatively modulates the vasopressin-induced and okadaic-acid-induced phosphorylation of phenylalanine 4-monoxygenase in intact rat hepatocytes. *Eur J Biochem* 1992 May 15;206(1):161-70.
- Dotremont H, Francois B, Diels M, Gillis P. Nutritional value of essential amino acids in the treatment of adults with phenylketonuria. *J Inherit Metab Dis* 1995;18(2):127-30.
- Drenth JP, Kleinjans JC. [Aspartame, a sweet alternative]. *Ned Tijdschr Geneesk* 1988 Apr 16;132(16):712-5. (Dut).
- Druml W, Roth E, Lenz K, Lochs H, Kopsa H. Phenylalanine and tyrosine metabolism in renal failure: dipeptides as tyrosine source. *Kidney Int Suppl* 1989 Nov;27:S282-6.
- Dunlop DS, Yang XR, Lajtha A. The effect of elevated plasma phenylalanine levels on protein synthesis rates in adult rat brain. *Biochem J* 1994 Sep 1;302 (Pt 2):601-10.
- Duran GP, Rohr FJ, Slonim A, Guttler F, Levy HL. Necessity of complete intake of phenylalanine-free amino acid mixture for metabolic control of phenylketonuria. *J Am Diet Assoc* 1999 Dec;99(12):1559-63.
- Dvorakova D, Fajkusova L. Direct analysis of R408W mutation in phenylalanine hydroxylase gene by allele-specific PCR amplification. *Hum Mol Genet* 1993 Mar;2(3):323.
- Dwivedy AK, Shah SN. Effect of hyperphenylalaninemia on Na⁺ + K⁺-ATPase in rat brain. *Exp Neurol* 1981 Dec;74(3):924-9.
- Dwivedy AK, Shah SN. Effect of hyperphenylalaninemia on polyphosphoinositides content of rat brain. *Experientia* 1982 Dec 15;38(12):1458-9.
- Dwivedy AK, Shah SN. Effects of phenylalanine and its deaminated metabolites on Na⁺,K⁺-ATPase activity in synaptosomes from rat brain. *Neurochem Res* 1982 Jun;7(6):717-25.
- Dworniczak B, Grudda K, Stumper J, Bartholome K, Aulehla-Scholz C, Horst J. Phenylalanine hydroxylase gene: novel missense mutation in exon 7 causing severe phenylketonuria. *Genomics* 1991 Jan;9(1):193-9.
- Dworniczak B, Kalaydjieva L, Aulehla-Scholz C, Ullrich K, Kremensky I, Radeva B, Horst J. Recurrent nonsense mutation in exon 7 of the phenylalanine hydroxylase gene. *Hum Genet* 1991 Oct;87(6):731-3.
- Dworniczak B, Kalaydjieva L, Pankoke S, Aulehla-Scholz C, Allen G, Horst J. Analysis of exon 7 of the human phenylalanine hydroxylase gene: a mutation hot spot? *Hum Mutat* 1992;1(2):138-46.
- Dworniczak B, Wedemeyer N, Eigel A, Horst J. PCR detection of the PvuII (Ea) RFLP at the human phenylalanine hydroxylase (PAH) locus. *Nucleic Acids Res* 1991 Apr 25;19(8):1958.
- Dworniczak B, Wedemeyer N, Horst J. PCR detection of the BglIII RFLP at the human phenylalanine hydroxylase (PAH) locus. *Nucleic Acids Res* 1991 Apr 25;19(8):1958.
- Dyck LE, Yang CR, Boulton AA. The biosynthesis of p-tyramine, m-tyramine, and beta-phenylethylamine by rat striatal slices. *J Neurosci Res* 1983;10(2):211-20.
- Dyer CA, Kendler A, Jean-Guillaume D, Awatramani R, Lee A, Mason LM, Kamholz J. GFAP-positive and myelin marker-positive glia in normal and pathologic environments. *J Neurosci Res* 2000 May 1;60(3):412-26.
- Dyer CA, Kendler A, Philibotte T, Gardiner P, Cruz J, Levy HL. Evidence for central nervous system glial

- cell plasticity in phenylketonuria. *J Neuropathol Exp Neurol* 1996 Jul;55(7):795-814.
- Dzhura I, Naidenov V, Zhuravleva S, Kostyuk P, Shuba Y. Expression of Ca²⁺ channels from rat brain with model phenylketonuria in *Xenopus* oocytes. *Brain Res* 1998 Feb 9;783(2):280-5.
- Eatock SA. Activation and reconstitution studies of the enzyme hydroxylase [masters thesis]. Ottawa (Canada): Carleton University; 1989.
- Edara S, Goodtzova K, Pegg AE. The role of tyrosine-158 in O6-alkylguanine-DNA alkyltransferase activity. *Carcinogenesis* 1995 Jul;16(7):1637-42.
- Edwards P. The effects of some neurotoxins on tetrahydrobiopterin [dissertation]. Birmingham (UK): University of Aston in Birmingham; 1988. 244 p.
- Effat L, Kuzmin A, Kasem N, Meguid NA, Kotb S, Eisensmith RC, Temtamy SA, Rushdi S, Woo S, el-Awady M. Haplotypes and mutations of the PAH locus in Egyptian families with PKU. *Eur J Hum Genet* 1999 Feb-Mar;7(2):259-62.
- Ege-Serpken D. Electrochemistry of methylated pterins: I. Electrochemical of 6,7-dimethyltetrahydropterin. II. Electrochemical oxidation 2-dimethylamino-3,6,7-trimethyl tetrahydropterin. III. Comparison electrochemical and spectroelectrochemical behavior of methylated pterins [dissertation]. Norman (OK): The University of Oklahoma; 1982. 336 p.
- Eiken HG, Knappskog PM, Apold J, Flatmark T. PKU mutation G46S is associated with increased aggregation and degradation of the phenylalanine hydroxylase enzyme. *Hum Mutat* 1996;7(3):228-38.
- Eiken HG, Knappskog PM, Apold J, Skjelkvale L, Boman H. A de novo phenylketonuria mutation: ATG (Met) to ATA (Ile) in the start codon of the phenylalanine hydroxylase gene. *Hum Mutat* 1992;1(5):388-91.
- Eiken HG, Knappskog PM, Motzfeldt K, Boman H, Apold J. Phenylketonuria genotypes correlated to metabolic phenotype groups in Norway. *Eur J Pediatr* 1996 Jul;155(7):554-60.
- Eisensmith RC, Woo SL. Gene therapy for phenylketonuria. *Acta Paediatr Suppl* 1994 Dec;407:124-9.
- Eisensmith RC, Woo SL. Molecular basis of phenylketonuria and related hyperphenylalaninemia: mutations and polymorphisms in the human phenylalanine hydroxylase gene. *Hum Mutat* 1992;1(1):13-23.
- Eisensmith RC, Woo SL. Molecular genetics of phenylketonuria: from molecular anthropology to gene therapy. *Adv Genet* 1995;32:199-271.
- Eisensmith RC, Woo SL. Phenylketonuria and the phenylalanine hydroxylase gene. *Mol Biol Med* 1991 Feb;8(1):3-18.
- Eisensmith RC, Woo SL. Somatic gene therapy for phenylketonuria and other hepatic deficiencies. *J Inher Metab Dis* 1996;19(4):412-23.
- Elkin RG, Rogler JC. Partial alleviation of phenylalanine toxicity in the chick by supplemental dietary tryptophan. *Poult Sci* 1983 Apr;62(4):647-58.
- Elkin RG, Rogler JC, Featherston WR. Dietary phenylalanine and tyrosine interrelationships in the Sprague-Dawley rat. *Proc Soc Exp Biol Med* 1981 Jul;167(3):310-7.
- Ellingsen S, Knappskog PM, Apold J, Eiken HG. Diverse PAH transcripts in lymphocytes of PKU patients with putative nonsense (G272X, Y356X) and missense (P281L, R408Q) mutations. *FEBS Lett* 1999 Sep 3;457(3):505-8.
- Elslinger MA, Theriault GR, Gauthier D. In vitro localization of the protein synthesis defect associated with experimental phenylketonuria. *Neurochem Res* 1989 Jan;14(1):81-4.
- Endo F. [Inborn errors of tyrosine metabolism: abnormalities in catabolic pathway of phenylalanine and tyrosine]. *Seikagaku* 1999 Nov;71(11):1327-31. (Jpn).
- Enwonwu CO, Afolabi BM, Salako LA, Idigbe EO, al-Hassan H, Rabiou RA. Hyperphenylalaninaemia in children with falciparum malaria. *QJM* 1999 Sep;92(9):495-503.
- Eriksson T, Carlsson A. Beta-adrenergic control of brain uptake of large neutral amino acids. *Life Sci* 1988;42(17):1583-9.
- Erlandsen H, Bjorgo E, Flatmark T, Stevens RC. Crystal structure and site-specific mutagenesis of pterin-bound human phenylalanine hydroxylase. *Biochemistry* 2000 Mar 7;39(9):2208-17.
- Erlandsen H, Flatmark T, Stevens RC, Hough E. Crystallographic analysis of the human phenylalanine hydroxylase catalytic domain with bound catechol inhibitors at 2.0 Å resolution. *Biochemistry* 1998 Nov 10;37(45):15638-46.
- Erlandsen H, Fusetti F, Martinez A, Hough E, Flatmark T, Stevens RC. Crystal structure of the catalytic domain of human phenylalanine hydroxylase reveals the structural basis for phenylketonuria [letter]. *Nat Struct Biol* 1997 Dec;4(12):995-1000.

- Erlandsen H, Stevens RC. The structural basis of phenylketonuria. *Mol Genet Metab* 1999 Oct;68(2):103-25.
- Eschrich K, van der Bolt FJ, de Kok A, van Berkel WJ. Role of Tyr201 and Tyr385 in substrate activation by p-hydroxybenzoate hydroxylase from *Pseudomonas fluorescens*. *Eur J Biochem* 1993 Aug 15;216(1):137-46.
- Esposito DL, Blakesley VA, Koval AP, Scrimgeour AG, LeRoith D. Tyrosine residues in the C-terminal domain of the insulin-like growth factor-I receptor mediate mitogenic and tumorigenic signals. *Endocrinology* 1997 Jul;138(7):2979-88.
- Fallstrom SP, Lindblad B, Steen G. On the renal tubular damage in hereditary tyrosinemia and on the formation of succinylacetoacetate and succinylacetone. *Acta Paediatr Scand* 1981;70(3):315-20.
- Fang B, Eisensmith RC, Li XH, Finegold MJ, Shedlovsky A, Dove W, Woo SL. Gene therapy for phenylketonuria: phenotypic correction in a genetically deficient mouse model by adenovirus-mediated hepatic gene transfer. *Gene Ther* 1994 Jul;1(4):247-54.
- Fang CH, Li BG, James JH, Fischer JE, Hasselgren PO. The anabolic effects of IGF-1 in skeletal muscle after burn injury are not caused by increased cell volume. *JPEN J Parenter Enteral Nutr* 1998 May-Jun;22(3):115-9.
- Farishian RA, Whittaker JR. Phenylalanine lowers melanin synthesis in mammalian melanocytes by reducing tyrosine uptake: implications for pigment reduction in phenylketonuria. *J Invest Dermatol* 1980 Feb;74(2):85-9.
- Farmer AA, Goss SJ. BWTG3 hepatoma cells can acquire phenylalanine hydroxylase, cystathionine synthase and CPS-I without genetic manipulation, but activation of the silent OTC gene requires cell fusion with hepatocytes. *J Cell Sci* 1991 Apr;98 (Pt 4):533-8.
- Farriaux JP, Dhondt JL. [Neonatal screening for phenylketonuria]. *J Genet Hum* 1981 Mar;29(1):3-11. (Fre).
- Farriaux JP, Dhont JL. [Hyperphenylalaninemia in 1983]. *Rev Med Brux* 1983 Apr;4(4):305-10. (Fre).
- Faust DM, Catherin AM, Barboux S, Belkadi L, Imaizumi-Scherrer T, Weiss MC. The activity of the highly inducible mouse phenylalanine hydroxylase gene promoter is dependent upon a tissue-specific, hormone-inducible enhancer. *Mol Cell Biol* 1996 Jun;16(6):3125-37.
- Faust DM, Imaizumi-Scherrer T, Fulchignoni-Lataud MC, Catherin AM, Iost I, Weiss MC. Activation of phenylalanine hydroxylase expression following genomic DNA transfection of hepatoma cells. *Differentiation* 1990 Jul;44(1):74-9.
- Fernstrom JD. Role of precursor availability in control of monoamine biosynthesis in brain. *Physiol Rev* 1983 Apr;63(2):484-546.
- Fernstrom JD, Fernstrom MH, Gillis MA. Acute effects of aspartame on large neutral amino acids and monoamines in rat brain. *Life Sci* 1983 Apr 4;32(14):1651-8.
- Fernstrom JD, Fernstrom MH, Grubb PE. Twenty-four-hour variations in rat blood and brain levels of the aromatic and branched-chain amino acids: chronic effects of dietary protein content. *Metabolism* 1987 Jul;36(7):643-50.
- Fernstrom JD, Fernstrom MH, Massoudi MS. In vivo tyrosine hydroxylation in rat retina: effect of aspartame ingestion in rats pretreated with p-chlorophenylalanine. *Am J Clin Nutr* 1991 Apr;53(4):923-9.
- Fernstrom MH, Baker RL, Fernstrom JD. In vivo tyrosine hydroxylation rate in retina: effects of phenylalanine and tyrosine administration in rats pretreated with p-chlorophenylalanine. *Brain Res* 1989 Oct 16;499(2):291-8.
- Ferraris S, Guardamagna O, Bracco G, Ponzzone A. [Trial of indirect screening of tetrahydrobiopterin deficiency]. *Pediatric* 1987;42(7):549-55. (Fre).
- Ficner R, Sauer UH, Stier G, Suck D. Three-dimensional structure of the bifunctional protein PCD/DCoH, a cytoplasmic enzyme interacting with transcription factor HNF1. *EMBO J* 1995 May 1;14(9):2034-42.
- Fiedler AE, Miller MJ, Bickel H, Cederbaum SD. Phenylalanine levels in PKU following minor surgery. *Am J Med Genet* 1982 Apr;11(4):411-4.
- Figlewicz DA, Druse MJ. Experimental hyperphenylalaninemia: effect on central nervous system myelin subfractions. *Exp Neurol* 1980 Feb;67(2):315-29.
- Filer LJ Jr, Baker GL, Stegink LD. Effect of aspartame loading on plasma and erythrocyte free amino acid concentrations in one-year-old infants. *J Nutr* 1983 Aug;113(8):1591-9.
- Filer LJ Jr, Stegink LD. Aspartame metabolism in normal adults, phenylketonuric heterozygotes, and diabetic subjects. *Diabetes Care* 1989 Jan;12(1):67-74.

- Fink RM, Elstner EF. Comparison of different methods for the determination of phenylalanine hydroxylase activity in rat liver and *Euglena gracilis*. *Z Naturforsch [C]* 1984 Jul-Aug;39(7-8):728-33.
- Fink RM, Elstner EF. Studies on the possible mechanism of inactivation of phenylalanine hydroxylase by destructive oxygen species. *Z Naturforsch [C]* 1984 Jul-Aug;39(7-8):734-7.
- Firgaira FA, Cotton RG, Danks DM, Fowler K, Lipson A, Yu JS. Prenatal determination of dihydropteridine reductase in a normal fetus at risk for malignant hyperphenylalaninemia. *Prenat Diagn* 1983 Jan;3(1):7-11.
- Fisberg RM, Da Silva-Fernandes ME, Fisberg M, Schmidt BJ. Plasma zinc, copper, and erythrocyte superoxide dismutase in children with phenylketonuria. *Nutrition* 1999 Jun;15(6):449-52.
- Fisch RO, Chang PN, Sines L, Weisberg S, Bessman SP. Relationship between phenylalanine tolerance and psychological characteristics of phenylketonuric families. *Biochem Med* 1985 Apr;33(2):236-45.
- Fisch RO, Tsai MY, Clark BA, Okagaki T. Semen studies on phenylketonurics. *Biochem Med* 1981 Dec;26(3):427-34.
- Fisch RO, Tsai MY, Gentry WC Jr. Studies of phenylketonurics with dermatitis. *J Am Acad Dermatol* 1981 Mar;4(3):284-90.
- Fisher MJ, Dickson AJ, Pogson CI. Phosphopeptide analysis of phenylalanine hydroxylase isolated from liver cells exposed to hormonal stimuli. *Biochem J* 1986 Jan 15;233(2):507-11.
- Fisher MJ, Dickson AJ, Pogson CI. The polyamine-dependent modulation of phenylalanine hydroxylase phosphorylation state and enzymic activity in isolated liver cells. *Biochem J* 1986 Jul 1;237(1):277-9.
- Fisher MJ, Pogson CI. The determination of flux through phenylalanine hydroxylase and homogentisate oxidase in isolated hepatocytes. *Biosci Rep* 1984 Oct;4(10):835-41.
- Fisher MJ, Pogson CI. Phenylalanine hydroxylase in liver cells. Correlation of glucagon-stimulated enzyme phosphorylation with expressed activity. *Biochem J* 1984 Apr 1;219(1):79-85.
- Fisher MJ, Santana MA, Pogson CI. Effects of adrenergic agents, vasopressin and ionophore A23187, on the phosphorylation of, and flux through, phenylalanine hydroxylase in rat liver cells. *Biochem J* 1984 Apr 1;219(1):87-90.
- Fitzgerald B, Morgan J, Keene N, Rollinson R, Hodgson A, Dalrymple-Smith J. An investigation into diet treatment for adults with previously untreated phenylketonuria and severe intellectual disability. *J Intellect Disabil Res* 2000 Feb;44(Pt 1):53-9.
- Fitzpatrick PF. The aromatic amino acid hydroxylases. *Adv Enzymol Relat Areas Mol Biol* 2000;74:235-94.
- Foster MS, Carroll JN, Niederhoffer EC. Phenylalanine- and tyrosine-dependent production of enterobactin in *Escherichia coli*. *FEMS Microbiol Lett* 1994 Mar 15;117(1):79-83.
- Franz M. Is it safe to consume aspartame during pregnancy? A review. *Nutrition update. Diabetes Educ* 1986 Spring;12(2):145-7.
- Frezal J, Farriaux JP. [Phenylketonuria yesterday and today. Evaluation of the work of systematic neonatal screening]. *Rev Prat* 1992 Nov 15;42(18):2316-26. (Fre).
- Friedman M, Gumbmann MR. The nutritive value and safety of D-phenylalanine and D-tyrosine in mice. *J Nutr* 1984 Nov;114(11):2089-96.
- Friedrich CA, Ferrell RE, Siciliano MJ, Kitto GB. Biochemical and genetic identity of alpha-keto acid reductase and cytoplasmic malate dehydrogenase from human erythrocytes. *Ann Hum Genet* 1988 Jan;52 (Pt 1):25-37.
- Froberg C. Nongrowing cells for production of metabolites: *Clostridium acetobutylicum* and phenylalanine from *Escherichia* [dissertation]. Stockholm (Sweden): Royal Institute of Technology; 1988. 95 p.
- Fuchs-Mettler M, Curtius HC, Baerlocher K, Ettlinger L. A new rearrangement reaction in tyrosine metabolism. *Eur J Biochem* 1980 Jul;108(2):527-34.
- Fukami MH, Haavik J, Flatmark T. Phenylalanine as substrate for tyrosine hydroxylase in bovine adrenal chromaffin cells. *Biochem J* 1990 Jun 1;268(2):525-8.
- Fukuda K, Tanaka T, Hyodo S, Kobayashi Y, Usui T. Hyperphenylalaninaemia due to impaired dihydrobiopterin biosynthesis: leukocyte function and effect of tetrahydrobiopterin therapy. *J Inheret Metab Dis* 1985;8(2):49-52.
- Fulton TR, Triano T, Rabe A, Loo YH. Phenylacetate and the enduring behavioral deficit in experimental phenylketonuria. *Life Sci* 1980 Oct 6;27(14):1271-81.
- Fusetti F, Erlandsen H, Flatmark T, Stevens RC. Structure of tetrameric human phenylalanine hydroxylase and its implications for phenylketonuria. *J Biol Chem* 1998 Jul 3;273(27):16962-7.
- Gal EM, Whitacre DH. Mechanism of irreversible inactivation of phenylalanine-4- and tryptophan-5-

hydroxylases by [4-³⁶Cl, 2-¹⁴C]p-chlorophenylalanine: a revision. *Neurochem Res* 1982 Jan;7(1):13-26.

Garcia de Juan JF. Valores de referencia de las magnitudes bioquímicas l-fenilalanina y l-tirosina en la población de Navarra: estudio de tirosinemia transitoria del recién nacido [Reference values of the biochemical magnitudes l-phenylalanine l-tyrosine in the Navarra population: study of transient neonatal tyrosinaemia] [dissertation]. Ciudad Universitaria (Spain): University of Navarra; 1991. 331 p. (Spa).

Gardiner RM. Transport of amino acids across the blood-brain barrier: implications for treatment of maternal phenylketonuria. *J Inherit Metab Dis* 1990;13(4):627-33.

Gardner AM, Martin LA, Gardner PR, Dou Y, Olson JS. Steady-state and transient kinetics of *Escherichia coli* nitric-oxide dioxygenase (flavo-hemoglobin). The B10 tyrosine hydroxyl is essential for dioxygen binding and catalysis. *J Biol Chem* 2000 Apr 28;275(17):12581-9.

Gatlin CL, Turecek F. Quantitative electrospray ionization mass spectrometric studies of ternary complexes of amino acids with Cusup 2sup + and phenanthroline. *J Mass Spectrom* 2000;35(2):172-7.

Gavioli F, Zannino L. [Dietetic treatment of phenylketonuria]. *Minerva Pediatr* 1980 Mar 31;32(6):417-32. (Ita).

Gehrmann J, Schott K, Neuhoﬀ V. Biochemical and developmental features of experimental phenylketonuria induced by L-ethionine in suckling rats. *Biochem Med Metab Biol* 1989 Jun;41(3):201-11.

Geltosky JE, Mitchell HK. Developmental regulation of phenylalanine hydroxylase activity in *Drosophila melanogaster*. *Biochem Genet* 1980 Aug;18(7-8):781-91.

Gerasimova NS, Steklova IV, Tuuminen T. Fluorometric method for phenylalanine microplate assay adapted for phenylketonuria screening. *Clin Chem* 1989 Oct;35(10):2112-5.

Gibbs BS. Expression and active site studies of rat liver phenylalanine hydroxylase (pterin binding site) [dissertation]. University Park (PA): The Pennsylvania State University; 1992. 146 p.

Gibbs BS, Benkovic SJ. Affinity labeling of the active site and the reactive sulfhydryl associated with activation of rat liver phenylalanine hydroxylase. *Biochemistry* 1991 Jul 9;30(27):6795-802.

Gibbs BS, Wojchowski D, Benkovic SJ. Expression of rat liver phenylalanine hydroxylase in insect cells and

site-directed mutagenesis of putative non-heme iron-binding sites. *J Biol Chem* 1993 Apr 15;268(11):8046-52.

Gibson JB, Berry GT, Palmieri MJ, Reynolds RA, Mazur AT, Segal S. Sugar nucleotide concentrations in red blood cells of patients on protein- and lactose-limited diets: effect of galactose supplementation. *Am J Clin Nutr* 1996 May;63(5):704-8.

Giovannini M, Biasucci G, Agostoni C, Luotti D, Riva E. Lipid status and fatty acid metabolism in phenylketonuria. *J Inherit Metab Dis* 1995;18(3):265-72.

Giovannini M, Valsasina R, Longhi R, Cesura AM, Galva MD, Riva E, Bondiolotti GP, Picotti GB. Serotonin and noradrenaline concentrations and serotonin uptake in platelets from hyperphenylalaninaemic patients. *J Inherit Metab Dis* 1988;11(3):285-90.

Glasfeld E. The spectroscopic characterization of the non-heme iron active phenylalanine hydroxylase [dissertation]. New Haven (CT): Yale University; 1994. 161 p.

Goebel-Schreiner B, Schreiner R. Identification of a new missense mutation in Japanese phenylketonuric patients. *J Inherit Metab Dis* 1993;16(6):950-6. Published erratum appears in *J Inherit Metab Dis* 1994;17(1):66.

Gold RJ, Maag UR, Neal JL, Scriver CR. The use of biochemical data in screening for mutant alleles and in genetic counselling. *Ann Hum Genet* 1974 Jan;37(3):315-26.

Goltsov AA, Eisensmith RC, Woo SL. Detection of the XmnI RFLP at the human PAH locus by PCR. *Nucleic Acids Res* 1992 Feb 25;20(4):927.

Gonczewicz M, Socha J, Ignys I, Zachman E, Wolnik-Brzozowska D. [Morphological state and the activity of dipeptidyl peptidases and disaccharidases of the intestinal mucosa in children with untreated phenylketonuria (PKU)]. *Pediatr Pol* 1980 Apr;55(4):427-32. (Pol).

Goodwill KE. Crystal structure determination of tyrosine hydroxylase [dissertation]. Berkeley (CA): University of California, Berkeley; 1997. 144 p.

Goodwill KE, Sabatier C, Marks C, Raag R, Fitzpatrick PF, Stevens RC. Crystal structure of tyrosine hydroxylase at 2.3 Å and its implications for inherited neurodegenerative diseases. *Nat Struct Biol* 1997 Jul;4(7):578-85.

Goodwill KE, Sabatier C, Stevens RC. Crystal structure of tyrosine hydroxylase with bound cofactor analogue and iron at 2.3 Å resolution: self-

- hydroxylation of Phe300 and the pterin-binding site. *Biochemistry* 1998 Sep 29;37(39):13437-45.
- Goodwin BL, Ruthven CR, Sandler M. Resistance of aryl-substituted phenylalanines to decarboxylation in the rat. *Gen Pharmacol* 1998 Sep;31(3):437-40.
- Gopalakrishnan TV. DNA-mediated restoration of phenylalanine hydroxylase gene expression in enzyme-deficient derivatives of enzyme-constitutive mouse cell hybrids. *Somat Cell Mol Genet* 1984 Jan;10(1):3-16.
- Gopalakrishnan TV, Littlefield JW. RNA from rat hepatoma cells can activate phenylalanine hydroxylase gene of mouse erythroleukemia cells. *Somatic Cell Genet* 1983 Jan;9(1):121-31.
- Gottschall DW. Studies on the mechanism of phenylalanine hydroxylase [dissertation]. University Park (PA): The Pennsylvania State University; 1981. 153 p.
- Gottschall DW, Dietrich RF, Benkovic SJ, Shiman R. Phenylalanine hydroxylase. Correlation of the iron content with activity and the preparation and reconstitution of the apoenzyme. *J Biol Chem* 1982 Jan 25;257(2):845-9.
- Govindjec R, Kono M, Balashov SP, Imasheva E, Sheves M, Ebrey TG. Effects of substitution of tyrosine 57 with asparagine and phenylalanine on the properties of bacteriorhodopsin. *Biochemistry* 1995 Apr 11;34(14):4828-38.
- Grasso AW, Wu GY. Therapeutic implications of delivery and expression of foreign genes in hepatocytes. *Adv Pharmacol* 1994;28:169-92.
- Green AK, Cotton RG, Jennings I, Fisher MJ. Experimental determination of the phosphorylation state of phenylalanine hydroxylase. *Biochem J* 1990 Jan 15;265(2):563-8.
- Green AK, Fisher MJ. The modulation of phenylalanine hydroxylase activity by okadaic acid. *Biochem Soc Trans* 1991 Apr;19(2):228S.
- Green AK, McDowall IL, Richardson SC, Fisher MJ. The effect of vanadate upon the expression of phenylalanine hydroxylase in streptozotocin-diabetic rat liver. *Biochim Biophys Acta* 1992 Oct 13;1180(1):21-7.
- Greengard O, Brass CA. Developmental changes of cerebral phenylalanine uptake from severely elevated blood levels. *Neurochem Res* 1984 Jun;9(6):837-48.
- Greengard O, Wolfe J. Cerebral serotonin regulation by phenylalanine analogues and during hyperphenylalaninemia. *Biochem Pharmacol* 1987 Mar 15;36(6):965-70.
- Greeves LG, Leeming RJ, Hyland K, Dempsey SI, Carson DJ. Neuroblastoma in a patient with dihydropteridine reductase deficiency. *Eur J Pediatr* 1990 Jul;149(10):713-5.
- Greeves LG, Patterson CC, Carson DJ, Thom R, Wolfenden MC, Zschocke J, Graham CA, Nevin NC, Trimble ER. Effect of genotype on changes in intelligence quotient after dietary relaxation in phenylketonuria and hyperphenylalaninaemia. *Arch Dis Child* 2000 Mar;82(3):216-21.
- Griffen DL. The origin, purification and characterization of two forms of phenylalanine hydroxylase in the Sprague-Dawley rat [dissertation]. University Park (PA): The Pennsylvania State University; 1986. 98 p.
- Griffiths P, Ward N, Harvie A, Cockburn F. Neuropsychological outcome of experimental manipulation of phenylalanine intake in treated phenylketonuria. *J Inher Metab Dis* 1998 Feb;21(1):29-38.
- Grimm U, Knapp A, Weber A, Seidlitz G, Wehnert M, Petruschka L. [Detection of phenylalanine hydroxylase activity in leukocytes and fibroblasts]. *Biomed Biochim Acta* 1983;42(9):1135-41. (Ger).
- Grimm U, Steinhauser I, Weber A. [Occurrence of phenylalanine hydroxylase in the human kidney]. *Biomed Biochim Acta* 1986;45(9):1141-4. (Ger).
- Grinde B. Effect of amino acid metabolites on lysosomal protein degradation. A regulatory role for kynurenine? *Eur J Biochem* 1984 Dec 17;145(3):623-7.
- Gromov PS, Bakharev VA, Annenkov GA. [Active form of dihydropteridine reductase in human chorion cells. Possibility of prenatal diagnosis]. *Vopr Med Khim* 1985 Jul-Aug;31(4):73-5. (Rus).
- Gromov PS, Val'iano NM, Akhunov VS, Annenkov GA. [Dihydropteridine reductase activity in leukocytes and cultured fibroblasts of health individuals and of patients with the classical form of phenylketonuria]. *Vopr Med Khim* 1983 Sep-Oct;29(5):66-9. (Rus).
- Gropper SS, Acosta PB, Clarke-Sheehan N, Wenz E, Cheng M, Koch R. Trace element status of children with PKU and normal children. *J Am Diet Assoc* 1988 Apr;88(4):459-65.
- Gu W, Song J, Bonner CA, Xie G, Jensen RA. PhhC is an essential aminotransferase for aromatic amino acid catabolism in *Pseudomonas aeruginosa*. *Microbiology* 1998 Nov;144 (Pt 11):3127-34.
- Guerin T, Walsh GA, Donlon J, Kaufman S. Correlation of rat hepatic phenylalanine hydroxylase,

- with tetrahydrobiopterin and GTP concentrations. *Int J Biochem Cell Biol* 1998 Sep;30(9):1047-54.
- Guldberg P, Henriksen KF, Lou HC, Guttler F. Aberrant phenylalanine metabolism in phenylketonuria heterozygotes. *J Inherit Metab Dis* 1998 Jun;21(4):365-72.
- Guldberg P, Henriksen KF, Mammen KC, Levy HL, Guttler F. Large deletions in the phenylalanine hydroxylase gene as a cause of phenylketonuria in India. *J Inherit Metab Dis* 1997 Nov;20(6):845-6.
- Guldberg P, Henriksen KF, Thony B, Blau N, Guttler F. Molecular heterogeneity of nonphenylketonuria hyperphenylalaninemia in 25 Danish patients. *Genomics* 1994 May 15;21(2):453-5.
- Guldberg P, Levy HL, Hanley WB, Koch R, Matalon R, Rouse BM, Trefz F, de la Cruz F, Henriksen KF, Guttler F. Phenylalanine hydroxylase gene mutations in the United States: report from the Maternal PKU Collaborative Study. *Am J Hum Genet* 1996 Jul;59(1):84-94.
- Guldberg P, Levy HL, Henriksen KF, Guttler F. Three prevalent mutations in a patient with phenylalanine hydroxylase deficiency: implications for diagnosis and genetic counselling. *J Med Genet* 1996 Feb;33(2):161-4.
- Guldberg P, Lou HC, Henriksen KF, Mikkelsen I, Olsen B, Holck B, Guttler F. A novel missense mutation in the phenylalanine hydroxylase gene of a homozygous Pakistani patient with non-PKU hyperphenylalaninemia. *Hum Mol Genet* 1993 Jul;2(7):1061-2.
- Guldberg P, Mallmann R, Henriksen KF, Guttler F. Phenylalanine hydroxylase deficiency in a population in Germany: mutational profile and nine novel mutations. *Hum Mutat* 1996;8(3):276-9.
- Guldberg P, Romano V, Ceratto N, Bosco P, Ciuna M, Indelicato A, Mollica F, Meli C, Giovannini M, Riva E, et al. Mutational spectrum of phenylalanine hydroxylase deficiency in Sicily: implications for diagnosis of hyperphenylalaninemia in southern Europe. *Hum Mol Genet* 1993 Oct;2(10):1703-7.
- Gunasekera RS. Pathophysiological mechanisms in dopa-responsive dystonia and regulation of the aromatic amino acid hydroxylases (tyrosine hydroxylase, tetrahydrobiopterin, phenylalanine) [dissertation]. Waco (TX): Baylor University; 1997. 211 p.
- Guttler F. [Does phenylalanine load disclose genetic variants?]. *Lakartidningen* 1974 Mar 20;71(12):1170-1. (Nor).
- Guttler F. [Folling's disease: 50 years and still a catalyst of new discoveries in clinical medicine]. *Nord Med* 1984;99(3):78-81. (Dan).
- Guttler F. [Folling's disease: 50-years and still a catalyst of new discoveries in medicine]. *Ugeskr Laeger* 1984 Jan 9;146(2):83-7. (Dan).
- Guttler F. Phenylketonuria: 50 years since Folling's discovery and still expanding our clinical and biochemical knowledge. *Acta Paediatr Scand* 1984 Nov;73(6):705-16.
- Guttler F, Azen C, Guldberg P, Romstad A, Hanley WB, Levy HL, Matalon R, Rouse BM, Trefz F, de la Cruz F, Koch R. Relationship among genotype, biochemical phenotype, and cognitive performance in females with phenylalanine hydroxylase deficiency: report from the Maternal Phenylketonuria Collaborative Study. *Pediatrics* 1999 Aug;104(2 Pt 1):258-62.
- Guttler F, Guldberg P. The influence of mutations of enzyme activity and phenylalanine tolerance in phenylalanine hydroxylase deficiency. *Eur J Pediatr* 1996 Jul;155 Suppl 1:S6-10.
- Guttler F, Guldberg P, Henriksen KF, Mikkelsen I, Olsen B, Lou H. Molecular basis for the phenotypical diversity of phenylketonuria and related hyperphenylalaninaemias. *J Inherit Metab Dis* 1993;16(3):602-4.
- Guttler F, Hansen G. Different phenotypes for phenylalanine hydroxylase deficiency. *Ann Clin Biochem* 1977 May;14(3):124-34.
- Guttler F, Hansen G. Serum tyrosine within the first hour after an oral load of phenylalanine. *Scand J Clin Lab Invest* 1977 Dec;37(8):717-21.
- Guttler F, Kaufman S, Milstien S. Phenylalanine has no effect on dihydropteridine reductase activity in phenylketonuria fibroblasts [letter]. *Lancet* 1977 Nov 26;2(8048):1139-40.
- Guttler F, Lou H. Aspartame may imperil dietary control of phenylketonuria [letter]. *Lancet* 1985 Mar 2;1(8427):525-6.
- Guttler F, Lou H. Dietary problems of phenylketonuria: effect on CNS transmitters and their possible role in behaviour and neuropsychological function. *J Inherit Metab Dis* 1986;9 Suppl 2:169-77.
- Guttler F, Lou H, Lykkelund C, Niederwieser A. Combined tetrahydrobiopterin-phenylalanine loading test in the detection of partially defective biopterin synthesis. *Eur J Pediatr* 1984 Jun;142(2):126-9.
- Haavik J. Studies on tetrahydropteridine dependent amino acid with special reference to bovine adrenal

- tyrosine (tyrosine hydroxylase) (enzymology, catecholamines) [dissertation]. Bergen (Norway): University of Bergen; 1988. 173 p.
- Haavik J, Doskeland AP, Flatmark T. Stereoselective effects in the interactions of pterin cofactors with rat-liver phenylalanine 4-monooxygenase. *Eur J Biochem* 1986 Oct 1;160(1):1-8.
- Hadasova E, Brysova V, Kadlcakova E. N-acetylation in healthy and diseased children. *Eur J Clin Pharmacol* 1990;39(1):43-7.
- Hages M, Pietrzik K. [Assessment of the folate supply in children with regard to cobalamin and iron maintenance. 3: Modification of the supply status by various diseases]. *Int J Vitam Nutr Res* 1985;55(3):287-94. (Ger).
- Haggerty DF, Chiappelli F, Kern R, Scully S, Lynch M. Regulation by glucocorticoids of rat-liver phenylalanine hydroxylase in vivo. *Biochem Biophys Res Commun* 1983 Sep 30;115(3):965-70.
- Hagihara B, Devathanan G, McCabe M. A micro-system for measuring oxygen kinetic parameters of bioprotein linked hydroxylations: L-dopa synthesis and Parkinson's disease. *Adv Exp Med Biol* 1986;200:271-81.
- Haley CJ, Harper AE. Glucagon stimulation of phenylalanine metabolism. The effects of acute and chronic glucagon treatment (Phenylalanine hydroxylase). *Metab Clin Exp* 1982 Jun;31(6):524-32.
- Hall GC, Jensen RA. Enzymological basis for growth inhibition by L-phenylalanine in the cyanobacterium *Synechocystis* sp. 29108. *J Bacteriol* 1980 Dec;144(3):1034-42.
- Hall SK, Robinson P, Green A. Could salivary phenylalanine concentrations replace blood concentrations? *Ann Clin Biochem* 2000 Mar;37(Pt 2):222-3.
- Halliday GM, Li YW, Joh TH, Cotton RG, Howe PR, Geffen LB, Blessing WW. Distribution of monoamine-synthesizing neurons in the human medulla oblongata. *J Comp Neurol* 1988 Jul 15;273(3):301-17.
- Han JH. Isolation of phenylalanine hydroxylase and enzymatic studies and 4-pyridylalanine [dissertation]. Atlanta (GA): Georgia Institute of Technology; 1988. 146 p.
- Harada T, Kagamiyama H, Hatakeyama K. Feedback regulation mechanisms for the control of GTP cyclohydrolase I activity. *Science* 1993 Jun 4;260(5113):1507-10.
- Harding CO, Wild K, Chang D, Messing A, Wolff JA. Metabolic engineering as therapy for inborn errors of metabolism--development of mice with phenylalanine hydroxylase expression in muscle. *Gene Ther* 1998 May;5(5):677-83.
- Hargreaves KM, Pardridge WM. Neutral amino acid transport at the human blood-brain barrier. *J Biol Chem* 1988 Dec 25;263(36):19392-7.
- Harper AE. Some recent developments in the study of amino acid metabolism. *Proc Nutr Soc* 1983 Sep;42(3):437-49.
- Harpey JP. [Biopterin synthesis defects: complete deficiencies (reductase and synthetase)]. *Arch Fr Pediatr* 1983;40 Suppl 1:231-5. (Fre).
- Hasegawa H, Kaufman S. Spontaneous activation of phenylalanine hydroxylase in rat liver extracts. *J Biol Chem* 1982 Mar 25;257(6):3084-9.
- Hasselbalch S, Knudsen GM, Toft PB, Hogh P, Tedeschi E, Holm S, Videbaek C, Henriksen O, Lou HC, Paulson OB. Cerebral glucose metabolism is decreased in white matter changes in patients with phenylketonuria. *Pediatr Res* 1996 Jul;40(1):21-4.
- Hatakeyama K, Hoshiga M, Suzuki S, Kagamiyama H. Enzymatic synthesis of 6R-[U-14C]tetrahydrobiopterin from [U-14C]GTP. *Anal Biochem* 1993 Feb 15;209(1):1-5.
- Henderson HE, Goodman R, Schram J, Diamond E, Daneel A. Biochemical screening for inherited metabolic disorders in the mentally retarded. *S Afr Med J* 1981 Nov 7;60(19):731-3.
- Henrie RN 2d, Lazarus RA, Benkovic SJ. Preparation of 2-amino-4(3H)-oxopyrimido[5,4-b] [1,4]thiazines (5-thiapterins) and their evaluation as cofactors for phenylalanine hydroxylase. *J Med Chem* 1983 Apr;26(4):559-63.
- Hermann ME, Monch E, Reinbacher M, Kohlen W, Brosicke HG. [Phenylalanine-free amino acid mixture: metabolic effects in relation to a single dose]. *Monatsschr Kinderheilkd* 1991 Oct;139(10):670-5. (Ger).
- Herrero E, Aragon MC, Gimenez C, Valdivieso F. Inhibition by L-phenylalanine of tryptophan transport by synaptosomal plasma membrane vesicles: implications in the pathogenesis of phenylketonuria. *J Inher Metab Dis* 1983;6(1):32-5.
- Herrmann FH, Wulff K, Wehnert M, Seidlitz G, Guttler F. Haplotype analysis of classical and mild phenotype of phenylketonuria in the German Democratic Republic. *Clin Genet* 1988 Sep;34(3):176-80.

- Herrmann ME, Brosicke HG, Keller M, Monch E, Helge H. Dependence of the utilization of a phenylalanine-free amino acid mixture on different amounts of single dose ingested. A case report. *Eur J Pediatr* 1994 Jul;153(7):501-3.
- Hertz MM, Bolwig TG, Grandjean P, Westergaard E. Lead poisoning and the blood-brain barrier. *Acta Neurol Scand* 1981 May;63(5):286-96.
- Hertzberg M, Jahromi K, Ferguson V, Dahl HH, Mercer J, Mickleson KN, Trent RJ. Phenylalanine hydroxylase gene haplotypes in Polynesians: evolutionary origins and absence of alleles associated with severe phenylketonuria. *Am J Hum Genet* 1989 Mar;44(3):382-7.
- Hill DA, Yen JT, Lee RT. Application of high performance liquid chromatography in determination of protein synthesis rates in pigs [abstract]. *J Anim Sci* 1988;66 Suppl 1:263.
- Hill MA, Marota JJ, Shiman R. Reaction of rat liver phenylalanine hydroxylase with fatty acid hydroperoxides. Characterization and mechanism. *J Biol Chem* 1988 Apr 25;263(12):5646-55.
- Hillas PJ. Studies of the chemical mechanism of tyrosine hydroxylase (phenylalanine, iron) [dissertation]. College Station (TX): Texas A & M University; 1997. 122 p.
- Hillman L, Schlotzhauer C, Lee D, Grasele J, Witter S, Allen S, Hillman R. Decreased bone mineralization in children with phenylketonuria under treatment. *Eur J Pediatr* 1996 Jul;155 Suppl 1:S148-52.
- Hiramatsu T, Cortiella J, Marchini JS, Chapman TE, Young VR. Source and amount of dietary nonspecific nitrogen in relation to whole-body leucine, phenylalanine, and tyrosine kinetics in young men. *Am J Clin Nutr* 1994 Jun;59(6):1347-55.
- Hirano M, Ueno S. Mutant GTP cyclohydrolase I in autosomal dominant dystonia and recessive hyperphenylalaninemia. *Neurology* 1999 Jan 1;52(1):182-4.
- Hirano S, Takagi Y, Kanamatsu T, Nakai K. Effects of hyperphenylalaninemia in the fetal stage on the postnatal development of fetal rat brain. *Neurochem Res* 1985 Aug;10(8):1071-81.
- Hjelm M, Kitney R, Lindsey P, Seakins J. Computer model of the metabolism of phenylalanine in normal subjects and in patients with phenylketonuria. *Comput Programs Biomed* 1984 Feb-Apr;18(1-2):21-31.
- Hoffman GR, Walkowicz MJ, Mason JM, Atkins JF. Genetic instability associated with the aroC321 allele in *Salmonella typhimurium* involves genetic duplication. *Mol Gen Genet* 1983;190(2):183-8.
- Hogan SE, Gates RD, MacDonald GW, Clarke JT. Experience with adolescents with phenylketonuria returned to phenylalanine-restricted diets. *J Am Diet Assoc* 1986 Sep;86(9):1203-7.
- Hoganson G, Berlow S, Kaufman S, Milstien S, Schuett V, Matalon R, Naylor E, Seifert W. Biopterin synthesis defects: problems in diagnosis. *Pediatrics* 1984 Dec;74(6):1004-11.
- Holt KS. Diets and development. *Child Care Health Dev* 1982 Jul-Aug;8(4):183-201.
- Hommes FA. The effect of hyperphenylalaninaemia on the muscarinic acetylcholine receptor in the HPH-5 mouse brain. *J Inherit Metab Dis* 1993;16(6):962-74.
- Hommes FA. Loss of neurotransmitter receptors by hyperphenylalaninemia in the HPH-5 mouse brain. *Acta Paediatr Suppl* 1994 Dec;407:120-1.
- Hommes FA. On the mechanism of permanent brain dysfunction in hyperphenylalaninemia. *Biochem Med Metab Biol* 1991 Dec;46(3):277-87.
- Hommes FA. The role of the blood-brain barrier in the aetiology of permanent brain dysfunction in hyperphenylalaninaemia. *J Inherit Metab Dis* 1989;12(1):41-6.
- Hommes FA, Eller AG, Taylor EH. Turnover of the fast components of myelin and myelin proteins in experimental hyperphenylalaninaemia. Relevance to termination of dietary treatment in human phenylketonuria. *J Inherit Metab Dis* 1982;5(1):21-7.
- Hommes FA, Lee JS. The control of 5-hydroxytryptamine and dopamine synthesis in the brain: a theoretical approach. *J Inherit Metab Dis* 1990;13(1):37-57.
- Hommes FA, Lee JS. The effect of plasma valine, isoleucine and leucine on the control of the flux through tyrosine- and tryptophan-hydroxylase in the brain. *J Inherit Metab Dis* 1990;13(2):151-5.
- Hommes FA, Moss L. Myelin turnover in hyperphenylalaninaemia. A re-evaluation with the HPH-5 mouse. *J Inherit Metab Dis* 1992;15(2):243-51.
- Horwitz DL, Bauer-Nehrling JK. Can aspartame meet our expectations? *J Am Diet Assoc* 1983 Aug;83(2):142-6.
- Hoshiga M, Hatakeyama K. Enzymatic synthesis of 6R-[U-14C]tetrahydrobiopterin from [U-14C]GTP. *Methods Enzymol* 1997;281:123-9.
- Hoshiga M, Hatakeyama K, Watanabe M, Shimada M, Kagamiyama H. Autoradiographic distribution of [14C]tetrahydrobiopterin and its developmental

- change in mice. *J Pharmacol Exp Ther* 1993 Nov;267(2):971-8.
- Hoskins JA, Gray J. Phenylalanine ammonia lyase in the management of phenylketonuria: the relationship between ingested cinnamate and urinary hippurate in humans. *Res Commun Chem Pathol Pharmacol* 1982 Feb;35(2):275-82.
- Hoskins JA, Greenway AM. The metabolism of L-tyrosine: the use of a putative precursor to investigate the increased production of m-hydroxymandelic acid in phenylketonuria. *Clin Chim Acta* 1983 Jun 15;130(3):329-38.
- Hoskins JA, Holliday SB, Greenway AM. The metabolism of cinnamic acid by healthy and phenylketonuric adults: a kinetic study. *Biomed Mass Spectrom* 1984 Jun;11(6):296-300.
- Hoskins JA, Jack G, Wade HE, Peiris RJ, Wright EC, Starr DJ, Stern J. Enzymatic control of phenylalanine intake in phenylketonuria. *Lancet* 1980 Feb 23;1(8165):392-4.
- House JD, Pencharz PB, Ball RO. Phenylalanine requirements determined by using L-[1-¹⁴C]phenylalanine in neonatal piglets receiving total parenteral nutrition supplemented with tyrosine. *Am J Clin Nutr* 1997 Apr;65(4):984-93.
- House JD, Pencharz PB, Ball RO. Tyrosine kinetics and requirements during total parenteral nutrition in the neonatal piglet: the effect of glycyl-L-tyrosine supplementation. *Pediatr Res* 1997 Apr;41(4 Pt 1):575-83.
- House JD, Thorpe JM, Wykes LJ, Pencharz PB, Ball RO. Evidence that phenylalanine hydroxylation rates are overestimated in neonatal subjects receiving total parenteral nutrition with a high phenylalanine content. *Pediatr Res* 1998 Apr;43(4 Pt 1):461-6.
- Howard K, Donlon J. Effects of experimental diabetes on rat hepatic phenylalanine hydroxylase in vivo. *Int J Biochem* 1988;20(11):1231-4.
- Howell RR, Stevenson RE. The offspring of phenylketonuric women. *Soc Biol* 1971 Sep;18:S19-29.
- Hsieh MC, Berry HK, Bofinger MK, Phillips PJ, Guilfoile MB, Hunt MM. Comparative diagnostic value of phenylalanine challenge and phenylalanine hydroxylase activity in phenylketonuria. *Clin Genet* 1983 Jun;23(6):415-21.
- Huang SZ, Ren ZR, Zeng YT, Woo SL. PAH 399 GTA (Val)---GTT(Val), a new silent mutation found in the Chinese. *Hum Genet* 1991 Jan;86(3):305-6.
- Huether G. Amino acid availability and brain development: effects of nutritional and metabolic inadequacies. *Eur J Clin Nutr* 1989;43 Suppl 1:19-25.
- Huether G. The depletion of tryptophan and serotonin in the brain of developing hyperphenylalaninemic rats is abolished by the additional administration of lysine. *Neurochem Res* 1986 Dec;11(12):1663-8.
- Huether G, Kaus R, Neuhoff V. Amino acid depletion in the blood and brain tissue of hyperphenylalaninemic rats is abolished by the administration of additional lysine: a contribution to the understanding of the metabolic defects in phenylketonuria. *Biochem Med* 1985 Jun;33(3):334-41.
- Huether G, Klapproth M, Neuhoff V. Fatty acid composition of myelin lipids from developing rat forebrain and spinal cord: influence of experimental hyperphenylalaninaemia. *Neurochem Res* 1986 Sep;11(9):1303-11.
- Huether G, Neuhoff V. Individual carboxylic ester hydrolases of the developing cerebellum. Influence of experimental hyperphenylalaninaemia. *Cell Mol Biol* 1982;28(3):313-7.
- Huether G, Neuhoff V, Kaus R. Brain development in experimental hyperphenylalaninaemia: disturbed proliferation and reduced cell numbers in the cerebellum. *Neuropediatrics* 1983 Feb;14(1):12-9.
- Hufton SE, Jennings IG, Cotton RG. Structure and function of the aromatic amino acid hydroxylases. *Biochem J* 1995 Oct 15;311 (Pt 2):353-66.
- Hufton SE, Jennings IG, Cotton RG. Structure/function analysis of the domains required for the multimerisation of phenylalanine hydroxylase. *Biochim Biophys Acta* 1998 Feb 17;1382(2):295-304.
- Hummel W. Screening and characterization of new enzymes for biosensing and analytics. *EXS* 1997;80:49-61.
- Hund HK. Zur Biosynthese von Phenylalanin und Tyrosin bei Vertretern der Ordnung Actinomycetales [The biosynthesis of phenylalanine and tyrosine by representatives of the order Actinomycetales] [dissertation]. Germany: University of Hohenheim; 1987. 81 p. (Ger).
- Hyanek J, Viletova H, Soukup J, Kobilkova J, Kubik M, Kunova V. [Changes in phenylalanine tolerance during the monitoring of diet therapy of pregnant women with phenylketonuria]. *Cesk Gynekol* 1988 Nov;53(9):650-3. (Cze).
- Hyanek J, Viletova H, Soukup J, Kobilkova J, Kubik M, Kunova V. Changes in phenylalanine tolerance while monitoring the dietetic treatment of pregnant

- women suffering from hyperphenylalaninaemia. *J Inher Metab Dis* 1988;11(4):427-8.
- Hyland K. Presentation, diagnosis, and treatment of the disorders of monoamine neurotransmitter metabolism. *Semin Perinatol* 1999 Apr;23(2):194-203.
- Hyland K, Gunasekera RS, Engle T, Arnold LA. Tetrahydrobiopterin and biogenic amine metabolism in the hph-1 mouse. *J Neurochem* 1996 Aug;67(2):752-9.
- Hyland K, Smith I, Leonard JV. Biopterins in arginase, dihydropteridine reductase and phenylalanine hydroxylase deficiency [letter]. *J Neurol Neurosurg Psychiatry* 1987 Feb;50(2):242.
- Imamura T, Shintaku H, Nakajima T, Sawada Y, Isshiki G, Oura T. Experimental research on a new treatment for maternal phenylketonuria(PKU). *Adv Exp Med Biol* 1993;338:277-80.
- Imura K, Okada A. Amino acid metabolism in pediatric patients. *Nutrition* 1998 Jan;14(1):143-8.
- Inoue S, Matsunaga Y, Iwane H, Sotomura M, Nose T. Entrapment of phenylalanine ammonia-lyase in silk fibroin for protection from proteolytic attack. *Biochem Biophys Res Commun* 1986 Nov 26;141(1):165-70.
- Iraqi I, Vissers S, Andre B, Urrestarazu A. Transcriptional induction by aromatic amino acids in *Saccharomyces cerevisiae*. *Mol Cell Biol* 1999 May;19(5):3360-71.
- Irons M, Levy HL. Metabolic syndromes with dermatologic manifestations. *Clin Rev Allergy* 1986 Feb;4(1):101-24.
- Isaacs CE, Greengard O. The effect of hyperphenylalaninaemia on glycine metabolism in developing rat brain. *Biochem J* 1980 Nov 15;192(2):441-8.
- Ishimitsu S, Fujimoto S, Ohara A. Formation of m-tyrosine and o-tyrosine from L-phenylalanine in various tissues of rats. *Chem Pharm Bull (Tokyo)* 1985 Sep;33(9):3887-92.
- Ishimitsu S, Fujimoto S, Ohara A. Studies on the formation of 3,4-dihydroxyphenylalanine, m-tyrosine and o-tyrosine from L-phenylalanine by rat liver and adrenal. *Chem Pharm Bull (Tokyo)* 1988 Jan;36(1):279-85.
- Ivarsen P, Frystyk J, Pedersen EB. The pattern of intracellular free amino acids in granulocytes from hemodialysis patients change to an oral protein supplement (granulocyte amino acids after protein in HD patients). *Clin Nephrol* 1999 Aug;52(2):110-8.
- Iwaki M, Parniak MA, Kaufman S. Studies on the primary structure of rat liver phenylalanine hydroxylase. *Biochem Biophys Res Commun* 1985 Jan 31;126(2):922-32.
- Iwaki M, Phillips RS, Kaufman S. Proteolytic modification of the amino-terminal and carboxyl-terminal regions of rat hepatic phenylalanine hydroxylase. *J Biol Chem* 1986 Feb 15;261(5):2051-6.
- Jacobson KB, Manos RE. Effects of sepiapterin and 6-acetyldihydrohomopterin on the guanosine triphosphate cyclohydrolase I of mouse, rat and the fruit-fly *Drosophila*. *Biochem J* 1989 May 15;260(1):135-41.
- Janssen PJ, van der Heijden CA. Aspartame: review of recent experimental and observational data. *Toxicology* 1988 Jun;50(1):1-26.
- Jardim LB, Giugliani R, Coelho JC, Dutra-Filho CS, Blau N. Possible high frequency of tetrahydrobiopterin deficiency in south Brazil. *J Inher Metab Dis* 1994;17(2):223-9.
- Jaruzelska J, Abadie V, d'Aubenton-Carafa Y, Brody E, Munnich A, Marie J. In vitro splicing deficiency induced by a C to T mutation at position -3 in the intron 10 acceptor site of the phenylalanine hydroxylase gene in a patient with phenylketonuria. *J Biol Chem* 1995 Sep 1;270(35):20370-5.
- Jaruzelska J, Henriksen KF, Guttler F, Riess O, Borski K, Blin N, Slomski R. The codon 408 mutation associated with haplotype 2 is predominant in Polish families with phenylketonuria. *Hum Genet* 1991 Jan;86(3):247-50.
- Jaruzelska J, Melle D, Matuszak R, Borski K, Munnich A. A new 15 bp deletion in exon 11 of the phenylalanine hydroxylase gene in phenylketonuria. *Hum Mol Genet* 1992 Dec;1(9):763-4.
- Jaruzelska J, Slomski R. [Molecular basis of phenylketonuria]. *Postepy Biochem* 1990;36(3-4):24-31. (Pol).
- Jennings I, Cotton R. Structural similarities among enzyme pterin binding sites as demonstrated by a monoclonal anti-idiotypic antibody. *J Biol Chem* 1990 Feb 5;265(4):1885-9.
- Jennings IG, Kemp BE, Cotton RG. Localization of cofactor binding sites with monoclonal anti-idiotypic antibodies: phenylalanine hydroxylase. *Proc Natl Acad Sci U S A* 1991 Jul 1;88(13):5734-8.
- Jennings IG, Russell RG, Armarego WL, Cotton RG. Functional analysis of the effect of monoclonal antibodies on monkey liver phenylalanine hydroxylase. *Biochem J* 1986 Apr 1;235(1):133-8.

- Jingzhong L, Hua X, Wei H, Zhangling Z, Jin Z, Qingyuan L. Cloning and expression of phenylalanine ammonia lyase cDNA in *Escherichia coli*. *Chin J Biotechnol* 1998;14(4):227-32.
- Jochum F, Terwolbeck K, Meinhold H, Behne D, Menzel H, Lombeck I. Effects of a low selenium state in patients with phenylketonuria. *Acta Paediatr* 1997 Jul;86(7):775-7.
- Johannik K, Van Hecke P, Francois B, Marchal G, Smet MH, Jaeken J, Breysem L, Wilms G, Baert AL. Localized brain proton NMR spectroscopy in young adult phenylketonuria patients. *Magn Reson Med* 1994 Jan;31(1):53-7.
- John SW, Rozen R, Laframboise R, Laberge C, Scriver CR. Five mutations at the PAH locus account for almost 90% of PKU mutations in French-Canadians from eastern Quebec. *Hum Mutat* 1992;1(1):72-4.
- John SW, Scriver CR, Laframboise R, Rozen R. In vitro and in vivo correlations for I65T and M1V mutations at the phenylalanine hydroxylase locus. *Hum Mutat* 1992;1(2):147-53.
- Johnen G, Kowlessur D, Citron BA, Kaufman S. Characterization of the wild-type form of 4a-carbinolamine dehydratase and two naturally occurring mutants associated with hyperphenylalaninemia. *Proc Natl Acad Sci U S A* 1995 Dec 19;92(26):12384-8. Published erratum appears in *Proc Natl Acad Sci U S A* 1996 Apr 30;93(9):4519.
- Johnson RC, Shah SN. Effect of hyperphenylalaninemia induced during suckling on brain DNA metabolism in rat pups. *Neurochem Res* 1984 Apr;9(4):517-28.
- Johnson RC, Shah SN. Effects of alpha-methylphenylalanine plus phenylalanine treatment during development on myelin in rat brain. *Neurochem Res* 1980 Jul;5(7):709-18.
- Johnson WG. DNA polymorphism-diet-cofactor-development hypothesis and the gene-teratogen model for schizophrenia and other developmental disorders. *Am J Med Genet* 1999 Aug 20;88(4):311-23.
- Johnston MV, Singer HS. Brain neurotransmitters and neuromodulators in pediatrics. *Pediatrics* 1982 Jul;70(1):57-68.
- Juminaga D, Wedemeyer WJ, Garduno-Juarez R, McDonald MA, Scheraga HA. Tyrosyl interactions in the folding and unfolding of bovine pancreatic ribonuclease A: a study of tyrosine-to-phenylalanine mutants. *Biochemistry* 1997 Aug 19;36(33):10131-45.
- Kadowaki M, Poso AR, Mortimore GE. Parallel control of hepatic proteolysis by phenylalanine and phenylpyruvate through independent inhibitory sites at the plasma membrane. *J Biol Chem* 1992 Nov 5;267(31):22060-5.
- Kapatos G, Kaufman S. Peripherally administered reduced pterins do enter the brain. *Science* 1981 May 22;212(4497):955-6.
- Kappock TJ 4th. Recombinant phenylalanine hydroxylase overexpression and characterization: structural, mechanistic, and spectroscopic its allosteric activation and active site iron reduction processes [dissertation]. New Haven (CT): Yale University; 1996. 588 p.
- Kappock TJ, Harkins PC, Friedenberg S, Caradonna JP. Spectroscopic and kinetic properties of unphosphorylated rat hepatic phenylalanine hydroxylase expressed in *Escherichia coli*. Comparison of resting and activated states. *J Biol Chem* 1995 Dec 22;270(51):30532-44.
- Kasahara T, Kasahara M. Interaction between the critical aromatic amino acid residues Tyr(352) and Phe(504) in the yeast Gal2 transporter. *FEBS Lett* 2000 Apr 7;471(1):103-7.
- Kasibhatla BS. Spectroscopic and reactivity studies of mononuclear and non-heme iron complexes [dissertation]. New Haven (CT): Yale University; 1998. 239 p.
- Katoh S, Sueoka T. Pteridine cofactor of phenylalanine hydroxylase in fetal rat liver. *Int J Biochem* 1983;15(1):57-64.
- Katoh S, Sueoka T, Hirayama K, Masuda I, Nakanishi N, Yamada S. [Phenylalanine hydroxylating activity in Tawa sarcoma]. *Josai Shika Daigaku Kiyo* 1981;10(1):27-31. (Jpn).
- Kauf E, Seidel J, Winnefeld K, Dawczynski H, Hafer R, Stein F, Vogt L. [Selenium in phenylketonuria patients. Effects of sodium selenite administration]. *Med Klin* 1997 Sep 15;92 Suppl 3:31-4. (Ger).
- Kaufman S. Biopterin-responsive hyperphenylalaninemia. *J Nutr Sci Vitaminol (Tokyo)* 1992;Spec No:601-6.
- Kaufman S. The enzymes of the hepatic phenylalanine hydroxylating system. *J Inher Metab Dis* 1978;1(2):63-5.
- Kaufman S. Enzymology of the phenylalanine-hydroxylating system. *Enzyme* 1987;38(1-4):286-95.
- Kaufman S. An evaluation of the possible neurotoxicity of metabolites of phenylalanine. *J*

- Pediatr 1989 May;114(5):895-900. Comment in: J Pediatr 1990 Apr;116(4):665-6.
- Kaufman S. Genetic disorders involving recycling and formation of tetrahydrobiopterin. *Adv Pharmacol* 1998;42:41-3.
- Kaufman S. Hyperphenylalaninaemia caused by defects in biopterin metabolism. *J Inher Metab Dis* 1985;8 Suppl 1:20-7.
- Kaufman S. A model of human phenylalanine metabolism in normal subjects and in phenylketonuric patients. *Proc Natl Acad Sci U S A* 1999 Mar 16;96(6):3160-4.
- Kaufman S. Novel aspects of metabolism and function of tetrahydrobiopterin. *J Nutr Sci Vitaminol (Tokyo)* 1992;Spec No:492-6.
- Kaufman S. Phenylalanine 4-monooxygenase from rat liver. *Methods Enzymol* 1987;142:3-17.
- Kaufman S. The phenylalanine hydroxylating system. *Adv Enzymol Relat Areas Mol Biol* 1993;67:77-264.
- Kaufman S. The phenylalanine hydroxylating system from mammalian liver. *Adv Enzymol* 1971;35:245-319.
- Kaufman S. Phenylketonuria and its variants. *Adv Hum Genet* 1983;13:217-97.
- Kaufman S. Regulation of the activity of hepatic phenylalanine hydroxylase. *Adv Enzyme Regul* 1986;25:37-64.
- Kaufman S. Regulatory properties of phenylalanine, tyrosine and tryptophan hydroxylases. *Biochem Soc Trans* 1985 Apr;13(2):433-6.
- Kaufman S. Tetrahydrobiopterin: basic biochemistry and role in human disease. Baltimore (MD): Johns Hopkins University Press; 1997. Phenylketonuria and its variants; p. 262-322.
- Kaufman S. Unsolved problems in diagnosis and therapy of hyperphenylalaninemia caused by defects in tetrahydrobiopterin metabolism. *J Pediatr* 1986 Oct;109(4):572-8.
- Kaufman S, Berlow S, Summer GK, Milstien S, Schulman JD, Orloff S, Spielberg S, Puschel S. Hyperphenylalaninemia due to a deficiency of biopterin. A variant form of phenylketonuria. *N Engl J Med* 1978 Sep 28;299(13):673-9.
- Kaufman S, Kapatos G, McInnes RR, Schulman JD, Rizzo WB. Use of tetrahydropterins in the treatment of hyperphenylalaninemia due to defective synthesis of tetrahydrobiopterin: evidence that peripherally administered tetrahydropterins enter the brain. *Pediatrics* 1982 Sep;70(3):376-80.
- Kaufman S, Kapatos G, Rizzo WB, Schulman JD, Tamarkin L, Van Loon GR. Tetrahydropterin therapy for hyperphenylalaninemia caused by defective synthesis of tetrahydrobiopterin. *Ann Neurol* 1983 Sep;14(3):308-15.
- Kaufman S, Mason K. Specificity of amino acids as activators and substrates for phenylalanine hydroxylase. *J Biol Chem* 1982 Dec 25;257(24):14667-78.
- Kaufman S, Milstien S. Phenylketonuria and its variants. *Ann Clin Lab Sci* 1977 Mar-Apr;7(2):178-85.
- Kee AJ, Smith RC. Organ clearance of tyrosyl-arginine and its effect on amino acid metabolism in young sheep. *Metabolism* 1993 Aug;42(8):958-66.
- Kerler F, Ziegler I, Schmid C, Bacher A. Synthesis of tetrahydrobiopterin in Friend erythroleukemia cells and its modulator effect on cell proliferation. *Exp Cell Res* 1990 Aug;189(2):151-6.
- Kharitonchik LA, Kodentsova VM, Vrzhesinskaia OA, Denisova SN, Spirichev VB. [Vitamin B 6 metabolism in phenylketonuria]. *Vopr Med Khim* 2000 Jan-Feb;46(1):81-8. (Rus).
- Kilani RA, Cole FS, Bier DM. Phenylalanine hydroxylase activity in preterm infants: is tyrosine a conditionally essential amino acid? *Am J Clin Nutr* 1995 Jun;61(6):1218-23.
- Kim DH, Nam GH, Jang DS, Choi G, Joo S, Kim JS, Oh BH, Choi KY. Roles of active site aromatic residues in catalysis by ketosteroid isomerase from *Pseudomonas putida* biotype B. *Biochemistry* 1999 Oct 19;38(42):13810-9.
- Kim KI, Bayley HS. Amino acid oxidation by young pigs receiving diets with varying levels of sulphur amino acids. *Br J Nutr* 1983 Sep;50(2):383-90.
- Kim KI, Elliott JI, Bayley HS. Oxidation of an indicator amino acid by young pigs receiving diets with varying levels of lysine or threonine, and an assessment of amino acid requirements. *Br J Nutr* 1983 Sep;50(2):391-9.
- Kim KI, McMillan I, Bayley HS. Determination of amino acid requirements of young pigs using an indicator amino acid. *Br J Nutr* 1983 Sep;50(2):369-82.
- Kindt E, Halvorsen S. The need of essential amino acids in children. An evaluation based on the intake of phenylalanine, tyrosine, leucine, isoleucine, and valine in children with phenylketonuria, tyrosine amino

- transferase defect, and maple syrup urine disease. *Am J Clin Nutr* 1980 Feb;33(2):279-86.
- Kindt E, Halvorsen S, Lie SO. Does a marginal protein intake result in osteoporosis? *J Inher Metab Dis* 1987;10(2):195.
- Kindt E, Holm H, Halvorsen S, Lie SO. Net protein utilization determined by rat bioassay of a protein hydrolysate and a diet for children with phenylketonuria. *Br J Nutr* 1985 Sep;54(2):349-53.
- Kindt E, Motzfeldt K, Halvorsen S, Lie SO. Is phenylalanine requirement in infants and children related to protein intake? *Br J Nutr* 1984 May;51(3):435-42.
- Kirby ML, Miyagawa ST. The effects of high phenylalanine concentration on chick embryonic development. *J Inher Metab Dis* 1990;13(4):634-40.
- Kitamura M. [Clinical laboratory--II]. *Rinsho Byori* 1986 Apr;34(4):423-6. (Jpn).
- Kleiman S, Bernstein J, Schwartz G, Eisensmith RC, Woo SL, Shiloh Y. A defective splice site at the phenylalanine hydroxylase gene in phenylketonuria and benign hyperphenylalaninemia among Palestinian Arabs. *Hum Mutat* 1992;1(4):340-3.
- Kleiman S, Li J, Schwartz G, Eisensmith RC, Woo SL, Shiloh Y. Inactivation of phenylalanine hydroxylase by a missense mutation, R270S, in a Palestinian kinship with phenylketonuria. *Hum Mol Genet* 1993 May;2(5):605-6.
- Kleiman S, Schwartz G, Woo SL, Shiloh Y. A 22-bp deletion in the phenylalanine hydroxylase gene causing phenylketonuria in an Arab family. *Hum Mutat* 1992;1(4):344-6.
- Kleiman S, Vanagaite L, Bernstein J, Schwartz G, Brand N, Elitzur A, Woo SL, Shiloh Y. Phenylketonuria: variable phenotypic outcomes of the R261Q mutation and maternal PKU in the offspring of a healthy homozygote. *J Med Genet* 1993 Apr;30(4):284-8.
- Klein LE, Nordlund JJ. Genetic basis of pigmentation and its disorders. *Int J Dermatol* 1981 Dec;20(10):621-31.
- Knapp A, Grimm U, Postrach E. [Phenylalanine-tyrosine metabolism in psoriasis vulgaris. Search on a genetic basic defect (author's transl)]. *Dermatol Monatsschr* 1980 Jul;166(7):470-7. (Ger).
- Knappskog M, Eiken HG, Martinez A, Olafsdotti S, Haavik J, Flatmark T, Apold J. Expression of wild type and mutant forms of human phenylalanine hydroxylase in *E. coli*. *Adv Exp Med Biol* 1993;338:59-62.
- Knappskog PM, Eiken HG, Martinez A, Bruland O, Apold J, Flatmark T. PKU mutation (D143G) associated with an apparent high residual enzyme activity: expression of a kinetic variant form of phenylalanine hydroxylase in three different systems. *Hum Mutat* 1996;8(3):236-46.
- Knappskog PM, Flatmark T, Aarden JM, Haavik J, Martinez A. Structure/function relationships in human phenylalanine hydroxylase. Effect of terminal deletions on the oligomerization, activation and cooperativity of substrate binding to the enzyme. *Eur J Biochem* 1996 Dec 15;242(3):813-21.
- Knappskog PM, Haavik J. Tryptophan fluorescence of human phenylalanine hydroxylase produced in *Escherichia coli*. *Biochemistry* 1995 Sep 19;34(37):11790-9.
- Knappskog PM, Martinez A. Effect of mutations at Cys237 on the activation state and activity of human phenylalanine hydroxylase. *FEBS Lett* 1997 Jun 2;409(1):7-11.
- Knudsen GM, Hasselbalch S, Toft PB, Christensen E, Paulson OB, Lou H. Blood-brain barrier transport of amino acids in healthy controls and in patients with phenylketonuria. *J Inher Metab Dis* 1995;18(6):653-64.
- Kobayashi H, Kato J, Morioka H, Stewart JD, Ohtsuka E. Tryptophan H33 plays an important role in pyrimidine (6-4) pyrimidone photoproduct binding by a high-affinity antibody. *Protein Eng* 1999 Oct;12(10):879-84.
- Kobe B, Jennings IG, House CM, Feil SC, Michell BJ, Tiganis T, Parker MW, Cotton RG, Kemp BE. Regulation and crystallization of phosphorylated and dephosphorylated forms of truncated dimeric phenylalanine hydroxylase. *Protein Sci* 1997 Jun;6(6):1352-7.
- Kobe B, Jennings IG, House CM, Michell BJ, Goodwill KE, Santarsiero BD, Stevens RC, Cotton RG, Kemp BE. Structural basis of autoregulation of phenylalanine hydroxylase. *Nat Struct Biol* 1999 May;6(5):442-8. Comment in: *Nat Struct Biol* 1999 May;6(5):401-2.
- Koch R, Blaskovics M. Four cases of hyperphenylalaninaemia: studies during pregnancy and of the offspring produced. *J Inher Metab Dis* 1982;5(1):11-5.
- Koch R, Fishler K, Azen C, Guldberg P, Guttler F. The relationship of genotype to phenotype in phenylalanine hydroxylase deficiency. *Biochem Mol Med* 1997 Apr;60(2):92-101.
- Koch R, Moseley K, Ning J, Romstad A, Guldberg P, Guttler F. Long-term beneficial effects of the

- phenylalanine-restricted diet in late-diagnosed individuals with phenylketonuria. *Mol Genet Metab* 1999 Jun;67(2):148-55.
- Kodentsova VM, Vrzhesinskaia OA, Denisova SN, Spirichev VB. [Metabolism of vitamins B1 and B2 during phenylketonuria]. *Vopr Med Khim* 1999 Mar-Apr;45(2):150-7. (Rus).
- Koizumi S, Matsushima Y, Nagatsu T, Iinuma H, Takeuchi T, Umezawa H. 3,4-dihydroxystyrene, a novel microbial inhibitor for phenylalanine hydroxylase and other pteridine-dependent monooxygenases. *Biochim Biophys Acta* 1984 Sep 11;789(2):111-8.
- Koizumi S, Tanaka F, Kaneda N, Kano K, Nagatsu T. Nanosecond pulse fluorometry of conformational change in phenylalanine hydroxylase associated with activation. *Biochemistry* 1988 Jan 26;27(2):640-6.
- Kolodny EH, Cable WJ. Inborn errors of metabolism. *Ann Neurol* 1982 Mar;11(3):221-32.
- Kolodny EH, Yatziv S. Laboratory approaches for inherited neurometabolic diseases. *Dev Med Child Neurol* 1985 Apr;27(2):252-7.
- Konecki DS, Wang Y, Trefz FK, Lichter-Konecki U, Woo SL. Structural characterization of the 5' regions of the human phenylalanine hydroxylase gene. *Biochemistry* 1992 Sep 8;31(35):8363-8.
- Korpi ER. Aromatic amino acid incorporation into proteins in rat brain slices: influences of other amino acids affecting transport. *Acta Physiol Scand* 1981 Aug;112(4):353-8.
- Kowlessur D, Citron BA, Kaufman S. Recombinant human phenylalanine hydroxylase: novel regulatory and structural properties. *Arch Biochem Biophys* 1996 Sep 1;333(1):85-95.
- Kowlessur D, Yang XJ, Kaufman S. Further studies of the role of Ser-16 in the regulation of the activity of phenylalanine hydroxylase. *Proc Natl Acad Sci U S A* 1995 May 23;92(11):4743-7.
- Kozak L, Blazkova M, Kuhrova V, Pijackova A, Ruzickova S, St'astna S. Mutation and haplotype analysis of phenylalanine hydroxylase alleles in classical PKU patients from the Czech Republic: identification of four novel mutations. *J Med Genet* 1997 Nov;34(11):893-8.
- Krause W, Halminski M, McDonald L, Dembure P, Salvo R, Freides D, Elsas L. Biochemical and neuropsychological effects of elevated plasma phenylalanine in patients with treated phenylketonuria. A model for the study of phenylalanine and brain function in man. *J Clin Invest* 1985 Jan;75(1):40-8.
- Kreis R, Pietz J, Penzien J, Herschkowitz N, Boesch C. Identification and quantitation of phenylalanine in the brain of patients with phenylketonuria by means of localized in vivo 1H magnetic-resonance spectroscopy. *J Magn Reson B* 1995 Jun;107(3):242-51.
- Krempf M, Hoerr RA, Pelletier VA, Marks LM, Gleason R, Young VR. An isotopic study of the effect of dietary carbohydrate on the metabolic fate of dietary leucine and phenylalanine. *Am J Clin Nutr* 1993 Feb;57(2):161-9.
- Kronick JB, Whelan DT, McCallion DJ. Experimental hyperphenylalaninemia in the pregnant guinea pig: possible phenylalanine teratogenesis and p-chlorophenylalanine embryotoxicity. *Teratology* 1987 Oct;36(2):245-58.
- Kucinskas V, Jurgelevicius V, Cimbalistiene L, Holmgren G. Distributions of phenylalanine hydroxylase mutations and haplotypes in Lithuanian phenylketonuria patients. *Hum Hered* 1994 Mar-Apr;44(2):110-3.
- Kudo Y, Boyd CA. Placental tyrosine transport and maternal phenylketonuria. *Acta Paediatr* 1996 Jan;85(1):109-10.
- Kudo Y, Boyd CA. Transport of amino acids by the human placenta: predicted effects thereon of maternal hyperphenylalaninaemia. *J Inher Metab Dis* 1990;13(4):617-26.
- Kure S, Hou DC, Ohura T, Iwamoto H, Suzuki S, Sugiyama N, Sakamoto O, Fujii K, Matsubara Y, Narisawa K. Tetrahydrobiopterin-responsive phenylalanine hydroxylase deficiency. *J Pediatr* 1999 Sep;135(3):375-8.
- Kuster T, Matasovic A, Niederwieser A. Application of gas chromatography-mass spectrometry to the study of biopterin metabolism in man. Detection of biolumazine and 2'-deoxysepialumazine. *J Chromatogr* 1984 May 4;290:303-10.
- Kuzmin AI, Eisensmith RC, Goltsov AA, Sergeeva NA, Schwartz EI, Woo SL. Complete spectrum of PAH mutations in Tataria: presence of Slavic, Turkic and Scandinavian mutations. *Eur J Hum Genet* 1995;3(4):246-55.
- Kwok SC, Ledley FD, DiLella AG, Robson KJ, Woo SL. Nucleotide sequence of a full-length complementary DNA clone and amino acid sequence of human phenylalanine hydroxylase. *Biochemistry* 1985 Jan 29;24(3):556-61.
- Labadie P. [Phenylalanine hydroxylase]. *Rev Prat* 1982 May 11;32(27):1884-90. (Fre).

- Lahdesmaki P. Inhibition of protein and aminoacyl-tRNA synthesis, and binding and transport sites for aromatic amino acids in the brain in vitro with aromatic acids. *Int J Neurosci* 1984 Mar;23(1):1-13.
- Lajtha A, Reilly MA, Dunlop DS. Aspartame consumption: lack of effects on neural function. *J Nutr Biochem* 1994 Jun;5(6):266-83.
- Lane JD, Schone B, Langenbeck U, Neuheff V. Characterization of experimental phenylketonuria. Augmentation of hyperphenylalaninemia with alpha-methylphenylalanine and p-chlorophenylalanine. *Biochim Biophys Acta* 1980 Jan 17;627(2):144-56.
- Langar H, Guillaume J, Metailler R, Fauconneau B. Augmentation of protein synthesis and degradation by poor dietary amino acid balance in European sea bass (*Dicentrarchus labrax*). *J Nutr* 1993 Oct;123(10):1754-61.
- Langenbeck U, Behbehani A, Luthe H. Renal transport of aromatic acids in patients with phenylketonuria. *J Inher Metab Dis* 1981;4(2):69-70.
- Langenbeck U, Behbehani A, Mench-Hoinowski A. A synopsis of the unconjugated acidic transamination metabolites of phenylalanine in phenylketonuria. *J Inher Metab Dis* 1992;15(1):136-44.
- Laptev AV, Chestkov VV. [The dynamics of the properties of liver phenylalanine hydroxylase in human embryogenesis]. *Ontogenez* 1990 Mar-Apr;21(2):138-44. (Rus).
- Laptev AV, Chestkov VV, Shchepkina IuV, Shishkin SS. [Phenylalanine hydroxylase of human embryos: its homology with the enzyme from the liver of adults]. *Ontogenez* 1988 Jul-Aug;19(4):385-9. (Rus).
- Laufs S, Blau N, Thony B. Retrovirus-mediated double transduction of the GTPCH and PTPS genes allows 6-pyruvoyltetrahydropterin synthase-deficient human fibroblasts to synthesize and release tetrahydrobiopterin. *J Neurochem* 1998 Jul;71(1):33-40.
- Lazarus RA, Dietrich RF, Wallick DE, Benkovic SJ. On the mechanism of action of phenylalanine hydroxylase. *Biochemistry* 1981 Nov 24;20(24):6834-41.
- Lazarus RA, Wallick DE, Dietrich RF, Gottschall DW, Benkovic SJ, Gaffney BJ, Shiman R. The mechanism of phenylalanine hydroxylase. *Fed Proc* 1982 Jul;41(9):2605-7.
- Leandro P, Rivera I, Lechner MC, de Almeida IT, Konecki D. The V388M mutation results in a kinetic variant form of phenylalanine hydroxylase. *Mol Genet Metab* 2000 Mar;69(3):204-12.
- Ledley FD, DiLella AG, Kwok SC, Woo SL. Homology between phenylalanine and tyrosine hydroxylases reveals common structural and functional domains. *Biochemistry* 1985 Jul 2;24(14):3389-94.
- Ledley FD, Grenett HE, DiLella AG, Kwok SC, Woo SL. Gene transfer and expression of human phenylalanine hydroxylase. *Science* 1985 Apr 5;228(4695):77-9.
- Ledley FD, Grenett HE, Dunbar BS, Woo SL. Mouse phenylalanine hydroxylase. Homology and divergence from human phenylalanine hydroxylase. *Biochem J* 1990 Apr 15;267(2):399-405.
- Ledley FD, Grenett HE, Woo SL. Biochemical characterization of recombinant human phenylalanine hydroxylase produced in *Escherichia coli*. *J Biol Chem* 1987 Feb 15;262(5):2228-33.
- Ledley FD, Koch R, Jew K, Beaudet A, O'Brien WE, Bartos DP, Woo SL. Phenylalanine hydroxylase expression in liver of a fetus with phenylketonuria. *J Pediatr* 1988 Sep;113(3):463-8.
- Ledley FD, Woo SL. P-chlorophenylalanine does not inhibit production of recombinant human phenylalanine hydroxylase in NIH3T3 cells or *E. coli*. *Biochem Biophys Res Commun* 1987 Jan 30;142(2):302-8.
- Leeming RJ. Microtiter plate assay for biopterin using cryopreserved *Crithidia fasciculata*. *Methods Enzymol* 1997;281:61-70.
- Leeming RJ. The role of tetrahydrobiopterin in neurological disease: a review. *J Ment Defic Res* 1981 Dec;25 Pt 4:231-41.
- Leeming RJ, Hall SK, Green A. The origin of red blood cell biopterin. *Mol Genet Metab* 1998 Dec;65(4):291-7.
- Leeming RJ, Hall SK, Surplice IM, Green A. Relationship between plasma and red cell biopterins in acute and chronic hyperphenylalaninaemia. *J Inher Metab Dis* 1990;13(6):883-7.
- Lehmann WD, Fischer R, Heinrich HC, Clemens P, Gruttner R. Metabolic conversion of L-[U-14C]phenylalanine to respiratory 14CO₂ in healthy subjects, phenylketonuria heterozygotes and classic phenylketonurics. *Clin Chim Acta* 1986 Jun 30;157(3):253-66.
- Lehmann WD, Heinrich HC. Impaired phenylalanine-tyrosine conversion in patients with iron-deficiency anemia studied by a L-(2H⁵)phenylalanine-loading test. *Am J Clin Nutr* 1986 Oct;44(4):468-74.

- Lehmann WD, Heinrich HC. The NIH-shift in the in vivo hydroxylation of ring-deuterated L-phenylalanine in man. *Arch Biochem Biophys* 1986 Oct;250(1):180-5.
- Lei XD, Kaufman S. Human white blood cells and hair follicles are good sources of mRNA for the pterin carbinolamine dehydratase/dimerization cofactor of HNF1 for mutation detection. *Biochem Biophys Res Commun* 1998 Jul 20;248(2):432-5.
- Lenke RR, Platt LD, Koch R. Ultrasonographic failure of early detection of fetal microcephaly in maternal phenylketonuria. *J Ultrasound Med* 1983 Apr;2(4):177-9.
- Lenzi G, Pistone D, Zammarchi E, Benini MP, La Torre A, Matteoni D. DHPR activity decrease in dried blood spots stored at 4 degrees C. *Enzyme* 1989;41(1):43-6.
- Leroux B, Dhondt JL. [Malignant hyperphenylalaninemia due to tetrahydrobiopterin deficiency]. *Arch Pediatr* 1996;3 Suppl 1:163s-166s. (Fre).
- Leuzzi V, Rinalduzzi S, Chiarotti F, Garzia P, Trasimeni G, Accornero N. Subclinical visual impairment in phenylketonuria. A neurophysiological study (VEP-P) with clinical, biochemical, and neuroradiological (MRI) correlations. *J Inherit Metab Dis* 1998 Jun;21(4):351-64.
- Leuzzi V, Trasimeni G, Gualdi GF, Antonozzi I. Biochemical, clinical and neuroradiological (MRI) correlations in late-detected PKU patients. *J Inherit Metab Dis* 1995;18(5):624-34.
- Levine RA. Tetrahydrobiopterin and biogenic amine metabolism in neuropsychiatry, immunology, and aging. *Ann N Y Acad Sci* 1988;521:129-39.
- Levy HL. Genetic screening. *Adv Hum Genet* 1973;4:1-104.
- Levy HL. Maternal phenylketonuria. *Prog Clin Biol Res* 1988;281:227-42.
- Levy HL. Nutritional therapy for selected inborn errors of metabolism. *J Am Coll Nutr* 1989;8 Suppl:54S-60S.
- Levy HL. Phenylketonuria: old disease, new approach to treatment. *Proc Natl Acad Sci U S A* 1999 Mar 2;96(5):1811-3. Comment on: *Proc Natl Acad Sci U S A* 1999 Mar 2;96(5):2339-44.
- Levy HL, Lenke RR, Koch R. Lack of fetal effect on blood phenylalanine concentration in maternal phenylketonuria. *J Pediatr* 1984 Feb;104(2):245-7.
- Levy HL, Lobbregt D, Koch R, de la Cruz F. Paternal phenylketonuria. *J Pediatr* 1991 May;118(5):741-3.
- Levy HL, Waisbren SE. PKU in adolescents: rationale and psychosocial factors in diet continuation. *Acta Paediatr Suppl* 1994 Dec;407:92-7.
- Lewis Vyoone T. Murine phenylketonuria: comparison of the natural history and management (phenylalanine hydroxylase, tyrosine, glycine) [dissertation]. New Orleans (LA): Tulane University; 1997. 101 p.
- Li J, Eisensmith RC, Wang T, Lo WH, Huang SZ, Zeng YT, Yuan LF, Liu SR, Woo SL. Identification of three novel missense PKU mutations among Chinese. *Genomics* 1992 Jul;13(3):894-5.
- Li J, Eisensmith RC, Wang T, Lo WH, Huang SZ, Zeng YT, Yuan LF, Liu SR, Woo SL. Phenylketonuria in China: identification and characterization of three novel nucleotide substitutions in the human phenylalanine hydroxylase gene. *Hum Mutat* 1994;3(3):312-4.
- Liappis N, Pohl B, Weber HP, el-Karkani H. [Free amino acids in the saliva of children with phenylketonuria]. *Klin Padiatr* 1986 Jan-Feb;198(1):25-8. (Ger).
- Lichter-Konecki U, Hipke CM, Konecki DS. Human phenylalanine hydroxylase gene expression in kidney and other nonhepatic tissues. *Mol Genet Metab* 1999 Aug;67(4):308-16.
- Lichter-Konecki U, Rupp A, Konecki DS, Trefz FK, Schmidt H, Burgard P. Relation between phenylalanine hydroxylase genotypes and phenotypic parameters of diagnosis and treatment of hyperphenylalaninaemic disorders. German Collaborative Study of PKU. *J Inherit Metab Dis* 1994;17(3):362-5.
- Liechty EA, Boyle DW, Moorehead H, Auble L, Denne SC. Aromatic amino acids are utilized and protein synthesis is stimulated during amino acid infusion in the ovine fetus. *J Nutr* 1999 Jun;129(6):1161-6.
- Lillevali H, Ounap K, Metspalu A. Phenylalanine hydroxylase gene mutation R408W is present on 84% of Estonian phenylketonuria chromosomes. *Eur J Hum Genet* 1996;4(5):296-300.
- Lin CH, Hsiao KJ, Tsai TF, Chao HK, Su TS. Identification of a missense phenylketonuria mutation at codon 408 in Chinese. *Hum Genet* 1992 Aug;89(6):593-6.
- Lin CM, Tan Y, Lee YM, Chang CC, Hsiao KJ. Expression of human phenylalanine hydroxylase activity in T lymphocytes of classical phenylketonuria

- children by retroviral-mediated gene transfer. *J Inherit Metab Dis* 1997 Nov;20(6):742-54.
- Lin SX, Baltzinger M, Remy P. Fast kinetic study of yeast phenylalanyl-tRNA synthetase: role of tRNAPhe in the discrimination between tyrosine and phenylalanine. *Biochemistry* 1984 Aug 28;23(18):4109-16.
- Lines DR. Aspartame doses for phenylketonuria [letter]. *J Nutr* 1981 Sep;111(9):1688-90.
- Lipinska L, Laskowska-Klita T, Cabalska B. Riboflavin status in phenylketonuric patients in the course of dietary treatment. *J Inherit Metab Dis* 1994;17(2):242.
- Lipson A, Yu J, O'Halloran M, Potter M, Wilken B. Dihydropteridine reductase deficiency: non-response to oral tetrahydrobiopterin load test. *J Inherit Metab Dis* 1984;7(2):69-71.
- Liu TJ, Kay MA, Darlington GJ, Woo SL. Reconstitution of enzymatic activity in hepatocytes of phenylalanine hydroxylase-deficient mice. *Somat Cell Mol Genet* 1992 Jan;18(1):89-96.
- Liu TT, Hsiao KJ, Lu SF, Wu SJ, Wu KF, Chiang SH, Liu XQ, Chen RG, Yu WM. Mutation analysis of the 6-pyruvoyl-tetrahydropterin synthase gene in Chinese hyperphenylalaninemia caused by tetrahydrobiopterin synthesis deficiency. *Hum Mutat* 1998;11(1):76-83.
- Lloyd B, Robson E, Smith I, Clayton BE. Blood selenium concentrations and glutathione peroxidase activity. *Arch Dis Child* 1989 Mar;64(3):352-6.
- Lo GS, Liang SC, Raha SR, Hunter JB, Longenecker JB. Biochemical and neurological effects of an experimental phenylketonuria-like condition in infant rats during the first 2 weeks after birth. *Am J Clin Nutr* 1981 Apr;34(4):498-506.
- Loeb KE. Spectroscopic definition of the non-heme ferrous active sites in bleomycin and phenylalanine hydroxylase: relevance to oxygen (magnetic circular dichroism) [dissertation]. Stanford (CA): Stanford University; 1998. 264 p.
- Lombeck I, Jochum F, Terwolbeck K. Selenium status in infants and children with phenylketonuria and in maternal phenylketonuria. *Eur J Pediatr* 1996 Jul;155 Suppl 1:S140-4.
- Lombeck I, Kasperek K, Bachmann D, Feinendegen LE, Bremer HJ. Selenium requirements in patients with inborn errors of amino acid metabolism and selenium deficiency. *Eur J Pediatr* 1980 Jun;134(1):65-8.
- Longhi R, Valsasina R, Butte C, Paccanelli S, Riva E, Giovannini M. Cranial computerized tomography in dihydropteridine reductase deficiency. *J Inherit Metab Dis* 1985;8(3):109-12.
- Loo YH, Fulton T, Miller K, Wisniewski HM. Phenylacetate and brain dysfunction in experimental phenylketonuria: synaptic development. *Life Sci* 1980 Oct 6;27(14):1283-90.
- Loo YH, Fulton TR, Hyde KR, Wisniewski HM. Biochemical indices of neuronal development in experimental phenylketonuria: high affinity transport systems and gangliosides. *Dev Neurosci* 1983-84;6(4-5):235-45.
- Loo YH, Hyde KR, Lin FH, Wisniewski HM. Cerebral biochemical abnormalities in experimental maternal phenylketonuria: gangliosides and sialoglycoproteins. *Life Sci* 1985 Dec 2;37(22):2099-109.
- Loo YH, Potempska A, Wisniewski HM. A biochemical explanation of phenyl acetate neurotoxicity in experimental phenylketonuria. *J Neurochem* 1985 Nov;45(5):1596-600.
- Lou HC. Dopamine precursors and brain function in phenylalanine hydroxylase deficiency. *Acta Paediatr Suppl* 1994 Dec;407:86-8.
- Lou HC, Guttler F, Lykkelund C, Bruhn P, Niederwieser A. Decreased vigilance and neurotransmitter synthesis after discontinuation of dietary treatment for phenylketonuria in adolescents. *Eur J Pediatr* 1985 May;144(1):17-20.
- Lou HC, Lykkelund C, Gerdes AM, Udesen H, Bruhn P. Increased vigilance and dopamine synthesis by large doses of tyrosine or phenylalanine restriction in phenylketonuria. *Acta Paediatr Scand* 1987 Jul;76(4):560-5.
- Lou HC, Toft PB, Andresen J, Mikkelsen I, Olsen B, Guldberg P, Guttler F. Unchanged MRI of myelin in adolescents with PKU supplied with non-phe essential amino acids after dietary relaxation. *Acta Paediatr* 1994 Dec;83(12):1312-4.
- Lovenberg WM. Biochemical regulation of brain function. *Nutr Rev* 1986 May;44 Suppl:6-11.
- Lucas A, Baker BA, Morley RM. Hyperphenylalaninaemia and outcome in intravenously fed preterm neonates. *Arch Dis Child* 1993 May;68(5 Spec No):579-83.
- Lunde HA, Lenney JF, Halvorsen S, Gjessing L. Serum carnosinase in blood and homocarnosine in CSF of patients with Folling's disease (PKU). *J Oslo City Hosp* 1987 Apr;37(4):29-33.

- Lunte CE. Investigation of pterins by liquid [dissertation]. West Lafayette (IN): Purdue University; 1984. 223 p.
- Lunte CE, Kissinger PT. Determination of phenylalanine hydroxylase activity by liquid chromatography/electrochemistry. *Anal Biochem* 1984 Jun;139(2):468-73.
- Luthy CL. Studies on tetrahydrobiopterin analogs: their oxidation interactions with phenylalanine hydroxylase [dissertation]. University Park (PA): The Pennsylvania State University; 1983. 110 p.
- Lykkelund C, Nielsen JB, Lou HC, Rasmussen V, Gerdes AM, Christensen E, Guttler F. Increased neurotransmitter biosynthesis in phenylketonuria induced by phenylalanine restriction or by supplementation of unrestricted diet with large amounts of tyrosine. *Eur J Pediatr* 1988 Dec;148(3):238-45.
- Maas JA, France J, Dijkstra J, Bannink A, McBride BW. Application of a mechanistic model to study competitive inhibition of amino acid uptake by the lactating bovine mammary gland. *J Dairy Sci* 1998 Jun;81(6):1724-34.
- Maas JA, France J, McBride BW. Model of milk protein synthesis. A mechanistic model of milk protein synthesis in the lactating bovine mammary gland. *J Theor Biol* 1997 Aug 7;187(3):363-78.
- MacCready RA, Levy HL. The problem of maternal phenylketonuria. *Am J Obstet Gynecol* 1972 May 1;113(1):121-8.
- Macfarlane RG, Midgley JM, Watson DG. Identification and quantitation of phenylalanine, tyrosine and dihydroxyphenylalanine in the thoracic nervous system of the locust, *Schistocerca gregaria*, by gas chromatography-negative-ion chemical ionisation mass spectrometry. *J Chromatog* 1990 Oct 26;532(1):1-11.
- Maddox MA. Is there a link between dementia and phenylketonuria? *J Gerontol Nurs* 1990 May;16(5):18-23.
- Maladkar NK. Biosynthesis of chlortetracycline. Part III--Hydroxylation of L-phenylalanine to L-tyrosine by *Streptomyces aureofaciens* and its relation to the biosynthesis of chlortetracycline. *Hindustan Antibiot Bull* 1986 Feb-Nov;28(1-4):30-6.
- Mallolas J, Mila M, Lambruschini N, Cambra FJ, Campistol J, Vilaseca MA. Biochemical phenotype and its relationship with genotype in hyperphenylalaninemia heterozygotes. *Mol Genet Metab* 1999 Jun;67(2):156-61.
- Mallolas J, Vilaseca MA, Campistol J, Lambruschini N, Cambra FJ, Estivill X, Mila M. Mutational spectrum of phenylalanine hydroxylase deficiency in the population resident in Catalonia: genotype-phenotype correlation. *Hum Genet* 1999 Nov;105(5):468-73.
- Malpuech G, Guyon A, Demeocq F, Piton A, Boespflug O, Vanlieferinghen P. [Malignant phenylketonuria caused by biopterin synthetase deficiency. Study of neuromediator catabolites in the cerebrospinal fluid during treatment]. *Arch Fr Pediatr* 1984 Jan;41(1):5-8. (Fre).
- Manjunath R, Shivaswamy V, Ramasarma T. Decrease of phenylalanine hydroxylase during hepatocyte proliferation. *Biochem Pharmacol* 1982 Apr 15;31(8):1521-5.
- Marchini JS, Castillo L, Chapman TE, Vogt JA, Ajami A, Young VR. Phenylalanine conversion to tyrosine: comparative determination with L-[ring-2H5]phenylalanine and L-[1-13C]phenylalanine as tracers in man. *Metabolism* 1993 Oct;42(10):1316-22.
- Marchini JS, Cortiella J, Hiramatsu T, Castillo L, Chapman TE, Young VR. Phenylalanine and tyrosine kinetics for different patterns and indispensable amino acid intakes in adult humans. *Am J Clin Nutr* 1994 Jul;60(1):79-86.
- Marconi W, Bartoli F, Gianna R, Morisi F, Spotorno G. Phenylalanine ammonia-lyase entrapped in fibers. *Biochimie* 1980;62(8-9):575-80.
- Marota JJ. The stoichiometric reduction of phenylalanine hydroxylase by cofactor and reversible inactivation by (tetrahydropterin, fluorescence, activation) [dissertation]. University Park (PA): The Pennsylvania State University; 1983. 108 p.
- Marota JJ, Shiman R. Stoichiometric reduction of phenylalanine hydroxylase by its cofactor: a requirement for enzymatic activity. *Biochemistry* 1984 Mar 13;23(6):1303-11.
- Martinez A, Andersson KK, Haavik J, Flatmark T. EPR and 1H-NMR spectroscopic studies on the paramagnetic iron at the active site of phenylalanine hydroxylase and its interaction with substrates and inhibitors. *Eur J Biochem* 1991 Jun 15;198(3):675-82.
- Martinez A, Haavik J, Flatmark T. Cooperative homotropic interaction of L-noradrenaline with the catalytic site of phenylalanine 4-monooxygenase. *Eur J Biochem* 1990 Oct 5;193(1):211-9.
- Martinez A, Knappskog PM, Olafsdottir S, Doskeland AP, Eiken HG, Svebak RM, Bozzini M, Apold J, Flatmark T. Expression of recombinant human phenylalanine hydroxylase as fusion protein in *Escherichia coli* circumvents proteolytic degradation

- by host cell proteases. Isolation and characterization of the wild-type enzyme. *Biochem J* 1995 Mar 1;306 (Pt 2):589-97.
- Martinez A, Olafsdottir S, Flatmark T. The cooperative binding of phenylalanine to phenylalanine 4-monooxygenase studied by ¹H-NMR paramagnetic relaxation. Changes in water accessibility to the iron at the active site upon substrate binding. *Eur J Biochem* 1993 Jan 15;211(1-2):259-66.
- Martinez A, Olafsdottir S, Haavik J, Flatmark T. Inactivation of purified phenylalanine hydroxylase by dithiothreitol. *Biochem Biophys Res Commun* 1992 Jan 15;182(1):92-8.
- Martinez-Pardo M, Colmenares AR, Garcia MJ, Perez B, Desviat LR, Ugarte M. Phenotype distribution in the Spanish phenylketonuria population and related genotypes. *J Inherit Metab Dis* 1994;17(3):366-8.
- Martinez SJ 3rd. The electronic spectroscopy of the amino acids tyrosine and phenylalanine and their analogs in a supersonic jet [dissertation]. Chicago: The University of Chicago; 1991.
- Marvit J, DiLella AG, Brayton K, Ledley FD, Robson KJ, Woo SL. GT to AT transition at a splice donor site causes skipping of the preceding exon in phenylketonuria. *Nucleic Acids Res* 1987 Jul 24;15(14):5613-28.
- Maskos Z, Rush JD, Koppenol WH. The hydroxylation of phenylalanine and tyrosine: a comparison with salicylate and tryptophan. *Arch Biochem Biophys* 1992 Aug 1;296(2):521-9.
- Matalon R, Justice P, Deanching MN. Phenylalanine hydroxylase in human placenta: novel system for study of phenylketonuria [letter]. *Lancet* 1977 Apr 16;1(8016):853-4.
- Matalon R, Matthews DE, Michals K, Bier D. The use of deuterated phenylalanine for the in vivo assay of phenylalanine hydroxylase activity in children. *J Inherit Metab Dis* 1982;5(1):17-9.
- Matalon R, Michals K, Azen C, Friedman EG, Koch R, Wenz E, Levy H, Rohr F, Rouse B, Castiglioni L, et al. Maternal PKU collaborative study: the effect of nutrient intake on pregnancy outcome. *J Inherit Metab Dis* 1991;14(3):371-4.
- Matalon R, Michals K, Blau N, Rouse B. Hyperphenylalaninemia due to inherited deficiencies of tetrahydrobiopterin. *Adv Pediatr* 1989;36:67-89.
- Matsuo K, Hommes F. Regional distribution of the phenylalanine-sensitive ATP-sulphurylase in brain. *J Inherit Metab Dis* 1987;10(1):62-5.
- Matsuo K, Hommes FA. The development of the muscarinic acetylcholine receptor in normal and hyperphenylalaninemic rat cerebrum. *Neurochem Res* 1988 Sep;13(9):867-70.
- Matsuo N. Hyperphenylalaninemia syndromes: current status of diagnosis and management. *Keio J Med* 1988 Mar;37(1):1-9.
- Mavrophilipos DV. Characterization of the iron environment of lipooxygenases paramagnetic resonance, metalloenzyme, high spin, non-heme) [dissertation]. Baltimore (MD): The Johns Hopkins University; 1986. 166 p.
- Mayo KA. Developmental regulation of gene expression in *Tetrahymena* [dissertation]. Santa Barbara (CA): University of California, Santa Barbara; 1984. 387 p.
- McCabe ER, McCabe L. Issues in the dietary management of phenylketonuria: breast-feeding and trace-metal nutriture. *Ann N Y Acad Sci* 1986;477:215-22.
- McCabe ER, Nord AM, Ernest A, McCabe L. Evaluation of a phenylalanine-free product for treatment of phenylketonuria. *Am J Dis Child* 1987 Dec;141(12):1327-9.
- McCargar LJ, Clandinin MT, Fawcett DM, Johnston JL. Short-term changes in energy intake and serum insulin, neutral amino acids, and urinary catecholamine excretion in women. *Am J Clin Nutr* 1988 Jun;47(6):932-41.
- McChesney R, Habermann J, Greengard O. Phenylalanine uptake in neonatal and infant rat brain. *Biol Neonate* 1988;54(5):275-84.
- McChesney R, Isaacs CE, Greengard O. Cerebral glycine content and phosphoserine phosphatase activity in hyperaminoacidemias. *Neurochem Res* 1987 Mar;12(3):289-95.
- McChesney RE. Amino acid and biogenic amine studies in experimental hyperphenylalaninemia [dissertation]. New York: City University of New York; 1988. 173 p.
- McDonald JD. Biochemical and genetic characterization of HPH-1: an mutation resulting in heritable hyperphenylalaninemia [dissertation]. Manhattan (KS): Kansas State University; 1987. 123 p.
- McDonald JD, Bode VC, Dove WF, Shedlovsky A. Pahhph-5: a mouse mutant deficient in phenylalanine hydroxylase. *Proc Natl Acad Sci U S A* 1990 Mar;87(5):1965-7.

- McDonald JD, Cotton RG, Jennings I, Ledley FD, Woo SL, Bode VC. Biochemical defect of the hph-1 mouse mutant is a deficiency in GTP-cyclohydrolase activity. *J Neurochem* 1988 Feb;50(2):655-7.
- McDowall IL, Palwala Y, Fisher MJ. Differential effects of streptozotocin-induced diabetes on phenylalanine hydroxylase protein and mRNA abundance in isolated rat liver cells. *Int J Biochem Cell Biol* 1996 Jul;28(7):761-70.
- McInnes RR, Kaufman S, Warsh JJ, Van Loon GR, Milstien S, Kapatos G, Soldin S, Walsh P, MacGregor D, Hanley WB. Biopterin synthesis defect. Treatment with L-dopa and 5-hydroxytryptophan compared with therapy with a tetrahydropterin. *J Clin Invest* 1984 Feb;73(2):458-69.
- McMurry MP, Chan GM, Leonard CO, Ernst SL. Bone mineral status in children with phenylketonuria--relationship to nutritional intake and phenylalanine control. *Am J Clin Nutr* 1992 May;55(5):997-1004.
- Medovar BI. [Effect of starvation on age-associated characteristics of phenylalanine metabolism in an experiment]. *Vopr Pitan* 1982 Jul-Aug;(4):52-5. (Rus).
- Meijer H, Jongbloed RJ, Hekking M, Spaapen LJ, Geraedts JP. RFLP haplotyping and mutation analysis of the phenylalanine hydroxylase gene in Dutch phenylketonuria families. *Hum Genet* 1993 Dec;92(6):588-92.
- Mellgren SI, Gotestam KG. Research on mental retardation in Norway 1970-1980: a review. *Appl Res Ment Retard* 1983;4(2):103-12.
- Menzel H, Steiner G, Lombeck I, Ohnesorge FK. Glutathione peroxidase and glutathione S-transferase activity of platelets. *Eur J Pediatr* 1983 Jun-Jul;140(3):244-7.
- Mercer JF, Grimes A, Jennings I, Cotton RG. Identification of two molecular-mass forms of phenylalanine hydroxylase that segregate independently in rats. Specific association of each form with certain rat strains. *Biochem J* 1984 May 1;219(3):891-8.
- Mercer JF, McAdam W, Chambers GW, Walker ID. The W and L allelic forms of phenylalanine hydroxylase in the rat differ by a threonine to isoleucine substitution. *Biochem J* 1986 Jun 15;236(3):679-83.
- Michals K, Lopus M, Matalon R. Phenylalanine metabolites as indicators of dietary compliance in children with phenylketonuria. *Biochem Med Metab Biol* 1988 Feb;39(1):18-23.
- Michals K, Matalon R. Phenylalanine metabolites, attention span and hyperactivity. *Am J Clin Nutr* 1985 Aug;42(2):361-5.
- Michiels L, Francois B, Raus J, Vandevyver C. Identification of seven new mutations in the phenylalanine hydroxylase gene, associated with hyperphenylalaninemia in the Belgian population. *Hum Mutat* 1998;Suppl 1:S123-4.
- Mikaeloff Y, Pinton F, Sevin C, Dhondt JL, Ponsot G. [Progressive convulsive encephalopathy: considering a abnormality of biopterin metabolism]. *Arch Pediatr* 1999 Jul;6(7):759-61. (Fre).
- Milla PJ, Kilby A, Rassam UB, Ersser R, Harries JT. Small intestinal absorption of amino acids and a dipeptide in pancreatic insufficiency. *Gut* 1983 Sep;24(9):818-24.
- Miller M, Hasson R, Resnick O. Availability of phenylalanine and tyrosine for brain norepinephrine synthesis in developmentally protein-malnourished rats. *Exp Neurol* 1982 Jul;77(1):163-78.
- Miller RJ, Benkovic SJ. L-[2,5-H₂]phenylalanine, an alternate substrate for rat liver phenylalanine hydroxylase. *Biochemistry* 1988 May 17;27(10):3658-63.
- Milner JA, Garton RL, Burns RA. Phenylalanine and tyrosine requirements of immature beagle dogs. *J Nutr* 1984 Dec;114(12):2212-6.
- Milner RD, Wirdnam PK. The pancreatic beta cell fraction in children with errors of amino acid metabolism. *Pediatr Res* 1982 Mar;16(3):213-6.
- Milstien S. Interconversion of 6- and 7-substituted tetrahydropterins via enzyme-generated 4a-hydroxytetrahydropterin intermediates. *Methods Enzymol* 1997;281:116-23.
- Milstien S, Dorche C, Kaufman S. Studies on the interaction of a thiol-dependent hydrogen peroxide scavenging enzyme and phenylalanine hydroxylase. *Arch Biochem Biophys* 1990 Nov 1;282(2):346-51.
- Milstien S, Holtzman NA, O'Flynn ME, Thomas GH, Butler IJ, Kaufman S. Hyperphenylalaninemia due to dihydropteridine reductase deficiency. Assay of the enzyme in fibroblasts from affected infants, heterozygotes, and in normal amniotic fluid cells. *J Pediatr* 1976 Nov;89(5):763-6.
- Milstien S, Jaffe H, Kowlessur D, Bonner TI. Purification and cloning of the GTP cyclohydrolase I feedback regulatory protein, GFRP. *J Biol Chem* 1996 Aug 16;271(33):19743-51.

- Milstien S, Kaufman S, Sakai N. Tetrahydrobiopterin biosynthesis defects examined in cytokine-stimulated fibroblasts. *J Inherit Metab Dis* 1993;16(6):975-81.
- Minato S. Purification of human liver phenylalanine hydroxylase with a monoclonal antibody to it and characterization of the enzyme. *Acta Paediatr Jpn* 1987 Aug;29(4):569-70.
- Minor LK. Effects of hormones on phenylalanine hydroxylase in primary rat hepatocytes maintained in chemically defined serum-free (insulin, glucagon, dexamethasone, albumin) [dissertation]. University Park (PA): The Pennsylvania State University; 1986. 127 p.
- Mitnaul LJ. The mechanism of regulation of phenylalanine hydroxylase by (6r)-tetrahydrobiopterin in cultured primary rat hepatocytes [dissertation]. University Park (PA): The Pennsylvania State University; 1994. 175 p.
- Mitnaul LJ, Shiman R. Coordinate regulation of tetrahydrobiopterin turnover and phenylalanine hydroxylase activity in rat liver cells. *Proc Natl Acad Sci U S A* 1995 Jan 31;92(3):885-9.
- Moats RA, Koch R, Moseley K, Guldborg P, Guttler F, Boles RG, Nelson MD Jr. Brain phenylalanine concentration in the management of adults with phenylketonuria. *J Inherit Metab Dis* 2000 Feb;23(1):7-14.
- Mockus SM. Structural and functional domains within aromatic amino acid hydroxylases [dissertation]. Winston Salem (NC): Wake Forest University, Bowman Gray School of Medicine; 1998. 219 p.
- Moller HE, Weglage J, Wiedermann D, Ullrich K. Blood-brain barrier phenylalanine transport and individual vulnerability in phenylketonuria. *J Cereb Blood Flow Metab* 1998 Nov;18(11):1184-91.
- Moller HE, Weglage J, Wiedermann D, Vermathen P, Bick U, Ullrich K. Kinetics of phenylalanine transport at the human blood-brain barrier investigated in vivo. *Brain Res* 1997 Dec 19;778(2):329-37.
- Moller N, Meek S, Bigelow M, Andrews J, Nair KS. The kidney is an important site for in vivo phenylalanine-to-tyrosine conversion in adult humans: A metabolic role of the kidney. *Proc Natl Acad Sci U S A* 2000 Feb 1;97(3):1242-6.
- Moller SE. Neutral amino acid plasma levels in healthy subjects: effect of complex carbohydrate consumed along with protein. *J Neural Transm* 1989;76(1):55-63.
- Monch E, Herrmann ME, Brosicke H, Schoffer A, Keller M. Utilisation of amino acid mixtures in adolescents with phenylketonuria. *Eur J Pediatr* 1996 Jul;155 Suppl 1:S115-20.
- Morales G, Requena JM, Jimenez-Ruiz A, Lopez MC, Ugarte M, Alonso C. Sequence and expression of the *Drosophila* phenylalanine hydroxylase mRNA. *Gene* 1990 Sep 14;93(2):213-9.
- More pointers on PKU [letter]. *MCN Am J Matern Child Nurs* 1987 Jul-Aug;12(4):239.
- Motta A, Laursen RA, Llinas M, Tulinsky A, Park CH. Complete assignment of the aromatic proton magnetic resonance spectrum of the kringle 1 domain from human plasminogen: structure of the ligand-binding site. *Biochemistry* 1987 Jun 30;26(13):3827-36.
- Munoz M, Emery PW, Peran S, Mann GE. Dietary regulation of amino acid transport activity in the exocrine pancreatic epithelium. *Biochim Biophys Acta* 1988 Nov 22;945(2):273-80.
- Muramatsu T, Salter DN, Coates ME. Protein turnover of breast muscle in germ-free and conventional chicks. *Br J Nutr* 1985 Jul;54(1):131-45.
- Nagasaki Y, Matsubara Y, Takano H, Fujii K, Senoo M, Akanuma J, Takahashi K, Kure S, Hara M, Kanegae Y, Saito I, Narisawa K. Reversal of hypopigmentation in phenylketonuria mice by adenovirus-mediated gene transfer. *Pediatr Res* 1999 Apr;45(4 Pt 1):465-73.
- Nagata S, Maru I, Ishihara F, Misono H, Nagasaki S. Cloning and expression of endo-beta-1,3-glucanase gene from *Flavobacterium dormitator* in *Escherichia coli* and characterization of the gene product. *Agric Biol Chem* 1990 Oct;54(10):2675-80.
- Nagatsu T, Ichinose H. Regulation of pteridine-requiring enzymes by the cofactor tetrahydrobiopterin. *Mol Neurobiol* 1999 Feb;19(1):79-96.
- Nagatsu T, Matsuura S, Sugimoto T. Physiological and clinical chemistry of biopterin. *Med Res Rev* 1989 Jan-Mar;9(1):25-44.
- Nair KS, Ford GC, Ekberg K, Fernqvist-Forbes E, Wahren J. Protein dynamics in whole body and in splanchnic and leg tissues in type I diabetic patients. *J Clin Invest* 1995 Jun;95(6):2926-37.
- Nair UJ, Nair J, Friesen MD, Bartsch H, Ohshima H. Ortho- and meta-tyrosine formation from phenylalanine in human saliva as a marker of hydroxyl radical generation during betel quid chewing. *Carcinogenesis* 1995 May;16(5):1195-8.
- Nakabayashi H, Owada M, Kitagawa T. A mild case of dihydropteridine reductase deficiency with residual

- activity in erythrocytes. *J Inher Metab Dis* 1984;7(3):135-6.
- Nakata H, Fujisawa H. Purification and characterization of phenylalanine 4-monooxygenase from rat liver. *Biochim Biophys Acta* 1980 Aug 7;614(2):313-27.
- Narisawa K, Arai N, Ishizawa S, Ogasawara Y, Onuma A, Iinuma K, Tada K. Dihydropteridine reductase deficiency: diagnosis by leukocyte enzyme assay. *Clin Chim Acta* 1980 Aug 19;105(3):335-42.
- Nath J, Powledge A, Wright DG. Studies of signal transduction in the respiratory burst-associated stimulation of fMet-Leu-Phe-induced tubulin tyrosination and Phorbol 12-Myristate 13-acetate-induced posttranslational incorporation of tyrosine into multiple proteins in activated neutrophils and HL-60 Cells. Washington: Walter Reed Army Institute of Research, Division of Medicine; 1989 Jan 15. 9 p. Available from: NTIS, Springfield, VA; AD-A212 530/0.
- Naughten ER. Continuation vs discontinuation of diet in phenylketonuria. *Eur J Clin Nutr* 1989;43 Suppl 1:7-12.
- Navab F, Winter CG. Effect of aging on intestinal absorption of aromatic amino acids in vitro in the rat. *Am J Physiol* 1988 Apr;254(4 Pt 1):G631-6.
- Naylor EW. Newborn screening for urea cycle disorders. *Adv Exp Med Biol* 1982;153:9-18.
- Neckameyer WS, White K. A single locus encodes both phenylalanine hydroxylase and tryptophan hydroxylase activities in *Drosophila*. *J Biol Chem* 1992 Feb 25;267(6):4199-206.
- Nemeroff CB, Mason GA, Hatley OL, Jahnke G, Prange AJ Jr. Lack of effect of a behaviorally active dose of cholecystokinin octapeptide upon aromatic amino acid levels in plasma and brain. *Brain Res* 1980 Feb 24;184(2):529-32.
- Nichol CA, Smith GK, Duch DS. Biosynthesis and metabolism of tetrahydrobiopterin and molybdopterin. *Annu Rev Biochem* 1985;54:729-64.
- Nicolini H, Cruz C, Camarena B, Fernanda Merino M, Bilbao G, Vela M, Velazquez A, Perez B, Desviat L, Ugarte M. Molecular analysis of the phenylalanine hydroxylase gene in Mexican phenylketonuric patients. *Arch Med Res* 1995 Spring;26(1):53-7.
- Niederwieser A, Blau N, Wang M, Joller P, Atares M, Cardesa-Garcia J. GTP cyclohydrolase I deficiency, a new enzyme defect causing hyperphenylalaninemia with neopterin, biopterin, dopamine, and serotonin deficiencies and muscular hypotonia. *Eur J Pediatr* 1984 Feb;141(4):208-14.
- Niederwieser A, Curtius HC. Tetrahydrobiopterin biosynthetic pathway and deficiency. *Enzyme* 1987;38(1-4):302-11.
- Niederwieser A, Curtius HC, Wang M, Leupold D. Atypical phenylketonuria with defective biopterin metabolism. Monotherapy with tetrahydrobiopterin or sepiapterin, screening and study of biosynthesis in man. *Eur J Pediatr* 1982 Mar;138(2):110-2.
- Niederwieser A, Leimbacher W, Curtius HC, Ponzone A, Rey F, Leupold D. Atypical phenylketonuria with dihydrobiopterin synthetase deficiency: absence of phosphate-eliminating enzyme activity demonstrated in liver. *Eur J Pediatr* 1985 May;144(1):13-6.
- Niederwieser A, Shintaku H, Hasler T, Curtius HC, Lehmann H, Guardamagna O, Schmidt H. Prenatal diagnosis of dihydrobiopterin synthetase deficiency, a variant form of phenylketonuria. *Eur J Pediatr* 1986 Aug;145(3):176-8.
- Niederwieser A, Shintaku H, Leimbacher W, Curtius HC, Hyaneck J, Zeman J, Endres W. Peripheral tetrahydrobiopterin deficiency with hyperphenylalaninaemia due to incomplete 6-pyruvoyl tetrahydropterin synthase deficiency or heterozygosity. *Eur J Pediatr* 1987 May;146(3):228-32.
- Nielsen JB, Lou HC, Guettler F. Effects of diet discontinuation and dietary tryptophan supplementation on neurotransmitter metabolism in phenylketonuria. *Brain Dysfunc* 1988 Jan-Feb;1(1):51-6.
- Nixon JC, Lee CL, Milstien S, Kaufman S, Bartholome K. Neopterin and biopterin levels in patients with atypical forms of phenylketonuria. *J Neurochem* 1980 Oct;35(4):898-904.
- Norum KR. Studies on inborn errors of metabolism in Norway. *Arteriosclerosis* 1989 Jan-Feb;9(1 Suppl):I164-8.
- Novello AC. Inherited metabolic diseases: collaborating for the health of all children. *Biochem Med Metab Biol* 1993 Jun;49(3):277-84.
- Nutrition classics, the *Journal of Clinical Investigation*, volume 34, 1955. Studies on phenylketonuria. I. Restricted phenylalanine intake in phenylketonuria. By Marvin D. Armstrong and Frank H. Tyler. *Nutr Rev* 1983 Jan;41(1):15-8.
- Nyhan WL. Understanding inherited metabolic disease. *Clin Symp* 1980;32(5):1-36.
- Nyhan WL, Sakati NA. Diagnostic recognition of genetic disease. Philadelphia: Lea & Febiger; 1987. Hyperphenylalaninemia and defective metabolism of tetrahydrobiopterin; p. 107-11.

- Okajima K, Inoue M, Morino Y. Studies on the mechanism for renal elimination of N-acetylphenylalanine: its pathophysiologic significance in phenylketonuria. *J Lab Clin Med* 1985 Jan;105(1):132-8.
- Okano Y, Chow IZ, Isshiki G, Inoue A, Oura T. Effects of phenylalanine loading on protein synthesis in the fetal heart and brain of rat: an experimental approach to maternal phenylketonuria. *J Inherit Metab Dis* 1986;9(1):15-24.
- Okano Y, Eisensmith RC, Guttler F, Lichter-Konecki U, Konecki DS, Trefz FK, Dasovich M, Wang T, Henriksen K, Lou H, et al. Molecular basis of phenotypic heterogeneity in phenylketonuria. *N Engl J Med* 1991 May 2;324(18):1232-8. Comment in: *N Engl J Med* 1991 May 2;324(18):1280-1.
- Okano Y, Isshiki G. Newborn mass screening and molecular genetics of phenylketonuria in east Asia. *Southeast Asian J Trop Med Public Health* 1995;26 Suppl 1:123-9.
- Okano Y, Wang T, Eisensmith RC, Guttler F, Woo SL. Recurrent mutation in the human phenylalanine hydroxylase gene. *Am J Hum Genet* 1990 May;46(5):919-24.
- Okano Y, Wang T, Eisensmith RC, Longhi R, Riva E, Giovannini M, Cerone R, Romano C, Woo SL. Phenylketonuria missense mutations in the Mediterranean. *Genomics* 1991 Jan;9(1):96-103.
- Olafsdottir S, Martinez A. The accessibility of iron at the active site of recombinant human phenylalanine hydroxylase to water as studied by ¹H NMR paramagnetic relaxation. Effect of L-Phe and comparison with the rat enzyme. *J Biol Chem* 1999 Mar 5;274(10):6280-4.
- Olek K, Wardenbach P, Byrd D. [Excretion of transamination products in hyperphenylalaninemia (author's transl)]. *Klin Wochenschr* 1980 Feb 1;58(3):135-40. (Ger).
- Onishi A, Liotta LJ, Benkovic SJ. Cloning and expression of *Chromobacterium violaceum* phenylalanine hydroxylase in *Escherichia coli* and comparison of amino acid sequence with mammalian aromatic amino acid hydroxylases. *J Biol Chem* 1991 Oct 5;266(28):18454-9.
- Oppliger T, Thony B, Kluge C, Matasovic A, Heizmann CW, Ponzzone A, Spada M, Blau N. Identification of mutations causing 6-pyruvoyl-tetrahydropterin synthase deficiency in four Italian families. *Hum Mutat* 1997;10(1):25-35.
- Paans AM, Pruijm J, Smit GP, Visser G, Willemsen AT, Ullrich K. Neurotransmitter positron emission tomographic-studies in adults with phenylketonuria, a pilot study. *Eur J Pediatr* 1996 Jul;155 Suppl 1:S78-81.
- Pacy PJ, Price GM, Halliday D, Quevedo MR, Millward DJ. Nitrogen homeostasis in man: the diurnal responses of protein synthesis and degradation and amino acid oxidation to diets with increasing protein intakes. *Clin Sci (Colch)* 1994 Jan;86(1):103-16.
- Papet I, Ostaszewski P, Glomot F, Obled C, Faure M, Bayle G, Nissen S, Arnal M, Grizard J. The effect of a high dose of 3-hydroxy-3-methylbutyrate on protein metabolism in growing lambs. *Br J Nutr* 1997 Jun;77(6):885-96.
- Pappas PW, Gamble HR. Membrane transport of aromatic amino acids by *Hymenolepis diminuta* (Cestoda). *Parasitology* 1980 Oct;81(2):395-403.
- Pardridge WM. Potential effects of the dipeptide sweetener aspartame on the brain. *Nutr Brain* 1986;7:199-241.
- Pardridge WM, Choi TB. Neutral amino acid transport at the human blood-brain barrier. *Fed Proc* 1986 Jun;45(7):2073-8.
- Park YS, Seoung CS, Lee SW, Oh KH, Lee DH, Yim J. Identification of three novel mutations in Korean phenylketonuria patients: R53H, N207D, and Y325X. *Hum Mutat* 1998;Suppl 1:S121-2.
- Parker CE, Shaw KN, Mitchell JB, Koch R, Wenz E, Fishler K. Clinical experience in dietary management of phenylketonuria with a new phenylalanine-free product. *J Pediatr* 1977 Dec;91(6):941-3.
- Parniak M, Hasegawa H, Wilgus H, Kaufman S. On the phosphate content of rat liver phenylalanine hydroxylase purified by hydrophobic chromatography. *Biochem Biophys Res Commun* 1981 Mar 31;99(2):707-14.
- Parniak MA, Davis M, Kaufman S, Kempner ES. Radiation target analysis indicates that phenylalanine hydroxylase in rat liver extracts is a functional monomer. *FEBS Lett* 1999 Apr 16;449(1):49-52.
- Parniak MA, Davis MD, Kaufman S. Effect of alkaline pH on the activity of rat liver phenylalanine hydroxylase. *J Biol Chem* 1988 Jan 25;263(3):1223-30.
- Parniak MA, Jennings IG, Cotton RG. Interaction with a monoclonal antibody alters the expression of cooperativity by phenylalanine hydroxylase from rat liver. *Biochem J* 1989 Jan 15;257(2):383-8.
- Parniak MA, Kaufman S. Rat liver phenylalanine hydroxylase. Activation by sulfhydryl modification. *J Biol Chem* 1981 Jul 10;256(13):6876-82.
- Paans AM, Pruijm J, Smit GP, Visser G, Willemsen AT, Ullrich K. Neurotransmitter positron emission tomographic-studies in adults with phenylketonuria, a

- Parniak MA, Pilkington J. Glucocorticoid stimulation of tetrahydrobiopterin levels and phenylalanine hydroxylase activity in rat hepatoma cells. *Biochem Cell Biol* 1989 Jun;67(6):293-6.
- Pasquo A, Britton KL, Baker PJ, Brearley G, Hinton RJ, Moir AJ, Stillman TJ, Rice DW. Crystallization of NAD⁺-dependent phenylalanine dehydrogenase from *Nocardia* sp239. *Acta Crystallogr D Biol Crystallogr* 1998 Mar 1;54 (Pt 2):269-72.
- Pastor CM, Williams D, Yoneyama T, Hatakeyama K, Singleton S, Naylor E, Billiar TR. Competition for tetrahydrobiopterin between phenylalanine hydroxylase and nitric oxide synthase in rat liver. *J Biol Chem* 1996 Oct 4;271(40):24534-8.
- Pechenova TN, Sushkova VV, Popova NN, Solodova EV, Gulyi MF. [Changes in the biosynthesis of acid-soluble collagen in the skin of rats with amino acid imbalances in their diets]. *Ukr Biokhim Zh* 1984 Jan-Feb;56(1):10-4. (Rus).
- Peluffo RO, Nervi AM, Gonzalez MS, Brenner RR. Effect of different amino acid diets on delta 5, delta 6 and delta 9 desaturases. *Lipids* 1984 Feb;19(2):154-7.
- Pember SO, Benkovic SJ, Villafranca JJ, Pasenkiewicz-Gierula M, Antholine WE. Adduct formation between the cupric site of phenylalanine hydroxylase from *Chromobacterium violaceum* and 6,7-dimethyltetrahydropterin. *Biochemistry* 1987 Jul 14;26(14):4477-83.
- Pember SO, Johnson KA, Villafranca JJ, Benkovic SJ. Mechanistic studies on phenylalanine hydroxylase from *Chromobacterium violaceum*. Evidence for the formation of an enzyme-oxygen complex. *Biochemistry* 1989 Mar 7;28(5):2124-30.
- Pember SO, Villafranca JJ, Benkovic SJ. *Chromobacterium violaceum* phenylalanine 4-monoxygenase. *Methods Enzymol* 1987;142:50-6.
- Pember SO, Villafranca JJ, Benkovic SJ. Phenylalanine hydroxylase from *Chromobacterium violaceum* is a copper-containing monoxygenase. Kinetics of the reductive activation of the enzyme. *Biochemistry* 1986 Oct 21;25(21):6611-9.
- Peng H, Armentano D, MacKenzie-Graham L, Shen RF, Darlington G, Ledley FD, Woo SL. Retroviral-mediated gene transfer and expression of human phenylalanine hydroxylase in primary mouse hepatocytes. *Proc Natl Acad Sci U S A* 1988 Nov;85(21):8146-50.
- Penrose LS. Phenylketonuria--a problem in eugenics. *Ann Hum Genet* 1998 May;62 (Pt 3):193-202.
- Perez B, Desviat LR, Die M, Cornejo V, Chamoles NA, Nicolini H, Ugarte M. Presence of the Mediterranean PKU mutation IVS10 in Latin America. *Hum Mol Genet* 1993 Aug;2(8):1289-90.
- Perez B, Desviat LR, Ugarte M. Analysis of the phenylalanine hydroxylase gene in the Spanish population: mutation profile and association with intragenic polymorphic markers. *Am J Hum Genet* 1997 Jan;60(1):95-102.
- Perez B, Desviat LR, Ugarte M. Expression analysis of mutation P244L, which causes mild hyperphenylalaninemia. *Hum Mutat* 1995;5(2):188-90.
- Pergolizzi RG. The Y base of eukaryotic phenylalanine-transfer ribonucleic biosynthesis and relation to growth of normal and neoplastic cell lines [dissertation]. New York: Columbia University; 1980. 192 p.
- Peterson NA, Shah SN, Raghupathy E, Rhoads DE. Presynaptic tyrosine availability in the phenylketonuric brain: a hypothetical evaluation. *Brain Res* 1983 Aug 1;272(1):189-93.
- Petruschka L, Rebrin I, Grimm U, Herrmann FH. The immunological evidence for a phenylalanine hydroxylase like immunoreactive protein in different human cells and tissues. *Clin Chim Acta* 1990 Dec 13;193(1-2):65-77.
- Phenylketonuria: from biochemistry to treatment. Proceedings of a round table. Troina, Italy, May 12-14, 1997. Abstracts. *J Inherit Metab Dis* 1998 Aug;21 Suppl 3:1-52.
- Phillips RS, Iwaki M, Kaufman S. Ligand effects on the limited proteolysis of phenylalanine hydroxylase: evidence for multiple conformational states. *Biochem Biophys Res Commun* 1983 Feb 10;110(3):919-25.
- Phillips RS, Kaufman S. Ligand effects on the phosphorylation state of hepatic phenylalanine hydroxylase. *J Biol Chem* 1984 Feb 25;259(4):2474-9.
- Phillips RS, Kaufman S. On the nature of the spontaneous activation of hepatic phenylalanine hydroxylase. *Trans N Y Acad Sci* 1983;41:87-95.
- Phillips RS, Parniak MA, Kaufman S. The interaction of aromatic amino acids with rat liver phenylalanine hydroxylase. *J Biol Chem* 1984 Jan 10;259(1):271-7.
- Phillips RS, Parniak MA, Kaufman S. Spectroscopic investigation of ligand interaction with hepatic phenylalanine hydroxylase: evidence for a conformational change associated with activation. *Biochemistry* 1984 Aug 14;23(17):3836-42.
- Piccardo MG, Rosa M, Russo L. The effects of a load of phenilalanine on glucose metabolism. *Boll Soc Ital Biol Sper* 1983 Jan 31;59(2):167-70.

- Piedrafita AC, Martinez-Ramirez AC, Silva FJ. A genetic analysis of aromatic amino acid hydroxylases involvement in DOPA synthesis during *Drosophila* adult development. *Insect Biochem Mol Biol* 1994 Jun;24(6):581-8. Published erratum appears in *Insect Biochem Mol Biol* 1995 Jan;25(1):151.
- Piel N, Lane JD, Huther G, Neuhoﬀ V. Impaired permeability of the blood-cerebrospinal fluid barrier in hyperphenylalaninaemia. *Neuropediatrics* 1982 May;13(2):88-92.
- Pierzchala K, Rosciszewska D, Kwiecinski J. [Adult age phenylketonuria with extrapyramidal syndrome: therapeutic management]. *Neurol Neurochir Pol* 1993 Nov-Dec;27(6):899-904. (Pol).
- Pietz J, Benninger C, Schmidt H, Scheffner D, Bickel H. Long-term development of intelligence (IQ) and EEG in 34 children with phenylketonuria treated early. *Eur J Pediatr* 1988 May;147(4):361-7.
- Pietz J, Kreis R, Boesch C, Penzien J, Rating D, Herschkowitz N. The dynamics of brain concentrations of phenylalanine and its clinical significance in patients with phenylketonuria determined by in vivo ¹H magnetic resonance spectroscopy. *Pediatr Res* 1995 Nov;38(5):657-63.
- Pietz J, Kreis R, Rupp A, Mayatepek E, Rating D, Boesch C, Bremer HJ. Large neutral amino acids block phenylalanine transport into brain tissue in patients with phenylketonuria. *J Clin Invest* 1999 Apr;103(8):1169-78.
- Pietz J, Kreis R, Schmidt H, Meyding-Lamade UK, Rupp A, Boesch C. Phenylketonuria: findings at MR imaging and localized in vivo H-1 MR spectroscopy of the brain in patients with early treatment. *Radiology* 1996 Nov;201(2):413-20.
- Pietz J, Meyding-Lamade UK, Schmidt H. Magnetic resonance imaging of the brain in adolescents with phenylketonuria and in one case of 6-pyruvoyl tetrahydropteridine synthase deficiency. *Eur J Pediatr* 1996 Jul;155 Suppl 1:S69-73.
- Pike DC, Hora MT, Bailey SW, Ayling JE. Pyrimidodiazepine, a ring-strained cofactor for phenylalanine hydroxylase. *Biochemistry* 1986 Aug 26;25(17):4762-71.
- Pinarbasi E, Kan MS, Duran C, Ford GC, Hornby DP. Substitution of the conserved phenylalanine in the S-adenosyl-L-methionine binding site of M.Mspl with tyrosine modifies the kinetic properties of the enzyme. *Biol Chem* 1998 Apr-May;379(4-5):591-4.
- Pitt D. The natural history of untreated phenylketonuria. *Med J Aust* 1971 Feb 13;1(7):378-83.
- Pittard J. The various strategies within the TyrR regulation of *Escherichia coli* to modulate gene expression. *Genes Cells* 1996 Aug;1(8):717-25.
- Poge AP, Baumann K, Muller E, Leichsenring M, Schmidt H, Bremer HJ. Long-chain polyunsaturated fatty acids in plasma and erythrocyte membrane lipids of children with phenylketonuria after controlled linoleic acid intake. *J Inher Metab Dis* 1998 Jun;21(4):373-81.
- Pogson CI, Dickson AJ, Knowles RG, Salter M, Santana MA, Stanley JC, Fisher MJ. Control of phenylalanine and tyrosine metabolism by phosphorylation mechanisms. *Adv Enzyme Regul* 1986;25:309-27.
- Pogson CI, Knowles RG, Salter M. The control of aromatic amino acid catabolism and its relationship to neurotransmitter amine synthesis. *Crit Rev Neurobiol* 1989;5(1):29-64.
- Pogson CI, Salter M, Knowles RG. Regulation of hepatic aromatic amino acid metabolism. *Biochem Soc Trans* 1986 Dec;14(6):999-1001.
- Pogson CI, Santana MA, Fisher MJ. Phenylalanine hydroxylase: metabolic aspects. *Biochem Soc Trans* 1985 Apr;13(2):439-41.
- Pogson D. Issues for consideration in dihydropteridine reductase (DHPR) deficiency: a variant form of hyperphenylalaninaemia. *J Intellect Disabil Res* 1997 Jun;41 (Pt 3):208-14.
- Poindexter BB, Karn CA, Ahlrichs JA, Wang J, Leitch CA, Liechty EA, Denne SC. Amino acids suppress proteolysis independent of insulin throughout the neonatal period. *Am J Physiol* 1997 Apr;272(4 Pt 1):E592-9.
- Pollegioni L, Fukui K, Massey V. Studies on the kinetic mechanism of pig kidney D-amino acid oxidase by site-directed mutagenesis of tyrosine 224 and tyrosine 228. *J Biol Chem* 1994 Dec 16;269(50):31666-73.
- Pometto AL 3d, Crawford DL. L-Phenylalanine and L-tyrosine catabolism by selected *Streptomyces* species. *Appl Environ Microbiol* 1985 Mar;49(3):727-9.
- Pomi L, Peano L, Colla D. [Use of screening for amino acid disorders in the study of the nutrition of the newborn infant: various milk formulas and changes in plasma amino acids]. *Pediatr Med Chir* 1984 Mar-Apr;6(2):261-8. (Ita).
- Pontoglio M, Faust DM, Doyen A, Yaniv M, Weiss MC. Hepatocyte nuclear factor 1alpha gene inactivation impairs chromatin remodeling and

- demethylation of the phenylalanine hydroxylase gene. *Mol Cell Biol* 1997 Sep;17(9):4948-56.
- Ponzzone A, Blau N, Guardamagna O, Ferrero GB, Dianzani I, Endres W. Progression of 6-pyruvoyl-tetrahydropterin synthase deficiency from a peripheral into a central phenotype. *J Inher Metab Dis* 1990;13(3):298-300.
- Ponzzone A, Guardamagna O, Dianzani I, Ponzzone R, Ferrero GB, Spada M, Cotton RG. Catalytic activity of tetrahydrobiopterin in dihydropteridine reductase deficiency and indications for treatment. *Pediatr Res* 1993 Feb;33(2):125-8.
- Ponzzone A, Guardamagna O, Ferraris S, Biasetti S, Bracco G, Niederwieser A. Neurotransmitter therapy and diet in malignant phenylketonuria [letter]. *Eur J Pediatr* 1987 Jan;146(1):93-4.
- Ponzzone A, Guardamagna O, Ferraris S, Bracco G, Niederwieser A, Cotton RG. Two mutations of dihydropteridine reductase deficiency. *Arch Dis Child* 1988 Feb;63(2):154-7.
- Ponzzone A, Guardamagna O, Ferraris S, Ferrero GB, Dianzani I, Cotton RG. Tetrahydrobiopterin loading test in hyperphenylalaninemia. *Pediatr Res* 1991 Nov;30(5):435-8.
- Ponzzone A, Guardamagna O, Spada M, Ponzzone R, Sartore M, Kierat L, Heizmann CW, Blau N. Hyperphenylalaninemia and pterin metabolism in serum and erythrocytes. *Clin Chim Acta* 1993 Jul 16;216(1-2):63-71.
- Popescu A, Butnariu J, Toma C, Scurtu C, Milcu M, Bojan O, Muschievici D. [Preliminary data on the detection of phenylketonuria in the Cluj district]. *Rev Pediatr Obstet Ginecol Pediatr* 1980 Apr-Jun;29(2):139-45. (Rum).
- Popescu V, Dragomir D, Osanu D, Arion C, Leu E, Esanu M, Mogos I. [Alkaptonuria. Considerations on 3 clinical cases]. *Rev Pediatr Obstet Ginecol Pediatr* 1983 Jul-Sep;32(3):247-60. (Rum).
- Potempska A, Loo YH, Wisniewski HM. On the possible mechanism of phenylacetate neurotoxicity: inhibition of choline acetyltransferase by phenylacetyl-CoA. *J Neurochem* 1984 May;42(5):1499-501.
- Powell TL, Davis AJ, Yuan JH, Austic RE. Developmental pattern of phenylalanine hydroxylase activity in the chicken. *Poult Sci* 1999 Jun;78(6):855-60.
- Prankel BH, Clemens PC, Burmester GJ. Competitive inhibition between large neutral amino acids at cell membrane of phenylketonuria patients [letter]. *Nutrition* 1994 Jan-Feb;10(1):90. Comment on: *Nutrition* 1993 Jan-Feb;9(1):37-42.
- Prankel BH, Clemens PC, Burmester JG. Urinary excretion of nucleosides varies with age and protein metabolism [letter]. *Clin Chim Acta* 1995 Jan 31;234(1-2):181-3. Comment on: *Clin Chim Acta* 1993 Aug 31;217(2):221-3.
- Presch I, Birnbacher R, Herkner K, Lubec G. The effect of estradiol and ovariectomy on tyrosine hydroxylase, tyrosine aminotransferase and phenylalanine hydroxylase. *Life Sci* 1997;60(7):479-84.
- Price CC. Changes in phenylalanine and tyrosine metabolism during brucei gambiense infection in *Microtus montanus* [dissertation]. Chapel Hill (NC): The University of North Carolina at Chapel Hill; 1986. 129 p.
- Price GM, Halliday D, Pacy PJ, Quevedo MR, Millward DJ. Nitrogen homeostasis in man: influence of protein intake on the amplitude of diurnal cycling of body nitrogen. *Clin Sci (Colch)* 1994 Jan;86(1):91-102.
- Prince AP, Leklem JE. Vitamin B-6 status of school-aged patients with phenylketonuria. *Am J Clin Nutr* 1994 Aug;60(2):262-8.
- Prince AP, McMurray MP, Buist NR. Treatment products and approaches for phenylketonuria: improved palatability and flexibility demonstrate safety, efficacy and acceptance in US clinical trials. *J Inher Metab Dis* 1997 Aug;20(4):486-98.
- Pueschel SM, Boylan J, Ellenbogen R. Studies on experimentally induced hyperphenylalaninemia. *J Ment Defic Res* 1988 Aug;32 (Pt 4):309-19.
- Puglisi-Allegra S, Cabib S, Pascucci T, Ventura R, Cali F, Romano V. Dramatic brain aminergic deficit in a genetic mouse model of phenylketonuria. *Neuroreport* 2000 Apr 27;11(6):1361-4.
- Putilina FE, Osadchaia LM. [Effect of chronic hyperphenylalaninemia and hypoxia on the effectiveness of the alpha-ketoglutarate shunt in the brain]. *Biokhimiia* 1985 Aug;50(8):1295-9. (Rus).
- Putilina FE, Osadchaia LM. [Use of different precursors of fatty acid biosynthesis in the brain in chronic hyperphenylalaninemia]. *Vopr Med Khim* 1984 Mar-Apr;30(2):100-3. (Rus).
- Ramano M, Diomede L, Guiso G, Caccia S, Perego C, Salmona M. Plasma and brain kinetics of large neutral amino acids and of striatum monoamines in rats given aspartame. *Food Chem Toxicol* 1990;28(5):317-21.

- Ramus SJ, Cotton RG. Polymorphism in the 3' untranslated region of the phenylalanine hydroxylase gene detected by enzyme mismatch cleavage: evolution of haplotypes. *Hum Genet* 1995 Dec;96(6):741-3.
- Ramus SJ, Forrest SM, Cotton RG. Illegitimate transcription of phenylalanine hydroxylase for detection of mutations in patients with phenylketonuria. *Hum Mutat* 1992;1(2):154-8.
- Ramus SJ, Forrest SM, Saleeba JA, Cotton RG. CpG hotspot causes second mutation in codon 408 of the phenylalanine hydroxylase gene. *Hum Genet* 1992 Sep-Oct;90(1-2):147-8.
- Ramus SJ, Treacy EP, Cotton RG. Characterization of phenylalanine hydroxylase alleles in untreated phenylketonuria patients from Victoria, Australia: origin of alleles and haplotypes. *Am J Hum Genet* 1995 May;56(5):1034-41.
- Randles D, Armarego WL. Reduced 6,6,8-trimethylpterins. Preparation, properties and enzymic reactivities with dihydropteridine reductase, phenylalanine hydroxylase and tyrosine hydroxylase. *Eur J Biochem* 1985 Jan 15;146(2):467-74.
- Rao DN, Kaufman S. Purification and state of activation of rat kidney phenylalanine hydroxylase. *J Biol Chem* 1986 Jul 5;261(19):8866-76.
- Ratzmann GW, Grimm U, Jahrig K. Increased concentrations of tyrosine and phenylalanine in the cerebrospinal fluid as a possible reflection of related changes of the brain tissue in newborns with intra-uterine growth retardation. *Biomed Biochim Acta* 1988;47(12):1037-41.
- Ratzmann GW, Grimm U, Jahrig K, Knapp A. On the brain barrier system function and changes of cerebrospinal fluid concentrations of phenylalanine and tyrosine in human phenylketonuria. *Biomed Biochim Acta* 1984;43(2):197-204.
- Ratzmann GW, Grimm U, Jahrig K, Knapp A. [Plasma-cerebrospinal fluid distribution of phenylalanine and tyrosine in children]. *Padiatr Grenzgeb* 1988;27(3):211-20. (Ger).
- Raw I, Schmidt BJ, Merzel J. Catecholamines and congenital pain insensitivity. *Braz J Med Biol Res* 1984;17(3-4):271-9.
- Realmuto GM, Garfinkel BD, Tuchman M, Tsai MY, Chang PN, Fisch RO, Shapiro S. Psychiatric diagnosis and behavioral characteristics of phenylketonuric children. *J Nerv Ment Dis* 1986 Sep;174(9):536-40.
- Rebrin I, Bailey SW, Ayling JE. Activity of the bifunctional protein 4a-hydroxy-tetrahydropterin dehydratase/DCoH during human fetal development: correlation with dihydropteridine reductase activity and tetrahydrobiopterin levels. *Biochem Biophys Res Commun* 1995 Dec 26;217(3):958-65.
- Rebrin I, Bailey SW, Boerth SR, Ardell MD, Ayling JE. Catalytic characterization of 4a-hydroxytetrahydropterin dehydratase. *Biochemistry* 1995 May 2;34(17):5801-10.
- Reddy S, Halliwell B, Jones AD, Longhurst JC. The use of phenylalanine to detect hydroxyl radical production in vivo: a cautionary note [letter]. *Free Radic Biol Med* 1999 Dec;27(11-12):1465.
- Rege AA. Purification and characterization of a tyrosine aminotransferase from *Crithidia fasciculata*. *Mol Biochem Parasitol* 1987 Aug;25(1):1-9.
- Regulation of aromatic amino acid catabolism. *Nutr Rev* 1986 Nov;44(11):377-9.
- Reilly C, Barrett JE, Patterson CM, Tinggi U, Latham SL, Marrinan A. Trace element nutrition status and dietary intake of children with phenylketonuria. *Am J Clin Nutr* 1990 Jul;52(1):159-65.
- Reinecke CJ, Mienie LJ, Hitzeroth HW, Op't Hof J. Screening for inborn errors of metabolism among mentally retarded patients. Outcome of a surgery at the Witrand Care and Rehabilitation Centre. *S Afr Med J* 1983 Jan 1;63(1):14-6.
- Rey F, Berthelon M, Caillaud C, Lyonnet S, Abadie V, Blandin-Savoja F, Feingold J, Saudubray JM, Frezal J, Munnich A, et al. Clinical and molecular heterogeneity of phenylalanine hydroxylase deficiencies in France. *Am J Hum Genet* 1988 Dec;43(6):914-21.
- Rey F, Munnich A, Lyonnet S, Rey J. [Classification and heterogeneity of hyperphenylalaninemia linked to a phenylalanine hydroxylase deficiency]. *Arch Fr Padiatr* 1987;44 Suppl 1:639-42. (Fre).
- Rey F, Saudubray JM, Leeming RJ, Niederwieser A, Curtius HC, Rey J. [Partial deficiency of tetrahydrobiopterin]. *Arch Fr Padiatr* 1983;40 Suppl 1:237-41. (Fre).
- Reynolds R, Burri R, Herschkowitz N. Retarded development of neurons and oligodendroglia in rat forebrain produced by hyperphenylalaninemia results in permanent deficits in myelin despite long recovery periods. *Exp Neurol* 1993 Dec;124(2):357-67.
- Ribeiro P, Pigeon D, Kaufman S. The hydroxylation of phenylalanine and tyrosine by tyrosine hydroxylase from cultured pheochromocytoma cells. *J Biol Chem* 1991 Aug 25;266(24):16207-11.
- Richardson SC, Aspbury RA, Fisher MJ. The role of reversible phosphorylation in the hormonal control of

- phenylalanine hydroxylase in isolated rat proximal kidney tubules. *Biochem J* 1993 Jun 1;292 (Pt 2):419-24.
- Richardson SC, Fisher MJ. Characterization of phenylalanine hydroxylase from rat kidney. *Int J Biochem* 1993 Apr;25(4):581-8.
- Richardson SC, Green AK, Fisher MJ. Phosphorylation-dephosphorylation of renal phenylalanine hydroxylase. *Biochem Soc Trans* 1991 Apr;19(2):229S.
- Rivera I, Cabral A, Almeida M, Leandro P, Carmona C, Eusebio F, Tasso T, Vilarinho L, Martins E, Lechner MC, de Almeida IT, Konecki DS, Lichter-Konecki U. The correlation of genotype and phenotype in Portuguese hyperphenylalaninemic patients. *Mol Genet Metab* 2000 Mar;69(3):195-203.
- Rivera I, Leandro P, Lichter-Konecki U, Tavares de Almeida I, Lechner MC. Population genetics of hyperphenylalaninaemia resulting from phenylalanine hydroxylase deficiency in Portugal. *J Med Genet* 1998 Apr;35(4):301-4.
- Roberts S, Morelos BS. Cerebral ribosomal protein phosphorylation in experimental hyperphenylalaninaemia. *Biochem J* 1980 Aug 15;190(2):405-19.
- Roberts S, Morelos BS. Inhibition of cerebral protein kinase activity and cyclic AMP-dependent ribosomal-protein phosphorylation in experimental hyperphenylalaninaemia. *Biochem J* 1982 Feb 15;202(2):343-51.
- Roberts SA. Aromatic amino acid metabolism in the human: estimation of tyrosine requirement in the neonate and adult [dissertation]. Toronto (Canada): University of Toronto; 1999. 223 p.
- Roberts SA, Ball RO, Filler RM, Moore AM, Pencharz PB. Phenylalanine and tyrosine metabolism in neonates receiving parenteral nutrition differing in pattern of amino acids. *Pediatr Res* 1998 Dec;44(6):907-14.
- Robinson EH, Wilson RP, Poe WE. Total aromatic amino acid requirement, phenylalanine requirement and tyrosine replacement value for fingerling channel catfish. *J Nutr* 1980 Sep;110(9):1805-12.
- Robson KJ, Beattie W, James RJ, Cotton RC, Morgan FJ, Woo SL. Sequence comparison of rat liver phenylalanine hydroxylase and its cDNA clones. *Biochemistry* 1984 Nov 20;23(24):5671-5.
- Rodriguez B, Torres N, Rincon AR, Bourges H, Panduro A, Tovar AR. Hepatic phenylalanine-hydroxylase and tyrosine-aminotransferase mRNA levels in rats adapted to diets with different concentrations of protein. *Rev Invest Clin* 1996 Nov-Dec;48(6):413-9.
- Romano V, Cali F, Guldborg P, Guttler F, Indelicato A, Bosco P, Ceratto N. Association between haplotypes, hind III-VNTR alleles and mutations at the PAH locus in Sicily. *Acta Paediatr Suppl* 1994 Dec;407:39-40.
- Romano V, Ceratto N, Chiavetta V, Bosco P. Identification of two new phenylalanine hydroxylase alleles in Sicilian phenylketonuric families. *J Inherit Metab Dis* 1993;16(3):599-601.
- Romano V, Guldborg P, Guttler F, Meli C, Mollica F, Pavone L, Giovannini M, Riva E, Biasucci G, Luotti D, Palillo L, Cali F, Ceratto N, Anello G, Bosco P. PAH deficiency in Italy: correlation of genotype with phenotype in the Sicilian population. *J Inherit Metab Dis* 1996;19(1):15-24.
- Romstad A, Guldborg P, Blau N, Guttler F. Single-step mutation scanning of the 6-pyruvoyltetrahydropterin synthase gene in patients with hyperphenylalaninemia. *Clin Chem* 1999 Dec;45(12):2102-8.
- Roth KS. Newborn metabolic screening: a search for nature's experiments. *South Med J* 1986 Jan;79(1):47-54.
- Rozenfel'd EL. [Models of enzymopathies and their role in elaborating methods of enzyme therapy (review)]. *Vopr Med Khim* 1981 Jan-Feb;27(1):7-18. (Rus).
- Ruch T, Kerr D. Decreased essential amino acid requirements without catabolism in phenylketonuria and maple syrup urine disease. *Am J Clin Nutr* 1982 Feb;35(2):217-28.
- Rudman D, Abbasi AA, Chaudry F, Mattson DE. Delayed plasma clearance of phenylalanine and tyrosine in elderly men. *J Am Geriatr Soc* 1991 Jan;39(1):33-8.
- Ruiz-Vazquez P, Moulard M, Silva FJ. Structure of the phenylalanine hydroxylase gene in *Drosophila melanogaster* and evidence of alternative promoter usage. *Biochem Biophys Res Commun* 1996 Aug 5;225(1):238-42.
- Ruiz-Vazquez P, Silva FJ. Aberrant splicing of the *Drosophila melanogaster* phenylalanine hydroxylase pre-mRNA caused by the insertion of a B104/roo transposable element in the Henna locus. *Insect Biochem Mol Biol* 1999 Apr;29(4):311-8.
- Rusche KM. Studies of the nitric oxide synthase catalytic and structural requirement for 6(R)-tetrahydro-l-biopterin [dissertation]. Ann Arbor (MI): The University of Michigan; 1998. 116 p.

- Sadler MJ. Recent aspartame studies. *Food Chem Toxicol* 1984 Sep;22(9):771-3.
- Sadler TW, Denno KM, Hunter ES 3d. Effects of altered maternal metabolism during gastrulation and neurulation stages of embryogenesis. *Ann N Y Acad Sci* 1993 Mar 15;678:48-61.
- Saez LP, Castillo F, Caballero FJ. Metabolism of L-phenylalanine and L-tyrosine by the phototrophic bacterium *Rhodobacter capsulatus*. *Curr Microbiol* 1999 Jan;38(1):51-6.
- Safos S, Chang TM. Enzyme replacement therapy in ENU2 phenylketonuric mice using oral microencapsulated phenylalanine ammonia-lyase: a preliminary report. *Artif Cells Blood Substit Immobil Biotechnol* 1995;23(6):681-92.
- Safronova EE, Annenkov GA. [Modification of Ayling's method for determining phenylalanine hydroxylase activity]. *Lab Delo* 1982;(5):296-9. (Rus).
- Safronova EE, Rybakova NA, Annenkov GA. [Use of modified Ayling's method for detection of homozygotes and heterozygotes for phenylketonuria gene]. *Vopr Med Khim* 1982 May-Jun;28(3):70-3. (Rus).
- Salter M, Knowles RG, Pogson CI. Quantification of the importance of individual steps in the control of aromatic amino acid metabolism. *Biochem J* 1986 Mar 15;234(3):635-47.
- Salter M, Stanley JC, Fisher MJ, Pogson CI. The influence of starvation and tryptophan administration on the metabolism of phenylalanine, tyrosine and tryptophan in isolated rat liver cells. *Biochem J* 1984 Jul 15;221(2):431-8.
- Samid D, Ram Z, Hudgins WR, Shack S, Liu L, Walbridge S, Oldfield EH, Myers CE. Selective activity of phenylacetate against malignant gliomas: resemblance to fetal brain damage in phenylketonuria. *Cancer Res* 1994 Feb 15;54(4):891-5.
- Samuels SE, Baracos VE. Tissue protein turnover is altered during catch-up growth following *Escherichia coli* infection in weanling rats. *J Nutr* 1995 Mar;125(3):520-30.
- Sanchez M, El-Khoury AE, Castillo L, Chapman TE, Filho AB, Beaumier L, Young VR. Twenty-four-hour intravenous and oral tracer studies with L-[1-¹³C]phenylalanine and L-[3,3-²H₂]tyrosine at a tyrosine-free, generous phenylalanine intake in adults. *Am J Clin Nutr* 1996 Apr;63(4):532-45.
- Sanchez M, el-Khoury AE, Castillo L, Chapman TE, Young VR. Phenylalanine and tyrosine kinetics in young men throughout a continuous 24-h period, at a low phenylalanine intake. *Am J Clin Nutr* 1995 Mar;61(3):555-70.
- Sanford YM, Orias E. Phenylketonuric Tetrahymena: phenylalanine hydroxylase mutants and other tyrosine auxotrophs. *Proc Natl Acad Sci U S A* 1981 Dec;78(12):7614-8.
- Santana MA, Fisher MJ, Bate AJ, Pogson CI. The effect of experimental diabetes on phenylalanine metabolism in isolated liver cells. *Biochem J* 1985 Apr 1;227(1):169-75.
- Sarkissian CN, Boulais DM, McDonald JD, Scriver CR. A heteroallelic mutant mouse model: A new orthologue for human hyperphenylalaninemia. *Mol Genet Metab* 2000 Mar;69(3):188-94.
- Sarkissian CN, Scriver CR, Mamer OA. Measurement of phenyllactate, phenylacetate, and phenylpyruvate by negative ion chemical ionization-gas chromatography/mass spectrometry in brain of mouse genetic models of phenylketonuria and non-phenylketonuria hyperphenylalaninemia. *Anal Biochem* 2000 May 1;280(2):242-9.
- Sarkissian CN, Shao Z, Blain F, Peevers R, Su H, Heft R, Chang TM, Scriver CR. A different approach to treatment of phenylketonuria: phenylalanine degradation with recombinant phenylalanine ammonia lyase. *Proc Natl Acad Sci U S A* 1999 Mar 2;96(5):2339-44. Comment in: *Proc Natl Acad Sci U S A* 1999 Mar 2;96(5):1811-3.
- Sato T, Imura E, Murata A, Minami S, Okabe T, Ohno I. Effects of maternal phenylalanine or tyrosine hydroxylase inhibition on postnatal maturation of catecholamine and amino acid metabolism in rats. *Acta Paediatr Jpn* 1988 Feb;30(1):56-62.
- Schallreuter KU. A review of recent advances on the regulation of pigmentation in the human epidermis. *Cell Mol Biol (Noisy-le-grand)* 1999 Nov;45(7):943-9.
- Schallreuter KU, Schulz-Douglas V, Bunz A, Beazley W, Korner C. Pteridines in the control of pigmentation. *J Invest Dermatol* 1997 Jul;109(1):31-5.
- Schallreuter KU, Wood JM. The importance of L-phenylalanine transport and its autocrine turnover to L-tyrosine for melanogenesis in human epidermal melanocytes. *Biochem Biophys Res Commun* 1999 Aug 27;262(2):423-8.
- Schallreuter KU, Wood JM, Pittelkow MR, Gutlich M, Lemke KR, Rodl W, Swanson NN, Hitzemann K, Ziegler I. Regulation of melanin biosynthesis in the human epidermis by tetrahydrobiopterin. *Science* 1994 Mar 11;263(5152):1444-6.

- Schallreuter KU, Wood JM, Ziegler I, Lemke KR, Pittelkow MR, Lindsey NJ, Gutlich M. Defective tetrahydrobiopterin and catecholamine biosynthesis in the depigmentation disorder vitiligo. *Biochim Biophys Acta* 1994 May 25;1226(2):181-92.
- Schallreuter KU, Zschesche M, Moore J, Panske A, Hibberts NA, Herrmann FH, Metelmann HR, Sawatzki J. In vivo evidence for compromised phenylalanine metabolism in vitiligo. *Biochem Biophys Res Commun* 1998 Feb 13;243(2):395-9.
- Schmid G, Bahner U, Peschkes J, Heidland A. Neurotransmitter and monoaminergic amino acid precursor levels in rat brain: effects of chronic renal failure and of malnutrition. *Miner Electrolyte Metab* 1996;22(1-3):115-8.
- Schmidt H, Lutz P, Batzler U. [Differential diagnosis of increased phenylalanine blood level in infancy. Results of the German collaborative study on phenylketonuria (PKU)/hyperphenylalaninemia (HPA)]. *Monatsschr Kinderheilkd* 1989 Feb;137(2):86-92. (Ger).
- Schott K, Gehrman J, Neuhoff V. Induction of hyperphenylalaninemia in mice by ethionine and phenylalanine. *Biochem Med Metab Biol* 1986 Aug;36(1):106-13.
- Schroter J, Schott KJ, Purtil MA, Neuhoff V. Lysosomal protein degradation in experimental hyperphenylalaninaemia. *J Inherit Metab Dis* 1986;9(3):273-82.
- Schulman JD, Kaufman S, Schneider JA, Scriver CR. Workshop on amino acid metabolism. *Prog Clin Biol Res* 1982;103 Pt B:473-7.
- Schulpis KH, Nounopoulos C, Scarpalezou A, Bouloukos A, Missiou-Tsagarakis S. Serum carnitine level in phenylketonuric children under dietary control in Greece. *Acta Paediatr Scand* 1990 Oct;79(10):930-4.
- Schulpis KH, Papakonstantinou E, Kalogirou S. Biotinidase activity in patients with phenylketonuria. *J Inherit Metab Dis* 1995;18(6):750-1.
- Schulpis KH, Platokouki H, Papakonstantinou ED, Adamtziki E, Bargeliotis A, Aronis S. Haemostatic variables in phenylketonuric children under dietary treatment. *J Inherit Metab Dis* 1996;19(5):603-9.
- Schultz K, Mestyan J, Soltesz G, Klujber L, Dober I. Metabolic effects of septicaemia in newborn and young infants with particular reference to the plasma free amino acids. *Acta Paediatr Acad Sci Hung* 1980;21(4):243-51.
- Schuster B, Retey J. The mechanism of action of phenylalanine ammonia-lyase: the role of prosthetic dehydroalanine. *Proc Natl Acad Sci U S A* 1995 Aug 29;92(18):8433-7.
- Scriver CR. Child health, the genome project and phenylketonuria. *Turk J Pediatr* 1993 Jul-Sep;35(3):227-37.
- Scriver CR. An ongoing debate over phenylalanine hydroxylase deficiency in phenylketonuria [editorial]. *J Clin Invest* 1998 Jun 15;101(12):2613-4.
- Scriver CR. Phenylketonuria: the glutamine hypothesis. *N Engl J Med* 1970 Apr 2;282(14):808-9.
- Scriver CR. Science, medicine and phenylketonuria. *Acta Paediatr Suppl* 1994 Dec;407:11-8.
- Scriver CR, Clow CL. Phenylketonuria and other phenylalanine hydroxylation mutants in man. *Annu Rev Genet* 1980;14:179-202.
- Scriver CR, Clow CL. Phenylketonuria: epitome of human biochemical genetics (first of two parts). *N Engl J Med* 1980 Dec 4;303(23):1336-42.
- Scriver CR, Clow CL. Phenylketonuria: epitome of human biochemical genetics (second of two parts). *N Engl J Med* 1980 Dec 11;303(24):1394-400.
- Scriver CR, Clow CL, Kaplan P, Niederwieser A. Hyperphenylalaninemia due to deficiency of 6-pyruvoyl tetrahydropterin synthase. Unusual gene dosage effect in heterozygotes. *Hum Genet* 1987 Oct;77(2):168-71.
- Scriver CR, Cole DE, Houghton SA, Levy HL, Grenier A, Laberge C. Cord-blood tyrosine levels in the full-term phenylketonuric fetus and the justification hypothesis. *Proc Natl Acad Sci U S A* 1980 Oct;77(10):6175-8.
- Scriver CR, Eisensmith RC, Woo SL, Kaufman S. The hyperphenylalaninemia of man and mouse. *Annu Rev Genet* 1994;28:141-65.
- Scriver CR, Kaufman S, Woo SL. Mendelian hyperphenylalaninemia. *Annu Rev Genet* 1988;22:301-21.
- Scriver CR, Waters PJ. Monogenic traits are not simple: lessons from phenylketonuria. *Trends Genet* 1999 Jul;15(7):267-72.
- Seakins JW, Hjelm M, Wang KJ. Statistical properties of the Michaelis-Menten equation and their implication for inborn errors of metabolism. *J Inherit Metab Dis* 1992;15(3):431-4.
- Seim AR, Reichelt KL. An enzyme/brain-barrier theory of psychiatric pathogenesis: unifying observations on phenylketonuria, autism,

- schizophrenia and postpartum psychosis. *Med Hypotheses* 1995 Nov;45(5):498-502.
- Seve B, Reeds PJ, Fuller MF, Cadenhead A, Hay SM. Protein synthesis and retention in some tissues of the young pig as influenced by dietary protein intake after early-weaning. Possible connection to the energy metabolism. *Reprod Nutr Dev* 1986;26(3):849-61.
- Shanbhogue RL, Bistran BR, Lakshman K, Crosby L, Swenson S, Wagner D, Jenkins RL, Blackburn GL. Whole body leucine, phenylalanine, and tyrosine kinetics in end-stage liver disease before and after hepatic transplantation. *Metabolism* 1987 Nov;36(11):1047-53.
- Sharifi BG. Synthesis and hydrolysis - l-phenylalanine-l-lysine (acylated non-acylated) and evaluation of their use as a nutritive breads [dissertation]. Manhattan (KS): Kansas State University; 1984. 91 p.
- Sharma SD. Immobilized phenylalanine ammonia lyase for the depletion of phenylalanine [dissertation]. Buffalo (NY): State University of New York at Buffalo; 1981. 124 p.
- Sharma SD, Cooley C, De La Pava E, Ambrus CM. Development of a refractory stage in a dog model for phenylketonuria. *Res Commun Chem Pathol Pharmacol* 1981 Jul;33(1):145-53.
- Shedlovsky A, McDonald JD, Symula D, Dove WF. Mouse models of human phenylketonuria. *Genetics* 1993 Aug;134(4):1205-10.
- Shen RS. Potent inhibitory effects of tyrosine metabolites on dihydropteridine reductase from human and sheep liver (Phenylketonuria). *Biochim Biophys Acta* 1984 Mar 29;785(3):181-5.
- Shiman R. Phenylalanine hydroxylase and dihydropterin reductase. In: Blakley RL, Benkovic SJ, editors. *Folates and pterins*. Vol 2. New York: Wiley; c1984. p. 179-249.
- Shiman R. Purification and assay of rat liver phenylalanine 4-monooxygenase. *Methods Enzymol* 1987;142:17-27.
- Shiman R. Relationship between the substrate activation site and catalytic site of phenylalanine hydroxylase. *J Biol Chem* 1980 Nov 10;255(21):10029-32.
- Shiman R, Gray DW. Formation and fate of tyrosine. Intracellular partitioning of newly synthesized tyrosine in mammalian liver. *J Biol Chem* 1998 Dec 25;273(52):34760-9.
- Shiman R, Gray DW. Substrate activation of phenylalanine hydroxylase. A kinetic characterization. *J Biol Chem* 1980 May 25;255(10):4793-800.
- Shiman R, Gray DW, Hill MA. Regulation of rat liver phenylalanine hydroxylase. I. Kinetic properties of the enzyme's iron and enzyme reduction site. *J Biol Chem* 1994 Oct 7;269(40):24637-46.
- Shiman R, Jefferson LS. Iron-dependent regulation of rat liver phenylalanine hydroxylase activity in vivo, in vitro, and in perfused liver. *J Biol Chem* 1982 Jan 25;257(2):839-44.
- Shiman R, Jones SH, Gray DW. Mechanism of phenylalanine regulation of phenylalanine hydroxylase. *J Biol Chem* 1990 Jul 15;265(20):11633-42.
- Shiman R, Mortimore GE, Schworer CM, Gray DW. Regulation of phenylalanine hydroxylase activity by phenylalanine in vivo, in vitro, and in perfused rat liver. *J Biol Chem* 1982 Oct 10;257(19):11213-6.
- Shiman R, Xia T, Hill MA, Gray DW. Regulation of rat liver phenylalanine hydroxylase. II. Substrate binding and the role of activation in the control of enzymatic activity. *J Biol Chem* 1994 Oct 7;269(40):24647-56.
- Shintaku H. [Malignant hyperphenylalaninemia--tetrahydrobiopterin (BH4) deficiency]. *Tanpakushitsu Kakusan Koso* 1988 Apr;33(5):493-6. (Jpn).
- Shintaku H, Isshiki G, Hase Y, Tsuruhara T, Oura T. Normal pterin values in urine and serum in neonates and its age-related change throughout life. *J Inher Metab Dis* 1982;5(4):241-2.
- Shintaku H, Nakajima T, Imamura T, Sawada Y, Isshiki G, Oura T. Experimental research on a fetal treatment for tetrahydrobiopterin deficiency. *Adv Exp Med Biol* 1993;338:273-6.
- Shintaku H, Niederwieser A, Leimbacher W, Curtius HC. Tetrahydrobiopterin deficiency: assay for 6-pyruvoyl-tetrahydropterin synthase activity in erythrocytes, and detection of patients and heterozygous carriers. *Eur J Pediatr* 1988 Jan;147(1):15-9.
- Short KR, Meek SE, Moller N, Ekberg K, Nair KS. Whole body protein kinetics using Phe and Tyr tracers: an evaluation of the accuracy of approximated flux values. *Am J Physiol* 1999 Jun;276(6 Pt 1):E1194-200.
- Shortland GJ, Walter JH, Fleming PJ, Halliday D. Phenylalanine kinetics in sick preterm neonates with respiratory distress syndrome. *Pediatr Res* 1994 Dec;36(6):713-8.

- Should dietary treatment of phenylketonuria be continued after infancy? *Nutr Rev* 1985 Jun;43(6):176-7.
- Siegmund HU, Kaufman S. Hydroxylation of 4-methylphenylalanine by rat liver phenylalanine hydroxylase. *J Biol Chem* 1991 Feb 15;266(5):2903-10.
- Sierra C, Vilaseca MA, Moyano D, Brandi N, Campistol J, Lambruschini N, Cambra FJ, Deulofeu R, Mira A. Antioxidant status in hyperphenylalaninemia. *Clin Chim Acta* 1998 Aug 10;276(1):1-9.
- Sievers E, Oldigs HD, Dorner K, Schaub J. Trace element excess in PKU diets? *J Inherit Metab Dis* 1990;13(6):897-905.
- Silva FJ, Bel Y, Botella LM, Cotton RG, Ferre J. Immunological detection of phenylalanine hydroxylase protein in *Drosophila melanogaster*. *Biochem J* 1992 Oct 1;287 (Pt 1):85-9.
- Simpson D. Phenylketonuria. *Midwives Chron* 1989 Feb;102(1213):37-41.
- Sirimanne SR. Syntheses and enzymatic studies of novel substrate analogs of phenylalanine hydroxylase and dopamine beta monooxygenase [dissertation]. Atlanta (GA): Georgia Institute of Technology; 1988. 354 p.
- Skorkowska-Zieleniewska J, Cabalska B, Golabek B, Symonowicz H, Nowakowska M. [Biochemical analysis of lead level in the hair of a mixed population. II. Comparison of the lead level in the hair of healthy children and in those with various diseases]. *Rocz Panstw Zakl Hig* 1984;35(4):337-40. (Pol).
- Skriabin BV, Koval'chuk LA, Khal'chitskii SE, Gol'tsov AA, Kaboev OK, Plutalov OV, Berlin IuA, Shvarts EI. [Identification of a nature of mutation in the 12th exon of phenylalanine hydroxylase gene in patients with phenylketonuria]. *Bioorg Khim* 1989 Dec;15(12):1690-2. (Rus).
- Slazyk WE, Spierto FW. Liquid-chromatographic measurement of biopterin and neopterin in serum and urine. *Clin Chem* 1990 Jul;36(7):1364-8.
- Smith I. Treatment of phenylalanine hydroxylase deficiency. *Acta Paediatr Suppl* 1994 Dec;407:60-5.
- Smith I, Glossop J, Beasley M. Fetal damage due to maternal phenylketonuria: effects of dietary treatment and maternal phenylalanine concentrations around the time of conception (an interim report from the UK Phenylketonuria Register). *J Inherit Metab Dis* 1990;13(4):651-7.
- Smith I, Howells DW, Hyland K. Pteridines and mono-amines: relevance to neurological damage. *Postgrad Med J* 1986 Feb;62(724):113-23.
- Smith I, Hyland K, Kendall B. Clinical role of pteridine therapy in tetrahydrobiopterin deficiency. *J Inherit Metab Dis* 1985;8 Suppl 1:39-45.
- Smith JE, Sheng ZF, Kallen RG. Effects of tyrosine-->phenylalanine mutations on auto- and trans-phosphorylation reactions catalyzed by the insulin receptor beta-subunit cytoplasmic domain. *DNA Cell Biol* 1994 Jun;13(6):593-604.
- Smith SC, Kemp BE, McAdam WJ, Mercer JF, Cotton RG. Two apparent molecular weight forms of human and monkey phenylalanine hydroxylase are due to phosphorylation. *J Biol Chem* 1984 Sep 25;259(18):11284-9.
- Smith SC, McAdam W, Cotton RG, Mercer JF. A novel two-dimensional polyacrylamide-gel pattern, which may be due to allelic genes, of phenylalanine hydroxylase in monkeys. *Biochem J* 1985 Oct 1;231(1):197-9.
- Smith SC, McAdam WJ, Kemp BE, Morgan FJ, Cotton RG. A monoclonal antibody to the phosphorylated form of phenylalanine hydroxylase. Definition of the phosphopeptide epitope. *Biochem J* 1987 Jun 15;244(3):625-31.
- Smith TK. Effect of leucine-rich dietary protein on in vitro protein synthesis in porcine muscle. *Proc Soc Exp Biol Med* 1985 Dec;180(3):538-43.
- Snyderman SE. Dietary and genetic therapy of inborn errors of metabolism: a summary. *Ann N Y Acad Sci* 1986;477:231-6.
- Snyderman SE, Sansaricq C, Pulmones MT. Successful long term therapy of biopterin deficiency. *J Inherit Metab Dis* 1987;10(3):260-6.
- Song J. Multi-level regulation of phenylalanine hydroxylase in *aeruginosa* [dissertation]. Gainesville (FL): University of Florida; 1997. 100 p.
- Song J, Jensen RA. PhhR, a divergently transcribed activator of the phenylalanine hydroxylase gene cluster of *Pseudomonas aeruginosa*. *Mol Microbiol* 1996 Nov;22(3):497-507.
- Song J, Xia T, Jensen RA. PhhB, a *Pseudomonas aeruginosa* homolog of mammalian pterin 4a-carbinolamine dehydratase/DCoH, does not regulate expression of phenylalanine hydroxylase at the transcriptional level. *J Bacteriol* 1999 May;181(9):2789-96.
- Sonntag WE, Lenham JE, Ingram RL. Effects of aging and dietary restriction on tissue protein synthesis:

- relationship to plasma insulin-like growth factor-1. *J Gerontol* 1992 Sep;47(5):B159-63.
- Spaapen LJ, Ketting D, Wadman SK, Bruinvis L, Duran M. Urinary D-4-hydroxyphenyllactate, D-phenyllactate and D-2-hydroxyisocaproate, abnormalities of bacterial origin. *J Inherit Metab Dis* 1987;10(4):383-90.
- Spada M, Dianzani I, Bonetti G, Biondi A, Leone L, Giannattasio S, Ponzone A. Phenylalanine and tyrosine metabolism in phenylketonuria heterozygotes: influence of different phenylalanine hydroxylase mutations. *J Inherit Metab Dis* 1998 Jun;21(3):236-9.
- Speer VC, Kile DL, Trew JC. Estimation of the isoleucine and aromatic amino acid requirements of pregnant swine. *J Anim Sci* 1990 Aug;68(8):2394-9.
- St James PS, Shapiro E, Waisbren SE. The Resource Mothers Program for Maternal Phenylketonuria. *Am J Public Health* 1999 May;89(5):762-4.
- Stanley JC, Fisher MJ, Pogson CI. The metabolism of L-phenylalanine and L-tyrosine by liver cells isolated from adrenalectomized rats and from streptozotocin-diabetic rats. *Biochem J* 1985 May 15;228(1):249-55.
- Stanley JC, Salter M, Fisher MJ, Pogson CI. The effect of pyridoxine deficiency on the metabolism of the aromatic amino acids by isolated rat liver cells. *Arch Biochem Biophys* 1985 Aug 1;240(2):792-800.
- Stegenga SL. Regulation of GTP Cyclohydrolase I: isolation and the rat GTP Cyclohydrolase I promoter (tetrahydrobiopterin, transcription) [dissertation]. Detroit (MI): Wayne State University; 1997. 255 p.
- Stegink LD, Brummel MC, Persoon TJ, Filer LJ Jr, Bell EF, Ziegler EE. Effect of sucrose on the metabolic disposition of aspartame. *Am J Clin Nutr* 1990 Aug;52(2):335-41.
- Stegink LD, Filer LJ Jr, Baker GL. Effect of aspartame plus monosodium L-glutamate ingestion on plasma and erythrocyte amino acid levels in normal adult subjects fed a high protein meal. *Am J Clin Nutr* 1982 Dec;36(6):1145-52.
- Stegink LD, Filer LJ Jr, Baker GL. Repeated ingestion of aspartame-sweetened beverage: effect on plasma amino acid concentrations in normal adults. *Metabolism* 1988 Mar;37(3):246-51.
- Stegink LD, Filer LJ Jr, Baker GL, McDonnell JE. Effect of an abuse dose of aspartame upon plasma and erythrocyte levels of amino acids in phenylketonuric heterozygous and normal adults. *J Nutr* 1980 Nov;110(11):2216-24.
- Stegink LD, Filer LJ Jr, Bell EF, Ziegler EE, Tephly TR, Krause WL. Repeated ingestion of aspartame-sweetened beverages: further observations in individuals heterozygous for phenylketonuria. *Metabolism* 1990 Oct;39(10):1076-81.
- Stegink LD, Filer LJ Jr, Brummel MC, Baker GL, Krause WL, Bell EF, Ziegler EE. Plasma amino acid concentrations and amino acid ratios in normal adults and adults heterozygous for phenylketonuria ingesting a hamburger and milk shake meal. *Am J Clin Nutr* 1991 Mar;53(3):670-5.
- Stegink LD, Koch R, Blaskovics ME, Filer LJ Jr, Baker GL, McDonnell JE. Plasma phenylalanine levels in phenylketonuric heterozygous and normal adults administered aspartame at 34 mg/kg body weight. *Toxicology* 1981;20(1):81-90.
- Stegink LD, Lindgren SD, Brummel MC, Stumbo PJ, Wolraich ML. Erythrocyte L-aspartyl-L-phenylalanine hydrolase activity and plasma phenylalanine and aspartate concentrations in children consuming diets high in aspartame. *Am J Clin Nutr* 1995 Dec;62(6):1206-11.
- Stewart RM, Hemli S, Kolodny EH, Miller AL, Pallotta JA. Carbohydrate metabolism in phenylketonuria. *Pediatr Res* 1980 Jul;14(7):849-53.
- Stoll B, Burrin DG, Henry J, Jahoor F, Reeds PJ. Phenylalanine utilization by the gut and liver measured with intravenous and intragastric tracers in pigs. *Am J Physiol* 1997 Dec;273(6 Pt 1):G1208-17.
- Stoll B, Burrin DG, Henry J, Yu H, Jahoor F, Reeds PJ. Dietary amino acids are the preferential source of hepatic protein synthesis in piglets. *J Nutr* 1998 Sep;128(9):1517-24.
- Stoll B, Burrin DG, Henry JF, Jahoor F, Reeds PJ. Dietary and systemic phenylalanine utilization for mucosal and hepatic constitutive protein synthesis in pigs. *Am J Physiol* 1999 Jan;276(1 Pt 1):G49-57.
- Stonier C, McGale EH, Aber GM. Studies of phenylalanine hydroxylase activity in patients with chronic renal failure: the effect of haemodialysis. *Clin Chim Acta* 1984 Nov 15;143(2):115-22.
- Sturtevant FM. Use of aspartame in pregnancy. *Int J Fertil* 1985;30(1):85-7.
- Suchozebraska-Jesionek D, Szymonik-Lesiuk S, Borkowska I. Shortlasting effect of L-phenylalanine on the level of aminoacyl-tRNA in chick embryo's brain. *Bull Acad Polonaise Sci Ser Sci Biol* 1984;32(1-2):1-8.
- Sugiyama H, Moriyama H, Shigematsu H. Induction of phenylalanine and tyrosine oxidation in the intoxicated larva of the silkworm, *obmyx mori* L (Lepidoptera: Bombycidae), with MTMC (m-Tolyl-N-

- methylcarbamate). *Appl Entomol Zool* 1982 May;17(2):166-71.
- Surplice IM, Griffiths PD, Green A, Leeming RJ. Dihydropteridine reductase activity in eluates from dried blood spots: automation of an assay for a national screening service. *J Inher Metab Dis* 1990;13(2):169-77.
- Svensson E, Eisensmith RC, Dworniczak B, von Döbeln U, Hagenfeldt L, Horst J, Woo SL. Two missense mutations causing mild hyperphenylalaninemia associated with DNA haplotype 12. *Hum Mutat* 1992;1(2):129-37.
- Svensson E, Iselius L, Hagenfeldt L. Severity of mutation in the phenylalanine hydroxylase gene influences phenylalanine metabolism in phenylketonuria and hyperphenylalaninaemia heterozygotes. *J Inher Metab Dis* 1994;17(2):215-22.
- Swaiman KF, Wu SR. Phenylalanine and phenylacetate adversely affect developing mammalian brain neurons. *Neurology* 1984 Sep;34(9):1246-50.
- Tabolin VI, Deshchekina MF, Demin VF, Vnukova AI, Volodin NN. [Selenium metabolism in normal and pathologic states; its significance in pediatrics]. *Pediatriia* 1983 Nov;(11):76-8. (Rus).
- Tada K, Narisawa K, Arai N, Ogasawara Y, Ishizawa S. A sibling case of hyperphenylalaninemia due to a deficiency of dihydropteridine reductase: biochemical and pathological findings. *Tohoku J Exp Med* 1980 Oct;132(2):123-31.
- Takada G. [Brain function in inborn error of amino acid metabolism]. *Tanpakushitsu Kakusan Koso* 1984 Dec;29(14):1783-93. (Jpn).
- Takahashi T, Kodama S, Nishio H, Takumi T, Matsuo T, Hase Y, Sawada Y. Transient hyperphenylalaninaemia with a high neopterin to biopterin ratio in urine. *J Inher Metab Dis* 1985;8(3):105-8.
- Takarada Y, Kalanin J, Yamashita K, Ohtsuka N, Kagawa S, Matsuoka A. Phenylketonuria mutant alleles in different populations: missense mutation in exon 7 of phenylalanine hydroxylase gene [letter]. *Clin Chem* 1993 Nov;39(11 Pt 1):2354-5.
- Takarada Y, Yamashita K, Ohtsuka N, Kagawa S, Matsuoka A. Novel homozygous mutation of phenylalanine hydroxylase gene in a Chinese patient with phenylketonuria [letter]. *Clin Chem* 1993 Jun;39(6):1350.
- Takarada Y, Yamashita K, Ohtsuka N, Kagawa S, Matsuoka A. Novel mutation in exon 7 of phenylalanine hydroxylase gene in a Chinese patient with phenylketonuria [letter]. *Clin Chem* 1993 Nov;39(11 Pt 1):2357.
- Takashima S, Chan F, Becker LE. Cortical dysgenesis in a variant of phenylketonuria (dihydropteridine reductase deficiency). *Pediatr Pathol* 1991 Sep-Oct;11(5):771-9.
- Tam SY, Roth RH. Mesoprefrontal dopaminergic neurons: can tyrosine availability influence their functions? *Biochem Pharmacol* 1997 Feb 21;53(4):441-53.
- Tanaka H, Nakatomi Y, Ogura M. Metabolism of phenylalanine, tyrosine and aspartic acid in growing rats at various dietary protein levels. *Agric Biol Chem* 1987 Feb;51(2):499-505.
- Tanaka H, Shibata K, Mori M, Ogura M. Metabolism of essential amino acids in growing rats at graded levels of soybean protein isolate. *J Nutr Sci Vitaminol (Tokyo)* 1995 Aug;41(4):433-43.
- Tanaka T, Aihara K, Iwai K, Kohashi M, Tomita K, Narisawa K, Arai N, Yoshida H, Usui T. Hyperphenylalaninemia due to impaired dihydrobiopterin biosynthesis. *Eur J Pediatr* 1981 Jul;136(3):275-80.
- Tanase-Mogos I, Ciortoloman H, Grigorescu G, Popescu M, Ankar V. [Combined and isolated forms of metabolic errors detected in children]. *Physiologie* 1980 Jan-Mar;17(1):57-66. (Fre).
- Taylor CJ, Moore G, Davidson DC. The effect of treatment on zinc, copper and calcium status in children with phenylketonuria. *J Inher Metab Dis* 1984;7(4):160-4.
- Taylor DS, Dahl HH, Mercer JF, Green AK, Fisher MJ. The effect of streptozotocin-induced diabetes on phenylalanine hydroxylase expression in rat liver. *Biochem J* 1989 Nov 15;264(1):185-90.
- Taylor EH 3rd. Effects of experimental hyperphenylalaninemia and synthesis at later stages of brain development [dissertation]. Augusta (GA): Medical College of Georgia; 1982.
- Taylor EH, Hommes FA. Effect of experimental hyperphenylalaninemia on myelin metabolism at later stages of brain development. *Int J Neurosci* 1983 Sep;20(3-4):217-27.
- Taylor EH, Hommes FA, Stewart DE. Effect of experimental hyperphenylalaninemia on biogenic amine synthesis at later stages of brain development. *Biochem Med* 1983 Jun;29(3):307-17.
- Teigen K, Froystein NA, Martinez A. The structural basis of the recognition of phenylalanine and pterin cofactors by phenylalanine hydroxylase: implications

- for the catalytic mechanism. *J Mol Biol* 1999 Dec 3;294(3):807-23.
- Tengamnuy P, Mitra AK. Transport of tyrosine and phenylalanine across the rat nasal mucosa. *Life Sci* 1988;43(7):585-93.
- Terwolbeck K, Behne D, Meinhold H, Menzel H, Lombeck I. Increased plasma T4-levels in children with low selenium state due to reduced type I iodothyronine 5'deiodinase activity? *J Trace Elem Electrolytes Health Dis* 1993 Mar;7(1):53-5.
- Tessari P, Deferrari G, Robaudo C, Vettore M, Pastorino N, De Biasi L, Garibotto G. Phenylalanine hydroxylation across the kidney in humans rapid communication. *Kidney Int* 1999 Dec;56(6):2168-72.
- Tessari P, Inchiostro S, Barazzoni R, Zanetti M, Vettore M, Biolo G, Iori E, Kiwanuka E, Tiengo A. Hyperglucagonemia stimulates phenylalanine oxidation in humans. *Diabetes* 1996 Apr;45(4):463-70.
- Thalhammer O, Lubec G, Konigshofer H, Scheibenreiter S, Coradello H. Intracellular phenylalanine and tyrosine concentration in homozygotes and heterozygotes for phenylketonuria (PKU) and hyperphenylalaninemia compared with normals. *Hum Genet* 1982;60(4):320-1.
- Thalhammer O, Pollak A, Lubec G, Konigshofer H. Intracellular concentrations of phenylalanine, tyrosine and alpha-aminobutyric acid in 13 homozygotes and 19 heterozygotes for phenylketonuria compared with 26 normals. *J Inher Metab Dis* 1981;4(2):73-4.
- Theile H, Bieck E. [Control of energy and nitrogen uptake during diet therapy of phenylketonuria]. *Kinderarztl Prax* 1981 Aug;49(8):425-30. (Ger).
- Thompson GN, Halliday D. Significant phenylalanine hydroxylation in vivo in patients with classical phenylketonuria. *J Clin Invest* 1990 Jul;86(1):317-22.
- Thompson GN, Pacy PJ, Watts RW, Halliday D. Protein metabolism in phenylketonuria and Lesch-Nyhan syndrome. *Pediatr Res* 1990 Sep;28(3):240-6.
- Thompson GN, Walter JH, Leonard JV, Halliday D. In vivo enzyme activity in inborn errors of metabolism. *Metabolism* 1990 Aug;39(8):799-807.
- Thony B, Auerbach G, Blau N. Tetrahydrobiopterin biosynthesis, regeneration and functions. *Biochem J* 2000 Apr 1;347 Pt 1:1-16.
- Thony B, Blau N. Mutations in the GTP cyclohydrolase I and 6-pyruvoyl-tetrahydropterin synthase genes. *Hum Mutat* 1997;10(1):11-20.
- Thony B, Heizmann CW, Mattei MG. Chromosomal location of two human genes encoding tetrahydrobiopterin-metabolizing enzymes: 6-pyruvoyl-tetrahydropterin synthase maps to 11q22.3-q23.3, and pterin-4 alpha-carbinolamine dehydratase maps to 10q22. *Genomics* 1994 Jan 15;19(2):365-8.
- Thony B, Leimbacher W, Blau N, Harvie A, Heizmann CW. Hyperphenylalaninemia due to defects in tetrahydrobiopterin metabolism: molecular characterization of mutations in 6-pyruvoyl-tetrahydropterin synthase. *Am J Hum Genet* 1994 May;54(5):782-92.
- Thony B, Leimbacher W, Burgisser D, Heizmann CW. Human 6-pyruvoyltetrahydropterin synthase: cDNA cloning and heterologous expression of the recombinant enzyme. *Biochem Biophys Res Commun* 1992 Dec 30;189(3):1437-43.
- Thony B, Leimbacher W, Stuhlmann H, Heizmann CW, Blau N. Retrovirus-mediated gene transfer of 6-pyruvoyl-tetrahydropterin synthase corrects tetrahydrobiopterin deficiency in fibroblasts from hyperphenylalaninemic patients. *Hum Gene Ther* 1996 Aug 20;7(13):1587-93.
- Thony B, Neuheiser F, Hauer CR, Heizmann CW. Molecular cloning and recombinant expression of the human liver phenylalanine hydroxylase stimulating factor revealed structural and functional identity to the dimerization cofactor for the nuclear transcription factor HNF-1 alpha. *Adv Exp Med Biol* 1993;338:103-6.
- Thony B, Neuheiser F, Kierat L, Rolland MO, Guibaud P, Schluter T, Germann R, Heidenreich RA, Duran M, de Klerk JB, Ayling JE, Blau N. Mutations in the pterin-4alpha-carbinolamine dehydratase (PCBD) gene cause a benign form of hyperphenylalaninemia. *Hum Genet* 1998 Aug;103(2):162-7.
- Thorpe JM. The effect of tyrosine and prior protein intake on the measurement of phenylalanine metabolism in vivo [dissertation]. Toronto (Canada): University of Toronto; 1999. 138 p.
- Tipper J, Kaufman S. Phenylalanine-induced phosphorylation and activation of rat hepatic phenylalanine hydroxylase in vivo. *J Biol Chem* 1992 Jan 15;267(2):889-96.
- Tork I, Halliday GM, Cotton RG. Application of antiphenylalanine hydroxylase antibodies to the study of the serotonergic system in the human brain. *J Chem Neuroanat* 1992 Jul-Aug;5(4):311-3.
- Torre P, Ponz F. Kinetics of the mediated transport and the passive net flux of phenylalanine across the rat small intestine in vivo. *Rev Esp Fisiol* 1983 Sep;39(3):333-7.

- Touraine RL, Guibaud P. [Genetics and hyperphenylalaninemia in 1992]. *Pediatric (Bucur)* 1992;47(1):9-21. Published erratum appears in *Pediatric* 1992;47(4):331. (Fre).
- Traeger-Synodinos J, Kanavakis E, Kalogerakou M, Soulpi K, Missiou-Tsangaraki S, Kattamis C. Preliminary mutation analysis in the phenylalanine hydroxylase gene in Greek PKU and HPA patients. *Hum Genet* 1994 Nov;94(5):573-5.
- Treacy E, Pitt JJ, Sellar K, Thompson GN, Ramus S, Cotton RG. In vivo disposal of phenylalanine in phenylketonuria: a study of two siblings. *J Inherit Metab Dis* 1996;19(5):595-602.
- Treacy EP, Delente JJ, Elkas G, Carter K, Lambert M, Waters PJ, Scriver CR. Analysis of phenylalanine hydroxylase genotypes and hyperphenylalaninemia phenotypes using L-[1-13C]phenylalanine oxidation rates in vivo: a pilot study. *Pediatr Res* 1997 Oct;42(4):430-5.
- Trefz F, de Sonnevile L, Matthis P, Benninger C, Lanz-Englert B, Bickel H. Neuropsychological and biochemical investigations in heterozygotes for phenylketonuria during ingestion of high dose aspartame (a sweetener containing phenylalanine). *Hum Genet* 1994 Apr;93(4):369-74.
- Trefz FK, Bartholome K, Bickel H, Lutz P, Schmidt H. In vivo determination of phenylalanine hydroxylase activity using heptadeutero-phenylalanine and comparison to the in vitro assay values. *Monogr Hum Genet* 1978;9:108-13.
- Trefz FK, Bartholome K, Bickel H, Lutz P, Schmidt H, Seyberth HW. In vivo residual activities of the phenylalanine hydroxylating system in phenylketonuria and variants. *J Inherit Metab Dis* 1981;4(2):101-2.
- Trefz FK, Erlenmaier T, Hunneman DH, Bartholome K, Lutz P. Sensitive in vivo assay of the phenylalanine hydroxylating system with a small intravenous dose of heptadeutero L-phenylalanine using high pressure liquid chromatography and capillary gas chromatography/mass fragmentography. *Clin Chim Acta* 1979 Dec 17;99(3):211-30.
- Tsay JT, Appleman JR, Beard WA, Prendergast NJ, Delcamp TJ, Freisheim JH, Blakley RL. Kinetic investigation of the functional role of phenylalanine-31 of recombinant human dihydrofolate reductase. *Biochemistry* 1990 Jul 10;29(27):6428-36.
- Tsukada Y, Takamatsu K. [Correlation between monoamine content in the brain and discriminative learning ability (author's transl)]. *Tanpakushitsu Kakusan Koso* 1981 Aug;26(11):1725-34. (Jpn).
- Turk E. Hyperphenylalaninemia - induced alterations of cerebral synthesis in the rat [dissertation]. Los Angeles: University of California; 1984. 173 p.
- Turri MO, Ilg EC, Thony B, Blau N. Structure, genomic localization and recombinant expression of the mouse 6-pyruvoyl-tetrahydropterin synthase gene. *Biol Chem* 1998 Dec;379(12):1441-7.
- Tyfield LA, Meredith AL, Osborn MJ, Harper PS. Identification of the haplotype pattern associated with the mutant PKU allele in the Gypsy population of Wales. *J Med Genet* 1989 Aug;26(8):499-503.
- Tyfield LA, Stephenson A, Cockburn F, Harvie A, Bidwell JL, Wood NA, Pilz DT, Harper P, Smith I. Sequence variation at the phenylalanine hydroxylase gene in the British Isles. *Am J Hum Genet* 1997 Feb;60(2):388-96.
- Udenfriend S, Cooper JR. The enzymatic conversion of phenylalanine to tyrosine. *J Biol Chem* 1952 Feb;194(2):503-11.
- Uebelhack R, Franke L, Kutter D, Thoma J, Seidel K. [In vitro synthesis of tyrosine from phenylalanine in human platelets]. *Biomed Biochim Acta* 1984;43(7):1037-9. (Ger).
- Uebelhack R, Franke L, Kutter D, Thoma J, Seidel K. Platelet phenylalanine hydroxylating activity in phenylketonurics and normal controls. *Biochem Med* 1985 Dec;34(3):376-9.
- Uma SM, Jyothy A, Reddy PP, Reddi OS. Aminoacidopathies in Andhra Pradesh; report of a screening programme. *J Inherit Metab Dis* 1982;5(4):211-4.
- Ushakova GA, Gubkina HA, Kachur VA, Lepekhin EA. Effect of experimental hyperphenylalaninemia on the postnatal rat brain. *Int J Dev Neurosci* 1997 Feb;15(1):29-36.
- Valdivieso F, Gimenez C, Benavides J, Aragon MC, Mayor F. [Pathogenesis of cerebral dysfunction in phenylketonuria]. *Rev Esp Fisiol* 1982;38 Suppl:189-93. (Spa).
- van der Heiden C, Brink W. Spectral studies of the interaction of the substrate 'quinonoid' 6-methyl dihydropterine and the coenzyme NADH used as marker in the dihydropteridine reductase assay. *J Inherit Metab Dis* 1982;5(3):132-6.
- van der Sijs-Bos CJ, Diepstraten CM, Juyn JA, Plaisier M, Giltay JC, van Spronsen FJ, Smit GP, Berger R, Smeitink JA, Poll-The BT, Ploos van Amstel JK. Phenylketonuria in The Netherlands: 93% of the mutations are detected by single-strand conformation analysis. *Hum Hered* 1996 Jul-Aug;46(4):185-90.

- van der Vliet A, O'Neill CA, Halliwell B, Cross CE, Kaur H. Aromatic hydroxylation and nitration of phenylalanine and tyrosine by peroxynitrite. Evidence for hydroxyl radical production from peroxynitrite. *FEBS Lett* 1994 Feb 14;339(1-2):89-92.
- van Spronsen FJ, Reijngoud DJ, Smit GP, Nagel GT, Stellaard F, Berger R, Heymans HS. Phenylketonuria. The in vivo hydroxylation rate of phenylalanine into tyrosine is decreased. *J Clin Invest* 1998 Jun 15;101(12):2875-80.
- van Toledo-Eppinga L, Kalhan SC, Kulik W, Jakobs C, Lafeber HN. Relative kinetics of phenylalanine and leucine in low birth weight infants during nutrient administration. *Pediatr Res* 1996 Jul;40(1):41-6.
- Varughese KI, Xuong NH, Whiteley JM. Structural and mechanistic implications of incorporating naturally occurring aberrant mutations of human dihydropteridine reductase into a rat model. *Int J Pept Protein Res* 1994 Sep;44(3):278-87.
- Verlinsky Y, Rechitsky S, Verlinsky O, Ivachnenko V, Lifchez A, Kaplan B, Moise J, Valle J, Borkowski A, Nefedova J, Goltsman E, Strom C, Kuliev A. Prepregnancy testing for single-gene disorders by polar body analysis. *Genet Test* 1999;3(2):185-90.
- Veropotvelian PN, Krupoder GI, Avksent'ev ON. [Phenylketonuria]. *Feldsher Akush* 1982;47(5):33-5. (Rus).
- Viktorova TV, Murzabaeva SSh, Karunas AU, Magzhanov RV, Khusnutdinova EK. [Molecular genetic analysis of phenylketonuria in Bashkiria]. *Genetika* 1997 Jul;33(7):992-5. (Rus).
- Vilaseca MA, Farre C, Ramon F. Phenylalanine determined in plasma with use of phenylalanine dehydrogenase and a centrifugal analyzer. *Clin Chem* 1993 Jan;39(1):129-31.
- Villasana D, Butler IJ, Williams JC, Roongta SM. Neurological deterioration in adult phenylketonuria. *J Inherit Metab Dis* 1989;12(4):451-7.
- Vis HL, Elmer C, Goyens P, Roumat G. [Phenylketonuria: current status of the problem]. *Bull Mem Acad R Med Belg* 1988;143(3-4):231-47. (Fre).
- Vorhees CV, Butcher RE, Berry HK. Progress in experimental phenylketonuria: a critical review. *Neurosci Biobehav Rev* 1981 Spring;5(1):177-90.
- Wachtel U. Review of current practices in management of inherited disorders of amino acid metabolism in Western Europe. *Hum Nutr Appl Nutr* 1986;40 Suppl 1:61-9.
- Waisbren SE, Chang P, Levy HL, Shifrin H, Allred E, Azen C, de la Cruz F, Hanley W, Koch R, Matalon R, Rouse B. Neonatal neurological assessment of offspring in maternal phenylketonuria. *J Inherit Metab Dis* 1998 Feb;21(1):39-48.
- Waldner-Sander S. Zur Biosynthese von Phenylalanin und Tyrosin bei Flavobakterien [Biosynthesis of phenylalanine and tyrosine from flavobacterium] [dissertation]. Hohenheim (Germany): University of Hohenheim; 1985. 88 p. (Ger).
- Walker V, Mills GA. Metabolism of intravenous phenylalanine by babies born before 33 weeks of gestation. *Biol Neonate* 1990;57(3-4):155-66.
- Walker V, Smythe PJ, Cook NJ, Ball NA, Veall RM, Whiteman P. Urinary screening for abnormalities of amino acid or mucopolysaccharide metabolism in patients in a hospital for the mentally handicapped in Wessex. *J Ment Defic Res* 1983 Jun;27 (Pt 2):105-14.
- Wallick DE. The role of iron in the mechanism of phenylalanine hydroxylase [dissertation]. University Park (PA): The Pennsylvania State University; 1985. 114 p.
- Wallick DE, Bloom LM, Gaffney BJ, Benkovic SJ. Reductive activation of phenylalanine hydroxylase and its effect on the redox state of the non-heme iron. *Biochemistry* 1984 Mar 13;23(6):1295-302.
- Walsh DA, Christian ZH. The effects of phenylalanine on cultured rat embryos. *Teratog Carcinog Mutagen* 1984;4(6):505-13.
- Walsh GA, Donlon J. Dexamethasone and phenylalanine hydroxylase activities in rats. *Biochem Soc Trans* 1990 Apr;18(2):320-1.
- Walter JH, Tyfield LA, Holton JB, Johnson C. Biochemical control, genetic analysis and magnetic resonance imaging in patients with phenylketonuria. *Eur J Pediatr* 1993 Oct;152(10):822-7.
- Wang K, Kitney RI, Seakins JW, Hjelm M. Study of the relationship between estimates of enzyme kinetic parameters. *J Theor Biol* 1992 Apr 21;155(4):485-95.
- Wang T, Okano Y, Eisensmith RC, Harvey ML, Lo WH, Huang SZ, Zeng YT, Yuan LF, Furuyama JI, Oura T, et al. Founder effect of a prevalent phenylketonuria mutation in the Oriental population. *Proc Natl Acad Sci U S A* 1991 Mar 15;88(6):2146-50.
- Wang T, Okano Y, Eisensmith RC, Lo WH, Huang SZ, Zeng YT, Yuan LF, Liu SR, Woo SL. Identification of three novel PKU mutations among Chinese: evidence for recombination or recurrent mutation at the PAH locus. *Genomics* 1992 May;13(1):230-1.

- Wang Y, DeMayo JL, Hahn TM, Finegold MJ, Konecki DS, Lichter-Konecki U, Woo SL. Tissue- and development-specific expression of the human phenylalanine hydroxylase/chloramphenicol acetyltransferase fusion gene in transgenic mice. *J Biol Chem* 1992 Jul 25;267(21):15105-10.
- Wang Y, Hahn TM, Tsai SY, Woo SL. Functional characterization of a unique liver gene promoter. *J Biol Chem* 1994 Mar 25;269(12):9137-46.
- Ward KP, Arthur JR, Russell G, Aggett PJ. Blood selenium content and glutathione peroxidase activity in children with cystic fibrosis, coeliac disease, asthma, and epilepsy. *Eur J Pediatr* 1984 Apr;142(1):21-4.
- Waters PI, Hewson AS, Scriver CR, Treacy EP, Martinez A, Knappskog PM, Parniak MA. Comparative analysis of phenylalanine hydroxylase A104D mutant, associated with variant phenylketonuria, and wild-type enzyme. *Biochem Soc Trans* 1997 May;25(2):362S.
- Waters PJ, Parniak MA, Akerman BR, Jones AO, Scriver CR. Missense mutations in the phenylalanine hydroxylase gene (PAH) can cause accelerated proteolytic turnover of PAH enzyme: a mechanism underlying phenylketonuria. *J Inherit Metab Dis* 1999 May;22(3):208-12.
- Waters PJ, Parniak MA, Akerman BR, Scriver CR. Characterization of phenylketonuria missense substitutions, distant from the phenylalanine hydroxylase active site, illustrates a paradigm for mechanism and potential modulation of phenotype. *Mol Genet Metab* 2000 Feb;69(2):101-10.
- Waters PJ, Parniak MA, Hewson AS, Scriver CR. Alterations in protein aggregation and degradation due to mild and severe missense mutations (A104D, R157N) in the human phenylalanine hydroxylase gene (PAH). *Hum Mutat* 1998;12(5):344-54.
- Waters PJ, Scriver CR, Parniak MA. Degradation rates differ between mutant and wild-type forms of phenylalanine hydroxylase expressed in vitro. *Biochem Soc Trans* 1998 Aug;26(3):S276.
- Webber S, Harzer G, Whiteley JM. Isolation of rat liver phenylalanine hydroxylase using a novel pteridine matrix. *Anal Biochem* 1980 Jul 15;106(1):63-72.
- Webber S, Whiteley JM. Separation of catalase from phenylalanine hydroxylase: use of a Sepharose anti-catalase IgG affinity matrix. *Biochem Biophys Res Commun* 1980 Nov 17;97(1):17-21.
- Wedemeyer N, Dworniczak B, Horst J. PCR detection of the MspI (Aa) RFLP at the human phenylalanine hydroxylase (PAH) locus. *Nucleic Acids Res* 1991 Apr 25;19(8):1959.
- Weglage J, Moller HE, Wiedermann D, Cipic-Schmidt S, Zschocke J, Ullrich K. In vivo NMR spectroscopy in patients with phenylketonuria: clinical significance of interindividual differences in brain phenylalanine concentrations. *J Inherit Metab Dis* 1998 Feb;21(1):81-2.
- Weglage J, Schmidt E, Funders B, Pietsch M, Ullrich K. Sustained attention in untreated non-PKU-hyperphenylalaninemia. *J Clin Exp Neuropsychol* 1996 Jun;18(3):343-8.
- Weglage J, Schuierer G, Kurlmann G, Bick R, Ullrich K. Different degrees of white matter abnormalities in untreated phenylketonurics: findings in magnetic resonance imaging. *J Inherit Metab Dis* 1993;16(6):1047-8.
- Weglage J, Ullrich K, Pietsch M, Funders B, Guttler F, Harms E. Intellectual, neurologic, and neuropsychologic outcome in untreated subjects with nonphenylketonuria hyperphenylalaninemia. German Collaborative Study on Phenylketonuria. *Pediatr Res* 1997 Sep;42(3):378-84.
- Weglage J, Wiedermann D, Moller H, Ullrich K. Pathogenesis of different clinical outcomes in spite of identical genotypes and comparable blood phenylalanine concentrations in phenylketonurics. *J Inherit Metab Dis* 1998 Apr;21(2):181-2.
- Weiss B, Hui M, Lajtha A. Attempts at induction of phenylalanine hydroxylase in thermophilic bacteria and induction of thermophily in mesophiles. *Res Commun Chem Pathol Pharmacol* 1981 May;32(2):329-34.
- Weiss G, Fuchs D, Werner-Felmayer G, Wachter H. Hyperphenylalaninemia [letter]. *Neurology* 1992 Mar;42(3 Pt 1):704-5. Comment on: *Neurology* 1991 May;41(5):730-7.
- Wellner D, Meister A. A survey of inborn errors of amino acid metabolism and transport in man. *Annu Rev Biochem* 1981;50:911-68.
- Wendel U, Hummel W, Langenbeck U. Monitoring of phenylketonuria: a colorimetric method for the determination of plasma phenylalanine using L-phenylalanine dehydrogenase. *Anal Biochem* 1989 Jul;180(1):91-4.
- Wendel U, Koppelkamm M, Hummel W, Sander J, Langenbeck U. A new approach to the newborn screening for hyperphenylalaninemias: use of L-phenylalanine dehydrogenase and microtiter plates. *Clin Chim Acta* 1990 Dec 3;192(3):165-70.

- Werner ER, Habisch H-J, Gorren ACF, Schmidt K, Canevari L, Werner-Felmayer G, Mayer B. Contrasting effects of Nsup 5-substituted tetrahydrobiopterin derivatives on phenylalanine hydroxylase, dihydropteridine reductase and nitric oxide synthase. *Biochem J* 2000 Jun 15;348(3):579-83.
- Wester TJ, Lobley() GE, Birnie LM, Lomax MA. Insulin stimulates phenylalanine uptake across the hind limb in fed lambs. *J Nutr* 2000 Mar;130(3):608-11.
- Westwood A, Barr DG. Phenylketonuria with a progressive neurological disorder not responsive to tetrahydrobiopterin. *Acta Paediatr Scand* 1982 Sep;71(5):859-61.
- Whipp MJ, Halsall DM, Pittard AJ. Isolation and characterization of an *Escherichia coli* K-12 mutant defective in tyrosine- and phenylalanine-specific transport systems. *J Bacteriol* 1980 Jul;143(1):1-7.
- Wiens M, Koziol C, Batel R, Muller WE. Phenylalanine hydroxylase from the sponge *Geodia cydonium*: implication for allorecognition and evolution of aromatic amino acid hydroxylases. *Dev Comp Immunol* 1998 Sep-Dec;22(5-6):469-78.
- Wigfield DC, Eatock SA. The effect of metals on the activity of L-phenylalanine hydroxylase. *J Trace Elem Electrolytes Health Dis* 1990 Sep;4(3):143-6.
- Williams JM, Morris JG, Rogers QR. Phenylalanine requirement of kittens and the sparing effect of tyrosine. *J Nutr* 1987 Jun;117(6):1102-7.
- Wilt SG. Long-term regulation of phenylalanine hydroxylase by primary rat hepatocytes: evidence for camp involvement [dissertation]. University Park (PA): The Pennsylvania State University; 1993. 127 p.
- Wittig A, Sauerwein WA, Coderre JA. Mechanisms of transport of p-borono-phenylalanine through the cell membrane in vitro. *Radiat Res* 2000;153(2):173-80.
- Wittstock U, Halkier BA. Cytochrome P450 CYP79A2 from *Arabidopsis thaliana* L. catalyzes the conversion of L-phenylalanine to phenylacetaldoxime in the biosynthesis of benzylglucosinolate. *J Biol Chem* 2000 May 12;275(19):14659-66.
- Wolf ME, Mosnaim AD. Phenylethylamine in neuropsychiatric disorders. *Gen Pharmacol* 1983;14(4):385-90.
- Wolf-Novak LC, Stegink LD, Brummel MC, Persoon TJ, Filer LJ Jr, Bell EF, Ziegler EE, Krause WL. Aspartame ingestion with and without carbohydrate in phenylketonuric and normal subjects: effect on plasma concentrations of amino acids, glucose, and insulin. *Metabolism* 1990 Apr;39(4):391-6.
- Wolfe JM. Regulation of cerebral serotonin metabolism in experimental phenylketonuria [dissertation]. New York: City University of New York; 1986. 170 p.
- Wong RG, Acosta PB, Jones D, Koch R. Mineral balance in treated phenylketonuric children. *J Am Diet Assoc* 1970 Sep;57(3):229-33.
- Woo SL. Molecular basis and population genetics of phenylketonuria. *Biochemistry* 1989 Jan 10;28(1):1-7.
- Woo SL, Gillam SS, Woolf LI. The isolation and properties of phenylalanine hydroxylase from human liver. *Biochem J* 1974 Jun;139(3):741-9.
- Wood JM, Schallreuter-Wood KU, Lindsey NJ, Callaghan S, Gardner ML. A specific tetrahydrobiopterin binding domain on tyrosinase controls melanogenesis. *Biochem Biophys Res Commun* 1995 Jan 17;206(2):480-5.
- Wood N, Tyfield L, Bidwell J. Rapid classification of phenylketonuria genotypes by analysis of heteroduplexes generated by PCR-amplifiable synthetic DNA. *Hum Mutat* 1993;2(2):131-7.
- Wretborn M, Humble E, Ragnarsson U, Engstrom L. Amino acid sequence at the phosphorylated site of rat liver phenylalanine hydroxylase and phosphorylation of a corresponding synthetic peptide. *Biochem Biophys Res Commun* 1980 Mar 28;93(2):403-8.
- Wulff K, Herrmann FH, Wehnert M, Seidlitz G, Schutz M. [Genetic diagnosis in classical phenylketonuria]. *Z Arztl Fortbild (Jena)* 1988;82(22):1127-31. (Ger).
- Wykes LJ, Ball RO, Menendez CE, Ginther DM, Pencharz PB. Glycine, leucine, and phenylalanine flux in low-birth-weight infants during parenteral and enteral feeding. *Am J Clin Nutr* 1992 May;55(5):971-5.
- Wyse AT, Noriler ME, Borges LF, Floriano PJ, Silva CG, Wajner M, Wannmacher CM. Alanine prevents the decrease of Na⁺,K⁺-ATPase activity in experimental phenylketonuria. *Metab Brain Dis* 1999 Jun;14(2):95-101.
- Wyse AT, Sarkis JJ, Cunha-Filho JS, Teixeira MV, Schetinger MR, Wajner M, Milton C, Wannmacher D. Effect of phenylalanine and its metabolites on ATP diphosphohydrolase activity in synaptosomes from rat cerebral cortex. *Neurochem Res* 1994 Sep;19(9):1175-80.
- Wyse AT, Sarkis JJ, Cunha-Filho JS, Teixeira MV, Schetinger MR, Wajner M, Wannmacher CM. ATP

- diphosphohydrolase activity in synaptosomes from cerebral cortex of rats subjected to chemically induced phenylketonuria. *Braz J Med Biol Res* 1995 Jun;28(6):643-9.
- Xia T. The mechanism of regulation of phenylalanine hydroxylase by (6R)-tetrahydrobiopterin and 7,8-dihydrobiopterin [dissertation]. University Park (PA): The Pennsylvania State University; 1990. 176 p.
- Xia T, Gray DW, Shiman R. Regulation of rat liver phenylalanine hydroxylase. III. Control of catalysis by (6R)-tetrahydrobiopterin and phenylalanine. *J Biol Chem* 1994 Oct 7;269(40):24657-65.
- Yadav G, Farag TI, al Awadi SA, Sam T, Marafie MJ, Bastaki L, el Khalifa MY, Kasrawi B, Wahba RA. Aminoacidopathies among institutionalised mentally retarded in Kuwait [letter]. *Clin Genet* 1992 Oct;42(4):212.
- Yadav GC, Reavey PC. Aminoacidopathies: a review of 3 years experience of investigations in a Kuwait hospital. *J Inherit Metab Dis* 1988;11(3):277-84.
- Yamakawa A, Kameoka Y, Hashimoto K, Yoshitake Y, Nishikawa K, Tanihara K, Date T. cDNA cloning and chromosomal mapping of genes encoding novel protein kinases termed PKU-alpha and PKU-beta, which have nuclear localization signal. *Gene* 1997 Nov 20;202(1-2):193-201.
- Yamamoto H. Brain phenylalanine and tyrosine levels and hepatic encephalopathy induced by CCl4 in rats. *Toxicology* 1990 Apr 30;61(3):241-7.
- Yamamoto Y, Makita K, Muramatsu K. Self-selection of phenylalanine in the rat. *J Nutr Sci Vitaminol (Tokyo)* 1984 Jun;30(3):273-83.
- Yamamoto Y, Suzuki T, Muramatsu K. Effects of high dietary phenylalanine and p-chlorophenylalanine (Para-chlorophenylalanine) treatment on phenylalanine metabolism in the rat (Amino acid balance). *Agric Biol Chem* 1982 Oct;46(10):2491-7.
- Yamashita M, Minato S, Arai M, Kishida Y, Nagatsu T, Umezawa H. Purification of phenylalanine hydroxylase from human adult and foetal livers with a monoclonal antibody. *Biochem Biophys Res Commun* 1985 Nov 27;133(1):202-7.
- Yanai K, Inuma K, Matsuzawa T, Ito M, Miyabayashi S, Narisawa K, Ido T, Yamada K, Tada K. Cerebral glucose utilization in pediatric neurological disorders determined by positron emission tomography. *Eur J Nucl Med* 1987;13(6):292-6.
- Yang AS. EPR studies of phenylalanine hydroxylase, transferrin and spin phosphorylase b [dissertation]. Baltimore (MD): The Johns Hopkins University; 1986. 199 p.
- Yang J, Wang P, Pittard AJ. Mechanism of repression of the aroP P2 promoter by the TyrR protein of *Escherichia coli*. *J Bacteriol* 1999 Oct;181(20):6411-8.
- Yang SI, Furuse M, Sugishita N, Okumura J. Effect of phenylalanine on pancreatic amylase secretion in chicks (*Gallus domesticus*). *Comp Biochem Physiol A Comp Physiol* 1990;97(4):531-3.
- Yannicelli S, Ryan A. Improvements in behaviour and physical manifestations in previously untreated adults with phenylketonuria using a phenylalanine-restricted diet: a national survey. *J Inherit Metab Dis* 1995;18(2):131-4.
- Yeoh GC, Edkins E, Mackenzie K, Fuller S, Mercer JF, Dahl HH. The development of phenylalanine hydroxylase in rat liver; in vivo, and in vitro studies utilizing fetal hepatocyte cultures. *Differentiation* 1988 Jun;38(1):42-8.
- Yoneyama T, Hatakeyama K. Decameric GTP cyclohydrolase I forms complexes with two pentameric GTP cyclohydrolase I feedback regulatory proteins in the presence of phenylalanine or of a combination of tetrahydrobiopterin and GTP. *J Biol Chem* 1998 Aug 7;273(32):20102-8.
- Yoon C. Total synthesis of folic acid analogs and biopterin analogs [dissertation]. Princeton (NJ): Princeton University; 1989. 161 p.
- Yoshioka S, Masada M, Yoshida T, Mizokami T, Akino M, Matsuo N, Tsuchiya T, Seki T, Arashima S, Kawaguchi M. A defective enzyme in hyperphenylalaninaemia due to biopterin deficiency. *J Inherit Metab Dis* 1983;6(3):127-8.
- Yudkoff M, Segal S. Absent phenylalanine hydroxylase activity without phenylketonuria. *Eur J Pediatr* 1980 Jun;134(1):85-6.
- Zachara BA, Wasowicz W, Gromadzinska J, Sklodowska M, Cabalska B. Red blood cell glutathione peroxidase activity as a function of selenium supplementation in dietary treated children with phenylketonuria. *Biomed Biochim Acta* 1987;46(2-3):S209-13.
- Zamotrinskii AV, Chestkov VV. [The use of highly sensitive immunoblotting for detecting the phenylalanine hydroxylase antigen in human platelets]. *Vopr Med Khim* 1990 Sep-Oct;36(5):34-6. (Rus).
- Zamotrinskii AV, Jennings IG, Cotton RG, Chestkov VV. [Detection of phenylalanine hydroxylase protein in human platelets. Immunochemical detection]. *Biokhimiia* 1990 Apr;55(4):760-5. (Rus).
- Zanic-Grubisic T, Lipovac K. Disturbances of amino acid transport in rats with experimental

hyperphenylalaninaemia. *J Inherit Metab Dis* 1981;4(2):105-6.

Zello GA. Human phenylalanine and lysine requirements determined by oxidation [dissertation]. Toronto (Canada): University of Toronto; 1992. 256 p.

Zello GA, Pencharz PB, Ball RO. Phenylalanine flux, oxidation, and conversion to tyrosine in humans studied with L-[1-13C]phenylalanine. *Am J Physiol* 1990 Dec;259(6 Pt 1):E835-43.

Zhao G. Biosynthesis of phenylalanine and tyrosine in *Pseudomonas* and *Zymomonas mobilis*: molecular cloning of the genes encoding cyclohexadienyl dehydratase and cyclohexadienyl characterization of the gene products [dissertation]. Gainesville (FL): The University of Florida; 1991. 129 p.

Zhao G. [Inherited metabolic aberration of phenylalanine in the family members of patients with essential hypertension and stroke]. *Chung Hua I Hsueh Tsa Chih (Taipei)* 1991 Jul;71(7):388-90, 28. (Chi).

Zschocke J, Carson DJ. Transient neonatal hyperphenylalaninaemia is not related to mutations at the phenylalanine hydroxylase gene. *J Inherit Metab Dis* 1995;18(3):369-70.

Zschocke J, Graham CA, Stewart FJ, Carson DJ, Nevin NC. Non-phenylketonuria hyperphenylalaninaemia in Northern Ireland: frequent mutation allows screening and early diagnosis. *Hum Mutat* 1994;4(2):114-8.

Zygulska M, Eigel A, Pietrzyk JJ, Horst J. Phenylalanine hydroxylase gene: a novel splice mutation in intron 2 in two German and Polish families with severe phenylketonuria. *Hum Mutat* 1993;2(3):238-9.

Zygulska M, Eigel A, Pietrzyk JJ, Miny P, Horst J. A novel mutation in exon 8 of the phenylalanine hydroxylase gene in the Polish population. *Hum Mutat* 1993;2(1):74-6.

Psychology, Neuropsychology, Sociology, and Behavior

Aarseth J, Vandvik IH, Heyerdahl S, Kindt E, Motzfeldt K, Halvorsen S. [Children with phenylketonuria (Folling's disease). Intellectual functions and psychological adaptation]. *Tidsskr Nor Laegeforen* 1989 Nov 30;109(33):3416-8. (Nor).

Abadie V, Rey F, Plainguet F, Rey J. [Intellectual development after relaxing the diet at the age of 5 years in typical phenylketonuria]. *Arch Fr Pediatr* 1992 Nov;49(9):773-8. (Fre).

Acosta PB, Dobson JC. Two metabolic factors in causation. In: Koch R, Dobson JC, editors. *The mentally retarded child and his family: a multidisciplinary handbook*. New York: Brunner/Mazel; c1976. p. 100-15.

Agostoni C. Early breastfeeding linked to higher intelligence quotient scores [letter]. *Acta Paediatr* 1996 May;85(5):639.

Allen RJ, Schwartz E, Hufstetler D. PKU diet termination at age three years: psychological stability with variable neurological effects. In: Naruse H, Irie M, editors. *Neonatal screening. Proceedings of the 2nd International Conference on Neonatal Thyroid Screening; 1982 Aug 16-19; Tokyo and the International Symposium on Neonatal Screening for Inborn Errors of Metabolism; 1982 Aug 19-21; Tokyo*. Princeton (NJ): Excerpta Medica; 1983. p. 229-30. (International congress series; no. 606).

Alm J, Bodegard G, Larsson A, Nyberg G, Zetterstrom R. Children with inborn errors of phenylalanine metabolism: prognosis and phenylalanine tolerance. *Acta Paediatr Scand* 1986 Jul;75(4):619-25.

Ananth J, Brown RD, Kravitz E. Familial manic depression, phenylketonuria and acromegaly [letter]. *Can J Psychiatry* 1982 Apr;27(3):258-60.

Anderson DN, Wilkinson AM, Abou-Saleh MT, Blair JA. Recovery from depression after electroconvulsive therapy is accompanied by evidence of increased tetrahydrobiopterin-dependent hydroxylation. *Acta Psychiatr Scand* 1994 Jul;90(1):10-3.

Anderson GH, Leiter LA. Effects of aspartame and phenylalanine on meal-time food intake of humans. *Appetite* 1988;11Suppl 1:48-53.

Antisdel JE, Chrisler JC. Comparison of eating attitudes and behaviors among adolescent and young women with type 1 diabetes mellitus and phenylketonuria. *J Dev Behav Pediatr* 2000 Apr;21(2):81-6.

- Archer LA, Cunningham CE, Whelan DT. Coping with dietary therapy in phenylketonuria: A case report. *Can J Behav Sci* 1988 Oct;20(4):461-6.
- Arnold GL, Kramer BM, Kirby RS, Plumeau PB, Blakely EM, Sanger Cregan LS, Davidson PW. Factors affecting cognitive, motor, behavioral and executive functioning in children with phenylketonuria. *Acta Paediatr* 1998 May;87(5):565-70.
- Awiszus D, Unger I. Coping with PKU: results of narrative interviews with parents. *Eur J Pediatr* 1990;149 Suppl 1:S45-51.
- Azen C, Koch R, Friedman E, Wenz E, Fishler K. Summary of findings from the United States Collaborative Study of children treated for phenylketonuria. *Eur J Pediatr* 1996 Jul;155 Suppl 1:S29-32.
- Azen CG, Koch R, Friedman EG, Berlow S, Coldwell J, Krause W, Matalon R, McCabe E, O'Flynn M, Peterson R, et al. Intellectual development in 12-year-old children treated for phenylketonuria. *Am J Dis Child* 1991 Jan;145(1):35-9. Comment in: *Am J Dis Child* 1991 Jan;145(1):33.
- Aziz AA, Blair JA, Leeming RJ, Sylvester PE. Tetrahydrobiopterin metabolism in Down's syndrome and in non-Down's syndrome mental retardation. *J Ment Defic Res* 1982 Jun;26 (Pt 2):67-71.
- Badali S, Izvorski R, Ozawa K, Diamond A, Ullman M. Phenylketonuria as a model for investigating the role of dorsolateral prefrontal cortex in language. *J Cogn Neurosci* 1999;95.
- Baker GB, Bornstein RA, Rouget AC, Ashton SE, et al. Phenylethylaminergic mechanisms in attention-deficit disorder. *Biol Psychiatry* Jan 1991;29(1):15-22.
- Barclay A, Walton O. Phenylketonuria: implications of initial serum phenylalanine levels on cognitive development. *Psychol Rep* 1988 Aug;63(1):135-42.
- Baron-Cohen S, Moriarty J. Developmental dysexecutive syndrome: Does it exist? A neuropsychological perspective. In: Robertson MM, Eapen V, et al., editors. *Movement and allied disorders in childhood*. Chichester (UK): John Wiley & Sons; 1995. p. 306-16.
- Barwell BE, Pollitt RJ. [Attitude of parents toward the prenatal diagnosis of phenylketonuria]. *Arch Fr Pediatr* 1987;44 Suppl 1:665-6. (Fre).
- Batshaw ML, Valle D, Bessman SP. Unsuccessful treatment of phenylketonuria with tyrosine. *J Pediatr* 1981 Jul;99(1):159-60.
- Batterham ES, Bayley HS. Effect of frequency of feeding of diets containing free or protein-bound lysine on the oxidation of [14C]lysine or [14C]phenylalanine by growing pigs. *Br J Nutr* 1989 Nov;62(3):647-55.
- Battistini S, De Stefano N, Parlanti S, Federico A. Unexpected white matter changes in an early treated PKU case and improvement after dietary treatment. *Funct Neurol* 1991 Apr-Jun;6(2):177-80.
- Baumeister AA, Baumeister AA. Dietary treatment of destructive behavior associated with hyperphenylalaninemia. *Clin Neuropharmacol* 1998 Jan-Feb;21(1):18-27.
- Beasley MG, Costello PM, Smith I. Intellectual status of young adults with phenylketonuria (PKU). In: Farriaux JP, Dhondt JL, editors. *New horizons in neonatal screening. Proceedings of the 9th International Neonatal Screening Symposium and the 2nd Meeting of the International Society for Neonatal Screening*; 1993 Sep 13-17; Lille, France. New York: Elsevier Science; 1994. p. 109-10. (International congress series; no. 1041).
- Beasley MG, Costello PM, Smith I. Outcome of treatment in young adults with phenylketonuria detected by routine neonatal screening between 1964 and 1971. *Q J Med* 1994 Mar;87(3):155-60.
- Beasley MG, Lobasher M, Henley S, Smith I. Errors in computation of WISC and WISC-R intelligence quotients from raw scores. *J Child Psychol Psychiatry* 1988 Jan;29(1):101-4.
- Belopolskaya NL. [Psychological preparation for school of the children with treated phenylketonuria]. *Defektologiya* 1988;2:69-75. (Rus).
- Berenbaum SA. Neuropsychological follow-up in neonatal screening: issues, methods and findings. *Acta Paediatr Suppl* 1999 Dec;88(432):83-7.
- Berry HK, Brunner RL, Hunt MM, White PP. Valine, isoleucine, and leucine. A new treatment for phenylketonuria. *Am J Dis Child* 1990 May;144(5):539-43.
- Berry HK, Hsieh MH, Bofinger MK, Schubert WK. Diagnosis of phenylalanine hydroxylase deficiency (phenylketonuria). *Am J Dis Child* 1982 Feb;136(2):111-4.
- Bessman SP. Historical perspective: tyrosine and maternal phenylketonuria, welcome news [editorial]. *Am J Clin Nutr* 1998 Mar;67(3):357-8. Comment on: *Am J Clin Nutr* 1998 Mar;67(3):473-6. Comment in: *Am J Clin Nutr* 1998 Mar;67(3):488; *Am J Clin Nutr* 1998 Dec;68(6):1304-6.

- Bessman SP. The justification theory: the essential nature of the non-essential amino acids. *Nutr Rev* 1979 Jul;37(7):209-20.
- Bessman SP, Williamson ML, Koch R. Diet, genetics, and mental retardation interaction between phenylketonuric heterozygous mother and fetus to produce nonspecific diminution of IQ: evidence in support of the justification hypothesis. *Proc Natl Acad Sci U S A* 1978 Mar;75(3):1562-6.
- Blaskovics M, Engel R, Podosin RL, Azen CG, Friedman EG. EEG pattern in phenylketonuria under early initiated dietary treatment. *Am J Dis Child* 1981 Sep;135(9):802-8.
- Blaskovics ME. Diagnosis in relationship to treatment of hyperphenylalaninaemia. *J Inherit Metab Dis* 1986;9 Suppl 2:178-82.
- Bludzin YuA, Zuber VL. [Composition of fatty acids of glycerophospholipids in the brain of growing rats during demyelination]. *Nervn Sist* 1982;1982(23):125-9. (Rus).
- Blumina MG, Lebedev BV, Kopylova NV, Sitnichenko EI, Gerasimova NS. [Relationship between the severity of brain damage in phenylketonuria and the degree of hyperphenylalaninemia]. *Zh Nevropatol Psikhiatr* 1980;80(12):1778-81. (Rus).
- Blomquist HK, Gustavson KH, Holmgren G. Severe mental retardation in five siblings due to maternal phenylketonuria. *Neuropediatrics* 1980 Aug;11(3):256-61.
- Blumina MG. [Children with late treated phenylketonuria at the auxiliary school]. *Defektologiya* 1980;5:25-31. (Rus).
- Bodley JL, Austin VJ, Hanley WB, Clarke JT, Zlotkin S. Low iron stores in infants and children with treated phenylketonuria: a population at risk for iron-deficiency anaemia and associated cognitive deficits. *Eur J Pediatr* 1993 Feb;152(2):140-3.
- Bornholdt S. Family functioning and child resilience among children with phenylketonuria [dissertation]. New York: City University of New York; 1999. 201 p.
- Branchey L, et al. Association between amino acid alterations and hallucinations in alcoholic patients. *Biol Psychiatry* 1985 Nov;20(11):1167-73.
- Brenton DP, Lilburn M. Maternal phenylketonuria. A study from the United Kingdom. *Eur J Pediatr* 1996 Jul;155 Suppl 1:S177-80.
- Brunner RL, Berch DB, Berry H. Phenylketonuria and complex spatial visualization: an analysis of information processing. *Dev Med Child Neurol* 1987 Aug;29(4):460-8.
- Brunner RL, Berry HK. Phenylketonuria and sustained attention: The continuous performance test. *Int J Clin Neuropsychol* 1987;9(2):68-70.
- Brunner RL, Brown EH, Berry HK. Phenylketonuria revisited: treatment of adults with behavioural manifestations. *J Inherit Metab Dis* 1987;10(2):171-3.
- Brunner RL, Jordan MK, Berry HK. Early-treated phenylketonuria: neuropsychologic consequences. *J Pediatr* 1983 Jun;102(6):831-5.
- Brusov OS, Lideman RR. [Nerve growth factor and the state of serotonergic system in endogenous depression and mental retardation]. *Vestn Ross Akad Med Nauk* 1992;(8):16-21. (Rus).
- Buist NR, Tuerck J, Lis E, Penn R. Effects of untreated maternal phenylketonuria and hyperphenylalaninemia on the fetus [letter]. *N Engl J Med* 1984 Jul 5;311(1):52-3.
- Bulakhova LA, Usherenko LS. [Biogenic amine metabolism in patients with oligophrenia of different origins]. *Zh Nevropatol Psikhiatr* 1983;83(10):1563-7. (Rus).
- Burgard P, Armbruster M, Schmidt E, Rupp A. Psychopathology of patients treated early for phenylketonuria: results of the German collaborative study of phenylketonuria. *Acta Paediatr Suppl* 1994 Dec;407:108-10.
- Burgard P, Bremer HJ, Buhrdel P, Clemens PC, Monch E, Przyrembel H, Trefz FK, Ullrich K. Rationale for the German recommendations for phenylalanine level control in phenylketonuria 1997. *Eur J Pediatr* 1999 Jan;158(1):46-54.
- Burgard P, Rey F, Rupp A, Abadie V, Rey J. Neuropsychologic functions of early treated patients with phenylketonuria, on and off diet: results of a cross-national and cross-sectional study. *Pediatr Res* 1997 Mar;41(3):368-74.
- Burgard P, Schmidt E, Rupp A, Schneider W, Bremer HJ. Intellectual development of the patients of the German Collaborative Study of children treated for phenylketonuria. *Eur J Pediatr* 1996 Jul;155 Suppl 1:S33-8.
- Burns JK, Azen CG, Rouse B, Vespa H. Impact of PKU on the reproductive patterns in collaborative study families. *Am J Med Genet* 1984 Nov;19(3):515-24.
- Cabral A, Portela R, Tasso T, Eusebio F, Guilherme A, Lorga L, De Almeida IT, Silveira C, Levy ML. [Phenylketonuria--physical and mental development

- of phenylketonuric children subjected to early treatment]. *Acta Med Port* 1989 Jan-Feb;2(1):1-5. (Por).
- Caldwell J. Maternal PKU -- a new threat to the unborn... a major cause of new cases of mental retardation. *Am-Baby Prenatal Ed* 1981 Oct;43:16 passim.
- Campistol Plana J, Arellano Pedrola M, Poo Arguelles P, Escofet Sotera C, Perez Olarte P, Vilaseca Busca MA. [Embryonic pathology caused by maternal phenylketonuria. A cause of underdiagnosed mental retardation. A report of 8 cases]. *An Esp Pediatr* 1999 Aug;51(2):139-42. (Spa).
- Carbary LJ, Carbary CN. PKU disease. *J Nurs Care* 1981 Dec;14:16-8.
- Cartier L, Clow CL, Lippman-Hand A, Morissette J, Scriver CR. Prevention of mental retardation in offspring of hyperphenylalaninemic mothers. *Am J Public Health* 1982 Dec;72(12):1386-90.
- Cechak P, Hejmanova L, Rupp A. Long-term follow-up of patients treated for phenylketonuria (PKU). Results from the Prague PKU Center. *Eur J Pediatr* 1996 Jul;155 Suppl 1:S59-63.
- Centerwall SA, Centerwall WR. The discovery of phenylketonuria: the story of a young couple, two retarded children, and a scientist. *Pediatrics* 2000 Jan;105(1 Pt 1):89-103.
- Cerone R, Schiaffino MC, Di Stefano S, Veneselli E. Phenylketonuria: diet for life or not? *Acta Paediatr* 1999 Jun;88(6):664-6.
- Chamove AS. Analysis of learning in retarded monkeys. *J Ment Defic Res* 1984 Mar;28 (Pt 1):21-41.
- Chamove AS. Dietary and metabolic effects on rhesus social behavior: phenylalanine-related dietary alterations. *Dev Psychobiol* 1980 May;13(3):299-307.
- Chamove AS. Long-term learning deficits of mentally retarded monkeys. *Am J Ment Defic* 1984 Jan;88(4):352-68.
- Chang P, Cook RD, Fisch RO. Prognostic factors of the intellectual outcome of phenylketonurics: On and off diet. *J Psychiatr Treat Eval* 1983;5(2-3):157-63.
- Chang PN, Weisberg S, Fisch RO. Growth development and its relationship to intellectual functioning of children with phenylketonuria. *J Dev Behav Pediatr* 1984 Jun;5(3):127-31.
- Choi YH, Furuse M, Okumura J, Shimoyama Y, Sugahara K, Denbow DM. Intracerebroventricularly administered phenylalanine and tyrosine: effects on feeding behavior and norepinephrine concentrations of specific brain sites in the chicken. *Asian Australas J Anim Sci* 1996 Jun;9(3):255-9.
- Cipic-Schmidt S, Trefz FK, Funders B, Seidlitz G, Ullrich K. German Maternal Phenylketonuria Study. *Eur J Pediatr* 1996 Jul;155 Suppl 1:S173-6.
- Clarke JT, Gates RD, Hogan SE, Barrett M, MacDonald GW. Neuropsychological studies on adolescents with phenylketonuria returned to phenylalanine-restricted diets. *Am J Ment Retard* 1987 Nov;92(3):255-62.
- Clarke S, Remington B, Light P. The role of referential speech in sign learning by mentally retarded children: A comparison of total communication and sign-alone training. *J Appl Behav Anal* 1988 Winter;21(4):419-26.
- Clary MA, Walter JH, Wraith JE, Jenkins JP, Alani SM, Tyler K, Whittle D. Magnetic resonance imaging of the brain in phenylketonuria. *Lancet* 1994 Jul 9;344(8915):87-90.
- Cobet G, Witkowski R. [Correlation between biochemical-biological parameters and intellectual development in treated phenylketonuria children]. *Samml Zwangl Abh Geb Psychiatr Neurol* 1982;50:269-75. (Ger).
- Colombo M, Troncoso L, Raimann E, Perales CG, Barros TL, Cornejo V. [Diagnosis of phenylketonuria in Chile]. *Rev Chil Pediatr* 1988 Jul-Aug;59(4):235-9. (Spa).
- Coskun T, Topcu M, Ustundag I, Ozalp I, Renda Y, Ciger A, Nurlu G. Neurophysiological studies of patients with classical phenylketonuria: evaluation of results of IQ scores, EEG and evoked potentials. *Turk J Pediatr* 1993 Jan-Mar;35(1):1-10.
- Costello PM, Beasley MG, Tillotson SL, Smith I. Intelligence in mild atypical phenylketonuria. *Eur J Pediatr* 1994 Apr;153(4):260-3.
- Costello PM, Beasley MG, Tillotson SL, Smith I. Intelligence in relation to phenylalanine concentrations in mild phenylketonuria (PKU). In: Farriaux JP, Dhondt JL, editors. *New horizons in neonatal screening. Proceedings of the 9th International Neonatal Screening Symposium and the 2nd Meeting of the International Society for Neonatal Screening*; 1993 Sep 13-17; Lille, France. New York: Elsevier Science; 1994. p. 107-8. (International congress series; no. 1041).
- Cowie V. The effect of the environment... can put fetuses at risk of mental subnormality. *Nurs Mirror* 1982 Sep 15;155(11):34-6.
- Cowie V. Genetic causes of retardation. *Nurs Mirror* 1982 Sep 15;155(11):29-34.

- Cowie V. Injury and insult--considerations of the neuropathological aetiology of mental subnormality. *Br J Psychiatry* 1980 Oct;137:305-12.
- Craft S, Gourovitch ML, Downton SB, Swanson JM, Bonforte S. Lateralized deficits in visual attention in males with developmental dopamine depletion. *Neuropsychologia* 1992 Apr;30(4):341-51.
- Crawford MD. Severe mental handicap: pathogenesis, treatment, and prevention. *Br Med J (Clin Res Ed)* 1982 Sep 18;285(6344):762-6.
- Crocker AC. Current strategies in prevention of mental retardation. *Pediatr Ann* 1982 May;11(5):450-4, 457.
- Crowley C, Koch R, Fishler K, Wenz E, Ireland J. Clinical trial of 'off diet' older phenylketonurics with a new phenylalanine-free product. *J Ment Defic Res* 1990 Aug;34 (Pt 4):361-9.
- Cutler P. Arginase deficiency and phenylketonuria [letter]. *J Neurol Neurosurg Psychiatry* 1986 Sep;49(9):1090.
- Dalery J, Maillet J, de Villard R. [Behavior problems in phenylketonuria. Attempt at a biochemical interpretation based on a personal case and a review of the literature]. *Encephale* 1983;9(3):279-90. (Fre).
- Davis BA, O'Reilly RL, Placatka CL, Paterson IA, Yu PH, Durden DA. Effect of dietary phenylalanine on the plasma concentrations of phenylalanine, phenylethylamine and phenylacetic acid in healthy volunteers. *Prog Neuropsychopharmacol Biol Psychiatry* 1991;15(5):611-23.
- Davis DD, McIntyre CW, Murray ME, Mims SS. Cognitive styles in children with dietary treated phenylketonuria. *Educ Psychol Res* 1986 Winter;6(1):9-15.
- de Cespedes C, Santisteban I, Ortiz D, Rojas E, Rodriguez J, Nanne C, Orlich J. [Patterns of urinary aminoacid excretion in exceptional children and patients with mental disorders in Costa Rica]. *Rev Biol Trop* 1983 Jun;31(1):1-9. (Spa).
- De Giorgis GF, Nonnis E, Crocioni F, Gregori P, Rosini MP, Leuzzi V, Loizzo A. Evolution of daytime quiet sleep components in early treated phenylketonuric infants. *Brain Dev* 1996 May-Jun;18(3):201-6.
- de Pediatria SC, de Neonatologia R. [Early diagnosis of phenylketonuria and congenital hypothyroidism. Prevention of mental retardation]. *Rev Chil Pediatr* 1988 May-Jun;59(3):200-3. (Spa).
- de Sonnevile LM, Schmidt E, Michel U, Batzler U. Preliminary neuropsychological test results. *Eur J Pediatr* 1990;149 Suppl 1:S39-44.
- de Valk HW, de Sonnevile LM, Duran M, Poll-The BT, Erkelens DW. [Phenylketonuria: a children's disease in adulthood]. *Ned Tijdschr Geneesk* 2000 Jan 1;144(1):11-5. (Dut).
- Dement'eva NF, Ermolina LA, Ezhkova VA, Mozhaeva EG. [Therapy and social adaptation of patients with mental retardation (a review of the literature)]. *Zh Nevropatol Psikiatr* 1981;81(3):439-50. (Rus).
- Dennis M, Lockyer L, Lazenby AL, Donnelly RE, Wilkinson M, Schoonheydt W. Intelligence patterns among children with high-functioning autism, phenylketonuria, and childhood head injury. *J Autism Dev Disord* 1999 Feb;29(1):5-17.
- Diamond A. Evidence for the importance of dopamine for prefrontal cortex functions early in life. *Philos Trans R Soc Lond B Biol Sci* 1996 Oct 29;351(1346):1483-93; discussion 1494.
- Diamond A. Phenylalanine levels of 6-10 mg/dl may not be as benign as once thought. *Acta Paediatr Suppl* 1994 Dec;407:89-91.
- Diamond A, Ciaramitaro V, Donner E, Djali S, Robinson MB. An animal model of early-treated PKU. *J Neurosci* 1994 May;14(5 Pt 2):3072-82.
- Diamond A, Prevor MB, Callender G, Druin DP. Prefrontal cortex cognitive deficits in children treated early and continuously for PKU. *Monogr Soc Res Child Dev* 1997;62(4):i-v, 1-208.
- Dirr KL, Katz AA. Cartoons vs. realistic illustration: picture preferences of adolescent patients. *J Biocommun* 1989;16(4):2-7.
- Dobson JC, Kushida E, Williamson M, Friedman EG. Intellectual performance of 36 phenylketonuria patients and their nonaffected siblings. *Pediatrics* 1976 Jul;58(1):53-8.
- Dobson JC, Williamson ML, Azen C, Koch R. Intellectual assessment of 111 four-year-old children with phenylketonuria. *Pediatrics* 1977 Dec;60(6):822-7.
- Donnai D. Pre-conceptual genetic advice. *Br J Family Planning* 1983 Oct;9(3):75-9.
- Dworkin RB. Common sense and common decency: some thoughts about maternal-fetal conflict. In: Humber JM, Almeder RF, editors. *Biomedical Ethics Reviews*, 1991. Bioethics and the fetus: medical, moral and legal issues. Totowa (NJ): Humana Press; 1991. p. 9-38.

- Ebomoyi E. Family planning needs in Nigeria [letter]. *World Health Forum* 1984;5(1):40-1.
- Education of students with phenylketonuria (PKU). Information for teachers, administrators and other school personnel. Bethesda (MD): National Inst. of Child Health and Human Development (US); 1991 Nov. Report No.: NIH-92-3318. Available from: ERIC, Springfield, VA; ED402717.
- Eisenberg L. Child mental health in the Americas: a public health approach. *Bull Pan Am Health Organ* 1992;26(3):230-41.
- Eisenberg L. Prevention: rhetoric and reality. *J R Soc Med* 1984 Apr;77(4):268-80.
- Endres W. [Phenylketonuria and its treatment in and beyond adolescence]. *Internist (Berl)* 1994 Mar;35(3):250-4. (Ger).
- Enns GM, Martinez DR, Kuzmin AI, Koch R, Wakeem CK, Woo SL, Eisensmith RC, Packman S. Molecular correlations in phenylketonuria: mutation patterns and corresponding biochemical and clinical phenotypes in a heterogeneous California population. *Pediatr Res* 1999 Nov;46(5):594-602.
- Estrov Y, Scaglia F, Bodamer OA. Psychiatric symptoms of inherited metabolic disease. *J Inherit Metab Dis* 2000 Feb;23(1):2-6.
- Faden RR, Chwalow AJ, Holtzman NA, Horn SD. A survey to evaluate parental consent as public policy for neonatal screening. *Am J Public Health* 1982 Dec;72(12):1347-52.
- Farriaux JP, Desombre-Denys D, Charles-Bassi MA, Dhondt JL. [Treatment of phenylketonuria. Remarks on 21 cases]. *Ann Pediatr (Paris)* 1980 May;27(5):291-5. (Fre).
- Farriaux JP, Dhondt JL, Largilliere C, Lacombe A, Valat S, Puech F. [Embryofetopathy of the newborn infant of a phenylketonuric mother. A diagnosis not to be missed]. *J Gynecol Obstet Biol Reprod (Paris)* 1993;22(1):49-52. (Fre).
- Faust D, Libon D, Puschel S. Neuropsychological functioning in treated phenylketonuria. *Int J Psychiatry Med* 1986-87;16(2):169-77.
- Fehrenbach AM. The influence of problem-solving skills on dietary compliance in mothers of children with phenylketonuria [dissertation]. Columbia (MO): University of Missouri - Columbia; 1981. 192 p.
- Fehrenbach AM, Peterson L. Parental problem-solving skills, stress, and dietary compliance in phenylketonuria. *J Consult Clin Psychol* 1989 Apr;57(2):237-41.
- Finney JW, Friman PC. Behavioral medicine approaches to the prevention of mental retardation. In: Russo DC, Kedesdy JH, et al., editors. *Behavioral medicine with the developmentally disabled*. New York: Plenum Press; 1988. p. 173-200. Sponsored by the U.S. Department of Health and Human Services.
- Fisch RO, Chang PN, Sines L, Weisberg S, Bessman SP. Relationship between phenylalanine tolerance and psychological characteristics of phenylketonuric families. *Biochem Med* 1985 Apr;33(2):236-45.
- Fisch RO, Chang PN, Weisberg S, Guldborg P, Guttler F, Tsai MY. Phenylketonuric patients decades after diet. *J Inherit Metab Dis* 1995;18(3):347-53.
- Fisch RO, Sines LK, Chang P. Personality characteristics of nonretarded phenylketonurics and their family members. *J Clin Psychiatry* 1981 Mar;42(3):106-13.
- Fishler K, Azen CG, Friedman EG, Koch R. School achievement in treated PKU children. *J Ment Defic Res* 1989 Dec;33 (Pt 6):493-8.
- Fishler K, Azen CG, Henderson R, Friedman EG, Koch R. Psychoeducational findings among children treated for phenylketonuria. *Am J Ment Defic* 1987 Jul;92(1):65-73.
- Fitzgerald B, Morgan J, Keene N, Rollinson R, Hodgson A, Dalrymple-Smith J. An investigation into diet treatment for adults with previously untreated phenylketonuria and severe intellectual disability. *J Intellect Disabil Res* 2000 Feb;44(Pt 1):53-9.
- Fletcher JC. Ethical issues in genetic screening and antenatal diagnosis. *Clin Obstet Gynecol* 1981 Dec;24(4):1151-68.
- Francois B. [Recent advances in the therapeutic approach to children with phenylketonuria]. *Rev Med Liege* 1984 May 15;39(10):416-21. (Fre).
- Fuggle P, Graham P. Metabolic/endocrine disorders and psychological functioning. In: Rutter M, Casaer P, et al., editors. *Biological risk factors for psychosocial disorders*. Cambridge (UK): Cambridge University Press; 1991. p. 175-98.
- Fulton TR, Triano T, Rabe A, Loo YH. Phenylacetate and the enduring behavioral deficit in experimental phenylketonuria. *Life Sci* 1980 Oct 6;27(14):1271-81.
- GangarosaEmerson ME, Jansiewicz ME, Emerson RL, Groover WD, Grant ML. Cognitive differences in children with type IIA and classical PKU. *Arch Clin Neuropsychol* 1999;14:7.
- Garcia Vera C, Baldellou Vazquez A, Gracia Romero J, Ventura Faci P, Perez-Gonzalez J. [An experimental

- study on the effects of maternal hyperphenylalaninemia on the central nervous system and behavior of offspring rats]. *An Esp Pediatr* 1998 Jan;48(1):11-6. (Spa).
- Garriga MM, Metcalfe DD. Aspartame intolerance. *Ann Allergy* 1988 Dec;61(6 Pt 2):63-9.
- Geesken RH, Licht R, deSonneville LM, Huijbregts SC, Ridderinkhof KR. Neurocognitive functioning in children with early-treated phenylketonuria. *Psychophysiology* 1999;36:S53.
- Gibbings B. Phenylketonuria--a personal view. *Mod Midwife* 1994 Oct;4(10):27.
- Gibson CJ, Deikel SM, Young SN, Binik Yitzchak M. Behavioural and biochemical effects of tryptophan, tyrosine and phenylalanine in mice. *Psychopharmacology* 1982 Feb;76(2):118-21.
- Giffin FD, Clarke JT, d'Entremont DM. Effect of dietary phenylalanine restriction on visual attention span in mentally retarded subjects with phenylketonuria. *Can J Neurol Sci* 1980 May;7(2):127-31.
- Gleason LA, Michals K, Matalon R, Langenberg P, Kamath S. A treatment program for adolescents with phenylketonuria. *Clin Pediatr (Phila)* 1992 Jun;31(6):331-5.
- Glick SD, Greengard O. Exaggerated cerebral lateralization in rats after early postnatal hyperphenylalaninemia. *Brain Res* 1980 Nov 24;202(1):243-8.
- Gourovitch ML. Interhemispheric transfer of information deficits in children early-treated phenylketonuria [dissertation]. St Louis (MO): Washington University; 1991. 133 p.
- Gourovitch ML, Craft S, Dowton SB, Ambrose P, Sparta S. Interhemispheric transfer in children with early-treated phenylketonuria. *J Clin Exp Neuropsychol* 1994 Jun;16(3):393-404.
- Greeves LG, Patterson CC, Carson DJ, Thom R, Wolfenden MC, Zschocke J, Graham CA, Nevin NC, Trimble ER. Effect of genotype on changes in intelligence quotient after dietary relaxation in phenylketonuria and hyperphenylalaninaemia. *Arch Dis Child* 2000 Mar;82(3):216-21.
- Griffiths P, Campbell R, Robinson P. Executive function in treated phenylketonuria as measured by the one-back and two-back versions of the continuous performance test. *J Inherit Metab Dis* 1998 Apr;21(2):125-35.
- Griffiths P, Paterson L, Harvie A. Neuropsychological effects of subsequent exposure to phenylalanine in adolescents and young adults with early-treated phenylketonuria. *J Intellect Disabil Res* 1995 Oct;39 (Pt 5):365-72.
- Griffiths P, Smith C, Harvie A. Transitory hyperphenylalaninaemia in children with continuously treated phenylketonuria. *Am J Ment Retard* 1997 Jul;102(1):27-36.
- Griffiths P, Tarrini M, Robinson P. Executive function and psychosocial adjustment in children with early treated phenylketonuria: correlation with historical and concurrent phenylalanine levels. *J Intellect Disabil Res* 1997 Aug;41 (Pt 4):317-23.
- Griffiths P, Ward N, Harvie A, Cockburn F. Neuropsychological outcome of experimental manipulation of phenylalanine intake in treated phenylketonuria. *J Inherit Metab Dis* 1998 Feb;21(1):29-38.
- Griffiths PV, Demellweek C, Fay N, Robinson PH, Davidson DC. Wechsler subscale IQ and subtest profile in early treated phenylketonuria. *Arch Dis Child* 2000 Mar;82(3):209-15.
- Gross PT, Berlow S, Schuett VE, Fariello RG. EEG in phenylketonuria. Attempt to establish clinical importance of EEG changes. *Arch Neurol* 1981 Feb;38(2):122-6.
- Guettler F, Guldberg P, Henriksen KF. Mutation genotype of mentally retarded patients with phenylketonuria. *Dev Brain Dysfunct* 1993 Jan-Jun;6(1-3):92-6.
- Guttler F, Azen C, Guldberg P, Romstad A, Hanley WB, Levy HL, Matalon R, Rouse BM, Trefz F, de la Cruz F, Koch R. Relationship among genotype, biochemical phenotype, and cognitive performance in females with phenylalanine hydroxylase deficiency: report from the Maternal Phenylketonuria Collaborative Study. *Pediatrics* 1999 Aug;104(2 Pt 1):258-62.
- Guttler F, Lou H. Dietary problems of phenylketonuria: effect on CNS transmitters and their possible role in behaviour and neuropsychological function. *J Inherit Metab Dis* 1986;9 Suppl 2:169-77.
- Guttler F, Lou H, Andresen J, Kok K, Mikkelsen I, Nielsen KB, Nielsen JB. Cognitive development in offspring of untreated and preconceptionally treated maternal phenylketonuria. *J Inherit Metab Dis* 1990;13(4):665-71.
- Guttler F, Wamberg E. Fasting serum phenylalanine in untreated institutionalised patients with phenylketonuria. *J Ment Defic Res* 1977 Mar;21(1):55-62.

- Hall JG. When is careless conception a form of child abuse? Lessons from maternal phenylketonuria [editorial]. *J Pediatr* 2000 Jan;136(1):12-3. Comment on: *J Pediatr* 2000 Jan;136(1):57-61.
- Hanaoka S, Lin J-M, Yamada M. Chemiluminescence behavior of the decomposition of hydrogen peroxide catalyzed by copper(II)-amino acid complexes and its application to the determination of tryptophan and phenylalanine. *Anal Chim Acta* 2000;409(1-2):65-73.
- Hanley WB, Clarke JT, Schoonheydt WE. Undiagnosed phenylketonuria in adult women: a hidden public health problem. *CMAJ* 1990 Sep 15;143(6):513-6.
- Hanley WB, Koch R, Levy HL, Matalon R, Rouse B, Azen C, de la Cruz F. The North American Maternal Phenylketonuria Collaborative Study, developmental assessment of the offspring: preliminary report. *Eur J Pediatr* 1996 Jul;155 Suppl 1:S169-72.
- Hanley WB, Lee AW, Hanley AJ, Lehotay DC, Austin VJ, Schoonheydt WE, Platt BA, Clarke JT. 'Hypotyrosinemia' in phenylketonuria. *Mol Genet Metabol* 2000;69(4):286-94.
- Hanulak AT, Hull EM. Behavioral deficits in a rat model of maternal PKU. *Psychobiology* 1987 Mar;15(1):75-8.
- Harper M, Reid AH. Use of a restricted protein diet in the treatment of behaviour disorder in a severely mentally retarded adult female phenylketonuric patient. *J Ment Defic Res* 1987 Jun;31 (Pt 2):209-12.
- Harper P, Roberts DF. Mating patterns and genetic disease. In: Mascie-Taylor CG, Boyce AJ, et al., editors. *Human mating patterns*. Cambridge (UK): Cambridge University Press; 1988. p. 169-81. (Society for the Study of Human Biology symposium series; no. 28).
- Harvey EL, Kirk SF. The use of a low phenylalanine diet in response to the challenging behaviour of a man with untreated phenylketonuria and profound learning disabilities. *J Intellect Disabil Res* 1995 Dec;39 (Pt 6):520-6.
- Heffernan JF, Trahms CM. A model preschool for patients with phenylketonuria. *J Am Diet Assoc* 1981 Sep;79(3):306-8.
- Hejzmanova L. [A summer camp for children with phenylketonuria--experience and possibilities]. *Cesk Pediatr* 1990 Aug;45(8):501-2. (Cze).
- Henderson HE, Goodman R, Schram J, Diamond E, Daneel A. Biochemical screening for inherited metabolic disorders in the mentally retarded. *S Afr Med J* 1981 Nov 7;60(19):731-3.
- Henderson RM, McCulloch DL, Herbert AM, Robinson PH, Taylor MJ. Visual event-related potentials in children with phenylketonuria. *Acta Paediatr* 2000 Jan;89(1):52-7.
- Hendrikx MM, van der Schot LW, Slijper FM, Huisman J, Kalverboer AF. Phenylketonuria and some aspects of emotional development. *Eur J Pediatr* 1994 Nov;153(11):832-5.
- Hickey CA, Covington C. Maternal phenylketonuria: case management as a preventive approach to a chronic condition affecting pregnancy. *NAACOGS Clin Issu Perinat Womens Health Nurs* 1990;1(2):214-25.
- Hilliges C, Awiszus D, Wendel U. Intellectual performance of children with maple syrup urine disease. *Eur J Pediatr* 1993 Feb;152(2):144-7.
- Hirano S, Takagi Y, Kanamatsu T, Nakai K. Effects of hyperphenylalaninemia in the fetal stage on the postnatal development of fetal rat brain. *Neurochem Res* 1985 Aug;10(8):1071-81.
- Holder MD. Effects of perinatal exposure to aspartame on rat pups. *Neurotoxicol Teratol* 1989 Jan-Feb;11(1):1-6.
- Holmgren G, Blomquist HK, Samuelson G. Positive effect of a late introduced modified diet in an 8-year-old pku child. *Neuropadiatrie* 1980 Feb;11(1):76-9.
- Holt KS. Diets and development. *Child Care Health Dev* 1982 Jul-Aug;8(4):183-201.
- Holtzman NA, Kronmal RA, van Doorninck W, Azen C, Koch R. Effect of age at loss of dietary control on intellectual performance and behavior of children with phenylketonuria. *N Engl J Med* 1986 Mar 6;314(10):593-8.
- Hommel FA. The role of the blood-brain barrier in the aetiology of permanent brain dysfunction in hyperphenylalaninaemia. *J Inherit Metab Dis* 1989;12(1):41-6.
- Hoskin RG, Sasitharan T, Howard R. The use of a low phenylalanine diet with amino acid supplement in the treatment of behavioural problems in a severely mentally retarded adult female with phenylketonuria. *J Intellect Disabil Res* 1992 Apr;36 (Pt 2):183-91.
- Howell RR, Stevenson RE. The offspring of phenylketonuric women. *Soc Biol* 1971 Sep;18:S19-29.
- Hsiao KJ, Chen CH, Liu TT, Wu SJ, Plettner C, Clemens P. Screening of congenital hypothyroidism, phenylketonuria, galactosemia, homocystinuria, and maple syrup urine disease in moderate to severe

- mentally retarded Chinese children. *Taiwan I Hsueh Hui Tsa Chih* 1989 Jan;88(1):18-22.
- Huisman J, Slijper FM, Hendriks MM, Kalverboer AF, van der Schot L. [Intelligence of phenylketonuria patients treated early; 10-year psychological follow-up in the Netherlands]. *Ned Tijdschr Geneesk* 1985 Nov 2;129(44):2120-3. (Dut).
- Huisman J, van der Schot LW, Hendriks MM, Kalverboer AF, Slijper FM. [Intellectual development of patients with phenylketonuria; 15-year national screening in The Netherlands]. *Ned Tijdschr Geneesk* 1992 Nov 14;136(46):2277-81. (Dut).
- Hyland K, Smith I, Leonard JV. Bipterins in arginase, dihydropteridine reductase and phenylalanine hydroxylase deficiency [letter]. *J Neurol Neurosurg Psychiatry* 1987 Feb;50(2):242.
- Ionescu S. [Psychophysiology of mental deficiency: evaluation of studies involving the recording of autonomic indices]. *Psychiatr Infant* 1985;28(1):39-134. (Fre).
- Jancar J. Increased life expectancy in people with untreated phenylketonuria. *J Intellect Disabil Res* 1998 Feb;42 (Pt 1):97-9.
- Janssen PJ, van der Heijden CA. Aspartame: review of recent experimental and observational data. *Toxicology* 1988 Jun;50(1):1-26.
- Jardim LB, Palma-Dias R, Silva LC, Ashton-Prolla P, Giugliani R. Maternal hyperphenylalaninaemia as a cause of microcephaly and mental retardation. *Acta Paediatr* 1996 Aug;85(8):943-6.
- Johnston MV, Singer HS. Brain neurotransmitters and neuromodulators in pediatrics. *Pediatrics* 1982 Jul;70(1):57-68.
- Jones SJ, Turano G, Kriss A, Shawkat F, Kendall B, Thompson AJ. Visual evoked potentials in phenylketonuria: association with brain MRI, dietary state, and IQ. *J Neurol Neurosurg Psychiatry* 1995 Sep;59(3):260-5.
- Jordan MK, Brunner RL, Hunt MM, Berry HK. Preliminary support for the oral administration of valine, isoleucine and leucine for phenylketonuria. *Dev Med Child Neurol* 1985 Feb;27(1):33-9.
- Kalverboer AF, van der Schot LW, Hendriks MM, Huisman J, Slijper FM, Stemerink BA. Social behaviour and task orientation in early-treated PKU. *Acta Paediatr Suppl* 1994 Dec;407:104-5.
- Kaplan H, Triano T, Donadio M. Behavioral deficit in phenylketonuric rats: role of aromatic acid metabolites of phenylalanine. *Dev Psychobiol* 1981 May;14(3):201-7.
- Kazak AE. Families with disabled children: stress and social networks in three samples. *J Abnorm Child Psychol* 1987 Mar;15(1):137-46.
- Kazak AE, Reber M, Carter A. Structural and qualitative aspects of social networks in families with young chronically ill children. *J Pediatr Psychol* 1988 Jun;13(2):171-82.
- Kazak AE, Reber M, Snitzer L. Childhood chronic disease and family functioning: a study of phenylketonuria. *Pediatrics* 1988 Feb;81(2):224-30.
- Kesby G. Repeated adverse fetal outcome in pregnancy complicated by uncontrolled maternal phenylketonuria. *J Paediatr Child Health* 1999 Oct;35(5):499-502.
- Kietduriyakul V, Komkris V, Tongkittikul K, Leanghibul P. The incidence of phenylketonuria in Thailand. *J Med Assoc Thai* 1989 Sep;72(9):516-9.
- Kirkman HN. Projections of a rebound in frequency of mental retardation from phenylketonuria. *Appl Res Ment Retard* 1982;3(3):319-28.
- Kirkman HN Jr, Hicks RE. More on untreated maternal hyperphenylalaninemia [letter]. *N Engl J Med* 1984 Oct 25;311(17):1125-6.
- Klein D, Marcoz JP, Mounoud RL, Bettschart W. [Final result of a clinical, genetic and cytogenetic investigation of 182 mentally retarded patients of a medico-educative institution]. *Schweiz Rundsch Med Prax* 1982 Jul 27;71(30):1209-21. (Fre).
- Knoll E, Wehle E, Thalhammer O. [Psychometry and psychological observations in early treated children with phenylketonuria (PKU) during 12 years (author's transl)]. *Klin Padiatr* 1980 Nov;192(6):599-607. (Ger).
- Koch R, Azen C, Friedman EG, Fishler K, Baumann-Frischling C, Lin T. Care of the adult with phenylketonuria. *Eur J Pediatr* 1996 Jul;155 Suppl 1:S90-2.
- Koch R, Azen C, Friedman EG, Williamson ML. Paired comparisons between early treated PKU children and their matched sibling controls on intelligence and school achievement test results at eight years of age. *J Inherit Metab Dis* 1984;7(2):86-90.
- Koch R, Azen CG, Friedman EG, Williamson ML. Preliminary report on the effects of diet discontinuation in PKU. *J Pediatr* 1982 Jun;100(6):870-5.
- Koch R, Azen CG, Hurst N, Friedman EG, Fishler K. The effects of diet discontinuation in children with

- phenylketonuria. *Eur J Pediatr* 1987;146 Suppl 1:A12-6.
- Koch R, Fishler K, Azen C, Guldborg P, Guttler F. The relationship of genotype to phenotype in phenylalanine hydroxylase deficiency. *Biochem Mol Med* 1997 Apr;60(2):92-101.
- Koch R, Levy HL, Matalon R, Rouse B, Hanley W, Azen C. The North American Collaborative Study of Maternal Phenylketonuria. Status report 1993. *Am J Dis Child* 1993 Nov;147(11):1224-30.
- Koch R, Shaw KN, Acosta PB, Fishler K, Schaeffler G, Wenz E, Wohlers A. An approach to management of phenylketonuria. *J Pediatr* 1970 Jun;76(6):815-28.
- Koch R, Yusin M, Fishler K. Successful adjustment to society by adults with phenylketonuria. *J Inherit Metab Dis* 1985;8(4):209-11.
- Kolb SE, Aguilar MC, Kaye C. A conference for the education of families who have a member with phenylketonuria. *J Pediatr Nurs* 1999 Aug;14(4):270-2.
- Komrower GM, Sardharwalla IB, Coutts JM, Ingham D. Management of maternal phenylketonuria: an emerging clinical problem. *Br Med J* 1979 May 26;1(6175):1383-7.
- Kowalska B. [Effect of maternal phenylketonuria on the development of 2 children with phenylketonuria]. *Pol Tyg Lek* 1986 Apr 7;41(14):448-50. (Pol).
- Krause W, Halminski M, McDonald L, Dembure P, Salvo R, Freides D, Elsas L. Biochemical and neuropsychological effects of elevated plasma phenylalanine in patients with treated phenylketonuria. A model for the study of phenylalanine and brain function in man. *J Clin Invest* 1985 Jan;75(1):40-8.
- Kurth E. Research in mental retardation in the German Democratic Republic (GDR). *Appl Res Ment Retard* 1984;5(3):361-73.
- LaBuda CJ, Hale RL. Anxiety in mice following acute aspartame and ethanol exposure. *Alcohol* 2000;20:69-74.
- Lacey DJ. Hippocampal dendritic abnormalities in a rat model of phenylketonuria. *Ann Neurol* 1984 Nov;16(5):577-80.
- Lajtha A, Reilly MA, Dunlop DS. Aspartame consumption: lack of effects on neural function. *J Nutr Biochem* 1994 Jun;5(6):266-83.
- Lane JD, Schone B, Langenbeck U, Neuhoff V. Characterization of experimental phenylketonuria. Augmentation of hyperphenylalaninemia with alpha-methylphenylalanine and p-chlorophenylalanine. *Biochim Biophys Acta* 1980 Jan 17;627(2):144-56.
- Lang MJ. Variant hyperphenylalaninemia: psychoeducational outcome of untreated individuals [dissertation]. Los Angeles: University of Southern California; 1988.
- Lang MJ, Koch R, Fishler K, Baker R. Nonphenylketonuric hyperphenylalaninemia. *Am J Dis Child* 1989 Dec;143(12):1464-6. Published erratum appears in *Am J Dis Child* 1990 Apr;144(4):484.
- Langenbeck U, Lukas HD, Mench-Hoinowski A, Stenzig KP, et al. Correlative study of mental and biochemical phenotypes in never treated patients with classic phenylketonuria. *Brain Dysfunct* 1988 Mar-Apr;1(2):103-10.
- Langerova E, Sindelarova M, Machackova V, Balastikova B, Nahunek K, Podhradská O, Mrkos A, Kasparkova Z. [Maternal phenylketonuria. Psychopathological study of families]. *Cesk Psychiatr* 1982 Oct;78(5):289-97. (Cze).
- Lastochkina NA. Characteristics of convulsive activity on the EEGs of patients with classic phenylketonuria. *Soviet Neurol Psychiatry* 1984 Summer;17(2):12-25.
- Lastochkina NA. [Characteristics of the EEG and systemic activity in classical phenylketonuria]. *Zh Nevropatol Psikhiatr* 1981;81(11):1684-90. (Rus).
- Lastochkina NA. [Convulsive activity of the EEG in patients with classic phenylketonuria]. *Z Nevropatol Psikhiatr Imeni S S Korsakova* 1983;83(3):399-406. (Rus).
- Lastochkina NA. [Features of the convulsive activity in the EEG of patients with classic phenylketonuria]. *Zh Nevropatol Psikhiatr* 1983;83(3):79-86. (Rus).
- Lebedev BV, Bliumina MG, Ladodo KS. [Pressing problems of phenylketonuria]. *Pediatriia* 1980 Jun;(6):65-7. (Rus).
- Legido A, Tonyes L, Carter D, Schoemaker A, Di George A, Grover WD. Treatment variables and intellectual outcome in children with classic phenylketonuria. A single-center-based study. *Clin Pediatr (Phila)* 1993 Jul;32(7):417-25.
- Lenke RR, Levy HL. Maternal phenylketonuria and hyperphenylalaninemia. An international survey of the outcome of untreated and treated pregnancies. *N Engl J Med* 1980 Nov 20;303(21):1202-8.
- Leuzzi V, Cardona F, Antonozzi I, Loizzo A. Visual, auditory, and somatosensory evoked potentials in early and late treated adolescents with

- phenylketonuria. *J Clin Neurophysiol* 1994 Nov;11(6):602-6.
- Leuzzi V, Fois D, Carducci C, Antonozzi I, Trasimeni G. Neuropsychological and neuroradiological (MRI) variations during phenylalanine load: protective effect of valine, leucine, and isoleucine supplementation. *J Child Neurol* 1997 Aug;12(5):338-40.
- Leuzzi V, Gualdi GF, Fabbri F, Trasimeni G, Di Biasi C, Antonozzi I. Neuroradiological (MRI) abnormalities in phenylketonuric subjects: clinical and biochemical correlations. *Neuropediatrics* 1993 Dec;24(6):302-6.
- Levine RA. Tetrahydrobiopterin and biogenic amine metabolism in neuropsychiatry, immunology, and aging. *Ann N Y Acad Sci* 1988;521:129-39.
- Levy HL. Maternal phenylketonuria. Review with emphasis on pathogenesis. *Enzyme* 1987;38(1-4):312-20.
- Levy HL. Maternal PKU. *Prog Clin Biol Res* 1985;177:109-22.
- Levy HL. Treatment of phenylketonuria. *Prog Clin Biol Res* 1979;34:171-82.
- Levy HL, Goss BS, Sullivan DK, Michals-Matalon K, Dobbs JM, Guldborg P, Guttler F. Maternal mild hyperphenylalaninemia: results of treated and untreated pregnancies in two sisters. *J Pediatr* 1994 Sep;125(3):467-9.
- Levy HL, Kaplan GN, Erickson AM. Comparison of treated and untreated pregnancies in a mother with phenylketonuria. *J Pediatr* 1982 Jun;100(6):876-80.
- Levy HL, Lobbregt D, Barnes PD, Poussaint TY. Maternal phenylketonuria: magnetic resonance imaging of the brain in offspring. *J Pediatr* 1996 Jun;128(6):770-5.
- Levy HL, Lobbregt D, Sansaricq C, Snyderman SE. Comparison of phenylketonuric and nonphenylketonuric sibs from untreated pregnancies in a mother with phenylketonuria. *Am J Med Genet* 1992 Nov 1;44(4):439-42.
- Levy HL, Shih VE, Karolkewicz V, French WA, Carr JR, Cass V, Kennedy JL Jr, MacCready RA. Persistent mild hyperphenylalaninemia in the untreated state. A prospective study. *N Engl J Med* 1971 Aug 19;285(8):424-9.
- Levy HL, Waisbren SE. (Children's Hospital, Boston, MA). Study of maternal PKU (phenylketonuria) and hyperphenylalaninemia. Final report. 1981 Sep 1-Aug 31. Rockville (MD): Bureau of Health Care Delivery and Assistance (US); 1987 Jun. Contract No.: MCH/CCS-87/11. 37 p. Available from: NTIS, Springfield, VA; PB88-173711.
- Levy HL, Waisbren SE. Effects of untreated maternal phenylketonuria and hyperphenylalaninemia on the fetus. *N Engl J Med* 1983 Nov 24;309(21):1269-74.
- Levy HL, Waisbren SE. PKU in adolescents: rationale and psychosocial factors in diet continuation. *Acta Paediatr Suppl* 1994 Dec;407:92-7.
- Levy HL, Waisbren SE. The PKU paradigm: the mixed results from early dietary treatment. *UCLA Symp Mol Cell Biol* 1987;55:539-51.
- Levy HL, Waisbren SE, Lobbregt D, Allred E, Leviton A, Koch R, Hanley WB, Rouse B, Matalon R, de la Cruz F. Maternal non-phenylketonuric mild hyperphenylalaninemia. *Eur J Pediatr* 1996 Jul;155 Suppl 1:S20-5.
- Levy HL, Waisbren SE, Lobbregt D, Allred E, Schuler A, Trefz FK, Schweitzer SM, Sardharwalla IB, Walter JH, Barwell BE, et al. Maternal mild hyperphenylalaninaemia: an international survey of offspring outcome. *Lancet* 1994 Dec 10;344(8937):1589-94. Comment in: *Lancet* 1995 Feb 11;345(8946):385-6.
- Lewis SA, Lyon IC, Elliott RB. Outcome of pregnancy in the rat with mild hyperphenylalaninaemia and hypertyrosinaemia: implications for the management of human maternal PKU. *J Inher Metab Dis* 1985;8(3):113-7.
- Leyton M, Young SN, Pihl RO, Etezadi S, Lauze C, Blier P, Baker GB, Benkelfat C. Effects on mood of acute phenylalanine/tyrosine depletion in healthy women. *Neuropsychopharmacology* 2000 Jan;22(1):52-63.
- Lipson A, Beuhler B, Bartley J, Walsh D, Yu J, O'Halloran M, Webster W. Maternal hyperphenylalaninemia fetal effects. *J Pediatr* 1984 Feb;104(2):216-20.
- Lipton J. The effects of phenylketonuria and hyperphenylalaninemia on (PKU, intelligence, cognition) [dissertation]. New York: Yeshiva University; 1984. 120 p.
- Livshits LA. [The molecular genetic nature of the mutations responsible for the development in Ukraine of more widely spread forms of neuromuscular pathology and mental retardation with a monogenic nature of the heredity]. *Tsitol Genet* 1998 Jan-Feb;32(1):3-8. (Rus).
- Lobascher ME, Cavanagh NP. Patterns of intellectual change in the dementing school child. *Child Care Health Dev* 1980 Sep-Oct;6(5):255-65.

- Lord J, Thomason MJ, Littlejohns P, Chalmers RA, Bain MD, Addison GM, Wilcox AH, Seymour CA. Secondary analysis of economic data: a review of cost-benefit studies of neonatal screening for phenylketonuria. *J Epidemiol Community Health* 1999 Mar;53(3):179-86.
- Lou HC. Dopamine precursors and brain function in phenylalanine hydroxylase deficiency. *Acta Paediatr Suppl* 1994 Dec;407:86-8.
- Lou HC, Toft PB, Andresen J, Mikkelsen I, Olsen B, Guttler F, Wieslander S, Henriksen O. An occipito-temporal syndrome in adolescents with optimally controlled hyperphenylalaninaemia. *J Inherit Metab Dis* 1992;15(5):687-95.
- Lovenberg WM. Biochemical regulation of brain function. *Nutr Rev* 1986 May;44 Suppl:6-11.
- Lowe TL, Tanaka K, Seashore MR, Young JG, Cohen DJ. Detection of phenylketonuria in autistic and psychotic children. *JAMA* 1980 Jan 11;243(2):126-8.
- Lowitzer AC. Maternal phenylketonuria: cause for concern among women with PKU. *Res Dev Disabil* 1987;8(1):1-14.
- Lykkelund C, Nielsen JB, Lou HC, Rasmussen V, Gerdes AM, Christensen E, Guttler F. Increased neurotransmitter biosynthesis in phenylketonuria induced by phenylalanine restriction or by supplementation of unrestricted diet with large amounts of tyrosine. *Eur J Pediatr* 1988 Dec;148(3):238-45.
- MacCready RA. Admissions of phenylketonuric patients to residential institutions before and after screening programs of the newborn infant. *J Pediatr* 1974 Sep;85(3):383-5.
- MacCready RA, Levy HL. The problem of maternal phenylketonuria. *Am J Obstet Gynecol* 1972 May 1;113(1):121-8.
- MacDonald A, Harris G, Rylance G, Asplin D, Booth IW. Abnormal feeding behaviours in phenylketonuria. *J Hum Nutr Diet* 1997 Jun;10(3):163-70.
- MacDonald A, Rylance GW, Asplin DA, Hall K, Harris G, Booth IW. Feeding problems in young PKU children. *Acta Paediatr Suppl* 1994 Dec;407:73-4.
- Mahowald MB. A feminist standpoint for genetics. *J Clin Ethics* 1996 Winter;7(4):333-40.
- Manghi E, Belloni L, Cambie F, Cerisola N, Dagnino G, Felisi G, Manghi D, Oppici W, Carella L. [Neurologic diseases, mental retardation and reduction in work capacity]. *Riv Neurol* 1985 Jul-Aug;55(4):256-300. (Ita).
- Mathur R, Manchanda SK. Ontogeny of phenylalanine (endogenous cholecystokinin) induced modulation of food intake in normal and undernourished rats. *Prog Neuropsychopharmacol Biol Psychiatry* 1991;15(3):405-13.
- Matsuishi T, Yamashita Y. [Neurochemical and neurotransmitter studies in patients with learning disabilities]. *No To Hattatsu* 1999 May;31(3):245-8. (Jpn).
- Matthews WS, Barabas G, Cusack E, Ferrari M. Social quotients of children with phenylketonuria before and after discontinuation of dietary therapy. *Am J Ment Defic* 1986 Jul;91(1):92-4.
- Mazzocco MM, Nord AM, Van Doorninck W, Greene CL, et al. Cognitive development among children with early-treated phenylketonuria. *Dev Neuropsychol* 1994;10(2):133-51.
- Mazzocco MM, Yannicelli S, Nord AM, van Doorninck W, Davidson-Mundt AJ, Greene CL. Cognition and tyrosine supplementation among school-aged children with phenylketonuria [letter]. *Am J Dis Child* 1992 Nov;146(11):1261-4.
- McCombe PA, McLaughlin DB, Chalk JB, Brown NN, McGill JJ, Pender MP. Spasticity and white matter abnormalities in adult phenylketonuria. *J Neurol Neurosurg Psychiatry* 1992 May;55(5):359-61.
- McCormack MK. Screening for genetic traits and diseases. *Am Fam Physician* 1981 Oct;24(4):153-66.
- McHugh PR, McKusick VA, editors. *Genes, brain, and behavior*. New York: Raven Press; 1991. 237 p. (Association for Research in Nervous and Mental Disease Research publications; vol. 69).
- McLean MS. Neurobehavioral consequences of hyperphenylalaninemia [dissertation]. Cincinnati (OH): University of Cincinnati; 1986. 195 p.
- Meijer WJ. [10 years' national screening study of the incidence of phenylketonuria in the Netherlands; 3d report of the National Advisory Phenylketonuria Commission]. *Ned Tijdschr Geneesk* 1985 Jan 12;129(2):74-6. (Dut).
- Mellgren SI, Gotestam KG. Research on mental retardation in Norway 1970-1980: a review. *Appl Res Ment Retard* 1983;4(2):103-12.
- Melnick CR, Michals KK, Matalon R. Linguistic development of children with phenylketonuria and normal intelligence. *J Pediatr* 1981 Feb;98(2):269-72.
- Messer SS. PKU: a mother's perspective. *Pediatr Nurs* 1985 Mar-Apr;11(2):121-3.

- Michals K. Educational behavioral program for PKU. Final report 1988 Nov 1- 1991 Oct 31. Chicago: Illinois University at Chicago, Department of Nutrition and Medical Dietetics; 1993 Nov. 47p. Contract No.: MCH/CCS-94/03. Available from: NTIS, Springfield, VA; PB95-209516. Sponsored by US Maternal and Child Health Bureau, Rockville, MD.
- Michals K, Azen C, Acosta P, Koch R, Matalon R. Blood phenylalanine levels and intelligence of 10-year-old children with PKU in the National Collaborative Study. *J Am Diet Assoc* 1988 Oct;88(10):1226-9.
- Michals K, Dominik M, Schuett V, Brown E, Matalon R. Return to diet therapy in patients with phenylketonuria. *J Pediatr* 1985 Jun;106(6):933-6.
- Michals K, Matalon R. Phenylalanine metabolites, attention span and hyperactivity. *Am J Clin Nutr* 1985 Aug;42(2):361-5.
- Michel U, Schmidt E, Batzler U. Results of psychological testing of patients aged 3-6 years. *Eur J Pediatr* 1990;149 Suppl 1:S34-8.
- Mims SK, McIntyre CW, Murray ME. An analysis of visual motor problems in children with dietary treated phenylketonuria. *Educ Psychol Res* 1983 Spring;3(2):111-21.
- Mollen E. Cognitive functioning of children with phenylketonuria disabilities [dissertation]. Ann Arbor (MI): The University of Michigan; 1984. 151 p.
- More pointers on PKU [letter]. *MCN Am J Matern Child Nurs* 1987 Jul-Aug;12(4):239.
- Mycos F. The patient care study as a learning and assessment tool in nurse education. *Nurs Times* 1981 Jul 22-28;77(30):1305-7.
- Naughten ER. Continuation vs discontinuation of diet in phenylketonuria. *Eur J Clin Nutr* 1989;43 Suppl 1:7-12.
- Naughten ER, Kiely B, Saul I, Murphy D. Phenylketonuria: outcome and problems in a diet-for-life clinic. *Eur J Pediatr* 1987;146 Suppl 1:A23-4.
- Nemeroff CB, Mason GA, Hatley OL, Jahnke G, Prange AJ Jr. Lack of effect of a behaviorally active dose of cholecystokinin octapeptide upon aromatic amino acid levels in plasma and brain. *Brain Res* 1980 Feb 24;184(2):529-32.
- Netley C, Hanley WB, Rudner HL. Phenylketonuria and its variants: observations on intellectual functioning. *Can Med Assoc J* 1984 Oct 1;131(7):751-5.
- Nevin NC, Carson NA. Severe mental retardation due to maternal phenylketonuria. *Ulster Med J* 1982;51(2):133-5.
- Nielsen JB, Lou HC, Guettler F. Effects of diet discontinuation and dietary tryptophan supplementation on neurotransmitter metabolism in phenylketonuria. *Brain Dysfunc* 1988 Jan-Feb;1(1):51-6.
- O'Flynn ME. Newborn screening for phenylketonuria: thirty years of progress. *Curr Probl Pediatr* 1992 Apr;22(4):159-65.
- O'Grady DJ, Berry HK, Sutherland BS. Cognitive development in early treated phenylketonuria. *Am J Dis Child* 1971 Jan;121(1):20-3.
- O'Tuama LA, Treves ST. Brain single-photon emission computed tomography for behavior disorders in children. *Semin Nucl Med* 1993 Jul;23(3):255-64.
- Overgaard C, Knudsen A. Pain-relieving effect of sucrose in newborns during heel prick. *Biol Neonate* 1999 May;75(5):279-84.
- Ozalp I, Coskun T, Ozguc M, Tokatli A, Yalaz K, Vanli L, Yilmaz E, Erbay A. Genetic and neurological evaluation of untreated and late-treated patients with phenylketonuria. *J Inher Metab Dis* 1994;17(3):371.
- Ozanne AE, Krimmer H, Murdoch BE. Speech and language skills in children with early treated phenylketonuria. *Am J Ment Retard* 1990 May;94(6):625-32.
- Palmour RM, Ervin FR, Baker GB, Young SN. An amino acid mixture deficient in phenylalanine and tyrosine reduces cerebrospinal fluid catecholamine metabolites and alcohol consumption in vervet monkeys. *Psychopharmacology (Berl)* 1998 Mar;136(1):1-7.
- Parker CE, Shaw KN, Mitchell JB, Koch R, Wenz E, Fishler K. Clinical experience in dietary management of phenylketonuria with a new phenylalanine-free product. *J Pediatr* 1977 Dec;91(6):941-3.
- Partington MW. Long term studies of untreated phenylketonuria II: the plasma phenylalanine level. *Neuropadiatrie* 1978 Aug;9(3):255-67.
- Pennington BF. Genetics of learning disabilities. *J Child Neurol* 1995 Jan;10 Suppl 1:S69-77.
- Pennington BF, Smith SD. Genetic influences on learning disabilities and speech and language disorders. *Child Dev* 1983 Apr;54(2):369-87.
- Pennington BF, van Doorninck WJ, McCabe LL, McCabe ER. Neuropsychological deficits in early

- treated phenylketonuric children. *Am J Ment Defic* 1985 Mar;89(5):467-74.
- Persha AJ. Early identification and prevention of mental retardation. *ICCW News B* 1992 Jan-Mar;40(1):9-12.
- Phenylketonuria grows up [editorial]. *Lancet* 1991 May 25;337(8752):1256-7.
- Pickering N, Billings P. Not my problem [letter]. *Hastings Cent Rep* 1993 Jan-Feb;23(1):45-6.
- Pierzchala K, Rosciszewska D, Kwiecinski J. [Adult age phenylketonuria with extrapyramidal syndrome: therapeutic management]. *Neurol Neurochir Pol* 1993 Nov-Dec;27(6):899-904. (Pol).
- Pietz J. Neurological aspects of adult phenylketonuria. *Curr Opin Neurol* 1998 Dec;11(6):679-88.
- Pietz J, Benninger C, Schmidt H, Scheffner D, Bickel H. Long-term development of intelligence (IQ) and EEG in 34 children with phenylketonuria treated early. *Eur J Pediatr* 1988 May;147(4):361-7.
- Pietz J, Dunckelmann R, Rupp A, Rating D, Meinck HM, Schmidt H, Bremer HJ. Neurological outcome in adult patients with early-treated phenylketonuria. *Eur J Pediatr* 1998 Oct;157(10):824-30.
- Pietz J, Fatkenheuer B, Burgard P, Armbruster M, Esser G, Schmidt H. Psychiatric disorders in adult patients with early-treated phenylketonuria. *Pediatrics* 1997 Mar;99(3):345-50.
- Pietz J, Kreis R, Boesch C, Penzien J, Rating D, Herschkowitz N. The dynamics of brain concentrations of phenylalanine and its clinical significance in patients with phenylketonuria determined by in vivo 1H magnetic resonance spectroscopy. *Pediatr Res* 1995 Nov;38(5):657-63.
- Pietz J, Kreis R, Schmidt H, Meyding-Lamade UK, Rupp A, Boesch C. Phenylketonuria: findings at MR imaging and localized in vivo H-1 MR spectroscopy of the brain in patients with early treatment. *Radiology* 1996 Nov;201(2):413-20.
- Pietz J, Landwehr R, Kutscha A, Schmidt H, de Sonneville L, Trefz FK. Effect of high-dose tyrosine supplementation on brain function in adults with phenylketonuria. *J Pediatr* 1995 Dec;127(6):936-43.
- Pietz J, Meyding-Lamade UK, Schmidt H. Magnetic resonance imaging of the brain in adolescents with phenylketonuria and in one case of 6-pyruvoyl tetrahydropteridine synthase deficiency. *Eur J Pediatr* 1996 Jul;155 Suppl 1:S69-73.
- Pietz J, Schmidt E, Matthis P, Kobialka B, Kutscha A, de Sonneville L. EEGs in phenylketonuria. I: Follow-up to adulthood; II: Short-term diet-related changes in EEGs and cognitive function. *Dev Med Child Neurol* 1993 Jan;35(1):54-64.
- Piggins HD. The short- and long-term effects of neonatal exposure to and/or (d-phenylalanine(6), Psi leucine(13)-chloroparpylamid(14))BN(6-14), a Bombesin receptor antagonist [dissertation]. Ottawa (Canada): University of Ottawa; 1991. 204 p.
- Pitt D. The natural history of untreated phenylketonuria. *Med J Aust* 1971 Feb 13;1(7):378-83.
- Pitt D. Phenylketonuria with normal intelligence: Report of two cases. *Aust J Ment Retard* 1971 Mar;1(5):160-2.
- Pitt DB, Danks DM. The natural history of untreated phenylketonuria over 20 years. *J Paediatr Child Health* 1991 Jun;27(3):189-90.
- Platt LD, Koch R, Hanley WB, Levy HL, Matalon R, Rouse B, Trefz F, de la Cruz F, Guttler F, Azen C, Friedman EG. The international study of pregnancy outcome in women with maternal phenylketonuria: report of a 12-year study. *Am J Obstet Gynecol* 2000 Feb;182(2):326-33.
- Pogson D. Issues for consideration in dihydropteridine reductase (DHPR) deficiency: a variant form of hyperphenylalaninaemia. *J Intellect Disabil Res* 1997 Jun;41 (Pt 3):208-14.
- Portadin KM. Psychosocial variables, self-reported adherence, and control in adolescents with phenylketonuria [dissertation]. Philadelphia: Temple University; 1998. 109 p.
- Potkin SG, Cannon-Spoor HE, DeLisi LE, Neckers LM, Wyatt RJ. Plasma phenylalanine, tyrosine, and tryptophan in schizophrenia. *Arch Gen Psychiatry* 1983 Jul;40(7):749-52.
- Potocnik U, Widhalm K. Long-term follow-up of children with classical phenylketonuria after diet discontinuation: a review. *J Am Coll Nutr* 1994 Jun;13(3):232-6.
- Primary prevention of mental, neurological and psychological disorders. Geneva: World Health Organization; 1998. Phenylketonuria; p. 40-53.
- Primrose DA. Phenylketonuria with normal intelligence. *J Ment Defic Res* 1983 Dec;27 (Pt 4):239-46.
- Pueschel SM. Central nervous system effects in individuals with phenylketonuria. *Dev Brain Dysfunc* 1996 Jul-Aug;90(4):165-79.

- Pueschel SM. On effective prevention of mental retardation. In: Russo DC, Kedesdy JH, et al., editors. Behavioral medicine with the developmentally disabled. New York: Plenum Press; 1988. p. 201-9.
- Pueschel SM, Fogelson-Doyle L, Kammerer B, Matsumiya Y. Neurophysiological, psychological, and nutritional investigations during discontinuation of the phenylalanine-restricted diet in children with classic phenylketonuria. *J Ment Defic Res* 1983 Mar;27 (Pt 1):61-7.
- Pueschel SM, Schrier AM, Povar ML, Boylan JM. Biological and behavioural assessments of young rhesus monkeys after intrauterine exposure to high phenylalanine concentrations. *J Ment Defic Res* 1985 Sep;29 (Pt 3):247-56.
- Pullon DH, Macfarlane SD, Lyon IC. Maternal phenylketonuria. *N Z Med J* 1990 Aug 22;103(896):397-8.
- Ramus SJ, Forrest SM, Pitt DB, Saleeba JA, Cotton RG. Comparison of genotype and intellectual phenotype in untreated PKU patients. *J Med Genet* 1993 May;30(5):401-5.
- Ramus SJ, Forrest SM, Pitt DD, Cotton RG. Genotype and intellectual phenotype in untreated phenylketonuria patients. *Pediatr Res* 1999 Apr;45(4 Pt 1):474-81.
- Rapoport D, Depondt E, Saudubray JM. [Diet therapy in phenylketonuria. Psychological aspects]. *Arch Fr Pediatr* 1983;40 Suppl 1:265-7. (Fre).
- Rapoport D, Saudubray JM, Ogier H, Hatt A, Berges J, Depondt E, Charpentier C, Frezal J. [Psychological prospects and scholastic performance of 33 children with early diagnosis of hyperphenylalaninemia]. *Arch Fr Pediatr* 1983;40 Suppl 1:273-9. (Fre).
- Ratzmann GW, Grimm U, Jahrig K. Increased concentrations of tyrosine and phenylalanine in the cerebrospinal fluid as a possible reflection of related changes of the brain tissue in newborns with intra-uterine growth retardation. *Biomed Biochim Acta* 1988;47(12):1037-41.
- Realmuto GM, Garfinkel BD, Tuchman M, Tsai MY, Chang PN, Fisch RO, Shapiro S. Psychiatric diagnosis and behavioral characteristics of phenylketonuric children. *J Nerv Ment Dis* 1986 Sep;174(9):536-40.
- Reber M, Kazak AE, Himmelberg P. Phenylalanine control and family functioning in early-treated phenylketonuria. *J Dev Behav Pediatr* 1987 Dec;8(6):311-7.
- Reinecke CJ, Mienie LJ, Hitzeroth HW, Op't Hof J. Screening for inborn errors of metabolism among mentally retarded patients. Outcome of a surgery at the Witrand Care and Rehabilitation Centre. *S Afr Med J* 1983 Jan 1;63(1):14-6.
- Reiss MJ. The ethics of genetic research on intelligence. *Bioethics* 2000;14(1):1-15.
- Reveley AM, Reveley MA. Screening for adult phenylketonuria in psychiatric inpatients. *Biol Psychiatry* 1982 Nov;17(11):1343-5.
- Rey F, Abadie V, Plainguet F, Rey J. Long-term follow up of patients with classical phenylketonuria after diet relaxation at 5 years of age. The Paris Study. *Eur J Pediatr* 1996 Jul;155 Suppl 1:S39-44.
- Reynolds R, Burri R, Herschkowitz N. Retarded development of neurons and oligodendroglia in rat forebrain produced by hyperphenylalaninemia results in permanent deficits in myelin despite long recovery periods. *Exp Neurol* 1993 Dec;124(2):357-67.
- Richardson MA, Reilly MA, Read LL, Flynn CJ, Suckow RF, Maher TJ, Sziraki I. Phenylalanine kinetics are associated with tardive dyskinesia in men but not in women. *Psychopharmacology (Berl)* 1999 Apr;143(4):347-57.
- Ris MD, Weber AM, Hunt MM, Berry HK, Williams SE, Leslie N. Adult psychosocial outcome in early-treated phenylketonuria. *J Inherit Metab Dis* 1997 Aug;20(4):499-508.
- Ris MD, Williams SE, Hunt MM, Berry HK, Leslie N. Early-treated phenylketonuria: adult neuropsychologic outcome. *J Pediatr* 1994 Mar;124(3):388-92.
- Rittinger O, Plochl E, Jarosch E. [Maternal phenylketonuria]. *Padiatr Padol* 1984;19(1):87-92. (Ger).
- Riva E, Agostoni C, Biasucci G, Trojan S, Luotti D, Fiori L, Giovannini M. Early breastfeeding is linked to higher intelligence quotient scores in dietary treated phenylketonuric children. *Acta Paediatr* 1996 Jan;85(1):56-8. Published erratum appears in *Acta Paediatr* 1996 May;85(5):639.
- Rivera I, Cabral A, Almeida M, Leandro P, Carmona C, Eusebio F, Tasso T, Vilarinho L, Martins E, Lechner MC, de Almeida IT, Konecki DS, Lichter-Konecki U. The correlation of genotype and phenotype in Portuguese hyperphenylalaninemic patients. *Mol Genet Metab* 2000 Mar;69(3):195-203.
- Robertson JA, Schulman JD. Pregnancy and prenatal harm to offspring: the case of mothers with PKU. *Hastings Cent Rep* 1987 Aug-Sep;17(4):23-33.
- Rogers PJ, Keedwell P, Blundell JE. Further analysis of the short-term inhibition of food intake in humans by the dipeptide L-aspartyl-L-phenylalanine methyl

- ester (aspartame). *Physiol Behav* 1991 Apr;49(4):739-43.
- Romano V, Guldberg P, Guttler F, Meli C, Mollica F, Pavone L, Giovannini M, Riva E, Biasucci G, Luotti D, Palillo L, Cali F, Ceratto N, Anello G, Bosco P. PAH deficiency in Italy: correlation of genotype with phenotype in the Sicilian population. *J Inher Metab Dis* 1996;19(1):15-24.
- Rouse B, Azen C, Koch R, Matalon R, Hanley W, de la Cruz F, Trefz F, Friedman E, Shifrin H. Maternal Phenylketonuria Collaborative Study (MPKUCS) offspring: facial anomalies, malformations, and early neurological sequelae. *Am J Med Genet* 1997 Mar 3;69(1):89-95.
- Rouse B, Matalon R, Koch R, Azen C, Levy H, Hanley W, Trefz F, de la Cruz F. Maternal phenylketonuria syndrome: congenital heart defects, microcephaly, and developmental outcomes. *J Pediatr* 2000 Jan;136(1):57-61. Comment in: *J Pediatr* 2000 Jan;136(1):12-3.
- Russell FF, Mills BC, Zucconi T. Relationship of parental attitudes and knowledge to treatment adherence in children with PKU. *Pediatr Nurs* 1988 Nov-Dec;14(6):514-6, 523.
- Ryan-Harshman M. Mealtime food intake and behavior of normal weight adult of phenylalanine and aspartame [dissertation]. Greensboro (NC): The University of North Carolina at Greensboro; 1987. 117 p.
- Ryan-Harshman M, Leiter LA, Anderson GH. Phenylalanine and aspartame fail to alter feeding behavior, mood and arousal in men. *Physiol Behav* 1987;39(2):247-53.
- Rylance G. Outcome of early detected and early treated phenylketonuria patients. *Postgrad Med J* 1989;65 Suppl 2:S7-9.
- Sadava D, Sutcliffe D. The effects of maternal hyperphenylalaninemia on learning in mature rats. *Life Sci* 1988;43(14):1119-23.
- Salardi S, Missiroli G, Piazzini S, Mandini M, Cassio A, Colli C, Tacconi M, Tolomelli M, Cacciari E. [Neuropsychological follow-up of children with phenylketonuria treated early]. *Pediatr Med Chir* 1992 Jul-Aug;14(4):409-13. (Ita).
- Samankova M. [Phenylketonuria from the viewpoint of the parents of affected children]. *Cesk Pediatr* 1989 Dec;44(12):738-40. (Cze).
- Sarkissian CN, Boulais DM, McDonald JD, Scriver CR. A heteroallelic mutant mouse model: A new orthologue for human hyperphenylalaninemia. *Mol Genet Metab* 2000 Mar;69(3):188-94.
- Sartorio R, Greco L, Carrozzo R, Budillon C, Andria G. A simplified test to detect PKU heterozygotes by discriminant analysis in mentally retarded children and their mothers. *Clin Genet* 1988 Apr;33(4):241-5.
- Saudubray JM, Rey F, Ogier H, Abadie V, Farriaux JP, Ghisolfi J, Guibaud P, Rey J, Vidailhet M. Intellectual and school performances in early-treated classical PKU patients. The French collaborative study. *Eur J Pediatr* 1987;146 Suppl 1:A20-2.
- Schaefer F, Burgard P, Batzler U, Rupp A, Schmidt H, Gilli G, Bickel H, Bremer HJ. Growth and skeletal maturation in children with phenylketonuria. *Acta Paediatr* 1994 May;83(5):534-41.
- Scheibenreiter S, Tiefenthaler M, Hinteregger V, Strobl W, Muhl A, Ewald A, Schadler M. Austrian report on longitudinal outcome in phenylketonuria. *Eur J Pediatr* 1996 Jul;155 Suppl 1:S45-9.
- Schmidt E, Burgard P, Rupp A. Effects of concurrent phenylalanine levels on sustained attention and calculation speed in patients treated early for phenylketonuria. *Eur J Pediatr* 1996 Jul;155 Suppl 1:S82-6.
- Schmidt E, Rupp A, Burgard P, Pietz J, Weglage J, de Sonneville L. Sustained attention in adult phenylketonuria: the influence of the concurrent phenylalanine-blood-level. *J Clin Exp Neuropsychol* 1994 Oct;16(5):681-8.
- Schmidt H, Burgard P, Pietz J, Rupp A. Intelligence and professional career in young adults treated early for phenylketonuria. *Eur J Pediatr* 1996 Jul;155 Suppl 1:S97-100.
- Schmidt H, Mahle M, Michel U, Pietz J. Continuation vs discontinuation of low-phenylalanine diet in PKU adolescents. *Eur J Pediatr* 1987;146 Suppl 1:A17-9.
- Schmitt JA, Jorissen BL, Sobczak S, Van Boxtel MP, Hogervorst E, Deutz NE, Riedel WJ. Tryptophan depletion impairs memory consolidation but improves focussed attention in healthy young volunteers. *J Psychopharmacol* 2000;14(1):21-9.
- Schor DP. Phenylketonuria and temperament in middle childhood. *Child Health Care* 1986 Winter;14(3):163-7.
- Schor DP. PKU and temperament. Rating children three through seven years old in PKU families. *Clin Pediatr (Phila)* 1983 Dec;22(12):807-11.
- Schuett VE, Brown ES. Diet policies of PKU clinics in the United States. *Am J Public Health* 1984 May;74(5):501-3.

- Schuett VE, Brown ES, Michals K. Reinstitution of diet therapy in PKU patients from twenty-two US clinics. *Am J Public Health* 1985 Jan;75(1):39-42.
- Schuler A, Kalmancey R, Barsi P, Somogyi CS, Toros I, Varadi I, Kovacs A, Blau N. Deprenyl in the treatment of patients with tetrahydrobiopterin deficiencies. *J Inherit Metab Dis* 2000;23(4):329-32.
- Schuler A, Somogyi C, Mate M, Pataki L, Toros I, Woo SL, Eisensmith RC, Fekete G. Cognitive development related to metabolic phenotype and mutation genotype in 25 Hungarian patients with phenylketonuria. *J Inherit Metab Dis* 1994;17(3):372. Published erratum appears in *J Inherit Metab Dis* 1994;17(6):651.
- Schuler A, Somogyi C, Toros I, Pataki L, Mete M, Kiss E, Nagy A. A longitudinal study of phenylketonuria based on the data of the Budapest Screening Center. *Eur J Pediatr* 1996 Jul;155 Suppl 1:S50-2.
- Schwarz HP, Pluss C, Triaca H, Schutz B, Kaufmann R, Scherz R, Bachmann C, Zuppinger K. [Disease course in 20 patients with an early diagnosis of phenylketonuria and hyperphenylalaninemia]. *Schweiz Med Wochenschr* 1988 Jan 23;118(3):94-9. (Ger).
- Schweitzer S, Wolff G, Brodehl J. [Psychosocial aspects of the treatment of phenylketonuria]. *Klin Padiatr* 1987 Mar-Apr;199(2):90-4. (Ger).
- Scott TM, Fyfe WM, Hart DM. Maternal phenylketonuria: abnormal baby despite low phenylalanine diet during pregnancy. *Arch Dis Child* 1980 Aug;55(8):634-7.
- Scriber CR. Phenylketonuria: the glutamine hypothesis. *N Engl J Med* 1970 Apr 2;282(14):808-9.
- Scriber CR, Clow CL. Phenylketonuria: epitome of human biochemical genetics (second of two parts). *N Engl J Med* 1980 Dec 11;303(24):1394-400.
- Scriber CR, Cole DE, Houghton SA, Levy HL, Grenier A, Laberge C. Cord-blood tyrosine levels in the full-term phenylketonuric fetus and the justification hypothesis. *Proc Natl Acad Sci U S A* 1980 Oct;77(10):6175-8.
- Scriber CR, Waters PJ. Monogenic traits are not simple: lessons from phenylketonuria. *Trends Genet* 1999 Jul;15(7):267-72.
- Scriber CR, Waters PJ, Sarkissian C, Ryan S, Prevost L, Cote D, Novak J, Teebi S, Nowacki PM. PAHdb: a locus-specific knowledgebase. *Hum Mutat* 2000;15(1):99-104.
- Seashore MR, Friedman E, Novelty RA, Bapat V. Loss of intellectual function in children with phenylketonuria after relaxation of dietary phenylalanine restriction. *Pediatrics* 1985 Feb;75(2):226-32.
- Seim AR, Reichelt KL. An enzyme/brain-barrier theory of psychiatric pathogenesis: unifying observations on phenylketonuria, autism, schizophrenia and postpartum psychosis. *Med Hypotheses* 1995 Nov;45(5):498-502.
- Sheehan BD, Tharyan P, McTavish SFB, Campling GM, Cowen PJ. Use of a dietary manipulation to deplete plasma tyrosine and phenylalanine in healthy subjects. *J Psychopharmacol* 1996;10(3):231-4.
- Shiloh S, Amitay M, Aizin N, Normand M, Elitzur A, Hadar R, Cohen BE. [Psychosocial characteristics of phenylketonuric women: birth defect prevention]. *Harefuah* 1992 Apr 15;122(8):487-92, 552. (Heb).
- Shiloh S, St. James P, Waisbren S. The development of a patient knowledge test on maternal phenylketonuria. *Patient Educ Couns* 1990 Oct;16(2):139-46.
- Shiloh S, Waisbren SE, Cohen BE, St James P, et al. Cross-cultural perspectives on coping with the risks of maternal phenylketonuria. *Psychol Health* 1993 Dec;8(6):435-46.
- Shiloh S, Waisbren SE, Levy HL. A psychosocial model of a medical problem: Maternal phenylketonuria. *J Prim Prev* 1989 Fall;10(1):51-62.
- Should dietary treatment of phenylketonuria be continued after infancy? *Nutr Rev* 1985 Jun;43(6):176-7.
- Shulman S, Fisch RO, Zempel CE, Gadish O, Chang PN. Children with phenylketonuria: the interface of family and child functioning. *J Dev Behav Pediatr* 1991 Oct;12(5):315-21.
- Sierra C, Vilaseca MA, Moyano D, Brandi N, Campistol J, Lambruschini N, Cambra FJ, Deulofeu R, Mira A. Antioxidant status in hyperphenylalaninemia. *Clin Chim Acta* 1998 Aug 10;276(1):1-9.
- Skarin SM. Sensory motor integration, school achievement, and behavior of with phenylketonuria [dissertation]. Los Angeles: University of Southern California; 1981.
- Slijper FM, Huisman J, Hendriks MM, Kalverboer AF, v.d. Schot L. The effects of diet discontinuation in children with phenylketonuria [letter]. *Eur J Pediatr* 1988 May;147(4):445.

- Slijper FM, Huisman J, Hendriks MM, Kalverboer AF, van der Schot L. [Intellectual development of phenylketonuria children treated early--a longitudinal study. 10 years' concomitant psychological study in The Netherlands]. *Monatsschr Kinderheilkd* 1989 Oct;137(10):662-5. (Ger).
- Smith I. The natural history of phenylketonuria. *Arch Dis Child* 1971 Dec;46(250):879.
- Smith I, Beasley M. Intelligence and behaviour in children with early treated phenylketonuria. A report from the MRC/DHSS phenylketonuria register. *Eur J Clin Nutr* 1989;43 Suppl 1:1-5.
- Smith I, Beasley MG, Ades AE. Effect on intelligence of relaxing the low phenylalanine diet in phenylketonuria. *Arch Dis Child* 1991 Mar;66(3):311-6.
- Smith I, Beasley MG, Ades AE. Intelligence and quality of dietary treatment in phenylketonuria. *Arch Dis Child* 1990 May;65(5):472-8.
- Smith I, Beasley MG, Wolff OH, Ades AE. Behavior disturbance in 8-year-old children with early treated phenylketonuria. Report from the MRC/DHSS Phenylketonuria Register. *J Pediatr* 1988 Mar;112(3):403-8.
- Smith I, Lobascher ME, Stevenson JE, Wolff OH, Schmidt H, Grubel-Kaiser S, Bickel H. Effect of stopping low-phenylalanine diet on intellectual progress of children with phenylketonuria. *Br Med J* 1978 Sep 9;2(6139):723-6.
- Smith I, Lobascher ME, Stevenson JE, Wolff OH, Schmidt H, Grubel-Kaiser S, Bickel H. Effect of stopping low-phenylalanine diet on intellectual progress of children with phenylketonuria. *Br Med J* 1978 Sep 9;2(6139):723-6.
- Smith I, Tillotson S. Outcome in offspring of women with mild hyperphenylalaninaemia [letter]. *Lancet* 1995 Feb 11;345(8946):385-6. Comment on: *Lancet* 1994 Dec 10;344(8937):1589-94.
- Smith I, Wolff OH. Natural history of phenylketonuria and influence of early treatment. *Lancet* 1974 Sep 7;2(7880):540-4.
- Smith ML, Hanley WB, Clarke JT, Klim P, Schoonheydt W, Austin V, Lehotay DC. Randomised controlled trial of tyrosine supplementation on neuropsychological performance in phenylketonuria. *Arch Dis Child* 1998 Feb;78(2):116-21.
- Smith ML, Klim P, Mallozzi E, Hanley WB. A test of the frontal-specificity hypothesis in the cognitive performance of adults with phenylketonuria. *Dev Neuropsychol* 1996;12(3):327-41.
- Smith ML, Saltzman J, Klim P, Hanley WB, Feigenbaum A, Clarke JT. Neuropsychological function in mild hyperphenylalaninemia. *Am J Ment Retard* 2000 Mar;105(2):69-80.
- Snyderman SE. Dietary and genetic therapy of inborn errors of metabolism: a summary. *Ann N Y Acad Sci* 1986;477:231-6.
- Sobell JL. Schizophrenia and heterozygosity for phenylketonuria [dissertation]. Minneapolis (MN): University of Minnesota; 1991. 224 p.
- Sobra J. [Nutrition and metabolic diseases with a mass incidence]. *Cas Lek Cesk* 1990 Jul 20;129(29):897-901. (Cze).
- Spitalnik DM. Independence training: parental expectations for independent functioning of pre-school children with phenylketonuria (PKU) pre-school children without interferences in their development [dissertation]. Philadelphia: Temple University; 1982. 209 p.
- Srivastava US, Thakur ML, Van TT, Radhakrishnamurthy R. Maternal food restriction, brain polysomes and poly-U stimulated protein synthesis in the newborn and 21-day-old rat progeny. *Nutr Res* 1993 Nov;13(11):1331-41.
- St James PJ, Younger MD, Hamilton BD, Waisbren SE. Unplanned pregnancies in young women with diabetes. An analysis of psychosocial factors. *Diabetes Care* 1993 Dec;16(12):1572-8.
- Statham H, Green J, Snowdon C. Mothers' consent to screening newborn babies for disease [letter]. *BMJ* 1993 Mar 27;306(6881):858-9.
- Steele S. Phenylketonuria: counseling and teaching functions of the nurse on an interdisciplinary team. *Issues Compr Pediatr Nurs* 1989;12(5):395-409.
- Stegink LD, Lindgren SD, Brummel MC, Stumbo PJ, Wolraich ML. Erythrocyte L-aspartyl-L-phenylalanine hydrolase activity and plasma phenylalanine and aspartate concentrations in children consuming diets high in aspartame. *Am J Clin Nutr* 1995 Dec;62(6):1206-11.
- Stein Z, Susser M. Effects of early nutrition on neurological and mental competence in human beings. *Psychol Med* 1985 Nov;15(4):717-26.
- Steiner KC, Smith HA. Application of cost-benefit analysis to a PKU screening program. *Inquiry* 1973 Dec;10(4):34-40.
- Stemerink BA, van der Meere JJ, van der Molen MW, Kalverboer AF, Hendriks MM, Huisman J, van der Schot LW, Slijper FM, van Spronsen FJ, Verkerk PH. Information processing in patients with early and

- continuously-treated phenylketonuria. *Eur J Pediatr* 1995 Sep;154(9):739-46.
- Stemerdink BA, van der Molen MW, Kalverboer AF, van der Meere JJ, Hendrikx MM, Huisman J, van der Schot LW, Slijper FM. Information processing deficits in children with early and continuously treated phenylketonuria? *Acta Paediatr Suppl* 1994 Dec;407:106-7.
- Stemerdink NB, van der Molen MW, Kalverboer AF, van der Meere JJ, Huisman J, de Jong LW, Slijper FM, Verkerk PH, van Spronsen FJ. Prefrontal dysfunction in early and continuously treated phenylketonuria. *Dev Neuropsychol* 1999;16(1):29-57.
- Stern AM. Psychoeducational status in relation to duration and quality of treatment in early and later diagnosed and treated children, adolescents, and young adults [dissertation]. Los Angeles (CA): University of Southern California; 1982.
- Strupp BJ, Bunsey M, Levitsky DA, Hamberger K. Deficient cumulative learning: an animal model of retarded cognitive development. *Neurotoxicol Teratol* 1994 Jan-Feb;16(1):71-9.
- Strupp BJ, Himmelstein S, Bunsey M, Levitsky DA, Kesler M. Cognitive profile of rats exposed to lactational hyperphenylalaninemia: correspondence with human mental retardation. *Dev Psychobiol* 1990 Apr;23(3):195-214.
- Strupp BJ, Levitsky D. An animal model of retarded cognitive development. In: Rovee-Collier C, Lipsitt LP, et al., editors. *Advances in infancy research*. Vol. 6. Norwood (NJ): Ablex Publishing Co.; 1990. p. 149-220. Sponsored by the March of Dimes Birth Defects Foundation and the U.S. Department of Agriculture Cooperative State Research Services.
- Strupp BJ, Levitsky DA, Blumstein L. PKU, learning, and models of mental retardation. *Dev Psychobiol* 1984 Mar;17(2):109-20.
- Sullivan JE. Emotional and behavioral functioning in early-treated phenylketonuria [dissertation]. Minneapolis: University of Minnesota; 1999.
- Sullivan JE, Chang P. Review: emotional and behavioral functioning in phenylketonuria. *J Pediatr Psychol* 1999 Jun;24(3):281-99.
- Sutovec J, Frank V. [Dynamics of the psychological development in children with phenylketonuria]. *Cesk Psychiatr* 1984 Apr;80(2):101-6. (Slo).
- Szymanski HV, Friedman S, Guthrie R. Screening for phenylketonuria in chronic psychiatric inpatients. *Hosp Community Psychiatry* 1984 Sep;35(9):936-8.
- Tada K, Tateda H, Arashima S, Sakai K, Kitagawa T, Aoki K, Suwa S, Kawamura M, Oura T, Takesada M, et al. Follow-up study of a nation-wide neonatal metabolic screening program in Japan. A collaborative study group of neonatal screening for inborn errors of metabolism in Japan. *Eur J Pediatr* 1984 Aug;142(3):204-7.
- Terry PO. Clinical social work roles in an integrative, interdisciplinary team: enhancing parental compliance. *Soc Work Health Care* 1981 Summer;6(4):1-15.
- Thalhammer O, Scheibenreiter S, Knoll E, Wehle E, Schon R. [12 years Austrian newborn screening for inborn errors of metabolism. Results with special reference to phenylketonuria, hyperphenylalaninemia and histidinemia (author's transl)]. *Klin Padiatr* 1980 Nov;192(6):589-98. (Ger).
- Theile H, Graustein I, Wasser S, Buhrdel P. [Effect of dietary non-compliance on development in phenylketonuria--studies of 14-year-old patients]. *Padiatr Padol* 1990;25(1):19-23. (Ger).
- Thibaud D, Ploussard JP, Vaquant PO, Chemouny S, Kleitz T. [Diagnosis of phenylketonuria in a 35-year-old mother in relation to prenatal diagnosis of intrauterine growth retardation with microcephaly]. *Arch Pediatr* 1998 Nov;5(11):1229-31. (Fre).
- Thieffry AF, Lebecq MF, Farriaux JP, Parquet P. [Psychological consequences, on the child and its family, of continuous management of phenylketonuric and hypothyroid children]. *Ann Pediatr (Paris)* 1985 Oct;32(8):651-9. (Fre).
- Thorne C. Know your organizations: the National Society for Phenylketonuria and Allied Disorders. *Health Visit* 1982 Jan;55(1):26.
- Tice KS, Wenz E, Jew K, Koch R. Reproductive counselling for adolescent females with phenylketonuria. *J Inher Metab Dis* 1980;3(3):105-7.
- Trefz F, de Sonneville L, Matthis P, Benninger C, Lanz-Englert B, Bickel H. Neuropsychological and biochemical investigations in heterozygotes for phenylketonuria during ingestion of high dose aspartame (a sweetener containing phenylalanine). *Hum Genet* 1994 Apr;93(4):369-74.
- Trefz FK, Batzler U, Konig T, Michel U, Schmidt E, Schmidt H, Bickel H. Significance of the in vivo deuterated phenylalanine load for long-term phenylalanine tolerance and psycho-intellectual outcome in patients with PKU. *Eur J Pediatr* 1990;149 Suppl 1:S25-7.
- Trefz FK, Burgard P, Konig T, Goebel-Schreiner B, Lichter-Konecki U, Konecki D, Schmidt E, Schmidt H, Bickel H. Genotype-phenotype correlations in

- phenylketonuria. *Clin Chim Acta* 1993 Jul 30;217(1):15-21.
- Tsukada Y, Takamatsu K. [Correlation between monoamine content in the brain and discriminative learning ability (author's transl)]. *Tanpakushitsu Kakusan Koso* 1981 Aug;26(11):1725-34. (Jpn).
- Tu JB. Phenylketonuria: the inadvisability of neuroleptic medication. *Biol Psychiatry* 1980 Oct;15(5):797-802.
- Tu JB. Theory and practice of psychopharmacogenetics. *Am J Med Genet* 1994 Dec 15;54(4):391-7.
- Ullrich K, Weglage J, Oberwittler C, Pietsch M, Funders B, van Eckhardstein H, Colombo JP. Effect of L-dopa on pattern visual evoked potentials (P-100) and neuropsychological tests in untreated adult patients with phenylketonuria. *J Inherit Metab Dis* 1994;17(3):349-52.
- Ullrich K, Weglage J, Oberwittler C, Pietsch M, Funders B, von Eckardstein H, Colombo JP. Effect of L-dopa on visual evoked potentials and neuropsychological tests in adult phenylketonuria patients. *Eur J Pediatr* 1996 Jul;155 Suppl 1:S74-7.
- Van Dyke DC, Lin Dyken DC. The new genetics, developmental disabilities, and early intervention. *Infants Young Child* 1993 Apr;5(4):8-19.
- Vaz Osorio R, Vilarinho L, Carmona C, Almeida M. Phenylketonuria in Portugal: Multidisciplinary approach. *Dev Brain Dysfunc* 1993 Jan-Jun;6(1-3):78-82.
- Velazquez A, Bilbao G, Gonzalez-Trujillo JL, Hernandez D, Perez-Andrade ME, Vela M, Ciceron I, Loera-Luna A, Cederbaum S, Phoenix B. Apparent higher frequency of phenylketonuria in the Mexican state of Jalisco. *Hum Genet* 1996 Jan;97(1):99-102.
- Vetrone P, Leuzzi V, Zazzara V, Antonozzi I. Psychological effects on parents of children with early detected phenylketonuria. *J Inherit Metab Dis* 1989;12(3):345-6.
- Vidailhet C, Vidailhet M, Guine AM, Gonot C, Tridon P, Guine JM. [Experience of the mothers of phenylketonuric children]. *Neuropsychiatr Enfance Adolesc* 1982 Apr-May;30(4-5):246-8. (Fre).
- Vis HL, Elmer C, Goyens P, Roumat G. [Phenylketonuria: current status of the problem]. *Bull Mem Acad R Med Belg* 1988;143(3-4):231-47. (Fre).
- Vogel F. Clinical consequences of heterozygosity for autosomal-recessive diseases. *Clin Genet* 1984 May;25(5):381-415.
- Vogel F. Phenotypic deviations in heterozygotes of phenylketonuria (PKU). *Prog Clin Biol Res* 1985;177:337-49.
- Vorhees CV. Concepts in teratology and developmental toxicology derived from animal research. *Ann N Y Acad Sci* 1989;562:31-41.
- Vorhees CV, Acuff-Smith KD, Weisenburger WP, Minck DR, Berry HK. Branched chain amino acids improve radial-arm maze acquisition and water maze forced-choice learning in rat offspring exposed in utero to hyperphenylalaninemia. *Neurotoxicol Teratol* 1992 Jan-Feb;14(1):35-41.
- Vorhees CV, Berry HK. Branched chain amino acids improve complex maze learning in rat offspring prenatally exposed to hyperphenylalaninemia: implications for maternal phenylketonuria. *Pediatr Res* 1989 Jun;25(6):568-72.
- Vyborova L, Nahunek K, Drtilkova I, Balastikova B, Sindelarova M, Machackova V, Podhradská O, Mrskos A. Psychic changes in phenylketonuric children at phenylalanine load. *Act Nerv Super (Praha)* 1981 Dec;23(4):298-300.
- Waisbren SE. Developmental and neuropsychological outcome in children born to mothers with phenylketonuria. *Ment Retard Dev Disabil Res Rev* 1999;5(2):125-31.
- Waisbren SE (Children's Hospital, Boston, MA). Study of psychosocial factors in maternal phenylketonuria. Final report. 1985 Nov 1-1991 Oct 31. Rockville (MD): Maternal and Child Health Bureau (US); 1993 Nov. Report No.: MCH/CCS-94/05. 43 p. Available from: NTIS, Springfield, VA; PB95-209144.
- Waisbren SE, Brown MJ, de Sonneville LM, Levy HL. Review of neuropsychological functioning in treated phenylketonuria: an information processing approach. *Acta Paediatr Suppl* 1994 Dec;407:98-103.
- Waisbren SE, Chang P, Levy HL, Shifrin H, Allred E, Azen C, de la Cruz F, Hanley W, Koch R, Matalon R, Rouse B. Neonatal neurological assessment of offspring in maternal phenylketonuria. *J Inherit Metab Dis* 1998 Feb;21(1):39-48.
- Waisbren SE, Hamilton BD, St. James PJ, Shiloh S, Levy HL. Psychosocial factors in maternal phenylketonuria: women's adherence to medical recommendations. *Am J Public Health* 1995 Dec;85(12):1636-41.
- Waisbren SE, Hanley W, Levy HL, Shifrin H, Allred E, Azen C, Chang PN, Cipcic-Schmidt S, de la Cruz F, Hall R, Matalon R, Nanson J, Rouse B, Trefz F, Koch R. Outcome at age 4 years in offspring of women with maternal phenylketonuria: the Maternal

- PKU Collaborative Study. *JAMA* 2000 Feb 9;283(6):756-62.
- Waisbren SE, Levy HL. Agoraphobia in phenylketonuria. *J Inherit Metab Dis* 1991;14(5):755-64.
- Waisbren SE, Levy HL. Effects of untreated maternal hyperphenylalaninemia on the fetus: further study of families identified by routine cord blood screening. *J Pediatr* 1990 Jun;116(6):926-9.
- Waisbren SE, Mahon BE, Schnell RR, Levy HL. Predictors of intelligence quotient and intelligence quotient change in persons treated for phenylketonuria early in life. *Pediatrics* 1987 Mar;79(3):351-5.
- Waisbren SE, Rokni H, Bailey I, Rohr F, Brown T, Warner-Rogers J. Social factors and the meaning of food in adherence to medical diets: results of a maternal phenylketonuria summer camp. *J Inherit Metab Dis* 1997 Mar;20(1):21-7.
- Waisbren SE, Schnell R, Levy HL. Intelligence and personality characteristics in adults with untreated atypical phenylketonuria and mild hyperphenylalaninemia. *J Pediatr* 1984 Dec;105(6):955-8.
- Waisbren SE, Schnell RR, Levy HL. Diet termination in children with phenylketonuria: a review of psychological assessments used to determine outcome. *J Inherit Metab Dis* 1980;3(4):149-53.
- Waisbren SE, Shiloh S, St James P, Levy HL. Psychosocial factors in maternal phenylketonuria: prevention of unplanned pregnancies. *Am J Public Health* 1991 Mar;81(3):299-304.
- Waisbren SE, Zaff J. Personality disorder in young women with treated phenylketonuria. *J Inherit Metab Dis* 1994;17(5):584-92.
- Walker JD, Crall JJ, McDonnell JE. Phenylketonuria and dentistry: review of the literature. *ASDC J Dent Child* 1982 Jul-Aug;49(4):280-4.
- Walker V, Smythe PJ, Cook NJ, Ball NA, Veall RM, Whiteman P. Urinary screening for abnormalities of amino acid or mucopolysaccharide metabolism in patients in a hospital for the mentally handicapped in Wessex. *J Ment Defic Res* 1983 Jun;27 (Pt 2):105-14.
- Wasser S, Ettrich KU, Schmidt KD, Selle D, Theile H. [Case studies of the effect of tyrosine administration in children with phenylketonuria on cognitive processes]. *Klin Padiatr* 1992 Nov-Dec;204(6):417-21. (Ger).
- Wasser S, Theile H. [The interaction of biological and social factors on the effect of treatment in cases of phenylketonuria (author's transl)]. *Padiatr Padol* 1981;16(4):417-26. (Ger).
- Wasser S, Theile H, Scheer A, Graustein I. [Reduced optimal obstetric and postnatal conditions in children with phenylketonuria and their effect on the success of treatment]. *Padiatr Padol* 1986;21(4):351-6. (Ger).
- Watts RW, Baraitser M, Chalmers RA, Purkiss P. Organic acidurias and amino acidurias in the aetiology of long-term mental handicap. *J Ment Defic Res* 1980 Dec;24 Pt 4:257-70.
- Weglage J. Phenylketonurie: psychosoziale Aspekte einer chronischen Erkrankung. Seattle (WA): Hogrefe; c1993. 136 p. (Ger).
- Weglage J, Funders B, Ullrich K, Rupp A, Schmidt E. Psychosocial aspects in phenylketonuria. *Eur J Pediatr* 1996 Jul;155 Suppl 1:S101-4.
- Weglage J, Funders B, von Teeffelen-Heithoff A, Ullrich K. [Phenylketonuria--change in therapeutic strategies. Study of intellectual development and dietary compliance of young phenylketonuria patients]. *Fortschr Med* 1993 Nov 10;111(31):485-8. (Ger).
- Weglage J, Funders B, von Teeffelen-Heithoff A, Ullrich K. [Phenylketonuria: illness experience and coping mechanisms]. *Z Kinder Jugendpsychiatr* 1993 Sep;21(3):156-62. (Ger).
- Weglage J, Funders B, Wilken B, Schubert D, Schmidt E, Burgard P, Ullrich K. Psychological and social findings in adolescents with phenylketonuria. *Eur J Pediatr* 1992 Jul;151(7):522-5.
- Weglage J, Funders B, Wilken B, Schubert D, Ullrich K. School performance and intellectual outcome in adolescents with phenylketonuria. *Acta Paediatr* 1993 Jun-Jul;82(6-7):582-6.
- Weglage J, Funders B, Wilken B, van Teeffelen-Heithoff A, Ullrich K. [Treatment of phenylketonuria: wish and reality]. *Monatsschr Kinderheilkd* 1993 Aug;141(8):670-4. (Ger).
- Weglage J, Grenzebach M, Pietsch M, Feldmann R, Linnenbank R, Denecke J, Koch HG. Behavioural and emotional problems in early-treated adolescents with phenylketonuria in comparison with diabetic patients and healthy controls. *J Inherit Metab Dis* 2000;23:487-96.
- Weglage J, Pietsch M, Denecke J, Sprinz A, Feldmann R, Grenzebach M, Ullrich K. Regression of neuropsychological deficits in early-treated phenylketonurics during adolescence. *J Inherit Metab Dis* 1999 Aug;22(6):693-705.
- Weglage J, Pietsch M, Funders B, Koch HG, Ullrich K. Deficits in selective and sustained attention processes in early treated children with

- phenylketonuria--result of impaired frontal lobe functions? *Eur J Pediatr* 1996 Mar;155(3):200-4.
- Weglage J, Pietsch M, Funders B, Koch HG, Ullrich K. Neurological findings in early treated phenylketonuria. *Acta Paediatr* 1995 Apr;84(4):411-5.
- Weglage J, Rupp A, Schmidt E. Personality characteristics in patients with phenylketonuria treated early. *Pediatr Res* 1994 May;35(5):611-3.
- Weglage J, Schmidt E, Funders B, Pietsch M, Ullrich K. Sustained attention in untreated non-PKU-hyperphenylalaninemia. *J Clin Exp Neuropsychol* 1996 Jun;18(3):343-8.
- Weglage J, Ullrich K, Pietsch M, Funders B, Guttler F, Harms E. Intellectual, neurologic, and neuropsychologic outcome in untreated subjects with nonphenylketonuria hyperphenylalaninemia. German Collaborative Study on Phenylketonuria. *Pediatr Res* 1997 Sep;42(3):378-84.
- Weglage J, Ullrich K, Pietsch M, Funders B, Zass R, Koch HG. Untreated non-phenylketonuric-hyperphenylalaninaemia: intellectual and neurological outcome. *Eur J Pediatr* 1996 Jul;155 Suppl 1:S26-8.
- Welsh M, Pennington B. Phenylketonuria. In: Yeates KO, Ris MS, Taylor HG, editors. *Pediatric neuropsychology: research, theory and practice*. New York: Guilford Press; 2000. p. 275-99.
- Welsh MC. A prefrontal dysfunction model of early-treated phenylketonuria. *Eur J Pediatr* 1996 Jul;155 Suppl 1:S87-9.
- Welsh MC, Pennington BF, Ozonoff S, Rouse B, et al. Neuropsychology of early-treated phenylketonuria: Specific executive function deficits. *Annu Progr Child Psychiatry Child Dev* 1991;466-91.
- Welsh MC, Pennington BF, Ozonoff S, Rouse B, McCabe ER. Neuropsychology of early-treated phenylketonuria: specific executive function deficits. *Child Dev* 1990 Dec;61(6):1697-713.
- Wilkinson H, Holbrook IB. Maternal phenylketonuria. *Ann Clin Biochem* 1998 Jul;35(Pt 4):539-41.
- Willet AB, Nelson JE, Foss DK. Screening for adult phenylketonuria in state psychiatric hospitals. *Am J Psychiatry* 1980 Dec;137(12):1607-8.
- Williams K. Benefits of normalizing plasma phenylalanine: impact on behaviour and health. A case report. *J Inherit Metab Dis* 1998 Dec;21(8):785-90.
- Williamson M, Dobson JC, Koch R. Collaborative study of children treated for phenylketonuria: study design. *Pediatrics* 1977 Dec;60(6):815-21.
- Williamson M, Koch R, Berlow S. Diet discontinuation in phenylketonuria [letter]. *Pediatrics* 1979 May;63(5):823-4.
- Williamson ML, Koch R, Azen C, Chang C. Correlates of intelligence test results in treated phenylketonuric children. *Pediatrics* 1981 Aug;68(2):161-7.
- Wolf ME, Mosnaim AD. Phenylethylamine in neuropsychiatric disorders. *Gen Pharmacol* 1983;14(4):385-90.
- Wong DL, Ciaranello RD. Molecular biological approaches to mental retardation. *Clin Neuropharmacol* 1986;9 Suppl 4:519-21.
- Woo SL. Molecular genetic analysis of phenylketonuria and mental retardation. *Res Publ Assoc Res Nerv Ment Dis* 1991;69:193-203.
- Woo SL. Molecular genetic-analysis of phenylketonuria and mental retardation. In: McHugh PR, McKusick VA, editors. *Genes, brain, and behavior*. New York: Raven; 1991. p. 193-204.
- Woolf LI. Late onset phenylalanine intoxication [letter]. *J Inherit Metab Dis* 1980;2(1):19-20.
- Wuu KD, Chiu PC, Li SY, Chen JY, Chao MC, Ko FJ, Wang TR, Hsiao KJ. Chromosomal and biochemical screening on mentally retarded school children in Taiwan. *Jinrui Idengaku Zasshi* 1991 Sep;36(3):267-74.
- Wuu KD, Hsiao KJ, Chen CH, Hsiao TS, Chang CY, Chu YK. Screening for inherited metabolic diseases and congenital hypothyroidism in 4,744 mentally retarded school children in Taiwan. *Jinrui Idengaku Zasshi* 1988 Mar;33(1):33-40.
- Yadav G, Farag TI, al Awadi SA, Sam T, Marafie MJ, Bastaki L, el Khalifa MY, Kasrawi B, Wahba RA. Aminoacidopathies among institutionalised mentally retarded in Kuwait [letter]. *Clin Genet* 1992 Oct;42(4):212.
- Yannicelli S, Ryan A. Improvements in behaviour and physical manifestations in previously untreated adults with phenylketonuria using a phenylalanine-restricted diet: a national survey. *J Inherit Metab Dis* 1995;18(2):131-4.
- Yeh SL, Ma FC, Shieh MJ, Wu KD, Hsiao KJ. [Dietary therapy of phenylketonuric patients in Taiwan]. *Taiwan I Hsueh Hui Tsa Chih* 1985 May;84(5):546-61. (Chi).
- Yoshimoto K, Yoshida T, Takeuchi Y, Ueda S. The effects of 6R-L-Erythro-5,6,7,8-Tetrahydrobiopterin on ethanol-induced sleep time and ethanol elimination in inbred strains of mice with different alcohol

preference. *Neuropsychobiology* 1997 Nov;36(4):188-93.

Young SN, Palmour RM. Research on genes: promises and limitations. *J Psychiatry Neurosci* 1999 Sep;24(4):300-3.

Yuan L, Fang B, Wang M, Wang T, Huang S, Yang T, Zhao S. [Comparison of genotype and intellectual phenotype in untreated phenylketonuric children]. *Chung Hua I Hsueh I Chuan Hsueh Tsa Chih* 1998 Oct 10;15(5):297-9. (Chi).

Zagreda L, Goodman J, Druin DP, McDonald D, Diamond A. Cognitive deficits in a genetic mouse model of the most common biochemical cause of human mental retardation. *J Neurosci* 1999 Jul 15;19(14):6175-82.

Zartler AS, Sassaman E. Linguistic development in PKU [letter]. *J Pediatr* 1981 Sep;99(3):501.

Zeman J, Pijackova A, Behulova J, Urge O, Saligova, Hyanek J. Intellectual and school performance in adolescents with phenylketonuria according to their dietary compliance. The Czech-Slovak Collaborative Study. *Eur J Pediatr* 1996 Jul;155 Suppl 1:S56-8.

Zwaan J. Eye findings in patients with phenylketonuria. *Arch Ophthalmol* 1983 Aug;101(8):1236-7.

Nutrition, Diet, and Diet Therapy

Aarseth J, Vandvik IH, Heyerdahl S, Kindt E, Motzfeldt K, Halvorsen S. [Children with phenylketonuria (Folling's disease). Intellectual functions and psychological adaptation]. *Tidsskr Nor Laegeforen* 1989 Nov 30;109(33):3416-8. (Nor).

Abadie V, Rey F, Plainguet F, Rey J. [Intellectual development after relaxing the diet at the age of 5 years in typical phenylketonuria]. *Arch Fr Pediatr* 1992 Nov;49(9):773-8. (Fre).

Abdallah RM, Starkey JR, Meadows GG. Dietary restriction of tyrosine and phenylalanine: inhibition of metastasis of three rodent tumors. *J Natl Cancer Inst* 1987 Apr;78(4):759-69.

Acosta PB. Nutrition studies in treated infants and children with phenylketonuria: vitamins, minerals, trace elements. *Eur J Pediatr* 1996 Jul;155 Suppl 1:S136-9.

Acosta PB, Alfin-Slater RB, Koch R. Serum lipids in children with phenylketonuria (PKU). *J Am Diet Assoc* 1973 Dec;63(6):631-5.

Acosta PB, Fernhoff PM, Warshaw HS, Elsas LJ, Hambidge KM, Ernest A, McCabe ER. Zinc status and growth of children undergoing treatment for phenylketonuria. *J Inherit Metab Dis* 1982;5(2):107-10.

Acosta PB, Fernhoff PM, Warshaw HS, Hambidge KM, Ernest A, McCabe ER, Elsas LJ 2d. Zinc and copper status of treated children with phenylketonuria. *JPEN J Parenter Enteral Nutr* 1981 Sep-Oct;5(5):406-9.

Acosta PB, Stepnick-Gropper S, Clarke-Sheehan N, Wenz E, Cheng M, Anderson K, Koch R. Trace element status of PKU children ingesting an elemental diet. *JPEN J Parenter Enteral Nutr* 1987 May-Jun;11(3):287-92.

Acosta PB, Trahms C, Wellman NS, Williamson M. Phenylalanine intakes of 1- to 6-year-old children with phenylketonuria undergoing therapy. *Am J Clin Nutr* 1983 Nov;38(5):694-700.

Acosta PB, Wenz E. Diet management of PKU for infants and preschool children. Rockville (MD): Department of Health, Education, and Welfare (US), Public Health Service, Health Services Administration, Bureau of Community Health Services; 1977. 30 p. (DHEW publication: no. (HSA) 77-5209).

Acosta PB, Wenz E, Williamson M. Methods of dietary inception in infants with PKU. *J Am Diet Assoc* 1978 Feb;72(2):164-9.

- Acosta PB, Wenz E, Williamson M. Nutrient intake of treated infants with phenylketonuria. *Am J Clin Nutr* 1977 Feb;30(2):198-208.
- Acosta PB, Williams M, Koch R, Dobson J. PKU [phenylketonuria] collaborative study--clinical effects of phenylalanine restricted diets. *Proc West Hemisphere Nutr Congr* 1974;4:358.
- Acosta PB, Yannicelli S. Nutrition support of inherited disorders of amino acid metabolism: part 2. *Top Clin Nutr* 1995 Mar;10(2):48-72.
- Acosta PB, Yannicelli S. Plasma micronutrient concentrations in infants undergoing therapy for phenylketonuria. *Biol Trace Elem Res* 1999 Jan;67(1):75-84.
- Acosta PB, Yannicelli S. Protein intake affects phenylalanine requirements and growth of infants with phenylketonuria. *Acta Paediatr Suppl* 1994 Dec;407:66-7.
- Acosta PB, Yannicelli S, Marriage B, Mantia C, Gaffield B, Porterfield M, Hunt M, McMaster N, Bernstein L, Parton P, Kuehn M, Lewis V. Nutrient intake and growth of infants with phenylketonuria undergoing therapy. *J Pediatr Gastroenterol Nutr* 1998 Sep;27(3):287-91.
- Acosta PB, Yannicelli S, Marriage B, Steiner R, Gaffield B, Arnold G, Lewis V, Cho S, Berstein L, Parton P, Leslie N, Korson M. Protein status of infants with phenylketonuria undergoing nutrition management. *J Am Coll Nutr* 1999 Apr;18(2):102-7.
- Afanas'eva NA, Bychkova AM, Livshits LA, Bariliak IR. [The clinical and molecular genetic characteristics of phenylketonuria patients in the Republic of Crimea]. *Tsitol Genet* 1998 Jan-Feb;32(1):8-14. (Rus).
- Agostoni C. Early breastfeeding linked to higher intelligence quotient scores [letter]. *Acta Paediatr* 1996 May;85(5):639.
- Agostoni C, Marangoni F, Riva E, Giovannini M, Galli C. Plasma arachidonic acid and serum thromboxane B2 concentrations in phenylketonuric children negatively correlate with dietary compliance. *Prostaglandins Leukot Essent Fatty Acids* 1997 Mar;56(3):219-22.
- Agostoni C, Riva E, Biasucci G, Luotti D, Bruzzese MG, Marangoni F, Giovannini M. The effects of n-3 and n-6 polyunsaturated fatty acids on plasma lipids and fatty acids of treated phenylketonuric children. *Prostaglandins Leukot Essent Fatty Acids* 1995 Dec;53(6):401-4.
- Agostoni C, Riva E, Galli C, Marangoni F, Luotti D, Giovannini M. Plasma arachidonic acid and serum thromboxane B2 concentrations in phenylketonuric children are correlated with dietary compliance. *Z Ernahrungswiss* 1998;37 Suppl 1:122-4.
- Agostoni C, Verduci E, Fiori L, Riva E, Giovannini M. Breastfeeding rates among hyperphenylalaninemic infants [letter]. *Acta Paediatr* 2000 Mar;89(3):366-7.
- Al-Qadreh A, Schulpis KH, Athanasopoulou H, Mengreli C, Skarpalezou A, Voskaki I. Bone mineral status in children with phenylketonuria under treatment. *Acta Paediatr* 1998 Nov;87(11):1162-6.
- Allen JR, Baur LA, Waters DL, Humphries IR, Allen BJ, Roberts DC, Gaskin KJ. Body protein in prepubertal children with phenylketonuria. *Eur J Clin Nutr* 1996 Mar;50(3):178-86.
- Allen JR, Humphries IR, Waters DL, Roberts DC, Lipson AH, Howman-Giles RG, Gaskin KJ. Decreased bone mineral density in children with phenylketonuria. *Am J Clin Nutr* 1994 Feb;59(2):419-22.
- Allen RJ, Brunberg J, Schwartz E, Schaefer AM, Jackson G. MRI characterization of cerebral dysgenesis in maternal PKU. *Acta Paediatr Suppl* 1994 Dec;407:83-5.
- Allen RJ, Schwartz E, Hufstetler D. PKU diet termination at age three years: psychological stability with variable neurological effects. In: Naruse H, Irie M, editors. *Neonatal screening. Proceedings of the 2nd International Conference on Neonatal Thyroid Screening; 1982 Aug 16-19; Tokyo and the International Symposium on Neonatal Screening for Inborn Errors of Metabolism; 1982 Aug 19-21; Tokyo.* Princeton (NJ): Excerpta Medica; 1983. p. 229-30. (International congress series; no. 606).
- Alm J, Bodegard G, Larsson A, Nyberg G, Zetterstrom R. Children with inborn errors of phenylalanine metabolism: prognosis and phenylalanine tolerance. *Acta Paediatr Scand* 1986 Jul;75(4):619-25.
- Alvarez Dominguez L, Campistol Plana J, Ribes Rubio A, Riverola de Vecina AT. [Phenylalanine metabolites in hyperphenylalaninemic children]. *An Esp Pediatr* 1992 May;36(5):371-4. (Spa).
- Ambrus CM, Anthonie S, Horvath C, Kalghatgi K, Lele AS, Eapen G, Ambrus JL, Ryan AJ, Li P. Extracorporeal enzyme reactors for depletion of phenylalanine in phenylketonuria. *Ann Intern Med* 1987 Apr;106(4):531-7.
- Ambulatory nutrition care: infants. *J Am Diet Assoc* 1989 Apr;89(4):S15-6.
- Ambulatory Nutrition Care: pregnant women. *J Am Diet Assoc* 1989 Apr;89(4 Suppl):S10-4.

- Anderson GH, Leiter LA. Effects of aspartame and phenylalanine on meal-time food intake of humans. *Appetite* 1988;11(Suppl 1):48-53.
- Anderson K. Vitamin B-6 status of children with phenylketonuria. *Nutr Rep Int* 1986 Sep;34(3):387-92.
- Anderson K, Acosta PB, Kennedy B. Osmolality of enteral formulas for maternal phenylketonuria. *J Inherit Metab Dis* 1986;9(1):39-44.
- Anderson K, Kennedy B, Acosta PB. Computer-implemented nutrition support of phenylketonuria. *J Am Diet Assoc* 1985 Dec;85(12):1623-5.
- Anderson PA, Baker DH, Sherry PA, Corbin JE. Histidine, phenylalanine-tyrosine and tryptophan requirements for growth of the young kitten. *J Anim Sci* 1980 Mar;50(3):479-83.
- Ando A, Momomura K, Tobe K, Yamamoto-Honda R, Sakura H, Tamori Y, Kaburagi Y, Koshio O, Akanuma Y, Yazaki Y, et al. Enhanced insulin-induced mitogenesis and mitogen-activated protein kinase activities in mutant insulin receptors with substitution of two COOH-terminal tyrosine autophosphorylation sites by phenylalanine. *J Biol Chem* 1992 Jun 25;267(18):12788-96.
- Antener I, Verwilghen AM, van Geert C, Mauron J. Biochemical study of malnutrition. Part V. Metabolism of phenylalanine and tyrosine. *Int J Vitam Nutr Res* 1981;51(3):297-306.
- Antisdel JE, Chrisler JC. Comparison of eating attitudes and behaviors among adolescent and young women with type 1 diabetes mellitus and phenylketonuria. *J Dev Behav Pediatr* 2000 Apr;21(2):81-6.
- Arakawa T, Saito TG, Minagawa A, Shioji R, Kobayashi M, Chikaoka H, Katsushima N. Higher excretion of urinary bound amino acids in infants: probably related to protein-anabolic effect of growth hormone. *Tohoku J Exp Med* 1982 May;137(1):1-10.
- Archer LA, Cunningham CE, Whelan DT. Coping with dietary therapy in phenylketonuria: A case report. *Can J Behav Sci* 1988 Oct;20(4):461-6.
- Argaet VP, Wilson TJ, Davidson BE. Purification of the *Escherichia coli* regulatory protein TyrR and analysis of its interactions with ATP, tyrosine, phenylalanine, and tryptophan. *J Biol Chem* 1994 Feb 18;269(7):5171-8.
- Arnau J, Guerrero L, Hortos M, Garcia-Regueiro JA. The composition of white film and white crystals found in dry-cured hams. *J Sci Food Agric* 1996 Apr;70(4):449-52.
- Artuch R, Vilaseca MA, Moreno J, Lambruschini N, Cambra FJ, Campistol J. Decreased serum ubiquinone-10 concentrations in phenylketonuria. *Am J Clin Nutr* 1999 Nov;70(5):892-5.
- Aspartame. Review of safety issues. Council on Scientific Affairs. *JAMA* 1985 Jul 19;254(3):400-2.
- Austic RE, Su CL, Strupp BJ, Levitsky DA. Effects of dietary mixtures of amino acids on fetal growth and maternal and fetal amino acid pools in experimental maternal phenylketonuria. *Am J Clin Nutr* 1999 Apr;69(4):687-96.
- Awiszus D, Unger I. Coping with PKU: results of narrative interviews with parents. *Eur J Pediatr* 1990;149 Suppl 1:S45-51.
- Azen C, Koch R, Friedman E, Wenz E, Fishler K. Summary of findings from the United States Collaborative Study of children treated for phenylketonuria. *Eur J Pediatr* 1996 Jul;155 Suppl 1:S29-32.
- Azen CG, Koch R, Friedman EG, Berlow S, Coldwell J, Krause W, Matalon R, McCabe E, O'Flynn M, Peterson R, et al. Intellectual development in 12-year-old children treated for phenylketonuria. *Am J Dis Child* 1991 Jan;145(1):35-9. Comment in: *Am J Dis Child* 1991 Jan;145(1):33.
- Baba H, Sato S, Inuzuka T, Miyatake T. Developmental changes of myelin-associated glycoprotein in rat brain: study on experimental hyperphenylalaninemia. *Neurochem Res* 1987 May;12(5):459-63.
- Backus RC, Howard KA, Rogers QR. The potency of dietary amino acids in elevating plasma cholecystokinin immunoreactivity in cats is related to amino acid hydrophobicity. *Regul Pept* 1997 Sep 26;72(1):31-40.
- Backwell FR, Bequette BJ, Wilson D, Calder AG, Metcalf JA, Wray-Cahen D, MacRae JC, Beever DE, Lobley GE. Utilization of dipeptides by the caprine mammary gland for milk protein synthesis. *Am J Physiol* 1994 Jul;267(1 Pt 2):R1-6.
- Bailey CA, Gibson RM, Kubena LF, Huff WE, Harvey RB. Impact of L-phenylalanine supplementation on the performance of three-week-old broilers fed diets containing ochratoxin A. 2. Effects of hematology and clinical chemistry. *Poultry Sci* 1990 Mar;69(3):420-25.
- Bain MD, Purkiss P, Jones M, Bingham P, Stacey TE, Chalmers RA. Dietary treatment eliminates succinylacetone from the urine of a patient with tyrosinaemia type 1. *Eur J Pediatr* 1990 Jun;149(9):637-9.

- Balasubramanian S, Carr RT, Bender CJ, Peisach J, Benkovic SJ. Histidines 138 and 143 are copper binding ligands in *Chromobacterium violaceum* phenylalanine hydroxylase. *Adv Exp Med Biol* 1993;338:67-70.
- Balasubramanian S, Carr RT, Bender CJ, Peisach J, Benkovic SJ. Identification of metal ligands in Cu(II)-inhibited *Chromobacterium violaceum* phenylalanine hydroxylase by electron spin echo envelope modulation analysis of histidine to serine mutations. *Biochemistry* 1994 Jul 19;33(28):8532-7.
- Baldellou Vazquez A, Ruiz-Echarri Zalaya MP, Salazar Garcia-Blanco MI. [Recommendations for the dietary treatment of phenylketonuria]. *An Esp Pediatr* 1999 Dec;51(6):625-8. (Spa).
- Ball RO, Atkinson JL, Bayley HS. Proline as an essential amino acid for the young pig. *Br J Nutr* 1986 May;55(3):659-68.
- Ball RO, Bayley HS. The effect of diarrhea on the oxidation of 14C-phenylalanine in piglets receiving diets varying in protein and proline concentration. *Can J Vet Res* 1986 Jul;50(3):393-6.
- Ball RO, Bayley HS. Influence of dietary protein concentration on the oxidation of phenylalanine by the young pig. *Br J Nutr* 1986 May;55(3):651-8.
- Ball RO, Bayley HS. Time course of the total and radioactive carbon dioxide production by piglets receiving dietary [14C]phenylalanine. *Can J Physiol Pharmacol* 1985 Sep;63(9):1170-4.
- Ball RO, Bayley HS. Tryptophan requirement of the 2.5-kg piglet determined by the oxidation of an indicator amino acid. *J Nutr* 1984 Oct;114(10):1741-6.
- Ballinger AB, Clark ML. L-phenylalanine releases cholecystokinin (CCK) and is associated with reduced food intake in humans: evidence for a physiological role of CCK in control of eating. *Metab Clin Exp* 1994 Jun;43(6):735-8.
- Barazzoni R, Zanetti M, Tiengo A, Tessari P. Protein metabolism in glucagonoma. *Diabetologia* 1999 Mar;42(3):326-9.
- Basile-Filho A, Beaumier L, El-Khoury AE, Yu YM, Kenneway M, Gleason RE, Young VR. Twenty-four-hour L-[1-(13)C]tyrosine and L-[3,3-(2)H2]phenylalanine oral tracer studies at generous, intermediate, and low phenylalanine intakes to estimate aromatic amino acid requirements in adults. *Am J Clin Nutr* 1998 Apr;67(4):640-59.
- Basile-Filho A, el-Khoury AE, Beaumier L, Wang SY, Young VR. Continuous 24-h L-[1-13C]phenylalanine and L-[3,3-2H2]tyrosine oral-tracer studies at an intermediate phenylalanine intake to estimate requirements in adults. *Am J Clin Nutr* 1997 Feb;65(2):473-88.
- Batshaw ML, Valle D, Bessman SP. Unsuccessful treatment of phenylketonuria with tyrosine. *J Pediatr* 1981 Jul;99(1):159-60.
- Batterham ES, Bayley HS. Effect of frequency of feeding of diets containing free or protein-bound lysine on the oxidation of [14C]lysine or [14C]phenylalanine by growing pigs. *Br J Nutr* 1989 Nov;62(3):647-55.
- Battistini S, De Stefano N, Parlanti S, Federico A. Unexpected white matter changes in an early treated PKU case and improvement after dietary treatment. *Funct Neurol* 1991 Apr-Jun;6(2):177-80.
- Baumeister AA, Baumeister AA. Dietary treatment of destructive behavior associated with hyperphenylalaninemia. *Clin Neuropharmacol* 1998 Jan-Feb;21(1):18-27.
- Beasley MG, Costello PM, Smith I. Outcome of treatment in young adults with phenylketonuria detected by routine neonatal screening between 1964 and 1971. *Q J Med* 1994 Mar;87(3):155-60.
- Beaudette T. Metabolic disorders of childhood: nutritional management. *Semin Nutr* 1994 Mar-Apr;13(4):1-18.
- Beaudette T, editor. Maternal nutritional status: effect on pregnancy outcome. *Semin Nutr* 1989 Mar-Apr;8(4):[24 p.].
- Behbehani AW. Termination of strict diet therapy in phenylketonuria. A study on EEG sleep patterns and computer spectral analysis. *Neuropediatrics* 1985 May;16(2):92-7.
- Beirne E, Carty MP, Donlon J. Effect of glucagon on hepatic phenylalanine hydroxylase in vivo. *Biosci Rep* 1985 Jun;5(6):463-7.
- Bell JM, John AM. Amino acid requirements of growing mice: arginine, lysine, tryptophan and phenylalanine. *J Nutr* 1981 Mar;111(3):525-30.
- Bell L, Acosta PB, Chan L. Amino acid content of low-protein recipes. *J Am Diet Assoc* 1982 Jun;80(6):579-80.
- Bellenir K, editor. Diet and nutrition sourcebook. 2nd ed. Detroit: Omnigraphics; c1999. 650 p.
- Bequette BJ, Backwell FR, Crompton LA. Current concepts of amino acid and protein metabolism in the mammary gland of the lactating ruminant. *J Dairy Sci* 1998 Sep;81(9):2540-59.

- Bequette BJ, Backwell FR, Dhanoa MS, Walker A, Calder AG, Wray-Cahen D, Metcalf JA, Sutton JD, Beever DE, Lobley GE. Kinetics of blood free and milk casein-amino acid labelling in the dairy goat at two stages of lactation. *Br J Nutr* 1994 Aug;72(2):211-20. Comment in: *Br J Nutr* 1996 Jan;75(1):139-40.
- Berger DC, Hilton MA, Hilton FK, Duncan SD, Radmacher PG, Greene SM. Intravenous gamma-glutamyl-tyrosine elevates brain tyrosine but not catecholamine concentrations in normal rats. *Metabolism* 1996 Jan;45(1):126-32.
- Berger R, Springer J, Hommes FA. Brain protein and myelin metabolism in hyperphenylalaninemic rats. *Cell Mol Biol* 1980;26(1):31-6.
- Berry HK, Hsieh MH, Bofinger MK, Schubert WK. Diagnosis of phenylalanine hydroxylase deficiency (phenylketonuria). *Am J Dis Child* 1982 Feb;136(2):111-4.
- Bertolo RF, Chen CZ, Law G, Pencharz PB, Ball RO. Threonine requirement of neonatal piglets receiving total parenteral nutrition is considerably lower than that of piglets receiving an identical diet intragastrically. *J Nutr* 1998 Oct;128(10):1752-9.
- Bessman SP. The justification theory: the essential nature of the non-essential amino acids. *Nutr Rev* 1979 Jul;37(7):209-20.
- Bessman SP. Phenylketonuria--a genetic intrauterine nutritional deficiency. *Nutr MD* 1992 Jan;18(1):5.
- Bessman SP, Choi H, Tomaszewski L. The justification theory: the effect of tyrosine deficiency on tubulin synthesis in the brain. *Prog Clin Biol Res* 1982;79:187-92.
- Bessman SP, Williamson ML, Koch R. Diet, genetics, and mental retardation interaction between phenylketonuric heterozygous mother and fetus to produce nonspecific diminution of IQ: evidence in support of the justification hypothesis. *Proc Natl Acad Sci U S A* 1978 Mar;75(3):1562-6.
- Bialik RJ, Li ET, Geoffroy P, Anderson GH. Route of delivery of phenylalanine influences its effect on short-term food intake in adult male rats. *J Nutr* 1989 Oct;119(10):1519-27.
- Bick U, Fahrendorf G, Ludolph AC, Vassallo P, Weglage J, Ullrich K. Disturbed myelination in patients with treated hyperphenylalaninaemia: evaluation with magnetic resonance imaging. *Eur J Pediatr* 1991 Jan;150(3):185-9.
- Bickel H. [Diet therapy and coenzyme therapy in hereditary metabolic diseases]. *Monatsschr Kinderheilkd* 1983 Aug;131(8):488-94. (Ger).
- Bickel H. Dietary restriction in inborn errors of amino acid metabolism. *Curr Concepts Nutr* 1979;8:35-53.
- Bickel H. Differential diagnosis and treatment of hyperphenylalaninaemia. *Prog Clin Biol Res* 1985;177:93-107.
- Bickel H. The first treatment of phenylketonuria. *Eur J Pediatr* 1996 Jul;155 Suppl 1:S2-3.
- Bickel H. Phenylketonuria: past, present, future. F. P. Hudson Memorial Lecture, Leeds, 1979. *J Inher Metab Dis* 1980;3(4):123-32.
- Bickel H. [Phenylketonuria. Yesterday, today and tomorrow]. *Arch Fr Pediatr* 1983;40 Suppl 1:207-13. (Fre).
- Bickel H, Bremer HJ. [On phenylketonuria. Carrying out of phenylalanine-low diet]. *Dtsch Med Wochenschr* 1967 Apr 14;92(15):700-10. (Ger).
- Bickel H, Trefz FK. [Aspartame: a sweetening agent with a high phenylalanine content]. *Monatsschr Kinderheilkd* 1986 Jul;134(7):478-80. (Ger).
- Binek PA, Johnson TC, Kelly CJ. Effect of alpha-methylphenylalanine and phenylalanine on brain polyribosomes and protein synthesis. *J Neurochem* 1981 Apr;36(4):1476-84.
- Binek-Singer P, Johnson TC. The effects of chronic hyperphenylalaninaemia on mouse brain protein synthesis can be prevented by other amino acids. *Biochem J* 1982 Aug 15;206(2):407-14.
- Biolo G, Maggi SP, Williams BD, Tipton KD, Wolfe RR. Increased rates of muscle protein turnover and amino acid transport after resistance exercise in humans. *Am J Physiol* 1995 Mar;268(3 Pt 1):E514-20.
- Biolo G, Tessari P, Inchiostro S, Bruttomesso D, Sabadin L, Fongher C, Panebianco G, Fratton MG, Tiengo A. Fasting and postmeal phenylalanine metabolism in mild type 2 diabetes. *Am J Physiol* 1992 Nov;263(5 Pt 1):E877-83.
- Bjorgo E, Knappskog PM, Martinez A, Stevens RC, Flatmark T. Partial characterization and three-dimensional-structural localization of eight mutations in exon 7 of the human phenylalanine hydroxylase gene associated with phenylketonuria. *Eur J Biochem* 1998 Oct 1;257(1):1-10.
- Blaauw Ide, Deutz NEP, Meyenfeldt MF von. In vivo amino acid metabolism of gut and liver during short and prolonged starvation. *Am J Physiol* 1996 Feb;270(2 Pt 1):G298-306.
- Blaskovics M, Engel R, Podosin RL, Azen CG, Friedman EG. EEG pattern in phenylketonuria under

- early initiated dietary treatment. *Am J Dis Child* 1981 Sep;135(9):802-8.
- Blaskovics ME. Diagnosis in relationship to treatment of hyperphenylalaninaemia. *J Inher Metab Dis* 1986;9 Suppl 2:178-82.
- Blass EM. Milk-induced hypoalgesia in human newborns. *Pediatrics* 1997 Jun;99(6):825-9.
- Bleukx W, Roels SP, Delcour JA. On the presence and activities of proteolytic enzymes in vital wheat gluten. *J Cereal Sci* 1997 Sep;26(2):183-93.
- Blumina MG. [Phenylalanine level in the serum of heterozygotes for phenylketonuria under intensified protein catabolism]. *Genetika* 1981;17(5):910-4. (Rus).
- Blomquist HK, Gustavson KH, Holmgren G. Severe mental retardation in five siblings due to maternal phenylketonuria. *Neuropediatrics* 1980 Aug;11(3):256-61.
- Blomstrand E, Newsholme EA. Effect of branched-chain amino acid supplementation on the exercise-induced change in aromatic amino acid concentration in human muscle. *Acta Physiol Scand* 1992 Nov;146(3):293-8.
- Blumina MG. [Children with late treated phenylketonuria at the auxiliary school]. *Defektologiya* 1980;5:25-31. (Rus).
- Bodamer OA, Leonard JV, Tasker RC, Hoffmann GF, Halliday D. Protein turnover in critically ill children. *Eur J Pediatr* 1997 Aug;156 Suppl 1:S59-61.
- Bodley JL, Austin VJ, Hanley WB, Clarke JT, Zlotkin S. Low iron stores in infants and children with treated phenylketonuria: a population at risk for iron-deficiency anaemia and associated cognitive deficits. *Eur J Pediatr* 1993 Feb;152(2):140-3.
- Bodsch W, Coenen HH, Stocklin G, Takahashi K, Hossmann KA. Biochemical and autoradiographic study of cerebral protein synthesis with [¹⁸F]- and [¹⁴C]fluorophenylalanine. *J Neurochem* 1988 Mar;50(3):979-83.
- Boebel KP, Baker DH. Comparative utilization of the isomers of phenylalanine and phenyllactic acid by chicks and rats. *J Nutr* 1982 Feb;112(2):367-76.
- Bohles H, Ullrich K, Endres W, Behbehani AW, Wendel U. Inadequate iron availability as a possible cause of low serum carnitine concentrations in patients with phenylketonuria. *Eur J Pediatr* 1991 Apr;150(6):425-8.
- Boron P, Szpakowicz T, Farbiszewski R, Flisiak R, Nowak H, Pytel B, Zimnoch L. [Studies of the effect of a protein-free diet and branched-chain amino acids (preparation Aminosteril-Hepa) on selected biochemical indicators in chronic experimental hepatic encephalopathy]. *Neuropatol Pol* 1989;27(3):437-47. (Pol).
- Bourget L, Chang TM. Effects of oral administration of artificial cells immobilized phenylalanine ammonia-lyase on intestinal amino acids of phenylketonuric rats. *Biomater Artif Cells Artif Organs* 1989;17(2):161-81.
- Bouteloup-Demange C, Boirie Y, Dechelotte P, Gachon P, Beaufre B. Gut mucosal protein synthesis in fed and fasted humans. *Am J Physiol* 1998 Mar;274(3 Pt 1):E541-6.
- Boyaval P, Moreira E, Desmazeaud MJ. [Transport of phenylalanine and tyrosine in *Brevibacterium linens*: specificity and incorporation into proteins]. *Can J Microbiol* 1984 Apr;30(4):430-8. (Fre).
- Boyce MW. The child with phenylketonuria (PKU). *Aust J Early Child* 1980 Jun;5(2):4-6.
- Boyce RA. The dietetic implications of maternal phenylketonuria. *Aust J Nutr Diet* 1991 Sep;48(3):82-8.
- Bradburn NC, Wappner RS, Lemons JA, Meyer BA, Roberts RS. Lactation and phenylketonuria. *Am J Perinatol* 1985 Apr;2(2):138-41.
- Brass CA, Isaacs CE, McChesney R, Greengard O. The effects of hyperphenylalaninemia on fetal development: a new animal model of maternal phenylketonuria. *Pediatr Res* 1982 May;16(5):388-94.
- Brenton DP. Maternal phenylketonuria. *Eur J Clin Nutr* 1989;43 Suppl 1:13-7.
- Brenton DP, Fraser D, Haseler ME, Krywawych S, Lachelin GC, Lilburn M, Stewart A. [Maternal phenylketonuria]. *Arch Fr Pediatr* 1987;44 Suppl 1:667-70. (Fre).
- Brenton DP, Lilburn M. Maternal phenylketonuria. A study from the United Kingdom. *Eur J Pediatr* 1996 Jul;155 Suppl 1:S177-80.
- Brenton DP, Tarn AC, Cabrera-Abreu JC, Lilburn M. Phenylketonuria: treatment in adolescence and adult life. *Eur J Pediatr* 1996 Jul;155 Suppl 1:S93-6.
- Brodie M. Maternal phenylketonuria: an Arkansas experience. *Top Clin Nutr* 1992 Dec;8(1):39-44.
- Bross R. Tyrosine requirements and resting energy expenditure in phenylketonuria [dissertation]. Toronto (Canada): University of Toronto; 1997. 261 p.

- Bross R, Ball RO, Clarke JT, Pencharz PB. Tyrosine requirements in children with classical PKU determined by indicator amino acid oxidation. *Am J Physiol Endocrinol Metab* 2000 Feb;278(2):E195-201.
- Brown EH, Berry HK, Olson J, Levinson J. Phenylketonuria and scleroderma. *J Inher Metab Dis* 1986;9(4):405-6.
- Brown MC, Guest JF. Economic impact of feeding a phenylalanine-restricted diet to adults with previously untreated phenylketonuria. *J Intellect Disabil Res* 1999 Feb;43 (Pt 1):30-7.
- Bruch RJ. The effect of L-aspartyl-L-phenylalanine methyl ester on biosynthesis in macrophage cells [masters thesis]. Denton (TX): Texas Woman's University; 1992. 54 p.
- Brunner RL, Brown EH, Berry HK. Phenylketonuria revisited: treatment of adults with behavioural manifestations. *J Inher Metab Dis* 1987;10(2):171-3.
- Brunner RL, Jordan MK, Berry HK. Early-treated phenylketonuria: neuropsychologic consequences. *J Pediatr* 1983 Jun;102(6):831-5.
- Buhrdel P, Dabritz S, Theile H. [Effect of dietary measures on body weight and height of children with phenylketonuria in East Germany]. *Klin Padiatr* 1997 Jan-Feb;209(1):26-9. (Ger).
- Buist NR, Prince AP, Huntington KL, Tuerck JM, Waggoner DD. A new amino acid mixture permits new approaches to the treatment of phenylketonuria. *Acta Paediatr Suppl* 1994 Dec;407:75-7. Published erratum appears in *Acta Paediatr* 1995 Aug;84(8):858.
- Burgard P, Armbruster M, Schmidt E, Rupp A. Psychopathology of patients treated early for phenylketonuria: results of the German collaborative study of phenylketonuria. *Acta Paediatr Suppl* 1994 Dec;407:108-10.
- Burgard P, Rey F, Rupp A, Abadie V, Rey J. Neuropsychologic functions of early treated patients with phenylketonuria, on and off diet: results of a cross-national and cross-sectional study. *Pediatr Res* 1997 Mar;41(3):368-74.
- Burgard P, Rupp A, Konecki DS, Trefz FK, Schmidt H, Lichter-Konecki U. Phenylalanine hydroxylase genotypes, predicted residual enzyme activity and phenotypic parameters of diagnosis and treatment of phenylketonuria. *Eur J Pediatr* 1996 Jul;155 Suppl 1:S11-5.
- Burgard P, Schmidt E, Rupp A, Schneider W, Bremer HJ. Intellectual development of the patients of the German Collaborative Study of children treated for phenylketonuria. *Eur J Pediatr* 1996 Jul;155 Suppl 1:S33-8.
- Burgert SL, Andersen DW, Stegink LD, Takeuchi H, Schedl HP. Metabolism of aspartame and its L-phenylalanine methyl ester decomposition product by the porcine gut. *Metab Clin Exp* 1991 Jun;40(6):612-8.
- Burlina AB, Bonafe L, Ferrari V, Suppiej A, Zacchello F, Burlina AP. Measurement of neurotransmitter metabolites in the cerebrospinal fluid of phenylketonuric patients under dietary treatment. *J Inher Metab Dis* 2000;23(4):313-6.
- Burns TS, Stargel WW, Hurwitz A. Bioavailability of phenylalanine and aspartate from aspartame (20 mg/kg) in capsules and solution. *Metab Clin Exp* 1990 Nov;39(11):1200-3.
- Burrin DG, Davis TA, Ebner S, Schoknecht PA, Fiorotto ML, Reeds PJ. Colostrum enhances the nutritional stimulation of vital organ protein synthesis in neonatal pigs. *J Nutr* 1997 Jul;127(7):1284-9.
- Burt RA. Legal and ethical aspects of interventions. In: Genetic variation and nutrition. Proceedings of the 1st International Conference on Genetic Variation and Nutrition; 1989 Jun 22-23; Washington, DC. New York: Karger; c1990. p. 266-76.
- Burton EG, Dal Monte P, Spears C, Frank P, Oppermann JA. Absorption by the rhesus monkey of phenylalanine methyl ester and species differences in its metabolism by blood, plasma and intestinal mucosa. *J Nutr* 1984 Oct;114(10):1940-5.
- Burton EG, Schoenhard GL, Hill JA, Schmidt RE, Hribar JD, Kotsonis FN, Oppermann JA. Identification of N-beta-L-aspartyl-L-phenylalanine as a normal constituent of human plasma and urine. *J Nutr* 1989 May;119(5):713-21.
- Bush RT, Dukes PC. Women with phenylketonuria: successful management of pregnancy and implications. *N Z Med J* 1985 Mar 27;98(775):181-3.
- Bushueva TV, Ladodo KS, Spirichev VB, Denisova SN, Rybakova EP. [Calcium homeostasis and calcium-regulating hormones in young children with phenylketonuria]. *Vopr Pitan* 1993 May-Jun;(3):16-21. (Rus).
- Bushueva TV, Vrzhesinskaia OA, Kodentsova VM, Rybakova EP, Denisova SN, Beketova NA, Taranova AG, Pereverzeva OG, Kharitonchik LA, Kopylova NV. [Comparative study of special products Tetraphen and Phenyl-free in diet therapy of children with phenylketonuria]. *Vopr Pitan* 1998;(2):14-8. (Rus).
- Butler IJ, O'Flynn ME, Seifert WE Jr, Howell RR. Neurotransmitter defects and treatment of disorders of hyperphenylalaninemia. *J Pediatr* 1981 May;98(5):729-33.

- Buyukgebiz B, Eroglu Y, Buy ukgebiz A. True precocious puberty associated with phenylketonuria. *J Pediatr Endocrinol* 1994 Oct-Dec;7(4):361-3.
- Byrd DJ, Kochen W, Schurrle L, Trefz FK. A study of urinary tryptophan metabolites in relation to the phenylalanine content of semi-synthetic diets in a patient with phenylketonuria. *Acta Vitaminol Enzymol* 1975;29(1-6):55-61.
- Caballero B. Dietary management of inborn errors of amino acid metabolism. *Clin Nutr* 1985 May-Jun;4(3):85-94.
- Caballero B, Mahon BE, Rohr FJ, Levy HL, Wurtman RJ. Plasma amino acid levels after single-dose aspartame consumption in phenylketonuria, mild hyperphenylalaninemia, and heterozygous state for phenylketonuria. *J Pediatr* 1986 Oct;109(4):668-71.
- Cabalska B. [Advances in the diagnosis and treatment of phenylketonuria]. *Pediatr Pol* 1984 Nov;59(11):905-15. (Pol).
- Cabalska B, Banas D, Skorkowska-Zieleniewska J. [Status of mineral nutrition of children with phenylketonuria treated with a low-phenylalanine diet. I. Iron and copper]. *Pediatr Pol* 1986 Mar;61(3):160-6. (Pol).
- Cabalska B, Skorkowska-Zieleniewska J, Nowakowska M. [Evaluation of the status of mineral nutrition of children with phenylketonuria treated by a low-phenylalanine diet. II. Zinc]. *Pediatr Pol* 1987 Oct;62(10):681-6. (Pol).
- Cabalska B, Skorkowska-Zieleniewska J, Nowakowska M, Banas D. [Status of mineral nutrition in children with phenylketonuria treated by low phenylalanine diet. III. Magnesium]. *Pediatr Pol* 1988 Jun;63(6):337-42. (Pol).
- Cabalska B, Zorska K, Nowaczewska I, Borzymowska J, Golabek B, Dawydzik B, Jasinska U. Termination of dietary treatment in phenylketonuria. In: Naruse H, Irie M, editors. Neonatal screening. Proceedings of the 2nd International Conference on Neonatal Thyroid Screening; 1982 Aug 16-19; Tokyo and the International Symposium on Neonatal Screening for Inborn Errors of Metabolism; 1982 Aug 19-21; Tokyo. Princeton (NJ): Excerpta Medica; 1983. p. 219-24. (International congress series; no. 606).
- Cabalska MB, Nowaczewska I, Senddecka E, Zorska K. Longitudinal study on early diagnosis and treatment of phenylketonuria in Poland. *Eur J Pediatr* 1996 Jul;155 Suppl 1:S53-5.
- Cabral A, Portela R, Tasso T, Eusebio F, Guilherme A, Lorga L, De Almeida IT, Silveira C, Levy ML. [Phenylketonuria--physical and mental development of phenylketonuric children subjected to early treatment]. *Acta Med Port* 1989 Jan-Feb;2(1):1-5. (Por).
- Cai ZN, Yu YN, Chen XX, Yuan LF. [High-level expression of phenylalanine ammonia lyase with enzyme activity in *E. coli* by BL21DE3(pET28C-rPAL-1-cDNA)]. *Chin J Pharmacol Toxicol* 2000;14(3):211-5. (Kor).
- California Department of Health Services, Genetic Disease Branch. Cost and availability of dietary treatment of phenylketonuria (PKU): report of a national survey. Berkeley (CA): The Branch; 1997. [76] leaves.
- Callus BA, Mathey-Prevot B. Hydrophobic residues Phe751 and Leu753 are essential for STAT5 transcriptional activity. *J Biol Chem* 2000 Jun 2;275(22):16954-62.
- Calomme M, Vanderpas J, Francois B, Van Caillie-Bertrand M, Vanovervelt N, Van Hoorebeke C, Vanden Berghe D. Effects of selenium supplementation on thyroid hormone metabolism in phenylketonuria subjects on a phenylalanine restricted diet. *Biol Trace Elem Res* 1995 Jan-Mar;47(1-3):349-53.
- Campistol Plana J, Alvarez Dominguez L, Riverola de Veciana AT, Castillo Rivera P, Giner Soria P. [Hyperphenylalaninemia and phenylketonuria. The importance of early diagnosis and follow up at a health center]. *An Esp Pediatr* 1991 Jan;34(1):51-6. (Spa).
- Carbohydrate and glycoprotein metabolism, maternal phenylketonuria. 27th annual SSIEM meeting. Munich, 1989. *J Inherit Metab Dis* 1990;13(4):393-671.
- Cardona F, Leuzzi V, Antonozzi I, Benedetti P, Loizzo A. The development of auditory and visual evoked potentials in early treated phenylketonuric children. *Electroencephalogr Clin Neurophysiol* 1991 Jan-Feb;80(1):8-15.
- Carlson HE. Prolactin stimulation by protein is mediated by amino acids in humans. *J Clin Endocrinol Metab* 1989 Jul;69(1):7-14.
- Carlson HE, Shah JH. Aspartame and its constituent amino acids: effects on prolactin, cortisol, growth hormone, insulin, and glucose in normal humans. *Am J Clin Nutr* 1989 Mar;49(3):427-32.
- Carr RT, Balasubramanian S, Hawkins PC, Benkovic SJ. Mechanism of metal-independent hydroxylation by *Chromobacterium violaceum* phenylalanine hydroxylase. *Biochemistry* 1995 Jun 6;34(22):7525-32.

- Carr RT, Benkovic SJ. An examination of the copper requirement of phenylalanine hydroxylase from *Chromobacterium violaceum*. *Biochemistry* 1993 Dec 28;32(51):14132-8.
- Carr RT, Benkovic SJ. A re-examination of the metal requirement of *Chromobacterium violaceum* phenylalanine hydroxylase. *Adv Exp Med Biol* 1993;338:63-6.
- Carreras AL, De Mattos-Dutra A, Meirelles R, Da Rocha BB, Wannmacher CMD, Pessoa-Pureur R. Phenylalanine inhibition of the phosphorylation of cytoskeletal proteins from cerebral cortex of young rats is prevented by alanine. *Eur J Clin Invest* 2000;30(6):536-42.
- Carson DJ, Greeves LG, Sweeney LE, Crone MD. Osteopenia and phenylketonuria. *Pediatr Radiol* 1990;20(8):598-9.
- Casamassimo PS, et al. Dental health in children with Phenylketonuria, PKU: and other inborn errors of metabolism managed by diet. Rockville (MD): Department of Health and Human Services (US), Public Health Service, Health Resources and Services Administration, Bureau of Health Care Delivery and Assistance, Division of Maternal and Child Health; 1984. 28 p. (DHHS publication; HRS-D-MC 84-1).
- Castillo L, Yu YM, Marchini JS, Chapman TE, Sanchez M, Young VR, Burke JF. Phenylalanine and tyrosine kinetics in critically ill children with sepsis. *Pediatr Res* 1994 May;35(5):580-8.
- Castillo M, Zafra MF, Garcia-Peregrin E. Effect of experimental hyperphenylalaninemia induced by dietary phenylalanine plus alpha-methylphenylalanine administration on amino acid concentration in neonatal chick brain, plasma, and liver. *Neurochem Res* 1988 Jun;13(6):547-50.
- Castillo M, Zafra MF, Garcia-Peregrin E. Inhibition of brain and liver 3-hydroxy-3-methylglutaryl-CoA reductase and mevalonate-5-pyrophosphate decarboxylase in experimental hyperphenylalaninemia. *Neurochem Res* 1988 Jun;13(6):551-5.
- Castoria G, Migliaccio A, Green S, Di Domenico M, Chambon P, Auricchio F. Properties of a purified estradiol-dependent calf uterus tyrosine kinase. *Biochemistry* 1993 Feb 23;32(7):1740-50.
- Catching up on an inborn error. *FDA Consum* 1980 Apr;14(3):19-20.
- Cechak P, Hejzmanova L, Rupp A. Long-term follow-up of patients treated for phenylketonuria (PKU). Results from the Prague PKU Center. *Eur J Pediatr* 1996 Jul;155 Suppl 1:S59-63.
- Cederbaum SD. Phenylketonuria. In: Velaquez A, Orlando HB, editors. *Genetic factors in nutrition*. Orlando (FL): Academic Press; c1984. p. 79-91.
- Cerone R, Barella C, Fantasia AR, Schiaffino MC. [Evaluation of a new amino acid mixture for the treatment of phenylketonuria]. *Minerva Pediatr* 1999 Nov-Dec;51(11-12):403-6. (Ita).
- Cerone R, Schiaffino MC, Di Stefano S, Veneselli E. Phenylketonuria: diet for life or not? *Acta Paediatr* 1999 Jun;88(6):664-6.
- Chamove AS. Dietary and metabolic effects on rhesus social behavior: phenylalanine-related dietary alterations. *Dev Psychobiol* 1980 May;13(3):299-307.
- Chan L, Bell L, Hanley WB. Revision of the Ontario phenylalanine equivalency system and development of a low protein equivalency system. *J Can Diet Assoc* 1982 Oct;43(4):326-30, 335-41.
- Chang P, Cook RD, Fisch RO. Prognostic factors of the intellectual outcome of phenylketonurics: On and off diet. *J Psychiatr Treat Eval* 1983;5(2-3):157-63.
- Chang PN, Weisberg S, Fisch RO. Growth development and its relationship to intellectual functioning of children with phenylketonuria. *J Dev Behav Pediatr* 1984 Jun;5(3):127-31.
- Chang TM, Bourget L, Lister C. A new theory of enterorecirculation of amino acids and its use for depleting unwanted amino acids using oral enzyme-artificial cells, as in removing phenylalanine in phenylketonuria. *Artif Cells Blood Substit Immobil Biotechnol* 1995;23(1):1-21.
- Chang HC. Immune status of children with phenylketonuria [dissertation]. Auburn University (AL): Auburn University; 1992. 121 p.
- Chehin R, Thorolfsson M, Knappskog PM, Martinez A, Flatmark T, Arrondo JL, Muga A. Domain structure and stability of human phenylalanine hydroxylase inferred from infrared spectroscopy. *FEBS Lett* 1998 Jan 30;422(2):225-30.
- Chen D, Frey PA. Phenylalanine hydroxylase from *Chromobacterium violaceum*. Uncoupled oxidation of tetrahydropterin and the role of iron in hydroxylation. *J Biol Chem* 1998 Oct 2;273(40):25594-601.
- Chen HY, Demidkina TV, Phillips RS. Site-directed mutagenesis of tyrosine-71 to phenylalanine in *Citrobacter freundii* tyrosine phenol-lyase: evidence for dual roles of tyrosine-71 as a general acid catalyst in the reaction mechanism and in cofactor binding. *Biochemistry* 1995 Sep 26;34(38):12276-83.
- Chen RG, Qian DL, Guo D. Benefit of neonatal screening for phenylketonuria. A report of the first case

- treated in China. *Chin Med J (Engl)* 1986 Jun;99(6):513-4.
- Chestkov VV, Kovalev LI, Shishkin SS, Annenkov GA. [Oligomerization of phenylalanine hydroxylase during its activation with phenylalanine]. *Vopr Med Khim* 1985 Jul-Aug;31(4):60-5. (Rus).
- Chestkov VV, Laptev AV, Shishkin SS. [Identification of the membrane form of phenylalanine hydroxylase from the human liver and characteristics of its subunit composition]. *Biokhimiia* 1988 Feb;53(2):322-7. (Rus).
- Chestkov VV, Laptev AV, Shishkin SS. Membrane-bound phenylalanine hydroxylase of human liver. *J Hepatol* 1992 Sep;16(1-2):11-5.
- Choi YH, Asakura K, Okumura J, Furuse M. Repulsive effect and palatability of dietary phenylalanine in laying hens. *Asian Australas J Anim Sci* 1996 Apr;9(2):159-64.
- Choung JJ, Chamberlain DG. Protein nutrition of dairy cows receiving grass silage diets. Effects on silage intake and milk production of postruminal supplements of casein or soya-protein isolate and the effects of intravenous infusions of a mixture of methionine, phenylalanine and tryptophan. *J Sci Food Agric* 1992;58(3):307-14.
- Christensen HN. Role of membrane transport in interorgan amino acid flows: where do the depleted amino acids go in phenylketonuria? *UCLA Symp Mol Cell Biol* 1987;55:1-17.
- Christianson DW, Mangani S, Shoham G, Lipscomb WN. Binding of D-phenylalanine and D-tyrosine to carboxypeptidase A. *J Biol Chem* 1989 Aug 5;264(22):12849-53.
- Chung S. The effect of maternal blood phenylalanine level on mouse maternal phenylketonuria offspring [dissertation]. Tucson: The University of Arizona; 1999. 74 p.
- Cinek T, Sadra A, Imboden JB. Cutting edge: Tyrosine-independent transmission of inhibitory signals by CTLA-4. *J Immunol* 2000 Jan 1;164(1):5-8.
- Cipic-Schmidt S, Trefz FK, Funders B, Seidlitz G, Ullrich K. German Maternal Phenylketonuria Study. *Eur J Pediatr* 1996 Jul;155 Suppl 1:S173-6.
- Citron BA, Davis MD, Kaufman S. Electrostatic activation of rat phenylalanine hydroxylase. *Biochem Biophys Res Commun* 1994 Jan 14;198(1):174-80.
- Citron BA, Davis MD, Kaufman S. Purification and biochemical characterization of recombinant rat liver phenylalanine hydroxylase produced in *Escherichia coli*. *Protein Expr Purif* 1992 Apr;3(2):93-100.
- Citron BA, Davis MD, Milstien S, Gutierrez J, Mendel DB, Crabtree GR, Kaufman S. Identity of 4a-carbinolamine dehydratase, a component of the phenylalanine hydroxylation system, and DCoH, a transregulator of homeodomain proteins. *Proc Natl Acad Sci U S A* 1992 Dec 15;89(24):11891-4.
- Citron BA, Kaufman S, Milstien S, Naylor EW, Greene CL, Davis MD. Mutation in the 4a-carbinolamine dehydratase gene leads to mild hyperphenylalaninemia with defective cofactor metabolism. *Am J Hum Genet* 1993 Sep;53(3):768-74.
- Clark AG. Mutation-selection balance with multiple alleles. *Genetica* 1998;102-103(1-6):41-7.
- Clark BJ. After a positive Guthrie--what next? Dietary management for the child with phenylketonuria. *Eur J Clin Nutr* 1992 Jun;46 Suppl 1:S33-9.
- Clark BJ, Cockburn F. Management of inborn errors of metabolism during pregnancy. *Acta Paediatr Scand Suppl* 1991;373:43-52.
- Clark D, Henderson M, Smith M, Dear PR. Plasma amino acid concentrations in parenterally fed preterm infants. *Arch Dis Child* 1989 Jul;64(7 Spec No):939-42.
- Clark SE, Karn CA, Ahlrichs JA, Wang J, Leitch CA, Leichty EA, Denne SC. Acute changes in leucine and phenylalanine kinetics produced by parenteral nutrition in premature infants. *Pediatr Res* 1997 Apr;41(4 Pt 1):568-74.
- Clarke JT, Gates RD, Hogan SE, Barrett M, MacDonald GW. Neuropsychological studies on adolescents with phenylketonuria returned to phenylalanine-restricted diets. *Am J Ment Retard* 1987 Nov;92(3):255-62.
- Cleary MA, Walter JH, Wraith JE, Jenkins JP, Alani SM, Tyler K, Whittle D. Magnetic resonance imaging of the brain in phenylketonuria. *Lancet* 1994 Jul 9;344(8915):87-90.
- Cleary MA, Walter JH, Wraith JE, White F, Tyler K, Jenkins JP. Magnetic resonance imaging in phenylketonuria: reversal of cerebral white matter change. *J Pediatr* 1995 Aug;127(2):251-5.
- Clemens PC, Burmester JG, Prankel BH, Wiegand G, Wulke AP, Plettner C. Phenylalanine and other amino acids in phenylketonuria. *J Inher Metab Dis* 1993;16(6):1045-6.
- Clemens PC, Burmester JG, Wiegand G, Prankel BH, Halfmann E, Erb N, Muller-Wickop J. Phenylalanine, other large neutral amino acids and RNA catabolites as markers for protein biosynthesis in phenylketonuria [letter]. *Metabolism* 1993 Apr;42(4):531-2. Comment on: *Metabolism* 1992 May;41(5):518-21.

- Clemens PC, Schunemann MH, Hoffmann GF, Kohlschutter A. Plasma concentrations of phenyllactic acid in phenylketonuria. *J Inherit Metab Dis* 1990;13(2):227-8.
- Clemens PC, Schunemann MH, Plettner C, Gruttner R. [The phenylalanine stress test in the classification of patients with phenylketonuria]. *Klin Padiatr* 1989 May-Jun;201(3):163-6. (Ger).
- Cloud HH. Feeding the special needs child: a new dimension for school food service. *Sch Food Serv Res Rev* 1992 Spring;16(1):47-51.
- Cobet G, Beyreiss K. [Resorption disorders in children with phenylketonuria]. *Acta Biol Med Ger* 1982;41(7-8):659-63. (Ger).
- Cobet G, Creutzburg U, Siebert G, Cobet U, Fischer I. [Dietary management of phenylketonuria patients using a personal computer]. *Padiatr Grenzgeb* 1993;31(4):227-35. (Ger).
- Cobet G, Grimm H, Seidlitz G, Theile H. [Anthropometric measurements of children with phenylketonuria under diet therapy]. *Arztl Jugendkd* 1984 Feb;75(1):20-8. (Ger).
- Cobet G, Koch R. [Usefulness of protein hydrolysates for the dietary treatment of phenylketonuria]. *Padiatr Grenzgeb* 1984;23(4):217-24. (Ger).
- Cobet G, Witkowski R. [Correlation between biochemical-biological parameters and intellectual development in treated phenylketonuria children]. *Samml Zwangl Abh Geb Psychiatr Neurol* 1982;50:269-75. (Ger).
- Cockburn F, Clark BJ. Recommendations for protein and amino acid intake in phenylketonuric patients. *Eur J Pediatr* 1996 Jul;155 Suppl 1:S125-9.
- Cole DE, Landry DA. Parenteral nutrition in a premature infant with phenylketonuria. *JPEN J Parenter Enteral Nutr* 1984 Jan-Feb;8(1):42-4.
- Coleman M. Nutritional treatments currently under investigation in autism. *Clin Nutr* 1989 Sep-Oct;8(5):210-2.
- Collins JE, Leonard JV. The dietary management of inborn errors of metabolism. *Hum Nutr Appl Nutr* 1985 Aug;39(4):255-72.
- Collins RJ, Boyle PJ, Clague AE, Barr AE, Latham SC. In vitro OKT3-induced mitogenesis in selenium-deficient patients on a diet for phenylketonuria. *Biol Trace Elem Res* 1991 Sep;30(3):233-44.
- Colombo M, Troncoso L, Raimann E, Perales CG, Barros TL, Cornejo V. [Diagnosis of phenylketonuria in Chile]. *Rev Chil Pediatr* 1988 Jul-Aug;59(4):235-9. (Spa).
- Connell A, Calder AG, Anderson SE, Lobley GE. Hepatic protein synthesis in the sheep: effect of intake as monitored by use of stable-isotope-labelled glycine, leucine and phenylalanine. *Br J Nutr* 1997 Feb;77(2):255-71.
- Cortes Castell E, Campello Oltra MJ, Moya Benavent M, Ballester Galindo I, Herrero Galiana A, Clemente Yago F. [Reference levels for phenylalanine and tyrosine in discs impregnated with blood during analysis by HPLC]. *An Esp Pediatr* 1988 May;28(5):405-8. (Spa).
- Cortiella J, Marchini JS, Branch S, Chapman TE, Young VR. Phenylalanine and tyrosine kinetics in relation to altered protein and phenylalanine and tyrosine intakes in healthy young men. *Am J Clin Nutr* 1992 Sep;56(3):517-25.
- Coskun T, Karagoz T, Kalkanoglu S, Tokatli A, Ozalp I, Thony B, Blau N. Guanosine triphosphate cyclohydrolase I deficiency: a rare cause of hyperphenylalaninemia. *Turk J Pediatr* 1999 Apr-Jun;41(2):231-7.
- Coskun T, Ozalp I, Tokatli A, Blau N, Niederwieser A. Hyperphenylalaninaemia due to tetrahydrobiopterin deficiency: a report of 16 cases. *J Inherit Metab Dis* 1993;16(3):605-7.
- Coskun T, Topcu M, Ustundag I, Ozalp I, Renda Y, Ciger A, Nurlu G. Neurophysiological studies of patients with classical phenylketonuria: evaluation of results of IQ scores, EEG and evoked potentials. *Turk J Pediatr* 1993 Jan-Mar;35(1):1-10.
- Costello PM, Beasley MG, Tillotson SL, Smith I. Intelligence in mild atypical phenylketonuria. *Eur J Pediatr* 1994 Apr;153(4):260-3.
- Cotton RG. Heterogeneity of phenylketonuria at the clinical, protein and DNA levels. *J Inherit Metab Dis* 1990;13(5):739-50.
- Cotton RG, Jennings I, Bracco G, Ponzzone A, Guardamagna O. Tetrahydrobiopterin non-responsiveness in dihydropteridine reductase deficiency is associated with the presence of mutant protein. *J Inherit Metab Dis* 1986;9(3):239-43.
- Craft S, Gourovitch ML, Dowton SB, Swanson JM, Bonforte S. Lateralized deficits in visual attention in males with developmental dopamine depletion. *Neuropsychologia* 1992 Apr;30(4):341-51.
- Crandall EA, Fernstrom JD. Effect of experimental diabetes on the levels of aromatic and branched-chain amino acids in rat blood and brain. *Diabetes* 1983 Mar;32(3):222-30.

- Crawford RD. Phenylalanine hydroxylase isozymes in regenerating liver: diet and age [dissertation]. Los Angeles (CA): University of Southern California; 1981.
- Crawford RD, Layne EC, Bessman SP. Phenylalanine hydroxylase isozymes in regenerating liver: effects of diet and age. *Biochem Med* 1985 Feb;33(1):77-89.
- Crawford MD. Severe mental handicap: pathogenesis, treatment, and prevention. *Br Med J (Clin Res Ed)* 1982 Sep 18;285(6344):762-6.
- Crowley C, Koch R, Fishler K, Wenz E, Ireland J. Clinical trial of 'off diet' older phenylketonurics with a new phenylalanine-free product. *J Ment Defic Res* 1990 Aug;34 (Pt 4):361-9.
- Curtius HC, Endres W, Blau N. Effect of high-protein meal plus aspartame ingestion on plasma phenylalanine concentrations in obligate heterozygotes for phenylketonuria. *Metabolism* 1994 Apr;43(4):413-6.
- Dalery J, Maillet J, de Villard R. [Behavior problems in phenylketonuria. Attempt at a biochemical interpretation based on a personal case and a review of the literature]. *Encephale* 1983;9(3):279-90. (Fre).
- Danicke S, Bottcher W, Jeroch H, Thielebein J, Simon O. Replacement of soybean oil with tallow in rye-based diets without xylanase increases protein synthesis in small intestine of broilers. *J Nutr* 2000 Apr;130(4):827-34.
- Danks DM, Bartholome K, Clayton BE, Curtius H, Grobe H, Kaufman S, Leeming R, Pfeleiderer W, Rembold H, Rey F. Malignant hyperphenylalaninaemia--current status (June 1977). *J Inherit Metab Dis* 1978;1(2):49-53.
- Danks DM, Cotton RG. Early diagnosis of hyperphenylalaninemia due to tetrahydrobiopterin deficiency (malignant hyperphenylalaninemia). *J Pediatr* 1980 May;96(5):854-6.
- Danks DM, Cotton RG. Future developments in phenylketonuria. *Enzyme* 1987;38(1-4):296-301.
- Darling G, Mathias P, O'Regan M, Naughten E. Serum selenium levels in individuals on PKU diets. *J Inherit Metab Dis* 1992;15(5):769-73.
- Darling PB. Threonine and phenylalanine metabolism in the human neonate protein turnover, oxidation [dissertation]. Toronto (Canada): University of Toronto; 1997. 230 p.
- Dashman T, Sansaricq C. Nutrition in the management of inborn errors of metabolism. *Clin Lab Med* 1993 Jun;13(2):407-32. Published erratum appears in *Clin Lab Med* 1993 Dec;13(4):following table of contents.
- Daubner SC, Hillas PJ, Fitzpatrick PF. Characterization of chimeric pterin-dependent hydroxylases: contributions of the regulatory domains of tyrosine and phenylalanine hydroxylase to substrate specificity. *Biochemistry* 1997 Sep 30;36(39):11574-82.
- Daubner SC, Hillas PJ, Fitzpatrick PF. Expression and characterization of the catalytic domain of human phenylalanine hydroxylase. *Arch Biochem Biophys* 1997 Dec 15;348(2):295-302.
- Davidson A. Management and counseling of children with inherited metabolic disorders. *J Pediatr Health Care* 1992 May-Jun;6(3):146-52.
- Davidson DC. Maternal phenylketonuria. *Postgrad Med J* 1989;65 Suppl 2:S10-20.
- Davidson DC. Maternal PKU pre-conception treatment--the need for free prescriptions. *Midwives Chron* 1989 Feb;102(1213):43.
- Davidson DC, Isherwood DM, Ireland JT, Rae PG. Outcome of pregnancy in a phenylketonuric mother after low phenylalanine diet introduced from the ninth week of pregnancy. *Eur J Pediatr* 1981 Sep;137(1):45-8.
- Davis BA, O'Reilly RL, Placatka CL, Paterson IA, Yu PH, Durden DA. Effect of dietary phenylalanine on the plasma concentrations of phenylalanine, phenylethylamine and phenylacetic acid in healthy volunteers. *Prog Neuropsychopharmacol Biol Psychiatry* 1991;15(5):611-23.
- Davis DD, McIntyre CW, Murray ME, Mims SS. Cognitive styles in children with dietary treated phenylketonuria. *Educ Psychol Res* 1986 Winter;6(1):9-15.
- Davis TA, Fiorotto ML, Nguyen HV, Burrin DG. Aminoacyl-tRNA and tissue free amino acid pools are equilibrated after a flooding dose of phenylalanine. *Am J Physiol* 1999 Jul;277(1 Pt. 1):E103-9.
- Davis TA, Karl IE, Tegtmeyer ED, Osborne DF, Klahr S, Harter HR. Muscle protein turnover: effects of exercise training and renal insufficiency. *Am J Physiol* 1985 Mar;248(3 Pt 1):E337-45.
- de Freitas MS, de Mattos-Dutra A, Schroder N, Wannmacher CMD, Pessoa-Pureur R. Effect of hyperphenylalaninemia chemically induced on in vitro incorporation of ³²P into cytoskeletal proteins from cerebral cortex of developing rats. *Exp Neurol* 1997 Feb;143(2):188-95.
- de Freitas O, Izumi C, Lara MG, Greene LJ. New approaches to the treatment of phenylketonuria. *Nutr Rev* 1999 Mar;57(3):65-70.

- De Giorgis GF, Antonozzi I, Del Castello PG, Rosano M, Loizzo A. EEG as a possible prognostic tool in phenylketonuria. *Electroencephalogr Clin Neurophysiol* 1983 Jan;55(1):60-8.
- De Klerk JB, Wadman SK, Dijkhuis HJ, Meuleman EE. Maternal PKU syndrome in an exceptional family with unexpected PKU. *J Inher Metab Dis* 1987;10(2):162-70.
- de Sanctis L, Alliaudi C, Spada M, Farrugia R, Cerone R, Biasucci G, Meli C, Zammarchi E, Coskun T, Blau N, Ponzzone A, Dianzani I. Genotype-phenotype correlation in dihydropteridine reductase deficiency. *J Inher Metab Dis* 2000;23(4):333-7.
- de Sonnevile LM, Schmidt E, Michel U, Batzler U. Preliminary neuropsychological test results. *Eur J Pediatr* 1990;149 Suppl 1:S39-44.
- de Valk HW, de Sonnevile LM, Duran M, Poll-The BT, Erkelens DW. [Phenylketonuria: a children's disease in adulthood]. *Ned Tijdschr Geneesk* 2000 Jan 1;144(1):11-5. (Dut).
- DeClue TJ, Davis J, Schocken DM, Kangas R, Benford SA. Serum lipid concentrations in subjects with phenylketonuria and their families. *Am J Dis Child* 1991 Nov;145(11):1266-8.
- Dement'eva NF, Ermolina LA, Ezhkova VA, Mozhaeva EG. [Therapy and social adaptation of patients with mental retardation (a review of the literature)]. *Zh Nevropatol Psikhiatr* 1981;81(3):439-50. (Rus).
- deMira NV, Marquez UM. [Diagnoses and treatment of phenylketonuria]. *Rev Saude Publica* 2000;34:86-96. (Por).
- Denne SC, Karn CA, Ahlrichs JA, Dorotheo AR, Wang J, Liechty EA. Proteolysis and phenylalanine hydroxylation in response to parenteral nutrition in extremely premature and normal newborns. *J Clin Invest* 1996 Feb 1;97(3):746-54.
- Dennis M, Lockyer L, Lazenby AL, Donnelly RE, Wilkinson M, Schoonheydt W. Intelligence patterns among children with high-functioning autism, phenylketonuria, and childhood head injury. *J Autism Dev Disord* 1999 Feb;29(1):5-17.
- Depondt E, Ogier H, Munnich A, Saudubray JM. [Phenylalanine-restricted diet. The portion-by-weight system]. *Arch Fr Pediatr* 1983;40 Suppl 1:251-6. (Fre).
- Dews PB. Summary report of an International Aspartame Workshop. *Food Chem Toxicol* 1987 Jul;25(7):549-52.
- Dhondt JL. Tetrahydrobiopterin deficiencies: preliminary analysis from an international survey. *J Pediatr* 1984 Apr;104(4):501-8.
- Dhondt JL. [Tetrahydrobiopterin deficiency. Lessons from the analysis of 90 patients collected in the international register]. *Arch Fr Pediatr* 1987;44 Suppl 1:655-9. (Fre).
- Dhondt JL, Delcroix M, Farriaux JP. Unconjugated pteridines in human milk. *Clin Chim Acta* 1982 May 6;121(1):33-5.
- Dhondt JL, Farriaux JP. Atypical cases of phenylketonuria. *Eur J Pediatr* 1987;146 Suppl 1:A38-43.
- Dhondt JL, Largilliere C, Farriaux JP. [An attempt at classification of the hyperphenylalaninemias. Apropos of 62 patients]. *Arch Fr Pediatr* 1983;40 Suppl 1:243-5. (Fre).
- Dhondt JL, Largilliere C, Moreno L, Farriaux JP. Physical growth in patients with phenylketonuria. *J Inher Metab Dis* 1995;18(2):135-7.
- Diament AJ. [Recent advances in inborn errors of metabolism]. *Arq Neuropsiquiatr* 1987 Jun;45(2):177-87. (Por).
- Diamond A. Phenylalanine levels of 6-10 mg/dl may not be as benign as once thought. *Acta Paediatr Suppl* 1994 Dec;407:89-91.
- Dianzani I, de Sanctis L, Smooker PM, Gough TJ, Alliaudi C, Brusco A, Spada M, Blau N, Dobos M, Zhang HP, Yang N, Ponzzone A, Armarego WL, Cotton RG. Dihydropteridine reductase deficiency: physical structure of the QDPR gene, identification of two new mutations and genotype-phenotype correlations. *Hum Mutat* 1998;12(4):267-73.
- Dickson PW, Jennings IG, Cotton RG. Delineation of the catalytic core of phenylalanine hydroxylase and identification of glutamate 286 as a critical residue for pterin function. *J Biol Chem* 1994 Aug 12;269(32):20369-75.
- Dietary treatment of phenylketonuria. *Nutr Rev* 1983 Jan;41(1):11-4.
- DiLella AG, Marvit J, Woo SLC. The molecular genetics of phenylketonuria. *UCLA Symp Mol Cell Biol* 1987;55:553-64.
- Dillehay L, Bass R, Englesberg E. Inhibition of growth of cells in culture by L-phenylalanine as a model system for the analysis of phenylketonuria. I. amino acid antagonism and the inhibition of protein synthesis. *J Cell Physiol* 1980 Mar;102(3):395-405.

- Diomede L, Romano M, Guiso G, Caccia S, Nava S, Salmons M. Interspecies and interstrain studies on the increased susceptibility to metrazol-induced convulsions in animals given aspartame. *Food Chem Toxicol* 1991 Feb;29(2):101-6.
- Dluzniewski A, Gastol-Lewinska L. Phenylalanine deficiency in food of rats. Part I. Phenylalanine-low diet for rats. *Pol J Pharmacol Pharm* 1981 Jan-Feb;33(1):87-90.
- Dobson JC, Kushida E, Williamson M, Friedman EG. Intellectual performance of 36 phenylketonuria patients and their nonaffected siblings. *Pediatrics* 1976 Jul;58(1):53-8.
- Dobson JC, Williamson ML, Azen C, Koch R. Intellectual assessment of 111 four-year-old children with phenylketonuria. *Pediatrics* 1977 Dec;60(6):822-7.
- Dong GZ. [Clinical analysis of 74 cases of phenylketonuria and hyperphenylalanemia]. *Chung Hua Shen Ching Ching Shen Ko Tsa Chih* 1986 Feb;19(1):49-51. (Chi).
- Donlon J, Beirne E. Modulations of rat hepatic phenylalanine hydroxylase due to induced diabetes or high-protein diet. *Biochem Biophys Res Commun* 1982 Sep 30;108(2):746-51.
- Donlon J, Kaufman S. Relationship between the multiple forms of rat hepatic phenylalanine hydroxylase and degree of phosphorylation. *J Biol Chem* 1980 Mar 10;255(5):2146-52.
- Doskeland AP, Doskeland SO, Ogreid D, Flatmark T. The effect of ligands of phenylalanine 4-monoxygenase on the cAMP-dependent phosphorylation of the enzyme. *J Biol Chem* 1984 Sep 25;259(18):11242-8.
- Doskeland AP, Haavik J, Flatmark T, Doskeland SO. Modulation by pterins of the phosphorylation and phenylalanine activation of phenylalanine 4-monoxygenase. *Biochem J* 1987 Mar 15;242(3):867-74.
- Doskeland AP, Vintermyr OK, Flatmark T, Cotton RG, Doskeland SO. Phenylalanine positively modulates the cAMP-dependent phosphorylation and negatively modulates the vasopressin-induced and okadaic-acid-induced phosphorylation of phenylalanine 4-monoxygenase in intact rat hepatocytes. *Eur J Biochem* 1992 May 15;206(1):161-70.
- Dotremont H, Francois B, Diels M, Gillis P. Nutritional value of essential amino acids in the treatment of adults with phenylketonuria. *J Inher Metab Dis* 1995;18(2):127-30.
- Drenth JP, Kleinjans JC. [Aspartame, a sweet alternative]. *Ned Tijdschr Geneesk* 1988 Apr 16;132(16):712-5. (Dut).
- Drogari E, Smith I, Beasley M, Lloyd JK. Timing of strict diet in relation to fetal damage in maternal phenylketonuria. An international collaborative study by the MRC/DHSS Phenylketonuria Register. *Lancet* 1987 Oct 24;2(8565):927-30.
- Druml W, Roth E, Lenz K, Lochs H, Kopsa H. Phenylalanine and tyrosine metabolism in renal failure: dipeptides as tyrosine source. *Kidney Int Suppl* 1989 Nov;27:S282-6.
- Du Fraysseix M, Rey F, Audran E, Boissin H, Rey J. [Dietetic therapy of phenylketonuria. New composition tables and exchange lists of fruits and vegetables expressed in volumetric measurements]. *Arch Fr Pediatr* 1983;40 Suppl 1:257-64. (Fre).
- Duch DS, Smith GK. Biosynthesis and function of tetrahydrobiopterin. *J Nutr Biochem* 1991 Aug;2(8):411-23.
- Dumars KW, Gawron TW, Pearce CL, Foster CA. Prevention of developmental disabilities: a model for organizing clinical activities. *Res Dev Disabil* 1987;8(4):507-20.
- Duncan LL, Elder SB. Breastfeeding the infant with PKU. *J Hum Lact* 1997 Sep;13(3):231-5.
- Dunlop DS, Yang XR, Lajtha A. The effect of elevated plasma phenylalanine levels on protein synthesis rates in adult rat brain. *Biochem J* 1994 Sep 1;302 (Pt 2):601-10.
- Duran GP, Rohr FJ, Slonim A, Guttler F, Levy HL. Necessity of complete intake of phenylalanine-free amino acid mixture for metabolic control of phenylketonuria. *J Am Diet Assoc* 1999 Dec;99(12):1559-63.
- Dyer CA, Kendler A, Jean-Guillaume D, Awatramani R, Lee A, Mason LM, Kamholz J. GFAP-positive and myelin marker-positive glia in normal and pathologic environments. *J Neurosci Res* 2000 May 1;60(3):412-26.
- Dyer CA, Kendler A, Philibotte T, Gardiner P, Cruz J, Levy HL. Evidence for central nervous system glial cell plasticity in phenylketonuria. *J Neuropathol Exp Neurol* 1996 Jul;55(7):795-814.
- Eiken HG, Knappskog PM, Apold J, Flatmark T. PKU mutation G46S is associated with increased aggregation and degradation of the phenylalanine hydroxylase enzyme. *Hum Mutat* 1996;7(3):228-38.

- Eisenberg L. Child mental health in the Americas: a public health approach. *Bull Pan Am Health Organ* 1992;26(3):230-41.
- Eisensmith RC, Woo SL. Phenylketonuria and the phenylalanine hydroxylase gene. *Mol Biol Med* 1991 Feb;8(1):3-18.
- Elkin RG. Metabolic interrelationships of phenylalanine and tyrosine in and rats fed crystalline amino acid diets [dissertation]. West Lafayette (IN): Purdue University; 1981. 130 p.
- Elkin RG, Chrisman CL, Rogler JC, Featherston WR. Influence of (dietary) phenylalanine and lysine deficiencies on thyroid morphology in the chick. *Poultry Sci* 1981 Apr;60(4):878-81.
- Elkin RG, Featherston WR, Rogler JC. Effects of dietary phenylalanine and tyrosine on circulating thyroid hormone levels and growth in the chick. *J Nutr* 1980 Jan;110(1):132-8.
- Elkin RG, Rogler JC. Partial alleviation of phenylalanine toxicity in the chick by supplemental dietary tryptophan. *Poult Sci* 1983 Apr;62(4):647-58.
- Elkin RG, Rogler JC, Featherston WR. Dietary phenylalanine and tyrosine interrelationships in the Sprague-Dawley rat. *Proc Soc Exp Biol Med* 1981 Jul;167(3):310-7.
- Elsiger MA, Theriault GR, Gauthier D. In vitro localization of the protein synthesis defect associated with experimental phenylketonuria. *Neurochem Res* 1989 Jan;14(1):81-4.
- Elstad CA, Meadows GG. Modulation of B16-BL6 murine melanoma metastatic phenotype by tyrosine and phenylalanine restriction in the absence of host selection pressures. *Anticancer Res* 1993 Mar-Apr;13(2):523-8.
- Elstad CA, Meadows GG, Aslakson CJ, Starkey JR. Evidence for nutrient modulation of tumor phenotype: impact of tyrosine and phenylalanine restriction. *Adv Exp Med Biol* 1994;354:171-83.
- Elstad CA, Thrall BD, Raha G, Meadows GG. Tyrosine and phenylalanine restriction sensitizes adriamycin-resistant P388 leukemia cells to adriamycin. *Nutr Cancer* 1996;25(1):47-60.
- Ems-McClung SC. Molecular engineering and characterization of recombinant for the dietary treatment of phenylketonuria (PKU) [dissertation]. Bloomington (IN): Indiana University; 1998. 158 p.
- Endres W. Diet in phenylketonuria: how long? Policies under discussion. *Ann Nutr Metab* 1998;42(2):63-7.
- Endres W. [Differential diagnosis and therapy of various forms of hyperphenylalaninemia: facts and fiction]. *Wien Klin Wochenschr* 1992;104(16):503-9. (Ger).
- Endres W. [Phenylketonuria and its treatment in and beyond adolescence]. *Internist (Berl)* 1994 Mar;35(3):250-4. (Ger).
- Erlandsen H, Flatmark T, Stevens RC, Hough E. Crystallographic analysis of the human phenylalanine hydroxylase catalytic domain with bound catechol inhibitors at 2.0 Å resolution. *Biochemistry* 1998 Nov 10;37(45):15638-46.
- Erlandsen H, Fusetti F, Martinez A, Hough E, Flatmark T, Stevens RC. Crystal structure of the catalytic domain of human phenylalanine hydroxylase reveals the structural basis for phenylketonuria [letter]. *Nat Struct Biol* 1997 Dec;4(12):995-1000.
- Erlandsen H, Martinez A, Knappskog PM, Haavik J, Hough E, Flatmark T. Crystallization and preliminary diffraction analysis of a truncated homodimer of human phenylalanine hydroxylase. *FEBS Lett* 1997 Apr 7;406(1-2):171-4.
- Erlandsen H, Stevens RC. The structural basis of phenylketonuria. *Mol Genet Metab* 1999 Oct;68(2):103-25.
- Ernest AE, et al. Guide to breast feeding the infant with PKU. [Rockville (MD)]: Department of Health and Human Services (US), Public Health Service, Health Services Administration, Bureau of Community Health Services; 1980. 51 p. (DHHS publication; no. (HSA) 79-5110).
- Esposito DL, Blakesley VA, Koval AP, Scrimgeour AG, LeRoith D. Tyrosine residues in the C-terminal domain of the insulin-like growth factor-I receptor mediate mitogenic and tumorigenic signals. *Endocrinology* 1997 Jul;138(7):2979-88.
- Evans SJ, Wynne-Williams TC, Russell CA, Fairbrother A. Hyperphenylalaninaemia in parenterally fed newborn babies [letter]. *Lancet* 1986 Dec 13;2(8520):1404-5.
- Fallstrom SP, Lindblad B, Steen G. On the renal tubular damage in hereditary tyrosinemia and on the formation of succinylacetoacetate and succinylacetone. *Acta Paediatr Scand* 1981;70(3):315-20.
- Fang CH, Li BG, James JH, Fischer JE, Hasselgren PO. The anabolic effects of IGF-1 in skeletal muscle after burn injury are not caused by increased cell volume. *JPEN J Parenter Enteral Nutr* 1998 May-Jun;22(3):115-9.

- Farquhar DL, Simpson GK, Steven F, Munro JF, Farquhar JW. Pre-conceptual dietary management for maternal phenylketonuria. *Acta Paediatr Scand* 1987 Mar;76(2):279-83.
- Farquhar DL, Steven F, Westwood A. Preliminary report on inverse diurnal variation of phenylalanine: implications in maternal phenylketonuria. *Hum Nutr Appl Nutr* 1985 Jun;39(3):224-6.
- Farriaux JP, Desombre-Denys D, Charles-Bassi MA, Dhondt JL. [Treatment of phenylketonuria. About twenty-one cases (author's transl)]. *Sem Hop* 1981 Feb 18-25;57(7-8):356-60. (Fre).
- Farriaux JP, Desombre-Denys D, Charles-Bassi MA, Dhondt JL. [Treatment of phenylketonuria. Remarks on 21 cases]. *Ann Pediatr (Paris)* 1980 May;27(5):291-5. (Fre).
- Farriaux JP, Dhondt JL, Largilliere C. [The newborn infant of the phenylketonuric mother]. *Arch Fr Pediatr* 1983;40 Suppl 1:283-7. (Fre).
- Farriaux JP, Dhondt JL, Largilliere C, Lacombe A, Valat S, Puech F. [Embryofetopathy of the newborn infant of a phenylketonuric mother. A diagnosis not to be missed]. *J Gynecol Obstet Biol Reprod (Paris)* 1993;22(1):49-52. (Fre).
- Fehrenbach AM. The influence of problem-solving skills on dietary compliance in mothers of children with phenylketonuria [dissertation]. Columbia (MO): University of Missouri - Columbia; 1981. 192 p.
- Fehrenbach AM, Peterson L. Parental problem-solving skills, stress, and dietary compliance in phenylketonuria. *J Consult Clin Psychol* 1989 Apr;57(2):237-41.
- Ferguson C. Monitoring the effect of varying the distribution of phenylalanine exchanges and protein substitute on serum phenylalanine -- a preliminary study. *J Hum Nutr Diet* 1996 Aug;9(4):293-302.
- Fernstrom JD. Role of precursor availability in control of monoamine biosynthesis in brain. *Physiol Rev* 1983 Apr;63(2):484-546.
- Fernstrom JD, Fernstrom MH, Gillis MA. Acute effects of aspartame on large neutral amino acids and monoamines in rat brain. *Life Sci* 1983 Apr 4;32(14):1651-8.
- Fernstrom JD, Fernstrom MH, Grubb PE. Twenty-four-hour variations in rat blood and brain levels of the aromatic and branched-chain amino acids: chronic effects of dietary protein content. *Metabolism* 1987 Jul;36(7):643-50.
- Fernstrom JD, Fernstrom MH, Massoudi MS. In vivo tyrosine hydroxylation in rat retina: effect of aspartame ingestion in rats pretreated with p-chlorophenylalanine. *Am J Clin Nutr* 1991 Apr;53(4):923-9.
- Ficner R, Sauer UH, Ceska TA, Stier G, Suck D. Crystallization and preliminary crystallographic studies of recombinant dimerization cofactor of transcription factor HNF1/pterin-4 alpha-carbinolamine dehydratase from liver. *FEBS Lett* 1995 Jan 2;357(1):62-4.
- Ficner R, Sauer UH, Stier G, Suck D. Three-dimensional structure of the bifunctional protein PCD/DCoH, a cytoplasmic enzyme interacting with transcription factor HNF1. *EMBO J* 1995 May 1;14(9):2034-42.
- Fiedler AE, Miller MJ, Bickel H, Cederbaum SD. Phenylalanine levels in PKU following minor surgery. *Am J Med Genet* 1982 Apr;11(4):411-4.
- Figlewicz DA, Druse MJ. Experimental hyperphenylalaninemia: effect on central nervous system myelin subfractions. *Exp Neurol* 1980 Feb;67(2):315-29.
- Filer LJ Jr, Baker GL, Stegink LD. Effect of aspartame loading on plasma and erythrocyte free amino acid concentrations in one-year-old infants. *J Nutr* 1983 Aug;113(8):1591-9.
- Filer LJ Jr, Stegink LD. Aspartame metabolism in normal adults, phenylketonuric heterozygotes, and diabetic subjects. *Diabetes Care* 1989 Jan;12(1):67-74.
- Fisberg RM, Da Silva-Fernandes ME, Fisberg M, Schmidt BJ. Plasma zinc, copper, and erythrocyte superoxide dismutase in children with phenylketonuria. *Nutrition* 1999 Jun;15(6):449-52.
- Fisberg RM, da Silva-Fernandes ME, Schmidt BJ, Fisberg M. Nutritional evaluation of children with phenylketonuria. *Sao Paulo Med J* 1999 Sep 2;117(5):185-91.
- Fisch RO. Outcome of untreated vs treated PKU pregnancies [letter]. *J Pediatr* 1987 Sep;111(3):475.
- Fisch RO, Chang PN, Weisberg S, Guldberg P, Guttler F, Tsai MY. Phenylketonuric patients decades after diet. *J Inherit Metab Dis* 1995;18(3):347-53.
- Fisch RO, Matalon R, Weisberg S, Michals K. Phenylketonuria: current dietary treatment practices in the United States and Canada. *J Am Coll Nutr* 1997 Apr;16(2):147-51.
- Fishler K, Azen CG, Friedman EG, Koch R. School achievement in treated PKU children. *J Ment Defic Res* 1989 Dec;33 (Pt 6):493-8.

- Fishler K, Azen CG, Henderson R, Friedman EG, Koch R. Psychoeducational findings among children treated for phenylketonuria. *Am J Ment Defic* 1987 Jul;92(1):65-73.
- Fitzgerald B, Morgan J, Keene N, Rollinson R, Hodgson A, Dalrymple-Smith J. An investigation into diet treatment for adults with previously untreated phenylketonuria and severe intellectual disability. *J Intellect Disabil Res* 2000 Feb;44(Pt 1):53-9.
- Fitzpatrick PF. The aromatic amino acid hydroxylases. *Adv Enzymol Relat Areas Mol Biol* 2000;74:235-94.
- Flannery DB, Hitchcock E, Mamunes P. Dietary management of phenylketonuria from birth using a phenylalanine-free product. *J Pediatr* 1983 Aug;103(2):247-9.
- Fountain SB, Hennes SK, Teyler TJ. Aspartame exposure and in Vitro hippocampal slice excitability and plasticity. *Fundam Appl Toxicol* 1988 Aug;11(2):221-8.
- Fox-Bacon C, McCamman S, Therou L, Moore W, Kipp DE. Maternal PKU and breastfeeding: case report of identical twin mothers. *Clin Pediatr (Phila)* 1997 Sep;36(9):539-42.
- Francois B, Diels M, de la Brassinne M. Iatrogenic skin lesions in phenylketonuric children due to a low tyrosine intake. *J Inherit Metab Dis* 1989;12 Suppl 2:332-4.
- Franke W, Dyrna G, Wegner H. [Oral findings in phenylketonuria with early and late dietetic therapy (author's transl)]. *Zahn Mund Kieferheilkd Zentralbl* 1982;70(3):211-6. (Ger).
- Franz M. Is it safe to consume aspartame during pregnancy? A review. *Nutrition update. Diabetes Educ* 1986 Spring;12(2):145-7.
- Freedman M. Consumption of aspartame by heterozygotes for phenylketonuria [letter]. *J Pediatr* 1987 Apr;110(4):662-3.
- Friedman EG, Koch R, Azen C, Levy H, Hanley W, Matalon R, Rouse B, Trefz F, de la Cruz F. The International Collaborative Study on maternal phenylketonuria: organization, study design and description of the sample. *Eur J Pediatr* 1996 Jul;155 Suppl 1:S158-61.
- Friedman JF. Low protein food products: A cornerstone in the management of PKU. *Top Clin Nutr* 1992 Dec;8(1):72-6.
- Friedman M, Gumbmann MR. The nutritive value and safety of D-phenylalanine and D-tyrosine in mice. *J Nutr* 1984 Nov;114(11):2089-96.
- Fusetti F, Erlandsen H, Flatmark T, Stevens RC. Structure of tetrameric human phenylalanine hydroxylase and its implications for phenylketonuria. *J Biol Chem* 1998 Jul 3;273(27):16962-7.
- Galli C, Agostoni C, Mosconi C, Riva E, Salari PC, Giovannini M. Reduced plasma C-20 and C-22 polyunsaturated fatty acids in children with phenylketonuria during dietary intervention. *J Pediatr* 1991 Oct;119(4):562-7.
- Garriga MM, Metcalfe DD. Aspartame intolerance. *Ann Allergy* 1988 Dec;61(6 Pt 2):63-9.
- Gavioli F, Zannino L. [Dietetic treatment of phenylketonuria]. *Minerva Pediatr* 1980 Mar 31;32(6):417-32. (Ita).
- Gerdes AM, Nielsen JB, Lou H, Guttler F. Plasma amino acids in phenylketonuric children treated either with phenylalanine-free amino acids or a protein hydrolysate. *Acta Paediatr Scand* 1990 Jan;79(1):69-72. Comment in: *Acta Paediatr Scand* 1991 May;80(5):577-80.
- Gerdes AM, Nielsen JB, Lou H, Guttler F. Plasma amino acids in term neonates and infants with phenylketonuria before and after institution of the diet. *Acta Paediatr Scand* 1990 Jan;79(1):64-8. Comment in: *Acta Paediatr Scand* 1991 May;80(5):577-80.
- Gerrard JW. Phenylketonuria revisited. *Clin Invest Med* 1994 Oct;17(5):510-3.
- Ghavami M, Levy HL, Erbe RW. Prevention of fetal damage through dietary control of maternal hyperphenylalaninemia. *Clin Obstet Gynecol* 1986 Sep;29(3):580-5.
- Gibbins B. Keeping phenylketonuria under control. *Mod Midwife* 1994 Oct;4(10):23-6.
- Gibbs BS, Wojchowski D, Benkovic SJ. Expression of rat liver phenylalanine hydroxylase in insect cells and site-directed mutagenesis of putative non-heme iron-binding sites. *J Biol Chem* 1993 Apr 15;268(11):8046-52.
- Gibson JB, Berry GT, Palmieri MJ, Reynolds RA, Mazur AT, Segal S. Sugar nucleotide concentrations in red blood cells of patients on protein- and lactose-limited diets: effect of galactose supplementation. *Am J Clin Nutr* 1996 May;63(5):704-8.
- Gibson RM. The relationship of phenylalanine to expression of broiler chickens [dissertation]. College Station (TX): Texas A & M University; 1988. 133 p.
- Gibson RM, Bailey CA, Kubena LF, Huff WE, Harvey RB. Impact of L-phenylalanine supplementation on the performance of three-week-old broilers fed diets containing ochratoxin A. 1.

- Effects on body weight, feed conversion, relative organ weight, and mortality. *Poultry Sci* 1990 Mar;69(3):414-9.
- Giffin FD, Clarke JT, d'Entremont DM. Effect of dietary phenylalanine restriction on visual attention span in mentally retarded subjects with phenylketonuria. *Can J Neurol Sci* 1980 May;7(2):127-31.
- Giovannini M, Agostoni C, Biasucci G, Rottoli A, Luotti D, Trojan S, Riva E. Fatty acid metabolism in phenylketonuria. *Eur J Pediatr* 1996 Jul;155 Suppl 1:S132-5.
- Giovannini M, Biasucci G, Luotti D, Fiori L, Riva E. Nutrition in children affected by inherited metabolic diseases. *Ann Ist Super Sanita* 1995;31(4):489-502.
- Glasgow JF, Moore R. Plasma amino acid ratio as an index of hepatocellular maturity in the neonate. *Biol Neonate* 1983;44(3):146-52.
- Goldman JM, Laws SC, Balchak SK, Cooper RL, Kavlock RJ. Endocrine-disrupting chemicals: Prepubertal exposures and effects on sexual maturation and thyroid activity in the female rat. A focus on the EDSTAC recommendations. *Crit Rev Toxicol* 2000;30(2):135-96.
- Goodwill KE, Sabatier C, Marks C, Raag R, Fitzpatrick PF, Stevens RC. Crystal structure of tyrosine hydroxylase at 2.3 Å and its implications for inherited neurodegenerative diseases. *Nat Struct Biol* 1997 Jul;4(7):578-85.
- Gordienko SV, Ermakova LN, Podol'skii MV, Belikov VM, Lamov VK, TSYriapkin VA. [Preparation of a mixture of amino acids for feeding patients with phenylketonuria]. *Khim Farm Zh* 1980 Dec;14(12):72-5. (Rus).
- Gourovitch ML, Craft S, Dowton SB, Ambrose P, Sparta S. Interhemispheric transfer in children with early-treated phenylketonuria. *J Clin Exp Neuropsychol* 1994 Jun;16(3):393-404.
- Graziado-Marques B, Kennedy B, Anderson K. Cost justifying computerization of diet analysis. *J Am Diet Assoc* 1991 Apr;91(4):469-70.
- Greeves LG. The physical and nutritional status of phenylketonuric patients attending the regional clinic in the Royal Belfast Hospital for Children with special reference to minerals and vitamins [dissertation]. Belfast (Ireland): Queen's University of Belfast; 1992. 250 p.
- Greeves LG, Carson DJ, Craig BG, McMaster D. Potentially life-threatening cardiac dysrhythmia in a child with selenium deficiency and phenylketonuria. *Acta Paediatr Scand* 1990 Dec;79(12):1259-62.
- Greeves LG, Carson DJ, Magee A, Patterson CC. Fractures and phenylketonuria. *Acta Paediatr* 1997 Mar;86(3):242-4.
- Greeves LG, McCarthy HL, Redmond A, Carson DJ. Coexistence of cystic fibrosis and phenylketonuria. *Ulster Med J* 1997 May;66(1):59-61.
- Greeves LG, Patterson CC, Carson DJ, Thom R, Wolfenden MC, Zschocke J, Graham CA, Nevin NC, Trimble ER. Effect of genotype on changes in intelligence quotient after dietary relaxation in phenylketonuria and hyperphenylalaninaemia. *Arch Dis Child* 2000 Mar;82(3):216-21.
- Greeves LG, Thomas PS, Carson DJ. Radiological assessment of the hand and wrist in phenylketonuria and hyperphenylalaninaemia. *Pediatr Radiol* 1995;25(5):353-5.
- Greve LC, Wheeler MD, Green-Burgeson DK, Zorn EM. Breast-feeding in the management of the newborn with phenylketonuria: a practical approach to dietary therapy. *J Am Diet Assoc* 1994 Mar;94(3):305-9. Published erratum appears in *J Am Diet Assoc* 1994 Jul;94(7):716.
- Griffin HG, Gasson MJ. Genetic aspects of aromatic amino acid biosynthesis in *Lactococcus lactis*. *Mol Gen Genet* 1995 Jan 6;246(1):119-27.
- Griffiths P, Paterson L, Harvie A. Neuropsychological effects of subsequent exposure to phenylalanine in adolescents and young adults with early-treated phenylketonuria. *J Intellect Disabil Res* 1995 Oct;39 (Pt 5):365-72.
- Griffiths P, Smith C, Harvie A. Transitory hyperphenylalaninaemia in children with continuously treated phenylketonuria. *Am J Ment Retard* 1997 Jul;102(1):27-36.
- Griffiths PV, Demellweek C, Fay N, Robinson PH, Davidson DC. Wechsler subscale IQ and subtest profile in early treated phenylketonuria. *Arch Dis Child* 2000 Mar;82(3):209-15.
- Grinde B. Effect of amino acid metabolites on lysosomal protein degradation. A regulatory role for kynurenine? *Eur J Biochem* 1984 Dec 17;145(3):623-7.
- Gropper SS, Acosta PB, Clarke-Sheehan N, Wenz E, Cheng M, Koch R. Trace element status of children with PKU and normal children. *J Am Diet Assoc* 1988 Apr;88(4):459-65.
- Gropper SS, Chaung HC. Immune status of children with Phenylketonuria. *Highlights Agric Res* 1993 Summer;40(2):6.

- Gropper SS, Chaung HC, Bernstein LE, Trahms C, Rarback S, Weese SJ. Immune status of children with phenylketonuria. *J Am Coll Nutr* 1995 Jun;14(3):264-70.
- Gropper SS, Naglak MC, Nardella M, Plyler A, Rarback S, Yannicelli S. Nutrient intakes of adolescents with phenylketonuria and infants and children with maple syrup urine disease on semisynthetic diets. *J Am Coll Nutr* 1993 Apr;12(2):108-14.
- Gropper SS, Yannicelli S. Plasma molybdenum concentrations in children with and without phenylketonuria. *Biol Trace Elem Res* 1993 Sep;38(3):227-31.
- Gross PT, Berlow S, Schuett VE, Fariello RG. EEG in phenylketonuria. Attempt to establish clinical importance of EEG changes. *Arch Neurol* 1981 Feb;38(2):122-6.
- Guerin T, Walsh GA, Donlon J, Kaufman S. Correlation of rat hepatic phenylalanine hydroxylase, with tetrahydrobiopterin and GTP concentrations. *Int J Biochem Cell Biol* 1998 Sep;30(9):1047-54.
- Guettler F, Guldborg P, Henriksen KF. Mutation genotype of mentally retarded patients with phenylketonuria. *Dev Brain Dysfunct* 1993 Jan-Jun;6(1-3):92-6.
- Guillet GY, Dore N, Hehunstre JP, Maleville J, Battin J. Pseudoscleroderma and phenylketonuria. *Int J Dermatol* 1983 Sep;22(7):422-6.
- Guiso G, Diomede L, Romano M, Caccia S, Sarati S, Salmona M. Effect of tyrosine on the potentiation by aspartame and phenylalanine of metrazol-induced convulsions in rats. *Food Chem Toxicol* 1991;29(12):855-7.
- Guthrie R. The introduction of newborn screening for phenylketonuria. A personal history. *Eur J Pediatr* 1996 Jul;155 Suppl 1:S4-5.
- Guttler F. [Folling's disease: 50-years and still a catalyst of new discoveries in medicine]. *Ugeskr Laeger* 1984 Jan 9;146(2):83-7. (Dan).
- Guttler F. Phenylketonuria: 50 years since Folling's discovery and still expanding our clinical and biochemical knowledge. *Acta Paediatr Scand* 1984 Nov;73(6):705-16.
- Guttler F, Hansen G. Different phenotypes for phenylalanine hydroxylase deficiency. *Ann Clin Biochem* 1977 May;14(3):124-34.
- Guttler F, Lou H. Aspartame may imperil dietary control of phenylketonuria [letter]. *Lancet* 1985 Mar 2;1(8427):525-6.
- Guttler F, Lou H. Dietary problems of phenylketonuria: effect on CNS transmitters and their possible role in behaviour and neuropsychological function. *J Inherit Metab Dis* 1986;9 Suppl 2:169-77.
- Guttler F, Lou H, Andresen J, Kok K, Mikkelsen I, Nielsen KB, Nielsen JB. Cognitive development in offspring of untreated and preconceptionally treated maternal phenylketonuria. *J Inherit Metab Dis* 1990;13(4):665-71.
- Guttler F, Wamberg E. Fasting serum phenylalanine in untreated institutionalised patients with phenylketonuria. *J Ment Defic Res* 1977 Mar;21(1):55-62.
- Guttler F, Wamberg E. On indications for treatment of the hyperphenylalaninemic neonate. *Acta Paediatr Scand* 1977 May;66(3):339-44.
- Haley CJ, Harper AE. Glucagon stimulation of phenylalanine metabolism. The effects of acute and chronic glucagon treatment (Phenylalanine hydroxylase). *Metab Clin Exp* 1982 Jun;31(6):524-32.
- Hall SK, Robinson P, Green A. Could salivary phenylalanine concentrations replace blood concentrations? *Ann Clin Biochem* 2000 Mar;37(Pt 2):222-3.
- Hammersen G, Schmidt H, Mahle M, Jurish-Homm H, Bickel H. Termination of dietary treatment in phenylketonuria. In: Naruse H, Irie M, editors. Neonatal screening. Proceedings of the 2nd International Conference on Neonatal Thyroid Screening; 1982 Aug 16-19; Tokyo and the International Symposium on Neonatal Screening for Inborn Errors of Metabolism; 1982 Aug 19-21; Tokyo. Princeton (NJ): Excerpta Medica; 1983. p. 225-8. (International congress series; no. 606).
- Hanley WB, Feigenbaum AS, Clarke JT, Schoonheydt WE, Austin VJ. Vitamin B12 deficiency in adolescents and young adults with phenylketonuria. *Eur J Pediatr* 1996 Jul;155 Suppl 1:S145-7.
- Hanley WB, Linsao L, Davidson W, Moes CA. Malnutrition with early treatment of phenylketonuria. *Pediatr Res* 1970 Jul;4(4):318-27.
- Harada T, Kagamiyama H, Hatakeyama K. Feedback regulation mechanisms for the control of GTP cyclohydrolase I activity. *Science* 1993 Jun 4;260(5113):1507-10.
- Harper AE. Some recent developments in the study of amino acid metabolism. *Proc Nutr Soc* 1983 Sep;42(3):437-49.
- Harper M, Reid AH. Use of a restricted protein diet in the treatment of behaviour disorder in a severely

- mentally retarded adult female phenylketonuric patient. *J Ment Defic Res* 1987 Jun;31 (Pt 2):209-12.
- Harvey EL, Kirk SF. The use of a low phenylalanine diet in response to the challenging behaviour of a man with untreated phenylketonuria and profound learning disabilities. *J Intellect Disabil Res* 1995 Dec;39 (Pt 6):520-6.
- Hasegawa H, Kaufman S. Spontaneous activation of phenylalanine hydroxylase in rat liver extracts. *J Biol Chem* 1982 Mar 25;257(6):3084-9.
- Hashishe MM. Genetic study of phenylketonuria. *J Egypt Public Health Assoc* 1992;67(3-4):443-63.
- Hayes JS, Rarback S, Berry BE, Clancy MK. Managing PKU: an update. *MCN Am J Matern Child Nurs* 1987 Mar-Apr;12(2):119-23. Published erratum appears in *MCN* 1987 Jul-Aug;12(4):239.
- Heffernan JF, Trahms CM. A model preschool for patients with phenylketonuria. *J Am Diet Assoc* 1981 Sep;79(3):306-8.
- Henderson RA. PKU and maternal PKU: the cure and the problem. *B C J Spec Ed* 1989;13(3):253-7.
- Hermann ME, Monch E, Reinbacher M, Kohlen W, Brosicke HG. [Phenylalanine-free amino acid mixture: metabolic effects in relation to a single dose]. *Monatsschr Kinderheilkd* 1991 Oct;139(10):670-5. (Ger).
- Herrmann ME, Brosicke HG, Keller M, Monch E, Helge H. Dependence of the utilization of a phenylalanine-free amino acid mixture on different amounts of single dose ingested. A case report. *Eur J Pediatr* 1994 Jul;153(7):501-3.
- Hickey CA, Covington C. Maternal phenylketonuria: case management as a preventive approach to a chronic condition affecting pregnancy. *NAACOGS Clin Issu Perinat Womens Health Nurs* 1990;1(2):214-25.
- Hidalgo IJ, Borchardt RT. Carrier-mediated transport of bile acids and amino acids in Caco-2 cells. *NATO ASI Ser Ser A Life Sci* 1991;218:77-91.
- Hildebrandt PG, Copeland RA, Spiro TG, Otlewski J, Laskowski M Jr, Prendergast FG. Tyrosine hydrogen-bonding and environmental effects in proteins probed by ultraviolet resonance Raman spectroscopy. *Biochemistry* 1988 Jul 26;27(15):5426-33.
- Hill DA, Yen JT, Lee RT. Application of high performance liquid chromatography in determination of protein synthesis rates in pigs [abstract]. *J Anim Sci* 1988;66 Suppl 1:263.
- Hillman L, Schlotzhauer C, Lee D, Grasela J, Witter S, Allen S, Hillman R. Decreased bone mineralization in children with phenylketonuria under treatment. *Eur J Pediatr* 1996 Jul;155 Suppl 1:S148-52.
- Hinrichs F, Biggemann B, Wendel U. [Breast feeding of infants with phenylketonuria]. *Klin Padiatr* 1994 May-Jun;206(3):175-7. (Ger).
- Hiramatsu T, Cortiella J, Marchini JS, Chapman TE, Young VR. Source and amount of dietary nonspecific nitrogen in relation to whole-body leucine, phenylalanine, and tyrosine kinetics in young men. *Am J Clin Nutr* 1994 Jun;59(6):1347-55.
- Hjelm M, Seakins J, Antoshechkin A. Indications of changed amino acid homeostasis in untreated and treated PKU. *Acta Paediatr Suppl* 1994 Dec;407:57-9.
- Hoff RH, Hengge AC, Wu L, Keng Y-F, Zhang Z-Y. Effects on general acid catalysis from mutations of the invariant tryptophan and arginine residues in the protein tyrosine phosphatase from *Yersinia*. *Biochemistry* 2000 Jan 11;39(1):46-54.
- Hogan SE, Gates RD, MacDonald GW, Clarke JT. Experience with adolescents with phenylketonuria returned to phenylalanine-restricted diets. *J Am Diet Assoc* 1986 Sep;86(9):1203-7.
- Hoganson G, Berlow S, Kaufman S, Milstien S, Schuett V, Matalon R, Naylor E, Seifert W. Biopterin synthesis defects: problems in diagnosis. *Pediatrics* 1984 Dec;74(6):1004-11.
- Holder MD. Effects of perinatal exposure to aspartame on rat pups. *Neurotoxicol Teratol* 1989 Jan-Feb;11(1):1-6.
- Holmgren G, Blomquist HK, Samuelson G. Positive effect of a late introduced modified diet in an 8-year-old pku child. *Neuropadiatrie* 1980 Feb;11(1):76-9.
- Holt KS. Diets and development. *Child Care Health Dev* 1982 Jul-Aug;8(4):183-201.
- Holtzman NA, Kronmal RA, van Doorninck W, Azen C, Koch R. Effect of age at loss of dietary control on intellectual performance and behavior of children with phenylketonuria. *N Engl J Med* 1986 Mar 6;314(10):593-8.
- Hombres FA. The effect of hyperphenylalaninaemia on the muscarinic acetylcholine receptor in the HPH-5 mouse brain. *J Inherit Metab Dis* 1993;16(6):962-74.
- Hombres FA, Eller AG, Taylor EH. Turnover of the fast components of myelin and myelin proteins in experimental hyperphenylalaninaemia. Relevance to termination of dietary treatment in human phenylketonuria. *J Inherit Metab Dis* 1982;5(1):21-7.

- Hommes FA, Lee JS. The effect of plasma valine, isoleucine and leucine on the control of the flux through tyrosine- and tryptophan-hydroxylase in the brain. *J Inher Metab Dis* 1990;13(2):151-5.
- Hommes FA, Moss L. Myelin turnover in hyperphenylalaninaemia. A re-evaluation with the HPH-5 mouse. *J Inher Metab Dis* 1992;15(2):243-51.
- Horwitz DL, Bauer-Nehrling JK. Can aspartame meet our expectations? *J Am Diet Assoc* 1983 Aug;83(2):142-6.
- Hoskin RG, Sasitharan T, Howard R. The use of a low phenylalanine diet with amino acid supplement in the treatment of behavioural problems in a severely mentally retarded adult female with phenylketonuria. *J Intellect Disabil Res* 1992 Apr;36 (Pt 2):183-91.
- Hoskins JA, Gray J. Phenylalanine ammonia lyase in the management of phenylketonuria: the relationship between ingested cinnamate and urinary hippurate in humans. *Res Commun Chem Pathol Pharmacol* 1982 Feb;35(2):275-82.
- Hoskins JA, Jack G, Wade HE, Peiris RJ, Wright EC, Starr DJ, Stern J. Enzymatic control of phenylalanine intake in phenylketonuria. *Lancet* 1980 Feb 23;1(8165):392-4.
- House JD, Pencharz PB, Ball RO. Phenylalanine requirements determined by using L-[1-14C]phenylalanine in neonatal piglets receiving total parenteral nutrition supplemented with tyrosine. *Am J Clin Nutr* 1997 Apr;65(4):984-93.
- House JD, Pencharz PB, Ball RO. Tyrosine kinetics and requirements during total parenteral nutrition in the neonatal piglet: the effect of glycyl-L-tyrosine supplementation. *Pediatr Res* 1997 Apr;41(4 Pt 1):575-83.
- House JD, Thorpe JM, Wykes LJ, Pencharz PB, Ball RO. Evidence that phenylalanine hydroxylation rates are overestimated in neonatal subjects receiving total parenteral nutrition with a high phenylalanine content. *Pediatr Res* 1998 Apr;43(4 Pt 1):461-6.
- Howell RR. Phenylketonuria in the general population. *N Engl J Med* 1970 Jun 25;282(26):1486-8.
- Howell RR, Stevenson RE. The offspring of phenylketonuric women. *Soc Biol* 1971 Sep;18:S19-29.
- Hsieh MC, Berry HK, Bofinger MK, Phillips PJ, Guilfoile MB, Hunt MM. Comparative diagnostic value of phenylalanine challenge and phenylalanine hydroxylase activity in phenylketonuria. *Clin Genet* 1983 Jun;23(6):415-21.
- Huang RT, Lin SJ, Kuo PL, Peng CJ. Successful management of a pregnancy with maternal phenylketonuria: report of a case. *J Formos Med Assoc* 1993 Feb;92(2):182-4.
- Huether G. Amino acid availability and brain development: effects of nutritional and metabolic inadequacies. *Eur J Clin Nutr* 1989;43 Suppl 1:19-25.
- Huether G. Regulation of the free amino acid pool of the developing brain: a lesson learned from experimental phenylketonuria. *UCLA Symp Mol Cell Biol* 1987;55:107-22.
- Huether G, Kaus R, Neuhoff V. Amino acid depletion in the blood and brain tissue of hyperphenylalaninemic rats is abolished by the administration of additional lysine: a contribution to the understanding of the metabolic defects in phenylketonuria. *Biochem Med* 1985 Jun;33(3):334-41.
- Huether G, Neuhoff V, Kaus R. Brain development in experimental hyperphenylalaninaemia: disturbed proliferation and reduced cell numbers in the cerebellum. *Neuropediatrics* 1983 Feb;14(1):12-9.
- Hufton SE, Jennings IG, Cotton RG. Structure/function analysis of the domains required for the multimerisation of phenylalanine hydroxylase. *Biochim Biophys Acta* 1998 Feb 17;1382(2):295-304.
- Huisman J, Slijper FM, Hendrikx MM, Kalverboer AF, van der Schot L. [Intelligence of phenylketonuria patients treated early; 10-year psychological follow-up in the Netherlands]. *Ned Tijdschr Geneesk* 1985 Nov 2;129(44):2120-3. (Dut).
- Hunt MM, Berry HK, White PP. Phenylketonuria, adolescence, and diet. *J Am Diet Assoc* 1985 Oct;85(10):1328-34.
- Hurst JD, Stullenbarger B. Implementation of a self-care approach in a pediatric interdisciplinary phenylketonuria (PKU) clinic. *J Pediatr Nurs* 1986 Jun;1(3):159-63.
- Hyanek J, Bendl J, Zeman J, Soukup K, Dolezal A, Kozich V, St'astna S, Kubik M, Viletova H. [Maternal hyperphenylalaninemia in a population of healthy Czech women. 18 years' experience with mass screening, diet therapy and metabolic monitoring]. *Cas Lek Cesk* 1996 Jan 17;135(2):50-3. (Cze).
- Hyanek J, Viletova H, Simova O, Dusek V, Simkova M, Hoza J. [Use of protein supplements in diet therapy of phenylketonuria and other hereditary amino acid metabolism disorders]. *Cesk Pediatr* 1980;35(2):53-4. (Cze).
- Hyanek J, Viletova H, Soukup J, Kobilkova J, Kubik M, Kunova V. [Changes in phenylalanine tolerance

- during the monitoring of diet therapy of pregnant women with phenylketonuria]. *Cesk Gynekol* 1988 Nov;53(9):650-3. (Cze).
- Hyanek J, Viletova H, Soukup J, Kobilkova J, Kubik M, Kunova V. Changes in phenylalanine tolerance while monitoring the dietetic treatment of pregnant women suffering from hyperphenylalaninaemia. *J Inher Metab Dis* 1988;11(4):427-8.
- Hyanek J, Viletova H, Zeman J, Vyhalkova H, Soukup J. [Offspring of mothers with hyperphenylalaninemia treated with a low phenylalanine diet before conception and during pregnancy]. *Cas Lek Cesk* 1988 Jun 3;127(23):715-9. (Cze).
- Iinuma K, Narisawa K, Tateda H, Suzuki K, Tada K, Onuma A. [Diet therapy and EEG in phenylketonuria]. *No To Hattatsu* 1983 Nov;15(6):497-502. (Jpn).
- Imura K, Okada A. Amino acid metabolism in pediatric patients. *Nutrition* 1998 Jan;14(1):143-8.
- Inoue M, Muto Y, Sakamoto H, Kigawa T, Takio K, Shimura Y, Yokoyama S. A characteristic arrangement of aromatic amino acid residues in the solution structure of the amino-terminal RNA-binding domain of *Drosophila sex-lethal*. *J Mol Biol* 1997 Sep 12;272(1):82-94.
- Iraqi I, Vissers S, Andre B, Urrestarazu A. Transcriptional induction by aromatic amino acids in *Saccharomyces cerevisiae*. *Mol Cell Biol* 1999 May;19(5):3360-71.
- Irons M, Levy HL. Metabolic syndromes with dermatologic manifestations. *Clin Rev Allergy* 1986 Feb;4(1):101-24.
- Ishihara A, Ohtsu Y, Iwamura H. Induction of biosynthetic enzymes for avenanthramides in elicitor-treated oat leaves. *Planta* 1999 Jun;208(4):512-8.
- Ishii H, Sasaki Y, Goshima Y, Kanai Y, Endou H, Ayusawa D, Ono H, Miyamae T, Misu Y. Involvement of rBAT in Nasup +-dependent and -independent transport of the neurotransmitter candidate L-DOPA in *Xenopus laevis* oocytes injected with rabbit small intestinal epithelium poly Asup + RNA. *Biochim Biophys Acta* 2000 Jun 1;1466(1-2):61-70.
- Ivarsen P, Frystyk J, Pedersen EB. The pattern of intracellular free amino acids in granulocytes from hemodialysis patients change to an oral protein supplement (granulocyte amino acids after protein in HD patients). *Clin Nephrol* 1999 Aug;52(2):110-8.
- Iwaki M, Phillips RS, Kaufman S. Proteolytic modification of the amino-terminal and carboxyl-terminal regions of rat hepatic phenylalanine hydroxylase. *J Biol Chem* 1986 Feb 15;261(5):2051-6.
- Janssen PJ, van der Heijden CA. Aspartame: review of recent experimental and observational data. *Toxicology* 1988 Jun;50(1):1-26.
- Jimenez N, Gonzalez-Candelas F, Silva FJ. Prephenate dehydratase from the aphid endosymbiont (*Buchnera*) displays changes in the regulatory domain that suggest its desensitization to inhibition by phenylalanine. *J Bacteriol* 2000 May;182(10):2967-9.
- Jimenez Soto Z. [Lists of food exchanges for use in phenylketonuria and maple-syrup urine disease]. *Arch Latinoam Nutr* 1993 Sep;43(3):211-6. (Spa).
- Jimenez Soto Z. [Methodology of care for children with phenylketonuria and maple-syrup urine disease]. *Arch Latinoam Nutr* 1993 Sep;43(3):204-10. (Spa).
- Jingzhong L, Hua X, Wei H, Zhangling Z, Jin Z, Qingyuan L. Cloning and expression of phenylalanine ammonia lyase cDNA in *Escherichia coli*. *Chin J Biotechnol* 1998;14(4):227-32.
- Jochum F, Terwolbeck K, Meinhold H, Behne D, Menzel H, Lombeck I. Effects of a low selenium state in patients with phenylketonuria. *Acta Paediatr* 1997 Jul;86(7):775-7.
- Johnen G, Kowlessur D, Citron BA, Kaufman S. Characterization of the wild-type form of 4a-carbinolamine dehydratase and two naturally occurring mutants associated with hyperphenylalaninemia. *Proc Natl Acad Sci U S A* 1995 Dec 19;92(26):12384-8. Published erratum appears in *Proc Natl Acad Sci U S A* 1996 Apr 30;93(9):4519.
- Johnson WG. DNA polymorphism-diet-cofactor-development hypothesis and the gene-teratogen model for schizophrenia and other developmental disorders. *Am J Med Genet* 1999 Aug 20;88(4):311-23.
- Jones SJ, Turano G, Kriss A, Shawkat F, Kendall B, Thompson AJ. Visual evoked potentials in phenylketonuria: association with brain MRI, dietary state, and IQ. *J Neurol Neurosurg Psychiatry* 1995 Sep;59(3):260-5.
- Jordan MK, Brunner RL, Hunt MM, Berry HK. Preliminary support for the oral administration of valine, isoleucine and leucine for phenylketonuria. *Dev Med Child Neurol* 1985 Feb;27(1):33-9.
- Juminaga D, Wedemeyer WJ, Garduno-Juarez R, McDonald MA, Scheraga HA. Tyrosyl interactions in the folding and unfolding of bovine pancreatic ribonuclease A: a study of tyrosine-to-phenylalanine mutants. *Biochemistry* 1997 Aug 19;36(33):10131-45.

- Kadowaki M, Poso AR, Mortimore GE. Parallel control of hepatic proteolysis by phenylalanine and phenylpyruvate through independent inhibitory sites at the plasma membrane. *J Biol Chem* 1992 Nov 5;267(31):22060-5.
- Kalverboer AF, van der Schot LW, Hendriks MM, Huisman J, Slijper FM, Stemerink BA. Social behaviour and task orientation in early-treated PKU. *Acta Paediatr Suppl* 1994 Dec;407:104-5.
- Kappock TJ, Harkins PC, Friedenbergs S, Caradonna JP. Spectroscopic and kinetic properties of unphosphorylated rat hepatic phenylalanine hydroxylase expressed in *Escherichia coli*. Comparison of resting and activated states. *J Biol Chem* 1995 Dec 22;270(51):30532-44.
- Kasahara T, Kasahara M. Interaction between the critical aromatic amino acid residues Tyr(352) and Phe(504) in the yeast Gal2 transporter. *FEBS Lett* 2000 Apr 7;471(1):103-7.
- Kastin AJ, Akerstrom V, Hackler L, Zadina JE. Phe(13),Tyr(19)-melanin-concentration hormone and the blood-brain barrier: role of protein binding. *J Neurochem* 2000 Jan;74(1):385-91.
- Kauf E, Seidel J, Winnefeld K, Dawczynski H, Hafer R, Stein F, Vogt L. [Selenium in phenylketonuria patients. Effects of sodium selenite administration]. *Med Klin* 1997 Sep 15;92 Suppl 3:31-4. (Ger).
- Kauf E, Vogt L, Seidel J, Winnefeld K, Richter H, Vogel H, Dawczynski H, Forberger A, Schlenvoigt D. Selenium deficiency in children with cystic fibrosis and phenylketonuria: metabolic and echocardiographic findings during sodium selenite therapy. In: Bohles H, Hofstetter R, Sewell AC, editors. *Metabolic cardiomyopathy*. Stuttgart (Germany): Wissenschaftliche Verlagsgesellschaft MBH; 1995. p. 153-8.
- Kaufman S. Classical phenylketonuria and its variants caused by defects in bipterin metabolism. *UCLA Symp Mol Cell Biol* 1987;55:517-38.
- Kaufman S. Experiencing classical enzymology in its prime. *Protein Sci* 1996 Aug;5(8):1742-6.
- Kaufman S. A model of human phenylalanine metabolism in normal subjects and in phenylketonuric patients. *Proc Natl Acad Sci U S A* 1999 Mar 16;96(6):3160-4.
- Kaufman S. Regulation of the activity of hepatic phenylalanine hydroxylase. *Adv Enzyme Regul* 1986;25:37-64.
- Kaufman S. Unsolved problems in diagnosis and therapy of hyperphenylalaninemia caused by defects in tetrahydrobiopterin metabolism. *J Pediatr* 1986 Oct;109(4):572-8.
- Kayaalp E, Treacy E, Waters PJ, Byck S, Nowacki P, Scriver CR. Human phenylalanine hydroxylase mutations and hyperphenylalaninemia phenotypes: a metanalysis of genotype-phenotype correlations. *Am J Hum Genet* 1997 Dec;61(6):1309-17.
- Keckskemethy HH, Lobbregt D, Levy HL. The use of gelatin capsules for ingestion of formula in dietary treatment of maternal phenylketonuria. *J Inher Metab Dis* 1993;16(1):111-8.
- Kennedy B, Anderson K, Acosta PB. Nutrition support of inborn errors of amino acid metabolism. *Int J Biomed Comput* 1985 Jul;17(1):69-76.
- Kim DH, Nam GH, Jang DS, Choi G, Joo S, Kim JS, Oh BH, Choi KY. Roles of active site aromatic residues in catalysis by ketosteroid isomerase from *Pseudomonas putida* biotype B. *Biochemistry* 1999 Oct 19;38(42):13810-9.
- Kim KI, Bayley HS. Amino acid oxidation by young pigs receiving diets with varying levels of sulphur amino acids. *Br J Nutr* 1983 Sep;50(2):383-90.
- Kim KI, Elliott JI, Bayley HS. Oxidation of an indicator amino acid by young pigs receiving diets with varying levels of lysine or threonine, and an assessment of amino acid requirements. *Br J Nutr* 1983 Sep;50(2):391-9.
- Kim KI, McMillan I, Bayley HS. Determination of amino acid requirements of young pigs using an indicator amino acid. *Br J Nutr* 1983 Sep;50(2):369-82.
- Kindt E, Halvorsen S. The need of essential amino acids in children. An evaluation based on the intake of phenylalanine, tyrosine, leucine, isoleucine, and valine in children with phenylketonuria, tyrosine amino transferase defect, and maple syrup urine disease. *Am J Clin Nutr* 1980 Feb;33(2):279-86.
- Kindt E, Halvorsen S, Lie SO. Does a marginal protein intake result in osteoporosis? *J Inher Metab Dis* 1987;10(2):195.
- Kindt E, Holm H, Halvorsen S, Lie SO. Net protein utilization determined by rat bioassay of a protein hydrolysate and a diet for children with phenylketonuria. *Br J Nutr* 1985 Sep;54(2):349-53.
- Kindt E, Lunde HA, Gjessing LR, Halvorsen S, Lie SO. Fasting plasma amino acid concentrations in PKU children on two different levels of protein intake. *Acta Paediatr Scand* 1988 Jan;77(1):60-6.
- Kindt E, Motzfeldt K, Halvorsen S, Lie SO. Is phenylalanine requirement in infants and children

related to protein intake? *Br J Nutr* 1984 May;51(3):435-42.

Kindt E, Motzfeldt K, Halvorsen S, Lie SO. Protein requirements in infants and children: a longitudinal study of children treated for phenylketonuria. *Am J Clin Nutr* 1983 May;37(5):778-85.

Kirby RB. Maternal phenylketonuria: a new cause for concern. *J Obstet Gynecol Neonatal Nurs* 1999 May-Jun;28(3):227-34.

Kirkman HN. Projections of a rebound in frequency of mental retardation from phenylketonuria. *Appl Res Ment Retard* 1982;3(3):319-28.

Kitagawa T, Owada M, Aoki K, Arai S, Oura T, Matsuda I, Igarashi Y, Tada K, Katayama S, Hashida W. Treatment of phenylketonuria with a formula consisting of low-phenylalanine peptide. A collaborative study. *Enzyme* 1987;38(1-4):321-7.

Kleppe R, Uhlemann K, Knappskog PM, Haavik J. Urea-induced denaturation of human phenylalanine hydroxylase. *J Biol Chem* 1999 Nov 19;274(47):33251-8.

Knappskog M, Eiken HG, Martinez A, Olafsdotti S, Haavik J, Flatmark T, Apold J. Expression of wild type and mutant forms of human phenylalanine hydroxylase in *E. coli*. *Adv Exp Med Biol* 1993;338:59-62.

Knappskog PM, Eiken HG, Martinez A, Bruland O, Apold J, Flatmark T. PKU mutation (D143G) associated with an apparent high residual enzyme activity: expression of a kinetic variant form of phenylalanine hydroxylase in three different systems. *Hum Mutat* 1996;8(3):236-46.

Knappskog PM, Flatmark T, Aarden JM, Haavik J, Martinez A. Structure/function relationships in human phenylalanine hydroxylase. Effect of terminal deletions on the oligomerization, activation and cooperativity of substrate binding to the enzyme. *Eur J Biochem* 1996 Dec 15;242(3):813-21.

Knappskog PM, Haavik J. Tryptophan fluorescence of human phenylalanine hydroxylase produced in *Escherichia coli*. *Biochemistry* 1995 Sep 19;34(37):11790-9.

Knoll E, Wehle E, Thalhammer O. [Psychometry and psychological observations in early treated children with phenylketonuria (PKU) during 12 years (author's transl)]. *Klin Padiatr* 1980 Nov;192(6):599-607. (Ger).

Kobayashi H, Kato J, Morioka H, Stewart JD, Ohtsuka E. Tryptophan H33 plays an important role in pyrimidine (6-4) pyrimidone photoproduct binding by

a high-affinity antibody. *Protein Eng* 1999 Oct;12(10):879-84.

Kobe B, Jennings IG, House CM, Feil SC, Michell BJ, Tiganis T, Parker MW, Cotton RG, Kemp BE. Regulation and crystallization of phosphorylated and dephosphorylated forms of truncated dimeric phenylalanine hydroxylase. *Protein Sci* 1997 Jun;6(6):1352-7.

Kobe B, Jennings IG, House CM, Michell BJ, Goodwill KE, Santarsiero BD, Stevens RC, Cotton RG, Kemp BE. Structural basis of autoregulation of phenylalanine hydroxylase. *Nat Struct Biol* 1999 May;6(5):442-8. Comment in: *Nat Struct Biol* 1999 May;6(5):401-2.

Koch R. Safety of aspartame as a sweetener [letter]. *N Engl J Med* 1975 Mar 13;292(11):596.

Koch R. Tyrosine supplementation for phenylketonuria treatment [editorial]. *Am J Clin Nutr* 1996 Dec;64(6):974-5. Comment on: *Am J Clin Nutr* 1996 Dec;64(6):916-21.

Koch R, Acosta PB, Williams JC. Nutritional therapy for pregnant women with a metabolic disorder. *Clin Perinatol* 1995 Mar;22(1):1-14.

Koch R, Azen C, Friedman EG, Fishler K, Baumann-Frischling C, Lin T. Care of the adult with phenylketonuria. *Eur J Pediatr* 1996 Jul;155 Suppl 1:S90-2.

Koch R, Azen C, Friedman EG, Williamson ML. Paired comparisons between early treated PKU children and their matched sibling controls on intelligence and school achievement test results at eight years of age. *J Inher Metab Dis* 1984;7(2):86-90.

Koch R, Azen CG, Friedman EG, Williamson ML. Preliminary report on the effects of diet discontinuation in PKU. *J Pediatr* 1982 Jun;100(6):870-5.

Koch R, Azen CG, Friedman EG, Williamson ML, O'Flynn M, Michals K. Updated report on the effects of diet discontinuation in PKU. In: Naruse H, Irie M, editors. Neonatal screening. Proceedings of the 2nd International Conference on Neonatal Thyroid Screening; 1982 Aug 16-19; Tokyo and the International Symposium on Neonatal Screening for Inborn Errors of Metabolism; 1982 Aug 19-21; Tokyo. Princeton (NJ): Excerpta Medica; 1983. p. 213-8. (International congress series; no. 606).

Koch R, Azen CG, Hurst N, Friedman EG, Fishler K. The effects of diet discontinuation in children with phenylketonuria. *Eur J Pediatr* 1987;146 Suppl 1:A12-6.

- Koch R, Blaskovics M. Four cases of hyperphenylalaninaemia: studies during pregnancy and of the offspring produced. *J Inherit Metab Dis* 1982;5(1):11-5.
- Koch R, Fishler K, Azen C, Guldberg P, Guttler F. The relationship of genotype to phenotype in phenylalanine hydroxylase deficiency. *Biochem Mol Med* 1997 Apr;60(2):92-101.
- Koch R, Friedman E, Azen C, Hanley W, Matalon R, Rouse B, Trefz F, Waisbren S, Michals-Matalon K, Acosta P, Guettler F, Ullrich K, Platt L, de la Cruz F, Levy H. The international collaborative study of Maternal Phenylketonuria Status Report 1998. *Ment Retard Dev Disabil Res Rev* 1999; 5(2):117-21.
- Koch R, Friedman EG, Wenz E, Jew K, Crowley C, Donnell G. Maternal phenylketonuria. *J Inherit Metab Dis* 1986;9 Suppl 2:159-68.
- Koch R, Hanley W, Levy H, Matalon R, Rouse B, Dela Cruz F, Azen C, Gross Friedman E. A preliminary report of the collaborative study of maternal phenylketonuria in the United States and Canada. *J Inherit Metab Dis* 1990;13(4):641-50.
- Koch R, Levy H, Hanley W, Matalon R, Rouse B, Trefz F, de la Cruz F. Outcome implications of the International Maternal Phenylketonuria Collaborative Study (MPKUCS): 1994. *Eur J Pediatr* 1996 Jul;155 Suppl 1:S162-4.
- Koch R, Levy HL, Matalon R, Rouse B, Hanley W, Azen C. The North American Collaborative Study of Maternal Phenylketonuria. Status report 1993. *Am J Dis Child* 1993 Nov;147(11):1224-30.
- Koch R, Levy HL, Matalon R, Rouse B, Hanley WB, Trefz F, Azen C, Friedman EG, de la Cruz F, Guttler F, et al. The international collaborative study of maternal phenylketonuria: status report 1994. *Acta Paediatr Suppl* 1994 Dec;407:111-9.
- Koch R, Moseley K, Ning J, Romstad A, Guldberg P, Guttler F. Long-term beneficial effects of the phenylalanine-restricted diet in late-diagnosed individuals with phenylketonuria. *Mol Genet Metab* 1999 Jun;67(2):148-55.
- Koch R, Schaeffler G, Shaw NF. Results of loading doses of aspartame by two phenylketonuric (PKU) children compared with two normal children. *J Toxicol Environ Health* 1976 Nov;2(2):459-69.
- Koch R, Shaw KN, Acosta PB, Fishler K, Schaeffler G, Wenz E, Wohlers A. An approach to management of phenylketonuria. *J Pediatr* 1970 Jun;76(6):815-28.
- Koch R, Shaw KN, Williamson M, Haber M. Use of aspartame in phenylketonuric heterozygous adults. *J Toxicol Environ Health* 1976 Nov;2(2):453-7.
- Koch R, Wenz E. Phenylketonuria. *Annu Rev Nutr* 1987;7:117-35.
- Koch R, Wenz E, Azen C, Friedman EG, Levy H, Rohr F, Rouse B, Castiglioni L, Matalon R, Michals-Matalon K, et al. The effect of nutrient intake on pregnancy outcome in maternal phenylketonuria. *Ann N Y Acad Sci* 1993 Mar 15;678:348-9.
- Koch R, Wenz E, Bauman C, Friedman EG, Azen C, Fishler K, Heiter W. Treatment outcome of maternal phenylketonuria. *Acta Paediatr Jpn* 1988 Aug;30(4):410-6.
- Koch RK. Issues in newborn screening for phenylketonuria. *Am Fam Physician* 1999 Oct 1;60(5):1462-6.
- Koepp P, Hinze G, Held KR. [Growth and nutrition: long term follow-up in early treated phenylketonuric and hyperphenylalaninemic children (author's transl)]. *Monatsschr Kinderheilkd* 1981 Mar;129(3):154-9. (Ger).
- Koizumi S, Tanaka F, Kaneda N, Kano K, Nagatsu T. Nanosecond pulse fluorometry of conformational change in phenylalanine hydroxylase associated with activation. *Biochemistry* 1988 Jan 26;27(2):640-6.
- Kolodny EH, Yatziv S. Laboratory approaches for inherited neurometabolic diseases. *Dev Med Child Neurol* 1985 Apr;27(2):252-7.
- Komrower GM, Sardharwalla IB, Coutts JM, Ingham D. Management of maternal phenylketonuria: an emerging clinical problem. *Br Med J* 1979 May 26;1(6175):1383-7.
- Konecki DS, Wang Y, Trefz FK, Lichter-Konecki U, Woo SL. Structural characterization of the 5' regions of the human phenylalanine hydroxylase gene. *Biochemistry* 1992 Sep 8;31(35):8363-8.
- Korinthenberg R, Ullrich K, Fullenkemper F. Evoked potentials and electroencephalography in adolescents with phenylketonuria. *Neuropediatrics* 1988 Nov;19(4):175-8.
- Korpi ER. Aromatic amino acid incorporation into proteins in rat brain slices: influences of other amino acids affecting transport. *Acta Physiol Scand* 1981 Aug;112(4):353-8.
- Koslacz-Folga A, Pakszys M, Cabalska B, Zdanowska W. [Evaluation of the maturity of the bioelectrical activity of the brain of infants with phenylketonuria during sleep]. *Probl Med Wieku Rozwoj* 1982;11:27-37. (Pol).
- Kowlessur D, Citron BA, Kaufman S. Recombinant human phenylalanine hydroxylase: novel regulatory

- and structural properties. *Arch Biochem Biophys* 1996 Sep 1;333(1):85-95.
- Kowlessur D, Yang XJ, Kaufman S. Further studies of the role of Ser-16 in the regulation of the activity of phenylalanine hydroxylase. *Proc Natl Acad Sci U S A* 1995 May 23;92(11):4743-7.
- Krauch G, Muller E, Anninos A, Bremer HJ. Comparison of the protein quality of dietetically treated phenylketonuria patients with the recommendations of the WHO Expert Consultation. *Eur J Pediatr* 1996 Jul;155 Suppl 1:S153-7.
- Krempf M, Hoerr RA, Pelletier VA, Marks LM, Gleason R, Young VR. An isotopic study of the effect of dietary carbohydrate on the metabolic fate of dietary leucine and phenylalanine. *Am J Clin Nutr* 1993 Feb;57(2):161-9.
- Krywawych S, Haseler M, Brenton DP. Theoretical and practical aspects of preventing fetal damage in women with phenylketonuria. *Nestle Nutr Workshop Ser* 1991;24:125-35.
- Laberge C, Ferreira P, Grenier A, Laframboise R, Morissette J. [Hyperphenylalaninemias. The Canadian and Quebec experience]. *Arch Fr Pediatr* 1987;44 Suppl 1:643-7. (Fre).
- Labrune P, Brunet C, Rey F, Pons JC, Dauphin F, Leroy D, Odievre M. [Problems stemming from pregnancy in a woman with phenylketonuria]. *Arch Fr Pediatr* 1989 Aug-Sep;46(7):509-11. (Fre).
- LaBuda CJ, Hale RL. Anxiety in mice following acute aspartame and ethanol exposure. *Alcohol* 2000;20:69-74.
- Laguna Serrano C. [Congenital errors of metabolism: phenylketonuria and hyperphenylalaninemias]. *An R Acad Nac Med (Madr)* 1982;99(4):783-814. (Spa).
- Lahdesmaki P. Inhibition of protein and aminoacyl-tRNA synthesis, and binding and transport sites for aromatic amino acids in the brain in vitro with aromatic acids. *Int J Neurosci* 1984 Mar;23(1):1-13.
- Laing S. Special feeds for special infants: 1. The baby with a metabolic or allergic disorder. *Prof Care Mother Child* 1995;5(5):123, 126-7.
- Lajtha A, Reilly MA, Dunlop DS. Aspartame consumption: lack of effects on neural function. *J Nutr Biochem* 1994 Jun;5(6):266-83.
- Landi A, Ducati A, Villani R, Longhi R, Riva E, Rodocanachi C, Giovannini M. Pattern-reversal visual evoked potentials in phenylketonuric children. *Childs Nerv Syst* 1987;3(5):278-81.
- Lane JD, Schone B, Langenbeck U, Neuheff V. Characterization of experimental phenylketonuria. Augmentation of hyperphenylalaninemia with alpha-methylphenylalanine and p-chlorophenylalanine. *Biochim Biophys Acta* 1980 Jan 17;627(2):144-56.
- Lang MJ, Koch R, Fishler K, Baker R. Nonphenylketonuric hyperphenylalaninemia. *Am J Dis Child* 1989 Dec;143(12):1464-6. Published erratum appears in *Am J Dis Child* 1990 Apr;144(4):484.
- Langar H, Guillaume J, Metailler R, Fauconneau B. Augmentation of protein synthesis and degradation by poor dietary amino acid balance in European sea bass (*Dicentrarchus labrax*). *J Nutr* 1993 Oct;123(10):1754-61.
- Laptev AV, Chestkov VV. [The dynamics of the properties of liver phenylalanine hydroxylase in human embryogenesis]. *Ontogenez* 1990 Mar-Apr;21(2):138-44. (Rus).
- Laurence JS, Blanpain C, Burgner JW, Parmentier M, LiWang PJ. CC chemokine MIP-1beta can function as a monomer and depends on Phe13 for receptor binding. *Biochemistry* 2000 Mar 28;39(12):3401-9.
- Leandro P, Rivera I, Lechner MC, de Almeida IT, Konecki D. The V388M mutation results in a kinetic variant form of phenylalanine hydroxylase. *Mol Genet Metab* 2000 Mar;69(3):204-12.
- Lebedev BV, Blumina MG, Ladodo KS. [Pressing problems of phenylketonuria]. *Pediatriia* 1980 Jun;(6):65-7. (Rus).
- Ledley FD. Somatic gene therapy for human disease: a problem of eugenics? *Trends Genet* 1987 Apr;3(4):112-5.
- Ledley FD, Grenett HE, Dunbar BS, Woo SL. Mouse phenylalanine hydroxylase. Homology and divergence from human phenylalanine hydroxylase. *Biochem J* 1990 Apr 15;267(2):399-405.
- Ledley FD, Grenett HE, Woo SL. Biochemical characterization of recombinant human phenylalanine hydroxylase produced in *Escherichia coli*. *J Biol Chem* 1987 Feb 15;262(5):2228-33.
- Ledley FD, Woo SL. P-chlorophenylalanine does not inhibit production of recombinant human phenylalanine hydroxylase in NIH3T3 cells or *E. coli*. *Biochem Biophys Res Commun* 1987 Jan 30;142(2):302-8.
- Ledley FD, Woo SLC. Prospects for somatic gene therapy of phenylketonuria. *UCLA Symp Mol Cell Biol* 1987;55:565-79.

- Leeming RJ, Hall SK, Surplice IM, Green A. Relationship between plasma and red cell bipterins in acute and chronic hyperphenylalaninaemia. *J Inher Metab Dis* 1990;13(6):883-7.
- Legido A, Tonyes L, Carter D, Schoemaker A, Di George A, Grover WD. Treatment variables and intellectual outcome in children with classic phenylketonuria. A single-center-based study. *Clin Pediatr (Phila)* 1993 Jul;32(7):417-25.
- Leititis JU, Stahl M, Tackmann W, Wick H, Wildberg A. Homozygous hypobetalipoproteinaemia and phenylketonuria. *Eur J Pediatr* 1985 Jul;144(2):174-6.
- Lenke RR, Koch R, Fishler K, Platt LD. Tyrosine supplementation during pregnancy in a woman with classical phenylketonuria. A case report. *J Reprod Med* 1983 Jun;28(6):411-4.
- Lenke RR, Levy HL. Maternal phenylketonuria and hyperphenylalaninemia. An international survey of the outcome of untreated and treated pregnancies. *N Engl J Med* 1980 Nov 20;303(21):1202-8.
- Lenke RR, Levy HL. Maternal phenylketonuria--results of dietary therapy. *Am J Obstet Gynecol* 1982 Mar 1;142(5):548-53.
- Leuschner RG, Kurihara R, Hammes WP. Formation of biogenic amines by proteolytic enterococci during cheese ripening. *J Sci Food Agric* 1999 Jun;79(8):1141-4.
- Leuzzi V, Gualdi GF, Fabbrizi F, Trasimeni G, Di Biasi C, Antonozzi I. Neuroradiological (MRI) abnormalities in phenylketonuric subjects: clinical and biochemical correlations. *Neuropediatrics* 1993 Dec;24(6):302-6.
- Leuzzi V, Trasimeni G, Gualdi GF, Antonozzi I. Biochemical, clinical and neuroradiological (MRI) correlations in late-detected PKU patients. *J Inher Metab Dis* 1995;18(5):624-34.
- Levy HL. Genetic screening. *Adv Hum Genet* 1973;4:1-104.
- Levy HL. Maternal phenylketonuria. Review with emphasis on pathogenesis. *Enzyme* 1987;38(1-4):312-20.
- Levy HL. Maternal PKU. *Prog Clin Biol Res* 1985;177:109-22.
- Levy HL. Nutritional therapy for selected inborn errors of metabolism. *J Am Coll Nutr* 1989;8 Suppl:54S-60S.
- Levy HL. Phenylketonuria--1986. *Pediatr Rev* 1986 Mar;7(9):269-75.
- Levy HL. Phenylketonuria: old disease, new approach to treatment. *Proc Natl Acad Sci U S A* 1999 Mar 2;96(5):1811-3. Comment on: *Proc Natl Acad Sci U S A* 1999 Mar 2;96(5):2339-44.
- Levy HL. Reply to SP Bessman [letter]. *Am J Clin Nutr* 1998 Mar;67(3):488. Comment on: *Am J Clin Nutr* 1998 Mar;67(3):357-8.
- Levy HL. Reproductive effects of maternal metabolic disorders: implications for pediatrics and obstetrics. *Turk J Pediatr* 1996 Jul-Sep;38(3):335-44.
- Levy HL. Treatment of phenylketonuria. *Prog Clin Biol Res* 1979;34:171-82.
- Levy HL, Goss BS, Sullivan DK, Michals-Matalon K, Dobbs JM, Guldberg P, Guttler F. Maternal mild hyperphenylalaninemia: results of treated and untreated pregnancies in two sisters. *J Pediatr* 1994 Sep;125(3):467-9.
- Levy HL, Kaplan GN, Erickson AM. Comparison of treated and untreated pregnancies in a mother with phenylketonuria. *J Pediatr* 1982 Jun;100(6):876-80.
- Levy HL, Karolkewicz V, Houghton SA, MacCreedy RA. Screening the "normal" population in Massachusetts for phenylketonuria. *N Engl J Med* 1970 Jun 25;282(26):1455-8.
- Levy HL, Lobbregt D, Barnes PD, Poussaint TY. Maternal phenylketonuria: magnetic resonance imaging of the brain in offspring. *J Pediatr* 1996 Jun;128(6):770-5.
- Levy HL, Shih VE, Karolkewicz V, French WA, Carr JR, Cass V, Kennedy JL Jr, MacCreedy RA. Persistent mild hyperphenylalaninemia in the untreated state. A prospective study. *N Engl J Med* 1971 Aug 19;285(8):424-9.
- Levy HL, Waisbren SE. PKU in adolescents: rationale and psychosocial factors in diet continuation. *Acta Paediatr Suppl* 1994 Dec;407:92-7.
- Levy HL, Waisbren SE. The PKU paradigm: the mixed results from early dietary treatment. *UCLA Symp Mol Cell Biol* 1987;55:539-51.
- Lewis V, Krause S, Myers C. Public and private academic medical partnerships in improving nutritional management in phenylketonuria [letter]. *Am J Public Health* 1997 Aug;87(8):1379.
- Leyton M, Young SN, Pihl RO, Etezadi S, Lauze C, Blier P, Baker GB, Benkelfat C. Effects on mood of acute phenylalanine/tyrosine depletion in healthy women. *Neuropsychopharmacology* 2000 Jan;22(1):52-63.

- Liappis N, Pohl B, Weber HP, el-Karkani H. [Free amino acids in the saliva of children with phenylketonuria]. *Klin Padiatr* 1986 Jan-Feb;198(1):25-8. (Ger).
- Liechty EA, Boyle DW, Moorehead H, Auble L, Denne SC. Aromatic amino acids are utilized and protein synthesis is stimulated during amino acid infusion in the ovine fetus. *J Nutr* 1999 Jun;129(6):1161-6.
- Lines DR. Aspartame doses for phenylketonuria [letter]. *J Nutr* 1981 Sep;111(9):1688-90.
- Link R. Phenylketonuria diet in adolescents--energy and nutrient intake--is it adequate? *Postgrad Med J* 1989;65 Suppl 2:S21-4.
- Lipinska L, Laskowska-Klita T, Cabalska B. Riboflavin status in phenylketonuric patients in the course of dietary treatment. *J Inher Metab Dis* 1994;17(2):242.
- Lipson A, Masters H, O'Halloran M, Thompson S, Coveney J, Yu J. The selenium status of children with phenylketonuria: results of selenium supplementation. *Aust Paediatr J* 1988 Apr;24(2):128-31.
- Liu TJ, Kay MA, Darlington GJ, Woo SL. Reconstitution of enzymatic activity in hepatocytes of phenylalanine hydroxylase-deficient mice. *Somat Cell Mol Genet* 1992 Jan;18(1):89-96.
- Lloyd B, Robson E, Smith I, Clayton BE. Blood selenium concentrations and glutathione peroxidase activity. *Arch Dis Child* 1989 Mar;64(3):352-6.
- Lluch Fernandez MD, Ramos Sanchez I, Marchante Cobos C, Perez Perez G, Martinez Martinez JJ, Estefania Gallardo C. [Phenylketonuria. Treatment and developmental control]. *An Esp Padiatr* 1988 Apr;28(4):327-30. (Spa).
- Lo GS, Liang SC, Raha SR, Hunter JB, Longenecker JB. Biochemical and neurological effects of an experimental phenylketonuria-like condition in infant rats during the first 2 weeks after birth. *Am J Clin Nutr* 1981 Apr;34(4):498-506.
- Lo GS, Longenecker JB. Induction of an experimental phenylketonuria-like condition in infant rats during the first 2 weeks after birth. *Am J Clin Nutr* 1981 Apr;34(4):490-7.
- Lombeck I, Ebert KH, Kasperek K, Feinendegen LE, Bremer HJ. Selenium intake of infants and young children, healthy children and dietetically treated patients with phenylketonuria. *Eur J Padiatr* 1984 Dec;143(2):99-102.
- Longhi R, Rottoli A, Vittorelli A, Zecchini G, Bonabitacola T, Bertassi F, Riva E, Giovannini M. Trace elements nutrition in hyperphenylalaninemic patients. Long-term follow up study. *Eur J Padiatr* 1987;146 Suppl 1:A32-7.
- Loo YH, Hyde KR, Lin FH, Wisniewski HM. Cerebral biochemical abnormalities in experimental maternal phenylketonuria: gangliosides and sialoglycoproteins. *Life Sci* 1985 Dec 2;37(22):2099-109.
- Lorijn RH, Sengers RC, Trijbels JM. Maternal phenylketonuria: the outcome of pregnancy. *Eur J Obstet Gynecol Reprod Biol* 1981 Nov;12(5):281-5.
- Lott JW. PKU: a nursing update. *J Padiatr Nurs* 1988 Feb;3(1):29-34.
- Lou H. Large doses of tryptophan and tyrosine as potential therapeutic alternative to dietary phenylalanine restriction in phenylketonuria [letter]. *Lancet* 1985 Jul 20;2(8447):150-1.
- Lou HC. Dopamine precursors and brain function in phenylalanine hydroxylase deficiency. *Acta Paediatr Suppl* 1994 Dec;407:86-8.
- Lou HC, Guttler F, Lykkelund C, Bruhn P, Niederwieser A. Decreased vigilance and neurotransmitter synthesis after discontinuation of dietary treatment for phenylketonuria in adolescents. *Eur J Padiatr* 1985 May;144(1):17-20.
- Lou HC, Lykkelund C, Gerdes AM, Udesen H, Bruhn P. Increased vigilance and dopamine synthesis by large doses of tyrosine or phenylalanine restriction in phenylketonuria. *Acta Paediatr Scand* 1987 Jul;76(4):560-5.
- Lou HC, Toft PB, Andresen J, Mikkelsen I, Olsen B, Guldberg P, Guttler F. Unchanged MRI of myelin in adolescents with PKU supplied with non-phe essential amino acids after dietary relaxation. *Acta Paediatr* 1994 Dec;83(12):1312-4.
- Lovenberg WM. Biochemical regulation of brain function. *Nutr Rev* 1986 May;44 Suppl:6-11.
- Lowitzer AC. Maternal phenylketonuria: cause for concern among women with PKU. *Res Dev Disabil* 1987;8(1):1-14.
- Lucas A, Baker BA, Morley RM. Hyperphenylalaninaemia and outcome in intravenously fed preterm neonates. *Arch Dis Child* 1993 May;68(5 Spec No):579-83.
- Ludolph AC, Ullrich K, Nedjat S, Masur H, Bick U. Neurological outcome in 22 treated adolescents with hyperphenylalaninemia. A clinical and electrophysiological study. *Acta Neurol Scand* 1992 Apr;85(4):243-8.

- Ludolph AC, Vetter U, Ullrich K. Studies of multimodal evoked potentials in treated phenylketonuria: the pattern of vulnerability. *Eur J Pediatr* 1996 Jul;155 Suppl 1:S64-8.
- Luke B. Maternal-fetal nutrition. *Clin Obstet Gynecol* 1994 Mar;37(1):93-109.
- Luke B, Johnson TR, Petrie RH. Clinical maternal-fetal nutrition. New York: Little, Brown; 1993. Maternal phenylketonuria; p. 251-68.
- Lunde HA, Lenney JF, Halvorsen S, Gjessing L. Serum carnosinase in blood and homocarnosine in CSF of patients with Folling's disease (PKU). *J Oslo City Hosp* 1987 Apr;37(4):29-33.
- Lupinovich VL, Kopylova NV. [Blood serum proteins studied by a method of polyacrylamide gel disc electrophoresis in children with phenylketonuria]. *Vopr Pitan* 1980 Nov-Dec;(6):24-6. (Rus).
- Lutz P, Schmidt H, Frey G, Bickel H. Standardized loading test with protein for the differentiation of phenylketonuria from hyperphenylalaninaemia. *J Inherit Metab Dis* 1982;5(1):29-35.
- Lykkelund C, Nielsen JB, Lou HC, Rasmussen V, Gerdes AM, Christensen E, Guttler F. Increased neurotransmitter biosynthesis in phenylketonuria induced by phenylalanine restriction or by supplementation of unrestricted diet with large amounts of tyrosine. *Eur J Pediatr* 1988 Dec;148(3):238-45.
- Lynch BC, Pitt DB, Maddison TG, Wraith JE, Danks DM. Maternal phenylketonuria: successful outcome in four pregnancies treated prior to conception. *Eur J Pediatr* 1988 Oct;148(1):72-5.
- Maas JA, France J, Dijkstra J, Bannink A, McBride BW. Application of a mechanistic model to study competitive inhibition of amino acid uptake by the lactating bovine mammary gland. *J Dairy Sci* 1998 Jun;81(6):1724-34.
- Maas JA, France J, McBride BW. Model of milk protein synthesis. A mechanistic model of milk protein synthesis in the lactating bovine mammary gland. *J Theor Biol* 1997 Aug 7;187(3):363-78.
- Mabry CC. Status report on phenylketonuria treatment: 1990 [editorial]. *Am J Dis Child* 1991 Jan;145(1):33. Comment on: *Am J Dis Child* 1991 Jan;145(1):35-9.
- MacCready RA, Levy HL. The problem of maternal phenylketonuria. *Am J Obstet Gynecol* 1972 May 1;113(1):121-8.
- MacDonald A, Harris G, Rylance G, Asplin D, Booth IW. Abnormal feeding behaviours in phenylketonuria. *J Hum Nutr Diet* 1997 Jun;10(3):163-70.
- MacDonald A, Rylance G, Hall SK, Asplin D, Booth IW. Factors affecting the variation in plasma phenylalanine in patients with phenylketonuria on diet. *Arch Dis Child* 1996 May;74(5):412-7.
- MacDonald A, Rylance GW, Asplin D, Hall SK, Booth IW. Does a single plasma phenylalanine predict quality of control in phenylketonuria? *Arch Dis Child* 1998 Feb;78(2):122-6.
- MacDonald A, Rylance GW, Asplin DA, Hall K, Harris G, Booth IW. Feeding problems in young PKU children. *Acta Paediatr Suppl* 1994 Dec;407:73-4.
- Mackey SA, Berlin CM Jr. Effect of dietary aspartame on plasma concentrations of phenylalanine and tyrosine in normal and homozygous phenylketonuric patients. *Clin Pediatr (Phila)* 1992 Jul;31(7):394-9.
- Maenz DD, Chenu C, Berteloot A. Heterotropic effects of dipolar amino acids on the activity of the anionic amino acid transport system X-(AG) in rabbit jejunal brush-border membrane vesicles. *J Biol Chem* 1993 Jul 25;268(21):15361-7.
- Maher TJ, Glaeser BS, Wurtman RJ. Diurnal variations in plasma concentrations of basic and neutral amino acids and in red cell concentrations of aspartate and glutamate: Effects of dietary protein intake. *Am J Clin Nutr* 1984 May;39(5):722-9.
- Mahle M, Schmidt H, Lutz P, Wendel U. [Initiation of treatment following screening for phenylketonuria]. *Monatsschr Kinderheilkd* 1984 Nov;132(11):865-6. (Ger).
- Marchini JS, Cortiella J, Hiramatsu T, Castillo L, Chapman TE, Young VR. Phenylalanine and tyrosine kinetics for different patterns and indispensable amino acid intakes in adult humans. *Am J Clin Nutr* 1994 Jul;60(1):79-86.
- Marino MA. Developing and testing a programmed instruction unit on PKU. *J Am Diet Assoc* 1980 Jan;76(1):29-34.
- Martinez A, Andersson KK, Haavik J, Flatmark T. EPR and ¹H-NMR spectroscopic studies on the paramagnetic iron at the active site of phenylalanine hydroxylase and its interaction with substrates and inhibitors. *Eur J Biochem* 1991 Jun 15;198(3):675-82.
- Martinez A, Haavik J, Flatmark T. Cooperative homotropic interaction of L-noradrenaline with the catalytic site of phenylalanine 4-monooxygenase. *Eur J Biochem* 1990 Oct 5;193(1):211-9.

- Martinez A, Knappskog PM, Olafsdottir S, Doskeland AP, Eiken HG, Svebak RM, Bozzini M, Apold J, Flatmark T. Expression of recombinant human phenylalanine hydroxylase as fusion protein in *Escherichia coli* circumvents proteolytic degradation by host cell proteases. Isolation and characterization of the wild-type enzyme. *Biochem J* 1995 Mar 1;306 (Pt 2):589-97.
- Martinez A, Olafsdottir S, Flatmark T. The cooperative binding of phenylalanine to phenylalanine 4-monooxygenase studied by 1H-NMR paramagnetic relaxation. Changes in water accessibility to the iron at the active site upon substrate binding. *Eur J Biochem* 1993 Jan 15;211(1-2):259-66.
- Matalon R, Michals K, Azen C, Friedman E, Koch R, Rouse B, Hanley WB, de la Cruz F. Maternal PKU Collaborative Study: pregnancy outcome and postnatal head growth. *J Inherit Metab Dis* 1994;17(3):353-5.
- Matalon R, Michals K, Azen C, Friedman EG, Koch R, Wenz E, Levy H, Rohr F, Rouse B, Castiglioni L, et al. Maternal PKU collaborative study: the effect of nutrient intake on pregnancy outcome. *J Inherit Metab Dis* 1991;14(3):371-4.
- Matalon R, Michals K, Gleason L. Maternal PKU: strategies for dietary treatment and monitoring compliance. *Ann N Y Acad Sci* 1986;477:223-30.
- Maternal Phenylketonuria Collaborative Study: a status report. *Nutr Rev* 1994 Nov;52(11):390-3.
- Mathur R, Manchanda SK. Ontogeny of phenylalanine (endogenous cholecystokinin) induced modulation of food intake in normal and undernourished rats. *Prog Neuropsychopharmacol Biol Psychiatry* 1991;15(3):405-13.
- Matsueda S, Niiyama Y. The effects of excess amino acids on maintenance of pregnancy and fetal growth in rats (Threonine, methionine, valine, isoleucine, leucine, tyrosine, phenylalanine, tryptophan, lysine). *J Nutr Sci Vitaminol* 1982;28(5):557-73.
- Matthews WS, Barabas G, Cusack E, Ferrari M. Social quotients of children with phenylketonuria before and after discontinuation of dietary therapy. *Am J Ment Defic* 1986 Jul;91(1):92-4.
- McArthur KE, Isenberg JI, Hogan DL, Dreier SJ. Intravenous infusion of L-isomers of phenylalanine and tryptophan stimulate gastric acid secretion at physiologic plasma concentrations in normal subjects and after parietal cell vagotomy. *J Clin Invest* 1983 May;71(5):1254-62.
- McCabe ER, McCabe L. Issues in the dietary management of phenylketonuria: breast-feeding and trace-metal nutriture. *Ann N Y Acad Sci* 1986;477:215-22.
- McCabe ER, Nord AM, Ernest A, McCabe L. Evaluation of a phenylalanine-free product for treatment of phenylketonuria. *Am J Dis Child* 1987 Dec;141(12):1327-9.
- McCabe L, Ernest AE, Neifert MR, Yannicelli S, Nord AM, Garry PJ, McCabe ER. The management of breast feeding among infants with phenylketonuria. *J Inherit Metab Dis* 1989;12(4):467-74.
- McDonald JD, Dyer CA, Gailis L, Kirby ML. Cardiovascular defects among the progeny of mouse phenylketonuria females. *Pediatr Res* 1997 Jul;42(1):103-7.
- McDowall IL, Palwala Y, Fisher MJ. Differential effects of streptozotocin-induced diabetes on phenylalanine hydroxylase protein and mRNA abundance in isolated rat liver cells. *Int J Biochem Cell Biol* 1996 Jul;28(7):761-70.
- McMurry MP, Chan GM, Leonard CO, Ernst SL. Bone mineral status in children with phenylketonuria--relationship to nutritional intake and phenylalanine control. *Am J Clin Nutr* 1992 May;55(5):997-1004.
- McSwigan JD, Vorhees CV, Brunner RL, Butcher RE, Berry HK. Amelioration of maze deficits from induced hyperphenylalaninemia in adult rats using valine, isoleucine, and leucine (Phenylketonuria, phenylalanine-restricted diet). *Behav Neural Biol* 1981 Nov;33(3):378-84.
- Medovar BI. [Effect of starvation on age-associated characteristics of phenylalanine metabolism in an experiment]. *Vopr Pitan* 1982 Jul-Aug;(4):52-5. (Rus).
- Menzel H, Steiner G, Lombeck I, Ohnesorge FK. Glutathione peroxidase and glutathione S-transferase activity of platelets. *Eur J Pediatr* 1983 Jun-Jul;140(3):244-7.
- Messer SS. PKU: a mother's perspective. *Pediatr Nurs* 1985 Mar-Apr;11(2):121-3.
- Michals K. Educational behavioral program for PKU. Final report 1988 Nov 1- 1991 Oct 31. Chicago: Illinois University at Chicago, Department of Nutrition and Medical Dietetics; 1993 Nov. 47p. Contract No.: MCH/CCS-94/03. Available from: NTIS, Springfield, VA; PB95-209516. Sponsored by US Maternal and Child Health Bureau, Rockville, MD.
- Michals K, Acosta PB, Austin V, Castiglioni L, Rohr F, Wenz E, Azen C. Nutrition and reproductive outcome in maternal phenylketonuria. *Eur J Pediatr* 1996 Jul;155 Suppl 1:S165-8.
- Michals K, Azen C, Acosta P, Koch R, Matalon R. Blood phenylalanine levels and intelligence of 10-

- year-old children with PKU in the National Collaborative Study. *J Am Diet Assoc* 1988 Oct;88(10):1226-9.
- Michals K, Dominik M, Schuett V, Brown E, Matalon R. Return to diet therapy in patients with phenylketonuria. *J Pediatr* 1985 Jun;106(6):933-6.
- Michals K, Lopus M, Matalon R. Phenylalanine metabolites as indicators of dietary compliance in children with phenylketonuria. *Biochem Med Metab Biol* 1988 Feb;39(1):18-23.
- Michals Matalon K, Acosta P, Azen C, Matalon R. Congenital heart disease in maternal phenylketonuria: effects of blood phenylalanine and nutrient intake. *Ment Retard Dev Disabil Res Rev* 1999;5(2):122-4.
- Michel U, Schmidt E, Batzler U. Results of psychological testing of patients aged 3-6 years. *Eur J Pediatr* 1990;149 Suppl 1:S34-8.
- Michels VV, Justice CL. Treatment of phenylketonuria during pregnancy. *Clin Genet* 1982 Feb;21(2):141-4.
- Mikaeloff Y, Pinton F, Sevin C, Dhondt JL, Ponsot G. [Progressive convulsive encephalopathy: considering a abnormality of bipterin metabolism]. *Arch Pediatr* 1999 Jul;6(7):759-61. (Fre).
- Millamena OM, Teruel MB, Kanazawa A, Teshima S. Quantitative dietary requirements of postlarval tiger shrimp, *Penaeus monodon*, for histidine, isoleucine, leucine, phenylalanine and tryptophan. *Aquaculture* 1999 Sep 1;179(1-4):169-79.
- Miller M, Hasson R, Resnick O. Availability of phenylalanine and tyrosine for brain norepinephrine synthesis in developmentally protein-malnourished rats. *Exp Neurol* 1982 Jul;77(1):163-78.
- Miller ME, Plumeau P, Blakely E. Elevated phenylalanine concentrations in benign hyperphenylalaninemia from evaporated milk feedings. *Clin Pediatr (Phila)* 1993 Feb;32(2):124-5.
- Miller SA, Chopra JG. Problems with human milk and infant formulas. *Pediatrics* 1984 Oct;74(4 Pt 2):639-47.
- Millner BN. Insurance coverage of special foods needed in the treatment of phenylketonuria. *Public Health Rep* 1993 Jan-Feb;108(1):60-5.
- Milner JA, Garton RL, Burns RA. Phenylalanine and tyrosine requirements of immature beagle dogs. *J Nutr* 1984 Dec;114(12):2212-6.
- Milstien S, Holtzman NA, O'Flynn ME, Thomas GH, Butler IJ, Kaufman S. Hyperphenylalaninemia due to dihydropteridine reductase deficiency. Assay of the enzyme in fibroblasts from affected infants, heterozygotes, and in normal amniotic fluid cells. *J Pediatr* 1976 Nov;89(5):763-6.
- Milstien S, Jaffe H, Kowlessur D, Bonner TI. Purification and cloning of the GTP cyclohydrolase I feedback regulatory protein, GFRP. *J Biol Chem* 1996 Aug 16;271(33):19743-51.
- Mims SK, McIntyre CW, Murray ME. An analysis of visual motor problems in children with dietary treated phenylketonuria. *Educ Psychol Res* 1983 Spring;3(2):111-21.
- Miranda da Cruz BD, Seidler H, Widhalm K. Iron status and iron supplementation in children with classical phenylketonuria. *J Am Coll Nutr* 1993 Oct;12(5):531-6.
- Missiou-Tsagaraki S, Soulpi K, Loumakou M. Phenylketonuria in Greece: 12 years' experience. *J Ment Defic Res* 1988 Aug;32 (Pt 4):271-87.
- Mitton SG, Burston D, Brueton MJ. Hyperphenylalanemia in parenterally fed newborn infants [letter]. *Lancet* 1988 Dec 24-31;2(8626-8627):1497-8.
- Miyahara M, Ito H, Nagasawa T, Kamimura T, Saito A, Kariya M, Izumi K, Kitamura M, Toyoda M, Saito Y. Determination of o-tyrosine production in aqueous solutions of phenylalanine irradiated with gamma ray, using high performance liquid chromatography with automated pre-column derivatization and LASER fluorometric detection. *J Health Sci* 2000;46(3):192-9.
- Moller HE, Vermathen P, Ullrich K, Weglage J, Koch HG, Peters PE. In-vivo NMR spectroscopy in patients with phenylketonuria: changes of cerebral phenylalanine levels under dietary treatment. *Neuropediatrics* 1995 Aug;26(4):199-202.
- Moller N, Meek S, Bigelow M, Andrews J, Nair KS. The kidney is an important site for in vivo phenylalanine-to-tyrosine conversion in adult humans: A metabolic role of the kidney. *Proc Natl Acad Sci U S A* 2000 Feb 1;97(3):1242-6.
- Moller SE. Neutral amino acid plasma levels in healthy subjects: effect of complex carbohydrate consumed along with protein. *J Neural Transm* 1989;76(1):55-63.
- Monch E, Herrmann ME, Brosicke H, Schoffer A, Keller M. Utilisation of amino acid mixtures in adolescents with phenylketonuria. *Eur J Pediatr* 1996 Jul;155 Suppl 1:S115-20.
- Monch E, Kneer J, Jakobs C, Arnold M, Diehl H, Batzler U. Examination of urine metabolites in the newborn period and during protein loading tests at 6

- months of age--Part 1. *Eur J Pediatr* 1990;149 Suppl 1:S17-24.
- More pointers on PKU [letter]. *MCN Am J Matern Child Nurs* 1987 Jul-Aug;12(4):239.
- Morris AF, Holton JB, Burman D, Colley JR. Phenylalanine and tyrosine levels in newborn screening blood samples. *Arch Dis Child* 1983 Apr;58(4):271-5.
- Motoda K, Takata M, Kiura K, Nakamura I, Harada M. SHP-1/immunoreceptor tyrosine-based inhibition motif-independent inhibitory signalling through murine natural killer cell receptor Ly-49A in a transfected B-cell line. *Immunology* 2000;100(3):370-7.
- Motta A, Laursen RA, Llinas M, Tulinsky A, Park CH. Complete assignment of the aromatic proton magnetic resonance spectrum of the kringle 1 domain from human plasminogen: structure of the ligand-binding site. *Biochemistry* 1987 Jun 30;26(13):3827-36.
- Motzfeldt K, Lilje R, Nylander G. Breastfeeding in phenylketonuria. *Acta Paediatr Suppl* 1999 Dec;88(432):25-7.
- Muller E. [Diet therapy in phenylketonuria]. *Dtsch Krankenpflegez* 1993 Feb;46(2):87-92. (Ger).
- Munoz M, Emery PW, Peran S, Mann GE. Dietary regulation of amino acid transport activity in the exocrine pancreatic epithelium. *Biochim Biophys Acta* 1988 Nov 22;945(2):273-80.
- Muntau AC, Beblo S, Koletzko B. [Phenylketonuria and hyperphenylalaninemia]. *Monatsschr Kinderheilkd* 2000;148(2):179-93. (Ger).
- Muramatsu T, Salter DN, Coates ME. Protein turnover of breast muscle in germ-free and conventional chicks. *Br J Nutr* 1985 Jul;54(1):131-45.
- Murphy D, Saul I, Kirby M. Maternal phenylketonuria and phenylalanine restricted diet. Studies of 7 pregnancies and of offsprings produced. *Ir J Med Sci* 1985 Feb;154(2):66-70.
- Nagasaki Y, Matsubara Y, Takano H, Fujii K, Senoo M, Akanuma J, Takahashi K, Kure S, Hara M, Kanegae Y, Saito I, Narisawa K. Reversal of hypopigmentation in phenylketonuria mice by adenovirus-mediated gene transfer. *Pediatr Res* 1999 Apr;45(4 Pt 1):465-73.
- Nagata S, Maru I, Ishihara F, Misono H, Nagasaki S. Cloning and expression of endo-beta-1,3-glucanase gene from *Flavobacterium dormitor* in *Escherichia coli* and characterization of the gene product. *Agric Biol Chem* 1990 Oct;54(10):2675-80.
- Nair KS, Ford GC, Ekberg K, Fernqvist-Forbes E, Wharen J. Protein dynamics in whole body and in splanchnic and leg tissues in type I diabetic patients. *J Clin Invest* 1995 Jun;95(6):2926-37.
- Nakhost Z, Hsieh DS, Shih V, Rha CK. Synthesis of low-phenylalanine polypeptides. *Int J Pept Protein Res* 1982 Sep;20(3):267-75.
- Naughten E, Saul IP. Maternal phenylketonuria--the Irish experience. *J Inher Metab Dis* 1990;13(4):658-64.
- Naughten ER. Continuation vs discontinuation of diet in phenylketonuria. *Eur J Clin Nutr* 1989;43 Suppl 1:7-12.
- Naughten ER, Kiely B, Saul I, Murphy D. Phenylketonuria: outcome and problems in a diet-for-life clinic. *Eur J Pediatr* 1987;146 Suppl 1:A23-4.
- Neckameyer WS, White K. A single locus encodes both phenylalanine hydroxylase and tryptophan hydroxylase activities in *Drosophila*. *J Biol Chem* 1992 Feb 25;267(6):4199-206.
- Nehls U, Ecke M, Hampp R. Sugar- and nitrogen-dependent regulation of an *Amanita muscaria* phenylalanine ammonium lyase gene. *J Bacteriol* 1999 Mar;181(6):1931-3.
- Netley C, Hanley WB, Rudner HL. Phenylketonuria and its variants: observations on intellectual functioning. *Can Med Assoc J* 1984 Oct 1;131(7):751-5.
- Nielsen JB, Lou HC, Guettler F. Effects of diet discontinuation and dietary tryptophan supplementation on neurotransmitter metabolism in phenylketonuria. *Brain Dysfunc* 1988 Jan-Feb;1(1):51-6.
- Nielsen KB. [Dietary treatment of women with Folling's disease. A review of current experiences and future perspectives]. *Ugeskr Laeger* 1985 Jan 21;147(4):246-9. (Dan).
- Nord AM, McCabe L, McCabe ER. Biochemical and nutritional status of children with hyperphenylalaninaemia. *J Inher Metab Dis* 1988;11(4):431-2.
- Norris JR, Meadows GG, Massey LK, Starkey JR, Sylvester DM, Liu SY. Tyrosine- and phenylalanine-restricted formula diet augments immunocompetence in healthy humans. *Am J Clin Nutr* 1990 Feb;51(2):188-96.
- Nutrition classics, the *Journal of Clinical Investigation*, volume 34, 1955. Studies on phenylketonuria. I. Restricted phenylalanine intake in

- phenylketonuria. By Marvin D. Armstrong and Frank H. Tyler. *Nutr Rev* 1983 Jan;41(1):15-8.
- Nyhan WL. Understanding inherited metabolic disease. *Clin Symp* 1980;32(5):1-36.
- O'Flynn ME. [Diet therapy in phenylketonuria--how long should it continue?]. *Hu Li Tsa Chih* 1970 Apr;17(2):32-4. (Chi).
- O'Flynn ME, Holtzman NA, Blaskovics M, Azen C, Williamson ML. The diagnosis of phenylketonuria: a report from the Collaborative Study of Children Treated for Phenylketonuria. *Am J Dis Child* 1980 Aug;134(8):769-74.
- O'Grady DJ, Berry HK, Sutherland BS. Cognitive development in early treated phenylketonuria. *Am J Dis Child* 1971 Jan;121(1):20-3.
- O'Hare JA, Minaker KL, Meneilly GS, Rowe JW, Pallotta JA, Young JB. Effect of insulin on plasma norepinephrine and 3,4-dihydroxyphenylalanine in obese men. *Metab Clin Exp* 1989 Apr;38(4):322-9.
- Ogier H, Depondt E, Munnich A, Saudubray JM. [Phenylalanine-restricted diet: the substitutes]. *Arch Fr Pediatr* 1983;40 Suppl 1:247-50. (Fre).
- Okajima K, Inoue M, Morino Y. Studies on the mechanism for renal elimination of N-acetylphenylalanine: its pathophysiologic significance in phenylketonuria. *J Lab Clin Med* 1985 Jan;105(1):132-8.
- Okano Y, Chow IZ, Isshiki G, Inoue A, Oura T. Effects of phenylalanine loading on protein synthesis in the fetal heart and brain of rat: an experimental approach to maternal phenylketonuria. *J Inherit Metab Dis* 1986;9(1):15-24.
- Okumura J, Yamaguchi K, Yanaka M. Growth and utilization of dietary nitrogen and energy in chicks fed excess phenylalanine or tyrosine diets. *Jpn Poultry Sci* 1980 Sep;17(5):256-64.
- Olafsdottir S, Martinez A. The accessibility of iron at the active site of recombinant human phenylalanine hydroxylase to water as studied by ¹H NMR paramagnetic relaxation. Effect of L-Phe and comparison with the rat enzyme. *J Biol Chem* 1999 Mar 5;274(10):6280-4.
- Olek K, Wardenbach P, Byrd D. [Excretion of transamination products in hyperphenylalaninemia (author's trans)]. *Klin Wochenschr* 1980 Feb 1;58(3):135-40. (Ger).
- Oppliger T, Thony B, Kluge C, Matasovic A, Heizmann CW, Ponzzone A, Spada M, Blau N. Identification of mutations causing 6-pyruvoyl-tetrahydropterin synthase deficiency in four Italian families. *Hum Mutat* 1997;10(1):25-35.
- Oppliger T, Thony B, Nar H, Burgisser D, Huber R, Heizmann CW, Blau N. Structural and functional consequences of mutations in 6-pyruvoyltetrahydropterin synthase causing hyperphenylalaninemia in humans. Phosphorylation is a requirement for in vivo activity. *J Biol Chem* 1995 Dec 8;270(49):29498-506.
- Oulis C, Kostopoulou M. [Phenylketonuria in children: problems of special interest to the dentist]. *Odontostomatol Proodos* 1984 Nov-Dec;38(6):341-50. (Gre).
- Owada M. [Maternal phenylketonuria]. *Ryoikibetsu Shokogun Shirizu* 1998;(18 Pt 1):119-23. (Jpn).
- Owada M. [Phenylketonuria (phenylalanine hydroxylase deficiency)]. *Ryoikibetsu Shokogun Shirizu* 1998;(18 Pt 1):114-8. (Jpn).
- Owada M, Abe M, Ono M, Kitagawa T, Sato Y. Successful treatment of maternal phenylketonuria with a formula consisting of low phenylalanine peptide as a protein source. *J Inherit Metab Dis* 1988;11(3):341-4.
- Owada M, Abe M, Tanimoto M, Minato M, Kitagawa T, Katayama S. Dietary treatment of PKU using a low-phenylalanine peptide milk. *Acta Paediatr Jpn* 1988 Aug;30(4):405-9.
- Ozalp I, Coskun T, Tokol S, Demircin G, Monch E. Inherited metabolic disorders in Turkey. *J Inherit Metab Dis* 1990;13(5):732-8.
- Ozanne AE, Krimmer H, Murdoch BE. Speech and language skills in children with early treated phenylketonuria. *Am J Ment Retard* 1990 May;94(6):625-32.
- Pacy PJ, Price GM, Halliday D, Quevedo MR, Millward DJ. Nitrogen homeostasis in man: the diurnal responses of protein synthesis and degradation and amino acid oxidation to diets with increasing protein intakes. *Clin Sci (Colch)* 1994 Jan;86(1):103-16.
- Palmour RM, Ervin FR, Baker GB, Young SN. An amino acid mixture deficient in phenylalanine and tyrosine reduces cerebrospinal fluid catecholamine metabolites and alcohol consumption in vervet monkeys. *Psychopharmacology (Berl)* 1998 Mar;136(1):1-7.
- Papet I, Ostaszewski P, Glomot F, Obled C, Faure M, Bayle G, Nissen S, Arnal M, Grizard J. The effect of a high dose of 3-hydroxy-3-methylbutyrate on protein metabolism in growing lambs. *Br J Nutr* 1997 Jun;77(6):885-96.

- Pardou A, Vuye A, Vis HL. Plasma amino acid patterns, one and two hours after continuous nasogastric alimentation of low birth weight infants fed two types of milk during the first month of life. *Biol Neonate* 1982;41(1-2):57-62.
- Pardridge WM. Potential effects of the dipeptide sweetener aspartame on the brain. *Nutr Brain* 1986;7:199-241.
- Pardridge WM, Choi TB. Neutral amino acid transport at the human blood-brain barrier. *Fed Proc* 1986 Jun;45(7):2073-8.
- Parker CE, Shaw KN, Mitchell JB, Koch R, Wenz E, Fishler K. Clinical experience in dietary management of phenylketonuria with a new phenylalanine-free product. *J Pediatr* 1977 Dec;91(6):941-3.
- Parniak MA, Kaufman S. Rat liver phenylalanine hydroxylase. Activation by sulfhydryl modification. *J Biol Chem* 1981 Jul 10;256(13):6876-82.
- Patterson RE, Eaton DL, Potter JD. The genetic revolution: change and challenge for the dietetics profession. *J Am Diet Assoc* 1999 Nov;99(11):1412-20.
- Paul D. A double-edged sword. *Nature* 2000 Jun 1;405(6786):515.
- Pavone L, Meli C, Nigro F, Lisi R, et al. Late diagnosed phenylketonuria patients: Clinical presentation and results of treatment. *Dev Brain Dysfunc* 1993 Jan-Jun;6(1-3):184-7.
- Peat B. Pregnancy complicated by maternal phenylketonuria. *Aust N Z J Obstet Gynaecol* 1993 May;33(2):163-5.
- Pechenova TN, Sushkova VV, Popova NN, Solodova EV, Gulyi MF. [Changes in the biosynthesis of acid-soluble collagen in the skin of rats with amino acid imbalances in their diets]. *Ukr Biokhim Zh* 1984 Jan-Feb;56(1):10-4. (Rus).
- [The pediatrician and early detection of hyperphenylalaninemia. Study Group on Hyperphenylalaninemia]. *An Esp Pediatr* 1993 May;38(5):477. (Spa).
- Pelcovitz D, Goldberg T. Enhancing nutrition compliance in children: inborn errors of metabolism as a paradigm. *Top Clin Nutr* 1995 Mar;10(2):73-8.
- Peluffo RO, Nervi AM, Gonzalez MS, Brenner RR. Effect of different amino acid diets on delta 5, delta 6 and delta 9 desaturases. *Lipids* 1984 Feb;19(2):154-7.
- Pember SO, Benkovic SJ, Villafranca JJ, Pasenkiewicz-Gierula M, Antholine WE. Adduct formation between the cupric site of phenylalanine hydroxylase from *Chromobacterium violaceum* and 6,7-dimethyltetrahydropterin. *Biochemistry* 1987 Jul 14;26(14):4477-83.
- Pember SO, Johnson KA, Villafranca JJ, Benkovic SJ. Mechanistic studies on phenylalanine hydroxylase from *Chromobacterium violaceum*. Evidence for the formation of an enzyme-oxygen complex. *Biochemistry* 1989 Mar 7;28(5):2124-30.
- Pennington BF, van Doorninck WJ, McCabe LL, McCabe ER. Neuropsychological deficits in early treated phenylketonuric children. *Am J Ment Defic* 1985 Mar;89(5):467-74.
- Persha AJ. Early identification and prevention of mental retardation. *ICCW News B* 1992 Jan-Mar;40(1):9-12.
- Petruschka L, Rebrin I, Grimm U, Herrmann FH. The immunological evidence for a phenylalanine hydroxylase like immunoreactive protein in different human cells and tissues. *Clin Chim Acta* 1990 Dec 13;193(1-2):65-77.
- [Phenylketonuria]. *FNIB* 1980 Jun;58(3):19-20. (Fre).
- Phenylketonuria: diagnosis and management. Proceedings of a symposium. London, 17 June 1987. *Postgrad Med J* 1989;65 Suppl 2:S1-26.
- Phenylketonuria grows up [editorial]. *Lancet* 1991 May 25;337(8752):1256-7.
- Phillips RS, Iwaki M, Kaufman S. Ligand effects on the limited proteolysis of phenylalanine hydroxylase: evidence for multiple conformational states. *Biochem Biophys Res Commun* 1983 Feb 10;110(3):919-25.
- Phillips RS, Kaufman S. Ligand effects on the phosphorylation state of hepatic phenylalanine hydroxylase. *J Biol Chem* 1984 Feb 25;259(4):2474-9.
- Phillips RS, Parniak MA, Kaufman S. Spectroscopic investigation of ligand interaction with hepatic phenylalanine hydroxylase: evidence for a conformational change associated with activation. *Biochemistry* 1984 Aug 14;23(17):3836-42.
- Pickering N, Billings P. Not my problem [letter]. *Hastings Cent Rep* 1993 Jan-Feb;23(1):45-6.
- Pietz J, Benninger C, Schmidt H, Scheffner D, Bickel H. Long-term development of intelligence (IQ) and EEG in 34 children with phenylketonuria treated early. *Eur J Pediatr* 1988 May;147(4):361-7.
- Pietz J, Fatkenheuer B, Burgard P, Armbruster M, Esser G, Schmidt H. Psychiatric disorders in adult patients with early-treated phenylketonuria. *Pediatrics* 1997 Mar;99(3):345-50.

- Pietz J, Kreis R, Rupp A, Mayatepek E, Rating D, Boesch C, Bremer HJ. Large neutral amino acids block phenylalanine transport into brain tissue in patients with phenylketonuria. *J Clin Invest* 1999 Apr;103(8):1169-78.
- Pietz J, Lutcke A, Sontheimer D, Benninger C, Pietz B, Batzler U, Heusser A. EEG development in early treated PKU patients from birth to 6 years of age. *Eur J Pediatr* 1990;149 Suppl 1:S28-33.
- Pietz J, Schmidt E, Matthis P, Kobialka B, Kutscha A, de Sonneville L. EEGs in phenylketonuria. I: Follow-up to adulthood; II: Short-term diet-related changes in EEGs and cognitive function. *Dev Med Child Neurol* 1993 Jan;35(1):54-64.
- Pittard J. The various strategies within the TyrR regulation of *Escherichia coli* to modulate gene expression. *Genes Cells* 1996 Aug;1(8):717-25.
- Platt LD, Koch R, Azen C, Hanley WB, Levy HL, Matalon R, Rouse B, de la Cruz F, Walla CA. Maternal phenylketonuria collaborative study, obstetric aspects and outcome: the first 6 years. *Am J Obstet Gynecol* 1992 Apr;166(4):1150-60; discussion 1160-2.
- Platt LD, Koch R, Hanley WB, Levy HL, Matalon R, Rouse B, Trefz F, de la Cruz F, Guttler F, Azen C, Friedman EG. The international study of pregnancy outcome in women with maternal phenylketonuria: report of a 12-year study. *Am J Obstet Gynecol* 2000 Feb;182(2):326-33.
- Plochl E. [Nutrition in congenital metabolic diseases]. *Padiatr Padol* 1984;19(4):343-8. (Ger).
- Pogge v Strandmann E, Senkel S, Ryffel GU. Ectopic pigmentation in *Xenopus* in response to DCoH/PCD, the cofactor of HNF1 transcription factor/pterin-4alpha-carbinolamine dehydratase. *Mech Dev* 2000;91(1-2):53-60.
- Pogson CI, Salter M, Knowles RG. Regulation of hepatic aromatic amino acid metabolism. *Biochem Soc Trans* 1986 Dec;14(6):999-1001.
- Pogson CI, Santana MA, Fisher MJ. Phenylalanine hydroxylase: metabolic aspects. *Biochem Soc Trans* 1985 Apr;13(2):439-41.
- Pollegioni L, Fukui K, Massey V. Studies on the kinetic mechanism of pig kidney D-amino acid oxidase by site-directed mutagenesis of tyrosine 224 and tyrosine 228. *J Biol Chem* 1994 Dec 16;269(50):31666-73.
- Pomi L, Peano L, Colla D. [Use of screening for amino acid disorders in the study of the nutrition of the newborn infant: various milk formulas and changes in plasma amino acids]. *Pediatr Med Chir* 1984 Mar-Apr;6(2):261-8. (Ita).
- Pontoglio M, Barra J, Hadchouel M, Doyen A, Kress C, Bach JP, Babinet C, Yaniv M. Hepatocyte nuclear factor 1 inactivation results in hepatic dysfunction, phenylketonuria, and renal Fanconi syndrome. *Cell* 1996 Feb 23;84(4):575-85.
- Pontoglio M, Faust DM, Doyen A, Yaniv M, Weiss MC. Hepatocyte nuclear factor 1alpha gene inactivation impairs chromatin remodeling and demethylation of the phenylalanine hydroxylase gene. *Mol Cell Biol* 1997 Sep;17(9):4948-56.
- Ponzzone A, Guardamagna O, Ferraris S, Biasetti S, Bracco G, Niederwieser A. Neurotransmitter therapy and diet in malignant phenylketonuria [letter]. *Eur J Pediatr* 1987 Jan;146(1):93-4.
- Ponzzone A, Guardamagna O, Ferraris S, Ferrero GB, Dianzani I, Cotton RG. Tetrahydrobiopterin loading test in hyperphenylalaninemia. *Pediatr Res* 1991 Nov;30(5):435-8.
- Ponzzone A, Spada M, Ferrero GB, Ponzzone R, Ferraris S. Newborn feeding and screening for phenylketonuria [letter]. *Acta Paediatr* 1999 Mar;88(3):347-8.
- Potocnik U, Widhalm K. Long-term follow-up of children with classical phenylketonuria after diet discontinuation: a review. *J Am Coll Nutr* 1994 Jun;13(3):232-6.
- Poustie VJ, Rutherford P. Dietary interventions for phenylketonuria. *Cochrane Database Syst Rev* 2000;(2):CD001304.
- Poustie VJ, Rutherford P. Tyrosine supplementation for phenylketonuria. *Cochrane Database Syst Rev* 2000;(2):CD001507.
- Prankel BH, Clemens PC, Burmester GJ. Competitive inhibition between large neutral amino acids at cell membrane of phenylketonuria patients [letter]. *Nutrition* 1994 Jan-Feb;10(1):90. Comment on: *Nutrition* 1993 Jan-Feb;9(1):37-42.
- Prankel BH, Clemens PC, Burmester JG. Urinary excretion of nucleosides varies with age and protein metabolism [letter]. *Clin Chim Acta* 1995 Jan 31;234(1-2):181-3. Comment on: *Clin Chim Acta* 1993 Aug 31;217(2):221-3.
- Prasad C, Dalton L, Levy H. Role of diet therapy in management of hereditary metabolic diseases. *Nutr Res* 1998 Feb;18(2):391-402.
- Pratt OE. A new approach to the treatment of phenylketonuria. *J Ment Defic Res* 1980 Sep;24(3):203-17.

- Preedy VR, Garlick PJ. The response of muscle protein synthesis to nutrient intake in postabsorptive rats: the role of insulin and amino acids. *Biosci Rep* 1986 Feb;6(2):177-83.
- Price GM, Halliday D, Pacy PJ, Quevedo MR, Millward DJ. Nitrogen homeostasis in man: influence of protein intake on the amplitude of diurnal cycling of body nitrogen. *Clin Sci (Colch)* 1994 Jan;86(1):91-102.
- Primrose DA. Phenylketonuria with normal intelligence. *J Ment Defic Res* 1983 Dec;27 (Pt 4):239-46.
- Prince AP. Vitamin B-6 status, energy and protein intakes, and amino acids in diets and plasma of school-aged patients with phenylketonuria: implications for an improved nutritional treatment [dissertation]. Corvallis (OR): Oregon State University; 1991. 294 p.
- Prince AP, Leklem JE. Vitamin B-6 status of school-aged patients with phenylketonuria. *Am J Clin Nutr* 1994 Aug;60(2):262-8.
- Prince AP, McMurray MP, Buist NR. Treatment products and approaches for phenylketonuria: improved palatability and flexibility demonstrate safety, efficacy and acceptance in US clinical trials. *J Inherit Metab Dis* 1997 Aug;20(4):486-98.
- Przyrembel H. Recommendations for protein and amino acid intake in phenylketonuria patients. *Eur J Pediatr* 1996 Jul;155 Suppl 1:S130-1.
- Pueschel SM, Fogelson-Doyle L, Kammerer B, Matsumiya Y. Neurophysiological, psychological, and nutritional investigations during discontinuation of the phenylalanine-restricted diet in children with classic phenylketonuria. *J Ment Defic Res* 1983 Mar;27 (Pt 1):61-7.
- Puntis JW, Edwards MA, Green A, Morgan I, Booth IW, Ball PA. Hyperphenylalaninaemia in parenterally fed newborn babies [letter]. *Lancet* 1986 Nov 8;2(8515):1105-6.
- Rakel S. [Nutrition of older children with phenylketonuria]. *Dev Brain Dysfunc* 1981 May;28(5):B25-8, passim. (Ger).
- Rakel S. [Nutrition of older children with phenylketonuria]. *Ernahr Umsch* 1981 Jun;28(6):B34-5, passim. (Ger).
- Ramano M, Diomede L, Guiso G, Caccia S, Perego C, Salmona M. Plasma and brain kinetics of large neutral amino acids and of striatum monoamines in rats given aspartame. *Food Chem Toxicol* 1990;28(5):317-21.
- Randell EW, Lehotay DC. An automated enzymatic method on the Roche COBAS MIRA S for monitoring phenylalanine in dried blood spots of patients with phenylketonuria. *Clin Biochem* 1996 Apr;29(2):133-8.
- Rapoport D, Depondt E, Saudubray JM. [Diet therapy in phenylketonuria. Psychological aspects]. *Arch Fr Pediatr* 1983;40 Suppl 1:265-7. (Fre).
- Rapoport D, Saudubray JM, Ogier H, Hatt A, Berges J, Depondt E, Charpentier C, Frezal J. [Psychological prospects and scholastic performance of 33 children with early diagnosis of hyperphenylalaninemia]. *Arch Fr Pediatr* 1983;40 Suppl 1:273-9. (Fre).
- Rasmussen BB, Tipton KD, Miller SL, Wolf SE, Wolfe RR. An oral essential amino acid-carbohydrate supplement enhances muscle protein anabolism after resistance exercise. *J Appl Physiol* 2000;88(2):386-92.
- Reber M, Kazak AE, Himmelberg P. Phenylalanine control and family functioning in early-treated phenylketonuria. *J Dev Behav Pediatr* 1987 Dec;8(6):311-7.
- Rebrin I, Bailey SW, Ayling JE. Activity of the bifunctional protein 4a-hydroxy-tetrahydropterin dehydratase/DChH during human fetal development: correlation with dihydropteridine reductase activity and tetrahydrobiopterin levels. *Biochem Biophys Res Commun* 1995 Dec 26;217(3):958-65.
- Recommendations on the dietary management of phenylketonuria. Report of Medical Research Council Working Party on Phenylketonuria. *Arch Dis Child* 1993 Mar;68(3):426-7.
- Reilly C, Barrett JE, Patterson CM, Tinggi U, Latham SL, Marrinan A. Trace element nutrition status and dietary intake of children with phenylketonuria. *Am J Clin Nutr* 1990 Jul;52(1):159-65.
- Rey F, Abadie V, Plainguet F, Rey J. Long-term follow up of patients with classical phenylketonuria after diet relaxation at 5 years of age. The Paris Study. *Eur J Pediatr* 1996 Jul;155 Suppl 1:S39-44.
- Reynolds R, Burri R, Herschkowitz N. Retarded development of neurons and oligodendroglia in rat forebrain produced by hyperphenylalaninemia results in permanent deficits in myelin despite long recovery periods. *Exp Neurol* 1993 Dec;124(2):357-67.
- Reynolds R, Burri R, Mahal S, Herschkowitz N. Disturbed myelinogenesis and recovery in hyperphenylalaninemia in rats: an immunohistochemical study. *Exp Neurol* 1992 Mar;115(3):347-67.
- Richardson SC, Aspbury RA, Fisher MJ. The role of reversible phosphorylation in the hormonal control of phenylalanine hydroxylase in isolated rat proximal

- kidney tubules. *Biochem J* 1993 Jun 1;292 (Pt 2):419-24.
- Richardson SC, Fisher MJ. Characterization of phenylalanine hydroxylase from rat kidney. *Int J Biochem* 1993 Apr;25(4):581-8.
- Ris MD, Williams SE, Hunt MM, Berry HK, Leslie N. Early-treated phenylketonuria: adult neuropsychologic outcome. *J Pediatr* 1994 Mar;124(3):388-92.
- Riva E, Agostoni C, Biasucci G, Giovannini M. Lipidic and fatty acid status in treated hyperphenylalaninemic children [letter]. *Acta Paediatr* 1994 Feb;83(2):132.
- Riva E, Agostoni C, Biasucci G, Trojan S, Luotti D, Fiori L, Giovannini M. Early breastfeeding is linked to higher intelligence quotient scores in dietary treated phenylketonuric children. *Acta Paediatr* 1996 Jan;85(1):56-8. Published erratum appears in *Acta Paediatr* 1996 May;85(5):639.
- Riva E, Fiocchi A, Agostoni C, Biasucci G, Sala M, Banderali G, Luotti D, Giovannini M. PKU-related dysgammaglobulinaemia: the effect of diet therapy on IgE and allergic sensitization. *J Inherit Metab Dis* 1994;17(6):710-7.
- Riva E, Paccanelli S, Longhi R, Giovannini M. [Use of a new amino acid mixture in the diet therapy of patients with classical phenylketonuria]. *Pediatr Med Chir* 1983 Nov-Dec;5(6):521-30. (Ita).
- Roberts S, Morelos BS. Cerebral ribosomal protein phosphorylation in experimental hyperphenylalaninaemia. *Biochem J* 1980 Aug 15;190(2):405-19.
- Roberts S, Morelos BS. Inhibition of cerebral protein kinase activity and cyclic AMP-dependent ribosomal-protein phosphorylation in experimental hyperphenylalaninaemia. *Biochem J* 1982 Feb 15;202(2):343-51.
- Roberts SA, Ball RO, Filler RM, Moore AM, Pencharz PB. Phenylalanine and tyrosine metabolism in neonates receiving parenteral nutrition differing in pattern of amino acids. *Pediatr Res* 1998 Dec;44(6):907-14.
- Robertson JA, Schulman JD. Pregnancy and prenatal harm to offspring: the case of mothers with PKU. *Hastings Cent Rep* 1987 Aug-Sep;17(4):23-33.
- Robinson EH, Wilson RP, Poe WE. Total aromatic amino acid requirement, phenylalanine requirement and tyrosine replacement value for fingerling channel catfish. *J Nutr* 1980 Sep;110(9):1805-12.
- Robinson M, White FJ, Cleary MA, Wraith E, Lam WK, Walter JH. Increased risk of vitamin B12 deficiency in patients with phenylketonuria on an unrestricted or relaxed diet. *J Pediatr* 2000 Apr;136(4):545-7.
- Rodriguez B, Torres N, Rincon AR, Bourges H, Panduro A, Tovar AR. Hepatic phenylalanine-hydroxylase and tyrosine-aminotransferase mRNA levels in rats adapted to diets with different concentrations of protein. *Rev Invest Clin* 1996 Nov-Dec;48(6):413-9.
- Rogers PJ, Keedwell P, Blundell JE. Further analysis of the short-term inhibition of food intake in humans by the dipeptide L-aspartyl-L-phenylalanine methyl ester (aspartame). *Physiol Behav* 1991 Apr;49(4):739-43.
- Rogers PJ, Fleming HC, Blundell JE. Aspartame ingested without tasting inhibits hunger and food intake. *Physiol Behav* 1990 Jun;47(6):1239-43.
- Rogowiecka E, Sendek E, Chazan B, Cabalska B, Bankowska E. [Maternal PKU syndrome as an obstetric problem: literature review and own clinical experience]. *Ginekol Pol* 1998 Dec;69(12):1007-15. (Pol).
- Rohr FJ, Doherty LB, Waisbren SE, Bailey IV, Ampola MG, Benacerraf B, Levy HL. New England Maternal PKU Project: prospective study of untreated and treated pregnancies and their outcomes. *J Pediatr* 1987 Mar;110(3):391-8.
- Rotter RG, Marquardt RR, Frohlich AA. Ochratoxin A toxicity in growing chicks: effect of supplemental dietary phenylalanine. *Nutr Rep Int* 1989 Dec;40(6):1091-100.
- Rottoli A, Riva E, Lista G, Borgatti L, Ortisi MT, Longhi R, Giovannini M. Plasma chromium and manganese levels in treated PKU patients. *J Inherit Metab Dis* 1986;9(2):215.
- Rouse B, Lockhart L, Matalon R, Azen C, Koch R, Hanley W, Levy H, dela Cruz F, Friedman E. Maternal phenylketonuria pregnancy outcome: a preliminary report of facial dysmorphism and major malformations. *J Inherit Metab Dis* 1990;13(3):289-91.
- Rouse B, Matalon R, Koch R, Azen C, Levy H, Hanley W, Trefz F, de la Cruz F. Maternal phenylketonuria syndrome: congenital heart defects, microcephaly, and developmental outcomes. *J Pediatr* 2000 Jan;136(1):57-61. Comment in: *J Pediatr* 2000 Jan;136(1):12-3.
- Ruch T, Kerr D. Decreased essential amino acid requirements without catabolism in phenylketonuria and maple syrup urine disease. *Am J Clin Nutr* 1982 Feb;35(2):217-28.

- Rudman D, Abbasi AA, Chaudry F, Mattson DE. Delayed plasma clearance of phenylalanine and tyrosine in elderly men. *J Am Geriatr Soc* 1991 Jan;39(1):33-8.
- Rupp A, Burgard P. Comparison of different indices of dietary control in phenylketonuria. *Acta Paediatr* 1995 May;84(5):521-7.
- Ryan-Harshman M. Mealtime food intake and behavior of normal weight adult of phenylalanine and aspartame [dissertation]. Greensboro (NC): The University of North Carolina at Greensboro; 1987. 117 p.
- Ryan-Harshman M, Leiter LA, Anderson GH. Phenylalanine and aspartame fail to alter feeding behavior, mood and arousal in men. *Physiol Behav* 1987;39(2):247-53.
- Rylance G. Outcome of early detected and early treated phenylketonuria patients. *Postgrad Med J* 1989;65 Suppl 2:S7-9.
- Saboe BJ, Alexander RC. Noncompliance with PKU treatment recommendations may be medical neglect in some states [letter]. *Pediatr Nurs* 1987 May-Jun;13(3):202-3, 215.
- Sadler MJ. Recent aspartame studies. *Food Chem Toxicol* 1984 Sep;22(9):771-3.
- Safos S, Chang TM. Enzyme replacement therapy in ENU2 phenylketonuric mice using oral microencapsulated phenylalanine ammonia-lyase: a preliminary report. *Artif Cells Blood Substit Immobil Biotechnol* 1995;23(6):681-92.
- Salardi S, Missiroli G, Piazzini S, Mandini M, Cassio A, Colli C, Tacconi M, Tolomelli M, Cacciari E. [Neuropsychological follow-up of children with phenylketonuria treated early]. *Pediatr Med Chir* 1992 Jul-Aug;14(4):409-13. (Ita).
- Samuels SE, Baracos VE. Tissue protein turnover is altered during catch-up growth following *Escherichia coli* infection in weanling rats. *J Nutr* 1995 Mar;125(3):520-30.
- Sanjurjo Crespo P. [Diet therapy of phenylketonuria. Current aspects]. *An Esp Pediatr* 1991 Oct;35(4):259-61. (Spa).
- Santana MA, Fisher MJ, Bate AJ, Pogson CI. The effect of experimental diabetes on phenylalanine metabolism in isolated liver cells. *Biochem J* 1985 Apr 1;227(1):169-75.
- Sarkissian CN, Shao Z, Blain F, Peevers R, Su H, Heft R, Chang TM, Scriver CR. A different approach to treatment of phenylketonuria: phenylalanine degradation with recombinant phenylalanine ammonia-lyase. *Proc Natl Acad Sci U S A* 1999 Mar 2;96(5):2339-44. Comment in: *Proc Natl Acad Sci U S A* 1999 Mar 2;96(5):1811-3.
- Saudubray JM, Rey F, Ogier H, Abadie V, Farriaux JP, Ghisolfi J, Guibaud P, Rey J, Vidailhet M. Intellectual and school performances in early-treated classical PKU patients. The French collaborative study. *Eur J Pediatr* 1987;146 Suppl 1:A20-2.
- Sazhinov GI, Kruglik VI, Solomadina LV. [New technologies in the manufacture of prospective products for child nutrition]. *Vopr Pitan* 1996;(5):41-4. (Rus).
- Scaglioni S, Virdis R, Zuccotti G, Vedovello M, Marcianesi M, Longhi R, Riva E, Giovannini M, Giovannelli G. Pubertal maturation and classical phenylketonuria. *J Inher Metab Dis* 1986;9(3):285-6.
- Schaefer F, Burgard P, Batzler U, Rupp A, Schmidt H, Gilli G, Bickel H, Bremer HJ. Growth and skeletal maturation in children with phenylketonuria. *Acta Paediatr* 1994 May;83(5):534-41.
- Schallreuter KU. A review of recent advances on the regulation of pigmentation in the human epidermis. *Cell Mol Biol (Noisy-le-grand)* 1999 Nov;45(7):943-9.
- Scheibenreiter S, Tiefenthaler M, Hinteregger V, Strobl W, Muhl A, Ewald A, Schadler M. Austrian report on longitudinal outcome in phenylketonuria. *Eur J Pediatr* 1996 Jul;155 Suppl 1:S45-9.
- Schmid G, Bahner U, Peschkes J, Heidland A. Neurotransmitter and monoaminergic amino acid precursor levels in rat brain: effects of chronic renal failure and of malnutrition. *Miner Electrolyte Metab* 1996;22(1-3):115-8.
- Schmid-Ruter E, Axmann KP. [Effect of social factors on dietary compliance in phenylketonuria]. *Offentl Gesundheitswes* 1985 Apr;47(4):170-2. (Ger).
- Schmidt E. [The German phenylketonuria study. Description of a longitudinal study and its results]. *Dtsch Krankenpflegez* 1993 Feb;46(2):84-6. (Ger).
- Schmidt E, Burgard P, Rupp A. Effects of concurrent phenylalanine levels on sustained attention and calculation speed in patients treated early for phenylketonuria. *Eur J Pediatr* 1996 Jul;155 Suppl 1:S82-6.
- Schmidt E, Rupp A, Burgard P, Pietz J, Weglage J, de Sonnevile L. Sustained attention in adult phenylketonuria: the influence of the concurrent phenylalanine-blood-level. *J Clin Exp Neuropsychol* 1994 Oct;16(5):681-8.

- Schmidt H, Burgard P, Pietz J, Rupp A. Intelligence and professional career in young adults treated early for phenylketonuria. *Eur J Pediatr* 1996 Jul;155 Suppl 1:S97-100.
- Schmidt H, Mahle M, Michel U, Pietz J. Continuation vs discontinuation of low-phenylalanine diet in PKU adolescents. *Eur J Pediatr* 1987;146 Suppl 1:A17-9.
- Schoeffler A, Herrmann ME, Broesicke HG, Moench E. Effect of dosage and timing of amino acid mixtures on nitrogen retention in patients with phenylketonuria. *J Nutr Med* 1994;4(4):415-8.
- Schor DP. Phenylketonuria and temperament in middle childhood. *Child Health Care* 1986 Winter;14(3):163-7.
- Schor DP. PKU and temperament. Rating children three through seven years old in PKU families. *Clin Pediatr (Phila)* 1983 Dec;22(12):807-11.
- Schreier K. [Modern possibilities in the early diagnosis of congenital metabolic diseases]. *Med Welt* 1982 Apr 2;33(13):462-5. (Ger).
- Schroter J, Schott KJ, Purtil MA, Neuhoﬀ V. Lysosomal protein degradation in experimental hyperphenylalaninaemia. *J Inherit Metab Dis* 1986;9(3):273-82.
- Schuett VE. *Low protein cookery for phenylketonuria*. 2nd ed., rev. and expanded. Madison (WI): University of Wisconsin Press; 1988. 569 p.
- Schuett VE, Gurda RF, Yandow JL (The Harry A. Waisman Center on Mental Retardation and Human Development, University of Wisconsin-Madison). *Treatment programs for PKU and selected other metabolic diseases in the United States: a survey*. Rockville (MD): Department of Health and Human Services (US), PublicHealth Service, Health Resources and Services Administration, Bureau of Health Care Delivery and Assistance; 1983. 35 p. (DHHS publication; no. (HRSA) 83-5296).
- Schuett VE, Brown ES. Diet policies of PKU clinics in the United States. *Am J Public Health* 1984 May;74(5):501-3.
- Schuett VE, Brown ES, Michals K. Reinstitution of diet therapy in PKU patients from twenty-two US clinics. *Am J Public Health* 1985 Jan;75(1):39-42.
- Schuett VE, Gurda RF, Brown ES. Diet discontinuation policies and practices of PKU clinics in the United States. *Am J Public Health* 1980 May;70(5):498-503.
- Schuler A, Kalmancey R, Barsi P, Somogyi CS, Toros I, Varadi I, Kovacs A, Blau N. Deprenyl in the treatment of patients with tetrahydrobiopterin deficiencies. *J Inherit Metab Dis* 2000;23(4):329-32.
- Schuler A, Somogyi C, Toros I, Pataki L, Mete M, Kiss E, Nagy A. A longitudinal study of phenylketonuria based on the data of the Budapest Screening Center. *Eur J Pediatr* 1996 Jul;155 Suppl 1:S50-2.
- Schulman JD. Treatment of the embryo and the fetus in the first trimester: current status and future prospects. *Am J Med Genet* 1990 Feb;35(2):197-200.
- Schulpi KH, Scarpalezou A. Triglycerides, cholesterol, HDL, LDL, and VLDL cholesterol in serum of phenylketonuric children under dietary control. *Clin Pediatr (Phila)* 1989 Oct;28(10):466-9.
- Schulpis KH, Nounopoulos C, Scarpalezou A, Bouloukos A, Missiou-Tsagarakis S. Serum carnitine level in phenylketonuric children under dietary control in Greece. *Acta Paediatr Scand* 1990 Oct;79(10):930-4.
- Schulpis KH, Nyalala JO, Papakonstantinou ED, Leondiadis L, Livaniou E, Ithakisios D, Georgala S. Biotin recycling impairment in phenylketonuric children with seborrheic dermatitis. *Int J Dermatol* 1998 Dec;37(12):918-21.
- Schulpis KH, Papakonstantinou E, Michelakakis H, Theodoridis T, Papandreou U, Constantopoulos A. Elevated serum prolactin concentrations in phenylketonuric patients on a 'loose diet'. *Clin Endocrinol (Oxf)* 1998 Jan;48(1):99-101.
- Schulpis KH, Platokouki H, Papakonstantinou ED, Adamtziki E, Bargeliotis A, Aronis S. Haemostatic variables in phenylketonuric children under dietary treatment. *J Inherit Metab Dis* 1996;19(5):603-9.
- Schulz B, Bremer HJ. Nutrient intake and food consumption of adolescents and young adults with phenylketonuria. *Acta Paediatr* 1995 Jul;84(7):743-8.
- Schuster B, Retey J. The mechanism of action of phenylalanine ammonia-lyase: the role of prosthetic dehydroalanine. *Proc Natl Acad Sci U S A* 1995 Aug 29;92(18):8433-7.
- Schwahn B, Mokov E, Scheidhauer K, Lettgen B, Schonau E. Decreased trabecular bone mineral density in patients with phenylketonuria measured by peripheral quantitative computed tomography. *Acta Paediatr* 1998 Jan;87(1):61-3.
- Schwarz HP, Pluss C, Triaca H, Schutz B, Kaufmann R, Scherz R, Bachmann C, Zuppinger K. [Disease course in 20 patients with an early diagnosis of phenylketonuria and hyperphenylalaninemia]. *Schweiz Med Wochenschr* 1988 Jan 23;118(3):94-9. (Ger).

- Schweitzer S, Wolff G, Brodehl J. [Psychosocial aspects of the treatment of phenylketonuria]. *Klin Padiatr* 1987 Mar-Apr;199(2):90-4. (Ger).
- Scott TM, Fyfe WM, Hart DM. Maternal phenylketonuria: abnormal baby despite low phenylalanine diet during pregnancy. *Arch Dis Child* 1980 Aug;55(8):634-7.
- Scriver CR. Mutants: consumers with special needs. *Nutr Rev* 1971 Jul;29(7):155-8.
- Scriver CR. Phenylketonuria: the glutamine hypothesis. *N Engl J Med* 1970 Apr 2;282(14):808-9.
- Scriver CR. Realized and potential neutralization of mutant genes in man by nutritional selection. *Fed Proc* 1976 Sep;35(11):2286-90.
- Scriver CR, Clow CL. Phenylketonuria and other phenylalanine hydroxylation mutants in man. *Annu Rev Genet* 1980;14:179-202.
- Scriver CR, Clow CL. Phenylketonuria: epitome of human biochemical genetics (first of two parts). *N Engl J Med* 1980 Dec 4;303(23):1336-42.
- Scriver CR, Clow CL. Phenylketonuria: epitome of human biochemical genetics (second of two parts). *N Engl J Med* 1980 Dec 11;303(24):1394-400.
- Seashore MR, Friedman E, Novelly RA, Bapat V. Loss of intellectual function in children with phenylketonuria after relaxation of dietary phenylalanine restriction. *Pediatrics* 1985 Feb;75(2):226-32.
- Seim AR, Reichelt KL. An enzyme/brain-barrier theory of psychiatric pathogenesis: unifying observations on phenylketonuria, autism, schizophrenia and postpartum psychosis. *Med Hypotheses* 1995 Nov;45(5):498-502.
- Sengers RC. [Early detection of phenylketonuria in the Netherlands, 1977-1979. 2d report of the National Care Commission on Phenylketonuria]. *Ned Tijdschr Geneesk* 1981 Dec 26;125(52):2135-40. (Dut).
- Seve B, Reeds PJ, Fuller MF, Cadenhead A, Hay SM. Protein synthesis and retention in some tissues of the young pig as influenced by dietary protein intake after early-weaning. Possible connection to the energy metabolism. *Reprod Nutr Dev* 1986;26(3):849-61.
- Sharifi BG. Synthesis and hydrolysis - l-phenylalanine-l-lysine (acylated non-acylated) and evaluation of their use as a nutritive breads [dissertation]. Manhattan (KS): Kansas State University; 1984. 91 p.
- Sharma SD, Cooley C, De La Pava E, Ambrus CM. Development of a refractory stage in a dog model for phenylketonuria. *Res Commun Chem Pathol Pharmacol* 1981 Jul;33(1):145-53.
- Shaw DW, Maravilla KR, Weinberger E, Garretson J, Trahms CM, Scott CR. MR imaging of phenylketonuria. *AJNR Am J Neuroradiol* 1991 May-Jun;12(3):403-6. Comment in: *AJNR Am J Neuroradiol* 1991 May-Jun;12(3):413-6.
- Shedlovsky A, McDonald JD, Symula D, Dove WF. Mouse models of human phenylketonuria. *Genetics* 1993 Aug;134(4):1205-10.
- Sheehan BD, Tharyan P, McTavish SFB, Campling GM, Cowen PJ. Use of a dietary manipulation to deplete plasma tyrosine and phenylalanine in healthy subjects. *J Psychopharmacol* 1996;10(3):231-4.
- Shen RS. Potent inhibitory effects of tyrosine metabolites on dihydropteridine reductase from human and sheep liver (Phenylketonuria). *Biochim Biophys Acta* 1984 Mar 29;785(3):181-5.
- Shiloh S, Amitay M, Aizin N, Normand M, Elitzur A, Hadar R, Cohen BE. [Psychosocial characteristics of phenylketonuric women: birth defect prevention]. *Harefuah* 1992 Apr 15;122(8):487-92, 552. (Heb).
- Shiman R. Relationship between the substrate activation site and catalytic site of phenylalanine hydroxylase. *J Biol Chem* 1980 Nov 10;255(21):10029-32.
- Short KR, Meek SE, Moller N, Ekberg K, Nair KS. Whole body protein kinetics using Phe and Tyr tracers: an evaluation of the accuracy of approximated flux values. *Am J Physiol* 1999 Jun;276(6 Pt 1):E1194-200.
- Should dietary treatment of phenylketonuria be continued after infancy? *Nutr Rev* 1985 Jun;43(6):176-7.
- Shulman S, Fisch RO, Zempel CE, Gadish O, Chang PN. Children with phenylketonuria: the interface of family and child functioning. *J Dev Behav Pediatr* 1991 Oct;12(5):315-21.
- Sievers E, Oldigs HD, Dorner K, Schaub J. Trace element excess in PKU diets? *J Inher Metab Dis* 1990;13(6):897-905.
- Silva FJ, Bel Y, Botella LM, Cotton RG, Ferre J. Immunological detection of phenylalanine hydroxylase protein in *Drosophila melanogaster*. *Biochem J* 1992 Oct 1;287 (Pt 1):85-9.
- Silva LC, Pires RF, Coelho JC, Jardim LB, Giugliani R. Evaluation of an aspartame loading test for the detection of heterozygotes for classical phenylketonuria. *Clin Genet* 1997 Apr;51(4):231-5.

- Simko V. Dietary challenge with high doses of amino acids phenylalanine, tryptophan, histidine and methionine in liver cirrhosis prone to hepatic encephalopathy. *Nutr Rep Int* 1984 Apr;29(4):929-39.
- Slijper FM, Huisman J, Hendriks MM, Kalverboer AF, v.d. Schot L. The effects of diet discontinuation in children with phenylketonuria [letter]. *Eur J Pediatr* 1988 May;147(4):445.
- Slijper FM, Huisman J, Hendriks MM, Kalverboer AF, van der Schot L. [Intellectual development of phenylketonuria children treated early--a longitudinal study. 10 years' concomitant psychological study in The Netherlands]. *Monatsschr Kinderheilkd* 1989 Oct;137(10):662-5. (Ger).
- Smijers JJ. [15 years of national screening for phenylketonuria in The Netherlands; 4th report of the National Advisory Commission Phenylketonuria (letter)]. *Ned Tijdschr Geneesk* 1991 Apr 27;135(17):776-7. (Dut).
- Smith I. Treatment of phenylalanine hydroxylase deficiency. *Acta Paediatr Suppl* 1994 Dec;407:60-5.
- Smith I, Beasley M. Intelligence and behaviour in children with early treated phenylketonuria. A report from the MRC/DHSS phenylketonuria register. *Eur J Clin Nutr* 1989;43 Suppl 1:1-5.
- Smith I, Beasley MG, Ades AE. Effect on intelligence of relaxing the low phenylalanine diet in phenylketonuria. *Arch Dis Child* 1991 Mar;66(3):311-6.
- Smith I, Beasley MG, Ades AE. Intelligence and quality of dietary treatment in phenylketonuria. *Arch Dis Child* 1990 May;65(5):472-8.
- Smith I, Beasley MG, Wolff OH, Ades AE. Behavior disturbance in 8-year-old children with early treated phenylketonuria. Report from the MRC/DHSS Phenylketonuria Register. *J Pediatr* 1988 Mar;112(3):403-8.
- Smith I, Glossop J, Beasley M. Fetal damage due to maternal phenylketonuria: effects of dietary treatment and maternal phenylalanine concentrations around the time of conception (an interim report from the UK Phenylketonuria Register). *J Inherit Metab Dis* 1990;13(4):651-7.
- Smith I, Lobascher ME, Stevenson JE, Wolff OH, Schmidt H, Grubel-Kaiser S, Bickel H. Effect of stopping low-phenylalanine diet on intellectual progress of children with phenylketonuria. *Br Med J* 1978 Sep 9;2(6139):723-6.
- Smith I, Lobascher ME, Stevenson JE, Wolff OH, Schmidt H, Grubel-Kaiser S, Bickel H. Effect of stopping low-phenylalanine diet on intellectual progress of children with phenylketonuria. *Br Med J* 1978 Sep 9;2(6139):723-6.
- Smith I, Wolff OH. Natural history of phenylketonuria and influence of early treatment. *Lancet* 1974 Sep 7;2(7880):540-4.
- Smith JE, Sheng ZF, Kallen RG. Effects of tyrosine-->phenylalanine mutations on auto- and trans-phosphorylation reactions catalyzed by the insulin receptor beta-subunit cytoplasmic domain. *DNA Cell Biol* 1994 Jun;13(6):593-604.
- Smith ML, Hanley WB, Clarke JT, Klim P, Schoonheydt W, Austin V, Lehotay DC. Randomised controlled trial of tyrosine supplementation on neuropsychological performance in phenylketonuria. *Arch Dis Child* 1998 Feb;78(2):116-21.
- Smith TK. Effect of leucine-rich dietary protein on in vitro protein synthesis in porcine muscle. *Proc Soc Exp Biol Med* 1985 Dec;180(3):538-43.
- Smooker PM, Gough TJ, Cotton RG, Alliaudi C, de Sanctis L, Dianzani I. A series of mutations in the dihydropteridine reductase gene resulting in either abnormal RNA splicing or DHPR protein defects. Mutations in brief no. 244. Online. *Hum Mutat* 1999;13(6):503-4.
- Snyderman SE. Dietary and genetic therapy of inborn errors of metabolism: a summary. *Ann N Y Acad Sci* 1986;477:231-6.
- Sobra J. [Nutrition and metabolic diseases with a mass incidence]. *Cas Lek Cesk* 1990 Jul 20;129(29):897-901. (Cze).
- Soeters RP, Sengers RC, van Dongen PW, Trijbels JM, Eskes TK. Maternal phenylketonuria: comparison of two treated full term pregnancies. *Eur J Pediatr* 1986 Aug;145(3):221-3.
- Song J, Jensen RA. PhhR, a divergently transcribed activator of the phenylalanine hydroxylase gene cluster of *Pseudomonas aeruginosa*. *Mol Microbiol* 1996 Nov;22(3):497-507.
- Song J, Xia T, Jensen RA. PhhB, a *Pseudomonas aeruginosa* homolog of mammalian pterin 4a-carbinolamine dehydratase/DCoH, does not regulate expression of phenylalanine hydroxylase at the transcriptional level. *J Bacteriol* 1999 May;181(9):2789-96.
- Sonntag WE, Lenham JE, Ingram RL. Effects of aging and dietary restriction on tissue protein synthesis: relationship to plasma insulin-like growth factor-1. *J Gerontol* 1992 Sep;47(5):B159-63.
- Southorn BG, Kelly JM, McBride BW. Phenylalanine flooding dose procedure is effective in measuring

- intestinal and liver protein synthesis in sheep. *J Nutr* 1992 Dec;122(12):2398-407.
- Speer VC, Kile DL, Trew JC. Estimation of the isoleucine and aromatic amino acid requirements of pregnant swine. *J Anim Sci* 1990 Aug;68(8):2394-9.
- Spero DA, Yu MC. Effects of maternal hyperphenylalaninemia on fetal brain development: a biochemical study. *Exp Neurol* 1983 Mar;79(3):641-54.
- Srivastava US, Thakur ML, Van TT, Radhakrishnamurty R. Maternal food restriction, brain polysomes and poly-U stimulated protein synthesis in the newborn and 21-day-old rat progeny. *Nutr Res* 1993 Nov;13(11):1331-41.
- Stanley JC, Salter M, Fisher MJ, Pogson CI. The effect of pyridoxine deficiency on the metabolism of the aromatic amino acids by isolated rat liver cells. *Arch Biochem Biophys* 1985 Aug 1;240(2):792-800.
- Start K. Treating phenylketonuria by a phenylalanine-free diet. *Prof Care Mother Child* 1998;8(4):109-10.
- Stavljenic LV, Rajic Z, Cvorisec D, Granic P, Mardesic D, Zaninovic M, Devernay Z. Changes in the composition of salivary amino acids, proteins and enzymes in children with phenylketonuria. *Acta Stomatol Croat* 1987;21(2):87-92.
- Steele S. Phenylketonuria: counseling and teaching functions of the nurse on an interdisciplinary team. *Issues Compr Pediatr Nurs* 1989;12(5):395-409.
- Stegink LD. Aspartame: review of the safety issues. *Food Technol* 1987 Jan;41(1):119-21.
- Stegink LD, Brummel MC, Persoon TJ, Filer LJJr, Bell EF, Ziegler EE. Effect of sucrose on the metabolic disposition of aspartame. *Am J Clin Nutr* 1990 Aug;52(2):335-41.
- Stegink LD, Filer LJ Jr, Baker GL. Effect of aspartame plus monosodium L-glutamate ingestion on plasma and erythrocyte amino acid levels in normal adult subjects fed a high protein meal. *Am J Clin Nutr* 1982 Dec;36(6):1145-52.
- Stegink LD, Filer LJ Jr, Baker GL. Repeated ingestion of aspartame-sweetened beverage: effect on plasma amino acid concentrations in normal adults. *Metabolism* 1988 Mar;37(3):246-51.
- Stegink LD, Filer LJ Jr, Baker GL, Bell EF, Ziegler EE, Brummel MC, Krause WL. Repeated ingestion of aspartame-sweetened beverage: effect on plasma amino acid concentrations in individuals heterozygous for phenylketonuria. *Metabolism* 1989 Jan;38(1):78-84.
- Stegink LD, Filer LJ Jr, Baker GL, McDonnell JE. Effect of an abuse dose of aspartame upon plasma and erythrocyte levels of amino acids in phenylketonuric heterozygous and normal adults. *J Nutr* 1980 Nov;110(11):2216-24.
- Stegink LD, Filer LJ Jr, Bell EF, Ziegler EE, Tephly TR, Krause WL. Repeated ingestion of aspartame-sweetened beverages: further observations in individuals heterozygous for phenylketonuria. *Metabolism* 1990 Oct;39(10):1076-81.
- Stegink LD, Filer LJ Jr, Brummel MC, Baker GL, Krause WL, Bell EF, Ziegler EE. Plasma amino acid concentrations and amino acid ratios in normal adults and adults heterozygous for phenylketonuria ingesting a hamburger and milk shake meal. *Am J Clin Nutr* 1991 Mar;53(3):670-5.
- Stegink LD, Koch R, Blaskovics ME, Filer LJ Jr, Baker GL, McDonnell JE. Plasma phenylalanine levels in phenylketonuric heterozygous and normal adults administered aspartame at 34 mg/kg body weight. *Toxicology* 1981;20(1):81-90.
- Stegink LD, Lindgren SD, Brummel MC, Stumbo PJ, Wolraich ML. Erythrocyte L-aspartyl-L-phenylalanine hydrolase activity and plasma phenylalanine and aspartate concentrations in children consuming diets high in aspartame. *Am J Clin Nutr* 1995 Dec;62(6):1206-11.
- Stegink LD, Wolf-Novak LC, Filer LJ Jr, Bell EF, Ziegler EE, Krause WL, Brummel MC. Aspartame-sweetened beverage: effect on plasma amino acid concentrations in normal adults and adults heterozygous for phenylketonuria. *J Nutr* 1987 Nov;117(11):1989-95.
- Stehle P, Weber S, Furst P. Parenteral glycyl-L-tyrosine maintains tyrosine pools and supports growth and nitrogen balance in phenylalanine-deficient rats. *J Nutr* 1996 Mar;126(3):663-7.
- Stein Z, Susser M. Effects of early nutrition on neurological and mental competence in human beings. *Psychol Med* 1985 Nov;15(4):717-26.
- Steiner G, Menzel H, Lombeck I, Ohnesorge FK, Bremer HJ. Plasma glutathione peroxidase after selenium supplementation in patients with reduced selenium state. *Eur J Pediatr* 1982 Mar;138(2):138-40.
- Stemerdink BA, van der Molen MW, Kalverboer AF, van der Meere JJ, Hendriks MM, Huisman J, van der Schot LW, Slijper FM. Information processing deficits in children with early and continuously treated phenylketonuria? *Acta Paediatr Suppl* 1994 Dec;407:106-7.
- Stern AM. Psychoeducational status in relation to duration and quality of treatment in early and later

- diagnosed and treated children, adolescents, and young adults [dissertation]. Los Angeles (CA): University of Southern California; 1982.
- Stewart RM, Hemli S, Kolodny EH, Miller AL, Pallotta JA. Carbohydrate metabolism in phenylketonuria. *Pediatr Res* 1980 Jul;14(7):849-53.
- Stoll B, Burrin DG, Henry J, Jahoor F, Reeds PJ. Phenylalanine utilization by the gut and liver measured with intravenous and intragastric tracers in pigs. *Am J Physiol* 1997 Dec;273(6 Pt 1):G1208-17.
- Stoll B, Burrin DG, Henry J, Yu H, Jahoor F, Reeds PJ. Dietary amino acids are the preferential source of hepatic protein synthesis in piglets. *J Nutr* 1998 Sep;128(9):1517-24.
- Stoll B, Burrin DG, Henry JF, Jahoor F, Reeds PJ. Dietary and systemic phenylalanine utilization for mucosal and hepatic constitutive protein synthesis in pigs. *Am J Physiol* 1999 Jan;276(1 Pt 1):G49-57.
- Strisciuglio P, Concolino D, Moricca MT, Rivalta L, Parlato G. Normal serum levels of vitamin B12 and folic acid in children with phenylketonuria [letter]. *Eur J Pediatr* 1995 Oct;154(10):866.
- Sturtevant FM. Use of aspartame in pregnancy. *Int J Fertil* 1985;30(1):85-7.
- Stutchfield PR, Isherwood DM, Weindling AM. Hyperphenylalaninaemia in parenterally fed newborn infants [letter]. *Lancet* 1987 Oct 31;2(8566):1027.
- Su CL, Austic RE. Improved model of maternal phenylketonuria in rats by use of lower dietary concentrations of alpha-methylphenylalanine and L-phenylalanine in a semipurified diet. *Nutr Res* 1998 Jun;18(6):989-1002.
- Suchozebraska-Jesionek D, Szymonik-Lesiuk S, Borkowska I. Shortlasting effect of L-phenylalanine on the level of aminoacyl-tRNA in chick embryo's brain. *Bull Acad Polonaise Sci Ser Sci Biol* 1984;32(1-2):1-8.
- Sullivan JE, Chang P. Review: emotional and behavioral functioning in phenylketonuria. *J Pediatr Psychol* 1999 Jun;24(3):281-99.
- Szabo L. Fenilketonuria kezelese es dietas utmutato. Budapest: Orszagos Csecsemo- es Gyermekesegszegugyi Inteze; 1982. 88 p. (Hun).
- Szabo L, Somogyi C, Mate M. Experience based on 800,000 newborn screening tests of the Budapest Phenylketonuria Centre. *Acta Paediatr Hung* 1985;26(2):113-25.
- Tada K, Tateda H, Arashima S, Sakai K, Kitagawa T, Aoki K, Suwa S, Kawamura M, Oura T, Takesada M, et al. Follow-up study of a nation-wide neonatal metabolic screening program in Japan. A collaborative study group of neonatal screening for inborn errors of metabolism in Japan. *Eur J Pediatr* 1984 Aug;142(3):204-7.
- Takagi M, Nishio Y, Oh G, Yoshida T. Control of L-phenylalanine production by dual feeding of glucose and L-tyrosine. *Biotechnol Bioeng* 1996 Dec 20;52(6):653-60.
- Tam SY, Ono N, Roth RH. Precursor control and influence of aspartame on midbrain dopamine neurons. *UCLA Symp Mol Cell Biol* 1987;55:421-35.
- Tanaka H, Nakatomi Y, Ogura M. Metabolism of phenylalanine, tyrosine and aspartic acid in growing rats at various dietary protein levels. *Agric Biol Chem* 1987 Feb;51(2):499-505.
- Tanaka H, Shibata K, Mori M, Ogura M. Metabolism of essential amino acids in growing rats at graded levels of soybean protein isolate. *J Nutr Sci Vitaminol (Tokyo)* 1995 Aug;41(4):433-43.
- Taylor CJ, Moore G, Davidson DC. The effect of treatment on zinc, copper and calcium status in children with phenylketonuria. *J Inherit Metab Dis* 1984;7(4):160-4.
- Taylor DS, Green AK, Fisher MJ. Impact of experimental diabetes on phenylalanine hydroxylase expression in rat liver. *Trans Biochem Soc* 1988 Dec;16(6):1057-8.
- Taylor EH, Hommes FA. Effect of experimental hyperphenylalaninemia on myelin metabolism at later stages of brain development. *Int J Neurosci* 1983 Sep;20(3-4):217-27.
- Teigen K, Froystein NA, Martinez A. The structural basis of the recognition of phenylalanine and pterin cofactors by phenylalanine hydroxylase: implications for the catalytic mechanism. *J Mol Biol* 1999 Dec 3;294(3):807-23.
- Tenbrinck MS, Stroud HW. Normal infant born to a mother with phenylketonuria. *JAMA* 1982 Apr 16;247(15):2139-40.
- Terry PO. Clinical social work roles in an integrative, interdisciplinary team: enhancing parental compliance. *Soc Work Health Care* 1981 Summer;6(4):1-15.
- Theile H, Bieck E. [Control of energy and nitrogen uptake during diet therapy of phenylketonuria]. *Kinderarztl Prax* 1981 Aug;49(8):425-30. (Ger).
- Theile H, Graustein I, Wasser S, Buhrdel P. [Effect of dietary non-compliance on development in phenylketonuria--studies of 14-year-old patients]. *Pediatr Padol* 1990;25(1):19-23. (Ger).

- Theile H, Wasser S, Buhrdel P, Graustein I. [Results, problems and consequences of early treatment of phenylketonuria]. *Z Gesamte Inn Med* 1989 Jun 1;44(11):317-20. (Ger).
- Thompson AJ, Smith I, Brenton D, Youl BD, Rylance G, Davidson DC, Kendall B, Lees AJ. Neurological deterioration in young adults with phenylketonuria. *Lancet* 1990 Sep 8;336(8715):602-5.
- Thompson AJ, Smith I, Kendall BE, Youl BD, Brenton D. Magnetic resonance imaging changes in early treated patients with phenylketonuria [letter]. *Lancet* 1991 May 18;337(8751):1224.
- Thompson AJ, Tillotson S, Smith I, Kendall B, Moore SG, Brenton DP. Brain MRI changes in phenylketonuria. Associations with dietary status. *Brain* 1993 Aug;116 (Pt 4):811-21.
- Thompson GN, Francis DE, Kirby DM, Compton R. Pregnancy in phenylketonuria: dietary treatment aimed at normalising maternal plasma phenylalanine concentration. *Arch Dis Child* 1991 Nov;66(11):1346-9.
- Thompson GN, Pacy PJ, Watts RW, Halliday D. Protein metabolism in phenylketonuria and Lesch-Nyhan syndrome. *Pediatr Res* 1990 Sep;28(3):240-6.
- Thony B, Auerbach G, Blau N. Tetrahydrobiopterin biosynthesis, regeneration and functions. *Biochem J* 2000 Apr 1;347 Pt 1:1-16.
- Thony B, Leimbacher W, Burgisser D, Heizmann CW. Human 6-pyruvoyltetrahydropterin synthase: cDNA cloning and heterologous expression of the recombinant enzyme. *Biochem Biophys Res Commun* 1992 Dec 30;189(3):1437-43.
- Thony B, Neuheiser F, Hauer CR, Heizmann CW. Molecular cloning and recombinant expression of the human liver phenylalanine hydroxylase stimulating factor revealed structural and functional identity to the dimerization cofactor for the nuclear transcription factor HNF-1 alpha. *Adv Exp Med Biol* 1993;338:103-6.
- Thony B, Neuheiser F, Kierat L, Blaskovics M, Arn PH, Ferreira P, Rebrin I, Ayling J, Blau N. Hyperphenylalaninemia with high levels of 7-biopterin is associated with mutations in the PCBD gene encoding the bifunctional protein pterin-4a-carbinolamine dehydratase and transcriptional coactivator (DCoH). *Am J Hum Genet* 1998 Jun;62(6):1302-11.
- Thorpe JM, Roberts SA, Ball RO, Pencharz PB. Effect of tyrosine intake on the rate of phenylalanine hydroxylation in adult males. *Metab Clin Exp* 2000;49(4):444-9.
- Thorpe JM, Roberts SA, Ball RO, Pencharz PB. Prior protein intake may affect phenylalanine kinetics measured in healthy adult volunteers consuming 1 g protein. kg-1. d-1. *J Nutr* 1999 Feb;129(2):343-8.
- Tice KS, Wenz E, Jew K, Koch R. Reproductive counselling for adolescent females with phenylketonuria. *J Inher Metab Dis* 1980;3(3):105-7.
- Tolmie JL, Harvie A, Cockburn F. The teratogenic effects of undiagnosed maternal hyperphenylalaninaemia: a case for prevention? *Br J Obstet Gynaecol* 1992 Apr;99(4):347-8.
- Torok E, Kovacs J. [Scleroderma associated with phenylketonuria]. *Orv Hetil* 1981 Sep 13;122(37):2273-5. (Hun).
- Torre P, Ponz F. Kinetics of the mediated transport and the passive net flux of phenylalanine across the rat small intestine in vivo. *Rev Esp Fisiol* 1983 Sep;39(3):333-7.
- Trace element intake in PKU children. *Nutr MD* 1991 May;17(5):3-4.
- Treacy E, Pitt JJ, Seller K, Thompson GN, Ramus S, Cotton RG. In vivo disposal of phenylalanine in phenylketonuria: a study of two siblings. *J Inher Metab Dis* 1996;19(5):595-602.
- Trefz F, de Sonneville L, Matthis P, Benninger C, Lanz-Englert B, Bickel H. Neuropsychological and biochemical investigations in heterozygotes for phenylketonuria during ingestion of high dose aspartame (a sweetener containing phenylalanine). *Hum Genet* 1994 Apr;93(4):369-74.
- Trefz FK, Batzler U, Konig T, Michel U, Schmidt E, Schmidt H, Bickel H. Significance of the in vivo deuterated phenylalanine load for long-term phenylalanine tolerance and psycho-intellectual outcome in patients with PKU. *Eur J Pediatr* 1990;149 Suppl 1:S25-7.
- Trefz FK, Burgard P, Konig T, Goebel-Schreiner B, Lichter-Konecki U, Konecki D, Schmidt E, Schmidt H, Bickel H. Genotype-phenotype correlations in phenylketonuria. *Clin Chim Acta* 1993 Jul 30;217(1):15-21.
- Truswell AS. ABC of nutrition. Therapeutic diets. *Br Med J (Clin Res Ed)* 1985 Sep 21;291(6498):807-11.
- Tsay JT, Appleman JR, Beard WA, Prendergast NJ, Delcamp TJ, Freisheim JH, Blakley RL. Kinetic investigation of the functional role of phenylalanine-31 of recombinant human dihydrofolate reductase. *Biochemistry* 1990 Jul 10;29(27):6428-36.

- Turri MO, Ilg EC, Thony B, Blau N. Structure, genomic localization and recombinant expression of the mouse 6-pyruvoyl-tetrahydropterin synthase gene. *Biol Chem* 1998 Dec;379(12):1441-7.
- Ullrich K, Moller H, Weglage J, Schuierer G, Bick U, Ludolph A, Hahn-Ullrich H, Funders B, Koch HG. White matter abnormalities in phenylketonuria: results of magnetic resonance measurements. *Acta Paediatr Suppl* 1994 Dec;407:78-82.
- Uma SM, Jyothy A, Reddy PP, Reddi OS. Aminoacidopathies in Andhra Pradesh; report of a screening programme. *J Inher Metab Dis* 1982;5(4):211-4.
- Ushakova GA, Gubkina HA, Kachur VA, Lepekhin EA. Effect of experimental hyperphenylalaninemia on the postnatal rat brain. *Int J Dev Neurosci* 1997 Feb;15(1):29-36.
- Vaca G, Hernandez A, Ibarra B, Velazquez A, Olivares N, Sanchez-Corona J, Medina C, Cantu JM. [Detection of inborn errors of metabolism in 1,117 patients studied because of suspected inherited disease]. *Arch Invest Med (Mex)* 1981;12(3):341-8. (Spa).
- Valdivieso F, Gimenez C, Benavides J, Aragon MC, Mayor F. [Pathogenesis of cerebral dysfunction in phenylketonuria]. *Rev Esp Fisiol* 1982;38 Suppl:189-93. (Spa).
- van der Schot LW, Doesburg WH, Sengers RC. The phenylalanine response curve in relation to growth and mental development in the first year of life. *Acta Paediatr Suppl* 1994 Dec;407:68-9.
- van Spronsen FJ, van Dijk T, Smit GP, van Rijn M, Reijngoud DJ, Berger R, Heymans HS. Large daily fluctuations in plasma tyrosine in treated patients with phenylketonuria. *Am J Clin Nutr* 1996 Dec;64(6):916-21. Comment in: *Am J Clin Nutr* 1996 Dec;64(6):974-5.
- van Spronsen FJ, van Dijk T, Smit GP, van Rijn M, Reijngoud DJ, Berger R, Heymans HS. Phenylketonuria: plasma phenylalanine responses to different distributions of the daily phenylalanine allowance over the day. *Pediatrics* 1996 Jun;97(6 Pt 1):839-44.
- van Spronsen FJ, van Rijn M, van Dijk T, Smit GP, Reijngoud DJ, Berger R, Heymans HS. Plasma phenylalanine and tyrosine responses to different nutritional conditions (fasting/postprandial) in patients with phenylketonuria: effect of sample timing. *Pediatrics* 1993 Oct;92(4):570-3.
- van Spronsen FJ, Verkerk PH, van Houten M, Smit GP, van der Meer SB, Bakker HD, Sengers RC. Does impaired growth of PKU patients correlate with the strictness of dietary treatment? National Dutch PKU Steering Committee. *Acta Paediatr* 1997 Aug;86(8):816-8.
- van Toledo-Eppinga L, Kalhan SC, Kulik W, Jakobs C, Lafeber HN. Relative kinetics of phenylalanine and leucine in low birth weight infants during nutrient administration. *Pediatr Res* 1996 Jul;40(1):41-6.
- Varughese KI, Xuong NH, Whiteley JM. Structural and mechanistic implications of incorporating naturally occurring aberrant mutations of human dihydropteridine reductase into a rat model. *Int J Pept Protein Res* 1994 Sep;44(3):278-87.
- Vasconcellos AM, Oliveira CP, Grassiano DM, Santos-Neto AL. Adsorption of phenylalanine from casein hydrolysates. *Appl Biochem Biotechnol* 1992 Oct;37(1):69-80.
- Vaz Osorio R, Vilarinho L, Carmona C, Almeida M. Phenylketonuria in Portugal: Multidisciplinary approach. *Dev Brain Dysfunc* 1993 Jan-Jun;6(1-3):78-82.
- Velazquez A. Gene-nutrient interactions in single-gene defects and polygenic diseases: methodologic considerations. In: Simopoulos AP, Nestel PJ, editors. Genetic variation and dietary response. New York: Karger; 1997. p. 145-64.
- Velazquez A, Vela-Amieva M, Ciceron-Arellano I, Ibarra-Gonzalez I, Perez-Andrade ME, Olivares-Sandoval Z, Jimenez-Sanchez G. Diagnosis of inborn errors of metabolism. *Arch Med Res* 2000 Mar 4;31(2):145-50.
- Verkerk PH, van Spronsen FJ, van Houten M, Smit GP, Sengers RC. Predictors of mean phenylalanine levels during the first five years of life in patients with phenylketonuria who were treated early. Dutch National PKU Steering Committee. *Acta Paediatr Suppl* 1994 Dec;407:70-2.
- Veropotvelian PN, Krupoder GI, Avksent'ev ON. [Phenylketonuria]. *Feldsher Akush* 1982;47(5):33-5. (Rus).
- Vilaseca MA, Briones P, Ferrer I, Campistol J, Riverola A, Castillo P, Ramon F. Controlled diet in phenylketonuria may cause serum carnitine deficiency. *J Inher Metab Dis* 1993;16(1):101-4.
- Villasana D, Butler IJ, Williams JC, Roongta SM. Neurological deterioration in adult phenylketonuria. *J Inher Metab Dis* 1989;12(4):451-7.
- Vorhees CV, Butcher RE, Berry HK. Progress in experimental phenylketonuria: a critical review. *Neurosci Biobehav Rev* 1981 Spring;5(1):177-90.

- Vorstenbosch EL, Potapov AP, De Graaf JM, Kraal B. The effect of mutations in EF-Tu on its affinity for tRNA as measured by two novel and independent methods of general applicability. *J Biochem Biophys Methods* 2000;42(1-2):1-14.
- Wachtel U. Review of current practices in management of inherited disorders of amino acid metabolism in Western Europe. *Hum Nutr Appl Nutr* 1986;40 Suppl 1:61-9.
- Waggoner WF. Aspartame--a review. *Pediatr Dent* 1984 Sep;6(3):153-8.
- Waisbren SE, Brown MJ, de Sonnevill LM, Levy HL. Review of neuropsychological functioning in treated phenylketonuria: an information processing approach. *Acta Paediatr Suppl* 1994 Dec;407:98-103.
- Waisbren SE, Hanley W, Levy HL, Shifrin H, Allred E, Azen C, Chang PN, Cipicic-Schmidt S, de la Cruz F, Hall R, Matalon R, Nanson J, Rouse B, Trefz F, Koch R. Outcome at age 4 years in offspring of women with maternal phenylketonuria: the Maternal PKU Collaborative Study. *JAMA* 2000 Feb 9;283(6):756-62.
- Waisbren SE, Levy HL. Agoraphobia in phenylketonuria. *J Inherit Metab Dis* 1991;14(5):755-64.
- Waisbren SE, Mahon BE, Schnell RR, Levy HL. Predictors of intelligence quotient and intelligence quotient change in persons treated for phenylketonuria early in life. *Pediatrics* 1987 Mar;79(3):351-5.
- Waisbren SE, Rokni H, Bailey I, Rohr F, Brown T, Warner-Rogers J. Social factors and the meaning of food in adherence to medical diets: results of a maternal phenylketonuria summer camp. *J Inherit Metab Dis* 1997 Mar;20(1):21-7.
- Waisbren SE, Schnell RR, Levy HL. Diet termination in children with phenylketonuria: a review of psychological assessments used to determine outcome. *J Inherit Metab Dis* 1980;3(4):149-53.
- Walker JD, Crall JJ, McDonnell JE. Phenylketonuria and dentistry: review of the literature. *ASDC J Dent Child* 1982 Jul-Aug;49(4):280-4.
- Walker V, Clayton BE, Ersser RS, Francis DE, Lilly P, Seakins JW, Smith I, Whiteman PD. Hyperphenylalaninaemia of various types among three-quarters of a million neonates tested in a screening programme. *Arch Dis Child* 1981 Oct;56(10):759-64.
- Walker V, Hall MA, Bulusu S, Allan A. Hyperphenylalaninaemia in parenterally fed newborn babies [letter]. *Lancet* 1986 Nov 29;2(8518):1284.
- Walker V, Mills GA. Metabolism of intravenous phenylalanine by babies born before 33 weeks of gestation. *Biol Neonate* 1990;57(3-4):155-66.
- Wallen MA, Packman S. Nutrition and inborn errors of metabolism. *Nutr Update* 1985;2:71-89.
- Walsh GA, Donlon J. Effects of starvation on rat phenylalanine hydroxylase activities. *Trans Biochem Soc* 1989 Apr;17(2):378-9.
- Walsh GA, Donlon J. State of phosphorylation of hepatic phenylalanine hydroxylase in diabetic rats. *Trans Biochem Soc* 1989 Apr;17(2):380-1.
- Walter JH. Late effects of phenylketonuria. *Arch Dis Child* 1995 Dec;73(6):485-6.
- Walter JH, White F, Wraith JE, Jenkins JP, Wilson BP. Complete reversal of moderate/severe brain MRI abnormalities in a patient with classical phenylketonuria. *J Inherit Metab Dis* 1997 Jul;20(3):367-9.
- Wang W, Ramdas L, Sun G, Ke S, Obeyesekere NU, Budde RJA, McMurray JS. Cyclic peptides incorporating 4-carboxyphenylalanine and phosphotyrosine are potent inhibitors of pp60(c-src). *Biochemistry* 2000 May 2;39(17):5221-8.
- Wang Y, DeMayo JL, Hahn TM, Finegold MJ, Konecki DS, Lichter-Konecki U, Woo SL. Tissue- and development-specific expression of the human phenylalanine hydroxylase/chloramphenicol acetyltransferase fusion gene in transgenic mice. *J Biol Chem* 1992 Jul 25;267(21):15105-10.
- Wang Y, Hahn TM, Tsai SY, Woo SL. Functional characterization of a unique liver gene promoter. *J Biol Chem* 1994 Mar 25;269(12):9137-46.
- Wappner R, Cho S, Kronmal RA, Schuett V, Seashore MR. Management of phenylketonuria for optimal outcome: a review of guidelines for phenylketonuria management and a report of surveys of parents, patients, and clinic directors. *Pediatrics* 1999 Dec;104(6):e68.
- Ward R. Meals for special children. *Community Outlook* 1984 Sep;319-20, 322.
- Wardley BL, Taitz LS. Clinical trial of a concentrated amino acid formula for older patients with phenylketonuria (Maxamum XP). *Eur J Clin Nutr* 1988 Jan;42(1):81-6.
- Wasser S, Theile H. [The interaction of biological and social factors on the effect of treatment in cases of phenylketonuria (author's transl)]. *Padiatr Padol* 1981;16(4):417-26. (Ger).

- Wasser S, Theile H, Graustein J. [Results of the electroencephalographic examination of children after the late treatment of phenylketonuria by diet]. *Pediatrria* 1980 Oct;(10):52-4. (Rus).
- Wasser S, Theile H, Scheer A, Graustein I. [Reduced optimal obstetric and postnatal conditions in children with phenylketonuria and their effect on the success of treatment]. *Pediatr Padol* 1986;21(4):351-6. (Ger).
- Waters PI, Hewson AS, Scriver CR, Treacy EP, Martinez A, Knappskog PM, Parniak MA. Comparative analysis of phenylalanine hydroxylase A104D mutant, associated with variant phenylketonuria, and wild-type enzyme. *Biochem Soc Trans* 1997 May;25(2):362S.
- Waters PJ, Parniak MA, Akerman BR, Scriver CR. Characterization of phenylketonuria missense substitutions, distant from the phenylalanine hydroxylase active site, illustrates a paradigm for mechanism and potential modulation of phenotype. *Mol Genet Metab* 2000 Feb;69(2):101-10.
- Waters PJ, Parniak MA, Hewson AS, Scriver CR. Alterations in protein aggregation and degradation due to mild and severe missense mutations (A104D, R157N) in the human phenylalanine hydroxylase gene (PAH). *Hum Mutat* 1998;12(5):344-54.
- Waters PJ, Scriver CR, Parniak MA. Degradation rates differ between mutant and wild-type forms of phenylalanine hydroxylase expressed in vitro. *Biochem Soc Trans* 1998 Aug;26(3):S276.
- Webster DR, Wallace J. PKU and diabetes: help requested [letter]. *J Inherit Metab Dis* 1995;18(5):649.
- Weglage J. Diätbehandlung bei Phenylketonurie : Indikationen, Wirkungen und Nebenwirkungen. Göttingen (Germany): Hogrefe; 2000. 197 p. (Ger).
- Weglage J, Funders B, von Teeffelen-Heithoff A, Ullrich K. [Phenylketonuria--change in therapeutic strategies. Study of intellectual development and dietary compliance of young phenylketonuria patients]. *Fortschr Med* 1993 Nov 10;111(31):485-8. (Ger).
- Weglage J, Funders B, von Teeffelen-Heithoff A, Ullrich K. [Phenylketonuria: illness experience and coping mechanisms]. *Z Kinder Jugendpsychiatr* 1993 Sep;21(3):156-62. (Ger).
- Weglage J, Funders B, Wilken B, Schubert D, Schmidt E, Burgard P, Ullrich K. Psychological and social findings in adolescents with phenylketonuria. *Eur J Pediatr* 1992 Jul;151(7):522-5.
- Weglage J, Funders B, Wilken B, Schubert D, Ullrich K. School performance and intellectual outcome in adolescents with phenylketonuria. *Acta Paediatr* 1993 Jun-Jul;82(6-7):582-6.
- Weglage J, Funders B, Wilken B, von Teeffelen-Heithoff A, Ullrich K. [Treatment of phenylketonuria: wish and reality]. *Monatsschr Kinderheilkd* 1993 Aug;141(8):670-4. (Ger).
- Weglage J, Pietsch M, Denecke J, Sprinz A, Feldmann R, Grenzebach M, Ullrich K. Regression of neuropsychological deficits in early-treated phenylketonurics during adolescence. *J Inherit Metab Dis* 1999 Aug;22(6):693-705.
- Weglage J, Pietsch M, Funders B, Koch HG, Ullrich K. Deficits in selective and sustained attention processes in early treated children with phenylketonuria--result of impaired frontal lobe functions? *Eur J Pediatr* 1996 Mar;155(3):200-4.
- Weglage J, Rupp A, Schmidt E. Personality characteristics in patients with phenylketonuria treated early. *Pediatr Res* 1994 May;35(5):611-3.
- Weglage J, Ullrich K, Pietsch M, Funders B, Zass R, Koch HG. Untreated non-phenylketonuric-hyperphenylalaninaemia: intellectual and neurological outcome. *Eur J Pediatr* 1996 Jul;155 Suppl 1:S26-8.
- Welsh MC. A prefrontal dysfunction model of early-treated phenylketonuria. *Eur J Pediatr* 1996 Jul;155 Suppl 1:S87-9.
- Welsh MC, Pennington BF, Ozonoff S, Rouse B, McCabe ER. Neuropsychology of early-treated phenylketonuria: specific executive function deficits. *Child Dev* 1990 Dec;61(6):1697-713.
- Wendel U, Langenbeck U. Towards self-monitoring and self-treatment in phenylketonuria--a way to better diet compliance. *Eur J Pediatr* 1996 Jul;155 Suppl 1:S105-7.
- Wendel U, Ullrich K, Schmidt H, Batzler U. Six-year follow up of phenylalanine intakes and plasma phenylalanine concentrations. *Eur J Pediatr* 1990;149 Suppl 1:S13-6.
- Wenz E. Aspartame and PKU [letter]. *J Am Diet Assoc* 1984 Jan;84(1):101.
- Wester TJ, Lobleby() GE, Birnie LM, Lomax MA. Insulin stimulates phenylalanine uptake across the hind limb in fed lambs. *J Nutr* 2000 Mar;130(3):608-11.
- White JE, Kronmal RA, Acosta PB. Excess weight among children with phenylketonuria. *J Am Coll Nutr* 1982;1(3):293-303.
- Whitehead RG. Nutritional requirements of healthy adolescents and their significance during the

- management of PKU. *Eur J Pediatr* 1987;146 Suppl 1:A25-31.
- Widhalm K. Protein status of infants with phenylketonuria undergoing therapy [editorial]. *J Am Coll Nutr* 1999 Apr;18(2):99.
- Wilkinson H, Holbrook IB. Maternal phenylketonuria. *Ann Clin Biochem* 1998 Jul;35(Pt 4):539-41.
- Williams JM, Morris JG, Rogers QR. Phenylalanine requirement of kittens and the sparing effect of tyrosine. *J Nutr* 1987 Jun;117(6):1102-7.
- Williams K. Benefits of normalizing plasma phenylalanine: impact on behaviour and health. A case report. *J Inher Metab Dis* 1998 Dec;21(8):785-90.
- Williams SR. Nutritional therapy in special conditions of pregnancy. In: Worthington-Roberts BS, Vermeesch J, Williams SR, editors. *Nutrition in pregnancy and lactation*. 2nd ed. St Louis (MO): Mosby; 1981. p. 105-34.
- Williamson M, Dobson JC, Koch R. Collaborative study of children treated for phenylketonuria: study design. *Pediatrics* 1977 Dec;60(6):815-21.
- Williamson M, Koch R, Berlow S. Diet discontinuation in phenylketonuria [letter]. *Pediatrics* 1979 May;63(5):823-4.
- Williamson ML, Koch R, Azen C, Chang C. Correlates of intelligence test results in treated phenylketonuric children. *Pediatrics* 1981 Aug;68(2):161-7.
- Witt M, Jaruzelska J, Kuczora I, Matuszak R, Cichy W, Borski K. A simplified method for detection of the mutations predominantly causing cystic fibrosis and phenylketonuria in Polish families. *Clin Genet* 1993 Jul;44(1):44-5.
- Wolf-Novak LC, Stegink LD, Brummel MC, Persoon TJ, Filer LJ Jr, Bell EF, Ziegler EE, Krause WL. Aspartame ingestion with and without carbohydrate in phenylketonuric and normal subjects: effect on plasma concentrations of amino acids, glucose, and insulin. *Metabolism* 1990 Apr;39(4):391-6.
- Wong LT, Ireton CI, Davidson AG. Personal computer program for the dietary management of phenylketonuria. *J Can Diet Assoc* 1985 Summer;46(3):190-4.
- Wong RG, Acosta PB, Jones D, Koch R. Mineral balance in treated phenylketonuric children. *J Am Diet Assoc* 1970 Sep;57(3):229-33.
- Woo SL. Molecular basis and population genetics of phenylketonuria. *Biochemistry* 1989 Jan 10;28(1):1-7.
- Woo SL, DiLella AG, Marvit J, Ledley FD. Molecular basis of phenylketonuria and recombinant DNA strategies for its therapy. *Enzyme* 1987;38(1-4):207-13.
- Wood N, Bidwell J. Genetic screening and testing by induced heteroduplex formation. *Electrophoresis* 1996 Jan;17(1):247-54.
- Woodring JH, Rosenbaum HD. Bone changes in phenylketonuria reassessed. *AJR Am J Roentgenol* 1981 Aug;137(2):241-3.
- Wraith JE, Coutts J. Inborn errors of metabolism in children. In: Dickerson JW, Lee HA, editors. *Nutrition in the clinical management of disease*. 2nd ed. London: Edward Arnold; 1988. p. 69-87.
- Wretborn M, Humble E, Ragnarsson U, Engstrom L. Amino acid sequence at the phosphorylated site of rat liver phenylalanine hydroxylase and phosphorylation of a corresponding synthetic peptide. *Biochem Biophys Res Commun* 1980 Mar 28;93(2):403-8.
- Wrobel K, Wrobel K. Determination of aspartame and phenylalanine in diet soft drinks by high-performance liquid chromatography with direct spectrofluorimetric detection. *J Chromatogr A* 1997 Jun 27;773(1-2):163-8.
- Wurtman RJ, Ritter-Walker E, editors. *Conference on Dietary Phenylalanine and Brain Function*; 1987 May 8-10; Washington, DC. Boston (MA): Birkhauser; c1988. 391 p.
- Wykes LJ, Ball RO, Menendez CE, Ginther DM, Pencharz PB. Glycine, leucine, and phenylalanine flux in low-birth-weight infants during parenteral and enteral feeding. *Am J Clin Nutr* 1992 May;55(5):971-5.
- Yamada K, Shuto K, Kojima T, Marumo H, Tanaka M. Lipid-lowering effects of N-[4-methylbenzylthiocarbonyl]-L-phenylalanine (KF1492), a new phenylalanine derivative. *J Pharmacobiodyn* 1982 Aug;5(8):611-8.
- Yamakawa A, Kameoka Y, Hashimoto K, Yoshitake Y, Nishikawa K, Tanihara K, Date T. cDNA cloning and chromosomal mapping of genes encoding novel protein kinases termed PKU-alpha and PKU-beta, which have nuclear localization signal. *Gene* 1997 Nov 20;202(1-2):193-201.
- Yamamoto Y, Makita K, Muramatsu K. Self-selection of phenylalanine in the rat. *J Nutr Sci Vitaminol (Tokyo)* 1984 Jun;30(3):273-83.
- Yamamoto Y, Suzuki T, Muramatsu K. Effects of high dietary phenylalanine and p-chlorophenylalanine (Para-chlorophenylalanine) treatment on

- phenylalanine metabolism in the rat (Amino acid balance). *Agric Biol Chem* 1982 Oct;46(10):2491-7.
- Yang J, Wang P, Pittard AJ. Mechanism of repression of the *aroP* P2 promoter by the TyrR protein of *Escherichia coli*. *J Bacteriol* 1999 Oct;181(20):6411-8.
- Yannicelli S, Ryan A. Improvements in behaviour and physical manifestations in previously untreated adults with phenylketonuria using a phenylalanine-restricted diet: a national survey. *J Inher Metab Dis* 1995;18(2):131-4.
- Yeh SL, Ma FC, Shieh MJ, Wu KD, Hsiao KJ. [Dietary therapy of phenylketonuric patients in Taiwan]. *Taiwan I Hsueh Hui Tsa Chih* 1985 May;84(5):546-61. (Chi).
- Yellowlees H. Aspartame [letter]. *Br Med J (Clin Res Ed)* 1983 Sep 24;287(6396):912-3.
- Yoneyama T, Hatakeyama K. Decameric GTP cyclohydrolase I forms complexes with two pentameric GTP cyclohydrolase I feedback regulatory proteins in the presence of phenylalanine or of a combination of tetrahydrobiopterin and GTP. *J Biol Chem* 1998 Aug 7;273(32):20102-8.
- Zachara B. [Selenium and glutathione peroxidase in the blood of children]. *Pol Tyg Lek* 1983 Jul 11-18;38(28-29):909-13. (Pol).
- Zachara BA, Wasowicz W, Gromadzinska J, Sklodowska M, Cabalska B. Red blood cell glutathione peroxidase activity as a function of selenium supplementation in dietary treated children with phenylketonuria. *Biomed Biochim Acta* 1987;46(2-3):S209-13.
- Zammarchi E, Donati MA, Pasquini E, Ciani F, Lori S, Fonda C. Electromyographic alterations in hyperphenylalaninemia due to dihydropteridine reductase deficiency. *J Child Neurol* 1997 Feb;12(2):137-9.
- Zamotrinskii AV, Jennings IG, Cotton RG, Chestkov VV. [Detection of phenylalanine hydroxylase protein in human platelets. Immunochemical detection]. *Biokhimiia* 1990 Apr;55(4):760-5. (Rus).
- Zelinskaia DI, Ladodo KS, Rybakova EP, Baikov AD. [Organization of dietetic assistance to children with phenylketonuria]. *Vopr Pitan* 1998;(2):12-4. (Rus).
- Zello GA, Pencharz PB, Ball RO. Phenylalanine flux, oxidation, and conversion to tyrosine in humans studied with L-[1-13C]phenylalanine. *Am J Physiol* 1990 Dec;259(6 Pt 1):E835-43.
- Zeman J, Pijackova A, Behulova J, Urge O, Saligova, Hyanek J. Intellectual and school performance in adolescents with phenylketonuria according to their dietary compliance. The Czech-Slovak Collaborative Study. *Eur J Pediatr* 1996 Jul;155 Suppl 1:S56-8.
- Ziyai F, Wong PW, Justice P, Michals K. Protein-induced hypoglycemia in a phenylketonuric patient. *J Pediatr* 1978 Apr;92(4):681-2.

Drug Therapy

al Aqeel A, Ozand PT, Gascon G, Nester M, al Nasser M, Brismar J, Blau N, Hughes H, Subramanyan SB, Reynolds CT. Biopterin-dependent hyperphenylalaninemia due to deficiency of 6-pyruvoyl tetrahydropterin synthase. *Neurology* 1991 May;41(5):730-7. Comment in: *Neurology* 1992 Mar;42(3 Pt 1):704-5.

al Aqeel A, Ozand PT, Gascon GG, Hughes H, Reynolds CT, Subramanyam SB. Response of 6-pyruvoyl-tetrahydropterin synthase deficiency to tetrahydrobiopterin. *J Child Neurol* 1992 Apr;7 Suppl:S26-30.

Ali BH, Al-Qarawi AA, Mousa HM, Bashir AK, Tanira MOM, Patel M, Bayoumi R. Concentration of amino acids in brains of mice treated with the traditional medicinal plant *Rhazya stricta* decne. *Indian J Pharmacol* 2000;32(3):253-4.

Batshaw ML, Valle D, Bessman SP. Unsuccessful treatment of phenylketonuria with tyrosine. *J Pediatr* 1981 Jul;99(1):159-60.

Baumeister AA, Baumeister AA. Dietary treatment of destructive behavior associated with hyperphenylalaninemia. *Clin Neuropharmacol* 1998 Jan-Feb;21(1):18-27.

Beck B, Brandt NJ, Christensen E, Niederwieser A, Pedersen PS. Diagnostic and therapeutic aspects of dihydrobiopterin deficiency. *Acta Paediatr Scand* 1983 May;72(3):449-54.

Berry HK, Bofinger MK, Hunt MM, Phillips PJ, Guilfoile MB. Reduction of cerebrospinal fluid phenylalanine after oral administration of valine, isoleucine, and leucine. *Pediatr Res* 1982 Sep;16(9):751-5.

Berry HK, Brunner RL, Hunt MM, White PP. Valine, isoleucine, and leucine. A new treatment for phenylketonuria. *Am J Dis Child* 1990 May;144(5):539-43.

Bickel H. [Diet therapy and coenzyme therapy in hereditary metabolic diseases]. *Monatsschr Kinderheilkd* 1983 Aug;131(8):488-94. (Ger).

Blau N, Dhondt JL. Tetrahydrobiopterin deficiency and an international database of patients. *Adv Exp Med Biol* 1993;338:255-61.

Blau N, Ichinose H, Nagatsu T, Heizmann CW, Zacchello F, Burlina AB. A missense mutation in a patient with guanosine triphosphate cyclohydrolase I deficiency missed in the newborn screening program. *J Pediatr* 1995 Mar;126(3):401-5.

Bourget L, Chang TM. Effects of oral administration of artificial cells immobilized phenylalanine ammonia-lyase on intestinal amino acids of phenylketonuric rats. *Biomater Artif Cells Artif Organs* 1989;17(2):161-81.

Bourget L, Chang TM. Phenylalanine ammonia-lyase immobilized in microcapsules for the depletion of phenylalanine in plasma in phenylketonuric rat model. *Biochim Biophys Acta* 1986 Oct 1;883(3):432-8.

Bourget L, Chang TM. Phenylalanine ammonia-lyase immobilized in semipermeable microcapsules for enzyme replacement in phenylketonuria. *FEBS Lett* 1985 Jan 21;180(1):5-8.

Brown KJ. Physiological phenylketonuria: a biochemical defect caused by delayed maturation of the phenylalanine hydroxylation pathway and by competition with the phenylalanine biosynthetic pathway. *Med Hypotheses* 1980 Feb;6(2):215-24.

Brusov OS, Lideman RR. [Nerve growth factor and the state of serotonergic system in endogenous depression and mental retardation]. *Vestn Ross Akad Med Nauk* 1992;(8):16-21. (Rus).

Curtius HC, Farner H, Rey F. In vivo studies of the tryptophan-5-hydroxylase system. Quantitation of serotonin and tryptamine using gas chromatography-mass fragmentography. *J Chromatogr* 1980 Oct 31;199:171-9.

Curtius HC, Niederwieser A, Levine R, Muldner H. Therapeutic efficacy of tetrahydrobiopterin in Parkinson's disease. *Adv Neurol* 1984;40:463-6.

Dement'eva NF, Ermolina LA, Ezhkova VA, Mozhaeva EG. [Therapy and social adaptation of patients with mental retardation (a review of the literature)]. *Zh Nevropatol Psikhiatr* 1981;81(3):439-50. (Rus).

Denno KM, Sadler TW. Phenylalanine and its metabolites induce embryopathies in mouse embryos in culture. *Teratology* 1990 Nov;42(5):565-70.

Dhondt JL. Tetrahydrobiopterin deficiencies: preliminary analysis from an international survey. *J Pediatr* 1984 Apr;104(4):501-8.

Diamond A. Evidence for the importance of dopamine for prefrontal cortex functions early in life. *Philos Trans R Soc Lond B Biol Sci* 1996 Oct 29;351(1346):1483-93; discussion 1494.

Diamond A, Ciaramitaro V, Donner E, Djali S, Robinson MB. An animal model of early-treated PKU. *J Neurosci* 1994 May;14(5 Pt 2):3072-82.

Eisensmith RC, Martinez DR, Kuzmin AI, Goltsov AA, Brown A, Singh R, Elsas LJ II, Woo SL.

- Molecular basis of phenylketonuria and a correlation between genotype and phenotype in a heterogeneous southeastern US population. *Pediatrics* 1996 Apr;97(4):512-6.
- Endres W, Niederwieser A, Curtius HC, Wang M, Ohrt B, Schaub J. Atypical phenylketonuria due to biopterin deficiency. Early treatment with tetrahydrobiopterin and neurotransmitter precursors, trials of monotherapy. *Helv Paediatr Acta* 1982;37(5):489-98.
- Evans SJ, Wynne-Williams TC, Russell CA, Fairbrother A. Hyperphenylalaninaemia in parenterally fed newborn babies [letter]. *Lancet* 1986 Dec 13;2(8520):1404-5.
- Farriaux JP, Desombre-Denys D, Charles-Bassi MA, Dhondt JL. [Treatment of phenylketonuria. About twenty-one cases (author's transl)]. *Sem Hop* 1981 Feb 18-25;57(7-8):356-60. (Fre).
- Fukuda K, Tanaka T, Hyodo S, Kobayashi Y, Usui T. Hyperphenylalaninaemia due to impaired dihydrobiopterin biosynthesis: leukocyte function and effect of tetrahydrobiopterin therapy. *J Inherit Metab Dis* 1985;8(2):49-52.
- Furukawa Y, Kish SJ, Bebin EM, Jacobson RD, Fryburg JS, Wilson WG, Shimadzu M, Hyland K, Trugman JM. Dystonia with motor delay in compound heterozygotes for GTP-cyclohydrolase I gene mutations. *Ann Neurol* 1998 Jul;44(1):10-6.
- Griffiths P, Ward N, Harvie A, Cockburn F. Neuropsychological outcome of experimental manipulation of phenylalanine intake in treated phenylketonuria. *J Inherit Metab Dis* 1998 Feb;21(1):29-38.
- Haktan M, Aydin A, Bahat H, Tuysuz B, Yazici H, Altay S. Progressive systemic scleroderma in an infant with partial phenylketonuria. *J Inherit Metab Dis* 1989;12(4):486-7.
- Hanley WB, Feigenbaum A, Clarke JT, Schoonheydt W, Austin V. Vitamin B12 deficiency in adolescents and young adults with phenylketonuria [letter]. *Lancet* 1993 Oct 16;342(8877):997.
- Hoganson G, Berlow S, Kaufman S, Milstien S, Schuett V, Matalon R, Naylor E, Seifert W. Biopterin synthesis defects: problems in diagnosis. *Pediatrics* 1984 Dec;74(6):1004-11.
- Hoskins JA, Jack G, Wade HE, Peiris RJ, Wright EC, Starr DJ, Stern J. Enzymatic control of phenylalanine intake in phenylketonuria. *Lancet* 1980 Feb 23;1(8165):392-4.
- Huether G. The depletion of tryptophan and serotonin in the brain of developing hyperphenylalaninemic rats is abolished by the additional administration of lysine. *Neurochem Res* 1986 Dec;11(12):1663-8.
- Imamura T, Shintaku H, Nakajima T, Sawada Y, Isshiki G, Oura T. Experimental research on a new treatment for maternal phenylketonuria(PKU). *Adv Exp Med Biol* 1993;338:277-80.
- Jordan MK, Brunner RL, Hunt MM, Berry HK. Preliminary support for the oral administration of valine, isoleucine and leucine for phenylketonuria. *Dev Med Child Neurol* 1985 Feb;27(1):33-9.
- Kauf E, Seidel J, Winnefeld K, Dawczynski H, Hafer R, Stein F, Vogt L. [Selenium in phenylketonuria patients. Effects of sodium selenite administration]. *Med Klin* 1997 Sep 15;92 Suppl 3:31-4. (Ger).
- Kaufman S. Biopterin-responsive hyperphenylalaninemia. *J Nutr Sci Vitaminol (Tokyo)* 1992;Spec No:601-6.
- Kaufman S. Hyperphenylalaninaemia caused by defects in biopterin metabolism. *J Inherit Metab Dis* 1985;8 Suppl 1:20-7.
- Kaufman S, Kapatos G, McInnes RR, Schulman JD, Rizzo WB. Use of tetrahydropterins in the treatment of hyperphenylalaninemia due to defective synthesis of tetrahydrobiopterin: evidence that peripherally administered tetrahydropterins enter the brain. *Pediatrics* 1982 Sep;70(3):376-80.
- Kaufman S, Kapatos G, Rizzo WB, Schulman JD, Tamarkin L, Van Loon GR. Tetrahydropterin therapy for hyperphenylalaninemia caused by defective synthesis of tetrahydrobiopterin. *Ann Neurol* 1983 Sep;14(3):308-15.
- Kilpatrick NM, Awang H, Wilcken B, Christodoulou J. The implication of phenylketonuria on oral health. *Pediatr Dent* 1999 Nov-Dec;21(7):433-7.
- Kirby ML, Miyagawa ST. The effects of high phenylalanine concentration on chick embryonic development. *J Inherit Metab Dis* 1990;13(4):634-40.
- Krause W, Epstein C, Averbook A, Dembure P, Elsas L. Phenylalanine alters the mean power frequency of electroencephalograms and plasma L-dopa in treated patients with phenylketonuria. *Pediatr Res* 1986 Nov;20(11):1112-6.
- Kure S, Hou DC, Ohura T, Iwamoto H, Suzuki S, Sugiyama N, Sakamoto O, Fujii K, Matsubara Y, Narisawa K. Tetrahydrobiopterin-responsive phenylalanine hydroxylase deficiency. *J Pediatr* 1999 Sep;135(3):375-8.
- Le Coutour X, Brouard J, Bordenave-Tilliard C. [Phenylketonuria: new questions for another

- generation]. *J Gynecol Obstet Biol Reprod (Paris)* 1992;21(1):85-8. (Fre).
- Ledley FD, Woo SL. P-chlorophenylalanine does not inhibit production of recombinant human phenylalanine hydroxylase in NIH3T3 cells or *E. coli*. *Biochem Biophys Res Commun* 1987 Jan 30;142(2):302-8.
- Leeming RJ, Hall SK, Green A. The origin of red blood cell biopterin. *Mol Genet Metab* 1998 Dec;65(4):291-7.
- Levy HL. Reply to SP Bessman [letter]. *Am J Clin Nutr* 1998 Mar;67(3):488. Comment on: *Am J Clin Nutr* 1998 Mar;67(3):357-8.
- Levy HL. Treatment of phenylketonuria. *Prog Clin Biol Res* 1979;34:171-82.
- Lines DR. Aspartame doses for phenylketonuria [letter]. *J Nutr* 1981 Sep;111(9):1688-90.
- Link RM, Wachtel U. [Clinical experiences with an amino acid preparation in children with phenylketonuria]. *Rev Med Liege* 1984 May 15;39(10):422-8. (Fre).
- Lombeck I, Kasperek K, Bachmann D, Feinendegen LE, Bremer HJ. Selenium requirements in patients with inborn errors of amino acid metabolism and selenium deficiency. *Eur J Pediatr* 1980 Jun;134(1):65-8.
- Lombeck I, Menzel H, Steiner G, Kasperek K. Selenium supplementation: plasma glutathione peroxidase an indicator of selenium intake. *Klin Padiatr* 1982 Sep-Oct;194(5):303-5.
- Lou H. Large doses of tryptophan and tyrosine as potential therapeutic alternative to dietary phenylalanine restriction in phenylketonuria [letter]. *Lancet* 1985 Jul 20;2(8447):150-1.
- Malpuech G, Guyon A, Demeocq F, Piton A, Boespflug O, Vanlieferinghen P. [Malignant phenylketonuria caused by biopterin synthetase deficiency. Study of neuromediator catabolites in the cerebrospinal fluid during treatment]. *Arch Fr Pediatr* 1984 Jan;41(1):5-8. (Fre).
- Maternal Phenylketonuria Collaborative Study: a status report. *Nutr Rev* 1994 Nov;52(11):390-3.
- Mazzocco MM, Yannicelli S, Nord AM, van Doorninck W, Davidson-Mundt AJ, Greene CL. Cognition and tyrosine supplementation among school-aged children with phenylketonuria [letter]. *Am J Dis Child* 1992 Nov;146(11):1261-4.
- McInnes RR, Kaufman S, Warsh JJ, Van Loon GR, Milstien S, Kapatoss G, Soldin S, Walsh P, MacGregor D, Hanley WB. Biopterin synthesis defect. Treatment with L-dopa and 5-hydroxytryptophan compared with therapy with a tetrahydropterin. *J Clin Invest* 1984 Feb;73(2):458-69.
- Michals K, Matalon R. Phenylalanine metabolites, attention span and hyperactivity. *Am J Clin Nutr* 1985 Aug;42(2):361-5.
- Muntau AC, Beblo S, Koletzko B. [Phenylketonuria and hyperphenylalaninemia]. *Monatsschr Kinderheilkd* 2000;148(2):179-93. (Ger).
- Niederwieser A, Blau N, Wang M, Joller P, Atares M, Cardesa-Garcia J. GTP cyclohydrolase I deficiency, a new enzyme defect causing hyperphenylalaninemia with neopterin, biopterin, dopamine, and serotonin deficiencies and muscular hypotonia. *Eur J Pediatr* 1984 Feb;141(4):208-14.
- Niederwieser A, Curtius HC, Wang M, Leupold D. Atypical phenylketonuria with defective biopterin metabolism. Monotherapy with tetrahydrobiopterin or sepiapterin, screening and study of biosynthesis in man. *Eur J Pediatr* 1982 Mar;138(2):110-2.
- Pearson KD, Gean-Marton AD, Levy HL, Davis KR. Phenylketonuria: MR imaging of the brain with clinical correlation. *Radiology* 1990 Nov;177(2):437-40.
- Pietz J, Landwehr R, Kutscha A, Schmidt H, de Sonnevile L, Trefz FK. Effect of high-dose tyrosine supplementation on brain function in adults with phenylketonuria. *J Pediatr* 1995 Dec;127(6):936-43.
- Ponzone A, Guardamagna O, Dianzani I, Ponzone R, Ferrero GB, Spada M, Cotton RG. Catalytic activity of tetrahydrobiopterin in dihydropteridine reductase deficiency and indications for treatment. *Pediatr Res* 1993 Feb;33(2):125-8.
- Ponzone A, Guardamagna O, Ferraris S, Biasetti S, Bracco G, Niederwieser A. Neurotransmitter therapy and diet in malignant phenylketonuria [letter]. *Eur J Pediatr* 1987 Jan;146(1):93-4.
- Ponzone A, Guardamagna O, Ferraris S, Bracco G, Niederwieser A, Cotton RG. Two mutations of dihydropteridine reductase deficiency. *Arch Dis Child* 1988 Feb;63(2):154-7.
- Poustie VJ, Rutherford P. Tyrosine supplementation for phenylketonuria. *Cochrane Database Syst Rev* 2000;(2):CD001507.
- Rohr FJ, Lobbregt D, Levy HL. Tyrosine supplementation in the treatment of maternal phenylketonuria. *Am J Clin Nutr* 1998 Mar;67(3):473-6. Comment in: *Am J Clin Nutr* 1998 Mar;67(3):357-8; *Am J Clin Nutr* 1998 Dec;68(6):1306-7.

- Roskamp R, Mallmann R, Liappis N, Soetadjii S. Circulating serum phenylalanine concentrations and the effect of arginine infusion on plasma levels of growth hormone and insulin in treated phenylketonuric children. *Acta Endocrinol (Copenh)* 1987 Apr;114(4):483-7.
- Safos S, Chang TM. Enzyme replacement therapy in ENU2 phenylketonuric mice using oral microencapsulated phenylalanine ammonia-lyase: a preliminary report. *Artif Cells Blood Substit Immobil Biotechnol* 1995;23(6):681-92.
- Salomon F, Fagioli I, Rey F, Salzarulo P. [EEG sleep activity in a phenylketonuric child of the 'new variant' type, before and after treatment with 5-HTP and L-DOPA (author's transl)]. *Rev Electroencephalogr Neurophysiol Clin* 1981 Nov;11(2):212-7. (Fre).
- Salomon F, Fagioli I, Rey F, Salzarulo P. Sleep patterns in the new variant phenylketonuria. *Neuropediatrics* 1981 Aug;12(3):287-91.
- Schuler A, Kalmancey R, Barsi P, Somogyi CS, Toros I, Varadi I, Kovacs A, Blau N. Deprenyl in the treatment of patients with tetrahydrobiopterin deficiencies. *J Inherit Metab Dis* 2000;23(4):329-32.
- Scriver CR. Mutants: consumers with special needs. *Nutr Rev* 1971 Jul;29(7):155-8.
- Shen RS, Richardson CJ, Rouse BM, Abell CW. An enzymatic assay of plasma phenylalanine and tyrosine for the detection and management of phenylketonuria. *Biochem Med* 1981 Oct;26(2):211-21.
- Shintaku H, Nakajima T, Imamura T, Sawada Y, Isshiki G, Oura T. Experimental research on a fetal treatment for tetrahydrobiopterin deficiency. *Adv Exp Med Biol* 1993;338:273-6.
- Should dietary treatment of phenylketonuria be continued after infancy? *Nutr Rev* 1985 Jun;43(6):176-7.
- Smith I, Hyland K, Kendall B. Clinical role of pteridine therapy in tetrahydrobiopterin deficiency. *J Inherit Metab Dis* 1985;8 Suppl 1:39-45.
- Takahashi T, Kodama S, Nishio H, Takumi T, Matsuo T, Hase Y, Sawada Y. Transient hyperphenylalaninaemia with a high neopterin to biopterin ratio in urine. *J Inherit Metab Dis* 1985;8(3):105-8.
- Tanaka T, Aihara K, Iwai K, Kohashi M, Tomita K, Narisawa K, Arai N, Yoshida H, Usui T. Hyperphenylalaninemia due to impaired dihydrobiopterin biosynthesis. *Eur J Pediatr* 1981 Jul;136(3):275-80.
- Tracking at-risk school children with PKU, galactosemia. *Tex Nurs* 1995 May;69(5):9-10.
- Tu JB. Phenylketonuria: the inadvisability of neuroleptic medication. *Biol Psychiatry* 1980 Oct;15(5):797-802.
- Tu JB. Theory and practice of psychopharmacogenetics. *Am J Med Genet* 1994 Dec 15;54(4):391-7.
- Ullrich K, Weglage J, Oberwittler C, Pietsch M, Funders B, von Eckardstein H, Colombo JP. Effect of L-dopa on visual evoked potentials and neuropsychological tests in adult phenylketonuria patients. *Eur J Pediatr* 1996 Jul;155 Suppl 1:S74-7.
- Villasana D, Butler IJ, Williams JC, Roongta SM. Neurological deterioration in adult phenylketonuria. *J Inherit Metab Dis* 1989;12(4):451-7.
- Vis HL, Elmer C, Goyens P, Roumat G. [Phenylketonuria: current status of the problem]. *Bull Mem Acad R Med Belg* 1988;143(3-4):231-47. (Fre).
- Weglage J, Bick U, Schuierer G, Pietsch M, Sprinz A, Zass R, Ullrich K. Progression of cerebral white matter abnormalities in early treated patients with phenylketonuria during adolescence [letter]. *Neuropediatrics* 1997 Aug;28(4):239-40.
- Westwood A, Barr DG. Phenylketonuria with a progressive neurological disorder not responsive to tetrahydrobiopterin. *Acta Paediatr Scand* 1982 Sep;71(5):859-61.
- Williamson M, Dobson JC, Koch R. Collaborative study of children treated for phenylketonuria: study design. *Pediatrics* 1977 Dec;60(6):815-21.
- Woody RC, Brewster MA, Glasier C. Progressive intracranial calcification in dihydropteridine reductase deficiency prior to folinic acid therapy. *Neurology* 1989 May;39(5):673-5.
- Zachara BA, Wasowicz W, Gromadzinska J, Sklodowska M, Cabalska B. Red blood cell glutathione peroxidase activity as a function of selenium supplementation in dietary treated children with phenylketonuria. *Biomed Biochim Acta* 1987;46(2-3):S209-13.

Other Therapies and Therapy in General

Acosta PB, Dobson JC. Two metabolic factors in causation. In: Koch R, Dobson JC, editors. *The mentally retarded child and his family: a multidisciplinary handbook*. New York: Brunner/Mazel; c1976. p. 100-15.

Ambrus CM, Horvath C, Kalghatgi K, Clowsley M, Huzella C, Warner R, Ambrus JL, Cooley CM, Mirand EA. Depletion of phenylalanine in the blood of phenylketonuric patients using a PAL-enzyme reactor. An in vitro study. *Res Commun Chem Pathol Pharmacol* 1982 Jul;37(1):105-11.

Anderson DN, Wilkinson AM, Abou-Saleh MT, Blair JA. Recovery from depression after electroconvulsive therapy is accompanied by evidence of increased tetrahydrobiopterin-dependent hydroxylation. *Acta Psychiatr Scand* 1994 Jul;90(1):10-3.

Aoki K. [Disorders of amino acids]. *Nippon Rinsho* 1993 Jan;51 Suppl:332-9. (Jpn).

Bickel H. Recent advances in the early detection and treatment of inborn errors with brain damage. *Neuropadiatrie* 1969 Jun-Jul;1(1):1-11.

Birnbacher R, Scheibenreiter S, Blau N, Bieglmayer C, Frisch H, Waldhauser F. Hyperprolactinemia, a tool in treatment control of tetrahydrobiopterin deficiency: endocrine studies in an affected girl. *Pediatr Res* 1998 Apr;43(4 Pt 1):472-7.

Blau N, Thony B, Spada M, Ponzzone A. Tetrahydrobiopterin and inherited hyperphenylalaninemias. *Turk J Pediatr* 1996 Jan-Mar;38(1):19-35.

Boyle PJ. Shaping priorities in genetic medicine. *Hastings Cent Rep* 1995 May-Jun;25(3 Suppl):S2-8.

Briard ML. [Neonatal screening for phenylketonuria and hypothyroidism in France. A 12-year experience]. *Ann Biol Clin (Paris)* 1988;46(6):387-92. (Fre).

Burgard P, Bremer HJ, Buhrdel P, Clemens PC, Monch E, Przyrembel H, Trefz FK, Ullrich K. Rationale for the German recommendations for phenylalanine level control in phenylketonuria 1997. *Eur J Pediatr* 1999 Jan;158(1):46-54.

Carson NA. Diagnosis and management of hyperphenylalaninaemia. *Arch Dis Child* 1971 Dec;46(250):878-9.

Chang TM. Medical applications of artificial cells in transfusion, phenylketonuria, essential amino acid

production, and liver support. *Ann N Y Acad Sci* 1988;542:507-14.

Clow CL, Reade TM, Scriver CR. Management of hereditary metabolic disease. The role of allied health personnel. *N Engl J Med* 1971 Jun 10;284(23):1292-8.

Cohen BE, Szeinberg A, Quint J, Normand M, Blonder J, Peled I. Malignant phenylketonuria due to defective synthesis of dihydrobiopterin. *Isr J Med Sci* 1985 Jun;21(6):520-5.

Collaborative Study of Children Treated for Phenylketonuria. Management of newborn infants with phenylketonuria. [Rockville (MD)]: Department of Health, Education, and Welfare (US), Public Health Service, Health Services Administration, Bureau of Community Health Services; 1978. 35 p. (DHEW publication; no. (HSA) 78-5211).

Cornejo V, Raimann E, Moraga M, Colombo M. [Program of neonatal screening for phenylketonuria]. *Rev Chil Pediatr* 1990 Nov-Dec;61(6):309-12. (Spa).

Coskun T, Ozalp I, Kale G, Gogus S. Scleroderma-like skin lesions in two patients with phenylketonuria. *Eur J Pediatr* 1990 Dec;150(2):109-10.

Cristiano RJ, Smith LC, Woo SL. Hepatic gene therapy: adenovirus enhancement of receptor-mediated gene delivery and expression in primary hepatocytes. *Proc Natl Acad Sci U S A* 1993 Mar 15;90(6):2122-6.

Danks DM, Cotton RG. Future developments in phenylketonuria. *Enzyme* 1987;38(1-4):296-301.

De Giorgis GF, Nonnis E, Crocioni F, Gregori P, Rosini MP, Leuzzi V, Loizzo A. Evolution of daytime quiet sleep components in early treated phenylketonuric infants. *Brain Dev* 1996 May-Jun;18(3):201-6.

Diamond A, Prevor MB, Callender G, Druin DP. Prefrontal cortex cognitive deficits in children treated early and continuously for PKU. *Monogr Soc Res Child Dev* 1997;62(4):i-v, 1-208.

Eisensmith RC, Kuzmin AI, Krougliak VA. Prospects for the treatment of phenylketonuria by gene therapy. *Ment Retard Dev Disabil Res Rev* 1999;5(2):136-43.

Eisensmith RC, Woo SL. Gene therapy for phenylketonuria. *Acta Paediatr Suppl* 1994 Dec;407:124-9.

Eisensmith RC, Woo SL. Gene therapy for phenylketonuria. *Eur J Pediatr* 1996 Jul;155 Suppl 1:S16-9.

- Eisensmith RC, Woo SL. Molecular genetics of phenylketonuria: from molecular anthropology to gene therapy. *Adv Genet* 1995;32:199-271.
- Eisensmith RC, Woo SL. The potential application of somatic gene therapy to the treatment of phenylketonuria and other monogenic diseases. In: Platt LD, Koch R, de la Cruz F, editors. *Genetic disorders and pregnancy outcomes*. Lancaster (UK): Parthenon; 1997. p. 113-20.
- Eisensmith RC, Woo SL. Somatic gene therapy for phenylketonuria and other hepatic deficiencies. *J Inherit Metab Dis* 1996;19(4):412-23.
- Endres W, Blau N, Curtius HC. Newborn screening and treatment of hyperphenylalaninemia due to tetrahydrobiopterin deficiency. In: Schmidt BJ, Diamant AJ, Loghin-Grosso NS, editors. *Current trends in infant screening*. Proceedings of the 7th International Screening Symposium; 1988 Nov 6-9; Sao Paulo, Brazil. New York: Excerpta Medica; 1989. p. 77-82. (International congress series; no. 848).
- Fang B, Eisensmith RC, Li XH, Finegold MJ, Shedlovsky A, Dove W, Woo SL. Gene therapy for phenylketonuria: phenotypic correction in a genetically deficient mouse model by adenovirus-mediated hepatic gene transfer. *Gene Ther* 1994 Jul;1(4):247-54.
- Farriaux JP. [The newborn infant of a mother with phenylketonuria. A new challenge]. *Arch Fr Pediatr* 1989 Mar;46(3):163-5. (Fre).
- Fernhoff PM, Fitzmaurice N, Milner J, McEwen CT, Dembure PP, Brown AL, Wright L, Acosta PB, Elsas LJ 2d. Coordinated system for comprehensive newborn metabolic screening. *South Med J* 1982 May;75(5):529-32.
- Fisch RO, Tagatz G, Stassart JP. Gestational carrier--a reproductive haven for offspring of mothers with phenylketonuria (PKU): an alternative therapy for maternal PKU. *J Inherit Metab Dis* 1993;16(6):957-61.
- Fletcher JC. Ethical issues in genetic screening and antenatal diagnosis. *Clin Obstet Gynecol* 1981 Dec;24(4):1151-68.
- Fost N. Genetic diagnosis and treatment: ethical considerations. *Am J Dis Child* 1993 Nov;147(11):1190-5.
- Francois B. [Recent advances in the therapeutic approach to children with phenylketonuria]. *Rev Med Liege* 1984 May 15;39(10):416-21. (Fre).
- Gardiner RM. Transport of amino acids across the blood-brain barrier: implications for treatment of maternal phenylketonuria. *J Inherit Metab Dis* 1990;13(4):627-33.
- Giovannini M, Biasucci G, Agostoni C, Bellu R, Riva E. Fatty acid supplementation in a case of maternal phenylketonuria. *J Inherit Metab Dis* 1994;17(5):630-1.
- Gleason LA, Michals K, Matalon R, Langenberg P, Kamath S. A treatment program for adolescents with phenylketonuria. *Clin Pediatr (Phila)* 1992 Jun;31(6):331-5.
- Grasso AW, Wu GY. Therapeutic implications of delivery and expression of foreign genes in hepatocytes. *Adv Pharmacol* 1994;28:169-92.
- Griffiths P, Campbell R, Robinson P. Executive function in treated phenylketonuria as measured by the one-back and two-back versions of the continuous performance test. *J Inherit Metab Dis* 1998 Apr;21(2):125-35.
- Guttler F. Impact of medical genetics concerning phenylketonuria: accomplishments, status and practical future possibilities. *Clin Genet* 1989 Nov;36(5):333-4.
- Guttler F, Guldberg P. Mutations in the phenylalanine hydroxylase gene: genetic determinants for the phenotypic variability of hyperphenylalaninemia. *Acta Paediatr Suppl* 1994 Dec;407:49-56.
- Harding CO, Wild K, Chang D, Messing A, Wolff JA. Metabolic engineering as therapy for inborn errors of metabolism--development of mice with phenylalanine hydroxylase expression in muscle. *Gene Ther* 1998 May;5(5):677-83.
- Hnikova O, Hejzmanova L, Marek J, Schreiberova O. [Blood somatomedin levels in neonates with congenital hypothyroidism and phenylketonuria]. *Cesk Pediatr* 1991 Dec;46(12):537-40. (Cze).
- Hyanek J. [Maternal hyperphenylalaninemia]. *Cesk Gynkol* 1993 Jun;58(3):149-51. (Cze).
- Hyanek J, Kubik M, Simkova M, Zeman J, Hous'kova H. [Phenylketonuria undiagnosed, unrecognizable and neglected. Review of failures in diagnosis, therapy, and prevention of hereditary disorders of phenylalanine]. *Cesk Pediatr* 1987 Mar;42(3):134-8. (Cze).
- Hyland K. Presentation, diagnosis, and treatment of the disorders of monoamine neurotransmitter metabolism. *Semin Perinatol* 1999 Apr;23(2):194-203.
- Inoue S, Matsunaga Y, Iwane H, Sotomura M, Nose T. Entrapment of phenylalanine ammonia-lyase in silk fibroin for protection from proteolytic attack. *Biochem Biophys Res Commun* 1986 Nov 26;141(1):165-70.

- Juengst ET. "Prevention" and the goals of genetic medicine. *Hum Gene Ther* 1995 Dec;6(12):1595-605.
- Kaufman S. Enzymology of the phenylalanine-hydroxylating system. *Enzyme* 1987;38(1-4):286-95.
- Kaufman S. Phenylketonuria and its variants. *Adv Hum Genet* 1983;13:217-97.
- Kaufman S, Berlow S, Summer GK, Milstien S, Schulman JD, Orloff S, Spielberg S, Pueschel S. Hyperphenylalaninemia due to a deficiency of bipterin. A variant form of phenylketonuria. *N Engl J Med* 1978 Sep 28;299(13):673-9.
- Larue C, Munnich A, Charpentier C, Saudubray JM, Frezal J, Remy MH, Rivat C. An extracorporeal hollow-fiber reactor for phenylketonuria using immobilized phenylalanine ammonia lyase. *Dev Pharmacol Ther* 1986;9(2):73-81.
- Ledley FD. Somatic gene therapy for human disease: a problem of eugenics? *Trends Genet* 1987 Apr;3(4):112-5.
- Ledley FD. Somatic gene therapy for human disease: background and prospects. Part II. *J Pediatr* 1987 Feb;110(2):167-74.
- Ledley FD, Grenett HE, McGinnis-Shelnutt M, Woo SL. Retroviral-mediated gene transfer of human phenylalanine hydroxylase into NIH 3T3 and hepatoma cells. *Proc Natl Acad Sci U S A* 1986 Jan;83(2):409-13.
- Ledley FD, Hahn T, Woo SL. Selection for phenylalanine hydroxylase activity in cells transformed with recombinant retroviruses. *Somat Cell Mol Genet* 1987 Mar;13(2):145-54.
- Ledley FD, Woo SLC. Prospects for somatic gene therapy of phenylketonuria. *UCLA Symp Mol Cell Biol* 1987;55:565-79.
- Lenke RR. Maternal phenylketonuria and hyperphenylalaninemia: a problem born of success. *J Pediatr Perinat Nutr* 1987 Spring-Summer;1(1):67-74.
- Leuzzi V, Cardona F, Antonozzi I, Loizzo A. Visual, auditory, and somatosensorial evoked potentials in early and late treated adolescents with phenylketonuria. *J Clin Neurophysiol* 1994 Nov;11(6):602-6.
- Leuzzi V, Fois D, Carducci C, Antonozzi I, Trasimeni G. Neuropsychological and neuroradiological (MRI) variations during phenylalanine load: protective effect of valine, leucine, and isoleucine supplementation. *J Child Neurol* 1997 Aug;12(5):338-40.
- Lewis SA, Lyon IC, Elliott RB. Outcome of pregnancy in the rat with mild hyperphenylalaninaemia and hypertyrosinaemia: implications for the management of human maternal PKU. *J Inher Metab Dis* 1985;8(3):113-7.
- Lichter-Konecki U, Rupp A, Konecki DS, Trefz FK, Schmidt H, Burgard P. Relation between phenylalanine hydroxylase genotypes and phenotypic parameters of diagnosis and treatment of hyperphenylalaninaemic disorders. German Collaborative Study of PKU. *J Inher Metab Dis* 1994;17(3):362-5.
- Lin CM, Tan Y, Lee YM, Chang CC, Hsiao KJ. Expression of human phenylalanine hydroxylase activity in T lymphocytes of classical phenylketonuria children by retroviral-mediated gene transfer. *J Inher Metab Dis* 1997 Nov;20(6):742-54.
- Lines D, Magarey A, Raymond J, Robertson E. Tyrosine supplementation in phenylketonuria [letter]. *J Paediatr Child Health* 1997 Apr;33(2):177.
- Liu TJ, Kay MA, Darlington GJ, Woo SL. Reconstitution of enzymatic activity in hepatocytes of phenylalanine hydroxylase-deficient mice. *Somat Cell Mol Genet* 1992 Jan;18(1):89-96.
- Lutz P, Schmidt H, Batzler U. Study design and description of patients. *Eur J Pediatr* 1990;149 Suppl 1:S5-12.
- Matalon R, Michals K. Phenylketonuria: screening, treatment and maternal PKU. *Clin Biochem* 1991 Aug;24(4):337-42.
- Matsuda I. [Inborn error of amino acids metabolism--general aspect]. *Ryoikibetsu Shokogun Shirizu* 1998;(18 Pt 1):109-13. (Jpn).
- Matsuo N. Hyperphenylalaninemia syndromes: current status of diagnosis and management. *Keio J Med* 1988 Mar;37(1):1-9.
- Medical Research Council Working Party on Phenylketonuria. Phenylketonuria due to phenylalanine hydroxylase deficiency: an unfolding story. *BMJ* 1993 Jan 9;306(6870):115-9.
- Moats RA, Koch R, Moseley K, Guldborg P, Guttler F, Boles RG, Nelson MD Jr. Brain phenylalanine concentration in the management of adults with phenylketonuria. *J Inher Metab Dis* 2000 Feb;23(1):7-14.
- Nagao M. [Molecular pathology and DNA diagnosis of phenylketonuria and hypermethioninemia]. *Tanpakushitsu Kakusan Koso* 1998 May;43(6):762-9. (Jpn).
- Nagasaki Y, Matsubara Y, Takano H, Fujii K, Senoo M, Akanuma J, Takahashi K, Kure S, Hara M, Kanegae Y, Saito I, Narisawa K. Reversal of

- hypopigmentation in phenylketonuria mice by adenovirus-mediated gene transfer. *Pediatr Res* 1999 Apr;45(4 Pt 1):465-73.
- Niederwieser A. Diagnosis and treatment of tetrahydrobiopterin deficiency (malignant hyperphenylalaninemia). In: Benson PF, editor. *Screening and management of potentially treatable genetic metabolic disorders. Proceedings of the workshop*; 1983 Mar 17-18; London. Boston: MTP Press for the Commission; c1984. p. 115-25. (EUR; 9020).
- Novello AC. Inherited metabolic diseases: collaborating for the health of all children. *Biochem Med Metab Biol* 1993 Jun;49(3):277-84.
- O'Flynn ME. Newborn screening for phenylketonuria: thirty years of progress. *Curr Probl Pediatr* 1992 Apr;22(4):159-65.
- Ozalp I, Coskun T, Ozguc M, Tokatli A, Yalaz K, Vanli L, Yilmaz E, Erbay A. Genetic and neurological evaluation of untreated and late-treated patients with phenylketonuria. *J Inherit Metab Dis* 1994;17(3):371.
- Peng H, Armentano D, MacKenzie-Graham L, Shen RF, Darlington G, Ledley FD, Woo SL. Retroviral-mediated gene transfer and expression of human phenylalanine hydroxylase in primary mouse hepatocytes. *Proc Natl Acad Sci U S A* 1988 Nov;85(21):8146-50.
- Phenylketonuria, an international survey of management over 40 years. Proceedings of a workshop. Fulda, November 16-19, 1994. *Eur J Pediatr* 1996 Jul;155 Suppl 1:S1-180.
- Phenylketonuria: from biochemistry to treatment. Proceedings of a round table. Troina, Italy, May 12-14, 1997. Abstracts. *J Inherit Metab Dis* 1998 Aug;21 Suppl 3:1-52.
- Pietz J, Dunckelmann R, Rupp A, Rating D, Meinck HM, Schmidt H, Bremer HJ. Neurological outcome in adult patients with early-treated phenylketonuria. *Eur J Pediatr* 1998 Oct;157(10):824-30.
- Pietz J, Kreis R, Schmidt H, Meyding-Lamade UK, Rupp A, Boesch C. Phenylketonuria: findings at MR imaging and localized in vivo H-1 MR spectroscopy of the brain in patients with early treatment. *Radiology* 1996 Nov;201(2):413-20.
- Powledge TM. Commerce and the future of gene transfer. In: Milunsky A, Annas GJ, editors. *Genetics and the law III*. New York: Plenum Press; 1985. p. 75-9.
- Raper SE, Wilson JM. Cell transplantation in liver-directed gene therapy. *Cell Transplant* 1993 Sep-Oct;2(5):381-400; discussion 407-10. Comment in: *Cell Transplant* 1993 Sep-Oct;2(5):401-3; *Cell Transplant* 1993 Sep-Oct;2(5):405-6.
- Ris MD, Weber AM, Hunt MM, Berry HK, Williams SE, Leslie N. Adult psychosocial outcome in early-treated phenylketonuria. *J Inherit Metab Dis* 1997 Aug;20(4):499-508.
- Robertson M. Towards a medical eugenics? [editorial]. *BMJ* 1984 Feb 11;288(6415):429-30.
- Roricht S, Meyer BU, Irlbacher K, Ludolph AC. Impairment of callosal and corticospinal system function in adolescents with early-treated phenylketonuria: a transcranial magnetic stimulation study. *J Neurol* 1999 Jan;246(1):21-30.
- Roth KS. Newborn metabolic screening: a search for nature's experiments. *South Med J* 1986 Jan;79(1):47-54.
- Rouse B, Azen C, Koch R, Matalon R, Hanley W, de la Cruz F, Trefz F, Friedman E, Shifrin H. Maternal Phenylketonuria Collaborative Study (MPKUCS) offspring: facial anomalies, malformations, and early neurological sequelae. *Am J Med Genet* 1997 Mar 3;69(1):89-95.
- Runge DM, Runge D. [Somatic gene therapy. Initial clinical applications and current research approach]. *Fortschr Med* 1995 Aug 30;113(24):337-40. Comment in: *Fortschr Med* 1995 Aug 30;113(24):341. (Ger).
- Russell FF, Mills BC, Zucconi T. Relationship of parental attitudes and knowledge to treatment adherence in children with PKU. *Pediatr Nurs* 1988 Nov-Dec;14(6):514-6, 523.
- Safos SK. Phenylketonuria: enzyme replacement therapy using phenylalanine ammonia-lyase [masters thesis]. Montreal (Canada): McGill University; 1996. 148 p.
- Samankova M. [Phenylketonuria from the viewpoint of the parents of affected children]. *Cesk Pediatr* 1989 Dec;44(12):738-40. (Cze).
- Schuett VE. National survey of treatment programs for PKU and selected other inherited metabolic diseases. [Rockville (MD)]: Department of Health and Human Services (US), Public Health Service, Health Resources and Services Administration, Bureau of Maternal and Child Health and Resources Development, Office of Maternal and Child Health; 1990. 83 p. (DHHS publication; no. HRS-M-CH-89-5).
- Schuett VE, Gurda RF, Yandow JL (The Harry A. Waisman Center on Mental Retardation and Human Development, University of Wisconsin-Madison). Treatment programs for PKU and selected other

- metabolic diseases in the United States: a survey . Rockville (MD): Department of Health and Human Services (US), PublicHealth Service, Health Resources and Services Administration, Bureau of Health Care Delivery and Assistance; 1983. 35 p. (DHHS publication; no. (HRSA) 83-5296).
- Schuett VE, Yandow JL, Pringle DJ. Screening & treatment of PKU [slide]. Carrboro (NC): Health Sciences Consortium; 1986. 131 slides: color; 1 audiocassette: 38 min., 1 7/8 ips. Accompanied by: 1 guide.
- Schweitzer LB, Desnick RJ. Inherited metabolic diseases: advances in delineation, diagnosis, and treatment. *Birth Defects Orig Artic Ser* 1983;19(5):39-71.
- Scriver CR, Eisensmith RC, Woo SL, Kaufman S. The hyperphenylalaninemias of man and mouse. *Annu Rev Genet* 1994;28:141-65.
- Seashore MR, Wappner R, Cho S, de La Cruz F. Development of guidelines for treatment of children with phenylketonuria: report of a meeting at the National Institute of Child Health and Human Development held August 15, 1995, National Institutes of Health, Bethesda, Maryland. *Pediatrics* 1999 Dec;104(6):e67.
- Seymour CA, Thomason MJ, Chalmers RA, Addison GM, Bain MD, Cockburn F, Littlejohns P, Lord J, Wilcox AH. Newborn screening for inborn errors of metabolism: a systematic review. *Health Technol Assess* 1997;1(11):i-iv, 1-95.
- Shedlovsky A, McDonald JD, Symula D, Dove WF. Mouse models of human phenylketonuria. *Genetics* 1993 Aug;134(4):1205-10.
- Shintaku H. [Malignant hyperphenylalaninemia--tetrahydrobiopterin (BH4) deficiency]. *Tanpakushitsu Kakusan Koso* 1988 Apr;33(5):493-6. (Jpn).
- Shintaku H. [The metabolic basis of the hyperphenylalaninemias and tyrosinemia]. *Nippon Rinsho* 1992 Jul;50(7):1542-7. (Jpn).
- Simpson D. Phenylketonuria. *Midwives Chron* 1989 Feb;102(1213):37-41.
- Smith I. Long term outcome of early treated PKU due to phenylalanine hydroxylase deficiency. In: Farriaux JP, Dhondt JL, editors. *New horizons in neonatal screening. Proceedings of the 9th International Neonatal Screening Symposium and the 2nd Meeting of the International Society for Neonatal Screening*; 1993 Sep 13-17; Lille, France. New York: Elsevier Science; 1994. p. 73-7. (International congress series; no. 1041).
- Snyderman SE. Dietary and genetic therapy of inborn errors of metabolism: a summary. *Ann N Y Acad Sci* 1986;477:231-6.
- Snyderman SE. Treatment of phenylketonuria [letter]. *Am J Clin Nutr* 1998 Dec;68(6):1304-6. Comment on: *Am J Clin Nutr* 1998 Mar;67(3):357-8.
- Steiner KC, Smith HA. Application of cost-benefit analysis to a PKU screening program. *Inquiry* 1973 Dec;10(4):34-40.
- Stemerdink BA, van der Meere JJ, van der Molen MW, Kalverboer AF, Hendriks MM, Huisman J, van der Schot LW, Slijper FM, van Spronsen FJ, Verkerk PH. Information processing in patients with early and continuously-treated phenylketonuria. *Eur J Pediatr* 1995 Sep;154(9):739-46.
- Thieffry AF, Lebecq MF, Farriaux JP, Parquet P. [Psychological consequences, on the child and its family, of continuous management of phenylketonuric and hypothyroid children]. *Ann Pediatr (Paris)* 1985 Oct;32(8):651-9. (Fre).
- Thony B, Leimbacher W, Stuhlmann H, Heizmann CW, Blau N. Retrovirus-mediated gene transfer of 6-pyruvoyl-tetrahydropterin synthase corrects tetrahydrobiopterin deficiency in fibroblasts from hyperphenylalaninemic patients. *Hum Gene Ther* 1996 Aug 20;7(13):1587-93.
- Touraine RL, Guibaud P. [Genetics and hyperphenylalaninemias in 1992]. *Pediatric (Bucur)* 1992;47(1):9-21. Published erratum appears in *Pediatric* 1992;47(4):331. (Fre).
- Trefz FK, Lichter-Konecki U, Konecki DS, Schlotter M, Bickel H. PKU and NON-PKU hyperphenylalaninemia: differentiation, indication for therapy and therapeutic results. *Acta Paediatr Jpn* 1988 Aug;30(4):397-404.
- Vajro P, Strisciuglio P, Houssin D, Huault G, Laurent J, Alvarez F, Bernard O. Correction of phenylketonuria after liver transplantation in a child with cirrhosis [letter]. *N Engl J Med* 1993 Jul 29;329(5):363.
- Waisbren SE, Doherty LB, Bailey IV, Rohr FJ, Levy HL. The New England Maternal PKU Project: identification of at-risk women. *Am J Public Health* 1988 Jul;78(7):789-92.
- Waisbren SE, Hamilton BD, St. James PJ, Shiloh S, Levy HL. Psychosocial factors in maternal phenylketonuria: women's adherence to medical recommendations. *Am J Public Health* 1995 Dec;85(12):1636-41.

Wapnir RA. L-tryptophan in maternal phenylketonuria [letter]. *Am J Clin Nutr* 1998 Dec;68(6):1306-7.

Comment on: *Am J Clin Nutr* 1998 Mar;67(3):473-6.

Wasser S, Ettrich KU, Schmidt KD, Selle D, Theile H. [Case studies of the effect of tyrosine administration in children with phenylketonuria on cognitive processes]. *Klin Padiatr* 1992 Nov-Dec;204(6):417-21. (Ger).

Weglage J, Pietsch M, Funders B, Koch HG, Ullrich K. Neurological findings in early treated phenylketonuria. *Acta Paediatr* 1995 Apr;84(4):411-5.

Weglage J, Ullrich K, Pietsch M, Funders B, Guttler F, Harms E. Intellectual, neurologic, and neuropsychologic outcome in untreated subjects with nonphenylketonuria hyperphenylalaninemia. German Collaborative Study on Phenylketonuria. *Pediatr Res* 1997 Sep;42(3):378-84.

Wilke BC, Vidailhet M, Favier A, Guillemin C, Ducros V, Arnaud J, Richard MJ. Selenium, glutathione peroxidase (GSH-Px) and lipid peroxidation products before and after selenium supplementation. *Clin Chim Acta* 1992 Apr 30;207(1-2):137-42.

Wilke BC, Vidailhet M, Richard MJ, Ducros V, Arnaud J, Favier A. [Trace elements balance in treated phenylketonuria children. Consequences of selenium deficiency on lipid peroxidation]. *Arch Latinoam Nutr* 1993 Jun;43(2):119-22. (Fre).

Woo SL, DiLella AG, Marvit J, Ledley FD. Molecular basis of phenylketonuria and potential somatic gene therapy. *Cold Spring Harb Symp Quant Biol* 1986;51 Pt 1:395-401.

Woo SL, DiLella AG, Marvit J, Ledley FD. Molecular basis of phenylketonuria and recombinant DNA strategies for its therapy. *Enzyme* 1987;38(1-4):207-13.

Zetterstrom R. Editorial comment on phenylketonuria [editorial]. *Acta Paediatr* 1995 Jul;84(7):716-8.

Zhou AQ. [Clinical and laboratory study on 36 cases of phenylketonuria]. *Chung Hua I Hsueh Tsa Chih* 1983 Mar;63(3):150-3. (Chi).

Maternal PKU

Abadie V, Depondt E, Farriaux JP, Lepercq J, Lyonnet S, Maurin N, Ogier de Baulny H, Vidailhet M. [Pregnancy and the child of a mother with phenylketonuria]. *Arch Pediatr* 1996 May;3(5):489-6. (Fre).

Allen RJ, Brunberg J, Schwartz E, Schaefer AM, Jackson G. MRI characterization of cerebral dysgenesis in maternal PKU. *Acta Paediatr Suppl* 1994 Dec;407:83-5.

Ambulatory Nutrition Care: pregnant women. *J Am Diet Assoc* 1989 Apr;89(4 Suppl):S10-4.

American Academy of Pediatrics, Committee on Genetics. New issues in newborn screening for phenylketonuria and congenital hypothyroidism. *Pediatrics* 1982 Jan;69(1):104-6.

Anderson K, Acosta PB, Kennedy B. Osmolality of enteral formulas for maternal phenylketonuria. *J Inher Metab Dis* 1986;9(1):39-44.

Aspartame. Review of safety issues. Council on Scientific Affairs. *JAMA* 1985 Jul 19;254(3):400-2.

Austic RE, Su CL, Strupp BJ, Levitsky DA. Effects of dietary mixtures of amino acids on fetal growth and maternal and fetal amino acid pools in experimental maternal phenylketonuria. *Am J Clin Nutr* 1999 Apr;69(4):687-96.

Bankier A. Syndrome quiz. Maternal phenylketonuria. *Aust Fam Physician* 1990 Oct;19(10):1595-6.

Batshaw ML, Valle D, Bessman SP. Unsuccessful treatment of phenylketonuria with tyrosine. *J Pediatr* 1981 Jul;99(1):159-60.

Beaudette T, editor. Maternal nutritional status: effect on pregnancy outcome. *Semin Nutr* 1989 Mar-Apr;8(4):[24 p.].

Bequette BJ, Backwell FR, Dhanoa MS, Walker A, Calder AG, Wray-Cahen D, Metcalf JA, Sutton JD, Beever DE, Lobley GE. Kinetics of blood free and milk casein-amino acid labelling in the dairy goat at two stages of lactation. *Br J Nutr* 1994 Aug;72(2):211-20. Comment in: *Br J Nutr* 1996 Jan;75(1):139-40.

Bessman SP. Historical perspective: tyrosine and maternal phenylketonuria, welcome news [editorial]. *Am J Clin Nutr* 1998 Mar;67(3):357-8. Comment on: *Am J Clin Nutr* 1998 Mar;67(3):473-6. Comment in: *Am J Clin Nutr* 1998 Mar;67(3):488; *Am J Clin Nutr* 1998 Dec;68(6):1304-6.

Bessman SP. Phenylketonuria--a genetic intrauterine nutritional deficiency. *Nutr MD* 1992 Jan;18(1):5.

- Bessman SP, Choi H, Tomaszewski L. The justification theory: the effect of tyrosine deficiency on tubulin synthesis in the brain. *Prog Clin Biol Res* 1982;79:187-92.
- Bessman SP, Williamson ML, Koch R. Diet, genetics, and mental retardation interaction between phenylketonuric heterozygous mother and fetus to produce nonspecific diminution of IQ: evidence in support of the justification hypothesis. *Proc Natl Acad Sci U S A* 1978 Mar;75(3):1562-6.
- Bickel H. [Diet therapy and coenzyme therapy in hereditary metabolic diseases]. *Monatsschr Kinderheilkd* 1983 Aug;131(8):488-94. (Ger).
- Blomquist HK, Gustavson KH, Holmgren G. Severe mental retardation in five siblings due to maternal phenylketonuria. *Neuropediatrics* 1980 Aug;11(3):256-61.
- Boyce RA. The dietetic implications of maternal phenylketonuria. *Aust J Nutr Diet* 1991 Sep;48(3):82-8.
- Bradburn NC, Wappner RS, Lemons JA, Meyer BA, Roberts RS. Lactation and phenylketonuria. *Am J Perinatol* 1985 Apr;2(2):138-41.
- Brass CA, Isaacs CE, McChesney R, Greengard O. The effects of hyperphenylalaninemia on fetal development: a new animal model of maternal phenylketonuria. *Pediatr Res* 1982 May;16(5):388-94.
- Brenton DP. Cardiac defects in the children of mothers with high concentrations of plasma phenylalanine. *Br Heart J* 1990 Mar;63(3):143-4.
- Brenton DP. Maternal phenylketonuria. *Eur J Clin Nutr* 1989;43 Suppl 1:13-7.
- Brenton DP, Fraser D, Haseler ME, Krywawych S, Lachelin GC, Lilburn M, Stewart A. [Maternal phenylketonuria]. *Arch Fr Pediatr* 1987;44 Suppl 1:667-70. (Fre).
- Brenton DP, Lilburn M. Maternal phenylketonuria. A study from the United Kingdom. *Eur J Pediatr* 1996 Jul;155 Suppl 1:S177-80.
- Brodie M. Maternal phenylketonuria: an Arkansas experience. *Top Clin Nutr* 1992 Dec;8(1):39-44.
- Buist NR, Tuerck J, Lis E, Penn R. Effects of untreated maternal phenylketonuria and hyperphenylalaninemia on the fetus [letter]. *N Engl J Med* 1984 Jul 5;311(1):52-3.
- Burns JK, Azen CG, Rouse B, Vespa H. Impact of PKU on the reproductive patterns in collaborative study families. *Am J Med Genet* 1984 Nov;19(3):515-24.
- Bush RT, Dukes PC. Women with phenylketonuria: successful management of pregnancy and implications. *N Z Med J* 1985 Mar 27;98(775):181-3.
- Butler IJ, O'Flynn ME, Seifert WE Jr, Howell RR. Neurotransmitter defects and treatment of disorders of hyperphenylalaninemia. *J Pediatr* 1981 May;98(5):729-33.
- Cabalska B, Miesowicz I, Zorska K, Nowaczewska I, Duczynska N. Influence of the phenylketonuric heterozygote on the developing fetus. *J Inherit Metab Dis* 1982;5(3):129-31.
- Cabalska B, Nowaczewska I, Duczynska N. Plasma amino acid pattern in phenylketonuric heterozygotes during pregnancy. *Biochem Med* 1982 Jun;27(3):269-77.
- Caldwell J. Maternal PKU -- a new threat to the unborn... a major cause of new cases of mental retardation. *Am-Baby Prenatal Ed* 1981 Oct;43:16 passim.
- Campistol Plana J, Arellano Pedrola M, Poo Arguelles P, Escofet Sotera C, Perez Olarte P, Vilaseca Busca MA. [Embryonic pathology caused by maternal phenylketonuria. A cause of underdiagnosed mental retardation. A report of 8 cases]. *An Esp Pediatr* 1999 Aug;51(2):139-42. (Spa).
- Carbohydrate and glycoprotein metabolism, maternal phenylketonuria. 27th annual SSIEM meeting. Munich, 1989. *J Inherit Metab Dis* 1990;13(4):393-671.
- Cartier L, Clow CL, Lippman-Hand A, Morissette J, Scriver CR. Prediction and prevention of maternal phenylketonuria (PKU) with a registry. In: Schmidt BJ, Diament AJ, Loghin-Grosso NS, editors. *Current trends in infant screening. Proceedings of the 7th International Screening Symposium; 1988 Nov 6-9; Sao Paulo, Brazil. New York: Excerpta Medica; 1989. p. 63. (International congress series; no. 848).*
- Cartier L, Clow CL, Lippman-Hand A, Morissette J, Scriver CR. Prevention of mental retardation in offspring of hyperphenylalaninemic mothers. *Am J Public Health* 1982 Dec;72(12):1386-90.
- Cechak P, Hejzmanova L, Rupp A. Long-term follow-up of patients treated for phenylketonuria (PKU). Results from the Prague PKU Center. *Eur J Pediatr* 1996 Jul;155 Suppl 1:S59-63.
- Cerone R, Cohen A, Romano C. Prevention and screening. *J Perinat Med* 1994;22 Suppl 1:5-8.
- Chamove AS. Analysis of learning in retarded monkeys. *J Ment Defic Res* 1984 Mar;28 (Pt 1):21-41.

- Chamove AS. Dietary and metabolic effects on rhesus social behavior: phenylalanine-related dietary alterations. *Dev Psychobiol* 1980 May;13(3):299-307.
- Chamove AS. Long-term learning deficits of mentally retarded monkeys. *Am J Ment Defic* 1984 Jan;88(4):352-68.
- Chung S. The effect of maternal blood phenylalanine level on mouse maternal phenylketonuria offspring [dissertation]. Tucson: The University of Arizona; 1999. 74 p.
- Cipic-Schmidt S, Trefz FK, Funders B, Seidlitz G, Ullrich K. German Maternal Phenylketonuria Study. *Eur J Pediatr* 1996 Jul;155 Suppl 1:S173-6.
- Clark BJ, Cockburn F. Management of inborn errors of metabolism during pregnancy. *Acta Paediatr Scand Suppl* 1991;373:43-52.
- Clark SE, Karn CA, Ahlrichs JA, Wang J, Leitch CA, Leichty EA, Denne SC. Acute changes in leucine and phenylalanine kinetics produced by parenteral nutrition in premature infants. *Pediatr Res* 1997 Apr;41(4 Pt 1):568-74.
- Cockburn F, Clark BJ. Recommendations for protein and amino acid intake in phenylketonuric patients. *Eur J Pediatr* 1996 Jul;155 Suppl 1:S125-9.
- Cockburn F, Farquhar JW, Forfar JO, Giles M, Robins SP. Maternal hyperphenylalaninaemia in the normal and phenylketonuric mother and its influence on maternal plasma and fetal fluid amino acid concentrations. *J Obstet Gynaecol Br Commonw* 1972 Aug;79(8):698-707.
- Cohen BE, Weiss R, Hadar R, Normand M, Shiloh S, Elhanati D. Group work with adolescent PKU girls and their mothers. *J Inherit Metab Dis* 1988;11(2):199-206.
- Corbeel L. [Problems posed by maternal phenylketonuria]. *Arch Fr Pediatr* 1983;40 Suppl 1:281-2. (Fre).
- Corsello G, Bosco P, Cali F, Greco D, Cammarata M, Ciaccio M, Piccione M, Romano V. Maternal phenylketonuria in two Sicilian families identified by maternal blood phenylalanine level screening and identification of a new phenylalanine hydroxylase gene mutation (P407L) [letter]. *Eur J Pediatr* 1999 Jan;158(1):83-4.
- Cowie V. The effect of the environment... can put fetuses at risk of mental subnormality. *Nurs Mirror* 1982 Sep 15;155(11):34-6.
- Cowie V. Injury and insult--considerations of the neuropathological aetiology of mental subnormality. *Br J Psychiatry* 1980 Oct;137:305-12.
- Dagenais DL, Courville L, Dagenais MG. A cost-benefit analysis of the Quebec Network of Genetic Medicine. *Soc Sci Med* 1985;20(6):601-7.
- Dahl HH, Osborn AH, Hutchison WM, Thorburn DR, Sheffield LJ. Late diagnosis of maternal PKU in a family segregating an arylsulfatase [corrected] E mutation causing symmetrical chondrodysplasia punctata. *Mol Genet Metab* 1999 Dec;68(4):503-6.
- Davidson DC. Maternal phenylketonuria. *Postgrad Med J* 1989;65 Suppl 2:S10-20.
- Davidson DC. Maternal PKU pre-conception treatment--the need for free prescriptions. *Midwives Chron* 1989 Feb;102(1213):43.
- Davidson DC, Isherwood DM, Ireland JT, Rae PG. Outcome of pregnancy in a phenylketonuric mother after low phenylalanine diet introduced from the ninth week of pregnancy. *Eur J Pediatr* 1981 Sep;137(1):45-8.
- de Freitas O, Izumi C, Lara MG, Greene LJ. New approaches to the treatment of phenylketonuria. *Nutr Rev* 1999 Mar;57(3):65-70.
- De Klerk JB, Wadman SK, Dijkhuis HJ, Meuleman EE. Maternal PKU syndrome in an exceptional family with unexpected PKU. *J Inherit Metab Dis* 1987;10(2):162-70.
- de Valk HW, de Sonnevill LM, Duran M, Poll-The BT, Erkelens DW. [Phenylketonuria: a children's disease in adulthood]. *Ned Tijdschr Geneesk* 2000 Jan 1;144(1):11-5. (Dut).
- deMira NV, Marquez UM. [Diagnoses and treatment of phenylketonuria]. *Rev Saude Publica* 2000;34:86-96. (Por).
- Denno KM, Sadler TW. Phenylalanine and its metabolites induce embryopathies in mouse embryos in culture. *Teratology* 1990 Nov;42(5):565-70.
- Dews PB. Summary report of an International Aspartame Workshop. *Food Chem Toxicol* 1987 Jul;25(7):549-52.
- Dhondt JL, Ardouin P, Hayte JM, Farriaux JP. Developmental aspects of pteridine metabolism and relationships with phenylalanine metabolism. *Clin Chim Acta* 1981 Oct 26;116(2):143-52.
- Dodinval P. [Does medical progress entail deterioration of our genetic heritage?]. *Rev Med Liege* 1980 Jan 1;35(1):11-9. (Fre).
- Dorland L, Poll-The BT, Duran M, Smeitink JA, Berger R. Phenylpyruvate, fetal damage, and maternal phenylketonuria syndrome [letter]. *Lancet* 1993 May 22;341(8856):1351-2.

- Drogari E, Smith I, Beasley M, Lloyd JK. Timing of strict diet in relation to fetal damage in maternal phenylketonuria. An international collaborative study by the MRC/DHSS Phenylketonuria Register. *Lancet* 1987 Oct 24;2(8565):927-30.
- Duran GP, Rohr FJ, Slonim A, Guttler F, Levy HL. Necessity of complete intake of phenylalanine-free amino acid mixture for metabolic control of phenylketonuria. *J Am Diet Assoc* 1999 Dec;99(12):1559-63.
- Eisenberg L. Child mental health in the Americas: a public health approach. *Bull Pan Am Health Organ* 1992;26(3):230-41.
- Endres W. [Differential diagnosis and therapy of various forms of hyperphenylalaninemia: facts and fiction]. *Wien Klin Wochenschr* 1992;104(16):503-9. (Ger).
- Faden RR, Chwalow AJ, Holtzman NA, Horn SD. A survey to evaluate parental consent as public policy for neonatal screening. *Am J Public Health* 1982 Dec;72(12):1347-52.
- Farquhar DL, Simpson GK, Steven F, Munro JF, Farquhar JW. Pre-conceptual dietary management for maternal phenylketonuria. *Acta Paediatr Scand* 1987 Mar;76(2):279-83.
- Farquhar DL, Steven F, Westwood A. Preliminary report on inverse diurnal variation of phenylalanine: implications in maternal phenylketonuria. *Hum Nutr Appl Nutr* 1985 Jun;39(3):224-6.
- Farriaux JP. [The newborn infant of a mother with phenylketonuria. A new challenge]. *Arch Fr Pediatr* 1989 Mar;46(3):163-5. (Fre).
- Farriaux JP, Dhondt JL, Largilliere C. [The newborn infant of the phenylketonuric mother]. *Arch Fr Pediatr* 1983;40 Suppl 1:283-7. (Fre).
- Farriaux JP, Dhont JL. [Hyperphenylalaninemia in 1983]. *Rev Med Brux* 1983 Apr;4(4):305-10. (Fre).
- Fisch RO. Outcome of untreated vs treated PKU pregnancies [letter]. *J Pediatr* 1987 Sep;111(3):475.
- Fisch RO, Burke B, Bass J, Ferrara TB, Matri A. Maternal phenylketonuria-chronology of the detrimental effects on embryogenesis and fetal development: pathological report, survey, clinical application. *Pediatr Pathol* 1986;5(3-4):449-61.
- Fisch RO, Matalon R, Weisberg S, Michals K. Children of fathers with phenylketonuria: an international survey. *J Pediatr* 1991 May;118(5):739-41.
- Fisch RO, Tagatz G, Stassart JP. Gestational carrier--a reproductive haven for offspring of mothers with phenylketonuria (PKU): an alternative therapy for maternal PKU. *J Inher Metab Dis* 1993;16(6):957-61.
- Fost N. Maternal-fetal conflicts: Ethical and legal considerations. In: Hutchings DE, et al., editors. *Prenatal abuse of licit and illicit drugs*. New York: New York Academy of Sciences; 1989. p. 248-54. (*Annals of the New York Academy of Sciences*; vol. 562).
- Fox-Bacon C, McCamman S, Therou L, Moore W, Kipp DE. Maternal PKU and breastfeeding: case report of identical twin mothers. *Clin Pediatr (Phila)* 1997 Sep;36(9):539-42.
- Franz M. Is it safe to consume aspartame during pregnancy? A review. *Nutrition update. Diabetes Educ* 1986 Spring;12(2):145-7.
- Freedman M. Consumption of aspartame by heterozygotes for phenylketonuria [letter]. *J Pediatr* 1987 Apr;110(4):662-3.
- Frezal J, Farriaux JP. [Phenylketonuria yesterday and today. Evaluation of the work of systematic neonatal screening]. *Rev Prat* 1992 Nov 15;42(18):2316-26. (Fre).
- Friedman EG, Koch R, Azen C, Levy H, Hanley W, Matalon R, Rouse B, Trefz F, de la Cruz F. The International Collaborative Study on maternal phenylketonuria: organization, study design and description of the sample. *Eur J Pediatr* 1996 Jul;155 Suppl 1:S158-61.
- Friedman JF. Low protein food products: A cornerstone in the management of PKU. *Top Clin Nutr* 1992 Dec;8(1):72-6.
- Fulton TR, Triano T, Rabe A, Loo YH. Phenylacetate and the enduring behavioral deficit in experimental phenylketonuria. *Life Sci* 1980 Oct 6;27(14):1271-81.
- Garcia C, Baldellou A, Gimenez-Mas JA, Gracia J, Sanz-Moncasi MP, Enriquez JA, Muino-Blanco MT, Lopez-Perez MJ, Perez-Gonzalez J. Synaptosomal development in rats from phenylketonuric mothers. *J Inher Metab Dis* 1996;19(3):385-6.
- Garcia Vera C, Baldellou Vazquez A, Gracia Romero J, Ventura Faci P, Perez-Gonzalez J. [An experimental study on the effects of maternal hyperphenylalaninemia on the central nervous system and behavior of offspring rats]. *An Esp Pediatr* 1998 Jan;48(1):11-6. (Spa).
- Gardiner RM. Transport of amino acids across the blood-brain barrier: implications for treatment of

- maternal phenylketonuria. *J Inherit Metab Dis* 1990;13(4):627-33.
- Gazmararian JA, Solomon FM. Receipt of home health care after early discharge: results from a national managed care organization. *Matern Child Health J* 1997 Sep;1(3):151-6.
- Ghavami M, Levy HL, Erbe RW. Prevention of fetal damage through dietary control of maternal hyperphenylalaninemia. *Clin Obstet Gynecol* 1986 Sep;29(3):580-5.
- Gibbins B. Keeping phenylketonuria under control. *Mod Midwife* 1994 Oct;4(10):23-6.
- Gibbins B. Phenylketonuria--a personal view. *Mod Midwife* 1994 Oct;4(10):27.
- Giovannini M, Biasucci G, Agostoni C, Bellu R, Riva E. Fatty acid supplementation in a case of maternal phenylketonuria. *J Inherit Metab Dis* 1994;17(5):630-1.
- Goldin KR. Maternal and infant serum phenylalanine levels and pregnancy outcome in infants of nonphenylketonuric mothers. *J Natl Med Assoc* 1993 Aug;85(8):617-20.
- Guldberg P, Levy HL, Hanley WB, Koch R, Matalon R, Rouse BM, Trefz F, de la Cruz F, Henriksen KF, Guttler F. Phenylalanine hydroxylase gene mutations in the United States: report from the Maternal PKU Collaborative Study. *Am J Hum Genet* 1996 Jul;59(1):84-94.
- Gungor N, Tokath A, Coskun T, Ozguc M, Ozalp I. Microcephaly in a hyperphenylalaninemic infant leading to the diagnosis of maternal hyperphenylalaninemia [letter]. *Eur J Pediatr* 1996 Mar;155(3):257-8. Comment in: *Eur J Pediatr* 1996 Nov;155(11):992.
- Gurry DL, Rae AI, Walters BN. Maternal PKU in Western Australia - a small controlled trial. In: Wilcken B, Webster D, editors. Neonatal screening in the nineties. Proceedings of the 8th International Neonatal Screening Symposium; 1991 Nov 12-15; Leura, New South Wales, Australia and the Arthur Veale Memorial Meeting; 1991 Nov 5-9; Auckland, New Zealand. Australia: The Symposium; 1991. p. 324-6.
- Guthrie R. Maternal PKU--a continuing problem [editorial]. *Am J Public Health* 1988 Jul;78(7):771.
- Guttler F. Phenylketonuria: 50 years since Folling's discovery and still expanding our clinical and biochemical knowledge. *Acta Paediatr Scand* 1984 Nov;73(6):705-16.
- Guttler F. The Scandinavian maternal PKU collaborative study. In: Wilcken B, Webster D, editors. Neonatal screening in the nineties. Proceedings of the 8th International Neonatal Screening Symposium; 1991 Nov 12-15; Leura, New South Wales, Australia and the Arthur Veale Memorial Meeting; 1991 Nov 5-9; Auckland, New Zealand. Australia: The Symposium; 1991. p. 323.
- Guttler F, Azen C, Guldberg P, Romstad A, Hanley WB, Levy HL, Matalon R, Rouse BM, Trefz F, de la Cruz F, Koch R. Relationship among genotype, biochemical phenotype, and cognitive performance in females with phenylalanine hydroxylase deficiency: report from the Maternal Phenylketonuria Collaborative Study. *Pediatrics* 1999 Aug;104(2 Pt 1):258-62.
- Guttler F, Lou H, Andresen J, Kok K, Mikkelsen I, Nielsen KB, Nielsen JB. Cognitive development in offspring of untreated and preconceptionally treated maternal phenylketonuria. *J Inherit Metab Dis* 1990;13(4):665-71.
- Hall JG. When is careless conception a form of child abuse? Lessons from maternal phenylketonuria [editorial]. *J Pediatr* 2000 Jan;136(1):12-3. Comment on: *J Pediatr* 2000 Jan;136(1):57-61.
- Hanley WB, Bell L. Maternal phenylketonuria: finding and treating women before conception. *Can Med Assoc J* 1982 Jun 1;126(11):1259-60.
- Hanley WB, Clarke JT, Schoonheydt W. Maternal phenylketonuria (PKU)--a review. *Clin Biochem* 1987 Jun;20(3):149-56.
- Hanley WB, Koch R, Levy HL, Matalon R, Rouse B, Azen C, de la Cruz F. The North American Maternal Phenylketonuria Collaborative Study, developmental assessment of the offspring: preliminary report. *Eur J Pediatr* 1996 Jul;155 Suppl 1:S169-72.
- Hanulak AT, Hull EM. Behavioral deficits in a rat model of maternal PKU. *Psychobiology* 1987 Mar;15(1):75-8.
- Harte FB, Molloy O, Cahalane SF. Maternal screening trial for inborn errors of metabolism. *Ir Med J* 1982 Aug;75(8):274-5.
- Hayes JS, Rarback S, Berry BE, Clancy MK. Managing PKU: an update. *MCN Am J Matern Child Nurs* 1987 Mar-Apr;12(2):119-23. Published erratum appears in *MCN* 1987 Jul-Aug;12(4):239.
- Henderson RA. PKU and maternal PKU: the cure and the problem. *B C J Spec Ed* 1989;13(3):253-7.
- Henglein D, Niederhoff H, Bode H. Origin of the left coronary artery from the right pulmonary artery and ventricular septal defect in a child of a mother with

- raised plasma phenylalanine concentrations throughout pregnancy. *Br Heart J* 1990 Mar;63(3):180-2.
- Hersh JH, Podruch PE, Rogers G, Weisskopf B. Toluene embryopathy. *J Pediatr* 1985 Jun;106(6):922-7.
- Hickey CA, Covington C. Maternal phenylketonuria: case management as a preventive approach to a chronic condition affecting pregnancy. *NAACOGS Clin Issu Perinat Womens Health Nurs* 1990;1(2):214-25.
- Hirano S, Takagi Y, Kanamatsu T, Nakai K. Effects of hyperphenylalaninemia in the fetal stage on the postnatal development of fetal rat brain. *Neurochem Res* 1985 Aug;10(8):1071-81.
- Holder MD. Effects of perinatal exposure to aspartame on rat pups. *Neurotoxicol Teratol* 1989 Jan-Feb;11(1):1-6.
- Holt KS. Diets and development. *Child Care Health Dev* 1982 Jul-Aug;8(4):183-201.
- Holtzman NA, Faden R, Chwalow AJ, Horn SD. Effect of informed parental consent on mothers' knowledge of newborn screening. *Pediatrics* 1983 Dec;72(6):807-12.
- Hornchen H. Hyperphenylalaninämien: Maternal Phenylketonurie - Behandlung und genetische Beratung. In: Bickel H, Wachtel U, editors. *Neugeborenen-Screening auf hereditäre Stoffwechselstörungen : gegenwärtiger Stand und künftige Entwicklung. 1 Tagung der Arbeitsgemeinschaft Neugeborenen-Screening.* New York: Thieme; 1983. p. 59-60. (Ger).
- Hoshiga M, Hatakeyama K, Watanabe M, Shimada M, Kagamiyama H. Autoradiographic distribution of [¹⁴C]tetrahydrobiopterin and its developmental change in mice. *J Pharmacol Exp Ther* 1993 Nov;267(2):971-8.
- Howell RR, Stevenson RE. The offspring of phenylketonuric women. *Soc Biol* 1971 Sep;18:S19-29.
- Hsiao KJ, Chen CH, Chiu PC, Huang SC, Wu KD. A Chinese family with phenylketonuria and maternal phenylketonuria detected by family screening. *Eur J Pediatr* 1986 Oct;145(5):409-12.
- Huang RT, Lin SJ, Kuo PL, Peng CJ. Successful management of a pregnancy with maternal phenylketonuria: report of a case. *J Formos Med Assoc* 1993 Feb;92(2):182-4.
- Hurst JD, Stullenbarger B. Implementation of a self-care approach in a pediatric interdisciplinary phenylketonuria (PKU) clinic. *J Pediatr Nurs* 1986 Jun;1(3):159-63.
- Hyanek J. [Maternal hyperphenylalaninemia]. *Cesk Gynekol* 1993 Jun;58(3):149-51. (Cze).
- Hyanek J, Bendl J, Zeman J, Soukup K, Dolezal A, Kozich V, St'astna S, Kubik M, Viletova H. [Maternal hyperphenylalaninemia in a population of healthy Czech women. 18 years' experience with mass screening, diet therapy and metabolic monitoring]. *Cas Lek Cesk* 1996 Jan 17;135(2):50-3. (Cze).
- Hyanek J, Homolka J, Trnka J, Seemanova E, Cervenka J, Tresohlava Z, Kapras J, Dolezal A, Sracek J, Vacha V, Hoza J, Losan F, Nevsimalova S, Mala M, Viletova H. Results of screening for phenylalanine and other amino acid disturbances among pregnant women. *J Inherit Metab Dis* 1980;2(3):59-63.
- Hyanek J, Viletova H, Soukup J, Kobilkova J, Kubik M, Kunova V. [Changes in phenylalanine tolerance during the monitoring of diet therapy of pregnant women with phenylketonuria]. *Cesk Gynekol* 1988 Nov;53(9):650-3. (Cze).
- Hyanek J, Viletova H, Soukup J, Kobilkova J, Kubik M, Kunova V. Changes in phenylalanine tolerance while monitoring the dietetic treatment of pregnant women suffering from hyperphenylalaninaemia. *J Inherit Metab Dis* 1988;11(4):427-8.
- Hyanek J, Viletova H, Zeman J, Vyhalkova H, Soukup J. [Offspring of mothers with hyperphenylalaninemia treated with a low phenylalanine diet before conception and during pregnancy]. *Cas Lek Cesk* 1988 Jun 3;127(23):715-9. (Cze).
- Imamura T, Okano Y, Shintaku H, Hase Y, Isshiki G. Molecular characterization of 6-pyruvoyl-tetrahydropterin synthase deficiency in Japanese patients. *J Hum Genet* 1999;44(3):163-8.
- Imamura T, Shintaku H, Nakajima T, Sawada Y, Isshiki G, Oura T. Experimental research on a new treatment for maternal phenylketonuria(PKU). *Adv Exp Med Biol* 1993;338:277-80.
- Jardim LB, Palma-Dias R, Silva LC, Ashton-Prolla P, Giugliani R. Maternal hyperphenylalaninaemia as a cause of microcephaly and mental retardation. *Acta Paediatr* 1996 Aug;85(8):943-6.
- Johnson WG. DNA polymorphism-diet-cofactor-development hypothesis and the gene-teratogen model for schizophrenia and other developmental disorders. *Am J Med Genet* 1999 Aug 20;88(4):311-23.
- Juttman RE, de Koning HJ, Meulmeester JF, van der Maas PJ. [Published effects of screening in parental

- and child health care]. *Ned Tijdschr Geneesk* 1996 Jun 22;140(25):1303-7. (Ger).
- Kalter H, Warkany J. Medical progress. Congenital malformations: etiologic factors and their role in prevention (first of two parts). *N Engl J Med* 1983 Feb 24;308(8):424-31.
- Katoh S, Sueoka T. Pteridine cofactor of phenylalanine hydroxylase in fetal rat liver. *Int J Biochem* 1983;15(1):57-64.
- Kazak AE. Families with disabled children: stress and social networks in three samples. *J Abnorm Child Psychol* 1987 Mar;15(1):137-46.
- Kecskemethy HH, Lobbregt D, Levy HL. The use of gelatin capsules for ingestion of formula in dietary treatment of maternal phenylketonuria. *J Inherit Metab Dis* 1993;16(1):111-8.
- Kennedy B, Anderson K, Acosta PB. Nutrition support of inborn errors of amino acid metabolism. *Int J Biomed Comput* 1985 Jul;17(1):69-76.
- Kesby G. Repeated adverse fetal outcome in pregnancy complicated by uncontrolled maternal phenylketonuria. *J Paediatr Child Health* 1999 Oct;35(5):499-502.
- Kilani RA, Cole FS, Bier DM. Phenylalanine hydroxylase activity in preterm infants: is tyrosine a conditionally essential amino acid? *Am J Clin Nutr* 1995 Jun;61(6):1218-23.
- Kirby RB. Maternal phenylketonuria: a new cause for concern. *J Obstet Gynecol Neonatal Nurs* 1999 May-Jun;28(3):227-34.
- Kirkman HN. Projections of a rebound in frequency of mental retardation from phenylketonuria. *Appl Res Ment Retard* 1982;3(3):319-28.
- Kirkman HN Jr, Hicks RE. More on untreated maternal hyperphenylalaninemia [letter]. *N Engl J Med* 1984 Oct 25;311(17):1125-6.
- Kitagawa T, Owada M, Aoki K, Arai S, Oura T, Matsuda I, Igarashi Y, Tada K, Katayama S, Hashida W. Treatment of phenylketonuria with a formula consisting of low-phenylalanine peptide. A collaborative study. *Enzyme* 1987;38(1-4):321-7.
- Kitamura M. [Clinical laboratory--II]. *Rinsho Byori* 1986 Apr;34(4):423-6. (Jpn).
- Kleiman S, Vanagaite L, Bernstein J, Schwartz G, Brand N, Elitzur A, Woo SL, Shiloh Y. Phenylketonuria: variable phenotypic outcomes of the R261Q mutation and maternal PKU in the offspring of a healthy homozygote. *J Med Genet* 1993 Apr;30(4):284-8.
- Koch R. Maternal PKU: a crisis on the horizon [videocassette]. Boston (MA): Fanlight Productions; [1995]. 1 videocassette: 28 min., sound, color, 1/2 in.
- Koch R. Safety of aspartame as a sweetener [letter]. *N Engl J Med* 1975 Mar 13;292(11):596.
- Koch R, Acosta PB, Williams JC. Nutritional therapy for pregnant women with a metabolic disorder. *Clin Perinatol* 1995 Mar;22(1):1-14.
- Koch R, Blaskovics M. Four cases of hyperphenylalaninaemia: studies during pregnancy and of the offspring produced. *J Inherit Metab Dis* 1982;5(1):11-5.
- Koch R, Friedman E, Azen C, Hanley W, Matalon R, Rouse B, Trefz F, Waisbren S, Michals-Matalon K, Acosta P, Guettler F, Ullrich K, Platt L, de la Cruz F, Levy H. The international collaborative study of Maternal Phenylketonuria Status Report 1998. *Ment Retard Dev Disabil Res Rev* 1999; 5(2):117-21.
- Koch R, Friedman EG, Azen C. The North American Maternal PKU Collaborative Study. In: Wilcken B, Webster D, editors. Neonatal screening in the nineties. Proceedings of the 8th International Neonatal Screening Symposium; 1991 Nov 12-15; Leura, New South Wales, Australia and the Arthur Veale Memorial Meeting; 1991 Nov 5-9; Auckland, New Zealand. Australia: The Symposium; 1991. p. 320-2.
- Koch R, Friedman EG, Wenz E, Jew K, Crowley C, Donnell G. Maternal phenylketonuria. *J Inherit Metab Dis* 1986;9 Suppl 2:159-68.
- Koch R, Guttler F, Guldborg P, Rouse B. Mild hyperphenylalaninemia and heterozygosity of the phenylalanine hydroxylase gene. *Mol Genet Metab* 1998 Feb;63(2):148-50.
- Koch R, Hanley W, Levy H, Matalon R, Rouse B, Dela Cruz F, Azen C, Gross Friedman E. A preliminary report of the collaborative study of maternal phenylketonuria in the United States and Canada. *J Inherit Metab Dis* 1990;13(4):641-50.
- Koch R, Jew K, Wenz E, Shaw KN, Crowley C, Fishler K, Lenke R, Platt L, Oizumi J. Maternal phenylketonuria (PKU). In: Naruse H, Irie M, editors. Neonatal screening. Proceedings of the 2nd International Conference on Neonatal Thyroid Screening; 1982 Aug 16-19; Tokyo and the International Symposium on Neonatal Screening for Inborn Errors of Metabolism; 1982 Aug 19-21; Tokyo. Princeton (NJ): Excerpta Medica; 1983. p. 241-2. (International congress series; no. 606).
- Koch R, Levy H, Hanley W, Matalon R, Rouse B, Trefz F, de la Cruz F. Outcome implications of the International Maternal Phenylketonuria Collaborative

- Study (MPKUCS): 1994. *Eur J Pediatr* 1996 Jul;155 Suppl 1:S162-4.
- Koch R, Levy HL, Matalon R, Rouse B, Hanley WB, Trefz F, Azen C, Friedman EG, de la Cruz F, Guttler F, et al. The international collaborative study of maternal phenylketonuria: status report 1994. *Acta Paediatr Suppl* 1994 Dec;407:111-9.
- Koch R, Wenz E, Azen C, Friedman EG, Levy H, Rohr F, Rouse B, Castiglioni L, Matalon R, Michals-Matalon K, et al. The effect of nutrient intake on pregnancy outcome in maternal phenylketonuria. *Ann N Y Acad Sci* 1993 Mar 15;678:348-9.
- Koch R, Wenz E, Bauman C, Friedman EG, Azen C, Fishler K, Heiter W. Treatment outcome of maternal phenylketonuria. *Acta Paediatr Jpn* 1988 Aug;30(4):410-6.
- Koch R, Williams J. Prevalence of congenital heart disease in patients with phenylketonuria [letter]. *J Pediatr* 1992 Jul;121(1):163-5. Comment on: *J Pediatr* 1991 Aug;119(2):282-3.
- Komrower GM, Sardharwalla IB, Coutts JM, Ingham D. Management of maternal phenylketonuria: an emerging clinical problem. *Br Med J* 1979 May 26;1(6175):1383-7.
- Kowalska B. [Effect of maternal phenylketonuria on the development of 2 children with phenylketonuria]. *Pol Tyg Lek* 1986 Apr 7;41(14):448-50. (Pol).
- Kronick JB, Whelan DT, McCallion DJ. Experimental hyperphenylalaninemia in the pregnant guinea pig: possible phenylalanine teratogenesis and p-chlorophenylalanine embryotoxicity. *Teratology* 1987 Oct;36(2):245-58.
- Krywawych S, Haseler M, Brenton DP. Theoretical and practical aspects of preventing fetal damage in women with phenylketonuria. *Nestle Nutr Workshop Ser* 1991;24:125-35.
- Kudo Y, Boyd CA. Placental tyrosine transport and maternal phenylketonuria. *Acta Paediatr* 1996 Jan;85(1):109-10.
- Kudo Y, Boyd CA. Transport of amino acids by the human placenta: predicted effects thereon of maternal hyperphenylalaninaemia. *J Inherit Metab Dis* 1990;13(4):617-26.
- Kyu H, Thu A, Cook PJ. Human genetics in Burma. *Hum Hered* 1981;31(5):291-5.
- Labrune P, Brunet C, Rey F, Pons JC, Dauphin F, Leroy D, Odievre M. [Problems stemming from pregnancy in a woman with phenylketonuria]. *Arch Fr Pediatr* 1989 Aug-Sep;46(7):509-11. (Fre).
- Lacey DJ. Cortical dendritic spine loss in rat pups whose mothers were prenatally injected with phenylacetate ('maternal PKU' model). *Brain Res* 1986 Jun;392(1-2):283-5.
- Lacey DJ, Terplan K. Abnormal cerebral cortical neurons in a child with maternal PKU syndrome. *J Child Neurol* 1987 Jul;2(3):201-4.
- Laguna Serrano C. [Congenital errors of metabolism: phenylketonuria and hyperphenylalanemias]. *An R Acad Nac Med (Madr)* 1982;99(4):783-814. (Spa).
- Laing S. Special feeds for special infants: 1. The baby with a metabolic or allergic disorder. *Prof Care Mother Child* 1995;5(5):123, 126-7.
- Lajtha A, Reilly MA, Dunlop DS. Aspartame consumption: lack of effects on neural function. *J Nutr Biochem* 1994 Jun;5(6):266-83.
- Langerova E, Sindelarova M, Machackova V, Balastikova B, Nahunek K, Podhradská O, Mrkos A, Kasparikova Z. [Maternal phenylketonuria. Psychopathological study of families]. *Cesk Psychiatr* 1982 Oct;78(5):289-97. (Cze).
- Laptev AV, Chestkov VV, Shchepkina IuV, Shishkin SS. [Phenylalanine hydroxylase of human embryos: its homology with the enzyme from the liver of adults]. *Ontogenez* 1988 Jul-Aug;19(4):385-9. (Rus).
- Le Coutour X, Brouard J, Bordenave-Tilliard C. [Phenylketonuria: new questions for another generation]. *J Gynecol Obstet Biol Reprod (Paris)* 1992;21(1):85-8. (Fre).
- Lenke RR. Maternal phenylketonuria and hyperphenylalanemia: a problem born of success. *J Pediatr Perinat Nutr* 1987 Spring-Summer;1(1):67-74.
- Lenke RR, Koch R, Fishler K, Platt LD. Tyrosine supplementation during pregnancy in a woman with classical phenylketonuria. A case report. *J Reprod Med* 1983 Jun;28(6):411-4.
- Lenke RR, Levy HL. Maternal phenylketonuria and hyperphenylalaninemia. An international survey of the outcome of untreated and treated pregnancies. *N Engl J Med* 1980 Nov 20;303(21):1202-8.
- Lenke RR, Levy HL. Maternal phenylketonuria--results of dietary therapy. *Am J Obstet Gynecol* 1982 Mar 1;142(5):548-53.
- Leonard HM, Fletcher JM. Inherited metabolic diseases: beyond newborn screening [editorial]. *Med J Aust* 1999 Jun 21;170(12):573-4. Comment on: *Med J Aust* 1999 Jun 21;170(12):592-5.
- Levy HL. Maternal phenylketonuria. *Prog Clin Biol Res* 1988;281:227-42.

- Levy HL. Maternal phenylketonuria. In: Schmidt BJ, Diamant AJ, Loghini-Grosso NS, editors. *Current trends in infant screening. Proceedings of the 7th International Screening Symposium*; 1988 Nov 6-9; Sao Paulo, Brazil. New York: Excerpta Medica; 1989. p. 55-62. (International congress series; no. 848).
- Levy HL. Maternal phenylketonuria and hyperphenylalaninemia. In: Naruse H, Irie M, editors. *Neonatal screening. Proceedings of the 2nd International Conference on Neonatal Thyroid Screening*; 1982 Aug 16-19; Tokyo and the *International Symposium on Neonatal Screening for Inborn Errors of Metabolism*; 1982 Aug 19-21; Tokyo. Princeton (NJ): Excerpta Medica; 1983. p. 231-4. (International congress series; no. 606).
- Levy HL. Maternal phenylketonuria. Review with emphasis on pathogenesis. *Enzyme* 1987;38(1-4):312-20.
- Levy HL. Maternal PKU. *Prog Clin Biol Res* 1985;177:109-22.
- Levy HL. Maternal PKU: control of an emerging problem. *Am J Public Health* 1982 Dec;72(12):1320-1.
- Levy HL. Neonatal screening for inborn errors of amino acid metabolism. *Clin Endocrinol Metab* 1974 Mar;3(1):153-66.
- Levy HL. Reply to SP Bessman [letter]. *Am J Clin Nutr* 1998 Mar;67(3):488. Comment on: *Am J Clin Nutr* 1998 Mar;67(3):357-8.
- Levy HL. Reproductive effects of maternal metabolic disorders: implications for pediatrics and obstetrics. *Turk J Pediatr* 1996 Jul-Sep;38(3):335-44.
- Levy HL. Treatment of phenylketonuria. *Prog Clin Biol Res* 1979;34:171-82.
- Levy HL, Ghavami M. Maternal phenylketonuria: a metabolic teratogen. *Teratology* 1996 Mar;53(3):176-84.
- Levy HL, Goss BS, Sullivan DK, Michals-Matalon K, Dobbs JM, Guldborg P, Guttler F. Maternal mild hyperphenylalaninemia: results of treated and untreated pregnancies in two sisters. *J Pediatr* 1994 Sep;125(3):467-9.
- Levy HL, Kaplan GN, Erickson AM. Comparison of treated and untreated pregnancies in a mother with phenylketonuria. *J Pediatr* 1982 Jun;100(6):876-80.
- Levy HL, Lenke RR, Crocker AC, editors. *Maternal PKU. Proceedings of a conference*; 1979 Dec 5; Boston. Rockville (MD): Department of Health and Human Services (US), Health Services Administration; 1982. 90 p. (DHHS publication; no. (HSA) 81-5299).
- Levy HL, Lenke RR, Koch R. Lack of fetal effect on blood phenylalanine concentration in maternal phenylketonuria. *J Pediatr* 1984 Feb;104(2):245-7.
- Levy HL, Lobbregt D, Barnes PD, Poussaint TY. Maternal phenylketonuria: magnetic resonance imaging of the brain in offspring. *J Pediatr* 1996 Jun;128(6):770-5.
- Levy HL, Lobbregt D, Platt LD, Benacerraf BR. Fetal ultrasonography in maternal PKU. *Prenat Diagn* 1996 Jul;16(7):599-604.
- Levy HL, Lobbregt D, Sansaricq C, Snyderman SE. Comparison of phenylketonuric and nonphenylketonuric sibs from untreated pregnancies in a mother with phenylketonuria. *Am J Med Genet* 1992 Nov 1;44(4):439-42.
- Levy HL, Waisbren SE. (Children's Hospital, Boston, MA). Study of maternal PKU (phenylketonuria) and hyperphenylalaninemia. Final report. 1981 Sep 1-Aug 31. Rockville (MD): Bureau of Health Care Delivery and Assistance (US); 1987 Jun. Contract No.: MCH/CCS-87/11. 37 p. Available from: NTIS, Springfield, VA; PB88-173711.
- Levy HL, Waisbren SE. Effects of untreated maternal phenylketonuria and hyperphenylalaninemia on the fetus. *N Engl J Med* 1983 Nov 24;309(21):1269-74.
- Levy HL, Waisbren SE. The PKU paradigm: the mixed results from early dietary treatment. *UCLA Symp Mol Cell Biol* 1987;55:539-51.
- Levy HL, Waisbren SE, Lobbregt D, Allred E, Leviton A, Koch R, Hanley WB, Rouse B, Matalon R, de la Cruz F. Maternal non-phenylketonuric mild hyperphenylalaninemia. *Eur J Pediatr* 1996 Jul;155 Suppl 1:S20-5.
- Levy HL, Waisbren SE, Lobbregt D, Allred E, Schuler A, Trefz FK, Schweitzer SM, Sardharwalla IB, Walter JH, Barwell BE, et al. Maternal mild hyperphenylalaninaemia: an international survey of offspring outcome. *Lancet* 1994 Dec 10;344(8937):1589-94. Comment in: *Lancet* 1995 Feb 11;345(8946):385-6.
- Lewis SA, Lyon IC, Elliott RB. Outcome of pregnancy in the rat with mild hyperphenylalaninaemia and hypertyrosinaemia: implications for the management of human maternal PKU. *J Inher Metab Dis* 1985;8(3):113-7.
- Liebl B, Fingerhut R, Roschinger W, Muntau A, Knerr I, Olgemoller B, Zapf A, Roscher AA. [Model project for updating neonatal screening in Bavaria: concept

- and initial results]. *Gesundheitswesen* 2000 Apr;62(4):189-95. (Ger).
- Lierse W. The vulnerability of retina neuroblast after metabolic errors. *Folia Morphol (Praha)* 1980;28(1):70-1.
- Lines DR. Aspartame doses for phenylketonuria [letter]. *J Nutr* 1981 Sep;111(9):1688-90.
- Lipson A, Beuhler B, Bartley J, Walsh D, Yu J, O'Halloran M, Webster W. Maternal hyperphenylalaninemia fetal effects. *J Pediatr* 1984 Feb;104(2):216-20.
- Lipson AH. Medications during pregnancy: birth defects and other risks. *Healthright* 1984 Nov;4(1):15-20.
- Lipson AH, Yu JS, O'Halloran MT, Williams R. Alcohol and phenylketonuria [letter]. *Lancet* 1981 Mar 28;1(8222):717-8.
- Lombeck I, Jochum F, Terwolbeck K. Selenium status in infants and children with phenylketonuria and in maternal phenylketonuria. *Eur J Pediatr* 1996 Jul;155 Suppl 1:S140-4.
- Loo YH, Fulton T, Miller K, Wisniewski HM. Phenylacetate and brain dysfunction in experimental phenylketonuria: synaptic development. *Life Sci* 1980 Oct 6;27(14):1283-90.
- Loo YH, Hyde KR, Lin FH, Wisniewski HM. Cerebral biochemical abnormalities in experimental maternal phenylketonuria: gangliosides and sialoglycoproteins. *Life Sci* 1985 Dec 2;37(22):2099-109.
- Loo YH, Potempska A, Wisniewski HM. A biochemical explanation of phenyl acetate neurotoxicity in experimental phenylketonuria. *J Neurochem* 1985 Nov;45(5):1596-600.
- Loo YH, Rabe A, Potempska A, Wang P, Fersko R, Wisniewski HM. Experimental maternal phenylketonuria: an examination of two animal models. *Dev Neurosci* 1983-84;6(4-5):227-34.
- Lorijn RH, Sengers RC, Trijbels JM. Maternal phenylketonuria: the outcome of pregnancy. *Eur J Obstet Gynecol Reprod Biol* 1981 Nov;12(5):281-5.
- Lott JW. PKU: a nursing update. *J Pediatr Nurs* 1988 Feb;3(1):29-34.
- Lowitzer AC. Maternal phenylketonuria: cause for concern among women with PKU. *Res Dev Disabil* 1987;8(1):1-14.
- Lucas A, Baker BA, Morley RM. Hyperphenylalaninaemia and outcome in intravenously fed preterm neonates. *Arch Dis Child* 1993 May;68(5 Spec No):579-83.
- Luder AS, Greene CL. Maternal phenylketonuria and hyperphenylalaninemia: implications for medical practice in the United States. *Am J Obstet Gynecol* 1989 Nov;161(5):1102-5.
- Luke B. Maternal-fetal nutrition. *Clin Obstet Gynecol* 1994 Mar;37(1):93-109.
- Luke B, Johnson TR, Petrie RH. Clinical maternal-fetal nutrition. New York: Little, Brown; 1993. Maternal phenylketonuria; p. 251-68.
- Luke B, Keith LG. The challenge of maternal phenylketonuria screening and treatment. *J Reprod Med* 1990 Jul;35(7):667-73.
- Lynch BC, Pitt DB, Maddison TG, Wraith JE, Danks DM. Maternal phenylketonuria: successful outcome in four pregnancies treated prior to conception. *Eur J Pediatr* 1988 Oct;148(1):72-5.
- Lyon IC. Maternal phenylketonuria [letter]. *N Z Med J* 1984 Mar 14;97(751):165-6.
- MacCready RA, Levy HL. The problem of maternal phenylketonuria. *Am J Obstet Gynecol* 1972 May 1;113(1):121-8.
- Machill G, Seidlitz G, Ebener U, Knapp A, Herrmann FH. Evaluation of the screening of pregnant women for phenylketonuria during 1972-1992. In: Farriaux JP, Dhondt JL, editors. New horizons in neonatal screening. Proceedings of the 9th International Neonatal Screening Symposium and the 2nd Meeting of the International Society for Neonatal Screening; 1993 Sep 13-17; Lille, France. New York: Elsevier Science; 1994. p. 119-22. (International congress series; no. 1041).
- Mahowald MB. A feminist standpoint for genetics. *J Clin Ethics* 1996 Winter;7(4):333-40.
- Marsh J, Sargent E. Factors affecting the duration of postnatal visits. *Midwifery* 1991 Dec;7(4):177-82.
- Matalon R, Michals K. Phenylketonuria: screening, treatment and maternal PKU. *Clin Biochem* 1991 Aug;24(4):337-42.
- Matalon R, Michals K, Azen C, Friedman E, Koch R, Rouse B, Hanley WB, de la Cruz F. Maternal PKU Collaborative Study: pregnancy outcome and postnatal head growth. *J Inher Metab Dis* 1994;17(3):353-5.
- Matalon R, Michals K, Azen C, Friedman EG, Koch R, Wenz E, Levy H, Rohr F, Rouse B, Castiglioni L, et al. Maternal PKU collaborative study: the effect of nutrient intake on pregnancy outcome. *J Inher Metab Dis* 1991;14(3):371-4.

- Matalon R, Michals K, Gleason L. Maternal PKU: strategies for dietary treatment and monitoring compliance. *Ann N Y Acad Sci* 1986;477:223-30.
- Maternal Phenylketonuria Collaborative Study: a status report. *Nutr Rev* 1994 Nov;52(11):390-3.
- Maternal phenylketonuria. Committee on Genetics. *Pediatrics* 1985 Aug;76(2):313-4.
- Matsueda S, Niiyama Y. The effects of excess amino acids on maintenance of pregnancy and fetal growth in rats (Threonine, methionine, valine, isoleucine, leucine, tyrosine, phenylalanine, tryptophan, lysine). *J Nutr Sci Vitaminol* 1982;28(5):557-73.
- Matthieu JM. [Maternal phenylketonuria: a misdiagnosed cause of embryopathy or fetal disease]. *Rev Med Suisse Romande* 1994 Oct;114(10):841-3. (Fre).
- McBurnie MA, Kronmal RA, Schuett VE, Koch R, Azeng CG. Physical growth of children treated for phenylketonuria. *Ann Hum Biol* 1991 Jul-Aug;18(4):357-68.
- McDonald JD. The PKU mouse project: its history, potential and implications. *Acta Paediatr Suppl* 1994 Dec;407:122-3.
- McDonald JD, Dyer CA, Gailis L, Kirby ML. Cardiovascular defects among the progeny of mouse phenylketonuria females. *Pediatr Res* 1997 Jul;42(1):103-7.
- Medical Research Council Working Party on Phenylketonuria. Phenylketonuria due to phenylalanine hydroxylase deficiency: an unfolding story. *BMJ* 1993 Jan 9;306(6870):115-9.
- Messer SS. PKU: a mother's perspective. *Pediatr Nurs* 1985 Mar-Apr;11(2):121-3.
- Michals K, Acosta PB, Austin V, Castiglioni L, Rohr F, Wenz E, Azen C. Nutrition and reproductive outcome in maternal phenylketonuria. *Eur J Pediatr* 1996 Jul;155 Suppl 1:S165-8.
- Michals Matalon K, Acosta P, Azen C, Matalon R. Congenital heart disease in maternal phenylketonuria: effects of blood phenylalanine and nutrient intake. *Ment Retard Dev Disabil Res Rev* 1999;5(2):122-4.
- Michels VV, Justice CL. Treatment of phenylketonuria during pregnancy. *Clin Genet* 1982 Feb;21(2):141-4.
- Miller ME, Plumeau P, Blakely E. Elevated phenylalanine concentrations in benign hyperphenylalaninemia from evaporated milk feedings. *Clin Pediatr (Phila)* 1993 Feb;32(2):124-5.
- Miller SA, Chopra JG. Problems with human milk and infant formulas. *Pediatrics* 1984 Oct;74(4 Pt 2):639-47.
- More pointers on PKU [letter]. *MCN Am J Matern Child Nurs* 1987 Jul-Aug;12(4):239.
- Mowat DR, Hayden MC, Thompson SM, Wilcken B. Maternal phenylketonuria: a continuing problem. *Med J Aust* 1999 Jun 21;170(12):592-5. Comment in: *Med J Aust* 1999 Jun 21;170(12):573-4.
- Murphy D, Saul I, Kirby M. Maternal phenylketonuria and phenylalanine restricted diet. Studies of 7 pregnancies and of offsprings produced. *Ir J Med Sci* 1985 Feb;154(2):66-70.
- National Center for Education in Maternal and Child Health (US). Proceedings of the Tri-Regional Conference on Completed Maternal and Child Health Research, Translating MCH Research Findings into Health Care Applications: A Challenge; 1988. Rockville (MD): The Center; 1989 Sep. 268 p. Report No.: NCEMCH-C071. Available from: NTIS, Springfield, VA; PB90-114356.
- Naughten E, Saul IP. Maternal phenylketonuria--the Irish experience. *J Inher Metab Dis* 1990;13(4):658-64.
- Nevin NC, Carson NA. Severe mental retardation due to maternal phenylketonuria. *Ulster Med J* 1982;51(2):133-5.
- Nielsen KB. [Dietary treatment of women with Folling's disease. A review of current experiences and future perspectives]. *Ugeskr Laeger* 1985 Jan 21;147(4):246-9. (Dan).
- O'Flynn ME. Newborn screening for phenylketonuria: thirty years of progress. *Curr Probl Pediatr* 1992 Apr;22(4):159-65.
- Okano Y, Chow IZ, Isshiki G, Inoue A, Oura T. Effects of phenylalanine loading on protein synthesis in the fetal heart and brain of rat: an experimental approach to maternal phenylketonuria. *J Inher Metab Dis* 1986;9(1):15-24.
- Oorthuys JW, Gons MH, Kwakman JV, Schutgens RB, Tegelaers WH. [Screening for raised serum phenylalanine levels in women of reproductive age in Volendam]. *Ned Tijdschr Geneesk* 1985 Jan 12;129(2):62-5. (Dut).
- Oura T, Hase Y. Japanese experiences in maternal phenylketonuria. In: Naruse H, Irie M, editors. Neonatal screening. Proceedings of the 2nd International Conference on Neonatal Thyroid Screening; 1982 Aug 16-19; Tokyo and the International Symposium on Neonatal Screening for

- Inborn Errors of Metabolism; 1982 Aug 19-21; Tokyo. Princeton (NJ): Excerpta Medica; 1983. p. 235-40. (International congress series; no. 606).
- Overgaard C, Knudsen A. Pain-relieving effect of sucrose in newborns during heel prick. *Biol Neonate* 1999 May;75(5):279-84.
- Owada M. [Maternal phenylketonuria]. *Ryoikibetsu Shokogun Shirizu* 1998;(18 Pt 1):119-23. (Jpn).
- Owada M, Abe M, Ono M, Kitagawa T, Sato Y. Successful treatment of maternal phenylketonuria with a formula consisting of low phenylalanine peptide as a protein source. *J Inher Metab Dis* 1988;11(3):341-4.
- Pardou A, Vuye A, Vis HL. Plasma amino acid patterns, one and two hours after continuous nasogastric alimentation of low birth weight infants fed two types of milk during the first month of life. *Biol Neonate* 1982;41(1-2):57-62.
- Peat B. Pregnancy complicated by maternal phenylketonuria. *Aust N Z J Obstet Gynaecol* 1993 May;33(2):163-5.
- Pennington BF, Smith SD. Genetic influences on learning disabilities and speech and language disorders. *Child Dev* 1983 Apr;54(2):369-87.
- Persha AJ. Early identification and prevention of mental retardation. *ICCW News B* 1992 Jan-Mar;40(1):9-12.
- Peterson AG, Platt LJ, Berry HK, Schafer IA, Quilty JF. Maternal PKU--a problem born of success. *Ohio State Med J* 1984 May;80(5):397-8.
- Petruschka L, Rebrin I, Grimm U, Herrmann FH. The immunological evidence for a phenylalanine hydroxylase like immunoreactive protein in different human cells and tissues. *Clin Chim Acta* 1990 Dec 13;193(1-2):65-77.
- Platt LD, Koch R, Azen C, Hanley WB, Levy HL, Matalon R, Rouse B, de la Cruz F, Walla CA. Maternal phenylketonuria collaborative study, obstetric aspects and outcome: the first 6 years. *Am J Obstet Gynecol* 1992 Apr;166(4):1150-60; discussion 1160-2.
- Platt LD, Koch R, Hanley WB, Levy HL, Matalon R, Rouse B, Trefz F, de la Cruz F, Guttler F, Azen C, Friedman EG. The international study of pregnancy outcome in women with maternal phenylketonuria: report of a 12-year study. *Am J Obstet Gynecol* 2000 Feb;182(2):326-33.
- Pollak S, Vardy PA, Barzilai A. [Maternal phenylketonuria syndrome]. *Harefuah* 1981 Jan 15;100(2):78-80. (Heb).
- Potempska A, Loo YH, Wisniewski HM. On the possible mechanism of phenylacetate neurotoxicity: inhibition of choline acetyltransferase by phenylacetyl-CoA. *J Neurochem* 1984 May;42(5):1499-501.
- Pueschel SM. Maternal phenylketonuria. *Soc Biol* 1985 Spring-Summer;32(1-2):31-44.
- Pueschel SM, Schrier AM, Povar ML, Boylan JM. Biological and behavioural assessments of young rhesus monkeys after intrauterine exposure to high phenylalanine concentrations. *J Ment Defic Res* 1985 Sep;29 (Pt 3):247-56.
- Pullon DH. Maternal phenylketonuria. In: Wilcken B, Webster D, editors. Neonatal screening in the nineties. Proceedings of the 8th International Neonatal Screening Symposium; 1991 Nov 12-15; Leura, New South Wales, Australia and the Arthur Veale Memorial Meeting; 1991 Nov 5-9; Auckland, New Zealand. Australia: The Symposium; 1991. p. 327-8.
- Pullon DH, Macfarlane SD, Lyon IC. Maternal phenylketonuria. *N Z Med J* 1990 Aug 22;103(896):397-8.
- Ratzmann GW, Grimm U, Jahrig K. Increased concentrations of tyrosine and phenylalanine in the cerebrospinal fluid as a possible reflection of related changes of the brain tissue in newborns with intrauterine growth retardation. *Biomed Biochim Acta* 1988;47(12):1037-41.
- Rebrin I, Bailey SW, Ayling JE. Activity of the bifunctional protein 4a-hydroxy-tetrahydropterin dehydratase/DCoH during human fetal development: correlation with dihydropteridine reductase activity and tetrahydrobiopterin levels. *Biochem Biophys Res Commun* 1995 Dec 26;217(3):958-65.
- Recommendations on the dietary management of phenylketonuria. Report of Medical Research Council Working Party on Phenylketonuria. *Arch Dis Child* 1993 Mar;68(3):426-7.
- Rittinger O, Plochl E, Jarosch E. [Maternal phenylketonuria]. *Padiatr Padol* 1984;19(1):87-92. (Ger).
- Robertson JA, Schulman JD. Pregnancy and prenatal harm to offspring: the case of mothers with PKU. *Hastings Cent Rep* 1987 Aug-Sep;17(4):23-33.
- Rogowiecka E, Sendek E, Chazan B, Cabalska B, Bankowska E. [Maternal PKU syndrome as an obstetric problem: literature review and own clinical experience]. *Ginekol Pol* 1998 Dec;69(12):1007-15. (Pol).
- Rohr FJ, Lobbregt D, Levy HL. Tyrosine supplementation in the treatment of maternal

- phenylketonuria. *Am J Clin Nutr* 1998 Mar;67(3):473-6. Comment in: *Am J Clin Nutr* 1998 Mar;67(3):357-8; *Am J Clin Nutr* 1998 Dec;68(6):1306-7.
- Rouse B, Azen C, Koch R, Matalon R, Hanley W, de la Cruz F, Trefz F, Friedman E, Shifrin H. Maternal Phenylketonuria Collaborative Study (MPKUCS) offspring: facial anomalies, malformations, and early neurological sequelae. *Am J Med Genet* 1997 Mar 3;69(1):89-95.
- Rouse B, Lockhart L, Matalon R, Azen C, Koch R, Hanley W, Levy H, de la Cruz F, Friedman E. Maternal phenylketonuria pregnancy outcome: a preliminary report of facial dysmorphology and major malformations. *J Inher Metab Dis* 1990;13(3):289-91.
- Rouse B, Matalon R, Koch R, Azen C, Levy H, Hanley W, Trefz F, de la Cruz F. Maternal phenylketonuria syndrome: congenital heart defects, microcephaly, and developmental outcomes. *J Pediatr* 2000 Jan;136(1):57-61. Comment in: *J Pediatr* 2000 Jan;136(1):12-3.
- Roux C, Rey F, Lyonnet S, Nizard S, Mulliez N, Munnich A. An animal model for maternal phenylketonuria. *J Med Genet* 1991 Oct;28(10):718-9.
- Saborio M. Experience in providing genetic services in Costa Rica. *Birth Defects Orig Artic Ser* 1992;28(3):96-102.
- Sadava D, Sutcliffe D. The effects of maternal hyperphenylalaninemia on learning in mature rats. *Life Sci* 1988;43(14):1119-23.
- Sadler TW, Denno KM, Hunter ES 3d. Effects of altered maternal metabolism during gastrulation and neurulation stages of embryogenesis. *Ann N Y Acad Sci* 1993 Mar 15;678:48-61.
- Saliba Z, Bah G, Martin D, Abadie V, Azar Z, Fraisse A, Sidi D, Kachaner J, Bonnet D. [Pseudo-inherited form of left heart obstructive defects revealing maternal phenylketonuria]. *Arch Mal Coeur Vaiss* 2000 May;93(5):649-52. (Fre).
- Salize HJ, Funders-Bucker B, Knorrek U, Kolbe S, Pietsch V, Seidlitz G, Ullrich K, Trefz FK. [Maternal phenylketonuria. Problems in detecting and risk educating identified females]. *Monatsschr Kinderheilkd* 1992 Jan;140(1):42-6. (Ger).
- Sartorio R, Greco L, Carozzo R, Budillon C, Andria G. A simplified test to detect PKU heterozygotes by discriminant analysis in mentally retarded children and their mothers. *Clin Genet* 1988 Apr;33(4):241-5.
- Sato T, Imura E, Murata A, Minami S, Okabe T, Ohno I. Effects of maternal phenylalanine or tyrosine hydroxylase inhibition on postnatal maturation of catecholamine and amino acid metabolism in rats. *Acta Paediatr Jpn* 1988 Feb;30(1):56-62.
- Saugstad LF. Birth weight of children with phenylketonuria [letter]. *Pediatrics* 1980 Jan;65(1):190-2.
- Sayle AE, Cooper GS, Savitz DA. Menstrual and reproductive history of mothers of galactosemic children. *Fertil Steril* 1996 Mar;65(3):534-8.
- Schoonheydt WE, Clarke JT, Hanley WB, Johnson JM, Lehotay DC. Feto-maternal plasma phenylalanine concentration gradient from 19 weeks gestation to term. *Clin Chim Acta* 1994 Mar;225(2):165-9.
- Schulman JD. Treatment of the embryo and the fetus in the first trimester: current status and future prospects. *Am J Med Genet* 1990 Feb;35(2):197-200.
- Scott TM, Fyfe WM, Hart DM. Maternal phenylketonuria: abnormal baby despite low phenylalanine diet during pregnancy. *Arch Dis Child* 1980 Aug;55(8):634-7.
- Scriver CR, Clow CL. Phenylketonuria and other phenylalanine hydroxylation mutants in man. *Annu Rev Genet* 1980;14:179-202.
- Scriver CR, Clow CL. Phenylketonuria: epitome of human biochemical genetics (first of two parts). *N Engl J Med* 1980 Dec 4;303(23):1336-42.
- Scriver CR, Clow CL. Phenylketonuria: epitome of human biochemical genetics (second of two parts). *N Engl J Med* 1980 Dec 11;303(24):1394-400.
- Scriver CR, Cole DE, Houghton SA, Levy HL, Grenier A, Laberge C. Cord-blood tyrosine levels in the full-term phenylketonuric fetus and the justification hypothesis. *Proc Natl Acad Sci U S A* 1980 Oct;77(10):6175-8.
- Seim AR, Reichelt KL. An enzyme/brain-barrier theory of psychiatric pathogenesis: unifying observations on phenylketonuria, autism, schizophrenia and postpartum psychosis. *Med Hypotheses* 1995 Nov;45(5):498-502.
- Shaw D, Macleod PM, Applegarth DA. Recurrent abortion and amino-acid abnormalities. *J Inher Metab Dis* 1991;14(5):851.
- Shedlovsky A, McDonald JD, Symula D, Dove WF. Mouse models of human phenylketonuria. *Genetics* 1993 Aug;134(4):1205-10.
- Shiloh S, Amitay M, Aizin N, Normand M, Elitzur A, Hadar R, Cohen BE. [Psychosocial characteristics of phenylketonuric women: birth defect prevention]. *Harefuah* 1992 Apr 15;122(8):487-92, 552. (Heb).

- Shiloh S, St. James P, Waisbren S. The development of a patient knowledge test on maternal phenylketonuria. *Patient Educ Couns* 1990 Oct;16(2):139-46.
- Shiloh S, Waisbren SE, Cohen BE, St James P, et al. Cross-cultural perspectives on coping with the risks of maternal phenylketonuria. *Psychol Health* 1993 Dec;8(6):435-46.
- Shiloh S, Waisbren SE, Levy HL. A psychosocial model of a medical problem: Maternal phenylketonuria. *J Prim Prev* 1989 Fall;10(1):51-62.
- Shintaku H, Nakajima T, Imamura T, Sawada Y, Isshiki G, Oura T. Experimental research on a fetal treatment for tetrahydrobiopterin deficiency. *Adv Exp Med Biol* 1993;338:273-6.
- Smith I, Glossop J, Beasley M. Fetal damage due to maternal phenylketonuria: effects of dietary treatment and maternal phenylalanine concentrations around the time of conception (an interim report from the UK Phenylketonuria Register). *J Inherit Metab Dis* 1990;13(4):651-7.
- Smith I, Tillotson S. Outcome in offspring of women with mild hyperphenylalaninaemia [letter]. *Lancet* 1995 Feb 11;345(8946):385-6. Comment on: *Lancet* 1994 Dec 10;344(8937):1589-94.
- Snyderman SE. Dietary and genetic therapy of inborn errors of metabolism: a summary. *Ann N Y Acad Sci* 1986;477:231-6.
- Soeters RP, Sengers RC, van Dongen PW, Trijbels JM, Eskes TK. Maternal phenylketonuria: comparison of two treated full term pregnancies. *Eur J Pediatr* 1986 Aug;145(3):221-3.
- Speer VC, Kile DL, Trew JC. Estimation of the isoleucine and aromatic amino acid requirements of pregnant swine. *J Anim Sci* 1990 Aug;68(8):2394-9.
- Spero DA. Maternal phenylketonuria: the effect on the morphological and biochemical maturation of the brain in utero [dissertation]. New Brunswick (NJ): College of Medicine and Dentistry of New Jersey, Graduate School of Biomedical Science; 1981. 191 p.
- Spero DA, Yu MC. Effects of maternal hyperphenylalaninemia on fetal brain development: a biochemical study. *Exp Neurol* 1983 Mar;79(3):641-54.
- Spero DA, Yu MC. Effects of maternal hyperphenylalaninemia on fetal brain development: a morphological study. *Exp Neurol* 1983 Mar;79(3):655-65.
- Srivastava US, Thakur ML, Van TT, Radhakrishnamurty R. Maternal food restriction, brain polysomes and poly-U stimulated protein synthesis in the newborn and 21-day-old rat progeny. *Nutr Res* 1993 Nov;13(11):1331-41.
- St James PJ, Younger MD, Hamilton BD, Waisbren SE. Unplanned pregnancies in young women with diabetes. An analysis of psychosocial factors. *Diabetes Care* 1993 Dec;16(12):1572-8.
- St James PS. The resource mothers program for maternal PKU: an ecological to intervention and program evaluation [dissertation]. Boston: University of Massachusetts; 1996. 216 p.
- St James PS, Shapiro E, Waisbren SE. The Resource Mothers Program for Maternal Phenylketonuria. *Am J Public Health* 1999 May;89(5):762-4.
- Starfield B. Motherhood and apple pie: the effectiveness of medical care for children. *Milbank Mem Fund Q Health Soc* 1985 Summer;63(3):523-46.
- Start K. Treating phenylketonuria by a phenylalanine-free diet. *Prof Care Mother Child* 1998;8(4):109-10.
- Statham H, Green J, Snowdon C. Mothers' consent to screening newborn babies for disease [letter]. *BMJ* 1993 Mar 27;306(6881):858-9.
- Stein Z, Susser M. Effects of early nutrition on neurological and mental competence in human beings. *Psychol Med* 1985 Nov;15(4):717-26.
- Strupp BJ, Bunsey M, Levitsky DA, Hamberger K. Deficient cumulative learning: an animal model of retarded cognitive development. *Neurotoxicol Teratol* 1994 Jan-Feb;16(1):71-9.
- Sturtevant FM. Use of aspartame in pregnancy. *Int J Fertil* 1985;30(1):85-7.
- Su CL, Austic RE. Improved model of maternal phenylketonuria in rats by use of lower dietary concentrations of alpha-methylphenylalanine and L-phenylalanine in a semipurified diet. *Nutr Res* 1998 Jun;18(6):989-1002.
- Superti-Furga A, Steinmann B, Duc G, Gitzelmann R. Maternal phenylketonuria syndrome in cousins caused by mild, unrecognized phenylketonuria in their mothers homozygous for the phenylalanine hydroxylase Arg-261-Gln mutation. *Eur J Pediatr* 1991 May;150(7):493-7.
- Superti-Furga A, Steinmann B, Duc G, Gitzelmann R. Microcephaly and maternal phenylketonuria [letter]. *Eur J Pediatr* 1996 Nov;155(11):992. Comment on: *Eur J Pediatr* 1996 Mar;155(3):257-8.
- Suyama I, Oura T, Kawamura T, Isshiki G, Ozaki H, Nishimura K. Experimental approaches to maternal phenylketonuria. In: Wilcken B, Webster D, editors.

- Neonatal screening in the nineties. Proceedings of the 8th International Neonatal Screening Symposium; 1991 Nov 12-15; Leura, New South Wales, Australia and the Arthur Veale Memorial Meeting; 1991 Nov 5-9; Auckland, New Zealand. Australia: The Symposium; 1991. p. 333-5.
- Szabo L, Somogyi C, Mate M. [Maternal phenylketonuria syndrome: teratogenic effect of hyperphenylalaninemia]. *Orv Hetil* 1982 Nov 21;123(47):2895-901. (Hun).
- Tenbrinck MS, Stroud HW. Normal infant born to a mother with phenylketonuria. *JAMA* 1982 Apr 16;247(15):2139-40.
- Thomas GH, Parmley TH, Stevenson RE, Howell RR. Developmental changes in amino acid concentrations in human amniotic fluid: abnormal findings in maternal phenylketonuria. *Am J Obstet Gynecol* 1971 Sep;111(1):38-42.
- Thompson GN, Francis DE, Kirby DM, Compton R. Pregnancy in phenylketonuria: dietary treatment aimed at normalising maternal plasma phenylalanine concentration. *Arch Dis Child* 1991 Nov;66(11):1346-9.
- Thompson S, Gruca M, Holliday K, Yu J, Lipson A. Maternal PKU - the Sydney experience. In: Wilcken B, Webster D, editors. Neonatal screening in the nineties. Proceedings of the 8th International Neonatal Screening Symposium; 1991 Nov 12-15; Leura, New South Wales, Australia and the Arthur Veale Memorial Meeting; 1991 Nov 5-9; Auckland, New Zealand. Australia: The Symposium; 1991. p. 329-31.
- Tice KS, Wenz E, Jew K, Koch R. Reproductive counselling for adolescent females with phenylketonuria. *J Inherit Metab Dis* 1980;3(3):105-7.
- Tillotson SL, Costello PM, Smith I. No reduction in birth weight in phenylketonuria. *Eur J Pediatr* 1995 Oct;154(10):847-9. Comment in: *Eur J Pediatr* 1997 Feb;156(2):157.
- Tolmie JL, Harvie A, Cockburn F. The teratogenic effects of undiagnosed maternal hyperphenylalaninaemia: a case for prevention? *Br J Obstet Gynaecol* 1992 Apr;99(4):347-8.
- Touraine RL, Guibaud P. [Genetics and hyperphenylalaninemia in 1992]. *Pediatrics* (Bucur) 1992;47(1):9-21. Published erratum appears in *Pediatrics* 1992;47(4):331. (Fre).
- Ugarte M, Maties M, Ugarte JL. The offspring of a phenylketonuric couple. *J Ment Defic Res* 1980 Jun;24(2):119-27.
- Verkerk PH, van Spronsen FJ, Smit GP, Sengers RC. Impaired prenatal and postnatal growth in Dutch patients with phenylketonuria. The National PKU Steering Committee. *Arch Dis Child* 1994 Aug;71(2):114-8. Comment in: *Arch Dis Child* 1995 Sep;73(3):276.
- Verkerk PH, van Spronsen FJ, van Houten M, Smit GP, Sengers RC. Predictors of mean phenylalanine levels during the first five years of life in patients with phenylketonuria who were treated early. Dutch National PKU Steering Committee. *Acta Paediatr Suppl* 1994 Dec;407:70-2.
- Vidailhet C, Vidailhet M, Guine AM, Gonot C, Tridon P, Guine JM. [Experience of the mothers of phenylketonuric children]. *Neuropsychiatr Enfance Adolesc* 1982 Apr-May;30(4-5):246-8. (Fre).
- Vogel F. Clinical consequences of heterozygosity for autosomal-recessive diseases. *Clin Genet* 1984 May;25(5):381-415.
- Vogel F. Phenotypic deviations in heterozygotes of phenylketonuria (PKU). *Prog Clin Biol Res* 1985;177:337-49.
- Volpe EP. Patient in the womb. Macon (GA): Mercer University Press; 1984. 157 p.
- Vorhees CV. Concepts in teratology and developmental toxicology derived from animal research. *Ann N Y Acad Sci* 1989;562:31-41.
- Vorhees CV, Acuff-Smith KD, Weisenburger WP, Minck DR, Berry HK. Branched chain amino acids improve radial-arm maze acquisition and water maze forced-choice learning in rat offspring exposed in utero to hyperphenylalaninemia. *Neurotoxicol Teratol* 1992 Jan-Feb;14(1):35-41.
- Vorhees CV, Berry HK. Branched chain amino acids improve complex maze learning in rat offspring prenatally exposed to hyperphenylalaninemia: implications for maternal phenylketonuria. *Pediatr Res* 1989 Jun;25(6):568-72.
- Vorhees CV, Butcher RE, Berry HK. Progress in experimental phenylketonuria: a critical review. *Neurosci Biobehav Rev* 1981 Spring;5(1):177-90.
- Wachtel U. Review of current practices in management of inherited disorders of amino acid metabolism in Western Europe. *Hum Nutr Appl Nutr* 1986;40 Suppl 1:61-9.
- Waisbren SE. Developmental and neuropsychological outcome in children born to mothers with phenylketonuria. *Ment Retard Dev Disabil Res Rev* 1999;5(2):125-31.

- Waisbren SE (Children's Hospital, Boston, MA). Study of psychosocial factors in maternal phenylketonuria. Final report. 1985 Nov 1-1991 Oct 31. Rockville (MD): Maternal and Child Health Bureau (US); 1993 Nov. Report No.: MCH/CCS-94/05. 43 p. Available from: NTIS, Springfield, VA; PB95-209144.
- Waisbren SE, Chang P, Levy HL, Shifrin H, Allred E, Azen C, de la Cruz F, Hanley W, Koch R, Matalon R, Rouse B. Neonatal neurological assessment of offspring in maternal phenylketonuria. *J Inherit Metab Dis* 1998 Feb;21(1):39-48.
- Waisbren SE, Doherty LB, Bailey IV, Rohr FJ, Levy HL. The New England Maternal PKU Project: identification of at-risk women. *Am J Public Health* 1988 Jul;78(7):789-92.
- Waisbren SE, Hamilton BD, St. James PJ, Shiloh S, Levy HL. Psychosocial factors in maternal phenylketonuria: women's adherence to medical recommendations. *Am J Public Health* 1995 Dec;85(12):1636-41.
- Waisbren SE, Hanley W, Levy HL, Shifrin H, Allred E, Azen C, Chang PN, Cipic-Schmidt S, de la Cruz F, Hall R, Matalon R, Nanson J, Rouse B, Trefz F, Koch R. Outcome at age 4 years in offspring of women with maternal phenylketonuria: the Maternal PKU Collaborative Study. *JAMA* 2000 Feb 9;283(6):756-62.
- Waisbren SE, Levy HL. Agoraphobia in phenylketonuria. *J Inherit Metab Dis* 1991;14(5):755-64.
- Waisbren SE, Levy HL. Effects of untreated maternal hyperphenylalaninemia on the fetus: further study of families identified by routine cord blood screening. *J Pediatr* 1990 Jun;116(6):926-9.
- Waisbren SE, Rokni H, Bailey I, Rohr F, Brown T, Warner-Rogers J. Social factors and the meaning of food in adherence to medical diets: results of a maternal phenylketonuria summer camp. *J Inherit Metab Dis* 1997 Mar;20(1):21-7.
- Waisbren SE, Shiloh S, St James P, Levy HL. Psychosocial factors in maternal phenylketonuria: prevention of unplanned pregnancies. *Am J Public Health* 1991 Mar;81(3):299-304.
- Waisbren SE, Zaff J. Personality disorder in young women with treated phenylketonuria. *J Inherit Metab Dis* 1994;17(5):584-92.
- Walker V, Mills GA. Metabolism of intravenous phenylalanine by babies born before 33 weeks of gestation. *Biol Neonate* 1990;57(3-4):155-66.
- Wallman CM. Lab values and diagnostics. Newborn genetic screening. *Neonat Netw* 1998 Apr;17(3):55-60, 22-4.
- Walsh DA, Christian ZH. The effects of phenylalanine on cultured rat embryos. *Teratog Carcinog Mutagen* 1984;4(6):505-13.
- Walter JH. Inborn errors of metabolism and pregnancy. *J Inherit Metab Dis* 2000;23(3):229-36.
- Walter JH. Late effects of phenylketonuria. *Arch Dis Child* 1995 Dec;73(6):485-6.
- Wapnir RA. L-tryptophan in maternal phenylketonuria [letter]. *Am J Clin Nutr* 1998 Dec;68(6):1306-7. Comment on: *Am J Clin Nutr* 1998 Mar;67(3):473-6.
- Ward J. New developments in common genetic diseases. *J Tenn Med Assoc* 1986 Aug;79(8):500-1.
- Ward KP, Arthur JR, Russell G, Aggett PJ. Blood selenium content and glutathione peroxidase activity in children with cystic fibrosis, coeliac disease, asthma, and epilepsy. *Eur J Pediatr* 1984 Apr;142(1):21-4.
- Wasser S, Theile H, Scheer A, Graustein I. [Reduced optimal obstetric and postnatal conditions in children with phenylketonuria and their effect on the success of treatment]. *Pediatr Padol* 1986;21(4):351-6. (Ger).
- Weglage J, Funders B, von Teeffelen-Heithoff A, Ullrich K. [Phenylketonuria: illness experience and coping mechanisms]. *Z Kinder Jugendpsychiatr* 1993 Sep;21(3):156-62. (Ger).
- Wenz E. Aspartame and PKU [letter]. *J Am Diet Assoc* 1984 Jan;84(1):101.
- Whitehead H, Holmes J, Roberts R, al-Mandhari NA, Greer A, Thom R, Donnelly P, Carson D, Traub AI, Hadden D. Maternal phenylketonuria 1987 to 1993, pregnancy outcome and early infant development: the Northern Ireland experience. *Br J Obstet Gynaecol* 1996 Oct;103(10):1041-4.
- Widaman KF. Process of analyses of data: Benefits and costs associated with collaborative studies. *Ment Retard Dev Disabil Res Rev* 1999;5(2):155-61.
- Wilkinson H, Holbrook IB. Maternal phenylketonuria. *Ann Clin Biochem* 1998 Jul;35(Pt 4):539-41.
- Williams SR. Nutritional therapy in special conditions of pregnancy. In: Worthington-Roberts BS, Vermeesch J, Williams SR, editors. *Nutrition in pregnancy and lactation*. 2nd ed. St Louis (MO): Mosby; 1981. p. 105-34.
- Woolf LI. Phenylketonuria in Turkey, Ireland and west Scotland. *J Inherit Metab Dis* 1994;17(2):246-7.

Wright L, Brown A, Davidson Mundt A. Newborn screening: the miracle and the challenge. *J Pediatr Nurs* 1992 Feb;7(1):26-42.

Yamashita M, Minato S, Arai M, Kishida Y, Nagatsu T, Umezawa H. Purification of phenylalanine hydroxylase from human adult and foetal livers with a monoclonal antibody. *Biochem Biophys Res Commun* 1985 Nov 27;133(1):202-7.

Yeoh GC, Edkins E, Mackenzie K, Fuller S, Mercer JF, Dahl HH. The development of phenylalanine hydroxylase in rat liver; in vivo, and in vitro studies utilizing fetal hepatocyte cultures. *Differentiation* 1988 Jun;38(1):42-8.

Zetterstrom R. Editorial comment on phenylketonuria [editorial]. *Acta Paediatr* 1995 Jul;84(7):716-8.

Animal, Plant, and Other Non-Human Studies

Abdallah RM, Starkey JR, Meadows GG. Dietary restriction of tyrosine and phenylalanine: inhibition of metastasis of three rodent tumors. *J Natl Cancer Inst* 1987 Apr;78(4):759-69.

Abita JP, Blandin-Savoja F, Rey F. Phenylalanine 4-monooxygenase from human liver. *Methods Enzymol* 1987;142:27-35.

Abita JP, Chamras H, Rosselin G, Rey F. Hormonal control of phenylalanine hydroxylase activity in isolated rat hepatocytes. *Biochem Biophys Res Commun* 1980 Feb 12;92(3):912-8.

Abita JP, Parniak M, Kaufman S. The activation of rat liver phenylalanine hydroxylase by limited proteolysis, lysolecithin, and tocopherol phosphate. Changes in conformation and catalytic properties. *J Biol Chem* 1984 Dec 10;259(23):14560-6.

Adak S, Wang Q, Stuehr DJ. Molecular basis for hyperactivity in tryptophan 409 mutants of neuronal NO synthase. *J Biol Chem* 2000 Jun 9;275(23):17434-9.

Al-Janabi JM. Purification of rat liver phenylalanine hydroxylase by affinity chromatography. *Arch Biochem Biophys* 1980 Apr 1;200(2):603-8.

Alejandre MJ, Marco C, Ramirez H, Segovia JL, Garcia-Peregrin E. Lipid composition of brain myelin from normal and hyperphenylalaninemic chick embryos. *Comp Biochem Physiol B* 1984;77(2):329-32.

Ali BH, Al-Qarawi AA, Mousa HM, Bashir AK, Tanira MOM, Patel M, Bayoumi R. Concentration of amino acids in brains of mice treated with the traditional medicinal plant *Rhazya stricta* decne. *Indian J Pharmacol* 2000;32(3):253-4.

Allen RJ, Brunberg J, Schwartz E, Schaefer AM, Jackson G. MRI characterization of cerebral dysgenesis in maternal PKU. *Acta Paediatr Suppl* 1994 Dec;407:83-5.

Ambrus CM, Horvath C, Kalghatgi K, Clowsley M, Huzella C, Warner R, Ambrus JL, Cooley CM, Mirand EA. Depletion of phenylalanine in the blood of phenylketonuric patients using a PAL-enzyme reactor. An in vitro study. *Res Commun Chem Pathol Pharmacol* 1982 Jul;37(1):105-11.

Ambrus CM, Sharma SD, Horvath C, Kalghatgi K, Anthonie S, Ambrus JL, Cooley C, Mirand EA. In vivo safety of hollow fiber enzyme-reactors with immobilized phenylalanine ammonia-lyase in a large

- animal model for phenylketonuria. *J Pharmacol Exp Ther* 1983 Mar;224(3):598-602.
- Anderson PA, Baker DH, Sherry PA, Corbin JE. Histidine, phenylalanine-tyrosine and tryptophan requirements for growth of the young kitten. *J Anim Sci* 1980 Mar;50(3):479-83.
- Andersson HC, Kohn LD, Bernardini I, Blom HJ, Tietze F, Gahl WA. Characterization of lysosomal monoiodotyrosine transport in rat thyroid cells. Evidence for transport by system h. *J Biol Chem* 1990 Jul 5;265(19):10950-4.
- Ando A, Momomura K, Tobe K, Yamamoto-Honda R, Sakura H, Tamori Y, Kaburagi Y, Koshio O, Akanuma Y, Yazaki Y, et al. Enhanced insulin-induced mitogenesis and mitogen-activated protein kinase activities in mutant insulin receptors with substitution of two COOH-terminal tyrosine autophosphorylation sites by phenylalanine. *J Biol Chem* 1992 Jun 25;267(18):12788-96.
- Annenkov GA. [Genetical heterogeneity of phenylketonuria]. *Vopr Med Khim* 1982 May-Jun;28(3):62-70. (Rus).
- Aragon MC, Gimenez C, Valdivieso F. Inhibition by L-phenylalanine of tyrosine transport by synaptosomal plasma membrane vesicles: implications in the pathogenesis of phenylketonuria. *J Neurochem* 1982 Oct;39(4):1185-7.
- Argaet VP, Wilson TJ, Davidson BE. Purification of the *Escherichia coli* regulatory protein TyrR and analysis of its interactions with ATP, tyrosine, phenylalanine, and tryptophan. *J Biol Chem* 1994 Feb 18;269(7):5171-8.
- Armarego WL, Randles D, Waring P. Dihydropteridine reductase (DHPR), its cofactors, and its mode of action. *Med Res Rev* 1984 Jul-Sep;4(3):267-321.
- Arnau J, Guerrero L, Hortos M, Garcia-Regueiro JA. The composition of white film and white crystals found in dry-cured hams. *J Sci Food Agric* 1996 Apr;70(4):449-52.
- Askin D, Green AK, Dickson AJ, Fisher MJ. Phenylalanine hydroxylation in isolated rat kidney tubules. *Int J Biochem* 1990;22(1):107-14.
- Aspartame. Review of safety issues. Council on Scientific Affairs. *JAMA* 1985 Jul 19;254(3):400-2.
- Austic RE, Su CL, Strupp BJ, Levitsky DA. Effects of dietary mixtures of amino acids on fetal growth and maternal and fetal amino acid pools in experimental maternal phenylketonuria. *Am J Clin Nutr* 1999 Apr;69(4):687-96.
- Avison MJ, Herschkowitz N, Novotny EJ, Petroff OA, Rothman DL, Colombo JP, Bachmann C, Shulman RG, Prichard JW. Proton NMR observation of phenylalanine and an aromatic metabolite in the rabbit brain in vivo. *Pediatr Res* 1990 Jun;27(6):566-70.
- Ayling JE. Discussion: Phenylalanine hydroxylase in human kidney; relevance to Phenylketonuria. *UCLA Forum Med Sci* 1975;(18):459-65.
- Ayling JE, Helfand GD, Pirson WD. Phenylalanine hydroxylase from human kidney. *Enzyme* 1975;20(1):6-19.
- Baba H, Sato S, Inuzuka T, Miyatake T. Developmental changes of myelin-associated glycoprotein in rat brain: study on experimental hyperphenylalaninemia. *Neurochem Res* 1987 May;12(5):459-63.
- Backus RC, Howard KA, Rogers QR. The potency of dietary amino acids in elevating plasma cholecystokinin immunoreactivity in cats is related to amino acid hydrophobicity. *Regul Pept* 1997 Sep 26;72(1):31-40.
- Backwell FR, Bequette BJ, Wilson D, Calder AG, Metcalf JA, Wray-Cahen D, MacRae JC, Beever DE, Loble GE. Utilization of dipeptides by the caprine mammary gland for milk protein synthesis. *Am J Physiol* 1994 Jul;267(1 Pt 2):R1-6.
- Bagchi SP. Cocaine and phencyclidine. Heterogenous dopaminergic interactions with tetrabenazine. *Neuropharmacology* 1985 Jan;24(1):37-41.
- Bailey CA, Gibson RM, Kubena LF, Huff WE, Harvey RB. Impact of L-phenylalanine supplementation on the performance of three-week-old broilers fed diets containing ochratoxin A. 2. Effects of hematology and clinical chemistry. *Poultry Sci* 1990 Mar;69(3):420-25.
- Bailey SW, Ayling JE. 6,6-Dimethylpterins: stable quinoid dihydropterin substrate for dihydropteridine reductase and tetrahydropterin cofactor for phenylalanine hydroxylase. *Biochemistry* 1983 Apr 12;22(8):1790-8.
- Bailey SW, Ayling JE. An assay for picomole levels of tyrosine and related phenols and its application to the measurement of phenylalanine hydroxylase activity. *Anal Biochem* 1980 Sep 1;107(1):156-64.
- Bailey SW, Ayling JE. Cleavage of the 5-amino substituent of pyrimidine cofactors by phenylalanine hydroxylase. *J Biol Chem* 1980 Aug 25;255(16):7774-81.
- Bailey SW, Boerth SR, Dillard SB, Ayling JE. The mechanism of cofactor regeneration during

- phenylalanine hydroxylation. *Adv Exp Med Biol* 1993;338:47-54.
- Bailey SW, Dillard SB, Ayling JE. Role of C6 chirality of tetrahydropterin cofactor in catalysis and regulation of tyrosine and phenylalanine hydroxylases. *Biochemistry* 1991 Oct 22;30(42):10226-35.
- Bailey SW, Weintraub ST, Hamilton SM, Ayling JE. Incorporation of molecular oxygen into pyrimidine cofactors by phenylalanine hydroxylase. *J Biol Chem* 1982 Jul 25;257(14):8253-60.
- Baker KG, Halliday GM, Halasz P, Hornung JP, Geffen LB, Cotton RG, Tork I. Cytoarchitecture of serotonin-synthesizing neurons in the pontine tegmentum of the human brain. *Synapse* 1991 Apr;7(4):301-20.
- Baker RE, Jefferson LS, Shiman R. Immunocytochemical identification of phenylalanine hydroxylase and albumin in cultured hepatoma cells and isolated rat hepatocytes. *J Cell Biol* 1981 Jul;90(1):145-52.
- Balasubramanian S, Carr RT, Bender CJ, Peisach J, Benkovic SJ. Histidines 138 and 143 are copper binding ligands in *Chromobacterium violaceum* phenylalanine hydroxylase. *Adv Exp Med Biol* 1993;338:67-70.
- Balasubramanian S, Carr RT, Bender CJ, Peisach J, Benkovic SJ. Identification of metal ligands in Cu(II)-inhibited *Chromobacterium violaceum* phenylalanine hydroxylase by electron spin echo envelope modulation analysis of histidine to serine mutations. *Biochemistry* 1994 Jul 19;33(28):8532-7.
- Ball RO, Atkinson JL, Bayley HS. Proline as an essential amino acid for the young pig. *Br J Nutr* 1986 May;55(3):659-68.
- Ball RO, Bayley HS. The effect of diarrhea on the oxidation of ¹⁴C-phenylalanine in piglets receiving diets varying in protein and proline concentration. *Can J Vet Res* 1986 Jul;50(3):393-6.
- Ball RO, Bayley HS. Influence of dietary protein concentration on the oxidation of phenylalanine by the young pig. *Br J Nutr* 1986 May;55(3):651-8.
- Ball RO, Bayley HS. Time course of the total and radioactive carbon dioxide production by piglets receiving dietary [¹⁴C]phenylalanine. *Can J Physiol Pharmacol* 1985 Sep;63(9):1170-4.
- Ball RO, Bayley HS. Tryptophan requirement of the 2.5-kg piglet determined by the oxidation of an indicator amino acid. *J Nutr* 1984 Oct;114(10):1741-6.
- Barendse W, Armitage SM, Womack JE, Hetzel J. Linkage relations between A2M, HOX3, INT1, KRAS2, and PAH on bovine chromosome 5. *Genomics* 1992 Sep;14(1):38-42.
- Barker HA. Amino acid degradation by anaerobic bacteria. *Annu Rev Biochem* 1981;50:23-40.
- Bartholome K, Dresel A. Studies on the molecular defect in phenylketonuria and hyperphenylalaninaemia using antibodies against phenylalanine hydroxylase. *J Inher Metab Dis* 1982;5(1):7-10.
- Batterham ES, Bayley HS. Effect of frequency of feeding of diets containing free or protein-bound lysine on the oxidation of [¹⁴C]lysine or [¹⁴C]phenylalanine by growing pigs. *Br J Nutr* 1989 Nov;62(3):647-55.
- Beirne E, Carty MP, Donlon J. Effect of glucagon on hepatic phenylalanine hydroxylase in vivo. *Biosci Rep* 1985 Jun;5(6):463-7.
- Bel Y, Ferre J. Regulation of pteridine biosynthesis and aromatic amino acid hydroxylation in *Drosophila melanogaster*. *Biochem Genet* 1989 Feb;27(1-2):59-76.
- Bel Y, Jacobson KB, Ferre J. A comparative study of *Drosophila* phenylalanine hydroxylase with a natural and a synthetic tetrahydropterin as cofactor. *Comp Biochem Physiol [B]* 1992 Nov;103(3):557-62.
- Bel Y, Jacobson KB, Silva FJ, Ferre J. Developmental and biochemical studies on the phenylalanine hydroxylation system in *Drosophila melanogaster*. *Insect Biochem Mol Biol* 1992 Oct;22(7):633-8.
- Bell JM, John AM. Amino acid requirements of growing mice: arginine, lysine, tryptophan and phenylalanine. *J Nutr* 1981 Mar;111(3):525-30.
- Benit P, Rey F, Blandin-Savoja F, Munnich A, Abadie V, Rey J. The mutant genotype is the main determinant of the metabolic phenotype in phenylalanine hydroxylase deficiency. *Mol Genet Metab* 1999 Sep;68(1):43-7.
- Bequette BJ, Backwell FR, Crompton LA. Current concepts of amino acid and protein metabolism in the mammary gland of the lactating ruminant. *J Dairy Sci* 1998 Sep;81(9):2540-59.
- Bequette BJ, Backwell FR, Dhanoa MS, Walker A, Calder AG, Wray-Cahen D, Metcalf JA, Sutton JD, Beever DE, Lobley GE. Kinetics of blood free and milk casein-amino acid labelling in the dairy goat at two stages of lactation. *Br J Nutr* 1994 Aug;72(2):211-20. Comment in: *Br J Nutr* 1996 Jan;75(1):139-40.
- Bequette BJ, Backwell FR, Kyle CE, Calder AG, Buchan V, Crompton LA, France J, MacCrae JC. Vascular sources of phenylalanine, tyrosine, lysine,

- and methionine for casein synthesis in lactating goats. *J Dairy Sci* 1999 Feb;82(2):362-77.
- Berger DC, Hilton MA, Hilton FK, Duncan SD, Radmacher PG, Greene SM. Intravenous gamma-glutamyl-tyrosine elevates brain tyrosine but not catecholamine concentrations in normal rats. *Metabolism* 1996 Jan;45(1):126-32.
- Berger R, Springer J, Hommes FA. Brain protein and myelin metabolism in hyperphenylalaninemic rats. *Cell Mol Biol* 1980;26(1):31-6.
- Bergqvist PB, Vogels BA, Bosman DK, Maas MA, Hjorth S, Chamuleau RA, Bengtsson F. Neocortical dialysate monoamines of rats after acute, subacute, and chronic liver shunt. *J Neurochem* 1995 Mar;64(3):1238-44.
- Berry A, Ahmad S, Liss A, Jensen RA. Enzymological features of aromatic amino acid biosynthesis reflect the phylogeny of mycoplasmas. *J Gen Microbiol* 1987 Aug;133 (Pt 8):2147-54.
- Bertolo RF, Chen CZ, Law G, Pencharz PB, Ball RO. Threonine requirement of neonatal piglets receiving total parenteral nutrition is considerably lower than that of piglets receiving an identical diet intragastrically. *J Nutr* 1998 Oct;128(10):1752-9.
- Bhatt DK. Acid phosphatase & 5'-nucleotidase activity in the brain of experimentally induced hyperphenylketonuric squirrels *Funambulus palmarum*. *Indian J Exp Biol* 1981 May;19(5):477-8.
- Bialik RJ, Li ET, Geoffroy P, Anderson GH. Route of delivery of phenylalanine influences its effect on short-term food intake in adult male rats. *J Nutr* 1989 Oct;119(10):1519-27.
- Bigham EC, Smith GK, Reinhard JF Jr, Mallory WR, Nichol CA, Morrison RW Jr. Synthetic analogues of tetrahydrobiopterin with cofactor activity for aromatic amino acid hydroxylases. *J Med Chem* 1987 Jan;30(1):40-5.
- Binek PA, Johnson TC, Kelly CJ. Effect of alpha-methylphenylalanine and phenylalanine on brain polyribosomes and protein synthesis. *J Neurochem* 1981 Apr;36(4):1476-84.
- Binek-Singer P, Johnson TC. The effects of chronic hyperphenylalaninaemia on mouse brain protein synthesis can be prevented by other amino acids. *Biochem J* 1982 Aug 15;206(2):407-14.
- Bjorgo E, Knappskog PM, Martinez A, Stevens RC, Flatmark T. Partial characterization and three-dimensional-structural localization of eight mutations in exon 7 of the human phenylalanine hydroxylase gene associated with phenylketonuria. *Eur J Biochem* 1998 Oct 1;257(1):1-10.
- Blaauw Ide, Deutz NEP, Meyenfeldt MF von. In vivo amino acid metabolism of gut and liver during short and prolonged starvation. *Am J Physiol* 1996 Feb;270(2 Pt 1):G298-306.
- Blagoeva PM. Aminoacids--precursors of melanin synthesis in hamster melanoma. *J Cancer Res Clin Oncol* 1984;108(3):366-8.
- Blaskovics ME. Diagnosis in relationship to treatment of hyperphenylalaninaemia. *J Inher Metab Dis* 1986;9 Suppl 2:178-82.
- Blau N, Niederwieser A. GTP-cyclohydrolases: a review. *J Clin Chem Clin Biochem* 1985 Apr;23(4):169-76.
- Bliudzin YuA, Zuber VL. [Composition of fatty acids of glycerophospholipids in the brain of growing rats during demyelination]. *Nervn Sist* 1982;1982(23):125-9. (Rus).
- Blomstrand E, Perrett D, Parry-Billings M, Newsholme EA. Effect of sustained exercise on plasma amino acid concentrations and on 5-hydroxytryptamine metabolism in six different brain regions in the rat. *Acta Physiol Scand* 1989 Jul;136(3):473-81.
- Bloom LM, Benkovic SJ, Gaffney BJ. Characterization of phenylalanine hydroxylase. *Biochemistry* 1986 Jul 29;25(15):4204-10.
- Bode VC, McDonald JD, Guenet JL, Simon D. hph-1: a mouse mutant with hereditary hyperphenylalaninemia induced by ethylnitrosourea mutagenesis. *Genetics* 1988 Feb;118(2):299-305.
- Bodsch W, Coenen HH, Stocklin G, Takahashi K, Hossmann KA. Biochemical and autoradiographic study of cerebral protein synthesis with [18F]- and [14C]fluorophenylalanine. *J Neurochem* 1988 Mar;50(3):979-83.
- Boebel KP, Baker DH. Comparative utilization of the isomers of phenylalanine and phenyllactic acid by chicks and rats. *J Nutr* 1982 Feb;112(2):367-76.
- Bonner CA. Molecular characterization of a bifunctional enzyme dehydratase/shikimate dehydrogenase and the post-prephenate enzymes needed for phenylalanine and tyrosine biosyntheses in SPP [dissertation]. Gainesville (FL): University of Florida; 1994. 159 p.
- Boron P, Szpakowicz T, Farbiszewski R, Flisiak R, Nowak H, Pytel B, Zimnoch L. [Studies of the effect of a protein-free diet and branched-chain amino acids (preparation Aminosteril-Hepa) on selected biochemical indicators in chronic experimental hepatic encephalopathy]. *Neuropatol Pol* 1989;27(3):437-47. (Pol).

- Borresen AL, Hovig E, Smith-Sorensen B, Vrieling H, Apold J, Brogger A. Screening for base mutations in the PAH and HPRT loci using the polymerase chain reaction (PCR) in combination with denaturing gradient gel electrophoresis (DGGE). *Prog Clin Biol Res* 1990;340A:389-98.
- Bourget L, Chang TM. Effects of oral administration of artificial cells immobilized phenylalanine ammonia-lyase on intestinal amino acids of phenylketonuric rats. *Biomater Artif Cells Artif Organs* 1989;17(2):161-81.
- Bourget L, Chang TM. Phenylalanine ammonia-lyase immobilized in microcapsules for the depletion of phenylalanine in plasma in phenylketonuric rat model. *Biochim Biophys Acta* 1986 Oct 1;883(3):432-8.
- Bourget L, Chang TM. Phenylalanine ammonia-lyase immobilized in semipermeable microcapsules for enzyme replacement in phenylketonuria. *FEBS Lett* 1985 Jan 21;180(1):5-8.
- Bourget LA. The effects of phenylalanine ammonia-lyase immobilized within artificial cells on the compartmental distribution of amino acids phenylketonuric rats [dissertation]. Montreal (Canada): McGill University; 1986. 300 p.
- Brand MP, Heales SJ, Land JM, Clark JB. Tetrahydrobiopterin deficiency and brain nitric oxide synthase in the hph1 mouse. *J Inher Metab Dis* 1995;18(1):33-9.
- Brass CA. Hyperphenylalaninemia in the developing rat: biochemical and behavioral alterations [dissertation]. New York: City of New York; 1983. 317 p.
- Brass CA, Greengard O. Modulation of cerebral catecholamine concentrations during hyperphenylalaninemia. *Biochem J* 1982 Dec 15;208(3):765-71.
- Brass CA, Isaacs CE, McChesney R, Greengard O. The effects of hyperphenylalaninemia on fetal development: a new animal model of maternal phenylketonuria. *Pediatr Res* 1982 May;16(5):388-94.
- Brearley GM, Price CP, Atkinson T, Hammond PM. Isolation, identification and characterisation of a soil bacterium producing an enzyme with L-phenylalanine oxidase activity. *Arch Microbiol* 1994 May;161(5):409-13.
- Brown ER, Coker GT 3d, O'Malley KL. Organization and evolution of the rat tyrosine hydroxylase gene. *Biochemistry* 1987 Aug 11;26(16):5208-12.
- Brown KJ. Physiological phenylketonuria: a biochemical defect caused by delayed maturation of the phenylalanine hydroxylation pathway and by competition with the phenylalanine biosynthetic pathway. *Med Hypotheses* 1980 Feb;6(2):215-24.
- Brown KJ, Vesey BV, Tannock GW, Bell EB, Lines DR, Elliott RB. The assay on a defined medium of the effects of beta-2-thienylalanine on the growth of anaerobic bacterial isolates from phenylketonuric patients. *Med Microbiol Immunol (Berl)* 1980 Feb;168(1):11-24.
- Brown RM, James R, Cotton RG. Amplification and expression of phenylalanine hydroxylase in mouse erythroleukemia cells. *Somat Cell Mol Genet* 1985 May;11(3):203-9.
- Bruch RJ. The effect of L-aspartyl-L-phenylalanine methyl ester on biosynthesis in macrophage cells [masters thesis]. Denton (TX): Texas Woman's University; 1992. 54 p.
- Buck M, Griffiths E. Regulation of aromatic amino acid transport by tRNA: role of 2-methylthio-N⁶-(delta²-isopentenyl)-adenosine. *Nucleic Acids Res* 1981 Jan 24;9(2):401-14.
- Burgert SL, Andersen DW, Stegink LD, Takeuchi H, Schedl HP. Metabolism of aspartame and its L-phenylalanine methyl ester decomposition product by the porcine gut. *Metab Clin Exp* 1991 Jun;40(6):612-8.
- Burri R, Matthieu JM, Vandeveld M, Lazeyras F, Posse S, Herschkowitz N. Brain damage and recovery in hyperphenylalaninemic rats. *Dev Neurosci* 1990;12(2):116-25.
- Burri R, Steffen C, Stieger S, Brodbeck U, Colombo JP, Herschkowitz N. Reduced myelinogenesis and recovery in hyperphenylalaninemic rats. Correlation between brain phenylalanine levels, characteristic brain enzymes for myelination, and brain development. *Mol Chem Neuropathol* 1990 Aug-Oct;13(1-2):57-69.
- Burrin DG, Davis TA, Ebner S, Schoknecht PA, Fiorotto ML, Reeds PJ. Colostrum enhances the nutritional stimulation of vital organ protein synthesis in neonatal pigs. *J Nutr* 1997 Jul;127(7):1284-9.
- Burton EG, Dal Monte P, Spears C, Frank P, Oppermann JA. Absorption by the rhesus monkey of phenylalanine methyl ester and species differences in its metabolism by blood, plasma and intestinal mucosa. *J Nutr* 1984 Oct;114(10):1940-5.
- Byng GS, Whitaker RJ, Shapiro CL, Jensen RA. The aromatic amino acid pathway branches at L-arogenate in *Euglena gracilis*. *Mol Cell Biol* 1981 May;1(5):426-38.
- Cai ZN, Yu YN, Chen XX, Yuan LF. [High-level expression of phenylalanine ammonia lyase with

- enzyme activity in *E. coli* by BL21DE3(pET28C-rPAL-1-cDNA)]. *Chin J Pharmacol Toxicol* 2000;14(3):211-5. (Kor).
- Callus BA, Mathey-Prevot B. Hydrophobic residues Phe751 and Leu753 are essential for STAT5 transcriptional activity. *J Biol Chem* 2000 Jun 2;275(22):16954-62.
- Calomme M, Vanderpas J, Francois B, Van Caillie-Bertrand M, Vanovervelt N, Van Hoorebeke C, Vanden Berghe D. Effects of selenium supplementation on thyroid hormone metabolism in phenylketonuria subjects on a phenylalanine restricted diet. *Biol Trace Elem Res* 1995 Jan-Mar;47(1-3):349-53.
- Carr RT. Mechanistic studies of metal independent phenylalanine Chromobacterium violaceum (monooxygenase) [dissertation]. University Park (PA): The Pennsylvania State University; 1994. 140 p.
- Carr RT, Balasubramanian S, Hawkins PC, Benkovic SJ. Mechanism of metal-independent hydroxylation by Chromobacterium violaceum phenylalanine hydroxylase. *Biochemistry* 1995 Jun 6;34(22):7525-32.
- Carr RT, Benkovic SJ. A re-examination of the metal requirement of Chromobacterium violaceum phenylalanine hydroxylase. *Adv Exp Med Biol* 1993;338:63-6.
- Carreras AL, De Mattos-Dutra A, Meirelles R, Da Rocha BB, Wannmacher CMD, Pessoa-Pureur R. Phenylalanine inhibition of the phosphorylation of cytoskeletal proteins from cerebral cortex of young rats is prevented by alanine. *Eur J Clin Invest* 2000;30(6):536-42.
- Castillo M, Zafra MF, Garcia-Peregrin E. Effect of experimental hyperphenylalaninemia induced by dietary phenylalanine plus alpha-methylphenylalanine administration on amino acid concentration in neonatal chick brain, plasma, and liver. *Neurochem Res* 1988 Jun;13(6):547-50.
- Castillo M, Zafra MF, Garcia-Peregrin E. Inhibition of brain and liver 3-hydroxy-3-methylglutaryl-CoA reductase and mevalonate-5-pyrophosphate decarboxylase in experimental hyperphenylalaninemia. *Neurochem Res* 1988 Jun;13(6):551-5.
- Castoria G, Migliaccio A, Green S, Di Domenico M, Chambon P, Auricchio F. Properties of a purified estradiol-dependent calf uterus tyrosine kinase. *Biochemistry* 1993 Feb 23;32(7):1740-50.
- Celikel R, Davis MD, Dai XP, Kaufman S, Xuong NH. Crystallization and preliminary X-ray analysis of phenylalanine hydroxylase from rat liver. *J Mol Biol* 1991 Apr 5;218(3):495-8.
- Chaeva LS. [Effect of experimental hyperphenylalaninemia on the metabolism of glucosyl and galactocerebrosides and sulfatides]. *Vopr Med Khim* 1983 Nov-Dec;29(6):51-4. (Rus).
- Chamove AS. Analysis of learning in retarded monkeys. *J Ment Defic Res* 1984 Mar;28 (Pt 1):21-41.
- Chamove AS. Dietary and metabolic effects on rhesus social behavior: phenylalanine-related dietary alterations. *Dev Psychobiol* 1980 May;13(3):299-307.
- Chamove AS. Long-term learning deficits of mentally retarded monkeys. *Am J Ment Defic* 1984 Jan;88(4):352-68.
- Chang TM, Bourget L, Lister C. A new theory of enterorecirculation of amino acids and its use for depleting unwanted amino acids using oral enzyme-artificial cells, as in removing phenylalanine in phenylketonuria. *Artif Cells Blood Substit Immobil Biotechnol* 1995;23(1):1-21.
- Chen D, Frey PA. Phenylalanine hydroxylase from Chromobacterium violaceum. Uncoupled oxidation of tetrahydropterin and the role of iron in hydroxylation. *J Biol Chem* 1998 Oct 2;273(40):25594-601.
- Chestkov VV, Kovalev LI, Shishkin SS, Annenkov GA. [Oligomerization of phenylalanine hydroxylase during its activation with phenylalanine]. *Vopr Med Khim* 1985 Jul-Aug;31(4):60-5. (Rus).
- Chestkov VV, Kugukova IuV, Kovalev LI, Shishkin SS. [Isolation and characteristics of highly-purified phenylalanine hydroxylase from the rat liver]. *Vopr Med Khim* 1986 Jan-Feb;32(1):123-7. (Rus).
- Chestkov VV, Laptev AV, Shishkin SS. [Detection and characteristics of membrane form of phenylalanine hydroxylase (EC 1.14.16.1) from the rat liver]. *Biokhimiia* 1988 Jan;53(1):158-65. (Rus).
- Chiappelli F, Haggerty DF, Lynch M, Popjak G. Translation of phenylalanine hydroxylase-specific mRNA in vitro: evidence for pretranslational control by glucocorticoids. *Proc Natl Acad Sci U S A* 1981 Apr;78(4):2105-9.
- Choi TB, Pardridge WM. Phenylalanine transport at the human blood-brain barrier. Studies with isolated human brain capillaries. *J Biol Chem* 1986 May 15;261(14):6536-41.
- Choi YH, Asakura K, Okumura J, Furuse M. Repulsive effect and palatability of dietary phenylalanine in laying hens. *Asian Australas J Anim Sci* 1996 Apr;9(2):159-64.

- Choi YH, Furuse M, Okumura J, Shimoyama Y, Sugahara K, Denbow DM. Intracerebroventricularly administered phenylalanine and tyrosine: effects on feeding behavior and norepinephrine concentrations of specific brain sites in the chicken. *Asian Australas J Anim Sci* 1996 Jun;9(3):255-9.
- Choo KH, Cotton RG, Jennings IG, Danks DM. Observations indicating the nature of the mutation in phenylketonuria. *J Inherit Metab Dis* 1980;2(4):79-84.
- Choo KH, Cotton RG, Jennings IG, Fowler K, Danks DM. Genetics of mammalian phenylalanine hydroxylase system. IV. Evidence of phenylalanine hydroxylase in a cultured human hepatoma cell line. *Biochem Genet* 1980 Oct;18(9-10):955-68.
- Choo KH, Filby RG, Jennings IG, Peterson G, Fowler K. Vectors for expression and amplification of cDNA in mammalian cells: expression of rat phenylalanine hydroxylase. *DNA* 1986 Dec;5(6):529-37.
- Choo KH, Jennings IG, Cotton RG. Comparative studies of four monoclonal antibodies to phenylalanine hydroxylase exhibiting different properties with respect to substrate-dependence, species-specificity and a range of effects on enzyme activity. *Biochem J* 1981 Dec 1;199(3):527-35.
- Choo KH, Myer J, Cotton RG, Camakaris J, Danks DM. Isolation of phenylalanine hydroxylase-stimulating monoclonal antibody by rat-myeloma--rat-spleen-cell fusion. *Biochem J* 1980 Nov 1;191(2):665-8.
- Choung JJ, Chamberlain DG. Protein nutrition of dairy cows receiving grass silage diets. Effects on silage intake and milk production of postruminal supplements of casein or soya-protein isolate and the effects of intravenous infusions of a mixture of methionine, phenylalanine and tryptophan. *J Sci Food Agric* 1992;58(3):307-14.
- Christensen HN. Hypothesis: where the depleted plasma amino acids go in phenylketonuria, and why. *Perspect Biol Med* 1987 Winter;30(2):186-96.
- Christensen HN. Where do the depleted plasma amino acids go in phenylketonuria? [letter]. *Biochem J* 1986 Jun 15;236(3):929-30.
- Chung S. The effect of maternal blood phenylalanine level on mouse maternal phenylketonuria offspring [dissertation]. Tucson: The University of Arizona; 1999. 74 p.
- Cinek T, Sadra A, Imboden JB. Cutting edge: Tyrosine-independent transmission of inhibitory signals by CTLA-4. *J Immunol* 2000 Jan 1;164(1):5-8.
- Citron BA, Davis MD, Kaufman S. Electrostatic activation of rat phenylalanine hydroxylase. *Biochem Biophys Res Commun* 1994 Jan 14;198(1):174-80.
- Citron BA, Davis MD, Kaufman S. Purification and biochemical characterization of recombinant rat liver phenylalanine hydroxylase produced in *Escherichia coli*. *Protein Expr Purif* 1992 Apr;3(2):93-100.
- Citron BA, Davis MD, Milstien S, Gutierrez J, Mendel DB, Crabtree GR, Kaufman S. Identity of 4a-carbinolamine dehydratase, a component of the phenylalanine hydroxylation system, and DCoH, a transregulator of homeodomain proteins. *Proc Natl Acad Sci U S A* 1992 Dec 15;89(24):11891-4.
- Collins MA. Neuroamine condensations in human subjects. *Adv Exp Med Biol* 1980;126:87-102.
- Connell A, Calder AG, Anderson SE, Lobley GE. Hepatic protein synthesis in the sheep: effect of intake as monitored by use of stable-isotope-labelled glycine, leucine and phenylalanine. *Br J Nutr* 1997 Feb;77(2):255-71.
- Cordero ME, Trejo M, Colombo M, Aranda V. Histological maturation of the neocortex in phenylketonuric rats. *Early Hum Dev* 1983 Jul;8(2):157-73.
- Cotton RG. A model for hyperphenylalaninaemia due to tetrahydrobiopterin deficiency. *J Inherit Metab Dis* 1986;9(1):4-14.
- Cotton RG, Howells DW, Saleeba JA, Dianzani I, Smooker PM, Jennings IG. Structure function studies of the phenylalanine hydroxylase active site and a summary of structural features. *Adv Exp Med Biol* 1993;338:55-7.
- Cotton RG, Jennings IG, Choo KH, Fowler K. Isolation and characterization of a myeloma--spleen-cell hybrid producing antibody to phenylalanine hydroxylase. *Biochem J* 1980 Dec 1;191(3):777-83.
- Cotton RG, McAdam W, Jennings I, Morgan FJ. A monoclonal antibody to aromatic amino acid hydroxylases. Identification of the epitope. *Biochem J* 1988 Oct 1;255(1):193-6.
- Crandall EA, Fernstrom JD. Effect of experimental diabetes on the levels of aromatic and branched-chain amino acids in rat blood and brain. *Diabetes* 1983 Mar;32(3):222-30.
- Crawford RD. Phenylalanine hydroxylase isozymes in regenerating liver: diet and age [dissertation]. Los Angeles (CA): University of Southern California; 1981.
- Crawford RD, Layne EC, Bessman SP. Effects of phenylalanine on phenylalanine hydroxylase

- separation and stability. *Biochem Med* 1985 Feb;33(1):90-8.
- Crawford RD, Layne EC, Bessman SP. Phenylalanine hydroxylase isozymes in regenerating liver: effects of diet and age. *Biochem Med* 1985 Feb;33(1):77-89.
- Crawford MD, Gibbs DA, Sheppard DM. Studies on human phenylalanine Mono-oxygenase. I. Restricted expression. *J Inher Metab Dis* 1981;4(4):191-5.
- Creppy EE, Chakor K, Fisher MJ, Dirheimer G. The mycotoxin ochratoxin A is a substrate for phenylalanine hydroxylase in isolated rat hepatocytes and in vivo. *Arch Toxicol* 1990;64(4):279-84.
- Cristiano RJ, Smith LC, Woo SL. Hepatic gene therapy: adenovirus enhancement of receptor-mediated gene delivery and expression in primary hepatocytes. *Proc Natl Acad Sci U S A* 1993 Mar 15;90(6):2122-6.
- Curtius HC, Adler C, Rebrin I, Heizmann C, Ghisla S. 7-Substituted pterins: formation during phenylalanine hydroxylation in the absence of dehydratase. *Biochem Biophys Res Commun* 1990 Nov 15;172(3):1060-6.
- Curtius HC, Ghisla S, Hasegawa H, Blau N, Rebrin I. Progress in the study of biosynthesis and role of 7-substituted pterins: function of pterin-4a-carbinolamine dehydratase. *Adv Exp Med Biol* 1993;338:107-10.
- Curtius HC, Kuster T, Matasovic A, Blau N, Dhondt JL. Primapterin, anapterin, and 6-oxo-primapterin, three new 7-substituted pterins identified in a patient with hyperphenylalaninemia. *Biochem Biophys Res Commun* 1988 Jun 16;153(2):715-21.
- Cutler P. Arginase deficiency and phenylketonuria [letter]. *J Neurol Neurosurg Psychiatry* 1986 Sep;49(9):1090.
- Cynober L. Amino acid metabolism in thermal burns. *JPEN J Parenter Enteral Nutr* 1989 Mar-Apr;13(2):196-205.
- D'Amato TA. Gene-enzyme relationships in *Nicotiana glauca*: subcellular localization of genes and enzymes for aromatic amino acid (chloroplasts, tryptophan, phenylalanine, metabolism, tyrosine) [dissertation]. Binghamton (NY): State University of New York at Binghamton; 1987. 163 p.
- D'Sa CM, Arthur RE Jr, States JC, Kuhn DM. Tryptophan hydroxylase: cloning and expression of the rat brain enzyme in mammalian cells. *J Neurochem* 1996 Sep;67(3):900-6.
- Dahl HH, Mercer JF. Isolation and sequence of a cDNA clone which contains the complete coding region of rat phenylalanine hydroxylase. Structural homology with tyrosine hydroxylase, glucocorticoid regulation, and use of alternate polyadenylation sites. *J Biol Chem* 1986 Mar 25;261(9):4148-53.
- Danicke S, Bottcher W, Jeroch H, Thielebein J, Simon O. Replacement of soybean oil with tallow in rye-based diets without xylanase increases protein synthesis in small intestine of broilers. *J Nutr* 2000 Apr;130(4):827-34.
- Darmon MC, Grima B, Cash CD, Maitre M, Mallet J. Isolation of a rat pineal gland cDNA clone homologous to tyrosine and phenylalanine hydroxylases. *FEBS Lett* 1986 Sep 29;206(1):43-6.
- Daubner SC, Hillas PJ, Fitzpatrick PF. Characterization of chimeric pterin-dependent hydroxylases: contributions of the regulatory domains of tyrosine and phenylalanine hydroxylase to substrate specificity. *Biochemistry* 1997 Sep 30;36(39):11574-82.
- Daubner SC, Hillas PJ, Fitzpatrick PF. Expression and characterization of the catalytic domain of human phenylalanine hydroxylase. *Arch Biochem Biophys* 1997 Dec 15;348(2):295-302.
- Davis MD, Kaufman S. 7-Tetrahydrobiopterin is an uncoupled cofactor for rat hepatic phenylalanine hydroxylase. *FEBS Lett* 1991 Jul 8;285(1):17-20.
- Davis MD, Kaufman S. Evidence for the formation of the 4a-carbinolamine during the tyrosine-dependent oxidation of tetrahydrobiopterin by rat liver phenylalanine hydroxylase. *J Biol Chem* 1989 May 25;264(15):8585-96.
- Davis MD, Kaufman S. Products of the tyrosine-dependent oxidation of tetrahydrobiopterin by rat liver phenylalanine hydroxylase. *Arch Biochem Biophys* 1993 Jul;304(1):9-16.
- Davis MD, Kaufman S. Studies on the partially uncoupled oxidation of tetrahydropterins by phenylalanine hydroxylase. *Neurochem Res* 1991 Jul;16(7):813-9.
- Davis MD, Kaufman S. The tyrosine-dependent oxidation of tetrahydropterins by lysolecithin-activated rat liver phenylalanine hydroxylase. *J Biol Chem* 1988 Nov 25;263(33):17312-6.
- Davis MD, Kaufman S, Milstien S. Conversion of 6-substituted tetrahydropterins to 7-isomers via phenylalanine hydroxylase-generated intermediates. *Proc Natl Acad Sci U S A* 1991 Jan 15;88(2):385-9.
- Davis MD, Parniak MA, Kaufman S, Kempner E. The role of phenylalanine in structure-function relationships of phenylalanine hydroxylase revealed by radiation target analysis. *Proc Natl Acad Sci U S A* 1997 Jan 21;94(2):491-5.

- Davis MD, Parniak MA, Kaufman S, Kempner E. Structure-function relationships of phenylalanine hydroxylase revealed by radiation target analysis. *Arch Biochem Biophys* 1996 Jan 15;325(2):235-41.
- Davis MD, Ribeiro P, Tipper J, Kaufman S. 7-tetrahydrobiopterin, a naturally occurring analogue of tetrahydrobiopterin, is a cofactor for and a potential inhibitor of the aromatic amino acid hydroxylases. *Proc Natl Acad Sci U S A* 1992 Nov 1;89(21):10109-13.
- Davis TA, Fiorotto ML, Nguyen HV, Burrin DG. Aminoacyl-tRNA and tissue free amino acid pools are equilibrated after a flooding dose of phenylalanine. *Am J Physiol* 1999 Jul;277(1 Pt. 1):E103-9.
- Davis TA, Karl IE, Tegtmeyer ED, Osborne DF, Klahr S, Harter HR. Muscle protein turnover: effects of exercise training and renal insufficiency. *Am J Physiol* 1985 Mar;248(3 Pt 1):E337-45.
- de Cespedes C, Thoene JG, Lowler K, Christensen HN. Evidence for inhibition of exodus of small neutral amino acids from non-brain tissues in hyperphenylalaninaemic rats. *J Inher Metab Dis* 1989;12(2):166-80.
- de Freitas MS, de Mattos-Dutra A, Schroder N, Wannmacher CMD, Pessoa-Pureur R. Effect of hyperphenylalaninemia chemically induced on in vitro incorporation of ³²P into cytoskeletal proteins from cerebral cortex of developing rats. *Exp Neurol* 1997 Feb;143(2):188-95.
- de Freitas O, Izumi C, Lara MG, Greene LJ. New approaches to the treatment of phenylketonuria. *Nutr Rev* 1999 Mar;57(3):65-70.
- De Lucca M, Perez B, Desviat LR, Ugarte M. Molecular basis of phenylketonuria in Venezuela: presence of two novel null mutations. *Hum Mutat* 1998;11(5):354-9.
- Denno KM, Sadler TW. Phenylalanine and its metabolites induce embryopathies in mouse embryos in culture. *Teratology* 1990 Nov;42(5):565-70.
- Depietro FR. The role of phenylalanine in catecholamine synthesis in pc12 pheochromocytoma cells (tyrosine) [dissertation]. Pittsburgh (PA): University of Pittsburgh; 1997. 195 p.
- Dews PB. Summary report of an International Aspartame Workshop. *Food Chem Toxicol* 1987 Jul;25(7):549-52.
- Dhondt JL, Ardouin P, Hayte JM, Farriaux JP. Developmental aspects of pteridine metabolism and relationships with phenylalanine metabolism. *Clin Chim Acta* 1981 Oct 26;116(2):143-52.
- Dhondt JL, Delcroix M, Farriaux JP. Unconjugated pteridines in human milk. *Clin Chim Acta* 1982 May 6;121(1):33-5.
- Dhondt JL, Farriaux JP. [Tetrahydrobiopterin. Metabolism and metabolic role of unconjugated pteridines (author's transl)]. *Pathol Biol (Paris)* 1980 Jun;28(6):397-405. (Fre).
- Dhondt JL, Henichart JP, Bernier JL, Dautrevaux M. In vitro effects of L- and D-parachlorophenylalanine on rat liver phenylalanine hydroxylase. *Biochimie* 1980;62(2-3):185-6.
- Dhondt JL, Kapatos G, Parniak M, Wilgus H, Kaufman S. Biopterin metabolism and phenylalanine hydroxylase activity during early liver regeneration. *Biochem Biophys Res Commun* 1982 Jun 15;106(3):786-93.
- Diamond A. Evidence for the importance of dopamine for prefrontal cortex functions early in life. *Philos Trans R Soc Lond B Biol Sci* 1996 Oct 29;351(1346):1483-93; discussion 1494.
- Diamond A. Phenylalanine levels of 6-10 mg/dl may not be as benign as once thought. *Acta Paediatr Suppl* 1994 Dec;407:89-91.
- Diamond A, Ciaramitaro V, Donner E, Djali S, Robinson MB. An animal model of early-treated PKU. *J Neurosci* 1994 May;14(5 Pt 2):3072-82.
- Dickson PW, Jennings IG, Cotton RG. Delineation of the catalytic core of phenylalanine hydroxylase and identification of glutamate 286 as a critical residue for pterin function. *J Biol Chem* 1994 Aug 12;269(32):20369-75.
- Dienel GA. Chronic hyperphenylalaninemia produces cerebral hyperglycinemia in immature rats. *J Neurochem* 1981 Jan;36(1):34-43.
- Dietary D-tyrosine as an antimetabolite in mice. *Nutr Rev* 1985 May;43(5):156-8.
- Dillehay L, Bass R, Englesberg E. Inhibition of growth of cells in culture by L-phenylalanine as a model system for the analysis of phenylketonuria. I. amino acid antagonism and the inhibition of protein synthesis. *J Cell Physiol* 1980 Mar;102(3):395-405.
- Diomedede L, Romano M, Guiso G, Caccia S, Nava S, Salmons M. Interspecies and interstrain studies on the increased susceptibility to metrazol-induced convulsions in animals given aspartame. *Food Chem Toxicol* 1991 Feb;29(2):101-6.
- Dix TA, Benkovic SJ. Mechanism of uncoupled tetrahydropterin oxidation by phenylalanine

- hydroxylase. *Biochemistry* 1985 Oct 8;24(21):5839-46.
- Dix TA, Bollag GE, Domanico PL, Benkovic SJ. Phenylalanine hydroxylase: absolute configuration and source of oxygen of the 4a-hydroxytetrahydropterin species. *Biochemistry* 1985 Jun 4;24(12):2955-8.
- Dluzniewski A, Gastol-Lewinska L. Phenylalanine deficiency in food of rats. Part I. Phenylalanine-low diet for rats. *Pol J Pharmacol Pharm* 1981 Jan-Feb;33(1):87-90.
- Donlon J, Beirne E. Modulations of rat hepatic phenylalanine hydroxylase due to induced diabetes or high-protein diet. *Biochem Biophys Res Commun* 1982 Sep 30;108(2):746-51.
- Donlon J, Kaufman S. Relationship between the multiple forms of rat hepatic phenylalanine hydroxylase and degree of phosphorylation. *J Biol Chem* 1980 Mar 10;255(5):2146-52.
- Doskeland A, Ljones T, Skotland T, Flatmark T. Phenylalanine 4-monooxygenase from bovine and rat liver: some physical and chemical properties. *Neurochem Res* 1982 Apr;7(4):407-21.
- Doskeland AP, Doskeland SO, Flatmark T. Phenylalanine 4-monooxygenase from bovine liver. *Methods Enzymol* 1987;142:35-44.
- Doskeland AP, Doskeland SO, Ogreid D, Flatmark T. The effect of ligands of phenylalanine 4-monooxygenase on the cAMP-dependent phosphorylation of the enzyme. *J Biol Chem* 1984 Sep 25;259(18):11242-8.
- Doskeland AP, Flatmark T. Recombinant human phenylalanine hydroxylase is a substrate for the ubiquitin-conjugating enzyme system. *Biochem J* 1996 Nov 1;319 (Pt 3):941-5.
- Doskeland AP, Martinez A, Knappskog PM, Flatmark T. Phosphorylation of recombinant human phenylalanine hydroxylase: effect on catalytic activity, substrate activation and protection against non-specific cleavage of the fusion protein by restriction protease. *Biochem J* 1996 Jan 15;313 (Pt 2):409-14.
- Doskeland AP, Schworer CM, Doskeland SO, Chrisman TD, Soderling TR, Corbin JD, Flatmark T. Some aspects of the phosphorylation of phenylalanine 4-monooxygenase by a calcium-dependent and calmodulin-dependent protein kinase. *Eur J Biochem* 1984 Nov 15;145(1):31-7.
- Doskeland AP, Vintermyr OK, Flatmark T, Cotton RG, Doskeland SO. Phenylalanine positively modulates the cAMP-dependent phosphorylation and negatively modulates the vasopressin-induced and okadaic-acid-induced phosphorylation of phenylalanine 4-monooxygenase in intact rat hepatocytes. *Eur J Biochem* 1992 May 15;206(1):161-70.
- Drenth JP, Kleinjans JC. [Aspartame, a sweet alternative]. *Ned Tijdschr Geneesk* 1988 Apr 16;132(16):712-5. (Dut).
- Druml W, Roth E, Lenz K, Lochs H, Kopsa H. Phenylalanine and tyrosine metabolism in renal failure: dipeptides as tyrosine source. *Kidney Int Suppl* 1989 Nov;27:S282-6.
- Duch DS, Smith GK. Biosynthesis and function of tetrahydrobiopterin. *J Nutr Biochem* 1991 Aug;2(8):411-23.
- Dunlop DS, Yang XR, Lajtha A. The effect of elevated plasma phenylalanine levels on protein synthesis rates in adult rat brain. *Biochem J* 1994 Sep 1;302 (Pt 2):601-10.
- Dwivedy AK, Shah SN. Effect of hyperphenylalaninemia on Na⁺ + K⁺-ATPase in rat brain. *Exp Neurol* 1981 Dec;74(3):924-9.
- Dwivedy AK, Shah SN. Effect of hyperphenylalaninemia on polyphosphoinositides content of rat brain. *Experientia* 1982 Dec 15;38(12):1458-9.
- Dwivedy AK, Shah SN. Effects of phenylalanine and its deaminated metabolites on Na⁺,K⁺-ATPase activity in synaptosomes from rat brain. *Neurochem Res* 1982 Jun;7(6):717-25.
- Dworniczak B, Grudda K, Stumper J, Bartholome K, Aulehla-Scholz C, Horst J. Phenylalanine hydroxylase gene: novel missense mutation in exon 7 causing severe phenylketonuria. *Genomics* 1991 Jan;9(1):193-9.
- Dyck LE, Yang CR, Boulton AA. The biosynthesis of p-tyramine, m-tyramine, and beta-phenylethylamine by rat striatal slices. *J Neurosci Res* 1983;10(2):211-20.
- Dyer CA. Pathophysiology of phenylketonuria. *Ment Retard Dev Disabil Res Rev* 1999;5(2):104-12.
- Dyer CA, Kendler A, Jean-Guillaume D, Awatramani R, Lee A, Mason LM, Kamholz J. GFAP-positive and myelin marker-positive glia in normal and pathologic environments. *J Neurosci Res* 2000 May 1;60(3):412-26.
- Dyer CA, Kendler A, Philibotte T, Gardiner P, Cruz J, Levy HL. Evidence for central nervous system glial cell plasticity in phenylketonuria. *J Neuropathol Exp Neurol* 1996 Jul;55(7):795-814.

- Dzhura I, Naidenov V, Zhuravleva S, Kostyuk P, Shuba Y. Expression of Ca²⁺ channels from rat brain with model phenylketonuria in *Xenopus* oocytes. *Brain Res* 1998 Feb 9;783(2):280-5.
- Edara S, Goodtzova K, Pegg AE. The role of tyrosine-158 in O⁶-alkylguanine-DNA alkyltransferase activity. *Carcinogenesis* 1995 Jul;16(7):1637-42.
- Edwards P. The effects of some neurotoxins on tetrahydrobiopterin [dissertation]. Birmingham (UK): University of Aston in Birmingham; 1988. 244 p.
- Eiken HG, Knappskog PM, Apold J, Flatmark T. PKU mutation G46S is associated with increased aggregation and degradation of the phenylalanine hydroxylase enzyme. *Hum Mutat* 1996;7(3):228-38.
- Eisensmith RC, Woo SL. Gene therapy for phenylketonuria. *Acta Paediatr Suppl* 1994 Dec;407:124-9.
- Eisensmith RC, Woo SL. Gene therapy for phenylketonuria. *Eur J Pediatr* 1996 Jul;155 Suppl 1:S16-9.
- Eisensmith RC, Woo SL. Phenylketonuria and the phenylalanine hydroxylase gene. *Mol Biol Med* 1991 Feb;8(1):3-18.
- Eisensmith RC, Woo SL. Somatic gene therapy for phenylketonuria and other hepatic deficiencies. *J Inher Metab Dis* 1996;19(4):412-23.
- El-Batal AI, Abo-State MA, Shihab A. Phenylalanine ammonia lyase production by gamma irradiated and analog-resistant mutants of *Rhodotorula glutinis*. *Acta Microbiol Pol* 2000;49(1):51-61.
- Elkin RG. Metabolic interrelationships of phenylalanine and tyrosine in and rats fed crystalline amino acid diets [dissertation]. West Lafayette (IN): Purdue University; 1981. 130 p.
- Elkin RG, Chrisman CL, Rogler JC, Featherston WR. Influence of (dietary) phenylalanine and lysine deficiencies on thyroid morphology in the chick. *Poultry Sci* 1981 Apr;60(4):878-81.
- Elkin RG, Featherston WR, Rogler JC. Effects of dietary phenylalanine and tyrosine on circulating thyroid hormone levels and growth in the chick. *J Nutr* 1980 Jan;110(1):132-8.
- Elkin RG, Rogler JC. Partial alleviation of phenylalanine toxicity in the chick by supplemental dietary tryptophan. *Poult Sci* 1983 Apr;62(4):647-58.
- Elkin RG, Rogler JC, Featherston WR. Dietary phenylalanine and tyrosine interrelationships in the Sprague-Dawley rat. *Proc Soc Exp Biol Med* 1981 Jul;167(3):310-7.
- Ellis HR, Daubner SC, Fitzpatrick PF. Mutation of serine 395 of tyrosine hydroxylase decouples oxygen-oxygen bond cleavage and tyrosine hydroxylation. *Biochemistry* 2000 Apr 11;39(14):4174-81.
- Elslinger MA, Theriault GR, Gauthier D. In vitro localization of the protein synthesis defect associated with experimental phenylketonuria. *Neurochem Res* 1989 Jan;14(1):81-4.
- Elstad CA, Meadows GG. Modulation of B16-BL6 murine melanoma metastatic phenotype by tyrosine and phenylalanine restriction in the absence of host selection pressures. *Anticancer Res* 1993 Mar-Apr;13(2):523-8.
- Elstad CA, Meadows GG, Aslakson CJ, Starkey JR. Evidence for nutrient modulation of tumor phenotype: impact of tyrosine and phenylalanine restriction. *Adv Exp Med Biol* 1994;354:171-83.
- Elstad CA, Thrall BD, Raha G, Meadows GG. Tyrosine and phenylalanine restriction sensitizes adriamycin-resistant P388 leukemia cells to adriamycin. *Nutr Cancer* 1996;25(1):47-60.
- Ems-McClung SC. Molecular engineering and characterization of recombinant for the dietary treatment of phenylketonuria (PKU) [dissertation]. Bloomington (IN): Indiana University; 1998. 158 p.
- Endo F. [Inborn errors of tyrosine metabolism: abnormalities in catabolic pathway of phenylalanine and tyrosine]. *Seikagaku* 1999 Nov;71(11):1327-31. (Jpn).
- Endres W. [Differential diagnosis and therapy of various forms of hyperphenylalaninemia: facts and fiction]. *Wien Klin Wochenschr* 1992;104(16):503-9. (Ger).
- Eriksson T, Carlsson A. Beta-adrenergic control of brain uptake of large neutral amino acids. *Life Sci* 1988;42(17):1583-9.
- Erlandsen H, Bjorgo E, Flatmark T, Stevens RC. Crystal structure and site-specific mutagenesis of pterin-bound human phenylalanine hydroxylase. *Biochemistry* 2000 Mar 7;39(9):2208-17.
- Erlandsen H, Flatmark T, Stevens RC, Hough E. Crystallographic analysis of the human phenylalanine hydroxylase catalytic domain with bound catechol inhibitors at 2.0 Å resolution. *Biochemistry* 1998 Nov 10;37(45):15638-46.
- Erlandsen H, Fusetti F, Martinez A, Hough E, Flatmark T, Stevens RC. Crystal structure of the catalytic domain of human phenylalanine hydroxylase reveals the structural basis for phenylketonuria [letter]. *Nat Struct Biol* 1997 Dec;4(12):995-1000.

- Eschrich K, van der Bolt FJ, de Kok A, van Berkel WJ. Role of Tyr201 and Tyr385 in substrate activation by p-hydroxybenzoate hydroxylase from *Pseudomonas fluorescens*. *Eur J Biochem* 1993 Aug 15;216(1):137-46.
- Esposito DL, Blakesley VA, Koval AP, Scrimgeour AG, LeRoith D. Tyrosine residues in the C-terminal domain of the insulin-like growth factor-I receptor mediate mitogenic and tumorigenic signals. *Endocrinology* 1997 Jul;138(7):2979-88.
- Fang B, Eisensmith RC, Li XH, Finegold MJ, Shedlovsky A, Dove W, Woo SL. Gene therapy for phenylketonuria: phenotypic correction in a genetically deficient mouse model by adenovirus-mediated hepatic gene transfer. *Gene Ther* 1994 Jul;1(4):247-54.
- Fang CH, Li BG, James JH, Fischer JE, Hasselgren PO. The anabolic effects of IGF-1 in skeletal muscle after burn injury are not caused by increased cell volume. *JPEN J Parenter Enteral Nutr* 1998 May-Jun;22(3):115-9.
- Farishian RA, Whittaker JR. Phenylalanine lowers melanin synthesis in mammalian melanocytes by reducing tyrosine uptake: implications for pigment reduction in phenylketonuria. *J Invest Dermatol* 1980 Feb;74(2):85-9.
- Farmer AA, Goss SJ. BWTG3 hepatoma cells can acquire phenylalanine hydroxylase, cystathionine synthase and CPS-I without genetic manipulation, but activation of the silent OTC gene requires cell fusion with hepatocytes. *J Cell Sci* 1991 Apr;98 (Pt 4):533-8.
- Faust DM, Catherin AM, Barbaux S, Belkadi L, Imaizumi-Scherrer T, Weiss MC. The activity of the highly inducible mouse phenylalanine hydroxylase gene promoter is dependent upon a tissue-specific, hormone-inducible enhancer. *Mol Cell Biol* 1996 Jun;16(6):3125-37.
- Faust DM, Imaizumi-Scherrer T, Fulchignoni-Lataud MC, Catherin AM, Iost I, Weiss MC. Activation of phenylalanine hydroxylase expression following genomic DNA transfection of hepatoma cells. *Differentiation* 1990 Jul;44(1):74-9.
- Fernstrom JD. Role of precursor availability in control of monoamine biosynthesis in brain. *Physiol Rev* 1983 Apr;63(2):484-546.
- Fernstrom JD, Fernstrom MH, Gillis MA. Acute effects of aspartame on large neutral amino acids and monoamines in rat brain. *Life Sci* 1983 Apr 4;32(14):1651-8.
- Fernstrom JD, Fernstrom MH, Grubb PE. Twenty-four-hour variations in rat blood and brain levels of the aromatic and branched-chain amino acids: chronic effects of dietary protein content. *Metabolism* 1987 Jul;36(7):643-50.
- Fernstrom JD, Fernstrom MH, Massoudi MS. In vivo tyrosine hydroxylation in rat retina: effect of aspartame ingestion in rats pretreated with p-chlorophenylalanine. *Am J Clin Nutr* 1991 Apr;53(4):923-9.
- Fernstrom MH, Baker RL, Fernstrom JD. In vivo tyrosine hydroxylation rate in retina: effects of phenylalanine and tyrosine administration in rats pretreated with p-chlorophenylalanine. *Brain Res* 1989 Oct 16;499(2):291-8.
- Ficner R, Sauer UH, Ceska TA, Stier G, Suck D. Crystallization and preliminary crystallographic studies of recombinant dimerization cofactor of transcription factor HNF1/pterin-4 alpha-carbinolamine dehydratase from liver. *FEBS Lett* 1995 Jan 2;357(1):62-4.
- Ficner R, Sauer UH, Stier G, Suck D. Three-dimensional structure of the bifunctional protein PCD/DcOH, a cytoplasmic enzyme interacting with transcription factor HNF1. *EMBO J* 1995 May 1;14(9):2034-42.
- Fink RM, Elstner EF. Comparison of different methods for the determination of phenylalanine hydroxylase activity in rat liver and *Euglena gracilis*. *Z Naturforsch [C]* 1984 Jul-Aug;39(7-8):728-33.
- Fink RM, Elstner EF. Studies on the possible mechanism of inactivation of phenylalanine hydroxylase by destructive oxygen species. *Z Naturforsch [C]* 1984 Jul-Aug;39(7-8):734-7.
- Fischer GM, Nemeti B, Farkas V, Debreceni B, Laszlo A, Schaffer Z, Somogyi C, Sandor A. Metabolism of carnitine in phenylacetic acid-treated rats and in patients with phenylketonuria. *Biochim Biophys Acta* 2000 Jun 15;1501(2-3):200-10.
- Fisher MJ, Dickson AJ, Pogson CI. Phosphopeptide analysis of phenylalanine hydroxylase isolated from liver cells exposed to hormonal stimuli. *Biochem J* 1986 Jan 15;233(2):507-11.
- Fisher MJ, Dickson AJ, Pogson CI. The polyamine-dependent modulation of phenylalanine hydroxylase phosphorylation state and enzymic activity in isolated liver cells. *Biochem J* 1986 Jul 1;237(1):277-9.
- Fisher MJ, Pogson CI. The determination of flux through phenylalanine hydroxylase and homogentisate oxidase in isolated hepatocytes. *Biosci Rep* 1984 Oct;4(10):835-41.
- Fisher MJ, Pogson CI. Phenylalanine hydroxylase in liver cells. Correlation of glucagon-stimulated enzyme

- phosphorylation with expressed activity. *Biochem J* 1984 Apr 1;219(1):79-85.
- Fisher MJ, Santana MA, Pogson CI. Effects of adrenergic agents, vasopressin and ionophore A23187, on the phosphorylation of, and flux through, phenylalanine hydroxylase in rat liver cells. *Biochem J* 1984 Apr 1;219(1):87-90.
- Forlani G, Lejczak B, Kafarski P. The herbicidally active compound N-2-(6-methyl-pyridyl)-aminomethylane bisphosphonic acid inhibits in vivo aromatic biosynthesis. *J Plant Growth Regul* 1999 Spring ;18(2):73-9.
- Foster MS, Carroll JN, Niederhoffer EC. Phenylalanine- and tyrosine-dependent production of enterobactin in *Escherichia coli*. *FEMS Microbiol Lett* 1994 Mar 15;117(1):79-83.
- Fountain SB, Hennes SK, Teyler TJ. Aspartame exposure and in Vitro hippocampal slice excitability and plasticity. *Fundam Appl Toxicol* 1988 Aug;11(2):221-8.
- Friedman M, Gumbmann MR. The nutritive value and safety of D-phenylalanine and D-tyrosine in mice. *J Nutr* 1984 Nov;114(11):2089-96.
- Friedrich CA. Cytoplasmic malate dehydrogenase is the aromatic alpha-keto reductase in man (phenylketonuria, PKU, tyrosine) [dissertation]. Houston: University of Texas Health Science Center at Houston, Graduate School of Biomedical Science; 1986. 137 p.
- Friedrich CA, Ferrell RE, Siciliano MJ, Kitto GB. Biochemical and genetic identity of alpha-keto acid reductase and cytoplasmic malate dehydrogenase from human erythrocytes. *Ann Hum Genet* 1988 Jan;52 (Pt 1):25-37.
- Froberg C. Nongrowing cells for production of metabolites: *Clostridium acetobutylicum* and phenylalanine from *Escherichia* [dissertation]. Stockholm (Sweden): Royal Institute of Technology; 1988. 95 p.
- Fukami MH, Haavik J, Flatmark T. Phenylalanine as substrate for tyrosine hydroxylase in bovine adrenal chromaffin cells. *Biochem J* 1990 Jun 1;268(2):525-8.
- Fulchignoni-Lataud MC, Weiss MC, Szpirer C, Levan G. Assignment of the rat genes coding for phenylalanine hydroxylase (PAH), tyrosine aminotransferase (TAT), and pyruvate kinase (PKL) to chromosomes 7, 19, 2, respectively. *Cytogenet Cell Genet* 1990;53(2-3):172-4.
- Fulton TR, Triano T, Rabe A, Loo YH. Phenylacetate and the enduring behavioral deficit in experimental phenylketonuria. *Life Sci* 1980 Oct 6;27(14):1271-81.
- Gal EM, Whitacre DH. Mechanism of irreversible inactivation of phenylalanine-4- and tryptophan-5-hydroxylases by [4-³⁶Cl, 2-¹⁴C]p-chlorophenylalanine: a revision. *Neurochem Res* 1982 Jan;7(1):13-26.
- Galli C, Agostoni C, Mosconi C, Riva E, Salari PC, Giovannini M. Reduced plasma C-20 and C-22 polyunsaturated fatty acids in children with phenylketonuria during dietary intervention. *J Pediatr* 1991 Oct;119(4):562-7.
- Garcia C, Baldellou A, Gimenez-Mas JA, Gracia J, Sanz-Moncasi MP, Enriquez JA, Muino-Blanco MT, Lopez-Perez MJ, Perez-Gonzalez J. Synaptosomal development in rats from phenylketonuric mothers. *J Inherit Metab Dis* 1996;19(3):385-6.
- Garcia Vera C, Baldellou Vazquez A, Gracia Romero J, Ventura Faci P, Perez-Gonzalez J. [An experimental study on the effects of maternal hyperphenylalaninemia on the central nervous system and behavior of offspring rats]. *An Esp Pediatr* 1998 Jan;48(1):11-6. (Spa).
- Gardiner RM. Transport of amino acids across the blood-brain barrier: implications for treatment of maternal phenylketonuria. *J Inherit Metab Dis* 1990;13(4):627-33.
- Gardner AM, Martin LA, Gardner PR, Dou Y, Olson JS. Steady-state and transient kinetics of *Escherichia coli* nitric-oxide dioxygenase (flavo-hemoglobin). The B10 tyrosine hydroxylase is essential for dioxygen binding and catalysis. *J Biol Chem* 2000 Apr 28;275(17):12581-9.
- Garriga MM, Metcalfe DD. Aspartame intolerance. *Ann Allergy* 1988 Dec;61(6 Pt 2):63-9.
- Gavioli F, Zannino L. [Dietetic treatment of phenylketonuria]. *Minerva Pediatr* 1980 Mar 31;32(6):417-32. (Ita).
- Gehrmann J, Schott K, Neuhoff V. Biochemical and developmental features of experimental phenylketonuria induced by L-ethionine in suckling rats. *Biochem Med Metab Biol* 1989 Jun;41(3):201-11.
- Geltosky JE, Mitchell HK. Developmental regulation of phenylalanine hydroxylase activity in *Drosophila melanogaster*. *Biochem Genet* 1980 Aug;18(7-8):781-91.
- Ghavami M, Levy HL, Erbe RW. Prevention of fetal damage through dietary control of maternal hyperphenylalaninemia. *Clin Obstet Gynecol* 1986 Sep;29(3):580-5.
- Gibbs BS. Expression and active site studies of rat liver phenylalanine hydroxylase (pterin binding site

- [dissertation]. University Park (PA): The Pennsylvania State University; 1992. 146 p.
- Gibbs BS, Benkovic SJ. Affinity labeling of the active site and the reactive sulfhydryl associated with activation of rat liver phenylalanine hydroxylase. *Biochemistry* 1991 Jul 9;30(27):6795-802.
- Gibbs BS, Wojchowski D, Benkovic SJ. Expression of rat liver phenylalanine hydroxylase in insect cells and site-directed mutagenesis of putative non-heme iron-binding sites. *J Biol Chem* 1993 Apr 15;268(11):8046-52.
- Gibson CJ, Deikel SM, Young SN, Binik Yitzchak M. Behavioural and biochemical effects of tryptophan, tyrosine and phenylalanine in mice. *Psychopharmacology* 1982 Feb;76(2):118-21.
- Gibson RM. The relationship of phenylalanine to expression of broiler chickens [dissertation]. College Station (TX): Texas A & M University; 1988. 133 p.
- Gibson RM, Bailey CA, Kubena LF, Huff WE, Harvey RB. Impact of L-phenylalanine supplementation on the performance of three-week-old broilers fed diets containing ochratoxin A. 1. Effects on body weight, feed conversion, relative organ weight, and mortality. *Poultry Sci* 1990 Mar;69(3):414-9.
- Gibson SB. Role of the TEC family tyrosine kinase EMT in T cell activation (phenylalanine) [dissertation]. Toronto (Canada): University of Toronto; 1997. 170 p.
- Giovannini M, Agostoni C, Biasucci G, Rottoli A, Luotti D, Trojan S, Riva E. Fatty acid metabolism in phenylketonuria. *Eur J Pediatr* 1996 Jul;155 Suppl 1:S132-5.
- Giovannini M, Biasucci G, Agostoni C, Luotti D, Riva E. Lipid status and fatty acid metabolism in phenylketonuria. *J Inher Metab Dis* 1995;18(3):265-72.
- Gjedde A, Crone C. Biochemical modulation of blood-brain barrier permeability. *Acta Neuropathol Suppl (Berl)* 1983;8:59-74.
- Glick SD, Greengard O. Exaggerated cerebral lateralization in rats after early postnatal hyperphenylalaninemia. *Brain Res* 1980 Nov 24;202(1):243-8.
- Goldman JM, Laws SC, Balchak SK, Cooper RL, Kavlock RJ. Endocrine-disrupting chemicals: Prepubertal exposures and effects on sexual maturation and thyroid activity in the female rat. A focus on the EDSTAC recommendations. *Crit Rev Toxicol* 2000;30(2):135-96.
- Goodwill KE. Crystal structure determination of tyrosine hydroxylase [dissertation]. Berkeley (CA): University of California, Berkeley; 1997. 144 p.
- Goodwill KE, Sabatier C, Marks C, Raag R, Fitzpatrick PF, Stevens RC. Crystal structure of tyrosine hydroxylase at 2.3 Å and its implications for inherited neurodegenerative diseases. *Nat Struct Biol* 1997 Jul;4(7):578-85.
- Goodwill KE, Sabatier C, Stevens RC. Crystal structure of tyrosine hydroxylase with bound cofactor analogue and iron at 2.3 Å resolution: self-hydroxylation of Phe300 and the pterin-binding site. *Biochemistry* 1998 Sep 29;37(39):13437-45.
- Goodwin BL, Ruthven CR, Sandler M. Resistance of aryl-substituted phenylalanines to decarboxylation in the rat. *Gen Pharmacol* 1998 Sep;31(3):437-40.
- Gopalakrishnan TV. DNA-mediated restoration of phenylalanine hydroxylase gene expression in enzyme-deficient derivatives of enzyme-constitutive mouse cell hybrids. *Somat Cell Mol Genet* 1984 Jan;10(1):3-16.
- Gopalakrishnan TV, Littlefield JW. RNA from rat hepatoma cells can activate phenylalanine hydroxylase gene of mouse erythroleukemia cells. *Somatic Cell Genet* 1983 Jan;9(1):121-31.
- Gottschall DW, Dietrich RF, Benkovic SJ, Shiman R. Phenylalanine hydroxylase. Correlation of the iron content with activity and the preparation and reconstitution of the apoenzyme. *J Biol Chem* 1982 Jan 25;257(2):845-9.
- Grasso AW, Wu GY. Therapeutic implications of delivery and expression of foreign genes in hepatocytes. *Adv Pharmacol* 1994;28:169-92.
- Green AK, Cotton RG, Jennings I, Fisher MJ. Experimental determination of the phosphorylation state of phenylalanine hydroxylase. *Biochem J* 1990 Jan 15;265(2):563-8.
- Green AK, Fisher MJ. The modulation of phenylalanine hydroxylase activity by okadaic acid. *Biochem Soc Trans* 1991 Apr;19(2):228S.
- Green AK, McDowall IL, Richardson SC, Fisher MJ. The effect of vanadate upon the expression of phenylalanine hydroxylase in streptozotocin-diabetic rat liver. *Biochim Biophys Acta* 1992 Oct 13;1180(1):21-7.
- Greengard O, Brass CA. Developmental changes of cerebral phenylalanine uptake from severely elevated blood levels. *Neurochem Res* 1984 Jun;9(6):837-48.
- Greengard O, Wolfe J. Cerebral serotonin regulation by phenylalanine analogues and during

- hyperphenylalaninemia. *Biochem Pharmacol* 1987 Mar 15;36(6):965-70.
- Griffen DL. The origin, purification and characterization of two forms of phenylalanine hydroxylase in the Sprague-Dawley rat [dissertation]. University Park (PA): The Pennsylvania State University; 1986. 98 p.
- Griffin HG, Gasson MJ. Genetic aspects of aromatic amino acid biosynthesis in *Lactococcus lactis*. *Mol Gen Genet* 1995 Jan 6;246(1):119-27.
- Grimm U, Steinhauser I, Weber A. [Occurrence of phenylalanine hydroxylase in the human kidney]. *Biomed Biochim Acta* 1986;45(9):1141-4. (Ger).
- Grinde B. Effect of amino acid metabolites on lysosomal protein degradation. A regulatory role for kynurenine? *Eur J Biochem* 1984 Dec 17;145(3):623-7.
- Gu W, Song J, Bonner CA, Xie G, Jensen RA. PhhC is an essential aminotransferase for aromatic amino acid catabolism in *Pseudomonas aeruginosa*. *Microbiology* 1998 Nov;144 (Pt 11):3127-34.
- Guerin T, Walsh GA, Donlon J, Kaufman S. Correlation of rat hepatic phenylalanine hydroxylase, with tetrahydrobiopterin and GTP concentrations. *Int J Biochem Cell Biol* 1998 Sep;30(9):1047-54.
- Guiso G, Diomede L, Romano M, Caccia S, Sarati S, Salmona M. Effect of tyrosine on the potentiation by aspartame and phenylalanine of metrazol-induced convulsions in rats. *Food Chem Toxicol* 1991;29(12):855-7.
- Guttler F, Woo SL. Molecular genetics of PKU. *J Inherit Metab Dis* 1986;9 Suppl 1:58-68.
- Haavik J, Doskeland AP, Flatmark T. Stereoselective effects in the interactions of pterin cofactors with rat-liver phenylalanine 4-monooxygenase. *Eur J Biochem* 1986 Oct 1;160(1):1-8.
- Haggerty DF, Chiappelli F, Kern R, Scully S, Lynch M. Regulation by glucocorticoids of rat-liver phenylalanine hydroxylase in vivo. *Biochem Biophys Res Commun* 1983 Sep 30;115(3):965-70.
- Hagihara B, Devathasan G, McCabe M. A micro-system for measuring oxygen kinetic parameters of biopterin linked hydroxylations: L-dopa synthesis and Parkinson's disease. *Adv Exp Med Biol* 1986;200:271-81.
- Han JH. Isolation of phenylalanine hydroxylase and enzymatic studies and 4-pyridylalanine [dissertation]. Atlanta (GA): Georgia Institute of Technology; 1988. 146 p.
- Hanulak AT, Hull EM. Behavioral deficits in a rat model of maternal PKU. *Psychobiology* 1987 Mar;15(1):75-8.
- Harada T, Kagamiyama H, Hatakeyama K. Feedback regulation mechanisms for the control of GTP cyclohydrolase I activity. *Science* 1993 Jun 4;260(5113):1507-10.
- Harding CO, Wild K, Chang D, Messing A, Wolff JA. Metabolic engineering as therapy for inborn errors of metabolism--development of mice with phenylalanine hydroxylase expression in muscle. *Gene Ther* 1998 May;5(5):677-83.
- Hargreaves KM, Pardridge WM. Neutral amino acid transport at the human blood-brain barrier. *J Biol Chem* 1988 Dec 25;263(36):19392-7.
- Harper AE. Some recent developments in the study of amino acid metabolism. *Proc Nutr Soc* 1983 Sep;42(3):437-49.
- Hasegawa H, Kaufman S. Spontaneous activation of phenylalanine hydroxylase in rat liver extracts. *J Biol Chem* 1982 Mar 25;257(6):3084-9.
- Hatakeyama K, Hoshiga M, Suzuki S, Kagamiyama H. Enzymatic synthesis of 6R-[U-14C]tetrahydrobiopterin from [U-14C]GTP. *Anal Biochem* 1993 Feb 15;209(1):1-5.
- Hauw JJ, Escourolle R. Abnormal delayed myelination (hypomyelination) in humans. *Bull Soc Belge Ophtalmol* 1983 Nov;208 Pt 1:89-95.
- Hayden MR, Nichols JL. Molecular genetic approaches to the study of the nervous system. *Dev Neurosci* 1983-84;6(4-5):189-214.
- Henrie RN 2d, Lazarus RA, Benkovic SJ. Preparation of 2-amino-4(3H)-oxopyrimido[5,4-b][1,4]thiazines (5-thiapterins) and their evaluation as cofactors for phenylalanine hydroxylase. *J Med Chem* 1983 Apr;26(4):559-63.
- Herrero E, Aragon MC, Gimenez C, Valdivieso F. Inhibition by L-phenylalanine of tryptophan transport by synaptosomal plasma membrane vesicles: implications in the pathogenesis of phenylketonuria. *J Inherit Metab Dis* 1983;6(1):32-5.
- Hertz MM, Bolwig TG, Grandjean P, Westergaard E. Lead poisoning and the blood-brain barrier. *Acta Neurol Scand* 1981 May;63(5):286-96.
- Hildebrandt PG, Copeland RA, Spiro TG, Otlewski J, Laskowski M Jr, Prendergast FG. Tyrosine hydrogen-bonding and environmental effects in proteins probed by ultraviolet resonance Raman spectroscopy. *Biochemistry* 1988 Jul 26;27(15):5426-33.

- Hill DA, Yen JT, Lee RT. Application of high performance liquid chromatography in determination of protein synthesis rates in pigs [abstract]. *J Anim Sci* 1988;66 Suppl 1:263.
- Hill MA, Marota JJ, Shiman R. Reaction of rat liver phenylalanine hydroxylase with fatty acid hydroperoxides. Characterization and mechanism. *J Biol Chem* 1988 Apr 25;263(12):5646-55.
- Hirano M, Ueno S. Mutant GTP cyclohydrolase I in autosomal dominant dystonia and recessive hyperphenylalaninemia. *Neurology* 1999 Jan 1;52(1):182-4.
- Hirano S, Takagi Y, Kanamatsu T, Nakai K. Effects of hyperphenylalaninemia in the fetal stage on the postnatal development of fetal rat brain. *Neurochem Res* 1985 Aug;10(8):1071-81.
- Hoff RH, Hengge AC, Wu L, Keng Y-F, Zhang Z-Y. Effects on general acid catalysis from mutations of the invariant tryptophan and arginine residues in the protein tyrosine phosphatase from *Yersinia*. *Biochemistry* 2000 Jan 11;39(1):46-54.
- Hogan RN, Coleman PD. Experimental hyperphenylalaninemia: dendritic alterations in cerebellum of rat. *Exp Neurol* 1981 Oct;74(1):234-44.
- Hogan RN, Coleman PD. Experimental hyperphenylalaninemia: dendritic alterations in motor cortex of rat. *Exp Neurol* 1981 Oct;74(1):218-33.
- Holder MD. Effects of perinatal exposure to aspartame on rat pups. *Neurotoxicol Teratol* 1989 Jan-Feb;11(1):1-6.
- Hommes FA. The effect of hyperphenylalaninaemia on the muscarinic acetylcholine receptor in the HPH-5 mouse brain. *J Inherit Metab Dis* 1993;16(6):962-74.
- Hommes FA. Loss of neurotransmitter receptors by hyperphenylalaninemia in the HPH-5 mouse brain. *Acta Paediatr Suppl* 1994 Dec;407:120-1.
- Hommes FA. On the mechanism of permanent brain dysfunction in hyperphenylalaninemia. *Biochem Med Metab Biol* 1991 Dec;46(3):277-87.
- Hommes FA. The role of the blood-brain barrier in the aetiology of permanent brain dysfunction in hyperphenylalaninaemia. *J Inherit Metab Dis* 1989;12(1):41-6.
- Hommes FA, Eller AG, Taylor EH. Turnover of the fast components of myelin and myelin proteins in experimental hyperphenylalaninaemia. Relevance to termination of dietary treatment in human phenylketonuria. *J Inherit Metab Dis* 1982;5(1):21-7.
- Hommes FA, Lee JS. The control of 5-hydroxytryptamine and dopamine synthesis in the brain: a theoretical approach. *J Inherit Metab Dis* 1990;13(1):37-57.
- Hommes FA, Moss L. Myelin turnover in hyperphenylalaninaemia. A re-evaluation with the HPH-5 mouse. *J Inherit Metab Dis* 1992;15(2):243-51.
- Hoshiga M, Hatakeyama K. Enzymatic synthesis of 6R-[U-14C]tetrahydrobiopterin from [U-14C]GTP. *Methods Enzymol* 1997;281:123-9.
- Hoshiga M, Hatakeyama K, Watanabe M, Shimada M, Kagamiyama H. Autoradiographic distribution of [14C]tetrahydrobiopterin and its developmental change in mice. *J Pharmacol Exp Ther* 1993 Nov;267(2):971-8.
- House JD, Pencharz PB, Ball RO. Phenylalanine requirements determined by using L-[1-14C]phenylalanine in neonatal piglets receiving total parenteral nutrition supplemented with tyrosine. *Am J Clin Nutr* 1997 Apr;65(4):984-93.
- House JD, Pencharz PB, Ball RO. Tyrosine kinetics and requirements during total parenteral nutrition in the neonatal piglet: the effect of glycyl-L-tyrosine supplementation. *Pediatr Res* 1997 Apr;41(4 Pt 1):575-83.
- House JD, Thorpe JM, Wykes LJ, Pencharz PB, Ball RO. Evidence that phenylalanine hydroxylation rates are overestimated in neonatal subjects receiving total parenteral nutrition with a high phenylalanine content. *Pediatr Res* 1998 Apr;43(4 Pt 1):461-6.
- Howard K, Donlon J. Effects of experimental diabetes on rat hepatic phenylalanine hydroxylase in vivo. *Int J Biochem* 1988;20(11):1231-4.
- Huether G. Amino acid availability and brain development: effects of nutritional and metabolic inadequacies. *Eur J Clin Nutr* 1989;43 Suppl 1:19-25.
- Huether G. The depletion of tryptophan and serotonin in the brain of developing hyperphenylalaninemic rats is abolished by the additional administration of lysine. *Neurochem Res* 1986 Dec;11(12):1663-8.
- Huether G. Regulation of the free amino acid pool of the developing brain: a lesson learned from experimental phenylketonuria. *UCLA Symp Mol Cell Biol* 1987;55:107-22.
- Huether G, Kaus R, Neuhoff V. Amino acid depletion in the blood and brain tissue of hyperphenylalaninemic rats is abolished by the administration of additional lysine: a contribution to the understanding of the metabolic defects in phenylketonuria. *Biochem Med* 1985 Jun;33(3):334-41.

- Huether G, Kaus R, Neuhoﬀ V. Brain development in experimental hyperphenylalaninaemia: myelination. *Neuropediatrics* 1982 Nov;13(4):177-82.
- Huether G, Klapproth M, Neuhoﬀ V. Fatty acid composition of myelin lipids from developing rat forebrain and spinal cord: influence of experimental hyperphenylalaninaemia. *Neurochem Res* 1986 Sep;11(9):1303-11.
- Huether G, Neuhoﬀ V. Individual carboxylic ester hydrolases of the developing cerebellum. Influence of experimental hyperphenylalaninaemia. *Cell Mol Biol* 1982;28(3):313-7.
- Huether G, Neuhoﬀ V. Use of alpha-methylphenylalanine for studies of brain development in experimental phenylketonuria. *J Inher Metab Dis* 1981;4(2):67-8.
- Huether G, Neuhoﬀ V, Kaus R. Brain development in experimental hyperphenylalaninaemia: disturbed proliferation and reduced cell numbers in the cerebellum. *Neuropediatrics* 1983 Feb;14(1):12-9.
- Hufton SE, Jennings IG, Cotton RG. Structure and function of the aromatic amino acid hydroxylases. *Biochem J* 1995 Oct 15;311 (Pt 2):353-66.
- Hufton SE, Jennings IG, Cotton RG. Structure/function analysis of the domains required for the multimerisation of phenylalanine hydroxylase. *Biochim Biophys Acta* 1998 Feb 17;1382(2):295-304.
- Hund HK. Zur Biosynthese von Phenylalanin und Tyrosin bei Vertretern der Ordnung Actinomycetales [The biosynthesis of phenylalanine and tyrosine by representatives of the order Actinomycetales] [dissertation]. Germany: University of Hohenheim; 1987. 81 p. (Ger).
- Hyanek J, Viletova H, Simova O, Dusek V, Simkova M, Hoza J. [Use of protein supplements in diet therapy of phenylketonuria and other hereditary amino acid metabolism disorders]. *Cesk Pediatr* 1980;35(2):53-4. (Cze).
- Hyland K, Gunasekera RS, Engle T, Arnold LA. Tetrahydrobiopterin and biogenic amine metabolism in the hph-1 mouse. *J Neurochem* 1996 Aug;67(2):752-9.
- Imamura T, Shintaku H, Nakajima T, Sawada Y, Isshiki G, Oura T. Experimental research on a new treatment for maternal phenylketonuria(PKU). *Adv Exp Med Biol* 1993;338:277-80.
- Inoue M, Muto Y, Sakamoto H, Kigawa T, Takio K, Shimura Y, Yokoyama S. A characteristic arrangement of aromatic amino acid residues in the solution structure of the amino-terminal RNA-binding domain of *Drosophila* sex-lethal. *J Mol Biol* 1997 Sep 12;272(1):82-94.
- Inoue S, Matsunaga Y, Iwane H, Sotomura M, Nose T. Entrapment of phenylalanine ammonia-lyase in silk fibroin for protection from proteolytic attack. *Biochem Biophys Res Commun* 1986 Nov 26;141(1):165-70.
- Isaacs CE, Greengard O. The effect of hyperphenylalaninaemia on glycine metabolism in developing rat brain. *Biochem J* 1980 Nov 15;192(2):441-8.
- Ishihara A, Ohtsu Y, Iwamura H. Induction of biosynthetic enzymes for avenanthramides in elicitor-treated oat leaves. *Planta* 1999 Jun;208(4):512-8.
- Ishii H, Sasaki Y, Goshima Y, Kanai Y, Endou H, Ayusawa D, Ono H, Miyamae T, Mitsu Y. Involvement of rBAT in Nasup +-dependent and - independent transport of the neurotransmitter candidate L-DOPA in *Xenopus laevis* oocytes injected with rabbit small intestinal epithelium poly Asup + RNA. *Biochim Biophys Acta* 2000 Jun 1;1466(1-2):61-70.
- Ishimitsu S, Fujimoto S, Ohara A. Formation of m-tyrosine and o-tyrosine from L-phenylalanine in various tissues of rats. *Chem Pharm Bull (Tokyo)* 1985 Sep;33(9):3887-92.
- Ishimitsu S, Fujimoto S, Ohara A. Studies on the formation of 3,4-dihydroxyphenylalanine, m-tyrosine and o-tyrosine from L-phenylalanine by rat liver and adrenal. *Chem Pharm Bull (Tokyo)* 1988 Jan;36(1):279-85.
- Iwaki M, Parniak MA, Kaufman S. Studies on the primary structure of rat liver phenylalanine hydroxylase. *Biochem Biophys Res Commun* 1985 Jan 31;126(2):922-32.
- Iwaki M, Phillips RS, Kaufman S. Proteolytic modification of the amino-terminal and carboxyl-terminal regions of rat hepatic phenylalanine hydroxylase. *J Biol Chem* 1986 Feb 15;261(5):2051-6.
- Jacobson KB, Manos RE. Effects of sepiapterin and 6-acetyldihydrohomopterin on the guanosine triphosphate cyclohydrolase I of mouse, rat and the fruit-fly *Drosophila*. *Biochem J* 1989 May 15;260(1):135-41.
- Janssen PJ, van der Heijden CA. Aspartame: review of recent experimental and observational data. *Toxicology* 1988 Jun;50(1):1-26.
- Jennings I, Cotton R. Structural similarities among enzyme pterin binding sites as demonstrated by a monoclonal anti-idiotypic antibody. *J Biol Chem* 1990 Feb 5;265(4):1885-9.

- Jennings IG, Kemp BE, Cotton RG. Localization of cofactor binding sites with monoclonal anti-idiotypic antibodies: phenylalanine hydroxylase. *Proc Natl Acad Sci U S A* 1991 Jul 1;88(13):5734-8.
- Jennings IG, Russell RG, Armarego WL, Cotton RG. Functional analysis of the effect of monoclonal antibodies on monkey liver phenylalanine hydroxylase. *Biochem J* 1986 Apr 1;235(1):133-8.
- Jimenez N, Gonzalez-Candelas F, Silva FJ. Prephenate dehydratase from the aphid endosymbiont (*Buchnera*) displays changes in the regulatory domain that suggest its desensitization to inhibition by phenylalanine. *J Bacteriol* 2000 May;182(10):2967-9.
- Jingzhong L, Hua X, Wei H, Zhangling Z, Jin Z, Qingyuan L. Cloning and expression of phenylalanine ammonia lyase cDNA in *Escherichia coli*. *Chin J Biotechnol* 1998;14(4):227-32.
- John SW, Scriver CR, Laframboise R, Rozen R. In vitro and in vivo correlations for I65T and M1V mutations at the phenylalanine hydroxylase locus. *Hum Mutat* 1992;1(2):147-53.
- Johnen G, Kowlessur D, Citron BA, Kaufman S. Characterization of the wild-type form of 4a-carbinolamine dehydratase and two naturally occurring mutants associated with hyperphenylalaninemia. *Proc Natl Acad Sci U S A* 1995 Dec 19;92(26):12384-8. Published erratum appears in *Proc Natl Acad Sci U S A* 1996 Apr 30;93(9):4519.
- Johnson RC, Shah SN. Effect of hyperphenylalaninemia induced during suckling on brain DNA metabolism in rat pups. *Neurochem Res* 1984 Apr;9(4):517-28.
- Johnson RC, Shah SN. Effects of alpha-methylphenylalanine plus phenylalanine treatment during development on myelin in rat brain. *Neurochem Res* 1980 Jul;5(7):709-18.
- Jordan MK, Brunner RL, Hunt MM, Berry HK. Preliminary support for the oral administration of valine, isoleucine and leucine for phenylketonuria. *Dev Med Child Neurol* 1985 Feb;27(1):33-9.
- Juminaga D, Wedemeyer WJ, Garduno-Juarez R, McDonald MA, Scheraga HA. Tyrosyl interactions in the folding and unfolding of bovine pancreatic ribonuclease A: a study of tyrosine-to-phenylalanine mutants. *Biochemistry* 1997 Aug 19;36(33):10131-45.
- Kadowaki M, Poso AR, Mortimore GE. Parallel control of hepatic proteolysis by phenylalanine and phenylpyruvate through independent inhibitory sites at the plasma membrane. *J Biol Chem* 1992 Nov 5;267(31):22060-5.
- Kapatos G, Kaufman S. Peripherally administered reduced pterins do enter the brain. *Science* 1981 May 22;212(4497):955-6.
- Kaplan H, Triano T, Donadio M. Behavioral deficit in phenylketonuric rats: role of aromatic acid metabolites of phenylalanine. *Dev Psychobiol* 1981 May;14(3):201-7.
- Kappock TJ 4th. Recombinant phenylalanine hydroxylase overexpression and characterization: structural, mechanistic, and spectroscopic its allosteric activation and active site iron reduction processes [dissertation]. New Haven (CT): Yale University; 1996. 588 p.
- Kappock TJ, Harkins PC, Friedenbergs S, Caradonna JP. Spectroscopic and kinetic properties of unphosphorylated rat hepatic phenylalanine hydroxylase expressed in *Escherichia coli*. Comparison of resting and activated states. *J Biol Chem* 1995 Dec 22;270(51):30532-44.
- Kastin AJ, Akerstrom V, Hackler L, Zadina JE. Phe(13), Tyr(19)-melanin-concentration hormone and the blood-brain barrier: role of protein binding. *J Neurochem* 2000 Jan;74(1):385-91.
- Katoh S, Sueoka T. Pteridine cofactor of phenylalanine hydroxylase in fetal rat liver. *Int J Biochem* 1983;15(1):57-64.
- Katoh S, Sueoka T, Hirayama K, Masuda I, Nakanishi N, Yamada S. [Phenylalanine hydroxylating activity in Tawa sarcoma]. *Josai Shika Daigaku Kiyu* 1981;10(1):27-31. (Jpn).
- Kaufman S. The enzymes of the hepatic phenylalanine hydroxylating system. *J Inher Metab Dis* 1978;1(2):63-5.
- Kaufman S. An evaluation of the possible neurotoxicity of metabolites of phenylalanine. *J Pediatr* 1989 May;114(5):895-900. Comment in: *J Pediatr* 1990 Apr;116(4):665-6.
- Kaufman S. Hyperphenylalaninaemia caused by defects in biopterin metabolism. *J Inher Metab Dis* 1985;8 Suppl 1:20-7.
- Kaufman S. New tetrahydrobiopterin-dependent systems. *Annu Rev Nutr* 1993;13:261-86.
- Kaufman S. Phenylalanine 4-monooxygenase from rat liver. *Methods Enzymol* 1987;142:3-17.
- Kaufman S. The phenylalanine hydroxylating system. *Adv Enzymol Relat Areas Mol Biol* 1993;67:77-264.
- Kaufman S. The phenylalanine hydroxylating system from mammalian liver. *Adv Enzymol* 1971;35:245-319.

- Kaufman S. Regulation of the activity of hepatic phenylalanine hydroxylase. *Adv Enzyme Regul* 1986;25:37-64.
- Kaufman S. Regulatory properties of phenylalanine, tyrosine and tryptophan hydroxylases. *Biochem Soc Trans* 1985 Apr;13(2):433-6.
- Kaufman S, Mason K. Specificity of amino acids as activators and substrates for phenylalanine hydroxylase. *J Biol Chem* 1982 Dec 25;257(24):14667-78.
- Kayaalp E, Treacy E, Waters PJ, Byck S, Nowacki P, Scriver CR. Human phenylalanine hydroxylase mutations and hyperphenylalaninemia phenotypes: a metanalysis of genotype-phenotype correlations. *Am J Hum Genet* 1997 Dec;61(6):1309-17.
- Kee AJ, Smith RC. Organ clearance of tyrosyl-arginine and its effect on amino acid metabolism in young sheep. *Metabolism* 1993 Aug;42(8):958-66.
- Kerler F, Ziegler I, Schmid C, Bacher A. Synthesis of tetrahydrobiopterin in Friend erythroleukemia cells and its modulator effect on cell proliferation. *Exp Cell Res* 1990 Aug;189(2):151-6.
- Kim KI, Bayley HS. Amino acid oxidation by young pigs receiving diets with varying levels of sulphur amino acids. *Br J Nutr* 1983 Sep;50(2):383-90.
- Kim KI, Elliott JI, Bayley HS. Oxidation of an indicator amino acid by young pigs receiving diets with varying levels of lysine or threonine, and an assessment of amino acid requirements. *Br J Nutr* 1983 Sep;50(2):391-9.
- Kim KI, McMillan I, Bayley HS. Determination of amino acid requirements of young pigs using an indicator amino acid. *Br J Nutr* 1983 Sep;50(2):369-82.
- Kindt E, Holm H, Halvorsen S, Lie SO. Net protein utilization determined by rat bioassay of a protein hydrolysate and a diet for children with phenylketonuria. *Br J Nutr* 1985 Sep;54(2):349-53.
- Kindt E, Motzfeldt K, Halvorsen S, Lie SO. Protein requirements in infants and children: a longitudinal study of children treated for phenylketonuria. *Am J Clin Nutr* 1983 May;37(5):778-85.
- Kirby ML, Miyagawa ST. The effects of high phenylalanine concentration on chick embryonic development. *J Inherit Metab Dis* 1990;13(4):634-40.
- Klein LE, Nordlund JJ. Genetic basis of pigmentation and its disorders. *Int J Dermatol* 1981 Dec;20(10):621-31.
- Kleppe R, Uhlemann K, Knappskog PM, Haavik J. Urea-induced denaturation of human phenylalanine hydroxylase. *J Biol Chem* 1999 Nov 19;274(47):33251-8.
- Knappskog M, Eiken HG, Martinez A, Olafsdotti S, Haavik J, Flatmark T, Apold J. Expression of wild type and mutant forms of human phenylalanine hydroxylase in *E. coli*. *Adv Exp Med Biol* 1993;338:59-62.
- Knappskog PM, Eiken HG, Martinez A, Bruland O, Apold J, Flatmark T. PKU mutation (D143G) associated with an apparent high residual enzyme activity: expression of a kinetic variant form of phenylalanine hydroxylase in three different systems. *Hum Mutat* 1996;8(3):236-46.
- Knappskog PM, Eiken HG, Martinez A, Flatmark T, Apold J. The PKU mutation S349P causes complete loss of catalytic activity in the recombinant phenylalanine hydroxylase enzyme. *Hum Genet* 1995 Feb;95(2):171-3.
- Knappskog PM, Haavik J. Tryptophan fluorescence of human phenylalanine hydroxylase produced in *Escherichia coli*. *Biochemistry* 1995 Sep 19;34(37):11790-9.
- Knappskog PM, Martinez A. Effect of mutations at Cys237 on the activation state and activity of human phenylalanine hydroxylase. *FEBS Lett* 1997 Jun 2;409(1):7-11.
- Kobe B, Jennings IG, House CM, Feil SC, Michell BJ, Tiganis T, Parker MW, Cotton RG, Kemp BE. Regulation and crystallization of phosphorylated and dephosphorylated forms of truncated dimeric phenylalanine hydroxylase. *Protein Sci* 1997 Jun;6(6):1352-7.
- Kobe B, Jennings IG, House CM, Michell BJ, Goodwill KE, Santarsiero BD, Stevens RC, Cotton RG, Kemp BE. Structural basis of autoregulation of phenylalanine hydroxylase. *Nat Struct Biol* 1999 May;6(5):442-8. Comment in: *Nat Struct Biol* 1999 May;6(5):401-2.
- Koizumi S, Matsushima Y, Nagatsu T, Iinuma H, Takeuchi T, Umezawa H. 3,4-dihydroxystyrene, a novel microbial inhibitor for phenylalanine hydroxylase and other pteridine-dependent monooxygenases. *Biochim Biophys Acta* 1984 Sep 11;789(2):111-8.
- Koizumi S, Tanaka F, Kaneda N, Kano K, Nagatsu T. Nanosecond pulse fluorometry of conformational change in phenylalanine hydroxylase associated with activation. *Biochemistry* 1988 Jan 26;27(2):640-6.
- Kornguth S, Anderson M, Markley JL, Shedlovsky A. Near-microscopic magnetic resonance imaging of the

- brains of phenylalanine hydroxylase-deficient mice, normal littermates, and of normal BALB/c mice at 9.4 Tesla. *Neuroimage* 1994 Jun;1(3):220-9.
- Korpi ER. Aromatic amino acid incorporation into proteins in rat brain slices: influences of other amino acids affecting transport. *Acta Physiol Scand* 1981 Aug;112(4):353-8.
- Kostiuk PG, Martyniuk AE. [Possible molecular mechanisms of brain dysfunction in phenylketonuria]. *Patol Fiziol Eksp Ter* 1992 Jul-Aug;(4):34-6. (Rus).
- Kowlessur D, Citron BA, Kaufman S. Recombinant human phenylalanine hydroxylase: novel regulatory and structural properties. *Arch Biochem Biophys* 1996 Sep 1;333(1):85-95.
- Kowlessur D, Yang XJ, Kaufman S. Further studies of the role of Ser-16 in the regulation of the activity of phenylalanine hydroxylase. *Proc Natl Acad Sci U S A* 1995 May 23;92(11):4743-7.
- Kronick JB, Whelan DT, McCallion DJ. Experimental hyperphenylalaninemia in the pregnant guinea pig: possible phenylalanine teratogenesis and p-chlorophenylalanine embryotoxicity. *Teratology* 1987 Oct;36(2):245-58.
- Kwok SC, Ledley FD, DiLella AG, Robson KJ, Woo SL. Nucleotide sequence of a full-length complementary DNA clone and amino acid sequence of human phenylalanine hydroxylase. *Biochemistry* 1985 Jan 29;24(3):556-61.
- Labadie P. [Phenylalanine hydroxylase]. *Rev Prat* 1982 May 11;32(27):1884-90. (Fre).
- LaBuda CJ, Hale RL. Anxiety in mice following acute aspartame and ethanol exposure. *Alcohol* 2000;20:69-74.
- Lacey DJ. Cortical dendritic spine loss in rat pups whose mothers were prenatally injected with phenylacetate ('maternal PKU' model). *Brain Res* 1986 Jun;392(1-2):283-5.
- Lacey DJ. Hippocampal dendritic abnormalities in a rat model of phenylketonuria. *Ann Neurol* 1984 Nov;16(5):577-80.
- Lacey DJ. Normalization of dendritic spine numbers in rat hippocampus after termination of phenylacetate injections (PKU model). *Brain Res* 1985 Mar 11;329(1-2):354-5.
- Lahdesmaki P. Inhibition of protein and aminoacyl-tRNA synthesis, and binding and transport sites for aromatic amino acids in the brain in vitro with aromatic acids. *Int J Neurosci* 1984 Mar;23(1):1-13.
- Lane JD, Neuheff V. Phenylketonuria: clinical and experimental considerations revealed by the use of animal models. *Naturwissenschaften* 1980 May;67(5):227-33.
- Lane JD, Schone B, Langenbeck U, Neuheff V. Characterization of experimental phenylketonuria. Augmentation of hyperphenylalaninemia with alpha-methylphenylalanine and p-chlorophenylalanine. *Biochim Biophys Acta* 1980 Jan 17;627(2):144-56.
- Langar H, Guillaume J, Metailler R, Fauconneau B. Augmentation of protein synthesis and degradation by poor dietary amino acid balance in European sea bass (*Dicentrarchus labrax*). *J Nutr* 1993 Oct;123(10):1754-61.
- Laufs S, Blau N, Thony B. Retrovirus-mediated double transduction of the GTPCH and PTPS genes allows 6-pyruvoyltetrahydropterin synthase-deficient human fibroblasts to synthesize and release tetrahydrobiopterin. *J Neurochem* 1998 Jul;71(1):33-40.
- Laurence JS, Blanpain C, Burgner JW, Parmentier M, LiWang PJ. CC chemokine MIP-1beta can function as a monomer and depends on Phe13 for receptor binding. *Biochemistry* 2000 Mar 28;39(12):3401-9.
- Lazarus RA, Dietrich RF, Wallick DE, Benkovic SJ. On the mechanism of action of phenylalanine hydroxylase. *Biochemistry* 1981 Nov 24;20(24):6834-41.
- Ledley FD, DiLella AG, Kwok SC, Woo SL. Homology between phenylalanine and tyrosine hydroxylases reveals common structural and functional domains. *Biochemistry* 1985 Jul 2;24(14):3389-94.
- Ledley FD, Grenett HE, DiLella AG, Kwok SC, Woo SL. Gene transfer and expression of human phenylalanine hydroxylase. *Science* 1985 Apr 5;228(4695):77-9.
- Ledley FD, Grenett HE, Dunbar BS, Woo SL. Mouse phenylalanine hydroxylase. Homology and divergence from human phenylalanine hydroxylase. *Biochem J* 1990 Apr 15;267(2):399-405.
- Ledley FD, Grenett HE, McGinnis-Shelnett M, Woo SL. Retroviral-mediated gene transfer of human phenylalanine hydroxylase into NIH 3T3 and hepatoma cells. *Proc Natl Acad Sci U S A* 1986 Jan;83(2):409-13.
- Ledley FD, Grenett HE, Woo SL. Biochemical characterization of recombinant human phenylalanine hydroxylase produced in *Escherichia coli*. *J Biol Chem* 1987 Feb 15;262(5):2228-33.

- Ledley FD, Hahn T, Woo SL. Selection for phenylalanine hydroxylase activity in cells transformed with recombinant retroviruses. *Somat Cell Mol Genet* 1987 Mar;13(2):145-54.
- Ledley FD, Ledbetter SA, Ledbetter DH, Woo SL. Localization of mouse phenylalanine hydroxylase locus on chromosome 10. *Cytogenet Cell Genet* 1988;47(3):125-6.
- Ledley FD, Woo SL. P-chlorophenylalanine does not inhibit production of recombinant human phenylalanine hydroxylase in NIH3T3 cells or *E. coli*. *Biochem Biophys Res Commun* 1987 Jan 30;142(2):302-8.
- Leeming RJ. Microtiter plate assay for bipterin using cryopreserved *Crithidia fasciculata*. *Methods Enzymol* 1997;281:61-70.
- Leeming RJ, Hall SK, Friday H, Hurley P, Green A. A microtitre plate method for measuring bipterin with cryopreserved *Crithidia fasciculata*. *Adv Exp Med Biol* 1993;338:267-70.
- Lei XD, Kaufman S. Identification of hepatic nuclear factor 1 binding sites in the 5' flanking region of the human phenylalanine hydroxylase gene: implication of a dual function of phenylalanine hydroxylase stimulator in the phenylalanine hydroxylation system. *Proc Natl Acad Sci U S A* 1998 Feb 17;95(4):1500-4.
- Leuschner RG, Kurihara R, Hammes WP. Formation of biogenic amines by proteolytic enterococci during cheese ripening. *J Sci Food Agric* 1999 Jun;79(8):1141-4.
- Levine RA. Tetrahydrobiopterin and biogenic amine metabolism in neuropsychiatry, immunology, and aging. *Ann N Y Acad Sci* 1988;521:129-39.
- Levy HL. Maternal phenylketonuria. Review with emphasis on pathogenesis. *Enzyme* 1987;38(1-4):312-20.
- Levy HL. Phenylketonuria: old disease, new approach to treatment. *Proc Natl Acad Sci U S A* 1999 Mar 2;96(5):1811-3. Comment on: *Proc Natl Acad Sci U S A* 1999 Mar 2;96(5):2339-44.
- Levy HL, Baullinger PC, Madigan PM. A rapid procedure for the determination of phenylalanine and tyrosine from blood filter paper specimens. *Clin Chim Acta* 1971 Feb;31(2):447-52.
- Levy HL, Ghavami M. Maternal phenylketonuria: a metabolic teratogen. *Teratology* 1996 Mar;53(3):176-84.
- Lewis SA, Lyon IC, Elliott RB. Outcome of pregnancy in the rat with mild hyperphenylalaninaemia and hypertyrosinaemia: implications for the management of human maternal PKU. *J Inher Metab Dis* 1985;8(3):113-7.
- Lewis Vyoone T. Murine phenylketonuria: comparison of the natural history and management (phenylalanine hydroxylase, tyrosine, glycine) [dissertation]. New Orleans (LA): Tulane University; 1997. 101 p.
- Lichter-Konecki U, Hipke CM, Konecki DS. Human phenylalanine hydroxylase gene expression in kidney and other nonhepatic tissues. *Mol Genet Metab* 1999 Aug;67(4):308-16.
- Lidksy AS, Robson KJ, Thirumalachary C, Barker PE, Ruddle FH, Woo SL. The PKU locus in man is on chromosome 12. *Am J Hum Genet* 1984 May;36(3):527-33.
- Lidksy AS, Law ML, Morse HG, Kao FT, Rabin M, Ruddle FH, Woo SL. Regional mapping of the phenylalanine hydroxylase gene and the phenylketonuria locus in the human genome. *Proc Natl Acad Sci U S A* 1985 Sep;82(18):6221-5.
- Liechty EA, Boyle DW, Moorehead H, Auble L, Denne SC. Aromatic amino acids are utilized and protein synthesis is stimulated during amino acid infusion in the ovine fetus. *J Nutr* 1999 Jun;129(6):1161-6.
- Liu TJ, Kay MA, Darlington GJ, Woo SL. Reconstitution of enzymatic activity in hepatocytes of phenylalanine hydroxylase-deficient mice. *Somat Cell Mol Genet* 1992 Jan;18(1):89-96.
- Lo GS, Liang SC, Raha SR, Hunter JB, Longenecker JB. Biochemical and neurological effects of an experimental phenylketonuria-like condition in infant rats during the first 2 weeks after birth. *Am J Clin Nutr* 1981 Apr;34(4):498-506.
- Lo GS, Longenecker JB. Induction of an experimental phenylketonuria-like condition in infant rats during the first 2 weeks after birth. *Am J Clin Nutr* 1981 Apr;34(4):490-7.
- Loo YH, Fulton T, Miller K, Wisniewski HM. Phenylacetate and brain dysfunction in experimental phenylketonuria: synaptic development. *Life Sci* 1980 Oct 6;27(14):1283-90.
- Loo YH, Fulton TR, Hyde KR, Wisniewski HM. Biochemical indices of neuronal development in experimental phenylketonuria: high affinity transport systems and gangliosides. *Dev Neurosci* 1983-84;6(4-5):235-45.
- Loo YH, Hyde KR, Lin FH, Wisniewski HM. Cerebral biochemical abnormalities in experimental maternal phenylketonuria: gangliosides and

- sialoglycoproteins. *Life Sci* 1985 Dec 2;37(22):2099-109.
- Loo YH, Potempska A, Wisniewski HM. A biochemical explanation of phenyl acetate neurotoxicity in experimental phenylketonuria. *J Neurochem* 1985 Nov;45(5):1596-600.
- Loo YH, Rabe A, Potempska A, Wang P, Fersko R, Wisniewski HM. Experimental maternal phenylketonuria: an examination of two animal models. *Dev Neurosci* 1983-84;6(4-5):227-34.
- Lunte CE, Kissinger PT. Determination of phenylalanine hydroxylase activity by liquid chromatography/electrochemistry. *Anal Biochem* 1984 Jun;139(2):468-73.
- Maas JA, France J, Dijkstra J, Bannink A, McBride BW. Application of a mechanistic model to study competitive inhibition of amino acid uptake by the lactating bovine mammary gland. *J Dairy Sci* 1998 Jun;81(6):1724-34.
- Maas JA, France J, McBride BW. Model of milk protein synthesis. A mechanistic model of milk protein synthesis in the lactating bovine mammary gland. *J Theor Biol* 1997 Aug 7;187(3):363-78.
- MacCready RA, Levy HL. The problem of maternal phenylketonuria. *Am J Obstet Gynecol* 1972 May 1;113(1):121-8.
- Macfarlane RG, Midgley JM, Watson DG. Identification and quantitation of phenylalanine, tyrosine and dihydroxyphenylalanine in the thoracic nervous system of the locust, *Schistocerca gregaria*, by gas chromatography-negative-ion chemical ionisation mass spectrometry. *J Chromatog* 1990 Oct 26;532(1):1-11.
- Maenz DD, Chenu C, Berteloot A. Heterotropic effects of dipolar amino acids on the activity of the anionic amino acid transport system X⁻(AG) in rabbit jejunal brush-border membrane vesicles. *J Biol Chem* 1993 Jul 25;268(21):15361-7.
- Manjunath R, Shivaswamy V, Ramasarma T. Decrease of phenylalanine hydroxylase during hepatocyte proliferation. *Biochem Pharmacol* 1982 Apr 15;31(8):1521-5.
- Marota JJ, Shiman R. Stoichiometric reduction of phenylalanine hydroxylase by its cofactor: a requirement for enzymatic activity. *Biochemistry* 1984 Mar 13;23(6):1303-11.
- Martinez A, Andersson KK, Haavik J, Flatmark T. EPR and 1H-NMR spectroscopic studies on the paramagnetic iron at the active site of phenylalanine hydroxylase and its interaction with substrates and inhibitors. *Eur J Biochem* 1991 Jun 15;198(3):675-82.
- Martinez A, Haavik J, Flatmark T. Cooperative homotropic interaction of L-noradrenaline with the catalytic site of phenylalanine 4-monooxygenase. *Eur J Biochem* 1990 Oct 5;193(1):211-9.
- Martinez A, Knappskog PM, Olafsdottir S, Doskeland AP, Eiken HG, Svebak RM, Bozzini M, Apold J, Flatmark T. Expression of recombinant human phenylalanine hydroxylase as fusion protein in *Escherichia coli* circumvents proteolytic degradation by host cell proteases. Isolation and characterization of the wild-type enzyme. *Biochem J* 1995 Mar 1;306 (Pt 2):589-97.
- Martinez A, Olafsdottir S, Flatmark T. The cooperative binding of phenylalanine to phenylalanine 4-monooxygenase studied by 1H-NMR paramagnetic relaxation. Changes in water accessibility to the iron at the active site upon substrate binding. *Eur J Biochem* 1993 Jan 15;211(1-2):259-66.
- Martinez A, Olafsdottir S, Haavik J, Flatmark T. Inactivation of purified phenylalanine hydroxylase by dithiothreitol. *Biochem Biophys Res Commun* 1992 Jan 15;182(1):92-8.
- Mathur R, Manchanda SK. Ontogeny of phenylalanine (endogenous cholecystokinin) induced modulation of food intake in normal and undernourished rats. *Prog Neuropsychopharmacol Biol Psychiatry* 1991;15(3):405-13.
- Matsueda S, Niiyama Y. The effects of excess amino acids on maintenance of pregnancy and fetal growth in rats (Threonine, methionine, valine, isoleucine, leucine, tyrosine, phenylalanine, tryptophan, lysine). *J Nutr Sci Vitaminol* 1982;28(5):557-73.
- Matsuo K, Hommes F. Regional distribution of the phenylalanine-sensitive ATP-sulphurylase in brain. *J Inher Metab Dis* 1987;10(1):62-5.
- Matsuo K, Hommes FA. The development of the muscarinic acetylcholine receptor in normal and hyperphenylalaninemic rat cerebrum. *Neurochem Res* 1988 Sep;13(9):867-70.
- Mavrophilipos DV. Characterization of the iron environment of lipoxygenases paramagnetic resonance, metalloenzyme, high spin, non-heme) [dissertation]. Baltimore (MD): The Johns Hopkins University; 1986. 166 p.
- Mayo KA. Developmental regulation of gene expression in *Tetrahymena* [dissertation]. Santa Barbara (CA): University of California, Santa Barbara; 1984. 387 p.
- McCabe ER, McCabe L. Issues in the dietary management of phenylketonuria: breast-feeding and trace-metal nutrition. *Ann N Y Acad Sci* 1986;477:215-22.

- McChesney R, Habermann J, Greengard O. Phenylalanine uptake in neonatal and infant rat brain. *Biol Neonate* 1988;54(5):275-84.
- McChesney R, Isaacs CE, Greengard O. Cerebral glycine content and phosphoserine phosphatase activity in hyperaminoacidemias. *Neurochem Res* 1987 Mar;12(3):289-95.
- McChesney RE. Amino acid and biogenic amine studies in experimental hyperphenylalaninemia [dissertation]. New York: City University of New York; 1988. 173 p.
- McDonald JD. Biochemical and genetic characterization of HPH-1: an mutation resulting in heritable hyperphenylalaninemia [dissertation]. Manhattan (KS): Kansas State University; 1987. 123 p.
- McDonald JD. The PKU mouse project: its history, potential and implications. *Acta Paediatr Suppl* 1994 Dec;407:122-3.
- McDonald JD, Bode VC. Hyperphenylalaninemia in the hph-1 mouse mutant. *Pediatr Res* 1988 Jan;23(1):63-7.
- McDonald JD, Bode VC, Dove WF, Shedlovsky A. Pahhph-5: a mouse mutant deficient in phenylalanine hydroxylase. *Proc Natl Acad Sci U S A* 1990 Mar;87(5):1965-7.
- McDonald JD, Bode VC, Dove WF, Shedlovsky A. The use of N-ethyl-N-nitrosourea to produce mouse models for human phenylketonuria and hyperphenylalaninemia. *Prog Clin Biol Res* 1990;340C:407-13.
- McDonald JD, Charlton CK. Characterization of mutations at the mouse phenylalanine hydroxylase locus. *Genomics* 1997 Feb 1;39(3):402-5.
- McDonald JD, Cotton RG, Jennings I, Ledley FD, Woo SL, Bode VC. Biochemical defect of the hph-1 mouse mutant is a deficiency in GTP-cyclohydrolase activity. *J Neurochem* 1988 Feb;50(2):655-7.
- McDonald JD, Dyer CA, Gailis L, Kirby ML. Cardiovascular defects among the progeny of mouse phenylketonuria females. *Pediatr Res* 1997 Jul;42(1):103-7.
- McDowall IL, Fisher MJ. Analysis of the 5'-flanking region of the rat phenylalanine hydroxylase gene. *Biochem Soc Trans* 1996 Aug;24(3):424S.
- McDowall IL, Fisher MJ. The immediate 5'-flanking region of the rat phenylalanine hydroxylase-encoding gene. *Gene* 1995 Feb 14;153(2):289-90.
- McDowall IL, Palwala Y, Fisher MJ. Differential effects of streptozotocin-induced diabetes on phenylalanine hydroxylase protein and mRNA abundance in isolated rat liver cells. *Int J Biochem Cell Biol* 1996 Jul;28(7):761-70.
- McLean MS. Neurobehavioral consequences of hyperphenylalaninemia [dissertation]. Cincinnati (OH): University of Cincinnati; 1986. 195 p.
- McSwigan JD, Vorhees CV, Brunner RL, Butcher RE, Berry HK. Amelioration of maze deficits from induced hyperphenylalaninemia in adult rats using valine, isoleucine, and leucine (Phenylketonuria, phenylalanine-restricted diet). *Behav Neural Biol* 1981 Nov;33(3):378-84.
- Medical Research Council Working Party on Phenylketonuria. Phenylketonuria due to phenylalanine hydroxylase deficiency: an unfolding story. *BMJ* 1993 Jan 9;306(6870):115-9.
- Medovar BI. [Effect of starvation on age-associated characteristics of phenylalanine metabolism in an experiment]. *Vopr Pitan* 1982 Jul-Aug;(4):52-5. (Rus).
- Mellgren SI, Gotestam KG. Research on mental retardation in Norway 1970-1980: a review. *Appl Res Ment Retard* 1983;4(2):103-12.
- Mercer JF, Grimes A, Jennings I, Cotton RG. Identification of two molecular-mass forms of phenylalanine hydroxylase that segregate independently in rats. Specific association of each form with certain rat strains. *Biochem J* 1984 May 1;219(3):891-8.
- Mercer JF, Hunt SM, Cotton RG. The two molecular weight forms of rat phenylalanine hydroxylase are encoded by different messenger RNAs. *J Biol Chem* 1983 May 10;258(9):5854-7.
- Mercer JF, McAdam W, Chambers GW, Walker ID. The W and L allelic forms of phenylalanine hydroxylase in the rat differ by a threonine to isoleucine substitution. *Biochem J* 1986 Jun 15;236(3):679-83.
- Mihalick SM, Langlois JC, Krienke JD, Dube WV. An olfactory discrimination procedure for mice. *J Exp Anal Behav* 2000; 73(3):305-18.
- Millamena OM, Teruel MB, Kanazawa A, Teshima S. Quantitative dietary requirements of postlarval tiger shrimp, *Penaeus monodon*, for histidine, isoleucine, leucine, phenylalanine and tryptophan. *Aquaculture* 1999 Sep 1;179(1-4):169-79.
- Miller M, Hasson R, Resnick O. Availability of phenylalanine and tyrosine for brain norepinephrine

- synthesis in developmentally protein-malnourished rats. *Exp Neurol* 1982 Jul;77(1):163-78.
- Miller ME, Plumeau P, Blakely E. Elevated phenylalanine concentrations in benign hyperphenylalaninemia from evaporated milk feedings. *Clin Pediatr (Phila)* 1993 Feb;32(2):124-5.
- Miller RJ, Benkovic SJ. L-[2,5-H₂]phenylalanine, an alternate substrate for rat liver phenylalanine hydroxylase. *Biochemistry* 1988 May 17;27(10):3658-63.
- Milner JA, Garton RL, Burns RA. Phenylalanine and tyrosine requirements of immature beagle dogs. *J Nutr* 1984 Dec;114(12):2212-6.
- Milstien S, Dorche C, Kaufman S. Studies on the interaction of a thiol-dependent hydrogen peroxide scavenging enzyme and phenylalanine hydroxylase. *Arch Biochem Biophys* 1990 Nov 1;282(2):346-51.
- Milstien S, Jaffe H, Kowlessur D, Bonner TI. Purification and cloning of the GTP cyclohydrolase I feedback regulatory protein, GFRP. *J Biol Chem* 1996 Aug 16;271(33):19743-51.
- Minor LK. Effects of hormones on phenylalanine hydroxylase in primary rat hepatocytes maintained in chemically defined serum-free (insulin, glucagon, dexamethasone, albumin) [dissertation]. University Park (PA): The Pennsylvania State University; 1986. 127 p.
- Mitnaul LJ. The mechanism of regulation of phenylalanine hydroxylase by (6r)-tetrahydrobiopterin in cultured primary rat hepatocytes [dissertation]. University Park (PA): The Pennsylvania State University; 1994. 175 p.
- Mitnaul LJ, Shiman R. Coordinate regulation of tetrahydrobiopterin turnover and phenylalanine hydroxylase activity in rat liver cells. *Proc Natl Acad Sci U S A* 1995 Jan 31;92(3):885-9.
- Morales G, Requena JM, Jimenez-Ruiz A, Lopez MC, Ugarte M, Alonso C. Sequence and expression of the *Drosophila* phenylalanine hydroxylase mRNA. *Gene* 1990 Sep 14;93(2):213-9.
- Motoda K, Takata M, Kiura K, Nakamura I, Harada M. SHP-1/immunoreceptor tyrosine-based inhibition motif-independent inhibitory signalling through murine natural killer cell receptor Ly-49A in a transfected B-cell line. *Immunology* 2000;100(3):370-7.
- Motta A, Laursen RA, Llinas M, Tulinsky A, Park CH. Complete assignment of the aromatic proton magnetic resonance spectrum of the kringle 1 domain from human plasminogen: structure of the ligand-binding site. *Biochemistry* 1987 Jun 30;26(13):3827-36.
- Munoz M, Emery PW, Peran S, Mann GE. Dietary regulation of amino acid transport activity in the exocrine pancreatic epithelium. *Biochim Biophys Acta* 1988 Nov 22;945(2):273-80.
- Muramatsu T, Salter DN, Coates ME. Protein turnover of breast muscle in germ-free and conventional chicks. *Br J Nutr* 1985 Jul;54(1):131-45.
- Nagasaki Y, Matsubara Y, Takano H, Fujii K, Senoo M, Akanuma J, Takahashi K, Kure S, Hara M, Kanegae Y, Saito I, Narisawa K. Reversal of hypopigmentation in phenylketonuria mice by adenovirus-mediated gene transfer. *Pediatr Res* 1999 Apr;45(4 Pt 1):465-73.
- Nagata S, Maru I, Ishihara F, Misono H, Nagasaki S. Cloning and expression of endo-beta-1,3-glucanase gene from *Flavobacterium dormitator* in *Escherichia coli* and characterization of the gene product. *Agric Biol Chem* 1990 Oct;54(10):2675-80.
- Nagatsu T, Ichinose H. Regulation of pteridine-requiring enzymes by the cofactor tetrahydrobiopterin. *Mol Neurobiol* 1999 Feb;19(1):79-96.
- Nagatsu T, Matsuura S, Sugimoto T. Physiological and clinical chemistry of biopterin. *Med Res Rev* 1989 Jan-Mar;9(1):25-44.
- Nakata H, Fujisawa H. Purification and characterization of phenylalanine 4-monooxygenase from rat liver. *Biochim Biophys Acta* 1980 Aug 7;614(2):313-27.
- Narisawa K, Arai N, Ishizawa S, Ogasawara Y, Onuma A, Iinuma K, Tada K. Dihydropteridine reductase deficiency: diagnosis by leukocyte enzyme assay. *Clin Chim Acta* 1980 Aug 19;105(3):335-42.
- Navab F, Winter CG. Effect of aging on intestinal absorption of aromatic amino acids in vitro in the rat. *Am J Physiol* 1988 Apr;254(4 Pt 1):G631-6.
- Neckameyer WS, White K. A single locus encodes both phenylalanine hydroxylase and tryptophan hydroxylase activities in *Drosophila*. *J Biol Chem* 1992 Feb 25;267(6):4199-206.
- Nehls U, Ecke M, Hampp R. Sugar- and nitrogen-dependent regulation of an *Amanita muscaria* phenylalanine ammonium lyase gene. *J Bacteriol* 1999 Mar;181(6):1931-3.
- Nemeroff CB, Mason GA, Hatley OL, Jahnke G, Prange AJ Jr. Lack of effect of a behaviorally active dose of cholecystokinin octapeptide upon aromatic amino acid levels in plasma and brain. *Brain Res* 1980 Feb 24;184(2):529-32.

- Nichol CA, Smith GK, Duch DS. Biosynthesis and metabolism of tetrahydrobiopterin and molybdopterin. *Annu Rev Biochem* 1985;54:729-64.
- Nishimiya Y, Tsumoto K, Shiroishi M, Yutani K, Kumagai I. Thermodynamic consequences of grafting enhanced affinity toward the mutated antigen onto an antibody. The case of anti-lysozyme antibody HyHEL-10. *J Biol Chem* 2000 Apr 28;275(17):12813-20.
- Nowacki P, Byck S, Prevost L, Scriver CR. The PAH mutation analysis consortium database: update 1996. *Nucleic Acids Res* 1997 Jan 1;25(1):139-42.
- Nowacki PM, Byck S, Prevost L, Scriver CR. PAH Mutation Analysis Consortium Database: 1997. Prototype for relational locus-specific mutation databases. *Nucleic Acids Res* 1998 Jan 1;26(1):220-5.
- Okajima K, Inoue M, Morino Y. Studies on the mechanism for renal elimination of N-acetylphenylalanine: its pathophysiologic significance in phenylketonuria. *J Lab Clin Med* 1985 Jan;105(1):132-8.
- Okano Y, Asada M, Kang Y, Nishi Y, Hase Y, Oura T, Isshiki G. Molecular characterization of phenylketonuria in Japanese patients. *Hum Genet* 1998 Nov;103(5):613-8.
- Okano Y, Chow IZ, Isshiki G, Inoue A, Oura T. Effects of phenylalanine loading on protein synthesis in the fetal heart and brain of rat: an experimental approach to maternal phenylketonuria. *J Inher Metab Dis* 1986;9(1):15-24.
- Okumura J, Yamaguchi K, Yanaka M. Growth and utilization of dietary nitrogen and energy in chicks fed excess phenylalanine or tyrosine diets. *Jpn Poultry Sci* 1980 Sep;17(5):256-64.
- Olafsdottir S, Martinez A. The accessibility of iron at the active site of recombinant human phenylalanine hydroxylase to water as studied by ¹H NMR paramagnetic relaxation. Effect of L-Phe and comparison with the rat enzyme. *J Biol Chem* 1999 Mar 5;274(10):6280-4.
- Onishi A, Liotta LJ, Benkovic SJ. Cloning and expression of *Chromobacterium violaceum* phenylalanine hydroxylase in *Escherichia coli* and comparison of amino acid sequence with mammalian aromatic amino acid hydroxylases. *J Biol Chem* 1991 Oct 5;266(28):18454-9.
- Oorschot DE, Jones DG. A quantitative ultrastructural study of the effects of phenylacetate on synaptic organization in the developing rat cerebral cortex. *Dev Neurosci* 1983-84;6(1):45-57.
- Oppliger T, Thony B, Nar H, Burgisser D, Huber R, Heizmann CW, Blau N. Structural and functional consequences of mutations in 6-pyruvoyltetrahydropterin synthase causing hyperphenylalaninemia in humans. Phosphorylation is a requirement for in vivo activity. *J Biol Chem* 1995 Dec 8;270(49):29498-506.
- Osadchaia LM, Putilina FE. [Effect of hyperphenylalaninemia on the metabolism of free amino acids in the brain]. *Nerv Sist* 1982;23:112-6. (Rus).
- Owada M, Abe M, Tanimoto M, Minato M, Kitagawa T, Katayama S. Dietary treatment of PKU using a low-phenylalanine peptide milk. *Acta Paediatr Jpn* 1988 Aug;30(4):405-9.
- Palmour RM, Ervin FR, Baker GB, Young SN. An amino acid mixture deficient in phenylalanine and tyrosine reduces cerebrospinal fluid catecholamine metabolites and alcohol consumption in vervet monkeys. *Psychopharmacology (Berl)* 1998 Mar;136(1):1-7.
- Papet I, Ostaszewski P, Glomot F, Obled C, Faure M, Bayle G, Nissen S, Arnal M, Grizard J. The effect of a high dose of 3-hydroxy-3-methylbutyrate on protein metabolism in growing lambs. *Br J Nutr* 1997 Jun;77(6):885-96.
- Pappas PW, Gamble HR. Membrane transport of aromatic amino acids by *Hymenolepis diminuta* (Cestoda). *Parasitology* 1980 Oct;81(2):395-403.
- Pardou A, Vuye A, Vis HL. Plasma amino acid patterns, one and two hours after continuous nasogastric alimentation of low birth weight infants fed two types of milk during the first month of life. *Biol Neonate* 1982;41(1-2):57-62.
- Pardridge WM, Choi TB. Neutral amino acid transport at the human blood-brain barrier. *Fed Proc* 1986 Jun;45(7):2073-8.
- Parniak M, Hasegawa H, Wilgus H, Kaufman S. On the phosphate content of rat liver phenylalanine hydroxylase purified by hydrophobic chromatography. *Biochem Biophys Res Commun* 1981 Mar 31;99(2):707-14.
- Parniak MA, Davis M, Kaufman S, Kempner ES. Radiation target analysis indicates that phenylalanine hydroxylase in rat liver extracts is a functional monomer. *FEBS Lett* 1999 Apr 16;449(1):49-52.
- Parniak MA, Davis MD, Kaufman S. Effect of alkaline pH on the activity of rat liver phenylalanine hydroxylase. *J Biol Chem* 1988 Jan 25;263(3):1223-30.

- Parniak MA, Jennings IG, Cotton RG. Interaction with a monoclonal antibody alters the expression of cooperativity by phenylalanine hydroxylase from rat liver. *Biochem J* 1989 Jan 15;257(2):383-8.
- Parniak MA, Kaufman S. Rat liver phenylalanine hydroxylase. Activation by sulfhydryl modification. *J Biol Chem* 1981 Jul 10;256(13):6876-82.
- Parniak MA, Pilkington J. Glucocorticoid stimulation of tetrahydrobiopterin levels and phenylalanine hydroxylase activity in rat hepatoma cells. *Biochem Cell Biol* 1989 Jun;67(6):293-6.
- Pastor CM, Williams D, Yoneyama T, Hatakeyama K, Singleton S, Naylor E, Billiar TR. Competition for tetrahydrobiopterin between phenylalanine hydroxylase and nitric oxide synthase in rat liver. *J Biol Chem* 1996 Oct 4;271(40):24534-8.
- Pechenova TN, Sushkova VV, Popova NN, Solodova EV, Gulyi MF. [Changes in the biosynthesis of acid-soluble collagen in the skin of rats with amino acid imbalances in their diets]. *Ukr Biokhim Zh* 1984 Jan-Feb;56(1):10-4. (Rus).
- Peluffo RO, Nervi AM, Gonzalez MS, Brenner RR. Effect of different amino acid diets on delta 5, delta 6 and delta 9 desaturases. *Lipids* 1984 Feb;19(2):154-7.
- Peng H, Armentano D, MacKenzie-Graham L, Shen RF, Darlington G, Ledley FD, Woo SL. Retroviral-mediated gene transfer and expression of human phenylalanine hydroxylase in primary mouse hepatocytes. *Proc Natl Acad Sci U S A* 1988 Nov;85(21):8146-50.
- Perez B, Desviat LR, Ugarte M. Expression analysis of mutation P244L, which causes mild hyperphenylalaninemia. *Hum Mutat* 1995;5(2):188-90.
- Pergolizzi RG. The Y base of eukaryotic phenylalanine-transfer ribonucleic biosynthesis and relation to growth of normal and neoplastic cell lines [dissertation]. New York: Columbia University; 1980. 192 p.
- Peterson NA, Shah SN, Raghupathy E, Rhoads DE. Presynaptic tyrosine availability in the phenylketonuric brain: a hypothetical evaluation. *Brain Res* 1983 Aug 1;272(1):189-93.
- Petruschka L, Rebrin I, Grimm U, Herrmann FH. The immunological evidence for a phenylalanine hydroxylase like immunoreactive protein in different human cells and tissues. *Clin Chim Acta* 1990 Dec 13;193(1-2):65-77.
- Phenylketonuria, an international survey of management over 40 years. Proceedings of a workshop. Fulda, November 16-19, 1994. *Eur J Pediatr* 1996 Jul;155 Suppl 1:S1-180.
- Phenylketonuria--Past, Present, Future. Proceedings of a symposium. Elsinore, Denmark, May 23-25, 1994. *Acta Paediatr Suppl* 1994 Dec;407:1-129.
- Phillips RS, Iwaki M, Kaufman S. Ligand effects on the limited proteolysis of phenylalanine hydroxylase: evidence for multiple conformational states. *Biochem Biophys Res Commun* 1983 Feb 10;110(3):919-25.
- Phillips RS, Kaufman S. Ligand effects on the phosphorylation state of hepatic phenylalanine hydroxylase. *J Biol Chem* 1984 Feb 25;259(4):2474-9.
- Phillips RS, Kaufman S. On the nature of the spontaneous activation of hepatic phenylalanine hydroxylase. *Trans N Y Acad Sci* 1983;41:87-95.
- Phillips RS, Parniak MA, Kaufman S. The interaction of aromatic amino acids with rat liver phenylalanine hydroxylase. *J Biol Chem* 1984 Jan 10;259(1):271-7.
- Phillips RS, Parniak MA, Kaufman S. Spectroscopic investigation of ligand interaction with hepatic phenylalanine hydroxylase: evidence for a conformational change associated with activation. *Biochemistry* 1984 Aug 14;23(17):3836-42.
- Phua SH, Wood NJ. A high-frequency TaqI polymorphism at the ovine phenylalanine hydroxylase (PAH) locus. *Anim Genet* 1996 Apr;27(2):124.
- Piccardo MG, Rosa M, Russo L. The effects of a load of phenylalanine on glucose metabolism. *Boll Soc Ital Biol Sper* 1983 Jan 31;59(2):167-70.
- Piedrafita AC, Martinez-Ramirez AC, Silva FJ. A genetic analysis of aromatic amino acid hydroxylases involvement in DOPA synthesis during *Drosophila* adult development. *Insect Biochem Mol Biol* 1994 Jun;24(6):581-8. Published erratum appears in *Insect Biochem Mol Biol* 1995 Jan;25(1):151.
- Piel N, Lane JD, Huther G, Neuheff V. Impaired permeability of the blood-cerebrospinal fluid barrier in hyperphenylalaninaemia. *Neuropediatrics* 1982 May;13(2):88-92.
- Piggins HD. The short- and long-term effects of neonatal exposure to and/or (d-phenylalanine(6), Psi leucine(13)-chloroparpylamid(14))BN(6-14), a Bombesin receptor antagonist [dissertation]. Ottawa (Canada): University of Ottawa; 1991. 204 p.
- Pike DC, Hora MT, Bailey SW, Ayling JE. Pyrimidodiazepine, a ring-strained cofactor for phenylalanine hydroxylase. *Biochemistry* 1986 Aug 26;25(17):4762-71.

- Pittard J. The various strategies within the TyrR regulation of *Escherichia coli* to modulate gene expression. *Genes Cells* 1996 Aug;1(8):717-25.
- Pogge v Strandmann E, Senkel S, Ryffel GU. Ectopic pigmentation in *Xenopus* in response to DCoH/PCD, the cofactor of HNF1 transcription factor/pterin-4alpha-carbinolamine dehydratase. *Mech Dev* 2000;91(1-2):53-60.
- Pogson CI, Dickson AJ, Knowles RG, Salter M, Santana MA, Stanley JC, Fisher MJ. Control of phenylalanine and tyrosine metabolism by phosphorylation mechanisms. *Adv Enzyme Regul* 1986;25:309-27.
- Pogson CI, Knowles RG, Salter M. The control of aromatic amino acid catabolism and its relationship to neurotransmitter amine synthesis. *Crit Rev Neurobiol* 1989;5(1):29-64.
- Pogson CI, Santana MA, Fisher MJ. Phenylalanine hydroxylase: metabolic aspects. *Biochem Soc Trans* 1985 Apr;13(2):439-41.
- Pollegioni L, Fukui K, Massey V. Studies on the kinetic mechanism of pig kidney D-amino acid oxidase by site-directed mutagenesis of tyrosine 224 and tyrosine 228. *J Biol Chem* 1994 Dec 16;269(50):31666-73.
- Pomi L, Peano L, Colla D. [Use of screening for amino acid disorders in the study of the nutrition of the newborn infant: various milk formulas and changes in plasma amino acids]. *Pediatr Med Chir* 1984 Mar-Apr;6(2):261-8. (Ita).
- Pontoglio M, Barra J, Hadchouel M, Doyen A, Kress C, Bach JP, Babinet C, Yaniv M. Hepatocyte nuclear factor 1 inactivation results in hepatic dysfunction, phenylketonuria, and renal Fanconi syndrome. *Cell* 1996 Feb 23;84(4):575-85.
- Pontoglio M, Faust DM, Doyen A, Yaniv M, Weiss MC. Hepatocyte nuclear factor 1alpha gene inactivation impairs chromatin remodeling and demethylation of the phenylalanine hydroxylase gene. *Mol Cell Biol* 1997 Sep;17(9):4948-56.
- Powell TL, Davis AJ, Yuan JH, Austic RE. Developmental pattern of phenylalanine hydroxylase activity in the chicken. *Poult Sci* 1999 Jun;78(6):855-60.
- Pratt OE. A new approach to the treatment of phenylketonuria. *J Ment Defic Res* 1980 Sep;24(3):203-17.
- Preedy VR, Garlick PJ. The response of muscle protein synthesis to nutrient intake in postabsorptive rats: the role of insulin and amino acids. *Biosci Rep* 1986 Feb;6(2):177-83.
- Presch I, Birnbacher R, Herkner K, Lubec G. The effect of estradiol and ovariectomy on tyrosine hydroxylase, tyrosine aminotransferase and phenylalanine hydroxylase. *Life Sci* 1997;60(7):479-84.
- Price CC. Changes in phenylalanine and tyrosine metabolism during brucei gambiense infection in *Microtus montanus* [dissertation]. Chapel Hill (NC): The University of North Carolina at Chapel Hill; 1986. 129 p.
- Pueschel SM. Maternal phenylketonuria. *Soc Biol* 1985 Spring-Summer;32(1-2):31-44.
- Pueschel SM, Boylan J, Ellenbogen R. Studies on experimentally induced hyperphenylalaninemia. *J Ment Defic Res* 1988 Aug;32 (Pt 4):309-19.
- Pueschel SM, Schrier AM, Povar ML, Boylan JM. Biological and behavioural assessments of young rhesus monkeys after intrauterine exposure to high phenylalanine concentrations. *J Ment Defic Res* 1985 Sep;29 (Pt 3):247-56.
- Puglisi-Allegra S, Cabib S, Pascucci T, Ventura R, Cali F, Romano V. Dramatic brain aminergic deficit in a genetic mouse model of phenylketonuria. *Neuroreport* 2000 Apr 27;11(6):1361-4.
- Putilina FE, Osadchaia LM. [Effect of chronic hyperphenylalaninemia and hypoxia on the effectiveness of the alpha-ketoglutarate shunt in the brain]. *Biokhimiia* 1985 Aug;50(8):1295-9. (Rus).
- Putilina FE, Osadchaia LM. [Use of different precursors of fatty acid biosynthesis in the brain in chronic hyperphenylalaninemia]. *Vopr Med Khim* 1984 Mar-Apr;30(2):100-3. (Rus).
- Ramano M, Diomedea L, Guiso G, Caccia S, Perego C, Salmona M. Plasma and brain kinetics of large neutral amino acids and of striatum monoamines in rats given aspartame. *Food Chem Toxicol* 1990;28(5):317-21.
- Randles D, Armarego WL. Reduced 6,6,8-trimethylpterins. Preparation, properties and enzymic reactivities with dihydropteridine reductase, phenylalanine hydroxylase and tyrosine hydroxylase. *Eur J Biochem* 1985 Jan 15;146(2):467-74.
- Rao DN, Kaufman S. Purification and state of activation of rat kidney phenylalanine hydroxylase. *J Biol Chem* 1986 Jul 5;261(19):8866-76.
- Raper SE, Wilson JM. Cell transplantation in liver-directed gene therapy. *Cell Transplant* 1993 Sep-Oct;2(5):381-400; discussion 407-10. Comment in: *Cell Transplant* 1993 Sep-Oct;2(5):401-3; *Cell Transplant* 1993 Sep-Oct;2(5):405-6.

- Ratzmann GW, Grimm U, Jahrig K. Increased concentrations of tyrosine and phenylalanine in the cerebrospinal fluid as a possible reflection of related changes of the brain tissue in newborns with intra-uterine growth retardation. *Biomed Biochim Acta* 1988;47(12):1037-41.
- Rebrin I, Bailey SW, Boerth SR, Ardell MD, Ayling JE. Catalytic characterization of 4a-hydroxytetrahydropterin dehydratase. *Biochemistry* 1995 May 2;34(17):5801-10.
- Reddy S, Halliwell B, Jones AD, Longhurst JC. The use of phenylalanine to detect hydroxyl radical production in vivo: a cautionary note [letter]. *Free Radic Biol Med* 1999 Dec;27(11-12):1465.
- Rege AA. Purification and characterization of a tyrosine aminotransferase from *Crithidia fasciculata*. *Mol Biochem Parasitol* 1987 Aug;25(1):1-9.
- Regulation of aromatic amino acid catabolism. *Nutr Rev* 1986 Nov;44(11):377-9.
- Reynolds R, Burri R, Herschkowitz N. Retarded development of neurons and oligodendroglia in rat forebrain produced by hyperphenylalaninemia results in permanent deficits in myelin despite long recovery periods. *Exp Neurol* 1993 Dec;124(2):357-67.
- Reynolds R, Burri R, Mahal S, Herschkowitz N. Disturbed myelinogenesis and recovery in hyperphenylalaninemia in rats: an immunohistochemical study. *Exp Neurol* 1992 Mar;115(3):347-67.
- Ribeiro P, Pigeon D, Kaufman S. The hydroxylation of phenylalanine and tyrosine by tyrosine hydroxylase from cultured pheochromocytoma cells. *J Biol Chem* 1991 Aug 25;266(24):16207-11.
- Richardson SC, Aspbury RA, Fisher MJ. The role of reversible phosphorylation in the hormonal control of phenylalanine hydroxylase in isolated rat proximal kidney tubules. *Biochem J* 1993 Jun 1;292 (Pt 2):419-24.
- Richardson SC, Fisher MJ. Characterization of phenylalanine hydroxylase from rat kidney. *Int J Biochem* 1993 Apr;25(4):581-8.
- Richardson SC, Green AK, Fisher MJ. Phosphorylation-dephosphorylation of renal phenylalanine hydroxylase. *Biochem Soc Trans* 1991 Apr;19(2):229S.
- Robain O, Wen GY, Wisniewski HM, Shek JW, Loo YH. Purkinje cell dendritic development in experimental phenylketonuria. A quantitative analysis. *Acta Neuropathol (Berl)* 1981;53(2):107-12.
- Robain O, Wisniewski HM, Loo YH, Wen GY. Experimental phenylketonuria: effect of phenylacetate intoxication on number of synapses in the cerebellar cortex of the rat. *Acta Neuropathol (Berl)* 1983;61(3-4):313-5.
- Roberts S, Morelos BS. Cerebral ribosomal protein phosphorylation in experimental hyperphenylalaninaemia. *Biochem J* 1980 Aug 15;190(2):405-19.
- Roberts S, Morelos BS. Inhibition of cerebral protein kinase activity and cyclic AMP-dependent ribosomal-protein phosphorylation in experimental hyperphenylalaninaemia. *Biochem J* 1982 Feb 15;202(2):343-51.
- Robinson EH, Wilson RP, Poe WE. Total aromatic amino acid requirement, phenylalanine requirement and tyrosine replacement value for fingerling channel catfish. *J Nutr* 1980 Sep;110(9):1805-12.
- Robson KJ, Beattie W, James RJ, Cotton RC, Morgan FJ, Woo SL. Sequence comparison of rat liver phenylalanine hydroxylase and its cDNA clones. *Biochemistry* 1984 Nov 20;23(24):5671-5.
- Robson KJ, Chandra T, MacGillivray RT, Woo SL. Polysome immunoprecipitation of phenylalanine hydroxylase mRNA from rat liver and cloning of its cDNA. *Proc Natl Acad Sci U S A* 1982 Aug;79(15):4701-5.
- Rodriguez B, Torres N, Rincon AR, Bourges H, Panduro A, Tovar AR. Hepatic phenylalanine-hydroxylase and tyrosine-aminotransferase mRNA levels in rats adapted to diets with different concentrations of protein. *Rev Invest Clin* 1996 Nov-Dec;48(6):413-9.
- Rose S. DNA in medicine. Human perfectibility. *Lancet* 1984 Dec 15;2(8416):1380-3.
- Rotter RG, Marquardt RR, Frohlich AA. Ochratoxin A toxicity in growing chicks: effect of supplemental dietary phenylalanine. *Nutr Rep Int* 1989 Dec;40(6):1091-100.
- Roux C, Rey F, Lyonnet S, Nizard S, Mulliez N, Munnich A. An animal model for maternal phenylketonuria. *J Med Genet* 1991 Oct;28(10):718-9.
- Rozenfel'd EL. [Models of enzymopathies and their role in elaborating methods of enzyme therapy (review)]. *Vopr Med Khim* 1981 Jan-Feb;27(1):7-18. (Rus).
- Ruiz-Vazquez P, Moulard M, Silva FJ. Structure of the phenylalanine hydroxylase gene in *Drosophila melanogaster* and evidence of alternative promoter usage. *Biochem Biophys Res Commun* 1996 Aug 5;225(1):238-42.

- Ruiz-Vazquez P, Silva FJ. Aberrant splicing of the *Drosophila melanogaster* phenylalanine hydroxylase pre-mRNA caused by the insertion of a B104/roo transposable element in the Henna locus. *Insect Biochem Mol Biol* 1999 Apr;29(4):311-8.
- Runge DM, Runge D. [Somatic gene therapy. Initial clinical applications and current research approach]. *Fortschr Med* 1995 Aug 30;113(24):337-40. Comment in: *Fortschr Med* 1995 Aug 30;113(24):341. (Ger).
- Sadava D, Sutcliffe D. The effects of maternal hyperphenylalaninemia on learning in mature rats. *Life Sci* 1988;43(14):1119-23.
- Sadler MJ. Recent aspartame studies. *Food Chem Toxicol* 1984 Sep;22(9):771-3.
- Sadler TW, Denno KM, Hunter ES 3d. Effects of altered maternal metabolism during gastrulation and neurulation stages of embryogenesis. *Ann N Y Acad Sci* 1993 Mar 15;678:48-61.
- Saez LP, Castillo F, Caballero FJ. Metabolism of L-phenylalanine and L-tyrosine by the phototrophic bacterium *Rhodobacter capsulatus*. *Curr Microbiol* 1999 Jan;38(1):51-6.
- Safos S, Chang TM. Enzyme replacement therapy in ENU2 phenylketonuric mice using oral microencapsulated phenylalanine ammonia-lyase: a preliminary report. *Artif Cells Blood Substit Immobil Biotechnol* 1995;23(6):681-92.
- Safronova EE, Annenkov GA. [Modification of Ayling's method for determining phenylalanine hydroxylase activity]. *Lab Delo* 1982;(5):296-9. (Rus).
- Salter M, Knowles RG, Pogson CI. Quantification of the importance of individual steps in the control of aromatic amino acid metabolism. *Biochem J* 1986 Mar 15;234(3):635-47.
- Salter M, Stanley JC, Fisher MJ, Pogson CI. The influence of starvation and tryptophan administration on the metabolism of phenylalanine, tyrosine and tryptophan in isolated rat liver cells. *Biochem J* 1984 Jul 15;221(2):431-8.
- Samid D, Ram Z, Hudgins WR, Shack S, Liu L, Walbridge S, Oldfield EH, Myers CE. Selective activity of phenylacetate against malignant gliomas: resemblance to fetal brain damage in phenylketonuria. *Cancer Res* 1994 Feb 15;54(4):891-5.
- Samuels SE, Baracos VE. Tissue protein turnover is altered during catch-up growth following *Escherichia coli* infection in weanling rats. *J Nutr* 1995 Mar;125(3):520-30.
- Sanford YM, Orias E. Phenylketonuric Tetrahymena: phenylalanine hydroxylase mutants and other tyrosine auxotrophs. *Proc Natl Acad Sci U S A* 1981 Dec;78(12):7614-8.
- Sarkissian CN, Boulais DM, McDonald JD, Scriver CR. A heteroallelic mutant mouse model: A new orthologue for human hyperphenylalaninemia. *Mol Genet Metab* 2000 Mar;69(3):188-94.
- Sarkissian CN, Scriver CR, Mamer OA. Measurement of phenyllactate, phenylacetate, and phenylpyruvate by negative ion chemical ionization-gas chromatography/mass spectrometry in brain of mouse genetic models of phenylketonuria and non-phenylketonuria hyperphenylalaninemia. *Anal Biochem* 2000 May 1;280(2):242-9.
- Sarkissian CN, Shao Z, Blain F, Peevers R, Su H, Heft R, Chang TM, Scriver CR. A different approach to treatment of phenylketonuria: phenylalanine degradation with recombinant phenylalanine ammonia lyase. *Proc Natl Acad Sci U S A* 1999 Mar 2;96(5):2339-44. Comment in: *Proc Natl Acad Sci U S A* 1999 Mar 2;96(5):1811-3.
- Sato T, Imura E, Murata A, Minami S, Okabe T, Ohno I. Effects of maternal phenylalanine or tyrosine hydroxylase inhibition on postnatal maturation of catecholamine and amino acid metabolism in rats. *Acta Paediatr Jpn* 1988 Feb;30(1):56-62.
- Scherer-Oppliger T, Matasovic A, Laufs S, Levy HL, Quackenbush EJ, Blau N, Thony B. Dominant negative allele (N47D) in a compound heterozygote for a variant of 6-pyruvoyltetrahydropterin synthase deficiency causing transient hyperphenylalaninemia. *Hum Mutat* 1999;13(4):286-9.
- Schmid G, Bahner U, Peschkes J, Heidland A. Neurotransmitter and monoaminergic amino acid precursor levels in rat brain: effects of chronic renal failure and of malnutrition. *Miner Electrolyte Metab* 1996;22(1-3):115-8.
- Schmidt K, Werner-felmayer G, Mayer B, Werner ER. Preferential inhibition of inducible nitric oxide synthase in intact cells by the 4-amino analogue of tetrahydrobiopterin. *Eur J Biochem* 1999 Jan;259(1-2):25-31.
- Schmitt JA, Jorissen BL, Sobczak S, Van Boxtel MP, Hogervorst E, Deutz NE, Riedel WJ. Tryptophan depletion impairs memory consolidation but improves focussed attention in healthy young volunteers. *J Psychopharmacol* 2000;14(1):21-9.
- Schott K, Gehrman J, Neuhoff V. Induction of hyperphenylalaninemia in mice by ethionine and phenylalanine. *Biochem Med Metab Biol* 1986 Aug;36(1):106-13.

- Schroter J, Schott KJ, Purtil MA, Neuhoff V. Lysosomal protein degradation in experimental hyperphenylalaninaemia. *J Inher Metab Dis* 1986;9(3):273-82.
- Schulpis KH, Platokouki H, Papakonstantinou ED, Adamtziki E, Bargeliotis A, Aronis S. Haemostatic variables in phenylketonuric children under dietary treatment. *J Inher Metab Dis* 1996;19(5):603-9.
- Schultz K, Mestyan J, Soltész G, Klujber L, Dober I. Metabolic effects of septicaemia in newborn and young infants with particular reference to the plasma free amino acids. *Acta Paediatr Acad Sci Hung* 1980;21(4):243-51.
- Schuster B, Retey J. The mechanism of action of phenylalanine ammonia-lyase: the role of prosthetic dehydroalanine. *Proc Natl Acad Sci U S A* 1995 Aug 29;92(18):8433-7.
- Scriver CR. Child health, the genome project and phenylketonuria. *Turk J Pediatr* 1993 Jul-Sep;35(3):227-37.
- Scriver CR. Whatever happened to PKU? *Clin Biochem* 1995 Apr;28(2):137-44.
- Scriver CR, Clow CL. Phenylketonuria and other phenylalanine hydroxylation mutants in man. *Annu Rev Genet* 1980;14:179-202.
- Scriver CR, Clow CL. Phenylketonuria: epitome of human biochemical genetics (first of two parts). *N Engl J Med* 1980 Dec 4;303(23):1336-42.
- Scriver CR, Eisensmith RC, Woo SL, Kaufman S. The hyperphenylalaninemia of man and mouse. *Annu Rev Genet* 1994;28:141-65.
- Scriver CR, Waters PJ. Monogenic traits are not simple: lessons from phenylketonuria. *Trends Genet* 1999 Jul;15(7):267-72.
- Scriver CR, Waters PJ, Sarkissian C, Ryan S, Prevost L, Cote D, Novak J, Teebi S, Nowacki PM. PAHdb: a locus-specific knowledgebase. *Hum Mutat* 2000;15(1):99-104.
- Seve B, Reeds PJ, Fuller MF, Cadenhead A, Hay SM. Protein synthesis and retention in some tissues of the young pig as influenced by dietary protein intake after early-weaning. Possible connection to the energy metabolism. *Reprod Nutr Dev* 1986;26(3):849-61.
- Sharifi BG. Synthesis and hydrolysis - l-phenylalanine-l-lysine (acylated non-acylated) and evaluation of their use as a nutritive breads [dissertation]. Manhattan (KS): Kansas State University; 1984. 91 p.
- Sharma SD. Immobilized phenylalanine ammonia lyase for the depletion of phenylalanine [dissertation]. Buffalo (NY): State University of New York at Buffalo; 1981. 124 p.
- Sharma SD, Cooley C, De La Pava E, Ambrus CM. Development of a refractory stage in a dog model for phenylketonuria. *Res Commun Chem Pathol Pharmacol* 1981 Jul;33(1):145-53.
- Shedlovsky A, McDonald JD, Symula D, Dove WF. Mouse models of human phenylketonuria. *Genetics* 1993 Aug;134(4):1205-10.
- Shen RS. Potent inhibitory effects of tyrosine metabolites on dihydropteridine reductase from human and sheep liver (Phenylketonuria). *Biochim Biophys Acta* 1984 Mar 29;785(3):181-5.
- Shiman R. Purification and assay of rat liver phenylalanine 4-monooxygenase. *Methods Enzymol* 1987;142:17-27.
- Shiman R. Relationship between the substrate activation site and catalytic site of phenylalanine hydroxylase. *J Biol Chem* 1980 Nov 10;255(21):10029-32.
- Shiman R, Gray DW. Formation and fate of tyrosine. Intracellular partitioning of newly synthesized tyrosine in mammalian liver. *J Biol Chem* 1998 Dec 25;273(52):34760-9.
- Shiman R, Gray DW. Substrate activation of phenylalanine hydroxylase. A kinetic characterization. *J Biol Chem* 1980 May 25;255(10):4793-800.
- Shiman R, Gray DW, Hill MA. Regulation of rat liver phenylalanine hydroxylase. I. Kinetic properties of the enzyme's iron and enzyme reduction site. *J Biol Chem* 1994 Oct 7;269(40):24637-46.
- Shiman R, Jefferson LS. Iron-dependent regulation of rat liver phenylalanine hydroxylase activity in vivo, in vitro, and in perfused liver. *J Biol Chem* 1982 Jan 25;257(2):839-44.
- Shiman R, Jones SH, Gray DW. Mechanism of phenylalanine regulation of phenylalanine hydroxylase. *J Biol Chem* 1990 Jul 15;265(20):11633-42.
- Shiman R, Mortimore GE, Schworer CM, Gray DW. Regulation of phenylalanine hydroxylase activity by phenylalanine in vivo, in vitro, and in perfused rat liver. *J Biol Chem* 1982 Oct 10;257(19):11213-6.
- Shiman R, Xia T, Hill MA, Gray DW. Regulation of rat liver phenylalanine hydroxylase. II. Substrate binding and the role of activation in the control of enzymatic activity. *J Biol Chem* 1994 Oct 7;269(40):24647-56.

- Shintaku H, Nakajima T, Imamura T, Sawada Y, Isshiki G, Oura T. Experimental research on a fetal treatment for tetrahydrobiopterin deficiency. *Adv Exp Med Biol* 1993;338:273-6.
- Siegmund HU, Kaufman S. Hydroxylation of 4-methylphenylalanine by rat liver phenylalanine hydroxylase. *J Biol Chem* 1991 Feb 15;266(5):2903-10.
- Silva FJ, Bel Y, Botella LM, Cotton RG, Ferre J. Immunological detection of phenylalanine hydroxylase protein in *Drosophila melanogaster*. *Biochem J* 1992 Oct 1;287 (Pt 1):85-9.
- Smith JE, Sheng ZF, Kallen RG. Effects of tyrosine-->phenylalanine mutations on auto- and trans-phosphorylation reactions catalyzed by the insulin receptor beta-subunit cytoplasmic domain. *DNA Cell Biol* 1994 Jun;13(6):593-604.
- Smith SC, Kemp BE, McAdam WJ, Mercer JF, Cotton RG. Two apparent molecular weight forms of human and monkey phenylalanine hydroxylase are due to phosphorylation. *J Biol Chem* 1984 Sep 25;259(18):11284-9.
- Smith SC, McAdam W, Cotton RG, Mercer JF. A novel two-dimensional polyacrylamide-gel pattern, which may be due to allelic genes, of phenylalanine hydroxylase in monkeys. *Biochem J* 1985 Oct 1;231(1):197-9.
- Smith TK. Effect of leucine-rich dietary protein on in vitro protein synthesis in porcine muscle. *Proc Soc Exp Biol Med* 1985 Dec;180(3):538-43.
- Song J. Multi-level regulation of phenylalanine hydroxylase in *aeruginosa* [dissertation]. Gainesville (FL): University of Florida; 1997. 100 p.
- Song J, Jensen RA. PhhR, a divergently transcribed activator of the phenylalanine hydroxylase gene cluster of *Pseudomonas aeruginosa*. *Mol Microbiol* 1996 Nov;22(3):497-507.
- Song J, Xia T, Jensen RA. PhhB, a *Pseudomonas aeruginosa* homolog of mammalian pterin 4a-carbinolamine dehydratase/DCoH, does not regulate expression of phenylalanine hydroxylase at the transcriptional level. *J Bacteriol* 1999 May;181(9):2789-96.
- Sonntag WE, Lenham JE, Ingram RL. Effects of aging and dietary restriction on tissue protein synthesis: relationship to plasma insulin-like growth factor-1. *J Gerontol* 1992 Sep;47(5):B159-63.
- Soto-Urzuza L, Xochinua-Corona YG, Flores-Encarnacion M, Baca BE. Purification and properties of aromatic amino acid aminotransferases from *Azospirillum brasilense* UAP 14 strain. *Can J Microbiol* 1996 Mar;42(3):294-8.
- Southorn BG, Kelly JM, McBride BW. Phenylalanine flooding dose procedure is effective in measuring intestinal and liver protein synthesis in sheep. *J Nutr* 1992 Dec;122(12):2398-407.
- Spaapen LJ, Ketting D, Wadman SK, Bruinvis L, Duran M. Urinary D-4-hydroxyphenyllactate, D-phenyllactate and D-2-hydroxyisocaproate, abnormalities of bacterial origin. *J Inher Metab Dis* 1987;10(4):383-90.
- Speer VC, Kile DL, Trew JC. Estimation of the isoleucine and aromatic amino acid requirements of pregnant swine. *J Anim Sci* 1990 Aug;68(8):2394-9.
- Spero DA, Yu MC. Effects of maternal hyperphenylalaninemia on fetal brain development: a biochemical study. *Exp Neurol* 1983 Mar;79(3):641-54.
- Spero DA, Yu MC. Effects of maternal hyperphenylalaninemia on fetal brain development: a morphological study. *Exp Neurol* 1983 Mar;79(3):655-65.
- Srivastava US, Thakur ML, Van TT, Radhakrishnamurty R. Maternal food restriction, brain polysomes and poly-U stimulated protein synthesis in the newborn and 21-day-old rat progeny. *Nutr Res* 1993 Nov;13(11):1331-41.
- Stanley JC, Fisher MJ, Pogson CI. The metabolism of L-phenylalanine and L-tyrosine by liver cells isolated from adrenalectomized rats and from streptozotocin-diabetic rats. *Biochem J* 1985 May 15;228(1):249-55.
- Stanley JC, Salter M, Fisher MJ, Pogson CI. The effect of pyridoxine deficiency on the metabolism of the aromatic amino acids by isolated rat liver cells. *Arch Biochem Biophys* 1985 Aug 1;240(2):792-800.
- Stegink LD. Aspartame: review of the safety issues. *Food Technol* 1987 Jan;41(1):119-21.
- Stehle P, Weber S, Furst P. Parenteral glycyL-L-tyrosine maintains tyrosine pools and supports growth and nitrogen balance in phenylalanine-deficient rats. *J Nutr* 1996 Mar;126(3):663-7.
- Stokes AH, Xu Y, Daunais JA, Tamir H, Gershon MD, Butkerait P, Kayser B, Altman J, Beck W, Vrana KE. p-ethynylphenylalanine: A potent inhibitor of tryptophan hydroxylase. *J Neurochem* 2000;74(5):2067-73.
- Stoll B, Burrin DG, Henry J, Jahoor F, Reeds PJ. Phenylalanine utilization by the gut and liver measured with intravenous and intragastric tracers in pigs. *Am J Physiol* 1997 Dec;273(6 Pt 1):G1208-17.

- Stoll B, Burrin DG, Henry J, Yu H, Jahoor F, Reeds PJ. Dietary amino acids are the preferential source of hepatic protein synthesis in piglets. *J Nutr* 1998 Sep;128(9):1517-24.
- Stoll B, Burrin DG, Henry JF, Jahoor F, Reeds PJ. Dietary and systemic phenylalanine utilization for mucosal and hepatic constitutive protein synthesis in pigs. *Am J Physiol* 1999 Jan;276(1 Pt 1):G49-57.
- Strupp BJ, Bunsey M, Levitsky DA, Hamberger K. Deficient cumulative learning: an animal model of retarded cognitive development. *Neurotoxicol Teratol* 1994 Jan-Feb;16(1):71-9.
- Strupp BJ, Himmelstein S, Bunsey M, Levitsky DA, Kesler M. Cognitive profile of rats exposed to lactational hyperphenylalaninemia: correspondence with human mental retardation. *Dev Psychobiol* 1990 Apr;23(3):195-214.
- Strupp BJ, Levitsky D. An animal model of retarded cognitive development. In: Rovee-Collier C, Lipsitt LP, et al., editors. *Advances in infancy research*. Vol. 6. Norwood (NJ): Ablex Publishing Co.; 1990. p. 149-220. Sponsored by the March of Dimes Birth Defects Foundation and the U.S. Department of Agriculture Cooperative State Research Services.
- Strupp BJ, Levitsky DA, Blumstein L. PKU, learning, and models of mental retardation. *Dev Psychobiol* 1984 Mar;17(2):109-20.
- Su CL, Austic RE. Improved model of maternal phenylketonuria in rats by use of lower dietary concentrations of alpha-methylphenylalanine and L-phenylalanine in a semipurified diet. *Nutr Res* 1998 Jun;18(6):989-1002.
- Suchozebraska-Jesionek D, Szymonik-Lesiuk S, Borkowska I. Shortlasting effect of L-phenylalanine on the level of aminoacyl-tRNA in chick embryo's brain. *Bull Acad Polonaise Sci Ser Sci Biol* 1984;32(1-2):1-8.
- Sugiyama H, Moriyama H, Shigematsu H. Induction of phenylalanine and tyrosine oxidation in the intoxicated larva of the silkworm, *obmyx mori* L (Lepidoptera: Bombycidae), with MTMC (m-Tolyl-N-methylcarbamate). *Appl Entomol Zool* 1982 May;17(2):166-71.
- Swaiman KF, Wu SR. Phenylalanine and phenylacetate adversely affect developing mammalian brain neurons. *Neurology* 1984 Sep;34(9):1246-50.
- Szabo E, Thelen A, Petersen M. Fungal elicitor preparations and methyl jasmonate enhance rosmarinic acid accumulation in suspension cultures of *Coleus blumei*. *Plant Cell Rep* 1999 Feb;18(6):485-9.
- Takagi M, Nishio Y, Oh G, Yoshida T. Control of L-phenylalanine production by dual feeding of glucose and L-tyrosine. *Biotechnol Bioeng* 1996 Dec 20;52(6):653-60.
- Tam SY, Ono N, Roth RH. Precursor control and influence of aspartame on midbrain dopamine neurons. *UCLA Symp Mol Cell Biol* 1987;55:421-35.
- Tam SY, Roth RH. Mesoprefrontal dopaminergic neurons: can tyrosine availability influence their functions? *Biochem Pharmacol* 1997 Feb 21;53(4):441-53.
- Tanaka H, Nakatomi Y, Ogura M. Metabolism of phenylalanine, tyrosine and aspartic acid in growing rats at various dietary protein levels. *Agric Biol Chem* 1987 Feb;51(2):499-505.
- Tanaka H, Shibata K, Mori M, Ogura M. Metabolism of essential amino acids in growing rats at graded levels of soybean protein isolate. *J Nutr Sci Vitaminol (Tokyo)* 1995 Aug;41(4):433-43.
- Taylor DS, Dahl HH, Mercer JF, Green AK, Fisher MJ. The effect of streptozotocin-induced diabetes on phenylalanine hydroxylase expression in rat liver. *Biochem J* 1989 Nov 15;264(1):185-90.
- Taylor DS, Green AK, Fisher MJ. Impact of experimental diabetes on phenylalanine hydroxylase expression in rat liver. *Trans Biochem Soc* 1988 Dec;16(6):1057-8.
- Taylor EH, Hommes FA. Effect of experimental hyperphenylalaninemia on myelin metabolism at later stages of brain development. *Int J Neurosci* 1983 Sep;20(3-4):217-27.
- Taylor EH, Hommes FA, Stewart DE. Effect of experimental hyperphenylalaninemia on biogenic amine synthesis at later stages of brain development. *Biochem Med* 1983 Jun;29(3):307-17.
- Tengamnuay P, Mitra AK. Transport of tyrosine and phenylalanine across the rat nasal mucosa. *Life Sci* 1988;43(7):585-93.
- Thompson AJ, Tillotson S, Smith I, Kendall B, Moore SG, Brenton DP. Brain MRI changes in phenylketonuria. Associations with dietary status. *Brain* 1993 Aug;116 (Pt 4):811-21.
- Thompson GN, Pacy PJ, Watts RW, Halliday D. Protein metabolism in phenylketonuria and Lesch-Nyhan syndrome. *Pediatr Res* 1990 Sep;28(3):240-6.
- Thony B, Auerbach G, Blau N. Tetrahydrobiopterin biosynthesis, regeneration and functions. *Biochem J* 2000 Apr 1;347 Pt 1:1-16.

- Thony B, Leimbacher W, Blau N, Harvie A, Heizmann CW. Hyperphenylalaninemia due to defects in tetrahydrobiopterin metabolism: molecular characterization of mutations in 6-pyruvoyl-tetrahydropterin synthase. *Am J Hum Genet* 1994 May;54(5):782-92.
- Thony B, Leimbacher W, Burgisser D, Heizmann CW. Human 6-pyruvoyltetrahydropterin synthase: cDNA cloning and heterologous expression of the recombinant enzyme. *Biochem Biophys Res Commun* 1992 Dec 30;189(3):1437-43.
- Thony B, Neuheiser F, Hauer CR, Heizmann CW. Molecular cloning and recombinant expression of the human liver phenylalanine hydroxylase stimulating factor revealed structural and functional identity to the dimerization cofactor for the nuclear transcription factor HNF-1 alpha. *Adv Exp Med Biol* 1993;338:103-6.
- Thony B, Neuheiser F, Kierat L, Blaskovics M, Arn PH, Ferreira P, Rebrin I, Ayling J, Blau N. Hyperphenylalaninemia with high levels of 7-biopterin is associated with mutations in the PCBD gene encoding the bifunctional protein pterin-4a-carbinolamine dehydratase and transcriptional coactivator (DCoH). *Am J Hum Genet* 1998 Jun;62(6):1302-11.
- Thorpe JM. The effect of tyrosine and prior protein intake on the measurement of phenylalanine metabolism in vivo [dissertation]. Toronto (Canada): University of Toronto; 1999. 138 p.
- Tipper J, Kaufman S. Phenylalanine-induced phosphorylation and activation of rat hepatic phenylalanine hydroxylase in vivo. *J Biol Chem* 1992 Jan 15;267(2):889-96.
- Tork I, Halliday GM, Cotton RG. Application of antiphenylalanine hydroxylase antibodies to the study of the serotonergic system in the human brain. *J Chem Neuroanat* 1992 Jul-Aug;5(4):311-3.
- Torre P, Ponz F. Kinetics of the mediated transport and the passive net flux of phenylalanine across the rat small intestine in vivo. *Rev Esp Fisiol* 1983 Sep;39(3):333-7.
- Touraine RL, Guibaud P. [Genetics and hyperphenylalaninemias in 1992]. *Pediatric (Bucur)* 1992;47(1):9-21. Published erratum appears in *Pediatric* 1992;47(4):331. (Fre).
- Tsay JT, Appleman JR, Beard WA, Prendergast NJ, Delcamp TJ, Freisheim JH, Blakley RL. Kinetic investigation of the functional role of phenylalanine-31 of recombinant human dihydrofolate reductase. *Biochemistry* 1990 Jul 10;29(27):6428-36.
- Tsukada Y, Takamatsu K. [Correlation between monoamine content in the brain and discriminative learning ability (author's transl)]. *Tanpakushitsu Kakusan Koso* 1981 Aug;26(11):1725-34. (Jpn).
- Turk E. Hyperphenylalaninemia - induced alterations of cerebral synthesis in the rat [dissertation]. Los Angeles: University of California; 1984. 173 p.
- Turri MO, Ilg EC, Thony B, Blau N. Structure, genomic localization and recombinant expression of the mouse 6-pyruvoyl-tetrahydropterin synthase gene. *Biol Chem* 1998 Dec;379(12):1441-7.
- Usenko VS, Kornilovskaya IN, Lizogubov VV, Apostolov EO, Gubkina EA, Ushakova GA, Lepekhin EA. Some morphological changes in the rat thyroid gland during experimental hyperphenylalaninemia. *Anat Rec* 1997 Jun;248(2):251-8.
- Ushakova GA, Gubkina HA, Kachur VA, Lepekhin EA. Effect of experimental hyperphenylalaninemia on the postnatal rat brain. *Int J Dev Neurosci* 1997 Feb;15(1):29-36.
- van der Vliet A, O'Neill CA, Halliwell B, Cross CE, Kaur H. Aromatic hydroxylation and nitration of phenylalanine and tyrosine by peroxynitrite. Evidence for hydroxyl radical production from peroxynitrite. *FEBS Lett* 1994 Feb 14;339(1-2):89-92.
- Varughese KI, Xuong NH, Whiteley JM. Structural and mechanistic implications of incorporating naturally occurring aberrant mutations of human dihydropteridine reductase into a rat model. *Int J Pept Protein Res* 1994 Sep;44(3):278-87.
- Vogel F. Clinical consequences of heterozygosity for autosomal-recessive diseases. *Clin Genet* 1984 May;25(5):381-415.
- Vorhees CV. Concepts in teratology and developmental toxicology derived from animal research. *Ann N Y Acad Sci* 1989;562:31-41.
- Vorhees CV, Acuff-Smith KD, Weisenburger WP, Minck DR, Berry HK. Branched chain amino acids improve radial-arm maze acquisition and water maze forced-choice learning in rat offspring exposed in utero to hyperphenylalaninemia. *Neurotoxicol Teratol* 1992 Jan-Feb;14(1):35-41.
- Vorhees CV, Berry HK. Branched chain amino acids improve complex maze learning in rat offspring prenatally exposed to hyperphenylalaninemia: implications for maternal phenylketonuria. *Pediatr Res* 1989 Jun;25(6):568-72.
- Vorhees CV, Butcher RE, Berry HK. Progress in experimental phenylketonuria: a critical review. *Neurosci Biobehav Rev* 1981 Spring;5(1):177-90.

- Waggoner WF. Aspartame--a review. *Pediatr Dent* 1984 Sep;6(3):153-8.
- Wallick DE, Bloom LM, Gaffney BJ, Benkovic SJ. Reductive activation of phenylalanine hydroxylase and its effect on the redox state of the non-heme iron. *Biochemistry* 1984 Mar 13;23(6):1295-302.
- Walsh DA, Christian ZH. The effects of phenylalanine on cultured rat embryos. *Teratog Carcinog Mutagen* 1984;4(6):505-13.
- Walsh GA, Donlon J. Dexamethasone and phenylalanine hydroxylase activities in rats. *Biochem Soc Trans* 1990 Apr;18(2):320-1.
- Walsh GA, Donlon J. Effects of starvation on rat phenylalanine hydroxylase activities. *Trans Biochem Soc* 1989 Apr;17(2):378-9.
- Walsh GA, Donlon J. State of phosphorylation of hepatic phenylalanine hydroxylase in diabetic rats. *Trans Biochem Soc* 1989 Apr;17(2):380-1.
- Wang T, Okano Y, Eisensmith RC, Lo WH, Huang SZ, Zeng YT, Yuan LF, Liu SR, Woo SL. Missense mutations prevalent in Orientals with phenylketonuria: molecular characterization and clinical implications. *Genomics* 1991 Jun;10(2):449-56.
- Wang W, Ramdas L, Sun G, Ke S, Obeyesekere NU, Budde RJA, McMurray JS. Cyclic peptides incorporating 4-carboxyphenylalanine and phosphotyrosine are potent inhibitors of pp60(c-src). *Biochemistry* 2000 May 2;39(17):5221-8.
- Wang Y, DeMayo JL, Hahn TM, Finegold MJ, Konecki DS, Lichter-Konecki U, Woo SL. Tissue- and development-specific expression of the human phenylalanine hydroxylase/chloramphenicol acetyltransferase fusion gene in transgenic mice. *J Biol Chem* 1992 Jul 25;267(21):15105-10.
- Wang Y, Hahn TM, Tsai SY, Woo SL. Functional characterization of a unique liver gene promoter. *J Biol Chem* 1994 Mar 25;269(12):9137-46.
- Wang YL, Yu B. Effect of peroxovanadate compound on phenylalanine hydroxylase gene expression. *Biol Trace Elem Res* 2000;74(3):237-44.
- Waters PJ, Parniak MA, Akerman BR, Scriver CR. Characterization of phenylketonuria missense substitutions, distant from the phenylalanine hydroxylase active site, illustrates a paradigm for mechanism and potential modulation of phenotype. *Mol Genet Metab* 2000 Feb;69(2):101-10.
- Waters PJ, Parniak MA, Hewson AS, Scriver CR. Alterations in protein aggregation and degradation due to mild and severe missense mutations (A104D, R157N) in the human phenylalanine hydroxylase gene (PAH). *Hum Mutat* 1998;12(5):344-54.
- Waters PJ, Parniak MA, Nowacki P, Scriver CR. In vitro expression analysis of mutations in phenylalanine hydroxylase: linking genotype to phenotype and structure to function. *Hum Mutat* 1998;11(1):4-17.
- Waters PJ, Scriver CR, Parniak MA. Degradation rates differ between mutant and wild-type forms of phenylalanine hydroxylase expressed in vitro. *Biochem Soc Trans* 1998 Aug;26(3):S276.
- Webber S, Harzer G, Whiteley JM. Isolation of rat liver phenylalanine hydroxylase using a novel pteridine matrix. *Anal Biochem* 1980 Jul 15;106(1):63-72.
- Webber S, Whiteley JM. Separation of catalase from phenylalanine hydroxylase: use of a Sepharose anti-catalase IgG affinity matrix. *Biochem Biophys Res Commun* 1980 Nov 17;97(1):17-21.
- Weiss B, Hui M, Lajtha A. Attempts at induction of phenylalanine hydroxylase in thermophilic bacteria and induction of thermophily in mesophiles. *Res Commun Chem Pathol Pharmacol* 1981 May;32(2):329-34.
- Wen GY, Wisniewski HM, Shek JW, Loo YH, Fulton TR. Neuropathology of phenylacetate poisoning in rats: an experimental model of phenylketonuria. *Ann Neurol* 1980 Jun;7(6):557-66.
- Werner ER, Habisch H-J, Gorren ACF, Schmidt K, Canevari L, Werner-Felmayer G, Mayer B. Contrasting effects of Nsup 5-substituted tetrahydrobiopterin derivatives on phenylalanine hydroxylase, dihydropteridine reductase and nitric oxide synthase. *Biochem J* 2000 Jun 15;348(3):579-83.
- Wester TJ, Lobley GE, Birnie LM, Lomax MA. Insulin stimulates phenylalanine uptake across the hind limb in fed lambs. *J Nutr* 2000 Mar;130(3):608-11.
- Whipp MJ, Halsall DM, Pittard AJ. Isolation and characterization of an Escherichia coli K-12 mutant defective in tyrosine- and phenylalanine-specific transport systems. *J Bacteriol* 1980 Jul;143(1):1-7.
- Wiens M, Koziol C, Batel R, Muller WE. Phenylalanine hydroxylase from the sponge Geodia cydonium: implication for allorecognition and evolution of aromatic amino acid hydroxylases. *Dev Comp Immunol* 1998 Sep-Dec;22(5-6):469-78.
- Wigfield DC, Eatock SA. The effect of metals on the activity of L-phenylalanine hydroxylase. *J Trace Elem Electrolytes Health Dis* 1990 Sep;4(3):143-6.

- Williams JM, Morris JG, Rogers QR. Phenylalanine requirement of kittens and the sparing effect of tyrosine. *J Nutr* 1987 Jun;117(6):1102-7.
- Wilt SG. Long-term regulation of phenylalanine hydroxylase by primary rat hepatocytes: evidence for camp involvement [dissertation]. University Park (PA): The Pennsylvania State University; 1993. 127 p.
- Wittig A, Sauerwein WA, Coderre JA. Mechanisms of transport of p-borono-phenylalanine through the cell membrane in vitro. *Radiat Res* 2000;153(2):173-80.
- Wittstock U, Halkier BA. Cytochrome P450 CYP79A2 from *Arabidopsis thaliana* L. catalyzes the conversion of L-phenylalanine to phenylacetaldoxime in the biosynthesis of benzylglucosinolate. *J Biol Chem* 2000 May 12;275(19):14659-66.
- Wolf ME, Mosnaim AD. Phenylethylamine in neuropsychiatric disorders. *Gen Pharmacol* 1983;14(4):385-90.
- Wolfe JM. Regulation of cerebral serotonin metabolism in experimental phenylketonuria [dissertation]. New York: City University of New York; 1986. 170 p.
- Woo SL, DiLella AG, Marvit J, Ledley FD. Molecular basis of phenylketonuria and recombinant DNA strategies for its therapy. *Enzyme* 1987;38(1-4):207-13.
- Woo SL, Gillam SS, Woolf LI. The isolation and properties of phenylalanine hydroxylase from human liver. *Biochem J* 1974 Jun;139(3):741-9.
- Woo SL, Guttler F, Ledley FD, Lidsky AS, Kwok SC, DiLella AG, Robson KJ. The human phenylalanine hydroxylase gene. *Prog Clin Biol Res* 1985;177:123-35.
- Woo SL, Robson JH, Guttler F. The possibility for prenatal diagnosis of PKU by linkage analyses based on phenylalanine hydroxylase locus specific DNA-polymorphisms. *J Inher Metab Dis* 1984;7 Suppl 2:139-40.
- Wood JM, Schallreuter-Wood KU, Lindsey NJ, Callaghan S, Gardner ML. A specific tetrahydrobiopterin binding domain on tyrosinase controls melanogenesis. *Biochem Biophys Res Commun* 1995 Jan 17;206(2):480-5.
- Wretborn M, Humble E, Ragnarsson U, Engstrom L. Amino acid sequence at the phosphorylated site of rat liver phenylalanine hydroxylase and phosphorylation of a corresponding synthetic peptide. *Biochem Biophys Res Commun* 1980 Mar 28;93(2):403-8.
- Wyse AT, Noriler ME, Borges LF, Floriano PJ, Silva CG, Wajner M, Wannmacher CM. Alanine prevents the decrease of Na⁺,K⁺-ATPase activity in experimental phenylketonuria. *Metab Brain Dis* 1999 Jun;14(2):95-101.
- Wyse AT, Sarkis JJ, Cunha-Filho JS, Teixeira MV, Schetinger MR, Wajner M, Milton C, Wannmacher D. Effect of phenylalanine and its metabolites on ATP diphosphohydrolase activity in synaptosomes from rat cerebral cortex. *Neurochem Res* 1994 Sep;19(9):1175-80.
- Wyse AT, Sarkis JJ, Cunha-Filho JS, Teixeira MV, Schetinger MR, Wajner M, Wannmacher CM. ATP diphosphohydrolase activity in synaptosomes from cerebral cortex of rats subjected to chemically induced phenylketonuria. *Braz J Med Biol Res* 1995 Jun;28(6):643-9.
- Xia T. The mechanism of regulation of phenylalanine hydroxylase by (6R)-tetrahydrobiopterin and 7,8-dihydrobiopterin [dissertation]. University Park (PA): The Pennsylvania State University; 1990. 176 p.
- Xia T, Gray DW, Shiman R. Regulation of rat liver phenylalanine hydroxylase. III. Control of catalysis by (6R)-tetrahydrobiopterin and phenylalanine. *J Biol Chem* 1994 Oct 7;269(40):24657-65.
- Yamada K, Shuto K, Kojima T, Marumo H, Tanaka M. Lipid-lowering effects of N-[4-methylbenzylthiocarbonyl]-L-phenylalanine (KF1492), a new phenylalanine derivative. *J Pharmacobiodyn* 1982 Aug;5(8):611-8.
- Yamakawa A, Kameoka Y, Hashimoto K, Yoshitake Y, Nishikawa K, Tanihara K, Date T. cDNA cloning and chromosomal mapping of genes encoding novel protein kinases termed PKU-alpha and PKU-beta, which have nuclear localization signal. *Gene* 1997 Nov 20;202(1-2):193-201.
- Yamamoto H. Brain phenylalanine and tyrosine levels and hepatic encephalopathy induced by CCl₄ in rats. *Toxicology* 1990 Apr 30;61(3):241-7.
- Yamamoto Y, Makita K, Muramatsu K. Self-selection of phenylalanine in the rat. *J Nutr Sci Vitaminol (Tokyo)* 1984 Jun;30(3):273-83.
- Yamamoto Y, Suzuki T, Muramatsu K. Effects of high dietary phenylalanine and p-chlorophenylalanine (Para-chlorophenylalanine) treatment on phenylalanine metabolism in the rat (Amino acid balance). *Agric Biol Chem* 1982 Oct;46(10):2491-7.
- Yang J, Wang P, Pittard AJ. Mechanism of repression of the aroP P2 promoter by the TyrR protein of *Escherichia coli*. *J Bacteriol* 1999 Oct;181(20):6411-8.

Yang R. Regulation of the rat tryptophan hydroxylase gene (serotonin, gland) [dissertation]. Newark (NJ): Rutgers - The State University; 1993. 138 p.

Yang SI, Furuse M, Sugishita N, Okumura J. Effect of phenylalanine on pancreatic amylase secretion in chicks (*Gallus domesticus*). *Comp Biochem Physiol A Comp Physiol* 1990;97(4):531-3.

Yeoh GC, Edkins E, Mackenzie K, Fuller S, Mercer JF, Dahl HH. The development of phenylalanine hydroxylase in rat liver; in vivo, and in vitro studies utilizing fetal hepatocyte cultures. *Differentiation* 1988 Jun;38(1):42-8.

Yoneyama T, Hatakeyama K. Decameric GTP cyclohydrolase I forms complexes with two pentameric GTP cyclohydrolase I feedback regulatory proteins in the presence of phenylalanine or of a combination of tetrahydrobiopterin and GTP. *J Biol Chem* 1998 Aug 7;273(32):20102-8.

Yoon C. Total synthesis of folic acid analogs and biopterin analogs [dissertation]. Princeton (NJ): Princeton University; 1989. 161 p.

Yoshimoto K, Yoshida T, Takeuchi Y, Ueda S. The effects of 6R-L-Erythro-5,6,7,8-Tetrahydrobiopterin on ethanol-induced sleep time and ethanol elimination in inbred strains of mice with different alcohol preference. *Neuropsychobiology* 1997 Nov;36(4):188-93.

Zagreda L, Goodman J, Druin DP, McDonald D, Diamond A. Cognitive deficits in a genetic mouse model of the most common biochemical cause of human mental retardation. *J Neurosci* 1999 Jul 15;19(14):6175-82.

Zanic-Grubisic T, Lipovac K. Disturbances of amino acid transport in rats with experimental hyperphenylalaninaemia. *J Inherit Metab Dis* 1981;4(2):105-6.

Zetterstrom R. Editorial comment on phenylketonuria [editorial]. *Acta Paediatr* 1995 Jul;84(7):716-8.

Zhao G. Biosynthesis of phenylalanine and tyrosine in *Pseudomonas* and *Zymomonas mobilis*: molecular cloning of the genes encoding cyclohexadienyl dehydratase and cyclohexadienyl characterization of the gene products [dissertation]. Gainesville (FL): The University of Florida; 1991. 129 p.

